DDI-MedLine.d133.s0	Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
verapamil	drug	15-23	bombesin	drug_n	28-35	effect
verapamil	drug	15-23	azoxymethane	drug_n	109-120	false
bombesin	drug_n	28-35	azoxymethane	drug_n	109-120	false

DDI-MedLine.d133.s1	BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.
bombesin	drug_n	54-61	verapamil hydrochloride	drug	67-89	false
bombesin	drug_n	54-61	verapamil	drug	92-100	false
bombesin	drug_n	54-61	calcium channel blocker	group	106-128	false
bombesin	drug_n	54-61	azoxymethane	drug_n	214-225	false
bombesin	drug_n	54-61	AOM	drug_n	228-230	false
verapamil hydrochloride	drug	67-89	verapamil	drug	92-100	false
verapamil hydrochloride	drug	67-89	calcium channel blocker	group	106-128	false
verapamil hydrochloride	drug	67-89	azoxymethane	drug_n	214-225	false
verapamil hydrochloride	drug	67-89	AOM	drug_n	228-230	false
verapamil	drug	92-100	calcium channel blocker	group	106-128	false
verapamil	drug	92-100	azoxymethane	drug_n	214-225	false
verapamil	drug	92-100	AOM	drug_n	228-230	false
calcium channel blocker	group	106-128	azoxymethane	drug_n	214-225	false
calcium channel blocker	group	106-128	AOM	drug_n	228-230	false
azoxymethane	drug_n	214-225	AOM	drug_n	228-230	false

DDI-MedLine.d133.s2	METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.
AOM	drug_n	100-102	bombesin	drug_n	159-166	false
AOM	drug_n	100-102	verapamil	drug	260-268	false
bombesin	drug_n	159-166	verapamil	drug	260-268	false

DDI-MedLine.d133.s4	Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.
verapamil	drug	9-17	bombesin	drug_n	122-129	false

DDI-MedLine.d133.s5	Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin.
Verapamil	drug	0-8	bombesin	drug_n	117-124	effect

DDI-MedLine.d73.s0	Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	drug_n	52-95	MPTP	drug_n	98-101	false
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	drug_n	52-95	methamphetamine	drug	108-122	false
MPTP	drug_n	98-101	methamphetamine	drug	108-122	false

DDI-MedLine.d73.s1	The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration.
MPTP	drug_n	56-59	methamphetamine	drug	144-158	false

DDI-MedLine.d73.s2	It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment.
MPTP	drug_n	21-24	pargyline	drug	143-151	effect

DDI-MedLine.d73.s3	The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
MPTP	drug	4-7	amphetamine	drug	83-93	effect
MPTP	drug	4-7	apomorphine	drug	147-157	effect
amphetamine	drug	83-93	apomorphine	drug	147-157	false

DDI-MedLine.d73.s4	Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.
Methamphetamine	drug	0-14	MPTP	drug_n	22-25	false
Methamphetamine	drug	0-14	pargyline	drug	107-115	effect
MPTP	drug_n	22-25	pargyline	drug	107-115	false

DDI-MedLine.d135.s0	Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats.
clozapine	drug	16-24	phencyclidine	drug_n	30-42	false

DDI-MedLine.d135.s1	Phencyclidine (PCP) produces psychotomimetic effects in humans that resemble schizophrenia symptoms.
Phencyclidine	drug_n	0-12	PCP	drug_n	15-17	false

DDI-MedLine.d135.s3	In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.
atypical antipsychotic	group	26-47	clozapine	drug	49-57	false
atypical antipsychotic	group	26-47	PCP	drug_n	108-110	false
clozapine	drug	49-57	PCP	drug_n	108-110	false

DDI-MedLine.d135.s4	PCP produced distinctive effects in each task: it substituted for the training dose in PCP discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.
PCP	drug_n	0-2	PCP	drug_n	87-89	false

DDI-MedLine.d135.s5	Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone.
clozapine	drug	18-26	PCP	drug_n	70-72	false

DDI-MedLine.d135.s6	These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication.
clozapine	drug	45-53	PCP	drug_n	111-113	false

DDI-MedLine.d135.s8	Since chronic dosing is required for therapeutic efficacy of antipsychotics, future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP.
antipsychotics	group	61-74	PCP	drug_n	183-185	false

DDI-MedLine.d126.s0	Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
Cypermethrin	drug	0-11	vitamin E	drug	77-85	effect
Cypermethrin	drug	0-11	allopurinol	drug	90-100	effect
vitamin E	drug	77-85	allopurinol	drug	90-100	false

DDI-MedLine.d126.s1	Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by cypermethrin, a Type II pyrethroid.
cypermethrin	drug	213-224	Type II pyrethroid	drug_n	229-246	false

DDI-MedLine.d126.s6	Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h.
allopurinol	drug	26-36	Vitamin E	drug	57-65	false
allopurinol	drug	26-36	cypermethrin	drug	280-291	effect
Vitamin E	drug	57-65	cypermethrin	drug	280-291	effect

DDI-MedLine.d126.s7	Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.
cypermethrin	drug	31-42	allopurinol	drug	198-208	effect
cypermethrin	drug	31-42	Vitamin E	drug	214-222	effect
allopurinol	drug	198-208	Vitamin E	drug	214-222	false

DDI-MedLine.d103.s1	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.
magnesium	drug	36-44	magnesium	drug	75-83	false
magnesium	drug	36-44	magnesium	drug	144-152	false
magnesium	drug	36-44	magnesium	drug	193-201	false
magnesium	drug	36-44	magnesium	drug	230-238	false
magnesium	drug	36-44	magnesium	drug	302-310	false
magnesium	drug	75-83	magnesium	drug	144-152	false
magnesium	drug	75-83	magnesium	drug	193-201	false
magnesium	drug	75-83	magnesium	drug	230-238	false
magnesium	drug	75-83	magnesium	drug	302-310	false
magnesium	drug	144-152	magnesium	drug	193-201	false
magnesium	drug	144-152	magnesium	drug	230-238	false
magnesium	drug	144-152	magnesium	drug	302-310	false
magnesium	drug	193-201	magnesium	drug	230-238	false
magnesium	drug	193-201	magnesium	drug	302-310	false
magnesium	drug	230-238	magnesium	drug	302-310	false

DDI-MedLine.d103.s2	Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy.
magnesium	drug	22-30	magnesium	drug	98-106	false

DDI-MedLine.d103.s3	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.
magnesium	drug	94-102	magnesium	drug	140-148	false
magnesium	drug	94-102	magnesium	drug	184-192	false
magnesium	drug	94-102	magnesium	drug	260-268	false
magnesium	drug	94-102	magnesium	drug	336-344	false
magnesium	drug	140-148	magnesium	drug	184-192	false
magnesium	drug	140-148	magnesium	drug	260-268	false
magnesium	drug	140-148	magnesium	drug	336-344	false
magnesium	drug	184-192	magnesium	drug	260-268	false
magnesium	drug	184-192	magnesium	drug	336-344	false
magnesium	drug	260-268	magnesium	drug	336-344	false

DDI-MedLine.d103.s4	Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment.
magnesium	drug	19-27	magnesium	drug	77-85	false

DDI-MedLine.d103.s5	Physiological oral magnesium supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with magnesium salts, with practically only one contra-indication: overt renal failure.
magnesium	drug	19-27	magnesium salt	drug	110-123	false

DDI-MedLine.d103.s6	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium.
magnesium	drug	37-45	magnesium sparing diuretics	group	86-112	false
magnesium	drug	37-45	vitamin B6	drug	140-149	false
magnesium	drug	37-45	vitamin D	group	175-183	false
magnesium	drug	37-45	selenium	drug	192-199	false
magnesium sparing diuretics	group	86-112	vitamin B6	drug	140-149	false
magnesium sparing diuretics	group	86-112	vitamin D	group	175-183	false
magnesium sparing diuretics	group	86-112	selenium	drug	192-199	false
vitamin B6	drug	140-149	vitamin D	group	175-183	false
vitamin B6	drug	140-149	selenium	drug	192-199	false
vitamin D	group	175-183	selenium	drug	192-199	false

DDI-MedLine.d103.s8	There are 3 types of indications: specific (for the treatment of some forms of magnesium deficit i.e. acute), pharmacological (i.e. without alterations of magnesium status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).
magnesium	drug	79-87	magnesium	drug	155-163	false

DDI-MedLine.d103.s15	Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic solutions and for preservation of transplants particularly.
magnesium	drug	71-79	cardioplegic solutions	drug	100-121	false

DDI-MedLine.d86.s0	Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
diltiazem	drug	57-65	sirolimus	drug	71-79	mechanism

DDI-MedLine.d86.s1	AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects.
sirolimus	drug	60-68	macrolide immunosuppressant	group	73-99	false
sirolimus	drug	60-68	calcium channel blocker	group	132-154	false
sirolimus	drug	60-68	diltiazem	drug	156-164	false
macrolide immunosuppressant	group	73-99	calcium channel blocker	group	132-154	false
macrolide immunosuppressant	group	73-99	diltiazem	drug	156-164	false
calcium channel blocker	group	132-154	diltiazem	drug	156-164	false

DDI-MedLine.d86.s2	Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists.
immunosuppressive drugs	group	82-104	calcium antagonists	group	154-172	false

DDI-MedLine.d86.s3	METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together.
sirolimus	drug	176-184	diltiazem	drug	216-224	false

DDI-MedLine.d86.s5	RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.
sirolimus	drug	66-74	diltiazem	drug	253-261	mechanism
sirolimus	drug	66-74	sirolimus	drug	323-331	false
diltiazem	drug	253-261	sirolimus	drug	323-331	false

DDI-MedLine.d86.s6	Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem.
sirolimus	drug	54-62	sirolimus	drug	111-119	false
sirolimus	drug	54-62	diltiazem	drug	136-144	false
sirolimus	drug	111-119	diltiazem	drug	136-144	mechanism

DDI-MedLine.d86.s7	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
diltiazem	drug	87-95	desacetyldiltiazem	drug_n	98-115	false
diltiazem	drug	87-95	desmethyldiltiazem	drug_n	122-139	false
diltiazem	drug	87-95	sirolimus	drug	182-190	false
diltiazem	drug	87-95	diltiazem	drug	231-239	false
desacetyldiltiazem	drug_n	98-115	desmethyldiltiazem	drug_n	122-139	false
desacetyldiltiazem	drug_n	98-115	sirolimus	drug	182-190	false
desacetyldiltiazem	drug_n	98-115	diltiazem	drug	231-239	false
desmethyldiltiazem	drug_n	122-139	sirolimus	drug	182-190	false
desmethyldiltiazem	drug_n	122-139	diltiazem	drug	231-239	false
sirolimus	drug	182-190	diltiazem	drug	231-239	false

DDI-MedLine.d86.s8	CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus.
diltiazem	drug	25-33	sirolimus	drug	68-76	mechanism
diltiazem	drug	25-33	sirolimus	drug	145-153	false
sirolimus	drug	68-76	sirolimus	drug	145-153	false

DDI-MedLine.d86.s9	Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.
sirolimus	drug	72-80	diltiazem	drug	82-90	advise
sirolimus	drug	72-80	sirolimus	drug	117-125	false
diltiazem	drug	82-90	sirolimus	drug	117-125	false

DDI-MedLine.d116.s0	Rifampin and warfarin: a drug interaction.
Rifampin	drug	0-7	warfarin	drug	13-20	int

DDI-MedLine.d116.s1	The drug interaction between warfarin and rifampin is not well known.
warfarin	drug	29-36	rifampin	drug	42-49	int

DDI-MedLine.d116.s2	Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously.
Rifampin	drug	0-7	warfarin	drug	43-50	mechanism

DDI-MedLine.d116.s3	The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
rifampin	drug	34-41	warfarin	drug	47-54	mechanism
rifampin	drug	34-41	warfarin	drug	119-126	false
warfarin	drug	47-54	warfarin	drug	119-126	false

DDI-MedLine.d116.s4	Withdrawal of rifampin decreased the warfarin requirement by 50%.
rifampin	drug	14-21	warfarin	drug	37-44	mechanism

DDI-MedLine.d116.s5	This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin.
rifampin	drug	46-53	warfarin	drug	113-120	mechanism

DDI-MedLine.d116.s6	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
rifampin	drug	14-21	warfarin	drug	30-37	effect
rifampin	drug	14-21	rifampin	drug	125-132	false
rifampin	drug	14-21	rifampin	drug	178-185	false
warfarin	drug	30-37	rifampin	drug	125-132	false
warfarin	drug	30-37	rifampin	drug	178-185	false
rifampin	drug	125-132	rifampin	drug	178-185	false

DDI-MedLine.d88.s0	The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
chlordiazepoxide	drug	15-30	amphetamine	drug	33-43	false
chlordiazepoxide	drug	15-30	cocaine	drug	49-55	false
amphetamine	drug	33-43	cocaine	drug	49-55	false

DDI-MedLine.d88.s1	Studies on two strains of pointer dogs have demonstrated that administration of a benzodiazepine (chlordiazepoxide) facilitates acquisition of goal-directed behavior in "genetically nervous"
benzodiazepine	group	82-95	chlordiazepoxide	drug	98-113	false

DDI-MedLine.d88.s4	The concomitant administration of either cocaine or amphetamine, compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects.
cocaine	drug	41-47	amphetamine	drug	52-62	false

DDI-MedLine.d66.s0	Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.
synthetic steroidal estrogen	group	42-69	synthetic steroidal progestogen	group	42-60;75-85	false

DDI-MedLine.d66.s1	The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine.
ethynyl estradiol	drug	53-69	levonorgestrel	drug	75-88	false

DDI-MedLine.d66.s2	The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol.
levonorgestrel	drug	149-162	ethynyl estradiol	drug	219-235	false

DDI-MedLine.d20.s0	Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
glycine	drug	20-26	glutamate	drug	32-40	effect

DDI-MedLine.d20.s4	The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.
glycine	drug	30-36	glutamate	drug	75-83	effect
glycine	drug	30-36	glutamate	drug	246-254	false
glutamate	drug	75-83	glutamate	drug	246-254	false

DDI-MedLine.d112.s0	Effect of dofetillide on the pharmacokinetics of digoxin.
dofetillide	drug	10-20	digoxin	drug	49-55	false

DDI-MedLine.d112.s1	The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study.
dofetilide	drug	14-23	digoxin	drug	65-71	false

DDI-MedLine.d112.s2	Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo;
dofetilide	drug	13-22	digoxin	drug	105-111	false

DDI-MedLine.d112.s3	therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.
dofetilide	drug	22-31	digoxin	drug	71-77	false

DDI-MedLine.d57.s1	The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.
antihistaminics	group	83-97	analgesic agents	group	111-126	false
antihistaminics	group	83-97	analgesic adjuvants	group	141-159	false
analgesic agents	group	111-126	analgesic adjuvants	group	141-159	false

DDI-MedLine.d57.s2	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.
diphenhydramine	drug	51-65	hydroxyzine	drug	68-78	false
diphenhydramine	drug	51-65	orphenadrine	drug	81-92	false
diphenhydramine	drug	51-65	pyrilamine	drug	95-104	false
diphenhydramine	drug	51-65	phenyltoloxamine	drug_n	107-122	false
diphenhydramine	drug	51-65	promethazine	drug	125-136	false
diphenhydramine	drug	51-65	methdilazine	drug	139-150	false
diphenhydramine	drug	51-65	tripelennamine	drug	157-170	false
hydroxyzine	drug	68-78	orphenadrine	drug	81-92	false
hydroxyzine	drug	68-78	pyrilamine	drug	95-104	false
hydroxyzine	drug	68-78	phenyltoloxamine	drug_n	107-122	false
hydroxyzine	drug	68-78	promethazine	drug	125-136	false
hydroxyzine	drug	68-78	methdilazine	drug	139-150	false
hydroxyzine	drug	68-78	tripelennamine	drug	157-170	false
orphenadrine	drug	81-92	pyrilamine	drug	95-104	false
orphenadrine	drug	81-92	phenyltoloxamine	drug_n	107-122	false
orphenadrine	drug	81-92	promethazine	drug	125-136	false
orphenadrine	drug	81-92	methdilazine	drug	139-150	false
orphenadrine	drug	81-92	tripelennamine	drug	157-170	false
pyrilamine	drug	95-104	phenyltoloxamine	drug_n	107-122	false
pyrilamine	drug	95-104	promethazine	drug	125-136	false
pyrilamine	drug	95-104	methdilazine	drug	139-150	false
pyrilamine	drug	95-104	tripelennamine	drug	157-170	false
phenyltoloxamine	drug_n	107-122	promethazine	drug	125-136	false
phenyltoloxamine	drug_n	107-122	methdilazine	drug	139-150	false
phenyltoloxamine	drug_n	107-122	tripelennamine	drug	157-170	false
promethazine	drug	125-136	methdilazine	drug	139-150	false
promethazine	drug	125-136	tripelennamine	drug	157-170	false
methdilazine	drug	139-150	tripelennamine	drug	157-170	false

DDI-MedLine.d14.s0	[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion.
angiotensin	drug_n	45-55	angiotensin 1	drug_n	184-196	false
angiotensin	drug_n	45-55	angiotensin 2	drug_n	202-214	false
angiotensin	drug_n	45-55	pentagastrin	drug	219-230	false
angiotensin	drug_n	45-55	histamine	drug	237-245	false
angiotensin 1	drug_n	184-196	angiotensin 2	drug_n	202-214	false
angiotensin 1	drug_n	184-196	pentagastrin	drug	219-230	false
angiotensin 1	drug_n	184-196	histamine	drug	237-245	false
angiotensin 2	drug_n	202-214	pentagastrin	drug	219-230	false
angiotensin 2	drug_n	202-214	histamine	drug	237-245	false
pentagastrin	drug	219-230	histamine	drug	237-245	false

DDI-MedLine.d14.s1	It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine.
pentagastrin	drug	89-100	histamine	drug	113-121	false

DDI-MedLine.d14.s2	Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.
angiotensins	drug_n	127-138	angiotensin	drug_n	167-177	false

DDI-MedLine.d15.s0	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.
cerulein	drug_n	16-23	3H-spiroperidol	drug_n	75-89	false
cerulein	drug_n	16-23	neuroleptics	group	137-148	false
cerulein	drug_n	16-23	haloperidol	drug	269-279	false
cerulein	drug_n	16-23	pyreneperone	drug_n	298-309	false
cerulein	drug_n	16-23	3H-spiroperidol	drug_n	368-382	false
cerulein	drug_n	16-23	apomorphine	drug	419-429	false
cerulein	drug_n	16-23	3H-spiroperidol	drug_n	466-480	false
cerulein	drug_n	16-23	apomorphine	drug	527-537	false
3H-spiroperidol	drug_n	75-89	neuroleptics	group	137-148	false
3H-spiroperidol	drug_n	75-89	haloperidol	drug	269-279	false
3H-spiroperidol	drug_n	75-89	pyreneperone	drug_n	298-309	false
3H-spiroperidol	drug_n	75-89	3H-spiroperidol	drug_n	368-382	false
3H-spiroperidol	drug_n	75-89	apomorphine	drug	419-429	false
3H-spiroperidol	drug_n	75-89	3H-spiroperidol	drug_n	466-480	false
3H-spiroperidol	drug_n	75-89	apomorphine	drug	527-537	false
neuroleptics	group	137-148	haloperidol	drug	269-279	false
neuroleptics	group	137-148	pyreneperone	drug_n	298-309	false
neuroleptics	group	137-148	3H-spiroperidol	drug_n	368-382	false
neuroleptics	group	137-148	apomorphine	drug	419-429	false
neuroleptics	group	137-148	3H-spiroperidol	drug_n	466-480	false
neuroleptics	group	137-148	apomorphine	drug	527-537	false
haloperidol	drug	269-279	pyreneperone	drug_n	298-309	false
haloperidol	drug	269-279	3H-spiroperidol	drug_n	368-382	false
haloperidol	drug	269-279	apomorphine	drug	419-429	false
haloperidol	drug	269-279	3H-spiroperidol	drug_n	466-480	false
haloperidol	drug	269-279	apomorphine	drug	527-537	false
pyreneperone	drug_n	298-309	3H-spiroperidol	drug_n	368-382	false
pyreneperone	drug_n	298-309	apomorphine	drug	419-429	false
pyreneperone	drug_n	298-309	3H-spiroperidol	drug_n	466-480	false
pyreneperone	drug_n	298-309	apomorphine	drug	527-537	false
3H-spiroperidol	drug_n	368-382	apomorphine	drug	419-429	false
3H-spiroperidol	drug_n	368-382	3H-spiroperidol	drug_n	466-480	false
3H-spiroperidol	drug_n	368-382	apomorphine	drug	527-537	false
apomorphine	drug	419-429	3H-spiroperidol	drug_n	466-480	false
apomorphine	drug	419-429	apomorphine	drug	527-537	false
3H-spiroperidol	drug_n	466-480	apomorphine	drug	527-537	false

DDI-MedLine.d15.s1	After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding.
neuroleptics	group	34-45	cerulein	drug_n	72-79	false
neuroleptics	group	34-45	3H-spiroperidol	drug_n	164-178	false
cerulein	drug_n	72-79	3H-spiroperidol	drug_n	164-178	false

DDI-MedLine.d15.s2	It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.
3H-spiroperidol	drug_n	49-63	apomorphine	drug	101-111	false
3H-spiroperidol	drug_n	49-63	neuroleptics	group	190-201	false
apomorphine	drug	101-111	neuroleptics	group	190-201	false

DDI-MedLine.d80.s1	In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.
progestin-only oral contraceptives	group	79-112	POC	group	115-117	false
progestin-only oral contraceptives	group	79-112	norgestrel	drug	166-175	false
progestin-only oral contraceptives	group	79-112	norethindrone	drug	192-204	false
POC	group	115-117	norgestrel	drug	166-175	false
POC	group	115-117	norethindrone	drug	192-204	false
norgestrel	drug	166-175	norethindrone	drug	192-204	false

DDI-MedLine.d140.s0	Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
everolimus	drug	27-36	cyclosporine	drug	182-193	false

DDI-MedLine.d140.s1	OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation.
everolimus	drug	82-91	cyclosporine	drug	97-108	false
everolimus	drug	82-91	ciclosporin	drug	116-126	false
cyclosporine	drug	97-108	ciclosporin	drug	116-126	false

DDI-MedLine.d140.s2	METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone.
everolimus	drug	127-136	cyclosporine	drug	197-208	false
everolimus	drug	127-136	prednisone	drug	214-223	false
cyclosporine	drug	197-208	prednisone	drug	214-223	false

DDI-MedLine.d140.s3	Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12.
everolimus	drug	43-52	cyclosporine	drug	58-69	false

DDI-MedLine.d140.s6	Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA.
cyclosporine	drug	25-36	everolimus	drug	89-98	false

DDI-MedLine.d140.s13	Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively).
Cyclosporine	drug	0-11	everolimus	drug	152-161	false

DDI-MedLine.d140.s15	For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.
everolimus	drug	22-31	cyclosporine	drug	77-88	false

DDI-MedLine.d8.s0	In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
KRM-1648	drug_n	21-28	ofloxacin	drug	68-76	false

DDI-MedLine.d8.s1	The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans.
benzoxazinorifamycin	drug_n	30-49	KRM-1648	drug_n	52-59	false
benzoxazinorifamycin	drug_n	30-49	ofloxacin	drug	98-106	false
KRM-1648	drug_n	52-59	ofloxacin	drug	98-106	false

DDI-MedLine.d8.s5	ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for rifampicin and rifabutin were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively.
rifampicin	drug	74-83	rifabutin	drug	89-97	false

DDI-MedLine.d8.s6	When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
ofloxacin	drug	19-27	KRM-1648	drug_n	30-37	effect
ofloxacin	drug	19-27	rifampicin	drug	143-152	false
ofloxacin	drug	19-27	rifabutin	drug	158-166	false
ofloxacin	drug	19-27	ofloxacin	drug	173-181	false
KRM-1648	drug_n	30-37	rifampicin	drug	143-152	false
KRM-1648	drug_n	30-37	rifabutin	drug	158-166	false
KRM-1648	drug_n	30-37	ofloxacin	drug	173-181	false
rifampicin	drug	143-152	rifabutin	drug	158-166	false
rifampicin	drug	143-152	ofloxacin	drug	173-181	effect
rifabutin	drug	158-166	ofloxacin	drug	173-181	effect

DDI-MedLine.d102.s0	Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
estradiol	drug	13-21	progesterone	drug	27-38	false
estradiol	drug	13-21	noradrenaline	drug	84-96	false
progesterone	drug	27-38	noradrenaline	drug	84-96	false

DDI-MedLine.d102.s1	The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta.
estradiol	drug	78-86	progesterone	drug	96-107	false
estradiol	drug	78-86	noradrenaline	drug	128-140	false
progesterone	drug	96-107	noradrenaline	drug	128-140	false

DDI-MedLine.d102.s3	injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days.
estradiol	drug	45-53	progesterone	drug	96-107	false

DDI-MedLine.d102.s5	Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively).
estradiol	drug	70-78	noradrenaline	drug	109-121	effect

DDI-MedLine.d102.s6	Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
estradiol	drug	42-50	noradrenaline	drug	80-92	effect
estradiol	drug	42-50	progesterone	drug	121-132	false
estradiol	drug	42-50	progesterone	drug	139-150	false
estradiol	drug	42-50	estradiol	drug	159-167	false
noradrenaline	drug	80-92	progesterone	drug	121-132	false
noradrenaline	drug	80-92	progesterone	drug	139-150	false
noradrenaline	drug	80-92	estradiol	drug	159-167	false
progesterone	drug	121-132	progesterone	drug	139-150	false
progesterone	drug	121-132	estradiol	drug	159-167	false
progesterone	drug	139-150	estradiol	drug	159-167	false

DDI-MedLine.d124.s0	Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
levofloxacin	drug	28-39	oxycodone	drug	45-53	false

DDI-MedLine.d124.s1	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
trovafloxacin	drug	90-102	ciprofloxacin	drug	108-120	false
trovafloxacin	drug	90-102	opiate	group	174-179	mechanism
trovafloxacin	drug	90-102	morphine	drug	189-196	mechanism
ciprofloxacin	drug	108-120	opiate	group	174-179	mechanism
ciprofloxacin	drug	108-120	morphine	drug	189-196	mechanism
opiate	group	174-179	morphine	drug	189-196	false

DDI-MedLine.d124.s2	This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures.
trovafloxacin	drug	67-79	ciprofloxacin	drug	85-97	false

DDI-MedLine.d124.s3	The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin.
oxycodone	drug	74-82	levofloxacin	drug	88-99	false

DDI-MedLine.d124.s6	1 hour after starting the oxycodone or levofloxacin 500 mg p.o.
oxycodone	drug	26-34	levofloxacin	drug	39-50	false

DDI-MedLine.d124.s9	There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.
levofloxacin	drug	173-184	levofloxacin	drug	193-204	false
levofloxacin	drug	173-184	oxycodone	drug	206-214	false
levofloxacin	drug	193-204	oxycodone	drug	206-214	false

DDI-MedLine.d124.s10	It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.
oxycodone	drug	27-35	levofloxacin	drug	41-52	false

DDI-MedLine.d7.s0	Enhanced theophylline clearance secondary to phenytoin therapy.
theophylline	drug	9-20	phenytoin	drug	45-53	mechanism

DDI-MedLine.d7.s1	This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration.
theophylline	drug	41-52	phenytoin	drug	102-110	mechanism

DDI-MedLine.d7.s4	With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.
phenytoin	drug	52-60	theophylline	drug	157-168	effect

DDI-MedLine.d74.s2	To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM).
arginine	drug	216-223	glucose	drug	233-239	false
arginine	drug	216-223	theophylline	drug	275-286	false
glucose	drug	233-239	theophylline	drug	275-286	false

DDI-MedLine.d74.s4	Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals.
Glucose	drug	0-6	theophylline	drug	38-49	false

DDI-MedLine.d74.s5	Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics.
Arginine	drug	0-7	glucose	drug	29-35	false
Arginine	drug	0-7	theophylline	drug	41-52	false
glucose	drug	29-35	theophylline	drug	41-52	false

DDI-MedLine.d74.s6	Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals.
Arginine	drug	0-7	glucose	drug	28-34	false
Arginine	drug	0-7	theophylline	drug	39-50	false
glucose	drug	28-34	theophylline	drug	39-50	false

DDI-MedLine.d74.s11	Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.
theophylline	drug	108-119	glucose	drug	156-162	false

DDI-MedLine.d139.s0	[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports.
neuroleptics	group	50-61	neuroleptics	group	173-184	false

DDI-MedLine.d114.s1	The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
ruthenium red	drug_n	15-27	RR	drug_n	30-31	false
ruthenium red	drug_n	15-27	inositol 1,4,5-trisphosphate	drug_n	37-64	false
ruthenium red	drug_n	15-27	InsP(3)	drug_n	67-73	false
RR	drug_n	30-31	inositol 1,4,5-trisphosphate	drug_n	37-64	false
RR	drug_n	30-31	InsP(3)	drug_n	67-73	false
inositol 1,4,5-trisphosphate	drug_n	37-64	InsP(3)	drug_n	67-73	false

DDI-MedLine.d114.s3	Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.
InsP(3)	drug_n	14-20	RR	drug_n	36-37	effect

DDI-MedLine.d114.s4	Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses.
RR	drug_n	50-51	InsP(3)	drug_n	80-86	effect

DDI-MedLine.d114.s6	In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3)-induced responses.
RR	drug_n	57-58	InsP(3)	drug_n	77-83	false

DDI-MedLine.d114.s8	In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3)-mediated responses of megakaryocytes.
RR	drug_n	32-33	InsP(3)	drug_n	94-100	false

DDI-MedLine.d68.s0	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
cimetidine	drug	15-24	verografin	drug	52-61	false
cimetidine	drug	15-24	iodamide	drug	67-74	false
cimetidine	drug	15-24	cimetidine	drug	115-124	false
cimetidine	drug	15-24	verografine	drug	157-167	false
cimetidine	drug	15-24	iodamide	drug	173-180	false
verografin	drug	52-61	iodamide	drug	67-74	false
verografin	drug	52-61	cimetidine	drug	115-124	false
verografin	drug	52-61	verografine	drug	157-167	false
verografin	drug	52-61	iodamide	drug	173-180	false
iodamide	drug	67-74	cimetidine	drug	115-124	false
iodamide	drug	67-74	verografine	drug	157-167	false
iodamide	drug	67-74	iodamide	drug	173-180	false
cimetidine	drug	115-124	verografine	drug	157-167	mechanism
cimetidine	drug	115-124	iodamide	drug	173-180	mechanism
verografine	drug	157-167	iodamide	drug	173-180	false

DDI-MedLine.d68.s1	The higher verografine and iodamide excretion was due to their increased renal tubular secretion.
verografine	drug	11-21	iodamide	drug	27-34	false

DDI-MedLine.d68.s2	In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport.
cimetidine	drug	9-18	cardiotrast	drug	47-57	false

DDI-MedLine.d68.s3	Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.
cimetidine	drug	44-53	verografine	drug	58-68	false
cimetidine	drug	44-53	iodamide	drug	74-81	false
verografine	drug	58-68	iodamide	drug	74-81	false

DDI-MedLine.d90.s0	Interaction of gentamycin and atracurium in anaesthetised horses.
gentamycin	drug	15-24	atracurium	drug	30-39	int

DDI-MedLine.d90.s1	Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by atracurium infusion in 7 horses anaesthetised with halothane.
atracurium	drug	101-110	halothane	drug	152-160	false

DDI-MedLine.d90.s3	Atracurium was again given by infusion to maintain 40% twitch for a second hour, then 2 mg gentamycin/kg bwt were given i.v.
Atracurium	drug	0-9	gentamycin	drug	91-100	false

DDI-MedLine.d90.s7	Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03).
atracurium	drug	65-74	atracurium	drug	107-116	false
atracurium	drug	65-74	gentamycin	drug	123-132	false
atracurium	drug	107-116	gentamycin	drug	123-132	effect

DDI-MedLine.d90.s8	Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin.
atracurium	drug	72-81	atracurium	drug	114-123	false
atracurium	drug	72-81	gentamycin	drug	130-139	false
atracurium	drug	114-123	gentamycin	drug	130-139	effect

DDI-MedLine.d90.s9	At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin.
atracurium	drug	55-64	atracurium	drug	90-99	false
atracurium	drug	55-64	gentamycin	drug	106-115	false
atracurium	drug	90-99	gentamycin	drug	106-115	effect

DDI-MedLine.d90.s11	It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.
gentamycin	drug	32-41	atracurium	drug	85-94	effect

DDI-MedLine.d84.s0	Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.
Ganoderma lucidum extract	drug_n	26-50	antibiotics	group	87-97	false

DDI-MedLine.d84.s3	To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
GL	drug_n	60-61	antibiotics	group	82-92	false
GL	drug_n	60-61	ampicillin	drug	95-104	false
GL	drug_n	60-61	cefazolin	drug	107-115	false
GL	drug_n	60-61	oxytetracycline	drug	118-132	false
GL	drug_n	60-61	chloramphenicol	drug	138-152	false
antibiotics	group	82-92	ampicillin	drug	95-104	false
antibiotics	group	82-92	cefazolin	drug	107-115	false
antibiotics	group	82-92	oxytetracycline	drug	118-132	false
antibiotics	group	82-92	chloramphenicol	drug	138-152	false
ampicillin	drug	95-104	cefazolin	drug	107-115	false
ampicillin	drug	95-104	oxytetracycline	drug	118-132	false
ampicillin	drug	95-104	chloramphenicol	drug	138-152	false
cefazolin	drug	107-115	oxytetracycline	drug	118-132	false
cefazolin	drug	107-115	chloramphenicol	drug	138-152	false
oxytetracycline	drug	118-132	chloramphenicol	drug	138-152	false

DDI-MedLine.d84.s4	The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.
GL	drug_n	34-35	antibiotics	group	47-57	effect

DDI-MedLine.d84.s5	Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.
GL	drug_n	28-29	cefazolin	drug	49-57	effect

DDI-MedLine.d123.s2	Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains.
galangin	drug	35-42	vancomycin	drug	73-82	false

DDI-MedLine.d56.s0	Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.
ouabain	drug	15-21	palytoxin	drug_n	30-38	false

DDI-MedLine.d56.s1	Palytoxin (PTX), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens.
Palytoxin	drug_n	0-8	PTX	drug_n	11-13	false

DDI-MedLine.d56.s2	In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction;
ouabain	drug	19-25	PTX	drug_n	39-41	effect

DDI-MedLine.d56.s5	When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished.
ouabain	drug	5-11	phentolamine	drug	58-69	effect
ouabain	drug	5-11	PTX	drug_n	119-121	false
phentolamine	drug	58-69	PTX	drug_n	119-121	false

DDI-MedLine.d56.s8	Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release.
ouabain	drug	26-32	PTX	drug_n	68-70	effect

DDI-MedLine.d56.s10	The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain.
ouabain	drug	93-99	ouabain	drug	299-305	false

DDI-MedLine.d54.s2	Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol.
alcohol	drug	151-157	alcohol	drug	228-234	false

DDI-MedLine.d54.s3	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days.
ethanol	drug	110-116	physostigmine	drug	130-142	false
ethanol	drug	110-116	atropine	drug	159-166	false
physostigmine	drug	130-142	atropine	drug	159-166	false

DDI-MedLine.d54.s8	Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
Physostigmine	drug	0-12	alcohol	drug	62-68	effect
Physostigmine	drug	0-12	alcohol	drug	123-129	effect
alcohol	drug	62-68	alcohol	drug	123-129	false

DDI-MedLine.d54.s10	Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2.
Atropine	drug	0-7	alcohol	drug	46-52	false

DDI-MedLine.d51.s1	We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice.
caffeine	drug	63-70	theophylline	drug	73-84	false
caffeine	drug	63-70	8-phenyltheophylline	drug_n	87-106	false
caffeine	drug	63-70	8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	false
caffeine	drug	63-70	DPCPX	drug_n	149-153	false
theophylline	drug	73-84	8-phenyltheophylline	drug_n	87-106	false
theophylline	drug	73-84	8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	false
theophylline	drug	73-84	DPCPX	drug_n	149-153	false
8-phenyltheophylline	drug_n	87-106	8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	false
8-phenyltheophylline	drug_n	87-106	DPCPX	drug_n	149-153	false
8-cyclopentyl-1,3-dipropylxanthine	drug_n	113-146	DPCPX	drug_n	149-153	false

DDI-MedLine.d51.s3	The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.
theophylline	drug	26-37	CGS 21680	drug_n	73-81	effect
theophylline	drug	26-37	N6-cyclopentyladenosine	drug_n	120-142	false
theophylline	drug	26-37	CPA	drug_n	145-147	false
CGS 21680	drug_n	73-81	N6-cyclopentyladenosine	drug_n	120-142	false
CGS 21680	drug_n	73-81	CPA	drug_n	145-147	false
N6-cyclopentyladenosine	drug_n	120-142	CPA	drug_n	145-147	false

DDI-MedLine.d51.s4	However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA.
theophylline	drug	31-42	CGS21680	drug_n	74-81	effect
theophylline	drug	31-42	DPCPX	drug_n	142-146	false
theophylline	drug	31-42	CGS 21680	drug	200-208	false
theophylline	drug	31-42	CPA	drug_n	217-219	false
CGS21680	drug_n	74-81	DPCPX	drug_n	142-146	false
CGS21680	drug_n	74-81	CGS 21680	drug	200-208	false
CGS21680	drug_n	74-81	CPA	drug_n	217-219	false
DPCPX	drug_n	142-146	CGS 21680	drug	200-208	false
DPCPX	drug_n	142-146	CPA	drug_n	217-219	false
CGS 21680	drug	200-208	CPA	drug_n	217-219	false

DDI-MedLine.d46.s0	Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.
fluoxetine	drug	33-42	cisapride	drug	47-55	false

DDI-MedLine.d46.s1	STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men.
fluoxetine	drug	43-52	cisapride	drug	107-115	false

DDI-MedLine.d46.s9	and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52).
cisapride	drug	26-34	fluoxetine	drug	72-81	false

DDI-MedLine.d46.s13	Coadministration of fluoxetine significantly decreased cisapride plasma concentrations.
fluoxetine	drug	20-29	cisapride	drug	55-63	mechanism

DDI-MedLine.d46.s14	There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine.
cisapride	drug	96-104	fluoxetine	drug	120-129	false

DDI-MedLine.d46.s15	Cisapride was well tolerated when administered alone or with fluoxetine.
Cisapride	drug	0-8	fluoxetine	drug	61-70	false

DDI-MedLine.d46.s16	CONCLUSION: Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine.
Cisapride	drug	12-20	fluoxetine	drug	98-107	false

DDI-MedLine.d95.s4	Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats.
Resveratrol	drug_n	0-10	noradrenaline	drug	116-128	false
Resveratrol	drug_n	0-10	KCl	drug	148-150	false
noradrenaline	drug	116-128	KCl	drug	148-150	false

DDI-MedLine.d95.s6	However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves.
L-NAME	drug_n	9-14	reseveratrol	drug_n	70-81	false

DDI-MedLine.d95.s7	Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats.
Indomethacin	drug	0-11	resveratrol	drug_n	46-56	false

DDI-MedLine.d95.s8	In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium.
noradrenaline	drug	3-15	resveratrol	drug_n	78-88	false

DDI-MedLine.d95.s9	This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.
resveratrol	drug_n	54-64	resveratrol	drug_n	190-200	false

DDI-MedLine.d22.s2	By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone.
spermidine	drug_n	13-22	putrescine	drug_n	35-44	false

DDI-MedLine.d22.s3	Spermine, and to a lesser extent, spermidine, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction.
Spermine	drug	0-7	spermidine	drug_n	34-43	false

DDI-MedLine.d137.s0	Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.
Glucose	drug	0-6	insulin	drug	12-18	false

DDI-MedLine.d137.s1	AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation.
insulin	drug	40-46	glucose	drug	52-58	false

DDI-MedLine.d137.s9	Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions.
glucose	drug	24-30	insulin	drug	36-42	false
glucose	drug	24-30	somatostatin	drug	63-74	false
insulin	drug	36-42	somatostatin	drug	63-74	false

DDI-MedLine.d137.s10	CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation.
Glucose	drug	28-34	insulin	drug	40-46	false

DDI-MedLine.d44.s2	In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month.
etofibrate	drug	30-39	etofibrate	drug	401-410	false

DDI-MedLine.d44.s6	Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.
Etofibrate	drug	0-9	heparin	drug	44-50	effect

DDI-MedLine.d132.s0	The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
non-nucleoside reverse transcriptase inhibitors	group	22-68	antiretroviral	group	73-86	false

DDI-MedLine.d132.s1	The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
non-nucleoside reverse transcriptase inhibitor	group	27-72	NNRTI	group	75-79	false
non-nucleoside reverse transcriptase inhibitor	group	27-72	antiretroviral	group	101-114	false
non-nucleoside reverse transcriptase inhibitor	group	27-72	protease inhibitor	group	147-164	false
non-nucleoside reverse transcriptase inhibitor	group	27-72	PI	group	167-168	false
NNRTI	group	75-79	antiretroviral	group	101-114	false
NNRTI	group	75-79	protease inhibitor	group	147-164	false
NNRTI	group	75-79	PI	group	167-168	false
antiretroviral	group	101-114	protease inhibitor	group	147-164	false
antiretroviral	group	101-114	PI	group	167-168	false
protease inhibitor	group	147-164	PI	group	167-168	false

DDI-MedLine.d132.s2	NNRTI-based regimens may have several advantages over PI-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.
NNRTI	group	0-4	PI	group	54-55	false

DDI-MedLine.d132.s3	No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine).
efavirenz	drug	90-98	nevirapine	drug	101-110	false
efavirenz	drug	90-98	delavirdine	drug	115-125	false
nevirapine	drug	101-110	delavirdine	drug	115-125	false

DDI-MedLine.d132.s4	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.
efavirenz	drug	5-13	nevirapine	drug	19-28	false
efavirenz	drug	5-13	PI	group	76-77	false
efavirenz	drug	5-13	indinavir	drug	79-87	false
efavirenz	drug	5-13	nevirapine	drug	166-175	false
efavirenz	drug	5-13	efavirenz	drug	216-224	false
nevirapine	drug	19-28	PI	group	76-77	false
nevirapine	drug	19-28	indinavir	drug	79-87	false
nevirapine	drug	19-28	nevirapine	drug	166-175	false
nevirapine	drug	19-28	efavirenz	drug	216-224	false
PI	group	76-77	indinavir	drug	79-87	false
PI	group	76-77	nevirapine	drug	166-175	false
PI	group	76-77	efavirenz	drug	216-224	false
indinavir	drug	79-87	nevirapine	drug	166-175	false
indinavir	drug	79-87	efavirenz	drug	216-224	false
nevirapine	drug	166-175	efavirenz	drug	216-224	false

DDI-MedLine.d132.s5	A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir.
nevirapine	drug	38-47	PI	group	72-73	false
nevirapine	drug	38-47	nelfinavir	drug	75-84	false
PI	group	72-73	nelfinavir	drug	75-84	false

DDI-MedLine.d132.s6	Limited comparative data in patients with high viral loads treated with nevirapine- or delavirdine-based regimens currently exist.
nevirapine	drug	72-81	delavirdine	drug	87-97	false

DDI-MedLine.d132.s8	The superiority of efavirenz over indinavir-based regimens has been observed in comparative data in a subset of patients with high viral loads.
efavirenz	drug	19-27	indinavir	drug	34-42	false

DDI-MedLine.d132.s10	Efavirenz has demonstrated superiority over nelfinavir in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances.
Efavirenz	drug	0-8	nelfinavir	drug	44-53	false

DDI-MedLine.d118.s0	Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
Sirolimus	drug	0-8	rapamycin	drug	31-39	false

DDI-MedLine.d118.s2	Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.
Sirolimus	drug	0-8	immunosuppressants	group	37-54	false
Sirolimus	drug	0-8	sirolimus	drug	148-156	false
Sirolimus	drug	0-8	cyclosporine	drug	231-242	false
Sirolimus	drug	0-8	tacrolimus	drug	247-256	false
immunosuppressants	group	37-54	sirolimus	drug	148-156	false
immunosuppressants	group	37-54	cyclosporine	drug	231-242	false
immunosuppressants	group	37-54	tacrolimus	drug	247-256	false
sirolimus	drug	148-156	cyclosporine	drug	231-242	false
sirolimus	drug	148-156	tacrolimus	drug	247-256	false
cyclosporine	drug	231-242	tacrolimus	drug	247-256	false

DDI-MedLine.d118.s3	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
sirolimus	drug	97-105	cyclosporine	drug	128-139	false
sirolimus	drug	97-105	tacrolimus	drug	144-153	false
sirolimus	drug	97-105	cyclosporine	drug	249-260	false
sirolimus	drug	97-105	tacrolimus	drug	265-274	false
cyclosporine	drug	128-139	tacrolimus	drug	144-153	false
cyclosporine	drug	128-139	cyclosporine	drug	249-260	false
cyclosporine	drug	128-139	tacrolimus	drug	265-274	false
tacrolimus	drug	144-153	cyclosporine	drug	249-260	false
tacrolimus	drug	144-153	tacrolimus	drug	265-274	false
cyclosporine	drug	249-260	tacrolimus	drug	265-274	false

DDI-MedLine.d98.s0	Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital.
cocaine	drug	33-39	pentobarbital	drug	107-119	false

DDI-MedLine.d98.s1	Mice from the 20th generation of three lines divergently selected for response to pentobarbital-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine-induced behavioral sensitization.
pentobarbital	drug	82-94	cocaine	drug	225-231	false

DDI-MedLine.d69.s0	Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.
contortrostatin	drug_n	70-84	echistatin	drug_n	141-150	false
contortrostatin	drug_n	70-84	flavoridin	drug_n	156-165	false
echistatin	drug_n	141-150	flavoridin	drug_n	156-165	false

DDI-MedLine.d69.s1	The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells.
contortrostatin	drug_n	28-42	echistatin	drug_n	96-105	false
contortrostatin	drug_n	28-42	flavoridin	drug_n	111-120	false
echistatin	drug_n	96-105	flavoridin	drug_n	111-120	false

DDI-MedLine.d69.s3	Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously.
Echistatin	drug_n	0-9	contortrostatin	drug_n	118-132	effect

DDI-MedLine.d69.s5	Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells.
Flavoridin	drug_n	0-9	contortrostatin	drug_n	78-92	effect

DDI-MedLine.d97.s8	Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.
thiabendazole	drug	92-104	melarsoprol	drug	143-153	effect

DDI-MedLine.d97.s10	Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.
anti-helminthic	group	59-73	melarsoprol	drug	171-181	false

DDI-MedLine.d13.s7	On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts.
amphetamine	drug	69-79	heroin	drug_n	247-252	false

DDI-MedLine.d13.s8	However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.
alcohol	drug	32-38	amphetamine	drug	99-109	false
alcohol	drug	32-38	heroin	drug_n	114-119	false
amphetamine	drug	99-109	heroin	drug_n	114-119	false

DDI-MedLine.d19.s4	Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems.
anticonvulsant agents	group	50-70	phenobarbitone	drug	81-94	false
anticonvulsant agents	group	50-70	phenytoin	drug	100-108	false
phenobarbitone	drug	81-94	phenytoin	drug	100-108	false

DDI-MedLine.d3.s0	Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
amprenavir	drug	36-45	rifabutin	drug	51-59	false
amprenavir	drug	36-45	rifampin	drug	64-71	false
rifabutin	drug	51-59	rifampin	drug	64-71	false

DDI-MedLine.d3.s1	The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
amprenavir	drug	92-101	rifabutin	drug	117-125	false
amprenavir	drug	92-101	rifampin	drug	130-137	false
rifabutin	drug	117-125	rifampin	drug	130-137	false

DDI-MedLine.d3.s3	All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days.
amprenavir	drug	22-31	rifabutin	drug	123-131	false
amprenavir	drug	22-31	rifampin	drug	172-179	false
rifabutin	drug	123-131	rifampin	drug	172-179	false

DDI-MedLine.d3.s4	Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days.
amprenavir	drug	23-32	rifabutin	drug	39-47	false
amprenavir	drug	23-32	amprenavir	drug	84-93	false
amprenavir	drug	23-32	rifampin	drug	100-107	false
rifabutin	drug	39-47	amprenavir	drug	84-93	false
rifabutin	drug	39-47	rifampin	drug	100-107	false
amprenavir	drug	84-93	rifampin	drug	100-107	false

DDI-MedLine.d3.s5	Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.
amprenavir	drug	51-60	rifabutin	drug	63-71	false
amprenavir	drug	51-60	rifampin	drug	78-85	false
amprenavir	drug	51-60	25-O-desacetyl metabolites	drug_n	97-122	false
rifabutin	drug	63-71	rifampin	drug	78-85	false
rifabutin	drug	63-71	25-O-desacetyl metabolites	drug_n	97-122	false
rifampin	drug	78-85	25-O-desacetyl metabolites	drug_n	97-122	false

DDI-MedLine.d3.s6	Rifabutin did not significantly affect amprenavir's pharmacokinetics.
Rifabutin	drug	0-8	amprenavir	drug	39-48	false

DDI-MedLine.d3.s7	Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.
Amprenavir	drug	0-9	rifabutin	drug	89-97	mechanism
Amprenavir	drug	0-9	25-O-desacetylrifabutin	drug_n	131-153	mechanism
rifabutin	drug	89-97	25-O-desacetylrifabutin	drug_n	131-153	false

DDI-MedLine.d3.s8	Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics.
Rifampin	drug	0-7	amprenavir	drug	48-57	mechanism
Rifampin	drug	0-7	amprenavir	drug	71-80	false
Rifampin	drug	0-7	rifampin	drug	99-106	false
amprenavir	drug	48-57	amprenavir	drug	71-80	false
amprenavir	drug	48-57	rifampin	drug	99-106	false
amprenavir	drug	71-80	rifampin	drug	99-106	false

DDI-MedLine.d3.s10	The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively.
rifabutin	drug	42-50	rifampin	drug	56-63	false

DDI-MedLine.d3.s11	Amprenavir plus rifampin was well tolerated.
Amprenavir	drug	0-9	rifampin	drug	16-23	false

DDI-MedLine.d3.s12	Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy.
Amprenavir	drug	0-9	rifabutin	drug	16-24	effect

DDI-MedLine.d3.s13	Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated.
Rifampin	drug	0-7	amprenavir	drug	55-64	mechanism

DDI-MedLine.d3.s14	Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated.
Amprenavir	drug	0-9	rifabutin	drug	48-56	mechanism
Amprenavir	drug	0-9	25-O-desacetylrifabutin	drug_n	62-84	mechanism
rifabutin	drug	48-56	25-O-desacetylrifabutin	drug_n	62-84	false

DDI-MedLine.d3.s15	Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.
Amprenavir	drug	0-9	rifampin	drug	35-42	false
Amprenavir	drug	0-9	rifabutin	drug	48-56	false
rifampin	drug	35-42	rifabutin	drug	48-56	false

DDI-MedLine.d0.s0	The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
phenytoin	drug	27-35	quetiapine	drug	92-101	false

DDI-MedLine.d0.s1	Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.
Quetiapine fumarate	drug	0-18	Seroquel	brand	22-29	false
Quetiapine fumarate	drug	0-18	atypical antipsychotic	group	55-76	false
Seroquel	brand	22-29	atypical antipsychotic	group	55-76	false

DDI-MedLine.d0.s4	This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.
phenytoin	drug	71-79	quetiapine	drug	134-143	mechanism

DDI-MedLine.d79.s0	If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
indinavir	drug	23-31	IDV	drug	34-36	false
indinavir	drug	23-31	didanosine	drug	40-49	false
indinavir	drug	23-31	IDV	drug	67-69	false
IDV	drug	34-36	didanosine	drug	40-49	false
IDV	drug	34-36	IDV	drug	67-69	false
didanosine	drug	40-49	IDV	drug	67-69	false

DDI-MedLine.d79.s1	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.
indinavir	drug	29-37	didanosine	drug	43-52	mechanism
indinavir	drug	29-37	indinavir	drug	101-109	false
indinavir	drug	29-37	didanosine	drug	145-154	false
indinavir	drug	29-37	indinavir	drug	171-179	false
didanosine	drug	43-52	indinavir	drug	101-109	false
didanosine	drug	43-52	didanosine	drug	145-154	false
didanosine	drug	43-52	indinavir	drug	171-179	false
indinavir	drug	101-109	didanosine	drug	145-154	false
indinavir	drug	101-109	indinavir	drug	171-179	false
didanosine	drug	145-154	indinavir	drug	171-179	false

DDI-MedLine.d79.s2	We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration.
indinavir	drug	12-20	indinavir	drug	127-135	false
indinavir	drug	12-20	indinavir	drug	160-168	false
indinavir	drug	12-20	didanosine	drug	193-202	false
indinavir	drug	127-135	indinavir	drug	160-168	false
indinavir	drug	127-135	didanosine	drug	193-202	false
indinavir	drug	160-168	didanosine	drug	193-202	false

DDI-MedLine.d79.s3	Median gastric pH was significantly higher when indinavir was taken after didanosine administration;
indinavir	drug	48-56	didanosine	drug	74-83	mechanism

DDI-MedLine.d79.s5	Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.
Indinavir	drug	0-8	didanosine	drug	87-96	advise

DDI-MedLine.d21.s2	Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents.
antidepressant drugs	group	15-34	hypoglycemic agents	group	106-124	int

DDI-MedLine.d21.s6	Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.
Imipramine	drug	0-9	moclobemide	drug	22-32	false
Imipramine	drug	0-9	clonazepam	drug	46-55	false
Imipramine	drug	0-9	fluoxetine	drug	71-80	false
Imipramine	drug	0-9	sertraline	drug	93-102	false
moclobemide	drug	22-32	clonazepam	drug	46-55	false
moclobemide	drug	22-32	fluoxetine	drug	71-80	false
moclobemide	drug	22-32	sertraline	drug	93-102	false
clonazepam	drug	46-55	fluoxetine	drug	71-80	false
clonazepam	drug	46-55	sertraline	drug	93-102	false
fluoxetine	drug	71-80	sertraline	drug	93-102	false

DDI-MedLine.d21.s8	An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min.
glucose	drug	8-14	glucose	drug	42-48	false

DDI-MedLine.d21.s9	Imipramine and clonazepam did not change fasting or overload glycemia.
Imipramine	drug	0-9	clonazepam	drug	15-24	false

DDI-MedLine.d21.s10	Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload.
Fluoxetine	drug	0-9	moclobemide	drug	15-25	false
Fluoxetine	drug	0-9	glucose	drug	43-49	false
moclobemide	drug	15-25	glucose	drug	43-49	false

DDI-MedLine.d21.s11	Sertraline neutralized the increase of glycemia induced by oral glucose overload.
Sertraline	drug	0-9	glucose	drug	64-70	false

DDI-MedLine.d21.s12	In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload.
glucose	drug	149-155	glucose	drug	180-186	false

DDI-MedLine.d21.s13	Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats.
sertraline	drug	7-16	glucose	drug	61-67	false

DDI-MedLine.d75.s3	The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not <
mu-selective opioids	group	44-46;70-86	delta(1)-selective opioids	group	49-57;70-86	false
mu-selective opioids	group	44-46;70-86	kappa-selective opioids	group	64-86	false
delta(1)-selective opioids	group	49-57;70-86	kappa-selective opioids	group	64-86	false

DDI-MedLine.d89.s0	Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
99mTc-methylene diphosphonate	drug	71-99	gentamicin	drug	107-116	effect

DDI-MedLine.d89.s1	Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys.
Gentamicin	drug	0-9	aminoglycoside antibiotic	group	17-41	false

DDI-MedLine.d89.s2	Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy.
gentamicin	drug	27-36	99mTc-MDP	drug	84-92	mechanism

DDI-MedLine.d89.s7	Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients.
gentamicin	drug	37-46	99mTc-MDP	drug	89-97	false
gentamicin	drug	37-46	radiopharmaceutical	group	106-124	false
99mTc-MDP	drug	89-97	radiopharmaceutical	group	106-124	false

DDI-MedLine.d89.s8	The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.
gentamicin	drug	79-88	gentamicin	drug	127-136	false

DDI-MedLine.d11.s4	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
immunosuppressive drugs	group	41-63	corticosteroids	group	74-88	false
immunosuppressive drugs	group	41-63	cyclosporin	drug	91-101	false
immunosuppressive drugs	group	41-63	azathioprine	drug	104-115	false
immunosuppressive drugs	group	41-63	methotrexate	drug	118-129	false
immunosuppressive drugs	group	41-63	cyclophosphamide	drug	132-147	false
corticosteroids	group	74-88	cyclosporin	drug	91-101	false
corticosteroids	group	74-88	azathioprine	drug	104-115	false
corticosteroids	group	74-88	methotrexate	drug	118-129	false
corticosteroids	group	74-88	cyclophosphamide	drug	132-147	false
cyclosporin	drug	91-101	azathioprine	drug	104-115	false
cyclosporin	drug	91-101	methotrexate	drug	118-129	false
cyclosporin	drug	91-101	cyclophosphamide	drug	132-147	false
azathioprine	drug	104-115	methotrexate	drug	118-129	false
azathioprine	drug	104-115	cyclophosphamide	drug	132-147	false
methotrexate	drug	118-129	cyclophosphamide	drug	132-147	false

DDI-MedLine.d28.s7	The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers"
thiazolidinediones	group	4-21	rosiglitazone	drug	24-36	false
thiazolidinediones	group	4-21	pioglitazone	drug	42-53	false
thiazolidinediones	group	4-21	antidiabetic agents	group	77-95	false
rosiglitazone	drug	24-36	pioglitazone	drug	42-53	false
rosiglitazone	drug	24-36	antidiabetic agents	group	77-95	false
pioglitazone	drug	42-53	antidiabetic agents	group	77-95	false

DDI-MedLine.d82.s1	The intestinal absorption of arsenate(As(V)) has been investigated in the chick by means of the in situ ligated duodenal loop technique.
arsenate	drug_n	29-36	As(V)	drug_n	38-42	false

DDI-MedLine.d82.s2	By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM.
arsenate	drug_n	40-47	As(V)	drug_n	123-127	false

DDI-MedLine.d82.s4	At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines.
As(V)	drug_n	10-14	As(V)	drug_n	90-94	false

DDI-MedLine.d82.s5	However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V).
As(V)	drug_n	39-43	As(V)	drug_n	137-141	false

DDI-MedLine.d82.s7	Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level.
arsenate	drug_n	13-20	phosphate	drug	26-34	false

DDI-MedLine.d82.s8	Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.
Vitamin D3	drug	0-9	arsenate	drug_n	95-102	mechanism

DDI-MedLine.d17.s0	In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
prostaglandin F2alpha	drug	24-44	oxytocin	drug	50-57	int

DDI-MedLine.d17.s1	The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro.
prostaglandin F2alpha	drug	19-39	oxytocin	drug	55-62	false

DDI-MedLine.d17.s3	In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha.
norepinephrine	drug	34-47	oxytocin	drug	53-60	false
norepinephrine	drug	34-47	PGF2alpha	drug	67-75	false
oxytocin	drug	53-60	PGF2alpha	drug	67-75	false

DDI-MedLine.d17.s4	PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin.
PGF2alpha	drug	0-8	oxytocin	drug	93-100	effect

DDI-MedLine.d17.s9	There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.
PGF2alpha	drug	39-47	oxytocin	drug	91-98	effect

DDI-MedLine.d34.s0	Interactions of cobalt and iron in absorption and retention.
cobalt	drug	16-21	iron	drug	27-30	mechanism

DDI-MedLine.d34.s1	The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats.
cobalt	drug	34-39	iron	drug	45-48	false
cobalt	drug	34-39	Co	drug	271-272	false
cobalt	drug	34-39	Fe	drug	297-298	false
iron	drug	45-48	Co	drug	271-272	false
iron	drug	45-48	Fe	drug	297-298	false
Co	drug	271-272	Fe	drug	297-298	false

DDI-MedLine.d34.s4	Cobalt excretion was enhanced by supplementary cobalt;
Cobalt	drug	0-5	cobalt	drug	47-52	false

DDI-MedLine.d34.s7	Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
iron	drug	11-14	cobalt	drug	58-63	mechanism
iron	drug	11-14	cobalt	drug	81-86	mechanism
cobalt	drug	58-63	cobalt	drug	81-86	false

DDI-MedLine.d34.s8	The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt.
Fe	drug	60-61	Fe	drug	83-84	false
Fe	drug	60-61	cobalt	drug	141-146	mechanism
Fe	drug	83-84	cobalt	drug	141-146	false

DDI-MedLine.d34.s9	Consequently, the effect of iron on the retention of cobalt was lower than on absorption.
iron	drug	28-31	cobalt	drug	53-58	mechanism

DDI-MedLine.d34.s11	Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred.
cobalt	drug	27-32	iron	drug	67-70	false
cobalt	drug	27-32	cobalt	drug	108-113	false
cobalt	drug	27-32	iron	drug	118-121	false
iron	drug	67-70	cobalt	drug	108-113	false
iron	drug	67-70	iron	drug	118-121	false
cobalt	drug	108-113	iron	drug	118-121	false

DDI-MedLine.d34.s12	Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)
iron	drug	15-18	Fe	drug	189-190	false

DDI-MedLine.d119.s1	Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986.
Fluvastatin	drug	0-10	synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor	group	25-100	false

DDI-MedLine.d119.s2	It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.
HMGCoA reductase inhibitors	group	63-89	lovastatin	drug	92-101	false
HMGCoA reductase inhibitors	group	63-89	simvastatin	drug	104-114	false
HMGCoA reductase inhibitors	group	63-89	pravastatin	drug	121-131	false
lovastatin	drug	92-101	simvastatin	drug	104-114	false
lovastatin	drug	92-101	pravastatin	drug	121-131	false
simvastatin	drug	104-114	pravastatin	drug	121-131	false

DDI-MedLine.d119.s15	Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability.
Cholestyramine	drug	0-13	fluvastatin	drug	103-113	mechanism

DDI-MedLine.d119.s16	Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy.
cholestyramine	drug	41-54	fluvastatin	drug	83-93	effect

DDI-MedLine.d119.s17	Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin.
warfarin	drug	30-37	warfarin	drug	132-139	false
warfarin	drug	30-37	fluvastatin	drug	145-155	false
warfarin	drug	132-139	fluvastatin	drug	145-155	false

DDI-MedLine.d119.s18	Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.
niacin	drug	46-51	propranolol	drug	57-67	false
niacin	drug	46-51	fluvastatin	drug	105-115	false
niacin	drug	46-51	digoxin	drug	197-203	false
niacin	drug	46-51	digoxin	drug	267-273	false
propranolol	drug	57-67	fluvastatin	drug	105-115	false
propranolol	drug	57-67	digoxin	drug	197-203	false
propranolol	drug	57-67	digoxin	drug	267-273	false
fluvastatin	drug	105-115	digoxin	drug	197-203	false
fluvastatin	drug	105-115	digoxin	drug	267-273	false
digoxin	drug	197-203	digoxin	drug	267-273	false

DDI-MedLine.d110.s0	18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
18-Methoxycoronaridine	drug_n	0-21	18-MC	drug_n	24-28	false
18-Methoxycoronaridine	drug_n	0-21	ibogaine	drug_n	35-42	false
18-MC	drug_n	24-28	ibogaine	drug_n	35-42	false

DDI-MedLine.d110.s2	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;
ibogaine	drug_n	5-12	18-MC	drug_n	26-30	false
ibogaine	drug_n	5-12	morphine	drug	92-99	false
ibogaine	drug_n	5-12	cocaine	drug	105-111	false
ibogaine	drug_n	5-12	ethanol	drug	149-155	false
ibogaine	drug_n	5-12	nicotine	drug	161-168	false
18-MC	drug_n	26-30	morphine	drug	92-99	false
18-MC	drug_n	26-30	cocaine	drug	105-111	false
18-MC	drug_n	26-30	ethanol	drug	149-155	false
18-MC	drug_n	26-30	nicotine	drug	161-168	false
morphine	drug	92-99	cocaine	drug	105-111	false
morphine	drug	92-99	ethanol	drug	149-155	false
morphine	drug	92-99	nicotine	drug	161-168	false
cocaine	drug	105-111	ethanol	drug	149-155	false
cocaine	drug	105-111	nicotine	drug	161-168	false
ethanol	drug	149-155	nicotine	drug	161-168	false

DDI-MedLine.d110.s3	unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water).
ibogaine	drug_n	7-14	18-MC	drug_n	17-21	false

DDI-MedLine.d110.s4	Both ibogaine and 18-MC ameliorate opioid withdrawal signs.
ibogaine	drug_n	5-12	18-MC	drug_n	18-22	false
ibogaine	drug_n	5-12	opioid	group	35-40	false
18-MC	drug_n	18-22	opioid	group	35-40	false

DDI-MedLine.d110.s5	Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens.
ibogaine	drug_n	5-12	18-MC	drug_n	18-22	false
ibogaine	drug_n	5-12	ibogaine	drug_n	101-108	false
18-MC	drug_n	18-22	ibogaine	drug_n	101-108	false

DDI-MedLine.d110.s6	Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
ibogaine	drug_n	5-12	18-MC	drug_n	18-22	false
ibogaine	drug_n	5-12	morphine	drug	30-37	effect
ibogaine	drug_n	5-12	nicotine	drug	51-58	effect
18-MC	drug_n	18-22	morphine	drug	30-37	effect
18-MC	drug_n	18-22	nicotine	drug	51-58	effect
morphine	drug	30-37	nicotine	drug	51-58	false

DDI-MedLine.d110.s7	only ibogaine enhances cocaine-induced increases in accumbal dopamine.
ibogaine	drug_n	5-12	cocaine	drug	23-29	effect

DDI-MedLine.d110.s8	Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants.
ibogaine	drug_n	5-12	18-MC	drug_n	18-22	false

DDI-MedLine.d110.s9	Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine;
Ibogaine	drug_n	0-7	18-MC	drug_n	25-29	false
Ibogaine	drug_n	0-7	morphine	drug	75-82	effect
18-MC	drug_n	25-29	morphine	drug	75-82	effect

DDI-MedLine.d110.s10	both compounds attenuate morphine-induced locomotion in morphine-experienced rats.
morphine	drug	25-32	morphine	drug	56-63	false

DDI-MedLine.d110.s13	Ibogaine, but not 18-MC, decreases heart rate at high doses.
Ibogaine	drug_n	0-7	18-MC	drug_n	18-22	false

DDI-MedLine.d110.s14	While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.
18-MC	drug_n	6-10	ibogaine	drug_n	16-23	false
18-MC	drug_n	6-10	18-MC	drug_n	100-104	false
18-MC	drug_n	6-10	ibogaine	drug_n	137-144	false
ibogaine	drug_n	16-23	18-MC	drug_n	100-104	false
ibogaine	drug_n	16-23	ibogaine	drug_n	137-144	false
18-MC	drug_n	100-104	ibogaine	drug_n	137-144	false

DDI-MedLine.d110.s15	Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite.
18-MC	drug_n	5-9	ibogaine	drug_n	15-22	false
18-MC	drug_n	5-9	ibogaine	drug_n	57-64	false
18-MC	drug_n	5-9	18-MC	drug_n	67-71	false
ibogaine	drug_n	15-22	ibogaine	drug_n	57-64	false
ibogaine	drug_n	15-22	18-MC	drug_n	67-71	false
ibogaine	drug_n	57-64	18-MC	drug_n	67-71	false

DDI-MedLine.d110.s16	The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.
18-MC	drug_n	22-26	ibogaine	drug_n	124-131	false

DDI-MedLine.d47.s0	Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
buforin II	drug_n	12-21	azithromycin	drug	53-64	false
buforin II	drug_n	12-21	minocycline	drug	70-80	false
azithromycin	drug	53-64	minocycline	drug	70-80	false

DDI-MedLine.d47.s1	The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated.
buforin II	drug_n	46-55	azithromycin	drug	87-98	false
buforin II	drug_n	46-55	minocycline	drug	104-114	false
azithromycin	drug	87-98	minocycline	drug	104-114	false

DDI-MedLine.d47.s3	Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested.
azithromycin	drug	69-80	minocycline	drug	85-95	false

DDI-MedLine.d47.s4	Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.
Buforin II	drug_n	0-9	azithromycin	drug	107-118	effect
Buforin II	drug_n	0-9	minocycline	drug	123-133	effect
azithromycin	drug	107-118	minocycline	drug	123-133	false

DDI-MedLine.d131.s0	Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
neurotensin	drug_n	50-60	enkephalins	drug_n	66-76	effect
neurotensin	drug_n	50-60	tuftsin	drug_n	81-87	effect
enkephalins	drug_n	66-76	tuftsin	drug_n	81-87	false

DDI-MedLine.d131.s1	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
neurotensin	drug_n	59-69	enkephalins	drug_n	80-90	false
neurotensin	drug_n	59-69	D-Ala2-metenkephalinamide	drug_n	118-142	false
neurotensin	drug_n	59-69	tuftsin	drug_n	148-154	false
enkephalins	drug_n	80-90	D-Ala2-metenkephalinamide	drug_n	118-142	false
enkephalins	drug_n	80-90	tuftsin	drug_n	148-154	false
D-Ala2-metenkephalinamide	drug_n	118-142	tuftsin	drug_n	148-154	false

DDI-MedLine.d131.s3	It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue.
neurotensin	drug_n	18-28	enkephalins	drug_n	82-92	effect

DDI-MedLine.d131.s4	On the contrary, neurotensin and tuftsin were agonists in induction of analgesia.
neurotensin	drug_n	17-27	tuftsin	drug_n	33-39	effect

DDI-MedLine.d131.s5	It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.
neurotensin	drug_n	21-31	tuftsin	drug_n	132-138	effect

DDI-MedLine.d105.s0	Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.
azithromycin	drug	21-32	zidovudine	drug	56-65	false
azithromycin	drug	21-32	dideoxyinosine	drug	71-84	false
zidovudine	drug	56-65	dideoxyinosine	drug	71-84	false

DDI-MedLine.d105.s1	Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine.
azithromycin	drug	80-91	zidovudine	drug	110-119	false
azithromycin	drug	80-91	dideoxyinosine	drug	125-138	false
zidovudine	drug	110-119	dideoxyinosine	drug	125-138	false

DDI-MedLine.d105.s3	The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.
zidovudine	drug	4-13	azithromycin	drug	56-67	false
zidovudine	drug	4-13	zidovudine	drug	180-189	false
azithromycin	drug	56-67	zidovudine	drug	180-189	false

DDI-MedLine.d105.s4	Subjects treated with 200 mg of dideoxyinosine twice daily for 21 days received 1200 mg of azithromycin or an equivalent amount of placebo/day for Days 8 to 21.
dideoxyinosine	drug	32-45	azithromycin	drug	91-102	false

DDI-MedLine.d105.s5	Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine.
Antiretroviral	group	0-13	zidovudine	drug	81-90	false
Antiretroviral	group	0-13	dideoxyinosine	drug	117-130	false
zidovudine	drug	81-90	dideoxyinosine	drug	117-130	false

DDI-MedLine.d105.s7	Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
Azithromycin	drug	0-11	zidovudine	drug	62-71	false
Azithromycin	drug	0-11	zidovudine	drug	114-123	mechanism
Azithromycin	drug	0-11	zidovudine	drug	196-205	mechanism
zidovudine	drug	62-71	zidovudine	drug	114-123	false
zidovudine	drug	62-71	zidovudine	drug	196-205	false
zidovudine	drug	114-123	zidovudine	drug	196-205	false

DDI-MedLine.d105.s8	Azithromycin had no significant effect on dideoxyinosine pharmacokinetics.
Azithromycin	drug	0-11	dideoxyinosine	drug	42-55	false

DDI-MedLine.d105.s9	Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.
azithromycin	drug	60-71	zidovudine	drug	112-121	false
azithromycin	drug	60-71	dideoxyinosine	drug	127-140	false
zidovudine	drug	112-121	dideoxyinosine	drug	127-140	false

DDI-MedLine.d115.s0	Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
cyclophosphamide	drug	12-27	doxorubicin	drug	30-40	false
cyclophosphamide	drug	12-27	vincristine	drug	43-53	false
cyclophosphamide	drug	12-27	prednisone	drug	60-69	false
cyclophosphamide	drug	12-27	highly active antiretroviral	group	89-116	false
doxorubicin	drug	30-40	vincristine	drug	43-53	false
doxorubicin	drug	30-40	prednisone	drug	60-69	false
doxorubicin	drug	30-40	highly active antiretroviral	group	89-116	false
vincristine	drug	43-53	prednisone	drug	60-69	false
vincristine	drug	43-53	highly active antiretroviral	group	89-116	false
prednisone	drug	60-69	highly active antiretroviral	group	89-116	false

DDI-MedLine.d115.s2	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.
cyclophosphamide	drug	244-259	doxorubicin	drug	262-272	false
cyclophosphamide	drug	244-259	vincristine	drug	275-285	false
cyclophosphamide	drug	244-259	prednisone	drug	292-301	false
cyclophosphamide	drug	244-259	cyclophosphamide	drug	440-455	false
cyclophosphamide	drug	244-259	doxorubicin	drug	458-468	false
cyclophosphamide	drug	244-259	teniposide	drug	471-480	false
cyclophosphamide	drug	244-259	prednisone	drug	487-496	false
cyclophosphamide	drug	244-259	vincristine	drug	503-513	false
cyclophosphamide	drug	244-259	bleomycin	drug	520-528	false
cyclophosphamide	drug	244-259	antiretroviral	group	549-562	false
doxorubicin	drug	262-272	vincristine	drug	275-285	false
doxorubicin	drug	262-272	prednisone	drug	292-301	false
doxorubicin	drug	262-272	cyclophosphamide	drug	440-455	false
doxorubicin	drug	262-272	doxorubicin	drug	458-468	false
doxorubicin	drug	262-272	teniposide	drug	471-480	false
doxorubicin	drug	262-272	prednisone	drug	487-496	false
doxorubicin	drug	262-272	vincristine	drug	503-513	false
doxorubicin	drug	262-272	bleomycin	drug	520-528	false
doxorubicin	drug	262-272	antiretroviral	group	549-562	false
vincristine	drug	275-285	prednisone	drug	292-301	false
vincristine	drug	275-285	cyclophosphamide	drug	440-455	false
vincristine	drug	275-285	doxorubicin	drug	458-468	false
vincristine	drug	275-285	teniposide	drug	471-480	false
vincristine	drug	275-285	prednisone	drug	487-496	false
vincristine	drug	275-285	vincristine	drug	503-513	false
vincristine	drug	275-285	bleomycin	drug	520-528	false
vincristine	drug	275-285	antiretroviral	group	549-562	false
prednisone	drug	292-301	cyclophosphamide	drug	440-455	false
prednisone	drug	292-301	doxorubicin	drug	458-468	false
prednisone	drug	292-301	teniposide	drug	471-480	false
prednisone	drug	292-301	prednisone	drug	487-496	false
prednisone	drug	292-301	vincristine	drug	503-513	false
prednisone	drug	292-301	bleomycin	drug	520-528	false
prednisone	drug	292-301	antiretroviral	group	549-562	false
cyclophosphamide	drug	440-455	doxorubicin	drug	458-468	false
cyclophosphamide	drug	440-455	teniposide	drug	471-480	false
cyclophosphamide	drug	440-455	prednisone	drug	487-496	false
cyclophosphamide	drug	440-455	vincristine	drug	503-513	false
cyclophosphamide	drug	440-455	bleomycin	drug	520-528	false
cyclophosphamide	drug	440-455	antiretroviral	group	549-562	false
doxorubicin	drug	458-468	teniposide	drug	471-480	false
doxorubicin	drug	458-468	prednisone	drug	487-496	false
doxorubicin	drug	458-468	vincristine	drug	503-513	false
doxorubicin	drug	458-468	bleomycin	drug	520-528	false
doxorubicin	drug	458-468	antiretroviral	group	549-562	false
teniposide	drug	471-480	prednisone	drug	487-496	false
teniposide	drug	471-480	vincristine	drug	503-513	false
teniposide	drug	471-480	bleomycin	drug	520-528	false
teniposide	drug	471-480	antiretroviral	group	549-562	false
prednisone	drug	487-496	vincristine	drug	503-513	false
prednisone	drug	487-496	bleomycin	drug	520-528	false
prednisone	drug	487-496	antiretroviral	group	549-562	false
vincristine	drug	503-513	bleomycin	drug	520-528	false
vincristine	drug	503-513	antiretroviral	group	549-562	false
bleomycin	drug	520-528	antiretroviral	group	549-562	false

DDI-MedLine.d115.s5	Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor.
Antiretroviral	group	0-13	reverse transcriptase inhibitors	group	41-72	false
Antiretroviral	group	0-13	protease inhibitor	group	82-99	false
reverse transcriptase inhibitors	group	41-72	protease inhibitor	group	82-99	false

DDI-MedLine.d115.s14	However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs.
antiretroviral drugs	group	112-125;146-150	antineoplastic drugs	group	131-150	advise

DDI-MedLine.d76.s1	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.
sodium carboxymethylcellulose	drug_n	56-84	NaCMC	drug_n	87-91	false
sodium carboxymethylcellulose	drug_n	56-84	carboxymethylcellulose-cysteine	drug_n	98-128	false
sodium carboxymethylcellulose	drug_n	56-84	CMC-Cys	drug_n	131-137	false
sodium carboxymethylcellulose	drug_n	56-84	sodium fluorescein	drug	183-200	false
sodium carboxymethylcellulose	drug_n	56-84	NaFlu	drug	203-207	false
sodium carboxymethylcellulose	drug_n	56-84	bacitracin	drug	235-244	false
sodium carboxymethylcellulose	drug_n	56-84	insulin	drug	250-256	false
NaCMC	drug_n	87-91	carboxymethylcellulose-cysteine	drug_n	98-128	false
NaCMC	drug_n	87-91	CMC-Cys	drug_n	131-137	false
NaCMC	drug_n	87-91	sodium fluorescein	drug	183-200	false
NaCMC	drug_n	87-91	NaFlu	drug	203-207	false
NaCMC	drug_n	87-91	bacitracin	drug	235-244	false
NaCMC	drug_n	87-91	insulin	drug	250-256	false
carboxymethylcellulose-cysteine	drug_n	98-128	CMC-Cys	drug_n	131-137	false
carboxymethylcellulose-cysteine	drug_n	98-128	sodium fluorescein	drug	183-200	false
carboxymethylcellulose-cysteine	drug_n	98-128	NaFlu	drug	203-207	false
carboxymethylcellulose-cysteine	drug_n	98-128	bacitracin	drug	235-244	false
carboxymethylcellulose-cysteine	drug_n	98-128	insulin	drug	250-256	false
CMC-Cys	drug_n	131-137	sodium fluorescein	drug	183-200	false
CMC-Cys	drug_n	131-137	NaFlu	drug	203-207	false
CMC-Cys	drug_n	131-137	bacitracin	drug	235-244	false
CMC-Cys	drug_n	131-137	insulin	drug	250-256	false
sodium fluorescein	drug	183-200	NaFlu	drug	203-207	false
sodium fluorescein	drug	183-200	bacitracin	drug	235-244	false
sodium fluorescein	drug	183-200	insulin	drug	250-256	false
NaFlu	drug	203-207	bacitracin	drug	235-244	false
NaFlu	drug	203-207	insulin	drug	250-256	false
bacitracin	drug	235-244	insulin	drug	250-256	false

DDI-MedLine.d76.s2	Cysteine was covalently linked to carbodiimide activated NaCMC.
Cysteine	drug	0-7	NaCMC	drug_n	57-61	false

DDI-MedLine.d76.s5	Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation.
NaCMC	drug_n	11-15	NaFlu	drug	108-112	false
NaCMC	drug_n	11-15	NaCMC	drug_n	134-138	false
NaCMC	drug_n	11-15	cysteine	drug	156-163	false
NaFlu	drug	108-112	NaCMC	drug_n	134-138	false
NaFlu	drug	108-112	cysteine	drug	156-163	false
NaCMC	drug_n	134-138	cysteine	drug	156-163	false

DDI-MedLine.d76.s7	Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2.
CMC-Cys	drug_n	32-38	cysteine	drug	78-85	false
CMC-Cys	drug_n	32-38	NaFlu	drug	153-157	false
cysteine	drug	78-85	NaFlu	drug	153-157	false

DDI-MedLine.d76.s8	NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone.
NaCMC	drug_n	0-4	cysteine	drug	42-49	false
NaCMC	drug_n	0-4	NaFlu	drug	95-99	false
NaCMC	drug_n	0-4	NaCMC	drug_n	113-117	false
cysteine	drug	42-49	NaFlu	drug	95-99	false
cysteine	drug	42-49	NaCMC	drug_n	113-117	false
NaFlu	drug	95-99	NaCMC	drug_n	113-117	false

DDI-MedLine.d76.s9	Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3).
bacitracin	drug	37-46	insulin	drug	52-58	false
bacitracin	drug	37-46	NaCMC	drug_n	76-80	false
bacitracin	drug	37-46	CMC-Cys	drug_n	173-179	false
insulin	drug	52-58	NaCMC	drug_n	76-80	false
insulin	drug	52-58	CMC-Cys	drug_n	173-179	false
NaCMC	drug_n	76-80	CMC-Cys	drug_n	173-179	false

DDI-MedLine.d76.s10	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
NaCMC	drug_n	15-19	cysteine	drug	26-33	false
NaCMC	drug_n	15-19	NaFlu	drug	121-125	false
NaCMC	drug_n	15-19	bacitracin	drug	155-164	false
NaCMC	drug_n	15-19	insulin	drug	170-176	false
cysteine	drug	26-33	NaFlu	drug	121-125	false
cysteine	drug	26-33	bacitracin	drug	155-164	false
cysteine	drug	26-33	insulin	drug	170-176	false
NaFlu	drug	121-125	bacitracin	drug	155-164	false
NaFlu	drug	121-125	insulin	drug	170-176	false
bacitracin	drug	155-164	insulin	drug	170-176	false

DDI-MedLine.d48.s3	Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A.
Diethyl pyrocarbonate	drug_n	0-20	toxin A	drug_n	94-100	false

DDI-MedLine.d48.s4	Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel.
toxin A	drug_n	16-22	diethyl pyrocarbonate	drug_n	29-49	false

DDI-MedLine.d48.s5	Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules.
toxin A	drug_n	13-19	diethyl pyrocarbonate	drug_n	34-54	false

DDI-MedLine.d48.s6	The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment.
diethyl pyrocarbonate	drug_n	15-35	hydroxylamine	drug_n	58-70	false

DDI-MedLine.d48.s11	Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.
toxin A	drug_n	22-28	zinc	drug	48-51	false
toxin A	drug_n	22-28	toxin A	drug_n	150-156	false
toxin A	drug_n	22-28	zinc	drug	164-167	false
zinc	drug	48-51	toxin A	drug_n	150-156	false
zinc	drug	48-51	zinc	drug	164-167	false
toxin A	drug_n	150-156	zinc	drug	164-167	false

DDI-MedLine.d67.s0	Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.
diazepam	drug	10-17	midazolam	drug	23-31	false
diazepam	drug	10-17	morphine	drug	66-73	false
diazepam	drug	10-17	metamizol	drug	76-84	false
diazepam	drug	10-17	indomethacin	drug	90-101	false
midazolam	drug	23-31	morphine	drug	66-73	false
midazolam	drug	23-31	metamizol	drug	76-84	false
midazolam	drug	23-31	indomethacin	drug	90-101	false
morphine	drug	66-73	metamizol	drug	76-84	false
morphine	drug	66-73	indomethacin	drug	90-101	false
metamizol	drug	76-84	indomethacin	drug	90-101	false

DDI-MedLine.d67.s1	The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
midazolam	drug	17-25	diazepam	drug	31-38	false
midazolam	drug	17-25	morphine	drug	69-76	false
midazolam	drug	17-25	metamizol	drug	90-98	false
midazolam	drug	17-25	indomethacin	drug	116-127	false
diazepam	drug	31-38	morphine	drug	69-76	false
diazepam	drug	31-38	metamizol	drug	90-98	false
diazepam	drug	31-38	indomethacin	drug	116-127	false
morphine	drug	69-76	metamizol	drug	90-98	false
morphine	drug	69-76	indomethacin	drug	116-127	false
metamizol	drug	90-98	indomethacin	drug	116-127	false

DDI-MedLine.d67.s3	Benzodiazepines were administered to mice 30 min before applying the analgesic drugs.
Benzodiazepines	group	0-14	analgesic drugs	group	69-83	false

DDI-MedLine.d67.s5	Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine.
Diazepam	drug	0-7	morphine	drug	60-67	effect
Diazepam	drug	0-7	morphine	drug	121-128	false
morphine	drug	60-67	morphine	drug	121-128	false

DDI-MedLine.d67.s6	Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin.
diazepam	drug	11-18	metamizol	drug	60-68	effect
diazepam	drug	11-18	indomethacin	drug	104-115	effect
metamizol	drug	60-68	indomethacin	drug	104-115	false

DDI-MedLine.d67.s7	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
Midazolam	drug	0-8	morphine	drug	92-99	effect
Midazolam	drug	0-8	metamizol	drug	102-110	effect
Midazolam	drug	0-8	indomethacin	drug	146-157	effect
morphine	drug	92-99	metamizol	drug	102-110	false
morphine	drug	92-99	indomethacin	drug	146-157	false
metamizol	drug	102-110	indomethacin	drug	146-157	false

DDI-MedLine.d120.s0	Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.
amphotericin B	drug	46-59	filipin	drug_n	75-81	false

DDI-MedLine.d120.s1	Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic;
polyene antibiotics	group	10-28	filipin	drug_n	42-48	false

DDI-MedLine.d120.s3	Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells;
filipin	drug_n	21-27	amphotericin B	drug	58-71	false
filipin	drug_n	21-27	polyene antibiotics	group	170-188	false
amphotericin B	drug	58-71	polyene antibiotics	group	170-188	false

DDI-MedLine.d120.s4	filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth;
filipin	drug_n	0-6	amphotericin B	drug	65-78	false

DDI-MedLine.d120.s5	and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.
filipin	drug_n	24-30	amphotericin B	drug	151-164	false

DDI-MedLine.d45.s0	Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
pentazocine	drug	22-32	tripelennamine	drug	38-51	false

DDI-MedLine.d45.s1	The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine
pentazocine	drug	68-78	tripelennamine	drug	84-97	false

DDI-MedLine.d45.s5	Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination.
heroin	drug_n	74-79	pentazocine	drug	93-103	false
heroin	drug_n	74-79	tripelennamine	drug	109-122	false
pentazocine	drug	93-103	tripelennamine	drug	109-122	effect

DDI-MedLine.d45.s6	Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine.
tripelennamine	drug	105-118	pentazocine	drug	200-210	effect

DDI-MedLine.d45.s9	aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S.
pentazocine	drug	22-32	tripelennamine	drug	38-51	false

DDI-MedLine.d55.s0	Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.
acetaminophen	drug	28-40	caffeine	drug	75-82	effect

DDI-MedLine.d55.s1	Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen.
caffeine	drug	6-13	acetaminophen	drug	50-62	false
caffeine	drug	6-13	caffeine	drug	115-122	false
caffeine	drug	6-13	acetaminophen	drug	149-161	false
acetaminophen	drug	50-62	caffeine	drug	115-122	false
acetaminophen	drug	50-62	acetaminophen	drug	149-161	false
caffeine	drug	115-122	acetaminophen	drug	149-161	false

DDI-MedLine.d55.s4	Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.
acetaminophen	drug	58-70	caffeine	drug	91-98	effect

DDI-MedLine.d107.s1	Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages.
ethanol	drug	98-104	acetaldehyde	drug_n	129-140	false

DDI-MedLine.d107.s3	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;
ethanol	drug	111-117	methanol	drug_n	120-127	false
ethanol	drug	111-117	alcohols	drug_n	137-144	false
ethanol	drug	111-117	acetaldehyde	drug_n	150-161	false
methanol	drug_n	120-127	alcohols	drug_n	137-144	false
methanol	drug_n	120-127	acetaldehyde	drug_n	150-161	false
alcohols	drug_n	137-144	acetaldehyde	drug_n	150-161	false

DDI-MedLine.d107.s9	These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde;
ethanol	drug	47-53	acetaldehyde	drug_n	128-139	effect

DDI-MedLine.d113.s0	Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.
temazepam	drug	30-38	ethanol	drug	65-71	mechanism

DDI-MedLine.d113.s1	The benzodiazepines are a family of anxiolytic and hypnotic drugs.
benzodiazepines	group	4-18	anxiolytic	group	36-45	false
benzodiazepines	group	4-18	hypnotic drugs	group	51-64	false
anxiolytic	group	36-45	hypnotic drugs	group	51-64	false

DDI-MedLine.d113.s3	In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.
temazepam	drug	105-113	benzodiazepine	group	118-131	false
temazepam	drug	105-113	ethanol	drug	138-144	mechanism
benzodiazepine	group	118-131	ethanol	drug	138-144	false

DDI-MedLine.d113.s5	The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis.
alcohol	drug	111-117	3-hydroxy-1,4-benzodiazepine	group	123-150	mechanism

DDI-MedLine.d61.s0	Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
digoxin	drug	34-40	amiodarone	drug	42-51	false

DDI-MedLine.d61.s1	Amiodarone is known to raise serum digoxin levels.
Amiodarone	drug	0-9	digoxin	drug	35-41	mechanism

DDI-MedLine.d61.s3	The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks.
digoxin	drug	34-40	digoxin	drug	93-99	false
digoxin	drug	34-40	amiodarone	drug	140-149	false
digoxin	drug	93-99	amiodarone	drug	140-149	false

DDI-MedLine.d61.s4	During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).
amiodarone	drug	7-16	digoxin	drug	56-62	mechanism

DDI-MedLine.d61.s8	Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics.
Amiodarone	drug	0-9	digoxin	drug	172-178	false

DDI-MedLine.d61.s9	These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
digoxin	drug	21-27	amiodarone	drug	58-67	mechanism
digoxin	drug	21-27	digoxin	drug	99-105	false
amiodarone	drug	58-67	digoxin	drug	99-105	false

DDI-MedLine.d100.s5	Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
Slow-channel calcium blockers	group	0-28	verapamil	drug	39-47	false
Slow-channel calcium blockers	group	0-28	diltiazem	drug	50-58	false
Slow-channel calcium blockers	group	0-28	nifedipine	drug	64-73	false
verapamil	drug	39-47	diltiazem	drug	50-58	false
verapamil	drug	39-47	nifedipine	drug	64-73	false
diltiazem	drug	50-58	nifedipine	drug	64-73	false

DDI-MedLine.d78.s1	The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria.
fluoroquinolones	group	4-19	antibiotics	group	52-62	false

DDI-MedLine.d78.s2	These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
norfloxacin	drug	24-34	ciprofloxacin	drug	37-49	false
norfloxacin	drug	24-34	ofloxacin	drug	52-60	false
norfloxacin	drug	24-34	enoxacin	drug	63-70	false
norfloxacin	drug	24-34	lomefloxacin	drug	77-88	false
ciprofloxacin	drug	37-49	ofloxacin	drug	52-60	false
ciprofloxacin	drug	37-49	enoxacin	drug	63-70	false
ciprofloxacin	drug	37-49	lomefloxacin	drug	77-88	false
ofloxacin	drug	52-60	enoxacin	drug	63-70	false
ofloxacin	drug	52-60	lomefloxacin	drug	77-88	false
enoxacin	drug	63-70	lomefloxacin	drug	77-88	false

DDI-MedLine.d78.s3	Advantages offered by this class of antibiotics include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral antibiotics are generally used.
antibiotics	group	36-46	antibiotics	drug	180-190	false

DDI-MedLine.d12.s0	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
Dexamethasone	drug	0-12	retinyl acetate	drug	18-32	false
Dexamethasone	drug	0-12	EGF	drug_n	66-68	effect
Dexamethasone	drug	0-12	insulin	drug	74-80	effect
retinyl acetate	drug	18-32	EGF	drug_n	66-68	effect
retinyl acetate	drug	18-32	insulin	drug	74-80	effect
EGF	drug_n	66-68	insulin	drug	74-80	false

DDI-MedLine.d12.s1	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).
transferrin	drug_n	101-111	EGF	drug_n	131-133	false
transferrin	drug_n	101-111	insulin	drug	151-157	false
EGF	drug_n	131-133	insulin	drug	151-157	false

DDI-MedLine.d12.s2	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
dexamethasone	drug	17-29	retinyl acetate	drug	35-49	false
dexamethasone	drug	17-29	transferrin	drug_n	125-135	false
dexamethasone	drug	17-29	EGF	drug_n	180-182	effect
dexamethasone	drug	17-29	insulin	drug	188-194	effect
retinyl acetate	drug	35-49	transferrin	drug_n	125-135	false
retinyl acetate	drug	35-49	EGF	drug_n	180-182	effect
retinyl acetate	drug	35-49	insulin	drug	188-194	effect
transferrin	drug_n	125-135	EGF	drug_n	180-182	false
transferrin	drug_n	125-135	insulin	drug	188-194	false
EGF	drug_n	180-182	insulin	drug	188-194	false

DDI-MedLine.d12.s3	Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
Dexamethasone	drug	0-12	retinyl acetate	drug	30-44	false
Dexamethasone	drug	0-12	EGF	drug_n	105-107	effect
retinyl acetate	drug	30-44	EGF	drug_n	105-107	effect

DDI-MedLine.d12.s4	Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
dexamethasone	drug	25-37	retinyl acetate	drug	62-76	false
dexamethasone	drug	25-37	EGF	drug_n	136-138	effect
retinyl acetate	drug	62-76	EGF	drug_n	136-138	effect

DDI-MedLine.d12.s5	Dexamethasone had a similar effect in the presence of insulin.
Dexamethasone	drug	0-12	insulin	drug	54-60	false

DDI-MedLine.d12.s6	However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin.
retinyl acetate	drug	9-23	insulin	drug	105-111	effect

DDI-MedLine.d12.s7	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
dexamethasone	drug	32-44	retinyl acetate	drug	50-64	false
dexamethasone	drug	32-44	glucocorticoids	group	86-100	false
dexamethasone	drug	32-44	retinoids	group	106-114	false
dexamethasone	drug	32-44	insulin	drug	223-229	effect
dexamethasone	drug	32-44	EGF	drug_n	235-237	effect
retinyl acetate	drug	50-64	glucocorticoids	group	86-100	false
retinyl acetate	drug	50-64	retinoids	group	106-114	false
retinyl acetate	drug	50-64	insulin	drug	223-229	effect
retinyl acetate	drug	50-64	EGF	drug_n	235-237	effect
glucocorticoids	group	86-100	retinoids	group	106-114	false
glucocorticoids	group	86-100	insulin	drug	223-229	effect
glucocorticoids	group	86-100	EGF	drug_n	235-237	effect
retinoids	group	106-114	insulin	drug	223-229	effect
retinoids	group	106-114	EGF	drug_n	235-237	effect
insulin	drug	223-229	EGF	drug_n	235-237	false

DDI-MedLine.d63.s0	Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
naloxone	drug	36-43	beta-endorphin	drug_n	111-124	false
naloxone	drug	36-43	morphine	drug	130-137	false
beta-endorphin	drug_n	111-124	morphine	drug	130-137	false

DDI-MedLine.d63.s2	The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied.
naloxone	drug	64-71	beta-endorphin	drug_n	144-157	false
naloxone	drug	64-71	morphine	drug	163-170	false
beta-endorphin	drug_n	144-157	morphine	drug	163-170	false

DDI-MedLine.d63.s3	Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats.
beta-endorphin	drug_n	30-43	morphine	drug	49-56	false

DDI-MedLine.d63.s4	Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
naloxone	drug	25-32	beta-endorphin	drug_n	184-197	effect
naloxone	drug	25-32	naloxone	drug	219-226	false
naloxone	drug	25-32	beta-endorphin	drug_n	317-330	false
beta-endorphin	drug_n	184-197	naloxone	drug	219-226	false
beta-endorphin	drug_n	184-197	beta-endorphin	drug_n	317-330	false
naloxone	drug	219-226	beta-endorphin	drug_n	317-330	effect

DDI-MedLine.d63.s5	On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms).
naloxone	drug	31-38	morphine	drug	145-152	effect

DDI-MedLine.d63.s6	Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine.
naloxone	drug	30-37	beta-endorphin	drug_n	173-186	effect
naloxone	drug	30-37	morphine	drug	192-199	effect
beta-endorphin	drug_n	173-186	morphine	drug	192-199	false

DDI-MedLine.d63.s7	The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
naloxone	drug	35-42	beta-endorphin	drug_n	109-122	false
naloxone	drug	35-42	morphine	drug	132-139	false
naloxone	drug	35-42	beta-endorphin	drug_n	206-219	false
naloxone	drug	35-42	morphine	drug	225-232	false
beta-endorphin	drug_n	109-122	morphine	drug	132-139	false
beta-endorphin	drug_n	109-122	beta-endorphin	drug_n	206-219	false
beta-endorphin	drug_n	109-122	morphine	drug	225-232	false
morphine	drug	132-139	beta-endorphin	drug_n	206-219	false
morphine	drug	132-139	morphine	drug	225-232	false
beta-endorphin	drug_n	206-219	morphine	drug	225-232	false

DDI-MedLine.d63.s8	descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.
beta-endorphin	drug_n	38-51	morphine	drug	57-64	false

DDI-MedLine.d5.s0	Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
coumaphos	drug_n	32-40	coumaphos	drug_n	68-76	false
coumaphos	drug_n	32-40	bishydroxycoumarin	drug	83-100	false
coumaphos	drug_n	32-40	trichlorfon	drug_n	103-113	false
coumaphos	drug_n	32-40	phenobarbital sodium	drug	120-139	false
coumaphos	drug_n	68-76	bishydroxycoumarin	drug	83-100	false
coumaphos	drug_n	68-76	trichlorfon	drug_n	103-113	false
coumaphos	drug_n	68-76	phenobarbital sodium	drug	120-139	false
bishydroxycoumarin	drug	83-100	trichlorfon	drug_n	103-113	false
bishydroxycoumarin	drug	83-100	phenobarbital sodium	drug	120-139	false
trichlorfon	drug_n	103-113	phenobarbital sodium	drug	120-139	false

DDI-MedLine.d5.s1	Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.
coumaphos	drug_n	37-45	bishydroxycoumarin	drug	48-65	false
coumaphos	drug_n	37-45	anticoagulant	group	71-83	false
coumaphos	drug_n	37-45	trichlorfon	drug_n	87-97	false
coumaphos	drug_n	37-45	organophosphorous compound	group	103-128	false
coumaphos	drug_n	37-45	phenobarbital sodium	drug	136-155	false
bishydroxycoumarin	drug	48-65	anticoagulant	group	71-83	false
bishydroxycoumarin	drug	48-65	trichlorfon	drug_n	87-97	false
bishydroxycoumarin	drug	48-65	organophosphorous compound	group	103-128	false
bishydroxycoumarin	drug	48-65	phenobarbital sodium	drug	136-155	false
anticoagulant	group	71-83	trichlorfon	drug_n	87-97	false
anticoagulant	group	71-83	organophosphorous compound	group	103-128	false
anticoagulant	group	71-83	phenobarbital sodium	drug	136-155	false
trichlorfon	drug_n	87-97	organophosphorous compound	group	103-128	false
trichlorfon	drug_n	87-97	phenobarbital sodium	drug	136-155	false
organophosphorous compound	group	103-128	phenobarbital sodium	drug	136-155	false

DDI-MedLine.d5.s2	A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers.
coumaphos	drug_n	24-32	bishydroxy-coumarin	drug	134-152	false

DDI-MedLine.d5.s3	The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day.
trichlorfon	drug_n	60-70	coumaphos	drug_n	267-275	effect

DDI-MedLine.d5.s4	In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present.
phenobarbital sodium	drug	23-42	coumaphos	drug_n	123-131	effect

DDI-MedLine.d59.s4	Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min.
Cytochalasin D	drug_n	0-13	carbachol	drug	75-83	effect

DDI-MedLine.d59.s5	Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store.
Cytochalasin D	drug_n	0-13	carbachol	drug	29-37	effect

DDI-MedLine.d23.s0	The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
ketamine	drug	15-22	Innovar	brand	31-37	false
ketamine	drug	15-22	digitalis	group	53-61	false
Innovar	brand	31-37	digitalis	group	53-61	false

DDI-MedLine.d23.s1	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
digitalis	group	19-27	ketamine	drug	65-72	false
digitalis	group	19-27	Innovar Vet	brand	75-85	false
digitalis	group	19-27	pentobarbital	drug	91-103	false
digitalis	group	19-27	ouabain	drug	120-126	false
digitalis	group	19-27	ouabain	drug	213-219	false
digitalis	group	19-27	ketamine	drug	227-234	false
digitalis	group	19-27	Innovar	brand	239-245	false
digitalis	group	19-27	pentobarbital	drug	257-269	false
ketamine	drug	65-72	Innovar Vet	brand	75-85	false
ketamine	drug	65-72	pentobarbital	drug	91-103	false
ketamine	drug	65-72	ouabain	drug	120-126	effect
ketamine	drug	65-72	ouabain	drug	213-219	false
ketamine	drug	65-72	ketamine	drug	227-234	false
ketamine	drug	65-72	Innovar	brand	239-245	false
ketamine	drug	65-72	pentobarbital	drug	257-269	false
Innovar Vet	brand	75-85	pentobarbital	drug	91-103	false
Innovar Vet	brand	75-85	ouabain	drug	120-126	effect
Innovar Vet	brand	75-85	ouabain	drug	213-219	false
Innovar Vet	brand	75-85	ketamine	drug	227-234	false
Innovar Vet	brand	75-85	Innovar	brand	239-245	false
Innovar Vet	brand	75-85	pentobarbital	drug	257-269	false
pentobarbital	drug	91-103	ouabain	drug	120-126	effect
pentobarbital	drug	91-103	ouabain	drug	213-219	false
pentobarbital	drug	91-103	ketamine	drug	227-234	false
pentobarbital	drug	91-103	Innovar	brand	239-245	false
pentobarbital	drug	91-103	pentobarbital	drug	257-269	false
ouabain	drug	120-126	ouabain	drug	213-219	false
ouabain	drug	120-126	ketamine	drug	227-234	false
ouabain	drug	120-126	Innovar	brand	239-245	false
ouabain	drug	120-126	pentobarbital	drug	257-269	false
ouabain	drug	213-219	ketamine	drug	227-234	false
ouabain	drug	213-219	Innovar	brand	239-245	false
ouabain	drug	213-219	pentobarbital	drug	257-269	false
ketamine	drug	227-234	Innovar	brand	239-245	false
ketamine	drug	227-234	pentobarbital	drug	257-269	false
Innovar	brand	239-245	pentobarbital	drug	257-269	false

DDI-MedLine.d23.s2	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
ouabain	drug	35-41	Innovar	brand	111-117	effect
ouabain	drug	35-41	ketamine	drug	120-127	effect
ouabain	drug	35-41	droperidol	drug	133-142	effect
ouabain	drug	35-41	fentayl	drug	176-182	false
ouabain	drug	35-41	pentobarbital	drug	199-211	false
Innovar	brand	111-117	ketamine	drug	120-127	false
Innovar	brand	111-117	droperidol	drug	133-142	false
Innovar	brand	111-117	fentayl	drug	176-182	false
Innovar	brand	111-117	pentobarbital	drug	199-211	false
ketamine	drug	120-127	droperidol	drug	133-142	false
ketamine	drug	120-127	fentayl	drug	176-182	false
ketamine	drug	120-127	pentobarbital	drug	199-211	false
droperidol	drug	133-142	fentayl	drug	176-182	false
droperidol	drug	133-142	pentobarbital	drug	199-211	false
fentayl	drug	176-182	pentobarbital	drug	199-211	false

DDI-MedLine.d2.s0	Failure of neomycin to modify ACTH induced hypertension in sheep.
neomycin	drug	11-18	ACTH	group	30-33	false

DDI-MedLine.d2.s1	Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension.
neomycin	drug	32-39	adrenocortical steroid	group	84-105	false
neomycin	drug	32-39	ACTH	drug	141-144	effect
adrenocortical steroid	group	84-105	ACTH	drug	141-144	false

DDI-MedLine.d2.s2	The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep.
neomycin	drug	20-27	ACTH	group	32-35	false

DDI-MedLine.d2.s3	Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.
Neomycin	drug	0-7	ACTH	group	71-74	false

DDI-MedLine.d134.s0	[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied.
radiopertechnetate	drug	50-67	sodium perchlorate	drug_n	72-89	false
radiopertechnetate	drug	50-67	sodium perchlorate	drug_n	170-187	false
radiopertechnetate	drug	50-67	radiopertechnetate	drug	267-284	false
sodium perchlorate	drug_n	72-89	sodium perchlorate	drug_n	170-187	false
sodium perchlorate	drug_n	72-89	radiopertechnetate	drug	267-284	false
sodium perchlorate	drug_n	170-187	radiopertechnetate	drug	267-284	false

DDI-MedLine.d134.s1	An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate.
perchlorate	drug_n	29-39	pertechnetate	drug	116-128	false
perchlorate	drug_n	29-39	radiopertechnetate	drug	237-254	false
pertechnetate	drug	116-128	radiopertechnetate	drug	237-254	false

DDI-MedLine.d134.s2	An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels.
perchlorate	drug_n	28-38	pertechnetate	drug	116-128	mechanism

DDI-MedLine.d49.s0	Interaction of clindamycin and gentamicin in vitro.
clindamycin	drug	15-25	gentamicin	drug	31-40	int

DDI-MedLine.d49.s1	The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates.
clindamycin	drug	41-51	gentamicin	drug	57-66	false

DDI-MedLine.d49.s3	Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested (0.1 to 100 mug/ml);
Gentamicin	drug	0-9	clindamycin	drug	50-60	false

DDI-MedLine.d49.s6	Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains.
clindamycin	drug	16-26	gentamicin	drug	32-41	effect

DDI-MedLine.d49.s7	All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than 3.1 mug/ml) and gentamicin (minimal inhibitory concentration greater than 6.2 mug/ml).
clindamycin	drug	155-165	gentamicin	drug	230-239	false

DDI-MedLine.d49.s8	Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains.
clindamycin	drug	16-26	gentamicin	drug	32-41	effect

DDI-MedLine.d81.s0	Hypothermia as an index of the disulfiram-ethanol reaction in the rat.
disulfiram	drug	31-40	ethanol	drug	42-48	false

DDI-MedLine.d81.s1	Decreased core temperature in female rats was investigated as one possible index of the disulfiram-ethanol reaction (DER).
disulfiram	drug	88-97	ethanol	drug	99-105	false

DDI-MedLine.d81.s2	Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge.
ethanol	drug	71-77	disulfiram	drug	117-126	effect
ethanol	drug	71-77	ethanol	drug	147-153	false
disulfiram	drug	117-126	ethanol	drug	147-153	false

DDI-MedLine.d81.s3	The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol.
ethanol	drug	58-64	ethanol	drug	142-148	false

DDI-MedLine.d81.s6	Maximal hypotension was found 120 minutes post ethanol, and returned to normal 300 minutes after ethanol.
ethanol	drug	47-53	ethanol	drug	97-103	false

DDI-MedLine.d111.s2	Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.
Acetaminophen	drug	0-12	lidocaine	drug	15-23	false
Acetaminophen	drug	0-12	phenobarbital	drug	26-38	false
Acetaminophen	drug	0-12	quinidine	drug	41-49	false
Acetaminophen	drug	0-12	theophylline	drug	52-63	false
Acetaminophen	drug	0-12	valproic acid	drug	70-82	false
lidocaine	drug	15-23	phenobarbital	drug	26-38	false
lidocaine	drug	15-23	quinidine	drug	41-49	false
lidocaine	drug	15-23	theophylline	drug	52-63	false
lidocaine	drug	15-23	valproic acid	drug	70-82	false
phenobarbital	drug	26-38	quinidine	drug	41-49	false
phenobarbital	drug	26-38	theophylline	drug	52-63	false
phenobarbital	drug	26-38	valproic acid	drug	70-82	false
quinidine	drug	41-49	theophylline	drug	52-63	false
quinidine	drug	41-49	valproic acid	drug	70-82	false
theophylline	drug	52-63	valproic acid	drug	70-82	false

DDI-MedLine.d111.s4	The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital.
acetaminophen	drug	70-82	phenobarbital	drug	84-96	false

DDI-MedLine.d111.s5	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
acetaminophen	drug	0-12	theophylline	drug	14-25	false
acetaminophen	drug	0-12	lidocaine	drug	28-36	false
acetaminophen	drug	0-12	quinidine	drug	38-46	false
acetaminophen	drug	0-12	phenobarbital	drug	49-61	false
acetaminophen	drug	0-12	acetaminophen	drug	63-75	false
acetaminophen	drug	0-12	phenobarbital	drug	78-90	false
acetaminophen	drug	0-12	valproic acid	drug	92-104	false
acetaminophen	drug	0-12	quinidine	drug	107-115	false
acetaminophen	drug	0-12	lidocaine	drug	117-125	false
acetaminophen	drug	0-12	theophylline	drug	128-139	false
acetaminophen	drug	0-12	acetaminophen	drug	141-153	false
acetaminophen	drug	0-12	valproic acid	drug	160-172	false
acetaminophen	drug	0-12	phenobarbital	drug	174-186	false
theophylline	drug	14-25	lidocaine	drug	28-36	false
theophylline	drug	14-25	quinidine	drug	38-46	false
theophylline	drug	14-25	phenobarbital	drug	49-61	false
theophylline	drug	14-25	acetaminophen	drug	63-75	false
theophylline	drug	14-25	phenobarbital	drug	78-90	false
theophylline	drug	14-25	valproic acid	drug	92-104	false
theophylline	drug	14-25	quinidine	drug	107-115	false
theophylline	drug	14-25	lidocaine	drug	117-125	false
theophylline	drug	14-25	theophylline	drug	128-139	false
theophylline	drug	14-25	acetaminophen	drug	141-153	false
theophylline	drug	14-25	valproic acid	drug	160-172	false
theophylline	drug	14-25	phenobarbital	drug	174-186	false
lidocaine	drug	28-36	quinidine	drug	38-46	false
lidocaine	drug	28-36	phenobarbital	drug	49-61	false
lidocaine	drug	28-36	acetaminophen	drug	63-75	false
lidocaine	drug	28-36	phenobarbital	drug	78-90	false
lidocaine	drug	28-36	valproic acid	drug	92-104	false
lidocaine	drug	28-36	quinidine	drug	107-115	false
lidocaine	drug	28-36	lidocaine	drug	117-125	false
lidocaine	drug	28-36	theophylline	drug	128-139	false
lidocaine	drug	28-36	acetaminophen	drug	141-153	false
lidocaine	drug	28-36	valproic acid	drug	160-172	false
lidocaine	drug	28-36	phenobarbital	drug	174-186	false
quinidine	drug	38-46	phenobarbital	drug	49-61	false
quinidine	drug	38-46	acetaminophen	drug	63-75	false
quinidine	drug	38-46	phenobarbital	drug	78-90	false
quinidine	drug	38-46	valproic acid	drug	92-104	false
quinidine	drug	38-46	quinidine	drug	107-115	false
quinidine	drug	38-46	lidocaine	drug	117-125	false
quinidine	drug	38-46	theophylline	drug	128-139	false
quinidine	drug	38-46	acetaminophen	drug	141-153	false
quinidine	drug	38-46	valproic acid	drug	160-172	false
quinidine	drug	38-46	phenobarbital	drug	174-186	false
phenobarbital	drug	49-61	acetaminophen	drug	63-75	false
phenobarbital	drug	49-61	phenobarbital	drug	78-90	false
phenobarbital	drug	49-61	valproic acid	drug	92-104	false
phenobarbital	drug	49-61	quinidine	drug	107-115	false
phenobarbital	drug	49-61	lidocaine	drug	117-125	false
phenobarbital	drug	49-61	theophylline	drug	128-139	false
phenobarbital	drug	49-61	acetaminophen	drug	141-153	false
phenobarbital	drug	49-61	valproic acid	drug	160-172	false
phenobarbital	drug	49-61	phenobarbital	drug	174-186	false
acetaminophen	drug	63-75	phenobarbital	drug	78-90	false
acetaminophen	drug	63-75	valproic acid	drug	92-104	false
acetaminophen	drug	63-75	quinidine	drug	107-115	false
acetaminophen	drug	63-75	lidocaine	drug	117-125	false
acetaminophen	drug	63-75	theophylline	drug	128-139	false
acetaminophen	drug	63-75	acetaminophen	drug	141-153	false
acetaminophen	drug	63-75	valproic acid	drug	160-172	false
acetaminophen	drug	63-75	phenobarbital	drug	174-186	false
phenobarbital	drug	78-90	valproic acid	drug	92-104	false
phenobarbital	drug	78-90	quinidine	drug	107-115	false
phenobarbital	drug	78-90	lidocaine	drug	117-125	false
phenobarbital	drug	78-90	theophylline	drug	128-139	false
phenobarbital	drug	78-90	acetaminophen	drug	141-153	false
phenobarbital	drug	78-90	valproic acid	drug	160-172	false
phenobarbital	drug	78-90	phenobarbital	drug	174-186	false
valproic acid	drug	92-104	quinidine	drug	107-115	false
valproic acid	drug	92-104	lidocaine	drug	117-125	false
valproic acid	drug	92-104	theophylline	drug	128-139	false
valproic acid	drug	92-104	acetaminophen	drug	141-153	false
valproic acid	drug	92-104	valproic acid	drug	160-172	false
valproic acid	drug	92-104	phenobarbital	drug	174-186	false
quinidine	drug	107-115	lidocaine	drug	117-125	false
quinidine	drug	107-115	theophylline	drug	128-139	false
quinidine	drug	107-115	acetaminophen	drug	141-153	false
quinidine	drug	107-115	valproic acid	drug	160-172	false
quinidine	drug	107-115	phenobarbital	drug	174-186	false
lidocaine	drug	117-125	theophylline	drug	128-139	false
lidocaine	drug	117-125	acetaminophen	drug	141-153	false
lidocaine	drug	117-125	valproic acid	drug	160-172	false
lidocaine	drug	117-125	phenobarbital	drug	174-186	false
theophylline	drug	128-139	acetaminophen	drug	141-153	false
theophylline	drug	128-139	valproic acid	drug	160-172	false
theophylline	drug	128-139	phenobarbital	drug	174-186	false
acetaminophen	drug	141-153	valproic acid	drug	160-172	false
acetaminophen	drug	141-153	phenobarbital	drug	174-186	false
valproic acid	drug	160-172	phenobarbital	drug	174-186	false

DDI-MedLine.d111.s7	Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.
phenobarbital	drug	24-36	quinidine	drug	39-47	false
phenobarbital	drug	24-36	theophylline	drug	54-65	false
phenobarbital	drug	24-36	ethanol	drug	127-133	false
quinidine	drug	39-47	theophylline	drug	54-65	false
quinidine	drug	39-47	ethanol	drug	127-133	false
theophylline	drug	54-65	ethanol	drug	127-133	false

DDI-MedLine.d111.s9	Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.
Acetaminophen	drug	0-12	theophylline	drug	40-51	mechanism

DDI-MedLine.d111.s10	Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L;
Theophylline	drug	0-11	acetaminophen	drug	38-50	mechanism

DDI-MedLine.d111.s12	Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.
Valproic acid	drug	0-12	phenobarbital	drug	36-48	mechanism

DDI-MedLine.d111.s14	Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
acetaminophen	drug	15-27	theophylline	drug	34-45	effect
acetaminophen	drug	15-27	phenobarbital	drug	48-60	false
acetaminophen	drug	15-27	acetaminophen	drug	67-79	false
acetaminophen	drug	15-27	valproic acid	drug	86-98	false
acetaminophen	drug	15-27	phenobarbital	drug	105-117	false
theophylline	drug	34-45	phenobarbital	drug	48-60	false
theophylline	drug	34-45	acetaminophen	drug	67-79	false
theophylline	drug	34-45	valproic acid	drug	86-98	false
theophylline	drug	34-45	phenobarbital	drug	105-117	false
phenobarbital	drug	48-60	acetaminophen	drug	67-79	effect
phenobarbital	drug	48-60	valproic acid	drug	86-98	false
phenobarbital	drug	48-60	phenobarbital	drug	105-117	false
acetaminophen	drug	67-79	valproic acid	drug	86-98	false
acetaminophen	drug	67-79	phenobarbital	drug	105-117	false
valproic acid	drug	86-98	phenobarbital	drug	105-117	effect

DDI-MedLine.d106.s0	Clinical implications of warfarin interactions with five sedatives.
warfarin	drug	25-32	sedatives	group	57-65	int

DDI-MedLine.d106.s1	The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.
anticoagulant	group	45-57	phenobarbital	drug	75-87	false
anticoagulant	group	45-57	secobarbital	drug	90-101	false
anticoagulant	group	45-57	glutethimide	drug	104-115	false
anticoagulant	group	45-57	chloral hydrate	drug	118-132	false
anticoagulant	group	45-57	methaqualone	drug	138-149	false
anticoagulant	group	45-57	coumarin	group	209-216	false
phenobarbital	drug	75-87	secobarbital	drug	90-101	false
phenobarbital	drug	75-87	glutethimide	drug	104-115	false
phenobarbital	drug	75-87	chloral hydrate	drug	118-132	false
phenobarbital	drug	75-87	methaqualone	drug	138-149	false
phenobarbital	drug	75-87	coumarin	group	209-216	false
secobarbital	drug	90-101	glutethimide	drug	104-115	false
secobarbital	drug	90-101	chloral hydrate	drug	118-132	false
secobarbital	drug	90-101	methaqualone	drug	138-149	false
secobarbital	drug	90-101	coumarin	group	209-216	false
glutethimide	drug	104-115	chloral hydrate	drug	118-132	false
glutethimide	drug	104-115	methaqualone	drug	138-149	false
glutethimide	drug	104-115	coumarin	group	209-216	false
chloral hydrate	drug	118-132	methaqualone	drug	138-149	false
chloral hydrate	drug	118-132	coumarin	group	209-216	false
methaqualone	drug	138-149	coumarin	group	209-216	false

DDI-MedLine.d106.s4	Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide;
phenobarbital	drug	67-79	secobarbital	drug	82-93	false
phenobarbital	drug	67-79	glutethimide	drug	99-110	false
secobarbital	drug	82-93	glutethimide	drug	99-110	false

DDI-MedLine.d106.s5	there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone.
chloral hydrate	drug	81-95	methaqualone	drug	101-112	false

DDI-MedLine.d106.s6	Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs.
Barbiturates	group	0-11	glutethimide	drug	17-28	false
Barbiturates	group	0-11	coumarin drugs	group	79-92	advise
glutethimide	drug	17-28	coumarin drugs	group	79-92	advise

DDI-MedLine.d106.s8	Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.
Chloral hydrate	drug	0-14	methaqualone	drug	20-31	false
Chloral hydrate	drug	0-14	anticoagulant agents	group	85-104	int
methaqualone	drug	20-31	anticoagulant agents	group	85-104	int

DDI-MedLine.d106.s9	It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.
chloral hydrate	drug	21-35	methaqualone	drug	41-52	false
chloral hydrate	drug	21-35	anticoagulant	group	151-163	false
methaqualone	drug	41-52	anticoagulant	group	151-163	false

DDI-MedLine.d93.s4	Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of trimethyl lead (TML) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle.
trimethyl lead	drug_n	109-122	TML	drug_n	125-127	false

DDI-MedLine.d93.s6	The 20% v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol.
alcohol	drug	24-30	ethanol	drug	83-89	false

DDI-MedLine.d93.s9	These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.
lead	drug_n	53-56	alcohol	drug	129-135	effect

DDI-MedLine.d125.s0	The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
gliftor	drug_n	42-48	1,3-difluoroacetone	drug_n	69-87	false
gliftor	drug_n	42-48	(-)-erythro-fluorocitrate	drug_n	92-116	false
1,3-difluoroacetone	drug_n	69-87	(-)-erythro-fluorocitrate	drug_n	92-116	false

DDI-MedLine.d125.s1	The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro.
1,3-difluoroacetone	drug_n	30-48	Gliftor	drug_n	111-117	false
1,3-difluoroacetone	drug_n	30-48	1,3-difluoro-2-propanol	drug_n	120-142	false
Gliftor	drug_n	111-117	1,3-difluoro-2-propanol	drug_n	120-142	false

DDI-MedLine.d125.s2	Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro.
1,3-difluoroacetone	drug_n	91-109	(-)-erythro-fluorocitrate	drug_n	114-138	false

DDI-MedLine.d125.s3	Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation.
1,3-difluoroacetone	drug_n	18-36	(-)-erythro-fluorocitrate	drug_n	94-118	false

DDI-MedLine.d125.s4	Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol.
1,3-difluoroacetone	drug_n	19-37	(-)-erythro-fluorocitrate	drug_n	88-112	false
1,3-difluoroacetone	drug_n	19-37	1,3-difluoro-2-propanol	drug_n	201-223	false
(-)-erythro-fluorocitrate	drug_n	88-112	1,3-difluoro-2-propanol	drug_n	201-223	false

DDI-MedLine.d125.s5	We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol.
1,3-difluoro-2-propanol	drug_n	38-60	1,3-difluoroacetone	drug_n	65-83	false
1,3-difluoro-2-propanol	drug_n	38-60	(-)-erythro-fluorocitrate	drug_n	181-205	false
1,3-difluoro-2-propanol	drug_n	38-60	1,3-difluoro-2-propanol	drug_n	212-234	false
1,3-difluoroacetone	drug_n	65-83	(-)-erythro-fluorocitrate	drug_n	181-205	false
1,3-difluoroacetone	drug_n	65-83	1,3-difluoro-2-propanol	drug_n	212-234	false
(-)-erythro-fluorocitrate	drug_n	181-205	1,3-difluoro-2-propanol	drug_n	212-234	false

DDI-MedLine.d125.s6	Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals.
4-methylpyrazole	drug	24-39	1,3-difluoro-2-propanol	drug_n	107-129	effect
4-methylpyrazole	drug	24-39	(-)-erythro-fluorocitrate	drug_n	162-186	false
4-methylpyrazole	drug	24-39	1,3-difluoro-2-propanol	drug_n	257-279	false
1,3-difluoro-2-propanol	drug_n	107-129	(-)-erythro-fluorocitrate	drug_n	162-186	false
1,3-difluoro-2-propanol	drug_n	107-129	1,3-difluoro-2-propanol	drug_n	257-279	false
(-)-erythro-fluorocitrate	drug_n	162-186	1,3-difluoro-2-propanol	drug_n	257-279	false

DDI-MedLine.d125.s7	However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo.
4-methylpyrazole	drug	27-42	1,3-difluoroacetone	drug_n	96-114	false
4-methylpyrazole	drug	27-42	(-)-erythro-fluorocitrate	drug_n	174-198	false
1,3-difluoroacetone	drug_n	96-114	(-)-erythro-fluorocitrate	drug_n	174-198	false

DDI-MedLine.d125.s8	We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.
4-methylpyrazole	drug	62-77	1,3-difluoro-2-propanol	drug_n	108-130	effect
4-methylpyrazole	drug	62-77	1,3-difluoro-2-propanol	drug_n	224-246	false
4-methylpyrazole	drug	62-77	1,3-difluoroacetone	drug_n	251-269	false
1,3-difluoro-2-propanol	drug_n	108-130	1,3-difluoro-2-propanol	drug_n	224-246	false
1,3-difluoro-2-propanol	drug_n	108-130	1,3-difluoroacetone	drug_n	251-269	false
1,3-difluoro-2-propanol	drug_n	224-246	1,3-difluoroacetone	drug_n	251-269	false

DDI-MedLine.d36.s0	Carbamazepine overdose recognized by a tricyclic antidepressant assay.
Carbamazepine	drug	0-12	tricyclic antidepressant	group	39-62	false

DDI-MedLine.d36.s2	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
carbamazepine	drug	73-85	tricyclic antidepressant	group	112-135	effect
carbamazepine	drug	73-85	carbamazepine	drug	190-202	false
carbamazepine	drug	73-85	tricyclic antidepressants	group	233-257	false
tricyclic antidepressant	group	112-135	carbamazepine	drug	190-202	false
tricyclic antidepressant	group	112-135	tricyclic antidepressants	group	233-257	false
carbamazepine	drug	190-202	tricyclic antidepressants	group	233-257	advise

DDI-MedLine.d129.s0	Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.
Green tea polyphenols	drug	0-20	enhancers	drug	32-40	false

DDI-MedLine.d129.s3	n-dodecyl gallate showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude tannic acid.
n-dodecyl gallate	drug	0-16	tannic acid	drug	128-138	false

DDI-MedLine.d16.s0	Interaction of ketamine and halothane in rats.
ketamine	drug	15-22	halothane	drug	28-36	int

DDI-MedLine.d16.s1	The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats.
ketamine	drug	44-51	halothane	drug	107-115	false

DDI-MedLine.d16.s3	However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im.
halothane	drug	9-17	ketamine	drug	169-176	mechanism

DDI-MedLine.d16.s4	The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1.
ketamine	drug	57-64	ketamine	drug	96-103	false

DDI-MedLine.d16.s5	The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone.
ketamine	drug	17-24	halothane	drug	76-84	mechanism
ketamine	drug	17-24	ketamine	drug	96-103	false
halothane	drug	76-84	ketamine	drug	96-103	false

DDI-MedLine.d16.s6	It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.
ketamine	drug	21-28	halothane	drug	87-95	effect

DDI-MedLine.d85.s0	Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
Misonidazole	drug_n	0-11	CCNU	drug	80-83	effect

DDI-MedLine.d85.s1	Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole.
nitrosourea	group	12-22	CCNU	drug	24-27	false
nitrosourea	group	12-22	CCNU	drug	184-187	false
nitrosourea	group	12-22	misonidazole	drug_n	246-257	false
CCNU	drug	24-27	CCNU	drug	184-187	false
CCNU	drug	24-27	misonidazole	drug_n	246-257	false
CCNU	drug	184-187	misonidazole	drug_n	246-257	false

DDI-MedLine.d85.s7	Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71.
Misonidazole	drug_n	0-11	CCNU	drug	53-56	effect

DDI-MedLine.d85.s9	Misonidazole has a complex effect on oral CCNU pharmacokinetics.
Misonidazole	drug_n	0-11	CCNU	drug	42-45	mechanism

DDI-MedLine.d85.s14	We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
CCNU	drug	98-101	misonidazole	drug_n	119-130	mechanism

DDI-MedLine.d25.s0	Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
simvastatin	drug	55-65	clarithromycin	drug	71-84	effect

DDI-MedLine.d25.s1	OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin.
clarithromycin	drug	80-93	simvastatin	drug	99-109	false

DDI-MedLine.d25.s9	DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism.
Clarithromycin	drug	12-25	simvastatin	drug	93-103	mechanism

DDI-MedLine.d25.s10	The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis.
macrolide antibiotics	group	34-54	hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors	group	66-128	effect

DDI-MedLine.d25.s12	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
Macrolide antibiotics	group	13-33	HMG-CoA reductase inhibitors	group	61-88	false
Macrolide antibiotics	group	13-33	atorvastatin	drug	128-139	mechanism
Macrolide antibiotics	group	13-33	cerivastatin	drug	142-153	mechanism
Macrolide antibiotics	group	13-33	lovastatin	drug	156-165	mechanism
Macrolide antibiotics	group	13-33	simvastatin	drug	168-178	mechanism
HMG-CoA reductase inhibitors	group	61-88	atorvastatin	drug	128-139	false
HMG-CoA reductase inhibitors	group	61-88	cerivastatin	drug	142-153	false
HMG-CoA reductase inhibitors	group	61-88	lovastatin	drug	156-165	false
HMG-CoA reductase inhibitors	group	61-88	simvastatin	drug	168-178	false
atorvastatin	drug	128-139	cerivastatin	drug	142-153	false
atorvastatin	drug	128-139	lovastatin	drug	156-165	false
atorvastatin	drug	128-139	simvastatin	drug	168-178	false
cerivastatin	drug	142-153	lovastatin	drug	156-165	false
cerivastatin	drug	142-153	simvastatin	drug	168-178	false
lovastatin	drug	156-165	simvastatin	drug	168-178	false

DDI-MedLine.d38.s0	Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
hydrocortisone	drug	6-19	d-amphetamine	drug	76-88	false

DDI-MedLine.d38.s2	However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans.
glucocorticoids	group	35-49	psychostimulants	group	95-110	false

DDI-MedLine.d38.s3	OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine.
hydrocortisone	drug	44-57	d-amphetamine	drug	116-128	false

DDI-MedLine.d38.s4	METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design.
Hydrocortisone	drug	9-22	d-amphetamine	drug	37-49	false

DDI-MedLine.d38.s8	However, hydrocortisone pretreatment did not affect any of the physiological, behavioral, or subjective effects of d-amphetamine.
hydrocortisone	drug	9-22	d-amphetamine	drug	115-127	false

DDI-MedLine.d38.s9	CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans.
glucocorticoids	group	43-57	d-amphetamine	drug	184-196	false

DDI-MedLine.d58.s3	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.
ginsenosides	drug_n	44-55	selective Ca(2+) channel blockers	group	129-161	false
ginsenosides	drug_n	44-55	nimodipine	drug	163-172	false
ginsenosides	drug_n	44-55	omega-conotoxin GVIA	drug_n	184-203	false
ginsenosides	drug_n	44-55	omega-agatoxin IVA	drug_n	218-235	false
selective Ca(2+) channel blockers	group	129-161	nimodipine	drug	163-172	false
selective Ca(2+) channel blockers	group	129-161	omega-conotoxin GVIA	drug_n	184-203	false
selective Ca(2+) channel blockers	group	129-161	omega-agatoxin IVA	drug_n	218-235	false
nimodipine	drug	163-172	omega-conotoxin GVIA	drug_n	184-203	false
nimodipine	drug	163-172	omega-agatoxin IVA	drug_n	218-235	false
omega-conotoxin GVIA	drug_n	184-203	omega-agatoxin IVA	drug_n	218-235	false

DDI-MedLine.d58.s6	Nimodipine had no effect on ginsenosides response.
Nimodipine	drug	0-9	ginsenosides	drug_n	28-39	false

DDI-MedLine.d58.s7	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.
ginsenosides	drug_n	24-35	omega-conotoxin GVIA	drug_n	135-154	false
ginsenosides	drug_n	24-35	omega-agatoxin IVA	drug_n	187-204	false
ginsenosides	drug_n	24-35	nimodipine	drug	237-246	false
ginsenosides	drug_n	24-35	omega-conotoxin GVIA	drug_n	248-267	false
ginsenosides	drug_n	24-35	omega-agatoxin VIA	drug_n	269-286	false
omega-conotoxin GVIA	drug_n	135-154	omega-agatoxin IVA	drug_n	187-204	false
omega-conotoxin GVIA	drug_n	135-154	nimodipine	drug	237-246	false
omega-conotoxin GVIA	drug_n	135-154	omega-conotoxin GVIA	drug_n	248-267	false
omega-conotoxin GVIA	drug_n	135-154	omega-agatoxin VIA	drug_n	269-286	false
omega-agatoxin IVA	drug_n	187-204	nimodipine	drug	237-246	false
omega-agatoxin IVA	drug_n	187-204	omega-conotoxin GVIA	drug_n	248-267	false
omega-agatoxin IVA	drug_n	187-204	omega-agatoxin VIA	drug_n	269-286	false
nimodipine	drug	237-246	omega-conotoxin GVIA	drug_n	248-267	false
nimodipine	drug	237-246	omega-agatoxin VIA	drug_n	269-286	false
omega-conotoxin GVIA	drug_n	248-267	omega-agatoxin VIA	drug_n	269-286	false

DDI-MedLine.d58.s8	Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng.
ginsenosides	drug_n	71-82	ginseng	drug	171-177	false

DDI-MedLine.d27.s0	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
picrotoxin	drug_n	117-126	diazepam	drug	174-181	effect
picrotoxin	drug_n	117-126	phenazepam	drug_n	184-193	effect
picrotoxin	drug_n	117-126	phenibut	drug_n	196-203	effect
picrotoxin	drug_n	117-126	amizyl	drug_n	209-214	effect
picrotoxin	drug_n	117-126	phentolamine	drug	242-253	effect
diazepam	drug	174-181	phenazepam	drug_n	184-193	false
diazepam	drug	174-181	phenibut	drug_n	196-203	false
diazepam	drug	174-181	amizyl	drug_n	209-214	false
diazepam	drug	174-181	phentolamine	drug	242-253	false
phenazepam	drug_n	184-193	phenibut	drug_n	196-203	false
phenazepam	drug_n	184-193	amizyl	drug_n	209-214	false
phenazepam	drug_n	184-193	phentolamine	drug	242-253	false
phenibut	drug_n	196-203	amizyl	drug_n	209-214	false
phenibut	drug_n	196-203	phentolamine	drug	242-253	false
amizyl	drug_n	209-214	phentolamine	drug	242-253	false

DDI-MedLine.d83.s1	Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia.
Olanzapine	drug	0-9	thienobenzodiazepine derivative	group	14-44	false
Olanzapine	drug	0-9	second generation (atypical) antipsychotic agent	group	52-99	false
thienobenzodiazepine derivative	group	14-44	second generation (atypical) antipsychotic agent	group	52-99	false

DDI-MedLine.d83.s3	In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms.
olanzapine	drug	86-95	haloperidol	drug	142-152	false

DDI-MedLine.d83.s4	The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment.
olanzapine	drug	76-85	haloperidol	drug	97-107	false

DDI-MedLine.d83.s5	In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.
olanzapine	drug	57-66	risperidone	drug	72-82	false
olanzapine	drug	57-66	olanzapine	drug	85-94	false
olanzapine	drug	57-66	risperidone	drug	159-169	false
risperidone	drug	72-82	olanzapine	drug	85-94	false
risperidone	drug	72-82	risperidone	drug	159-169	false
olanzapine	drug	85-94	risperidone	drug	159-169	false

DDI-MedLine.d83.s6	In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology.
risperidone	drug	75-85	olanzapine	drug	117-126	false

DDI-MedLine.d83.s7	Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol.
olanzapine	drug	53-62	risperidone	drug	204-214	false
olanzapine	drug	53-62	haloperidol	drug	219-229	false
risperidone	drug	204-214	haloperidol	drug	219-229	false

DDI-MedLine.d83.s8	However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder.
olanzapine	drug	99-108	risperidone	drug	114-124	false

DDI-MedLine.d83.s9	Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology.
olanzapine	drug	30-39	olanzapine	drug	158-167	false

DDI-MedLine.d83.s10	Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone.
Olanzapine	drug	0-9	haloperidol	drug	79-89	false
Olanzapine	drug	0-9	risperidone	drug	95-105	false
haloperidol	drug	79-89	risperidone	drug	95-105	false

DDI-MedLine.d83.s11	In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval.
olanzapine	drug	13-22	clozapine	drug	86-94	false
olanzapine	drug	13-22	risperidone	drug	155-165	false
clozapine	drug	86-94	risperidone	drug	155-165	false

DDI-MedLine.d83.s13	In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine.
haloperidol	drug	19-29	olanzapine	drug	95-104	false
haloperidol	drug	19-29	risperidone	drug	206-216	false
haloperidol	drug	19-29	olanzapine	drug	284-293	false
olanzapine	drug	95-104	risperidone	drug	206-216	false
olanzapine	drug	95-104	olanzapine	drug	284-293	false
risperidone	drug	206-216	olanzapine	drug	284-293	false

DDI-MedLine.d83.s15	Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol.
olanzapine	drug	40-49	haloperidol	drug	174-184	false

DDI-MedLine.d83.s16	Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug.
risperidone	drug	14-24	olanzapine	drug	27-36	false

DDI-MedLine.d83.s17	Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone.
Olanzapine	drug	0-9	haloperidol	drug	124-134	false
Olanzapine	drug	0-9	risperidone	drug	171-181	false
haloperidol	drug	124-134	risperidone	drug	171-181	false

DDI-MedLine.d83.s18	CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia.
Olanzapine	drug	13-22	haloperidol	drug	83-93	false

DDI-MedLine.d83.s19	The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
haloperidol	drug	77-87	risperidone	drug	93-103	false
haloperidol	drug	77-87	olanzapine	drug	180-189	false
risperidone	drug	93-103	olanzapine	drug	180-189	false

DDI-MedLine.d53.s0	Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
vitamin D	group	61-69	antiestrogens	group	75-87	false

DDI-MedLine.d53.s1	1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro.
25-Dihydroxycholecalciferol D3	drug	2-31	1,25(OH)2D3	drug	34-44	false
25-Dihydroxycholecalciferol D3	drug	2-31	vitamin D	group	73-81	false
1,25(OH)2D3	drug	34-44	vitamin D	group	73-81	false

DDI-MedLine.d53.s3	In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells.
1,25(OH)2D3	drug	71-81	antiestrogen	group	91-102	false
1,25(OH)2D3	drug	71-81	4-hydroxytamoxifen	drug_n	104-121	false
1,25(OH)2D3	drug	71-81	TAM	drug_n	124-126	false
antiestrogen	group	91-102	4-hydroxytamoxifen	drug_n	104-121	false
antiestrogen	group	91-102	TAM	drug_n	124-126	false
4-hydroxytamoxifen	drug_n	104-121	TAM	drug_n	124-126	false

DDI-MedLine.d53.s4	Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone.
TAM	drug_n	22-24	1,25(OH)2D3	drug	92-102	effect

DDI-MedLine.d53.s5	Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation.
1,25(OH)2D3	drug	24-34	TAM	drug_n	40-42	effect

DDI-MedLine.d53.s9	These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.
vitamin-D	group	90-98	estrogen	group	137-144	false

DDI-MedLine.d87.s0	ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
ADL 8-2698	drug	0-9	morphine	drug	114-121	effect

DDI-MedLine.d87.s1	ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia.
ADL-8-2698	drug	0-9	peripherally restricted opioid antagonist	group	22-62	false
ADL-8-2698	drug	0-9	opioid	group	93-98	effect
peripherally restricted opioid antagonist	group	22-62	opioid	group	93-98	false

DDI-MedLine.d87.s2	Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study.
morphine	drug	157-164	ADL 8-2698	drug	195-204	false
morphine	drug	157-164	morphine	drug	229-236	false
ADL 8-2698	drug	195-204	morphine	drug	229-236	false

DDI-MedLine.d87.s4	Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004).
Morphine	drug	0-7	ADL 8-2698	drug	106-115	effect

DDI-MedLine.d87.s5	Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo.
ADL 8-2698	drug	89-98	morphine	drug	134-141	false

DDI-MedLine.d87.s7	Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002).
Morphine	drug	0-7	ADL 8-2698	drug	61-70	false

DDI-MedLine.d87.s8	We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
ADL 8-2698	drug	17-26	morphine	drug	37-44	effect

DDI-MedLine.d127.s6	Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin.
thiazide diuretics	group	20-37	digoxin	drug	92-98	false

DDI-MedLine.d104.s0	The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
DCG-IV	drug_n	15-20	L-CCG-1	drug_n	26-32	false
DCG-IV	drug_n	15-20	phencyclidine	drug_n	39-51	false
DCG-IV	drug_n	15-20	PCP	drug_n	54-56	false
L-CCG-1	drug_n	26-32	phencyclidine	drug_n	39-51	false
L-CCG-1	drug_n	26-32	PCP	drug_n	54-56	false
phencyclidine	drug_n	39-51	PCP	drug_n	54-56	false

DDI-MedLine.d104.s2	injection of phencyclidine (PCP) were observed by measuring locomotor activity and stereotyped behavior.
phencyclidine	drug_n	13-25	PCP	drug_n	28-30	false

DDI-MedLine.d104.s3	Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found.
DCG-IV	drug_n	71-76	L-CCG-1	drug_n	82-88	false
DCG-IV	drug_n	71-76	PCP	drug_n	134-136	false
L-CCG-1	drug_n	82-88	PCP	drug_n	134-136	false

DDI-MedLine.d104.s4	The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion.
DCG-IV	drug_n	15-20	PCP	drug_n	68-70	effect

DDI-MedLine.d104.s8	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.
PCP	drug_n	49-51	PCP	drug_n	171-173	false
PCP	drug_n	49-51	DCG-IV	drug_n	176-181	false
PCP	drug_n	49-51	L-CCG-1	drug_n	188-194	false
PCP	drug_n	171-173	DCG-IV	drug_n	176-181	false
PCP	drug_n	171-173	L-CCG-1	drug_n	188-194	false
DCG-IV	drug_n	176-181	L-CCG-1	drug_n	188-194	false

DDI-MedLine.d62.s1	As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by methamphetamine (METH) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects.
methamphetamine	drug	141-155	METH	drug	158-161	false

DDI-MedLine.d62.s4	Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine.
METH	drug	46-49	SCH-23390	drug_n	234-242	effect
METH	drug	46-49	atypical neuroleptic	group	258-277	false
METH	drug	46-49	clozapine	drug	279-287	false
SCH-23390	drug_n	234-242	atypical neuroleptic	group	258-277	false
SCH-23390	drug_n	234-242	clozapine	drug	279-287	false
atypical neuroleptic	group	258-277	clozapine	drug	279-287	false

DDI-MedLine.d9.s3	For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved.
calcium-entry blocking agents	group	8-36	verapamil	drug	74-82	false
calcium-entry blocking agents	group	8-36	nifedipine	drug	85-94	false
calcium-entry blocking agents	group	8-36	diltiazem	drug	100-108	false
verapamil	drug	74-82	nifedipine	drug	85-94	false
verapamil	drug	74-82	diltiazem	drug	100-108	false
nifedipine	drug	85-94	diltiazem	drug	100-108	false

DDI-MedLine.d9.s5	by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements;
verapamil	drug	45-53	diltiazem	drug	59-67	false
verapamil	drug	45-53	nifedipine	drug	87-96	false
diltiazem	drug	59-67	nifedipine	drug	87-96	false

DDI-MedLine.d128.s1	The 16,16-dimethylprostaglandin E2 (dmPGE2)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction.
16,16-dimethylprostaglandin E2	drug_n	4-33	dmPGE2	drug_n	36-41	false

DDI-MedLine.d128.s10	On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration.
dmPGE2	drug_n	62-67	dmPGE2	drug_n	179-184	false

DDI-MedLine.d128.s12	Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.)
Loperamide	drug	0-9	morphine	drug	15-22	false

DDI-MedLine.d128.s13	Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
Loperamide	drug	0-9	morphine	drug	15-22	false
Loperamide	drug	0-9	dmPGE2	drug_n	64-69	effect
morphine	drug	15-22	dmPGE2	drug_n	64-69	effect

DDI-MedLine.d128.s15	N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
N-methyllevallorphan	drug_n	0-19	loperamide	drug	85-94	effect
N-methyllevallorphan	drug_n	0-19	morphine	drug	133-140	effect
loperamide	drug	85-94	morphine	drug	133-140	false

DDI-MedLine.d39.s0	Effect of estradiol on endotoxin-induced changes in steroid hormone levels and lethality in male rats.
estradiol	drug	10-18	endotoxin	drug_n	23-31	false

DDI-MedLine.d39.s1	We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin.
estradiol	drug	36-44	endotoxin	drug_n	141-149	false
estradiol	drug	36-44	endotoxin	drug_n	216-224	false
endotoxin	drug_n	141-149	endotoxin	drug_n	216-224	false

DDI-MedLine.d39.s2	Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin.
estradiol	drug	13-21	endotoxin	drug_n	56-64	effect
estradiol	drug	13-21	endotoxin	drug_n	129-137	false
endotoxin	drug_n	56-64	endotoxin	drug_n	129-137	false

DDI-MedLine.d39.s3	The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold).
estradiol	drug	37-45	endotoxin	drug_n	49-57	mechanism
estradiol	drug	37-45	endotoxin	drug_n	109-117	false
endotoxin	drug_n	49-57	endotoxin	drug_n	109-117	false

DDI-MedLine.d39.s4	The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%
estradiol	drug	37-45	endotoxin	drug_n	49-57	false
estradiol	drug	37-45	endotoxin	drug_n	117-125	false
endotoxin	drug_n	49-57	endotoxin	drug_n	117-125	false

DDI-MedLine.d39.s6	Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner.
estradiol	drug	10-18	endotoxin	drug_n	65-73	effect

DDI-MedLine.d39.s8	These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.
estrogen	group	61-68	estrogens	group	108-116	false

DDI-MedLine.d4.s0	[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied.
sandimmune	brand	15-24	immunodepressant	group	119-134	false
sandimmune	brand	15-24	sandimmune	brand	146-155	false
immunodepressant	group	119-134	sandimmune	brand	146-155	false

DDI-MedLine.d40.s0	Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans.
miconazole	drug	38-47	miconazole	drug	60-69	false

DDI-MedLine.d40.s1	The antifungal drug, miconazole nitrate, inhibits the growth of several species of Candida.
antifungal drug	group	4-18	miconazole nitrate	drug	21-38	false

DDI-MedLine.d18.s0	Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
budesonide	drug	42-51	Survanta	brand	56-63	false
budesonide	drug	42-51	lung surfactant	group	74-88	false
Survanta	brand	56-63	lung surfactant	group	74-88	false

DDI-MedLine.d18.s1	The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined.
pulmonary surfactant	group	16-35	Survanta	brand	63-70	false
pulmonary surfactant	group	16-35	budesonide	drug	121-130	false
Survanta	brand	63-70	budesonide	drug	121-130	false

DDI-MedLine.d18.s2	Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments.
budesonide	drug	21-30	ethanol	drug	55-61	false

DDI-MedLine.d18.s6	Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies.
Survanta	brand	0-7	budesonide	drug	48-57	false

DDI-MedLine.d18.s7	Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate.
Survanta	brand	0-7	sodium dodecyl sulfate	drug_n	68-89	false

DDI-MedLine.d18.s8	Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase.
budesonide	drug	33-42	budesonide	drug	121-130	false
budesonide	drug	33-42	Survanta	brand	144-151	false
budesonide	drug	121-130	Survanta	brand	144-151	false

DDI-MedLine.d30.s1	The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
N-allylnormetazocine	drug_n	47-66	NANM	drug_n	69-72	false
N-allylnormetazocine	drug_n	47-66	phencyclidine	drug_n	103-115	false
N-allylnormetazocine	drug_n	47-66	PCP	drug_n	118-120	false
NANM	drug_n	69-72	phencyclidine	drug_n	103-115	false
NANM	drug_n	69-72	PCP	drug_n	118-120	false
phencyclidine	drug_n	103-115	PCP	drug_n	118-120	false

DDI-MedLine.d30.s2	Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;
(+)-NANM	drug_n	22-29	PCP	drug_n	34-36	false

DDI-MedLine.d30.s6	In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM.
(-)-NANM	drug_n	12-19	(+)-NANM	drug_n	57-64	false
(-)-NANM	drug_n	12-19	(-)-NANM	drug_n	111-118	false
(-)-NANM	drug_n	12-19	(+)-NANM	drug_n	146-153	false
(+)-NANM	drug_n	57-64	(-)-NANM	drug_n	111-118	false
(+)-NANM	drug_n	57-64	(+)-NANM	drug_n	146-153	false
(-)-NANM	drug_n	111-118	(+)-NANM	drug_n	146-153	false

DDI-MedLine.d30.s7	In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding.
(-)-NANM	drug_n	17-24	(+)-NANM	drug_n	35-42	false
(-)-NANM	drug_n	17-24	morphine	drug	88-95	effect
(+)-NANM	drug_n	35-42	morphine	drug	88-95	false

DDI-MedLine.d30.s8	In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone;
(-)-NANM	drug_n	27-34	(+)-NANM	drug_n	45-52	false
(-)-NANM	drug_n	27-34	PCP	drug_n	57-59	false
(-)-NANM	drug_n	27-34	naloxone	drug	82-89	effect
(+)-NANM	drug_n	45-52	PCP	drug_n	57-59	false
(+)-NANM	drug_n	45-52	naloxone	drug	82-89	false
PCP	drug_n	57-59	naloxone	drug	82-89	false

DDI-MedLine.d30.s9	the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
naloxone	drug	13-20	(-)-NANM	drug_n	60-67	effect
naloxone	drug	13-20	morphine	drug	150-157	effect
(-)-NANM	drug_n	60-67	morphine	drug	150-157	false

DDI-MedLine.d30.s10	In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP.
naloxone	drug	12-19	(-)-NANM	drug_n	65-72	false
naloxone	drug	12-19	(+)-NANM	drug_n	75-82	false
naloxone	drug	12-19	PCP	drug_n	87-89	false
(-)-NANM	drug_n	65-72	(+)-NANM	drug_n	75-82	false
(-)-NANM	drug_n	65-72	PCP	drug_n	87-89	false
(+)-NANM	drug_n	75-82	PCP	drug_n	87-89	false

DDI-MedLine.d30.s11	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
Haloperidol	drug	0-10	(+)-NANM	drug_n	106-113	effect
Haloperidol	drug	0-10	PCP	drug_n	118-120	effect
Haloperidol	drug	0-10	NANM	drug_n	250-253	false
(+)-NANM	drug_n	106-113	PCP	drug_n	118-120	false
(+)-NANM	drug_n	106-113	NANM	drug_n	250-253	false
PCP	drug_n	118-120	NANM	drug_n	250-253	false

DDI-MedLine.d109.s0	Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
rofecoxib	drug	10-18	digoxin	drug	47-53	false

DDI-MedLine.d109.s1	The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects.
rofecoxib	drug	75-83	digoxin	drug	129-135	false

DDI-MedLine.d109.s5	Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose.
digoxin	drug	44-50	digoxin	drug	114-120	false

DDI-MedLine.d109.s7	For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively.
digoxin	drug	4-10	rofecoxib	drug	107-115	false
digoxin	drug	4-10	digoxin	drug	119-125	false
digoxin	drug	4-10	digoxin	drug	137-143	false
rofecoxib	drug	107-115	digoxin	drug	119-125	false
rofecoxib	drug	107-115	digoxin	drug	137-143	false
digoxin	drug	119-125	digoxin	drug	137-143	false

DDI-MedLine.d109.s9	The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively.
rofecoxib	drug	68-76	digoxin	drug	80-86	false
rofecoxib	drug	68-76	digoxin	drug	102-108	false
digoxin	drug	80-86	digoxin	drug	102-108	false

DDI-MedLine.d109.s11	The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively.
digoxin	drug	61-67	rofecoxib	drug	101-109	false

DDI-MedLine.d109.s13	Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.
Rofecoxib	drug	0-8	digoxin	drug	102-108	false

DDI-MedLine.d1.s1	Since the arrival of oral erection-supporting medication, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection-supporting medication in particular.
erection-supporting medication	group	26-55	erection-supporting medication	group	163-192	false

DDI-MedLine.d1.s5	Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure.
Sildenafil	drug	0-9	long-acting nitrates	group	48-67	advise
Sildenafil	drug	0-9	short-acting nitrates	group	92-112	advise
long-acting nitrates	group	48-67	short-acting nitrates	group	92-112	false

DDI-MedLine.d1.s6	No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors.
beta-receptor blockers	group	40-61	calcium antagonists	group	64-82	false
beta-receptor blockers	group	40-61	thiazide diuretics	group	85-92;103-111	false
beta-receptor blockers	group	40-61	loop diuretics	group	98-111	false
beta-receptor blockers	group	40-61	ACE inhibitors	group	117-130	false
calcium antagonists	group	64-82	thiazide diuretics	group	85-92;103-111	false
calcium antagonists	group	64-82	loop diuretics	group	98-111	false
calcium antagonists	group	64-82	ACE inhibitors	group	117-130	false
thiazide diuretics	group	85-92;103-111	loop diuretics	group	98-111	false
thiazide diuretics	group	85-92;103-111	ACE inhibitors	group	117-130	false
loop diuretics	group	98-111	ACE inhibitors	group	117-130	false

DDI-MedLine.d122.s1	Many people use both alcohol and nicotine (i.e., cigarettes and other tobacco products).
alcohol	drug	21-27	nicotine	drug	33-40	false

DDI-MedLine.d122.s3	The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.
alcohol	drug	18-24	nicotine	drug	29-36	false

DDI-MedLine.d122.s4	Moreover, the mechanisms underlying the development of dependence may be similar for alcohol and nicotine.
alcohol	drug	85-91	nicotine	drug	97-104	false

DDI-MedLine.d99.s0	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
Fluvoxamine	drug	0-10	tolbutamide	drug	63-73	mechanism

DDI-MedLine.d99.s1	OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9.
fluvoxamine	drug	64-74	tolbutamide	drug	80-90	false
fluvoxamine	drug	64-74	fluvoxamine	drug	108-118	false
tolbutamide	drug	80-90	fluvoxamine	drug	108-118	false

DDI-MedLine.d99.s8	Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC.
tolbutamide	drug	24-34	tolbutamide	drug	64-74	false
tolbutamide	drug	24-34	4-hydroxytolbutamide	drug_n	101-120	false
tolbutamide	drug	24-34	carboxytolbutamide	drug_n	126-143	false
tolbutamide	drug	64-74	4-hydroxytolbutamide	drug_n	101-120	false
tolbutamide	drug	64-74	carboxytolbutamide	drug_n	126-143	false
4-hydroxytolbutamide	drug_n	101-120	carboxytolbutamide	drug_n	126-143	false

DDI-MedLine.d99.s9	RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.
fluvoxamine	drug	31-41	tolbutamide	drug	131-141	mechanism

DDI-MedLine.d99.s11	The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).
4-hydroxytolbutamide	drug_n	26-45	carboxytolbutamide	drug_n	51-68	false
4-hydroxytolbutamide	drug_n	26-45	tolbutamide	drug	179-189	false
4-hydroxytolbutamide	drug_n	26-45	tolbutamide	drug	265-275	false
carboxytolbutamide	drug_n	51-68	tolbutamide	drug	179-189	false
carboxytolbutamide	drug_n	51-68	tolbutamide	drug	265-275	false
tolbutamide	drug	179-189	tolbutamide	drug	265-275	false

DDI-MedLine.d29.s0	Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin.
probenecid	drug	10-19	cloxacillin	drug	79-89	false

DDI-MedLine.d29.s2	(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.
penicillins	group	49-59	cephaloridine	drug	65-77	false
penicillins	group	49-59	probenecid	drug	111-120	mechanism
cephaloridine	drug	65-77	probenecid	drug	111-120	mechanism

DDI-MedLine.d29.s3	To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.
probenecid	drug	21-30	cloxacillin	drug	75-85	false
probenecid	drug	21-30	cloxacillin	drug	124-134	false
probenecid	drug	21-30	probenecid	drug	274-283	false
cloxacillin	drug	75-85	cloxacillin	drug	124-134	false
cloxacillin	drug	75-85	probenecid	drug	274-283	false
cloxacillin	drug	124-134	probenecid	drug	274-283	false

DDI-MedLine.d29.s4	No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (13.0 and 12.6 liters, respectively).
cloxacillin	drug	93-103	probenecid	drug	122-131	false

DDI-MedLine.d29.s8	This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.
probenecid	drug	41-50	cloxacillin	drug	74-84	mechanism

DDI-MedLine.d42.s4	METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction.
sildenafil	drug	84-93	sildenafil	drug	291-300	false
sildenafil	drug	84-93	Viagra	brand	303-308	false
sildenafil	drug	291-300	Viagra	brand	303-308	false

DDI-MedLine.d42.s5	RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]).
Sildenafil	drug	9-18	selective serotonin reuptake inhibitors	group	205-243	false
Sildenafil	drug	9-18	SSRIs	group	246-250	false
selective serotonin reuptake inhibitors	group	205-243	SSRIs	group	246-250	false

DDI-MedLine.d42.s9	however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy.
nitrate	group	81-87	sildenafil	drug	179-188	effect

DDI-MedLine.d42.s10	In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes sildenafil, may experience increased drug concentrations and possible toxicity from normal doses of sildenafil.
sildenafil	drug	99-108	sildenafil	drug	199-208	false

DDI-MedLine.d130.s0	High-dose cisplatin with sodium thiosulfate protection.
cisplatin	drug	10-18	sodium thiosulfate	drug	25-42	effect

DDI-MedLine.d130.s2	Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.
Sodium thiosulfate	drug	0-17	cisplatin	drug	47-55	effect

DDI-MedLine.d130.s3	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin.
thiosulfate	drug	34-44	cisplatin	drug	75-83	false
thiosulfate	drug	34-44	thiosulfate	drug	130-140	false
thiosulfate	drug	34-44	cisplatin	drug	221-229	false
cisplatin	drug	75-83	thiosulfate	drug	130-140	false
cisplatin	drug	75-83	cisplatin	drug	221-229	false
thiosulfate	drug	130-140	cisplatin	drug	221-229	false

DDI-MedLine.d130.s4	Cisplatin was administered over the last two hours of the thiosulfate infusion.
Cisplatin	drug	0-8	thiosulfate	drug	58-68	false

DDI-MedLine.d130.s6	Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.
cisplatin	drug	14-22	thiosulfate	drug	83-93	false
cisplatin	drug	14-22	thiosulfate	drug	147-157	false
cisplatin	drug	14-22	cisplatin	drug	281-289	false
thiosulfate	drug	83-93	thiosulfate	drug	147-157	false
thiosulfate	drug	83-93	cisplatin	drug	281-289	false
thiosulfate	drug	147-157	cisplatin	drug	281-289	false

DDI-MedLine.d130.s8	This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.
thiosulfate	drug	58-68	cisplatin	drug	136-144	mechanism

DDI-MedLine.d60.s2	The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed.
phenytoin	drug	27-35	fluvoxamine	drug	93-103	false
phenytoin	drug	27-35	phenytoin	drug	154-162	false
phenytoin	drug	27-35	drugs	drug	174-178	false
fluvoxamine	drug	93-103	phenytoin	drug	154-162	false
fluvoxamine	drug	93-103	drugs	drug	174-178	false
phenytoin	drug	154-162	drugs	drug	174-178	false

DDI-MedLine.d60.s3	During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed.
phenytoin	drug	7-15	phenytoin	drug	77-85	false

DDI-MedLine.d60.s4	The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1).
CYP2C9	drug	17-22	CYP2C9	drug	127-132	false

DDI-MedLine.d60.s5	The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.
CYP2C9	drug	54-59	fluvoxamine	drug	73-83	false

DDI-MedLine.d94.s11	The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium.
isoproterenol	drug	20-32	norepinephrine	drug	64-77	false

DDI-MedLine.d94.s12	The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
cocaine	drug	22-28	desipramine	drug	34-44	false
cocaine	drug	22-28	norepinephrine	drug	108-121	effect
desipramine	drug	34-44	norepinephrine	drug	108-121	effect

DDI-MedLine.d94.s13	Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).
mazindol	drug	70-77	norepinephrine	drug	135-148	false

DDI-MedLine.d94.s16	This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only.
cocaine	drug	99-105	desipramine	drug	111-121	false

DDI-MedLine.d94.s17	Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine.
norepinephrine	drug	12-25	cocaine	drug	90-96	false
norepinephrine	drug	12-25	desipramine	drug	102-112	false
cocaine	drug	90-96	desipramine	drug	102-112	false

DDI-DrugBank.d144.s0	Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.
ketoconazole	drug	35-46	budesonide	drug	192-201	mechanism

DDI-DrugBank.d144.s1	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
ketoconazole	drug	57-68	intraconazole	drug	71-83	false
ketoconazole	drug	57-68	ritonavir	drug	86-94	false
ketoconazole	drug	57-68	indinavir	drug	97-105	false
ketoconazole	drug	57-68	saquinavir	drug	108-117	false
ketoconazole	drug	57-68	erythromycin	drug	120-131	false
ketoconazole	drug	57-68	budesonide	drug	171-180	advise
intraconazole	drug	71-83	ritonavir	drug	86-94	false
intraconazole	drug	71-83	indinavir	drug	97-105	false
intraconazole	drug	71-83	saquinavir	drug	108-117	false
intraconazole	drug	71-83	erythromycin	drug	120-131	false
intraconazole	drug	71-83	budesonide	drug	171-180	advise
ritonavir	drug	86-94	indinavir	drug	97-105	false
ritonavir	drug	86-94	saquinavir	drug	108-117	false
ritonavir	drug	86-94	erythromycin	drug	120-131	false
ritonavir	drug	86-94	budesonide	drug	171-180	advise
indinavir	drug	97-105	saquinavir	drug	108-117	false
indinavir	drug	97-105	erythromycin	drug	120-131	false
indinavir	drug	97-105	budesonide	drug	171-180	advise
saquinavir	drug	108-117	erythromycin	drug	120-131	false
saquinavir	drug	108-117	budesonide	drug	171-180	advise
erythromycin	drug	120-131	budesonide	drug	171-180	advise

DDI-DrugBank.d52.s0	Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation
thrombolytics	group	27-39	streptokinase	drug	55-67	false
thrombolytics	group	27-39	REFLUDAN	brand	158-165	false
streptokinase	drug	55-67	REFLUDAN	brand	158-165	false

DDI-DrugBank.d52.s1	Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding.
coumarin derivatives	group	27-46	vitamin K antagonists	group	49-69	false

DDI-DrugBank.d198.s4	Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.
Cimetidine	drug	0-9	vardenafil	drug	44-53	false
Cimetidine	drug	0-9	vardenafil	drug	113-122	false
Cimetidine	drug	0-9	Vardenafil	drug	156-165	false
vardenafil	drug	44-53	vardenafil	drug	113-122	false
vardenafil	drug	44-53	Vardenafil	drug	156-165	false
vardenafil	drug	113-122	Vardenafil	drug	156-165	false

DDI-DrugBank.d198.s5	Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.
Erythromycin	drug	0-11	vardenafil	drug	58-67	mechanism
Erythromycin	drug	0-11	Vardenafil	drug	129-138	false
vardenafil	drug	58-67	Vardenafil	drug	129-138	false

DDI-DrugBank.d198.s6	It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.
Vardenafil	drug	54-63	erythromycin	drug	115-126	advise

DDI-DrugBank.d198.s7	Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.
Ketoconazole	drug	0-11	vardenafil	drug	64-73	mechanism
Ketoconazole	drug	0-11	Vardenafil	drug	135-144	false
vardenafil	drug	64-73	Vardenafil	drug	135-144	false

DDI-DrugBank.d198.s8	A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.
Vardenafil	drug	7-16	ketoconazole	drug	94-105	advise

DDI-DrugBank.d198.s9	Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.
ketoconazole	drug	22-33	Vardenafil	drug	122-131	false
ketoconazole	drug	22-33	ketoconazole	drug	206-217	false
Vardenafil	drug	122-131	ketoconazole	drug	206-217	advise

DDI-DrugBank.d198.s10	HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
HIV Protease Inhibitors	group	0-22	Indinavir	drug	25-33	false
HIV Protease Inhibitors	group	0-22	Vardenafil	drug	72-81	false
HIV Protease Inhibitors	group	0-22	vardenafil	drug	123-132	false
HIV Protease Inhibitors	group	0-22	vardenafil	drug	160-169	false
HIV Protease Inhibitors	group	0-22	vardenafil	drug	201-210	false
Indinavir	drug	25-33	Vardenafil	drug	72-81	mechanism
Indinavir	drug	25-33	vardenafil	drug	123-132	false
Indinavir	drug	25-33	vardenafil	drug	160-169	false
Indinavir	drug	25-33	vardenafil	drug	201-210	false
Vardenafil	drug	72-81	vardenafil	drug	123-132	false
Vardenafil	drug	72-81	vardenafil	drug	160-169	false
Vardenafil	drug	72-81	vardenafil	drug	201-210	false
vardenafil	drug	123-132	vardenafil	drug	160-169	false
vardenafil	drug	123-132	vardenafil	drug	201-210	false
vardenafil	drug	160-169	vardenafil	drug	201-210	false

DDI-DrugBank.d198.s11	It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.
Vardenafil	drug	48-57	indinavir	drug	114-122	advise

DDI-DrugBank.d198.s12	Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.
Ritonavir	drug	0-8	Vardenafil	drug	47-56	mechanism
Ritonavir	drug	0-8	vardenafil	drug	97-106	false
Ritonavir	drug	0-8	vardenafil	drug	138-147	false
Vardenafil	drug	47-56	vardenafil	drug	97-106	false
Vardenafil	drug	47-56	vardenafil	drug	138-147	false
vardenafil	drug	97-106	vardenafil	drug	138-147	false

DDI-DrugBank.d198.s13	The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.
vardenafil	drug	67-76	ritonavir	drug	81-89	mechanism

DDI-DrugBank.d198.s14	Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.
Ritonavir	drug	0-8	vardenafil	drug	51-60	mechanism

DDI-DrugBank.d198.s15	Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.
Vardenafil	drug	62-71	ritonavir	drug	128-136	advise

DDI-DrugBank.d198.s16	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, Maalox, and ranitidine.
vardenafil	drug	79-88	glyburide	drug	115-123	false
vardenafil	drug	79-88	warfarin	drug	126-133	false
vardenafil	drug	79-88	digoxin	drug	136-142	false
vardenafil	drug	79-88	Maalox	brand	145-150	false
vardenafil	drug	79-88	ranitidine	drug	157-166	false
glyburide	drug	115-123	warfarin	drug	126-133	false
glyburide	drug	115-123	digoxin	drug	136-142	false
glyburide	drug	115-123	Maalox	brand	145-150	false
glyburide	drug	115-123	ranitidine	drug	157-166	false
warfarin	drug	126-133	digoxin	drug	136-142	false
warfarin	drug	126-133	Maalox	brand	145-150	false
warfarin	drug	126-133	ranitidine	drug	157-166	false
digoxin	drug	136-142	Maalox	brand	145-150	false
digoxin	drug	136-142	ranitidine	drug	157-166	false
Maalox	brand	145-150	ranitidine	drug	157-166	false

DDI-DrugBank.d198.s17	In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.
warfarin	drug	7-14	vardenafil	drug	23-32	false

DDI-DrugBank.d198.s22	In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
Nitrates	group	17-24	nitrates	group	77-84	false
Nitrates	group	17-24	vardenafil	drug	121-130	false
Nitrates	group	17-24	Vardenafil	drug	227-236	false
nitrates	group	77-84	vardenafil	drug	121-130	mechanism
nitrates	group	77-84	Vardenafil	drug	227-236	false
vardenafil	drug	121-130	Vardenafil	drug	227-236	false

DDI-DrugBank.d198.s23	These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.
Vardenafil	drug	37-46	NTG	drug	84-86	false

DDI-DrugBank.d198.s24	Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.
nitrates	group	43-50	Vardenafil	drug	140-149	false
nitrates	group	43-50	nitrates	group	155-162	false
Vardenafil	drug	140-149	nitrates	group	155-162	advise

DDI-DrugBank.d198.s25	Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.
Nifedipine	drug	0-9	Vardenafil	drug	12-21	false
Nifedipine	drug	0-9	nifedipine	drug	69-78	false
Nifedipine	drug	0-9	nifedipine	drug	192-201	false
Vardenafil	drug	12-21	nifedipine	drug	69-78	false
Vardenafil	drug	12-21	nifedipine	drug	192-201	false
nifedipine	drug	69-78	nifedipine	drug	192-201	false

DDI-DrugBank.d198.s26	Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.
Nifedipine	drug	0-9	Vardenafil	drug	46-55	false

DDI-DrugBank.d198.s27	In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.
nifedipine	drug	57-66	Vardenafil	drug	69-78	effect

DDI-DrugBank.d198.s28	Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.
Alpha-blockers	group	0-13	Vardenafil	drug	21-30	false
Alpha-blockers	group	0-13	terazosin	drug	131-139	false
Vardenafil	drug	21-30	terazosin	drug	131-139	effect

DDI-DrugBank.d198.s29	With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
Vardenafil	drug	28-37	terazosin	drug	49-57	effect

DDI-DrugBank.d198.s30	With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
Vardenafil	drug	28-37	terazosin	drug	49-57	effect

DDI-DrugBank.d198.s31	When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.
Vardenafil	drug	5-14	terazosin	drug	42-50	effect
Vardenafil	drug	5-14	Vardenafil	drug	109-118	false
terazosin	drug	42-50	Vardenafil	drug	109-118	false

DDI-DrugBank.d198.s32	In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
tamsulosin	drug	24-33	Vardenafil	drug	86-95	false
tamsulosin	drug	24-33	tamsulosin	drug	107-116	false
Vardenafil	drug	86-95	tamsulosin	drug	107-116	effect

DDI-DrugBank.d198.s33	Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.
Vardenafil	drug	45-54	tamsulosin	drug	66-75	effect

DDI-DrugBank.d198.s34	The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.
Vardenafil	drug	37-46	alpha-blockers	group	53-66	false

DDI-DrugBank.d198.s35	Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.
Vardenafil	drug	21-30	alpha-blocker	group	66-78	advise

DDI-DrugBank.d198.s36	Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.
Ritonavir	drug	0-8	indinavir	drug	14-22	false
Ritonavir	drug	0-8	Vardenafil	drug	68-77	false
Ritonavir	drug	0-8	ritonavir	drug	95-103	false
Ritonavir	drug	0-8	ritonavir	drug	126-134	false
indinavir	drug	14-22	Vardenafil	drug	68-77	false
indinavir	drug	14-22	ritonavir	drug	95-103	false
indinavir	drug	14-22	ritonavir	drug	126-134	false
Vardenafil	drug	68-77	ritonavir	drug	95-103	mechanism
Vardenafil	drug	68-77	ritonavir	drug	126-134	false
ritonavir	drug	95-103	ritonavir	drug	126-134	false

DDI-DrugBank.d198.s37	Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.
Vardenafil	drug	32-41	indinavir	drug	59-67	mechanism
Vardenafil	drug	32-41	indinavir	drug	90-98	false
indinavir	drug	59-67	indinavir	drug	90-98	false

DDI-DrugBank.d198.s38	Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.
Alcohol	drug	0-6	Alcohol	drug	9-15	false
Alcohol	drug	0-6	vardenafil	drug	103-112	false
Alcohol	drug	9-15	vardenafil	drug	103-112	false

DDI-DrugBank.d198.s39	Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).
Vardenafil	drug	0-9	alcohol	drug	65-71	false
Vardenafil	drug	0-9	alcohol	drug	155-161	false
alcohol	drug	65-71	alcohol	drug	155-161	false

DDI-DrugBank.d198.s40	Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).
Aspirin	brand	0-6	Vardenafil	drug	9-18	false
Aspirin	brand	0-6	aspirin	brand	97-103	false
Vardenafil	drug	9-18	aspirin	brand	97-103	false

DDI-DrugBank.d198.s41	Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).
Vardenafil	drug	20-29	glyburide	drug	72-80	false
Vardenafil	drug	20-29	warfarin	drug	123-130	false
glyburide	drug	72-80	warfarin	drug	123-130	false

DDI-DrugBank.d550.s0	Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
Contraceptives	group	5-18	cefditoren pivoxil	drug	38-55	false
Contraceptives	group	5-18	ethinyl estradiol	drug	98-114	false
Contraceptives	group	5-18	contraceptives	group	155-168	false
cefditoren pivoxil	drug	38-55	ethinyl estradiol	drug	98-114	false
cefditoren pivoxil	drug	38-55	contraceptives	group	155-168	false
ethinyl estradiol	drug	98-114	contraceptives	group	155-168	false

DDI-DrugBank.d550.s1	Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.
cefditoren pivoxil	drug	76-93	antacids	group	123-130	advise

DDI-DrugBank.d550.s2	H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
H2-Receptor Antagonists	group	0-22	famotidine	drug	90-99	false
H2-Receptor Antagonists	group	0-22	cefditoren pivoxil	drug	164-181	false
famotidine	drug	90-99	cefditoren pivoxil	drug	164-181	mechanism

DDI-DrugBank.d550.s3	Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with H2 receptor antagonists.
cefditoren pivoxil	drug	76-93	H2 receptor antagonists	group	123-145	false

DDI-DrugBank.d550.s4	Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
Probenecid	drug	0-9	b-lactam antibiotics	group	26-45	false
Probenecid	drug	0-9	probenecid	drug	69-78	false
Probenecid	drug	0-9	cefditoren pivoxil	drug	85-102	false
Probenecid	drug	0-9	cefditoren	drug	154-163	false
b-lactam antibiotics	group	26-45	probenecid	drug	69-78	false
b-lactam antibiotics	group	26-45	cefditoren pivoxil	drug	85-102	mechanism
b-lactam antibiotics	group	26-45	cefditoren	drug	154-163	false
probenecid	drug	69-78	cefditoren pivoxil	drug	85-102	mechanism
probenecid	drug	69-78	cefditoren	drug	154-163	false
cefditoren pivoxil	drug	85-102	cefditoren	drug	154-163	false

DDI-DrugBank.d240.s0	Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
Ethopropazine	drug	0-12	alcohol	drug	32-38	effect
Ethopropazine	drug	0-12	CNS depressants	group	49-63	effect
alcohol	drug	32-38	CNS depressants	group	49-63	false

DDI-DrugBank.d240.s1	It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action.
amantadine	drug	26-35	anticholinergic drugs	group	46-66	false
amantadine	drug	26-35	MAOIs	group	71-75	false
anticholinergic drugs	group	46-66	MAOIs	group	71-75	false

DDI-DrugBank.d240.s2	Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
Ethopropazine	drug	0-12	chlorpromazine	drug	32-45	mechanism
Ethopropazine	drug	0-12	chlorpromazine	drug	77-90	false
chlorpromazine	drug	32-45	chlorpromazine	drug	77-90	false

DDI-DrugBank.d433.s2	Also, the potential for hepatic injury should be considered when Rebif  is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on Rebif .
Rebif	brand	65-69	Rebif	brand	214-218	false

DDI-DrugBank.d457.s0	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
Barbiturates	group	0-11	contraceptives	group	52-65	effect
Barbiturates	group	0-11	antibiotics	group	76-86	effect
Barbiturates	group	0-11	quinidine	drug	89-97	effect
Barbiturates	group	0-11	theophylline	drug	100-111	effect
Barbiturates	group	0-11	corticosteroids	group	114-128	effect
Barbiturates	group	0-11	anticoagulants	group	131-144	effect
Barbiturates	group	0-11	beta blockers	group	151-163	effect
contraceptives	group	52-65	antibiotics	group	76-86	false
contraceptives	group	52-65	quinidine	drug	89-97	false
contraceptives	group	52-65	theophylline	drug	100-111	false
contraceptives	group	52-65	corticosteroids	group	114-128	false
contraceptives	group	52-65	anticoagulants	group	131-144	false
contraceptives	group	52-65	beta blockers	group	151-163	false
antibiotics	group	76-86	quinidine	drug	89-97	false
antibiotics	group	76-86	theophylline	drug	100-111	false
antibiotics	group	76-86	corticosteroids	group	114-128	false
antibiotics	group	76-86	anticoagulants	group	131-144	false
antibiotics	group	76-86	beta blockers	group	151-163	false
quinidine	drug	89-97	theophylline	drug	100-111	false
quinidine	drug	89-97	corticosteroids	group	114-128	false
quinidine	drug	89-97	anticoagulants	group	131-144	false
quinidine	drug	89-97	beta blockers	group	151-163	false
theophylline	drug	100-111	corticosteroids	group	114-128	false
theophylline	drug	100-111	anticoagulants	group	131-144	false
theophylline	drug	100-111	beta blockers	group	151-163	false
corticosteroids	group	114-128	anticoagulants	group	131-144	false
corticosteroids	group	114-128	beta blockers	group	151-163	false
anticoagulants	group	131-144	beta blockers	group	151-163	false

DDI-DrugBank.d189.s0	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.
Levosimendan	drug	34-45	captopril	drug	116-124	false
Levosimendan	drug	34-45	beta-blockers	group	127-139	false
Levosimendan	drug	34-45	felodipine	drug	142-151	false
Levosimendan	drug	34-45	digoxin	drug	154-160	false
Levosimendan	drug	34-45	warfarin	drug	163-170	false
Levosimendan	drug	34-45	isosorbide mononitrate	drug	173-194	false
Levosimendan	drug	34-45	carvedilol	drug	197-206	false
Levosimendan	drug	34-45	ethanol	drug	209-215	false
Levosimendan	drug	34-45	itraconazole	drug	220-231	false
captopril	drug	116-124	beta-blockers	group	127-139	false
captopril	drug	116-124	felodipine	drug	142-151	false
captopril	drug	116-124	digoxin	drug	154-160	false
captopril	drug	116-124	warfarin	drug	163-170	false
captopril	drug	116-124	isosorbide mononitrate	drug	173-194	false
captopril	drug	116-124	carvedilol	drug	197-206	false
captopril	drug	116-124	ethanol	drug	209-215	false
captopril	drug	116-124	itraconazole	drug	220-231	false
beta-blockers	group	127-139	felodipine	drug	142-151	false
beta-blockers	group	127-139	digoxin	drug	154-160	false
beta-blockers	group	127-139	warfarin	drug	163-170	false
beta-blockers	group	127-139	isosorbide mononitrate	drug	173-194	false
beta-blockers	group	127-139	carvedilol	drug	197-206	false
beta-blockers	group	127-139	ethanol	drug	209-215	false
beta-blockers	group	127-139	itraconazole	drug	220-231	false
felodipine	drug	142-151	digoxin	drug	154-160	false
felodipine	drug	142-151	warfarin	drug	163-170	false
felodipine	drug	142-151	isosorbide mononitrate	drug	173-194	false
felodipine	drug	142-151	carvedilol	drug	197-206	false
felodipine	drug	142-151	ethanol	drug	209-215	false
felodipine	drug	142-151	itraconazole	drug	220-231	false
digoxin	drug	154-160	warfarin	drug	163-170	false
digoxin	drug	154-160	isosorbide mononitrate	drug	173-194	false
digoxin	drug	154-160	carvedilol	drug	197-206	false
digoxin	drug	154-160	ethanol	drug	209-215	false
digoxin	drug	154-160	itraconazole	drug	220-231	false
warfarin	drug	163-170	isosorbide mononitrate	drug	173-194	false
warfarin	drug	163-170	carvedilol	drug	197-206	false
warfarin	drug	163-170	ethanol	drug	209-215	false
warfarin	drug	163-170	itraconazole	drug	220-231	false
isosorbide mononitrate	drug	173-194	carvedilol	drug	197-206	false
isosorbide mononitrate	drug	173-194	ethanol	drug	209-215	false
isosorbide mononitrate	drug	173-194	itraconazole	drug	220-231	false
carvedilol	drug	197-206	ethanol	drug	209-215	false
carvedilol	drug	197-206	itraconazole	drug	220-231	false
ethanol	drug	209-215	itraconazole	drug	220-231	false

DDI-DrugBank.d194.s0	Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride).
ETOPOPHOS	brand	47-55	levamisole hydrochloride	drug	124-147	advise

DDI-DrugBank.d194.s1	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
cyclosporin A	drug	10-22	etoposide	drug	92-100	mechanism
cyclosporin A	drug	10-22	etoposide	drug	132-140	false
cyclosporin A	drug	10-22	etoposide	drug	198-206	false
cyclosporin A	drug	10-22	etoposide	drug	220-228	false
etoposide	drug	92-100	etoposide	drug	132-140	false
etoposide	drug	92-100	etoposide	drug	198-206	false
etoposide	drug	92-100	etoposide	drug	220-228	false
etoposide	drug	132-140	etoposide	drug	198-206	false
etoposide	drug	132-140	etoposide	drug	220-228	false
etoposide	drug	198-206	etoposide	drug	220-228	false

DDI-DrugBank.d350.s3	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.
CANCIDAS	brand	73-80	itraconazole	drug	101-112	false
CANCIDAS	brand	73-80	amphotericin B	drug	115-128	false
CANCIDAS	brand	73-80	mycophenolate	drug	131-143	false
CANCIDAS	brand	73-80	nelfinavir	drug	146-155	false
CANCIDAS	brand	73-80	tacrolimus	drug	161-170	false
itraconazole	drug	101-112	amphotericin B	drug	115-128	false
itraconazole	drug	101-112	mycophenolate	drug	131-143	false
itraconazole	drug	101-112	nelfinavir	drug	146-155	false
itraconazole	drug	101-112	tacrolimus	drug	161-170	false
amphotericin B	drug	115-128	mycophenolate	drug	131-143	false
amphotericin B	drug	115-128	nelfinavir	drug	146-155	false
amphotericin B	drug	115-128	tacrolimus	drug	161-170	false
mycophenolate	drug	131-143	nelfinavir	drug	146-155	false
mycophenolate	drug	131-143	tacrolimus	drug	161-170	false
nelfinavir	drug	146-155	tacrolimus	drug	161-170	false

DDI-DrugBank.d350.s4	CANCIDAS has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.
CANCIDAS	brand	0-7	itraconazole	drug	50-61	false
CANCIDAS	brand	0-7	amphotericin B	drug	64-77	false
itraconazole	drug	50-61	amphotericin B	drug	64-77	false

DDI-DrugBank.d350.s5	CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
CANCIDAS	brand	0-7	tacrolimus	drug	38-47	mechanism
CANCIDAS	brand	0-7	tacrolimus	drug	183-192	false
CANCIDAS	brand	0-7	CANCIDAS	brand	268-275	false
CANCIDAS	brand	0-7	tacrolimus	drug	344-353	false
tacrolimus	drug	38-47	tacrolimus	drug	183-192	false
tacrolimus	drug	38-47	CANCIDAS	brand	268-275	false
tacrolimus	drug	38-47	tacrolimus	drug	344-353	false
tacrolimus	drug	183-192	CANCIDAS	brand	268-275	false
tacrolimus	drug	183-192	tacrolimus	drug	344-353	false
CANCIDAS	brand	268-275	tacrolimus	drug	344-353	false

DDI-DrugBank.d350.s6	For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
tacrolimus	drug	62-71	tacrolimus	drug	110-119	false

DDI-DrugBank.d350.s7	In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.
cyclosporine	drug	25-36	caspofungin	drug	99-109	mechanism

DDI-DrugBank.d350.s8	CANCIDAS did not increase the plasma levels of cyclosporine.
CANCIDAS	brand	0-7	cyclosporine	drug	47-58	false

DDI-DrugBank.d350.s9	There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.
CANCIDAS	brand	57-64	cyclosporine	drug	70-81	effect

DDI-DrugBank.d350.s10	A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.
rifampin	drug	35-42	caspofungin	drug	94-104	mechanism

DDI-DrugBank.d350.s11	Patients on rifampin should receive 70 mg of CANCIDAS daily.
rifampin	drug	12-19	CANCIDAS	brand	45-52	advise

DDI-DrugBank.d350.s12	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
efavirenz	drug	146-154	nevirapine	drug	157-166	false
efavirenz	drug	146-154	phenytoin	drug	169-177	false
efavirenz	drug	146-154	dexamethasone	drug	180-192	false
efavirenz	drug	146-154	carbamazepine	drug	198-210	false
efavirenz	drug	146-154	CANCIDAS	brand	218-225	mechanism
efavirenz	drug	146-154	caspofungin	drug	277-287	false
nevirapine	drug	157-166	phenytoin	drug	169-177	false
nevirapine	drug	157-166	dexamethasone	drug	180-192	false
nevirapine	drug	157-166	carbamazepine	drug	198-210	false
nevirapine	drug	157-166	CANCIDAS	brand	218-225	mechanism
nevirapine	drug	157-166	caspofungin	drug	277-287	false
phenytoin	drug	169-177	dexamethasone	drug	180-192	false
phenytoin	drug	169-177	carbamazepine	drug	198-210	false
phenytoin	drug	169-177	CANCIDAS	brand	218-225	mechanism
phenytoin	drug	169-177	caspofungin	drug	277-287	false
dexamethasone	drug	180-192	carbamazepine	drug	198-210	false
dexamethasone	drug	180-192	CANCIDAS	brand	218-225	mechanism
dexamethasone	drug	180-192	caspofungin	drug	277-287	false
carbamazepine	drug	198-210	CANCIDAS	brand	218-225	mechanism
carbamazepine	drug	198-210	caspofungin	drug	277-287	false
CANCIDAS	brand	218-225	caspofungin	drug	277-287	false

DDI-DrugBank.d350.s14	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
CANCIDAS	brand	5-12	efavirenz	drug	74-82	advise
CANCIDAS	brand	5-12	nevirapine	drug	85-94	advise
CANCIDAS	brand	5-12	phenytoin	drug	97-105	advise
CANCIDAS	brand	5-12	dexamethasone	drug	108-120	advise
CANCIDAS	brand	5-12	carbamazepine	drug	126-138	advise
CANCIDAS	brand	5-12	CANCIDAS	brand	173-180	false
efavirenz	drug	74-82	nevirapine	drug	85-94	false
efavirenz	drug	74-82	phenytoin	drug	97-105	false
efavirenz	drug	74-82	dexamethasone	drug	108-120	false
efavirenz	drug	74-82	carbamazepine	drug	126-138	false
efavirenz	drug	74-82	CANCIDAS	brand	173-180	false
nevirapine	drug	85-94	phenytoin	drug	97-105	false
nevirapine	drug	85-94	dexamethasone	drug	108-120	false
nevirapine	drug	85-94	carbamazepine	drug	126-138	false
nevirapine	drug	85-94	CANCIDAS	brand	173-180	false
phenytoin	drug	97-105	dexamethasone	drug	108-120	false
phenytoin	drug	97-105	carbamazepine	drug	126-138	false
phenytoin	drug	97-105	CANCIDAS	brand	173-180	false
dexamethasone	drug	108-120	carbamazepine	drug	126-138	false
dexamethasone	drug	108-120	CANCIDAS	brand	173-180	false
carbamazepine	drug	126-138	CANCIDAS	brand	173-180	false

DDI-DrugBank.d536.s1	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
thiazides	group	24-32	diuretics	group	44-52	false
thiazides	group	24-32	corticosteroids	group	55-69	false
thiazides	group	24-32	phenothiazines	group	72-85	false
thiazides	group	24-32	thyroid products	group	88-103	false
thiazides	group	24-32	estrogens	group	106-114	false
thiazides	group	24-32	contraceptives	group	122-135	false
thiazides	group	24-32	phenytoin	drug	138-146	false
thiazides	group	24-32	nicotinic acid	drug	149-162	false
thiazides	group	24-32	sympathomimetics	group	165-180	false
thiazides	group	24-32	calcium channel-blocking drugs	group	183-212	false
thiazides	group	24-32	isoniazid	drug	219-227	false
diuretics	group	44-52	corticosteroids	group	55-69	false
diuretics	group	44-52	phenothiazines	group	72-85	false
diuretics	group	44-52	thyroid products	group	88-103	false
diuretics	group	44-52	estrogens	group	106-114	false
diuretics	group	44-52	contraceptives	group	122-135	false
diuretics	group	44-52	phenytoin	drug	138-146	false
diuretics	group	44-52	nicotinic acid	drug	149-162	false
diuretics	group	44-52	sympathomimetics	group	165-180	false
diuretics	group	44-52	calcium channel-blocking drugs	group	183-212	false
diuretics	group	44-52	isoniazid	drug	219-227	false
corticosteroids	group	55-69	phenothiazines	group	72-85	false
corticosteroids	group	55-69	thyroid products	group	88-103	false
corticosteroids	group	55-69	estrogens	group	106-114	false
corticosteroids	group	55-69	contraceptives	group	122-135	false
corticosteroids	group	55-69	phenytoin	drug	138-146	false
corticosteroids	group	55-69	nicotinic acid	drug	149-162	false
corticosteroids	group	55-69	sympathomimetics	group	165-180	false
corticosteroids	group	55-69	calcium channel-blocking drugs	group	183-212	false
corticosteroids	group	55-69	isoniazid	drug	219-227	false
phenothiazines	group	72-85	thyroid products	group	88-103	false
phenothiazines	group	72-85	estrogens	group	106-114	false
phenothiazines	group	72-85	contraceptives	group	122-135	false
phenothiazines	group	72-85	phenytoin	drug	138-146	false
phenothiazines	group	72-85	nicotinic acid	drug	149-162	false
phenothiazines	group	72-85	sympathomimetics	group	165-180	false
phenothiazines	group	72-85	calcium channel-blocking drugs	group	183-212	false
phenothiazines	group	72-85	isoniazid	drug	219-227	false
thyroid products	group	88-103	estrogens	group	106-114	false
thyroid products	group	88-103	contraceptives	group	122-135	false
thyroid products	group	88-103	phenytoin	drug	138-146	false
thyroid products	group	88-103	nicotinic acid	drug	149-162	false
thyroid products	group	88-103	sympathomimetics	group	165-180	false
thyroid products	group	88-103	calcium channel-blocking drugs	group	183-212	false
thyroid products	group	88-103	isoniazid	drug	219-227	false
estrogens	group	106-114	contraceptives	group	122-135	false
estrogens	group	106-114	phenytoin	drug	138-146	false
estrogens	group	106-114	nicotinic acid	drug	149-162	false
estrogens	group	106-114	sympathomimetics	group	165-180	false
estrogens	group	106-114	calcium channel-blocking drugs	group	183-212	false
estrogens	group	106-114	isoniazid	drug	219-227	false
contraceptives	group	122-135	phenytoin	drug	138-146	false
contraceptives	group	122-135	nicotinic acid	drug	149-162	false
contraceptives	group	122-135	sympathomimetics	group	165-180	false
contraceptives	group	122-135	calcium channel-blocking drugs	group	183-212	false
contraceptives	group	122-135	isoniazid	drug	219-227	false
phenytoin	drug	138-146	nicotinic acid	drug	149-162	false
phenytoin	drug	138-146	sympathomimetics	group	165-180	false
phenytoin	drug	138-146	calcium channel-blocking drugs	group	183-212	false
phenytoin	drug	138-146	isoniazid	drug	219-227	false
nicotinic acid	drug	149-162	sympathomimetics	group	165-180	false
nicotinic acid	drug	149-162	calcium channel-blocking drugs	group	183-212	false
nicotinic acid	drug	149-162	isoniazid	drug	219-227	false
sympathomimetics	group	165-180	calcium channel-blocking drugs	group	183-212	false
sympathomimetics	group	165-180	isoniazid	drug	219-227	false
calcium channel-blocking drugs	group	183-212	isoniazid	drug	219-227	false

DDI-DrugBank.d536.s3	When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.
Acarbose	drug	54-61	sulfonylureas	group	83-95	false
Acarbose	drug	54-61	insulin	drug	100-106	false
sulfonylureas	group	83-95	insulin	drug	100-106	false

DDI-DrugBank.d536.s4	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
Intestinal adsorbents	group	0-20	charcoal	drug	30-37	false
Intestinal adsorbents	group	0-20	digestive enzyme preparations	group	44-72	false
Intestinal adsorbents	group	0-20	amylase	drug	124-130	false
Intestinal adsorbents	group	0-20	pancreatin	drug	133-142	false
Intestinal adsorbents	group	0-20	Acarbose	drug	170-177	mechanism
charcoal	drug	30-37	digestive enzyme preparations	group	44-72	false
charcoal	drug	30-37	amylase	drug	124-130	false
charcoal	drug	30-37	pancreatin	drug	133-142	false
charcoal	drug	30-37	Acarbose	drug	170-177	mechanism
digestive enzyme preparations	group	44-72	amylase	drug	124-130	false
digestive enzyme preparations	group	44-72	pancreatin	drug	133-142	false
digestive enzyme preparations	group	44-72	Acarbose	drug	170-177	false
amylase	drug	124-130	pancreatin	drug	133-142	false
amylase	drug	124-130	Acarbose	drug	170-177	mechanism
pancreatin	drug	133-142	Acarbose	drug	170-177	mechanism

DDI-DrugBank.d536.s5	Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.
Acarbose	drug	0-7	digoxin	drug	54-60	mechanism
Acarbose	drug	0-7	digoxin	drug	111-117	false
digoxin	drug	54-60	digoxin	drug	111-117	false

DDI-DrugBank.d536.s6	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.
Acarbose	drug	46-53	digoxin	drug	123-129	false
Acarbose	drug	46-53	nifedipine	drug	132-141	false
Acarbose	drug	46-53	propranolol	drug	144-154	false
Acarbose	drug	46-53	ranitidine	drug	160-169	false
digoxin	drug	123-129	nifedipine	drug	132-141	false
digoxin	drug	123-129	propranolol	drug	144-154	false
digoxin	drug	123-129	ranitidine	drug	160-169	false
nifedipine	drug	132-141	propranolol	drug	144-154	false
nifedipine	drug	132-141	ranitidine	drug	160-169	false
propranolol	drug	144-154	ranitidine	drug	160-169	false

DDI-DrugBank.d536.s7	Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.
Acarbose	drug	0-7	sulfonylurea	drug	69-80	false
Acarbose	drug	0-7	glyburide	drug	82-90	false
sulfonylurea	drug	69-80	glyburide	drug	82-90	false

DDI-DrugBank.d536.s8	Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
Acarbose	drug	0-7	digoxin	drug	20-26	false
Acarbose	drug	0-7	digoxin	drug	79-85	false
Acarbose	drug	0-7	digoxin	drug	148-154	false
Acarbose	drug	0-7	digoxin	drug	240-246	false
digoxin	drug	20-26	digoxin	drug	79-85	false
digoxin	drug	20-26	digoxin	drug	148-154	false
digoxin	drug	20-26	digoxin	drug	240-246	false
digoxin	drug	79-85	digoxin	drug	148-154	false
digoxin	drug	79-85	digoxin	drug	240-246	false
digoxin	drug	148-154	digoxin	drug	240-246	false

DDI-DrugBank.d536.s9	The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.
metformin	drug	14-22	Acarbose	drug	46-53	false

DDI-DrugBank.d536.s10	However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
metformin	drug	34-42	Acarbose	drug	89-96	mechanism
metformin	drug	34-42	metformin	drug	141-149	false
Acarbose	drug	89-96	metformin	drug	141-149	mechanism

DDI-DrugBank.d536.s11	There is little if any clinically significant interaction between Acarbose and metformin.
Acarbose	drug	66-73	metformin	drug	79-87	false

DDI-DrugBank.d80.s0	Potential drug interactions between Mentax (butenafine HCl cream) Cream, 1%, and other drugs have not been systematically evaluated.
Mentax	brand	36-41	butenafine HCl	drug	44-57	false

DDI-DrugBank.d30.s0	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.
hydrochlorothiazide	drug	98-116	digoxin	drug	119-125	false
hydrochlorothiazide	drug	98-116	warfarin	drug	128-135	false
hydrochlorothiazide	drug	98-116	cimetidine	drug	138-147	false
hydrochlorothiazide	drug	98-116	phenobarbital	drug	153-165	false
digoxin	drug	119-125	warfarin	drug	128-135	false
digoxin	drug	119-125	cimetidine	drug	138-147	false
digoxin	drug	119-125	phenobarbital	drug	153-165	false
warfarin	drug	128-135	cimetidine	drug	138-147	false
warfarin	drug	128-135	phenobarbital	drug	153-165	false
cimetidine	drug	138-147	phenobarbital	drug	153-165	false

DDI-DrugBank.d30.s1	Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.
Rifampin	drug	0-7	losartan	drug	73-80	mechanism

DDI-DrugBank.d30.s3	Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.
Ketoconazole	drug	0-11	losartan	drug	46-53	false
Ketoconazole	drug	0-11	losartan	drug	116-123	false
Ketoconazole	drug	0-11	erythromycin	drug	130-141	false
losartan	drug	46-53	losartan	drug	116-123	false
losartan	drug	46-53	erythromycin	drug	130-141	false
losartan	drug	116-123	erythromycin	drug	130-141	false

DDI-DrugBank.d30.s4	Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.
Fluconazole	drug	0-10	losartan	drug	95-102	mechanism

DDI-DrugBank.d30.s8	As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
potassium-sparing diuretics	group	81-107	spironolactone	drug	116-129	false
potassium-sparing diuretics	group	81-107	triamterene	drug	132-142	false
potassium-sparing diuretics	group	81-107	amiloride	drug	145-153	false
potassium-sparing diuretics	group	81-107	potassium	drug	157-165	false
spironolactone	drug	116-129	triamterene	drug	132-142	false
spironolactone	drug	116-129	amiloride	drug	145-153	false
spironolactone	drug	116-129	potassium	drug	157-165	false
triamterene	drug	132-142	amiloride	drug	145-153	false
triamterene	drug	132-142	potassium	drug	157-165	false
amiloride	drug	145-153	potassium	drug	157-165	false

DDI-DrugBank.d30.s9	As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin
antihypertensive agents	group	14-36	losartan	drug	70-77	false
antihypertensive agents	group	14-36	non-steroidal anti-inflammatory drug	group	101-136	false
antihypertensive agents	group	14-36	indomethacin	drug	138-149	false
losartan	drug	70-77	non-steroidal anti-inflammatory drug	group	101-136	false
losartan	drug	70-77	indomethacin	drug	138-149	effect
non-steroidal anti-inflammatory drug	group	101-136	indomethacin	drug	138-149	false

DDI-DrugBank.d56.s0	Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.
amyl nitrite	drug	7-18	alcohol	drug	35-41	effect

DDI-DrugBank.d88.s0	Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
Antacid	group	0-6	aluminum hydroxide	drug	26-43	false
Antacid	group	0-6	magnesium hydroxide	drug	50-68	false
Antacid	group	0-6	antacid	group	81-87	false
Antacid	group	0-6	Maalox	brand	90-95	false
Antacid	group	0-6	capecitabine	drug	126-137	false
aluminum hydroxide	drug	26-43	magnesium hydroxide	drug	50-68	false
aluminum hydroxide	drug	26-43	antacid	group	81-87	false
aluminum hydroxide	drug	26-43	Maalox	brand	90-95	false
aluminum hydroxide	drug	26-43	capecitabine	drug	126-137	false
magnesium hydroxide	drug	50-68	antacid	group	81-87	false
magnesium hydroxide	drug	50-68	Maalox	brand	90-95	false
magnesium hydroxide	drug	50-68	capecitabine	drug	126-137	false
antacid	group	81-87	Maalox	brand	90-95	false
antacid	group	81-87	capecitabine	drug	126-137	false
Maalox	brand	90-95	capecitabine	drug	126-137	false

DDI-DrugBank.d88.s1	There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR);
capecitabine	drug	55-66	5-DFCR	drug_n	88-93	false

DDI-DrugBank.d88.s2	there was no effect on the 3 major metabolites (5-DFUR, 5-FU and FBAL).
5-DFUR	drug_n	48-53	5-FU	drug_n	56-59	false
5-DFUR	drug_n	48-53	FBAL	drug_n	65-68	false
5-FU	drug_n	56-59	FBAL	drug_n	65-68	false

DDI-DrugBank.d88.s3	Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
Coumarin Anticoagulants	group	0-22	capecitabine	drug	109-120	false
Coumarin Anticoagulants	group	0-22	coumarin-derivative anticoagulants	group	141-174	false
Coumarin Anticoagulants	group	0-22	warfarin	drug	184-191	false
Coumarin Anticoagulants	group	0-22	phenprocoumon	drug	197-209	false
capecitabine	drug	109-120	coumarin-derivative anticoagulants	group	141-174	effect
capecitabine	drug	109-120	warfarin	drug	184-191	false
capecitabine	drug	109-120	phenprocoumon	drug	197-209	effect
coumarin-derivative anticoagulants	group	141-174	warfarin	drug	184-191	false
coumarin-derivative anticoagulants	group	141-174	phenprocoumon	drug	197-209	false
warfarin	drug	184-191	phenprocoumon	drug	197-209	false

DDI-DrugBank.d88.s4	Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).
coumarin-derivative anticoagulants	group	16-49	capecitabine	drug	70-81	advise

DDI-DrugBank.d88.s5	Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
Leucovorin	drug	0-9	5-fluorouracil	drug	33-46	false
Leucovorin	drug	0-9	leucovorin	drug	97-106	false
5-fluorouracil	drug	33-46	leucovorin	drug	97-106	mechanism

DDI-DrugBank.d88.s6	Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
leucovorin	drug	116-125	fluorouracil	drug	131-142	effect

DDI-DrugBank.d237.s1	In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.
cisapride	drug	113-121	cisapride	drug	211-219	false

DDI-DrugBank.d237.s2	Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Antibiotics	group	0-10	clarithromycin	drug	52-65	false
Antibiotics	group	0-10	erythromycin	drug	68-79	false
Antibiotics	group	0-10	troleandomycin	drug	86-99	false
Antibiotics	group	0-10	cisapride	drug	136-144	false
Antibiotics	group	0-10	cisapride	drug	189-197	false
clarithromycin	drug	52-65	erythromycin	drug	68-79	false
clarithromycin	drug	52-65	troleandomycin	drug	86-99	false
clarithromycin	drug	52-65	cisapride	drug	136-144	mechanism
clarithromycin	drug	52-65	cisapride	drug	189-197	false
erythromycin	drug	68-79	troleandomycin	drug	86-99	false
erythromycin	drug	68-79	cisapride	drug	136-144	mechanism
erythromycin	drug	68-79	cisapride	drug	189-197	false
troleandomycin	drug	86-99	cisapride	drug	136-144	mechanism
troleandomycin	drug	86-99	cisapride	drug	189-197	false
cisapride	drug	136-144	cisapride	drug	189-197	false

DDI-DrugBank.d237.s3	Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
Anticholinergics	group	0-15	anticholinergic compounds	group	55-79	false
Anticholinergics	group	0-15	belladonna alkaloids	group	90-109	false
Anticholinergics	group	0-15	dicyclomine	drug	115-125	false
Anticholinergics	group	0-15	cisapride	drug	186-194	false
anticholinergic compounds	group	55-79	belladonna alkaloids	group	90-109	false
anticholinergic compounds	group	55-79	dicyclomine	drug	115-125	false
anticholinergic compounds	group	55-79	cisapride	drug	186-194	effect
belladonna alkaloids	group	90-109	dicyclomine	drug	115-125	false
belladonna alkaloids	group	90-109	cisapride	drug	186-194	effect
dicyclomine	drug	115-125	cisapride	drug	186-194	effect

DDI-DrugBank.d237.s4	Anticoagulants (Oral): In patients receiving oral anticoagulants, the coagulation times were increased in some cases.
Anticoagulants	group	0-13	anticoagulants	group	50-63	false

DDI-DrugBank.d237.s5	It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.
cisapride	drug	107-115	anticoagulant	group	164-176	advise

DDI-DrugBank.d237.s6	Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Antidepressants	group	0-14	nefazodone	drug	45-54	false
Antidepressants	group	0-14	cisapride	drug	83-91	false
Antidepressants	group	0-14	cisapride	drug	136-144	false
nefazodone	drug	45-54	cisapride	drug	83-91	mechanism
nefazodone	drug	45-54	cisapride	drug	136-144	false
cisapride	drug	83-91	cisapride	drug	136-144	false

DDI-DrugBank.d237.s7	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Antifungals	group	0-10	fluconazole	drug	56-66	false
Antifungals	group	0-10	itraconazole	drug	69-80	false
Antifungals	group	0-10	ketoconazole	drug	92-103	false
Antifungals	group	0-10	cisapride	drug	140-148	false
Antifungals	group	0-10	cisapride	drug	193-201	false
fluconazole	drug	56-66	itraconazole	drug	69-80	false
fluconazole	drug	56-66	ketoconazole	drug	92-103	false
fluconazole	drug	56-66	cisapride	drug	140-148	mechanism
fluconazole	drug	56-66	cisapride	drug	193-201	false
itraconazole	drug	69-80	ketoconazole	drug	92-103	false
itraconazole	drug	69-80	cisapride	drug	140-148	mechanism
itraconazole	drug	69-80	cisapride	drug	193-201	false
ketoconazole	drug	92-103	cisapride	drug	140-148	mechanism
ketoconazole	drug	92-103	cisapride	drug	193-201	false
cisapride	drug	140-148	cisapride	drug	193-201	false

DDI-DrugBank.d237.s8	Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
ketoconazole	drug	46-57	cisapride	drug	95-103	mechanism
ketoconazole	drug	46-57	cisapride	drug	156-164	false
cisapride	drug	95-103	cisapride	drug	156-164	false

DDI-DrugBank.d237.s9	A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
cisapride	drug	82-90	ketoconazole	drug	96-107	effect

DDI-DrugBank.d237.s10	H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
H2 Receptor Antagonists	group	0-22	Cimetidine	drug	25-34	false
H2 Receptor Antagonists	group	0-22	cisapride	drug	112-120	false
H2 Receptor Antagonists	group	0-22	cisapride	drug	145-153	false
H2 Receptor Antagonists	group	0-22	ranitidine	drug	197-206	false
Cimetidine	drug	25-34	cisapride	drug	112-120	mechanism
Cimetidine	drug	25-34	cisapride	drug	145-153	false
Cimetidine	drug	25-34	ranitidine	drug	197-206	false
cisapride	drug	112-120	cisapride	drug	145-153	false
cisapride	drug	112-120	ranitidine	drug	197-206	false
cisapride	drug	145-153	ranitidine	drug	197-206	false

DDI-DrugBank.d237.s11	The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
cimetidine	drug	35-44	ranitidine	drug	50-59	false
cimetidine	drug	35-44	cisapride	drug	110-118	mechanism
ranitidine	drug	50-59	cisapride	drug	110-118	mechanism

DDI-DrugBank.d237.s12	Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
Protease Inhibitors	group	0-18	indinavir	drug	49-57	false
Protease Inhibitors	group	0-18	ritonavir	drug	63-71	false
Protease Inhibitors	group	0-18	cisapride	drug	108-116	false
Protease Inhibitors	group	0-18	cisapride	drug	160-168	false
indinavir	drug	49-57	ritonavir	drug	63-71	false
indinavir	drug	49-57	cisapride	drug	108-116	mechanism
indinavir	drug	49-57	cisapride	drug	160-168	false
ritonavir	drug	63-71	cisapride	drug	108-116	mechanism
ritonavir	drug	63-71	cisapride	drug	160-168	false
cisapride	drug	108-116	cisapride	drug	160-168	false

DDI-DrugBank.d237.s13	Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.
cisapride	drug	49-57	cisapride	drug	92-100	false

DDI-DrugBank.d237.s14	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
Cisapride	drug	0-8	antiarrhythmics	group	102-116	advise
Cisapride	drug	0-8	quinidine	drug	156-164	advise
Cisapride	drug	0-8	procainamide	drug	170-181	advise
Cisapride	drug	0-8	sotalol	drug	207-213	advise
antiarrhythmics	group	102-116	quinidine	drug	156-164	false
antiarrhythmics	group	102-116	procainamide	drug	170-181	false
antiarrhythmics	group	102-116	sotalol	drug	207-213	false
quinidine	drug	156-164	procainamide	drug	170-181	false
quinidine	drug	156-164	sotalol	drug	207-213	false
procainamide	drug	170-181	sotalol	drug	207-213	false

DDI-DrugBank.d237.s15	tricyclic antidepressants (such as amitriptyline);
tricyclic antidepressants	group	0-24	amitriptyline	drug	35-47	false

DDI-DrugBank.d237.s16	certain tetracyclic antidepressants (such as maprotiline);
tetracyclic antidepressants	group	8-34	maprotiline	drug	45-55	false

DDI-DrugBank.d237.s17	certain antipsychotic medications (such as sertindole);
antipsychotic medications	group	8-32	sertindole	drug	43-52	false

DDI-DrugBank.d237.s18	astemizole, bepridil, sparfloxacin, and terodiline.
astemizole	drug	0-9	bepridil	drug	12-19	false
astemizole	drug	0-9	sparfloxacin	drug	22-33	false
astemizole	drug	0-9	terodiline	drug	40-49	false
bepridil	drug	12-19	sparfloxacin	drug	22-33	false
bepridil	drug	12-19	terodiline	drug	40-49	false
sparfloxacin	drug	22-33	terodiline	drug	40-49	false

DDI-DrugBank.d296.s0	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
Diphenhydramine hydrochloride	drug	0-28	alcohol	drug	56-62	effect
Diphenhydramine hydrochloride	drug	0-28	CNS depressants	group	74-88	effect
Diphenhydramine hydrochloride	drug	0-28	hypnotics	group	91-99	effect
Diphenhydramine hydrochloride	drug	0-28	sedatives	group	102-110	effect
Diphenhydramine hydrochloride	drug	0-28	tranquilizers	group	113-125	effect
alcohol	drug	56-62	CNS depressants	group	74-88	false
alcohol	drug	56-62	hypnotics	group	91-99	false
alcohol	drug	56-62	sedatives	group	102-110	false
alcohol	drug	56-62	tranquilizers	group	113-125	false
CNS depressants	group	74-88	hypnotics	group	91-99	false
CNS depressants	group	74-88	sedatives	group	102-110	false
CNS depressants	group	74-88	tranquilizers	group	113-125	false
hypnotics	group	91-99	sedatives	group	102-110	false
hypnotics	group	91-99	tranquilizers	group	113-125	false
sedatives	group	102-110	tranquilizers	group	113-125	false

DDI-DrugBank.d296.s1	MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
MAO inhibitors	group	0-13	antihistamines	group	77-90	effect

DDI-DrugBank.d116.s0	Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.
amantadine	drug	37-46	central nervous system stimulants	group	82-114	advise

DDI-DrugBank.d508.s1	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
heparin	drug	40-46	vitamin K antagonists	group	52-72	false
heparin	drug	40-46	acetylsalicylic acid	drug	119-138	false
heparin	drug	40-46	dipyridamole	drug	141-152	false
heparin	drug	40-46	Abciximab	drug	158-166	false
heparin	drug	40-46	Activase	brand	246-253	effect
vitamin K antagonists	group	52-72	acetylsalicylic acid	drug	119-138	false
vitamin K antagonists	group	52-72	dipyridamole	drug	141-152	false
vitamin K antagonists	group	52-72	Abciximab	drug	158-166	false
vitamin K antagonists	group	52-72	Activase	brand	246-253	effect
acetylsalicylic acid	drug	119-138	dipyridamole	drug	141-152	false
acetylsalicylic acid	drug	119-138	Abciximab	drug	158-166	false
acetylsalicylic acid	drug	119-138	Activase	brand	246-253	int
dipyridamole	drug	141-152	Abciximab	drug	158-166	false
dipyridamole	drug	141-152	Activase	brand	246-253	effect
Abciximab	drug	158-166	Activase	brand	246-253	effect

DDI-DrugBank.d508.s2	Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
Antithrombotics	group	7-21	Aspirin	brand	23-29	false
Antithrombotics	group	7-21	heparin	drug	35-41	false
Antithrombotics	group	7-21	Activase	brand	112-119	false
Aspirin	brand	23-29	heparin	drug	35-41	false
Aspirin	brand	23-29	Activase	brand	112-119	false
heparin	drug	35-41	Activase	brand	112-119	false

DDI-DrugBank.d508.s3	Because heparin, aspirin, or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
heparin	drug	8-14	aspirin	brand	17-23	false
heparin	drug	8-14	Activase	brand	29-36	false
aspirin	brand	17-23	Activase	brand	29-36	false

DDI-DrugBank.d508.s4	The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.
heparin	drug	23-29	aspirin	brand	34-40	false

DDI-DrugBank.d347.s0	Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.
FACTIVE	brand	34-40	theophylline	drug	95-106	false
FACTIVE	brand	34-40	digoxin	drug	109-115	false
FACTIVE	brand	34-40	ethinylestradiol	drug	123-138	false
FACTIVE	brand	34-40	contraceptive product	group	160-180	false
theophylline	drug	95-106	digoxin	drug	109-115	false
theophylline	drug	95-106	ethinylestradiol	drug	123-138	false
theophylline	drug	95-106	contraceptive product	group	160-180	false
digoxin	drug	109-115	ethinylestradiol	drug	123-138	false
digoxin	drug	109-115	contraceptive product	group	160-180	false
ethinylestradiol	drug	123-138	contraceptive product	group	160-180	false

DDI-DrugBank.d347.s1	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
FACTIVE	brand	30-36	calcium carbonate	drug	42-58	mechanism
FACTIVE	brand	30-36	cimetidine	drug	61-70	mechanism
FACTIVE	brand	30-36	omeprazole	drug	73-82	mechanism
FACTIVE	brand	30-36	estrogen	group	91-98	mechanism
FACTIVE	brand	30-36	progesterone	drug	100-111	mechanism
FACTIVE	brand	30-36	contraceptive	group	118-130	mechanism
FACTIVE	brand	30-36	gemifloxacin	drug	182-193	false
calcium carbonate	drug	42-58	cimetidine	drug	61-70	false
calcium carbonate	drug	42-58	omeprazole	drug	73-82	false
calcium carbonate	drug	42-58	estrogen	group	91-98	false
calcium carbonate	drug	42-58	progesterone	drug	100-111	false
calcium carbonate	drug	42-58	contraceptive	group	118-130	false
calcium carbonate	drug	42-58	gemifloxacin	drug	182-193	false
cimetidine	drug	61-70	omeprazole	drug	73-82	false
cimetidine	drug	61-70	estrogen	group	91-98	false
cimetidine	drug	61-70	progesterone	drug	100-111	false
cimetidine	drug	61-70	contraceptive	group	118-130	false
cimetidine	drug	61-70	gemifloxacin	drug	182-193	false
omeprazole	drug	73-82	estrogen	group	91-98	false
omeprazole	drug	73-82	progesterone	drug	100-111	false
omeprazole	drug	73-82	contraceptive	group	118-130	false
omeprazole	drug	73-82	gemifloxacin	drug	182-193	false
estrogen	group	91-98	progesterone	drug	100-111	false
estrogen	group	91-98	contraceptive	group	118-130	false
estrogen	group	91-98	gemifloxacin	drug	182-193	false
progesterone	drug	100-111	contraceptive	group	118-130	false
progesterone	drug	100-111	gemifloxacin	drug	182-193	false
contraceptive	group	118-130	gemifloxacin	drug	182-193	false

DDI-DrugBank.d347.s2	Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.
FACTIVE	brand	30-36	probenecid	drug	43-52	mechanism
FACTIVE	brand	30-36	gemifloxacin	drug	105-116	false
probenecid	drug	43-52	gemifloxacin	drug	105-116	false

DDI-DrugBank.d347.s3	FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.
FACTIVE	brand	0-6	warfarin	drug	65-72	false
FACTIVE	brand	0-6	warfarin	drug	104-111	false
warfarin	drug	65-72	warfarin	drug	104-111	false

DDI-DrugBank.d347.s4	However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.
quinolones	group	22-31	warfarin	drug	92-99	effect
quinolones	group	22-31	quinolone antimicrobial	group	222-244	false
quinolones	group	22-31	warfarin	drug	281-288	false
warfarin	drug	92-99	quinolone antimicrobial	group	222-244	false
warfarin	drug	92-99	warfarin	drug	281-288	false
quinolone antimicrobial	group	222-244	warfarin	drug	281-288	advise

DDI-DrugBank.d347.s6	The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
gemifloxacin	drug	23-34	antacid	group	101-107	false
gemifloxacin	drug	23-34	aluminum	drug	120-127	mechanism
gemifloxacin	drug	23-34	magnesium	drug	133-141	mechanism
antacid	group	101-107	aluminum	drug	120-127	false
antacid	group	101-107	magnesium	drug	133-141	false
aluminum	drug	120-127	magnesium	drug	133-141	false

DDI-DrugBank.d347.s7	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
Magnesium	drug	0-8	aluminum	drug	18-25	false
Magnesium	drug	0-8	antacids	group	38-45	false
Magnesium	drug	0-8	ferrous sulfate	drug	68-82	false
Magnesium	drug	0-8	iron	drug	85-88	false
Magnesium	drug	0-8	multivitamin preparations	group	92-116	false
Magnesium	drug	0-8	zinc	drug	129-132	false
Magnesium	drug	0-8	Videx	brand	161-165	false
Magnesium	drug	0-8	didanosine	drug	168-177	false
Magnesium	drug	0-8	FACTIVE	brand	307-313	advise
aluminum	drug	18-25	antacids	group	38-45	false
aluminum	drug	18-25	ferrous sulfate	drug	68-82	false
aluminum	drug	18-25	iron	drug	85-88	false
aluminum	drug	18-25	multivitamin preparations	group	92-116	false
aluminum	drug	18-25	zinc	drug	129-132	false
aluminum	drug	18-25	Videx	brand	161-165	false
aluminum	drug	18-25	didanosine	drug	168-177	false
aluminum	drug	18-25	FACTIVE	brand	307-313	advise
antacids	group	38-45	ferrous sulfate	drug	68-82	false
antacids	group	38-45	iron	drug	85-88	false
antacids	group	38-45	multivitamin preparations	group	92-116	false
antacids	group	38-45	zinc	drug	129-132	false
antacids	group	38-45	Videx	brand	161-165	false
antacids	group	38-45	didanosine	drug	168-177	false
antacids	group	38-45	FACTIVE	brand	307-313	false
ferrous sulfate	drug	68-82	iron	drug	85-88	false
ferrous sulfate	drug	68-82	multivitamin preparations	group	92-116	false
ferrous sulfate	drug	68-82	zinc	drug	129-132	false
ferrous sulfate	drug	68-82	Videx	brand	161-165	false
ferrous sulfate	drug	68-82	didanosine	drug	168-177	false
ferrous sulfate	drug	68-82	FACTIVE	brand	307-313	advise
iron	drug	85-88	multivitamin preparations	group	92-116	false
iron	drug	85-88	zinc	drug	129-132	false
iron	drug	85-88	Videx	brand	161-165	false
iron	drug	85-88	didanosine	drug	168-177	false
iron	drug	85-88	FACTIVE	brand	307-313	advise
multivitamin preparations	group	92-116	zinc	drug	129-132	false
multivitamin preparations	group	92-116	Videx	brand	161-165	false
multivitamin preparations	group	92-116	didanosine	drug	168-177	false
multivitamin preparations	group	92-116	FACTIVE	brand	307-313	advise
zinc	drug	129-132	Videx	brand	161-165	false
zinc	drug	129-132	didanosine	drug	168-177	false
zinc	drug	129-132	FACTIVE	brand	307-313	advise
Videx	brand	161-165	didanosine	drug	168-177	false
Videx	brand	161-165	FACTIVE	brand	307-313	advise
didanosine	drug	168-177	FACTIVE	brand	307-313	advise

DDI-DrugBank.d347.s8	Sucralfate should not be taken within 2 hours of FACTIVE.
Sucralfate	drug	0-9	FACTIVE	brand	49-55	advise

DDI-DrugBank.d265.s0	Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.
Chlorthalidone	drug	0-13	antihypertensive drugs	group	60-81	effect

DDI-DrugBank.d265.s7	Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
Chlorthalidone	drug	0-13	tubocurarine	drug	68-79	effect

DDI-DrugBank.d265.s8	Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
Chlorthalidone	drug	0-13	norepinephrine	drug	73-86	effect

DDI-DrugBank.d86.s0	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
antipsychotic drug	group	82-99	chlorpromazine	drug	106-119	false
antipsychotic drug	group	82-99	antiparkinsonian drug	group	126-146	effect
antipsychotic drug	group	82-99	trihexyphenidyl	drug	153-167	effect
antipsychotic drug	group	82-99	tricyclic antidepressant	group	180-203	effect
antipsychotic drug	group	82-99	amitriptyline	drug	210-222	effect
chlorpromazine	drug	106-119	antiparkinsonian drug	group	126-146	effect
chlorpromazine	drug	106-119	trihexyphenidyl	drug	153-167	effect
chlorpromazine	drug	106-119	tricyclic antidepressant	group	180-203	effect
chlorpromazine	drug	106-119	amitriptyline	drug	210-222	effect
antiparkinsonian drug	group	126-146	trihexyphenidyl	drug	153-167	false
antiparkinsonian drug	group	126-146	tricyclic antidepressant	group	180-203	effect
antiparkinsonian drug	group	126-146	amitriptyline	drug	210-222	effect
trihexyphenidyl	drug	153-167	tricyclic antidepressant	group	180-203	effect
trihexyphenidyl	drug	153-167	amitriptyline	drug	210-222	effect
tricyclic antidepressant	group	180-203	amitriptyline	drug	210-222	false

DDI-DrugBank.d86.s1	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
anti-depressants	group	48-63	anti-anxiety drugs	group	65-82	false
anti-depressants	group	48-63	beta-blockers	group	128-140	false
anti-depressants	group	48-63	propranolol	drug	149-159	false
anti-depressants	group	48-63	sparfloxacin	drug	163-174	false
anti-depressants	group	48-63	grepafloxacin	drug	177-189	false
anti-depressants	group	48-63	guanethidine	drug	192-203	false
anti-depressants	group	48-63	guanadrel	drug	206-214	false
anti-depressants	group	48-63	metrizamide	drug	217-227	false
anti-depressants	group	48-63	cabergoline	drug	230-240	false
anti-depressants	group	48-63	lithium	drug	243-249	false
anti-depressants	group	48-63	narcotic	group	252-259	false
anti-depressants	group	48-63	codeine	drug	284-290	false
anti-depressants	group	48-63	antihistamines	group	338-351	false
anti-depressants	group	48-63	diphenhydramine	drug	360-374	false
anti-anxiety drugs	group	65-82	beta-blockers	group	128-140	false
anti-anxiety drugs	group	65-82	propranolol	drug	149-159	false
anti-anxiety drugs	group	65-82	sparfloxacin	drug	163-174	false
anti-anxiety drugs	group	65-82	grepafloxacin	drug	177-189	false
anti-anxiety drugs	group	65-82	guanethidine	drug	192-203	false
anti-anxiety drugs	group	65-82	guanadrel	drug	206-214	false
anti-anxiety drugs	group	65-82	metrizamide	drug	217-227	false
anti-anxiety drugs	group	65-82	cabergoline	drug	230-240	false
anti-anxiety drugs	group	65-82	lithium	drug	243-249	false
anti-anxiety drugs	group	65-82	narcotic	group	252-259	false
anti-anxiety drugs	group	65-82	codeine	drug	284-290	false
anti-anxiety drugs	group	65-82	antihistamines	group	338-351	false
anti-anxiety drugs	group	65-82	diphenhydramine	drug	360-374	false
beta-blockers	group	128-140	propranolol	drug	149-159	false
beta-blockers	group	128-140	sparfloxacin	drug	163-174	false
beta-blockers	group	128-140	grepafloxacin	drug	177-189	false
beta-blockers	group	128-140	guanethidine	drug	192-203	false
beta-blockers	group	128-140	guanadrel	drug	206-214	false
beta-blockers	group	128-140	metrizamide	drug	217-227	false
beta-blockers	group	128-140	cabergoline	drug	230-240	false
beta-blockers	group	128-140	lithium	drug	243-249	false
beta-blockers	group	128-140	narcotic	group	252-259	false
beta-blockers	group	128-140	codeine	drug	284-290	false
beta-blockers	group	128-140	antihistamines	group	338-351	false
beta-blockers	group	128-140	diphenhydramine	drug	360-374	false
propranolol	drug	149-159	sparfloxacin	drug	163-174	false
propranolol	drug	149-159	grepafloxacin	drug	177-189	false
propranolol	drug	149-159	guanethidine	drug	192-203	false
propranolol	drug	149-159	guanadrel	drug	206-214	false
propranolol	drug	149-159	metrizamide	drug	217-227	false
propranolol	drug	149-159	cabergoline	drug	230-240	false
propranolol	drug	149-159	lithium	drug	243-249	false
propranolol	drug	149-159	narcotic	group	252-259	false
propranolol	drug	149-159	codeine	drug	284-290	false
propranolol	drug	149-159	antihistamines	group	338-351	false
propranolol	drug	149-159	diphenhydramine	drug	360-374	false
sparfloxacin	drug	163-174	grepafloxacin	drug	177-189	false
sparfloxacin	drug	163-174	guanethidine	drug	192-203	false
sparfloxacin	drug	163-174	guanadrel	drug	206-214	false
sparfloxacin	drug	163-174	metrizamide	drug	217-227	false
sparfloxacin	drug	163-174	cabergoline	drug	230-240	false
sparfloxacin	drug	163-174	lithium	drug	243-249	false
sparfloxacin	drug	163-174	narcotic	group	252-259	false
sparfloxacin	drug	163-174	codeine	drug	284-290	false
sparfloxacin	drug	163-174	antihistamines	group	338-351	false
sparfloxacin	drug	163-174	diphenhydramine	drug	360-374	false
grepafloxacin	drug	177-189	guanethidine	drug	192-203	false
grepafloxacin	drug	177-189	guanadrel	drug	206-214	false
grepafloxacin	drug	177-189	metrizamide	drug	217-227	false
grepafloxacin	drug	177-189	cabergoline	drug	230-240	false
grepafloxacin	drug	177-189	lithium	drug	243-249	false
grepafloxacin	drug	177-189	narcotic	group	252-259	false
grepafloxacin	drug	177-189	codeine	drug	284-290	false
grepafloxacin	drug	177-189	antihistamines	group	338-351	false
grepafloxacin	drug	177-189	diphenhydramine	drug	360-374	false
guanethidine	drug	192-203	guanadrel	drug	206-214	false
guanethidine	drug	192-203	metrizamide	drug	217-227	false
guanethidine	drug	192-203	cabergoline	drug	230-240	false
guanethidine	drug	192-203	lithium	drug	243-249	false
guanethidine	drug	192-203	narcotic	group	252-259	false
guanethidine	drug	192-203	codeine	drug	284-290	false
guanethidine	drug	192-203	antihistamines	group	338-351	false
guanethidine	drug	192-203	diphenhydramine	drug	360-374	false
guanadrel	drug	206-214	metrizamide	drug	217-227	false
guanadrel	drug	206-214	cabergoline	drug	230-240	false
guanadrel	drug	206-214	lithium	drug	243-249	false
guanadrel	drug	206-214	narcotic	group	252-259	false
guanadrel	drug	206-214	codeine	drug	284-290	false
guanadrel	drug	206-214	antihistamines	group	338-351	false
guanadrel	drug	206-214	diphenhydramine	drug	360-374	false
metrizamide	drug	217-227	cabergoline	drug	230-240	false
metrizamide	drug	217-227	lithium	drug	243-249	false
metrizamide	drug	217-227	narcotic	group	252-259	false
metrizamide	drug	217-227	codeine	drug	284-290	false
metrizamide	drug	217-227	antihistamines	group	338-351	false
metrizamide	drug	217-227	diphenhydramine	drug	360-374	false
cabergoline	drug	230-240	lithium	drug	243-249	false
cabergoline	drug	230-240	narcotic	group	252-259	false
cabergoline	drug	230-240	codeine	drug	284-290	false
cabergoline	drug	230-240	antihistamines	group	338-351	false
cabergoline	drug	230-240	diphenhydramine	drug	360-374	false
lithium	drug	243-249	narcotic	group	252-259	false
lithium	drug	243-249	codeine	drug	284-290	false
lithium	drug	243-249	antihistamines	group	338-351	false
lithium	drug	243-249	diphenhydramine	drug	360-374	false
narcotic	group	252-259	codeine	drug	284-290	false
narcotic	group	252-259	antihistamines	group	338-351	false
narcotic	group	252-259	diphenhydramine	drug	360-374	false
codeine	drug	284-290	antihistamines	group	338-351	false
codeine	drug	284-290	diphenhydramine	drug	360-374	false
antihistamines	group	338-351	diphenhydramine	drug	360-374	false

DDI-DrugBank.d437.s4	HIV Protease Inhibitors: The effect of amprenavir on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.
HIV Protease Inhibitors	group	0-22	amprenavir	drug	39-48	false
HIV Protease Inhibitors	group	0-22	HIV protease inhibitors	group	88-110	false
amprenavir	drug	39-48	HIV protease inhibitors	group	88-110	false

DDI-DrugBank.d437.s5	Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.
Indinavir	drug	0-8	amprenavir	drug	109-118	mechanism

DDI-DrugBank.d437.s7	Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.
Saquinavir	drug	0-9	amprenavir	drug	127-136	mechanism

DDI-DrugBank.d437.s8	Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.
Nelfinavir	drug	0-9	amprenavir	drug	110-119	mechanism

DDI-DrugBank.d437.s9	Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.
Methadone	drug	0-8	amprenavir	drug	31-40	false
Methadone	drug	0-8	methadone	drug	46-54	false
Methadone	drug	0-8	methadone	drug	86-94	false
amprenavir	drug	31-40	methadone	drug	46-54	effect
amprenavir	drug	31-40	methadone	drug	86-94	false
methadone	drug	46-54	methadone	drug	86-94	false

DDI-DrugBank.d437.s10	Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
amprenavir	drug	20-29	methadone	drug	35-43	mechanism
amprenavir	drug	20-29	amprenavir	drug	148-157	false
methadone	drug	35-43	amprenavir	drug	148-157	false

DDI-DrugBank.d437.s13	Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
Amprenavir	drug	37-46	ritonavir	drug	61-69	effect

DDI-DrugBank.d437.s14	Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
Amprenavir	drug	97-106	ritonavir	drug	112-120	advise

DDI-DrugBank.d437.s15	For comprehensive information concerning laboratory test alterations associated with ritonavir, physicians should refer to the complete prescribing information for NORVIR (ritonavir).
ritonavir	drug	85-93	NORVIR	brand	164-169	false
ritonavir	drug	85-93	ritonavir	drug	172-180	false
NORVIR	brand	164-169	ritonavir	drug	172-180	false

DDI-DrugBank.d216.s0	CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
Ethanol	drug	17-23	eszopiclone	drug	105-115	false
Ethanol	drug	17-23	ethanol	drug	121-127	false
Ethanol	drug	17-23	ethanol	drug	163-169	false
eszopiclone	drug	105-115	ethanol	drug	121-127	effect
eszopiclone	drug	105-115	ethanol	drug	163-169	false
ethanol	drug	121-127	ethanol	drug	163-169	false

DDI-DrugBank.d216.s1	Paroxetine: Coadministration of single doses of eszopiclone 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.
Paroxetine	drug	0-9	eszopiclone	drug	48-58	false
Paroxetine	drug	0-9	paroxetine	drug	69-78	false
eszopiclone	drug	48-58	paroxetine	drug	69-78	false

DDI-DrugBank.d216.s2	Lorazepam: Coadministration of single doses of eszopiclone 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.
Lorazepam	drug	0-8	eszopiclone	drug	47-57	false
Lorazepam	drug	0-8	lorazepam	drug	68-76	false
eszopiclone	drug	47-57	lorazepam	drug	68-76	false

DDI-DrugBank.d216.s3	Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.
Olanzapine	drug	0-9	eszopiclone	drug	32-42	false
Olanzapine	drug	0-9	olanzapine	drug	53-62	false
eszopiclone	drug	32-42	olanzapine	drug	53-62	effect

DDI-DrugBank.d216.s6	Drugs That Inhibit CYP3A4 (Ketoconazole) CYP3A4 is a major metabolic pathway for elimination of eszopiclone.
Ketoconazole	drug	27-38	eszopiclone	drug	96-106	false

DDI-DrugBank.d216.s7	The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
eszopiclone	drug	11-21	ketoconazole	drug	69-80	mechanism

DDI-DrugBank.d216.s9	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.
itraconazole	drug	41-52	clarithromycin	drug	55-68	false
itraconazole	drug	41-52	nefazodone	drug	71-80	false
itraconazole	drug	41-52	troleandomycin	drug	83-96	false
itraconazole	drug	41-52	ritonavir	drug	99-107	false
itraconazole	drug	41-52	nelfinavir	drug	110-119	false
clarithromycin	drug	55-68	nefazodone	drug	71-80	false
clarithromycin	drug	55-68	troleandomycin	drug	83-96	false
clarithromycin	drug	55-68	ritonavir	drug	99-107	false
clarithromycin	drug	55-68	nelfinavir	drug	110-119	false
nefazodone	drug	71-80	troleandomycin	drug	83-96	false
nefazodone	drug	71-80	ritonavir	drug	99-107	false
nefazodone	drug	71-80	nelfinavir	drug	110-119	false
troleandomycin	drug	83-96	ritonavir	drug	99-107	false
troleandomycin	drug	83-96	nelfinavir	drug	110-119	false
ritonavir	drug	99-107	nelfinavir	drug	110-119	false

DDI-DrugBank.d216.s10	Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
Rifampicin	drug	26-35	zopiclone	drug	46-54	false
Rifampicin	drug	26-35	rifampicin	drug	104-113	false
zopiclone	drug	46-54	rifampicin	drug	104-113	mechanism

DDI-DrugBank.d216.s15	Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.
Digoxin	drug	38-44	eszopiclone	drug	63-73	false
Digoxin	drug	38-44	digoxin	drug	119-125	false
eszopiclone	drug	63-73	digoxin	drug	119-125	false

DDI-DrugBank.d216.s16	Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin
Warfarin	drug	0-7	Eszopiclone	drug	10-20	false
Warfarin	drug	0-7	(R)-warfarin	drug	95-98;107-114	false
Warfarin	drug	0-7	(S)-warfarin	drug	104-115	false
Warfarin	drug	0-7	warfarin	drug	233-240	false
Eszopiclone	drug	10-20	(R)-warfarin	drug	95-98;107-114	false
Eszopiclone	drug	10-20	(S)-warfarin	drug	104-115	false
Eszopiclone	drug	10-20	warfarin	drug	233-240	false
(R)-warfarin	drug	95-98;107-114	(S)-warfarin	drug	104-115	false
(R)-warfarin	drug	95-98;107-114	warfarin	drug	233-240	false
(S)-warfarin	drug	104-115	warfarin	drug	233-240	false

DDI-DrugBank.d23.s0	HEMABATE may augment the activity of other oxytocic agents.
HEMABATE	brand	0-7	oxytocic agents	group	43-57	effect

DDI-DrugBank.d114.s1	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, sedatives, tranquilizers).
psychotropic drugs	group	76-93	narcotics	group	102-110	false
psychotropic drugs	group	76-93	analgesics	group	113-122	false
psychotropic drugs	group	76-93	antiemetics	group	125-135	false
psychotropic drugs	group	76-93	sedatives	group	138-146	false
psychotropic drugs	group	76-93	tranquilizers	group	149-161	false
narcotics	group	102-110	analgesics	group	113-122	false
narcotics	group	102-110	antiemetics	group	125-135	false
narcotics	group	102-110	sedatives	group	138-146	false
narcotics	group	102-110	tranquilizers	group	149-161	false
analgesics	group	113-122	antiemetics	group	125-135	false
analgesics	group	113-122	sedatives	group	138-146	false
analgesics	group	113-122	tranquilizers	group	149-161	false
antiemetics	group	125-135	sedatives	group	138-146	false
antiemetics	group	125-135	tranquilizers	group	149-161	false
sedatives	group	138-146	tranquilizers	group	149-161	false

DDI-DrugBank.d114.s2	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
aminoglycosides	group	65-79	indomethacin	drug	82-93	false
aminoglycosides	group	65-79	cytotoxic	group	115-123	false
aminoglycosides	group	65-79	doxorubicin	drug	159-169	false
aminoglycosides	group	65-79	methotrexate	drug	194-205	false
aminoglycosides	group	65-79	asparaginase	drug	208-219	false
aminoglycosides	group	65-79	PROLEUKIN	brand	235-243	effect
indomethacin	drug	82-93	cytotoxic	group	115-123	false
indomethacin	drug	82-93	doxorubicin	drug	159-169	false
indomethacin	drug	82-93	methotrexate	drug	194-205	false
indomethacin	drug	82-93	asparaginase	drug	208-219	false
indomethacin	drug	82-93	PROLEUKIN	brand	235-243	effect
cytotoxic	group	115-123	doxorubicin	drug	159-169	false
cytotoxic	group	115-123	methotrexate	drug	194-205	false
cytotoxic	group	115-123	asparaginase	drug	208-219	false
cytotoxic	group	115-123	PROLEUKIN	brand	235-243	effect
doxorubicin	drug	159-169	methotrexate	drug	194-205	false
doxorubicin	drug	159-169	asparaginase	drug	208-219	false
doxorubicin	drug	159-169	PROLEUKIN	brand	235-243	effect
methotrexate	drug	194-205	asparaginase	drug	208-219	false
methotrexate	drug	194-205	PROLEUKIN	brand	235-243	effect
asparaginase	drug	208-219	PROLEUKIN	brand	235-243	effect

DDI-DrugBank.d114.s3	The safety and efficacy of PROLEUKIN in combination with any antineoplastic agents have not been established.
PROLEUKIN	brand	27-35	antineoplastic agents	group	61-81	false

DDI-DrugBank.d114.s5	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
PROLEUKIN	brand	121-129	antineoplastic agents	group	135-155	effect
PROLEUKIN	brand	121-129	dacarbazine	drug	172-182	effect
PROLEUKIN	brand	121-129	cis-platinum	drug	185-196	effect
PROLEUKIN	brand	121-129	tamoxifen	drug	199-207	effect
PROLEUKIN	brand	121-129	interferon-alfa	drug	213-227	effect
antineoplastic agents	group	135-155	dacarbazine	drug	172-182	false
antineoplastic agents	group	135-155	cis-platinum	drug	185-196	false
antineoplastic agents	group	135-155	tamoxifen	drug	199-207	false
antineoplastic agents	group	135-155	interferon-alfa	drug	213-227	false
dacarbazine	drug	172-182	cis-platinum	drug	185-196	false
dacarbazine	drug	172-182	tamoxifen	drug	199-207	false
dacarbazine	drug	172-182	interferon-alfa	drug	213-227	false
cis-platinum	drug	185-196	tamoxifen	drug	199-207	false
cis-platinum	drug	185-196	interferon-alfa	drug	213-227	false
tamoxifen	drug	199-207	interferon-alfa	drug	213-227	false

DDI-DrugBank.d114.s8	Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.
PROLEUKIN	brand	161-169	interferon-alfa	drug	175-189	effect

DDI-DrugBank.d114.s9	Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
interferon-alfa	drug	140-154	PROLEUKIN	brand	160-168	effect

DDI-DrugBank.d114.s10	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
glucocorticoids	group	9-23	PROLEUKIN	brand	51-59	effect
glucocorticoids	group	9-23	PROLEUKIN	brand	212-220	false
glucocorticoids	group	9-23	PROLEUKIN	brand	264-272	false
glucocorticoids	group	9-23	Beta-blockers	group	305-317	false
glucocorticoids	group	9-23	antihypertensives	group	329-345	false
glucocorticoids	group	9-23	PROLEUKIN	brand	388-396	false
PROLEUKIN	brand	51-59	PROLEUKIN	brand	212-220	false
PROLEUKIN	brand	51-59	PROLEUKIN	brand	264-272	false
PROLEUKIN	brand	51-59	Beta-blockers	group	305-317	false
PROLEUKIN	brand	51-59	antihypertensives	group	329-345	false
PROLEUKIN	brand	51-59	PROLEUKIN	brand	388-396	false
PROLEUKIN	brand	212-220	PROLEUKIN	brand	264-272	false
PROLEUKIN	brand	212-220	Beta-blockers	group	305-317	false
PROLEUKIN	brand	212-220	antihypertensives	group	329-345	false
PROLEUKIN	brand	212-220	PROLEUKIN	brand	388-396	false
PROLEUKIN	brand	264-272	Beta-blockers	group	305-317	false
PROLEUKIN	brand	264-272	antihypertensives	group	329-345	false
PROLEUKIN	brand	264-272	PROLEUKIN	brand	388-396	false
Beta-blockers	group	305-317	antihypertensives	group	329-345	false
Beta-blockers	group	305-317	PROLEUKIN	brand	388-396	effect
antihypertensives	group	329-345	PROLEUKIN	brand	388-396	effect

DDI-DrugBank.d114.s11	Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
Iodinated Contrast Media	group	29-52	interleukin-2	drug	154-166	false
Iodinated Contrast Media	group	29-52	radiographic iodinated contrast media	group	223-259	false
interleukin-2	drug	154-166	radiographic iodinated contrast media	group	223-259	effect

DDI-DrugBank.d543.s0	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
anticholinergic drugs	group	69-89	amantadine	drug	92-101	false
anticholinergic drugs	group	69-89	antiarrhythmic agents	group	103-123	false
anticholinergic drugs	group	69-89	quinidine	drug	140-148	false
anticholinergic drugs	group	69-89	antihistamines	group	152-165	false
anticholinergic drugs	group	69-89	antipsychotic agents	group	167-186	false
anticholinergic drugs	group	69-89	phenothiazines	group	194-207	false
anticholinergic drugs	group	69-89	benzodiazepines	group	211-225	false
amantadine	drug	92-101	antiarrhythmic agents	group	103-123	false
amantadine	drug	92-101	quinidine	drug	140-148	false
amantadine	drug	92-101	antihistamines	group	152-165	false
amantadine	drug	92-101	antipsychotic agents	group	167-186	false
amantadine	drug	92-101	phenothiazines	group	194-207	false
amantadine	drug	92-101	benzodiazepines	group	211-225	false
antiarrhythmic agents	group	103-123	quinidine	drug	140-148	false
antiarrhythmic agents	group	103-123	antihistamines	group	152-165	false
antiarrhythmic agents	group	103-123	antipsychotic agents	group	167-186	false
antiarrhythmic agents	group	103-123	phenothiazines	group	194-207	false
antiarrhythmic agents	group	103-123	benzodiazepines	group	211-225	false
quinidine	drug	140-148	antihistamines	group	152-165	false
quinidine	drug	140-148	antipsychotic agents	group	167-186	false
quinidine	drug	140-148	phenothiazines	group	194-207	false
quinidine	drug	140-148	benzodiazepines	group	211-225	false
antihistamines	group	152-165	antipsychotic agents	group	167-186	false
antihistamines	group	152-165	phenothiazines	group	194-207	false
antihistamines	group	152-165	benzodiazepines	group	211-225	false
antipsychotic agents	group	167-186	phenothiazines	group	194-207	false
antipsychotic agents	group	167-186	benzodiazepines	group	211-225	false
phenothiazines	group	194-207	benzodiazepines	group	211-225	false

DDI-DrugBank.d543.s1	MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
MAO inhibitors	group	0-13	narcotic analgesics	group	16-34	false
MAO inhibitors	group	0-13	meperidine	drug	43-52	false
MAO inhibitors	group	0-13	nitrates	group	56-63	false
MAO inhibitors	group	0-13	nitrites	group	69-76	false
MAO inhibitors	group	0-13	sympathomimetic agents	group	79-100	false
MAO inhibitors	group	0-13	tricyclic antidepressants	group	103-127	false
narcotic analgesics	group	16-34	meperidine	drug	43-52	false
narcotic analgesics	group	16-34	nitrates	group	56-63	false
narcotic analgesics	group	16-34	nitrites	group	69-76	false
narcotic analgesics	group	16-34	sympathomimetic agents	group	79-100	false
narcotic analgesics	group	16-34	tricyclic antidepressants	group	103-127	false
meperidine	drug	43-52	nitrates	group	56-63	false
meperidine	drug	43-52	nitrites	group	69-76	false
meperidine	drug	43-52	sympathomimetic agents	group	79-100	false
meperidine	drug	43-52	tricyclic antidepressants	group	103-127	false
nitrates	group	56-63	nitrites	group	69-76	false
nitrates	group	56-63	sympathomimetic agents	group	79-100	false
nitrates	group	56-63	tricyclic antidepressants	group	103-127	false
nitrites	group	69-76	sympathomimetic agents	group	79-100	false
nitrites	group	69-76	tricyclic antidepressants	group	103-127	false
sympathomimetic agents	group	79-100	tricyclic antidepressants	group	103-127	false

DDI-DrugBank.d543.s2	Anticholinergics antagonize the effects of antiglaucoma agents.
Anticholinergics	group	0-15	antiglaucoma agents	group	43-61	false

DDI-DrugBank.d543.s4	Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
Anticholinergic agents	group	0-21	digoxin	drug	122-128	mechanism

DDI-DrugBank.d543.s6	Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.
Anticholinergic drugs	group	0-20	metoclopramide	drug	108-121	mechanism

DDI-DrugBank.d543.s7	Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
antacids	group	8-15	anticholinergic agents	group	54-75	mechanism

DDI-DrugBank.d362.s2	In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic acid, indicating no potential for protein binding-based drug interactions.
des-ciclesonide	drug	65-79	warfarin	drug	101-108	false
des-ciclesonide	drug	65-79	salicylic acid	drug	113-126	false
warfarin	drug	101-108	salicylic acid	drug	113-126	false

DDI-DrugBank.d362.s3	In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin.
ciclesonide	drug	65-75	erythromycin	drug	86-97	false
ciclesonide	drug	65-75	des-ciclesonide	drug	185-199	false
ciclesonide	drug	65-75	erythromycin	drug	204-215	false
erythromycin	drug	86-97	des-ciclesonide	drug	185-199	false
erythromycin	drug	86-97	erythromycin	drug	204-215	false
des-ciclesonide	drug	185-199	erythromycin	drug	204-215	false

DDI-DrugBank.d362.s4	In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
ciclesonide	drug	71-81	ketoconazole	drug	92-103	mechanism
ciclesonide	drug	71-81	des-ciclesonide	drug	181-195	false
ciclesonide	drug	71-81	ciclesonide	drug	256-266	false
ketoconazole	drug	92-103	des-ciclesonide	drug	181-195	false
ketoconazole	drug	92-103	ciclesonide	drug	256-266	false
des-ciclesonide	drug	181-195	ciclesonide	drug	256-266	false

DDI-DrugBank.d362.s5	Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
ketoconazole	drug	11-22	ciclesonide	drug	76-86	advise

DDI-DrugBank.d396.s0	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
narcotic analgesics	group	25-43	antipsychotics	group	46-59	false
narcotic analgesics	group	25-43	antianxiety agents	group	62-79	false
narcotic analgesics	group	25-43	CNS depressants	group	91-105	false
narcotic analgesics	group	25-43	alcohol	drug	118-124	false
narcotic analgesics	group	25-43	hydrocodone	drug	146-156	effect
narcotic analgesics	group	25-43	acetaminophen	drug	162-174	false
antipsychotics	group	46-59	antianxiety agents	group	62-79	false
antipsychotics	group	46-59	CNS depressants	group	91-105	false
antipsychotics	group	46-59	alcohol	drug	118-124	false
antipsychotics	group	46-59	hydrocodone	drug	146-156	effect
antipsychotics	group	46-59	acetaminophen	drug	162-174	false
antianxiety agents	group	62-79	CNS depressants	group	91-105	false
antianxiety agents	group	62-79	alcohol	drug	118-124	false
antianxiety agents	group	62-79	hydrocodone	drug	146-156	effect
antianxiety agents	group	62-79	acetaminophen	drug	162-174	false
CNS depressants	group	91-105	alcohol	drug	118-124	false
CNS depressants	group	91-105	hydrocodone	drug	146-156	effect
CNS depressants	group	91-105	acetaminophen	drug	162-174	false
alcohol	drug	118-124	hydrocodone	drug	146-156	effect
alcohol	drug	118-124	acetaminophen	drug	162-174	false
hydrocodone	drug	146-156	acetaminophen	drug	162-174	false

DDI-DrugBank.d396.s2	The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
MAO inhibitors	group	11-24	tricyclic antidepressants	group	29-53	false
MAO inhibitors	group	11-24	hydrocodone	drug	60-70	effect
MAO inhibitors	group	11-24	antidepressant	group	123-136	false
MAO inhibitors	group	11-24	hydrocodone	drug	141-151	false
tricyclic antidepressants	group	29-53	hydrocodone	drug	60-70	effect
tricyclic antidepressants	group	29-53	antidepressant	group	123-136	false
tricyclic antidepressants	group	29-53	hydrocodone	drug	141-151	false
hydrocodone	drug	60-70	antidepressant	group	123-136	false
hydrocodone	drug	60-70	hydrocodone	drug	141-151	false
antidepressant	group	123-136	hydrocodone	drug	141-151	false

DDI-DrugBank.d396.s3	The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.
anticholinergics	group	22-37	hydrocodone	drug	44-54	effect

DDI-DrugBank.d278.s0	Enoxaparin dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of eptifibatide or the level of platelet aggregation in healthy adults.
Enoxaparin	drug	0-9	eptifibatide	drug	113-124	false

DDI-DrugBank.d2.s0	PROSTIN E2 may augment the activity of other oxytocic drugs.
PROSTIN E2	brand	0-9	oxytocic drugs	group	45-58	effect

DDI-DrugBank.d18.s0	Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
benzodiazepines	group	13-27	lorazepam	drug	40-48	false
benzodiazepines	group	13-27	barbiturates	group	125-136	effect
benzodiazepines	group	13-27	alcohol	drug	141-147	effect
lorazepam	drug	40-48	barbiturates	group	125-136	effect
lorazepam	drug	40-48	alcohol	drug	141-147	effect
barbiturates	group	125-136	alcohol	drug	141-147	false

DDI-DrugBank.d18.s1	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
Lorazepam	drug	11-19	benzodiazepines	group	54-68	false
Lorazepam	drug	11-19	ethyl alcohol	drug	144-156	effect
Lorazepam	drug	11-19	phenothiazines	group	159-172	effect
Lorazepam	drug	11-19	barbiturates	group	175-186	effect
Lorazepam	drug	11-19	MAO inhibitors	group	189-202	effect
Lorazepam	drug	11-19	antidepressants	group	215-229	effect
Lorazepam	drug	11-19	scopolamine	drug	236-246	false
Lorazepam	drug	11-19	lorazepam	drug	286-294	false
benzodiazepines	group	54-68	ethyl alcohol	drug	144-156	effect
benzodiazepines	group	54-68	phenothiazines	group	159-172	effect
benzodiazepines	group	54-68	barbiturates	group	175-186	effect
benzodiazepines	group	54-68	MAO inhibitors	group	189-202	effect
benzodiazepines	group	54-68	antidepressants	group	215-229	effect
benzodiazepines	group	54-68	scopolamine	drug	236-246	false
benzodiazepines	group	54-68	lorazepam	drug	286-294	false
ethyl alcohol	drug	144-156	phenothiazines	group	159-172	false
ethyl alcohol	drug	144-156	barbiturates	group	175-186	false
ethyl alcohol	drug	144-156	MAO inhibitors	group	189-202	false
ethyl alcohol	drug	144-156	antidepressants	group	215-229	false
ethyl alcohol	drug	144-156	scopolamine	drug	236-246	false
ethyl alcohol	drug	144-156	lorazepam	drug	286-294	false
phenothiazines	group	159-172	barbiturates	group	175-186	false
phenothiazines	group	159-172	MAO inhibitors	group	189-202	false
phenothiazines	group	159-172	antidepressants	group	215-229	false
phenothiazines	group	159-172	scopolamine	drug	236-246	false
phenothiazines	group	159-172	lorazepam	drug	286-294	false
barbiturates	group	175-186	MAO inhibitors	group	189-202	false
barbiturates	group	175-186	antidepressants	group	215-229	false
barbiturates	group	175-186	scopolamine	drug	236-246	false
barbiturates	group	175-186	lorazepam	drug	286-294	false
MAO inhibitors	group	189-202	antidepressants	group	215-229	false
MAO inhibitors	group	189-202	scopolamine	drug	236-246	false
MAO inhibitors	group	189-202	lorazepam	drug	286-294	false
antidepressants	group	215-229	scopolamine	drug	236-246	false
antidepressants	group	215-229	lorazepam	drug	286-294	false
scopolamine	drug	236-246	lorazepam	drug	286-294	effect

DDI-DrugBank.d168.s0	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
alcohol	drug	28-34	CNS depressants	group	45-59	false
alcohol	drug	28-34	antihistamines	group	135-148	false
alcohol	drug	28-34	anticholinergics	group	152-167	false
alcohol	drug	28-34	antihistamines	group	314-327	false
alcohol	drug	28-34	monoamine oxidase (MAO) inhibitors	group	335-368	false
alcohol	drug	28-34	antihistamines	drug	391-404	false
alcohol	drug	28-34	antihistamines	drug	482-495	false
CNS depressants	group	45-59	antihistamines	group	135-148	false
CNS depressants	group	45-59	anticholinergics	group	152-167	false
CNS depressants	group	45-59	antihistamines	group	314-327	false
CNS depressants	group	45-59	monoamine oxidase (MAO) inhibitors	group	335-368	false
CNS depressants	group	45-59	antihistamines	drug	391-404	false
CNS depressants	group	45-59	antihistamines	drug	482-495	false
antihistamines	group	135-148	anticholinergics	group	152-167	false
antihistamines	group	135-148	antihistamines	group	314-327	false
antihistamines	group	135-148	monoamine oxidase (MAO) inhibitors	group	335-368	false
antihistamines	group	135-148	antihistamines	drug	391-404	false
antihistamines	group	135-148	antihistamines	drug	482-495	false
anticholinergics	group	152-167	antihistamines	group	314-327	false
anticholinergics	group	152-167	monoamine oxidase (MAO) inhibitors	group	335-368	false
anticholinergics	group	152-167	antihistamines	drug	391-404	false
anticholinergics	group	152-167	antihistamines	drug	482-495	false
antihistamines	group	314-327	monoamine oxidase (MAO) inhibitors	group	335-368	false
antihistamines	group	314-327	antihistamines	drug	391-404	false
antihistamines	group	314-327	antihistamines	drug	482-495	false
monoamine oxidase (MAO) inhibitors	group	335-368	antihistamines	drug	391-404	false
monoamine oxidase (MAO) inhibitors	group	335-368	antihistamines	drug	482-495	false
antihistamines	drug	391-404	antihistamines	drug	482-495	false

DDI-DrugBank.d341.s1	However, it was observed that the pharmacokinetics of ENBREL  was unaltered by concomitant methotrexate in rheumatoid arthritis patients.
ENBREL	brand	54-59	methotrexate	drug	91-102	false

DDI-DrugBank.d341.s2	In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).
ENBREL	brand	92-97	anakinra	drug	104-111	effect
ENBREL	brand	92-97	ENBREL	brand	209-214	false
anakinra	drug	104-111	ENBREL	brand	209-214	false

DDI-DrugBank.d341.s3	Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).
ENBREL	brand	50-55	anakinra	drug	62-69	effect

DDI-DrugBank.d341.s4	Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
sulfasalazine	drug	66-78	ENBREL	brand	90-95	effect
sulfasalazine	drug	66-78	ENBREL	brand	216-221	false
sulfasalazine	drug	66-78	sulfasalazine	drug	229-241	false
ENBREL	brand	90-95	ENBREL	brand	216-221	false
ENBREL	brand	90-95	sulfasalazine	drug	229-241	false
ENBREL	brand	216-221	sulfasalazine	drug	229-241	false

DDI-DrugBank.d558.s1	Drug-Drug Interactions Cimetidine: Concomitant use of cimetidine is contraindicated.
Cimetidine	drug	23-32	cimetidine	drug	54-63	false

DDI-DrugBank.d558.s2	Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.
Cimetidine	drug	0-9	TIKOSYN	brand	76-82	mechanism
Cimetidine	drug	0-9	dofetilide	drug	136-145	false
TIKOSYN	brand	76-82	dofetilide	drug	136-145	false

DDI-DrugBank.d558.s3	Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).
Cimetidine	drug	0-9	dofetilide	drug	75-84	mechanism

DDI-DrugBank.d558.s5	If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
TIKOSYN	brand	22-28	anti-ulcer	group	34-43	false
TIKOSYN	brand	22-28	omeprazole	drug	75-84	false
TIKOSYN	brand	22-28	ranitidine	drug	87-96	false
TIKOSYN	brand	22-28	antacids	group	102-109	false
TIKOSYN	brand	22-28	aluminum hydroxide	drug	112-119;135-143	false
TIKOSYN	brand	22-28	magnesium hydroxide	drug	125-143	false
TIKOSYN	brand	22-28	cimetidine	drug	174-183	advise
TIKOSYN	brand	22-28	TIKOSYN	brand	251-257	false
anti-ulcer	group	34-43	omeprazole	drug	75-84	false
anti-ulcer	group	34-43	ranitidine	drug	87-96	false
anti-ulcer	group	34-43	antacids	group	102-109	false
anti-ulcer	group	34-43	aluminum hydroxide	drug	112-119;135-143	false
anti-ulcer	group	34-43	magnesium hydroxide	drug	125-143	false
anti-ulcer	group	34-43	cimetidine	drug	174-183	false
anti-ulcer	group	34-43	TIKOSYN	brand	251-257	false
omeprazole	drug	75-84	ranitidine	drug	87-96	false
omeprazole	drug	75-84	antacids	group	102-109	false
omeprazole	drug	75-84	aluminum hydroxide	drug	112-119;135-143	false
omeprazole	drug	75-84	magnesium hydroxide	drug	125-143	false
omeprazole	drug	75-84	cimetidine	drug	174-183	false
omeprazole	drug	75-84	TIKOSYN	brand	251-257	false
ranitidine	drug	87-96	antacids	group	102-109	false
ranitidine	drug	87-96	aluminum hydroxide	drug	112-119;135-143	false
ranitidine	drug	87-96	magnesium hydroxide	drug	125-143	false
ranitidine	drug	87-96	cimetidine	drug	174-183	false
ranitidine	drug	87-96	TIKOSYN	brand	251-257	false
antacids	group	102-109	aluminum hydroxide	drug	112-119;135-143	false
antacids	group	102-109	magnesium hydroxide	drug	125-143	false
antacids	group	102-109	cimetidine	drug	174-183	false
antacids	group	102-109	TIKOSYN	brand	251-257	false
aluminum hydroxide	drug	112-119;135-143	magnesium hydroxide	drug	125-143	false
aluminum hydroxide	drug	112-119;135-143	cimetidine	drug	174-183	false
aluminum hydroxide	drug	112-119;135-143	TIKOSYN	brand	251-257	false
magnesium hydroxide	drug	125-143	cimetidine	drug	174-183	false
magnesium hydroxide	drug	125-143	TIKOSYN	brand	251-257	false
cimetidine	drug	174-183	TIKOSYN	brand	251-257	false

DDI-DrugBank.d558.s6	Verapamil: Concomitant use of verapamil is contraindicated.
Verapamil	drug	0-8	verapamil	drug	30-38	false

DDI-DrugBank.d558.s7	Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
TIKOSYN	brand	21-27	verapamil	drug	34-42	mechanism
TIKOSYN	brand	21-27	dofetilide	drug	69-78	false
TIKOSYN	brand	21-27	dofetilide	drug	136-145	false
verapamil	drug	34-42	dofetilide	drug	69-78	false
verapamil	drug	34-42	dofetilide	drug	136-145	false
dofetilide	drug	69-78	dofetilide	drug	136-145	false

DDI-DrugBank.d558.s8	In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
verapamil	drug	117-125	dofetilide	drug	132-141	effect

DDI-DrugBank.d558.s9	Ketoconazole: Concomitant use of ketoconazole is contraindicated.
Ketoconazole	drug	0-11	ketoconazole	drug	33-44	false

DDI-DrugBank.d558.s10	Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
Ketoconazole	drug	0-11	TIKOSYN	brand	91-97	mechanism
Ketoconazole	drug	0-11	dofetilide	drug	151-160	false
TIKOSYN	brand	91-97	dofetilide	drug	151-160	false

DDI-DrugBank.d558.s11	Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.
Trimethoprim	drug	0-11	Sulfamethoxazole	drug	42-57	false
Trimethoprim	drug	0-11	trimethoprim	drug	79-90	false
Trimethoprim	drug	0-11	sulfamethoxazole	drug	121-136	false
Sulfamethoxazole	drug	42-57	trimethoprim	drug	79-90	false
Sulfamethoxazole	drug	42-57	sulfamethoxazole	drug	121-136	false
trimethoprim	drug	79-90	sulfamethoxazole	drug	121-136	false

DDI-DrugBank.d558.s12	Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.
Hydrochlorothiazide	drug	0-18	HCTZ	drug	21-24	false
Hydrochlorothiazide	drug	0-18	Triamterene	drug	56-66	false
Hydrochlorothiazide	drug	0-18	HCTZ	drug	88-91	false
Hydrochlorothiazide	drug	0-18	triamterene	drug	122-132	false
HCTZ	drug	21-24	Triamterene	drug	56-66	false
HCTZ	drug	21-24	HCTZ	drug	88-91	false
HCTZ	drug	21-24	triamterene	drug	122-132	false
Triamterene	drug	56-66	HCTZ	drug	88-91	false
Triamterene	drug	56-66	triamterene	drug	122-132	false
HCTZ	drug	88-91	triamterene	drug	122-132	false

DDI-DrugBank.d558.s13	HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).
HCTZ	drug	0-3	HCTZ	drug	17-20	false
HCTZ	drug	0-3	triamterene	drug	22-32	false
HCTZ	drug	0-3	TIKOSYN	brand	72-78	false
HCTZ	drug	0-3	diuretic	group	126-133	false
HCTZ	drug	17-20	triamterene	drug	22-32	false
HCTZ	drug	17-20	TIKOSYN	brand	72-78	false
HCTZ	drug	17-20	diuretic	group	126-133	false
triamterene	drug	22-32	TIKOSYN	brand	72-78	false
triamterene	drug	22-32	diuretic	group	126-133	false
TIKOSYN	brand	72-78	diuretic	group	126-133	false

DDI-DrugBank.d558.s14	In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.
HCTZ	drug	22-25	dofetilide	drug	34-43	mechanism

DDI-DrugBank.d558.s18	In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics.
TIKOSYN	brand	55-61	diuretics	group	67-75	false
TIKOSYN	brand	55-61	diuretics	group	177-185	false
diuretics	group	67-75	diuretics	group	177-185	false

DDI-DrugBank.d558.s19	Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).
potassium depleting diuretics	group	28-56	TIKOSYN	brand	136-142	false

DDI-DrugBank.d558.s22	In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
triamterene	drug	68-78	metformin	drug	81-89	false
triamterene	drug	68-78	amiloride	drug	95-103	false
triamterene	drug	68-78	dofetilide	drug	165-174	advise
metformin	drug	81-89	amiloride	drug	95-103	false
metformin	drug	81-89	dofetilide	drug	165-174	advise
amiloride	drug	95-103	dofetilide	drug	165-174	advise

DDI-DrugBank.d558.s25	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
macrolide antibiotics	group	36-56	azole antifungal agents	group	59-81	false
macrolide antibiotics	group	36-56	protease inhibitors	group	84-102	false
macrolide antibiotics	group	36-56	serotonin reuptake inhibitors	group	105-133	false
macrolide antibiotics	group	36-56	amiodarone	drug	136-145	false
macrolide antibiotics	group	36-56	cannabinoids	group	148-159	false
macrolide antibiotics	group	36-56	diltiazem	drug	162-170	false
macrolide antibiotics	group	36-56	nefazadone	drug	191-200	false
macrolide antibiotics	group	36-56	norfloxacin	drug	203-213	false
macrolide antibiotics	group	36-56	quinine	drug	216-222	false
macrolide antibiotics	group	36-56	zafirlukast	drug	225-235	false
macrolide antibiotics	group	36-56	TIKOSYN	brand	279-285	advise
macrolide antibiotics	group	36-56	dofetilide	drug	320-329	false
azole antifungal agents	group	59-81	protease inhibitors	group	84-102	false
azole antifungal agents	group	59-81	serotonin reuptake inhibitors	group	105-133	false
azole antifungal agents	group	59-81	amiodarone	drug	136-145	false
azole antifungal agents	group	59-81	cannabinoids	group	148-159	false
azole antifungal agents	group	59-81	diltiazem	drug	162-170	false
azole antifungal agents	group	59-81	nefazadone	drug	191-200	false
azole antifungal agents	group	59-81	norfloxacin	drug	203-213	false
azole antifungal agents	group	59-81	quinine	drug	216-222	false
azole antifungal agents	group	59-81	zafirlukast	drug	225-235	false
azole antifungal agents	group	59-81	TIKOSYN	brand	279-285	advise
azole antifungal agents	group	59-81	dofetilide	drug	320-329	false
protease inhibitors	group	84-102	serotonin reuptake inhibitors	group	105-133	false
protease inhibitors	group	84-102	amiodarone	drug	136-145	false
protease inhibitors	group	84-102	cannabinoids	group	148-159	false
protease inhibitors	group	84-102	diltiazem	drug	162-170	false
protease inhibitors	group	84-102	nefazadone	drug	191-200	false
protease inhibitors	group	84-102	norfloxacin	drug	203-213	false
protease inhibitors	group	84-102	quinine	drug	216-222	false
protease inhibitors	group	84-102	zafirlukast	drug	225-235	false
protease inhibitors	group	84-102	TIKOSYN	brand	279-285	advise
protease inhibitors	group	84-102	dofetilide	drug	320-329	false
serotonin reuptake inhibitors	group	105-133	amiodarone	drug	136-145	false
serotonin reuptake inhibitors	group	105-133	cannabinoids	group	148-159	false
serotonin reuptake inhibitors	group	105-133	diltiazem	drug	162-170	false
serotonin reuptake inhibitors	group	105-133	nefazadone	drug	191-200	false
serotonin reuptake inhibitors	group	105-133	norfloxacin	drug	203-213	false
serotonin reuptake inhibitors	group	105-133	quinine	drug	216-222	false
serotonin reuptake inhibitors	group	105-133	zafirlukast	drug	225-235	false
serotonin reuptake inhibitors	group	105-133	TIKOSYN	brand	279-285	advise
serotonin reuptake inhibitors	group	105-133	dofetilide	drug	320-329	false
amiodarone	drug	136-145	cannabinoids	group	148-159	false
amiodarone	drug	136-145	diltiazem	drug	162-170	false
amiodarone	drug	136-145	nefazadone	drug	191-200	false
amiodarone	drug	136-145	norfloxacin	drug	203-213	false
amiodarone	drug	136-145	quinine	drug	216-222	false
amiodarone	drug	136-145	zafirlukast	drug	225-235	false
amiodarone	drug	136-145	TIKOSYN	brand	279-285	advise
amiodarone	drug	136-145	dofetilide	drug	320-329	false
cannabinoids	group	148-159	diltiazem	drug	162-170	false
cannabinoids	group	148-159	nefazadone	drug	191-200	false
cannabinoids	group	148-159	norfloxacin	drug	203-213	false
cannabinoids	group	148-159	quinine	drug	216-222	false
cannabinoids	group	148-159	zafirlukast	drug	225-235	false
cannabinoids	group	148-159	TIKOSYN	brand	279-285	advise
cannabinoids	group	148-159	dofetilide	drug	320-329	false
diltiazem	drug	162-170	nefazadone	drug	191-200	false
diltiazem	drug	162-170	norfloxacin	drug	203-213	false
diltiazem	drug	162-170	quinine	drug	216-222	false
diltiazem	drug	162-170	zafirlukast	drug	225-235	false
diltiazem	drug	162-170	TIKOSYN	brand	279-285	advise
diltiazem	drug	162-170	dofetilide	drug	320-329	false
nefazadone	drug	191-200	norfloxacin	drug	203-213	false
nefazadone	drug	191-200	quinine	drug	216-222	false
nefazadone	drug	191-200	zafirlukast	drug	225-235	false
nefazadone	drug	191-200	TIKOSYN	brand	279-285	advise
nefazadone	drug	191-200	dofetilide	drug	320-329	false
norfloxacin	drug	203-213	quinine	drug	216-222	false
norfloxacin	drug	203-213	zafirlukast	drug	225-235	false
norfloxacin	drug	203-213	TIKOSYN	brand	279-285	advise
norfloxacin	drug	203-213	dofetilide	drug	320-329	false
quinine	drug	216-222	zafirlukast	drug	225-235	false
quinine	drug	216-222	TIKOSYN	brand	279-285	advise
quinine	drug	216-222	dofetilide	drug	320-329	false
zafirlukast	drug	225-235	TIKOSYN	brand	279-285	advise
zafirlukast	drug	225-235	dofetilide	drug	320-329	false
TIKOSYN	brand	279-285	dofetilide	drug	320-329	false

DDI-DrugBank.d558.s27	Other Drug Interaction Information Digoxin: Studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics of digoxin.
Digoxin	drug	35-41	TIKOSYN	brand	90-96	false
Digoxin	drug	35-41	digoxin	drug	138-144	false
TIKOSYN	brand	90-96	digoxin	drug	138-144	false

DDI-DrugBank.d558.s28	In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.
digoxin	drug	47-53	dofetilide	drug	60-69	effect

DDI-DrugBank.d558.s29	It is not clear whether this represents an interaction with TIKOSYN or the presence of more severe structural heart disease in patients on digoxin;
TIKOSYN	brand	60-66	digoxin	drug	139-145	false

DDI-DrugBank.d558.s32	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
amlodipine	drug	36-45	phenytoin	drug	48-56	false
amlodipine	drug	36-45	glyburide	drug	59-67	false
amlodipine	drug	36-45	ranitidine	drug	70-79	false
amlodipine	drug	36-45	omeprazole	drug	82-91	false
amlodipine	drug	36-45	estrogens	group	151-159	false
amlodipine	drug	36-45	medroxyprogesterone	drug	165-183	false
amlodipine	drug	36-45	antacid	group	187-193	false
amlodipine	drug	36-45	aluminum hydroxide	drug	196-203;219-227	false
amlodipine	drug	36-45	magnesium hydroxide	drug	209-227	false
amlodipine	drug	36-45	theophylline	drug	235-246	false
amlodipine	drug	36-45	TIKOSYN	brand	287-293	false
phenytoin	drug	48-56	glyburide	drug	59-67	false
phenytoin	drug	48-56	ranitidine	drug	70-79	false
phenytoin	drug	48-56	omeprazole	drug	82-91	false
phenytoin	drug	48-56	estrogens	group	151-159	false
phenytoin	drug	48-56	medroxyprogesterone	drug	165-183	false
phenytoin	drug	48-56	antacid	group	187-193	false
phenytoin	drug	48-56	aluminum hydroxide	drug	196-203;219-227	false
phenytoin	drug	48-56	magnesium hydroxide	drug	209-227	false
phenytoin	drug	48-56	theophylline	drug	235-246	false
phenytoin	drug	48-56	TIKOSYN	brand	287-293	false
glyburide	drug	59-67	ranitidine	drug	70-79	false
glyburide	drug	59-67	omeprazole	drug	82-91	false
glyburide	drug	59-67	estrogens	group	151-159	false
glyburide	drug	59-67	medroxyprogesterone	drug	165-183	false
glyburide	drug	59-67	antacid	group	187-193	false
glyburide	drug	59-67	aluminum hydroxide	drug	196-203;219-227	false
glyburide	drug	59-67	magnesium hydroxide	drug	209-227	false
glyburide	drug	59-67	theophylline	drug	235-246	false
glyburide	drug	59-67	TIKOSYN	brand	287-293	false
ranitidine	drug	70-79	omeprazole	drug	82-91	false
ranitidine	drug	70-79	estrogens	group	151-159	false
ranitidine	drug	70-79	medroxyprogesterone	drug	165-183	false
ranitidine	drug	70-79	antacid	group	187-193	false
ranitidine	drug	70-79	aluminum hydroxide	drug	196-203;219-227	false
ranitidine	drug	70-79	magnesium hydroxide	drug	209-227	false
ranitidine	drug	70-79	theophylline	drug	235-246	false
ranitidine	drug	70-79	TIKOSYN	brand	287-293	false
omeprazole	drug	82-91	estrogens	group	151-159	false
omeprazole	drug	82-91	medroxyprogesterone	drug	165-183	false
omeprazole	drug	82-91	antacid	group	187-193	false
omeprazole	drug	82-91	aluminum hydroxide	drug	196-203;219-227	false
omeprazole	drug	82-91	magnesium hydroxide	drug	209-227	false
omeprazole	drug	82-91	theophylline	drug	235-246	false
omeprazole	drug	82-91	TIKOSYN	brand	287-293	false
estrogens	group	151-159	medroxyprogesterone	drug	165-183	false
estrogens	group	151-159	antacid	group	187-193	false
estrogens	group	151-159	aluminum hydroxide	drug	196-203;219-227	false
estrogens	group	151-159	magnesium hydroxide	drug	209-227	false
estrogens	group	151-159	theophylline	drug	235-246	false
estrogens	group	151-159	TIKOSYN	brand	287-293	false
medroxyprogesterone	drug	165-183	antacid	group	187-193	false
medroxyprogesterone	drug	165-183	aluminum hydroxide	drug	196-203;219-227	false
medroxyprogesterone	drug	165-183	magnesium hydroxide	drug	209-227	false
medroxyprogesterone	drug	165-183	theophylline	drug	235-246	false
medroxyprogesterone	drug	165-183	TIKOSYN	brand	287-293	false
antacid	group	187-193	aluminum hydroxide	drug	196-203;219-227	false
antacid	group	187-193	magnesium hydroxide	drug	209-227	false
antacid	group	187-193	theophylline	drug	235-246	false
antacid	group	187-193	TIKOSYN	brand	287-293	false
aluminum hydroxide	drug	196-203;219-227	magnesium hydroxide	drug	209-227	false
aluminum hydroxide	drug	196-203;219-227	theophylline	drug	235-246	false
aluminum hydroxide	drug	196-203;219-227	TIKOSYN	brand	287-293	false
magnesium hydroxide	drug	209-227	theophylline	drug	235-246	false
magnesium hydroxide	drug	209-227	TIKOSYN	brand	287-293	false
theophylline	drug	235-246	TIKOSYN	brand	287-293	false

DDI-DrugBank.d558.s33	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.
TIKOSYN	brand	59-65	warfarin	drug	127-134	false
TIKOSYN	brand	59-65	propranolol	drug	164-174	false
TIKOSYN	brand	59-65	phenytoin	drug	197-205	false
TIKOSYN	brand	59-65	theophylline	drug	208-219	false
TIKOSYN	brand	59-65	contraceptives	group	230-243	false
warfarin	drug	127-134	propranolol	drug	164-174	false
warfarin	drug	127-134	phenytoin	drug	197-205	false
warfarin	drug	127-134	theophylline	drug	208-219	false
warfarin	drug	127-134	contraceptives	group	230-243	false
propranolol	drug	164-174	phenytoin	drug	197-205	false
propranolol	drug	164-174	theophylline	drug	208-219	false
propranolol	drug	164-174	contraceptives	group	230-243	false
phenytoin	drug	197-205	theophylline	drug	208-219	false
phenytoin	drug	197-205	contraceptives	group	230-243	false
theophylline	drug	208-219	contraceptives	group	230-243	false

DDI-DrugBank.d558.s35	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
ACE inhibitors	group	40-53	anticoagulants	group	61-74	false
ACE inhibitors	group	40-53	calcium channel blockers	group	77-100	false
ACE inhibitors	group	40-53	beta blockers	group	103-115	false
ACE inhibitors	group	40-53	cardiac glycosides	group	118-135	false
ACE inhibitors	group	40-53	nitrates	group	240-247	false
ACE inhibitors	group	40-53	sulphonylureas	group	250-263	false
ACE inhibitors	group	40-53	loop diuretics	group	266-279	false
ACE inhibitors	group	40-53	potassium sparing diuretics	group	282-308	false
ACE inhibitors	group	40-53	thiazide diuretics	group	311-328	false
anticoagulants	group	61-74	calcium channel blockers	group	77-100	false
anticoagulants	group	61-74	beta blockers	group	103-115	false
anticoagulants	group	61-74	cardiac glycosides	group	118-135	false
anticoagulants	group	61-74	nitrates	group	240-247	false
anticoagulants	group	61-74	sulphonylureas	group	250-263	false
anticoagulants	group	61-74	loop diuretics	group	266-279	false
anticoagulants	group	61-74	potassium sparing diuretics	group	282-308	false
anticoagulants	group	61-74	thiazide diuretics	group	311-328	false
calcium channel blockers	group	77-100	beta blockers	group	103-115	false
calcium channel blockers	group	77-100	cardiac glycosides	group	118-135	false
calcium channel blockers	group	77-100	nitrates	group	240-247	false
calcium channel blockers	group	77-100	sulphonylureas	group	250-263	false
calcium channel blockers	group	77-100	loop diuretics	group	266-279	false
calcium channel blockers	group	77-100	potassium sparing diuretics	group	282-308	false
calcium channel blockers	group	77-100	thiazide diuretics	group	311-328	false
beta blockers	group	103-115	cardiac glycosides	group	118-135	false
beta blockers	group	103-115	nitrates	group	240-247	false
beta blockers	group	103-115	sulphonylureas	group	250-263	false
beta blockers	group	103-115	loop diuretics	group	266-279	false
beta blockers	group	103-115	potassium sparing diuretics	group	282-308	false
beta blockers	group	103-115	thiazide diuretics	group	311-328	false
cardiac glycosides	group	118-135	nitrates	group	240-247	false
cardiac glycosides	group	118-135	sulphonylureas	group	250-263	false
cardiac glycosides	group	118-135	loop diuretics	group	266-279	false
cardiac glycosides	group	118-135	potassium sparing diuretics	group	282-308	false
cardiac glycosides	group	118-135	thiazide diuretics	group	311-328	false
nitrates	group	240-247	sulphonylureas	group	250-263	false
nitrates	group	240-247	loop diuretics	group	266-279	false
nitrates	group	240-247	potassium sparing diuretics	group	282-308	false
nitrates	group	240-247	thiazide diuretics	group	311-328	false
sulphonylureas	group	250-263	loop diuretics	group	266-279	false
sulphonylureas	group	250-263	potassium sparing diuretics	group	282-308	false
sulphonylureas	group	250-263	thiazide diuretics	group	311-328	false
loop diuretics	group	266-279	potassium sparing diuretics	group	282-308	false
loop diuretics	group	266-279	thiazide diuretics	group	311-328	false
potassium sparing diuretics	group	282-308	thiazide diuretics	group	311-328	false

DDI-DrugBank.d558.s37	The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.
dofetilide	drug	23-32	thiazide diuretics	group	72-89	mechanism

DDI-DrugBank.d130.s0	Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
Lincomycin	drug	0-9	neuromuscular blocking agents	group	105-133	effect

DDI-DrugBank.d130.s2	Antagonism between lincomycin and erythromycin in vitro has been demonstrated.
lincomycin	drug	19-28	erythromycin	drug	34-45	effect

DDI-DrugBank.d420.s0	Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
Antacids	group	0-7	aluminum	drug	10-17	false
Antacids	group	0-7	magnesium	drug	23-31	false
Antacids	group	0-7	cefdinir	drug	83-90	false
Antacids	group	0-7	Maalox TC	brand	112-120	false
aluminum	drug	10-17	magnesium	drug	23-31	false
aluminum	drug	10-17	cefdinir	drug	83-90	false
aluminum	drug	10-17	Maalox TC	brand	112-120	false
magnesium	drug	23-31	cefdinir	drug	83-90	false
magnesium	drug	23-31	Maalox TC	brand	112-120	false
cefdinir	drug	83-90	Maalox TC	brand	112-120	mechanism

DDI-DrugBank.d420.s2	There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.
cefdinir	drug	36-43	antacid	group	69-75	false
cefdinir	drug	36-43	cefdinir	drug	125-132	false
antacid	group	69-75	cefdinir	drug	125-132	false

DDI-DrugBank.d420.s3	If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.
antacids	group	3-10	OMNICEF	brand	32-38	false
antacids	group	3-10	OMNICEF	brand	49-55	false
antacids	group	3-10	antacid	group	110-116	false
OMNICEF	brand	32-38	OMNICEF	brand	49-55	false
OMNICEF	brand	32-38	antacid	group	110-116	false
OMNICEF	brand	49-55	antacid	group	110-116	advise

DDI-DrugBank.d420.s4	Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
Probenecid	drug	0-9	b-lactam antibiotics	group	26-45	false
Probenecid	drug	0-9	probenecid	drug	48-57	false
Probenecid	drug	0-9	cefdinir	drug	91-98	false
Probenecid	drug	0-9	cefdinir	drug	169-176	false
b-lactam antibiotics	group	26-45	probenecid	drug	48-57	false
b-lactam antibiotics	group	26-45	cefdinir	drug	91-98	mechanism
b-lactam antibiotics	group	26-45	cefdinir	drug	169-176	false
probenecid	drug	48-57	cefdinir	drug	91-98	mechanism
probenecid	drug	48-57	cefdinir	drug	169-176	false
cefdinir	drug	91-98	cefdinir	drug	169-176	false

DDI-DrugBank.d420.s5	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
Iron Supplements	group	0-15	Iron	drug	42-45	false
Iron Supplements	group	0-15	cefdinir	drug	77-84	false
Iron Supplements	group	0-15	iron supplement	group	105-119	false
Iron Supplements	group	0-15	iron	drug	151-154	false
Iron Supplements	group	0-15	vitamins	group	170-177	false
Iron Supplements	group	0-15	iron	drug	216-219	false
Iron	drug	42-45	cefdinir	drug	77-84	false
Iron	drug	42-45	iron supplement	group	105-119	false
Iron	drug	42-45	iron	drug	151-154	false
Iron	drug	42-45	vitamins	group	170-177	false
Iron	drug	42-45	iron	drug	216-219	false
cefdinir	drug	77-84	iron supplement	group	105-119	false
cefdinir	drug	77-84	iron	drug	151-154	mechanism
cefdinir	drug	77-84	vitamins	group	170-177	false
cefdinir	drug	77-84	iron	drug	216-219	mechanism
iron supplement	group	105-119	iron	drug	151-154	false
iron supplement	group	105-119	vitamins	group	170-177	false
iron supplement	group	105-119	iron	drug	216-219	false
iron	drug	151-154	vitamins	group	170-177	false
iron	drug	151-154	iron	drug	216-219	false
vitamins	group	170-177	iron	drug	216-219	false

DDI-DrugBank.d420.s6	If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
iron supplements	group	3-18	OMNICEF	brand	40-46	false
iron supplements	group	3-18	OMNICEF	brand	57-63	advise
OMNICEF	brand	40-46	OMNICEF	brand	57-63	false

DDI-DrugBank.d420.s7	The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.
iron	drug_n	52-55	iron	drug_n	68-71	false
iron	drug_n	52-55	cefdinir	drug	105-112	false
iron	drug_n	68-71	cefdinir	drug	105-112	false

DDI-DrugBank.d420.s8	Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.
iron	drug_n	27-30	iron	drug_n	75-78	false
iron	drug_n	27-30	cefdinir	drug	115-122	false
iron	drug_n	75-78	cefdinir	drug	115-122	false

DDI-DrugBank.d420.s9	Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.
OMNICEF	brand	11-17	iron	drug_n	64-67	false

DDI-DrugBank.d420.s11	The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.
cefdinir	drug	77-84	iron	drug	116-119	mechanism

DDI-DrugBank.d420.s12	Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.
nitroprusside	drug	112-124	nitroferricyanide	drug	152-168	false

DDI-DrugBank.d135.s0	Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.
Lapatinib	drug	11-19	Lapatinib	drug	77-85	false

DDI-DrugBank.d135.s5	Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.
Lapatinib	drug	57-65	lapatinib	drug	189-197	false

DDI-DrugBank.d135.s7	Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
Ketoconazole	drug	0-11	ketoconazole	drug	44-55	false
Ketoconazole	drug	0-11	lapatinib	drug	139-147	false
ketoconazole	drug	44-55	lapatinib	drug	139-147	mechanism

DDI-DrugBank.d135.s8	Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.
Carbamazepine	drug	0-12	carbamazepine	drug	65-77	false
Carbamazepine	drug	0-12	lapatinib	drug	176-184	false
carbamazepine	drug	65-77	lapatinib	drug	176-184	mechanism

DDI-DrugBank.d135.s10	If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.
TYKERB	brand	3-8	lapatinib	drug	83-91	false

DDI-DrugBank.d135.s11	Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).
lapatinib	drug	77-85	capecitabine	drug	92-103	false
lapatinib	drug	77-85	capecitabine	drug	192-203	false
capecitabine	drug	92-103	capecitabine	drug	192-203	false

DDI-DrugBank.d158.s0	Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
ammonium chloride	drug	40-56	sodium acid phosphate	drug	59-79	false
ammonium chloride	drug	40-56	amphetamine	drug	145-155	mechanism
sodium acid phosphate	drug	59-79	amphetamine	drug	145-155	mechanism

DDI-DrugBank.d158.s2	Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.
Adrenergic blockers	group	0-18	Adrenergic blockers	group	20-38	false
Adrenergic blockers	group	0-18	amphetamines	group	57-68	false
Adrenergic blockers	group	20-38	amphetamines	group	57-68	effect

DDI-DrugBank.d158.s3	Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
Antidepressants	group	0-14	tricyclic	group	17-25	false
Antidepressants	group	0-14	Amphetamines	group	27-38	false
Antidepressants	group	0-14	tricyclic antidepressants	drug	68-92	false
Antidepressants	group	0-14	sympathomimetic agents	group	97-118	false
tricyclic	group	17-25	Amphetamines	group	27-38	false
tricyclic	group	17-25	tricyclic antidepressants	drug	68-92	false
tricyclic	group	17-25	sympathomimetic agents	group	97-118	false
Amphetamines	group	27-38	tricyclic antidepressants	drug	68-92	effect
Amphetamines	group	27-38	sympathomimetic agents	group	97-118	effect
tricyclic antidepressants	drug	68-92	sympathomimetic agents	group	97-118	false

DDI-DrugBank.d158.s4	d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
d-amphetamine	drug	0-12	desipramine	drug	19-29	mechanism
d-amphetamine	drug	0-12	protriptyline	drug	34-46	mechanism
d-amphetamine	drug	0-12	tricyclics	group	67-76	mechanism
d-amphetamine	drug	0-12	d-amphetamine	drug	141-153	false
desipramine	drug	19-29	protriptyline	drug	34-46	false
desipramine	drug	19-29	tricyclics	group	67-76	false
desipramine	drug	19-29	d-amphetamine	drug	141-153	false
protriptyline	drug	34-46	tricyclics	group	67-76	false
protriptyline	drug	34-46	d-amphetamine	drug	141-153	false
tricyclics	group	67-76	d-amphetamine	drug	141-153	false

DDI-DrugBank.d158.s6	MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
MAO inhibitors	group	0-13	MAOI antidepressants	group	15-34	false
MAO inhibitors	group	0-13	furazolidone	drug	64-75	false
MAO inhibitors	group	0-13	amphetamine	drug	83-93	false
MAOI antidepressants	group	15-34	furazolidone	drug	64-75	false
MAOI antidepressants	group	15-34	amphetamine	drug	83-93	mechanism
furazolidone	drug	64-75	amphetamine	drug	83-93	mechanism

DDI-DrugBank.d158.s10	Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
Antihistamines	group	0-13	Amphetamines	group	16-27	false
Antihistamines	group	0-13	antihistamines	group	67-80	false
Amphetamines	group	16-27	antihistamines	group	67-80	effect

DDI-DrugBank.d158.s11	Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
Antihypertensives	group	0-16	Amphetamines	group	19-30	false
Antihypertensives	group	0-16	antihypertensives	drug	74-90	false
Amphetamines	group	19-30	antihypertensives	drug	74-90	effect

DDI-DrugBank.d158.s12	Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.
Chlorpromazine	drug	0-13	Chlorpromazine	drug	16-29	false
Chlorpromazine	drug	0-13	amphetamines	group	126-137	false
Chlorpromazine	drug	0-13	amphetamine	group	164-174	false
Chlorpromazine	drug	16-29	amphetamines	group	126-137	effect
Chlorpromazine	drug	16-29	amphetamine	group	164-174	false
amphetamines	group	126-137	amphetamine	group	164-174	false

DDI-DrugBank.d158.s13	Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
Ethosuximide	drug	0-11	Amphetamines	group	14-25	false
Ethosuximide	drug	0-11	ethosuximide	drug	62-73	false
Amphetamines	group	14-25	ethosuximide	drug	62-73	mechanism

DDI-DrugBank.d158.s14	Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.
Haloperidol	drug	0-10	Haloperidol	drug	13-23	false
Haloperidol	drug	0-10	amphetamines	group	101-112	false
Haloperidol	drug	13-23	amphetamines	group	101-112	effect

DDI-DrugBank.d158.s15	Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.
Lithium carbonate	drug	0-16	amphetamines	group	60-71	false
Lithium carbonate	drug	0-16	lithium carbonate	drug	93-109	false
amphetamines	group	60-71	lithium carbonate	drug	93-109	effect

DDI-DrugBank.d158.s16	Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
Meperidine	drug	0-9	Amphetamines	group	12-23	false
Meperidine	drug	0-9	meperidine	drug	60-69	false
Amphetamines	group	12-23	meperidine	drug	60-69	effect

DDI-DrugBank.d158.s17	Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.
Methenamine	drug	0-10	amphetamines	group	41-52	false
Methenamine	drug	0-10	methenamine	drug	121-131	false
amphetamines	group	41-52	methenamine	drug	121-131	mechanism

DDI-DrugBank.d158.s18	Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
Norepinephrine	drug	0-13	Amphetamines	group	16-27	false
Norepinephrine	drug	0-13	norepinephrine	drug	62-75	false
Amphetamines	group	16-27	norepinephrine	drug	62-75	effect

DDI-DrugBank.d158.s19	Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
Phenobarbital	drug	0-12	Amphetamines	group	15-26	false
Phenobarbital	drug	0-12	phenobarbital	drug	63-75	false
Amphetamines	group	15-26	phenobarbital	drug	63-75	mechanism

DDI-DrugBank.d158.s21	Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
Phenytoin	drug	0-8	Amphetamines	group	11-22	false
Phenytoin	drug	0-8	phenytoin	drug	59-67	false
Amphetamines	group	11-22	phenytoin	drug	59-67	mechanism

DDI-DrugBank.d158.s23	Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
Propoxyphene	drug	0-11	propoxyphene	drug	26-37	false
Propoxyphene	drug	0-11	amphetamine	drug	51-61	false
propoxyphene	drug	26-37	amphetamine	drug	51-61	effect

DDI-DrugBank.d158.s24	Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
Veratrum alkaloids	group	0-17	Amphetamines	group	20-31	false
Veratrum alkaloids	group	0-17	veratrum alkaloids	group	67-84	false
Amphetamines	group	20-31	veratrum alkaloids	group	67-84	effect

DDI-DrugBank.d131.s0	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
benzodiazepines	group	4-18	alprazolam	drug	31-40	false
benzodiazepines	group	4-18	psychotropic medications	group	115-138	effect
benzodiazepines	group	4-18	anticonvulsants	group	141-155	effect
benzodiazepines	group	4-18	antihistaminics	group	158-172	effect
benzodiazepines	group	4-18	ethanol	drug	175-181	effect
alprazolam	drug	31-40	psychotropic medications	group	115-138	effect
alprazolam	drug	31-40	anticonvulsants	group	141-155	effect
alprazolam	drug	31-40	antihistaminics	group	158-172	effect
alprazolam	drug	31-40	ethanol	drug	175-181	effect
psychotropic medications	group	115-138	anticonvulsants	group	141-155	false
psychotropic medications	group	115-138	antihistaminics	group	158-172	false
psychotropic medications	group	115-138	ethanol	drug	175-181	false
anticonvulsants	group	141-155	antihistaminics	group	158-172	false
anticonvulsants	group	141-155	ethanol	drug	175-181	false
antihistaminics	group	158-172	ethanol	drug	175-181	false

DDI-DrugBank.d131.s1	The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
imipramine	drug	42-51	desipramine	drug	57-67	false
imipramine	drug	42-51	alprazolam	drug	182-191	mechanism
desipramine	drug	57-67	alprazolam	drug	182-191	mechanism

DDI-DrugBank.d131.s3	Drugs That Inhibit Alprazolam Metabolism Via Cytochrome P450 3A: The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).
Alprazolam	drug	19-28	alprazolam	drug	85-94	false

DDI-DrugBank.d131.s5	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
Alprazolam	drug	120-129	alprazolam	drug	184-193	false
Alprazolam	drug	120-129	fluoxetine	drug	217-226	false
Alprazolam	drug	120-129	alprazolam	drug	233-242	false
Alprazolam	drug	120-129	alprazolam	drug	290-299	false
alprazolam	drug	184-193	fluoxetine	drug	217-226	false
alprazolam	drug	184-193	alprazolam	drug	233-242	false
alprazolam	drug	184-193	alprazolam	drug	290-299	false
fluoxetine	drug	217-226	alprazolam	drug	233-242	mechanism
fluoxetine	drug	217-226	alprazolam	drug	290-299	false
alprazolam	drug	233-242	alprazolam	drug	290-299	false

DDI-DrugBank.d131.s6	Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.
propoxyphene	drug	20-31	alprazolam	drug	79-88	mechanism

DDI-DrugBank.d131.s7	Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.
contraceptives	group	25-38	alprazolam	drug	86-95	mechanism

DDI-DrugBank.d131.s8	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
benzodiazepines	group	107-121	alprazolam	drug	148-157	false
benzodiazepines	group	107-121	alprazolam	drug	200-209	false
benzodiazepines	group	107-121	benzodiazepines	group	220-234	false
benzodiazepines	group	107-121	alprazolam	drug	289-298	false
benzodiazepines	group	107-121	benzodiazepines	group	342-356	false
benzodiazepines	group	107-121	alprazolam	drug	369-378	false
benzodiazepines	group	107-121	alprazolam	drug	421-430	false
benzodiazepines	group	107-121	diltiazem	drug	451-459	false
benzodiazepines	group	107-121	isoniazid	drug	462-470	false
benzodiazepines	group	107-121	macrolide antibiotics	group	473-493	false
benzodiazepines	group	107-121	erythromycin	drug	503-514	false
benzodiazepines	group	107-121	clarithromycin	drug	520-533	false
alprazolam	drug	148-157	alprazolam	drug	200-209	false
alprazolam	drug	148-157	benzodiazepines	group	220-234	false
alprazolam	drug	148-157	alprazolam	drug	289-298	false
alprazolam	drug	148-157	benzodiazepines	group	342-356	false
alprazolam	drug	148-157	alprazolam	drug	369-378	false
alprazolam	drug	148-157	alprazolam	drug	421-430	false
alprazolam	drug	148-157	diltiazem	drug	451-459	false
alprazolam	drug	148-157	isoniazid	drug	462-470	false
alprazolam	drug	148-157	macrolide antibiotics	group	473-493	false
alprazolam	drug	148-157	erythromycin	drug	503-514	false
alprazolam	drug	148-157	clarithromycin	drug	520-533	false
alprazolam	drug	200-209	benzodiazepines	group	220-234	false
alprazolam	drug	200-209	alprazolam	drug	289-298	false
alprazolam	drug	200-209	benzodiazepines	group	342-356	false
alprazolam	drug	200-209	alprazolam	drug	369-378	false
alprazolam	drug	200-209	alprazolam	drug	421-430	false
alprazolam	drug	200-209	diltiazem	drug	451-459	false
alprazolam	drug	200-209	isoniazid	drug	462-470	false
alprazolam	drug	200-209	macrolide antibiotics	group	473-493	false
alprazolam	drug	200-209	erythromycin	drug	503-514	false
alprazolam	drug	200-209	clarithromycin	drug	520-533	false
benzodiazepines	group	220-234	alprazolam	drug	289-298	false
benzodiazepines	group	220-234	benzodiazepines	group	342-356	false
benzodiazepines	group	220-234	alprazolam	drug	369-378	false
benzodiazepines	group	220-234	alprazolam	drug	421-430	false
benzodiazepines	group	220-234	diltiazem	drug	451-459	false
benzodiazepines	group	220-234	isoniazid	drug	462-470	false
benzodiazepines	group	220-234	macrolide antibiotics	group	473-493	false
benzodiazepines	group	220-234	erythromycin	drug	503-514	false
benzodiazepines	group	220-234	clarithromycin	drug	520-533	false
alprazolam	drug	289-298	benzodiazepines	group	342-356	false
alprazolam	drug	289-298	alprazolam	drug	369-378	false
alprazolam	drug	289-298	alprazolam	drug	421-430	false
alprazolam	drug	289-298	diltiazem	drug	451-459	false
alprazolam	drug	289-298	isoniazid	drug	462-470	false
alprazolam	drug	289-298	macrolide antibiotics	group	473-493	false
alprazolam	drug	289-298	erythromycin	drug	503-514	false
alprazolam	drug	289-298	clarithromycin	drug	520-533	false
benzodiazepines	group	342-356	alprazolam	drug	369-378	false
benzodiazepines	group	342-356	alprazolam	drug	421-430	false
benzodiazepines	group	342-356	diltiazem	drug	451-459	false
benzodiazepines	group	342-356	isoniazid	drug	462-470	false
benzodiazepines	group	342-356	macrolide antibiotics	group	473-493	false
benzodiazepines	group	342-356	erythromycin	drug	503-514	false
benzodiazepines	group	342-356	clarithromycin	drug	520-533	false
alprazolam	drug	369-378	alprazolam	drug	421-430	false
alprazolam	drug	369-378	diltiazem	drug	451-459	false
alprazolam	drug	369-378	isoniazid	drug	462-470	false
alprazolam	drug	369-378	macrolide antibiotics	group	473-493	false
alprazolam	drug	369-378	erythromycin	drug	503-514	false
alprazolam	drug	369-378	clarithromycin	drug	520-533	false
alprazolam	drug	421-430	diltiazem	drug	451-459	int
alprazolam	drug	421-430	isoniazid	drug	462-470	int
alprazolam	drug	421-430	macrolide antibiotics	group	473-493	int
alprazolam	drug	421-430	erythromycin	drug	503-514	int
alprazolam	drug	421-430	clarithromycin	drug	520-533	int
diltiazem	drug	451-459	isoniazid	drug	462-470	false
diltiazem	drug	451-459	macrolide antibiotics	group	473-493	false
diltiazem	drug	451-459	erythromycin	drug	503-514	false
diltiazem	drug	451-459	clarithromycin	drug	520-533	false
isoniazid	drug	462-470	macrolide antibiotics	group	473-493	false
isoniazid	drug	462-470	erythromycin	drug	503-514	false
isoniazid	drug	462-470	clarithromycin	drug	520-533	false
macrolide antibiotics	group	473-493	erythromycin	drug	503-514	false
macrolide antibiotics	group	473-493	clarithromycin	drug	520-533	false
erythromycin	drug	503-514	clarithromycin	drug	520-533	false

DDI-DrugBank.d131.s9	Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
alprazolam	drug	30-39	alprazolam	drug	82-91	false
alprazolam	drug	30-39	sertraline	drug	112-121	false
alprazolam	drug	30-39	paroxetine	drug	127-136	false
alprazolam	drug	82-91	sertraline	drug	112-121	int
alprazolam	drug	82-91	paroxetine	drug	127-136	int
sertraline	drug	112-121	paroxetine	drug	127-136	false

DDI-DrugBank.d131.s10	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
benzodiazepines	group	30-44	alprazolam	drug	57-66	false
benzodiazepines	group	30-44	ergotamine	drug	123-132	int
benzodiazepines	group	30-44	cyclosporine	drug	135-146	int
benzodiazepines	group	30-44	amiodarone	drug	149-158	int
benzodiazepines	group	30-44	nicardipine	drug	161-171	int
benzodiazepines	group	30-44	nifedipine	drug	178-187	int
alprazolam	drug	57-66	ergotamine	drug	123-132	int
alprazolam	drug	57-66	cyclosporine	drug	135-146	int
alprazolam	drug	57-66	amiodarone	drug	149-158	int
alprazolam	drug	57-66	nicardipine	drug	161-171	int
alprazolam	drug	57-66	nifedipine	drug	178-187	int
ergotamine	drug	123-132	cyclosporine	drug	135-146	false
ergotamine	drug	123-132	amiodarone	drug	149-158	false
ergotamine	drug	123-132	nicardipine	drug	161-171	false
ergotamine	drug	123-132	nifedipine	drug	178-187	false
cyclosporine	drug	135-146	amiodarone	drug	149-158	false
cyclosporine	drug	135-146	nicardipine	drug	161-171	false
cyclosporine	drug	135-146	nifedipine	drug	178-187	false
amiodarone	drug	149-158	nicardipine	drug	161-171	false
amiodarone	drug	149-158	nifedipine	drug	178-187	false
nicardipine	drug	161-171	nifedipine	drug	178-187	false

DDI-DrugBank.d179.s1	Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
Sulfapyridine	drug	0-12	Acetaminophen	drug	56-68	int
Sulfapyridine	drug	0-12	Tylenol	brand	77-83	int
Acetaminophen	drug	56-68	Tylenol	brand	77-83	false

DDI-DrugBank.d179.s2	- Amiodarone (e.g., Cordarone) or
Amiodarone	drug	2-11	Cordarone	brand	20-28	false

DDI-DrugBank.d179.s3	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
Anabolic steroids	group	2-18	nandrolone	drug	21-30	false
Anabolic steroids	group	2-18	Anabolin	brand	39-46	false
Anabolic steroids	group	2-18	oxandrolone	drug	50-60	false
Anabolic steroids	group	2-18	Anavar	brand	69-74	false
Anabolic steroids	group	2-18	oxymetholone	drug	78-89	false
Anabolic steroids	group	2-18	Anadrol	brand	98-104	false
Anabolic steroids	group	2-18	stanozolol	drug	108-117	false
Anabolic steroids	group	2-18	Winstrol	brand	126-133	false
nandrolone	drug	21-30	Anabolin	brand	39-46	false
nandrolone	drug	21-30	oxandrolone	drug	50-60	false
nandrolone	drug	21-30	Anavar	brand	69-74	false
nandrolone	drug	21-30	oxymetholone	drug	78-89	false
nandrolone	drug	21-30	Anadrol	brand	98-104	false
nandrolone	drug	21-30	stanozolol	drug	108-117	false
nandrolone	drug	21-30	Winstrol	brand	126-133	false
Anabolin	brand	39-46	oxandrolone	drug	50-60	false
Anabolin	brand	39-46	Anavar	brand	69-74	false
Anabolin	brand	39-46	oxymetholone	drug	78-89	false
Anabolin	brand	39-46	Anadrol	brand	98-104	false
Anabolin	brand	39-46	stanozolol	drug	108-117	false
Anabolin	brand	39-46	Winstrol	brand	126-133	false
oxandrolone	drug	50-60	Anavar	brand	69-74	false
oxandrolone	drug	50-60	oxymetholone	drug	78-89	false
oxandrolone	drug	50-60	Anadrol	brand	98-104	false
oxandrolone	drug	50-60	stanozolol	drug	108-117	false
oxandrolone	drug	50-60	Winstrol	brand	126-133	false
Anavar	brand	69-74	oxymetholone	drug	78-89	false
Anavar	brand	69-74	Anadrol	brand	98-104	false
Anavar	brand	69-74	stanozolol	drug	108-117	false
Anavar	brand	69-74	Winstrol	brand	126-133	false
oxymetholone	drug	78-89	Anadrol	brand	98-104	false
oxymetholone	drug	78-89	stanozolol	drug	108-117	false
oxymetholone	drug	78-89	Winstrol	brand	126-133	false
Anadrol	brand	98-104	stanozolol	drug	108-117	false
Anadrol	brand	98-104	Winstrol	brand	126-133	false
stanozolol	drug	108-117	Winstrol	brand	126-133	false

DDI-DrugBank.d179.s6	- Carbamazepine (e.g., Tegretol) or
Carbamazepine	drug	2-14	Tegretol	brand	23-30	false

DDI-DrugBank.d179.s7	- Carmustine (e.g., BiCNU) or
Carmustine	drug	2-11	BiCNU	brand	20-24	false

DDI-DrugBank.d179.s8	- Chloroquine (e.g., Aralen) or
Chloroquine	drug	2-12	Aralen	brand	21-26	false

DDI-DrugBank.d179.s9	- Dantrolene (e.g., Dantrium) or
Dantrolene	drug	2-11	Dantrium	brand	20-27	false

DDI-DrugBank.d179.s10	- Daunorubicin (e.g., Cerubidine) or
Daunorubicin	drug	2-13	Cerubidine	brand	22-31	false

DDI-DrugBank.d179.s11	- Disulfiram (e.g., Antabuse) or
Disulfiram	drug	2-11	Antabuse	brand	20-27	false

DDI-DrugBank.d179.s12	- Divalproex (e.g., Depakote) or
Divalproex	drug	2-11	Depakote	brand	20-27	false

DDI-DrugBank.d179.s14	- Etretinate (e.g., Tegison) or
Etretinate	drug	2-11	Tegison	brand	20-26	false

DDI-DrugBank.d179.s16	- Hydroxychloroquine (e.g., Plaquenil) or
Hydroxychloroquine	drug	2-19	Plaquenil	brand	28-36	false

DDI-DrugBank.d179.s17	- Mercaptopurine (e.g., Purinethol) or
Mercaptopurine	drug	2-15	Purinethol	brand	24-33	false

DDI-DrugBank.d179.s18	- Naltrexone (e.g., Trexan) (with long-term, high-dose use) or
Naltrexone	drug	2-11	Trexan	brand	20-25	false

DDI-DrugBank.d179.s19	- Oral contraceptives (birth control pills) containing estrogen or
contraceptives	group	7-20	estrogen	group	55-62	false

DDI-DrugBank.d179.s21	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
Phenothiazines	group	2-15	acetophenazine	drug	18-31	false
Phenothiazines	group	2-15	Tindal	brand	40-45	false
Phenothiazines	group	2-15	chlorpromazine	drug	49-62	false
Phenothiazines	group	2-15	Thorazine	brand	71-79	false
Phenothiazines	group	2-15	fluphenazine	drug	83-94	false
Phenothiazines	group	2-15	Prolixin	brand	103-110	false
Phenothiazines	group	2-15	mesoridazine	brand	114-125	false
Phenothiazines	group	2-15	Serentil	brand	134-141	false
Phenothiazines	group	2-15	perphenazine	drug	145-156	false
Phenothiazines	group	2-15	Trilafon	brand	165-172	false
Phenothiazines	group	2-15	prochlorperazine	drug	176-191	false
Phenothiazines	group	2-15	Compazine	brand	200-208	false
Phenothiazines	group	2-15	promazine	drug	212-220	false
Phenothiazines	group	2-15	Sparine	brand	229-235	false
Phenothiazines	group	2-15	promethazine	drug	239-250	false
Phenothiazines	group	2-15	Phenergan	brand	259-267	false
Phenothiazines	group	2-15	thioridazine	drug	271-282	false
Phenothiazines	group	2-15	Mellaril	brand	291-298	false
Phenothiazines	group	2-15	trifluoperazine	drug	302-316	false
Phenothiazines	group	2-15	Stelazine	brand	325-333	false
Phenothiazines	group	2-15	triflupromazine	drug	337-351	false
Phenothiazines	group	2-15	Vesprin	brand	360-366	false
Phenothiazines	group	2-15	trimeprazine	drug	370-381	false
Phenothiazines	group	2-15	Temaril	brand	390-396	false
acetophenazine	drug	18-31	Tindal	brand	40-45	false
acetophenazine	drug	18-31	chlorpromazine	drug	49-62	false
acetophenazine	drug	18-31	Thorazine	brand	71-79	false
acetophenazine	drug	18-31	fluphenazine	drug	83-94	false
acetophenazine	drug	18-31	Prolixin	brand	103-110	false
acetophenazine	drug	18-31	mesoridazine	brand	114-125	false
acetophenazine	drug	18-31	Serentil	brand	134-141	false
acetophenazine	drug	18-31	perphenazine	drug	145-156	false
acetophenazine	drug	18-31	Trilafon	brand	165-172	false
acetophenazine	drug	18-31	prochlorperazine	drug	176-191	false
acetophenazine	drug	18-31	Compazine	brand	200-208	false
acetophenazine	drug	18-31	promazine	drug	212-220	false
acetophenazine	drug	18-31	Sparine	brand	229-235	false
acetophenazine	drug	18-31	promethazine	drug	239-250	false
acetophenazine	drug	18-31	Phenergan	brand	259-267	false
acetophenazine	drug	18-31	thioridazine	drug	271-282	false
acetophenazine	drug	18-31	Mellaril	brand	291-298	false
acetophenazine	drug	18-31	trifluoperazine	drug	302-316	false
acetophenazine	drug	18-31	Stelazine	brand	325-333	false
acetophenazine	drug	18-31	triflupromazine	drug	337-351	false
acetophenazine	drug	18-31	Vesprin	brand	360-366	false
acetophenazine	drug	18-31	trimeprazine	drug	370-381	false
acetophenazine	drug	18-31	Temaril	brand	390-396	false
Tindal	brand	40-45	chlorpromazine	drug	49-62	false
Tindal	brand	40-45	Thorazine	brand	71-79	false
Tindal	brand	40-45	fluphenazine	drug	83-94	false
Tindal	brand	40-45	Prolixin	brand	103-110	false
Tindal	brand	40-45	mesoridazine	brand	114-125	false
Tindal	brand	40-45	Serentil	brand	134-141	false
Tindal	brand	40-45	perphenazine	drug	145-156	false
Tindal	brand	40-45	Trilafon	brand	165-172	false
Tindal	brand	40-45	prochlorperazine	drug	176-191	false
Tindal	brand	40-45	Compazine	brand	200-208	false
Tindal	brand	40-45	promazine	drug	212-220	false
Tindal	brand	40-45	Sparine	brand	229-235	false
Tindal	brand	40-45	promethazine	drug	239-250	false
Tindal	brand	40-45	Phenergan	brand	259-267	false
Tindal	brand	40-45	thioridazine	drug	271-282	false
Tindal	brand	40-45	Mellaril	brand	291-298	false
Tindal	brand	40-45	trifluoperazine	drug	302-316	false
Tindal	brand	40-45	Stelazine	brand	325-333	false
Tindal	brand	40-45	triflupromazine	drug	337-351	false
Tindal	brand	40-45	Vesprin	brand	360-366	false
Tindal	brand	40-45	trimeprazine	drug	370-381	false
Tindal	brand	40-45	Temaril	brand	390-396	false
chlorpromazine	drug	49-62	Thorazine	brand	71-79	false
chlorpromazine	drug	49-62	fluphenazine	drug	83-94	false
chlorpromazine	drug	49-62	Prolixin	brand	103-110	false
chlorpromazine	drug	49-62	mesoridazine	brand	114-125	false
chlorpromazine	drug	49-62	Serentil	brand	134-141	false
chlorpromazine	drug	49-62	perphenazine	drug	145-156	false
chlorpromazine	drug	49-62	Trilafon	brand	165-172	false
chlorpromazine	drug	49-62	prochlorperazine	drug	176-191	false
chlorpromazine	drug	49-62	Compazine	brand	200-208	false
chlorpromazine	drug	49-62	promazine	drug	212-220	false
chlorpromazine	drug	49-62	Sparine	brand	229-235	false
chlorpromazine	drug	49-62	promethazine	drug	239-250	false
chlorpromazine	drug	49-62	Phenergan	brand	259-267	false
chlorpromazine	drug	49-62	thioridazine	drug	271-282	false
chlorpromazine	drug	49-62	Mellaril	brand	291-298	false
chlorpromazine	drug	49-62	trifluoperazine	drug	302-316	false
chlorpromazine	drug	49-62	Stelazine	brand	325-333	false
chlorpromazine	drug	49-62	triflupromazine	drug	337-351	false
chlorpromazine	drug	49-62	Vesprin	brand	360-366	false
chlorpromazine	drug	49-62	trimeprazine	drug	370-381	false
chlorpromazine	drug	49-62	Temaril	brand	390-396	false
Thorazine	brand	71-79	fluphenazine	drug	83-94	false
Thorazine	brand	71-79	Prolixin	brand	103-110	false
Thorazine	brand	71-79	mesoridazine	brand	114-125	false
Thorazine	brand	71-79	Serentil	brand	134-141	false
Thorazine	brand	71-79	perphenazine	drug	145-156	false
Thorazine	brand	71-79	Trilafon	brand	165-172	false
Thorazine	brand	71-79	prochlorperazine	drug	176-191	false
Thorazine	brand	71-79	Compazine	brand	200-208	false
Thorazine	brand	71-79	promazine	drug	212-220	false
Thorazine	brand	71-79	Sparine	brand	229-235	false
Thorazine	brand	71-79	promethazine	drug	239-250	false
Thorazine	brand	71-79	Phenergan	brand	259-267	false
Thorazine	brand	71-79	thioridazine	drug	271-282	false
Thorazine	brand	71-79	Mellaril	brand	291-298	false
Thorazine	brand	71-79	trifluoperazine	drug	302-316	false
Thorazine	brand	71-79	Stelazine	brand	325-333	false
Thorazine	brand	71-79	triflupromazine	drug	337-351	false
Thorazine	brand	71-79	Vesprin	brand	360-366	false
Thorazine	brand	71-79	trimeprazine	drug	370-381	false
Thorazine	brand	71-79	Temaril	brand	390-396	false
fluphenazine	drug	83-94	Prolixin	brand	103-110	false
fluphenazine	drug	83-94	mesoridazine	brand	114-125	false
fluphenazine	drug	83-94	Serentil	brand	134-141	false
fluphenazine	drug	83-94	perphenazine	drug	145-156	false
fluphenazine	drug	83-94	Trilafon	brand	165-172	false
fluphenazine	drug	83-94	prochlorperazine	drug	176-191	false
fluphenazine	drug	83-94	Compazine	brand	200-208	false
fluphenazine	drug	83-94	promazine	drug	212-220	false
fluphenazine	drug	83-94	Sparine	brand	229-235	false
fluphenazine	drug	83-94	promethazine	drug	239-250	false
fluphenazine	drug	83-94	Phenergan	brand	259-267	false
fluphenazine	drug	83-94	thioridazine	drug	271-282	false
fluphenazine	drug	83-94	Mellaril	brand	291-298	false
fluphenazine	drug	83-94	trifluoperazine	drug	302-316	false
fluphenazine	drug	83-94	Stelazine	brand	325-333	false
fluphenazine	drug	83-94	triflupromazine	drug	337-351	false
fluphenazine	drug	83-94	Vesprin	brand	360-366	false
fluphenazine	drug	83-94	trimeprazine	drug	370-381	false
fluphenazine	drug	83-94	Temaril	brand	390-396	false
Prolixin	brand	103-110	mesoridazine	brand	114-125	false
Prolixin	brand	103-110	Serentil	brand	134-141	false
Prolixin	brand	103-110	perphenazine	drug	145-156	false
Prolixin	brand	103-110	Trilafon	brand	165-172	false
Prolixin	brand	103-110	prochlorperazine	drug	176-191	false
Prolixin	brand	103-110	Compazine	brand	200-208	false
Prolixin	brand	103-110	promazine	drug	212-220	false
Prolixin	brand	103-110	Sparine	brand	229-235	false
Prolixin	brand	103-110	promethazine	drug	239-250	false
Prolixin	brand	103-110	Phenergan	brand	259-267	false
Prolixin	brand	103-110	thioridazine	drug	271-282	false
Prolixin	brand	103-110	Mellaril	brand	291-298	false
Prolixin	brand	103-110	trifluoperazine	drug	302-316	false
Prolixin	brand	103-110	Stelazine	brand	325-333	false
Prolixin	brand	103-110	triflupromazine	drug	337-351	false
Prolixin	brand	103-110	Vesprin	brand	360-366	false
Prolixin	brand	103-110	trimeprazine	drug	370-381	false
Prolixin	brand	103-110	Temaril	brand	390-396	false
mesoridazine	brand	114-125	Serentil	brand	134-141	false
mesoridazine	brand	114-125	perphenazine	drug	145-156	false
mesoridazine	brand	114-125	Trilafon	brand	165-172	false
mesoridazine	brand	114-125	prochlorperazine	drug	176-191	false
mesoridazine	brand	114-125	Compazine	brand	200-208	false
mesoridazine	brand	114-125	promazine	drug	212-220	false
mesoridazine	brand	114-125	Sparine	brand	229-235	false
mesoridazine	brand	114-125	promethazine	drug	239-250	false
mesoridazine	brand	114-125	Phenergan	brand	259-267	false
mesoridazine	brand	114-125	thioridazine	drug	271-282	false
mesoridazine	brand	114-125	Mellaril	brand	291-298	false
mesoridazine	brand	114-125	trifluoperazine	drug	302-316	false
mesoridazine	brand	114-125	Stelazine	brand	325-333	false
mesoridazine	brand	114-125	triflupromazine	drug	337-351	false
mesoridazine	brand	114-125	Vesprin	brand	360-366	false
mesoridazine	brand	114-125	trimeprazine	drug	370-381	false
mesoridazine	brand	114-125	Temaril	brand	390-396	false
Serentil	brand	134-141	perphenazine	drug	145-156	false
Serentil	brand	134-141	Trilafon	brand	165-172	false
Serentil	brand	134-141	prochlorperazine	drug	176-191	false
Serentil	brand	134-141	Compazine	brand	200-208	false
Serentil	brand	134-141	promazine	drug	212-220	false
Serentil	brand	134-141	Sparine	brand	229-235	false
Serentil	brand	134-141	promethazine	drug	239-250	false
Serentil	brand	134-141	Phenergan	brand	259-267	false
Serentil	brand	134-141	thioridazine	drug	271-282	false
Serentil	brand	134-141	Mellaril	brand	291-298	false
Serentil	brand	134-141	trifluoperazine	drug	302-316	false
Serentil	brand	134-141	Stelazine	brand	325-333	false
Serentil	brand	134-141	triflupromazine	drug	337-351	false
Serentil	brand	134-141	Vesprin	brand	360-366	false
Serentil	brand	134-141	trimeprazine	drug	370-381	false
Serentil	brand	134-141	Temaril	brand	390-396	false
perphenazine	drug	145-156	Trilafon	brand	165-172	false
perphenazine	drug	145-156	prochlorperazine	drug	176-191	false
perphenazine	drug	145-156	Compazine	brand	200-208	false
perphenazine	drug	145-156	promazine	drug	212-220	false
perphenazine	drug	145-156	Sparine	brand	229-235	false
perphenazine	drug	145-156	promethazine	drug	239-250	false
perphenazine	drug	145-156	Phenergan	brand	259-267	false
perphenazine	drug	145-156	thioridazine	drug	271-282	false
perphenazine	drug	145-156	Mellaril	brand	291-298	false
perphenazine	drug	145-156	trifluoperazine	drug	302-316	false
perphenazine	drug	145-156	Stelazine	brand	325-333	false
perphenazine	drug	145-156	triflupromazine	drug	337-351	false
perphenazine	drug	145-156	Vesprin	brand	360-366	false
perphenazine	drug	145-156	trimeprazine	drug	370-381	false
perphenazine	drug	145-156	Temaril	brand	390-396	false
Trilafon	brand	165-172	prochlorperazine	drug	176-191	false
Trilafon	brand	165-172	Compazine	brand	200-208	false
Trilafon	brand	165-172	promazine	drug	212-220	false
Trilafon	brand	165-172	Sparine	brand	229-235	false
Trilafon	brand	165-172	promethazine	drug	239-250	false
Trilafon	brand	165-172	Phenergan	brand	259-267	false
Trilafon	brand	165-172	thioridazine	drug	271-282	false
Trilafon	brand	165-172	Mellaril	brand	291-298	false
Trilafon	brand	165-172	trifluoperazine	drug	302-316	false
Trilafon	brand	165-172	Stelazine	brand	325-333	false
Trilafon	brand	165-172	triflupromazine	drug	337-351	false
Trilafon	brand	165-172	Vesprin	brand	360-366	false
Trilafon	brand	165-172	trimeprazine	drug	370-381	false
Trilafon	brand	165-172	Temaril	brand	390-396	false
prochlorperazine	drug	176-191	Compazine	brand	200-208	false
prochlorperazine	drug	176-191	promazine	drug	212-220	false
prochlorperazine	drug	176-191	Sparine	brand	229-235	false
prochlorperazine	drug	176-191	promethazine	drug	239-250	false
prochlorperazine	drug	176-191	Phenergan	brand	259-267	false
prochlorperazine	drug	176-191	thioridazine	drug	271-282	false
prochlorperazine	drug	176-191	Mellaril	brand	291-298	false
prochlorperazine	drug	176-191	trifluoperazine	drug	302-316	false
prochlorperazine	drug	176-191	Stelazine	brand	325-333	false
prochlorperazine	drug	176-191	triflupromazine	drug	337-351	false
prochlorperazine	drug	176-191	Vesprin	brand	360-366	false
prochlorperazine	drug	176-191	trimeprazine	drug	370-381	false
prochlorperazine	drug	176-191	Temaril	brand	390-396	false
Compazine	brand	200-208	promazine	drug	212-220	false
Compazine	brand	200-208	Sparine	brand	229-235	false
Compazine	brand	200-208	promethazine	drug	239-250	false
Compazine	brand	200-208	Phenergan	brand	259-267	false
Compazine	brand	200-208	thioridazine	drug	271-282	false
Compazine	brand	200-208	Mellaril	brand	291-298	false
Compazine	brand	200-208	trifluoperazine	drug	302-316	false
Compazine	brand	200-208	Stelazine	brand	325-333	false
Compazine	brand	200-208	triflupromazine	drug	337-351	false
Compazine	brand	200-208	Vesprin	brand	360-366	false
Compazine	brand	200-208	trimeprazine	drug	370-381	false
Compazine	brand	200-208	Temaril	brand	390-396	false
promazine	drug	212-220	Sparine	brand	229-235	false
promazine	drug	212-220	promethazine	drug	239-250	false
promazine	drug	212-220	Phenergan	brand	259-267	false
promazine	drug	212-220	thioridazine	drug	271-282	false
promazine	drug	212-220	Mellaril	brand	291-298	false
promazine	drug	212-220	trifluoperazine	drug	302-316	false
promazine	drug	212-220	Stelazine	brand	325-333	false
promazine	drug	212-220	triflupromazine	drug	337-351	false
promazine	drug	212-220	Vesprin	brand	360-366	false
promazine	drug	212-220	trimeprazine	drug	370-381	false
promazine	drug	212-220	Temaril	brand	390-396	false
Sparine	brand	229-235	promethazine	drug	239-250	false
Sparine	brand	229-235	Phenergan	brand	259-267	false
Sparine	brand	229-235	thioridazine	drug	271-282	false
Sparine	brand	229-235	Mellaril	brand	291-298	false
Sparine	brand	229-235	trifluoperazine	drug	302-316	false
Sparine	brand	229-235	Stelazine	brand	325-333	false
Sparine	brand	229-235	triflupromazine	drug	337-351	false
Sparine	brand	229-235	Vesprin	brand	360-366	false
Sparine	brand	229-235	trimeprazine	drug	370-381	false
Sparine	brand	229-235	Temaril	brand	390-396	false
promethazine	drug	239-250	Phenergan	brand	259-267	false
promethazine	drug	239-250	thioridazine	drug	271-282	false
promethazine	drug	239-250	Mellaril	brand	291-298	false
promethazine	drug	239-250	trifluoperazine	drug	302-316	false
promethazine	drug	239-250	Stelazine	brand	325-333	false
promethazine	drug	239-250	triflupromazine	drug	337-351	false
promethazine	drug	239-250	Vesprin	brand	360-366	false
promethazine	drug	239-250	trimeprazine	drug	370-381	false
promethazine	drug	239-250	Temaril	brand	390-396	false
Phenergan	brand	259-267	thioridazine	drug	271-282	false
Phenergan	brand	259-267	Mellaril	brand	291-298	false
Phenergan	brand	259-267	trifluoperazine	drug	302-316	false
Phenergan	brand	259-267	Stelazine	brand	325-333	false
Phenergan	brand	259-267	triflupromazine	drug	337-351	false
Phenergan	brand	259-267	Vesprin	brand	360-366	false
Phenergan	brand	259-267	trimeprazine	drug	370-381	false
Phenergan	brand	259-267	Temaril	brand	390-396	false
thioridazine	drug	271-282	Mellaril	brand	291-298	false
thioridazine	drug	271-282	trifluoperazine	drug	302-316	false
thioridazine	drug	271-282	Stelazine	brand	325-333	false
thioridazine	drug	271-282	triflupromazine	drug	337-351	false
thioridazine	drug	271-282	Vesprin	brand	360-366	false
thioridazine	drug	271-282	trimeprazine	drug	370-381	false
thioridazine	drug	271-282	Temaril	brand	390-396	false
Mellaril	brand	291-298	trifluoperazine	drug	302-316	false
Mellaril	brand	291-298	Stelazine	brand	325-333	false
Mellaril	brand	291-298	triflupromazine	drug	337-351	false
Mellaril	brand	291-298	Vesprin	brand	360-366	false
Mellaril	brand	291-298	trimeprazine	drug	370-381	false
Mellaril	brand	291-298	Temaril	brand	390-396	false
trifluoperazine	drug	302-316	Stelazine	brand	325-333	false
trifluoperazine	drug	302-316	triflupromazine	drug	337-351	false
trifluoperazine	drug	302-316	Vesprin	brand	360-366	false
trifluoperazine	drug	302-316	trimeprazine	drug	370-381	false
trifluoperazine	drug	302-316	Temaril	brand	390-396	false
Stelazine	brand	325-333	triflupromazine	drug	337-351	false
Stelazine	brand	325-333	Vesprin	brand	360-366	false
Stelazine	brand	325-333	trimeprazine	drug	370-381	false
Stelazine	brand	325-333	Temaril	brand	390-396	false
triflupromazine	drug	337-351	Vesprin	brand	360-366	false
triflupromazine	drug	337-351	trimeprazine	drug	370-381	false
triflupromazine	drug	337-351	Temaril	brand	390-396	false
Vesprin	brand	360-366	trimeprazine	drug	370-381	false
Vesprin	brand	360-366	Temaril	brand	390-396	false
trimeprazine	drug	370-381	Temaril	brand	390-396	false

DDI-DrugBank.d179.s22	- Plicamycin (e.g., Mithracin) or
Plicamycin	drug	2-11	Mithracin	brand	20-28	false

DDI-DrugBank.d179.s23	- Valproic acid (e.g., Depakene) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver
Valproic acid	drug	2-14	Depakene	brand	23-30	false
Valproic acid	drug	2-14	sulfapyridine	drug	40-52	false
Depakene	brand	23-30	sulfapyridine	drug	40-52	false

DDI-DrugBank.d179.s24	- Acetohydroxamic acid (e.g., Lithostat) or
Acetohydroxamic acid	drug	2-21	Lithostat	brand	30-38	false

DDI-DrugBank.d179.s26	- Furazolidone (e.g., Furoxone) or
Furazolidone	drug	2-13	Furoxone	brand	22-29	false

DDI-DrugBank.d179.s27	- Nitrofurantoin (e.g., Furadantin) or
Nitrofurantoin	drug	2-15	Furadantin	brand	24-33	false

DDI-DrugBank.d179.s29	- Procainamide (e.g., Pronestyl) or
Procainamide	drug	2-13	Pronestyl	brand	22-30	false

DDI-DrugBank.d179.s30	- Quinidine (e.g., Quinidex) or
Quinidine	drug	2-10	Quinidex	brand	19-26	false

DDI-DrugBank.d179.s31	- Quinine (e.g., Quinamm) or
Quinine	drug	2-8	Quinamm	brand	17-23	false

DDI-DrugBank.d179.s32	- Sulfoxone (e.g., Diasone) or
Sulfoxone	drug	2-10	Diasone	brand	19-25	false

DDI-DrugBank.d179.s33	- Vitamin K (e.g., AquaMEPHYTON, Synkayvite) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood
Vitamin K	group	2-10	AquaMEPHYTON	brand	19-30	false
Vitamin K	group	2-10	Synkayvite	brand	33-42	false
Vitamin K	group	2-10	sulfapyridine	drug	52-64	false
AquaMEPHYTON	brand	19-30	Synkayvite	brand	33-42	false
AquaMEPHYTON	brand	19-30	sulfapyridine	drug	52-64	false
Synkayvite	brand	33-42	sulfapyridine	drug	52-64	false

DDI-DrugBank.d179.s34	- Anticoagulants (blood thinners) or
Anticoagulants	group	2-15	blood thinner	group	18-30	false

DDI-DrugBank.d179.s35	- Ethotoin (e.g., Peganone) or
Ethotoin	drug	2-9	Peganone	brand	18-25	false

DDI-DrugBank.d179.s36	- Mephenytoin (e.g., Mesantoin) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines
Mephenytoin	drug	2-12	Mesantoin	brand	21-29	false
Mephenytoin	drug	2-12	sulfapyridine	drug	39-51	false
Mesantoin	brand	21-29	sulfapyridine	drug	39-51	false

DDI-DrugBank.d179.s37	- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics
Antidiabetics	group	2-14	antidiabetics	group	72-84	false
Antidiabetics	group	2-14	sulfapyridine	drug	91-103	false
Antidiabetics	group	2-14	antidiabetics	group	197-209	false
antidiabetics	group	72-84	sulfapyridine	drug	91-103	effect
antidiabetics	group	72-84	antidiabetics	group	197-209	false
sulfapyridine	drug	91-103	antidiabetics	group	197-209	false

DDI-DrugBank.d179.s38	- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
Methotrexate	drug	2-13	Mexate	brand	22-27	false
Methotrexate	drug	2-13	methotrexate	drug	37-48	false
Methotrexate	drug	2-13	sulfapyridine	drug	55-67	false
Methotrexate	drug	2-13	methotrexate	drug	156-167	false
Mexate	brand	22-27	methotrexate	drug	37-48	false
Mexate	brand	22-27	sulfapyridine	drug	55-67	false
Mexate	brand	22-27	methotrexate	drug	156-167	false
methotrexate	drug	37-48	sulfapyridine	drug	55-67	effect
methotrexate	drug	37-48	methotrexate	drug	156-167	false
sulfapyridine	drug	55-67	methotrexate	drug	156-167	false

DDI-DrugBank.d179.s39	- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood
Methyldopa	drug	2-11	Aldomet	brand	20-26	false
Methyldopa	drug	2-11	methyldopa	drug	36-45	false
Methyldopa	drug	2-11	sulfapyridine	drug	52-64	false
Aldomet	brand	20-26	methyldopa	drug	36-45	false
Aldomet	brand	20-26	sulfapyridine	drug	52-64	false
methyldopa	drug	36-45	sulfapyridine	drug	52-64	effect

DDI-DrugBank.d179.s40	- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
Phenytoin	drug	2-10	Dilantin	brand	19-26	false
Phenytoin	drug	2-10	phenytoin	drug	36-44	false
Phenytoin	drug	2-10	sulfapyridine	drug	51-63	false
Phenytoin	drug	2-10	phenytoin	drug	152-160	false
Dilantin	brand	19-26	phenytoin	drug	36-44	false
Dilantin	brand	19-26	sulfapyridine	drug	51-63	false
Dilantin	brand	19-26	phenytoin	drug	152-160	false
phenytoin	drug	36-44	sulfapyridine	drug	51-63	effect
phenytoin	drug	36-44	phenytoin	drug	152-160	false
sulfapyridine	drug	51-63	phenytoin	drug	152-160	false

DDI-DrugBank.d142.s0	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
LEVSIN	brand	76-81	antimuscarinics	group	124-138	effect
LEVSIN	brand	76-81	amantadine	drug	141-150	effect
LEVSIN	brand	76-81	haloperidol	drug	153-163	effect
LEVSIN	brand	76-81	phenothiazines	group	166-179	effect
LEVSIN	brand	76-81	monoamine oxidase (MAO) inhibitors	group	182-215	effect
LEVSIN	brand	76-81	tricyclic antidepressants	group	218-242	effect
LEVSIN	brand	76-81	antihistamines	group	252-265	effect
antimuscarinics	group	124-138	amantadine	drug	141-150	false
antimuscarinics	group	124-138	haloperidol	drug	153-163	false
antimuscarinics	group	124-138	phenothiazines	group	166-179	false
antimuscarinics	group	124-138	monoamine oxidase (MAO) inhibitors	group	182-215	false
antimuscarinics	group	124-138	tricyclic antidepressants	group	218-242	false
antimuscarinics	group	124-138	antihistamines	group	252-265	false
amantadine	drug	141-150	haloperidol	drug	153-163	false
amantadine	drug	141-150	phenothiazines	group	166-179	false
amantadine	drug	141-150	monoamine oxidase (MAO) inhibitors	group	182-215	false
amantadine	drug	141-150	tricyclic antidepressants	group	218-242	false
amantadine	drug	141-150	antihistamines	group	252-265	false
haloperidol	drug	153-163	phenothiazines	group	166-179	false
haloperidol	drug	153-163	monoamine oxidase (MAO) inhibitors	group	182-215	false
haloperidol	drug	153-163	tricyclic antidepressants	group	218-242	false
haloperidol	drug	153-163	antihistamines	group	252-265	false
phenothiazines	group	166-179	monoamine oxidase (MAO) inhibitors	group	182-215	false
phenothiazines	group	166-179	tricyclic antidepressants	group	218-242	false
phenothiazines	group	166-179	antihistamines	group	252-265	false
monoamine oxidase (MAO) inhibitors	group	182-215	tricyclic antidepressants	group	218-242	false
monoamine oxidase (MAO) inhibitors	group	182-215	antihistamines	group	252-265	false
tricyclic antidepressants	group	218-242	antihistamines	group	252-265	false

DDI-DrugBank.d142.s1	Antacids may interfere with the absorption of LEVSIN.
Antacids	group	0-7	LEVSIN	brand	46-51	mechanism

DDI-DrugBank.d549.s0	In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine, diltiazem, or captopril.
iloprost	drug	94-101	nifedipine	drug	114-123	false
iloprost	drug	94-101	diltiazem	drug	126-134	false
iloprost	drug	94-101	captopril	drug	140-148	false
nifedipine	drug	114-123	diltiazem	drug	126-134	false
nifedipine	drug	114-123	captopril	drug	140-148	false
diltiazem	drug	126-134	captopril	drug	140-148	false

DDI-DrugBank.d549.s1	However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
iloprost	drug	9-16	vasodilators	group	74-85	effect
iloprost	drug	9-16	antihypertensive agents	group	91-113	effect
vasodilators	group	74-85	antihypertensive agents	group	91-113	false

DDI-DrugBank.d549.s2	Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.
iloprost	drug	6-13	anticoagulants	group	135-148	effect

DDI-DrugBank.d549.s3	During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
iloprost	drug	24-31	anticoagulants	group	60-73	false
iloprost	drug	24-31	diuretics	group	76-84	false
iloprost	drug	24-31	cardiac glycosides	group	87-104	false
iloprost	drug	24-31	calcium channel blockers	group	107-130	false
iloprost	drug	24-31	analgesics	group	133-142	false
iloprost	drug	24-31	antipyretics	group	145-156	false
iloprost	drug	24-31	nonsteroidal antiinflammatories	group	159-189	false
iloprost	drug	24-31	corticosteroids	group	192-206	false
anticoagulants	group	60-73	diuretics	group	76-84	false
anticoagulants	group	60-73	cardiac glycosides	group	87-104	false
anticoagulants	group	60-73	calcium channel blockers	group	107-130	false
anticoagulants	group	60-73	analgesics	group	133-142	false
anticoagulants	group	60-73	antipyretics	group	145-156	false
anticoagulants	group	60-73	nonsteroidal antiinflammatories	group	159-189	false
anticoagulants	group	60-73	corticosteroids	group	192-206	false
diuretics	group	76-84	cardiac glycosides	group	87-104	false
diuretics	group	76-84	calcium channel blockers	group	107-130	false
diuretics	group	76-84	analgesics	group	133-142	false
diuretics	group	76-84	antipyretics	group	145-156	false
diuretics	group	76-84	nonsteroidal antiinflammatories	group	159-189	false
diuretics	group	76-84	corticosteroids	group	192-206	false
cardiac glycosides	group	87-104	calcium channel blockers	group	107-130	false
cardiac glycosides	group	87-104	analgesics	group	133-142	false
cardiac glycosides	group	87-104	antipyretics	group	145-156	false
cardiac glycosides	group	87-104	nonsteroidal antiinflammatories	group	159-189	false
cardiac glycosides	group	87-104	corticosteroids	group	192-206	false
calcium channel blockers	group	107-130	analgesics	group	133-142	false
calcium channel blockers	group	107-130	antipyretics	group	145-156	false
calcium channel blockers	group	107-130	nonsteroidal antiinflammatories	group	159-189	false
calcium channel blockers	group	107-130	corticosteroids	group	192-206	false
analgesics	group	133-142	antipyretics	group	145-156	false
analgesics	group	133-142	nonsteroidal antiinflammatories	group	159-189	false
analgesics	group	133-142	corticosteroids	group	192-206	false
antipyretics	group	145-156	nonsteroidal antiinflammatories	group	159-189	false
antipyretics	group	145-156	corticosteroids	group	192-206	false
nonsteroidal antiinflammatories	group	159-189	corticosteroids	group	192-206	false

DDI-DrugBank.d549.s4	Intravenous infusion of iloprost had no effect on the pharmacokinetics of digoxin.
iloprost	drug	24-31	digoxin	drug	74-80	false

DDI-DrugBank.d549.s5	Acetylsalicylic acid did not alter the clearance (pharmacokinetics) of iloprost.
Acetylsalicylic acid	drug	0-19	iloprost	drug	71-78	false

DDI-DrugBank.d308.s0	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
HYDROXYZINE	drug	27-37	CENTRAL NERVOUS SYSTEM DEPRESSANTS	group	100-133	effect
HYDROXYZINE	drug	27-37	NARCOTICS	group	143-151	effect
HYDROXYZINE	drug	27-37	NON-NARCOTIC ANALGESICS	group	154-176	effect
HYDROXYZINE	drug	27-37	BARBITURATES	group	182-193	effect
CENTRAL NERVOUS SYSTEM DEPRESSANTS	group	100-133	NARCOTICS	group	143-151	false
CENTRAL NERVOUS SYSTEM DEPRESSANTS	group	100-133	NON-NARCOTIC ANALGESICS	group	154-176	false
CENTRAL NERVOUS SYSTEM DEPRESSANTS	group	100-133	BARBITURATES	group	182-193	false
NARCOTICS	group	143-151	NON-NARCOTIC ANALGESICS	group	154-176	false
NARCOTICS	group	143-151	BARBITURATES	group	182-193	false
NON-NARCOTIC ANALGESICS	group	154-176	BARBITURATES	group	182-193	false

DDI-DrugBank.d308.s1	Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.
central nervous system depressants	group	15-48	hydroxyzine	drug	86-96	advise

DDI-DrugBank.d308.s3	Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased.
CNS depressant drugs	group	65-84	alcohol	drug	120-126	false

DDI-DrugBank.d192.s0	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
Dexbrompheniramine	drug	0-17	alcohol	drug	37-43	effect
Dexbrompheniramine	drug	0-17	CNS depressants	group	54-68	effect
Dexbrompheniramine	drug	0-17	antihistamines	group	144-157	false
Dexbrompheniramine	drug	0-17	anticholinergics	group	161-176	effect
Dexbrompheniramine	drug	0-17	antihistamines	group	323-336	false
Dexbrompheniramine	drug	0-17	monoamine oxidase (MAO) inhibitors	group	344-377	effect
Dexbrompheniramine	drug	0-17	antihistamines	group	400-413	false
Dexbrompheniramine	drug	0-17	antihistamines	group	491-504	false
alcohol	drug	37-43	CNS depressants	group	54-68	false
alcohol	drug	37-43	antihistamines	group	144-157	false
alcohol	drug	37-43	anticholinergics	group	161-176	false
alcohol	drug	37-43	antihistamines	group	323-336	false
alcohol	drug	37-43	monoamine oxidase (MAO) inhibitors	group	344-377	false
alcohol	drug	37-43	antihistamines	group	400-413	false
alcohol	drug	37-43	antihistamines	group	491-504	false
CNS depressants	group	54-68	antihistamines	group	144-157	false
CNS depressants	group	54-68	anticholinergics	group	161-176	false
CNS depressants	group	54-68	antihistamines	group	323-336	false
CNS depressants	group	54-68	monoamine oxidase (MAO) inhibitors	group	344-377	false
CNS depressants	group	54-68	antihistamines	group	400-413	false
CNS depressants	group	54-68	antihistamines	group	491-504	false
antihistamines	group	144-157	anticholinergics	group	161-176	false
antihistamines	group	144-157	antihistamines	group	323-336	false
antihistamines	group	144-157	monoamine oxidase (MAO) inhibitors	group	344-377	false
antihistamines	group	144-157	antihistamines	group	400-413	false
antihistamines	group	144-157	antihistamines	group	491-504	false
anticholinergics	group	161-176	antihistamines	group	323-336	false
anticholinergics	group	161-176	monoamine oxidase (MAO) inhibitors	group	344-377	false
anticholinergics	group	161-176	antihistamines	group	400-413	false
anticholinergics	group	161-176	antihistamines	group	491-504	false
antihistamines	group	323-336	monoamine oxidase (MAO) inhibitors	group	344-377	false
antihistamines	group	323-336	antihistamines	group	400-413	false
antihistamines	group	323-336	antihistamines	group	491-504	false
monoamine oxidase (MAO) inhibitors	group	344-377	antihistamines	group	400-413	false
monoamine oxidase (MAO) inhibitors	group	344-377	antihistamines	group	491-504	false
antihistamines	group	400-413	antihistamines	group	491-504	false

DDI-DrugBank.d422.s0	Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.
reserpine	drug	37-45	beta blocking agents	group	92-111	effect

DDI-DrugBank.d422.s1	Patients treated concurrently with BREVIBLOC (esmolol HCl) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
BREVIBLOC	brand	35-43	esmolol HCl	drug	46-56	false

DDI-DrugBank.d422.s2	A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.
BREVIBLOC	brand	31-39	warfarin	drug	45-52	false
BREVIBLOC	brand	31-39	BREVIBLOC	brand	96-104	false
BREVIBLOC	brand	31-39	warfarin	drug	110-117	false
BREVIBLOC	brand	31-39	warfarin	drug	134-141	false
warfarin	drug	45-52	BREVIBLOC	brand	96-104	false
warfarin	drug	45-52	warfarin	drug	110-117	false
warfarin	drug	45-52	warfarin	drug	134-141	false
BREVIBLOC	brand	96-104	warfarin	drug	110-117	false
BREVIBLOC	brand	96-104	warfarin	drug	134-141	false
warfarin	drug	110-117	warfarin	drug	134-141	false

DDI-DrugBank.d422.s3	BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.
BREVIBLOC	brand	0-8	warfarin	drug	65-72	mechanism

DDI-DrugBank.d422.s4	When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.
digoxin	drug	5-11	BREVIBLOC	brand	17-25	mechanism
digoxin	drug	5-11	digoxin	drug	126-132	false
BREVIBLOC	brand	17-25	digoxin	drug	126-132	false

DDI-DrugBank.d422.s5	Digoxin did not affect BREVIBLOC pharmacokinetics.
Digoxin	drug	0-6	BREVIBLOC	brand	23-31	false

DDI-DrugBank.d422.s6	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
morphine	drug	17-24	BREVIBLOC	brand	30-38	false
morphine	drug	17-24	morphine	drug	105-112	false
morphine	drug	17-24	BREVIBLOC	brand	141-149	false
morphine	drug	17-24	morphine	drug	218-225	false
BREVIBLOC	brand	30-38	morphine	drug	105-112	false
BREVIBLOC	brand	30-38	BREVIBLOC	brand	141-149	false
BREVIBLOC	brand	30-38	morphine	drug	218-225	false
morphine	drug	105-112	BREVIBLOC	brand	141-149	false
morphine	drug	105-112	morphine	drug	218-225	false
BREVIBLOC	brand	141-149	morphine	drug	218-225	mechanism

DDI-DrugBank.d422.s8	The effect of BREVIBLOC on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery.
BREVIBLOC	drug	14-22	succinylcholine	drug	43-57	false

DDI-DrugBank.d422.s9	The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.
succinylcholine	drug	39-53	BREVIBLOC	brand	73-81	effect

DDI-DrugBank.d422.s10	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
BREVIBLOC	brand	102-110	digoxin	drug	188-194	advise
BREVIBLOC	brand	102-110	morphine	drug	197-204	advise
BREVIBLOC	brand	102-110	succinylcholine	drug	207-221	advise
BREVIBLOC	brand	102-110	warfarin	drug	226-233	advise
digoxin	drug	188-194	morphine	drug	197-204	false
digoxin	drug	188-194	succinylcholine	drug	207-221	false
digoxin	drug	188-194	warfarin	drug	226-233	false
morphine	drug	197-204	succinylcholine	drug	207-221	false
morphine	drug	197-204	warfarin	drug	226-233	false
succinylcholine	drug	207-221	warfarin	drug	226-233	false

DDI-DrugBank.d422.s13	Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.
BREVIBLOC	brand	56-64	verapamil	drug	70-78	advise

DDI-DrugBank.d422.s15	Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
BREVIBLOC	brand	14-22	dopamine	drug	158-165	advise
BREVIBLOC	brand	14-22	epinephrine	drug	168-178	advise
BREVIBLOC	brand	14-22	norepinephrine	drug	185-198	advise
dopamine	drug	158-165	epinephrine	drug	168-178	false
dopamine	drug	158-165	norepinephrine	drug	185-198	false
epinephrine	drug	168-178	norepinephrine	drug	185-198	false

DDI-DrugBank.d233.s0	Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
Allopurinol	drug	9-19	azathioprine	drug	66-77	false
Allopurinol	drug	9-19	allopurinol	drug	95-105	false
azathioprine	drug	66-77	allopurinol	drug	95-105	mechanism

DDI-DrugBank.d233.s1	Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
azathioprine	drug	19-30	allopurinol	drug	36-46	advise
azathioprine	drug	19-30	azathioprine	drug	94-105	false
allopurinol	drug	36-46	azathioprine	drug	94-105	false

DDI-DrugBank.d233.s3	Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
Angiotensln Converting Enzyme Inhibitors	group	9-48	angiotensin converting enzyme inhibitors	group	62-101	false
Angiotensln Converting Enzyme Inhibitors	group	9-48	azathioprine	drug	142-153	false
angiotensin converting enzyme inhibitors	group	62-101	azathioprine	drug	142-153	effect

DDI-DrugBank.d285.s1	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)
barbiturates	group	67-78	phenytoin sodium	drug	98-113	false
barbiturates	group	67-78	carbamazepine	drug	116-128	false
barbiturates	group	67-78	griseofulvin	drug	148-159	false
barbiturates	group	67-78	ampicillin	drug	162-171	false
barbiturates	group	67-78	tetracyclines	group	178-190	false
phenytoin sodium	drug	98-113	carbamazepine	drug	116-128	false
phenytoin sodium	drug	98-113	griseofulvin	drug	148-159	false
phenytoin sodium	drug	98-113	ampicillin	drug	162-171	false
phenytoin sodium	drug	98-113	tetracyclines	group	178-190	false
carbamazepine	drug	116-128	griseofulvin	drug	148-159	false
carbamazepine	drug	116-128	ampicillin	drug	162-171	false
carbamazepine	drug	116-128	tetracyclines	group	178-190	false
griseofulvin	drug	148-159	ampicillin	drug	162-171	false
griseofulvin	drug	148-159	tetracyclines	group	178-190	false
ampicillin	drug	162-171	tetracyclines	group	178-190	false

DDI-DrugBank.d113.s0	Warfarin: Meclofenamate sodium enhances the effect of warfarin.
Warfarin	drug	0-7	Meclofenamate sodium	drug	10-29	effect
Warfarin	drug	0-7	warfarin	drug	54-61	false
Meclofenamate sodium	drug	10-29	warfarin	drug	54-61	false

DDI-DrugBank.d113.s1	Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.
meclofenamate sodium	drug	16-35	warfarin	drug	69-76	advise
meclofenamate sodium	drug	16-35	warfarin	drug	93-100	false
warfarin	drug	69-76	warfarin	drug	93-100	false

DDI-DrugBank.d113.s2	Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.
Aspirin	brand	0-6	aspirin	brand	38-44	false
Aspirin	brand	0-6	meclofenamate sodium	drug	56-75	false
aspirin	brand	38-44	meclofenamate sodium	drug	56-75	mechanism

DDI-DrugBank.d113.s3	The urinary excretion of meclofenamate sodium is unaffected by aspirin, indicating no change in meclofenamate sodium absorption.
meclofenamate sodium	drug	25-44	aspirin	brand	63-69	false
meclofenamate sodium	drug	25-44	meclofenamate sodium	drug	96-115	false
aspirin	brand	63-69	meclofenamate sodium	drug	96-115	false

DDI-DrugBank.d113.s4	Meclofenamate sodium does not affect serum salicylate levels.
Meclofenamate sodium	drug	0-19	salicylate	group	43-52	false

DDI-DrugBank.d113.s6	Propoxyphene: The concurrent administration of propoxyphene hydrochloride does not affect the bioavailability of meclofenamate sodium.
Propoxyphene	drug	0-11	propoxyphene hydrochloride	drug	47-72	false
Propoxyphene	drug	0-11	meclofenamate sodium	drug	113-132	false
propoxyphene hydrochloride	drug	47-72	meclofenamate sodium	drug	113-132	false

DDI-DrugBank.d113.s7	Antacids: Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of meclofenamate sodium.
Antacids	group	0-7	aluminum hydroxide	drug	40-47;63-71	false
Antacids	group	0-7	magnesium hydroxide	drug	53-71	false
Antacids	group	0-7	meclofenamate sodium	drug	112-131	false
aluminum hydroxide	drug	40-47;63-71	magnesium hydroxide	drug	53-71	false
aluminum hydroxide	drug	40-47;63-71	meclofenamate sodium	drug	112-131	false
magnesium hydroxide	drug	53-71	meclofenamate sodium	drug	112-131	false

DDI-DrugBank.d339.s0	Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.
Carbamazepine	drug	0-12	carbamazepine	drug	24-36	false
Carbamazepine	drug	0-12	SUPRAX	brand	97-102	false
carbamazepine	drug	24-36	SUPRAX	brand	97-102	mechanism

DDI-DrugBank.d339.s2	Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
Warfarin	drug	0-7	Anticoagulants	group	13-26	false
Warfarin	drug	0-7	cefixime	drug	115-122	effect
Anticoagulants	group	13-26	cefixime	drug	115-122	effect

DDI-DrugBank.d339.s3	Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.
nitroprusside	drug	112-124	nitroferricyanide	drug	151-167	false

DDI-DrugBank.d279.s0	The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.
CAMPTOSAR	brand	23-31	antineoplastic agents	group	118-138	effect

DDI-DrugBank.d279.s3	Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.
CAMPTOSAR	brand	56-64	dexamethasone	drug	113-125	effect

DDI-DrugBank.d279.s8	The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).
prochlorperazine	drug	115-130	CAMPTOSAR	brand	168-176	effect

DDI-DrugBank.d279.s10	It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.
laxative	group	26-33	CAMPTOSAR	brand	59-67	effect

DDI-DrugBank.d279.s11	In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.
CAMPTOSAR	brand	94-102	diuretics	group	140-148	false
CAMPTOSAR	brand	94-102	CAMPTOSAR	brand	169-177	false
diuretics	group	140-148	CAMPTOSAR	brand	169-177	effect

DDI-DrugBank.d299.s1	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
ergotamine	drug	80-89	ergot-type medications	group	105-126	false
ergotamine	drug	80-89	dihydroergotamine	drug	134-150	false
ergotamine	drug	80-89	methysergide	drug	155-166	false
ergotamine	drug	80-89	AXERT	brand	173-177	advise
ergot-type medications	group	105-126	dihydroergotamine	drug	134-150	false
ergot-type medications	group	105-126	methysergide	drug	155-166	false
ergot-type medications	group	105-126	AXERT	brand	173-177	advise
dihydroergotamine	drug	134-150	methysergide	drug	155-166	false
dihydroergotamine	drug	134-150	AXERT	brand	173-177	advise
methysergide	drug	155-166	AXERT	brand	173-177	advise

DDI-DrugBank.d299.s2	Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
Monoamine Oxidase Inhibitors	group	0-27	moclobemide	drug	50-60	false
Monoamine Oxidase Inhibitors	group	0-27	almotriptan	drug	92-102	false
moclobemide	drug	50-60	almotriptan	drug	92-102	mechanism

DDI-DrugBank.d299.s4	Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.
5-HT1B/1D Agonists	group	6-23	5-HT1B/1D agonists	group	50-67	false
5-HT1B/1D Agonists	group	6-23	AXERT	brand	103-107	false
5-HT1B/1D agonists	group	50-67	AXERT	brand	103-107	advise

DDI-DrugBank.d299.s5	Propanolol: The pharmacokinetics of almotriptan were not affected by coadministration of propranolol.
Propanolol	drug	0-9	almotriptan	drug	36-46	false
Propanolol	drug	0-9	propranolol	drug	89-99	false
almotriptan	drug	36-46	propranolol	drug	89-99	false

DDI-DrugBank.d299.s6	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
Selective Serotonin Reuptake Inhibitors	group	0-38	SSRIs	group	41-45	false
Selective Serotonin Reuptake Inhibitors	group	0-38	SSRIs	group	49-53	false
Selective Serotonin Reuptake Inhibitors	group	0-38	fluoxetine	drug	62-71	false
Selective Serotonin Reuptake Inhibitors	group	0-38	fluvoxamine	drug	74-84	false
Selective Serotonin Reuptake Inhibitors	group	0-38	paroxetine	drug	87-96	false
Selective Serotonin Reuptake Inhibitors	group	0-38	sertraline	drug	99-108	false
Selective Serotonin Reuptake Inhibitors	group	0-38	5-HT1 agonists	group	215-228	false
SSRIs	group	41-45	SSRIs	group	49-53	false
SSRIs	group	41-45	fluoxetine	drug	62-71	false
SSRIs	group	41-45	fluvoxamine	drug	74-84	false
SSRIs	group	41-45	paroxetine	drug	87-96	false
SSRIs	group	41-45	sertraline	drug	99-108	false
SSRIs	group	41-45	5-HT1 agonists	group	215-228	false
SSRIs	group	49-53	fluoxetine	drug	62-71	false
SSRIs	group	49-53	fluvoxamine	drug	74-84	false
SSRIs	group	49-53	paroxetine	drug	87-96	false
SSRIs	group	49-53	sertraline	drug	99-108	false
SSRIs	group	49-53	5-HT1 agonists	group	215-228	effect
fluoxetine	drug	62-71	fluvoxamine	drug	74-84	false
fluoxetine	drug	62-71	paroxetine	drug	87-96	false
fluoxetine	drug	62-71	sertraline	drug	99-108	false
fluoxetine	drug	62-71	5-HT1 agonists	group	215-228	effect
fluvoxamine	drug	74-84	paroxetine	drug	87-96	false
fluvoxamine	drug	74-84	sertraline	drug	99-108	false
fluvoxamine	drug	74-84	5-HT1 agonists	group	215-228	effect
paroxetine	drug	87-96	sertraline	drug	99-108	false
paroxetine	drug	87-96	5-HT1 agonists	group	215-228	effect
sertraline	drug	99-108	5-HT1 agonists	group	215-228	effect

DDI-DrugBank.d299.s7	If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.
AXERT	brand	30-34	SSRI	group	43-46	advise

DDI-DrugBank.d299.s8	Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
Verapamil	drug	0-8	almotriptan	drug	31-41	false
Verapamil	drug	0-8	verapamil	drug	47-55	false
Verapamil	drug	0-8	almotriptan	drug	112-122	false
almotriptan	drug	31-41	verapamil	drug	47-55	mechanism
almotriptan	drug	31-41	almotriptan	drug	112-122	false
verapamil	drug	47-55	almotriptan	drug	112-122	false

DDI-DrugBank.d299.s10	Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
almotriptan	drug	20-30	ketoconazole	drug	64-75	mechanism
almotriptan	drug	20-30	almotriptan	drug	235-245	false
ketoconazole	drug	64-75	almotriptan	drug	235-245	false

DDI-DrugBank.d299.s11	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
almotriptan	drug	33-43	itraconazole	drug	87-98	false
almotriptan	drug	33-43	ritonavir	drug	101-109	false
almotriptan	drug	33-43	erythromycin	drug	116-127	false
almotriptan	drug	33-43	almotriptan	drug	175-185	false
almotriptan	drug	33-43	almotriptan	drug	208-218	false
itraconazole	drug	87-98	ritonavir	drug	101-109	false
itraconazole	drug	87-98	erythromycin	drug	116-127	false
itraconazole	drug	87-98	almotriptan	drug	175-185	false
itraconazole	drug	87-98	almotriptan	drug	208-218	advise
ritonavir	drug	101-109	erythromycin	drug	116-127	false
ritonavir	drug	101-109	almotriptan	drug	175-185	false
ritonavir	drug	101-109	almotriptan	drug	208-218	advise
erythromycin	drug	116-127	almotriptan	drug	175-185	false
erythromycin	drug	116-127	almotriptan	drug	208-218	advise
almotriptan	drug	175-185	almotriptan	drug	208-218	false

DDI-DrugBank.d272.s0	The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.
bromocriptine mesylate	drug	18-39	alcohol	drug	116-122	false
bromocriptine mesylate	drug	18-39	bromocriptine mesylate	drug	159-180	false
alcohol	drug	116-122	bromocriptine mesylate	drug	159-180	effect

DDI-DrugBank.d272.s1	Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
Bromocriptine mesylate	drug	0-21	dopamine antagonists	group	41-60	int
Bromocriptine mesylate	drug	0-21	butyrophenones	group	63-76	int
dopamine antagonists	group	41-60	butyrophenones	group	63-76	false

DDI-DrugBank.d272.s2	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
bromocriptine mesylate	drug	64-85	phenothiazines	group	88-101	effect
bromocriptine mesylate	drug	64-85	haloperidol	drug	104-114	effect
bromocriptine mesylate	drug	64-85	metoclopramide	drug	117-130	effect
bromocriptine mesylate	drug	64-85	pimozide	drug	133-140	effect
phenothiazines	group	88-101	haloperidol	drug	104-114	false
phenothiazines	group	88-101	metoclopramide	drug	117-130	false
phenothiazines	group	88-101	pimozide	drug	133-140	false
haloperidol	drug	104-114	metoclopramide	drug	117-130	false
haloperidol	drug	104-114	pimozide	drug	133-140	false
metoclopramide	drug	117-130	pimozide	drug	133-140	false

DDI-DrugBank.d272.s3	Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.
bromocriptine mesylate	drug	19-40	ergot alkaloids	group	53-67	advise

DDI-DrugBank.d31.s0	MAO inhibitors should be used with caution in patients receiving hydralazine.
MAO inhibitors	group	0-13	hydralazine	drug	65-75	advise

DDI-DrugBank.d31.s1	When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.
antihypertensive drugs	group	27-48	diazoxide	drug	59-67	effect
antihypertensive drugs	group	27-48	hydralazine	drug	99-109	effect
diazoxide	drug	59-67	hydralazine	drug	99-109	false

DDI-DrugBank.d31.s2	Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.
diazoxide	drug	45-53	hydralazine	drug	69-79	effect

DDI-DrugBank.d31.s3	Beta-blockers (metoprolol, propranolol) serum concentrations and pharmacologic effects may be increased.
Beta-blockers	group	0-12	metoprolol	drug	15-24	false
Beta-blockers	group	0-12	propranolol	drug	27-37	false
metoprolol	drug	15-24	propranolol	drug	27-37	false

DDI-DrugBank.d31.s5	Propranolol increases hydralazines serum concentrations.
Propranolol	drug	0-10	hydralazine	drug	22-32	mechanism

DDI-DrugBank.d31.s6	Acebutolol, atenolol, and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.
Acebutolol	drug	0-9	atenolol	drug	12-19	false
Acebutolol	drug	0-9	nadolol	drug	26-32	false
atenolol	drug	12-19	nadolol	drug	26-32	false

DDI-DrugBank.d31.s7	NSAIDs may decrease the hemodynamic effects of hydralazine;
NSAIDs	group	0-5	hydralazine	drug	47-57	effect

DDI-DrugBank.d75.s1	In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin.
digoxin	drug	61-67	warfarin	drug	73-80	false
digoxin	drug	61-67	anagrelide	drug	117-126	false
digoxin	drug	61-67	anagrelide	drug	138-147	false
digoxin	drug	61-67	digoxin	drug	177-183	false
digoxin	drug	61-67	warfarin	drug	188-195	false
warfarin	drug	73-80	anagrelide	drug	117-126	false
warfarin	drug	73-80	anagrelide	drug	138-147	false
warfarin	drug	73-80	digoxin	drug	177-183	false
warfarin	drug	73-80	warfarin	drug	188-195	false
anagrelide	drug	117-126	anagrelide	drug	138-147	false
anagrelide	drug	117-126	digoxin	drug	177-183	false
anagrelide	drug	117-126	warfarin	drug	188-195	false
anagrelide	drug	138-147	digoxin	drug	177-183	false
anagrelide	drug	138-147	warfarin	drug	188-195	false
digoxin	drug	177-183	warfarin	drug	188-195	false

DDI-DrugBank.d75.s2	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
anagrelide	drug	122-131	aspirin	brand	157-163	false
anagrelide	drug	122-131	acetaminophen	drug	166-178	false
anagrelide	drug	122-131	furosemide	drug	181-190	false
anagrelide	drug	122-131	iron	drug	193-196	false
anagrelide	drug	122-131	ranitidine	drug	199-208	false
anagrelide	drug	122-131	hydroxyurea	drug	211-221	false
anagrelide	drug	122-131	allopurinol	drug	228-238	false
aspirin	brand	157-163	acetaminophen	drug	166-178	false
aspirin	brand	157-163	furosemide	drug	181-190	false
aspirin	brand	157-163	iron	drug	193-196	false
aspirin	brand	157-163	ranitidine	drug	199-208	false
aspirin	brand	157-163	hydroxyurea	drug	211-221	false
aspirin	brand	157-163	allopurinol	drug	228-238	false
acetaminophen	drug	166-178	furosemide	drug	181-190	false
acetaminophen	drug	166-178	iron	drug	193-196	false
acetaminophen	drug	166-178	ranitidine	drug	199-208	false
acetaminophen	drug	166-178	hydroxyurea	drug	211-221	false
acetaminophen	drug	166-178	allopurinol	drug	228-238	false
furosemide	drug	181-190	iron	drug	193-196	false
furosemide	drug	181-190	ranitidine	drug	199-208	false
furosemide	drug	181-190	hydroxyurea	drug	211-221	false
furosemide	drug	181-190	allopurinol	drug	228-238	false
iron	drug	193-196	ranitidine	drug	199-208	false
iron	drug	193-196	hydroxyurea	drug	211-221	false
iron	drug	193-196	allopurinol	drug	228-238	false
ranitidine	drug	199-208	hydroxyurea	drug	211-221	false
ranitidine	drug	199-208	allopurinol	drug	228-238	false
hydroxyurea	drug	211-221	allopurinol	drug	228-238	false

DDI-DrugBank.d75.s4	An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated.
anagrelide	drug	78-87	aspirin	brand	145-151	false

DDI-DrugBank.d75.s6	No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed.
anagrelide	drug	60-69	acetylsalicylic acid	drug	75-94	false

DDI-DrugBank.d75.s8	Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.
Anagrelide	drug	0-9	aspirin	brand	123-129	effect

DDI-DrugBank.d75.s10	It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.
fluvoxamine	drug	78-88	anagrelide	drug	176-185	mechanism

DDI-DrugBank.d75.s12	Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.
Anagrelide	drug	0-9	theophylline	drug	213-224	mechanism

DDI-DrugBank.d75.s14	The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
milrinone	drug	76-84	enoximone	drug	87-95	false
milrinone	drug	76-84	amrinone	drug	98-105	false
milrinone	drug	76-84	olprinone	drug_n	108-116	false
milrinone	drug	76-84	cilostazol	drug	122-131	false
milrinone	drug	76-84	anagrelide	drug	155-164	effect
enoximone	drug	87-95	amrinone	drug	98-105	false
enoximone	drug	87-95	olprinone	drug_n	108-116	false
enoximone	drug	87-95	cilostazol	drug	122-131	false
enoximone	drug	87-95	anagrelide	drug	155-164	effect
amrinone	drug	98-105	olprinone	drug_n	108-116	false
amrinone	drug	98-105	cilostazol	drug	122-131	false
amrinone	drug	98-105	anagrelide	drug	155-164	effect
olprinone	drug_n	108-116	cilostazol	drug	122-131	false
olprinone	drug_n	108-116	anagrelide	drug	155-164	effect
cilostazol	drug	122-131	anagrelide	drug	155-164	effect

DDI-DrugBank.d75.s15	There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.
sucralfate	drug	51-60	anagrelide	drug	81-90	mechanism

DDI-DrugBank.d11.s0	Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
Albuterol	drug	23-31	STRATTERA	brand	35-43	false
Albuterol	drug	23-31	albuterol	drug	160-168	false
Albuterol	drug	23-31	beta2 agonists	group	180-193	false
Albuterol	drug	23-31	albuterol	drug	218-226	false
STRATTERA	brand	35-43	albuterol	drug	160-168	advise
STRATTERA	brand	35-43	beta2 agonists	group	180-193	false
STRATTERA	brand	35-43	albuterol	drug	218-226	false
albuterol	drug	160-168	beta2 agonists	group	180-193	false
albuterol	drug	160-168	albuterol	drug	218-226	false
beta2 agonists	group	180-193	albuterol	drug	218-226	false

DDI-DrugBank.d11.s1	CYP2D6 inhibitors - Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine.
Atomoxetine	drug	20-30	4-hydroxyatomoxetine	drug_n	82-101	false

DDI-DrugBank.d11.s3	Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
STRATTERA	brand	21-29	paroxetine	drug	98-107	advise
STRATTERA	brand	21-29	fluoxetine	drug	110-119	advise
STRATTERA	brand	21-29	quinidine	drug	126-134	advise
paroxetine	drug	98-107	fluoxetine	drug	110-119	false
paroxetine	drug	98-107	quinidine	drug	126-134	false
fluoxetine	drug	110-119	quinidine	drug	126-134	false

DDI-DrugBank.d11.s4	In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
paroxetine	drug	31-40	fluoxetine	drug	45-54	false
paroxetine	drug	31-40	atomoxetine	drug	68-78	mechanism
paroxetine	drug	31-40	atomoxetine	drug	157-167	false
fluoxetine	drug	45-54	atomoxetine	drug	68-78	mechanism
fluoxetine	drug	45-54	atomoxetine	drug	157-167	false
atomoxetine	drug	68-78	atomoxetine	drug	157-167	false

DDI-DrugBank.d537.s0	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
Bentiromide	drug	0-10	acetaminophen	drug	30-42	int
Bentiromide	drug	0-10	Tylenol	brand	51-57	int
Bentiromide	drug	0-10	chloramphenicol	drug	61-75	int
Bentiromide	drug	0-10	Chloromycetin	brand	84-96	int
Bentiromide	drug	0-10	anesthetics	group	106-116	int
Bentiromide	drug	0-10	benzocaine	drug	125-134	int
Bentiromide	drug	0-10	lidocaine	drug	140-148	int
Bentiromide	drug	0-10	para-aminobenzoic acid	drug_n	152-173	int
Bentiromide	drug	0-10	PABA	drug_n	176-179	int
Bentiromide	drug	0-10	multivitamins	group	233-245	int
Bentiromide	drug	0-10	procainamide	drug	249-260	int
Bentiromide	drug	0-10	Pronestyl	brand	269-277	int
Bentiromide	drug	0-10	sulfonamides	group	281-292	int
Bentiromide	drug	0-10	thiazide diuretics	group	313-330	int
acetaminophen	drug	30-42	Tylenol	brand	51-57	false
acetaminophen	drug	30-42	chloramphenicol	drug	61-75	false
acetaminophen	drug	30-42	Chloromycetin	brand	84-96	false
acetaminophen	drug	30-42	anesthetics	group	106-116	false
acetaminophen	drug	30-42	benzocaine	drug	125-134	false
acetaminophen	drug	30-42	lidocaine	drug	140-148	false
acetaminophen	drug	30-42	para-aminobenzoic acid	drug_n	152-173	false
acetaminophen	drug	30-42	PABA	drug_n	176-179	false
acetaminophen	drug	30-42	multivitamins	group	233-245	false
acetaminophen	drug	30-42	procainamide	drug	249-260	false
acetaminophen	drug	30-42	Pronestyl	brand	269-277	false
acetaminophen	drug	30-42	sulfonamides	group	281-292	false
acetaminophen	drug	30-42	thiazide diuretics	group	313-330	false
Tylenol	brand	51-57	chloramphenicol	drug	61-75	false
Tylenol	brand	51-57	Chloromycetin	brand	84-96	false
Tylenol	brand	51-57	anesthetics	group	106-116	false
Tylenol	brand	51-57	benzocaine	drug	125-134	false
Tylenol	brand	51-57	lidocaine	drug	140-148	false
Tylenol	brand	51-57	para-aminobenzoic acid	drug_n	152-173	false
Tylenol	brand	51-57	PABA	drug_n	176-179	false
Tylenol	brand	51-57	multivitamins	group	233-245	false
Tylenol	brand	51-57	procainamide	drug	249-260	false
Tylenol	brand	51-57	Pronestyl	brand	269-277	false
Tylenol	brand	51-57	sulfonamides	group	281-292	false
Tylenol	brand	51-57	thiazide diuretics	group	313-330	false
chloramphenicol	drug	61-75	Chloromycetin	brand	84-96	false
chloramphenicol	drug	61-75	anesthetics	group	106-116	false
chloramphenicol	drug	61-75	benzocaine	drug	125-134	false
chloramphenicol	drug	61-75	lidocaine	drug	140-148	false
chloramphenicol	drug	61-75	para-aminobenzoic acid	drug_n	152-173	false
chloramphenicol	drug	61-75	PABA	drug_n	176-179	false
chloramphenicol	drug	61-75	multivitamins	group	233-245	false
chloramphenicol	drug	61-75	procainamide	drug	249-260	false
chloramphenicol	drug	61-75	Pronestyl	brand	269-277	false
chloramphenicol	drug	61-75	sulfonamides	group	281-292	false
chloramphenicol	drug	61-75	thiazide diuretics	group	313-330	false
Chloromycetin	brand	84-96	anesthetics	group	106-116	false
Chloromycetin	brand	84-96	benzocaine	drug	125-134	false
Chloromycetin	brand	84-96	lidocaine	drug	140-148	false
Chloromycetin	brand	84-96	para-aminobenzoic acid	drug_n	152-173	false
Chloromycetin	brand	84-96	PABA	drug_n	176-179	false
Chloromycetin	brand	84-96	multivitamins	group	233-245	false
Chloromycetin	brand	84-96	procainamide	drug	249-260	false
Chloromycetin	brand	84-96	Pronestyl	brand	269-277	false
Chloromycetin	brand	84-96	sulfonamides	group	281-292	false
Chloromycetin	brand	84-96	thiazide diuretics	group	313-330	false
anesthetics	group	106-116	benzocaine	drug	125-134	false
anesthetics	group	106-116	lidocaine	drug	140-148	false
anesthetics	group	106-116	para-aminobenzoic acid	drug_n	152-173	false
anesthetics	group	106-116	PABA	drug_n	176-179	false
anesthetics	group	106-116	multivitamins	group	233-245	false
anesthetics	group	106-116	procainamide	drug	249-260	false
anesthetics	group	106-116	Pronestyl	brand	269-277	false
anesthetics	group	106-116	sulfonamides	group	281-292	false
anesthetics	group	106-116	thiazide diuretics	group	313-330	false
benzocaine	drug	125-134	lidocaine	drug	140-148	false
benzocaine	drug	125-134	para-aminobenzoic acid	drug_n	152-173	false
benzocaine	drug	125-134	PABA	drug_n	176-179	false
benzocaine	drug	125-134	multivitamins	group	233-245	false
benzocaine	drug	125-134	procainamide	drug	249-260	false
benzocaine	drug	125-134	Pronestyl	brand	269-277	false
benzocaine	drug	125-134	sulfonamides	group	281-292	false
benzocaine	drug	125-134	thiazide diuretics	group	313-330	false
lidocaine	drug	140-148	para-aminobenzoic acid	drug_n	152-173	false
lidocaine	drug	140-148	PABA	drug_n	176-179	false
lidocaine	drug	140-148	multivitamins	group	233-245	false
lidocaine	drug	140-148	procainamide	drug	249-260	false
lidocaine	drug	140-148	Pronestyl	brand	269-277	false
lidocaine	drug	140-148	sulfonamides	group	281-292	false
lidocaine	drug	140-148	thiazide diuretics	group	313-330	false
para-aminobenzoic acid	drug_n	152-173	PABA	drug_n	176-179	false
para-aminobenzoic acid	drug_n	152-173	multivitamins	group	233-245	false
para-aminobenzoic acid	drug_n	152-173	procainamide	drug	249-260	false
para-aminobenzoic acid	drug_n	152-173	Pronestyl	brand	269-277	false
para-aminobenzoic acid	drug_n	152-173	sulfonamides	group	281-292	false
para-aminobenzoic acid	drug_n	152-173	thiazide diuretics	group	313-330	false
PABA	drug_n	176-179	multivitamins	group	233-245	false
PABA	drug_n	176-179	procainamide	drug	249-260	false
PABA	drug_n	176-179	Pronestyl	brand	269-277	false
PABA	drug_n	176-179	sulfonamides	group	281-292	false
PABA	drug_n	176-179	thiazide diuretics	group	313-330	false
multivitamins	group	233-245	procainamide	drug	249-260	false
multivitamins	group	233-245	Pronestyl	brand	269-277	false
multivitamins	group	233-245	sulfonamides	group	281-292	false
multivitamins	group	233-245	thiazide diuretics	group	313-330	false
procainamide	drug	249-260	Pronestyl	brand	269-277	false
procainamide	drug	249-260	sulfonamides	group	281-292	false
procainamide	drug	249-260	thiazide diuretics	group	313-330	false
Pronestyl	brand	269-277	sulfonamides	group	281-292	false
Pronestyl	brand	269-277	thiazide diuretics	group	313-330	false
sulfonamides	group	281-292	thiazide diuretics	group	313-330	false

DDI-DrugBank.d382.s4	Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
Aprepitant	drug	0-9	S(-) warfarin	drug	54-66	mechanism
Aprepitant	drug	0-9	tolbutamide	drug	72-82	mechanism
S(-) warfarin	drug	54-66	tolbutamide	drug	72-82	false

DDI-DrugBank.d382.s5	Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
Aprepitant	drug	20-29	phenytoin	drug	115-123	mechanism

DDI-DrugBank.d382.s6	Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.
Aprepitant	drug	0-9	Aprepitant	drug	148-157	false
Aprepitant	drug	0-9	digoxin	drug	164-170	false
Aprepitant	drug	148-157	digoxin	drug	164-170	false

DDI-DrugBank.d382.s7	5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.
5-HT3 antagonists	group	0-16	aprepitant	drug	57-66	false
5-HT3 antagonists	group	0-16	ondansetron	drug	137-147	false
5-HT3 antagonists	group	0-16	granisetron	drug	152-162	false
aprepitant	drug	57-66	ondansetron	drug	137-147	false
aprepitant	drug	57-66	granisetron	drug	152-162	false
ondansetron	drug	137-147	granisetron	drug	152-162	false

DDI-DrugBank.d382.s9	Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
Corticosteroids	group	0-14	Dexamethasone	drug	17-29	false
Corticosteroids	group	0-14	Aprepitant	drug	32-41	false
Corticosteroids	group	0-14	dexamethasone	drug	82-94	false
Corticosteroids	group	0-14	Aprepitant	drug	141-150	false
Corticosteroids	group	0-14	dexamethasone	drug	181-193	false
Corticosteroids	group	0-14	dexamethasone	drug	267-279	false
Dexamethasone	drug	17-29	Aprepitant	drug	32-41	false
Dexamethasone	drug	17-29	dexamethasone	drug	82-94	false
Dexamethasone	drug	17-29	Aprepitant	drug	141-150	false
Dexamethasone	drug	17-29	dexamethasone	drug	181-193	false
Dexamethasone	drug	17-29	dexamethasone	drug	267-279	false
Aprepitant	drug	32-41	dexamethasone	drug	82-94	mechanism
Aprepitant	drug	32-41	Aprepitant	drug	141-150	false
Aprepitant	drug	32-41	dexamethasone	drug	181-193	false
Aprepitant	drug	32-41	dexamethasone	drug	267-279	false
dexamethasone	drug	82-94	Aprepitant	drug	141-150	false
dexamethasone	drug	82-94	dexamethasone	drug	181-193	false
dexamethasone	drug	82-94	dexamethasone	drug	267-279	false
Aprepitant	drug	141-150	dexamethasone	drug	181-193	mechanism
Aprepitant	drug	141-150	dexamethasone	drug	267-279	false
dexamethasone	drug	181-193	dexamethasone	drug	267-279	false

DDI-DrugBank.d382.s10	The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.
dexamethasone	drug	9-21	Aprepitant	drug	93-102	advise
dexamethasone	drug	9-21	dexamethasone	drug	129-141	false
dexamethasone	drug	9-21	Aprepitant	drug	194-203	false
Aprepitant	drug	93-102	dexamethasone	drug	129-141	false
Aprepitant	drug	93-102	Aprepitant	drug	194-203	false
dexamethasone	drug	129-141	Aprepitant	drug	194-203	false

DDI-DrugBank.d382.s11	The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
dexamethasone	drug	18-30	Aprepitant	drug	70-79	mechanism
dexamethasone	drug	18-30	dexamethasone	drug	134-146	false
Aprepitant	drug	70-79	dexamethasone	drug	134-146	false

DDI-DrugBank.d382.s13	Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
Aprepitant	drug	0-9	methylprednisolone	drug	107-124	mechanism
Aprepitant	drug	0-9	methylprednisolone	drug	200-217	false
methylprednisolone	drug	107-124	methylprednisolone	drug	200-217	false

DDI-DrugBank.d382.s14	The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
methylprednisolone	drug	7-24	methylprednisolone	drug	84-101	false
methylprednisolone	drug	7-24	Aprepitant	drug	172-181	advise
methylprednisolone	drug	7-24	methylprednisolone	drug	207-224	false
methylprednisolone	drug	7-24	Aprepitant	drug	277-286	false
methylprednisolone	drug	84-101	Aprepitant	drug	172-181	advise
methylprednisolone	drug	84-101	methylprednisolone	drug	207-224	false
methylprednisolone	drug	84-101	Aprepitant	drug	277-286	false
Aprepitant	drug	172-181	methylprednisolone	drug	207-224	false
Aprepitant	drug	172-181	Aprepitant	drug	277-286	false
methylprednisolone	drug	207-224	Aprepitant	drug	277-286	false

DDI-DrugBank.d382.s15	Warfarin: A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.
Warfarin	drug	0-7	Aprepitant	drug	34-43	false
Warfarin	drug	0-7	warfarin	drug	152-159	false
Aprepitant	drug	34-43	warfarin	drug	152-159	false

DDI-DrugBank.d382.s16	Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
Aprepitant	drug	32-41	R(+) warfarin	drug	64-67;77-84	false
Aprepitant	drug	32-41	S(-) warfarin	drug	72-84	false
Aprepitant	drug	32-41	S(-)warfarin	drug	135-146	false
Aprepitant	drug	32-41	Aprepitant	drug	335-344	false
R(+) warfarin	drug	64-67;77-84	S(-) warfarin	drug	72-84	false
R(+) warfarin	drug	64-67;77-84	S(-)warfarin	drug	135-146	false
R(+) warfarin	drug	64-67;77-84	Aprepitant	drug	335-344	false
S(-) warfarin	drug	72-84	S(-)warfarin	drug	135-146	false
S(-) warfarin	drug	72-84	Aprepitant	drug	335-344	false
S(-)warfarin	drug	135-146	Aprepitant	drug	335-344	mechanism

DDI-DrugBank.d382.s17	In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.
warfarin	drug	23-30	Aprepitant	drug	193-202	advise

DDI-DrugBank.d382.s18	Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
Tolbutamide	drug	0-10	Aprepitant	drug	13-22	false
Tolbutamide	drug	0-10	tolbutamide	drug	107-117	false
Tolbutamide	drug	0-10	tolbutamide	drug	212-222	false
Tolbutamide	drug	0-10	Aprepitant	drug	308-317	false
Aprepitant	drug	13-22	tolbutamide	drug	107-117	false
Aprepitant	drug	13-22	tolbutamide	drug	212-222	false
Aprepitant	drug	13-22	Aprepitant	drug	308-317	false
tolbutamide	drug	107-117	tolbutamide	drug	212-222	false
tolbutamide	drug	107-117	Aprepitant	drug	308-317	false
tolbutamide	drug	212-222	Aprepitant	drug	308-317	mechanism

DDI-DrugBank.d382.s19	Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
contraceptives	group	5-18	Aprepitant	drug	21-30	false
contraceptives	group	5-18	contraceptive	group	100-112	false
contraceptives	group	5-18	ethinyl estradiol	drug	135-151	false
contraceptives	group	5-18	norethindrone	drug	165-177	false
contraceptives	group	5-18	ethinyl estradiol	drug	201-217	false
contraceptives	group	5-18	norethindrone	drug	252-264	false
Aprepitant	drug	21-30	contraceptive	group	100-112	false
Aprepitant	drug	21-30	ethinyl estradiol	drug	135-151	mechanism
Aprepitant	drug	21-30	norethindrone	drug	165-177	mechanism
Aprepitant	drug	21-30	ethinyl estradiol	drug	201-217	false
Aprepitant	drug	21-30	norethindrone	drug	252-264	false
contraceptive	group	100-112	ethinyl estradiol	drug	135-151	false
contraceptive	group	100-112	norethindrone	drug	165-177	false
contraceptive	group	100-112	ethinyl estradiol	drug	201-217	false
contraceptive	group	100-112	norethindrone	drug	252-264	false
ethinyl estradiol	drug	135-151	norethindrone	drug	165-177	false
ethinyl estradiol	drug	135-151	ethinyl estradiol	drug	201-217	false
ethinyl estradiol	drug	135-151	norethindrone	drug	252-264	false
norethindrone	drug	165-177	ethinyl estradiol	drug	201-217	false
norethindrone	drug	165-177	norethindrone	drug	252-264	false
ethinyl estradiol	drug	201-217	norethindrone	drug	252-264	false

DDI-DrugBank.d382.s20	therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.
contraceptives	group	32-45	Aprepitant	drug	72-81	effect

DDI-DrugBank.d382.s21	Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.
Aprepitant	drug	28-37	contraceptives	group	69-82	advise

DDI-DrugBank.d382.s22	Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
Midazolam	drug	0-8	Aprepitant	drug	11-20	false
Midazolam	drug	0-8	midazolam	drug	43-51	false
Midazolam	drug	0-8	midazolam	drug	155-163	false
Midazolam	drug	0-8	Aprepitant	drug	224-233	false
Aprepitant	drug	11-20	midazolam	drug	43-51	mechanism
Aprepitant	drug	11-20	midazolam	drug	155-163	false
Aprepitant	drug	11-20	Aprepitant	drug	224-233	false
midazolam	drug	43-51	midazolam	drug	155-163	false
midazolam	drug	43-51	Aprepitant	drug	224-233	false
midazolam	drug	155-163	Aprepitant	drug	224-233	false

DDI-DrugBank.d382.s23	The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
midazolam	drug	60-68	benzodiazepines	group	79-93	false
midazolam	drug	60-68	alprazolam	drug	119-128	false
midazolam	drug	60-68	triazolam	drug	131-139	false
midazolam	drug	60-68	Aprepitant	drug	202-211	advise
benzodiazepines	group	79-93	alprazolam	drug	119-128	false
benzodiazepines	group	79-93	triazolam	drug	131-139	false
benzodiazepines	group	79-93	Aprepitant	drug	202-211	advise
alprazolam	drug	119-128	triazolam	drug	131-139	false
alprazolam	drug	119-128	Aprepitant	drug	202-211	advise
triazolam	drug	131-139	Aprepitant	drug	202-211	advise

DDI-DrugBank.d382.s24	In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.
midazolam	drug	52-60	Aprepitant	drug	63-72	false
midazolam	drug	52-60	midazolam	drug	138-146	false
midazolam	drug	52-60	Aprepitant	drug	218-227	false
Aprepitant	drug	63-72	midazolam	drug	138-146	false
Aprepitant	drug	63-72	Aprepitant	drug	218-227	false
midazolam	drug	138-146	Aprepitant	drug	218-227	false

DDI-DrugBank.d382.s25	Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
Aprepitant	drug	0-9	midazolam	drug	32-40	mechanism
Aprepitant	drug	0-9	midazolam	drug	83-91	mechanism
Aprepitant	drug	0-9	Aprepitant	drug	135-144	false
midazolam	drug	32-40	midazolam	drug	83-91	false
midazolam	drug	32-40	Aprepitant	drug	135-144	false
midazolam	drug	83-91	Aprepitant	drug	135-144	false

DDI-DrugBank.d382.s30	therefore, coadministration of Aprepitant with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant.
Aprepitant	drug	31-40	aprepitant	drug	131-140	false

DDI-DrugBank.d382.s31	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
Aprepitant	drug	44-53	ketoconazole	drug	92-103	advise
Aprepitant	drug	44-53	itraconazole	drug	106-117	advise
Aprepitant	drug	44-53	nefazodone	drug	120-129	advise
Aprepitant	drug	44-53	troleandomycin	drug	132-145	advise
Aprepitant	drug	44-53	clarithromycin	drug	148-161	advise
Aprepitant	drug	44-53	ritonavir	drug	164-172	advise
Aprepitant	drug	44-53	nelfinavir	drug	175-184	advise
ketoconazole	drug	92-103	itraconazole	drug	106-117	false
ketoconazole	drug	92-103	nefazodone	drug	120-129	false
ketoconazole	drug	92-103	troleandomycin	drug	132-145	false
ketoconazole	drug	92-103	clarithromycin	drug	148-161	false
ketoconazole	drug	92-103	ritonavir	drug	164-172	false
ketoconazole	drug	92-103	nelfinavir	drug	175-184	false
itraconazole	drug	106-117	nefazodone	drug	120-129	false
itraconazole	drug	106-117	troleandomycin	drug	132-145	false
itraconazole	drug	106-117	clarithromycin	drug	148-161	false
itraconazole	drug	106-117	ritonavir	drug	164-172	false
itraconazole	drug	106-117	nelfinavir	drug	175-184	false
nefazodone	drug	120-129	troleandomycin	drug	132-145	false
nefazodone	drug	120-129	clarithromycin	drug	148-161	false
nefazodone	drug	120-129	ritonavir	drug	164-172	false
nefazodone	drug	120-129	nelfinavir	drug	175-184	false
troleandomycin	drug	132-145	clarithromycin	drug	148-161	false
troleandomycin	drug	132-145	ritonavir	drug	164-172	false
troleandomycin	drug	132-145	nelfinavir	drug	175-184	false
clarithromycin	drug	148-161	ritonavir	drug	164-172	false
clarithromycin	drug	148-161	nelfinavir	drug	175-184	false
ritonavir	drug	164-172	nelfinavir	drug	175-184	false

DDI-DrugBank.d382.s32	Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
diltiazem	drug	42-50	aprepitant	drug	107-116	advise

DDI-DrugBank.d382.s34	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
Aprepitant	drug	31-40	rifampin	drug	97-104	mechanism
Aprepitant	drug	31-40	carbamazepine	drug	107-119	false
Aprepitant	drug	31-40	phenytoin	drug	122-130	mechanism
Aprepitant	drug	31-40	aprepitant	drug	180-189	mechanism
Aprepitant	drug	31-40	Aprepitant	drug	232-241	false
rifampin	drug	97-104	carbamazepine	drug	107-119	false
rifampin	drug	97-104	phenytoin	drug	122-130	false
rifampin	drug	97-104	aprepitant	drug	180-189	false
rifampin	drug	97-104	Aprepitant	drug	232-241	false
carbamazepine	drug	107-119	phenytoin	drug	122-130	false
carbamazepine	drug	107-119	aprepitant	drug	180-189	false
carbamazepine	drug	107-119	Aprepitant	drug	232-241	false
phenytoin	drug	122-130	aprepitant	drug	180-189	false
phenytoin	drug	122-130	Aprepitant	drug	232-241	false
aprepitant	drug	180-189	Aprepitant	drug	232-241	false

DDI-DrugBank.d382.s35	Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a
Ketoconazole	drug	0-11	Aprepitant	drug	43-52	false

DDI-DrugBank.d382.s36	Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
Ketoconazole	drug	0-11	Aprepitant	drug	43-52	false
Ketoconazole	drug	0-11	ketoconazole	drug	116-127	false
Ketoconazole	drug	0-11	aprepitant	drug	168-177	false
Ketoconazole	drug	0-11	aprepitant	drug	245-254	false
Aprepitant	drug	43-52	ketoconazole	drug	116-127	mechanism
Aprepitant	drug	43-52	aprepitant	drug	168-177	false
Aprepitant	drug	43-52	aprepitant	drug	245-254	false
ketoconazole	drug	116-127	aprepitant	drug	168-177	false
ketoconazole	drug	116-127	aprepitant	drug	245-254	false
aprepitant	drug	168-177	aprepitant	drug	245-254	false

DDI-DrugBank.d382.s38	Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
Rifampin	drug	0-7	Aprepitant	drug	39-48	false
Rifampin	drug	0-7	rifampin	drug	112-119	false
Rifampin	drug	0-7	aprepitant	drug	158-167	false
Aprepitant	drug	39-48	rifampin	drug	112-119	mechanism
Aprepitant	drug	39-48	aprepitant	drug	158-167	false
rifampin	drug	112-119	aprepitant	drug	158-167	false

DDI-DrugBank.d382.s39	Coadministration of Aprepitant with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of Aprepitant.
Aprepitant	drug	20-29	Aprepitant	drug	140-149	false

DDI-DrugBank.d382.s41	Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
Diltiazem	drug	0-8	aprepitant	drug	77-86	false
Diltiazem	drug	0-8	diltiazem	drug	178-186	false
Diltiazem	drug	0-8	aprepitant	drug	254-263	false
Diltiazem	drug	0-8	diltiazem	drug	309-317	false
aprepitant	drug	77-86	diltiazem	drug	178-186	mechanism
aprepitant	drug	77-86	aprepitant	drug	254-263	false
aprepitant	drug	77-86	diltiazem	drug	309-317	false
diltiazem	drug	178-186	aprepitant	drug	254-263	false
diltiazem	drug	178-186	diltiazem	drug	309-317	false
aprepitant	drug	254-263	diltiazem	drug	309-317	false

DDI-DrugBank.d382.s43	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.
Paroxetine	drug	0-9	aprepitant	drug	52-61	false
Paroxetine	drug	0-9	paroxetine	drug	151-160	false
Paroxetine	drug	0-9	aprepitant	drug	270-279	false
Paroxetine	drug	0-9	paroxetine	drug	285-294	false
aprepitant	drug	52-61	paroxetine	drug	151-160	mechanism
aprepitant	drug	52-61	aprepitant	drug	270-279	false
aprepitant	drug	52-61	paroxetine	drug	285-294	false
paroxetine	drug	151-160	aprepitant	drug	270-279	false
paroxetine	drug	151-160	paroxetine	drug	285-294	false
aprepitant	drug	270-279	paroxetine	drug	285-294	false

DDI-DrugBank.d27.s0	No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.
hydrochlorothiazide	drug	119-137	digoxin	drug	140-146	false
hydrochlorothiazide	drug	119-137	warfarin	drug	149-156	false
hydrochlorothiazide	drug	119-137	nifedipine	drug	163-172	false
digoxin	drug	140-146	warfarin	drug	149-156	false
digoxin	drug	140-146	nifedipine	drug	163-172	false
warfarin	drug	149-156	nifedipine	drug	163-172	false

DDI-DrugBank.d27.s1	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.
sulphenazole	drug	153-164	tolbutamide	drug	167-177	false
sulphenazole	drug	153-164	nifedipine	drug	183-192	false
tolbutamide	drug	167-177	nifedipine	drug	183-192	false

DDI-DrugBank.d27.s2	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.
irbesartan	drug	61-70	warfarin	drug	99-106	false

DDI-DrugBank.d27.s4	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.
warfarin	drug	63-70	hydrochlorothiazide	drug	73-91	false
warfarin	drug	63-70	digoxin	drug	97-103	false
warfarin	drug	63-70	irbesartan	drug	106-115	false
warfarin	drug	63-70	warfarin	drug	184-191	false
warfarin	drug	63-70	digoxin	drug	235-241	false
hydrochlorothiazide	drug	73-91	digoxin	drug	97-103	false
hydrochlorothiazide	drug	73-91	irbesartan	drug	106-115	false
hydrochlorothiazide	drug	73-91	warfarin	drug	184-191	false
hydrochlorothiazide	drug	73-91	digoxin	drug	235-241	false
digoxin	drug	97-103	irbesartan	drug	106-115	false
digoxin	drug	97-103	warfarin	drug	184-191	false
digoxin	drug	97-103	digoxin	drug	235-241	false
irbesartan	drug	106-115	warfarin	drug	184-191	false
irbesartan	drug	106-115	digoxin	drug	235-241	false
warfarin	drug	184-191	digoxin	drug	235-241	false

DDI-DrugBank.d27.s5	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide
irbesartan	drug	24-33	nifedipine	drug	76-85	false
irbesartan	drug	24-33	hydrochlorothiazide	drug	90-108	false
nifedipine	drug	76-85	hydrochlorothiazide	drug	90-108	false

DDI-DrugBank.d481.s0	Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.
calcium	drug	25-31	EMCYT	brand	82-86	mechanism

DDI-DrugBank.d359.s1	Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
PEGANONE	brand	44-51	Phenurone	brand	87-95	advise
PEGANONE	brand	44-51	phenacemide	drug	98-108	advise
Phenurone	brand	87-95	phenacemide	drug	98-108	false

DDI-DrugBank.d359.s2	A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
hydantoin antiepileptic	group	34-56	phenytoin	drug	59-67	int
hydantoin antiepileptic	group	34-56	coumarin anticoagulant	group	78-99	int
phenytoin	drug	59-67	coumarin anticoagulant	group	78-99	false

DDI-DrugBank.d359.s3	Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
phenytoin	drug	12-20	coumarin	group	46-53	mechanism
phenytoin	drug	12-20	coumarin anticoagulants	group	127-149	mechanism
coumarin	group	46-53	coumarin anticoagulants	group	127-149	false

DDI-DrugBank.d359.s4	Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.
coumarin anticoagulants	group	16-38	phenytoin	drug	123-131	mechanism

DDI-DrugBank.d359.s5	Although there is no documentation of such, a similar interaction between ethotoin and the coumarin anticoagulants may occur.
ethotoin	drug	74-81	coumarin anticoagulants	group	91-113	false

DDI-DrugBank.d359.s6	Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.
PEGANONE	brand	48-55	coumarin anticoagulants	group	79-101	advise

DDI-DrugBank.d202.s0	Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.
tricyclic antidepressants	group	37-61	cimetidine	drug	108-117	mechanism

DDI-DrugBank.d202.s1	Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.
tricyclic antidepressants	group	147-171	cimetidine	drug	178-187	effect

DDI-DrugBank.d202.s2	In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.
tricyclic antidepressants	group	71-95	cimetidine	drug	169-178	mechanism

DDI-DrugBank.d202.s3	In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.
cimetidine	drug	63-72	tricyclic antidepressants	group	130-154	mechanism

DDI-DrugBank.d202.s4	The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.
tricyclic antidepressants	group	28-52	cimetidine	drug	96-105	effect

DDI-DrugBank.d202.s6	There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
antidepressants	group	90-104	nortriptyline	drug	117-129	false
antidepressants	group	90-104	fluoxetine hydrochloride	drug	137-160	mechanism
nortriptyline	drug	117-129	fluoxetine hydrochloride	drug	137-160	mechanism

DDI-DrugBank.d202.s7	Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other.
Fluoxetine	drug	0-9	norfluoxetine	drug_n	93-105	false

DDI-DrugBank.d202.s8	Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.
reserpine	drug	18-26	tricyclic antidepressant	group	50-73	effect

DDI-DrugBank.d202.s9	Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.
nortriptyline hydrochloride	drug	73-99	anticholinergic drugs	group	120-140	advise
nortriptyline hydrochloride	drug	73-99	sympathomimetic drugs	group	145-165	advise
anticholinergic drugs	group	120-140	sympathomimetic drugs	group	145-165	false

DDI-DrugBank.d202.s12	Such individuals are referred to as  poor metabolizers  of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants.
debrisoquin	drug	73-83	dextromethorphan	drug	86-101	false
debrisoquin	drug	73-83	tricyclic antidepressants	group	112-136	false
dextromethorphan	drug	86-101	tricyclic antidepressants	group	112-136	false

DDI-DrugBank.d202.s14	In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.
antidepressants	group	82-96	tricyclic antidepressants	group	99-123	false
antidepressants	group	82-96	selective serotonin reuptake inhibitors	group	126-164	false
tricyclic antidepressants	group	99-123	selective serotonin reuptake inhibitors	group	126-164	false

DDI-DrugBank.d202.s15	Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	group	19-43	tricyclic antidepressant	group	160-183	false

DDI-DrugBank.d202.s16	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
tricyclic antidepressants	group	32-56	antidepressants	group	131-145	advise
tricyclic antidepressants	group	32-56	phenothiazines	group	148-161	advise
tricyclic antidepressants	group	32-56	carbamazepine	drug	164-176	advise
tricyclic antidepressants	group	32-56	Type 1C antiarrhythmics	group	183-205	advise
tricyclic antidepressants	group	32-56	propafenone	drug	212-222	advise
tricyclic antidepressants	group	32-56	flecainide	drug	225-234	advise
tricyclic antidepressants	group	32-56	encainide	drug	241-249	advise
tricyclic antidepressants	group	32-56	quinidine	drug	286-294	advise
antidepressants	group	131-145	phenothiazines	group	148-161	false
antidepressants	group	131-145	carbamazepine	drug	164-176	false
antidepressants	group	131-145	Type 1C antiarrhythmics	group	183-205	false
antidepressants	group	131-145	propafenone	drug	212-222	false
antidepressants	group	131-145	flecainide	drug	225-234	false
antidepressants	group	131-145	encainide	drug	241-249	false
antidepressants	group	131-145	quinidine	drug	286-294	false
phenothiazines	group	148-161	carbamazepine	drug	164-176	false
phenothiazines	group	148-161	Type 1C antiarrhythmics	group	183-205	false
phenothiazines	group	148-161	propafenone	drug	212-222	false
phenothiazines	group	148-161	flecainide	drug	225-234	false
phenothiazines	group	148-161	encainide	drug	241-249	false
phenothiazines	group	148-161	quinidine	drug	286-294	false
carbamazepine	drug	164-176	Type 1C antiarrhythmics	group	183-205	false
carbamazepine	drug	164-176	propafenone	drug	212-222	false
carbamazepine	drug	164-176	flecainide	drug	225-234	false
carbamazepine	drug	164-176	encainide	drug	241-249	false
carbamazepine	drug	164-176	quinidine	drug	286-294	false
Type 1C antiarrhythmics	group	183-205	propafenone	drug	212-222	false
Type 1C antiarrhythmics	group	183-205	flecainide	drug	225-234	false
Type 1C antiarrhythmics	group	183-205	encainide	drug	241-249	false
Type 1C antiarrhythmics	group	183-205	quinidine	drug	286-294	false
propafenone	drug	212-222	flecainide	drug	225-234	false
propafenone	drug	212-222	encainide	drug	241-249	false
propafenone	drug	212-222	quinidine	drug	286-294	false
flecainide	drug	225-234	encainide	drug	241-249	false
flecainide	drug	225-234	quinidine	drug	286-294	false
encainide	drug	241-249	quinidine	drug	286-294	false

DDI-DrugBank.d307.s1	In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.
AED	group	21-23	oxcarbazepine	drug	99-111	mechanism
AED	group	21-23	MHD	drug_n	117-119	false
oxcarbazepine	drug	99-111	MHD	drug_n	117-119	false

DDI-DrugBank.d307.s3	Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5.
oxcarbazepine	drug	25-37	MHD	drug_n	99-101	false

DDI-DrugBank.d307.s4	Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.
OXC	drug	36-38	MHD	drug_n	44-46	false

DDI-DrugBank.d307.s5	The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.
OXC	drug	30-32	MHD	drug_n	38-40	false

DDI-DrugBank.d307.s7	Increases of 22% with MHD and 47% with oxcarbazepine were observed.
MHD	drug_n	22-24	oxcarbazepine	drug	39-51	false

DDI-DrugBank.d307.s8	As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid, lamotrigine).
MHD	drug_n	3-5	valproic acid	drug	222-234	false
MHD	drug_n	3-5	lamotrigine	drug	237-247	false
valproic acid	drug	222-234	lamotrigine	drug	237-247	false

DDI-DrugBank.d307.s9	In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.
oxcarbazepine	drug	13-25	MHD	drug_n	31-33	false
oxcarbazepine	drug	13-25	dihydropyridine calcium antagonists	group	140-174	false
oxcarbazepine	drug	13-25	contraceptives	group	185-198	false
MHD	drug_n	31-33	dihydropyridine calcium antagonists	group	140-174	false
MHD	drug_n	31-33	contraceptives	group	185-198	false
dihydropyridine calcium antagonists	group	140-174	contraceptives	group	185-198	false

DDI-DrugBank.d307.s11	Antiepileptic drugs: Potential interactions between Trileptal and other AEDs were assessed in clinical studies.
Antiepileptic drugs	group	0-18	Trileptal	brand	52-60	false
Antiepileptic drugs	group	0-18	AEDs	group	72-75	false
Trileptal	brand	52-60	AEDs	group	72-75	false

DDI-DrugBank.d307.s16	Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)
Trileptal	brand	13-21	AED	group	26-28	false

DDI-DrugBank.d307.s17	Influence of AED On MHD Concentration (Mean change, 90% Confidence Interval)
AED	group	13-15	MHD	drug_n	20-22	false

DDI-DrugBank.d307.s35	1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.
Trileptal	brand	94-102	phenytoin	drug	140-148	false
Trileptal	brand	94-102	Trileptal	brand	179-187	false
phenytoin	drug	140-148	Trileptal	brand	179-187	mechanism

DDI-DrugBank.d307.s36	Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.
Trileptal	brand	31-39	phenytoin	drug	119-127	advise

DDI-DrugBank.d307.s37	The increase of phenobarbital level, however, is small (15%) when given with Trileptal.
phenobarbital	drug	16-28	Trileptal	brand	77-85	mechanism

DDI-DrugBank.d307.s38	Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).
carbamazepine	drug	49-61	phenytoin	drug	64-72	false
carbamazepine	drug	49-61	phenobarbital	drug	78-90	false
carbamazepine	drug	49-61	MHD	drug_n	142-144	false
phenytoin	drug	64-72	phenobarbital	drug	78-90	false
phenytoin	drug	64-72	MHD	drug_n	142-144	false
phenobarbital	drug	78-90	MHD	drug_n	142-144	false

DDI-DrugBank.d307.s40	Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).
contraceptives	group	9-22	Trileptal	brand	45-53	false
contraceptives	group	9-22	contraceptive	group	68-80	false
contraceptives	group	9-22	ethinylestradiol	drug	168-183	false
contraceptives	group	9-22	levonorgestrel	drug	194-207	false
Trileptal	brand	45-53	contraceptive	group	68-80	mechanism
Trileptal	brand	45-53	ethinylestradiol	drug	168-183	false
Trileptal	brand	45-53	levonorgestrel	drug	194-207	false
contraceptive	group	68-80	ethinylestradiol	drug	168-183	false
contraceptive	group	68-80	levonorgestrel	drug	194-207	false
ethinylestradiol	drug	168-183	levonorgestrel	drug	194-207	false

DDI-DrugBank.d307.s43	Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.
Trileptal	brand	29-37	hormonal contraceptives	group	44-66	effect
Trileptal	brand	29-37	contraceptives	group	85-98	false
hormonal contraceptives	group	44-66	contraceptives	group	85-98	false

DDI-DrugBank.d307.s45	Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].
Calcium Antagonist	group	0-17	Trileptal	brand	57-65	false
Calcium Antagonist	group	0-17	felodipine	drug	79-88	false
Trileptal	brand	57-65	felodipine	drug	79-88	mechanism

DDI-DrugBank.d307.s46	Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.
Verapamil	drug	0-8	MHD	drug_n	77-79	false

DDI-DrugBank.d307.s47	Other drug interactions Cimetidine, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.
Cimetidine	drug	24-33	erythromycin	drug	36-47	false
Cimetidine	drug	24-33	dextropropoxyphene	drug	53-70	false
Cimetidine	drug	24-33	MHD	drug_n	113-115	false
erythromycin	drug	36-47	dextropropoxyphene	drug	53-70	false
erythromycin	drug	36-47	MHD	drug_n	113-115	false
dextropropoxyphene	drug	53-70	MHD	drug_n	113-115	false

DDI-DrugBank.d307.s48	Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal.
warfarin	drug	13-20	Trileptal	brand	95-103	false

DDI-DrugBank.d298.s0	Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
Cyclopentolate	drug	0-13	carbachol	drug	62-70	effect
Cyclopentolate	drug	0-13	pilocarpine	drug	75-85	effect
carbachol	drug	62-70	pilocarpine	drug	75-85	false

DDI-DrugBank.d399.s0	Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.
dapsone	drug	36-42	Lamprene	brand	90-97	effect

DDI-DrugBank.d399.s1	If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
dapsone	drug	84-90	clofazimine	drug	96-106	advise

DDI-DrugBank.d489.s0	The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine, nifedipine, chlorthalidone, and hydrochlorothiazide.
Kerlone	brand	50-56	cimetidine	drug	101-110	false
Kerlone	brand	50-56	nifedipine	drug	113-122	false
Kerlone	brand	50-56	chlorthalidone	drug	125-138	false
Kerlone	brand	50-56	hydrochlorothiazide	drug	145-163	false
cimetidine	drug	101-110	nifedipine	drug	113-122	false
cimetidine	drug	101-110	chlorthalidone	drug	125-138	false
cimetidine	drug	101-110	hydrochlorothiazide	drug	145-163	false
nifedipine	drug	113-122	chlorthalidone	drug	125-138	false
nifedipine	drug	113-122	hydrochlorothiazide	drug	145-163	false
chlorthalidone	drug	125-138	hydrochlorothiazide	drug	145-163	false

DDI-DrugBank.d489.s1	Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.
Kerlone	brand	30-36	anticoagulant	group	52-64	false
Kerlone	brand	30-36	warfarin	drug	66-73	false
Kerlone	brand	30-36	warfarin	drug	136-143	false
anticoagulant	group	52-64	warfarin	drug	66-73	false
anticoagulant	group	52-64	warfarin	drug	136-143	false
warfarin	drug	66-73	warfarin	drug	136-143	false

DDI-DrugBank.d489.s2	Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
reserpine	drug	37-45	beta-blocking	drug	92-104	effect

DDI-DrugBank.d489.s4	Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
beta-blockers	group	66-78	clonidine	drug	84-92	advise
beta-blockers	group	66-78	beta-blocker	group	112-123	false
beta-blockers	group	66-78	clonidine	drug	206-214	false
clonidine	drug	84-92	beta-blocker	group	112-123	false
clonidine	drug	84-92	clonidine	drug	206-214	false
beta-blocker	group	112-123	clonidine	drug	206-214	advise

DDI-DrugBank.d489.s5	Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.
calcium antagonists	group	37-55	beta-adrenergic blocking agents	group	89-119	advise

DDI-DrugBank.d489.s6	Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.
beta-adrenergic blocking agents	group	116-146	calcium antagonist	group	161-178	effect

DDI-DrugBank.d489.s7	Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.
calcium antagonist	group	44-61	dihydropyridine derivative	group	70-95	false
calcium antagonist	group	44-61	nifedipine	drug	104-113	false
calcium antagonist	group	44-61	verapamil	drug	249-257	false
calcium antagonist	group	44-61	diltiazem	drug	262-270	false
dihydropyridine derivative	group	70-95	nifedipine	drug	104-113	false
dihydropyridine derivative	group	70-95	verapamil	drug	249-257	false
dihydropyridine derivative	group	70-95	diltiazem	drug	262-270	false
nifedipine	drug	104-113	verapamil	drug	249-257	false
nifedipine	drug	104-113	diltiazem	drug	262-270	false
verapamil	drug	249-257	diltiazem	drug	262-270	false

DDI-DrugBank.d489.s8	Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
beta-blockers	group	69-81	epinephrine	drug	104-114	effect
beta-blockers	group	69-81	beta-blockers	group	156-168	false
epinephrine	drug	104-114	beta-blockers	group	156-168	false

DDI-DrugBank.d390.s0	Antipsychotic drugs such as phenothiazines or haloperidol;
Antipsychotic drugs	group	0-18	phenothiazines	group	28-41	false
Antipsychotic drugs	group	0-18	haloperidol	drug	46-56	false
phenothiazines	group	28-41	haloperidol	drug	46-56	false

DDI-DrugBank.d19.s1	DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.
DISULFIRAM	drug	0-9	PHENYTOIN	drug	67-75	advise

DDI-DrugBank.d19.s2	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
PHENYTOIN	drug	68-76	DISULFIRAM	drug	115-124	false
PHENYTOIN	drug	68-76	PHENYTOIN	drug	142-150	false
PHENYTOIN	drug	68-76	PHENYTOIN	drug	172-180	false
DISULFIRAM	drug	115-124	PHENYTOIN	drug	142-150	effect
DISULFIRAM	drug	115-124	PHENYTOIN	drug	172-180	false
PHENYTOIN	drug	142-150	PHENYTOIN	drug	172-180	false

DDI-DrugBank.d19.s6	It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.
anticoagulants	group	49-62	disulfiram	drug	91-100	advise
anticoagulants	group	49-62	disulfiram	drug	109-118	false
disulfiram	drug	91-100	disulfiram	drug	109-118	false

DDI-DrugBank.d19.s7	Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;
isoniazid	drug	16-24	disulfiram	drug	31-40	advise

DDI-DrugBank.d19.s9	In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
disulfiram	drug	35-44	nitrite	drug	50-56	effect
disulfiram	drug	35-44	disulfiram	drug	149-158	false
disulfiram	drug	35-44	nitrites	group	175-182	false
nitrite	drug	50-56	disulfiram	drug	149-158	false
nitrite	drug	50-56	nitrites	group	175-182	false
disulfiram	drug	149-158	nitrites	group	175-182	effect

DDI-DrugBank.d357.s0	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
5HT3 Antagonists	group	0-15	apomorphine	drug	90-100	false
5HT3 Antagonists	group	0-15	ondansetron	drug	124-134	false
5HT3 Antagonists	group	0-15	apomorphine	drug	160-170	false
5HT3 Antagonists	group	0-15	5HT3 antagonist class	group	190-210	false
5HT3 Antagonists	group	0-15	ondansetron	drug	237-247	false
5HT3 Antagonists	group	0-15	granisetron	drug	250-260	false
5HT3 Antagonists	group	0-15	dolasetron	drug	263-272	false
5HT3 Antagonists	group	0-15	palonosetron	drug	275-286	false
5HT3 Antagonists	group	0-15	alosetron	drug	293-301	false
apomorphine	drug	90-100	ondansetron	drug	124-134	effect
apomorphine	drug	90-100	apomorphine	drug	160-170	false
apomorphine	drug	90-100	5HT3 antagonist class	group	190-210	false
apomorphine	drug	90-100	ondansetron	drug	237-247	false
apomorphine	drug	90-100	granisetron	drug	250-260	false
apomorphine	drug	90-100	dolasetron	drug	263-272	false
apomorphine	drug	90-100	palonosetron	drug	275-286	false
apomorphine	drug	90-100	alosetron	drug	293-301	false
ondansetron	drug	124-134	apomorphine	drug	160-170	false
ondansetron	drug	124-134	5HT3 antagonist class	group	190-210	false
ondansetron	drug	124-134	ondansetron	drug	237-247	false
ondansetron	drug	124-134	granisetron	drug	250-260	false
ondansetron	drug	124-134	dolasetron	drug	263-272	false
ondansetron	drug	124-134	palonosetron	drug	275-286	false
ondansetron	drug	124-134	alosetron	drug	293-301	false
apomorphine	drug	160-170	5HT3 antagonist class	group	190-210	advise
apomorphine	drug	160-170	ondansetron	drug	237-247	advise
apomorphine	drug	160-170	granisetron	drug	250-260	advise
apomorphine	drug	160-170	dolasetron	drug	263-272	advise
apomorphine	drug	160-170	palonosetron	drug	275-286	advise
apomorphine	drug	160-170	alosetron	drug	293-301	advise
5HT3 antagonist class	group	190-210	ondansetron	drug	237-247	false
5HT3 antagonist class	group	190-210	granisetron	drug	250-260	false
5HT3 antagonist class	group	190-210	dolasetron	drug	263-272	false
5HT3 antagonist class	group	190-210	palonosetron	drug	275-286	false
5HT3 antagonist class	group	190-210	alosetron	drug	293-301	false
ondansetron	drug	237-247	granisetron	drug	250-260	false
ondansetron	drug	237-247	dolasetron	drug	263-272	false
ondansetron	drug	237-247	palonosetron	drug	275-286	false
ondansetron	drug	237-247	alosetron	drug	293-301	false
granisetron	drug	250-260	dolasetron	drug	263-272	false
granisetron	drug	250-260	palonosetron	drug	275-286	false
granisetron	drug	250-260	alosetron	drug	293-301	false
dolasetron	drug	263-272	palonosetron	drug	275-286	false
dolasetron	drug	263-272	alosetron	drug	293-301	false
palonosetron	drug	275-286	alosetron	drug	293-301	false

DDI-DrugBank.d357.s1	Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
Antihypertensive Medication	group	0-26	Vasodilators	group	33-44	false
Antihypertensive Medication	group	0-26	antihypertensive medications	group	141-168	false
Antihypertensive Medication	group	0-26	vasodilators	group	173-184	false
Vasodilators	group	33-44	antihypertensive medications	group	141-168	false
Vasodilators	group	33-44	vasodilators	group	173-184	false
antihypertensive medications	group	141-168	vasodilators	group	173-184	effect

DDI-DrugBank.d357.s3	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
Dopamine Antagonists	group	0-19	apomorphine	drug	28-38	false
Dopamine Antagonists	group	0-19	dopamine agonist	group	45-60	false
Dopamine Antagonists	group	0-19	dopamine antagonists	group	83-102	false
Dopamine Antagonists	group	0-19	neuroleptics	group	117-128	false
Dopamine Antagonists	group	0-19	phenothiazines	group	131-144	false
Dopamine Antagonists	group	0-19	butyrophenones	group	147-160	false
Dopamine Antagonists	group	0-19	thioxanthenes	group	163-175	false
Dopamine Antagonists	group	0-19	metoclopramide	drug	181-194	false
Dopamine Antagonists	group	0-19	APOKYN	brand	231-236	false
apomorphine	drug	28-38	dopamine agonist	group	45-60	false
apomorphine	drug	28-38	dopamine antagonists	group	83-102	false
apomorphine	drug	28-38	neuroleptics	group	117-128	false
apomorphine	drug	28-38	phenothiazines	group	131-144	false
apomorphine	drug	28-38	butyrophenones	group	147-160	false
apomorphine	drug	28-38	thioxanthenes	group	163-175	false
apomorphine	drug	28-38	metoclopramide	drug	181-194	false
apomorphine	drug	28-38	APOKYN	brand	231-236	false
dopamine agonist	group	45-60	dopamine antagonists	group	83-102	false
dopamine agonist	group	45-60	neuroleptics	group	117-128	false
dopamine agonist	group	45-60	phenothiazines	group	131-144	false
dopamine agonist	group	45-60	butyrophenones	group	147-160	false
dopamine agonist	group	45-60	thioxanthenes	group	163-175	false
dopamine agonist	group	45-60	metoclopramide	drug	181-194	false
dopamine agonist	group	45-60	APOKYN	brand	231-236	false
dopamine antagonists	group	83-102	neuroleptics	group	117-128	false
dopamine antagonists	group	83-102	phenothiazines	group	131-144	false
dopamine antagonists	group	83-102	butyrophenones	group	147-160	false
dopamine antagonists	group	83-102	thioxanthenes	group	163-175	false
dopamine antagonists	group	83-102	metoclopramide	drug	181-194	effect
dopamine antagonists	group	83-102	APOKYN	brand	231-236	false
neuroleptics	group	117-128	phenothiazines	group	131-144	false
neuroleptics	group	117-128	butyrophenones	group	147-160	false
neuroleptics	group	117-128	thioxanthenes	group	163-175	false
neuroleptics	group	117-128	metoclopramide	drug	181-194	false
neuroleptics	group	117-128	APOKYN	brand	231-236	false
phenothiazines	group	131-144	butyrophenones	group	147-160	false
phenothiazines	group	131-144	thioxanthenes	group	163-175	false
phenothiazines	group	131-144	metoclopramide	drug	181-194	false
phenothiazines	group	131-144	APOKYN	brand	231-236	effect
butyrophenones	group	147-160	thioxanthenes	group	163-175	false
butyrophenones	group	147-160	metoclopramide	drug	181-194	false
butyrophenones	group	147-160	APOKYN	brand	231-236	effect
thioxanthenes	group	163-175	metoclopramide	drug	181-194	false
thioxanthenes	group	163-175	APOKYN	brand	231-236	effect
metoclopramide	drug	181-194	APOKYN	brand	231-236	effect

DDI-DrugBank.d357.s4	Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.
neuroleptics	group	54-65	dopamine agonists	group	91-107	advise

DDI-DrugBank.d400.s0	Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
Aspirin	brand	0-6	NSAIDs	group	23-28	false
Aspirin	brand	0-6	Ponstel	brand	61-67	false
Aspirin	brand	0-6	aspirin	brand	73-79	false
NSAIDs	group	23-28	Ponstel	brand	61-67	false
NSAIDs	group	23-28	aspirin	brand	73-79	advise
Ponstel	brand	61-67	aspirin	brand	73-79	advise

DDI-DrugBank.d400.s1	Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
Methotrexate	drug	0-11	NSAIDs	group	14-19	false
Methotrexate	drug	0-11	methotrexate	drug	65-76	false
NSAIDs	group	14-19	methotrexate	drug	65-76	mechanism

DDI-DrugBank.d400.s3	Caution should be used when NSAIDs are administered concomitantly with methotrexate.
NSAIDs	group	28-33	methotrexate	drug	71-82	advise

DDI-DrugBank.d400.s4	ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
ACE inhibitors	group	0-13	NSAIDs	group	37-42	false
ACE inhibitors	group	0-13	ACE inhibitors	group	88-101	false
NSAIDs	group	37-42	ACE inhibitors	group	88-101	effect

DDI-DrugBank.d400.s5	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
NSAIDs	group	66-71	ACE inhibitors	group	92-105	advise

DDI-DrugBank.d400.s6	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	drug	0-9	NSAIDs	group	86-91	false
Furosemide	drug	0-9	furosemide	drug	130-139	false
Furosemide	drug	0-9	thiazides	group	145-153	false
NSAIDs	group	86-91	furosemide	drug	130-139	effect
NSAIDs	group	86-91	thiazides	group	145-153	effect
furosemide	drug	130-139	thiazides	group	145-153	false

DDI-DrugBank.d400.s8	During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
Ponstel	brand	30-36	furosemide	drug	43-52	advise

DDI-DrugBank.d400.s9	Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
Lithium	drug	0-6	NSAIDs	group	9-14	false
Lithium	drug	0-6	lithium	drug	53-59	false
Lithium	drug	0-6	lithium	drug	93-99	false
NSAIDs	group	9-14	lithium	drug	53-59	mechanism
NSAIDs	group	9-14	lithium	drug	93-99	mechanism
lithium	drug	53-59	lithium	drug	93-99	false

DDI-DrugBank.d400.s12	Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
NSAIDs	group	11-16	lithium	drug	22-28	advise
NSAIDs	group	11-16	lithium	drug	112-118	false
lithium	drug	22-28	lithium	drug	112-118	false

DDI-DrugBank.d400.s13	Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
Warfarin	drug	0-7	warfarin	drug	25-32	false
Warfarin	drug	0-7	NSAIDs	group	38-43	false
warfarin	drug	25-32	NSAIDs	group	38-43	effect

DDI-DrugBank.d400.s14	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
Antacids	group	0-7	antacid	group	56-62	false
Antacids	group	0-7	magnesium hydroxide	drug	87-105	false
Antacids	group	0-7	mefenamic acid	drug	122-135	false
Antacids	group	0-7	mefenamic acid	drug	167-180	false
Antacids	group	0-7	fluconazole	drug	271-281	false
Antacids	group	0-7	lovastatin	drug	284-293	false
Antacids	group	0-7	trimethoprim	drug	299-310	false
antacid	group	56-62	magnesium hydroxide	drug	87-105	false
antacid	group	56-62	mefenamic acid	drug	122-135	false
antacid	group	56-62	mefenamic acid	drug	167-180	false
antacid	group	56-62	fluconazole	drug	271-281	false
antacid	group	56-62	lovastatin	drug	284-293	false
antacid	group	56-62	trimethoprim	drug	299-310	false
magnesium hydroxide	drug	87-105	mefenamic acid	drug	122-135	mechanism
magnesium hydroxide	drug	87-105	mefenamic acid	drug	167-180	false
magnesium hydroxide	drug	87-105	fluconazole	drug	271-281	false
magnesium hydroxide	drug	87-105	lovastatin	drug	284-293	false
magnesium hydroxide	drug	87-105	trimethoprim	drug	299-310	false
mefenamic acid	drug	122-135	mefenamic acid	drug	167-180	false
mefenamic acid	drug	122-135	fluconazole	drug	271-281	false
mefenamic acid	drug	122-135	lovastatin	drug	284-293	false
mefenamic acid	drug	122-135	trimethoprim	drug	299-310	false
mefenamic acid	drug	167-180	fluconazole	drug	271-281	false
mefenamic acid	drug	167-180	lovastatin	drug	284-293	false
mefenamic acid	drug	167-180	trimethoprim	drug	299-310	false
fluconazole	drug	271-281	lovastatin	drug	284-293	false
fluconazole	drug	271-281	trimethoprim	drug	299-310	false
lovastatin	drug	284-293	trimethoprim	drug	299-310	false

DDI-DrugBank.d500.s0	Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
tetracyclines	group	8-20	anticoagulant	group	98-110	advise
tetracyclines	group	8-20	anticoagulant	group	161-173	false
anticoagulant	group	98-110	anticoagulant	group	161-173	false

DDI-DrugBank.d500.s1	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
penicillin	drug	73-82	tetracyclines	group	117-129	false
penicillin	drug	73-82	penicillin	group	151-160	false
tetracyclines	group	117-129	penicillin	group	151-160	advise

DDI-DrugBank.d500.s2	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
tetracyclines	group	14-26	antacids	group	43-50	false
tetracyclines	group	14-26	aluminum	drug	63-70	mechanism
tetracyclines	group	14-26	calcium	drug	73-79	mechanism
tetracyclines	group	14-26	magnesium	drug	85-93	mechanism
tetracyclines	group	14-26	iron	drug	100-103	mechanism
antacids	group	43-50	aluminum	drug	63-70	false
antacids	group	43-50	calcium	drug	73-79	false
antacids	group	43-50	magnesium	drug	85-93	false
antacids	group	43-50	iron	drug	100-103	false
aluminum	drug	63-70	calcium	drug	73-79	false
aluminum	drug	63-70	magnesium	drug	85-93	false
aluminum	drug	63-70	iron	drug	100-103	false
calcium	drug	73-79	magnesium	drug	85-93	false
calcium	drug	73-79	iron	drug	100-103	false
magnesium	drug	85-93	iron	drug	100-103	false

DDI-DrugBank.d500.s3	Absorption of tetracycline is impaired by bismuth subsalicylate.
tetracycline	drug	14-25	bismuth subsalicylate	drug	42-62	mechanism

DDI-DrugBank.d500.s4	Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
Barbiturates	group	0-11	carbamazepine	drug	14-26	false
Barbiturates	group	0-11	phenytoin	drug	33-41	false
Barbiturates	group	0-11	doxycycline	drug	69-79	mechanism
carbamazepine	drug	14-26	phenytoin	drug	33-41	false
carbamazepine	drug	14-26	doxycycline	drug	69-79	mechanism
phenytoin	drug	33-41	doxycycline	drug	69-79	mechanism

DDI-DrugBank.d500.s5	The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
tetracycline	drug	22-33	Penthrane	brand	39-47	effect
tetracycline	drug	22-33	methoxyflurane	drug	50-63	effect
Penthrane	brand	39-47	methoxyflurane	drug	50-63	false

DDI-DrugBank.d500.s6	Concurrent use of tetracycline may render oral contraceptives less effective.
tetracycline	drug	18-29	contraceptives	group	47-60	effect

DDI-DrugBank.d294.s0	Drug/LaboratoryTest Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels.
Dactinomycin	drug	33-44	antibacterial drug	group	110-127	false

DDI-DrugBank.d152.s0	Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
estrogen	group	62-69	contraceptives	group	87-100	false

DDI-DrugBank.d330.s1	Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.
aminoglycosides	group	66-80	polymyxins	group	86-95	false
aminoglycosides	group	66-80	neomycin sulfate	drug	182-197	false
polymyxins	group	86-95	neomycin sulfate	drug	182-197	false

DDI-DrugBank.d330.s2	Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
neomycin	drug	5-12	penicillin V	drug	58-69	mechanism
neomycin	drug	5-12	vitamin B-12	drug	77-88	mechanism
neomycin	drug	5-12	methotrexate	drug	91-102	mechanism
neomycin	drug	5-12	5-fluorouracil	drug	108-121	mechanism
penicillin V	drug	58-69	vitamin B-12	drug	77-88	false
penicillin V	drug	58-69	methotrexate	drug	91-102	false
penicillin V	drug	58-69	5-fluorouracil	drug	108-121	false
vitamin B-12	drug	77-88	methotrexate	drug	91-102	false
vitamin B-12	drug	77-88	5-fluorouracil	drug	108-121	false
methotrexate	drug	91-102	5-fluorouracil	drug	108-121	false

DDI-DrugBank.d330.s5	Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
neomycin sulfate	drug	5-20	coumarin	group	48-55	effect
neomycin sulfate	drug	5-20	anticoagulants	group	60-73	effect
coumarin	group	48-55	anticoagulants	group	60-73	false

DDI-DrugBank.d85.s0	The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
NSAIDs	group	11-16	ACE inhibitors	group	48-61	effect

DDI-DrugBank.d85.s5	Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.
hydantoin	group	45-53	sulfonamide	group	56-66	false
hydantoin	group	45-53	sulfonylurea	group	71-82	false
sulfonamide	group	56-66	sulfonylurea	group	71-82	false

DDI-DrugBank.d85.s6	Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
naproxen	drug	30-37	aspirin	brand	43-49	advise
naproxen	drug	30-37	naproxen	drug	78-85	false
naproxen	drug	30-37	aspirin	brand	164-170	false
aspirin	brand	43-49	naproxen	drug	78-85	false
aspirin	brand	43-49	aspirin	brand	164-170	false
naproxen	drug	78-85	aspirin	brand	164-170	advise

DDI-DrugBank.d85.s8	Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.
lithium	drug	20-26	lithium	drug	69-75	false

DDI-DrugBank.d85.s9	Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
Naproxen	drug	0-7	NSAIDs	group	19-24	false
Naproxen	drug	0-7	propranolol	drug	68-78	effect
Naproxen	drug	0-7	beta-blockers	group	90-102	effect
NSAIDs	group	19-24	propranolol	drug	68-78	effect
NSAIDs	group	19-24	beta-blockers	group	90-102	effect
propranolol	drug	68-78	beta-blockers	group	90-102	false

DDI-DrugBank.d85.s10	Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.
Probenecid	drug	0-9	naproxen	drug	40-47	mechanism

DDI-DrugBank.d85.s11	Caution should be used if naproxen is administered concomitantly with methotrexate.
naproxen	drug	26-33	methotrexate	drug	70-81	advise

DDI-DrugBank.d85.s12	Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
Naproxen	drug	0-7	naproxen sodium	drug	10-24	false
Naproxen	drug	0-7	NSAIDs	group	36-41	false
Naproxen	drug	0-7	methotrexate	drug	97-108	mechanism
Naproxen	drug	0-7	methotrexate	drug	166-177	false
naproxen sodium	drug	10-24	NSAIDs	group	36-41	false
naproxen sodium	drug	10-24	methotrexate	drug	97-108	mechanism
naproxen sodium	drug	10-24	methotrexate	drug	166-177	false
NSAIDs	group	36-41	methotrexate	drug	97-108	mechanism
NSAIDs	group	36-41	methotrexate	drug	166-177	false
methotrexate	drug	97-108	methotrexate	drug	166-177	false

DDI-DrugBank.d376.s0	May interact with addictive medications, especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).
central nervous system (CNS) depressants	group	52-91	alcohol	drug	185-191	false
central nervous system (CNS) depressants	group	52-91	ethinamate	drug	320-329	false
alcohol	drug	185-191	ethinamate	drug	320-329	false

DDI-DrugBank.d241.s0	Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
FLOLAN	brand	55-60	diuretics	group	83-91	effect
FLOLAN	brand	55-60	antihypertensive agents	group	94-116	effect
FLOLAN	brand	55-60	vasodilators	group	128-139	effect
diuretics	group	83-91	antihypertensive agents	group	94-116	false
diuretics	group	83-91	vasodilators	group	128-139	false
antihypertensive agents	group	94-116	vasodilators	group	128-139	false

DDI-DrugBank.d241.s1	When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
antiplatelet agents	group	11-29	anticoagulants	group	34-47	false
antiplatelet agents	group	11-29	FLOLAN	brand	100-105	effect
anticoagulants	group	34-47	FLOLAN	brand	100-105	effect

DDI-DrugBank.d241.s2	However, patients receiving infusions of FLOLAN in clinical trials were maintained on anticoagulants without evidence of increased bleeding.
FLOLAN	brand	41-46	anticoagulants	group	86-99	false

DDI-DrugBank.d241.s3	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
FLOLAN	brand	20-25	digoxin	drug	41-47	false
FLOLAN	brand	20-25	diuretics	group	50-58	false
FLOLAN	brand	20-25	anticoagulants	group	61-74	false
FLOLAN	brand	20-25	vasodilators	group	82-93	false
FLOLAN	brand	20-25	oxygen	drug	113-118	false
FLOLAN	brand	20-25	furosemide	drug	202-211	false
FLOLAN	brand	20-25	digoxin	drug	216-222	false
FLOLAN	brand	20-25	FLOLAN	brand	245-250	false
FLOLAN	brand	20-25	furosemide	drug	302-311	false
FLOLAN	brand	20-25	digoxin	drug	326-332	false
digoxin	drug	41-47	diuretics	group	50-58	false
digoxin	drug	41-47	anticoagulants	group	61-74	false
digoxin	drug	41-47	vasodilators	group	82-93	false
digoxin	drug	41-47	oxygen	drug	113-118	false
digoxin	drug	41-47	furosemide	drug	202-211	false
digoxin	drug	41-47	digoxin	drug	216-222	false
digoxin	drug	41-47	FLOLAN	brand	245-250	false
digoxin	drug	41-47	furosemide	drug	302-311	false
digoxin	drug	41-47	digoxin	drug	326-332	false
diuretics	group	50-58	anticoagulants	group	61-74	false
diuretics	group	50-58	vasodilators	group	82-93	false
diuretics	group	50-58	oxygen	drug	113-118	false
diuretics	group	50-58	furosemide	drug	202-211	false
diuretics	group	50-58	digoxin	drug	216-222	false
diuretics	group	50-58	FLOLAN	brand	245-250	false
diuretics	group	50-58	furosemide	drug	302-311	false
diuretics	group	50-58	digoxin	drug	326-332	false
anticoagulants	group	61-74	vasodilators	group	82-93	false
anticoagulants	group	61-74	oxygen	drug	113-118	false
anticoagulants	group	61-74	furosemide	drug	202-211	false
anticoagulants	group	61-74	digoxin	drug	216-222	false
anticoagulants	group	61-74	FLOLAN	brand	245-250	false
anticoagulants	group	61-74	furosemide	drug	302-311	false
anticoagulants	group	61-74	digoxin	drug	326-332	false
vasodilators	group	82-93	oxygen	drug	113-118	false
vasodilators	group	82-93	furosemide	drug	202-211	false
vasodilators	group	82-93	digoxin	drug	216-222	false
vasodilators	group	82-93	FLOLAN	brand	245-250	false
vasodilators	group	82-93	furosemide	drug	302-311	false
vasodilators	group	82-93	digoxin	drug	326-332	false
oxygen	drug	113-118	furosemide	drug	202-211	false
oxygen	drug	113-118	digoxin	drug	216-222	false
oxygen	drug	113-118	FLOLAN	brand	245-250	false
oxygen	drug	113-118	furosemide	drug	302-311	false
oxygen	drug	113-118	digoxin	drug	326-332	false
furosemide	drug	202-211	digoxin	drug	216-222	false
furosemide	drug	202-211	FLOLAN	brand	245-250	mechanism
furosemide	drug	202-211	furosemide	drug	302-311	false
furosemide	drug	202-211	digoxin	drug	326-332	false
digoxin	drug	216-222	FLOLAN	brand	245-250	mechanism
digoxin	drug	216-222	furosemide	drug	302-311	false
digoxin	drug	216-222	digoxin	drug	326-332	false
FLOLAN	brand	245-250	furosemide	drug	302-311	false
FLOLAN	brand	245-250	digoxin	drug	326-332	false
furosemide	drug	302-311	digoxin	drug	326-332	false

DDI-DrugBank.d241.s5	However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.
digoxin	drug	21-27	digoxin	drug	52-58	false
digoxin	drug	21-27	FLOLAN	brand	108-113	mechanism
digoxin	drug	21-27	digoxin	drug	173-179	false
digoxin	drug	52-58	FLOLAN	brand	108-113	false
digoxin	drug	52-58	digoxin	drug	173-179	false
FLOLAN	brand	108-113	digoxin	drug	173-179	false

DDI-DrugBank.d424.s2	The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone.
atovaquone	drug	40-49	phenytoin	drug	132-140	false
atovaquone	drug	40-49	phenytoin	drug	178-186	false
atovaquone	drug	40-49	atovaquone	drug	216-225	false
phenytoin	drug	132-140	phenytoin	drug	178-186	false
phenytoin	drug	132-140	atovaquone	drug	216-225	false
phenytoin	drug	178-186	atovaquone	drug	216-225	false

DDI-DrugBank.d424.s3	Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
Rifampin	drug	0-7	rifampin	drug	30-37	false
Rifampin	drug	0-7	MEPRON	brand	43-48	false
Rifampin	drug	0-7	atovaquone	drug	127-136	false
rifampin	drug	30-37	MEPRON	brand	43-48	mechanism
rifampin	drug	30-37	atovaquone	drug	127-136	false
MEPRON	brand	43-48	atovaquone	drug	127-136	false

DDI-DrugBank.d424.s4	Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.
rifampin	drug	16-23	MEPRON	brand	86-91	advise

DDI-DrugBank.d424.s5	Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.
Rifabutin	drug	0-8	rifamycin	drug	19-27	false
Rifabutin	drug	0-8	rifampin	drug	57-64	false
Rifabutin	drug	0-8	rifampin	drug	126-133	false
rifamycin	drug	19-27	rifampin	drug	57-64	false
rifamycin	drug	19-27	rifampin	drug	126-133	false
rifampin	drug	57-64	rifampin	drug	126-133	false

DDI-DrugBank.d424.s6	No interaction trials have been conducted with MEPRON and rifabutin.
MEPRON	brand	47-52	rifabutin	drug	58-66	false

DDI-DrugBank.d81.s0	Nitroglycerin: DynaCirc  (isradipine) has been safely coadministered with nitroglycerin.
Nitroglycerin	drug	0-12	DynaCirc	brand	15-22	false
Nitroglycerin	drug	0-12	isradipine	drug	26-35	false
Nitroglycerin	drug	0-12	nitroglycerin	drug	74-86	false
DynaCirc	brand	15-22	isradipine	drug	26-35	false
DynaCirc	brand	15-22	nitroglycerin	drug	74-86	false
isradipine	drug	26-35	nitroglycerin	drug	74-86	false

DDI-DrugBank.d81.s1	Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.
Hydrochlorothiazide	drug	0-18	DynaCirc	brand	103-110	false
Hydrochlorothiazide	drug	0-18	isradipine	drug	114-123	false
Hydrochlorothiazide	drug	0-18	hydrochlorothiazide	drug	130-148	false
DynaCirc	brand	103-110	isradipine	drug	114-123	false
DynaCirc	brand	103-110	hydrochlorothiazide	drug	130-148	false
isradipine	drug	114-123	hydrochlorothiazide	drug	130-148	false

DDI-DrugBank.d81.s2	In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.
isradipine	drug	49-58	hydrochlorothiazide	drug	72-90	false
isradipine	drug	49-58	isradipine	drug	154-163	false
hydrochlorothiazide	drug	72-90	isradipine	drug	154-163	false

DDI-DrugBank.d81.s3	Propranolol: In a single dose study in normal volunteers, coadministration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability.
Propranolol	drug	0-10	propranolol	drug	78-88	false
Propranolol	drug	0-10	isradipine	drug	152-161	false
propranolol	drug	78-88	isradipine	drug	152-161	false

DDI-DrugBank.d81.s6	propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.
propranolol	drug	0-10	isradipine	drug	165-174	false
propranolol	drug	0-10	propranolol	drug	213-223	false
propranolol	drug	0-10	propranolol	drug	238-248	false
propranolol	drug	0-10	isradipine	drug	287-296	false
isradipine	drug	165-174	propranolol	drug	213-223	false
isradipine	drug	165-174	propranolol	drug	238-248	false
isradipine	drug	165-174	isradipine	drug	287-296	false
propranolol	drug	213-223	propranolol	drug	238-248	false
propranolol	drug	213-223	isradipine	drug	287-296	false
propranolol	drug	238-248	isradipine	drug	287-296	false

DDI-DrugBank.d81.s7	Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
Cimetidine	drug	0-9	cimetidine	drug	67-76	false
Cimetidine	drug	0-9	isradipine	drug	122-131	false
Cimetidine	drug	0-9	isradipine	drug	172-181	false
cimetidine	drug	67-76	isradipine	drug	122-131	mechanism
cimetidine	drug	67-76	isradipine	drug	172-181	false
isradipine	drug	122-131	isradipine	drug	172-181	false

DDI-DrugBank.d81.s8	If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
isradipine	drug	3-12	cimetidine	drug	68-77	advise

DDI-DrugBank.d81.s9	Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.
Rifampicin	drug	0-9	rifampicin	drug	66-75	false
Rifampicin	drug	0-9	isradipine	drug	125-134	false
Rifampicin	drug	0-9	isradipine	drug	163-172	false
rifampicin	drug	66-75	isradipine	drug	125-134	mechanism
rifampicin	drug	66-75	isradipine	drug	163-172	false
isradipine	drug	125-134	isradipine	drug	163-172	false

DDI-DrugBank.d81.s10	If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
rifampicin	drug	3-12	isradipine	drug	35-44	mechanism
rifampicin	drug	3-12	isradipine	drug	197-206	false
isradipine	drug	35-44	isradipine	drug	197-206	false

DDI-DrugBank.d81.s11	Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.
Warfarin	drug	0-7	isradipine	drug	122-131	false
Warfarin	drug	0-7	warfarin	drug	145-152	false
Warfarin	drug	0-7	warfarin	drug	193-200	false
Warfarin	drug	0-7	isradipine	drug	302-311	false
isradipine	drug	122-131	warfarin	drug	145-152	false
isradipine	drug	122-131	warfarin	drug	193-200	false
isradipine	drug	122-131	isradipine	drug	302-311	false
warfarin	drug	145-152	warfarin	drug	193-200	false
warfarin	drug	145-152	isradipine	drug	302-311	false
warfarin	drug	193-200	isradipine	drug	302-311	false

DDI-DrugBank.d81.s12	Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.
warfarin	drug	16-23	isradipine	drug	29-38	false

DDI-DrugBank.d81.s13	Digoxin: The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.
Digoxin	drug	0-6	DynaCirc	brand	43-50	false
Digoxin	drug	0-6	isradipine	drug	54-63	false
Digoxin	drug	0-6	digoxin	drug	70-76	false
Digoxin	drug	0-6	digoxin	drug	176-182	false
DynaCirc	brand	43-50	isradipine	drug	54-63	false
DynaCirc	brand	43-50	digoxin	drug	70-76	false
DynaCirc	brand	43-50	digoxin	drug	176-182	false
isradipine	drug	54-63	digoxin	drug	70-76	false
isradipine	drug	54-63	digoxin	drug	176-182	false
digoxin	drug	70-76	digoxin	drug	176-182	false

DDI-DrugBank.d81.s14	Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
Fentanyl	drug	0-7	fentanyl	drug	65-72	false
Fentanyl	drug	0-7	beta blocker	group	111-122	false
Fentanyl	drug	0-7	calcium channel blocker	group	130-152	false
fentanyl	drug	65-72	beta blocker	group	111-122	effect
fentanyl	drug	65-72	calcium channel blocker	group	130-152	effect
beta blocker	group	111-122	calcium channel blocker	group	130-152	false

DDI-DrugBank.d81.s15	Even though such interactions have not been seen in clinical studies with DynaCirc  (isradipine), an increased volume of circulating fluids might be required if such an interaction were to occur.
DynaCirc	brand	74-81	isradipine	drug	85-94	false

DDI-DrugBank.d26.s0	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
narcotic analgesic	group	25-42	anesthetics	group	54-64	false
narcotic analgesic	group	25-42	phenothiazines	group	67-80	false
narcotic analgesic	group	25-42	tranquilizers	group	83-95	false
narcotic analgesic	group	25-42	sedative-hypnotics	group	98-115	false
narcotic analgesic	group	25-42	tricyclic antidepressants	group	118-142	false
narcotic analgesic	group	25-42	CNS depressants	group	153-167	false
narcotic analgesic	group	25-42	alcohol	drug	180-186	false
narcotic analgesic	group	25-42	DILAUDID	brand	208-215	effect
anesthetics	group	54-64	phenothiazines	group	67-80	false
anesthetics	group	54-64	tranquilizers	group	83-95	false
anesthetics	group	54-64	sedative-hypnotics	group	98-115	false
anesthetics	group	54-64	tricyclic antidepressants	group	118-142	false
anesthetics	group	54-64	CNS depressants	group	153-167	false
anesthetics	group	54-64	alcohol	drug	180-186	false
anesthetics	group	54-64	DILAUDID	brand	208-215	effect
phenothiazines	group	67-80	tranquilizers	group	83-95	false
phenothiazines	group	67-80	sedative-hypnotics	group	98-115	false
phenothiazines	group	67-80	tricyclic antidepressants	group	118-142	false
phenothiazines	group	67-80	CNS depressants	group	153-167	false
phenothiazines	group	67-80	alcohol	drug	180-186	false
phenothiazines	group	67-80	DILAUDID	brand	208-215	effect
tranquilizers	group	83-95	sedative-hypnotics	group	98-115	false
tranquilizers	group	83-95	tricyclic antidepressants	group	118-142	false
tranquilizers	group	83-95	CNS depressants	group	153-167	false
tranquilizers	group	83-95	alcohol	drug	180-186	false
tranquilizers	group	83-95	DILAUDID	brand	208-215	effect
sedative-hypnotics	group	98-115	tricyclic antidepressants	group	118-142	false
sedative-hypnotics	group	98-115	CNS depressants	group	153-167	false
sedative-hypnotics	group	98-115	alcohol	drug	180-186	false
sedative-hypnotics	group	98-115	DILAUDID	brand	208-215	effect
tricyclic antidepressants	group	118-142	CNS depressants	group	153-167	false
tricyclic antidepressants	group	118-142	alcohol	drug	180-186	false
tricyclic antidepressants	group	118-142	DILAUDID	brand	208-215	effect
CNS depressants	group	153-167	alcohol	drug	180-186	false
CNS depressants	group	153-167	DILAUDID	brand	208-215	effect
alcohol	drug	180-186	DILAUDID	brand	208-215	effect

DDI-DrugBank.d384.s0	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
vitamin D analogues	group	17-35	Vitamin D2	drug	38-47	false
vitamin D analogues	group	17-35	Vitamin D3	drug	50-59	false
vitamin D analogues	group	17-35	Calcitriol	drug	62-71	false
vitamin D analogues	group	17-35	Calcidiol	drug	78-86	false
vitamin D analogues	group	17-35	Cholestyramine	drug	90-103	false
vitamin D analogues	group	17-35	Cholestyramine	drug	106-119	false
vitamin D analogues	group	17-35	fat soluble vitamins	group	174-193	false
Vitamin D2	drug	38-47	Vitamin D3	drug	50-59	false
Vitamin D2	drug	38-47	Calcitriol	drug	62-71	false
Vitamin D2	drug	38-47	Calcidiol	drug	78-86	false
Vitamin D2	drug	38-47	Cholestyramine	drug	90-103	false
Vitamin D2	drug	38-47	Cholestyramine	drug	106-119	false
Vitamin D2	drug	38-47	fat soluble vitamins	group	174-193	false
Vitamin D3	drug	50-59	Calcitriol	drug	62-71	false
Vitamin D3	drug	50-59	Calcidiol	drug	78-86	false
Vitamin D3	drug	50-59	Cholestyramine	drug	90-103	false
Vitamin D3	drug	50-59	Cholestyramine	drug	106-119	false
Vitamin D3	drug	50-59	fat soluble vitamins	group	174-193	false
Calcitriol	drug	62-71	Calcidiol	drug	78-86	false
Calcitriol	drug	62-71	Cholestyramine	drug	90-103	false
Calcitriol	drug	62-71	Cholestyramine	drug	106-119	false
Calcitriol	drug	62-71	fat soluble vitamins	group	174-193	false
Calcidiol	drug	78-86	Cholestyramine	drug	90-103	false
Calcidiol	drug	78-86	Cholestyramine	drug	106-119	false
Calcidiol	drug	78-86	fat soluble vitamins	group	174-193	false
Cholestyramine	drug	90-103	Cholestyramine	drug	106-119	false
Cholestyramine	drug	90-103	fat soluble vitamins	group	174-193	false
Cholestyramine	drug	106-119	fat soluble vitamins	group	174-193	mechanism

DDI-DrugBank.d384.s2	Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
Phenytoin	drug	0-8	Phenobarbital	drug	10-22	false
Phenytoin	drug	0-8	phenytoin	drug	49-57	false
Phenytoin	drug	0-8	phenobarbital	drug	62-74	false
Phenytoin	drug	0-8	vitamin D	group	117-125	false
Phenytoin	drug	0-8	calcitriol	drug	171-180	false
Phenobarbital	drug	10-22	phenytoin	drug	49-57	false
Phenobarbital	drug	10-22	phenobarbital	drug	62-74	false
Phenobarbital	drug	10-22	vitamin D	group	117-125	false
Phenobarbital	drug	10-22	calcitriol	drug	171-180	false
phenytoin	drug	49-57	phenobarbital	drug	62-74	false
phenytoin	drug	49-57	vitamin D	group	117-125	false
phenytoin	drug	49-57	calcitriol	drug	171-180	mechanism
phenobarbital	drug	62-74	vitamin D	group	117-125	false
phenobarbital	drug	62-74	calcitriol	drug	171-180	mechanism
vitamin D	group	117-125	calcitriol	drug	171-180	false

DDI-DrugBank.d384.s3	Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
calcitriol	drug	21-30	Rocaltrol	brand	80-88	false

DDI-DrugBank.d384.s4	Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
Thiazides	group	0-8	Thiazides	group	11-19	false
Thiazides	group	0-8	calcium	drug	75-81	false
Thiazides	group	11-19	calcium	drug	75-81	false

DDI-DrugBank.d384.s5	Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
thiazides	group	63-71	vitamin D	group	78-86	effect

DDI-DrugBank.d384.s7	Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
Digitalis	group	0-8	Vitamin D	group	11-19	false
Digitalis	group	0-8	digitalis	group	95-103	false
Vitamin D	group	11-19	digitalis	group	95-103	advise

DDI-DrugBank.d384.s8	Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
Ketoconazole	drug	0-11	Ketoconazole	drug	14-25	false
Ketoconazole	drug	0-11	vitamin D	group	79-87	false
Ketoconazole	drug	14-25	vitamin D	group	79-87	mechanism

DDI-DrugBank.d384.s10	However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
ketoconazole	drug	45-56	vitamin D	group	63-71	false

DDI-DrugBank.d384.s11	Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
Corticosteroids	group	0-14	vitamin D analogues	group	72-90	false
Corticosteroids	group	0-14	corticosteroids	group	131-145	false
vitamin D analogues	group	72-90	corticosteroids	group	131-145	mechanism

DDI-DrugBank.d384.s13	Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
Vitamin D	group	0-8	vitamin D analogues	group	46-64	false

DDI-DrugBank.d384.s14	Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
Calcium	drug	0-6	calcium	drug	55-61	false

DDI-DrugBank.d384.s15	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
Magnesium	drug	0-8	Magnesium	drug	11-19	false
Magnesium	drug	0-8	antacids	group	50-57	false
Magnesium	drug	0-8	vitamin D	group	140-148	false
Magnesium	drug	11-19	antacids	group	50-57	false
Magnesium	drug	11-19	vitamin D	group	140-148	advise
antacids	group	50-57	vitamin D	group	140-148	advise

DDI-DrugBank.d104.s0	Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
Fenfluramine	drug	0-11	antihypertensive drugs	group	49-70	effect
Fenfluramine	drug	0-11	guanethidine	drug	79-90	effect
Fenfluramine	drug	0-11	methyldopa	drug	93-102	effect
Fenfluramine	drug	0-11	reserpine	drug	105-113	effect
antihypertensive drugs	group	49-70	guanethidine	drug	79-90	false
antihypertensive drugs	group	49-70	methyldopa	drug	93-102	false
antihypertensive drugs	group	49-70	reserpine	drug	105-113	false
guanethidine	drug	79-90	methyldopa	drug	93-102	false
guanethidine	drug	79-90	reserpine	drug	105-113	false
methyldopa	drug	93-102	reserpine	drug	105-113	false

DDI-DrugBank.d104.s1	Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.
CNS depressant drugs	group	6-25	fenfluramine	drug	74-85	advise

DDI-DrugBank.d552.s0	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
Nabilone	drug	0-7	psychoactive drugs	group	78-95	advise
Nabilone	drug	0-7	CNS depressants	group	100-114	advise
Nabilone	drug	0-7	alcohol	drug	127-133	advise
Nabilone	drug	0-7	barbiturates	group	136-147	advise
Nabilone	drug	0-7	narcotic analgesics	group	153-171	advise
psychoactive drugs	group	78-95	CNS depressants	group	100-114	false
psychoactive drugs	group	78-95	alcohol	drug	127-133	false
psychoactive drugs	group	78-95	barbiturates	group	136-147	false
psychoactive drugs	group	78-95	narcotic analgesics	group	153-171	false
CNS depressants	group	100-114	alcohol	drug	127-133	false
CNS depressants	group	100-114	barbiturates	group	136-147	false
CNS depressants	group	100-114	narcotic analgesics	group	153-171	false
alcohol	drug	127-133	barbiturates	group	136-147	false
alcohol	drug	127-133	narcotic analgesics	group	153-171	false
barbiturates	group	136-147	narcotic analgesics	group	153-171	false

DDI-DrugBank.d552.s1	Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
Nabilone	drug	0-7	diazepam	drug	89-96	effect
Nabilone	drug	0-7	secobarbitone sodium	brand	99-118	effect
Nabilone	drug	0-7	alcohol	drug	121-127	effect
Nabilone	drug	0-7	codeine	drug	132-138	effect
diazepam	drug	89-96	secobarbitone sodium	brand	99-118	false
diazepam	drug	89-96	alcohol	drug	121-127	false
diazepam	drug	89-96	codeine	drug	132-138	false
secobarbitone sodium	brand	99-118	alcohol	drug	121-127	false
secobarbitone sodium	brand	99-118	codeine	drug	132-138	false
alcohol	drug	121-127	codeine	drug	132-138	false

DDI-DrugBank.d404.s0	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
vitamin D	group	17-25	Vitamin D2	drug	38-47	false
vitamin D	group	17-25	Vitamin D3	drug	50-59	false
vitamin D	group	17-25	Calcitriol	drug	62-71	false
vitamin D	group	17-25	Calcidiol	drug	78-86	false
vitamin D	group	17-25	Cholestyramine	drug	90-103	false
vitamin D	group	17-25	Cholestyramine	drug	106-119	false
vitamin D	group	17-25	fat soluble vitamins	group	174-193	false
Vitamin D2	drug	38-47	Vitamin D3	drug	50-59	false
Vitamin D2	drug	38-47	Calcitriol	drug	62-71	false
Vitamin D2	drug	38-47	Calcidiol	drug	78-86	false
Vitamin D2	drug	38-47	Cholestyramine	drug	90-103	false
Vitamin D2	drug	38-47	Cholestyramine	drug	106-119	false
Vitamin D2	drug	38-47	fat soluble vitamins	group	174-193	false
Vitamin D3	drug	50-59	Calcitriol	drug	62-71	false
Vitamin D3	drug	50-59	Calcidiol	drug	78-86	false
Vitamin D3	drug	50-59	Cholestyramine	drug	90-103	false
Vitamin D3	drug	50-59	Cholestyramine	drug	106-119	false
Vitamin D3	drug	50-59	fat soluble vitamins	group	174-193	false
Calcitriol	drug	62-71	Calcidiol	drug	78-86	false
Calcitriol	drug	62-71	Cholestyramine	drug	90-103	false
Calcitriol	drug	62-71	Cholestyramine	drug	106-119	false
Calcitriol	drug	62-71	fat soluble vitamins	group	174-193	false
Calcidiol	drug	78-86	Cholestyramine	drug	90-103	false
Calcidiol	drug	78-86	Cholestyramine	drug	106-119	false
Calcidiol	drug	78-86	fat soluble vitamins	group	174-193	false
Cholestyramine	drug	90-103	Cholestyramine	drug	106-119	false
Cholestyramine	drug	90-103	fat soluble vitamins	group	174-193	false
Cholestyramine	drug	106-119	fat soluble vitamins	group	174-193	mechanism

DDI-DrugBank.d404.s2	Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
Phenytoin	drug	0-8	Phenobarbital	drug	10-22	false
Phenytoin	drug	0-8	phenytoin	drug	49-57	false
Phenytoin	drug	0-8	phenobarbital	drug	62-74	false
Phenytoin	drug	0-8	vitamin D	group	117-125	false
Phenytoin	drug	0-8	calcitriol	drug	171-180	false
Phenobarbital	drug	10-22	phenytoin	drug	49-57	false
Phenobarbital	drug	10-22	phenobarbital	drug	62-74	false
Phenobarbital	drug	10-22	vitamin D	group	117-125	false
Phenobarbital	drug	10-22	calcitriol	drug	171-180	false
phenytoin	drug	49-57	phenobarbital	drug	62-74	false
phenytoin	drug	49-57	vitamin D	group	117-125	false
phenytoin	drug	49-57	calcitriol	drug	171-180	false
phenobarbital	drug	62-74	vitamin D	group	117-125	false
phenobarbital	drug	62-74	calcitriol	drug	171-180	false
vitamin D	group	117-125	calcitriol	drug	171-180	false

DDI-DrugBank.d404.s3	Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
calcitriol	drug	21-30	Rocaltrol	brand	80-88	false

DDI-DrugBank.d404.s4	Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
Thiazides	group	0-8	Thiazides	group	11-19	false

DDI-DrugBank.d404.s5	Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
thiazides	group	63-71	vitamin D	group	78-86	effect

DDI-DrugBank.d404.s7	Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
Digitalis	group	0-8	Vitamin D	group	11-19	false
Digitalis	group	0-8	digitalis	group	95-103	false
Vitamin D	group	11-19	digitalis	group	95-103	advise

DDI-DrugBank.d404.s8	Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
Ketoconazole	drug	0-11	Ketoconazole	drug	14-25	false
Ketoconazole	drug	0-11	vitamin D	group	79-87	false
Ketoconazole	drug	14-25	vitamin D	group	79-87	mechanism

DDI-DrugBank.d404.s10	However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
ketoconazole	drug	45-56	vitamin D	group	63-71	false

DDI-DrugBank.d404.s11	Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
Corticosteroids	group	0-14	vitamin D	group	72-80	false
Corticosteroids	group	0-14	corticosteroids	group	131-145	false
vitamin D	group	72-80	corticosteroids	group	131-145	effect

DDI-DrugBank.d404.s13	Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
Vitamin D	group	0-8	vitamin D	group	46-54	false

DDI-DrugBank.d404.s14	Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
Calcium	drug	0-6	calcium	drug	55-61	false

DDI-DrugBank.d404.s15	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
Magnesium	drug	0-8	Magnesium	drug	11-19	false
Magnesium	drug	0-8	antacids	group	50-57	false
Magnesium	drug	0-8	vitamin D	group	140-148	false
Magnesium	drug	11-19	antacids	group	50-57	false
Magnesium	drug	11-19	vitamin D	group	140-148	effect
antacids	group	50-57	vitamin D	group	140-148	effect

DDI-DrugBank.d467.s2	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
bexarotene	drug	34-43	ketoconazole	drug	69-80	false
bexarotene	drug	34-43	itraconazole	drug	83-94	false
bexarotene	drug	34-43	erythromycin	drug	97-108	false
bexarotene	drug	34-43	gemfibrozil	drug	111-121	false
bexarotene	drug	34-43	bexarotene	drug	237-246	false
ketoconazole	drug	69-80	itraconazole	drug	83-94	false
ketoconazole	drug	69-80	erythromycin	drug	97-108	false
ketoconazole	drug	69-80	gemfibrozil	drug	111-121	false
ketoconazole	drug	69-80	bexarotene	drug	237-246	mechanism
itraconazole	drug	83-94	erythromycin	drug	97-108	false
itraconazole	drug	83-94	gemfibrozil	drug	111-121	false
itraconazole	drug	83-94	bexarotene	drug	237-246	mechanism
erythromycin	drug	97-108	gemfibrozil	drug	111-121	false
erythromycin	drug	97-108	bexarotene	drug	237-246	mechanism
gemfibrozil	drug	111-121	bexarotene	drug	237-246	mechanism

DDI-DrugBank.d467.s3	Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
rifampin	drug	13-20	phenytoin	drug	23-31	false
rifampin	drug	13-20	phenobarbital	drug	34-46	false
rifampin	drug	13-20	bexarotene	drug	123-132	mechanism
phenytoin	drug	23-31	phenobarbital	drug	34-46	false
phenytoin	drug	23-31	bexarotene	drug	123-132	mechanism
phenobarbital	drug	34-46	bexarotene	drug	123-132	mechanism

DDI-DrugBank.d467.s4	Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
Targretin	brand	30-38	gemfibrozil	drug	53-63	mechanism
Targretin	brand	30-38	bexarotene	drug	127-136	false
Targretin	brand	30-38	gemfibrozil	drug	212-222	false
gemfibrozil	drug	53-63	bexarotene	drug	127-136	false
gemfibrozil	drug	53-63	gemfibrozil	drug	212-222	false
bexarotene	drug	127-136	gemfibrozil	drug	212-222	false

DDI-DrugBank.d467.s5	Under similar conditions, bexarotene concentrations were not affected by concomitant atorvastatin administration.
bexarotene	drug	26-35	atorvastatin	drug	85-96	false

DDI-DrugBank.d467.s6	Concomitant administration of gemfibrozil with Targretin capsules is not recommended.
gemfibrozil	drug	30-40	Targretin	brand	47-55	advise

DDI-DrugBank.d374.s0	Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
Auranofin	drug	0-8	gold medication	group	82-96	advise
Auranofin	drug	0-8	Solganal	brand	109-116	advise
Auranofin	drug	0-8	Myochrysine	brand	122-132	advise
gold medication	group	82-96	Solganal	brand	109-116	false
gold medication	group	82-96	Myochrysine	brand	122-132	false
Solganal	brand	109-116	Myochrysine	brand	122-132	false

DDI-DrugBank.d374.s1	Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
Auranofin	drug	0-8	penicillamine	drug	43-55	advise
Auranofin	drug	0-8	Depen	brand	58-62	advise
Auranofin	drug	0-8	Cuprimine	brand	65-73	advise
penicillamine	drug	43-55	Depen	brand	58-62	false
penicillamine	drug	43-55	Cuprimine	brand	65-73	false
Depen	brand	58-62	Cuprimine	brand	65-73	false

DDI-DrugBank.d8.s0	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
ALFENTA	brand	106-112	CNS depressants	group	156-170	effect
ALFENTA	brand	106-112	barbiturates	group	180-191	effect
ALFENTA	brand	106-112	tranquilizers	group	194-206	effect
ALFENTA	brand	106-112	opioids	group	209-215	effect
ALFENTA	brand	106-112	anesthetics	group	240-250	effect
CNS depressants	group	156-170	barbiturates	group	180-191	false
CNS depressants	group	156-170	tranquilizers	group	194-206	false
CNS depressants	group	156-170	opioids	group	209-215	false
CNS depressants	group	156-170	anesthetics	group	240-250	false
barbiturates	group	180-191	tranquilizers	group	194-206	false
barbiturates	group	180-191	opioids	group	209-215	false
barbiturates	group	180-191	anesthetics	group	240-250	false
tranquilizers	group	194-206	opioids	group	209-215	false
tranquilizers	group	194-206	anesthetics	group	240-250	false
opioids	group	209-215	anesthetics	group	240-250	false

DDI-DrugBank.d8.s3	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
volatile inhalation anesthetics	group	60-90	ALFENTA	brand	160-166	mechanism
volatile inhalation anesthetics	group	60-90	erythromycin	drug	201-212	false
volatile inhalation anesthetics	group	60-90	ALFENTA	brand	219-225	false
volatile inhalation anesthetics	group	60-90	ALFENTA	brand	253-259	false
ALFENTA	brand	160-166	erythromycin	drug	201-212	false
ALFENTA	brand	160-166	ALFENTA	brand	219-225	false
ALFENTA	brand	160-166	ALFENTA	brand	253-259	false
erythromycin	drug	201-212	ALFENTA	brand	219-225	mechanism
erythromycin	drug	201-212	ALFENTA	brand	253-259	false
ALFENTA	brand	219-225	ALFENTA	brand	253-259	false

DDI-DrugBank.d8.s4	Cimetidine reduces the clearance of ALFENTA.
Cimetidine	drug	0-9	ALFENTA	brand	36-42	mechanism

DDI-DrugBank.d8.s5	Therefore smaller ALFENTA doses will be required with prolonged administration and the duration of action of ALFENTA my be extended.
ALFENTA	brand	18-24	ALFENTA	brand	109-115	false

DDI-DrugBank.d529.s0	Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).
Antacids	group	0-7	flurbiprofen	drug	28-39	false
Antacids	group	0-7	antacid	group	89-95	false
Antacids	group	0-7	flurbiprofen	drug	130-141	false
flurbiprofen	drug	28-39	antacid	group	89-95	false
flurbiprofen	drug	28-39	flurbiprofen	drug	130-141	false
antacid	group	89-95	flurbiprofen	drug	130-141	false

DDI-DrugBank.d529.s2	Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
Anticoagulants	group	0-13	Flurbiprofen	drug	16-27	false
Anticoagulants	group	0-13	nonsteroidal anti-inflammatory drugs	group	40-75	false
Anticoagulants	group	0-13	anti-coagulants	group	145-159	false
Flurbiprofen	drug	16-27	nonsteroidal anti-inflammatory drugs	group	40-75	false
Flurbiprofen	drug	16-27	anti-coagulants	group	145-159	effect
nonsteroidal anti-inflammatory drugs	group	40-75	anti-coagulants	group	145-159	effect

DDI-DrugBank.d529.s3	The physician should be cautious when administering flurbiprofen to patients taking anticoagulants.
flurbiprofen	drug	52-63	anticoagulants	group	84-97	advise

DDI-DrugBank.d529.s4	Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.
Aspirin	brand	0-6	aspirin	brand	38-44	false
Aspirin	brand	0-6	flurbiprofen	drug	50-61	false
Aspirin	brand	0-6	flurbiprofen	drug	91-102	false
aspirin	brand	38-44	flurbiprofen	drug	50-61	mechanism
aspirin	brand	38-44	flurbiprofen	drug	91-102	false
flurbiprofen	drug	50-61	flurbiprofen	drug	91-102	false

DDI-DrugBank.d529.s5	This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).
aspirin	brand	15-21	nonsteroidal anti-inflammatory drugs	group	72-107	false

DDI-DrugBank.d529.s6	Concurrent use of flurbiprofen and aspirin is therefore not recommended.
flurbiprofen	drug	18-29	aspirin	brand	35-41	advise

DDI-DrugBank.d529.s7	Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).
Beta-adrenergic Blocking Agents	group	0-30	flurbiprofen	drug	47-58	false
Beta-adrenergic Blocking Agents	group	0-30	propranolol	drug	90-100	false
Beta-adrenergic Blocking Agents	group	0-30	atenolol	drug	106-113	false
flurbiprofen	drug	47-58	propranolol	drug	90-100	false
flurbiprofen	drug	47-58	atenolol	drug	106-113	false
propranolol	drug	90-100	atenolol	drug	106-113	false

DDI-DrugBank.d529.s8	Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.
Flurbiprofen	drug	0-11	propranolol	drug	80-90	effect
Flurbiprofen	drug	0-11	atenolol	drug	100-107	false
propranolol	drug	80-90	atenolol	drug	100-107	false

DDI-DrugBank.d529.s10	Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.
Flurbiprofen	drug	0-11	propranolol	drug	124-134	int

DDI-DrugBank.d529.s11	Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.
flurbiprofen	drug	21-32	beta-blocker	group	40-51	advise

DDI-DrugBank.d529.s12	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
Cimetidine	drug	0-9	Ranitidine	drug	12-21	false
Cimetidine	drug	0-9	cimetidine	drug	70-79	false
Cimetidine	drug	0-9	ranitidine	drug	84-93	false
Cimetidine	drug	0-9	flurbiprofen	drug	110-121	false
Cimetidine	drug	0-9	flurbiprofen	drug	257-268	false
Cimetidine	drug	0-9	cimetidine	drug	284-293	false
Ranitidine	drug	12-21	cimetidine	drug	70-79	false
Ranitidine	drug	12-21	ranitidine	drug	84-93	false
Ranitidine	drug	12-21	flurbiprofen	drug	110-121	false
Ranitidine	drug	12-21	flurbiprofen	drug	257-268	false
Ranitidine	drug	12-21	cimetidine	drug	284-293	false
cimetidine	drug	70-79	ranitidine	drug	84-93	false
cimetidine	drug	70-79	flurbiprofen	drug	110-121	false
cimetidine	drug	70-79	flurbiprofen	drug	257-268	false
cimetidine	drug	70-79	cimetidine	drug	284-293	false
ranitidine	drug	84-93	flurbiprofen	drug	110-121	false
ranitidine	drug	84-93	flurbiprofen	drug	257-268	false
ranitidine	drug	84-93	cimetidine	drug	284-293	false
flurbiprofen	drug	110-121	flurbiprofen	drug	257-268	false
flurbiprofen	drug	110-121	cimetidine	drug	284-293	false
flurbiprofen	drug	257-268	cimetidine	drug	284-293	mechanism

DDI-DrugBank.d529.s13	Digoxin: Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.
Digoxin	drug	0-6	flurbiprofen	drug	50-61	false
Digoxin	drug	0-6	digoxin	drug	67-73	false
flurbiprofen	drug	50-61	digoxin	drug	67-73	false

DDI-DrugBank.d529.s14	Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.
Diuretics	group	0-8	flurbiprofen	drug	56-67	false
Diuretics	group	0-8	nonsteroidal anti-inflammatory drugs	group	80-115	false
Diuretics	group	0-8	furosemide	drug	152-161	false
flurbiprofen	drug	56-67	nonsteroidal anti-inflammatory drugs	group	80-115	false
flurbiprofen	drug	56-67	furosemide	drug	152-161	effect
nonsteroidal anti-inflammatory drugs	group	80-115	furosemide	drug	152-161	effect

DDI-DrugBank.d529.s16	Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.
nonsteroidal anti-inflammatory drugs	group	6-41	thiazide diuretics	group	114-131	effect
nonsteroidal anti-inflammatory drugs	group	6-41	potassium-sparing diuretics	group	158-184	effect
thiazide diuretics	group	114-131	potassium-sparing diuretics	group	158-184	false

DDI-DrugBank.d529.s17	Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.
flurbiprofen	drug	19-30	furosemide	drug	36-45	advise
flurbiprofen	drug	19-30	diuretics	group	56-64	advise
furosemide	drug	36-45	diuretics	group	56-64	false

DDI-DrugBank.d529.s18	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).
Hypoglycemic Agents	group	5-23	flurbiprofen	drug	40-51	false
Hypoglycemic Agents	group	5-23	glyburide	drug	109-117	false
Hypoglycemic Agents	group	5-23	metformin	drug	126-134	false
Hypoglycemic Agents	group	5-23	chlorpropamide	drug	142-155	false
Hypoglycemic Agents	group	5-23	phenformin	drug	162-171	false
Hypoglycemic Agents	group	5-23	glyburide	drug	183-191	false
Hypoglycemic Agents	group	5-23	phenformin	drug	198-207	false
flurbiprofen	drug	40-51	glyburide	drug	109-117	false
flurbiprofen	drug	40-51	metformin	drug	126-134	false
flurbiprofen	drug	40-51	chlorpropamide	drug	142-155	false
flurbiprofen	drug	40-51	phenformin	drug	162-171	false
flurbiprofen	drug	40-51	glyburide	drug	183-191	false
flurbiprofen	drug	40-51	phenformin	drug	198-207	false
glyburide	drug	109-117	metformin	drug	126-134	false
glyburide	drug	109-117	chlorpropamide	drug	142-155	false
glyburide	drug	109-117	phenformin	drug	162-171	false
glyburide	drug	109-117	glyburide	drug	183-191	false
glyburide	drug	109-117	phenformin	drug	198-207	false
metformin	drug	126-134	chlorpropamide	drug	142-155	false
metformin	drug	126-134	phenformin	drug	162-171	false
metformin	drug	126-134	glyburide	drug	183-191	false
metformin	drug	126-134	phenformin	drug	198-207	false
chlorpropamide	drug	142-155	phenformin	drug	162-171	false
chlorpropamide	drug	142-155	glyburide	drug	183-191	false
chlorpropamide	drug	142-155	phenformin	drug	198-207	false
phenformin	drug	162-171	glyburide	drug	183-191	false
phenformin	drug	162-171	phenformin	drug	198-207	false
glyburide	drug	183-191	phenformin	drug	198-207	false

DDI-DrugBank.d529.s19	Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.
flurbiprofen	drug	105-116	hypoglycemic agents	group	122-140	effect

DDI-DrugBank.d393.s0	Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.
cetirizine	drug	41-50	pseudoephedrine	drug	82-96	false
cetirizine	drug	41-50	antipyrine	drug	99-108	false
cetirizine	drug	41-50	ketoconazole	drug	111-122	false
cetirizine	drug	41-50	erythromycin	drug	125-136	false
cetirizine	drug	41-50	azithromycin	drug	142-153	false
pseudoephedrine	drug	82-96	antipyrine	drug	99-108	false
pseudoephedrine	drug	82-96	ketoconazole	drug	111-122	false
pseudoephedrine	drug	82-96	erythromycin	drug	125-136	false
pseudoephedrine	drug	82-96	azithromycin	drug	142-153	false
antipyrine	drug	99-108	ketoconazole	drug	111-122	false
antipyrine	drug	99-108	erythromycin	drug	125-136	false
antipyrine	drug	99-108	azithromycin	drug	142-153	false
ketoconazole	drug	111-122	erythromycin	drug	125-136	false
ketoconazole	drug	111-122	azithromycin	drug	142-153	false
erythromycin	drug	125-136	azithromycin	drug	142-153	false

DDI-DrugBank.d393.s2	In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
theophylline	drug	28-39	cetirizine	drug	76-85	mechanism
theophylline	drug	28-39	cetirizine	drug	153-162	false
cetirizine	drug	76-85	cetirizine	drug	153-162	false

DDI-DrugBank.d393.s3	The disposition of theophylline was not altered by concomitant cetirizine administration.
theophylline	drug	19-30	cetirizine	drug	63-72	false

DDI-DrugBank.d393.s4	Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.
theophylline	drug	89-100	azithromycin	drug	117-128	false
theophylline	drug	89-100	pseudoephedrine	drug	131-145	false
theophylline	drug	89-100	ketoconazole	drug	148-159	false
theophylline	drug	89-100	erythromycin	drug	165-176	false
azithromycin	drug	117-128	pseudoephedrine	drug	131-145	false
azithromycin	drug	117-128	ketoconazole	drug	148-159	false
azithromycin	drug	117-128	erythromycin	drug	165-176	false
pseudoephedrine	drug	131-145	ketoconazole	drug	148-159	false
pseudoephedrine	drug	131-145	erythromycin	drug	165-176	false
ketoconazole	drug	148-159	erythromycin	drug	165-176	false

DDI-DrugBank.d393.s5	There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;
cetirizine	drug	47-56	theophylline	drug	85-96	mechanism

DDI-DrugBank.d519.s3	Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.
Plenaxis	brand	29-36	testosterone	drug	83-94	false

DDI-DrugBank.d139.s0	Broad-Spectrum Antibiotics-Broad-spectrum antibiotics may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.
Broad-Spectrum Antibiotics	group	0-25	Broad-spectrum antibiotics	group	27-52	false
Broad-Spectrum Antibiotics	group	0-25	vitamin K	group	95-103	false
Broad-spectrum antibiotics	group	27-52	vitamin K	group	95-103	false

DDI-DrugBank.d139.s1	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
Cephalosporins	group	0-13	Cephalosporins	group	15-28	false
Cephalosporins	group	0-13	cefmenoxime	drug	79-89	false
Cephalosporins	group	0-13	cefoperazone	drug	92-103	false
Cephalosporins	group	0-13	cefotetan	drug	106-114	false
Cephalosporins	group	0-13	cefamandole	drug	117-127	false
Cephalosporins	group	0-13	latamoxef	drug	130-138	false
Cephalosporins	group	0-13	cefazolin	drug	163-171	false
Cephalosporins	group	15-28	cefmenoxime	drug	79-89	false
Cephalosporins	group	15-28	cefoperazone	drug	92-103	false
Cephalosporins	group	15-28	cefotetan	drug	106-114	false
Cephalosporins	group	15-28	cefamandole	drug	117-127	false
Cephalosporins	group	15-28	latamoxef	drug	130-138	false
Cephalosporins	group	15-28	cefazolin	drug	163-171	false
cefmenoxime	drug	79-89	cefoperazone	drug	92-103	false
cefmenoxime	drug	79-89	cefotetan	drug	106-114	false
cefmenoxime	drug	79-89	cefamandole	drug	117-127	false
cefmenoxime	drug	79-89	latamoxef	drug	130-138	false
cefmenoxime	drug	79-89	cefazolin	drug	163-171	false
cefoperazone	drug	92-103	cefotetan	drug	106-114	false
cefoperazone	drug	92-103	cefamandole	drug	117-127	false
cefoperazone	drug	92-103	latamoxef	drug	130-138	false
cefoperazone	drug	92-103	cefazolin	drug	163-171	false
cefotetan	drug	106-114	cefamandole	drug	117-127	false
cefotetan	drug	106-114	latamoxef	drug	130-138	false
cefotetan	drug	106-114	cefazolin	drug	163-171	false
cefamandole	drug	117-127	latamoxef	drug	130-138	false
cefamandole	drug	117-127	cefazolin	drug	163-171	false
latamoxef	drug	130-138	cefazolin	drug	163-171	false

DDI-DrugBank.d139.s3	Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.
Cholestyramine	drug	0-13	cholestyramine	drug	37-50	false
Cholestyramine	drug	0-13	vitamin K	group	56-64	false
Cholestyramine	drug	0-13	vitamin K	group	95-103	false
cholestyramine	drug	37-50	vitamin K	group	56-64	mechanism
cholestyramine	drug	37-50	vitamin K	group	95-103	false
vitamin K	group	56-64	vitamin K	group	95-103	false

DDI-DrugBank.d139.s4	Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.
Colestipol	drug	0-9	colestipol	drug	33-42	false
Colestipol	drug	0-9	vitamin K	group	48-56	false
Colestipol	drug	0-9	vitamin K	group	87-95	false
colestipol	drug	33-42	vitamin K	group	48-56	mechanism
colestipol	drug	33-42	vitamin K	group	87-95	false
vitamin K	group	48-56	vitamin K	group	87-95	false

DDI-DrugBank.d139.s5	Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.
Mineral Oil	drug_n	0-10	mineral oil	drug_n	34-44	false
Mineral Oil	drug_n	0-10	vitamin K	group	50-58	false
Mineral Oil	drug_n	0-10	vitamin K	group	89-97	false
mineral oil	drug_n	34-44	vitamin K	group	50-58	mechanism
mineral oil	drug_n	34-44	vitamin K	group	89-97	false
vitamin K	group	50-58	vitamin K	group	89-97	false

DDI-DrugBank.d139.s6	Orlistat-Orlistat may decrease the absorption of vitamin K.
Orlistat	drug	0-7	Orlistat	drug	9-16	false
Orlistat	drug	0-7	vitamin K	group	49-57	false
Orlistat	drug	9-16	vitamin K	group	49-57	mechanism

DDI-DrugBank.d139.s7	Salicylates-Salicylates in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.
Salicylates	group	0-10	Salicylates	group	12-22	false

DDI-DrugBank.d139.s8	Warfarin-Vitamin K can antagonize the effect of warfarin
Warfarin	drug	0-7	Vitamin K	group	9-17	false
Warfarin	drug	0-7	warfarin	drug	48-55	false
Vitamin K	group	9-17	warfarin	drug	48-55	effect

DDI-DrugBank.d401.s0	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
anticholinergic	group	31-45	AKINETON	brand	102-109	false
anticholinergic	group	31-45	narcotic analgesics	group	212-230	effect
anticholinergic	group	31-45	meperidine	drug	240-249	effect
anticholinergic	group	31-45	phenothiazines	group	256-269	effect
anticholinergic	group	31-45	antipsychotics	group	281-294	effect
anticholinergic	group	31-45	tricyclic antidepressants	group	297-321	effect
anticholinergic	group	31-45	antiarrhythmics	group	332-346	effect
anticholinergic	group	31-45	quinidine	drug	360-368	effect
anticholinergic	group	31-45	antihistamines	group	381-394	effect
AKINETON	brand	102-109	narcotic analgesics	group	212-230	effect
AKINETON	brand	102-109	meperidine	drug	240-249	effect
AKINETON	brand	102-109	phenothiazines	group	256-269	effect
AKINETON	brand	102-109	antipsychotics	group	281-294	effect
AKINETON	brand	102-109	tricyclic antidepressants	group	297-321	effect
AKINETON	brand	102-109	antiarrhythmics	group	332-346	effect
AKINETON	brand	102-109	quinidine	drug	360-368	effect
AKINETON	brand	102-109	antihistamines	group	381-394	effect
narcotic analgesics	group	212-230	meperidine	drug	240-249	false
narcotic analgesics	group	212-230	phenothiazines	group	256-269	false
narcotic analgesics	group	212-230	antipsychotics	group	281-294	false
narcotic analgesics	group	212-230	tricyclic antidepressants	group	297-321	false
narcotic analgesics	group	212-230	antiarrhythmics	group	332-346	false
narcotic analgesics	group	212-230	quinidine	drug	360-368	false
narcotic analgesics	group	212-230	antihistamines	group	381-394	false
meperidine	drug	240-249	phenothiazines	group	256-269	false
meperidine	drug	240-249	antipsychotics	group	281-294	false
meperidine	drug	240-249	tricyclic antidepressants	group	297-321	false
meperidine	drug	240-249	antiarrhythmics	group	332-346	false
meperidine	drug	240-249	quinidine	drug	360-368	false
meperidine	drug	240-249	antihistamines	group	381-394	false
phenothiazines	group	256-269	antipsychotics	group	281-294	false
phenothiazines	group	256-269	tricyclic antidepressants	group	297-321	false
phenothiazines	group	256-269	antiarrhythmics	group	332-346	false
phenothiazines	group	256-269	quinidine	drug	360-368	false
phenothiazines	group	256-269	antihistamines	group	381-394	false
antipsychotics	group	281-294	tricyclic antidepressants	group	297-321	false
antipsychotics	group	281-294	antiarrhythmics	group	332-346	false
antipsychotics	group	281-294	quinidine	drug	360-368	false
antipsychotics	group	281-294	antihistamines	group	381-394	false
tricyclic antidepressants	group	297-321	antiarrhythmics	group	332-346	false
tricyclic antidepressants	group	297-321	quinidine	drug	360-368	false
tricyclic antidepressants	group	297-321	antihistamines	group	381-394	false
antiarrhythmics	group	332-346	quinidine	drug	360-368	false
antiarrhythmics	group	332-346	antihistamines	group	381-394	false
quinidine	drug	360-368	antihistamines	group	381-394	false

DDI-DrugBank.d149.s0	Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.
HUMORSOL	brand	30-37	succinylcholine	drug	44-58	int
HUMORSOL	brand	30-37	anticholinesterase agents	group	74-98	int
succinylcholine	drug	44-58	anticholinesterase agents	group	74-98	false

DDI-DrugBank.d358.s0	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
PLETAL	brand	6-11	PLETAL	brand	105-110	false
PLETAL	brand	6-11	ketoconazole	drug	164-175	false
PLETAL	brand	6-11	erythromycin	drug	181-192	false
PLETAL	brand	6-11	omeprazole	drug	227-236	false
PLETAL	brand	105-110	ketoconazole	drug	164-175	advise
PLETAL	brand	105-110	erythromycin	drug	181-192	advise
PLETAL	brand	105-110	omeprazole	drug	227-236	advise
ketoconazole	drug	164-175	erythromycin	drug	181-192	false
ketoconazole	drug	164-175	omeprazole	drug	227-236	false
erythromycin	drug	181-192	omeprazole	drug	227-236	false

DDI-DrugBank.d358.s1	Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
omeprazole	drug	47-56	erythromycin	drug	62-73	false
omeprazole	drug	47-56	cilostazol	drug	124-133	mechanism
erythromycin	drug	62-73	cilostazol	drug	124-133	mechanism

DDI-DrugBank.d358.s2	Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..
cilostazol	drug	67-76	diltiazem	drug	119-127	mechanism

DDI-DrugBank.d358.s3	Pletal does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to C.P.A. inhibition.
Pletal	brand	0-5	lovastatin	drug	120-129	false

DDI-DrugBank.d61.s0	In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators, and inhaled corticosteroids, with no evidence of increased frequency of adverse events or laboratory abnormalities.
Tilade	brand	21-26	bronchodilators	group	116-130	false
Tilade	brand	21-26	corticosteroids	group	145-159	false
bronchodilators	group	116-130	corticosteroids	group	145-159	false

DDI-DrugBank.d71.s3	There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.
lamivudine	drug	48-57	TMP	drug	95-97	false
lamivudine	drug	48-57	SMX	drug	99-101	false
TMP	drug	95-97	SMX	drug	99-101	false

DDI-DrugBank.d71.s5	Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.
Lamivudine	drug	0-9	zalcitabine	drug	15-25	effect

DDI-DrugBank.d71.s6	Therefore, use of lamivudine in combination with zalcitabine is not recommended
lamivudine	drug	18-27	zalcitabine	drug	49-59	advise

DDI-DrugBank.d183.s1	INOmax has been administered with tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.
INOmax	brand	0-5	tolazoline	drug	34-43	false
INOmax	brand	0-5	dopamine	drug	46-53	false
INOmax	brand	0-5	dobutamine	drug	56-65	false
INOmax	brand	0-5	steroids	group	68-75	false
INOmax	brand	0-5	surfactant	drug	78-87	false
tolazoline	drug	34-43	dopamine	drug	46-53	false
tolazoline	drug	34-43	dobutamine	drug	56-65	false
tolazoline	drug	34-43	steroids	group	68-75	false
tolazoline	drug	34-43	surfactant	drug	78-87	false
dopamine	drug	46-53	dobutamine	drug	56-65	false
dopamine	drug	46-53	steroids	group	68-75	false
dopamine	drug	46-53	surfactant	drug	78-87	false
dobutamine	drug	56-65	steroids	group	68-75	false
dobutamine	drug	56-65	surfactant	drug	78-87	false
steroids	group	68-75	surfactant	drug	78-87	false

DDI-DrugBank.d183.s2	Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
nitric oxide donor compounds	group	62-89	sodium nitroprusside	drug	102-121	false
nitric oxide donor compounds	group	62-89	nitroglycerin	drug	127-139	false
nitric oxide donor compounds	group	62-89	INOmax	brand	175-180	effect
sodium nitroprusside	drug	102-121	nitroglycerin	drug	127-139	false
sodium nitroprusside	drug	102-121	INOmax	brand	175-180	effect
nitroglycerin	drug	127-139	INOmax	brand	175-180	effect

DDI-DrugBank.d360.s1	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.
barbiturates	group	67-78	phenylbutazone	drug	81-94	false
barbiturates	group	67-78	phenytoin sodium	drug	97-112	false
barbiturates	group	67-78	carbamazepine	drug	115-127	false
barbiturates	group	67-78	griseofulvin	drug	130-141	false
barbiturates	group	67-78	topiramate	drug	144-153	false
barbiturates	group	67-78	ampicillin	drug	174-183	false
barbiturates	group	67-78	tetracyclines	group	189-201	false
phenylbutazone	drug	81-94	phenytoin sodium	drug	97-112	false
phenylbutazone	drug	81-94	carbamazepine	drug	115-127	false
phenylbutazone	drug	81-94	griseofulvin	drug	130-141	false
phenylbutazone	drug	81-94	topiramate	drug	144-153	false
phenylbutazone	drug	81-94	ampicillin	drug	174-183	false
phenylbutazone	drug	81-94	tetracyclines	group	189-201	false
phenytoin sodium	drug	97-112	carbamazepine	drug	115-127	false
phenytoin sodium	drug	97-112	griseofulvin	drug	130-141	false
phenytoin sodium	drug	97-112	topiramate	drug	144-153	false
phenytoin sodium	drug	97-112	ampicillin	drug	174-183	false
phenytoin sodium	drug	97-112	tetracyclines	group	189-201	false
carbamazepine	drug	115-127	griseofulvin	drug	130-141	false
carbamazepine	drug	115-127	topiramate	drug	144-153	false
carbamazepine	drug	115-127	ampicillin	drug	174-183	false
carbamazepine	drug	115-127	tetracyclines	group	189-201	false
griseofulvin	drug	130-141	topiramate	drug	144-153	false
griseofulvin	drug	130-141	ampicillin	drug	174-183	false
griseofulvin	drug	130-141	tetracyclines	group	189-201	false
topiramate	drug	144-153	ampicillin	drug	174-183	false
topiramate	drug	144-153	tetracyclines	group	189-201	false
ampicillin	drug	174-183	tetracyclines	group	189-201	false

DDI-DrugBank.d360.s2	A possible interaction has been suggested with hormonal contraceptives and the herbal supplement St. Johns Wort based on some reports of oral contraceptive users experiencing breakthrough bleeding shortly after starting St. Johns Wort.
hormonal contraceptives	group	47-69	contraceptive	group	142-154	false

DDI-DrugBank.d392.s0	Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
Panretin	brand	26-33	DEET	drug	89-92	advise
Panretin	brand	26-33	N-diethyl-m-toluamide	drug	98-118	advise
DEET	drug	89-92	N-diethyl-m-toluamide	drug	98-118	false

DDI-DrugBank.d392.s1	Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation.
DEET	drug	43-46	DEET	drug	62-65	false

DDI-DrugBank.d392.s2	Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.
antiretroviral agents	group	109-129	protease inhibitors	group	142-160	false
antiretroviral agents	group	109-129	macrolide antibiotics	group	163-183	false
antiretroviral agents	group	109-129	azole antifungals	group	190-206	false
antiretroviral agents	group	109-129	Panretin	brand	223-230	false
protease inhibitors	group	142-160	macrolide antibiotics	group	163-183	false
protease inhibitors	group	142-160	azole antifungals	group	190-206	false
protease inhibitors	group	142-160	Panretin	brand	223-230	false
macrolide antibiotics	group	163-183	azole antifungals	group	190-206	false
macrolide antibiotics	group	163-183	Panretin	brand	223-230	false
azole antifungals	group	190-206	Panretin	brand	223-230	false

DDI-DrugBank.d108.s0	Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
Isocarboxazid	drug	0-12	Antabuse	brand	72-79	advise
Isocarboxazid	drug	0-12	disulfiram	drug	82-91	advise
Antabuse	brand	72-79	disulfiram	drug	82-91	false

DDI-DrugBank.d108.s1	In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.
MAO inhibitor	group	63-75	disulfiram	drug	82-91	effect

DDI-DrugBank.d108.s2	Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.
Isocarboxazid	drug	19-31	psychotropic agents	group	43-61	advise

DDI-DrugBank.d108.s5	The monoamine oxidase inhibitory effects of Isocarboxazid may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following Isocarboxazid.
Isocarboxazid	drug	44-56	Isocarboxazid	drug	205-217	false

DDI-DrugBank.d261.s0	Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
Tetracycline	drug	0-11	bacteriostatic antibiotic	group	16-40	false
Tetracycline	drug	0-11	penicillin	drug	85-94	effect
bacteriostatic antibiotic	group	16-40	penicillin	drug	85-94	false

DDI-DrugBank.d494.s0	Concomitant use with other calcium-containing medicines (including antacids) may cause too much calcium in the blood or urine, which may increase the chance of side effects.
calcium	drug	27-33	antacids	group	67-74	false
calcium	drug	27-33	calcium	drug	96-102	false
antacids	group	67-74	calcium	drug	96-102	false

DDI-DrugBank.d494.s1	Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.
calcium acetate	drug	6-20	digitalis glycosides	group	27-46	effect
calcium acetate	drug	6-20	calcium	drug	99-105	false
digitalis glycosides	group	27-46	calcium	drug	99-105	false

DDI-DrugBank.d475.s0	No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.
nizatidine	drug	43-52	theophylline	drug	58-69	false
nizatidine	drug	43-52	chlordiazepoxide	drug	72-87	false
nizatidine	drug	43-52	lorazepam	drug	90-98	false
nizatidine	drug	43-52	lidocaine	drug	101-109	false
nizatidine	drug	43-52	phenytoin	drug	112-120	false
nizatidine	drug	43-52	warfarin	drug	127-134	false
theophylline	drug	58-69	chlordiazepoxide	drug	72-87	false
theophylline	drug	58-69	lorazepam	drug	90-98	false
theophylline	drug	58-69	lidocaine	drug	101-109	false
theophylline	drug	58-69	phenytoin	drug	112-120	false
theophylline	drug	58-69	warfarin	drug	127-134	false
chlordiazepoxide	drug	72-87	lorazepam	drug	90-98	false
chlordiazepoxide	drug	72-87	lidocaine	drug	101-109	false
chlordiazepoxide	drug	72-87	phenytoin	drug	112-120	false
chlordiazepoxide	drug	72-87	warfarin	drug	127-134	false
lorazepam	drug	90-98	lidocaine	drug	101-109	false
lorazepam	drug	90-98	phenytoin	drug	112-120	false
lorazepam	drug	90-98	warfarin	drug	127-134	false
lidocaine	drug	101-109	phenytoin	drug	112-120	false
lidocaine	drug	101-109	warfarin	drug	127-134	false
phenytoin	drug	112-120	warfarin	drug	127-134	false

DDI-DrugBank.d475.s3	In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
aspirin	brand	47-53	salicylate	group	81-90	false
aspirin	brand	47-53	nizatidine	drug	114-123	mechanism
salicylate	group	81-90	nizatidine	drug	114-123	false

DDI-DrugBank.d456.s0	Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.
ketoconazole	drug	46-57	erlotinib	drug	69-77	mechanism

DDI-DrugBank.d456.s1	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
TARCEVA	brand	52-58	ketoconazole	drug	65-76	advise
TARCEVA	brand	52-58	atazanavir	drug	142-151	advise
TARCEVA	brand	52-58	clarithromycin	drug	154-167	advise
TARCEVA	brand	52-58	indinavir	drug	170-178	advise
TARCEVA	brand	52-58	itraconazole	drug	181-192	advise
TARCEVA	brand	52-58	nefazodone	drug	195-204	advise
TARCEVA	brand	52-58	nelfinavir	drug	207-216	advise
TARCEVA	brand	52-58	ritonavir	drug	219-227	advise
TARCEVA	brand	52-58	saquinavir	drug	230-239	advise
TARCEVA	brand	52-58	telithromycin	drug	242-254	advise
TARCEVA	brand	52-58	troleandomycin	drug	257-270	advise
TARCEVA	brand	52-58	TAO	drug	273-275	advise
TARCEVA	brand	52-58	voriconazole	drug	283-294	advise
ketoconazole	drug	65-76	atazanavir	drug	142-151	false
ketoconazole	drug	65-76	clarithromycin	drug	154-167	false
ketoconazole	drug	65-76	indinavir	drug	170-178	false
ketoconazole	drug	65-76	itraconazole	drug	181-192	false
ketoconazole	drug	65-76	nefazodone	drug	195-204	false
ketoconazole	drug	65-76	nelfinavir	drug	207-216	false
ketoconazole	drug	65-76	ritonavir	drug	219-227	false
ketoconazole	drug	65-76	saquinavir	drug	230-239	false
ketoconazole	drug	65-76	telithromycin	drug	242-254	false
ketoconazole	drug	65-76	troleandomycin	drug	257-270	false
ketoconazole	drug	65-76	TAO	drug	273-275	false
ketoconazole	drug	65-76	voriconazole	drug	283-294	false
atazanavir	drug	142-151	clarithromycin	drug	154-167	false
atazanavir	drug	142-151	indinavir	drug	170-178	false
atazanavir	drug	142-151	itraconazole	drug	181-192	false
atazanavir	drug	142-151	nefazodone	drug	195-204	false
atazanavir	drug	142-151	nelfinavir	drug	207-216	false
atazanavir	drug	142-151	ritonavir	drug	219-227	false
atazanavir	drug	142-151	saquinavir	drug	230-239	false
atazanavir	drug	142-151	telithromycin	drug	242-254	false
atazanavir	drug	142-151	troleandomycin	drug	257-270	false
atazanavir	drug	142-151	TAO	drug	273-275	false
atazanavir	drug	142-151	voriconazole	drug	283-294	false
clarithromycin	drug	154-167	indinavir	drug	170-178	false
clarithromycin	drug	154-167	itraconazole	drug	181-192	false
clarithromycin	drug	154-167	nefazodone	drug	195-204	false
clarithromycin	drug	154-167	nelfinavir	drug	207-216	false
clarithromycin	drug	154-167	ritonavir	drug	219-227	false
clarithromycin	drug	154-167	saquinavir	drug	230-239	false
clarithromycin	drug	154-167	telithromycin	drug	242-254	false
clarithromycin	drug	154-167	troleandomycin	drug	257-270	false
clarithromycin	drug	154-167	TAO	drug	273-275	false
clarithromycin	drug	154-167	voriconazole	drug	283-294	false
indinavir	drug	170-178	itraconazole	drug	181-192	false
indinavir	drug	170-178	nefazodone	drug	195-204	false
indinavir	drug	170-178	nelfinavir	drug	207-216	false
indinavir	drug	170-178	ritonavir	drug	219-227	false
indinavir	drug	170-178	saquinavir	drug	230-239	false
indinavir	drug	170-178	telithromycin	drug	242-254	false
indinavir	drug	170-178	troleandomycin	drug	257-270	false
indinavir	drug	170-178	TAO	drug	273-275	false
indinavir	drug	170-178	voriconazole	drug	283-294	false
itraconazole	drug	181-192	nefazodone	drug	195-204	false
itraconazole	drug	181-192	nelfinavir	drug	207-216	false
itraconazole	drug	181-192	ritonavir	drug	219-227	false
itraconazole	drug	181-192	saquinavir	drug	230-239	false
itraconazole	drug	181-192	telithromycin	drug	242-254	false
itraconazole	drug	181-192	troleandomycin	drug	257-270	false
itraconazole	drug	181-192	TAO	drug	273-275	false
itraconazole	drug	181-192	voriconazole	drug	283-294	false
nefazodone	drug	195-204	nelfinavir	drug	207-216	false
nefazodone	drug	195-204	ritonavir	drug	219-227	false
nefazodone	drug	195-204	saquinavir	drug	230-239	false
nefazodone	drug	195-204	telithromycin	drug	242-254	false
nefazodone	drug	195-204	troleandomycin	drug	257-270	false
nefazodone	drug	195-204	TAO	drug	273-275	false
nefazodone	drug	195-204	voriconazole	drug	283-294	false
nelfinavir	drug	207-216	ritonavir	drug	219-227	false
nelfinavir	drug	207-216	saquinavir	drug	230-239	false
nelfinavir	drug	207-216	telithromycin	drug	242-254	false
nelfinavir	drug	207-216	troleandomycin	drug	257-270	false
nelfinavir	drug	207-216	TAO	drug	273-275	false
nelfinavir	drug	207-216	voriconazole	drug	283-294	false
ritonavir	drug	219-227	saquinavir	drug	230-239	false
ritonavir	drug	219-227	telithromycin	drug	242-254	false
ritonavir	drug	219-227	troleandomycin	drug	257-270	false
ritonavir	drug	219-227	TAO	drug	273-275	false
ritonavir	drug	219-227	voriconazole	drug	283-294	false
saquinavir	drug	230-239	telithromycin	drug	242-254	false
saquinavir	drug	230-239	troleandomycin	drug	257-270	false
saquinavir	drug	230-239	TAO	drug	273-275	false
saquinavir	drug	230-239	voriconazole	drug	283-294	false
telithromycin	drug	242-254	troleandomycin	drug	257-270	false
telithromycin	drug	242-254	TAO	drug	273-275	false
telithromycin	drug	242-254	voriconazole	drug	283-294	false
troleandomycin	drug	257-270	TAO	drug	273-275	false
troleandomycin	drug	257-270	voriconazole	drug	283-294	false
TAO	drug	273-275	voriconazole	drug	283-294	false

DDI-DrugBank.d456.s2	Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.
rifampicin	drug	38-47	erlotinib	drug	59-67	mechanism

DDI-DrugBank.d456.s5	If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.
TARCEVA	brand	7-13	rifampicin	drug	97-106	advise

DDI-DrugBank.d456.s6	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.
rifabutin	drug	55-63	rifapentine	drug	66-76	false
rifabutin	drug	55-63	phenytoin	drug	79-87	false
rifabutin	drug	55-63	carbamazepine	drug	90-102	false
rifabutin	drug	55-63	phenobarbital	drug	105-117	false
rifapentine	drug	66-76	phenytoin	drug	79-87	false
rifapentine	drug	66-76	carbamazepine	drug	90-102	false
rifapentine	drug	66-76	phenobarbital	drug	105-117	false
phenytoin	drug	79-87	carbamazepine	drug	90-102	false
phenytoin	drug	79-87	phenobarbital	drug	105-117	false
carbamazepine	drug	90-102	phenobarbital	drug	105-117	false

DDI-DrugBank.d456.s13	Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR
warfarin	drug	16-23	coumarin-derivative anticoagulants	group	34-67	false

DDI-DrugBank.d199.s0	Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
Metoclopramide	drug	0-13	MONUROL	brand	41-47	false
Metoclopramide	drug	0-13	metoclopramide	drug	50-63	false
Metoclopramide	drug	0-13	fosfomycin	drug	172-181	false
MONUROL	brand	41-47	metoclopramide	drug	50-63	mechanism
MONUROL	brand	41-47	fosfomycin	drug	172-181	false
metoclopramide	drug	50-63	fosfomycin	drug	172-181	false

DDI-DrugBank.d199.s2	Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.
Cimetidine	drug	0-9	Cimetidine	drug	12-21	false
Cimetidine	drug	0-9	fosfomycin	drug	63-72	false
Cimetidine	drug	0-9	MONUROL	brand	99-105	false
Cimetidine	drug	12-21	fosfomycin	drug	63-72	false
Cimetidine	drug	12-21	MONUROL	brand	99-105	false
fosfomycin	drug	63-72	MONUROL	brand	99-105	false

DDI-DrugBank.d6.s2	If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.
Enflurane	drug	145-153	halothane	drug	165-173	false
Enflurane	drug	145-153	nitrous oxide	drug	178-190	false
halothane	drug	165-173	nitrous oxide	drug	178-190	false

DDI-DrugBank.d223.s2	Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	group	69-93	TCAs	group	96-99	false

DDI-DrugBank.d223.s7	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	drug	0-9	antidepressants	group	66-80	false
cimetidine	drug	0-9	phenothiazines	group	83-96	false
cimetidine	drug	0-9	Type 1C antiarrhythmics	group	107-129	false
cimetidine	drug	0-9	propafenone	drug	131-141	false
cimetidine	drug	0-9	flecainide	drug	147-156	false
antidepressants	group	66-80	phenothiazines	group	83-96	false
antidepressants	group	66-80	Type 1C antiarrhythmics	group	107-129	false
antidepressants	group	66-80	propafenone	drug	131-141	false
antidepressants	group	66-80	flecainide	drug	147-156	false
phenothiazines	group	83-96	Type 1C antiarrhythmics	group	107-129	false
phenothiazines	group	83-96	propafenone	drug	131-141	false
phenothiazines	group	83-96	flecainide	drug	147-156	false
Type 1C antiarrhythmics	group	107-129	propafenone	drug	131-141	false
Type 1C antiarrhythmics	group	107-129	flecainide	drug	147-156	false
propafenone	drug	131-141	flecainide	drug	147-156	false

DDI-DrugBank.d223.s8	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	group	14-52	SSRIs	group	55-59	false
selective serotonin reuptake inhibitors	group	14-52	citalopram	drug	69-78	false
selective serotonin reuptake inhibitors	group	14-52	escitalopram	drug	81-92	false
selective serotonin reuptake inhibitors	group	14-52	fluoxetine	drug	95-104	false
selective serotonin reuptake inhibitors	group	14-52	sertraline	drug	107-116	false
selective serotonin reuptake inhibitors	group	14-52	paroxetine	drug	123-132	false
SSRIs	group	55-59	citalopram	drug	69-78	false
SSRIs	group	55-59	escitalopram	drug	81-92	false
SSRIs	group	55-59	fluoxetine	drug	95-104	false
SSRIs	group	55-59	sertraline	drug	107-116	false
SSRIs	group	55-59	paroxetine	drug	123-132	false
citalopram	drug	69-78	escitalopram	drug	81-92	false
citalopram	drug	69-78	fluoxetine	drug	95-104	false
citalopram	drug	69-78	sertraline	drug	107-116	false
citalopram	drug	69-78	paroxetine	drug	123-132	false
escitalopram	drug	81-92	fluoxetine	drug	95-104	false
escitalopram	drug	81-92	sertraline	drug	107-116	false
escitalopram	drug	81-92	paroxetine	drug	123-132	false
fluoxetine	drug	95-104	sertraline	drug	107-116	false
fluoxetine	drug	95-104	paroxetine	drug	123-132	false
sertraline	drug	107-116	paroxetine	drug	123-132	false

DDI-DrugBank.d223.s9	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	group	20-23	TCA	group	25-27	int
SSRI	group	20-23	SSRI	group	141-144	false
TCA	group	25-27	SSRI	group	141-144	false

DDI-DrugBank.d223.s10	Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
TCAs	group	63-66	SSRIs	group	84-88	advise

DDI-DrugBank.d223.s12	Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	group	19-43	tricyclic antidepressant	group	156-179	false

DDI-DrugBank.d223.s14	It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
TCA	group	27-29	TCA	group	56-58	false

DDI-DrugBank.d223.s16	Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
quinidine	drug	42-50	selective serotonin reuptake inhibitors	group	53-91	false
quinidine	drug	42-50	SSRIs	group	94-98	false
quinidine	drug	42-50	doxepin	drug	143-149	mechanism
selective serotonin reuptake inhibitors	group	53-91	SSRIs	group	94-98	false
selective serotonin reuptake inhibitors	group	53-91	doxepin	drug	143-149	mechanism
SSRIs	group	94-98	doxepin	drug	143-149	mechanism

DDI-DrugBank.d223.s19	MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors.
MAO Inhibitors	group	0-13	MAO inhibitors	group	123-136	false

DDI-DrugBank.d223.s20	Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN.
MAO inhibitors	group	11-24	SINEQUAN	brand	117-124	advise

DDI-DrugBank.d223.s22	Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.
Cimetidine	drug	0-9	Cimetidine	drug	12-21	false
Cimetidine	drug	0-9	tricyclic antidepressants	group	136-160	false
Cimetidine	drug	12-21	tricyclic antidepressants	group	136-160	mechanism

DDI-DrugBank.d223.s23	Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.
tricyclic antidepressant	group	156-179	cimetidine	drug	186-195	effect

DDI-DrugBank.d223.s24	Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.
tricyclic antidepressant	group	35-58	cimetidine	drug	133-142	mechanism

DDI-DrugBank.d223.s25	In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.
tricyclic antidepressants	group	60-84	cimetidine	drug	107-116	false
tricyclic antidepressants	group	60-84	cimetidine	drug	146-155	false
tricyclic antidepressants	group	60-84	tricyclic antidepressant	group	218-241	false
cimetidine	drug	107-116	cimetidine	drug	146-155	false
cimetidine	drug	107-116	tricyclic antidepressant	group	218-241	false
cimetidine	drug	146-155	tricyclic antidepressant	group	218-241	mechanism

DDI-DrugBank.d223.s26	Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.
Alcohol	drug	0-6	alcohol	drug	41-47	false
Alcohol	drug	0-6	SINEQUAN	brand	128-135	false
alcohol	drug	41-47	SINEQUAN	brand	128-135	mechanism

DDI-DrugBank.d223.s28	Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
Tolazamide	drug	0-9	tolazamide	drug	104-113	false
Tolazamide	drug	0-9	doxepin	drug	156-162	false
tolazamide	drug	104-113	doxepin	drug	156-162	effect

DDI-DrugBank.d51.s0	ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, and steroids, commonly used in the treatment of chronic obstructive pulmonary disease.
ATROVENT	brand	0-7	sympathomimetic bronchodilators	group	84-114	false
ATROVENT	brand	0-7	methylxanthines	group	117-131	false
ATROVENT	brand	0-7	steroids	group	138-145	false
sympathomimetic bronchodilators	group	84-114	methylxanthines	group	117-131	false
sympathomimetic bronchodilators	group	84-114	steroids	group	138-145	false
methylxanthines	group	117-131	steroids	group	138-145	false

DDI-DrugBank.d51.s1	With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT Inhalation Aerosol and these drugs with respect to effectiveness.
albuterol	drug	22-30	ATROVENT	brand	105-112	false

DDI-DrugBank.d51.s2	Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
Anticholinergic agents	group	0-21	ipratropium bromide	drug	33-51	false
Anticholinergic agents	group	0-21	anticholinergic medications	group	182-208	false
ipratropium bromide	drug	33-51	anticholinergic medications	group	182-208	effect

DDI-DrugBank.d51.s3	Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.
ATROVENT	brand	56-63	anticholinergic	group	95-109	advise

DDI-DrugBank.d417.s0	Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
Netilmicin	drug	0-9	loop diuretics	group	64-77	advise
Netilmicin	drug	0-9	furosemide	drug	87-96	advise
Netilmicin	drug	0-9	ethacrynic acid	drug	102-116	advise
loop diuretics	group	64-77	furosemide	drug	87-96	false
loop diuretics	group	64-77	ethacrynic acid	drug	102-116	false
furosemide	drug	87-96	ethacrynic acid	drug	102-116	false

DDI-DrugBank.d288.s0	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).
TAXOL	brand	45-49	cisplatin	drug	71-79	false
TAXOL	brand	45-49	TAXOL	brand	169-173	false
TAXOL	brand	45-49	cisplatin	drug	191-199	false
TAXOL	brand	45-49	TAXOL	brand	239-243	false
TAXOL	brand	45-49	cisplatin	drug	252-260	false
cisplatin	drug	71-79	TAXOL	brand	169-173	false
cisplatin	drug	71-79	cisplatin	drug	191-199	false
cisplatin	drug	71-79	TAXOL	brand	239-243	false
cisplatin	drug	71-79	cisplatin	drug	252-260	false
TAXOL	brand	169-173	cisplatin	drug	191-199	effect
TAXOL	brand	169-173	TAXOL	brand	239-243	false
TAXOL	brand	169-173	cisplatin	drug	252-260	false
cisplatin	drug	191-199	TAXOL	brand	239-243	false
cisplatin	drug	191-199	cisplatin	drug	252-260	false
TAXOL	brand	239-243	cisplatin	drug	252-260	false

DDI-DrugBank.d288.s1	Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.
paclitaxel	drug	68-77	TAXOL	brand	115-119	false
paclitaxel	drug	68-77	cisplatin	drug	148-156	false
TAXOL	brand	115-119	cisplatin	drug	148-156	mechanism

DDI-DrugBank.d288.s4	Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
TAXOL	brand	31-35	protease inhibitors	group	65-83	false
TAXOL	brand	31-35	ritonavir	drug	86-94	false
TAXOL	brand	31-35	saquinavir	drug	97-106	false
TAXOL	brand	31-35	indinavir	drug	109-117	false
TAXOL	brand	31-35	nelfinavir	drug	124-133	false
protease inhibitors	group	65-83	ritonavir	drug	86-94	false
protease inhibitors	group	65-83	saquinavir	drug	97-106	false
protease inhibitors	group	65-83	indinavir	drug	109-117	false
protease inhibitors	group	65-83	nelfinavir	drug	124-133	false
ritonavir	drug	86-94	saquinavir	drug	97-106	false
ritonavir	drug	86-94	indinavir	drug	109-117	false
ritonavir	drug	86-94	nelfinavir	drug	124-133	false
saquinavir	drug	97-106	indinavir	drug	109-117	false
saquinavir	drug	97-106	nelfinavir	drug	124-133	false
indinavir	drug	109-117	nelfinavir	drug	124-133	false

DDI-DrugBank.d288.s5	Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
doxorubicin	drug	56-66	doxorubicinol	drug_n	95-107	false
doxorubicin	drug	56-66	paclitaxel	drug	132-141	false
doxorubicin	drug	56-66	doxorubicin	drug	147-157	false
doxorubicinol	drug_n	95-107	paclitaxel	drug	132-141	false
doxorubicinol	drug_n	95-107	doxorubicin	drug	147-157	false
paclitaxel	drug	132-141	doxorubicin	drug	147-157	mechanism

DDI-DrugBank.d288.s11	Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.
cyclosporin	drug	131-141	teniposide	drug	173-182	false
cyclosporin	drug	131-141	TAXOL	brand	238-242	advise
teniposide	drug	173-182	TAXOL	brand	238-242	advise

DDI-DrugBank.d288.s12	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).
TAXOL	brand	97-101	corticosteroids	group	131-145	false
TAXOL	brand	97-101	dexamethasone	drug	156-168	false
TAXOL	brand	97-101	H2 antagonists	group	193-206	false
TAXOL	brand	97-101	cimetidine	drug	217-226	false
TAXOL	brand	97-101	ranitidine	drug	231-240	false
corticosteroids	group	131-145	dexamethasone	drug	156-168	false
corticosteroids	group	131-145	H2 antagonists	group	193-206	false
corticosteroids	group	131-145	cimetidine	drug	217-226	false
corticosteroids	group	131-145	ranitidine	drug	231-240	false
dexamethasone	drug	156-168	H2 antagonists	group	193-206	false
dexamethasone	drug	156-168	cimetidine	drug	217-226	false
dexamethasone	drug	156-168	ranitidine	drug	231-240	false
H2 antagonists	group	193-206	cimetidine	drug	217-226	false
H2 antagonists	group	193-206	ranitidine	drug	231-240	false
cimetidine	drug	217-226	ranitidine	drug	231-240	false

DDI-DrugBank.d288.s14	However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.
bronchodilators	group	86-100	TAXOL	brand	177-181	false

DDI-DrugBank.d9.s0	Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
Azlocillin	drug	0-9	amikacin	drug	57-64	advise
Azlocillin	drug	0-9	ciprofloxacin	drug	67-79	advise
Azlocillin	drug	0-9	gentamicin	drug	82-91	advise
Azlocillin	drug	0-9	netilmicin	drug	94-103	advise
Azlocillin	drug	0-9	tobramycin	drug	109-118	advise
amikacin	drug	57-64	ciprofloxacin	drug	67-79	false
amikacin	drug	57-64	gentamicin	drug	82-91	false
amikacin	drug	57-64	netilmicin	drug	94-103	false
amikacin	drug	57-64	tobramycin	drug	109-118	false
ciprofloxacin	drug	67-79	gentamicin	drug	82-91	false
ciprofloxacin	drug	67-79	netilmicin	drug	94-103	false
ciprofloxacin	drug	67-79	tobramycin	drug	109-118	false
gentamicin	drug	82-91	netilmicin	drug	94-103	false
gentamicin	drug	82-91	tobramycin	drug	109-118	false
netilmicin	drug	94-103	tobramycin	drug	109-118	false

DDI-DrugBank.d389.s0	Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
Antihistamines	group	0-13	tricyclic antidepressants	group	42-66	effect
Antihistamines	group	0-13	barbiturates	group	69-80	effect
Antihistamines	group	0-13	alcohol	drug	83-89	effect
Antihistamines	group	0-13	CNS depressants	group	102-116	effect
tricyclic antidepressants	group	42-66	barbiturates	group	69-80	false
tricyclic antidepressants	group	42-66	alcohol	drug	83-89	false
tricyclic antidepressants	group	42-66	CNS depressants	group	102-116	false
barbiturates	group	69-80	alcohol	drug	83-89	false
barbiturates	group	69-80	CNS depressants	group	102-116	false
alcohol	drug	83-89	CNS depressants	group	102-116	false

DDI-DrugBank.d389.s1	MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
MAO inhibitors	group	0-13	antihistamines	group	68-81	effect

DDI-DrugBank.d389.s2	Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
Sympathomimetic amines	group	0-21	reserpine	drug	66-74	effect
Sympathomimetic amines	group	0-21	veratrum alkaloids	group	77-94	effect
Sympathomimetic amines	group	0-21	methyldopa	drug	97-106	effect
Sympathomimetic amines	group	0-21	mecamylamine	drug	112-123	effect
reserpine	drug	66-74	veratrum alkaloids	group	77-94	false
reserpine	drug	66-74	methyldopa	drug	97-106	false
reserpine	drug	66-74	mecamylamine	drug	112-123	false
veratrum alkaloids	group	77-94	methyldopa	drug	97-106	false
veratrum alkaloids	group	77-94	mecamylamine	drug	112-123	false
methyldopa	drug	97-106	mecamylamine	drug	112-123	false

DDI-DrugBank.d389.s3	Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
sympathomimetics	group	11-26	MAO inhibitors	group	47-60	effect
sympathomimetics	group	11-26	beta adrenergic blockers	group	66-89	effect
MAO inhibitors	group	47-60	beta adrenergic blockers	group	66-89	false

DDI-DrugBank.d474.s1	These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
anticoagulants	group	42-55	platelet inhibitors	group	58-76	false
anticoagulants	group	42-55	acetylsalicylic acid	drug	88-107	false
anticoagulants	group	42-55	NSAIDs	group	124-129	false
anticoagulants	group	42-55	ketorolac tromethamine	drug	142-163	false
anticoagulants	group	42-55	dipyridamole	drug	167-178	false
anticoagulants	group	42-55	sulfinpyrazone	drug	184-197	false
platelet inhibitors	group	58-76	acetylsalicylic acid	drug	88-107	false
platelet inhibitors	group	58-76	NSAIDs	group	124-129	false
platelet inhibitors	group	58-76	ketorolac tromethamine	drug	142-163	false
platelet inhibitors	group	58-76	dipyridamole	drug	167-178	false
platelet inhibitors	group	58-76	sulfinpyrazone	drug	184-197	false
acetylsalicylic acid	drug	88-107	NSAIDs	group	124-129	false
acetylsalicylic acid	drug	88-107	ketorolac tromethamine	drug	142-163	false
acetylsalicylic acid	drug	88-107	dipyridamole	drug	167-178	false
acetylsalicylic acid	drug	88-107	sulfinpyrazone	drug	184-197	false
NSAIDs	group	124-129	ketorolac tromethamine	drug	142-163	false
NSAIDs	group	124-129	dipyridamole	drug	167-178	false
NSAIDs	group	124-129	sulfinpyrazone	drug	184-197	false
ketorolac tromethamine	drug	142-163	dipyridamole	drug	167-178	false
ketorolac tromethamine	drug	142-163	sulfinpyrazone	drug	184-197	false
dipyridamole	drug	167-178	sulfinpyrazone	drug	184-197	false

DDI-DrugBank.d118.s0	In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.
thimerosal	drug_n	80-89	latanoprost	drug	106-116	false

DDI-DrugBank.d356.s0	When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.
amiloride	drug	5-13	angiotensin-converting enzyme inhibitor	group	57-95	effect

DDI-DrugBank.d356.s2	Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
Lithium	drug	0-6	diuretics	group	43-51	advise

DDI-DrugBank.d356.s4	In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
non-steroidal anti-inflammatory agent	group	42-78	loop diuretics	group	150-153;187-195	effect
non-steroidal anti-inflammatory agent	group	42-78	potassium-sparing diuretics	group	156-172;187-195	effect
non-steroidal anti-inflammatory agent	group	42-78	thiazide diuretics	group	178-195	effect
loop diuretics	group	150-153;187-195	potassium-sparing diuretics	group	156-172;187-195	false
loop diuretics	group	150-153;187-195	thiazide diuretics	group	178-195	false
potassium-sparing diuretics	group	156-172;187-195	thiazide diuretics	group	178-195	false

DDI-DrugBank.d356.s5	Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
MIDAMOR	brand	16-22	non-steroidal anti-inflammatory agents	group	28-65	advise
MIDAMOR	brand	16-22	diuretic	group	172-179	false
non-steroidal anti-inflammatory agents	group	28-65	diuretic	group	172-179	false

DDI-DrugBank.d356.s6	Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
indomethacin	drug	6-17	potassium-sparing diuretics	group	23-49	effect
indomethacin	drug	6-17	MIDAMOR	brand	62-68	effect
potassium-sparing diuretics	group	23-49	MIDAMOR	brand	62-68	false

DDI-DrugBank.d281.s0	Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.
Probenecid	drug	0-9	cephalosporins	group	51-64	mechanism
Probenecid	drug	0-9	cephalosporin	group	132-144	false
cephalosporins	group	51-64	cephalosporin	group	132-144	false

DDI-DrugBank.d128.s0	May interact with wthionamide (Trecator-SC) and isoniazid (Nydrazid).
Trecator-SC	brand	31-41	isoniazid	drug	48-56	false
Trecator-SC	brand	31-41	Nydrazid	brand	59-66	false
isoniazid	drug	48-56	Nydrazid	brand	59-66	false

DDI-DrugBank.d499.s1	The possibility of increased interaction should be kept in mind when Orudis doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.
Orudis	brand	69-74	ketoprofen	drug	131-140	false

DDI-DrugBank.d499.s3	Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.
Antacids	group	0-7	magnesium hydroxide	drug	40-58	false
Antacids	group	0-7	aluminum hydroxide	drug	64-81	false
Antacids	group	0-7	ketoprofen	drug	147-156	false
Antacids	group	0-7	Orudis	brand	174-179	false
magnesium hydroxide	drug	40-58	aluminum hydroxide	drug	64-81	false
magnesium hydroxide	drug	40-58	ketoprofen	drug	147-156	false
magnesium hydroxide	drug	40-58	Orudis	brand	174-179	false
aluminum hydroxide	drug	64-81	ketoprofen	drug	147-156	false
aluminum hydroxide	drug	64-81	Orudis	brand	174-179	false
ketoprofen	drug	147-156	Orudis	brand	174-179	false

DDI-DrugBank.d499.s5	Aspirin: Ketoprofen does not alter aspirin absorption;
Aspirin	brand	0-6	Ketoprofen	drug	9-18	false
Aspirin	brand	0-6	aspirin	brand	35-41	false
Ketoprofen	drug	9-18	aspirin	brand	35-41	false

DDI-DrugBank.d499.s6	however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.
aspirin	brand	72-78	ketoprofen	drug	90-99	mechanism
aspirin	brand	72-78	ketoprofen	drug	131-140	mechanism
aspirin	brand	72-78	aspirin	brand	184-190	false
aspirin	brand	72-78	aspirin	brand	212-218	false
ketoprofen	drug	90-99	ketoprofen	drug	131-140	false
ketoprofen	drug	90-99	aspirin	brand	184-190	false
ketoprofen	drug	90-99	aspirin	brand	212-218	false
ketoprofen	drug	131-140	aspirin	brand	184-190	false
ketoprofen	drug	131-140	aspirin	brand	212-218	false
aspirin	brand	184-190	aspirin	brand	212-218	false

DDI-DrugBank.d499.s8	Therefore, concurrent use of aspirin and ketoprofen is not recommended.
aspirin	brand	29-35	ketoprofen	drug	41-50	advise

DDI-DrugBank.d499.s10	Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
Diuretic	group	0-7	Hydrochlorothiazide	drug	10-28	false
Diuretic	group	0-7	ketoprofen	drug	56-65	false
Diuretic	group	0-7	hydrochlorothiazide	drug	145-163	false
Hydrochlorothiazide	drug	10-28	ketoprofen	drug	56-65	effect
Hydrochlorothiazide	drug	10-28	hydrochlorothiazide	drug	145-163	false
ketoprofen	drug	56-65	hydrochlorothiazide	drug	145-163	false

DDI-DrugBank.d499.s13	Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.
Digoxin	drug	0-6	ketoprofen	drug	71-80	false
Digoxin	drug	0-6	digoxin	drug	86-92	false
Digoxin	drug	0-6	ketoprofen	drug	127-136	false
Digoxin	drug	0-6	digoxin	drug	172-178	false
ketoprofen	drug	71-80	digoxin	drug	86-92	false
ketoprofen	drug	71-80	ketoprofen	drug	127-136	false
ketoprofen	drug	71-80	digoxin	drug	172-178	false
digoxin	drug	86-92	ketoprofen	drug	127-136	false
digoxin	drug	86-92	digoxin	drug	172-178	false
ketoprofen	drug	127-136	digoxin	drug	172-178	false

DDI-DrugBank.d499.s15	Warfarin: In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.
Warfarin	drug	0-7	ketoprofen	drug	68-77	false
Warfarin	drug	0-7	warfarin	drug	130-137	false
ketoprofen	drug	68-77	warfarin	drug	130-137	false

DDI-DrugBank.d499.s16	Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.
warfarin	drug	57-64	ketoprofen	drug	110-119	false

DDI-DrugBank.d499.s17	Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.
ketoprofen	drug	64-73	ketoprofen	drug	142-151	false
ketoprofen	drug	64-73	warfarin	drug	157-164	false
ketoprofen	drug	142-151	warfarin	drug	157-164	advise

DDI-DrugBank.d499.s19	Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
Probenecid	drug	0-9	Probenecid	drug	12-21	false
Probenecid	drug	0-9	ketoprofen	drug	53-62	false
Probenecid	drug	0-9	ketoprofen	drug	100-109	false
Probenecid	drug	12-21	ketoprofen	drug	53-62	mechanism
Probenecid	drug	12-21	ketoprofen	drug	100-109	false
ketoprofen	drug	53-62	ketoprofen	drug	100-109	false

DDI-DrugBank.d499.s20	Therefore, the combination of ketoprofen and probenecid is not recommended.
ketoprofen	drug	30-39	probenecid	drug	45-54	advise

DDI-DrugBank.d499.s22	Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
Methotrexate	drug	0-11	Ketoprofen	drug	14-23	false
Methotrexate	drug	0-11	NSAIDs	group	37-42	false
Methotrexate	drug	0-11	methotrexate	drug	85-96	false
Ketoprofen	drug	14-23	NSAIDs	group	37-42	false
Ketoprofen	drug	14-23	methotrexate	drug	85-96	mechanism
NSAIDs	group	37-42	methotrexate	drug	85-96	mechanism

DDI-DrugBank.d499.s24	Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.
Lithium	drug	0-6	Nonsteroidal anti-inflammatory agents	group	9-45	false
Lithium	drug	0-6	lithium	drug	97-103	false
Nonsteroidal anti-inflammatory agents	group	9-45	lithium	drug	97-103	mechanism

DDI-DrugBank.d499.s25	It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.
lithium	drug	30-36	ketoprofen	drug	63-72	false
lithium	drug	30-36	lithium	drug	97-103	false
ketoprofen	drug	63-72	lithium	drug	97-103	advise

DDI-DrugBank.d565.s1	Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
beta-blockers	group	105-117	digitalis	group	122-130	false
beta-blockers	group	105-117	Tiazac	brand	151-156	effect
digitalis	group	122-130	Tiazac	brand	151-156	effect

DDI-DrugBank.d565.s7	Controlled and uncontrolled domestic studies suggest that concomitant use of diltiazem hydrochloride and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.
diltiazem hydrochloride	drug	77-99	beta-blockers	group	105-117	false

DDI-DrugBank.d565.s8	Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
diltiazem hydrochloride	drug	18-40	propranolol	drug	61-71	mechanism
diltiazem hydrochloride	drug	18-40	propranolol	drug	121-131	false
diltiazem hydrochloride	drug	18-40	propranolol	drug	179-189	false
propranolol	drug	61-71	propranolol	drug	121-131	false
propranolol	drug	61-71	propranolol	drug	179-189	false
propranolol	drug	121-131	propranolol	drug	179-189	false

DDI-DrugBank.d565.s9	In vitro, propranolol appears to be displaced from its binding sites by diltiazem.
propranolol	drug	10-20	diltiazem	drug	72-80	mechanism

DDI-DrugBank.d565.s10	If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted.
propranolol	drug	69-79	propranolol	drug	103-113	false

DDI-DrugBank.d565.s12	A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.
diltiazem	drug	75-83	cimetidine	drug	144-153	false
diltiazem	drug	75-83	diltiazem	drug	188-196	false
cimetidine	drug	144-153	diltiazem	drug	188-196	mechanism

DDI-DrugBank.d565.s14	The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.
cimetidine	drug	30-39	diltiazem	drug	151-159	mechanism

DDI-DrugBank.d565.s15	Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.
diltiazem	drug	29-37	cimetidine	drug	163-172	advise

DDI-DrugBank.d565.s18	Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
diltiazem hydrochloride	drug	18-40	digoxin	drug	47-53	mechanism
diltiazem hydrochloride	drug	18-40	digoxin	drug	100-106	false
digoxin	drug	47-53	digoxin	drug	100-106	false

DDI-DrugBank.d565.s20	Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.
digoxin	drug	66-72	digoxin	drug	105-111	false
digoxin	drug	66-72	diltiazem hydrochloride	drug	179-201	false
digoxin	drug	105-111	diltiazem hydrochloride	drug	179-201	advise

DDI-DrugBank.d565.s22	The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.
anesthetics	group	121-131	calcium channel blockers	group	155-178	effect

DDI-DrugBank.d565.s23	When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.
anesthetics	group	25-35	calcium channel blockers	group	41-64	advise

DDI-DrugBank.d565.s25	A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.
diltiazem	drug	38-46	cyclosporine	drug	52-63	int

DDI-DrugBank.d565.s26	In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.
cyclosporine	drug	59-70	cyclosporine	drug	127-138	false
cyclosporine	drug	59-70	diltiazem	drug	209-217	mechanism
cyclosporine	drug	127-138	diltiazem	drug	209-217	false

DDI-DrugBank.d565.s27	If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
cyclosporine	drug	53-64	diltiazem	drug	118-126	advise

DDI-DrugBank.d565.s28	The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.
cyclosporine	drug	14-25	diltiazem	drug	30-38	false

DDI-DrugBank.d565.s30	Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
diltiazem	drug	30-38	carbamazepine	drug	45-57	mechanism
diltiazem	drug	30-38	carbamazepine	drug	115-127	false
carbamazepine	drug	45-57	carbamazepine	drug	115-127	false

DDI-DrugBank.d565.s33	Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
diltiazem	drug	20-28	midazolam	drug	51-59	mechanism
diltiazem	drug	20-28	triazolam	drug	65-73	mechanism
midazolam	drug	51-59	triazolam	drug	65-73	false

DDI-DrugBank.d565.s34	The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
midazolam	drug	29-37	triazolam	drug	43-51	false
midazolam	drug	29-37	diltiazem	drug	112-120	mechanism
triazolam	drug	43-51	diltiazem	drug	112-120	mechanism

DDI-DrugBank.d565.s35	These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
diltiazem	drug	42-50	midazolam	drug	144-152	effect
diltiazem	drug	42-50	triazolam	drug	158-166	effect
midazolam	drug	144-152	triazolam	drug	158-166	false

DDI-DrugBank.d565.s37	In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
diltiazem	drug	44-52	lovastatin	drug	72-81	mechanism
diltiazem	drug	44-52	lovastatin	drug	124-133	false
diltiazem	drug	44-52	lovastatin	drug	152-161	false
lovastatin	drug	72-81	lovastatin	drug	124-133	false
lovastatin	drug	72-81	lovastatin	drug	152-161	false
lovastatin	drug	124-133	lovastatin	drug	152-161	false

DDI-DrugBank.d565.s38	no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.
pravastatin	drug	13-23	diltiazem	drug	58-66	false

DDI-DrugBank.d565.s39	Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.
Diltiazem	drug	0-8	lovastatin	drug	59-68	false
Diltiazem	drug	0-8	pravastatin	drug	73-83	false
lovastatin	drug	59-68	pravastatin	drug	73-83	false

DDI-DrugBank.d565.s41	Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.
rifampin	drug	20-27	diltiazem	drug	34-42	mechanism
rifampin	drug	20-27	diltiazem	drug	56-64	false
diltiazem	drug	34-42	diltiazem	drug	56-64	false

DDI-DrugBank.d565.s42	Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
diltiazem	drug	20-28	rifampin	drug	35-42	advise

DDI-DrugBank.d103.s0	Short-Acting beta2-agonists: Aerosol bronchodilators of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using formoterol.
Short-Acting beta2-agonists	group	0-26	bronchodilators	group	37-51	false
Short-Acting beta2-agonists	group	0-26	formoterol	drug	159-168	false
bronchodilators	group	37-51	formoterol	drug	159-168	false

DDI-DrugBank.d103.s2	Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.
sympathomimetic agents	group	36-57	FORADIL	brand	101-107	effect

DDI-DrugBank.d103.s3	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
Monoamine Oxidase Inhibitors	group	0-27	Tricyclic Antidepressants	group	33-57	false
Monoamine Oxidase Inhibitors	group	0-27	FORADIL	brand	60-66	false
Monoamine Oxidase Inhibitors	group	0-27	monoamine oxidase inhibitors	group	143-170	false
Monoamine Oxidase Inhibitors	group	0-27	tricyclic antidepressants	group	175-199	false
Monoamine Oxidase Inhibitors	group	0-27	formoterol	drug	223-232	false
Tricyclic Antidepressants	group	33-57	FORADIL	brand	60-66	false
Tricyclic Antidepressants	group	33-57	monoamine oxidase inhibitors	group	143-170	false
Tricyclic Antidepressants	group	33-57	tricyclic antidepressants	group	175-199	false
Tricyclic Antidepressants	group	33-57	formoterol	drug	223-232	false
FORADIL	brand	60-66	monoamine oxidase inhibitors	group	143-170	advise
FORADIL	brand	60-66	tricyclic antidepressants	group	175-199	advise
FORADIL	brand	60-66	formoterol	drug	223-232	false
monoamine oxidase inhibitors	group	143-170	tricyclic antidepressants	group	175-199	false
monoamine oxidase inhibitors	group	143-170	formoterol	drug	223-232	false
tricyclic antidepressants	group	175-199	formoterol	drug	223-232	false

DDI-DrugBank.d103.s4	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
Corticosteroids	group	0-14	Methylxanthines	group	17-31	false
Corticosteroids	group	0-14	Diuretics	group	37-45	false
Corticosteroids	group	0-14	xanthine derivatives	group	75-94	false
Corticosteroids	group	0-14	steroids	group	97-104	false
Corticosteroids	group	0-14	diuretics	group	110-118	false
Corticosteroids	group	0-14	beta2-agonists.	group	169-183	false
Methylxanthines	group	17-31	Diuretics	group	37-45	false
Methylxanthines	group	17-31	xanthine derivatives	group	75-94	false
Methylxanthines	group	17-31	steroids	group	97-104	false
Methylxanthines	group	17-31	diuretics	group	110-118	false
Methylxanthines	group	17-31	beta2-agonists.	group	169-183	false
Diuretics	group	37-45	xanthine derivatives	group	75-94	false
Diuretics	group	37-45	steroids	group	97-104	false
Diuretics	group	37-45	diuretics	group	110-118	false
Diuretics	group	37-45	beta2-agonists.	group	169-183	false
xanthine derivatives	group	75-94	steroids	group	97-104	false
xanthine derivatives	group	75-94	diuretics	group	110-118	false
xanthine derivatives	group	75-94	beta2-agonists.	group	169-183	effect
steroids	group	97-104	diuretics	group	110-118	false
steroids	group	97-104	beta2-agonists.	group	169-183	effect
diuretics	group	110-118	beta2-agonists.	group	169-183	effect

DDI-DrugBank.d103.s8	Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
quinidine	drug	26-34	disopyramide	drug	37-48	false
quinidine	drug	26-34	procainamide	drug	51-62	false
quinidine	drug	26-34	phenothiazines	group	65-78	false
quinidine	drug	26-34	antihistamines	group	81-94	false
quinidine	drug	26-34	tricyclic antidepressants	group	101-125	false
disopyramide	drug	37-48	procainamide	drug	51-62	false
disopyramide	drug	37-48	phenothiazines	group	65-78	false
disopyramide	drug	37-48	antihistamines	group	81-94	false
disopyramide	drug	37-48	tricyclic antidepressants	group	101-125	false
procainamide	drug	51-62	phenothiazines	group	65-78	false
procainamide	drug	51-62	antihistamines	group	81-94	false
procainamide	drug	51-62	tricyclic antidepressants	group	101-125	false
phenothiazines	group	65-78	antihistamines	group	81-94	false
phenothiazines	group	65-78	tricyclic antidepressants	group	101-125	false
antihistamines	group	81-94	tricyclic antidepressants	group	101-125	false

DDI-DrugBank.d103.s10	It is important that patients understand how to use FORADIL  (formoterol fumarate) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.
FORADIL	brand	52-58	formoterol fumarate	drug	62-80	false

DDI-DrugBank.d103.s15	Acute symptoms should be treated with a short-acting, inhaled  beta2-agonist such as salbutamol (the physician should provide the patient with such medication and instruct the patient in how it should be used).
beta2-agonist	group	63-75	salbutamol	drug	85-94	false

DDI-DrugBank.d103.s20	FORADIL should not be used as a substitute for oral or inhaled corticosteroids.
FORADIL	brand	0-6	corticosteroids	group	63-77	false

DDI-DrugBank.d103.s26	Guardians of children who have been prescribed FORADIL should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of short-acting  beta2-agonists.
FORADIL	brand	47-53	short-acting  beta2-agonists	group	196-223	false

DDI-DrugBank.d493.s0	Methotrexate: HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX.
Methotrexate	drug	0-11	HUMIRA	brand	14-19	false
Methotrexate	drug	0-11	MTX	drug	90-92	false
HUMIRA	brand	14-19	MTX	drug	90-92	false

DDI-DrugBank.d493.s1	The data do not suggest the need for dose adjustment of either HUMIRA or MTX.
HUMIRA	brand	63-68	MTX	drug	73-75	false

DDI-DrugBank.d493.s2	Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
Anakinra	drug	0-7	anakinra	drug	39-46	false
Anakinra	drug	0-7	interleukin-1 antagonist	group	52-75	false
Anakinra	drug	0-7	TNF-blocking agent	group	90-107	false
anakinra	drug	39-46	interleukin-1 antagonist	group	52-75	false
anakinra	drug	39-46	TNF-blocking agent	group	90-107	effect
interleukin-1 antagonist	group	52-75	TNF-blocking agent	group	90-107	effect

DDI-DrugBank.d493.s3	The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.
anakinra	drug	27-34	HUMIRA	brand	61-66	false

DDI-DrugBank.d493.s4	Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
anakinra	drug	30-37	TNF-blocking agents	group	50-68	effect
anakinra	drug	30-37	HUMIRA	brand	81-86	effect
TNF-blocking agents	group	50-68	HUMIRA	brand	81-86	false

DDI-DrugBank.d10.s1	Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.
corticosteroid	group	93-106	ACTH	drug	111-114	false
corticosteroid	group	93-106	Betaseron	brand	219-227	false
ACTH	drug	111-114	Betaseron	brand	219-227	false

DDI-DrugBank.d10.s2	Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.
Betaseron	brand	0-8	antipyrine	drug	128-137	mechanism
Betaseron	brand	0-8	Betaseron	brand	211-219	false
antipyrine	drug	128-137	Betaseron	brand	211-219	false

DDI-DrugBank.d286.s0	Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
Ethoxzolamide	drug	0-12	tricyclics	group	41-50	effect
Ethoxzolamide	drug	0-12	amphetamines	group	53-64	effect
Ethoxzolamide	drug	0-12	procainamide	drug	67-78	effect
Ethoxzolamide	drug	0-12	quinidine	drug	85-93	effect
tricyclics	group	41-50	amphetamines	group	53-64	false
tricyclics	group	41-50	procainamide	drug	67-78	false
tricyclics	group	41-50	quinidine	drug	85-93	false
amphetamines	group	53-64	procainamide	drug	67-78	false
amphetamines	group	53-64	quinidine	drug	85-93	false
procainamide	drug	67-78	quinidine	drug	85-93	false

DDI-DrugBank.d286.s1	It may increase excretion of barbiturates, lithium, and ASA and may also increase the toxicity of salicylates.
barbiturates	group	29-40	lithium	drug	43-49	false
barbiturates	group	29-40	ASA	drug	56-58	false
barbiturates	group	29-40	salicylates	group	98-108	false
lithium	drug	43-49	ASA	drug	56-58	false
lithium	drug	43-49	salicylates	group	98-108	false
ASA	drug	56-58	salicylates	group	98-108	false

DDI-DrugBank.d286.s2	Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
ethoxzolamide	drug	20-32	diuretics	group	45-53	effect
ethoxzolamide	drug	20-32	amphotericin B	drug	56-69	effect
ethoxzolamide	drug	20-32	corticosteroids	group	76-90	effect
diuretics	group	45-53	amphotericin B	drug	56-69	false
diuretics	group	45-53	corticosteroids	group	76-90	false
amphotericin B	drug	56-69	corticosteroids	group	76-90	false

DDI-DrugBank.d514.s0	Opioids are strong central nervous system depressants, but regular users develop physiological tolerance allowing gradually increased dosages.
Opioids	group	0-6	central nervous system depressants	group	19-52	false

DDI-DrugBank.d514.s1	In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.
central nervous system depressants	group	26-59	heroin	drug_n	62-67	effect

DDI-DrugBank.d514.s2	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
heroin	drug_n	22-27	central nervous system depressants	group	81-114	effect
heroin	drug_n	22-27	alcohol	drug	127-133	effect
heroin	drug_n	22-27	benzodiazepines	group	136-150	effect
heroin	drug_n	22-27	diazepam	drug	160-167	effect
heroin	drug_n	22-27	Valium	brand	170-175	effect
heroin	drug_n	22-27	methadone	drug	204-212	effect
central nervous system depressants	group	81-114	alcohol	drug	127-133	false
central nervous system depressants	group	81-114	benzodiazepines	group	136-150	false
central nervous system depressants	group	81-114	diazepam	drug	160-167	false
central nervous system depressants	group	81-114	Valium	brand	170-175	false
central nervous system depressants	group	81-114	methadone	drug	204-212	false
alcohol	drug	127-133	benzodiazepines	group	136-150	false
alcohol	drug	127-133	diazepam	drug	160-167	false
alcohol	drug	127-133	Valium	brand	170-175	false
alcohol	drug	127-133	methadone	drug	204-212	false
benzodiazepines	group	136-150	diazepam	drug	160-167	false
benzodiazepines	group	136-150	Valium	brand	170-175	false
benzodiazepines	group	136-150	methadone	drug	204-212	false
diazepam	drug	160-167	Valium	brand	170-175	false
diazepam	drug	160-167	methadone	drug	204-212	false
Valium	brand	170-175	methadone	drug	204-212	false

DDI-DrugBank.d514.s3	Ironically, benzodiazepines are often used in the treatment of heroin addiction while they cause much more severe withdrawal symptoms.
benzodiazepines	group	12-26	heroin	drug	63-68	false

DDI-DrugBank.d514.s4	Cocaine sometimes proves to be fatal when used in combination with heroin.
Cocaine	drug	0-6	heroin	drug_n	67-72	effect

DDI-DrugBank.d566.s0	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
Cholestyramine	drug	0-13	resin	group	15-19	false
Cholestyramine	drug	0-13	phenylbutazone	group	95-108	mechanism
Cholestyramine	drug	0-13	warfarin	drug	111-118	mechanism
Cholestyramine	drug	0-13	thiazide diuretics	group	121-138	mechanism
Cholestyramine	drug	0-13	propranolol	drug	152-162	mechanism
Cholestyramine	drug	0-13	tetracycline	drug	184-195	mechanism
Cholestyramine	drug	0-13	penicillin G	drug	197-208	mechanism
Cholestyramine	drug	0-13	phenobarbital	drug	211-223	mechanism
Cholestyramine	drug	0-13	thyroxine	drug	238-246	mechanism
Cholestyramine	drug	0-13	estrogens	group	262-270	mechanism
Cholestyramine	drug	0-13	progestins	group	276-285	mechanism
Cholestyramine	drug	0-13	digitalis	group	292-300	mechanism
resin	group	15-19	phenylbutazone	group	95-108	false
resin	group	15-19	warfarin	drug	111-118	false
resin	group	15-19	thiazide diuretics	group	121-138	false
resin	group	15-19	propranolol	drug	152-162	false
resin	group	15-19	tetracycline	drug	184-195	false
resin	group	15-19	penicillin G	drug	197-208	false
resin	group	15-19	phenobarbital	drug	211-223	false
resin	group	15-19	thyroxine	drug	238-246	false
resin	group	15-19	estrogens	group	262-270	false
resin	group	15-19	progestins	group	276-285	false
resin	group	15-19	digitalis	group	292-300	false
phenylbutazone	group	95-108	warfarin	drug	111-118	false
phenylbutazone	group	95-108	thiazide diuretics	group	121-138	false
phenylbutazone	group	95-108	propranolol	drug	152-162	false
phenylbutazone	group	95-108	tetracycline	drug	184-195	false
phenylbutazone	group	95-108	penicillin G	drug	197-208	false
phenylbutazone	group	95-108	phenobarbital	drug	211-223	false
phenylbutazone	group	95-108	thyroxine	drug	238-246	false
phenylbutazone	group	95-108	estrogens	group	262-270	false
phenylbutazone	group	95-108	progestins	group	276-285	false
phenylbutazone	group	95-108	digitalis	group	292-300	false
warfarin	drug	111-118	thiazide diuretics	group	121-138	false
warfarin	drug	111-118	propranolol	drug	152-162	false
warfarin	drug	111-118	tetracycline	drug	184-195	false
warfarin	drug	111-118	penicillin G	drug	197-208	false
warfarin	drug	111-118	phenobarbital	drug	211-223	false
warfarin	drug	111-118	thyroxine	drug	238-246	false
warfarin	drug	111-118	estrogens	group	262-270	false
warfarin	drug	111-118	progestins	group	276-285	false
warfarin	drug	111-118	digitalis	group	292-300	false
thiazide diuretics	group	121-138	propranolol	drug	152-162	false
thiazide diuretics	group	121-138	tetracycline	drug	184-195	false
thiazide diuretics	group	121-138	penicillin G	drug	197-208	false
thiazide diuretics	group	121-138	phenobarbital	drug	211-223	false
thiazide diuretics	group	121-138	thyroxine	drug	238-246	false
thiazide diuretics	group	121-138	estrogens	group	262-270	false
thiazide diuretics	group	121-138	progestins	group	276-285	false
thiazide diuretics	group	121-138	digitalis	group	292-300	false
propranolol	drug	152-162	tetracycline	drug	184-195	false
propranolol	drug	152-162	penicillin G	drug	197-208	false
propranolol	drug	152-162	phenobarbital	drug	211-223	false
propranolol	drug	152-162	thyroxine	drug	238-246	false
propranolol	drug	152-162	estrogens	group	262-270	false
propranolol	drug	152-162	progestins	group	276-285	false
propranolol	drug	152-162	digitalis	group	292-300	false
tetracycline	drug	184-195	penicillin G	drug	197-208	false
tetracycline	drug	184-195	phenobarbital	drug	211-223	false
tetracycline	drug	184-195	thyroxine	drug	238-246	false
tetracycline	drug	184-195	estrogens	group	262-270	false
tetracycline	drug	184-195	progestins	group	276-285	false
tetracycline	drug	184-195	digitalis	group	292-300	false
penicillin G	drug	197-208	phenobarbital	drug	211-223	false
penicillin G	drug	197-208	thyroxine	drug	238-246	false
penicillin G	drug	197-208	estrogens	group	262-270	false
penicillin G	drug	197-208	progestins	group	276-285	false
penicillin G	drug	197-208	digitalis	group	292-300	false
phenobarbital	drug	211-223	thyroxine	drug	238-246	false
phenobarbital	drug	211-223	estrogens	group	262-270	false
phenobarbital	drug	211-223	progestins	group	276-285	false
phenobarbital	drug	211-223	digitalis	group	292-300	false
thyroxine	drug	238-246	estrogens	group	262-270	false
thyroxine	drug	238-246	progestins	group	276-285	false
thyroxine	drug	238-246	digitalis	group	292-300	false
estrogens	group	262-270	progestins	group	276-285	false
estrogens	group	262-270	digitalis	group	292-300	false
progestins	group	276-285	digitalis	group	292-300	false

DDI-DrugBank.d566.s2	Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
Cholestyramine	drug	0-13	resin	group	15-19	false
Cholestyramine	drug	0-13	cholestyramine	drug	132-145	false
Cholestyramine	drug	0-13	resin	group	147-151	false
Cholestyramine	drug	0-13	digitalis	group	219-227	false
Cholestyramine	drug	0-13	cholestyramine	drug	300-313	false
Cholestyramine	drug	0-13	resin	group	315-319	false
resin	group	15-19	cholestyramine	drug	132-145	false
resin	group	15-19	resin	group	147-151	false
resin	group	15-19	digitalis	group	219-227	false
resin	group	15-19	cholestyramine	drug	300-313	false
resin	group	15-19	resin	group	315-319	false
cholestyramine	drug	132-145	resin	group	147-151	false
cholestyramine	drug	132-145	digitalis	group	219-227	mechanism
cholestyramine	drug	132-145	cholestyramine	drug	300-313	false
cholestyramine	drug	132-145	resin	group	315-319	false
resin	group	147-151	digitalis	group	219-227	false
resin	group	147-151	cholestyramine	drug	300-313	false
resin	group	147-151	resin	group	315-319	false
digitalis	group	219-227	cholestyramine	drug	300-313	false
digitalis	group	219-227	resin	group	315-319	false
cholestyramine	drug	300-313	resin	group	315-319	false

DDI-DrugBank.d566.s3	Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.
cholestyramine	drug	8-21	cholestyramine	drug	41-54	false
cholestyramine	drug	8-21	resin	group	56-60	false
cholestyramine	drug	8-21	fat soluble vitamins	group	152-171	false
cholestyramine	drug	41-54	resin	group	56-60	false
cholestyramine	drug	41-54	fat soluble vitamins	group	152-171	false
resin	group	56-60	fat soluble vitamins	group	152-171	false

DDI-DrugBank.d566.s4	When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.
cholestyramine	drug	5-18	resin	group	20-24	false
cholestyramine	drug	5-18	fat-soluble vitamins	group	134-153	false
resin	group	20-24	fat-soluble vitamins	group	134-153	false

DDI-DrugBank.d566.s5	SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
CHOLESTYRAMINE	drug	6-19	RESIN	group	21-25	false
CHOLESTYRAMINE	drug	6-19	CHOLESTYRAMINE	drug	162-175	false
CHOLESTYRAMINE	drug	6-19	RESIN	group	177-181	false
RESIN	group	21-25	CHOLESTYRAMINE	drug	162-175	false
RESIN	group	21-25	RESIN	group	177-181	false
CHOLESTYRAMINE	drug	162-175	RESIN	group	177-181	false

DDI-DrugBank.d28.s1	Results from existing clinical trials suggest no significant interactions between COPAXONE  and other therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days.
COPAXONE	brand	82-89	corticosteroids	group	174-188	false

DDI-DrugBank.d28.s2	COPAXONE  has not been formally evaluated in combination with Interferon beta.
COPAXONE	brand	0-7	Interferon beta	drug	62-76	false

DDI-DrugBank.d28.s3	However, 10 patients who switched from therapy with Interferon beta to COPAXONE  did not report any serious and unexpected adverse reactions thought to be related to treatment.
Interferon beta	drug	52-66	COPAXONE	brand	71-78	false

DDI-DrugBank.d548.s0	Potential for Other Drugs to Affect Duloxetine: Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.
Duloxetine	drug	36-45	duloxetine	drug	91-100	false

DDI-DrugBank.d548.s1	Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.
duloxetine	drug	41-50	fluvoxamine	drug	57-67	mechanism
duloxetine	drug	41-50	duloxetine	drug	185-194	false
fluvoxamine	drug	57-67	duloxetine	drug	185-194	false

DDI-DrugBank.d548.s3	Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.
duloxetine	drug	52-61	duloxetine	drug	94-103	false
duloxetine	drug	52-61	duloxetine	drug	177-186	false
duloxetine	drug	94-103	duloxetine	drug	177-186	false

DDI-DrugBank.d548.s4	Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
Paroxetine	drug	0-9	duloxetine	drug	53-62	mechanism
Paroxetine	drug	0-9	paroxetine	drug	157-166	false
duloxetine	drug	53-62	paroxetine	drug	157-166	false

DDI-DrugBank.d548.s5	Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine).
fluoxetine	drug	77-86	quinidine	drug	89-97	false

DDI-DrugBank.d548.s6	Potential for Duloxetine to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.
Duloxetine	drug	14-23	duloxetine	drug	128-137	false

DDI-DrugBank.d548.s8	When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
duloxetine	drug	5-14	desipramine	drug	101-111	mechanism
duloxetine	drug	5-14	desipramine	drug	145-155	false
desipramine	drug	101-111	desipramine	drug	145-155	false

DDI-DrugBank.d548.s9	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
Duloxetine	drug	32-41	antidepressants	group	170-184	advise
Duloxetine	drug	32-41	tricyclic antidepressants	group	187-211	advise
Duloxetine	drug	32-41	TCAs	group	214-217	advise
Duloxetine	drug	32-41	nortriptyline	drug	229-241	advise
Duloxetine	drug	32-41	amitriptyline	drug	244-256	advise
Duloxetine	drug	32-41	imipramine	drug	263-272	advise
Duloxetine	drug	32-41	phenothiazines	group	276-289	advise
Duloxetine	drug	32-41	Type 1C antiarrhythmics	group	295-317	advise
Duloxetine	drug	32-41	propafenone	drug	326-336	advise
Duloxetine	drug	32-41	flecainide	drug	339-348	advise
antidepressants	group	170-184	tricyclic antidepressants	group	187-211	false
antidepressants	group	170-184	TCAs	group	214-217	false
antidepressants	group	170-184	nortriptyline	drug	229-241	false
antidepressants	group	170-184	amitriptyline	drug	244-256	false
antidepressants	group	170-184	imipramine	drug	263-272	false
antidepressants	group	170-184	phenothiazines	group	276-289	false
antidepressants	group	170-184	Type 1C antiarrhythmics	group	295-317	false
antidepressants	group	170-184	propafenone	drug	326-336	false
antidepressants	group	170-184	flecainide	drug	339-348	false
tricyclic antidepressants	group	187-211	TCAs	group	214-217	false
tricyclic antidepressants	group	187-211	nortriptyline	drug	229-241	false
tricyclic antidepressants	group	187-211	amitriptyline	drug	244-256	false
tricyclic antidepressants	group	187-211	imipramine	drug	263-272	false
tricyclic antidepressants	group	187-211	phenothiazines	group	276-289	false
tricyclic antidepressants	group	187-211	Type 1C antiarrhythmics	group	295-317	false
tricyclic antidepressants	group	187-211	propafenone	drug	326-336	false
tricyclic antidepressants	group	187-211	flecainide	drug	339-348	false
TCAs	group	214-217	nortriptyline	drug	229-241	false
TCAs	group	214-217	amitriptyline	drug	244-256	false
TCAs	group	214-217	imipramine	drug	263-272	false
TCAs	group	214-217	phenothiazines	group	276-289	false
TCAs	group	214-217	Type 1C antiarrhythmics	group	295-317	false
TCAs	group	214-217	propafenone	drug	326-336	false
TCAs	group	214-217	flecainide	drug	339-348	false
nortriptyline	drug	229-241	amitriptyline	drug	244-256	false
nortriptyline	drug	229-241	imipramine	drug	263-272	false
nortriptyline	drug	229-241	phenothiazines	group	276-289	false
nortriptyline	drug	229-241	Type 1C antiarrhythmics	group	295-317	false
nortriptyline	drug	229-241	propafenone	drug	326-336	false
nortriptyline	drug	229-241	flecainide	drug	339-348	false
amitriptyline	drug	244-256	imipramine	drug	263-272	false
amitriptyline	drug	244-256	phenothiazines	group	276-289	false
amitriptyline	drug	244-256	Type 1C antiarrhythmics	group	295-317	false
amitriptyline	drug	244-256	propafenone	drug	326-336	false
amitriptyline	drug	244-256	flecainide	drug	339-348	false
imipramine	drug	263-272	phenothiazines	group	276-289	false
imipramine	drug	263-272	Type 1C antiarrhythmics	group	295-317	false
imipramine	drug	263-272	propafenone	drug	326-336	false
imipramine	drug	263-272	flecainide	drug	339-348	false
phenothiazines	group	276-289	Type 1C antiarrhythmics	group	295-317	false
phenothiazines	group	276-289	propafenone	drug	326-336	false
phenothiazines	group	276-289	flecainide	drug	339-348	false
Type 1C antiarrhythmics	group	295-317	propafenone	drug	326-336	false
Type 1C antiarrhythmics	group	295-317	flecainide	drug	339-348	false
propafenone	drug	326-336	flecainide	drug	339-348	false

DDI-DrugBank.d548.s10	Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.
TCA	group	7-9	TCA	group	71-73	false
TCA	group	7-9	TCA	group	103-105	false
TCA	group	7-9	Duloxetine	drug	131-140	false
TCA	group	71-73	TCA	group	103-105	false
TCA	group	71-73	Duloxetine	drug	131-140	false
TCA	group	103-105	Duloxetine	drug	131-140	advise

DDI-DrugBank.d548.s11	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.
thioridazine	drug	126-137	Duloxetine	drug	140-149	false
thioridazine	drug	126-137	thioridazine	drug	155-166	false
Duloxetine	drug	140-149	thioridazine	drug	155-166	advise

DDI-DrugBank.d548.s13	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
Duloxetine	drug	0-9	Alcohol	drug	87-93	false
Duloxetine	drug	0-9	Duloxetine	drug	101-110	false
Duloxetine	drug	0-9	ethanol	drug	116-122	false
Duloxetine	drug	0-9	Duloxetine	drug	214-223	false
Duloxetine	drug	0-9	alcohol	drug	294-300	false
Alcohol	drug	87-93	Duloxetine	drug	101-110	false
Alcohol	drug	87-93	ethanol	drug	116-122	false
Alcohol	drug	87-93	Duloxetine	drug	214-223	false
Alcohol	drug	87-93	alcohol	drug	294-300	false
Duloxetine	drug	101-110	ethanol	drug	116-122	false
Duloxetine	drug	101-110	Duloxetine	drug	214-223	false
Duloxetine	drug	101-110	alcohol	drug	294-300	false
ethanol	drug	116-122	Duloxetine	drug	214-223	false
ethanol	drug	116-122	alcohol	drug	294-300	false
Duloxetine	drug	214-223	alcohol	drug	294-300	false

DDI-DrugBank.d548.s14	In the Duloxetine clinical trials database, three Duloxetine-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.
Duloxetine	drug	7-16	Duloxetine	drug	50-59	false

DDI-DrugBank.d548.s21	However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.
Duloxetine	drug	30-39	aluminum	drug	46-53	false
Duloxetine	drug	30-39	magnesium	drug	60-68	false
Duloxetine	drug	30-39	antacids	group	81-88	false
Duloxetine	drug	30-39	Duloxetine	drug	102-111	false
Duloxetine	drug	30-39	famotidine	drug	118-127	false
Duloxetine	drug	30-39	duloxetine	drug	181-190	false
aluminum	drug	46-53	magnesium	drug	60-68	false
aluminum	drug	46-53	antacids	group	81-88	false
aluminum	drug	46-53	Duloxetine	drug	102-111	false
aluminum	drug	46-53	famotidine	drug	118-127	false
aluminum	drug	46-53	duloxetine	drug	181-190	false
magnesium	drug	60-68	antacids	group	81-88	false
magnesium	drug	60-68	Duloxetine	drug	102-111	false
magnesium	drug	60-68	famotidine	drug	118-127	false
magnesium	drug	60-68	duloxetine	drug	181-190	false
antacids	group	81-88	Duloxetine	drug	102-111	false
antacids	group	81-88	famotidine	drug	118-127	false
antacids	group	81-88	duloxetine	drug	181-190	false
Duloxetine	drug	102-111	famotidine	drug	118-127	false
Duloxetine	drug	102-111	duloxetine	drug	181-190	false
famotidine	drug	118-127	duloxetine	drug	181-190	false

DDI-DrugBank.d548.s22	It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption.
proton pump inhibitors	group	56-77	duloxetine	drug	87-96	false

DDI-DrugBank.d394.s0	The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
sodium nitroprusside	drug	26-45	hypotensive drugs	group	82-98	effect
sodium nitroprusside	drug	26-45	ganglionic blocking agents	group	111-136	effect
sodium nitroprusside	drug	26-45	anesthetics	group	178-188	effect
hypotensive drugs	group	82-98	ganglionic blocking agents	group	111-136	false
hypotensive drugs	group	82-98	anesthetics	group	178-188	false
ganglionic blocking agents	group	111-136	anesthetics	group	178-188	false

DDI-DrugBank.d120.s1	anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol;
anticholinergics	group	0-15	diphenidol	drug	163-172	false

DDI-DrugBank.d120.s2	apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.
apomorphine	drug	0-10	diphenidol	drug	33-42	false
apomorphine	drug	0-10	emetic	group	61-66	false
apomorphine	drug	0-10	apomorphine	drug	80-90	false
diphenidol	drug	33-42	emetic	group	61-66	false
diphenidol	drug	33-42	apomorphine	drug	80-90	effect
emetic	group	61-66	apomorphine	drug	80-90	false

DDI-DrugBank.d112.s0	Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.
probenecid	drug	20-29	penciclovir	drug	154-164	mechanism

DDI-DrugBank.d112.s1	The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase.
6-deoxy penciclovir	drug_n	18-36	penciclovir	drug	41-51	false

DDI-DrugBank.d212.s2	In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.
levetiracetam	drug	13-25	valproic acid	drug	75-87	false

DDI-DrugBank.d212.s5	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
phenytoin	drug	90-98	valproate	drug	101-109	false
phenytoin	drug	90-98	contraceptive	group	117-129	false
phenytoin	drug	90-98	digoxin	drug	132-138	false
phenytoin	drug	90-98	warfarin	drug	141-148	false
phenytoin	drug	90-98	probenecid	drug	151-160	false
valproate	drug	101-109	contraceptive	group	117-129	false
valproate	drug	101-109	digoxin	drug	132-138	false
valproate	drug	101-109	warfarin	drug	141-148	false
valproate	drug	101-109	probenecid	drug	151-160	false
contraceptive	group	117-129	digoxin	drug	132-138	false
contraceptive	group	117-129	warfarin	drug	141-148	false
contraceptive	group	117-129	probenecid	drug	151-160	false
digoxin	drug	132-138	warfarin	drug	141-148	false
digoxin	drug	132-138	probenecid	drug	151-160	false
warfarin	drug	141-148	probenecid	drug	151-160	false

DDI-DrugBank.d212.s6	Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.
Keppra	brand	31-36	Antiepileptic Drugs	group	49-67	false
Keppra	brand	31-36	AEDs	group	70-73	false
Keppra	brand	31-36	Phenytoin	drug	76-84	false
Keppra	brand	31-36	Keppra	brand	86-91	false
Keppra	brand	31-36	phenytoin	drug	162-170	false
Antiepileptic Drugs	group	49-67	AEDs	group	70-73	false
Antiepileptic Drugs	group	49-67	Phenytoin	drug	76-84	false
Antiepileptic Drugs	group	49-67	Keppra	brand	86-91	false
Antiepileptic Drugs	group	49-67	phenytoin	drug	162-170	false
AEDs	group	70-73	Phenytoin	drug	76-84	false
AEDs	group	70-73	Keppra	brand	86-91	false
AEDs	group	70-73	phenytoin	drug	162-170	false
Phenytoin	drug	76-84	Keppra	brand	86-91	false
Phenytoin	drug	76-84	phenytoin	drug	162-170	false
Keppra	brand	86-91	phenytoin	drug	162-170	false

DDI-DrugBank.d212.s7	Pharmacokinetics of levetiracetam were also not affected by phenytoin.
levetiracetam	drug	20-32	phenytoin	drug	60-68	false

DDI-DrugBank.d212.s8	Valproate Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.
Valproate	drug	0-8	Keppra	brand	10-15	false
Valproate	drug	0-8	valproate	drug	78-86	false
Keppra	brand	10-15	valproate	drug	78-86	false

DDI-DrugBank.d212.s9	Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.
Valproate	drug	0-8	levetiracetam	drug	66-78	false

DDI-DrugBank.d212.s11	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
Keppra	brand	36-41	AEDs	group	54-57	false
Keppra	brand	36-41	carbamazepine	drug	60-72	false
Keppra	brand	36-41	gabapentin	drug	75-84	false
Keppra	brand	36-41	lamotrigine	drug	87-97	false
Keppra	brand	36-41	phenobarbital	drug	100-112	false
Keppra	brand	36-41	phenytoin	drug	115-123	false
Keppra	brand	36-41	primidone	drug	126-134	false
Keppra	brand	36-41	valproate	drug	140-148	false
Keppra	brand	36-41	levetiracetam	drug	212-224	false
Keppra	brand	36-41	AEDs	group	236-239	false
AEDs	group	54-57	carbamazepine	drug	60-72	false
AEDs	group	54-57	gabapentin	drug	75-84	false
AEDs	group	54-57	lamotrigine	drug	87-97	false
AEDs	group	54-57	phenobarbital	drug	100-112	false
AEDs	group	54-57	phenytoin	drug	115-123	false
AEDs	group	54-57	primidone	drug	126-134	false
AEDs	group	54-57	valproate	drug	140-148	false
AEDs	group	54-57	levetiracetam	drug	212-224	false
AEDs	group	54-57	AEDs	group	236-239	false
carbamazepine	drug	60-72	gabapentin	drug	75-84	false
carbamazepine	drug	60-72	lamotrigine	drug	87-97	false
carbamazepine	drug	60-72	phenobarbital	drug	100-112	false
carbamazepine	drug	60-72	phenytoin	drug	115-123	false
carbamazepine	drug	60-72	primidone	drug	126-134	false
carbamazepine	drug	60-72	valproate	drug	140-148	false
carbamazepine	drug	60-72	levetiracetam	drug	212-224	false
carbamazepine	drug	60-72	AEDs	group	236-239	false
gabapentin	drug	75-84	lamotrigine	drug	87-97	false
gabapentin	drug	75-84	phenobarbital	drug	100-112	false
gabapentin	drug	75-84	phenytoin	drug	115-123	false
gabapentin	drug	75-84	primidone	drug	126-134	false
gabapentin	drug	75-84	valproate	drug	140-148	false
gabapentin	drug	75-84	levetiracetam	drug	212-224	false
gabapentin	drug	75-84	AEDs	group	236-239	false
lamotrigine	drug	87-97	phenobarbital	drug	100-112	false
lamotrigine	drug	87-97	phenytoin	drug	115-123	false
lamotrigine	drug	87-97	primidone	drug	126-134	false
lamotrigine	drug	87-97	valproate	drug	140-148	false
lamotrigine	drug	87-97	levetiracetam	drug	212-224	false
lamotrigine	drug	87-97	AEDs	group	236-239	false
phenobarbital	drug	100-112	phenytoin	drug	115-123	false
phenobarbital	drug	100-112	primidone	drug	126-134	false
phenobarbital	drug	100-112	valproate	drug	140-148	false
phenobarbital	drug	100-112	levetiracetam	drug	212-224	false
phenobarbital	drug	100-112	AEDs	group	236-239	false
phenytoin	drug	115-123	primidone	drug	126-134	false
phenytoin	drug	115-123	valproate	drug	140-148	false
phenytoin	drug	115-123	levetiracetam	drug	212-224	false
phenytoin	drug	115-123	AEDs	group	236-239	false
primidone	drug	126-134	valproate	drug	140-148	false
primidone	drug	126-134	levetiracetam	drug	212-224	false
primidone	drug	126-134	AEDs	group	236-239	false
valproate	drug	140-148	levetiracetam	drug	212-224	false
valproate	drug	140-148	AEDs	group	236-239	false
levetiracetam	drug	212-224	AEDs	group	236-239	false

DDI-DrugBank.d212.s12	These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.
levetiracetam	drug	25-37	AEDs	group	92-95	false
levetiracetam	drug	25-37	AEDs	group	112-115	false
levetiracetam	drug	25-37	levetiracetam	drug	158-170	false
AEDs	group	92-95	AEDs	group	112-115	false
AEDs	group	92-95	levetiracetam	drug	158-170	false
AEDs	group	112-115	levetiracetam	drug	158-170	false

DDI-DrugBank.d212.s13	Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.
AEDs	group	10-13	levetiracetam	drug	104-116	false
AEDs	group	10-13	AEDs	group	167-170	false
levetiracetam	drug	104-116	AEDs	group	167-170	mechanism

DDI-DrugBank.d212.s14	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.
Levetiracetam	drug	35-47	carbamazepine	drug	91-103	false
Levetiracetam	drug	35-47	valproate	drug	106-114	false
Levetiracetam	drug	35-47	topiramate	drug	117-126	false
Levetiracetam	drug	35-47	lamotrigine	drug	132-142	false
carbamazepine	drug	91-103	valproate	drug	106-114	false
carbamazepine	drug	91-103	topiramate	drug	117-126	false
carbamazepine	drug	91-103	lamotrigine	drug	132-142	false
valproate	drug	106-114	topiramate	drug	117-126	false
valproate	drug	106-114	lamotrigine	drug	132-142	false
topiramate	drug	117-126	lamotrigine	drug	132-142	false

DDI-DrugBank.d212.s15	Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
Contraceptives	group	29-42	Keppra	brand	44-49	false
Contraceptives	group	29-42	contraceptive	group	123-135	false
Contraceptives	group	29-42	ethinyl estradiol	drug	156-172	false
Contraceptives	group	29-42	levonorgestrel	drug	186-199	false
Keppra	brand	44-49	contraceptive	group	123-135	false
Keppra	brand	44-49	ethinyl estradiol	drug	156-172	false
Keppra	brand	44-49	levonorgestrel	drug	186-199	false
contraceptive	group	123-135	ethinyl estradiol	drug	156-172	false
contraceptive	group	123-135	levonorgestrel	drug	186-199	false
ethinyl estradiol	drug	156-172	levonorgestrel	drug	186-199	false

DDI-DrugBank.d212.s16	Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam.
contraceptive	group	30-42	levetiracetam	drug	86-98	false

DDI-DrugBank.d212.s17	Digoxin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.
Digoxin	drug	0-6	Keppra	brand	8-13	false
Digoxin	drug	0-6	digoxin	drug	107-113	false
Keppra	brand	8-13	digoxin	drug	107-113	false

DDI-DrugBank.d212.s18	Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.
digoxin	drug	20-26	levetiracetam	drug	70-82	false

DDI-DrugBank.d212.s19	Warfarin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.
Warfarin	drug	0-7	Keppra	brand	9-14	false
Warfarin	drug	0-7	R warfarin	drug	81-81;89-96	false
Warfarin	drug	0-7	S warfarin	drug	87-96	false
Keppra	brand	9-14	R warfarin	drug	81-81;89-96	false
Keppra	brand	9-14	S warfarin	drug	87-96	false
R warfarin	drug	81-81;89-96	S warfarin	drug	87-96	false

DDI-DrugBank.d212.s21	Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam.
warfarin	drug	20-27	levetiracetam	drug	68-80	false

DDI-DrugBank.d212.s22	Probenecid: Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.
Probenecid	drug	0-9	Probenecid	drug	12-21	false
Probenecid	drug	0-9	levetiracetam	drug	156-168	false
Probenecid	drug	12-21	levetiracetam	drug	156-168	false

DDI-DrugBank.d212.s25	The effect of Keppra  on probenecid was not studied.
Keppra	brand	14-19	probenecid	drug	25-34	false

DDI-DrugBank.d41.s0	Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
Cholestyramine	drug	0-13	Charcoal	drug	19-26	false
Cholestyramine	drug	0-13	cholestyramine	drug	46-59	false
Cholestyramine	drug	0-13	activated charcoal	drug	64-81	false
Cholestyramine	drug	0-13	leflunomide	drug	208-218	false
Charcoal	drug	19-26	cholestyramine	drug	46-59	false
Charcoal	drug	19-26	activated charcoal	drug	64-81	false
Charcoal	drug	19-26	leflunomide	drug	208-218	false
cholestyramine	drug	46-59	activated charcoal	drug	64-81	false
cholestyramine	drug	46-59	leflunomide	drug	208-218	mechanism
activated charcoal	drug	64-81	leflunomide	drug	208-218	mechanism

DDI-DrugBank.d41.s3	In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.
ARAVA	brand	39-43	methotrexate	drug	50-61	effect

DDI-DrugBank.d41.s9	NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.
NSAIDs	group	0-5	diclofenac	drug	107-116	false
NSAIDs	group	0-5	ibuprofen	drug	122-130	false
diclofenac	drug	107-116	ibuprofen	drug	122-130	false

DDI-DrugBank.d41.s12	Tolbutamide: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.
Tolbutamide	drug	0-10	tolbutamide	drug	112-122	false

DDI-DrugBank.d41.s14	Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.
Rifampin	drug	0-7	ARAVA	brand	67-71	false
Rifampin	drug	0-7	rifampin	drug	113-120	false
Rifampin	drug	0-7	ARAVA	brand	181-185	false
ARAVA	brand	67-71	rifampin	drug	113-120	mechanism
ARAVA	brand	67-71	ARAVA	brand	181-185	false
rifampin	drug	113-120	ARAVA	brand	181-185	false

DDI-DrugBank.d41.s15	Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.
ARAVA	brand	29-33	ARAVA	brand	148-152	false
ARAVA	brand	29-33	rifampin	drug	158-165	false
ARAVA	brand	148-152	rifampin	drug	158-165	advise

DDI-DrugBank.d41.s16	Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.
Warfarin	drug	0-7	ARAVA	brand	62-66	false
Warfarin	drug	0-7	warfarin	drug	72-79	false
ARAVA	brand	62-66	warfarin	drug	72-79	effect

DDI-DrugBank.d187.s2	Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.
Acetaminophen	drug	0-12	acetaminophen	drug	34-46	false
Acetaminophen	drug	0-12	Isoniazid	drug	93-101	false
acetaminophen	drug	34-46	Isoniazid	drug	93-101	effect

DDI-DrugBank.d187.s3	It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.
isoniazid	drug	102-110	acetaminophen	drug	116-128	effect

DDI-DrugBank.d187.s5	Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.
isoniazid	drug	38-46	acetaminophen	drug	170-182	mechanism

DDI-DrugBank.d187.s7	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
Carbamazepine	drug	0-12	Isoniazid	drug	15-23	false
Carbamazepine	drug	0-12	carbamazepine	drug	60-72	false
Carbamazepine	drug	0-12	Carbamazepine	drug	104-116	false
Carbamazepine	drug	0-12	isoniazid	drug	186-194	false
Carbamazepine	drug	0-12	carbamazepine	drug	219-231	false
Carbamazepine	drug	0-12	anticonvulsant	group	312-325	false
Isoniazid	drug	15-23	carbamazepine	drug	60-72	mechanism
Isoniazid	drug	15-23	Carbamazepine	drug	104-116	false
Isoniazid	drug	15-23	isoniazid	drug	186-194	false
Isoniazid	drug	15-23	carbamazepine	drug	219-231	false
Isoniazid	drug	15-23	anticonvulsant	group	312-325	false
carbamazepine	drug	60-72	Carbamazepine	drug	104-116	false
carbamazepine	drug	60-72	isoniazid	drug	186-194	false
carbamazepine	drug	60-72	carbamazepine	drug	219-231	false
carbamazepine	drug	60-72	anticonvulsant	group	312-325	false
Carbamazepine	drug	104-116	isoniazid	drug	186-194	advise
Carbamazepine	drug	104-116	carbamazepine	drug	219-231	false
Carbamazepine	drug	104-116	anticonvulsant	group	312-325	false
isoniazid	drug	186-194	carbamazepine	drug	219-231	false
isoniazid	drug	186-194	anticonvulsant	group	312-325	false
carbamazepine	drug	219-231	anticonvulsant	group	312-325	false

DDI-DrugBank.d187.s8	Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.
Ketoconazole	drug	0-11	Ketoconazole	drug	39-50	false
Ketoconazole	drug	0-11	Isoniazid	drug	56-64	false
Ketoconazole	drug	39-50	Isoniazid	drug	56-64	int

DDI-DrugBank.d187.s9	Phenytoin: Isoniazid may increase serum levels of phenytoin.
Phenytoin	drug	0-8	Isoniazid	drug	11-19	false
Phenytoin	drug	0-8	phenytoin	drug	50-58	false
Isoniazid	drug	11-19	phenytoin	drug	50-58	mechanism

DDI-DrugBank.d187.s10	To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made.
phenytoin	drug	9-17	anticonvulsant	group	63-76	false

DDI-DrugBank.d187.s11	Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.
isoniazid	drug	74-82	theophylline	drug	88-99	mechanism
isoniazid	drug	74-82	theophylline	drug	137-148	false
isoniazid	drug	74-82	isoniazid	drug	213-221	false
theophylline	drug	88-99	theophylline	drug	137-148	false
theophylline	drug	88-99	isoniazid	drug	213-221	false
theophylline	drug	137-148	isoniazid	drug	213-221	false

DDI-DrugBank.d187.s12	Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.
theophylline	drug	31-42	theophylline	drug	54-65	false
theophylline	drug	31-42	theophylline	drug	147-158	false
theophylline	drug	54-65	theophylline	drug	147-158	false

DDI-DrugBank.d187.s13	Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.
Valproate	drug	0-8	valproate	drug	84-92	false
Valproate	drug	0-8	isoniazid	drug	120-128	false
valproate	drug	84-92	isoniazid	drug	120-128	mechanism

DDI-DrugBank.d187.s14	Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.
valproate	drug	7-15	isoniazid	drug	56-64	false
valproate	drug	7-15	valproate	drug	70-78	false
valproate	drug	7-15	valproate	drug	139-147	false
isoniazid	drug	56-64	valproate	drug	70-78	advise
isoniazid	drug	56-64	valproate	drug	139-147	false
valproate	drug	70-78	valproate	drug	139-147	false

DDI-DrugBank.d69.s0	Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.
Cerubidine	brand	7-16	doxorubicin	drug	59-69	effect

DDI-DrugBank.d69.s1	Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.
Cerubidine	brand	0-9	doxorubicin	drug	115-125	advise
Cerubidine	brand	0-9	Cerubidine	brand	130-139	false
doxorubicin	drug	115-125	Cerubidine	brand	130-139	false

DDI-DrugBank.d69.s2	Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.
Cyclophosphamide	drug	0-15	Cerubidine	brand	40-49	effect

DDI-DrugBank.d571.s4	Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.
antidiabetic agents	group	17-35	VELCADE	brand	47-53	advise
antidiabetic agents	group	17-35	antidiabetic medication	group	160-182	false
VELCADE	brand	47-53	antidiabetic medication	group	160-182	false

DDI-DrugBank.d0.s0	The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.
alcohol	drug	26-32	Acamprosate	drug	38-48	false
alcohol	drug	26-32	alcohol	drug	97-103	false
alcohol	drug	26-32	acamprosate	drug	108-118	false
Acamprosate	drug	38-48	alcohol	drug	97-103	false
Acamprosate	drug	38-48	acamprosate	drug	108-118	false
alcohol	drug	97-103	acamprosate	drug	108-118	false

DDI-DrugBank.d0.s1	Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate.
disulfiram	drug	56-65	diazepam	drug	70-77	false
disulfiram	drug	56-65	acamprosate	drug	119-129	false
diazepam	drug	70-77	acamprosate	drug	119-129	false

DDI-DrugBank.d0.s2	Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
naltrexone	drug	21-30	Acamprosate	drug	37-47	mechanism
naltrexone	drug	21-30	acamprosate	drug	114-124	false
Acamprosate	drug	37-47	acamprosate	drug	114-124	false

DDI-DrugBank.d0.s4	The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate.
naltrexone	drug	24-33	6-beta-naltrexol	drug_n	60-75	false
naltrexone	drug	24-33	Acamprosate	drug	126-136	false
6-beta-naltrexol	drug_n	60-75	Acamprosate	drug	126-136	false

DDI-DrugBank.d0.s5	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
Acamprosate	drug	93-103	anxiolytics	group	124-134	false
Acamprosate	drug	93-103	hypnotics	group	137-145	false
Acamprosate	drug	93-103	sedatives	group	151-159	false
Acamprosate	drug	93-103	benzodiazepines	group	172-186	false
Acamprosate	drug	93-103	non-opioid analgesics	group	193-213	false
anxiolytics	group	124-134	hypnotics	group	137-145	false
anxiolytics	group	124-134	sedatives	group	151-159	false
anxiolytics	group	124-134	benzodiazepines	group	172-186	false
anxiolytics	group	124-134	non-opioid analgesics	group	193-213	false
hypnotics	group	137-145	sedatives	group	151-159	false
hypnotics	group	137-145	benzodiazepines	group	172-186	false
hypnotics	group	137-145	non-opioid analgesics	group	193-213	false
sedatives	group	151-159	benzodiazepines	group	172-186	false
sedatives	group	151-159	non-opioid analgesics	group	193-213	false
benzodiazepines	group	172-186	non-opioid analgesics	group	193-213	false

DDI-DrugBank.d0.s6	Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
Acamprosate	drug	16-26	antidepressants	group	47-61	effect

DDI-DrugBank.d235.s2	Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, tricyclic antidepressants, phenothiazines.
CNS depressants	group	37-51	MAO inhibitors	group	54-67	false
CNS depressants	group	37-51	tricyclic antidepressants	group	70-94	false
CNS depressants	group	37-51	phenothiazines	group	97-110	false
MAO inhibitors	group	54-67	tricyclic antidepressants	group	70-94	false
MAO inhibitors	group	54-67	phenothiazines	group	97-110	false
tricyclic antidepressants	group	70-94	phenothiazines	group	97-110	false

DDI-DrugBank.d235.s4	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
azole antifungals	group	27-43	ciprofloxacin	drug	46-58	false
azole antifungals	group	27-43	clarithromycin	drug	61-74	false
azole antifungals	group	27-43	diclofenac	drug	77-86	false
azole antifungals	group	27-43	doxycycline	drug	89-99	false
azole antifungals	group	27-43	erythromycin	drug	102-113	false
azole antifungals	group	27-43	imatinib	drug	116-123	false
azole antifungals	group	27-43	isoniazid	drug	126-134	false
azole antifungals	group	27-43	nefazodone	drug	137-146	false
azole antifungals	group	27-43	nicardipine	drug	149-159	false
azole antifungals	group	27-43	propofol	drug	162-169	false
azole antifungals	group	27-43	protease inhibitors	group	172-190	false
azole antifungals	group	27-43	quinidine	drug	193-201	false
azole antifungals	group	27-43	verapamil	drug	208-216	false
ciprofloxacin	drug	46-58	clarithromycin	drug	61-74	false
ciprofloxacin	drug	46-58	diclofenac	drug	77-86	false
ciprofloxacin	drug	46-58	doxycycline	drug	89-99	false
ciprofloxacin	drug	46-58	erythromycin	drug	102-113	false
ciprofloxacin	drug	46-58	imatinib	drug	116-123	false
ciprofloxacin	drug	46-58	isoniazid	drug	126-134	false
ciprofloxacin	drug	46-58	nefazodone	drug	137-146	false
ciprofloxacin	drug	46-58	nicardipine	drug	149-159	false
ciprofloxacin	drug	46-58	propofol	drug	162-169	false
ciprofloxacin	drug	46-58	protease inhibitors	group	172-190	false
ciprofloxacin	drug	46-58	quinidine	drug	193-201	false
ciprofloxacin	drug	46-58	verapamil	drug	208-216	false
clarithromycin	drug	61-74	diclofenac	drug	77-86	false
clarithromycin	drug	61-74	doxycycline	drug	89-99	false
clarithromycin	drug	61-74	erythromycin	drug	102-113	false
clarithromycin	drug	61-74	imatinib	drug	116-123	false
clarithromycin	drug	61-74	isoniazid	drug	126-134	false
clarithromycin	drug	61-74	nefazodone	drug	137-146	false
clarithromycin	drug	61-74	nicardipine	drug	149-159	false
clarithromycin	drug	61-74	propofol	drug	162-169	false
clarithromycin	drug	61-74	protease inhibitors	group	172-190	false
clarithromycin	drug	61-74	quinidine	drug	193-201	false
clarithromycin	drug	61-74	verapamil	drug	208-216	false
diclofenac	drug	77-86	doxycycline	drug	89-99	false
diclofenac	drug	77-86	erythromycin	drug	102-113	false
diclofenac	drug	77-86	imatinib	drug	116-123	false
diclofenac	drug	77-86	isoniazid	drug	126-134	false
diclofenac	drug	77-86	nefazodone	drug	137-146	false
diclofenac	drug	77-86	nicardipine	drug	149-159	false
diclofenac	drug	77-86	propofol	drug	162-169	false
diclofenac	drug	77-86	protease inhibitors	group	172-190	false
diclofenac	drug	77-86	quinidine	drug	193-201	false
diclofenac	drug	77-86	verapamil	drug	208-216	false
doxycycline	drug	89-99	erythromycin	drug	102-113	false
doxycycline	drug	89-99	imatinib	drug	116-123	false
doxycycline	drug	89-99	isoniazid	drug	126-134	false
doxycycline	drug	89-99	nefazodone	drug	137-146	false
doxycycline	drug	89-99	nicardipine	drug	149-159	false
doxycycline	drug	89-99	propofol	drug	162-169	false
doxycycline	drug	89-99	protease inhibitors	group	172-190	false
doxycycline	drug	89-99	quinidine	drug	193-201	false
doxycycline	drug	89-99	verapamil	drug	208-216	false
erythromycin	drug	102-113	imatinib	drug	116-123	false
erythromycin	drug	102-113	isoniazid	drug	126-134	false
erythromycin	drug	102-113	nefazodone	drug	137-146	false
erythromycin	drug	102-113	nicardipine	drug	149-159	false
erythromycin	drug	102-113	propofol	drug	162-169	false
erythromycin	drug	102-113	protease inhibitors	group	172-190	false
erythromycin	drug	102-113	quinidine	drug	193-201	false
erythromycin	drug	102-113	verapamil	drug	208-216	false
imatinib	drug	116-123	isoniazid	drug	126-134	false
imatinib	drug	116-123	nefazodone	drug	137-146	false
imatinib	drug	116-123	nicardipine	drug	149-159	false
imatinib	drug	116-123	propofol	drug	162-169	false
imatinib	drug	116-123	protease inhibitors	group	172-190	false
imatinib	drug	116-123	quinidine	drug	193-201	false
imatinib	drug	116-123	verapamil	drug	208-216	false
isoniazid	drug	126-134	nefazodone	drug	137-146	false
isoniazid	drug	126-134	nicardipine	drug	149-159	false
isoniazid	drug	126-134	propofol	drug	162-169	false
isoniazid	drug	126-134	protease inhibitors	group	172-190	false
isoniazid	drug	126-134	quinidine	drug	193-201	false
isoniazid	drug	126-134	verapamil	drug	208-216	false
nefazodone	drug	137-146	nicardipine	drug	149-159	false
nefazodone	drug	137-146	propofol	drug	162-169	false
nefazodone	drug	137-146	protease inhibitors	group	172-190	false
nefazodone	drug	137-146	quinidine	drug	193-201	false
nefazodone	drug	137-146	verapamil	drug	208-216	false
nicardipine	drug	149-159	propofol	drug	162-169	false
nicardipine	drug	149-159	protease inhibitors	group	172-190	false
nicardipine	drug	149-159	quinidine	drug	193-201	false
nicardipine	drug	149-159	verapamil	drug	208-216	false
propofol	drug	162-169	protease inhibitors	group	172-190	false
propofol	drug	162-169	quinidine	drug	193-201	false
propofol	drug	162-169	verapamil	drug	208-216	false
protease inhibitors	group	172-190	quinidine	drug	193-201	false
protease inhibitors	group	172-190	verapamil	drug	208-216	false
quinidine	drug	193-201	verapamil	drug	208-216	false

DDI-DrugBank.d110.s0	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
anesthetic solutions	group	28-47	epinephrine	drug	60-70	false
anesthetic solutions	group	28-47	norepinephrine	drug	75-88	false
anesthetic solutions	group	28-47	monoamine oxidase inhibitors	group	112-139	false
anesthetic solutions	group	28-47	tricyclic antidepressants	group	142-166	effect
anesthetic solutions	group	28-47	phenothiazines	group	171-184	effect
epinephrine	drug	60-70	norepinephrine	drug	75-88	false
epinephrine	drug	60-70	monoamine oxidase inhibitors	group	112-139	effect
epinephrine	drug	60-70	tricyclic antidepressants	group	142-166	effect
epinephrine	drug	60-70	phenothiazines	group	171-184	effect
norepinephrine	drug	75-88	monoamine oxidase inhibitors	group	112-139	effect
norepinephrine	drug	75-88	tricyclic antidepressants	group	142-166	effect
norepinephrine	drug	75-88	phenothiazines	group	171-184	effect
monoamine oxidase inhibitors	group	112-139	tricyclic antidepressants	group	142-166	false
monoamine oxidase inhibitors	group	112-139	phenothiazines	group	171-184	false
tricyclic antidepressants	group	142-166	phenothiazines	group	171-184	false

DDI-DrugBank.d110.s3	Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
vasopressor drugs	group	29-45	ergot-type oxytocic drugs	group	114-138	effect

DDI-DrugBank.d110.s5	Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.
chloroprocaine	drug	11-24	sulfonamide drug	group	73-88	advise

DDI-DrugBank.d388.s0	Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
Catecholamine-depleting drugs	group	0-28	reserpine	drug	39-47	false
Catecholamine-depleting drugs	group	0-28	beta-blocking agents	group	94-113	effect
reserpine	drug	39-47	beta-blocking agents	group	94-113	effect

DDI-DrugBank.d388.s1	Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.
acebutolol	drug	22-31	catecholamine depletors	group	38-60	advise

DDI-DrugBank.d388.s2	Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.
beta-adrenergic antagonists	group	79-105	alpha-adrenergic stimulants	group	111-137	effect

DDI-DrugBank.d388.s4	Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.
beta-adrenoceptor blocking agents	group	43-75	nonsteroidal anti-inflammatory drugs	group	80-115	effect

DDI-DrugBank.d388.s5	No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
digoxin	drug	33-39	hydrochlorothiazide	drug	42-60	false
digoxin	drug	33-39	hydralazine	drug	63-73	false
digoxin	drug	33-39	sulfinpyrazone	drug	76-89	false
digoxin	drug	33-39	contraceptives	group	97-110	false
digoxin	drug	33-39	tolbutamide	drug	113-123	false
digoxin	drug	33-39	warfarin	drug	129-136	false
hydrochlorothiazide	drug	42-60	hydralazine	drug	63-73	false
hydrochlorothiazide	drug	42-60	sulfinpyrazone	drug	76-89	false
hydrochlorothiazide	drug	42-60	contraceptives	group	97-110	false
hydrochlorothiazide	drug	42-60	tolbutamide	drug	113-123	false
hydrochlorothiazide	drug	42-60	warfarin	drug	129-136	false
hydralazine	drug	63-73	sulfinpyrazone	drug	76-89	false
hydralazine	drug	63-73	contraceptives	group	97-110	false
hydralazine	drug	63-73	tolbutamide	drug	113-123	false
hydralazine	drug	63-73	warfarin	drug	129-136	false
sulfinpyrazone	drug	76-89	contraceptives	group	97-110	false
sulfinpyrazone	drug	76-89	tolbutamide	drug	113-123	false
sulfinpyrazone	drug	76-89	warfarin	drug	129-136	false
contraceptives	group	97-110	tolbutamide	drug	113-123	false
contraceptives	group	97-110	warfarin	drug	129-136	false
tolbutamide	drug	113-123	warfarin	drug	129-136	false

DDI-DrugBank.d497.s0	AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.
AZOPT	brand	0-4	brinzolamide	drug	7-18	false
AZOPT	brand	0-4	carbonic anhydrase inhibitor	group	57-84	false
brinzolamide	drug	7-18	carbonic anhydrase inhibitor	group	57-84	false

DDI-DrugBank.d497.s2	However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.
carbonic anhydrase inhibitors	group	39-67	salicylate	drug	135-144	int

DDI-DrugBank.d497.s3	Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%.
AZOPT	brand	94-98	brinzolamide	drug	101-112	false

DDI-DrugBank.d234.s0	Interaction with central nervous system depressants other than benzodiazepines has not been specifically studied;
central nervous system depressants	group	17-50	benzodiazepines	group	63-77	false

DDI-DrugBank.d234.s1	however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.
ROMAZICON	brand	52-60	narcotics	group	85-93	false
ROMAZICON	brand	52-60	anesthetics	group	109-119	false
ROMAZICON	brand	52-60	muscle relaxants	group	122-137	false
narcotics	group	85-93	anesthetics	group	109-119	false
narcotics	group	85-93	muscle relaxants	group	122-137	false
anesthetics	group	109-119	muscle relaxants	group	122-137	false

DDI-DrugBank.d234.s2	Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.
ROMAZICON	brand	43-51	cyclic antidepressants	group	203-224	effect
ROMAZICON	brand	43-51	benzodiazepine	group	263-276	false
ROMAZICON	brand	43-51	flumazenil	drug	288-297	false
cyclic antidepressants	group	203-224	benzodiazepine	group	263-276	false
cyclic antidepressants	group	203-224	flumazenil	drug	288-297	false
benzodiazepine	group	263-276	flumazenil	drug	288-297	false

DDI-DrugBank.d234.s4	Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.
ROMAZICON	brand	9-17	benzodiazepine	group	121-134	effect

DDI-DrugBank.d234.s5	ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.
ROMAZICON	brand	0-8	benzodiazepines	group	40-54	effect

DDI-DrugBank.d234.s6	The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.
zopiclone	drug	79-87	ROMAZICON	brand	142-150	effect

DDI-DrugBank.d234.s7	The pharmacokinetics of benzodiazepines are unaltered in the presence of flumazenil and vice versa.
benzodiazepines	group	24-38	flumazenil	drug	73-82	false

DDI-DrugBank.d234.s8	There is no pharmacokinetic interaction between ethanol and flumazenil.
ethanol	drug	48-54	flumazenil	drug	60-69	false

DDI-DrugBank.d234.s9	Use in Ambulatory Patients The effects of ROMAZICON may wear off before a long-acting benzodiazepine is completely cleared from the body.
ROMAZICON	brand	42-50	long-acting benzodiazepine	group	74-99	false

DDI-DrugBank.d234.s11	An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam) have been used.
long-acting benzodiazepines	group	82-108	diazepam	drug	119-126	false
long-acting benzodiazepines	group	82-108	short-acting benzodiazepines	group	147-174	false
long-acting benzodiazepines	group	82-108	midazolam	drug	195-203	false
diazepam	drug	119-126	short-acting benzodiazepines	group	147-174	false
diazepam	drug	119-126	midazolam	drug	195-203	false
short-acting benzodiazepines	group	147-174	midazolam	drug	195-203	false

DDI-DrugBank.d234.s12	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
benzodiazepines	group	84-98	benzodiazepine	group	215-228	false
benzodiazepines	group	84-98	alcohol	drug	231-237	false
benzodiazepines	group	84-98	sedative	group	243-250	false
benzodiazepines	group	84-98	ROMAZICON	brand	322-330	false
benzodiazepine	group	215-228	alcohol	drug	231-237	false
benzodiazepine	group	215-228	sedative	group	243-250	false
benzodiazepine	group	215-228	ROMAZICON	brand	322-330	false
alcohol	drug	231-237	sedative	group	243-250	false
alcohol	drug	231-237	ROMAZICON	brand	322-330	false
sedative	group	243-250	ROMAZICON	brand	322-330	false

DDI-DrugBank.d303.s0	Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
Metformin	drug	0-8	cephalexin	drug	60-69	false
Metformin	drug	0-8	metformin	drug	75-83	false
Metformin	drug	0-8	metformin	drug	93-101	false
Metformin	drug	0-8	metformin	drug	179-187	false
cephalexin	drug	60-69	metformin	drug	75-83	mechanism
cephalexin	drug	60-69	metformin	drug	93-101	false
cephalexin	drug	60-69	metformin	drug	179-187	false
metformin	drug	75-83	metformin	drug	93-101	false
metformin	drug	75-83	metformin	drug	179-187	false
metformin	drug	93-101	metformin	drug	179-187	false

DDI-DrugBank.d303.s1	No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.
cephalexin	drug	53-62	metformin	drug	68-76	false

DDI-DrugBank.d303.s2	Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
cephalexin	drug	103-112	metformin	drug	118-126	mechanism

DDI-DrugBank.d303.s3	Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
metformin	drug	63-71	cephalexin	drug	121-130	false
metformin	drug	63-71	metformin	drug	136-144	false
cephalexin	drug	121-130	metformin	drug	136-144	advise

DDI-DrugBank.d303.s4	Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
Probenecid	drug	0-9	b-lactams	group	26-34	false
Probenecid	drug	0-9	cephalexin	drug	60-69	false
Probenecid	drug	0-9	probenecid	drug	87-96	false
b-lactams	group	26-34	cephalexin	drug	60-69	false
b-lactams	group	26-34	probenecid	drug	87-96	false
cephalexin	drug	60-69	probenecid	drug	87-96	mechanism

DDI-DrugBank.d148.s0	Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.
Heparin	drug	0-6	heparin	drug	15-21	false
Heparin	drug	0-6	heparin	drug	59-65	false
Heparin	drug	0-6	Argatroban	drug	118-127	false
Heparin	drug	0-6	heparin	drug	133-139	false
heparin	drug	15-21	heparin	drug	59-65	false
heparin	drug	15-21	Argatroban	drug	118-127	false
heparin	drug	15-21	heparin	drug	133-139	false
heparin	drug	59-65	Argatroban	drug	118-127	false
heparin	drug	59-65	heparin	drug	133-139	false
Argatroban	drug	118-127	heparin	drug	133-139	false

DDI-DrugBank.d148.s1	However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.
Argatroban	drug	12-21	heparin	drug	61-67	false
Argatroban	drug	12-21	Argatroban	drug	167-176	false
heparin	drug	61-67	Argatroban	drug	167-176	false

DDI-DrugBank.d148.s2	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
Aspirin	brand	0-6	Acetaminophen	drug	8-20	false
Aspirin	brand	0-6	Argatroban	drug	116-125	false
Aspirin	brand	0-6	aspirin	brand	158-164	false
Aspirin	brand	0-6	Argatroban	drug	227-236	false
Aspirin	brand	0-6	acetaminophen	drug	268-280	false
Aspirin	brand	0-6	Argatroban	drug	380-389	false
Acetaminophen	drug	8-20	Argatroban	drug	116-125	false
Acetaminophen	drug	8-20	aspirin	brand	158-164	false
Acetaminophen	drug	8-20	Argatroban	drug	227-236	false
Acetaminophen	drug	8-20	acetaminophen	drug	268-280	false
Acetaminophen	drug	8-20	Argatroban	drug	380-389	false
Argatroban	drug	116-125	aspirin	brand	158-164	false
Argatroban	drug	116-125	Argatroban	drug	227-236	false
Argatroban	drug	116-125	acetaminophen	drug	268-280	false
Argatroban	drug	116-125	Argatroban	drug	380-389	false
aspirin	brand	158-164	Argatroban	drug	227-236	false
aspirin	brand	158-164	acetaminophen	drug	268-280	false
aspirin	brand	158-164	Argatroban	drug	380-389	false
Argatroban	drug	227-236	acetaminophen	drug	268-280	false
Argatroban	drug	227-236	Argatroban	drug	380-389	false
acetaminophen	drug	268-280	Argatroban	drug	380-389	false

DDI-DrugBank.d148.s3	Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between Argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated.
anticoagulant agents	group	5-24	Argatroban	drug	74-83	false
anticoagulant agents	group	5-24	warfarin	drug	89-96	false
Argatroban	drug	74-83	warfarin	drug	89-96	false

DDI-DrugBank.d148.s4	However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
Argatroban	drug	32-41	warfarin	drug	47-54	effect

DDI-DrugBank.d148.s5	Thrombolytic agents: The safety and effectiveness of Argatroban with thrombolytic agents have not been established.
Thrombolytic agents	group	0-18	Argatroban	drug	53-62	false
Thrombolytic agents	group	0-18	thrombolytic agents	group	69-87	false
Argatroban	drug	53-62	thrombolytic agents	group	69-87	false

DDI-DrugBank.d148.s6	Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
Argatroban	drug	38-47	antiplatelet agents	group	54-72	effect
Argatroban	drug	38-47	thrombolytics	group	75-87	effect
Argatroban	drug	38-47	anticoagulants	group	100-113	effect
antiplatelet agents	group	54-72	thrombolytics	group	75-87	false
antiplatelet agents	group	54-72	anticoagulants	group	100-113	false
thrombolytics	group	75-87	anticoagulants	group	100-113	false

DDI-DrugBank.d148.s7	Drug-drug interactions have not been observed between Argatroban and digoxin or erythromycin.
Argatroban	drug	54-63	digoxin	drug	69-75	false
Argatroban	drug	54-63	erythromycin	drug	80-91	false
digoxin	drug	69-75	erythromycin	drug	80-91	false

DDI-DrugBank.d504.s0	There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.
loxapine	drug	122-129	lorazepam	drug	135-143	effect

DDI-DrugBank.d563.s0	Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.
ETHYOL	brand	63-68	antihypertensive medications	group	92-119	advise

DDI-DrugBank.d238.s2	Anafranil should not be used with MAO inhibitors.
Anafranil	brand	0-8	MAO inhibitors	group	34-47	advise

DDI-DrugBank.d238.s3	Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
Anafranil	brand	69-77	anticholinergic	group	100-114	advise
Anafranil	brand	69-77	sympathomimetic drugs	group	119-139	advise
anticholinergic	group	100-114	sympathomimetic drugs	group	119-139	false

DDI-DrugBank.d238.s4	Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
tricyclic antidepressants	group	8-32	guanethidine	drug	91-102	effect
tricyclic antidepressants	group	8-32	clonidine	drug	105-113	effect
tricyclic antidepressants	group	8-32	CMI	drug	178-180	effect
tricyclic antidepressants	group	8-32	tricyclic antidepressants	group	228-252	effect
guanethidine	drug	91-102	clonidine	drug	105-113	false
guanethidine	drug	91-102	CMI	drug	178-180	false
guanethidine	drug	91-102	tricyclic antidepressants	group	228-252	false
clonidine	drug	105-113	CMI	drug	178-180	false
clonidine	drug	105-113	tricyclic antidepressants	group	228-252	false
CMI	drug	178-180	tricyclic antidepressants	group	228-252	false

DDI-DrugBank.d238.s5	The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;
CMI	drug	28-30	haloperidol	drug	103-113	mechanism

DDI-DrugBank.d238.s6	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
tricyclic antidepressants	group	41-65	methylphenidate	drug	139-153	mechanism
tricyclic antidepressants	group	41-65	cimetidine	drug	191-200	mechanism
tricyclic antidepressants	group	41-65	fluoxetine	drug	203-212	mechanism
tricyclic antidepressants	group	41-65	barbiturates	group	297-308	mechanism
tricyclic antidepressants	group	41-65	phenytoin	drug	311-319	mechanism
tricyclic antidepressants	group	41-65	CMI	drug	366-368	false
methylphenidate	drug	139-153	cimetidine	drug	191-200	false
methylphenidate	drug	139-153	fluoxetine	drug	203-212	false
methylphenidate	drug	139-153	barbiturates	group	297-308	false
methylphenidate	drug	139-153	phenytoin	drug	311-319	false
methylphenidate	drug	139-153	CMI	drug	366-368	mechanism
cimetidine	drug	191-200	fluoxetine	drug	203-212	false
cimetidine	drug	191-200	barbiturates	group	297-308	false
cimetidine	drug	191-200	phenytoin	drug	311-319	false
cimetidine	drug	191-200	CMI	drug	366-368	mechanism
fluoxetine	drug	203-212	barbiturates	group	297-308	false
fluoxetine	drug	203-212	phenytoin	drug	311-319	false
fluoxetine	drug	203-212	CMI	drug	366-368	mechanism
barbiturates	group	297-308	phenytoin	drug	311-319	false
barbiturates	group	297-308	CMI	drug	366-368	mechanism
phenytoin	drug	311-319	CMI	drug	366-368	mechanism

DDI-DrugBank.d238.s7	Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.
CMI	drug	18-20	phenobarbital	drug	73-85	mechanism

DDI-DrugBank.d238.s10	Poor metabolizers have higher than expected lasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	group	68-92	TCAs	group	95-98	false

DDI-DrugBank.d238.s15	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	drug	0-9	antidepressants	group	66-80	false
cimetidine	drug	0-9	phenothiazines	group	83-96	false
cimetidine	drug	0-9	Type 1C antiarrhythmics	group	107-129	false
cimetidine	drug	0-9	propafenone	drug	131-141	false
cimetidine	drug	0-9	flecainide	drug	147-156	false
antidepressants	group	66-80	phenothiazines	group	83-96	false
antidepressants	group	66-80	Type 1C antiarrhythmics	group	107-129	false
antidepressants	group	66-80	propafenone	drug	131-141	false
antidepressants	group	66-80	flecainide	drug	147-156	false
phenothiazines	group	83-96	Type 1C antiarrhythmics	group	107-129	false
phenothiazines	group	83-96	propafenone	drug	131-141	false
phenothiazines	group	83-96	flecainide	drug	147-156	false
Type 1C antiarrhythmics	group	107-129	propafenone	drug	131-141	false
Type 1C antiarrhythmics	group	107-129	flecainide	drug	147-156	false
propafenone	drug	131-141	flecainide	drug	147-156	false

DDI-DrugBank.d238.s16	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	group	14-52	SSRIs	group	55-59	false
selective serotonin reuptake inhibitors	group	14-52	fluoxetine	drug	69-78	false
selective serotonin reuptake inhibitors	group	14-52	sertraline	drug	81-90	false
selective serotonin reuptake inhibitors	group	14-52	paroxetine	drug	93-102	false
selective serotonin reuptake inhibitors	group	14-52	fluvoxamine	drug	109-119	false
SSRIs	group	55-59	fluoxetine	drug	69-78	false
SSRIs	group	55-59	sertraline	drug	81-90	false
SSRIs	group	55-59	paroxetine	drug	93-102	false
SSRIs	group	55-59	fluvoxamine	drug	109-119	false
fluoxetine	drug	69-78	sertraline	drug	81-90	false
fluoxetine	drug	69-78	paroxetine	drug	93-102	false
fluoxetine	drug	69-78	fluvoxamine	drug	109-119	false
sertraline	drug	81-90	paroxetine	drug	93-102	false
sertraline	drug	81-90	fluvoxamine	drug	109-119	false
paroxetine	drug	93-102	fluvoxamine	drug	109-119	false

DDI-DrugBank.d238.s17	Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.
Fluvoxamine	drug	0-10	TCA	group	81-83	mechanism

DDI-DrugBank.d238.s18	The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	group	20-23	TCA	group	25-27	int
SSRI	group	20-23	SSRI	group	140-143	false
TCA	group	25-27	SSRI	group	140-143	false

DDI-DrugBank.d238.s19	Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
TCAs	group	63-66	SSRIs	group	84-88	advise

DDI-DrugBank.d238.s20	Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
TCA	group	72-74	fluoxetine	drug	119-128	advise

DDI-DrugBank.d238.s21	Concomitant use of agents in the tricyclic antidepressant class (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.
tricyclic antidepressant class	group	33-62	Anafranil	brand	80-88	false
tricyclic antidepressant class	group	33-62	tricyclic antidepressant agent	group	202-231	false
Anafranil	brand	80-88	tricyclic antidepressant agent	group	202-231	false

DDI-DrugBank.d238.s23	It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).
TCA	group	27-29	tricyclic antidepressant class	group	69-98	false
TCA	group	27-29	Anafranil	brand	110-118	false
tricyclic antidepressant class	group	69-98	Anafranil	brand	110-118	false

DDI-DrugBank.d238.s24	Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
Anafranil	brand	8-16	Anafranil	brand	74-82	false
Anafranil	brand	8-16	warfarin	drug	155-162	false
Anafranil	brand	8-16	digoxin	drug	165-171	false
Anafranil	brand	74-82	warfarin	drug	155-162	mechanism
Anafranil	brand	74-82	digoxin	drug	165-171	mechanism
warfarin	drug	155-162	digoxin	drug	165-171	false

DDI-DrugBank.d79.s0	The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
lymecycline	drug	18-28	iron	drug	106-109	mechanism
lymecycline	drug	18-28	zinc	drug	114-117	mechanism
iron	drug	106-109	zinc	drug	114-117	false

DDI-DrugBank.d79.s1	Oral contraceptives may be less effective while you are taking lymecycline.
contraceptives	group	5-18	lymecycline	drug	63-73	effect

DDI-DrugBank.d5.s0	Few systemic data have been collected on the metabolism of WELLBUTRIN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN on the metabolism of other drugs.
WELLBUTRIN	brand	59-68	WELLBUTRIN	brand	187-196	false

DDI-DrugBank.d5.s2	In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme.
bupropion	drug	31-39	hydroxybupropion	drug_n	69-84	false

DDI-DrugBank.d5.s3	Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
WELLBUTRIN	brand	63-72	orphenadrine	drug	124-135	int
WELLBUTRIN	brand	63-72	cyclophosphamide	drug	141-156	int
orphenadrine	drug	124-135	cyclophosphamide	drug	141-156	false

DDI-DrugBank.d5.s4	The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes.
threohydrobupropion	drug_n	4-22	bupropion	drug	38-46	false

DDI-DrugBank.d5.s5	The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.
cimetidine	drug	45-54	bupropion	drug	83-91	false

DDI-DrugBank.d5.s6	Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.
cimetidine	drug	97-106	bupropion	drug	133-141	false
cimetidine	drug	97-106	hydroxybupropion	drug_n	147-162	false
bupropion	drug	133-141	hydroxybupropion	drug_n	147-162	false

DDI-DrugBank.d5.s7	However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.
threohydrobupropion	drug_n	105-123	erythrohydrobupropion	drug_n	129-149	false

DDI-DrugBank.d5.s8	While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
bupropion	drug	77-85	carbamazepine	drug	94-106	mechanism
bupropion	drug	77-85	phenobarbital	drug	109-121	mechanism
bupropion	drug	77-85	phenytoin	drug	124-132	mechanism
carbamazepine	drug	94-106	phenobarbital	drug	109-121	false
carbamazepine	drug	94-106	phenytoin	drug	124-132	false
phenobarbital	drug	109-121	phenytoin	drug	124-132	false

DDI-DrugBank.d5.s12	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.
antidepressants	group	78-92	tricyclics	group	107-116	false
antidepressants	group	78-92	beta-blockers	group	120-132	false
antidepressants	group	78-92	antiarrhythmics	drug	135-149	false
antidepressants	group	78-92	antipsychotics	group	156-169	false
tricyclics	group	107-116	beta-blockers	group	120-132	false
tricyclics	group	107-116	antiarrhythmics	drug	135-149	false
tricyclics	group	107-116	antipsychotics	group	156-169	false
beta-blockers	group	120-132	antiarrhythmics	drug	135-149	false
beta-blockers	group	120-132	antipsychotics	group	156-169	false
antiarrhythmics	drug	135-149	antipsychotics	group	156-169	false

DDI-DrugBank.d5.s13	Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.
bupropion	drug	9-17	bupropion	drug	57-65	false
bupropion	drug	9-17	hydroxybupropion	drug_n	71-86	false
bupropion	drug	57-65	hydroxybupropion	drug_n	71-86	false

DDI-DrugBank.d5.s14	In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.
bupropion	drug	125-133	desipramine	drug	198-208	mechanism
bupropion	drug	125-133	desipramine	drug	247-257	false
desipramine	drug	198-208	desipramine	drug	247-257	false

DDI-DrugBank.d5.s17	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
bupropion	drug	32-40	antidepressants	group	112-126	advise
bupropion	drug	32-40	nortriptyline	drug	135-147	advise
bupropion	drug	32-40	imipramine	drug	150-159	advise
bupropion	drug	32-40	desipramine	drug	162-172	advise
bupropion	drug	32-40	paroxetine	drug	175-184	advise
bupropion	drug	32-40	fluoxetine	drug	187-196	advise
bupropion	drug	32-40	sertraline	drug	199-208	advise
bupropion	drug	32-40	antipsychotics	group	212-225	advise
bupropion	drug	32-40	haloperidol	drug	234-244	advise
bupropion	drug	32-40	risperidone	drug	247-257	advise
bupropion	drug	32-40	thioridazine	drug	260-271	advise
bupropion	drug	32-40	beta-blockers	group	275-287	advise
bupropion	drug	32-40	metoprolol	drug	296-305	advise
bupropion	drug	32-40	Type 1C antiarrhythmics	group	313-335	advise
bupropion	drug	32-40	propafenone	drug	344-354	advise
bupropion	drug	32-40	flecainide	drug	357-366	advise
antidepressants	group	112-126	nortriptyline	drug	135-147	false
antidepressants	group	112-126	imipramine	drug	150-159	false
antidepressants	group	112-126	desipramine	drug	162-172	false
antidepressants	group	112-126	paroxetine	drug	175-184	false
antidepressants	group	112-126	fluoxetine	drug	187-196	false
antidepressants	group	112-126	sertraline	drug	199-208	false
antidepressants	group	112-126	antipsychotics	group	212-225	false
antidepressants	group	112-126	haloperidol	drug	234-244	false
antidepressants	group	112-126	risperidone	drug	247-257	false
antidepressants	group	112-126	thioridazine	drug	260-271	false
antidepressants	group	112-126	beta-blockers	group	275-287	false
antidepressants	group	112-126	metoprolol	drug	296-305	false
antidepressants	group	112-126	Type 1C antiarrhythmics	group	313-335	false
antidepressants	group	112-126	propafenone	drug	344-354	false
antidepressants	group	112-126	flecainide	drug	357-366	false
nortriptyline	drug	135-147	imipramine	drug	150-159	false
nortriptyline	drug	135-147	desipramine	drug	162-172	false
nortriptyline	drug	135-147	paroxetine	drug	175-184	false
nortriptyline	drug	135-147	fluoxetine	drug	187-196	false
nortriptyline	drug	135-147	sertraline	drug	199-208	false
nortriptyline	drug	135-147	antipsychotics	group	212-225	false
nortriptyline	drug	135-147	haloperidol	drug	234-244	false
nortriptyline	drug	135-147	risperidone	drug	247-257	false
nortriptyline	drug	135-147	thioridazine	drug	260-271	false
nortriptyline	drug	135-147	beta-blockers	group	275-287	false
nortriptyline	drug	135-147	metoprolol	drug	296-305	false
nortriptyline	drug	135-147	Type 1C antiarrhythmics	group	313-335	false
nortriptyline	drug	135-147	propafenone	drug	344-354	false
nortriptyline	drug	135-147	flecainide	drug	357-366	false
imipramine	drug	150-159	desipramine	drug	162-172	false
imipramine	drug	150-159	paroxetine	drug	175-184	false
imipramine	drug	150-159	fluoxetine	drug	187-196	false
imipramine	drug	150-159	sertraline	drug	199-208	false
imipramine	drug	150-159	antipsychotics	group	212-225	false
imipramine	drug	150-159	haloperidol	drug	234-244	false
imipramine	drug	150-159	risperidone	drug	247-257	false
imipramine	drug	150-159	thioridazine	drug	260-271	false
imipramine	drug	150-159	beta-blockers	group	275-287	false
imipramine	drug	150-159	metoprolol	drug	296-305	false
imipramine	drug	150-159	Type 1C antiarrhythmics	group	313-335	false
imipramine	drug	150-159	propafenone	drug	344-354	false
imipramine	drug	150-159	flecainide	drug	357-366	false
desipramine	drug	162-172	paroxetine	drug	175-184	false
desipramine	drug	162-172	fluoxetine	drug	187-196	false
desipramine	drug	162-172	sertraline	drug	199-208	false
desipramine	drug	162-172	antipsychotics	group	212-225	false
desipramine	drug	162-172	haloperidol	drug	234-244	false
desipramine	drug	162-172	risperidone	drug	247-257	false
desipramine	drug	162-172	thioridazine	drug	260-271	false
desipramine	drug	162-172	beta-blockers	group	275-287	false
desipramine	drug	162-172	metoprolol	drug	296-305	false
desipramine	drug	162-172	Type 1C antiarrhythmics	group	313-335	false
desipramine	drug	162-172	propafenone	drug	344-354	false
desipramine	drug	162-172	flecainide	drug	357-366	false
paroxetine	drug	175-184	fluoxetine	drug	187-196	false
paroxetine	drug	175-184	sertraline	drug	199-208	false
paroxetine	drug	175-184	antipsychotics	group	212-225	false
paroxetine	drug	175-184	haloperidol	drug	234-244	false
paroxetine	drug	175-184	risperidone	drug	247-257	false
paroxetine	drug	175-184	thioridazine	drug	260-271	false
paroxetine	drug	175-184	beta-blockers	group	275-287	false
paroxetine	drug	175-184	metoprolol	drug	296-305	false
paroxetine	drug	175-184	Type 1C antiarrhythmics	group	313-335	false
paroxetine	drug	175-184	propafenone	drug	344-354	false
paroxetine	drug	175-184	flecainide	drug	357-366	false
fluoxetine	drug	187-196	sertraline	drug	199-208	false
fluoxetine	drug	187-196	antipsychotics	group	212-225	false
fluoxetine	drug	187-196	haloperidol	drug	234-244	false
fluoxetine	drug	187-196	risperidone	drug	247-257	false
fluoxetine	drug	187-196	thioridazine	drug	260-271	false
fluoxetine	drug	187-196	beta-blockers	group	275-287	false
fluoxetine	drug	187-196	metoprolol	drug	296-305	false
fluoxetine	drug	187-196	Type 1C antiarrhythmics	group	313-335	false
fluoxetine	drug	187-196	propafenone	drug	344-354	false
fluoxetine	drug	187-196	flecainide	drug	357-366	false
sertraline	drug	199-208	antipsychotics	group	212-225	false
sertraline	drug	199-208	haloperidol	drug	234-244	false
sertraline	drug	199-208	risperidone	drug	247-257	false
sertraline	drug	199-208	thioridazine	drug	260-271	false
sertraline	drug	199-208	beta-blockers	group	275-287	false
sertraline	drug	199-208	metoprolol	drug	296-305	false
sertraline	drug	199-208	Type 1C antiarrhythmics	group	313-335	false
sertraline	drug	199-208	propafenone	drug	344-354	false
sertraline	drug	199-208	flecainide	drug	357-366	false
antipsychotics	group	212-225	haloperidol	drug	234-244	false
antipsychotics	group	212-225	risperidone	drug	247-257	false
antipsychotics	group	212-225	thioridazine	drug	260-271	false
antipsychotics	group	212-225	beta-blockers	group	275-287	false
antipsychotics	group	212-225	metoprolol	drug	296-305	false
antipsychotics	group	212-225	Type 1C antiarrhythmics	group	313-335	false
antipsychotics	group	212-225	propafenone	drug	344-354	false
antipsychotics	group	212-225	flecainide	drug	357-366	false
haloperidol	drug	234-244	risperidone	drug	247-257	false
haloperidol	drug	234-244	thioridazine	drug	260-271	false
haloperidol	drug	234-244	beta-blockers	group	275-287	false
haloperidol	drug	234-244	metoprolol	drug	296-305	false
haloperidol	drug	234-244	Type 1C antiarrhythmics	group	313-335	false
haloperidol	drug	234-244	propafenone	drug	344-354	false
haloperidol	drug	234-244	flecainide	drug	357-366	false
risperidone	drug	247-257	thioridazine	drug	260-271	false
risperidone	drug	247-257	beta-blockers	group	275-287	false
risperidone	drug	247-257	metoprolol	drug	296-305	false
risperidone	drug	247-257	Type 1C antiarrhythmics	group	313-335	false
risperidone	drug	247-257	propafenone	drug	344-354	false
risperidone	drug	247-257	flecainide	drug	357-366	false
thioridazine	drug	260-271	beta-blockers	group	275-287	false
thioridazine	drug	260-271	metoprolol	drug	296-305	false
thioridazine	drug	260-271	Type 1C antiarrhythmics	group	313-335	false
thioridazine	drug	260-271	propafenone	drug	344-354	false
thioridazine	drug	260-271	flecainide	drug	357-366	false
beta-blockers	group	275-287	metoprolol	drug	296-305	false
beta-blockers	group	275-287	Type 1C antiarrhythmics	group	313-335	false
beta-blockers	group	275-287	propafenone	drug	344-354	false
beta-blockers	group	275-287	flecainide	drug	357-366	false
metoprolol	drug	296-305	Type 1C antiarrhythmics	group	313-335	false
metoprolol	drug	296-305	propafenone	drug	344-354	false
metoprolol	drug	296-305	flecainide	drug	357-366	false
Type 1C antiarrhythmics	group	313-335	propafenone	drug	344-354	false
Type 1C antiarrhythmics	group	313-335	flecainide	drug	357-366	false
propafenone	drug	344-354	flecainide	drug	357-366	false

DDI-DrugBank.d5.s19	MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .
MAO Inhibitors	group	0-13	bupropion	drug	74-82	false
MAO Inhibitors	group	0-13	MAO inhibitor	group	103-115	false
MAO Inhibitors	group	0-13	phenelzine	drug	117-126	false
bupropion	drug	74-82	MAO inhibitor	group	103-115	false
bupropion	drug	74-82	phenelzine	drug	117-126	effect
MAO inhibitor	group	103-115	phenelzine	drug	117-126	false

DDI-DrugBank.d5.s20	Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
Levodopa	drug	0-7	Amantadine	drug	13-22	false
Levodopa	drug	0-7	bupropion	drug	119-127	false
Levodopa	drug	0-7	levodopa	drug	154-161	false
Levodopa	drug	0-7	amantadine	drug	166-175	false
Amantadine	drug	13-22	bupropion	drug	119-127	false
Amantadine	drug	13-22	levodopa	drug	154-161	false
Amantadine	drug	13-22	amantadine	drug	166-175	false
bupropion	drug	119-127	levodopa	drug	154-161	effect
bupropion	drug	119-127	amantadine	drug	166-175	effect
levodopa	drug	154-161	amantadine	drug	166-175	false

DDI-DrugBank.d5.s21	Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
WELLBUTRIN	brand	18-27	levodopa	drug	66-73	advise
WELLBUTRIN	brand	18-27	amantadine	drug	78-87	advise
levodopa	drug	66-73	amantadine	drug	78-87	false

DDI-DrugBank.d5.s22	Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
WELLBUTRIN	brand	65-74	antipsychotics	group	94-107	advise
WELLBUTRIN	brand	65-74	antidepressants	group	116-130	advise
WELLBUTRIN	brand	65-74	theophylline	drug	133-144	advise
WELLBUTRIN	brand	65-74	steroids	group	156-163	advise
antipsychotics	group	94-107	antidepressants	group	116-130	false
antipsychotics	group	94-107	theophylline	drug	133-144	false
antipsychotics	group	94-107	steroids	group	156-163	false
antidepressants	group	116-130	theophylline	drug	133-144	false
antidepressants	group	116-130	steroids	group	156-163	false
theophylline	drug	133-144	steroids	group	156-163	false

DDI-DrugBank.d5.s25	Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.
Alcohol	drug	0-6	alcohol	drug	114-120	false
Alcohol	drug	0-6	alcohol	drug	162-168	false
Alcohol	drug	0-6	WELLBUTRIN	brand	192-201	false
alcohol	drug	114-120	alcohol	drug	162-168	false
alcohol	drug	114-120	WELLBUTRIN	brand	192-201	false
alcohol	drug	162-168	WELLBUTRIN	brand	192-201	effect

DDI-DrugBank.d5.s26	The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)
alcohol	drug	19-25	WELLBUTRIN	brand	49-58	advise

DDI-DrugBank.d371.s1	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
docetaxel	drug	51-59	cyclosporine	drug	197-208	mechanism
docetaxel	drug	51-59	terfenadine	drug	211-221	mechanism
docetaxel	drug	51-59	ketoconazole	drug	224-235	mechanism
docetaxel	drug	51-59	erythromycin	drug	238-249	mechanism
docetaxel	drug	51-59	troleandomycin	drug	256-269	mechanism
cyclosporine	drug	197-208	terfenadine	drug	211-221	false
cyclosporine	drug	197-208	ketoconazole	drug	224-235	false
cyclosporine	drug	197-208	erythromycin	drug	238-249	false
cyclosporine	drug	197-208	troleandomycin	drug	256-269	false
terfenadine	drug	211-221	ketoconazole	drug	224-235	false
terfenadine	drug	211-221	erythromycin	drug	238-249	false
terfenadine	drug	211-221	troleandomycin	drug	256-269	false
ketoconazole	drug	224-235	erythromycin	drug	238-249	false
ketoconazole	drug	224-235	troleandomycin	drug	256-269	false
erythromycin	drug	238-249	troleandomycin	drug	256-269	false

DDI-DrugBank.d180.s0	Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.
Digitalis	group	0-8	Bretylium Tosylate	drug	88-105	effect

DDI-DrugBank.d180.s1	The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
catecholamines	group	23-36	dopamine	drug	46-53	false
catecholamines	group	23-36	norepinephrine	drug	58-71	false
catecholamines	group	23-36	Bretylium Tosylate	drug	89-106	effect
dopamine	drug	46-53	norepinephrine	drug	58-71	false
dopamine	drug	46-53	Bretylium Tosylate	drug	89-106	effect
norepinephrine	drug	58-71	Bretylium Tosylate	drug	89-106	effect

DDI-DrugBank.d180.s3	Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.
lidocaine	drug	80-88	Bretylium Tosylate	drug	94-111	false

DDI-DrugBank.d137.s0	Nitrates: The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.
Nitrates	group	0-7	Bepridil	drug	33-40	false
Nitrates	group	0-7	nitrates	group	70-77	false
Bepridil	drug	33-40	nitrates	group	70-77	false

DDI-DrugBank.d137.s1	Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.
nitroglycerin	drug	11-23	Bepridil	drug	98-105	false

DDI-DrugBank.d137.s2	Beta-blocking Agents: The concomitant use of Bepridil and beta-blocking agents has been well tolerated in patients with stable angina.
Beta-blocking Agents	group	0-19	Bepridil	drug	45-52	false
Beta-blocking Agents	group	0-19	beta-blocking agents	group	58-77	false
Bepridil	drug	45-52	beta-blocking agents	group	58-77	false

DDI-DrugBank.d137.s4	Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.
Digoxin	drug	0-6	bepridil hydrochloride	drug	54-75	false
Digoxin	drug	0-6	digoxin	drug	197-203	false
bepridil hydrochloride	drug	54-75	digoxin	drug	197-203	mechanism

DDI-DrugBank.d137.s5	Limited clinical data in angina patients receiving concomitant bepridil hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels.
bepridil hydrochloride	drug	63-84	digoxin	drug	90-96	false

DDI-DrugBank.d137.s7	Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.
Hypoglycemics	group	5-17	Bepridil	drug	20-27	false
Hypoglycemics	group	5-17	insulin	drug	156-162	false
Hypoglycemics	group	5-17	hypoglycemic agents	group	172-190	false
Bepridil	drug	20-27	insulin	drug	156-162	false
Bepridil	drug	20-27	hypoglycemic agents	group	172-190	false
insulin	drug	156-162	hypoglycemic agents	group	172-190	false

DDI-DrugBank.d137.s9	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.
bepridil hydrochloride	drug	86-107	anti-arrhythmic agents	group	120-141	false
bepridil hydrochloride	drug	86-107	quinidine	drug	151-159	false
bepridil hydrochloride	drug	86-107	procainamide	drug	165-176	false
bepridil hydrochloride	drug	86-107	cardiac glycosides	group	179-196	false
bepridil hydrochloride	drug	86-107	tricyclic anti-depressants	group	202-227	false
anti-arrhythmic agents	group	120-141	quinidine	drug	151-159	false
anti-arrhythmic agents	group	120-141	procainamide	drug	165-176	false
anti-arrhythmic agents	group	120-141	cardiac glycosides	group	179-196	false
anti-arrhythmic agents	group	120-141	tricyclic anti-depressants	group	202-227	false
quinidine	drug	151-159	procainamide	drug	165-176	false
quinidine	drug	151-159	cardiac glycosides	group	179-196	false
quinidine	drug	151-159	tricyclic anti-depressants	group	202-227	false
procainamide	drug	165-176	cardiac glycosides	group	179-196	false
procainamide	drug	165-176	tricyclic anti-depressants	group	202-227	false
cardiac glycosides	group	179-196	tricyclic anti-depressants	group	202-227	false

DDI-DrugBank.d137.s10	Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
Anti-arrhythmics	group	0-15	tricyclic anti-depressants	group	21-46	false
Anti-arrhythmics	group	0-15	bepridil hydrochloride	drug	115-136	effect
tricyclic anti-depressants	group	21-46	bepridil hydrochloride	drug	115-136	effect

DDI-DrugBank.d137.s11	Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
Cardiac glycosides	group	0-17	bepridil hydrochloride	drug	88-109	effect

DDI-DrugBank.d317.s4	decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;
antithrombin III	drug	39-54	antithrombin III	drug	67-82	false

DDI-DrugBank.d317.s5	increased levels of fibrinogen and fibrinogen activity;
fibrinogen	drug	20-29	fibrinogen	drug	35-44	false

DDI-DrugBank.d317.s13	Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively.
corticosteroids	group	171-185	sex steroids	group	191-202	false

DDI-DrugBank.d329.s0	When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.
ertapenem	drug	5-13	probenecid	drug	39-48	false
ertapenem	drug	5-13	probenecid	drug	79-88	false
ertapenem	drug	5-13	ertapenem	drug	163-171	false
probenecid	drug	39-48	probenecid	drug	79-88	false
probenecid	drug	39-48	ertapenem	drug	163-171	false
probenecid	drug	79-88	ertapenem	drug	163-171	mechanism

DDI-DrugBank.d329.s1	Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.
ertapenem	drug	15-23	probenecid	drug	41-50	mechanism

DDI-DrugBank.d329.s3	Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.
probenecid	drug	68-77	ertapenem	drug	106-114	advise

DDI-DrugBank.d329.s4	In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
ertapenem	drug	31-39	digoxin	drug	95-101	false
ertapenem	drug	31-39	vinblastine	drug	106-116	false
ertapenem	drug	31-39	ertapenem	drug	127-135	false
digoxin	drug	95-101	vinblastine	drug	106-116	false
digoxin	drug	95-101	ertapenem	drug	127-135	false
vinblastine	drug	106-116	ertapenem	drug	127-135	false

DDI-DrugBank.d570.s0	Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
estrogen	group	97-104	contraceptives	group	122-135	false

DDI-DrugBank.d67.s0	In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.
desloratadine	drug	140-152	erythromycin	drug	223-234	false
desloratadine	drug	140-152	ketoconazole	drug	260-271	false
erythromycin	drug	223-234	ketoconazole	drug	260-271	false

DDI-DrugBank.d67.s1	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
desloratadine	drug	76-88	azithromycin	drug	148-159	false
desloratadine	drug	76-88	fluoxetine	drug	224-233	false
desloratadine	drug	76-88	fluoxetine	drug	303-312	false
desloratadine	drug	76-88	cimetidine	drug	329-338	false
azithromycin	drug	148-159	fluoxetine	drug	224-233	false
azithromycin	drug	148-159	fluoxetine	drug	303-312	false
azithromycin	drug	148-159	cimetidine	drug	329-338	false
fluoxetine	drug	224-233	fluoxetine	drug	303-312	false
fluoxetine	drug	224-233	cimetidine	drug	329-338	false
fluoxetine	drug	303-312	cimetidine	drug	329-338	false

DDI-DrugBank.d67.s2	Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.
desloratadine	drug	69-81	3-hydroxydesloratadine	drug_n	87-108	false
desloratadine	drug	69-81	desloratadine	drug	193-205	false
3-hydroxydesloratadine	drug_n	87-108	desloratadine	drug	193-205	false

DDI-DrugBank.d67.s3	Table 1 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers
Desloratadine	drug	19-31	3-Hydroxydesloratadine	drug_n	37-58	false

DDI-DrugBank.d67.s5	Desloratadine 3-Hydroxydesloratadine
Desloratadine	drug	0-12	3-Hydroxydesloratadine	drug_n	14-35	false

DDI-DrugBank.d343.s0	Aspirin, warfarin, heparin, NSAIDs
Aspirin	brand	0-6	warfarin	drug	9-16	false
Aspirin	brand	0-6	heparin	drug	19-25	false
Aspirin	brand	0-6	NSAIDs	group	28-33	false
warfarin	drug	9-16	heparin	drug	19-25	false
warfarin	drug	9-16	NSAIDs	group	28-33	false
heparin	drug	19-25	NSAIDs	group	28-33	false

DDI-DrugBank.d363.s0	No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials.
muscle relaxants	group	120-135	anesthetic agents	group	168-184	false

DDI-DrugBank.d363.s2	Like isoflurane, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.
isoflurane	drug	5-14	desflurane	drug	17-26	false
isoflurane	drug	5-14	epinephrine	drug	124-134	false
desflurane	drug	17-26	epinephrine	drug	124-134	false

DDI-DrugBank.d136.s0	Alcohol (increases bioavailability by 50%), cimetidine, and valproates.
Alcohol	drug	0-6	cimetidine	drug	44-53	false

DDI-DrugBank.d410.s0	Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
Vasoconstrictors	group	0-15	D.H.E. 45	brand	18-26	false
Vasoconstrictors	group	0-15	dihydroergotamine mesylate	drug	30-55	false
Vasoconstrictors	group	0-15	peripheral vasoconstrictors	group	97-123	false
D.H.E. 45	brand	18-26	dihydroergotamine mesylate	drug	30-55	false
D.H.E. 45	brand	18-26	peripheral vasoconstrictors	group	97-123	effect
dihydroergotamine mesylate	drug	30-55	peripheral vasoconstrictors	group	97-123	effect

DDI-DrugBank.d410.s1	Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
Sumatriptan	drug	0-10	Sumatriptan	drug	13-23	false
Sumatriptan	drug	0-10	D.H.E. 45	brand	117-125	false
Sumatriptan	drug	0-10	dihydroergotamine mesylate	drug	129-154	false
Sumatriptan	drug	13-23	D.H.E. 45	brand	117-125	effect
Sumatriptan	drug	13-23	dihydroergotamine mesylate	drug	129-154	effect
D.H.E. 45	brand	117-125	dihydroergotamine mesylate	drug	129-154	false

DDI-DrugBank.d410.s2	Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
Sumatriptan	drug	0-10	D.H.E. 45	brand	16-24	advise
Sumatriptan	drug	0-10	dihydroergotamine mesylate	drug	28-53	advise
D.H.E. 45	brand	16-24	dihydroergotamine mesylate	drug	28-53	false

DDI-DrugBank.d410.s3	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
Beta Blockers	group	0-12	D.H.E. 45	brand	126-134	false
Beta Blockers	group	0-12	dihydroergotamine mesylate	drug	138-163	false
Beta Blockers	group	0-12	propranolol	drug	211-221	false
Beta Blockers	group	0-12	propranolol	drug	253-263	false
Beta Blockers	group	0-12	ergotamine	drug	311-320	false
D.H.E. 45	brand	126-134	dihydroergotamine mesylate	drug	138-163	false
D.H.E. 45	brand	126-134	propranolol	drug	211-221	false
D.H.E. 45	brand	126-134	propranolol	drug	253-263	false
D.H.E. 45	brand	126-134	ergotamine	drug	311-320	false
dihydroergotamine mesylate	drug	138-163	propranolol	drug	211-221	false
dihydroergotamine mesylate	drug	138-163	propranolol	drug	253-263	false
dihydroergotamine mesylate	drug	138-163	ergotamine	drug	311-320	false
propranolol	drug	211-221	propranolol	drug	253-263	false
propranolol	drug	211-221	ergotamine	drug	311-320	false
propranolol	drug	253-263	ergotamine	drug	311-320	effect

DDI-DrugBank.d410.s4	Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
Nicotine	drug	0-7	Nicotine	drug	10-17	false
Nicotine	drug	0-7	ergot	drug	113-117	false
Nicotine	drug	10-17	ergot	drug	113-117	effect

DDI-DrugBank.d410.s5	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
Macrolide Antibiotics	group	0-20	erythromycin	drug	29-40	false
Macrolide Antibiotics	group	0-20	troleandomycin	drug	46-59	false
Macrolide Antibiotics	group	0-20	ergot alkaloid class	group	77-96	false
Macrolide Antibiotics	group	0-20	D.H.E. 45	brand	108-116	false
Macrolide Antibiotics	group	0-20	dihydroergotamine mesylate	drug	120-145	false
Macrolide Antibiotics	group	0-20	antibiotics	group	209-219	false
Macrolide Antibiotics	group	0-20	macrolide class	group	228-242	false
erythromycin	drug	29-40	troleandomycin	drug	46-59	false
erythromycin	drug	29-40	ergot alkaloid class	group	77-96	false
erythromycin	drug	29-40	D.H.E. 45	brand	108-116	false
erythromycin	drug	29-40	dihydroergotamine mesylate	drug	120-145	false
erythromycin	drug	29-40	antibiotics	group	209-219	false
erythromycin	drug	29-40	macrolide class	group	228-242	false
troleandomycin	drug	46-59	ergot alkaloid class	group	77-96	false
troleandomycin	drug	46-59	D.H.E. 45	brand	108-116	false
troleandomycin	drug	46-59	dihydroergotamine mesylate	drug	120-145	false
troleandomycin	drug	46-59	antibiotics	group	209-219	false
troleandomycin	drug	46-59	macrolide class	group	228-242	false
ergot alkaloid class	group	77-96	D.H.E. 45	brand	108-116	false
ergot alkaloid class	group	77-96	dihydroergotamine mesylate	drug	120-145	false
ergot alkaloid class	group	77-96	antibiotics	group	209-219	false
ergot alkaloid class	group	77-96	macrolide class	group	228-242	mechanism
D.H.E. 45	brand	108-116	dihydroergotamine mesylate	drug	120-145	false
D.H.E. 45	brand	108-116	antibiotics	group	209-219	false
D.H.E. 45	brand	108-116	macrolide class	group	228-242	mechanism
dihydroergotamine mesylate	drug	120-145	antibiotics	group	209-219	false
dihydroergotamine mesylate	drug	120-145	macrolide class	group	228-242	mechanism
antibiotics	group	209-219	macrolide class	group	228-242	false

DDI-DrugBank.d410.s6	Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.
ergotamine	drug	67-76	antibiotics	group	127-137	effect

DDI-DrugBank.d410.s7	SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.
SSRIs	group	0-4	5-HT1 agonists	group	81-94	false
SSRIs	group	0-4	SSRIs	group	127-131	false
5-HT1 agonists	group	81-94	SSRIs	group	127-131	effect

DDI-DrugBank.d410.s8	fluoxetine, fluvoxamine, paroxetine, sertraline).
fluoxetine	drug	0-9	fluvoxamine	drug	12-22	false
fluoxetine	drug	0-9	paroxetine	drug	25-34	false
fluoxetine	drug	0-9	sertraline	drug	37-46	false
fluvoxamine	drug	12-22	paroxetine	drug	25-34	false
fluvoxamine	drug	12-22	sertraline	drug	37-46	false
paroxetine	drug	25-34	sertraline	drug	37-46	false

DDI-DrugBank.d410.s9	There have been no reported cases from spontaneous reports of drug interaction between SSRIs and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
SSRIs	group	87-91	D.H.E. 45	brand	97-105	false
SSRIs	group	87-91	dihydroergotamine mesylate	drug	109-134	false
D.H.E. 45	brand	97-105	dihydroergotamine mesylate	drug	109-134	false

DDI-DrugBank.d410.s10	Oral Contraceptives: The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP has not been studied.
Contraceptives	group	5-18	contraceptives	group	40-53	false
Contraceptives	group	5-18	D.H.E. 45	brand	82-90	false
Contraceptives	group	5-18	dihydroergotamine mesylate	drug	94-119	false
contraceptives	group	40-53	D.H.E. 45	brand	82-90	false
contraceptives	group	40-53	dihydroergotamine mesylate	drug	94-119	false
D.H.E. 45	brand	82-90	dihydroergotamine mesylate	drug	94-119	false

DDI-DrugBank.d526.s1	Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.
Amphotericin B	drug	0-13	potassium-depleting diuretics	group	18-46	false
Amphotericin B	drug	0-13	benzothiadiazines	group	49-65	false
Amphotericin B	drug	0-13	ethacrynic acid	drug	86-100	false
Amphotericin B	drug	0-13	furosemide	drug	106-115	false
potassium-depleting diuretics	group	18-46	benzothiadiazines	group	49-65	false
potassium-depleting diuretics	group	18-46	ethacrynic acid	drug	86-100	false
potassium-depleting diuretics	group	18-46	furosemide	drug	106-115	false
benzothiadiazines	group	49-65	ethacrynic acid	drug	86-100	false
benzothiadiazines	group	49-65	furosemide	drug	106-115	false
ethacrynic acid	drug	86-100	furosemide	drug	106-115	false

DDI-DrugBank.d526.s4	Digitalis glycosides enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalemia.
Digitalis glycosides	group	0-19	digitalis	group	60-68	false

DDI-DrugBank.d526.s9	Antidiabetic drugs (oral agents and insulin) diminished antidiabetic effect.
Antidiabetic drugs	group	0-17	insulin	drug	36-42	false

DDI-DrugBank.d526.s14	Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.
salicylate	group	7-16	steroids	group	65-72	false
salicylate	group	7-16	aspirin	brand	101-107	false
steroids	group	65-72	aspirin	brand	101-107	effect

DDI-DrugBank.d526.s15	Monitor salicylate levels or the therapeutic effect for which aspirin is given;
salicylate	group	8-17	aspirin	brand	62-68	false

DDI-DrugBank.d526.s17	Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
Barbiturates	group	0-11	phenytoin	drug	14-22	false
Barbiturates	group	0-11	rifampin	drug	28-35	false
Barbiturates	group	0-11	fludrocortisone acetate	drug	70-92	mechanism
phenytoin	drug	14-22	rifampin	drug	28-35	false
phenytoin	drug	14-22	fludrocortisone acetate	drug	70-92	mechanism
rifampin	drug	28-35	fludrocortisone acetate	drug	70-92	mechanism

DDI-DrugBank.d526.s18	Observe the patient for possible diminished effect of steroid and increase the steroid dosage accordingly.
steroid	group	54-60	steroid	group	79-85	false

DDI-DrugBank.d526.s19	Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.
Anabolic steroids	group	0-16	androgens	group	47-55	false
Anabolic steroids	group	0-16	oxymetholone	drug	65-76	false
Anabolic steroids	group	0-16	methandrostenolone	drug	79-96	false
Anabolic steroids	group	0-16	norethandrolone	drug	99-113	false
androgens	group	47-55	oxymetholone	drug	65-76	false
androgens	group	47-55	methandrostenolone	drug	79-96	false
androgens	group	47-55	norethandrolone	drug	99-113	false
oxymetholone	drug	65-76	methandrostenolone	drug	79-96	false
oxymetholone	drug	65-76	norethandrolone	drug	99-113	false
methandrostenolone	drug	79-96	norethandrolone	drug	99-113	false

DDI-DrugBank.d526.s24	When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.
estrogen	group	5-12	corticosteroid	group	51-64	false
estrogen	group	5-12	estrogen	group	133-140	false
corticosteroid	group	51-64	estrogen	group	133-140	false

DDI-DrugBank.d522.s0	Terfenadine: In a prospective study involving six-healthy-male volunteers, dirithromycin did not affect the metabolism of terfenadine.
Terfenadine	drug	0-10	dirithromycin	drug	75-87	false
Terfenadine	drug	0-10	terfenadine	drug	122-132	false
dirithromycin	drug	75-87	terfenadine	drug	122-132	false

DDI-DrugBank.d522.s1	These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.
terfenadine	drug	30-40	terfenadine	drug	92-102	false
terfenadine	drug	30-40	dirithromycin	drug	124-136	false
terfenadine	drug	92-102	dirithromycin	drug	124-136	false

DDI-DrugBank.d522.s3	The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.
terfenadine	drug	24-34	terfenadine	drug	143-153	false
terfenadine	drug	24-34	terfenadine	drug	171-181	false
terfenadine	drug	24-34	dirithromycin	drug	188-200	false
terfenadine	drug	143-153	terfenadine	drug	171-181	false
terfenadine	drug	143-153	dirithromycin	drug	188-200	false
terfenadine	drug	171-181	dirithromycin	drug	188-200	false

DDI-DrugBank.d522.s5	in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.
terfenadine	drug	25-35	terfenadine	drug	56-66	false
terfenadine	drug	25-35	terfenadine	drug	93-103	false
terfenadine	drug	25-35	dirithromycin	drug	110-122	false
terfenadine	drug	56-66	terfenadine	drug	93-103	false
terfenadine	drug	56-66	dirithromycin	drug	110-122	false
terfenadine	drug	93-103	dirithromycin	drug	110-122	mechanism

DDI-DrugBank.d522.s7	The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.
terfenadine	drug	43-53	terfenadine	drug	74-84	false
terfenadine	drug	43-53	dirithromycin	drug	91-103	false
terfenadine	drug	74-84	dirithromycin	drug	91-103	effect

DDI-DrugBank.d522.s8	Also, in vitro experiments demonstrated a lack of interaction between dirithromycin and terfenadine.
dirithromycin	drug	70-82	terfenadine	drug	88-98	false

DDI-DrugBank.d522.s9	Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
erythromycin	drug	39-50	terfenadine	drug	56-66	int
erythromycin	drug	39-50	dirithromycin	drug	88-100	false
terfenadine	drug	56-66	dirithromycin	drug	88-100	false

DDI-DrugBank.d522.s10	Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.
terfenadine	drug	91-101	macrolide antibiotics	group	128-148	effect

DDI-DrugBank.d522.s11	In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.
macrolides	group	18-27	terfenadine	drug	71-81	advise

DDI-DrugBank.d522.s12	Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.
Theophylline	drug	0-11	dirithromycin	drug	56-68	false
Theophylline	drug	0-11	theophylline	drug	114-125	false
Theophylline	drug	0-11	theophylline	drug	237-248	false
dirithromycin	drug	56-68	theophylline	drug	114-125	false
dirithromycin	drug	56-68	theophylline	drug	237-248	false
theophylline	drug	114-125	theophylline	drug	237-248	false

DDI-DrugBank.d522.s13	In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.
dirithromycin	drug	39-51	theophylline	drug	83-94	false
dirithromycin	drug	39-51	theophylline	drug	142-153	false
dirithromycin	drug	39-51	theophylline	drug	179-190	false
theophylline	drug	83-94	theophylline	drug	142-153	false
theophylline	drug	83-94	theophylline	drug	179-190	false
theophylline	drug	142-153	theophylline	drug	179-190	false

DDI-DrugBank.d522.s14	However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.
theophylline	drug	9-20	theophylline	drug	169-180	false
theophylline	drug	9-20	theophylline	drug	254-265	false
theophylline	drug	169-180	theophylline	drug	254-265	false

DDI-DrugBank.d522.s15	Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
Antacids	group	0-7	H 2 receptor antagonists	group	12-35	false
Antacids	group	0-7	dirithromycin	drug	43-55	false
Antacids	group	0-7	antacids	group	95-102	false
Antacids	group	0-7	H 2 -receptor antagonists	group	107-131	false
Antacids	group	0-7	dirithromycin	drug	152-164	false
H 2 receptor antagonists	group	12-35	dirithromycin	drug	43-55	false
H 2 receptor antagonists	group	12-35	antacids	group	95-102	false
H 2 receptor antagonists	group	12-35	H 2 -receptor antagonists	group	107-131	false
H 2 receptor antagonists	group	12-35	dirithromycin	drug	152-164	false
dirithromycin	drug	43-55	antacids	group	95-102	mechanism
dirithromycin	drug	43-55	H 2 -receptor antagonists	group	107-131	mechanism
dirithromycin	drug	43-55	dirithromycin	drug	152-164	false
antacids	group	95-102	H 2 -receptor antagonists	group	107-131	false
antacids	group	95-102	dirithromycin	drug	152-164	false
H 2 -receptor antagonists	group	107-131	dirithromycin	drug	152-164	false

DDI-DrugBank.d522.s19	Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
Triazolam	drug	0-8	Erythromycin	drug	11-22	false
Triazolam	drug	0-8	triazolam	drug	71-79	false
Triazolam	drug	0-8	triazolam	drug	133-141	false
Erythromycin	drug	11-22	triazolam	drug	71-79	mechanism
Erythromycin	drug	11-22	triazolam	drug	133-141	effect
triazolam	drug	71-79	triazolam	drug	133-141	false

DDI-DrugBank.d522.s20	Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
Digoxin	drug	0-6	erythromycin	drug	39-50	false
Digoxin	drug	0-6	digoxin	drug	56-62	false
Digoxin	drug	0-6	digoxin	drug	104-110	false
erythromycin	drug	39-50	digoxin	drug	56-62	mechanism
erythromycin	drug	39-50	digoxin	drug	104-110	false
digoxin	drug	56-62	digoxin	drug	104-110	false

DDI-DrugBank.d522.s21	Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
Anticoagulants	group	0-13	erythromycin	drug	80-91	false
Anticoagulants	group	0-13	anticoagulants	group	102-115	false
erythromycin	drug	80-91	anticoagulants	group	102-115	effect

DDI-DrugBank.d522.s23	Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
Ergotamine	drug	0-9	erythromycin	drug	30-41	false
Ergotamine	drug	0-9	ergotamine	drug	47-56	false
Ergotamine	drug	0-9	dihydroergotamine	drug	61-77	false
erythromycin	drug	30-41	ergotamine	drug	47-56	effect
erythromycin	drug	30-41	dihydroergotamine	drug	61-77	effect
ergotamine	drug	47-56	dihydroergotamine	drug	61-77	false

DDI-DrugBank.d522.s24	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
erythromycin	drug	84-95	cyclosporine	drug	130-141	int
erythromycin	drug	84-95	hexobarbital	drug	144-155	int
erythromycin	drug	84-95	carbamazepine	drug	158-170	int
erythromycin	drug	84-95	alfentanil	drug	173-182	int
erythromycin	drug	84-95	disopyramide	drug	185-196	int
erythromycin	drug	84-95	phenytoin	drug	199-207	int
erythromycin	drug	84-95	bromocriptine	drug	210-222	int
erythromycin	drug	84-95	valproate	drug	225-233	int
erythromycin	drug	84-95	astemizole	drug	236-245	int
erythromycin	drug	84-95	lovastatin	drug	252-261	int
cyclosporine	drug	130-141	hexobarbital	drug	144-155	false
cyclosporine	drug	130-141	carbamazepine	drug	158-170	false
cyclosporine	drug	130-141	alfentanil	drug	173-182	false
cyclosporine	drug	130-141	disopyramide	drug	185-196	false
cyclosporine	drug	130-141	phenytoin	drug	199-207	false
cyclosporine	drug	130-141	bromocriptine	drug	210-222	false
cyclosporine	drug	130-141	valproate	drug	225-233	false
cyclosporine	drug	130-141	astemizole	drug	236-245	false
cyclosporine	drug	130-141	lovastatin	drug	252-261	false
hexobarbital	drug	144-155	carbamazepine	drug	158-170	false
hexobarbital	drug	144-155	alfentanil	drug	173-182	false
hexobarbital	drug	144-155	disopyramide	drug	185-196	false
hexobarbital	drug	144-155	phenytoin	drug	199-207	false
hexobarbital	drug	144-155	bromocriptine	drug	210-222	false
hexobarbital	drug	144-155	valproate	drug	225-233	false
hexobarbital	drug	144-155	astemizole	drug	236-245	false
hexobarbital	drug	144-155	lovastatin	drug	252-261	false
carbamazepine	drug	158-170	alfentanil	drug	173-182	false
carbamazepine	drug	158-170	disopyramide	drug	185-196	false
carbamazepine	drug	158-170	phenytoin	drug	199-207	false
carbamazepine	drug	158-170	bromocriptine	drug	210-222	false
carbamazepine	drug	158-170	valproate	drug	225-233	false
carbamazepine	drug	158-170	astemizole	drug	236-245	false
carbamazepine	drug	158-170	lovastatin	drug	252-261	false
alfentanil	drug	173-182	disopyramide	drug	185-196	false
alfentanil	drug	173-182	phenytoin	drug	199-207	false
alfentanil	drug	173-182	bromocriptine	drug	210-222	false
alfentanil	drug	173-182	valproate	drug	225-233	false
alfentanil	drug	173-182	astemizole	drug	236-245	false
alfentanil	drug	173-182	lovastatin	drug	252-261	false
disopyramide	drug	185-196	phenytoin	drug	199-207	false
disopyramide	drug	185-196	bromocriptine	drug	210-222	false
disopyramide	drug	185-196	valproate	drug	225-233	false
disopyramide	drug	185-196	astemizole	drug	236-245	false
disopyramide	drug	185-196	lovastatin	drug	252-261	false
phenytoin	drug	199-207	bromocriptine	drug	210-222	false
phenytoin	drug	199-207	valproate	drug	225-233	false
phenytoin	drug	199-207	astemizole	drug	236-245	false
phenytoin	drug	199-207	lovastatin	drug	252-261	false
bromocriptine	drug	210-222	valproate	drug	225-233	false
bromocriptine	drug	210-222	astemizole	drug	236-245	false
bromocriptine	drug	210-222	lovastatin	drug	252-261	false
valproate	drug	225-233	astemizole	drug	236-245	false
valproate	drug	225-233	lovastatin	drug	252-261	false
astemizole	drug	236-245	lovastatin	drug	252-261	false

DDI-DrugBank.d541.s0	May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).
beta-adrenergic blocking agents	group	33-63	adrenergic bronchodilators	group	128-153	false
beta-adrenergic blocking agents	group	33-63	disopyramide	drug	182-193	false
beta-adrenergic blocking agents	group	33-63	quinidine	drug	196-204	false
beta-adrenergic blocking agents	group	33-63	phenothiazines	group	207-220	false
beta-adrenergic blocking agents	group	33-63	procainamide	drug	227-238	false
adrenergic bronchodilators	group	128-153	disopyramide	drug	182-193	false
adrenergic bronchodilators	group	128-153	quinidine	drug	196-204	false
adrenergic bronchodilators	group	128-153	phenothiazines	group	207-220	false
adrenergic bronchodilators	group	128-153	procainamide	drug	227-238	false
disopyramide	drug	182-193	quinidine	drug	196-204	false
disopyramide	drug	182-193	phenothiazines	group	207-220	false
disopyramide	drug	182-193	procainamide	drug	227-238	false
quinidine	drug	196-204	phenothiazines	group	207-220	false
quinidine	drug	196-204	procainamide	drug	227-238	false
phenothiazines	group	207-220	procainamide	drug	227-238	false

DDI-DrugBank.d247.s1	All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
vasopressors	group	4-15	monoamine oxidase (MAO) inhibitors	group	62-95	advise

DDI-DrugBank.d247.s2	Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
Epinephrine	drug	0-10	sympathomimetic drugs	group	64-84	advise
Epinephrine	drug	0-10	isoproterenol	drug	95-107	advise
sympathomimetic drugs	group	64-84	isoproterenol	drug	95-107	false

DDI-DrugBank.d247.s5	Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
epinephrine	drug	18-28	cyclopropane	drug	52-63	effect
epinephrine	drug	18-28	halogenated hydrocarbon general anesthetics	group	68-110	effect
epinephrine	drug	18-28	halothane	drug	120-128	effect
cyclopropane	drug	52-63	halogenated hydrocarbon general anesthetics	group	68-110	false
cyclopropane	drug	52-63	halothane	drug	120-128	false
halogenated hydrocarbon general anesthetics	group	68-110	halothane	drug	120-128	false

DDI-DrugBank.d247.s7	Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
Epinephrine	drug	0-10	digitalis	group	67-75	advise
Epinephrine	drug	0-10	glycosides	group	78-87	advise
Epinephrine	drug	0-10	sympathomimetic drugs	group	138-158	false
digitalis	group	67-75	glycosides	group	78-87	false
digitalis	group	67-75	sympathomimetic drugs	group	138-158	false
glycosides	group	78-87	sympathomimetic drugs	group	138-158	false

DDI-DrugBank.d247.s8	Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.
Diuretic agents	group	0-14	epinephrine	drug	72-82	effect

DDI-DrugBank.d247.s9	Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
Epinephrine	drug	0-10	guanethidine	drug	59-70	effect

DDI-DrugBank.d426.s1	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
ergotamine	drug	67-76	ergot-type medications	group	92-113	false
ergotamine	drug	67-76	dihydroergotamine	drug	121-137	false
ergotamine	drug	67-76	methysergide	drug	142-153	false
ergotamine	drug	67-76	FROVA	brand	160-164	advise
ergot-type medications	group	92-113	dihydroergotamine	drug	121-137	false
ergot-type medications	group	92-113	methysergide	drug	142-153	false
ergot-type medications	group	92-113	FROVA	brand	160-164	advise
dihydroergotamine	drug	121-137	methysergide	drug	142-153	false
dihydroergotamine	drug	121-137	FROVA	brand	160-164	advise
methysergide	drug	142-153	FROVA	brand	160-164	advise

DDI-DrugBank.d426.s3	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
Selective serotonin reuptake inhibitors	group	0-38	SSRIs	group	41-45	false
Selective serotonin reuptake inhibitors	group	0-38	fluoxetine	drug	55-64	false
Selective serotonin reuptake inhibitors	group	0-38	fluvoxamine	drug	67-77	false
Selective serotonin reuptake inhibitors	group	0-38	paroxetine	drug	80-89	false
Selective serotonin reuptake inhibitors	group	0-38	sertraline	drug	92-101	false
Selective serotonin reuptake inhibitors	group	0-38	5-HT1 agonists	group	210-223	effect
SSRIs	group	41-45	fluoxetine	drug	55-64	false
SSRIs	group	41-45	fluvoxamine	drug	67-77	false
SSRIs	group	41-45	paroxetine	drug	80-89	false
SSRIs	group	41-45	sertraline	drug	92-101	false
SSRIs	group	41-45	5-HT1 agonists	group	210-223	effect
fluoxetine	drug	55-64	fluvoxamine	drug	67-77	false
fluoxetine	drug	55-64	paroxetine	drug	80-89	false
fluoxetine	drug	55-64	sertraline	drug	92-101	false
fluoxetine	drug	55-64	5-HT1 agonists	group	210-223	effect
fluvoxamine	drug	67-77	paroxetine	drug	80-89	false
fluvoxamine	drug	67-77	sertraline	drug	92-101	false
fluvoxamine	drug	67-77	5-HT1 agonists	group	210-223	effect
paroxetine	drug	80-89	sertraline	drug	92-101	false
paroxetine	drug	80-89	5-HT1 agonists	group	210-223	effect
sertraline	drug	92-101	5-HT1 agonists	group	210-223	effect

DDI-DrugBank.d426.s4	If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
frovatriptan	drug	30-41	SSRI	group	50-53	advise

DDI-DrugBank.d231.s0	Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.
Furosemide	drug	0-9	aminoglycoside antibiotics	group	50-75	effect

DDI-DrugBank.d231.s2	Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.
Furosemide	drug	0-9	ethacrynic acid	drug	49-63	advise

DDI-DrugBank.d231.s3	Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
salicylates	group	33-43	furosemide	drug	64-73	effect
salicylates	group	33-43	salicylate	group	116-125	false
furosemide	drug	64-73	salicylate	group	116-125	false

DDI-DrugBank.d231.s4	Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
Furosemide	drug	0-9	tubocurarine	drug	79-90	effect
Furosemide	drug	0-9	succinylcholine	drug	125-139	effect
tubocurarine	drug	79-90	succinylcholine	drug	125-139	false

DDI-DrugBank.d231.s5	Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.
Lithium	drug	0-6	diuretics	group	43-51	advise
Lithium	drug	0-6	lithium	drug	73-79	false
Lithium	drug	0-6	lithium	drug	121-127	false
diuretics	group	43-51	lithium	drug	73-79	false
diuretics	group	43-51	lithium	drug	121-127	false
lithium	drug	73-79	lithium	drug	121-127	false

DDI-DrugBank.d231.s6	Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.
Furosemide	drug	0-9	antihypertensive drugs	group	68-89	effect

DDI-DrugBank.d231.s7	Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
ganglionic adrenergic blocking drugs	group	25-34;50-74	peripheral adrenergic blocking drugs	group	39-74	false

DDI-DrugBank.d231.s8	Furosemide may decrease arterial responsiveness to norepinephrine.
Furosemide	drug	0-9	norepinephrine	drug	51-64	effect

DDI-DrugBank.d231.s10	Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.
sucralfate	drug	39-48	furosemide	drug	54-63	effect
sucralfate	drug	39-48	furosemide	drug	132-141	false
furosemide	drug	54-63	furosemide	drug	132-141	false

DDI-DrugBank.d231.s12	The intake of furosemide and sucralfate should be separated by at least two hours.
furosemide	drug	14-23	sucralfate	drug	29-38	advise

DDI-DrugBank.d231.s13	Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
furosemide	drug	101-110	acetylsalicylic acid	drug	116-135	effect

DDI-DrugBank.d231.s14	There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
furosemide	drug	130-139	NSAIDs	group	170-175	effect

DDI-DrugBank.d231.s15	Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
indomethacin	drug	53-64	furosemide	drug	125-134	effect

DDI-DrugBank.d231.s17	Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
indomethacin	drug	24-35	furosemide	drug	41-50	advise
indomethacin	drug	24-35	furosemide	drug	150-159	false
furosemide	drug	41-50	furosemide	drug	150-159	false

DDI-DrugBank.d161.s1	For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.
Gemzar	brand	43-48	cisplatin	drug	54-62	false

DDI-DrugBank.d469.s0	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;
TRACRIUM	brand	61-68	enflurane	drug	79-87	effect

DDI-DrugBank.d469.s3	certain antibiotics, especially the aminoglycosides and polymyxins;
antibiotics	group	8-18	aminoglycosides	group	36-50	false
antibiotics	group	8-18	polymyxins	group	56-65	false
aminoglycosides	group	36-50	polymyxins	group	56-65	false

DDI-DrugBank.d469.s7	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
TRACRIUM	brand	61-68	enflurane	drug	79-87	effect
TRACRIUM	brand	61-68	isoflurane	drug	89-98	effect
TRACRIUM	brand	61-68	halothane	drug	100-108	effect
TRACRIUM	brand	61-68	antibiotics	group	118-128	effect
TRACRIUM	brand	61-68	aminoglycosides	group	146-160	effect
TRACRIUM	brand	61-68	polymyxins	group	166-175	effect
TRACRIUM	brand	61-68	lithium	drug	177-183	effect
TRACRIUM	brand	61-68	magnesium	drug	185-193	effect
TRACRIUM	brand	61-68	procainamide	drug	201-212	effect
TRACRIUM	brand	61-68	quinidine	drug	218-226	effect
enflurane	drug	79-87	isoflurane	drug	89-98	false
enflurane	drug	79-87	halothane	drug	100-108	false
enflurane	drug	79-87	antibiotics	group	118-128	false
enflurane	drug	79-87	aminoglycosides	group	146-160	false
enflurane	drug	79-87	polymyxins	group	166-175	false
enflurane	drug	79-87	lithium	drug	177-183	false
enflurane	drug	79-87	magnesium	drug	185-193	false
enflurane	drug	79-87	procainamide	drug	201-212	false
enflurane	drug	79-87	quinidine	drug	218-226	false
isoflurane	drug	89-98	halothane	drug	100-108	false
isoflurane	drug	89-98	antibiotics	group	118-128	false
isoflurane	drug	89-98	aminoglycosides	group	146-160	false
isoflurane	drug	89-98	polymyxins	group	166-175	false
isoflurane	drug	89-98	lithium	drug	177-183	false
isoflurane	drug	89-98	magnesium	drug	185-193	false
isoflurane	drug	89-98	procainamide	drug	201-212	false
isoflurane	drug	89-98	quinidine	drug	218-226	false
halothane	drug	100-108	antibiotics	group	118-128	false
halothane	drug	100-108	aminoglycosides	group	146-160	false
halothane	drug	100-108	polymyxins	group	166-175	false
halothane	drug	100-108	lithium	drug	177-183	false
halothane	drug	100-108	magnesium	drug	185-193	false
halothane	drug	100-108	procainamide	drug	201-212	false
halothane	drug	100-108	quinidine	drug	218-226	false
antibiotics	group	118-128	aminoglycosides	group	146-160	false
antibiotics	group	118-128	polymyxins	group	166-175	false
antibiotics	group	118-128	lithium	drug	177-183	false
antibiotics	group	118-128	magnesium	drug	185-193	false
antibiotics	group	118-128	procainamide	drug	201-212	false
antibiotics	group	118-128	quinidine	drug	218-226	false
aminoglycosides	group	146-160	polymyxins	group	166-175	false
aminoglycosides	group	146-160	lithium	drug	177-183	false
aminoglycosides	group	146-160	magnesium	drug	185-193	false
aminoglycosides	group	146-160	procainamide	drug	201-212	false
aminoglycosides	group	146-160	quinidine	drug	218-226	false
polymyxins	group	166-175	lithium	drug	177-183	false
polymyxins	group	166-175	magnesium	drug	185-193	false
polymyxins	group	166-175	procainamide	drug	201-212	false
polymyxins	group	166-175	quinidine	drug	218-226	false
lithium	drug	177-183	magnesium	drug	185-193	false
lithium	drug	177-183	procainamide	drug	201-212	false
lithium	drug	177-183	quinidine	drug	218-226	false
magnesium	drug	185-193	procainamide	drug	201-212	false
magnesium	drug	185-193	quinidine	drug	218-226	false
procainamide	drug	201-212	quinidine	drug	218-226	false

DDI-DrugBank.d469.s9	The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.
succinylcholine	drug	28-42	TRACRIUM	brand	160-167	effect

DDI-DrugBank.d469.s10	TRACRIUM should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.
TRACRIUM	brand	0-7	succinylcholine	drug	71-85	advise

DDI-DrugBank.d423.s0	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
monoamine oxidase inhibitors	group	35-62	MAOIs	group	65-69	false
monoamine oxidase inhibitors	group	35-62	selegiline hydrochloride	drug	79-102	false
monoamine oxidase inhibitors	group	35-62	serotoninergic agents	group	125-145	effect
monoamine oxidase inhibitors	group	35-62	fluoxetine	drug	154-163	effect
monoamine oxidase inhibitors	group	35-62	fluvoxamine	drug	166-176	effect
monoamine oxidase inhibitors	group	35-62	paroxetine	drug	179-188	effect
monoamine oxidase inhibitors	group	35-62	sertraline	drug	191-200	effect
monoamine oxidase inhibitors	group	35-62	venlafaxine	drug	203-213	effect
MAOIs	group	65-69	selegiline hydrochloride	drug	79-102	false
MAOIs	group	65-69	serotoninergic agents	group	125-145	effect
MAOIs	group	65-69	fluoxetine	drug	154-163	effect
MAOIs	group	65-69	fluvoxamine	drug	166-176	effect
MAOIs	group	65-69	paroxetine	drug	179-188	effect
MAOIs	group	65-69	sertraline	drug	191-200	effect
MAOIs	group	65-69	venlafaxine	drug	203-213	effect
selegiline hydrochloride	drug	79-102	serotoninergic agents	group	125-145	effect
selegiline hydrochloride	drug	79-102	fluoxetine	drug	154-163	effect
selegiline hydrochloride	drug	79-102	fluvoxamine	drug	166-176	effect
selegiline hydrochloride	drug	79-102	paroxetine	drug	179-188	effect
selegiline hydrochloride	drug	79-102	sertraline	drug	191-200	effect
selegiline hydrochloride	drug	79-102	venlafaxine	drug	203-213	effect
serotoninergic agents	group	125-145	fluoxetine	drug	154-163	false
serotoninergic agents	group	125-145	fluvoxamine	drug	166-176	false
serotoninergic agents	group	125-145	paroxetine	drug	179-188	false
serotoninergic agents	group	125-145	sertraline	drug	191-200	false
serotoninergic agents	group	125-145	venlafaxine	drug	203-213	false
fluoxetine	drug	154-163	fluvoxamine	drug	166-176	false
fluoxetine	drug	154-163	paroxetine	drug	179-188	false
fluoxetine	drug	154-163	sertraline	drug	191-200	false
fluoxetine	drug	154-163	venlafaxine	drug	203-213	false
fluvoxamine	drug	166-176	paroxetine	drug	179-188	false
fluvoxamine	drug	166-176	sertraline	drug	191-200	false
fluvoxamine	drug	166-176	venlafaxine	drug	203-213	false
paroxetine	drug	179-188	sertraline	drug	191-200	false
paroxetine	drug	179-188	venlafaxine	drug	203-213	false
sertraline	drug	191-200	venlafaxine	drug	203-213	false

DDI-DrugBank.d423.s1	Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.
dexfenfluramine	drug	8-22	dexfenfluramine	drug	72-86	false
dexfenfluramine	drug	8-22	MAO inhibitor	group	128-140	false
dexfenfluramine	drug	72-86	MAO inhibitor	group	128-140	advise

DDI-DrugBank.d423.s2	At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.
MAO inhibitor	group	60-72	dexfenfluramine	drug	107-121	advise

DDI-DrugBank.d423.s3	At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.
dexfenfluramine	drug	58-72	MAO inhibitor	group	109-121	advise

DDI-DrugBank.d423.s4	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
selective serotonin reuptake inhibitors	group	121-159	SSRIs	group	162-166	false
selective serotonin reuptake inhibitors	group	121-159	Imitrex	brand	210-216	effect
selective serotonin reuptake inhibitors	group	121-159	sumatriptan succinate	drug	219-239	effect
selective serotonin reuptake inhibitors	group	121-159	dihydroergotamine	drug	246-262	effect
SSRIs	group	162-166	Imitrex	brand	210-216	effect
SSRIs	group	162-166	sumatriptan succinate	drug	219-239	effect
SSRIs	group	162-166	dihydroergotamine	drug	246-262	effect
Imitrex	brand	210-216	sumatriptan succinate	drug	219-239	false
Imitrex	brand	210-216	dihydroergotamine	drug	246-262	false
sumatriptan succinate	drug	219-239	dihydroergotamine	drug	246-262	false

DDI-DrugBank.d423.s6	Dexfenfluramine should not be administered with other serotoninergic agents.
Dexfenfluramine	drug	0-14	serotoninergic agents	group	54-74	advise

DDI-DrugBank.d68.s1	Digoxin: Supraventricular arrhythmias may mask the cardiotoxicity associated with excessive digoxin levels.
Digoxin	drug	0-6	digoxin	drug	92-98	false

DDI-DrugBank.d68.s3	Coadministration of digoxin did not have effects on either the safety or efficacy of ibutilide in the clinical trials.
digoxin	drug	20-26	ibutilide	drug	85-93	false

DDI-DrugBank.d68.s4	Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.
Calcium channel blocking agents	group	0-30	calcium channel blockers	group	53-76	false
Calcium channel blocking agents	group	0-30	ibutilide	drug	138-146	false
calcium channel blockers	group	53-76	ibutilide	drug	138-146	false

DDI-DrugBank.d68.s5	Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.
Beta-adrenergic blocking agents	group	0-30	beta-adrenergic blocking agents	group	53-83	false
Beta-adrenergic blocking agents	group	0-30	ibutilide	drug	145-153	false
beta-adrenergic blocking agents	group	53-83	ibutilide	drug	145-153	false

DDI-DrugBank.d269.s1	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
debrisoquin	drug	21-31	carvedilol	drug	50-59	false
debrisoquin	drug	21-31	quinidine	drug	103-111	false
debrisoquin	drug	21-31	fluoxetine	drug	114-123	false
debrisoquin	drug	21-31	paroxetine	drug	126-135	false
debrisoquin	drug	21-31	propafenone	drug	142-152	false
debrisoquin	drug	21-31	carvedilol	drug	263-272	false
carvedilol	drug	50-59	quinidine	drug	103-111	false
carvedilol	drug	50-59	fluoxetine	drug	114-123	false
carvedilol	drug	50-59	paroxetine	drug	126-135	false
carvedilol	drug	50-59	propafenone	drug	142-152	false
carvedilol	drug	50-59	carvedilol	drug	263-272	false
quinidine	drug	103-111	fluoxetine	drug	114-123	false
quinidine	drug	103-111	paroxetine	drug	126-135	false
quinidine	drug	103-111	propafenone	drug	142-152	false
quinidine	drug	103-111	carvedilol	drug	263-272	effect
fluoxetine	drug	114-123	paroxetine	drug	126-135	false
fluoxetine	drug	114-123	propafenone	drug	142-152	false
fluoxetine	drug	114-123	carvedilol	drug	263-272	effect
paroxetine	drug	126-135	propafenone	drug	142-152	false
paroxetine	drug	126-135	carvedilol	drug	263-272	effect
propafenone	drug	142-152	carvedilol	drug	263-272	effect

DDI-DrugBank.d269.s3	Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
agents with b-blocking properties	group	53-85	reserpine	drug	137-145	effect
agents with b-blocking properties	group	53-85	monoamine oxidase inhibitors	group	151-178	effect
reserpine	drug	137-145	monoamine oxidase inhibitors	group	151-178	false

DDI-DrugBank.d269.s4	Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
Clonidine	drug	0-8	clonidine	drug	41-49	false
Clonidine	drug	0-8	agents with b-blocking properties	group	56-88	false
clonidine	drug	41-49	agents with b-blocking properties	group	56-88	effect

DDI-DrugBank.d269.s5	When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.
agents with b-blocking properties	group	32-64	clonidine	drug	70-78	advise
agents with b-blocking properties	group	32-64	b-blocking agent	group	105-120	false
clonidine	drug	70-78	b-blocking agent	group	105-120	false

DDI-DrugBank.d269.s7	Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
Cyclosporine	drug	0-11	cyclosporine	drug	46-57	false
Cyclosporine	drug	0-11	carvedilol	drug	112-121	false
cyclosporine	drug	46-57	carvedilol	drug	112-121	mechanism

DDI-DrugBank.d269.s8	In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.
cyclosporine	drug	38-49	cyclosporine	drug	90-101	false

DDI-DrugBank.d269.s10	Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
cyclosporine	drug	96-107	carvedilol	drug	165-174	advise
cyclosporine	drug	96-107	cyclosporine	drug	205-216	false
carvedilol	drug	165-174	cyclosporine	drug	205-216	advise

DDI-DrugBank.d269.s11	Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
Digoxin	drug	0-6	Digoxin	drug	9-15	false
Digoxin	drug	0-6	digoxin	drug	64-70	false
Digoxin	drug	0-6	carvedilol	drug	76-85	false
Digoxin	drug	9-15	digoxin	drug	64-70	false
Digoxin	drug	9-15	carvedilol	drug	76-85	false
digoxin	drug	64-70	carvedilol	drug	76-85	mechanism

DDI-DrugBank.d269.s12	Both digoxin and COREG slow AV conduction.
digoxin	drug	5-11	COREG	brand	17-21	effect

DDI-DrugBank.d269.s13	Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.
digoxin	drug	35-41	COREG	brand	103-107	advise

DDI-DrugBank.d269.s14	Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.
Rifampin	drug	47-54	carvedilol	drug	89-98	mechanism

DDI-DrugBank.d269.s16	Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.
Calcium Channel Blockers	group	0-23	COREG	brand	128-132	false
Calcium Channel Blockers	group	0-23	diltiazem	drug	158-166	false
COREG	brand	128-132	diltiazem	drug	158-166	effect

DDI-DrugBank.d269.s17	As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
agents with b-blocking properties	group	14-46	COREG	brand	52-56	false
agents with b-blocking properties	group	14-46	calcium channel blockers	group	92-115	false
agents with b-blocking properties	group	14-46	verapamil	drug	124-132	false
agents with b-blocking properties	group	14-46	diltiazem	drug	137-145	false
COREG	brand	52-56	calcium channel blockers	group	92-115	false
COREG	brand	52-56	verapamil	drug	124-132	advise
COREG	brand	52-56	diltiazem	drug	137-145	advise
calcium channel blockers	group	92-115	verapamil	drug	124-132	false
calcium channel blockers	group	92-115	diltiazem	drug	137-145	false
verapamil	drug	124-132	diltiazem	drug	137-145	false

DDI-DrugBank.d269.s18	Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.
Insulin	drug	0-6	Hypoglycemics	group	16-28	false
Insulin	drug	0-6	Agents with b-blocking properties	group	31-63	false
Insulin	drug	0-6	insulin	drug	112-118	false
Insulin	drug	0-6	hypoglycemics	group	129-141	false
Hypoglycemics	group	16-28	Agents with b-blocking properties	group	31-63	false
Hypoglycemics	group	16-28	insulin	drug	112-118	false
Hypoglycemics	group	16-28	hypoglycemics	group	129-141	false
Agents with b-blocking properties	group	31-63	insulin	drug	112-118	effect
Agents with b-blocking properties	group	31-63	hypoglycemics	group	129-141	effect
insulin	drug	112-118	hypoglycemics	group	129-141	false

DDI-DrugBank.d269.s19	Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended.
insulin	drug	30-36	hypoglycemics	group	46-58	false

DDI-DrugBank.d458.s3	The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
NIZORAL	brand	63-69	Ketoconazole	drug	149-160	false
NIZORAL	brand	63-69	terfenadine	drug	196-206	false
NIZORAL	brand	63-69	terfenadine	drug	259-269	false
Ketoconazole	drug	149-160	terfenadine	drug	196-206	mechanism
Ketoconazole	drug	149-160	terfenadine	drug	259-269	false
terfenadine	drug	196-206	terfenadine	drug	259-269	false

DDI-DrugBank.d458.s5	Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.
ketoconazole	drug	40-51	astemizole	drug	80-89	effect
ketoconazole	drug	40-51	astemizole	drug	131-140	false
ketoconazole	drug	40-51	desmethylastemizole	drug_n	168-186	false
astemizole	drug	80-89	astemizole	drug	131-140	false
astemizole	drug	80-89	desmethylastemizole	drug_n	168-186	false
astemizole	drug	131-140	desmethylastemizole	drug_n	168-186	false

DDI-DrugBank.d458.s6	Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.
astemizole	drug	20-29	ketoconazole	drug	36-47	advise

DDI-DrugBank.d458.s7	Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.
ketoconazole	drug	47-58	cisapride	drug	96-104	mechanism
ketoconazole	drug	47-58	cisapride	drug	156-164	false
cisapride	drug	96-104	cisapride	drug	156-164	false

DDI-DrugBank.d458.s8	Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
ketoconazole	drug	43-54	cisapride	drug	60-68	effect

DDI-DrugBank.d458.s9	Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.
ketoconazole	drug	40-51	cisapride	drug	66-74	advise

DDI-DrugBank.d458.s10	Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
Ketoconazole	drug	0-11	cyclosporine	drug	49-60	mechanism
Ketoconazole	drug	0-11	tacrolimus	drug	63-72	mechanism
Ketoconazole	drug	0-11	methylprednisolone	drug	79-96	mechanism
cyclosporine	drug	49-60	tacrolimus	drug	63-72	false
cyclosporine	drug	49-60	methylprednisolone	drug	79-96	false
tacrolimus	drug	63-72	methylprednisolone	drug	79-96	false

DDI-DrugBank.d458.s11	Dosage adjustment may be required if cyclosporine, tacrolimus, or methylprednisolone are given concomitantly with NIZORAL  Tablets.
cyclosporine	drug	37-48	tacrolimus	drug	51-60	false
cyclosporine	drug	37-48	methylprednisolone	drug	66-83	false
cyclosporine	drug	37-48	NIZORAL	brand	114-120	false
tacrolimus	drug	51-60	methylprednisolone	drug	66-83	false
tacrolimus	drug	51-60	NIZORAL	brand	114-120	false
methylprednisolone	drug	66-83	NIZORAL	brand	114-120	false

DDI-DrugBank.d458.s12	Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
NIZORAL	brand	20-26	midazolam	drug	42-50	mechanism
NIZORAL	brand	20-26	triazolam	drug	55-63	mechanism
midazolam	drug	42-50	triazolam	drug	55-63	false

DDI-DrugBank.d458.s18	It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.
digoxin	drug	39-45	ketoconazole	drug	84-95	advise

DDI-DrugBank.d458.s19	When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.
imidazole compounds	group	20-38	ketoconazole	drug	45-56	false
imidazole compounds	group	20-38	coumarin	group	98-105	effect
ketoconazole	drug	45-56	coumarin	group	98-105	effect

DDI-DrugBank.d458.s20	In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.
imidazole drugs	group	31-45	coumarin drugs	group	51-64	advise

DDI-DrugBank.d458.s21	Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.
miconazole	drug	87-96	imidazole	group	102-110	false
miconazole	drug	87-96	hypoglycemic agents	group	122-140	effect
miconazole	drug	87-96	ketoconazole	drug	229-240	false
miconazole	drug	87-96	imidazole	group	254-262	false
imidazole	group	102-110	hypoglycemic agents	group	122-140	false
imidazole	group	102-110	ketoconazole	drug	229-240	false
imidazole	group	102-110	imidazole	group	254-262	false
hypoglycemic agents	group	122-140	ketoconazole	drug	229-240	false
hypoglycemic agents	group	122-140	imidazole	group	254-262	false
ketoconazole	drug	229-240	imidazole	group	254-262	false

DDI-DrugBank.d458.s22	Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.
ketoconazole	drug	30-41	phenytoin	drug	56-64	mechanism

DDI-DrugBank.d458.s23	It is suggested to monitor both ketoconazole and phenytoin.
ketoconazole	drug	32-43	phenytoin	drug	49-57	advise

DDI-DrugBank.d458.s24	Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.
rifampin	drug	30-37	ketoconazole	drug	44-55	mechanism

DDI-DrugBank.d458.s25	INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.
INH	drug	0-2	Isoniazid	drug	5-13	false
INH	drug	0-2	ketoconazole	drug	43-54	mechanism
Isoniazid	drug	5-13	ketoconazole	drug	43-54	mechanism

DDI-DrugBank.d458.s27	After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.
ketoconazole	drug	42-53	loratadine	drug	89-98	mechanism
ketoconazole	drug	42-53	loratadine	drug	136-145	false
loratadine	drug	89-98	loratadine	drug	136-145	false

DDI-DrugBank.d458.s30	Also, there were no clinically significant differences in adverse events when loratadine was administered with or without ketoconazole.
loratadine	drug	78-87	ketoconazole	drug	122-133	false

DDI-DrugBank.d533.s0	Effects of Other Drugs on Aliskiren Based on in-vitro studies, aliskiren is metabolized by CYP 3A4.
Aliskiren	drug	26-34	aliskiren	drug	63-71	false

DDI-DrugBank.d533.s1	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
lovastatin	drug	21-30	atenolol	drug	33-40	false
lovastatin	drug	21-30	warfarin	drug	43-50	false
lovastatin	drug	21-30	furosemide	drug	53-62	false
lovastatin	drug	21-30	digoxin	drug	65-71	false
lovastatin	drug	21-30	celecoxib	drug	74-82	false
lovastatin	drug	21-30	hydrochlorothiazide	drug	85-103	false
lovastatin	drug	21-30	ramipril	drug	106-113	false
lovastatin	drug	21-30	valsartan	drug	116-124	false
lovastatin	drug	21-30	metformin	drug	127-135	false
lovastatin	drug	21-30	amlodipine	drug	141-150	false
lovastatin	drug	21-30	aliskiren	drug	206-214	false
atenolol	drug	33-40	warfarin	drug	43-50	false
atenolol	drug	33-40	furosemide	drug	53-62	false
atenolol	drug	33-40	digoxin	drug	65-71	false
atenolol	drug	33-40	celecoxib	drug	74-82	false
atenolol	drug	33-40	hydrochlorothiazide	drug	85-103	false
atenolol	drug	33-40	ramipril	drug	106-113	false
atenolol	drug	33-40	valsartan	drug	116-124	false
atenolol	drug	33-40	metformin	drug	127-135	false
atenolol	drug	33-40	amlodipine	drug	141-150	false
atenolol	drug	33-40	aliskiren	drug	206-214	false
warfarin	drug	43-50	furosemide	drug	53-62	false
warfarin	drug	43-50	digoxin	drug	65-71	false
warfarin	drug	43-50	celecoxib	drug	74-82	false
warfarin	drug	43-50	hydrochlorothiazide	drug	85-103	false
warfarin	drug	43-50	ramipril	drug	106-113	false
warfarin	drug	43-50	valsartan	drug	116-124	false
warfarin	drug	43-50	metformin	drug	127-135	false
warfarin	drug	43-50	amlodipine	drug	141-150	false
warfarin	drug	43-50	aliskiren	drug	206-214	false
furosemide	drug	53-62	digoxin	drug	65-71	false
furosemide	drug	53-62	celecoxib	drug	74-82	false
furosemide	drug	53-62	hydrochlorothiazide	drug	85-103	false
furosemide	drug	53-62	ramipril	drug	106-113	false
furosemide	drug	53-62	valsartan	drug	116-124	false
furosemide	drug	53-62	metformin	drug	127-135	false
furosemide	drug	53-62	amlodipine	drug	141-150	false
furosemide	drug	53-62	aliskiren	drug	206-214	false
digoxin	drug	65-71	celecoxib	drug	74-82	false
digoxin	drug	65-71	hydrochlorothiazide	drug	85-103	false
digoxin	drug	65-71	ramipril	drug	106-113	false
digoxin	drug	65-71	valsartan	drug	116-124	false
digoxin	drug	65-71	metformin	drug	127-135	false
digoxin	drug	65-71	amlodipine	drug	141-150	false
digoxin	drug	65-71	aliskiren	drug	206-214	false
celecoxib	drug	74-82	hydrochlorothiazide	drug	85-103	false
celecoxib	drug	74-82	ramipril	drug	106-113	false
celecoxib	drug	74-82	valsartan	drug	116-124	false
celecoxib	drug	74-82	metformin	drug	127-135	false
celecoxib	drug	74-82	amlodipine	drug	141-150	false
celecoxib	drug	74-82	aliskiren	drug	206-214	false
hydrochlorothiazide	drug	85-103	ramipril	drug	106-113	false
hydrochlorothiazide	drug	85-103	valsartan	drug	116-124	false
hydrochlorothiazide	drug	85-103	metformin	drug	127-135	false
hydrochlorothiazide	drug	85-103	amlodipine	drug	141-150	false
hydrochlorothiazide	drug	85-103	aliskiren	drug	206-214	false
ramipril	drug	106-113	valsartan	drug	116-124	false
ramipril	drug	106-113	metformin	drug	127-135	false
ramipril	drug	106-113	amlodipine	drug	141-150	false
ramipril	drug	106-113	aliskiren	drug	206-214	false
valsartan	drug	116-124	metformin	drug	127-135	false
valsartan	drug	116-124	amlodipine	drug	141-150	false
valsartan	drug	116-124	aliskiren	drug	206-214	false
metformin	drug	127-135	amlodipine	drug	141-150	false
metformin	drug	127-135	aliskiren	drug	206-214	false
amlodipine	drug	141-150	aliskiren	drug	206-214	false

DDI-DrugBank.d533.s2	Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
irbesartan	drug	21-30	aliskiren	drug	40-48	mechanism

DDI-DrugBank.d533.s3	Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.
atorvastatin	drug	21-32	aliskiren	drug	70-78	mechanism

DDI-DrugBank.d533.s4	Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
Ketoconazole	drug	0-11	ketoconazole	drug	54-65	false
Ketoconazole	drug	0-11	aliskiren	drug	72-80	false
Ketoconazole	drug	0-11	aliskiren	drug	142-150	false
ketoconazole	drug	54-65	aliskiren	drug	72-80	mechanism
ketoconazole	drug	54-65	aliskiren	drug	142-150	false
aliskiren	drug	72-80	aliskiren	drug	142-150	false

DDI-DrugBank.d533.s6	Effects of Aliskiren on Other Drugs Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.
Aliskiren	drug	11-19	Aliskiren	drug	36-44	false

DDI-DrugBank.d533.s7	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
aliskiren	drug	21-29	lovastatin	drug	84-93	false
aliskiren	drug	21-29	digoxin	drug	96-102	false
aliskiren	drug	21-29	valsartan	drug	105-113	false
aliskiren	drug	21-29	amlodipine	drug	116-125	false
aliskiren	drug	21-29	metformin	drug	128-136	false
aliskiren	drug	21-29	celecoxib	drug	139-147	false
aliskiren	drug	21-29	atenolol	drug	150-157	false
aliskiren	drug	21-29	atorvastatin	drug	160-171	false
aliskiren	drug	21-29	ramipril	drug	174-181	false
aliskiren	drug	21-29	hydrochlorothiazide	drug	186-204	false
lovastatin	drug	84-93	digoxin	drug	96-102	false
lovastatin	drug	84-93	valsartan	drug	105-113	false
lovastatin	drug	84-93	amlodipine	drug	116-125	false
lovastatin	drug	84-93	metformin	drug	128-136	false
lovastatin	drug	84-93	celecoxib	drug	139-147	false
lovastatin	drug	84-93	atenolol	drug	150-157	false
lovastatin	drug	84-93	atorvastatin	drug	160-171	false
lovastatin	drug	84-93	ramipril	drug	174-181	false
lovastatin	drug	84-93	hydrochlorothiazide	drug	186-204	false
digoxin	drug	96-102	valsartan	drug	105-113	false
digoxin	drug	96-102	amlodipine	drug	116-125	false
digoxin	drug	96-102	metformin	drug	128-136	false
digoxin	drug	96-102	celecoxib	drug	139-147	false
digoxin	drug	96-102	atenolol	drug	150-157	false
digoxin	drug	96-102	atorvastatin	drug	160-171	false
digoxin	drug	96-102	ramipril	drug	174-181	false
digoxin	drug	96-102	hydrochlorothiazide	drug	186-204	false
valsartan	drug	105-113	amlodipine	drug	116-125	false
valsartan	drug	105-113	metformin	drug	128-136	false
valsartan	drug	105-113	celecoxib	drug	139-147	false
valsartan	drug	105-113	atenolol	drug	150-157	false
valsartan	drug	105-113	atorvastatin	drug	160-171	false
valsartan	drug	105-113	ramipril	drug	174-181	false
valsartan	drug	105-113	hydrochlorothiazide	drug	186-204	false
amlodipine	drug	116-125	metformin	drug	128-136	false
amlodipine	drug	116-125	celecoxib	drug	139-147	false
amlodipine	drug	116-125	atenolol	drug	150-157	false
amlodipine	drug	116-125	atorvastatin	drug	160-171	false
amlodipine	drug	116-125	ramipril	drug	174-181	false
amlodipine	drug	116-125	hydrochlorothiazide	drug	186-204	false
metformin	drug	128-136	celecoxib	drug	139-147	false
metformin	drug	128-136	atenolol	drug	150-157	false
metformin	drug	128-136	atorvastatin	drug	160-171	false
metformin	drug	128-136	ramipril	drug	174-181	false
metformin	drug	128-136	hydrochlorothiazide	drug	186-204	false
celecoxib	drug	139-147	atenolol	drug	150-157	false
celecoxib	drug	139-147	atorvastatin	drug	160-171	false
celecoxib	drug	139-147	ramipril	drug	174-181	false
celecoxib	drug	139-147	hydrochlorothiazide	drug	186-204	false
atenolol	drug	150-157	atorvastatin	drug	160-171	false
atenolol	drug	150-157	ramipril	drug	174-181	false
atenolol	drug	150-157	hydrochlorothiazide	drug	186-204	false
atorvastatin	drug	160-171	ramipril	drug	174-181	false
atorvastatin	drug	160-171	hydrochlorothiazide	drug	186-204	false
ramipril	drug	174-181	hydrochlorothiazide	drug	186-204	false

DDI-DrugBank.d533.s8	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated in a well-controlled clinical trial.
Warfarin	drug	0-7	aliskiren	drug	25-33	false
Warfarin	drug	0-7	warfarin	drug	38-45	false
aliskiren	drug	25-33	warfarin	drug	38-45	false

DDI-DrugBank.d533.s9	Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
Furosemide	drug	0-9	aliskiren	drug	17-25	false
Furosemide	drug	0-9	furosemide	drug	52-61	false
Furosemide	drug	0-9	furosemide	drug	84-93	false
aliskiren	drug	17-25	furosemide	drug	52-61	mechanism
aliskiren	drug	17-25	furosemide	drug	84-93	false
furosemide	drug	52-61	furosemide	drug	84-93	false

DDI-DrugBank.d547.s0	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
candesartan cilexetil	drug	66-86	glyburide	drug	119-127	false
candesartan cilexetil	drug	66-86	nifedipine	drug	130-139	false
candesartan cilexetil	drug	66-86	digoxin	drug	142-148	false
candesartan cilexetil	drug	66-86	warfarin	drug	151-158	false
candesartan cilexetil	drug	66-86	hydrochlorothiazide	drug	161-179	false
candesartan cilexetil	drug	66-86	contraceptives	group	191-204	false
candesartan cilexetil	drug	66-86	enalapril	drug	243-251	false
glyburide	drug	119-127	nifedipine	drug	130-139	false
glyburide	drug	119-127	digoxin	drug	142-148	false
glyburide	drug	119-127	warfarin	drug	151-158	false
glyburide	drug	119-127	hydrochlorothiazide	drug	161-179	false
glyburide	drug	119-127	contraceptives	group	191-204	false
glyburide	drug	119-127	enalapril	drug	243-251	false
nifedipine	drug	130-139	digoxin	drug	142-148	false
nifedipine	drug	130-139	warfarin	drug	151-158	false
nifedipine	drug	130-139	hydrochlorothiazide	drug	161-179	false
nifedipine	drug	130-139	contraceptives	group	191-204	false
nifedipine	drug	130-139	enalapril	drug	243-251	false
digoxin	drug	142-148	warfarin	drug	151-158	false
digoxin	drug	142-148	hydrochlorothiazide	drug	161-179	false
digoxin	drug	142-148	contraceptives	group	191-204	false
digoxin	drug	142-148	enalapril	drug	243-251	false
warfarin	drug	151-158	hydrochlorothiazide	drug	161-179	false
warfarin	drug	151-158	contraceptives	group	191-204	false
warfarin	drug	151-158	enalapril	drug	243-251	false
hydrochlorothiazide	drug	161-179	contraceptives	group	191-204	false
hydrochlorothiazide	drug	161-179	enalapril	drug	243-251	false
contraceptives	group	191-204	enalapril	drug	243-251	false

DDI-DrugBank.d547.s2	Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
Lithium	drug	0-6	lithium	drug	38-44	false
Lithium	drug	0-6	lithium	drug	130-136	false
Lithium	drug	0-6	ACE inhibitors	group	143-156	false
Lithium	drug	0-6	angiotensin II receptor antagonists	group	173-207	false
lithium	drug	38-44	lithium	drug	130-136	false
lithium	drug	38-44	ACE inhibitors	group	143-156	false
lithium	drug	38-44	angiotensin II receptor antagonists	group	173-207	false
lithium	drug	130-136	ACE inhibitors	group	143-156	mechanism
lithium	drug	130-136	angiotensin II receptor antagonists	group	173-207	mechanism
ACE inhibitors	group	143-156	angiotensin II receptor antagonists	group	173-207	false

DDI-DrugBank.d547.s3	An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
lithium	drug	21-27	lithium	drug	98-104	false
lithium	drug	21-27	ATACAND	brand	111-117	false
lithium	drug	21-27	lithium	drug	151-157	false
lithium	drug	98-104	ATACAND	brand	111-117	mechanism
lithium	drug	98-104	lithium	drug	151-157	false
ATACAND	brand	111-117	lithium	drug	151-157	false

DDI-DrugBank.d476.s0	ZEBETA should not be combined with other beta-blocking agents.
ZEBETA	brand	0-5	beta-blocking agents	group	41-60	advise

DDI-DrugBank.d476.s1	Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
reserpine	drug	58-66	guanethidine	drug	71-82	false
reserpine	drug	58-66	ZEBETA	brand	167-172	effect
guanethidine	drug	71-82	ZEBETA	brand	167-172	effect

DDI-DrugBank.d476.s2	In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.
clonidine	drug	46-54	ZEBETA	brand	112-117	false
clonidine	drug	46-54	clonidine	drug	177-185	false
ZEBETA	brand	112-117	clonidine	drug	177-185	advise

DDI-DrugBank.d476.s3	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
ZEBETA	brand	0-5	myocardial depressants	group	37-58	advise
ZEBETA	brand	0-5	calcium antagonists	group	108-126	advise
ZEBETA	brand	0-5	phenylalkylamine	group	149-164	advise
ZEBETA	brand	0-5	verapamil	drug	167-175	advise
ZEBETA	brand	0-5	benzothiazepine	group	182-196	advise
ZEBETA	brand	0-5	diltiazem	drug	199-207	advise
ZEBETA	brand	0-5	antiarrhythmic agents	group	223-243	advise
ZEBETA	brand	0-5	disopyramide	drug	254-265	advise
myocardial depressants	group	37-58	calcium antagonists	group	108-126	false
myocardial depressants	group	37-58	phenylalkylamine	group	149-164	false
myocardial depressants	group	37-58	verapamil	drug	167-175	false
myocardial depressants	group	37-58	benzothiazepine	group	182-196	false
myocardial depressants	group	37-58	diltiazem	drug	199-207	false
myocardial depressants	group	37-58	antiarrhythmic agents	group	223-243	false
myocardial depressants	group	37-58	disopyramide	drug	254-265	false
calcium antagonists	group	108-126	phenylalkylamine	group	149-164	false
calcium antagonists	group	108-126	verapamil	drug	167-175	false
calcium antagonists	group	108-126	benzothiazepine	group	182-196	false
calcium antagonists	group	108-126	diltiazem	drug	199-207	false
calcium antagonists	group	108-126	antiarrhythmic agents	group	223-243	false
calcium antagonists	group	108-126	disopyramide	drug	254-265	false
phenylalkylamine	group	149-164	verapamil	drug	167-175	false
phenylalkylamine	group	149-164	benzothiazepine	group	182-196	false
phenylalkylamine	group	149-164	diltiazem	drug	199-207	false
phenylalkylamine	group	149-164	antiarrhythmic agents	group	223-243	false
phenylalkylamine	group	149-164	disopyramide	drug	254-265	false
verapamil	drug	167-175	benzothiazepine	group	182-196	false
verapamil	drug	167-175	diltiazem	drug	199-207	false
verapamil	drug	167-175	antiarrhythmic agents	group	223-243	false
verapamil	drug	167-175	disopyramide	drug	254-265	false
benzothiazepine	group	182-196	diltiazem	drug	199-207	false
benzothiazepine	group	182-196	antiarrhythmic agents	group	223-243	false
benzothiazepine	group	182-196	disopyramide	drug	254-265	false
diltiazem	drug	199-207	antiarrhythmic agents	group	223-243	false
diltiazem	drug	199-207	disopyramide	drug	254-265	false
antiarrhythmic agents	group	223-243	disopyramide	drug	254-265	false

DDI-DrugBank.d476.s4	Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.
rifampin	drug	18-25	ZEBETA	brand	64-69	mechanism
rifampin	drug	18-25	ZEBETA	brand	122-127	false
ZEBETA	brand	64-69	ZEBETA	brand	122-127	false

DDI-DrugBank.d476.s6	Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, digoxin, and cimetidine.
thiazide diuretics	group	118-135	digoxin	drug	138-144	false
thiazide diuretics	group	118-135	cimetidine	drug	151-160	false
digoxin	drug	138-144	cimetidine	drug	151-160	false

DDI-DrugBank.d476.s7	There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin.
ZEBETA	brand	23-28	warfarin	drug	81-88	false

DDI-DrugBank.d3.s1	Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
Warfarin	drug	0-7	Digoxin	drug	10-16	false
Warfarin	drug	0-7	Salicylate	group	19-28	false
Warfarin	drug	0-7	Heparin	drug	35-41	false
Warfarin	drug	0-7	warfarin	drug	67-74	false
Warfarin	drug	0-7	ketorolac tromethamine	drug	123-144	false
Warfarin	drug	0-7	ketorolac	drug	176-184	false
Digoxin	drug	10-16	Salicylate	group	19-28	false
Digoxin	drug	10-16	Heparin	drug	35-41	false
Digoxin	drug	10-16	warfarin	drug	67-74	false
Digoxin	drug	10-16	ketorolac tromethamine	drug	123-144	false
Digoxin	drug	10-16	ketorolac	drug	176-184	false
Salicylate	group	19-28	Heparin	drug	35-41	false
Salicylate	group	19-28	warfarin	drug	67-74	false
Salicylate	group	19-28	ketorolac tromethamine	drug	123-144	false
Salicylate	group	19-28	ketorolac	drug	176-184	false
Heparin	drug	35-41	warfarin	drug	67-74	false
Heparin	drug	35-41	ketorolac tromethamine	drug	123-144	false
Heparin	drug	35-41	ketorolac	drug	176-184	false
warfarin	drug	67-74	ketorolac tromethamine	drug	123-144	mechanism
warfarin	drug	67-74	ketorolac	drug	176-184	false
ketorolac tromethamine	drug	123-144	ketorolac	drug	176-184	false

DDI-DrugBank.d3.s2	Ketorolac does not alter digoxin protein binding.
Ketorolac	drug	0-8	digoxin	drug	25-31	false

DDI-DrugBank.d3.s3	In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.
salicylate	group	65-74	ketorolac	drug	105-113	mechanism
salicylate	group	65-74	ketorolac	drug	215-223	false
ketorolac	drug	105-113	ketorolac	drug	215-223	false

DDI-DrugBank.d3.s4	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.
digoxin	drug	30-36	warfarin	drug	39-46	false
digoxin	drug	30-36	ibuprofen	drug	49-57	false
digoxin	drug	30-36	naproxen	drug	60-67	false
digoxin	drug	30-36	piroxicam	drug	70-78	false
digoxin	drug	30-36	acetaminophen	drug	81-93	false
digoxin	drug	30-36	phenytoin	drug	96-104	false
digoxin	drug	30-36	ketorolac tromethamine	drug	135-156	false
warfarin	drug	39-46	ibuprofen	drug	49-57	false
warfarin	drug	39-46	naproxen	drug	60-67	false
warfarin	drug	39-46	piroxicam	drug	70-78	false
warfarin	drug	39-46	acetaminophen	drug	81-93	false
warfarin	drug	39-46	phenytoin	drug	96-104	false
warfarin	drug	39-46	ketorolac tromethamine	drug	135-156	false
ibuprofen	drug	49-57	naproxen	drug	60-67	false
ibuprofen	drug	49-57	piroxicam	drug	70-78	false
ibuprofen	drug	49-57	acetaminophen	drug	81-93	false
ibuprofen	drug	49-57	phenytoin	drug	96-104	false
ibuprofen	drug	49-57	ketorolac tromethamine	drug	135-156	false
naproxen	drug	60-67	piroxicam	drug	70-78	false
naproxen	drug	60-67	acetaminophen	drug	81-93	false
naproxen	drug	60-67	phenytoin	drug	96-104	false
naproxen	drug	60-67	ketorolac tromethamine	drug	135-156	false
piroxicam	drug	70-78	acetaminophen	drug	81-93	false
piroxicam	drug	70-78	phenytoin	drug	96-104	false
piroxicam	drug	70-78	ketorolac tromethamine	drug	135-156	false
acetaminophen	drug	81-93	phenytoin	drug	96-104	false
acetaminophen	drug	81-93	ketorolac tromethamine	drug	135-156	false
phenytoin	drug	96-104	ketorolac tromethamine	drug	135-156	false

DDI-DrugBank.d3.s5	In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg warfarin, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin.
warfarin	drug	101-108	warfarin	drug	185-192	false

DDI-DrugBank.d3.s6	In another study, TORADOLIV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo.
heparin	drug	69-75	heparin	drug	234-240	false

DDI-DrugBank.d3.s7	Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
TORADOL	brand	73-79	warfarin	drug	85-92	false
TORADOL	brand	73-79	heparin	drug	97-103	false
TORADOL	brand	73-79	TORADOL	brand	128-134	false
TORADOL	brand	73-79	anticoagulants	group	155-168	false
warfarin	drug	85-92	heparin	drug	97-103	false
warfarin	drug	85-92	TORADOL	brand	128-134	false
warfarin	drug	85-92	anticoagulants	group	155-168	false
heparin	drug	97-103	TORADOL	brand	128-134	false
heparin	drug	97-103	anticoagulants	group	155-168	false
TORADOL	brand	128-134	anticoagulants	group	155-168	advise

DDI-DrugBank.d3.s8	Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
Furosemide	drug	0-9	TORADOL	brand	12-18	false
Furosemide	drug	0-9	diuretic	group	38-45	false
Furosemide	drug	0-9	furosemide	drug	59-68	false
TORADOL	brand	12-18	diuretic	group	38-45	false
TORADOL	brand	12-18	furosemide	drug	59-68	effect
diuretic	group	38-45	furosemide	drug	59-68	false

DDI-DrugBank.d3.s9	Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
Probenecid	drug	0-9	TORADOL	brand	42-48	false
Probenecid	drug	0-9	probenecid	drug	59-68	false
Probenecid	drug	0-9	ketorolac	drug	105-113	false
Probenecid	drug	0-9	ketorolac	drug	144-152	false
TORADOL	brand	42-48	probenecid	drug	59-68	mechanism
TORADOL	brand	42-48	ketorolac	drug	105-113	false
TORADOL	brand	42-48	ketorolac	drug	144-152	false
probenecid	drug	59-68	ketorolac	drug	105-113	false
probenecid	drug	59-68	ketorolac	drug	144-152	false
ketorolac	drug	105-113	ketorolac	drug	144-152	false

DDI-DrugBank.d3.s10	Therefore, concomitant use of TORADOL and probenecid is contraindicated.
TORADOL	brand	30-36	probenecid	drug	42-51	advise

DDI-DrugBank.d3.s11	Lithium: Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.
Lithium	drug	0-6	lithium	drug	29-35	false
Lithium	drug	0-6	lithium	drug	81-87	false
lithium	drug	29-35	lithium	drug	81-87	false

DDI-DrugBank.d3.s12	The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
TORADOL	brand	14-20	lithium	drug	32-38	false
TORADOL	brand	14-20	lithium	drug	85-91	false
TORADOL	brand	14-20	TORADOL	brand	114-120	false
lithium	drug	32-38	lithium	drug	85-91	false
lithium	drug	32-38	TORADOL	brand	114-120	false
lithium	drug	85-91	TORADOL	brand	114-120	mechanism

DDI-DrugBank.d3.s13	Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.
Methotrexate	drug	0-11	methotrexate	drug	44-55	false
Methotrexate	drug	0-11	NSAIDs	group	66-71	false
Methotrexate	drug	0-11	methotrexate	drug	118-129	false
Methotrexate	drug	0-11	methotrexate	drug	158-169	false
methotrexate	drug	44-55	NSAIDs	group	66-71	mechanism
methotrexate	drug	44-55	methotrexate	drug	118-129	false
methotrexate	drug	44-55	methotrexate	drug	158-169	false
NSAIDs	group	66-71	methotrexate	drug	118-129	false
NSAIDs	group	66-71	methotrexate	drug	158-169	false
methotrexate	drug	118-129	methotrexate	drug	158-169	false

DDI-DrugBank.d3.s14	The effect of TORADOL on methotrexate clearance has not been studied.
TORADOL	brand	14-20	methotrexate	drug	25-36	false

DDI-DrugBank.d3.s15	Nondepolarizing Muscle Relaxants: In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and nondepolarizing muscle relaxants that resulted in apnea.
Nondepolarizing Muscle Relaxants	group	0-31	nondepolarizing muscle relaxants	group	137-168	false

DDI-DrugBank.d3.s16	The concurrent use of TORADOL with muscle relaxants has not been formally studied.
TORADOL	brand	22-28	muscle relaxants	group	35-50	false

DDI-DrugBank.d3.s17	ACE Inhibitors: Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.
ACE Inhibitors	group	0-13	ACE inhibitors	group	35-48	false

DDI-DrugBank.d3.s18	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
Antiepileptic Drugs	group	0-18	TORADOL	brand	93-99	false
Antiepileptic Drugs	group	0-18	antiepileptic drugs	group	105-123	false
Antiepileptic Drugs	group	0-18	phenytoin	drug	126-134	false
Antiepileptic Drugs	group	0-18	carbamazepine	drug	137-149	false
TORADOL	brand	93-99	antiepileptic drugs	group	105-123	effect
TORADOL	brand	93-99	phenytoin	drug	126-134	effect
TORADOL	brand	93-99	carbamazepine	drug	137-149	effect
antiepileptic drugs	group	105-123	phenytoin	drug	126-134	false
antiepileptic drugs	group	105-123	carbamazepine	drug	137-149	false
phenytoin	drug	126-134	carbamazepine	drug	137-149	false

DDI-DrugBank.d3.s19	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
Psychoactive Drugs	group	0-17	TORADOL	brand	59-65	false
Psychoactive Drugs	group	0-17	psychoactive drugs	group	95-112	false
Psychoactive Drugs	group	0-17	fluoxetine	drug	115-124	false
Psychoactive Drugs	group	0-17	thiothixene	drug	127-137	false
Psychoactive Drugs	group	0-17	alprazolam	drug	140-149	false
TORADOL	brand	59-65	psychoactive drugs	group	95-112	effect
TORADOL	brand	59-65	fluoxetine	drug	115-124	effect
TORADOL	brand	59-65	thiothixene	drug	127-137	effect
TORADOL	brand	59-65	alprazolam	drug	140-149	effect
psychoactive drugs	group	95-112	fluoxetine	drug	115-124	false
psychoactive drugs	group	95-112	thiothixene	drug	127-137	false
psychoactive drugs	group	95-112	alprazolam	drug	140-149	false
fluoxetine	drug	115-124	thiothixene	drug	127-137	false
fluoxetine	drug	115-124	alprazolam	drug	140-149	false
thiothixene	drug	127-137	alprazolam	drug	140-149	false

DDI-DrugBank.d3.s20	Morphine: TORADOLIV/IM has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions.
Morphine	drug	0-7	morphine	drug	63-70	false

DDI-DrugBank.d3.s21	Do not mix TORADOL and morphine in the same syringe.
TORADOL	brand	11-17	morphine	drug	23-30	false

DDI-DrugBank.d498.s0	Certain antibiotics, especially neomycin, streptomycin and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.
antibiotics	group	8-18	neomycin	drug	32-39	false
antibiotics	group	8-18	streptomycin	drug	42-53	false
antibiotics	group	8-18	kanamycin	drug	59-67	false
neomycin	drug	32-39	streptomycin	drug	42-53	false
neomycin	drug	32-39	kanamycin	drug	59-67	false
streptomycin	drug	42-53	kanamycin	drug	59-67	false

DDI-DrugBank.d498.s1	These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.
antibiotics	group	6-16	anticholinesterase	group	149-166	advise

DDI-DrugBank.d498.s2	Local and some general anesthetics, antiarrhythmic agents and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis;
anesthetics	group	23-33	antiarrhythmic agents	group	36-56	false

DDI-DrugBank.d506.s0	If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
phenytoin	drug	3-11	Norpace	brand	74-80	mechanism
phenytoin	drug	3-11	Norpace CR	brand	85-94	mechanism
phenytoin	drug	3-11	disopyramide	drug	120-131	false
Norpace	brand	74-80	Norpace CR	brand	85-94	false
Norpace	brand	74-80	disopyramide	drug	120-131	false
Norpace CR	brand	85-94	disopyramide	drug	120-131	false

DDI-DrugBank.d506.s2	Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.
antiarrhythmic drugs	group	6-25	quinidine	drug	32-40	false
antiarrhythmic drugs	group	6-25	procainamide	drug	43-54	false
antiarrhythmic drugs	group	6-25	lidocaine	drug	57-65	false
antiarrhythmic drugs	group	6-25	propranolol	drug	68-78	false
antiarrhythmic drugs	group	6-25	Norpace	brand	127-133	false
quinidine	drug	32-40	procainamide	drug	43-54	false
quinidine	drug	32-40	lidocaine	drug	57-65	false
quinidine	drug	32-40	propranolol	drug	68-78	false
quinidine	drug	32-40	Norpace	brand	127-133	false
procainamide	drug	43-54	lidocaine	drug	57-65	false
procainamide	drug	43-54	propranolol	drug	68-78	false
procainamide	drug	43-54	Norpace	brand	127-133	false
lidocaine	drug	57-65	propranolol	drug	68-78	false
lidocaine	drug	57-65	Norpace	brand	127-133	false
propranolol	drug	68-78	Norpace	brand	127-133	false

DDI-DrugBank.d506.s4	In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam.
Norpace	brand	76-82	propranolol	drug	115-125	false
Norpace	brand	76-82	diazepam	drug	130-137	false
propranolol	drug	115-125	diazepam	drug	130-137	false

DDI-DrugBank.d506.s5	Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
Norpace	brand	30-36	quinidine	drug	42-50	mechanism
Norpace	brand	30-36	disopyramide	drug	91-102	false
Norpace	brand	30-36	quinidine	drug	142-150	false
quinidine	drug	42-50	disopyramide	drug	91-102	false
quinidine	drug	42-50	quinidine	drug	142-150	false
disopyramide	drug	91-102	quinidine	drug	142-150	false

DDI-DrugBank.d506.s6	Norpace does not increase serum digoxin levels.
Norpace	brand	0-6	digoxin	drug	32-38	false

DDI-DrugBank.d506.s7	Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.
disopyramide phosphate	drug	16-37	erythromycin	drug	43-54	mechanism
disopyramide phosphate	drug	16-37	disopyramide	drug	116-127	false
erythromycin	drug	43-54	disopyramide	drug	116-127	false

DDI-DrugBank.d506.s9	Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.
verapamil	drug	44-52	disopyramide phosphate	drug	58-79	false
verapamil	drug	44-52	disopyramide	drug	95-106	false
verapamil	drug	44-52	verapamil	drug	176-184	false
disopyramide phosphate	drug	58-79	disopyramide	drug	95-106	false
disopyramide phosphate	drug	58-79	verapamil	drug	176-184	false
disopyramide	drug	95-106	verapamil	drug	176-184	advise

DDI-DrugBank.d219.s0	ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
ACE-inhibitors	group	0-13	NSAIDs	group	36-41	false
ACE-inhibitors	group	0-13	ACE-inhibitors	group	87-100	false
NSAIDs	group	36-41	ACE-inhibitors	group	87-100	effect

DDI-DrugBank.d219.s1	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
NSAIDs	group	66-71	ACE-inhibitors	group	92-105	advise

DDI-DrugBank.d219.s2	Antacids: The concomitant administration of antacids has no apparent effect on the extent of absorption of Lodine.
Antacids	group	0-7	antacids	group	44-51	false
Antacids	group	0-7	Lodine	brand	107-112	false
antacids	group	44-51	Lodine	brand	107-112	false

DDI-DrugBank.d219.s4	Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.
Aspirin	brand	0-6	Lodine	brand	14-19	false
Aspirin	brand	0-6	aspirin	brand	42-48	false
Aspirin	brand	0-6	etodolac	drug	114-121	false
Lodine	brand	14-19	aspirin	brand	42-48	mechanism
Lodine	brand	14-19	etodolac	drug	114-121	false
aspirin	brand	42-48	etodolac	drug	114-121	false

DDI-DrugBank.d219.s6	however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.
NSAIDs	group	23-28	Lodine	brand	61-66	false
NSAIDs	group	23-28	aspirin	brand	72-78	false
Lodine	brand	61-66	aspirin	brand	72-78	advise

DDI-DrugBank.d219.s7	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
Lodine	brand	36-41	NSAIDs	group	55-60	false
Lodine	brand	36-41	cyclosporine	drug	192-203	mechanism
Lodine	brand	36-41	digoxin	drug	206-212	mechanism
Lodine	brand	36-41	methotrexate	drug	215-226	mechanism
NSAIDs	group	55-60	cyclosporine	drug	192-203	mechanism
NSAIDs	group	55-60	digoxin	drug	206-212	mechanism
NSAIDs	group	55-60	methotrexate	drug	215-226	mechanism
cyclosporine	drug	192-203	digoxin	drug	206-212	false
cyclosporine	drug	192-203	methotrexate	drug	215-226	false
digoxin	drug	206-212	methotrexate	drug	215-226	false

DDI-DrugBank.d219.s9	Patients receiving these drugs who are given Lodine, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs.
Lodine	brand	45-50	NSAID	group	66-70	false

DDI-DrugBank.d219.s10	Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or hydrochlorothiazide.
Diuretics	group	0-8	furosemide	drug	87-96	false
Diuretics	group	0-8	hydrochlorothiazide	drug	101-119	false
furosemide	drug	87-96	hydrochlorothiazide	drug	101-119	false

DDI-DrugBank.d219.s11	Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
Lodine	brand	86-91	furosemide	drug	130-139	effect
Lodine	brand	86-91	thiazides	group	145-153	effect
furosemide	drug	130-139	thiazides	group	145-153	false

DDI-DrugBank.d219.s14	Glyburide: Etodolac has no apparent pharmacokinetic interaction when administered with glyburide.
Glyburide	drug	0-8	Etodolac	drug	11-18	false
Glyburide	drug	0-8	glyburide	drug	87-95	false
Etodolac	drug	11-18	glyburide	drug	87-95	false

DDI-DrugBank.d219.s15	Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
Lithium	drug	0-6	NSAIDs	group	9-14	false
Lithium	drug	0-6	lithium	drug	53-59	false
Lithium	drug	0-6	lithium	drug	93-99	false
NSAIDs	group	9-14	lithium	drug	53-59	mechanism
NSAIDs	group	9-14	lithium	drug	93-99	false
lithium	drug	53-59	lithium	drug	93-99	false

DDI-DrugBank.d219.s18	Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
NSAIDs	group	11-16	lithium	drug	22-28	effect
NSAIDs	group	11-16	lithium	drug	112-118	false
lithium	drug	22-28	lithium	drug	112-118	false

DDI-DrugBank.d219.s19	Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
Phenylbutazone	drug	0-13	Phenylbutazone	drug	16-29	false
Phenylbutazone	drug	0-13	etodolac	drug	86-93	false
Phenylbutazone	drug	16-29	etodolac	drug	86-93	mechanism

DDI-DrugBank.d219.s20	Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
etodolac	drug	54-61	phenylbutazone	drug	107-120	advise

DDI-DrugBank.d219.s21	Phenytoin: Etodolac has no apparent pharmacokinetic interaction when administered with phenytoin.
Phenytoin	drug	0-8	Etodolac	drug	11-18	false
Phenytoin	drug	0-8	phenytoin	drug	87-95	false
Etodolac	drug	11-18	phenytoin	drug	87-95	false

DDI-DrugBank.d219.s22	Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.
Warfarin	drug	0-7	warfarin	drug	25-32	false
Warfarin	drug	0-7	NSAIDs	group	38-43	false
warfarin	drug	25-32	NSAIDs	group	38-43	effect

DDI-DrugBank.d219.s23	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
warfarin	drug	88-95	Lodine	brand	101-106	mechanism
warfarin	drug	88-95	etodolac	drug	110-117	mechanism
warfarin	drug	88-95	warfarin	drug	179-186	false
warfarin	drug	88-95	warfarin	drug	238-245	false
Lodine	brand	101-106	etodolac	drug	110-117	false
Lodine	brand	101-106	warfarin	drug	179-186	false
Lodine	brand	101-106	warfarin	drug	238-245	false
etodolac	drug	110-117	warfarin	drug	179-186	false
etodolac	drug	110-117	warfarin	drug	238-245	false
warfarin	drug	179-186	warfarin	drug	238-245	false

DDI-DrugBank.d219.s24	There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with Lodine as measured by prothrombin time.
warfarin	drug	69-76	warfarin	drug	101-108	false
warfarin	drug	69-76	Lodine	brand	128-133	false
warfarin	drug	101-108	Lodine	brand	128-133	false

DDI-DrugBank.d219.s25	Thus, concomitant therapy with warfarin and Lodine should not require dosage adjustment of either drug.
warfarin	drug	31-38	Lodine	brand	44-49	false

DDI-DrugBank.d219.s26	However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.
etodolac	drug	148-155	warfarin	drug	196-203	effect

DDI-DrugBank.d219.s27	Drug/Laboratory Test Interactions The urine of patients who take Lodine can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of etodolac.
Lodine	brand	65-70	etodolac	drug	187-194	false

DDI-DrugBank.d248.s0	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).
anticoagulants	group	13-26	barbiturates	group	67-78	false
anticoagulants	group	13-26	rifampin	drug	81-88	false
anticoagulants	group	13-26	diethylstilbestrol	drug	176-193	false
anticoagulants	group	13-26	corticosteroids	group	197-211	false
anticoagulants	group	13-26	corticosteroids	group	234-248	false
barbiturates	group	67-78	rifampin	drug	81-88	false
barbiturates	group	67-78	diethylstilbestrol	drug	176-193	false
barbiturates	group	67-78	corticosteroids	group	197-211	false
barbiturates	group	67-78	corticosteroids	group	234-248	false
rifampin	drug	81-88	diethylstilbestrol	drug	176-193	false
rifampin	drug	81-88	corticosteroids	group	197-211	false
rifampin	drug	81-88	corticosteroids	group	234-248	false
diethylstilbestrol	drug	176-193	corticosteroids	group	197-211	false
diethylstilbestrol	drug	176-193	corticosteroids	group	234-248	false
corticosteroids	group	197-211	corticosteroids	group	234-248	false

DDI-DrugBank.d72.s0	Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.
Itraconazole	drug	0-11	busulfan	drug	23-30	mechanism

DDI-DrugBank.d72.s1	Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.
Fluconazole	drug	0-10	5-HT3 antiemetics	group	21-37	false
Fluconazole	drug	0-10	ondansetron	drug	39-49	false
Fluconazole	drug	0-10	Zofran	brand	52-57	false
Fluconazole	drug	0-10	granisetron	drug	64-74	false
Fluconazole	drug	0-10	Kytril	brand	77-82	false
Fluconazole	drug	0-10	BUSULFEX	brand	109-116	false
5-HT3 antiemetics	group	21-37	ondansetron	drug	39-49	false
5-HT3 antiemetics	group	21-37	Zofran	brand	52-57	false
5-HT3 antiemetics	group	21-37	granisetron	drug	64-74	false
5-HT3 antiemetics	group	21-37	Kytril	brand	77-82	false
5-HT3 antiemetics	group	21-37	BUSULFEX	brand	109-116	false
ondansetron	drug	39-49	Zofran	brand	52-57	false
ondansetron	drug	39-49	granisetron	drug	64-74	false
ondansetron	drug	39-49	Kytril	brand	77-82	false
ondansetron	drug	39-49	BUSULFEX	brand	109-116	false
Zofran	brand	52-57	granisetron	drug	64-74	false
Zofran	brand	52-57	Kytril	brand	77-82	false
Zofran	brand	52-57	BUSULFEX	brand	109-116	false
granisetron	drug	64-74	Kytril	brand	77-82	false
granisetron	drug	64-74	BUSULFEX	brand	109-116	false
Kytril	brand	77-82	BUSULFEX	brand	109-116	false

DDI-DrugBank.d72.s2	Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.
Phenytoin	drug	0-8	busulfan	drug	37-44	mechanism

DDI-DrugBank.d72.s3	Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
BUSULFEX	brand	30-37	phenytoin	drug	77-85	mechanism
BUSULFEX	brand	30-37	BUSULFEX	brand	105-112	false
BUSULFEX	brand	30-37	phenytoin	drug	206-214	false
phenytoin	drug	77-85	BUSULFEX	brand	105-112	false
phenytoin	drug	77-85	phenytoin	drug	206-214	false
BUSULFEX	brand	105-112	phenytoin	drug	206-214	false

DDI-DrugBank.d72.s4	Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
busulfan	drug	8-15	acetaminophen	drug	86-98	false
busulfan	drug	8-15	BUSULFEX	brand	140-147	false
busulfan	drug	8-15	busulfan	drug	171-178	false
busulfan	drug	8-15	acetaminophen	drug	223-235	false
acetaminophen	drug	86-98	BUSULFEX	brand	140-147	mechanism
acetaminophen	drug	86-98	busulfan	drug	171-178	false
acetaminophen	drug	86-98	acetaminophen	drug	223-235	false
BUSULFEX	brand	140-147	busulfan	drug	171-178	false
BUSULFEX	brand	140-147	acetaminophen	drug	223-235	false
busulfan	drug	171-178	acetaminophen	drug	223-235	false

DDI-DrugBank.d342.s0	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
alcohol	drug	28-34	CNS depressants	group	45-59	false
alcohol	drug	28-34	antihistamines	group	135-148	false
alcohol	drug	28-34	anticholinergics	group	152-167	false
alcohol	drug	28-34	antihistamines	group	314-327	false
alcohol	drug	28-34	monoamine oxidase (MAO) inhibitors	group	335-368	false
alcohol	drug	28-34	antihistamines	group	391-404	false
alcohol	drug	28-34	antihistamines	group	482-495	false
CNS depressants	group	45-59	antihistamines	group	135-148	false
CNS depressants	group	45-59	anticholinergics	group	152-167	false
CNS depressants	group	45-59	antihistamines	group	314-327	false
CNS depressants	group	45-59	monoamine oxidase (MAO) inhibitors	group	335-368	false
CNS depressants	group	45-59	antihistamines	group	391-404	false
CNS depressants	group	45-59	antihistamines	group	482-495	false
antihistamines	group	135-148	anticholinergics	group	152-167	false
antihistamines	group	135-148	antihistamines	group	314-327	false
antihistamines	group	135-148	monoamine oxidase (MAO) inhibitors	group	335-368	false
antihistamines	group	135-148	antihistamines	group	391-404	false
antihistamines	group	135-148	antihistamines	group	482-495	false
anticholinergics	group	152-167	antihistamines	group	314-327	false
anticholinergics	group	152-167	monoamine oxidase (MAO) inhibitors	group	335-368	false
anticholinergics	group	152-167	antihistamines	group	391-404	false
anticholinergics	group	152-167	antihistamines	group	482-495	false
antihistamines	group	314-327	monoamine oxidase (MAO) inhibitors	group	335-368	false
antihistamines	group	314-327	antihistamines	group	391-404	false
antihistamines	group	314-327	antihistamines	group	482-495	false
monoamine oxidase (MAO) inhibitors	group	335-368	antihistamines	group	391-404	false
monoamine oxidase (MAO) inhibitors	group	335-368	antihistamines	group	482-495	false
antihistamines	group	391-404	antihistamines	group	482-495	false

DDI-DrugBank.d277.s0	In evaluating the potential for interactions among co-administered antiepilepsy drugs (AEDs), whether or not an AED induces or does not induce metabolic enzymes is an important consideration.
AEDs	group	87-90	AED	group	112-114	false

DDI-DrugBank.d277.s1	Phenytoin, phenobarbital and carbamazepine are ge nerally classified as enzyme inducers;
Phenytoin	drug	0-8	phenobarbital	drug	11-23	false
Phenytoin	drug	0-8	carbamazepine	drug	29-41	false
phenobarbital	drug	11-23	carbamazepine	drug	29-41	false

DDI-DrugBank.d277.s2	valproate and gabapentin are not.
valproate	drug	0-8	gabapentin	drug	14-23	false

DDI-DrugBank.d277.s3	GABITRIL is considered to be a non-enzyme inducing AED.
GABITRIL	brand	0-7	AED	group	51-53	false

DDI-DrugBank.d277.s5	Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
GABITRIL	brand	11-18	AEDs	group	49-52	false
GABITRIL	brand	11-18	Phenytoin	drug	57-65	false
GABITRIL	brand	11-18	Tiagabine	drug	68-76	false
GABITRIL	brand	11-18	phenytoin	drug	137-145	false
AEDs	group	49-52	Phenytoin	drug	57-65	false
AEDs	group	49-52	Tiagabine	drug	68-76	false
AEDs	group	49-52	phenytoin	drug	137-145	false
Phenytoin	drug	57-65	Tiagabine	drug	68-76	false
Phenytoin	drug	57-65	phenytoin	drug	137-145	false
Tiagabine	drug	68-76	phenytoin	drug	137-145	false

DDI-DrugBank.d277.s6	Carbamazepine: Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.
Carbamazepine	drug	0-12	Tiagabine	drug	15-23	false
Carbamazepine	drug	0-12	carbamazepine	drug	84-96	false
Tiagabine	drug	15-23	carbamazepine	drug	84-96	false

DDI-DrugBank.d277.s7	Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
Valproate	drug	0-8	Tiagabine	drug	11-19	false
Valproate	drug	0-8	valproate	drug	74-82	false
Tiagabine	drug	11-19	valproate	drug	74-82	mechanism

DDI-DrugBank.d277.s8	Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.
Phenobarbital	drug	0-12	Primidone	drug	17-25	false
Phenobarbital	drug	0-12	tiagabine	drug	109-117	false
Phenobarbital	drug	0-12	phenobarbital	drug	142-154	false
Phenobarbital	drug	0-12	primidone	drug	159-167	false
Primidone	drug	17-25	tiagabine	drug	109-117	false
Primidone	drug	17-25	phenobarbital	drug	142-154	false
Primidone	drug	17-25	primidone	drug	159-167	false
tiagabine	drug	109-117	phenobarbital	drug	142-154	false
tiagabine	drug	109-117	primidone	drug	159-167	false
phenobarbital	drug	142-154	primidone	drug	159-167	false

DDI-DrugBank.d277.s9	The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.
tiagabine	drug	16-24	phenobarbital	drug	123-135	false
tiagabine	drug	16-24	primidone	drug	140-148	false
phenobarbital	drug	123-135	primidone	drug	140-148	false

DDI-DrugBank.d277.s10	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
AEDs	group	37-40	GABITRIL	brand	46-53	false
AEDs	group	37-40	Carbamazepine	drug	57-69	false
AEDs	group	37-40	tiagabine	drug	122-130	false
AEDs	group	37-40	carbamazepine	drug	176-188	false
AEDs	group	37-40	AEDs	group	229-232	false
GABITRIL	brand	46-53	Carbamazepine	drug	57-69	false
GABITRIL	brand	46-53	tiagabine	drug	122-130	false
GABITRIL	brand	46-53	carbamazepine	drug	176-188	false
GABITRIL	brand	46-53	AEDs	group	229-232	false
Carbamazepine	drug	57-69	tiagabine	drug	122-130	false
Carbamazepine	drug	57-69	carbamazepine	drug	176-188	false
Carbamazepine	drug	57-69	AEDs	group	229-232	false
tiagabine	drug	122-130	carbamazepine	drug	176-188	mechanism
tiagabine	drug	122-130	AEDs	group	229-232	false
carbamazepine	drug	176-188	AEDs	group	229-232	false

DDI-DrugBank.d277.s11	Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.
Phenytoin	drug	0-8	tiagabine	drug	61-69	false
Phenytoin	drug	0-8	phenytoin	drug	115-123	false
Phenytoin	drug	0-8	AEDs	group	164-167	false
tiagabine	drug	61-69	phenytoin	drug	115-123	mechanism
tiagabine	drug	61-69	AEDs	group	164-167	false
phenytoin	drug	115-123	AEDs	group	164-167	false

DDI-DrugBank.d277.s12	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
Phenobarbital	drug	0-12	Primidone	drug	15-23	false
Phenobarbital	drug	0-12	tiagabine	drug	77-85	false
Phenobarbital	drug	0-12	phenobarbital	drug	131-143	false
Phenobarbital	drug	0-12	primidone	drug	146-154	false
Phenobarbital	drug	0-12	AEDs	group	195-198	false
Primidone	drug	15-23	tiagabine	drug	77-85	false
Primidone	drug	15-23	phenobarbital	drug	131-143	false
Primidone	drug	15-23	primidone	drug	146-154	false
Primidone	drug	15-23	AEDs	group	195-198	false
tiagabine	drug	77-85	phenobarbital	drug	131-143	mechanism
tiagabine	drug	77-85	primidone	drug	146-154	mechanism
tiagabine	drug	77-85	AEDs	group	195-198	false
phenobarbital	drug	131-143	primidone	drug	146-154	false
phenobarbital	drug	131-143	AEDs	group	195-198	false
primidone	drug	146-154	AEDs	group	195-198	false

DDI-DrugBank.d277.s13	Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
Valproate	drug	0-8	tiagabine	drug	27-35	false
Valproate	drug	0-8	valproate	drug	56-64	false
Valproate	drug	0-8	tiagabine	drug	95-103	false
Valproate	drug	0-8	valproate	drug	127-135	false
Valproate	drug	0-8	tiagabine	drug	161-169	false
tiagabine	drug	27-35	valproate	drug	56-64	false
tiagabine	drug	27-35	tiagabine	drug	95-103	false
tiagabine	drug	27-35	valproate	drug	127-135	false
tiagabine	drug	27-35	tiagabine	drug	161-169	false
valproate	drug	56-64	tiagabine	drug	95-103	false
valproate	drug	56-64	valproate	drug	127-135	false
valproate	drug	56-64	tiagabine	drug	161-169	false
tiagabine	drug	95-103	valproate	drug	127-135	false
tiagabine	drug	95-103	tiagabine	drug	161-169	false
valproate	drug	127-135	tiagabine	drug	161-169	mechanism

DDI-DrugBank.d277.s15	Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.
GABITRIL	brand	15-22	Cimetidine	drug	43-52	false
GABITRIL	brand	15-22	cimetidine	drug	77-86	false
GABITRIL	brand	15-22	tiagabine	drug	120-128	false
GABITRIL	brand	15-22	tiagabine	drug	159-167	false
Cimetidine	drug	43-52	cimetidine	drug	77-86	false
Cimetidine	drug	43-52	tiagabine	drug	120-128	false
Cimetidine	drug	43-52	tiagabine	drug	159-167	false
cimetidine	drug	77-86	tiagabine	drug	120-128	false
cimetidine	drug	77-86	tiagabine	drug	159-167	false
tiagabine	drug	120-128	tiagabine	drug	159-167	false

DDI-DrugBank.d277.s16	Theophylline: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.
Theophylline	drug	0-11	tiagabine	drug	37-45	false
Theophylline	drug	0-11	theophylline	drug	86-97	false
tiagabine	drug	37-45	theophylline	drug	86-97	false

DDI-DrugBank.d277.s17	Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.
Warfarin	drug	0-7	R-warfarin	drug	91-100	false
Warfarin	drug	0-7	S-warfarin	drug	105-114	false
Warfarin	drug	0-7	tiagabine	drug	137-145	false
R-warfarin	drug	91-100	S-warfarin	drug	105-114	false
R-warfarin	drug	91-100	tiagabine	drug	137-145	false
S-warfarin	drug	105-114	tiagabine	drug	137-145	false

DDI-DrugBank.d277.s19	Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.
Digoxin	drug	0-6	tiagabine	drug	39-47	false
Digoxin	drug	0-6	digoxin	drug	101-107	false
Digoxin	drug	0-6	digoxin	drug	149-155	false
tiagabine	drug	39-47	digoxin	drug	101-107	false
tiagabine	drug	39-47	digoxin	drug	149-155	false
digoxin	drug	101-107	digoxin	drug	149-155	false

DDI-DrugBank.d277.s20	Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.
Ethanol	drug	0-6	Triazolam	drug	11-19	false
Ethanol	drug	0-6	triazolam	drug	90-98	false
Ethanol	drug	0-6	tiagabine	drug	115-123	false
Triazolam	drug	11-19	triazolam	drug	90-98	false
Triazolam	drug	11-19	tiagabine	drug	115-123	false
triazolam	drug	90-98	tiagabine	drug	115-123	false

DDI-DrugBank.d277.s21	The pharmacokinetics of ethanol were not affected by multiple-dose administration of tiagabine.
ethanol	drug	24-30	tiagabine	drug	85-93	false

DDI-DrugBank.d277.s22	Tiagabine has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or alcohol.
Tiagabine	drug	0-8	alcohol	drug	105-111	false

DDI-DrugBank.d277.s23	Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
ethanol	drug	87-93	triazolam	drug	98-106	false
ethanol	drug	87-93	tiagabine	drug	154-162	advise
triazolam	drug	98-106	tiagabine	drug	154-162	advise

DDI-DrugBank.d277.s24	Oral Contraceptives: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.
Contraceptives	group	5-18	tiagabine	drug	53-61	false
Contraceptives	group	5-18	contraceptives	group	129-142	false
tiagabine	drug	53-61	contraceptives	group	129-142	false

DDI-DrugBank.d277.s25	Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.
Antipyrine	drug	0-9	Antipyrine	drug	13-22	false
Antipyrine	drug	0-9	tiagabine	drug	91-99	false
Antipyrine	drug	13-22	tiagabine	drug	91-99	false

DDI-DrugBank.d277.s26	This indicates that tiagabine does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of antipyrine.
tiagabine	drug	20-28	antipyrine	drug	144-153	false

DDI-DrugBank.d277.s27	Interaction of GABITRIL with Highly Protein Bound Drugs: In vitro data showed that tiagabine is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.
GABITRIL	brand	15-22	tiagabine	drug	83-91	false

DDI-DrugBank.d271.s0	Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic antidepressants and theophylline.
nicotine	drug	72-79	tricyclic antidepressants	group	169-193	false
nicotine	drug	72-79	theophylline	drug	199-210	false
tricyclic antidepressants	group	169-193	theophylline	drug	199-210	false

DDI-DrugBank.d166.s0	Trecator has been found to temporarily raise serum concentrations of isoniazid.
Trecator	brand	0-7	isoniazid	drug	69-77	mechanism

DDI-DrugBank.d166.s1	Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.
Trecator	brand	0-7	antituberculous drugs	group	53-73	effect

DDI-DrugBank.d166.s2	In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
ethionamide	drug	51-61	cycloserine	drug	84-94	effect

DDI-DrugBank.d117.s0	Concomitant use with iron supplements may result in the reduced absorption of iron.
iron supplement	group	21-35	iron	drug	78-81	false

DDI-DrugBank.d251.s0	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
clarithromycin	drug	10-23	Didanosine	drug	26-35	false
clarithromycin	drug	10-23	Fluconazole	drug	38-48	false
clarithromycin	drug	10-23	Fluoxetine	drug	51-60	false
clarithromycin	drug	10-23	Ketoconazole	drug	74-85	false
clarithromycin	drug	10-23	Phenytoin	drug	88-96	false
clarithromycin	drug	10-23	carbamazepine	drug	114-126	false
clarithromycin	drug	10-23	Rifabutin	drug	129-137	false
clarithromycin	drug	10-23	Rifampin	drug	140-147	false
clarithromycin	drug	10-23	Saquinavir	drug	161-170	false
Didanosine	drug	26-35	Fluconazole	drug	38-48	false
Didanosine	drug	26-35	Fluoxetine	drug	51-60	false
Didanosine	drug	26-35	Ketoconazole	drug	74-85	false
Didanosine	drug	26-35	Phenytoin	drug	88-96	false
Didanosine	drug	26-35	carbamazepine	drug	114-126	false
Didanosine	drug	26-35	Rifabutin	drug	129-137	false
Didanosine	drug	26-35	Rifampin	drug	140-147	false
Didanosine	drug	26-35	Saquinavir	drug	161-170	false
Fluconazole	drug	38-48	Fluoxetine	drug	51-60	false
Fluconazole	drug	38-48	Ketoconazole	drug	74-85	false
Fluconazole	drug	38-48	Phenytoin	drug	88-96	false
Fluconazole	drug	38-48	carbamazepine	drug	114-126	false
Fluconazole	drug	38-48	Rifabutin	drug	129-137	false
Fluconazole	drug	38-48	Rifampin	drug	140-147	false
Fluconazole	drug	38-48	Saquinavir	drug	161-170	false
Fluoxetine	drug	51-60	Ketoconazole	drug	74-85	false
Fluoxetine	drug	51-60	Phenytoin	drug	88-96	false
Fluoxetine	drug	51-60	carbamazepine	drug	114-126	false
Fluoxetine	drug	51-60	Rifabutin	drug	129-137	false
Fluoxetine	drug	51-60	Rifampin	drug	140-147	false
Fluoxetine	drug	51-60	Saquinavir	drug	161-170	false
Ketoconazole	drug	74-85	Phenytoin	drug	88-96	false
Ketoconazole	drug	74-85	carbamazepine	drug	114-126	false
Ketoconazole	drug	74-85	Rifabutin	drug	129-137	false
Ketoconazole	drug	74-85	Rifampin	drug	140-147	false
Ketoconazole	drug	74-85	Saquinavir	drug	161-170	false
Phenytoin	drug	88-96	carbamazepine	drug	114-126	false
Phenytoin	drug	88-96	Rifabutin	drug	129-137	false
Phenytoin	drug	88-96	Rifampin	drug	140-147	false
Phenytoin	drug	88-96	Saquinavir	drug	161-170	false
carbamazepine	drug	114-126	Rifabutin	drug	129-137	false
carbamazepine	drug	114-126	Rifampin	drug	140-147	false
carbamazepine	drug	114-126	Saquinavir	drug	161-170	false
Rifabutin	drug	129-137	Rifampin	drug	140-147	false
Rifabutin	drug	129-137	Saquinavir	drug	161-170	false
Rifampin	drug	140-147	Saquinavir	drug	161-170	false

DDI-DrugBank.d96.s0	Dimenhydrinate may decrease emetic response to apomorphine.
Dimenhydrinate	drug	0-13	emetic	group	28-33	false
Dimenhydrinate	drug	0-13	apomorphine	drug	47-57	effect
emetic	group	28-33	apomorphine	drug	47-57	false

DDI-DrugBank.d328.s0	The drug interaction studies with valdecoxib were performed both with valdecoxib and a rapidly hydrolyzed intravenous prodrug form.
valdecoxib	drug	34-43	valdecoxib	drug	70-79	false

DDI-DrugBank.d328.s4	Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
Aspirin	brand	0-6	aspirin	brand	39-45	false
Aspirin	brand	0-6	valdecoxib	drug	52-61	false
Aspirin	brand	0-6	valdecoxib	drug	142-151	false
aspirin	brand	39-45	valdecoxib	drug	52-61	effect
aspirin	brand	39-45	valdecoxib	drug	142-151	false
valdecoxib	drug	52-61	valdecoxib	drug	142-151	false

DDI-DrugBank.d328.s5	Because of its lack of anti-platelet effect valdecoxib is not a substitute for aspirin for cardiovascular prophylaxis.
valdecoxib	drug	44-53	aspirin	brand	79-85	false

DDI-DrugBank.d328.s6	In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.
valdecoxib	drug	85-94	valdecoxib	drug	134-143	false
valdecoxib	drug	85-94	aspirin	brand	171-177	false
valdecoxib	drug	134-143	aspirin	brand	171-177	false

DDI-DrugBank.d328.s7	Methotrexate: Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate.
Methotrexate	drug	0-11	Valdecoxib 10 mg	drug	14-29	false
Methotrexate	drug	0-11	methotrexate	drug	114-125	false
Valdecoxib 10 mg	drug	14-29	methotrexate	drug	114-125	false

DDI-DrugBank.d328.s8	ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
ACE-inhibitors	group	0-13	NSAIDs	group	36-41	false
ACE-inhibitors	group	0-13	ACE-inhibitors	group	87-100	false
NSAIDs	group	36-41	ACE-inhibitors	group	87-100	effect

DDI-DrugBank.d328.s9	This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.
BEXTRA	brand	66-71	ACE-inhibitors	group	92-105	advise

DDI-DrugBank.d328.s10	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	drug	0-9	NSAIDs	group	86-91	false
Furosemide	drug	0-9	furosemide	drug	130-139	false
Furosemide	drug	0-9	thiazides	group	145-153	false
NSAIDs	group	86-91	furosemide	drug	130-139	effect
NSAIDs	group	86-91	thiazides	group	145-153	effect
furosemide	drug	130-139	thiazides	group	145-153	false

DDI-DrugBank.d328.s12	Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
Anticonvulsants	group	0-14	Phenytoin	drug	17-25	false
Anticonvulsants	group	0-14	valdecoxib	drug	67-76	false
Anticonvulsants	group	0-14	phenytoin	drug	191-199	false
Phenytoin	drug	17-25	valdecoxib	drug	67-76	false
Phenytoin	drug	17-25	phenytoin	drug	191-199	false
valdecoxib	drug	67-76	phenytoin	drug	191-199	mechanism

DDI-DrugBank.d328.s13	Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.
valdecoxib	drug	31-40	phenytoin	drug	103-111	advise

DDI-DrugBank.d328.s14	Valdecoxib did not have a statistically significant effect on the pharmacokinetics of phenytoin (a CYP 2C9 and CYP 2C19 substrate).
Valdecoxib	drug	0-9	phenytoin	drug	86-94	false

DDI-DrugBank.d328.s17	Dextromethorphan: Dextromethorphan is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.
Dextromethorphan	drug	0-15	Dextromethorphan	drug	18-33	false

DDI-DrugBank.d328.s18	Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.
valdecoxib	drug	22-31	dextromethorphan	drug	94-109	mechanism
valdecoxib	drug	22-31	valdecoxib	drug	158-167	false
dextromethorphan	drug	94-109	valdecoxib	drug	158-167	false

DDI-DrugBank.d328.s19	Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.
dextromethorphan	drug	8-23	valdecoxib	drug	80-89	mechanism

DDI-DrugBank.d328.s20	Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
Lithium	drug	0-6	Valdecoxib	drug	9-18	false
Lithium	drug	0-6	lithium	drug	75-81	false
Lithium	drug	0-6	lithium	drug	176-182	false
Valdecoxib	drug	9-18	lithium	drug	75-81	mechanism
Valdecoxib	drug	9-18	lithium	drug	176-182	false
lithium	drug	75-81	lithium	drug	176-182	false

DDI-DrugBank.d328.s21	Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.
Lithium	drug	0-6	BEXTRA	brand	98-103	false
Lithium	drug	0-6	lithium	drug	127-133	false
BEXTRA	brand	98-103	lithium	drug	127-133	advise

DDI-DrugBank.d328.s22	Lithium carbonate (450 mg BID for 7 days) had no effect on valdecoxib pharmacokinetics.
Lithium carbonate	drug	0-16	valdecoxib	drug	59-68	false

DDI-DrugBank.d328.s23	Warfarin: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.
Warfarin	drug	0-7	valdecoxib	drug	24-33	false
Warfarin	drug	0-7	warfarin	drug	66-73	false
Warfarin	drug	0-7	BEXTRA	brand	145-150	false
valdecoxib	drug	24-33	warfarin	drug	66-73	false
valdecoxib	drug	24-33	BEXTRA	brand	145-150	false
warfarin	drug	66-73	BEXTRA	brand	145-150	false

DDI-DrugBank.d328.s24	Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
Valdecoxib	drug	0-9	R-warfarin	drug	78-87	mechanism
Valdecoxib	drug	0-9	S-warfarin	drug	93-102	mechanism
Valdecoxib	drug	0-9	warfarin	drug	207-214	effect
R-warfarin	drug	78-87	S-warfarin	drug	93-102	false
R-warfarin	drug	78-87	warfarin	drug	207-214	false
S-warfarin	drug	93-102	warfarin	drug	207-214	false

DDI-DrugBank.d328.s26	Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.
Anticoagulant	brand	0-12	BEXTRA	brand	114-119	false
Anticoagulant	brand	0-12	warfarin	drug	143-150	false
BEXTRA	brand	114-119	warfarin	drug	143-150	advise

DDI-DrugBank.d328.s27	Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.
Fluconazole	drug	0-10	Ketoconazole	drug	16-27	false
Fluconazole	drug	0-10	Ketoconazole	drug	30-41	false
Fluconazole	drug	0-10	fluconazole	drug	47-57	false
Ketoconazole	drug	16-27	Ketoconazole	drug	30-41	false
Ketoconazole	drug	16-27	fluconazole	drug	47-57	false
Ketoconazole	drug	30-41	fluconazole	drug	47-57	false

DDI-DrugBank.d328.s28	Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
valdecoxib	drug	42-51	ketoconazole	drug	82-93	mechanism
valdecoxib	drug	42-51	fluconazole	drug	99-109	mechanism
valdecoxib	drug	42-51	valdecoxib	drug	158-167	false
ketoconazole	drug	82-93	fluconazole	drug	99-109	false
ketoconazole	drug	82-93	valdecoxib	drug	158-167	false
fluconazole	drug	99-109	valdecoxib	drug	158-167	false

DDI-DrugBank.d328.s29	Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
valdecoxib	drug	25-34	fluconazole	drug	79-89	mechanism
valdecoxib	drug	25-34	ketoconazole	drug	124-135	mechanism
fluconazole	drug	79-89	ketoconazole	drug	124-135	false

DDI-DrugBank.d328.s30	Glyburide: Glyburide is a CYP 2C9 substrate.
Glyburide	drug	0-8	Glyburide	drug	11-19	false

DDI-DrugBank.d328.s31	Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.
valdecoxib	drug	20-29	glyburide	drug	59-67	false
valdecoxib	drug	20-29	glyburide	drug	142-150	false
glyburide	drug	59-67	glyburide	drug	142-150	false

DDI-DrugBank.d328.s32	Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.
valdecoxib	drug	20-29	glyburide	drug	80-88	false
valdecoxib	drug	20-29	glyburide	drug	216-224	false
glyburide	drug	80-88	glyburide	drug	216-224	false

DDI-DrugBank.d328.s33	Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
valdecoxib	drug	20-29	glyburide	drug	80-88	mechanism
valdecoxib	drug	20-29	glyburide	drug	97-105	false
valdecoxib	drug	20-29	glyburide	drug	140-148	false
valdecoxib	drug	20-29	glyburide	drug	180-188	false
glyburide	drug	80-88	glyburide	drug	97-105	false
glyburide	drug	80-88	glyburide	drug	140-148	false
glyburide	drug	80-88	glyburide	drug	180-188	false
glyburide	drug	97-105	glyburide	drug	140-148	false
glyburide	drug	97-105	glyburide	drug	180-188	false
glyburide	drug	140-148	glyburide	drug	180-188	false

DDI-DrugBank.d328.s35	Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.
valdecoxib	drug	47-56	glyburide	drug	197-205	false
valdecoxib	drug	47-56	valdecoxib	drug	236-245	false
glyburide	drug	197-205	valdecoxib	drug	236-245	advise

DDI-DrugBank.d328.s36	Coadministration of glyburide with doses higher than 40 mg valdecoxib (e.g., 40 mg BID) have not been studied.
glyburide	drug	20-28	valdecoxib	drug	59-68	false

DDI-DrugBank.d328.s37	Omeprazole: Omeprazole is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.
Omeprazole	drug	0-9	Omeprazole	drug	12-21	false

DDI-DrugBank.d328.s38	Valdecoxib steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of omeprazole (40 mg QD).
Valdecoxib	drug	0-9	omeprazole	drug	113-122	false

DDI-DrugBank.d328.s39	Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.
valdecoxib	drug	22-31	omeprazole	drug	55-64	mechanism

DDI-DrugBank.d328.s40	Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of omeprazole and valdecoxib.
omeprazole	drug	102-111	valdecoxib	drug	117-126	false

DDI-DrugBank.d328.s41	However, because higher doses (up to 360 mg QD) of omeprazole are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for omeprazole is recommended at current doses.
omeprazole	drug	51-60	omeprazole	drug	135-144	false

DDI-DrugBank.d328.s42	Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.
valdecoxib	drug	20-29	omeprazole	drug	63-72	false

DDI-DrugBank.d328.s43	Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).
Contraceptives	group	5-18	Valdecoxib	drug	21-30	false
Contraceptives	group	5-18	contraceptive	group	98-110	false
Contraceptives	group	5-18	norethindrone	drug	112-124	false
Contraceptives	group	5-18	ethinyl estradiol	drug	126-142	false
Contraceptives	group	5-18	Ortho-Novum	brand	171-181	false
Valdecoxib	drug	21-30	contraceptive	group	98-110	false
Valdecoxib	drug	21-30	norethindrone	drug	112-124	false
Valdecoxib	drug	21-30	ethinyl estradiol	drug	126-142	false
Valdecoxib	drug	21-30	Ortho-Novum	brand	171-181	false
contraceptive	group	98-110	norethindrone	drug	112-124	false
contraceptive	group	98-110	ethinyl estradiol	drug	126-142	false
contraceptive	group	98-110	Ortho-Novum	brand	171-181	false
norethindrone	drug	112-124	ethinyl estradiol	drug	126-142	false
norethindrone	drug	112-124	Ortho-Novum	brand	171-181	false
ethinyl estradiol	drug	126-142	Ortho-Novum	brand	171-181	false

DDI-DrugBank.d328.s44	Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.
valdecoxib	drug	20-29	Ortho-Novum	brand	35-45	mechanism
valdecoxib	drug	20-29	norethindrone	drug	79-91	false
valdecoxib	drug	20-29	ethinyl estradiol	drug	97-113	false
Ortho-Novum	brand	35-45	norethindrone	drug	79-91	false
Ortho-Novum	brand	35-45	ethinyl estradiol	drug	97-113	false
norethindrone	drug	79-91	ethinyl estradiol	drug	97-113	false

DDI-DrugBank.d328.s46	These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.
norethindrone	drug	29-41	ethinyl estradiol	drug	47-63	false
norethindrone	drug	29-41	contraceptive	group	123-135	false
norethindrone	drug	29-41	valdecoxib	drug	154-163	false
ethinyl estradiol	drug	47-63	contraceptive	group	123-135	false
ethinyl estradiol	drug	47-63	valdecoxib	drug	154-163	false
contraceptive	group	123-135	valdecoxib	drug	154-163	advise

DDI-DrugBank.d328.s47	Diazepam: Diazepam (Valium) is a CYP 3A4 and CYP 2C19 substrate.
Diazepam	drug	0-7	Diazepam	drug	10-17	false
Diazepam	drug	0-7	Valium	brand	20-25	false
Diazepam	drug	10-17	Valium	brand	20-25	false

DDI-DrugBank.d328.s48	Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
diazepam	drug	19-26	valdecoxib	drug	89-98	mechanism
diazepam	drug	19-26	valdecoxib	drug	150-159	false
diazepam	drug	19-26	diazepam	drug	233-240	false
valdecoxib	drug	89-98	valdecoxib	drug	150-159	false
valdecoxib	drug	89-98	diazepam	drug	233-240	false
valdecoxib	drug	150-159	diazepam	drug	233-240	false

DDI-DrugBank.d328.s49	Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.
diazepam	drug	37-44	valdecoxib	drug	87-96	false
diazepam	drug	37-44	diazepam	drug	236-243	false
valdecoxib	drug	87-96	diazepam	drug	236-243	effect

DDI-DrugBank.d93.s0	Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
Pulmozyme	brand	36-44	antibiotics	group	178-188	false
Pulmozyme	brand	36-44	bronchodilators	group	191-205	false
Pulmozyme	brand	36-44	vitamins	group	228-235	false
Pulmozyme	brand	36-44	corticosteroids	group	254-268	false
Pulmozyme	brand	36-44	analgesics	group	275-284	false
antibiotics	group	178-188	bronchodilators	group	191-205	false
antibiotics	group	178-188	vitamins	group	228-235	false
antibiotics	group	178-188	corticosteroids	group	254-268	false
antibiotics	group	178-188	analgesics	group	275-284	false
bronchodilators	group	191-205	vitamins	group	228-235	false
bronchodilators	group	191-205	corticosteroids	group	254-268	false
bronchodilators	group	191-205	analgesics	group	275-284	false
vitamins	group	228-235	corticosteroids	group	254-268	false
vitamins	group	228-235	analgesics	group	275-284	false
corticosteroids	group	254-268	analgesics	group	275-284	false

DDI-DrugBank.d228.s0	Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.
Antizol	brand	14-20	ethanol	drug	124-130	mechanism

DDI-DrugBank.d228.s1	Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.
ethanol	drug	11-17	Antizol	brand	56-62	mechanism

DDI-DrugBank.d228.s2	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
Antizol	brand	58-64	phenytoin	drug	135-143	mechanism
Antizol	brand	58-64	carbamazepine	drug	146-158	mechanism
Antizol	brand	58-64	cimetidine	drug	161-170	mechanism
Antizol	brand	58-64	ketoconazole	drug	173-184	mechanism
phenytoin	drug	135-143	carbamazepine	drug	146-158	false
phenytoin	drug	135-143	cimetidine	drug	161-170	false
phenytoin	drug	135-143	ketoconazole	drug	173-184	false
carbamazepine	drug	146-158	cimetidine	drug	161-170	false
carbamazepine	drug	146-158	ketoconazole	drug	173-184	false
cimetidine	drug	161-170	ketoconazole	drug	173-184	false

DDI-DrugBank.d171.s0	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
Tagamet	brand	0-6	warfarin-type anticoagulants	group	130-157	mechanism
Tagamet	brand	0-6	phenytoin	drug	160-168	mechanism
Tagamet	brand	0-6	propranolol	drug	171-181	mechanism
Tagamet	brand	0-6	nifedipine	drug	184-193	mechanism
Tagamet	brand	0-6	chlordiazepoxide	drug	196-211	mechanism
Tagamet	brand	0-6	diazepam	drug	214-221	mechanism
Tagamet	brand	0-6	tricyclic antidepressants	group	232-256	mechanism
Tagamet	brand	0-6	lidocaine	drug	259-267	mechanism
Tagamet	brand	0-6	theophylline	drug	270-281	mechanism
Tagamet	brand	0-6	metronidazole	drug	287-299	mechanism
warfarin-type anticoagulants	group	130-157	phenytoin	drug	160-168	false
warfarin-type anticoagulants	group	130-157	propranolol	drug	171-181	false
warfarin-type anticoagulants	group	130-157	nifedipine	drug	184-193	false
warfarin-type anticoagulants	group	130-157	chlordiazepoxide	drug	196-211	false
warfarin-type anticoagulants	group	130-157	diazepam	drug	214-221	false
warfarin-type anticoagulants	group	130-157	tricyclic antidepressants	group	232-256	false
warfarin-type anticoagulants	group	130-157	lidocaine	drug	259-267	false
warfarin-type anticoagulants	group	130-157	theophylline	drug	270-281	false
warfarin-type anticoagulants	group	130-157	metronidazole	drug	287-299	false
phenytoin	drug	160-168	propranolol	drug	171-181	false
phenytoin	drug	160-168	nifedipine	drug	184-193	false
phenytoin	drug	160-168	chlordiazepoxide	drug	196-211	false
phenytoin	drug	160-168	diazepam	drug	214-221	false
phenytoin	drug	160-168	tricyclic antidepressants	group	232-256	false
phenytoin	drug	160-168	lidocaine	drug	259-267	false
phenytoin	drug	160-168	theophylline	drug	270-281	false
phenytoin	drug	160-168	metronidazole	drug	287-299	false
propranolol	drug	171-181	nifedipine	drug	184-193	false
propranolol	drug	171-181	chlordiazepoxide	drug	196-211	false
propranolol	drug	171-181	diazepam	drug	214-221	false
propranolol	drug	171-181	tricyclic antidepressants	group	232-256	false
propranolol	drug	171-181	lidocaine	drug	259-267	false
propranolol	drug	171-181	theophylline	drug	270-281	false
propranolol	drug	171-181	metronidazole	drug	287-299	false
nifedipine	drug	184-193	chlordiazepoxide	drug	196-211	false
nifedipine	drug	184-193	diazepam	drug	214-221	false
nifedipine	drug	184-193	tricyclic antidepressants	group	232-256	false
nifedipine	drug	184-193	lidocaine	drug	259-267	false
nifedipine	drug	184-193	theophylline	drug	270-281	false
nifedipine	drug	184-193	metronidazole	drug	287-299	false
chlordiazepoxide	drug	196-211	diazepam	drug	214-221	false
chlordiazepoxide	drug	196-211	tricyclic antidepressants	group	232-256	false
chlordiazepoxide	drug	196-211	lidocaine	drug	259-267	false
chlordiazepoxide	drug	196-211	theophylline	drug	270-281	false
chlordiazepoxide	drug	196-211	metronidazole	drug	287-299	false
diazepam	drug	214-221	tricyclic antidepressants	group	232-256	false
diazepam	drug	214-221	lidocaine	drug	259-267	false
diazepam	drug	214-221	theophylline	drug	270-281	false
diazepam	drug	214-221	metronidazole	drug	287-299	false
tricyclic antidepressants	group	232-256	lidocaine	drug	259-267	false
tricyclic antidepressants	group	232-256	theophylline	drug	270-281	false
tricyclic antidepressants	group	232-256	metronidazole	drug	287-299	false
lidocaine	drug	259-267	theophylline	drug	270-281	false
lidocaine	drug	259-267	metronidazole	drug	287-299	false
theophylline	drug	270-281	metronidazole	drug	287-299	false

DDI-DrugBank.d171.s2	therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.
anticoagulant	group	86-98	Tagamet	brand	127-133	advise

DDI-DrugBank.d171.s3	Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.
phenytoin	drug	17-25	lidocaine	drug	28-36	false
phenytoin	drug	17-25	theophylline	drug	42-53	false
lidocaine	drug	28-36	theophylline	drug	42-53	false

DDI-DrugBank.d171.s4	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
Tagamet	brand	64-70	theophylline	drug	146-157	mechanism
Tagamet	brand	64-70	Theo-Dur	brand	160-167	mechanism
Tagamet	brand	64-70	theophylline	drug	243-254	false
theophylline	drug	146-157	Theo-Dur	brand	160-167	false
theophylline	drug	146-157	theophylline	drug	243-254	false
Theo-Dur	brand	160-167	theophylline	drug	243-254	false

DDI-DrugBank.d106.s0	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.
nisoldipine	drug	40-50	cimetidine 400 mg	drug	100-116	mechanism

DDI-DrugBank.d106.s1	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).
Ranitidine	drug	0-9	nisoldipine	drug	66-76	false

DDI-DrugBank.d106.s3	Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.
phenytoin	drug	20-28	SULAR	brand	41-45	mechanism
phenytoin	drug	20-28	nisoldipine	drug	89-99	false
SULAR	brand	41-45	nisoldipine	drug	89-99	false

DDI-DrugBank.d106.s4	Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.
SULAR	brand	20-24	phenytoin	drug	31-39	advise
SULAR	brand	20-24	antihypertensive	group	103-118	false
phenytoin	drug	31-39	antihypertensive	group	103-118	false

DDI-DrugBank.d106.s5	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.
nisoldipine	drug	37-47	beta-blockers	group	53-65	false
nisoldipine	drug	37-47	atenolol	drug	68-75	false
nisoldipine	drug	37-47	propranolol	drug	78-88	false
beta-blockers	group	53-65	atenolol	drug	68-75	false
beta-blockers	group	53-65	propranolol	drug	78-88	false
atenolol	drug	68-75	propranolol	drug	78-88	false

DDI-DrugBank.d106.s6	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.
Propranolol	drug	0-10	nisoldipine	drug	93-103	effect

DDI-DrugBank.d106.s7	The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.
SULAR	brand	29-33	atenolol	drug	71-78	effect
SULAR	brand	29-33	antihypertensive	group	109-124	false
atenolol	drug	71-78	antihypertensive	group	109-124	false

DDI-DrugBank.d106.s8	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
Quinidine	drug	0-8	nisoldipine	drug	63-73	mechanism

DDI-DrugBank.d106.s9	The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.
nisoldipine	drug	60-70	quinidine	drug	89-97	mechanism

DDI-DrugBank.d106.s11	No significant interactions were found between nisoldipine and warfarin or digoxin.
nisoldipine	drug	47-57	warfarin	drug	63-70	false
nisoldipine	drug	47-57	digoxin	drug	75-81	false
warfarin	drug	63-70	digoxin	drug	75-81	false

DDI-DrugBank.d368.s0	DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.
DIAMOX	brand	0-5	phenytoin	drug	16-24	mechanism
DIAMOX	brand	0-5	phenytoin	drug	68-76	mechanism
phenytoin	drug	16-24	phenytoin	drug	68-76	false

DDI-DrugBank.d368.s3	By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.
primidone	drug	49-57	DIAMOX	brand	60-65	false
primidone	drug	49-57	primidone	drug	104-112	false
DIAMOX	brand	60-65	primidone	drug	104-112	mechanism

DDI-DrugBank.d368.s4	Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.
DIAMOX	brand	74-79	primidone	drug	103-111	advise

DDI-DrugBank.d368.s6	Acetazolamide may increase the effects of other folic acid antagonists.
Acetazolamide	drug	0-12	folic acid antagonists	group	48-69	effect

DDI-DrugBank.d368.s9	Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
Acetazolamide	drug	0-12	amphetamine	drug	45-55	mechanism

DDI-DrugBank.d368.s10	Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
Acetazolamide	drug	0-12	quinidine	drug	43-51	mechanism

DDI-DrugBank.d368.s11	Acetazolamide may prevent the urinary antiseptic effect of methenamine.
Acetazolamide	drug	0-12	methenamine	drug	59-69	effect

DDI-DrugBank.d368.s12	Acetazolamide increases lithium excretion and the lithium may be decreased.
Acetazolamide	drug	0-12	lithium	drug	24-30	mechanism
Acetazolamide	drug	0-12	lithium	drug	50-56	false
lithium	drug	24-30	lithium	drug	50-56	false

DDI-DrugBank.d368.s13	Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
Acetazolamide	drug	0-12	sodium bicarbonate	drug	18-35	effect

DDI-DrugBank.d368.s14	Acetazolamide may elevate cyclosporine levels.
Acetazolamide	drug	0-12	cyclosporine	drug	26-37	mechanism

DDI-DrugBank.d518.s0	Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.
barbiturates	group	37-48	narcotics	group	57-65	false
barbiturates	group	37-48	ketamine	drug	94-101	effect
narcotics	group	57-65	ketamine	drug	94-101	effect

DDI-DrugBank.d518.s1	Ketamine is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained.
Ketamine	drug	0-7	anesthetic agents	group	75-91	false

DDI-DrugBank.d355.s2	Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
oxyphenbutazone	drug	29-43	androgens	group	49-57	mechanism
oxyphenbutazone	drug	29-43	oxyphenbutazone	drug	98-112	false
androgens	group	49-57	oxyphenbutazone	drug	98-112	false

DDI-DrugBank.d355.s3	In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
androgens	group	47-55	insulin	drug	99-105	effect

DDI-DrugBank.d133.s0	Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
BOTOX	brand	21-25	aminoglycosides	group	31-45	advise
BOTOX	brand	21-25	curare-like compounds	group	114-134	advise
BOTOX	brand	21-25	toxin	drug	196-200	false
aminoglycosides	group	31-45	curare-like compounds	group	114-134	false
aminoglycosides	group	31-45	toxin	drug	196-200	false
curare-like compounds	group	114-134	toxin	drug	196-200	false

DDI-DrugBank.d133.s2	Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
botulinum toxin	group	81-95	botulinum toxin	group	165-179	effect

DDI-DrugBank.d462.s0	Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.
Aminoglycosides	group	0-14	piperacillin	drug	31-42	false
Aminoglycosides	group	0-14	aminoglycoside	group	52-65	false
Aminoglycosides	group	0-14	aminoglycoside	group	122-135	false
piperacillin	drug	31-42	aminoglycoside	group	52-65	effect
piperacillin	drug	31-42	aminoglycoside	group	122-135	false
aminoglycoside	group	52-65	aminoglycoside	group	122-135	false

DDI-DrugBank.d462.s1	Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.
Vecuronium	drug	0-9	piperacillin	drug	51-62	false
Vecuronium	drug	0-9	vecuronium	drug	137-146	false
piperacillin	drug	51-62	vecuronium	drug	137-146	effect

DDI-DrugBank.d462.s3	In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.
piperacillin	drug	67-78	vecuronium	drug	120-129	effect

DDI-DrugBank.d462.s4	Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.
non-depolarizing muscle relaxants	group	112-144	piperacillin	drug	184-195	effect

DDI-DrugBank.d462.s5	Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.
Probenecid	drug	0-9	probenecid	drug	36-45	false
Probenecid	drug	0-9	PIPRACIL	brand	81-88	false
Probenecid	drug	0-9	piperacillin	drug	114-125	false
probenecid	drug	36-45	PIPRACIL	brand	81-88	mechanism
probenecid	drug	36-45	piperacillin	drug	114-125	false
PIPRACIL	brand	81-88	piperacillin	drug	114-125	false

DDI-DrugBank.d462.s6	Anticoagulants: Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function.
Anticoagulants	group	0-13	heparin	drug	148-154	false
Anticoagulants	group	0-13	anticoagulants	group	162-175	false
heparin	drug	148-154	anticoagulants	group	162-175	false

DDI-DrugBank.d462.s7	Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.
Methotrexate	drug	0-11	Piperacillin sodium	drug	14-32	false
Methotrexate	drug	0-11	methotrexate	drug	62-73	false
Piperacillin sodium	drug	14-32	methotrexate	drug	62-73	mechanism

DDI-DrugBank.d462.s9	Drug/Laboratory Test Interactions As with other penicillins, the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper-reduction method.
penicillins	drug	48-58	PIPRACIL	brand	83-90	false

DDI-DrugBank.d462.s11	There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection.
piperacillin	drug	132-143	tazobactam	drug	145-154	false

DDI-DrugBank.d227.s0	Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
Isoflurane	drug	0-9	muscle relaxants	group	57-72	effect
Isoflurane	drug	0-9	nondepolarizing muscle relaxants	group	88-119	effect
muscle relaxants	group	57-72	nondepolarizing muscle relaxants	group	88-119	false

DDI-DrugBank.d256.s0	Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
Clindamycin	drug	0-10	neuromuscular blocking agents	group	106-134	effect

DDI-DrugBank.d256.s2	Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
clindamycin	drug	41-51	erythromycin	drug	57-68	effect

DDI-DrugBank.d35.s0	Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
EPA	drug	31-33	aspirin	brand	51-57	int
EPA	drug	31-33	non-steroidal anti-inflammatory drugs	group	69-105	int
EPA	drug	31-33	ginkgo	drug	153-158	int
EPA	drug	31-33	Ginkgo biloba	drug	161-173	int
aspirin	brand	51-57	non-steroidal anti-inflammatory drugs	group	69-105	false
aspirin	brand	51-57	ginkgo	drug	153-158	false
aspirin	brand	51-57	Ginkgo biloba	drug	161-173	false
non-steroidal anti-inflammatory drugs	group	69-105	ginkgo	drug	153-158	false
non-steroidal anti-inflammatory drugs	group	69-105	Ginkgo biloba	drug	161-173	false
ginkgo	drug	153-158	Ginkgo biloba	drug	161-173	false

DDI-DrugBank.d289.s6	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
Hormonal Contraceptives	group	0-22	Contraceptives	group	82-95	false
Hormonal Contraceptives	group	0-22	bosentan	drug	158-165	false
Hormonal Contraceptives	group	0-22	hormonal contraceptive	group	180-201	false
Hormonal Contraceptives	group	0-22	Ortho-Novum	brand	203-213	false
Hormonal Contraceptives	group	0-22	norethindrone	drug	245-257	false
Hormonal Contraceptives	group	0-22	ethinyl estradiol	drug	263-279	false
Contraceptives	group	82-95	bosentan	drug	158-165	false
Contraceptives	group	82-95	hormonal contraceptive	group	180-201	false
Contraceptives	group	82-95	Ortho-Novum	brand	203-213	false
Contraceptives	group	82-95	norethindrone	drug	245-257	false
Contraceptives	group	82-95	ethinyl estradiol	drug	263-279	false
bosentan	drug	158-165	hormonal contraceptive	group	180-201	false
bosentan	drug	158-165	Ortho-Novum	brand	203-213	mechanism
bosentan	drug	158-165	norethindrone	drug	245-257	false
bosentan	drug	158-165	ethinyl estradiol	drug	263-279	false
hormonal contraceptive	group	180-201	Ortho-Novum	brand	203-213	false
hormonal contraceptive	group	180-201	norethindrone	drug	245-257	false
hormonal contraceptive	group	180-201	ethinyl estradiol	drug	263-279	false
Ortho-Novum	brand	203-213	norethindrone	drug	245-257	false
Ortho-Novum	brand	203-213	ethinyl estradiol	drug	263-279	false
norethindrone	drug	245-257	ethinyl estradiol	drug	263-279	false

DDI-DrugBank.d289.s8	Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.
hormonal contraceptives	group	11-33	TRACLEER	brand	125-132	effect

DDI-DrugBank.d289.s10	Specific interaction studies have demonstrated the following: Cyclosporine A: During the first day of concomitant administration, trough concentrations of bosentan were increased by about 30-fold.
Cyclosporine A	drug	62-75	bosentan	drug	155-162	false

DDI-DrugBank.d289.s11	Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.
bosentan	drug	13-20	cyclosporine A	drug	92-105	mechanism

DDI-DrugBank.d289.s12	The concomitant administration of bosentan and cyclosporine A is contraindicated.
bosentan	drug	34-41	cyclosporine A	drug	47-60	advise

DDI-DrugBank.d289.s13	Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.
bosentan	drug	21-28	cyclosporine A	drug	69-82	mechanism

DDI-DrugBank.d289.s14	Tacrolimus: Co-administration of tacrolimus and bosentan has not been studied in man.
Tacrolimus	drug	0-9	tacrolimus	drug	33-42	false
Tacrolimus	drug	0-9	bosentan	drug	48-55	false
tacrolimus	drug	33-42	bosentan	drug	48-55	false

DDI-DrugBank.d289.s15	Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
tacrolimus	drug	21-30	bosentan	drug	36-43	mechanism
tacrolimus	drug	21-30	bosentan	drug	101-108	false
bosentan	drug	36-43	bosentan	drug	101-108	false

DDI-DrugBank.d289.s16	Caution should be exercised if tacrolimus and bosentan are used together.
tacrolimus	drug	31-40	bosentan	drug	46-53	advise

DDI-DrugBank.d289.s17	Glyburide: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide.
Glyburide	drug	0-8	glyburide	drug	125-133	false

DDI-DrugBank.d289.s18	Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.
TRACLEER	brand	45-52	glyburide	drug	58-66	advise
TRACLEER	brand	45-52	hypoglycemic agents	group	104-122	false
glyburide	drug	58-66	hypoglycemic agents	group	104-122	false

DDI-DrugBank.d289.s19	Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
bosentan	drug	21-28	glyburide	drug	69-77	mechanism

DDI-DrugBank.d289.s21	Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.
Bosentan	drug	0-7	hypoglycemic agents	group	72-90	mechanism

DDI-DrugBank.d289.s23	Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
Ketoconazole	drug	0-11	bosentan	drug	35-42	false
Ketoconazole	drug	0-11	ketoconazole	drug	62-73	false
Ketoconazole	drug	0-11	bosentan	drug	142-149	false
bosentan	drug	35-42	ketoconazole	drug	62-73	mechanism
bosentan	drug	35-42	bosentan	drug	142-149	false
ketoconazole	drug	62-73	bosentan	drug	142-149	false

DDI-DrugBank.d289.s24	No dose adjustment of bosentan is necessary, but increased effects of bosentan should be considered.
bosentan	drug	22-29	bosentan	drug	70-77	false

DDI-DrugBank.d289.s25	Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
Simvastatin	drug	0-10	Statins	group	22-28	false
Simvastatin	drug	0-10	bosentan	drug	52-59	false
Simvastatin	drug	0-10	simvastatin	drug	100-110	false
Statins	group	22-28	bosentan	drug	52-59	false
Statins	group	22-28	simvastatin	drug	100-110	false
bosentan	drug	52-59	simvastatin	drug	100-110	mechanism

DDI-DrugBank.d289.s27	Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
Bosentan	drug	0-7	statins	group	67-73	mechanism
Bosentan	drug	0-7	lovastatin	drug	127-136	mechanism
Bosentan	drug	0-7	atorvastatin	drug	142-153	mechanism
statins	group	67-73	lovastatin	drug	127-136	false
statins	group	67-73	atorvastatin	drug	142-153	false
lovastatin	drug	127-136	atorvastatin	drug	142-153	false

DDI-DrugBank.d289.s29	Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.
statins	group	34-40	TRACLEER	brand	89-96	advise
statins	group	34-40	statin	group	130-135	false
TRACLEER	brand	89-96	statin	group	130-135	false

DDI-DrugBank.d289.s30	Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
Warfarin	drug	0-7	bosentan	drug	31-38	false
Warfarin	drug	0-7	S-warfarin	drug	109-118	false
Warfarin	drug	0-7	R-warfarin	drug	145-154	false
bosentan	drug	31-38	S-warfarin	drug	109-118	mechanism
bosentan	drug	31-38	R-warfarin	drug	145-154	mechanism
S-warfarin	drug	109-118	R-warfarin	drug	145-154	false

DDI-DrugBank.d289.s31	Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.
bosentan	drug	55-62	warfarin	drug	68-75	false
bosentan	drug	55-62	warfarin	drug	177-184	false
bosentan	drug	55-62	warfarin	drug	262-269	false
bosentan	drug	55-62	bosentan	drug	359-366	false
warfarin	drug	68-75	warfarin	drug	177-184	false
warfarin	drug	68-75	warfarin	drug	262-269	false
warfarin	drug	68-75	bosentan	drug	359-366	false
warfarin	drug	177-184	warfarin	drug	262-269	false
warfarin	drug	177-184	bosentan	drug	359-366	false
warfarin	drug	262-269	bosentan	drug	359-366	false

DDI-DrugBank.d289.s32	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.
Digoxin	drug	0-6	Nimodipine	drug	9-18	false
Digoxin	drug	0-6	Losartan	drug	24-31	false
Digoxin	drug	0-6	Bosentan	drug	34-41	false
Digoxin	drug	0-6	digoxin	drug	96-102	false
Digoxin	drug	0-6	nimodipine	drug	108-117	false
Digoxin	drug	0-6	losartan	drug	124-131	false
Digoxin	drug	0-6	bosentan	drug	179-186	false
Nimodipine	drug	9-18	Losartan	drug	24-31	false
Nimodipine	drug	9-18	Bosentan	drug	34-41	false
Nimodipine	drug	9-18	digoxin	drug	96-102	false
Nimodipine	drug	9-18	nimodipine	drug	108-117	false
Nimodipine	drug	9-18	losartan	drug	124-131	false
Nimodipine	drug	9-18	bosentan	drug	179-186	false
Losartan	drug	24-31	Bosentan	drug	34-41	false
Losartan	drug	24-31	digoxin	drug	96-102	false
Losartan	drug	24-31	nimodipine	drug	108-117	false
Losartan	drug	24-31	losartan	drug	124-131	false
Losartan	drug	24-31	bosentan	drug	179-186	false
Bosentan	drug	34-41	digoxin	drug	96-102	false
Bosentan	drug	34-41	nimodipine	drug	108-117	false
Bosentan	drug	34-41	losartan	drug	124-131	false
Bosentan	drug	34-41	bosentan	drug	179-186	false
digoxin	drug	96-102	nimodipine	drug	108-117	false
digoxin	drug	96-102	losartan	drug	124-131	false
digoxin	drug	96-102	bosentan	drug	179-186	false
nimodipine	drug	108-117	losartan	drug	124-131	false
nimodipine	drug	108-117	bosentan	drug	179-186	false
losartan	drug	124-131	bosentan	drug	179-186	false

DDI-DrugBank.d174.s1	Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
nabumetone	drug	47-56	warfarin	drug	63-70	advise
nabumetone	drug	47-56	NSAIDs	group	117-122	false
warfarin	drug	63-70	NSAIDs	group	117-122	int

DDI-DrugBank.d174.s2	Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.
aluminum	drug	33-40	antacid	group	53-59	false
aluminum	drug	33-40	6MNA	drug_n	113-116	false
antacid	group	53-59	6MNA	drug_n	113-116	false

DDI-DrugBank.d22.s0	Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
Aminosalicylic acid	drug	0-18	digoxin	drug	47-53	mechanism
Aminosalicylic acid	drug	0-18	Lanoxin	brand	56-62	mechanism
Aminosalicylic acid	drug	0-18	Lanoxicaps	drug	65-74	false
digoxin	drug	47-53	Lanoxin	brand	56-62	false
digoxin	drug	47-53	Lanoxicaps	drug	65-74	false
Lanoxin	brand	56-62	Lanoxicaps	drug	65-74	false

DDI-DrugBank.d22.s1	In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.
digoxin	drug	32-38	aminosalicylic acid	drug	53-71	advise
digoxin	drug	32-38	digoxin	drug	90-96	false
aminosalicylic acid	drug	53-71	digoxin	drug	90-96	false

DDI-DrugBank.d22.s2	Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.
Aminosalicylic acid	drug	0-18	vitamin B12	drug	56-66	mechanism

DDI-DrugBank.d22.s3	Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.
vitamin B12	drug	33-43	aminosalicylic acid	drug	69-87	advise

DDI-DrugBank.d353.s0	Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
Ethanol	drug	0-6	etretinate	drug	41-50	false
Ethanol	drug	0-6	acitretin	drug	95-103	false
Ethanol	drug	0-6	ethanol	drug	109-115	false
etretinate	drug	41-50	acitretin	drug	95-103	false
etretinate	drug	41-50	ethanol	drug	109-115	false
acitretin	drug	95-103	ethanol	drug	109-115	mechanism

DDI-DrugBank.d353.s1	Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
Glibenclamide	drug	0-12	acitretin	drug	56-64	false
Glibenclamide	drug	0-12	glibenclamide	drug	125-137	false
Glibenclamide	drug	0-12	sulfonylurea	group	142-153	false
Glibenclamide	drug	0-12	chlorpropamide	drug	166-179	false
acitretin	drug	56-64	glibenclamide	drug	125-137	effect
acitretin	drug	56-64	sulfonylurea	group	142-153	false
acitretin	drug	56-64	chlorpropamide	drug	166-179	false
glibenclamide	drug	125-137	sulfonylurea	group	142-153	false
glibenclamide	drug	125-137	chlorpropamide	drug	166-179	false
sulfonylurea	group	142-153	chlorpropamide	drug	166-179	false

DDI-DrugBank.d353.s2	Repeating the study with 6 healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.
glibenclamide	drug	69-81	acitretin	drug	111-119	false

DDI-DrugBank.d353.s4	Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between acitretin and combined oral contraceptives.
Hormonal Contraceptives	group	0-22	acitretin	drug	103-111	false
Hormonal Contraceptives	group	0-22	combined oral contraceptives	group	117-144	false
acitretin	drug	103-111	combined oral contraceptives	group	117-144	false

DDI-DrugBank.d353.s5	However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.
acitretin	drug	38-46	progestin	drug	103-111	effect

DDI-DrugBank.d353.s6	Microdosed minipill progestin preparations are not recommended for use with Soriatane.
progestin	drug	20-28	Soriatane	drug	76-84	advise

DDI-DrugBank.d353.s7	It is not known whether other progestational contraceptives, such as implants and injectables, are adequate methods of contraception during acitretin therapy.
progestational contraceptives	group	30-58	acitretin	drug	140-148	false

DDI-DrugBank.d353.s8	Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.
Methotrexate	drug	0-11	methotrexate	drug	94-105	false
Methotrexate	drug	0-11	etretinate	drug	111-120	false
methotrexate	drug	94-105	etretinate	drug	111-120	effect

DDI-DrugBank.d353.s9	Consequently, the combination of methotrexate with acitretin is also contraindicated.
methotrexate	drug	33-44	acitretin	drug	51-59	advise

DDI-DrugBank.d353.s10	Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
Phenytoin	drug	0-8	acitretin	drug	14-22	false
Phenytoin	drug	0-8	phenytoin	drug	51-59	false
Phenytoin	drug	0-8	phenytoin	drug	85-93	false
acitretin	drug	14-22	phenytoin	drug	51-59	mechanism
acitretin	drug	14-22	phenytoin	drug	85-93	false
phenytoin	drug	51-59	phenytoin	drug	85-93	false

DDI-DrugBank.d353.s11	Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.
Tetracyclines	group	0-12	acitretin	drug	26-34	false
Tetracyclines	group	0-12	tetracyclines	group	40-52	false
acitretin	drug	26-34	tetracyclines	group	40-52	effect

DDI-DrugBank.d353.s12	Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
Vitamin A	group	0-8	retinoids	group	19-27	false
Vitamin A	group	0-8	vitamin A	group	60-68	false
Vitamin A	group	0-8	retinoids	group	88-96	false
Vitamin A	group	0-8	acitretin	drug	103-111	false
retinoids	group	19-27	vitamin A	group	60-68	false
retinoids	group	19-27	retinoids	group	88-96	false
retinoids	group	19-27	acitretin	drug	103-111	false
vitamin A	group	60-68	retinoids	group	88-96	false
vitamin A	group	60-68	acitretin	drug	103-111	advise
retinoids	group	88-96	acitretin	drug	103-111	advise

DDI-DrugBank.d353.s13	Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide.
acitretin	drug	66-74	cimetidine	drug	80-89	false
acitretin	drug	66-74	digoxin	drug	92-98	false
acitretin	drug	66-74	glyburide	drug	104-112	false
cimetidine	drug	80-89	digoxin	drug	92-98	false
cimetidine	drug	80-89	glyburide	drug	104-112	false
digoxin	drug	92-98	glyburide	drug	104-112	false

DDI-DrugBank.d353.s14	Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.
acitretin	drug	34-42	anticoagulants of the coumarin type	group	70-104	false
acitretin	drug	34-42	warfarin	drug	107-114	false
anticoagulants of the coumarin type	group	70-104	warfarin	drug	107-114	false

DDI-DrugBank.d54.s0	Oral Anticoagulants: Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors.
Anticoagulants	group	5-18	Thyroid hormones	group	21-36	false

DDI-DrugBank.d54.s2	Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.
anticoagulants	group	28-41	thyroid	group	68-74	advise

DDI-DrugBank.d54.s5	Insulin or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.
Insulin	drug	0-6	Hypoglycemics	group	16-28	false
Insulin	drug	0-6	insulin	drug	93-99	false
Insulin	drug	0-6	hypoglycemic	group	109-120	false
Hypoglycemics	group	16-28	insulin	drug	93-99	false
Hypoglycemics	group	16-28	hypoglycemic	group	109-120	false
insulin	drug	93-99	hypoglycemic	group	109-120	false

DDI-DrugBank.d54.s7	Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.
insulin	drug	19-25	hypoglycemics	group	35-47	false

DDI-DrugBank.d54.s8	Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
Cholestyramine	drug	0-13	Cholestyramine	drug	16-29	false
Cholestyramine	drug	0-13	T4	drug	42-43	false
Cholestyramine	drug	0-13	T3	drug	49-50	false
Cholestyramine	drug	0-13	thyroid hormones	group	105-120	false
Cholestyramine	drug	16-29	T4	drug	42-43	mechanism
Cholestyramine	drug	16-29	T3	drug	49-50	mechanism
Cholestyramine	drug	16-29	thyroid hormones	group	105-120	false
T4	drug	42-43	T3	drug	49-50	false
T4	drug	42-43	thyroid hormones	group	105-120	false
T3	drug	49-50	thyroid hormones	group	105-120	false

DDI-DrugBank.d54.s10	Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.
cholestyramine	drug	64-77	thyroid hormones	group	83-98	advise

DDI-DrugBank.d54.s11	Estrogen, Oral Contraceptives: Estrogens tend to increase serum thyroxine-binding globulin (TBg).
Estrogen	group	0-7	Contraceptives	group	15-28	false
Estrogen	group	0-7	Estrogens	group	31-39	false
Contraceptives	group	15-28	Estrogens	group	31-39	false

DDI-DrugBank.d54.s12	In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.
levothyroxine	drug	100-112	estrogens	group	136-144	mechanism
levothyroxine	drug	100-112	thyroid	group	174-180	false
estrogens	group	136-144	thyroid	group	174-180	false

DDI-DrugBank.d54.s14	Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
thyroid	group	42-48	estrogens	group	138-146	advise
thyroid	group	42-48	estrogen	group	151-158	false
thyroid	group	42-48	contraceptives	group	176-189	advise
estrogens	group	138-146	estrogen	group	151-158	false
estrogens	group	138-146	contraceptives	group	176-189	false
estrogen	group	151-158	contraceptives	group	176-189	false

DDI-DrugBank.d54.s15	Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
Tricyclic Antidepressants	group	0-24	thyroid products	group	34-49	false
Tricyclic Antidepressants	group	0-24	imipramine	drug	56-65	false
Tricyclic Antidepressants	group	0-24	tricyclic antidepressants	group	77-101	false
thyroid products	group	34-49	imipramine	drug	56-65	effect
thyroid products	group	34-49	tricyclic antidepressants	group	77-101	effect
imipramine	drug	56-65	tricyclic antidepressants	group	77-101	false

DDI-DrugBank.d54.s17	Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.
Digitalis	group	0-8	Thyroid preparations	group	11-30	false
Digitalis	group	0-8	digitalis	group	68-76	false
Thyroid preparations	group	11-30	digitalis	group	68-76	effect

DDI-DrugBank.d54.s19	Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.
Ketamine	drug	0-7	thyroid preparation	group	45-63	false
Ketamine	drug	0-7	anesthetic	group	82-91	false
thyroid preparation	group	45-63	anesthetic	group	82-91	effect

DDI-DrugBank.d54.s21	Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
Vasopressor	group	0-10	Thyroxine	drug	14-22	false
Vasopressor	group	0-10	epinephrine	drug	82-92	false
Vasopressor	group	0-10	norepinephrine	drug	98-111	false
Thyroxine	drug	14-22	epinephrine	drug	82-92	effect
Thyroxine	drug	14-22	norepinephrine	drug	98-111	effect
epinephrine	drug	82-92	norepinephrine	drug	98-111	false

DDI-DrugBank.d54.s24	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
thyroid hormone	group	136-150	androgens	group	161-169	false
thyroid hormone	group	136-150	corticosteroids	group	172-186	false
thyroid hormone	group	136-150	estrogens	group	189-197	false
thyroid hormone	group	136-150	contraceptives	group	205-218	false
thyroid hormone	group	136-150	estrogens	group	231-239	false
thyroid hormone	group	136-150	iodine	group	242-247	false
thyroid hormone	group	136-150	salicylates	group	314-324	false
androgens	group	161-169	corticosteroids	group	172-186	false
androgens	group	161-169	estrogens	group	189-197	false
androgens	group	161-169	contraceptives	group	205-218	false
androgens	group	161-169	estrogens	group	231-239	false
androgens	group	161-169	iodine	group	242-247	false
androgens	group	161-169	salicylates	group	314-324	false
corticosteroids	group	172-186	estrogens	group	189-197	false
corticosteroids	group	172-186	contraceptives	group	205-218	false
corticosteroids	group	172-186	estrogens	group	231-239	false
corticosteroids	group	172-186	iodine	group	242-247	false
corticosteroids	group	172-186	salicylates	group	314-324	false
estrogens	group	189-197	contraceptives	group	205-218	false
estrogens	group	189-197	estrogens	group	231-239	false
estrogens	group	189-197	iodine	group	242-247	false
estrogens	group	189-197	salicylates	group	314-324	false
contraceptives	group	205-218	estrogens	group	231-239	false
contraceptives	group	205-218	iodine	group	242-247	false
contraceptives	group	205-218	salicylates	group	314-324	false
estrogens	group	231-239	iodine	group	242-247	false
estrogens	group	231-239	salicylates	group	314-324	false
iodine	group	242-247	salicylates	group	314-324	false

DDI-DrugBank.d54.s27	Pregnancy estrogens and estrogen-containing oral contraceptives increase TBg concentrations.
estrogens	group	10-18	estrogen	group	24-31	false
estrogens	group	10-18	contraceptives	group	49-62	false
estrogen	group	24-31	contraceptives	group	49-62	false

DDI-DrugBank.d54.s29	Decreases in TBg concentrations are observed in nephrosis, acromegaly and after androgen or corticosteroid therapy.
androgen	group	80-87	corticosteroid	group	92-105	false

DDI-DrugBank.d205.s0	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
Zarontin	brand	6-13	ethosuximide	drug	16-27	false
Zarontin	brand	6-13	antiepileptic drugs	group	74-92	int
Zarontin	brand	6-13	ethosuximide	drug	168-179	false
Zarontin	brand	6-13	phenytoin	drug	193-201	false
Zarontin	brand	6-13	valproic acid	drug	220-232	false
Zarontin	brand	6-13	ethosuximide	drug	282-293	false
ethosuximide	drug	16-27	antiepileptic drugs	group	74-92	int
ethosuximide	drug	16-27	ethosuximide	drug	168-179	false
ethosuximide	drug	16-27	phenytoin	drug	193-201	false
ethosuximide	drug	16-27	valproic acid	drug	220-232	false
ethosuximide	drug	16-27	ethosuximide	drug	282-293	false
antiepileptic drugs	group	74-92	ethosuximide	drug	168-179	false
antiepileptic drugs	group	74-92	phenytoin	drug	193-201	false
antiepileptic drugs	group	74-92	valproic acid	drug	220-232	false
antiepileptic drugs	group	74-92	ethosuximide	drug	282-293	false
ethosuximide	drug	168-179	phenytoin	drug	193-201	mechanism
ethosuximide	drug	168-179	valproic acid	drug	220-232	false
ethosuximide	drug	168-179	ethosuximide	drug	282-293	false
phenytoin	drug	193-201	valproic acid	drug	220-232	false
phenytoin	drug	193-201	ethosuximide	drug	282-293	false
valproic acid	drug	220-232	ethosuximide	drug	282-293	mechanism

DDI-DrugBank.d97.s3	Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir, resulting in lowered plasma concentrations of indinavir.
indinavir	drug	81-89	indinavir	drug	138-146	false

DDI-DrugBank.d97.s4	Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.
CRIXIVAN	brand	20-27	indinavir	drug	95-103	false
CRIXIVAN	brand	20-27	indinavir	drug	158-166	false
indinavir	drug	95-103	indinavir	drug	158-166	false

DDI-DrugBank.d97.s8	Antiarrhythmics: amiodarone
Antiarrhythmics	group	0-14	amiodarone	drug	17-26	false

DDI-DrugBank.d97.s10	Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine
dihydroergotamine	drug	19-35	ergonovine	drug	38-47	false
dihydroergotamine	drug	19-35	ergotamine	drug	50-59	false
dihydroergotamine	drug	19-35	methylergonovine	drug	62-77	false
ergonovine	drug	38-47	ergotamine	drug	50-59	false
ergonovine	drug	38-47	methylergonovine	drug	62-77	false
ergotamine	drug	50-59	methylergonovine	drug	62-77	false

DDI-DrugBank.d97.s12	Sedative/hypnotics: midazolam, triazolam
Sedative	group	0-7	hypnotics	group	9-17	false
Sedative	group	0-7	midazolam	drug	20-28	false
Sedative	group	0-7	triazolam	drug	31-39	false
hypnotics	group	9-17	midazolam	drug	20-28	false
hypnotics	group	9-17	triazolam	drug	31-39	false
midazolam	drug	20-28	triazolam	drug	31-39	false

DDI-DrugBank.d97.s16	Neuroleptic: pimozide
Neuroleptic	group	0-10	pimozide	drug	13-20	false

DDI-DrugBank.d97.s19	May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors.
CRIXIVAN	brand	66-73	protease inhibitors	group	94-112	false

DDI-DrugBank.d97.s20	Antimycobacterial: rifampin
Antimycobacterial	group	0-16	rifampin	drug	19-26	false

DDI-DrugBank.d97.s21	May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors or other coadministered antiretroviral agents.
CRIXIVAN	brand	66-73	protease inhibitors	group	94-112	false
CRIXIVAN	brand	66-73	antiretroviral agents	group	138-158	false
protease inhibitors	group	94-112	antiretroviral agents	group	138-158	false

DDI-DrugBank.d97.s22	HMG-CoA Reductase inhibitors: lovastatin, simvastatin
HMG-CoA Reductase inhibitors	group	0-27	lovastatin	drug	30-39	false
HMG-CoA Reductase inhibitors	group	0-27	simvastatin	drug	42-52	false
lovastatin	drug	30-39	simvastatin	drug	42-52	false

DDI-DrugBank.d97.s24	Protease inhibitor: atazanavir
Protease inhibitor	group	0-17	atazanavir	drug	20-29	false

DDI-DrugBank.d97.s25	Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia.
CRIXIVAN	brand	5-12	atazanavir	drug	18-27	false

DDI-DrugBank.d97.s26	Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.
CRIXIVAN	brand	74-81	atazanavir	drug	87-96	advise

DDI-DrugBank.d97.s35	Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.
CRIXIVAN	brand	18-25	delavirdine	drug	84-94	advise

DDI-DrugBank.d97.s37	Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.
Indinavir	drug	0-8	didanosine	drug	14-23	advise

DDI-DrugBank.d97.s40	The optimal dose of indinavir, when given in combination with efavirenz, is not known.
indinavir	drug	20-28	efavirenz	drug	62-70	false

DDI-DrugBank.d97.s41	Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.
indinavir	drug	15-23	indinavir	drug	93-101	false
indinavir	drug	15-23	efavirenz	drug	121-129	false
indinavir	drug	93-101	efavirenz	drug	121-129	mechanism

DDI-DrugBank.d97.s47	Indinavir concentrations may be decreased in the presence of nevirapine.
Indinavir	drug	0-8	nevirapine	drug	61-70	mechanism

DDI-DrugBank.d97.s50	indinavir concentration   ritonavir concentration
indinavir	drug	0-8	ritonavir	drug	26-34	false

DDI-DrugBank.d97.s52	Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.
indinavir	drug	104-112	ritonavir	drug	134-142	effect
indinavir	drug	104-112	CRIXIVAN	brand	165-172	false
ritonavir	drug	134-142	CRIXIVAN	brand	165-172	false

DDI-DrugBank.d97.s57	Antiarrhythmics: bepridil, lidocaine (systemic) and quinidine
Antiarrhythmics	group	0-14	bepridil	drug	17-24	false
Antiarrhythmics	group	0-14	lidocaine	drug	27-35	false
Antiarrhythmics	group	0-14	quinidine	drug	52-60	false
bepridil	drug	17-24	lidocaine	drug	27-35	false
bepridil	drug	17-24	quinidine	drug	52-60	false
lidocaine	drug	27-35	quinidine	drug	52-60	false

DDI-DrugBank.d97.s59	Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.
antiarrhythmics	group	81-95	CRIXIVAN	brand	122-129	advise

DDI-DrugBank.d97.s60	Anticonvulsants: carbamazepine, phenobarbital, phenytoin
Anticonvulsants	group	0-14	carbamazepine	drug	17-29	false
Anticonvulsants	group	0-14	phenobarbital	drug	32-44	false
Anticonvulsants	group	0-14	phenytoin	drug	47-55	false
carbamazepine	drug	17-29	phenobarbital	drug	32-44	false
carbamazepine	drug	17-29	phenytoin	drug	47-55	false
phenobarbital	drug	32-44	phenytoin	drug	47-55	false

DDI-DrugBank.d97.s63	CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.
CRIXIVAN	brand	0-7	indinavir	drug	47-55	effect

DDI-DrugBank.d97.s64	Calcium Channel Blockers, Dihydropyridine: e.g., felodipine, nifedipine, nicardipine
Calcium Channel Blockers	group	0-23	Dihydropyridine	group	26-40	false
Calcium Channel Blockers	group	0-23	felodipine	drug	49-58	false
Calcium Channel Blockers	group	0-23	nifedipine	drug	61-70	false
Calcium Channel Blockers	group	0-23	nicardipine	drug	73-83	false
Dihydropyridine	group	26-40	felodipine	drug	49-58	false
Dihydropyridine	group	26-40	nifedipine	drug	61-70	false
Dihydropyridine	group	26-40	nicardipine	drug	73-83	false
felodipine	drug	49-58	nifedipine	drug	61-70	false
felodipine	drug	49-58	nicardipine	drug	73-83	false
nifedipine	drug	61-70	nicardipine	drug	73-83	false

DDI-DrugBank.d97.s68	clarithromycin concentration   indinavir concentration
clarithromycin	drug	0-13	indinavir	drug	31-39	false

DDI-DrugBank.d97.s70	HMG-CoA Reductase Inhibitor: atorvastatin
HMG-CoA Reductase Inhibitor	group	0-26	atorvastatin	drug	29-40	false

DDI-DrugBank.d97.s72	Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
atorvastatin	drug	28-39	HMG-CoA reductase inhibitors	group	78-105	false
atorvastatin	drug	28-39	pravastatin	drug	161-171	false
atorvastatin	drug	28-39	fluvastatin	drug	174-184	false
atorvastatin	drug	28-39	rosuvastatin	drug	190-201	false
atorvastatin	drug	28-39	CRIXIVAN	brand	223-230	advise
HMG-CoA reductase inhibitors	group	78-105	pravastatin	drug	161-171	false
HMG-CoA reductase inhibitors	group	78-105	fluvastatin	drug	174-184	false
HMG-CoA reductase inhibitors	group	78-105	rosuvastatin	drug	190-201	false
HMG-CoA reductase inhibitors	group	78-105	CRIXIVAN	brand	223-230	advise
pravastatin	drug	161-171	fluvastatin	drug	174-184	false
pravastatin	drug	161-171	rosuvastatin	drug	190-201	false
pravastatin	drug	161-171	CRIXIVAN	brand	223-230	false
fluvastatin	drug	174-184	rosuvastatin	drug	190-201	false
fluvastatin	drug	174-184	CRIXIVAN	brand	223-230	false
rosuvastatin	drug	190-201	CRIXIVAN	brand	223-230	false

DDI-DrugBank.d97.s73	Immunosuppressants: cyclosporine, tacrolimus, sirolimus
Immunosuppressants	group	0-17	cyclosporine	drug	20-31	false
Immunosuppressants	group	0-17	tacrolimus	drug	34-43	false
Immunosuppressants	group	0-17	sirolimus	drug	46-54	false
cyclosporine	drug	20-31	tacrolimus	drug	34-43	false
cyclosporine	drug	20-31	sirolimus	drug	46-54	false
tacrolimus	drug	34-43	sirolimus	drug	46-54	false

DDI-DrugBank.d97.s78	Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.
CRIXIVAN	brand	18-25	itraconazole	drug	85-96	advise

DDI-DrugBank.d97.s83	indinavir concentration   rifabutin concentration
indinavir	drug	0-8	rifabutin	drug	26-34	false

DDI-DrugBank.d97.s84	Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
rifabutin	drug	18-26	CRIXIVAN	brand	77-84	false
rifabutin	drug	18-26	rifabutin	drug	156-164	false
rifabutin	drug	18-26	CRIXIVAN	brand	170-177	false
CRIXIVAN	brand	77-84	rifabutin	drug	156-164	false
CRIXIVAN	brand	77-84	CRIXIVAN	brand	170-177	false
rifabutin	drug	156-164	CRIXIVAN	brand	170-177	advise

DDI-DrugBank.d97.s87	Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.
Sildenafil	drug	0-9	indinavir	drug	108-116	advise

DDI-DrugBank.d97.s90	Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.
Tadalafil	drug	0-8	indinavir	drug	107-115	advise

DDI-DrugBank.d97.s93	Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.
Vardenafil	drug	0-9	indinavir	drug	108-116	advise

DDI-DrugBank.d367.s1	In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.
doxazosin mesylate	drug	44-61	digoxin	drug	99-105	false
doxazosin mesylate	drug	44-61	warfarin	drug	108-115	false
doxazosin mesylate	drug	44-61	phenytoin	drug	118-126	false
doxazosin mesylate	drug	44-61	indomethacin	drug	131-142	false
digoxin	drug	99-105	warfarin	drug	108-115	false
digoxin	drug	99-105	phenytoin	drug	118-126	false
digoxin	drug	99-105	indomethacin	drug	131-142	false
warfarin	drug	108-115	phenytoin	drug	118-126	false
warfarin	drug	108-115	indomethacin	drug	131-142	false
phenytoin	drug	118-126	indomethacin	drug	131-142	false

DDI-DrugBank.d367.s3	Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs.
Doxazosin mesylate	drug	0-17	thiazide diuretics	group	115-132	false
Doxazosin mesylate	drug	0-17	beta-blocking agent	group	135-153	false
Doxazosin mesylate	drug	0-17	nonsteroidal anti-inflammatory drugs	group	161-196	false
thiazide diuretics	group	115-132	beta-blocking agent	group	135-153	false
thiazide diuretics	group	115-132	nonsteroidal anti-inflammatory drugs	group	161-196	false
beta-blocking agent	group	135-153	nonsteroidal anti-inflammatory drugs	group	161-196	false

DDI-DrugBank.d367.s4	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
doxazosin	drug	96-104	cimetidine	drug	145-154	mechanism
doxazosin	drug	96-104	doxazosin	drug	219-227	false
doxazosin	drug	96-104	doxazosin	drug	331-339	false
cimetidine	drug	145-154	doxazosin	drug	219-227	false
cimetidine	drug	145-154	doxazosin	drug	331-339	false
doxazosin	drug	219-227	doxazosin	drug	331-339	false

DDI-DrugBank.d367.s9	Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).
Analgesic	group	0-8	anti-inflammatory	group	10-26	false
Analgesic	group	0-8	acetaminophen	drug	35-47	false
Analgesic	group	0-8	aspirin	brand	50-56	false
Analgesic	group	0-8	codeine	drug	59-65	false
Analgesic	group	0-8	codeine	drug	71-77	false
Analgesic	group	0-8	ibuprofen	drug	93-101	false
Analgesic	group	0-8	indomethacin	drug	104-115	false
anti-inflammatory	group	10-26	acetaminophen	drug	35-47	false
anti-inflammatory	group	10-26	aspirin	brand	50-56	false
anti-inflammatory	group	10-26	codeine	drug	59-65	false
anti-inflammatory	group	10-26	codeine	drug	71-77	false
anti-inflammatory	group	10-26	ibuprofen	drug	93-101	false
anti-inflammatory	group	10-26	indomethacin	drug	104-115	false
acetaminophen	drug	35-47	aspirin	brand	50-56	false
acetaminophen	drug	35-47	codeine	drug	59-65	false
acetaminophen	drug	35-47	codeine	drug	71-77	false
acetaminophen	drug	35-47	ibuprofen	drug	93-101	false
acetaminophen	drug	35-47	indomethacin	drug	104-115	false
aspirin	brand	50-56	codeine	drug	59-65	false
aspirin	brand	50-56	codeine	drug	71-77	false
aspirin	brand	50-56	ibuprofen	drug	93-101	false
aspirin	brand	50-56	indomethacin	drug	104-115	false
codeine	drug	59-65	codeine	drug	71-77	false
codeine	drug	59-65	ibuprofen	drug	93-101	false
codeine	drug	59-65	indomethacin	drug	104-115	false
codeine	drug	71-77	ibuprofen	drug	93-101	false
codeine	drug	71-77	indomethacin	drug	104-115	false
ibuprofen	drug	93-101	indomethacin	drug	104-115	false

DDI-DrugBank.d367.s11	Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).
Antibiotics	group	0-10	erythromycin	drug	19-30	false
Antibiotics	group	0-10	trimethoprim	drug	33-44	false
Antibiotics	group	0-10	sulfamethoxazole	drug	50-65	false
Antibiotics	group	0-10	amoxicillin	drug	68-78	false
erythromycin	drug	19-30	trimethoprim	drug	33-44	false
erythromycin	drug	19-30	sulfamethoxazole	drug	50-65	false
erythromycin	drug	19-30	amoxicillin	drug	68-78	false
trimethoprim	drug	33-44	sulfamethoxazole	drug	50-65	false
trimethoprim	drug	33-44	amoxicillin	drug	68-78	false
sulfamethoxazole	drug	50-65	amoxicillin	drug	68-78	false

DDI-DrugBank.d367.s13	Antihistamines (e.g., chlorpheniramine).
Antihistamines	group	0-13	chlorpheniramine	group	22-37	false

DDI-DrugBank.d367.s15	Cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol).
atenolol	drug	29-36	hydrochlorothiazide	drug	39-57	false
atenolol	drug	29-36	propranolol	drug	60-70	false
hydrochlorothiazide	drug	39-57	propranolol	drug	60-70	false

DDI-DrugBank.d367.s23	Sedatives and tranquilizers (e.g., diazepam).
Sedatives	group	0-8	tranquilizers	group	14-26	false
Sedatives	group	0-8	diazepam	drug	35-42	false
tranquilizers	group	14-26	diazepam	drug	35-42	false

DDI-DrugBank.d100.s0	Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
cephalosporins	group	83-96	aminoglycoside antibiotics	group	102-127	effect

DDI-DrugBank.d100.s1	Drug/Laboratory Test Interactions Cephalosporins, including cefotaxime sodium, are known to occasionally induce a positive direct Coombs test.
Cephalosporins	group	34-47	cefotaxime sodium	drug	60-76	false

DDI-DrugBank.d119.s2	Probenecid    Prolonged action of etomidate
Probenecid	drug	0-9	etomidate	drug	34-42	false

DDI-DrugBank.d119.s4	Zimelidine    etomidate antagonism
Zimelidine	drug_n	0-9	etomidate	drug	14-22	false

DDI-DrugBank.d119.s6	Aminophylline     Etomidate antagonism
Aminophylline	drug	0-12	Etomidate	drug	18-26	false

DDI-DrugBank.d380.s0	Buprenorphine is metabolized to norbuprenorphine by cytochrome CYP 3A4.
Buprenorphine	drug	0-12	norbuprenorphine	drug_n	32-47	false

DDI-DrugBank.d380.s1	Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine, patients already on CYP 3A4 inhibitors such as azole antifungals (e.g.
buprenorphine	drug	65-77	azole antifungals	group	127-143	false

DDI-DrugBank.d380.s2	ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
ketoconazole	drug	0-11	macrolide antibiotics	group	15-35	false
ketoconazole	drug	0-11	erythromycin	drug	43-54	false
ketoconazole	drug	0-11	HIV protease inhibitors	group	62-84	false
ketoconazole	drug	0-11	ritonavir	drug	92-100	false
ketoconazole	drug	0-11	indinavir	drug	103-111	false
ketoconazole	drug	0-11	saquinavir	drug	117-126	false
ketoconazole	drug	0-11	SUBUTEX	brand	155-161	false
ketoconazole	drug	0-11	SUBOXONE	brand	166-173	false
macrolide antibiotics	group	15-35	erythromycin	drug	43-54	false
macrolide antibiotics	group	15-35	HIV protease inhibitors	group	62-84	false
macrolide antibiotics	group	15-35	ritonavir	drug	92-100	false
macrolide antibiotics	group	15-35	indinavir	drug	103-111	false
macrolide antibiotics	group	15-35	saquinavir	drug	117-126	false
macrolide antibiotics	group	15-35	SUBUTEX	brand	155-161	false
macrolide antibiotics	group	15-35	SUBOXONE	brand	166-173	false
erythromycin	drug	43-54	HIV protease inhibitors	group	62-84	false
erythromycin	drug	43-54	ritonavir	drug	92-100	false
erythromycin	drug	43-54	indinavir	drug	103-111	false
erythromycin	drug	43-54	saquinavir	drug	117-126	false
erythromycin	drug	43-54	SUBUTEX	brand	155-161	false
erythromycin	drug	43-54	SUBOXONE	brand	166-173	false
HIV protease inhibitors	group	62-84	ritonavir	drug	92-100	false
HIV protease inhibitors	group	62-84	indinavir	drug	103-111	false
HIV protease inhibitors	group	62-84	saquinavir	drug	117-126	false
HIV protease inhibitors	group	62-84	SUBUTEX	brand	155-161	false
HIV protease inhibitors	group	62-84	SUBOXONE	brand	166-173	false
ritonavir	drug	92-100	indinavir	drug	103-111	false
ritonavir	drug	92-100	saquinavir	drug	117-126	false
ritonavir	drug	92-100	SUBUTEX	brand	155-161	false
ritonavir	drug	92-100	SUBOXONE	brand	166-173	false
indinavir	drug	103-111	saquinavir	drug	117-126	false
indinavir	drug	103-111	SUBUTEX	brand	155-161	false
indinavir	drug	103-111	SUBOXONE	brand	166-173	false
saquinavir	drug	117-126	SUBUTEX	brand	155-161	false
saquinavir	drug	117-126	SUBOXONE	brand	166-173	false
SUBUTEX	brand	155-161	SUBOXONE	brand	166-173	false

DDI-DrugBank.d380.s3	Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.
buprenorphine	drug	64-76	benzodiazepines	group	82-96	int

DDI-DrugBank.d380.s4	There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.
buprenorphine	drug	141-153	benzodiazepines	drug	159-173	effect

DDI-DrugBank.d380.s5	In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.
buprenorphine	drug	24-36	SUBUTEX	brand	79-85	false

DDI-DrugBank.d380.s6	SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
SUBUTEX	brand	0-6	SUBOXONE	brand	12-19	false
SUBUTEX	brand	0-6	benzodiazepines	group	70-84	advise
SUBOXONE	brand	12-19	benzodiazepines	group	70-84	advise

DDI-DrugBank.d380.s7	Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
benzodiazepines	group	92-106	SUBOXONE	brand	135-142	advise
benzodiazepines	group	92-106	SUBUTEX	brand	147-153	advise
SUBOXONE	brand	135-142	SUBUTEX	brand	147-153	false

DDI-DrugBank.d439.s0	Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
Corticotropin	drug	0-12	diuretic	group	66-73	effect

DDI-DrugBank.d334.s0	Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.
diuretics	group	56-64	PRINIVIL	brand	240-247	effect

DDI-DrugBank.d334.s1	The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.
PRINIVIL	brand	44-51	diuretic	group	98-105	false
PRINIVIL	brand	44-51	PRINIVIL	brand	175-182	false
diuretic	group	98-105	PRINIVIL	brand	175-182	effect

DDI-DrugBank.d334.s2	If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.
diuretic	group	35-42	PRINIVIL	brand	67-74	advise

DDI-DrugBank.d334.s3	When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.
diuretic	group	7-14	PRINIVIL	brand	63-70	effect

DDI-DrugBank.d334.s4	Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.
ACE inhibitors	group	13-26	diuretics	group	48-56	false
ACE inhibitors	group	13-26	ACE inhibitor	group	88-100	false
ACE inhibitors	group	13-26	diuretic	group	141-148	false
diuretics	group	48-56	ACE inhibitor	group	88-100	false
diuretics	group	48-56	diuretic	group	141-148	false
ACE inhibitor	group	88-100	diuretic	group	141-148	advise

DDI-DrugBank.d334.s5	Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.
Non-steroidal Anti-inflammatory Agents	group	0-37	non-steroidal anti-inflammatory drugs	group	116-152	false
Non-steroidal Anti-inflammatory Agents	group	0-37	lisinopril	drug	180-189	false
non-steroidal anti-inflammatory drugs	group	116-152	lisinopril	drug	180-189	effect

DDI-DrugBank.d334.s7	Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.
NSAIDs	group	21-26	ACE inhibitors	group	72-85	effect
NSAIDs	group	21-26	lisinopril	drug	98-107	effect
ACE inhibitors	group	72-85	lisinopril	drug	98-107	false

DDI-DrugBank.d334.s8	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
NSAIDs	group	66-71	ACE inhibitors	group	92-105	advise

DDI-DrugBank.d334.s9	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
PRINIVIL	brand	99-106	PRINIVIL	brand	131-138	false
PRINIVIL	brand	99-106	indomethacin	drug	165-176	false
PRINIVIL	brand	99-106	indomethacin	drug	190-201	false
PRINIVIL	brand	131-138	indomethacin	drug	165-176	false
PRINIVIL	brand	131-138	indomethacin	drug	190-201	false
indomethacin	drug	165-176	indomethacin	drug	190-201	false

DDI-DrugBank.d334.s10	Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.
PRINIVIL	brand	14-21	nitrates	group	56-63	false
PRINIVIL	brand	14-21	digoxin	drug	72-78	false
nitrates	group	56-63	digoxin	drug	72-78	false

DDI-DrugBank.d334.s12	No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide.
PRINIVIL	brand	67-74	propranolol	drug	104-114	false
PRINIVIL	brand	67-74	hydrochlorothiazide	drug	119-137	false
propranolol	drug	104-114	hydrochlorothiazide	drug	119-137	false

DDI-DrugBank.d334.s14	Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.
PRINIVIL	brand	35-42	thiazide-type diuretics	group	80-102	effect

DDI-DrugBank.d334.s15	Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
PRINIVIL	brand	7-14	potassium-sparing diuretics	group	21-47	effect
PRINIVIL	brand	7-14	spironolactone	drug	56-69	effect
PRINIVIL	brand	7-14	triamterene	drug	72-82	effect
PRINIVIL	brand	7-14	amiloride	drug	88-96	effect
PRINIVIL	brand	7-14	potassium	drug	100-108	effect
potassium-sparing diuretics	group	21-47	spironolactone	drug	56-69	false
potassium-sparing diuretics	group	21-47	triamterene	drug	72-82	false
potassium-sparing diuretics	group	21-47	amiloride	drug	88-96	false
potassium-sparing diuretics	group	21-47	potassium	drug	100-108	false
spironolactone	drug	56-69	triamterene	drug	72-82	false
spironolactone	drug	56-69	amiloride	drug	88-96	false
spironolactone	drug	56-69	potassium	drug	100-108	false
triamterene	drug	72-82	amiloride	drug	88-96	false
triamterene	drug	72-82	potassium	drug	100-108	false
amiloride	drug	88-96	potassium	drug	100-108	false

DDI-DrugBank.d334.s18	Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
Lithium	drug	0-6	Lithium	drug	9-15	false
Lithium	drug	0-6	lithium	drug	66-72	false
Lithium	drug	0-6	ACE inhibitors	group	144-157	false
Lithium	drug	9-15	lithium	drug	66-72	false
Lithium	drug	9-15	ACE inhibitors	group	144-157	false
lithium	drug	66-72	ACE inhibitors	group	144-157	effect

DDI-DrugBank.d334.s19	Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.
Lithium	drug	0-6	lithium	drug	64-70	false
Lithium	drug	0-6	ACE inhibitor	group	80-92	false
lithium	drug	64-70	ACE inhibitor	group	80-92	effect

DDI-DrugBank.d334.s20	It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.
lithium	drug	29-35	PRINIVIL	brand	71-78	false
lithium	drug	29-35	lithium	drug	115-121	false
PRINIVIL	brand	71-78	lithium	drug	115-121	advise

DDI-DrugBank.d14.s0	The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.
nitroglycerin	drug	28-40	vasodilators	group	78-89	effect

DDI-DrugBank.d14.s2	Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
calcium channel blockers	group	66-89	nitrates	group	103-110	effect

DDI-DrugBank.d78.s0	Antacids, Sucralfate, Metal Cations, Multivitamins Quinolones form chelates with alkaline earth and transition metal cations.
Antacids	group	0-7	Sucralfate	drug	10-19	false
Antacids	group	0-7	Multivitamins	group	37-49	false
Antacids	group	0-7	Quinolones	group	51-60	false
Sucralfate	drug	10-19	Multivitamins	group	37-49	false
Sucralfate	drug	10-19	Quinolones	group	51-60	false
Multivitamins	group	37-49	Quinolones	group	51-60	false

DDI-DrugBank.d78.s1	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
quinolones	group	18-27	antacids	group	34-41	false
quinolones	group	18-27	aluminum	drug	54-61	mechanism
quinolones	group	18-27	magnesium	drug	64-72	mechanism
quinolones	group	18-27	calcium	drug	78-84	mechanism
quinolones	group	18-27	sucralfate	drug	92-101	mechanism
quinolones	group	18-27	iron	drug	131-134	mechanism
quinolones	group	18-27	multivitamins	group	145-157	mechanism
quinolones	group	18-27	iron	drug	170-173	mechanism
quinolones	group	18-27	zinc	drug	178-181	mechanism
quinolones	group	18-27	VIDEX	brand	255-259	mechanism
quinolones	group	18-27	didanosine	drug	262-271	mechanism
quinolones	group	18-27	quinolones	group	394-403	false
antacids	group	34-41	aluminum	drug	54-61	false
antacids	group	34-41	magnesium	drug	64-72	false
antacids	group	34-41	calcium	drug	78-84	false
antacids	group	34-41	sucralfate	drug	92-101	false
antacids	group	34-41	iron	drug	131-134	false
antacids	group	34-41	multivitamins	group	145-157	false
antacids	group	34-41	iron	drug	170-173	false
antacids	group	34-41	zinc	drug	178-181	false
antacids	group	34-41	VIDEX	brand	255-259	false
antacids	group	34-41	didanosine	drug	262-271	false
antacids	group	34-41	quinolones	group	394-403	false
aluminum	drug	54-61	magnesium	drug	64-72	false
aluminum	drug	54-61	calcium	drug	78-84	false
aluminum	drug	54-61	sucralfate	drug	92-101	false
aluminum	drug	54-61	iron	drug	131-134	false
aluminum	drug	54-61	multivitamins	group	145-157	false
aluminum	drug	54-61	iron	drug	170-173	false
aluminum	drug	54-61	zinc	drug	178-181	false
aluminum	drug	54-61	VIDEX	brand	255-259	false
aluminum	drug	54-61	didanosine	drug	262-271	false
aluminum	drug	54-61	quinolones	group	394-403	false
magnesium	drug	64-72	calcium	drug	78-84	false
magnesium	drug	64-72	sucralfate	drug	92-101	false
magnesium	drug	64-72	iron	drug	131-134	false
magnesium	drug	64-72	multivitamins	group	145-157	false
magnesium	drug	64-72	iron	drug	170-173	false
magnesium	drug	64-72	zinc	drug	178-181	false
magnesium	drug	64-72	VIDEX	brand	255-259	false
magnesium	drug	64-72	didanosine	drug	262-271	false
magnesium	drug	64-72	quinolones	group	394-403	false
calcium	drug	78-84	sucralfate	drug	92-101	false
calcium	drug	78-84	iron	drug	131-134	false
calcium	drug	78-84	multivitamins	group	145-157	false
calcium	drug	78-84	iron	drug	170-173	false
calcium	drug	78-84	zinc	drug	178-181	false
calcium	drug	78-84	VIDEX	brand	255-259	false
calcium	drug	78-84	didanosine	drug	262-271	false
calcium	drug	78-84	quinolones	group	394-403	false
sucralfate	drug	92-101	iron	drug	131-134	false
sucralfate	drug	92-101	multivitamins	group	145-157	false
sucralfate	drug	92-101	iron	drug	170-173	false
sucralfate	drug	92-101	zinc	drug	178-181	false
sucralfate	drug	92-101	VIDEX	brand	255-259	false
sucralfate	drug	92-101	didanosine	drug	262-271	false
sucralfate	drug	92-101	quinolones	group	394-403	false
iron	drug	131-134	multivitamins	group	145-157	false
iron	drug	131-134	iron	drug	170-173	false
iron	drug	131-134	zinc	drug	178-181	false
iron	drug	131-134	VIDEX	brand	255-259	false
iron	drug	131-134	didanosine	drug	262-271	false
iron	drug	131-134	quinolones	group	394-403	false
multivitamins	group	145-157	iron	drug	170-173	false
multivitamins	group	145-157	zinc	drug	178-181	false
multivitamins	group	145-157	VIDEX	brand	255-259	false
multivitamins	group	145-157	didanosine	drug	262-271	false
multivitamins	group	145-157	quinolones	group	394-403	false
iron	drug	170-173	zinc	drug	178-181	false
iron	drug	170-173	VIDEX	brand	255-259	false
iron	drug	170-173	didanosine	drug	262-271	false
iron	drug	170-173	quinolones	group	394-403	false
zinc	drug	178-181	VIDEX	brand	255-259	false
zinc	drug	178-181	didanosine	drug	262-271	false
zinc	drug	178-181	quinolones	group	394-403	false
VIDEX	brand	255-259	didanosine	drug	262-271	false
VIDEX	brand	255-259	quinolones	group	394-403	false
didanosine	drug	262-271	quinolones	group	394-403	false

DDI-DrugBank.d78.s3	Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
Caffeine	drug	0-7	Theobromine	drug	9-19	false
Caffeine	drug	0-7	Grepafloxacin	drug	21-33	false
Caffeine	drug	0-7	quinolones	group	47-56	false
Caffeine	drug	0-7	caffeine	drug	89-96	false
Caffeine	drug	0-7	theobromine	drug	102-112	false
Theobromine	drug	9-19	Grepafloxacin	drug	21-33	false
Theobromine	drug	9-19	quinolones	group	47-56	false
Theobromine	drug	9-19	caffeine	drug	89-96	false
Theobromine	drug	9-19	theobromine	drug	102-112	false
Grepafloxacin	drug	21-33	quinolones	group	47-56	false
Grepafloxacin	drug	21-33	caffeine	drug	89-96	mechanism
Grepafloxacin	drug	21-33	theobromine	drug	102-112	mechanism
quinolones	group	47-56	caffeine	drug	89-96	mechanism
quinolones	group	47-56	theobromine	drug	102-112	mechanism
caffeine	drug	89-96	theobromine	drug	102-112	false

DDI-DrugBank.d78.s5	In some patients, this may lead to reduced clearance, prolongation of plasma half-life, and enhanced effects of caffeine and theobromine.
caffeine	drug	112-119	theobromine	drug	125-135	false

DDI-DrugBank.d78.s6	Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.
Theophylline	drug	0-11	Grepafloxacin	drug	14-26	false
Theophylline	drug	0-11	theophylline	drug	76-87	false
Grepafloxacin	drug	14-26	theophylline	drug	76-87	mechanism

DDI-DrugBank.d78.s7	Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.
theophylline	drug	6-17	grepafloxacin	drug	48-60	false
theophylline	drug	6-17	theophylline	drug	102-113	false
grepafloxacin	drug	48-60	theophylline	drug	102-113	mechanism

DDI-DrugBank.d78.s8	When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
grepafloxacin	drug	38-50	theophylline	drug	79-90	false
grepafloxacin	drug	38-50	theophylline	drug	97-108	false
grepafloxacin	drug	38-50	grepafloxacin	drug	180-192	false
grepafloxacin	drug	38-50	theophylline	drug	218-229	false
theophylline	drug	79-90	theophylline	drug	97-108	false
theophylline	drug	79-90	grepafloxacin	drug	180-192	false
theophylline	drug	79-90	theophylline	drug	218-229	false
theophylline	drug	97-108	grepafloxacin	drug	180-192	advise
theophylline	drug	97-108	theophylline	drug	218-229	false
grepafloxacin	drug	180-192	theophylline	drug	218-229	false

DDI-DrugBank.d78.s9	Warfarin: In subjects receiving warfarin, no significant change in clotting time was observed when grepafloxacin was coadministered.
Warfarin	drug	0-7	warfarin	drug	32-39	false
Warfarin	drug	0-7	grepafloxacin	drug	99-111	false
warfarin	drug	32-39	grepafloxacin	drug	99-111	false

DDI-DrugBank.d78.s10	However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.
quinolones	group	22-31	warfarin	drug	78-85	effect
quinolones	group	22-31	quinolone antimicrobial	group	196-218	false
quinolones	group	22-31	warfarin	drug	241-248	false
warfarin	drug	78-85	quinolone antimicrobial	group	196-218	false
warfarin	drug	78-85	warfarin	drug	241-248	false
quinolone antimicrobial	group	196-218	warfarin	drug	241-248	advise

DDI-DrugBank.d78.s11	Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.
grepafloxacin	drug	97-109	theophylline	drug	114-125	false
grepafloxacin	drug	97-109	grepafloxacin	drug	142-154	false
grepafloxacin	drug	97-109	theophylline	drug	165-176	false
theophylline	drug	114-125	grepafloxacin	drug	142-154	false
theophylline	drug	114-125	theophylline	drug	165-176	false
grepafloxacin	drug	142-154	theophylline	drug	165-176	mechanism

DDI-DrugBank.d78.s13	substrates, in vitro data suggest similar effects of grepafloxacin in CYP3A4 mediated metabolism and theophylline metabolism.
grepafloxacin	drug	53-65	theophylline	drug	101-112	false

DDI-DrugBank.d78.s14	In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.
quinolones	group	19-28	cyclosporine	drug	95-106	mechanism

DDI-DrugBank.d78.s16	include terfenadine, astemizole, cisapride, midazolam, and triazolam.
terfenadine	drug	8-18	astemizole	drug	21-30	false
terfenadine	drug	8-18	cisapride	drug	33-41	false
terfenadine	drug	8-18	midazolam	drug	44-52	false
terfenadine	drug	8-18	triazolam	drug	59-67	false
astemizole	drug	21-30	cisapride	drug	33-41	false
astemizole	drug	21-30	midazolam	drug	44-52	false
astemizole	drug	21-30	triazolam	drug	59-67	false
cisapride	drug	33-41	midazolam	drug	44-52	false
cisapride	drug	33-41	triazolam	drug	59-67	false
midazolam	drug	44-52	triazolam	drug	59-67	false

DDI-DrugBank.d78.s19	Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.
Nonsteroidal Anti-inflammatory Drugs	group	0-35	NSAIDs	group	38-43	false
Nonsteroidal Anti-inflammatory Drugs	group	0-35	nonsteroidal anti inflammatory drug	group	83-117	false
Nonsteroidal Anti-inflammatory Drugs	group	0-35	quinolone	group	126-134	false
NSAIDs	group	38-43	nonsteroidal anti inflammatory drug	group	83-117	false
NSAIDs	group	38-43	quinolone	group	126-134	false
nonsteroidal anti inflammatory drug	group	83-117	quinolone	group	126-134	effect

DDI-DrugBank.d78.s20	Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.
Antidiabetic Agents	group	0-18	quinolones	group	152-161	false
Antidiabetic Agents	group	0-18	antidiabetic agent	group	170-187	false
quinolones	group	152-161	antidiabetic agent	group	170-187	effect

DDI-DrugBank.d84.s0	The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied.
Exjade	brand	34-39	aluminum	drug	45-52	false
Exjade	brand	34-39	antacid preparations	group	65-84	false
aluminum	drug	45-52	antacid preparations	group	65-84	false

DDI-DrugBank.d84.s1	Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
deferasirox	drug	9-19	aluminum	drug	46-53	false
deferasirox	drug	9-19	iron	drug	64-67	false
deferasirox	drug	9-19	Exjade	brand	70-75	false
deferasirox	drug	9-19	aluminum	drug	102-109	false
deferasirox	drug	9-19	antacid preparations	group	122-141	false
aluminum	drug	46-53	iron	drug	64-67	false
aluminum	drug	46-53	Exjade	brand	70-75	false
aluminum	drug	46-53	aluminum	drug	102-109	false
aluminum	drug	46-53	antacid preparations	group	122-141	false
iron	drug	64-67	Exjade	brand	70-75	false
iron	drug	64-67	aluminum	drug	102-109	false
iron	drug	64-67	antacid preparations	group	122-141	false
Exjade	brand	70-75	aluminum	drug	102-109	advise
Exjade	brand	70-75	antacid preparations	group	122-141	false
aluminum	drug	102-109	antacid preparations	group	122-141	false

DDI-DrugBank.d84.s2	In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin.
Exjade	brand	23-28	digoxin	drug	71-77	false

DDI-DrugBank.d84.s3	The effect of digoxin on Exjade pharmacokinetics has not been studied.
digoxin	drug	14-20	Exjade	brand	25-30	false

DDI-DrugBank.d84.s4	The concomitant administration of Exjade and vitamin C has not been formally studied.
Exjade	brand	34-39	vitamin C	drug	45-53	false

DDI-DrugBank.d84.s6	The interaction of Exjade with hydroxyurea has not been formally studied.
Exjade	brand	19-24	hydroxyurea	drug	31-41	false

DDI-DrugBank.d84.s7	No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.
deferasirox	drug	17-27	hydroxyurea	drug	43-53	false

DDI-DrugBank.d123.s0	Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
quinolones	group	5-14	ciprofloxacin	drug	27-39	false
quinolones	group	5-14	caffeine	drug	99-106	mechanism
ciprofloxacin	drug	27-39	caffeine	drug	99-106	mechanism

DDI-DrugBank.d123.s2	Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
quinolones	group	5-14	ciprofloxacin	drug	27-39	false
quinolones	group	5-14	cyclosporine	drug	131-142	effect
ciprofloxacin	drug	27-39	cyclosporine	drug	131-142	effect

DDI-DrugBank.d123.s3	Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
Glyburide	drug	0-8	ciprofloxacin	drug	45-57	false
Glyburide	drug	0-8	sulfonylurea	group	68-79	false
Glyburide	drug	0-8	glyburide	drug	81-89	false
ciprofloxacin	drug	45-57	sulfonylurea	group	68-79	effect
ciprofloxacin	drug	45-57	glyburide	drug	81-89	effect
sulfonylurea	group	68-79	glyburide	drug	81-89	false

DDI-DrugBank.d123.s4	Histamine H2-receptor antagonists: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin.
Histamine H2-receptor antagonists	group	0-32	Histamine H2-receptor antagonists	group	35-67	false
Histamine H2-receptor antagonists	group	0-32	ciprofloxacin	drug	132-144	false
Histamine H2-receptor antagonists	group	35-67	ciprofloxacin	drug	132-144	false

DDI-DrugBank.d123.s5	Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
Methotrexate	drug	0-11	methotrexate	drug	40-51	false
Methotrexate	drug	0-11	ciprofloxacin	drug	103-115	false
Methotrexate	drug	0-11	methotrexate	drug	168-179	false
methotrexate	drug	40-51	ciprofloxacin	drug	103-115	mechanism
methotrexate	drug	40-51	methotrexate	drug	168-179	false
ciprofloxacin	drug	103-115	methotrexate	drug	168-179	false

DDI-DrugBank.d123.s7	Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
methotrexate	drug	26-37	ciprofloxacin	drug	94-106	advise

DDI-DrugBank.d123.s8	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
quinolone	group	71-79	ciprofloxacin	drug	92-104	false
quinolone	group	71-79	magnesium	drug	159-167	mechanism
quinolone	group	71-79	aluminum	drug	172-179	mechanism
quinolone	group	71-79	antacids	group	181-188	mechanism
quinolone	group	71-79	sucralfate	drug	191-200	mechanism
quinolone	group	71-79	VIDEX	brand	203-207	mechanism
quinolone	group	71-79	calcium	drug	279-285	mechanism
quinolone	group	71-79	iron	drug	288-291	mechanism
quinolone	group	71-79	zinc	drug	297-300	mechanism
quinolone	group	71-79	ciprofloxacin	drug	347-359	false
ciprofloxacin	drug	92-104	magnesium	drug	159-167	mechanism
ciprofloxacin	drug	92-104	aluminum	drug	172-179	mechanism
ciprofloxacin	drug	92-104	antacids	group	181-188	mechanism
ciprofloxacin	drug	92-104	sucralfate	drug	191-200	mechanism
ciprofloxacin	drug	92-104	VIDEX	brand	203-207	mechanism
ciprofloxacin	drug	92-104	calcium	drug	279-285	mechanism
ciprofloxacin	drug	92-104	iron	drug	288-291	mechanism
ciprofloxacin	drug	92-104	zinc	drug	297-300	mechanism
ciprofloxacin	drug	92-104	ciprofloxacin	drug	347-359	mechanism
magnesium	drug	159-167	aluminum	drug	172-179	false
magnesium	drug	159-167	antacids	group	181-188	false
magnesium	drug	159-167	sucralfate	drug	191-200	false
magnesium	drug	159-167	VIDEX	brand	203-207	false
magnesium	drug	159-167	calcium	drug	279-285	false
magnesium	drug	159-167	iron	drug	288-291	false
magnesium	drug	159-167	zinc	drug	297-300	false
magnesium	drug	159-167	ciprofloxacin	drug	347-359	false
aluminum	drug	172-179	antacids	group	181-188	false
aluminum	drug	172-179	sucralfate	drug	191-200	false
aluminum	drug	172-179	VIDEX	brand	203-207	false
aluminum	drug	172-179	calcium	drug	279-285	false
aluminum	drug	172-179	iron	drug	288-291	false
aluminum	drug	172-179	zinc	drug	297-300	false
aluminum	drug	172-179	ciprofloxacin	drug	347-359	false
antacids	group	181-188	sucralfate	drug	191-200	false
antacids	group	181-188	VIDEX	brand	203-207	false
antacids	group	181-188	calcium	drug	279-285	false
antacids	group	181-188	iron	drug	288-291	false
antacids	group	181-188	zinc	drug	297-300	false
antacids	group	181-188	ciprofloxacin	drug	347-359	false
sucralfate	drug	191-200	VIDEX	brand	203-207	false
sucralfate	drug	191-200	calcium	drug	279-285	false
sucralfate	drug	191-200	iron	drug	288-291	false
sucralfate	drug	191-200	zinc	drug	297-300	false
sucralfate	drug	191-200	ciprofloxacin	drug	347-359	false
VIDEX	brand	203-207	calcium	drug	279-285	false
VIDEX	brand	203-207	iron	drug	288-291	false
VIDEX	brand	203-207	zinc	drug	297-300	false
VIDEX	brand	203-207	ciprofloxacin	drug	347-359	false
calcium	drug	279-285	iron	drug	288-291	false
calcium	drug	279-285	zinc	drug	297-300	false
calcium	drug	279-285	ciprofloxacin	drug	347-359	false
iron	drug	288-291	zinc	drug	297-300	false
iron	drug	288-291	ciprofloxacin	drug	347-359	false
zinc	drug	297-300	ciprofloxacin	drug	347-359	false

DDI-DrugBank.d123.s10	This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.
ciprofloxacin	drug	66-78	antacids	group	144-151	advise

DDI-DrugBank.d123.s11	Non-steroidal anti-inflammatory drugs (but not aspirin): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.
Non-steroidal anti-inflammatory drugs	group	0-36	aspirin	brand	47-53	false
Non-steroidal anti-inflammatory drugs	group	0-36	quinolones	group	108-117	false
aspirin	brand	47-53	quinolones	group	108-117	false

DDI-DrugBank.d123.s12	Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
Omeprazole	drug	0-9	ciprofloxacin	drug	49-61	false
Omeprazole	drug	0-9	Proquin XR	brand	86-95	false
Omeprazole	drug	0-9	Proquin XR	brand	121-130	false
Omeprazole	drug	0-9	omeprazole	drug	156-165	false
ciprofloxacin	drug	49-61	Proquin XR	brand	86-95	false
ciprofloxacin	drug	49-61	Proquin XR	brand	121-130	false
ciprofloxacin	drug	49-61	omeprazole	drug	156-165	false
Proquin XR	brand	86-95	Proquin XR	brand	121-130	false
Proquin XR	brand	86-95	omeprazole	drug	156-165	false
Proquin XR	brand	121-130	omeprazole	drug	156-165	false

DDI-DrugBank.d123.s13	Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..
Omeprazole	drug	0-9	Proquin XR	brand	43-52	false

DDI-DrugBank.d123.s14	Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
Phenytoin	drug	0-8	phenytoin	drug	35-43	false
Phenytoin	drug	0-8	ciprofloxacin	drug	124-136	false
phenytoin	drug	35-43	ciprofloxacin	drug	124-136	mechanism

DDI-DrugBank.d123.s15	Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
Probenecid	drug	0-9	Probenecid	drug	12-21	false
Probenecid	drug	0-9	ciprofloxacin	drug	66-78	false
Probenecid	drug	0-9	ciprofloxacin	drug	121-133	false
Probenecid	drug	12-21	ciprofloxacin	drug	66-78	mechanism
Probenecid	drug	12-21	ciprofloxacin	drug	121-133	mechanism
ciprofloxacin	drug	66-78	ciprofloxacin	drug	121-133	false

DDI-DrugBank.d123.s16	Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
Theophylline	drug	0-11	quinolones	group	33-42	false
Theophylline	drug	0-11	ciprofloxacin	drug	74-86	false
Theophylline	drug	0-11	theophylline	drug	93-104	false
Theophylline	drug	0-11	theophylline	drug	151-162	false
quinolones	group	33-42	ciprofloxacin	drug	74-86	false
quinolones	group	33-42	theophylline	drug	93-104	mechanism
quinolones	group	33-42	theophylline	drug	151-162	false
ciprofloxacin	drug	74-86	theophylline	drug	93-104	mechanism
ciprofloxacin	drug	74-86	theophylline	drug	151-162	false
theophylline	drug	93-104	theophylline	drug	151-162	false

DDI-DrugBank.d123.s19	Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
Warfarin	drug	0-7	Quinolones	group	10-19	false
Warfarin	drug	0-7	anticoagulant	group	75-87	false
Warfarin	drug	0-7	warfarin	drug	89-96	false
Quinolones	group	10-19	anticoagulant	group	75-87	false
Quinolones	group	10-19	warfarin	drug	89-96	effect
anticoagulant	group	75-87	warfarin	drug	89-96	false

DDI-DrugBank.d352.s0	Antidiabetic drug requirements (i.e., insulin) may be altered.
Antidiabetic drug	group	0-16	insulin	drug	38-44	false

DDI-DrugBank.d352.s3	conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
diethylpropion	drug	12-25	antihypertensive drugs	group	46-67	int
diethylpropion	drug	12-25	guanethidine	drug	76-87	int
diethylpropion	drug	12-25	a-methyldopa	drug	90-101	int
antihypertensive drugs	group	46-67	guanethidine	drug	76-87	false
antihypertensive drugs	group	46-67	a-methyldopa	drug	90-101	false
guanethidine	drug	76-87	a-methyldopa	drug	90-101	false

DDI-DrugBank.d352.s4	Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
phenothiazines	group	18-31	diethylpropion	drug	72-85	effect

DDI-DrugBank.d172.s6	Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
celecoxib	drug	22-30	fluconazole	drug	90-100	int
celecoxib	drug	22-30	lithium	drug	106-112	int
fluconazole	drug	90-100	lithium	drug	106-112	false

DDI-DrugBank.d172.s7	Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
nonsteroidal anti-inflammatory drugs	group	16-51	NSAIDs	group	54-59	false
nonsteroidal anti-inflammatory drugs	group	16-51	furosemide	drug	107-116	int
nonsteroidal anti-inflammatory drugs	group	16-51	ACE inhibitors	group	122-135	int
NSAIDs	group	54-59	furosemide	drug	107-116	int
NSAIDs	group	54-59	ACE inhibitors	group	122-135	int
furosemide	drug	107-116	ACE inhibitors	group	122-135	false

DDI-DrugBank.d172.s8	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
celecoxib	drug	12-20	glyburide	drug	73-81	false
celecoxib	drug	12-20	ketoconazole	drug	84-95	false
celecoxib	drug	12-20	methotrexate	drug	98-109	false
celecoxib	drug	12-20	phenytoin	drug	112-120	false
celecoxib	drug	12-20	tolbutamide	drug	123-133	false
celecoxib	drug	12-20	warfarin	drug	140-147	false
glyburide	drug	73-81	ketoconazole	drug	84-95	false
glyburide	drug	73-81	methotrexate	drug	98-109	false
glyburide	drug	73-81	phenytoin	drug	112-120	false
glyburide	drug	73-81	tolbutamide	drug	123-133	false
glyburide	drug	73-81	warfarin	drug	140-147	false
ketoconazole	drug	84-95	methotrexate	drug	98-109	false
ketoconazole	drug	84-95	phenytoin	drug	112-120	false
ketoconazole	drug	84-95	tolbutamide	drug	123-133	false
ketoconazole	drug	84-95	warfarin	drug	140-147	false
methotrexate	drug	98-109	phenytoin	drug	112-120	false
methotrexate	drug	98-109	tolbutamide	drug	123-133	false
methotrexate	drug	98-109	warfarin	drug	140-147	false
phenytoin	drug	112-120	tolbutamide	drug	123-133	false
phenytoin	drug	112-120	warfarin	drug	140-147	false
tolbutamide	drug	123-133	warfarin	drug	140-147	false

DDI-DrugBank.d172.s9	ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
ACE inhibitors	group	0-13	NSAIDs	group	37-42	false
ACE inhibitors	group	0-13	Angiotensin Converting Enzyme (ACE) inhibitors	group	88-133	false
NSAIDs	group	37-42	Angiotensin Converting Enzyme (ACE) inhibitors	group	88-133	effect

DDI-DrugBank.d172.s10	This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.
CELEBREX	brand	66-73	ACE-inhibitors	group	94-107	advise

DDI-DrugBank.d172.s11	Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	drug	0-9	NSAIDs	group	86-91	false
Furosemide	drug	0-9	furosemide	drug	130-139	false
Furosemide	drug	0-9	thiazides	group	145-153	false
NSAIDs	group	86-91	furosemide	drug	130-139	effect
NSAIDs	group	86-91	thiazides	group	145-153	effect
furosemide	drug	130-139	thiazides	group	145-153	false

DDI-DrugBank.d172.s13	Aspirin: CELEBREX can be used with low dose aspirin.
Aspirin	brand	0-6	CELEBREX	brand	9-16	false
Aspirin	brand	0-6	aspirin	brand	44-50	false
CELEBREX	brand	9-16	aspirin	brand	44-50	advise

DDI-DrugBank.d172.s14	However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
aspirin	brand	39-45	CELEBREX	brand	52-59	effect
aspirin	brand	39-45	CELEBREX	brand	153-160	false
CELEBREX	brand	52-59	CELEBREX	brand	153-160	false

DDI-DrugBank.d172.s15	Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis.
CELEBREX	brand	41-48	aspirin	brand	74-80	false

DDI-DrugBank.d172.s16	Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
Fluconazole	drug	0-10	fluconazole	drug	43-53	false
Fluconazole	drug	0-10	celecoxib	drug	103-111	false
fluconazole	drug	43-53	celecoxib	drug	103-111	mechanism

DDI-DrugBank.d172.s17	This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
celecoxib	drug	42-50	fluconazole	drug	79-89	mechanism

DDI-DrugBank.d172.s18	CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.
CELEBREX	brand	0-7	fluconazole	drug	83-93	advise

DDI-DrugBank.d172.s19	Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
Lithium	drug	0-6	lithium	drug	69-75	false
Lithium	drug	0-6	lithium	drug	141-147	false
Lithium	drug	0-6	CELEBREX	brand	165-172	false
Lithium	drug	0-6	lithium	drug	219-225	false
lithium	drug	69-75	lithium	drug	141-147	false
lithium	drug	69-75	CELEBREX	brand	165-172	false
lithium	drug	69-75	lithium	drug	219-225	false
lithium	drug	141-147	CELEBREX	brand	165-172	mechanism
lithium	drug	141-147	lithium	drug	219-225	false
CELEBREX	brand	165-172	lithium	drug	219-225	false

DDI-DrugBank.d172.s20	Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.
lithium	drug	12-18	CELEBREX	brand	63-70	advise

DDI-DrugBank.d172.s21	Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate.
Methotrexate	drug	0-11	methotrexate	drug	78-89	false
Methotrexate	drug	0-11	CELEBREX	brand	92-99	false
Methotrexate	drug	0-11	methotrexate	drug	162-173	false
methotrexate	drug	78-89	CELEBREX	brand	92-99	false
methotrexate	drug	78-89	methotrexate	drug	162-173	false
CELEBREX	brand	92-99	methotrexate	drug	162-173	false

DDI-DrugBank.d172.s22	Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.
Warfarin	drug	0-7	celecoxib	drug	24-32	false
Warfarin	drug	0-7	warfarin	drug	66-73	false
Warfarin	drug	0-7	warfarin	drug	153-160	false
celecoxib	drug	24-32	warfarin	drug	66-73	false
celecoxib	drug	24-32	warfarin	drug	153-160	false
warfarin	drug	66-73	warfarin	drug	153-160	false

DDI-DrugBank.d172.s23	In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time.
celecoxib	drug	19-27	warfarin	drug	71-78	false

DDI-DrugBank.d172.s24	However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.
CELEBREX	brand	51-58	warfarin	drug	65-72	advise

DDI-DrugBank.d326.s0	Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).
Phenothiazines	group	0-13	piperazine	drug	24-33	false
Phenothiazines	group	0-13	phenothiazine	group	41-53	false
piperazine	drug	24-33	phenothiazine	group	41-53	effect

DDI-DrugBank.d326.s1	Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.
Pyrantel	drug	0-7	Antiminth	drug	16-24	false
Pyrantel	drug	0-7	piperazine	drug	36-45	false
Pyrantel	drug	0-7	pyrantel	drug	51-58	false
Pyrantel	drug	0-7	piperazine	drug	97-106	false
Antiminth	drug	16-24	piperazine	drug	36-45	false
Antiminth	drug	16-24	pyrantel	drug	51-58	false
Antiminth	drug	16-24	piperazine	drug	97-106	false
piperazine	drug	36-45	pyrantel	drug	51-58	effect
piperazine	drug	36-45	piperazine	drug	97-106	false
pyrantel	drug	51-58	piperazine	drug	97-106	false

DDI-DrugBank.d453.s0	Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.
Cytosine arabinoside	drug	0-19	cytostatic agent	group	24-39	false
Cytosine arabinoside	drug	0-19	flucytosine	drug	101-111	effect
cytostatic agent	group	24-39	flucytosine	drug	101-111	false

DDI-DrugBank.d567.s5	Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
Itraconazole	drug	0-11	Ketoconazole	drug	13-24	false
Itraconazole	drug	0-11	Erythromycin	drug	26-37	false
Itraconazole	drug	0-11	Clarithromycin	drug	39-52	false
Itraconazole	drug	0-11	Telithromycin	drug	54-66	false
Itraconazole	drug	0-11	HIV protease inhibitors	group	68-90	false
Itraconazole	drug	0-11	Nefazodone	drug	92-101	false
Itraconazole	drug	0-11	Cyclosporine	drug	103-114	false
Ketoconazole	drug	13-24	Erythromycin	drug	26-37	false
Ketoconazole	drug	13-24	Clarithromycin	drug	39-52	false
Ketoconazole	drug	13-24	Telithromycin	drug	54-66	false
Ketoconazole	drug	13-24	HIV protease inhibitors	group	68-90	false
Ketoconazole	drug	13-24	Nefazodone	drug	92-101	false
Ketoconazole	drug	13-24	Cyclosporine	drug	103-114	false
Erythromycin	drug	26-37	Clarithromycin	drug	39-52	false
Erythromycin	drug	26-37	Telithromycin	drug	54-66	false
Erythromycin	drug	26-37	HIV protease inhibitors	group	68-90	false
Erythromycin	drug	26-37	Nefazodone	drug	92-101	false
Erythromycin	drug	26-37	Cyclosporine	drug	103-114	false
Clarithromycin	drug	39-52	Telithromycin	drug	54-66	false
Clarithromycin	drug	39-52	HIV protease inhibitors	group	68-90	false
Clarithromycin	drug	39-52	Nefazodone	drug	92-101	false
Clarithromycin	drug	39-52	Cyclosporine	drug	103-114	false
Telithromycin	drug	54-66	HIV protease inhibitors	group	68-90	false
Telithromycin	drug	54-66	Nefazodone	drug	92-101	false
Telithromycin	drug	54-66	Cyclosporine	drug	103-114	false
HIV protease inhibitors	group	68-90	Nefazodone	drug	92-101	false
HIV protease inhibitors	group	68-90	Cyclosporine	drug	103-114	false
Nefazodone	drug	92-101	Cyclosporine	drug	103-114	false

DDI-DrugBank.d567.s9	Gemfibrozil Other fibrates Niacin (nicotinic acid) (=1 g/day)
Gemfibrozil	drug	0-10	fibrates	group	18-25	false
Gemfibrozil	drug	0-10	Niacin	drug	27-32	false
Gemfibrozil	drug	0-10	nicotinic acid	drug	35-48	false
fibrates	group	18-25	Niacin	drug	27-32	false
fibrates	group	18-25	nicotinic acid	drug	35-48	false
Niacin	drug	27-32	nicotinic acid	drug	35-48	false

DDI-DrugBank.d567.s11	Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).
Danazol	drug	0-6	danazol	drug	91-97	false
Danazol	drug	0-6	lovastatin	drug	133-142	false
danazol	drug	91-97	lovastatin	drug	133-142	effect

DDI-DrugBank.d567.s12	Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
Amiodarone	drug	0-9	Verapamil	drug	14-22	false
Amiodarone	drug	0-9	amiodarone	drug	86-95	false
Amiodarone	drug	0-9	verapamil	drug	100-108	false
Amiodarone	drug	0-9	HMG-CoA reductase inhibitor class	group	169-201	false
Verapamil	drug	14-22	amiodarone	drug	86-95	false
Verapamil	drug	14-22	verapamil	drug	100-108	false
Verapamil	drug	14-22	HMG-CoA reductase inhibitor class	group	169-201	false
amiodarone	drug	86-95	verapamil	drug	100-108	false
amiodarone	drug	86-95	HMG-CoA reductase inhibitor class	group	169-201	effect
verapamil	drug	100-108	HMG-CoA reductase inhibitor class	group	169-201	effect

DDI-DrugBank.d567.s13	Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.
Coumarin Anticoagulant	group	0-21	lovastatin	drug	60-69	false
Coumarin Anticoagulant	group	0-21	warfarin	drug	91-98	false
lovastatin	drug	60-69	warfarin	drug	91-98	false

DDI-DrugBank.d567.s14	However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.
HMG-CoA reductase inhibitor	group	17-43	warfarin	drug	168-175	effect

DDI-DrugBank.d567.s15	Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.
coumarin anticoagulant	group	93-114	lovastatin	drug	136-145	effect

DDI-DrugBank.d567.s16	It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.
anticoagulants	group	42-55	lovastatin	drug	105-114	advise

DDI-DrugBank.d567.s19	Lovastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.
Lovastatin	drug	0-9	anticoagulants	group	116-129	false

DDI-DrugBank.d567.s20	Propranolol: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol.
Propranolol	drug	0-10	lovastatin	drug	169-178	false
Propranolol	drug	0-10	propranolol	drug	184-194	false
lovastatin	drug	169-178	propranolol	drug	184-194	false

DDI-DrugBank.d567.s21	Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.
Digoxin	drug	0-6	lovastatin	drug	78-87	false
Digoxin	drug	0-6	digoxin	drug	93-99	false
Digoxin	drug	0-6	digoxin	drug	126-132	false
lovastatin	drug	78-87	digoxin	drug	93-99	false
lovastatin	drug	78-87	digoxin	drug	126-132	false
digoxin	drug	93-99	digoxin	drug	126-132	false

DDI-DrugBank.d567.s22	Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide
Hypoglycemic Agents	group	5-23	MEVACOR	brand	56-62	false
Hypoglycemic Agents	group	5-23	glipizide	drug	163-171	false
Hypoglycemic Agents	group	5-23	chlorpropamide	drug	181-194	false
MEVACOR	brand	56-62	glipizide	drug	163-171	false
MEVACOR	brand	56-62	chlorpropamide	drug	181-194	false
glipizide	drug	163-171	chlorpropamide	drug	181-194	false

DDI-DrugBank.d332.s0	Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
doxapram	drug	18-25	sympathomimetic	group	57-71	effect
doxapram	drug	18-25	monoamine oxidase inhibiting drugs	group	76-109	effect
sympathomimetic	group	57-71	monoamine oxidase inhibiting drugs	group	76-109	false

DDI-DrugBank.d332.s1	In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.
muscle relaxants	group	30-45	doxapram	drug	48-55	false
muscle relaxants	group	30-45	muscle relaxant drugs	group	102-122	false
doxapram	drug	48-55	muscle relaxant drugs	group	102-122	effect

DDI-DrugBank.d217.s0	Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
theophylline	drug	26-37	quinolone	group	75-83	mechanism

DDI-DrugBank.d217.s1	There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.
theophylline	drug	27-38	norfloxacin	drug	101-111	false
theophylline	drug	27-38	theophylline	drug	117-128	false
norfloxacin	drug	101-111	theophylline	drug	117-128	effect

DDI-DrugBank.d217.s2	Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
theophylline	drug	25-36	theophylline	drug	87-98	false

DDI-DrugBank.d217.s3	Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.
cyclosporine	drug	25-36	cyclosporine	drug	81-92	false
cyclosporine	drug	25-36	norfloxacin	drug	99-109	false
cyclosporine	drug	81-92	norfloxacin	drug	99-109	mechanism

DDI-DrugBank.d217.s4	Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
cyclosporine	drug	11-22	cyclosporine	drug	73-84	false

DDI-DrugBank.d217.s5	Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
Quinolones	group	0-9	norfloxacin	drug	22-32	false
Quinolones	group	0-9	anticoagulants	group	67-80	effect
Quinolones	group	0-9	warfarin	drug	93-100	effect
norfloxacin	drug	22-32	anticoagulants	group	67-80	effect
norfloxacin	drug	22-32	warfarin	drug	93-100	effect
anticoagulants	group	67-80	warfarin	drug	93-100	false

DDI-DrugBank.d217.s7	The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
quinolones	group	34-43	norfloxacin	drug	55-65	false
quinolones	group	34-43	glyburide	drug	72-80	effect
quinolones	group	34-43	sulfonylurea agent	group	85-102	false
norfloxacin	drug	55-65	glyburide	drug	72-80	effect
norfloxacin	drug	55-65	sulfonylurea agent	group	85-102	false
glyburide	drug	72-80	sulfonylurea agent	group	85-102	false

DDI-DrugBank.d217.s9	Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
norfloxacin	drug	32-42	probenecid	drug	103-112	false
norfloxacin	drug	32-42	norfloxacin	drug	118-128	false
probenecid	drug	103-112	norfloxacin	drug	118-128	mechanism

DDI-DrugBank.d217.s10	The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.
nitrofurantoin	drug	23-36	nitrofurantoin	drug	63-76	false
nitrofurantoin	drug	23-36	Norfloxacin	drug	121-131	false
nitrofurantoin	drug	63-76	Norfloxacin	drug	121-131	effect

DDI-DrugBank.d217.s11	Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
Multivitamins	group	0-12	iron	drug	44-47	false
Multivitamins	group	0-12	zinc	drug	52-55	false
Multivitamins	group	0-12	antacids	group	58-65	false
Multivitamins	group	0-12	sucralfate	drug	70-79	false
Multivitamins	group	0-12	norfloxacin	drug	172-182	advise
Multivitamins	group	0-12	norfloxacin	drug	273-283	false
iron	drug	44-47	zinc	drug	52-55	false
iron	drug	44-47	antacids	group	58-65	false
iron	drug	44-47	sucralfate	drug	70-79	false
iron	drug	44-47	norfloxacin	drug	172-182	advise
iron	drug	44-47	norfloxacin	drug	273-283	false
zinc	drug	52-55	antacids	group	58-65	false
zinc	drug	52-55	sucralfate	drug	70-79	false
zinc	drug	52-55	norfloxacin	drug	172-182	advise
zinc	drug	52-55	norfloxacin	drug	273-283	false
antacids	group	58-65	sucralfate	drug	70-79	false
antacids	group	58-65	norfloxacin	drug	172-182	advise
antacids	group	58-65	norfloxacin	drug	273-283	false
sucralfate	drug	70-79	norfloxacin	drug	172-182	advise
sucralfate	drug	70-79	norfloxacin	drug	273-283	false
norfloxacin	drug	172-182	norfloxacin	drug	273-283	false

DDI-DrugBank.d217.s12	Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
Videx	brand	0-4	Didanosine	drug	7-16	false
Videx	brand	0-4	norfloxacin	drug	178-188	advise
Videx	brand	0-4	norfloxacin	drug	289-299	false
Didanosine	drug	7-16	norfloxacin	drug	178-188	advise
Didanosine	drug	7-16	norfloxacin	drug	289-299	false
norfloxacin	drug	178-188	norfloxacin	drug	289-299	false

DDI-DrugBank.d217.s13	Some quinolones have also been shown to interfere with the metabolism of caffeine.
quinolones	group	5-14	caffeine	drug	73-80	mechanism

DDI-DrugBank.d312.s1	In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN.
irinotecan	drug	55-64	5-FU	drug	66-69	false
irinotecan	drug	55-64	leucovorin	drug	71-80	false
irinotecan	drug	55-64	AVASTIN	brand	110-116	false
5-FU	drug	66-69	leucovorin	drug	71-80	false
5-FU	drug	66-69	AVASTIN	brand	110-116	false
leucovorin	drug	71-80	AVASTIN	brand	110-116	false

DDI-DrugBank.d312.s2	Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN.
Irinotecan	drug	0-9	AVASTIN	brand	101-107	false

DDI-DrugBank.d312.s3	The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.
SN38	drug_n	22-25	irinotecan	drug	53-62	false
SN38	drug_n	22-25	AVASTIN	brand	144-150	false
irinotecan	drug	53-62	AVASTIN	brand	144-150	false

DDI-DrugBank.d312.s5	Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.
SN38	drug_n	90-93	irinotecan	drug	135-144	false
SN38	drug_n	90-93	AVASTIN	brand	150-156	false
irinotecan	drug	135-144	AVASTIN	brand	150-156	false

DDI-DrugBank.d222.s0	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
atropine	drug	5-12	pralidoxime	drug	18-28	effect
atropine	drug	5-12	atropine	drug	194-201	false
atropine	drug	5-12	pralidoxime	drug	225-235	false
atropine	drug	5-12	atropine	drug	266-273	false
pralidoxime	drug	18-28	atropine	drug	194-201	false
pralidoxime	drug	18-28	pralidoxime	drug	225-235	false
pralidoxime	drug	18-28	atropine	drug	266-273	false
atropine	drug	194-201	pralidoxime	drug	225-235	false
atropine	drug	194-201	atropine	drug	266-273	false
pralidoxime	drug	225-235	atropine	drug	266-273	effect

DDI-DrugBank.d222.s1	The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.
atropine	drug	147-154	pralidoxime	drug	160-170	advise

DDI-DrugBank.d222.s2	Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.
barbiturates	group	6-17	anticholinesterases	group	42-60	advise

DDI-DrugBank.d215.s0	Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
anileridine	drug	32-42	opioids	group	73-79	advise
anileridine	drug	32-42	sedatives	group	82-90	advise
anileridine	drug	32-42	phenothiazines	group	93-106	advise
anileridine	drug	32-42	anesthetics	group	112-122	advise
opioids	group	73-79	sedatives	group	82-90	false
opioids	group	73-79	phenothiazines	group	93-106	false
opioids	group	73-79	anesthetics	group	112-122	false
sedatives	group	82-90	phenothiazines	group	93-106	false
sedatives	group	82-90	anesthetics	group	112-122	false
phenothiazines	group	93-106	anesthetics	group	112-122	false

DDI-DrugBank.d262.s0	The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
alcohol	drug	23-29	central nervous system depressants	group	40-73	false

DDI-DrugBank.d250.s0	Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction.
antibiotics	group	14-24	aminoglycosides	group	27-41	false
antibiotics	group	14-24	polymyxin	group	47-55	false
aminoglycosides	group	27-41	polymyxin	group	47-55	false

DDI-DrugBank.d250.s2	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
Curariform muscle relaxants	brand	0-26	tubocurarine	drug	33-44	false
Curariform muscle relaxants	brand	0-26	succinylcholine	drug	81-95	false
Curariform muscle relaxants	brand	0-26	gallamine	drug	98-106	false
Curariform muscle relaxants	brand	0-26	decamethonium	drug	109-121	false
Curariform muscle relaxants	brand	0-26	sodium citrate	drug	127-140	false
Curariform muscle relaxants	brand	0-26	Coly-Mycin M	brand	259-270	effect
tubocurarine	drug	33-44	succinylcholine	drug	81-95	false
tubocurarine	drug	33-44	gallamine	drug	98-106	false
tubocurarine	drug	33-44	decamethonium	drug	109-121	false
tubocurarine	drug	33-44	sodium citrate	drug	127-140	false
tubocurarine	drug	33-44	Coly-Mycin M	brand	259-270	effect
succinylcholine	drug	81-95	gallamine	drug	98-106	false
succinylcholine	drug	81-95	decamethonium	drug	109-121	false
succinylcholine	drug	81-95	sodium citrate	drug	127-140	false
succinylcholine	drug	81-95	Coly-Mycin M	brand	259-270	effect
gallamine	drug	98-106	decamethonium	drug	109-121	false
gallamine	drug	98-106	sodium citrate	drug	127-140	false
gallamine	drug	98-106	Coly-Mycin M	brand	259-270	effect
decamethonium	drug	109-121	sodium citrate	drug	127-140	false
decamethonium	drug	109-121	Coly-Mycin M	brand	259-270	effect
sodium citrate	drug	127-140	Coly-Mycin M	brand	259-270	effect

DDI-DrugBank.d250.s3	Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.
Sodium cephalothin	drug	0-17	Coly-Mycin M	brand	53-64	effect

DDI-DrugBank.d250.s4	The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.
sodium cephalothin	drug	23-40	Coly-Mycin M	brand	46-57	advise

DDI-DrugBank.d229.s0	Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.
Cromolyn sodium	drug	35-49	isoproterenol	drug	55-67	false

DDI-DrugBank.d229.s3	The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.
cromolyn sodium	drug	33-47	isoproterenol	drug	168-180	effect

DDI-DrugBank.d442.s0	Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.
warfarin	drug	79-86	flutamide	drug	102-110	effect

DDI-DrugBank.d442.s1	Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.
anticoagulant	group	85-97	EULEXIN	brand	126-132	false
anticoagulant	group	85-97	warfarin	drug	179-186	false
EULEXIN	brand	126-132	warfarin	drug	179-186	advise

DDI-DrugBank.d122.s0	Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
cephalosporins	group	73-86	aminoglycoside antibiotics	group	93-118	effect
cephalosporins	group	73-86	diuretics	group	130-138	effect
cephalosporins	group	73-86	furosemide	drug	148-157	effect
aminoglycoside antibiotics	group	93-118	diuretics	group	130-138	false
aminoglycoside antibiotics	group	93-118	furosemide	drug	148-157	false
diuretics	group	130-138	furosemide	drug	148-157	false

DDI-DrugBank.d122.s1	Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics.
aminoglycosides	group	82-96	aminoglycosidic antibiotics	group	208-234	false

DDI-DrugBank.d122.s3	Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
Chloramphenicol	drug	0-14	beta-lactam antibiotics	group	53-75	effect
Chloramphenicol	drug	0-14	ceftazidime	drug	88-98	effect
beta-lactam antibiotics	group	53-75	ceftazidime	drug	88-98	false

DDI-DrugBank.d446.s0	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
Chlorotrianisene	drug	0-15	antidepressants	group	35-49	int
Chlorotrianisene	drug	0-15	aspirin	brand	52-58	int
Chlorotrianisene	drug	0-15	barbiturates	group	61-72	int
Chlorotrianisene	drug	0-15	bromocriptine	drug	75-87	int
Chlorotrianisene	drug	0-15	calcium	drug	90-96	int
Chlorotrianisene	drug	0-15	corticosteroids	group	111-125	int
Chlorotrianisene	drug	0-15	corticotropin	drug	128-140	int
Chlorotrianisene	drug	0-15	cyclosporine	drug	143-154	int
Chlorotrianisene	drug	0-15	dantrolene	drug	157-166	int
Chlorotrianisene	drug	0-15	nicotine	drug	169-176	int
Chlorotrianisene	drug	0-15	somatropin	drug	179-188	int
Chlorotrianisene	drug	0-15	tamoxifen	drug	191-199	int
Chlorotrianisene	drug	0-15	warfarin	drug	206-213	int
antidepressants	group	35-49	aspirin	brand	52-58	false
antidepressants	group	35-49	barbiturates	group	61-72	false
antidepressants	group	35-49	bromocriptine	drug	75-87	false
antidepressants	group	35-49	calcium	drug	90-96	false
antidepressants	group	35-49	corticosteroids	group	111-125	false
antidepressants	group	35-49	corticotropin	drug	128-140	false
antidepressants	group	35-49	cyclosporine	drug	143-154	false
antidepressants	group	35-49	dantrolene	drug	157-166	false
antidepressants	group	35-49	nicotine	drug	169-176	false
antidepressants	group	35-49	somatropin	drug	179-188	false
antidepressants	group	35-49	tamoxifen	drug	191-199	false
antidepressants	group	35-49	warfarin	drug	206-213	false
aspirin	brand	52-58	barbiturates	group	61-72	false
aspirin	brand	52-58	bromocriptine	drug	75-87	false
aspirin	brand	52-58	calcium	drug	90-96	false
aspirin	brand	52-58	corticosteroids	group	111-125	false
aspirin	brand	52-58	corticotropin	drug	128-140	false
aspirin	brand	52-58	cyclosporine	drug	143-154	false
aspirin	brand	52-58	dantrolene	drug	157-166	false
aspirin	brand	52-58	nicotine	drug	169-176	false
aspirin	brand	52-58	somatropin	drug	179-188	false
aspirin	brand	52-58	tamoxifen	drug	191-199	false
aspirin	brand	52-58	warfarin	drug	206-213	false
barbiturates	group	61-72	bromocriptine	drug	75-87	false
barbiturates	group	61-72	calcium	drug	90-96	false
barbiturates	group	61-72	corticosteroids	group	111-125	false
barbiturates	group	61-72	corticotropin	drug	128-140	false
barbiturates	group	61-72	cyclosporine	drug	143-154	false
barbiturates	group	61-72	dantrolene	drug	157-166	false
barbiturates	group	61-72	nicotine	drug	169-176	false
barbiturates	group	61-72	somatropin	drug	179-188	false
barbiturates	group	61-72	tamoxifen	drug	191-199	false
barbiturates	group	61-72	warfarin	drug	206-213	false
bromocriptine	drug	75-87	calcium	drug	90-96	false
bromocriptine	drug	75-87	corticosteroids	group	111-125	false
bromocriptine	drug	75-87	corticotropin	drug	128-140	false
bromocriptine	drug	75-87	cyclosporine	drug	143-154	false
bromocriptine	drug	75-87	dantrolene	drug	157-166	false
bromocriptine	drug	75-87	nicotine	drug	169-176	false
bromocriptine	drug	75-87	somatropin	drug	179-188	false
bromocriptine	drug	75-87	tamoxifen	drug	191-199	false
bromocriptine	drug	75-87	warfarin	drug	206-213	false
calcium	drug	90-96	corticosteroids	group	111-125	false
calcium	drug	90-96	corticotropin	drug	128-140	false
calcium	drug	90-96	cyclosporine	drug	143-154	false
calcium	drug	90-96	dantrolene	drug	157-166	false
calcium	drug	90-96	nicotine	drug	169-176	false
calcium	drug	90-96	somatropin	drug	179-188	false
calcium	drug	90-96	tamoxifen	drug	191-199	false
calcium	drug	90-96	warfarin	drug	206-213	false
corticosteroids	group	111-125	corticotropin	drug	128-140	false
corticosteroids	group	111-125	cyclosporine	drug	143-154	false
corticosteroids	group	111-125	dantrolene	drug	157-166	false
corticosteroids	group	111-125	nicotine	drug	169-176	false
corticosteroids	group	111-125	somatropin	drug	179-188	false
corticosteroids	group	111-125	tamoxifen	drug	191-199	false
corticosteroids	group	111-125	warfarin	drug	206-213	false
corticotropin	drug	128-140	cyclosporine	drug	143-154	false
corticotropin	drug	128-140	dantrolene	drug	157-166	false
corticotropin	drug	128-140	nicotine	drug	169-176	false
corticotropin	drug	128-140	somatropin	drug	179-188	false
corticotropin	drug	128-140	tamoxifen	drug	191-199	false
corticotropin	drug	128-140	warfarin	drug	206-213	false
cyclosporine	drug	143-154	dantrolene	drug	157-166	false
cyclosporine	drug	143-154	nicotine	drug	169-176	false
cyclosporine	drug	143-154	somatropin	drug	179-188	false
cyclosporine	drug	143-154	tamoxifen	drug	191-199	false
cyclosporine	drug	143-154	warfarin	drug	206-213	false
dantrolene	drug	157-166	nicotine	drug	169-176	false
dantrolene	drug	157-166	somatropin	drug	179-188	false
dantrolene	drug	157-166	tamoxifen	drug	191-199	false
dantrolene	drug	157-166	warfarin	drug	206-213	false
nicotine	drug	169-176	somatropin	drug	179-188	false
nicotine	drug	169-176	tamoxifen	drug	191-199	false
nicotine	drug	169-176	warfarin	drug	206-213	false
somatropin	drug	179-188	tamoxifen	drug	191-199	false
somatropin	drug	179-188	warfarin	drug	206-213	false
tamoxifen	drug	191-199	warfarin	drug	206-213	false

DDI-DrugBank.d320.s0	Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.
Chirocaine	brand	0-9	anesthetics	group	75-85	advise

DDI-DrugBank.d320.s1	In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.
levobupivacaine	drug	86-100	desbutyl levobupivacaine	drug_n	105-128	false
levobupivacaine	drug	86-100	3-hydroxy levobupivacaine	drug_n	134-158	false
desbutyl levobupivacaine	drug_n	105-128	3-hydroxy levobupivacaine	drug_n	134-158	false

DDI-DrugBank.d320.s2	Thus agents likely to be concomitantly administered with Chirocaine that are metabolized by this isoenzyme family may potentially interact with Chirocaine.
Chirocaine	brand	57-66	Chirocaine	brand	144-153	false

DDI-DrugBank.d320.s3	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
levobupivacaine	drug	86-100	phenytoin	drug	156-164	mechanism
levobupivacaine	drug	86-100	phenobarbital	drug	167-179	mechanism
levobupivacaine	drug	86-100	rifampin	drug	182-189	mechanism
levobupivacaine	drug	86-100	ketoconazole	drug	237-248	mechanism
phenytoin	drug	156-164	phenobarbital	drug	167-179	false
phenytoin	drug	156-164	rifampin	drug	182-189	false
phenytoin	drug	156-164	ketoconazole	drug	237-248	false
phenobarbital	drug	167-179	rifampin	drug	182-189	false
phenobarbital	drug	167-179	ketoconazole	drug	237-248	false
rifampin	drug	182-189	ketoconazole	drug	237-248	false

DDI-DrugBank.d320.s5	macrolide antibiotics e.g., erythromycin;
macrolide antibiotics	group	0-20	erythromycin	drug	28-39	false

DDI-DrugBank.d320.s6	and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).
calcium channel antagonists	group	4-30	verapamil	drug	38-46	false
calcium channel antagonists	group	4-30	omeprazole	drug	67-76	false
calcium channel antagonists	group	4-30	furafylline	drug	102-112	false
calcium channel antagonists	group	4-30	clarithromycin	drug	118-131	false
verapamil	drug	38-46	omeprazole	drug	67-76	false
verapamil	drug	38-46	furafylline	drug	102-112	false
verapamil	drug	38-46	clarithromycin	drug	118-131	false
omeprazole	drug	67-76	furafylline	drug	102-112	false
omeprazole	drug	67-76	clarithromycin	drug	118-131	false
furafylline	drug	102-112	clarithromycin	drug	118-131	false

DDI-DrugBank.d320.s7	Dosage adjustment may be warranted when levobupivacaine is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic levobupivacaine levels may rise resulting in toxicity.
levobupivacaine	drug	40-54	levobupivacaine	drug	142-156	false

DDI-DrugBank.d507.s0	The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.
guanfacine	drug	42-51	CNS-depressant drug	group	73-91	effect

DDI-DrugBank.d507.s1	The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
guanfacine	drug	22-31	phenobarbital	drug	85-97	mechanism
guanfacine	drug	22-31	phenytoin	drug	102-110	mechanism
phenobarbital	drug	85-97	phenytoin	drug	102-110	false

DDI-DrugBank.d507.s4	TCAs decrease the hypotensive effect of guanfacine.
TCAs	group	0-3	guanfacine	drug	40-49	effect

DDI-DrugBank.d507.s5	Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
Noncardioselective beta-blockers	group	0-31	nadolol	drug	34-40	false
Noncardioselective beta-blockers	group	0-31	timolol	drug	54-60	false
Noncardioselective beta-blockers	group	0-31	guanfacine	drug	104-113	effect
nadolol	drug	34-40	timolol	drug	54-60	false
nadolol	drug	34-40	guanfacine	drug	104-113	effect
timolol	drug	54-60	guanfacine	drug	104-113	effect

DDI-DrugBank.d507.s7	The gradual withdrawal of guafacine or a cardioselective beta-blocker could be substituted.
guafacine	drug	26-34	cardioselective beta-blocker	group	41-68	false

DDI-DrugBank.d507.s8	Anticoagulants: Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks.
Anticoagulants	group	0-13	anticoagulants	group	57-70	false
Anticoagulants	group	0-13	guanfacine	drug	83-92	false
anticoagulants	group	57-70	guanfacine	drug	83-92	false

DDI-DrugBank.d507.s10	In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported.
guanfacine	drug	36-45	diuretics	group	78-86	false

DDI-DrugBank.d507.s12	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
cardiac glycosides	group	68-85	sedatives	group	94-102	false
cardiac glycosides	group	68-85	hypnotics	group	108-116	false
cardiac glycosides	group	68-85	coronary vasodilators	group	125-145	false
cardiac glycosides	group	68-85	hypoglycemics	group	158-170	false
cardiac glycosides	group	68-85	NSAIDs	group	212-217	false
cardiac glycosides	group	68-85	antihyperlipidemics	group	225-243	false
cardiac glycosides	group	68-85	antigout drugs	group	251-264	false
cardiac glycosides	group	68-85	contraceptives	group	277-290	false
cardiac glycosides	group	68-85	bronchodilators	group	298-312	false
cardiac glycosides	group	68-85	insulin	drug	320-326	false
cardiac glycosides	group	68-85	beta blockers	group	338-350	false
sedatives	group	94-102	hypnotics	group	108-116	false
sedatives	group	94-102	coronary vasodilators	group	125-145	false
sedatives	group	94-102	hypoglycemics	group	158-170	false
sedatives	group	94-102	NSAIDs	group	212-217	false
sedatives	group	94-102	antihyperlipidemics	group	225-243	false
sedatives	group	94-102	antigout drugs	group	251-264	false
sedatives	group	94-102	contraceptives	group	277-290	false
sedatives	group	94-102	bronchodilators	group	298-312	false
sedatives	group	94-102	insulin	drug	320-326	false
sedatives	group	94-102	beta blockers	group	338-350	false
hypnotics	group	108-116	coronary vasodilators	group	125-145	false
hypnotics	group	108-116	hypoglycemics	group	158-170	false
hypnotics	group	108-116	NSAIDs	group	212-217	false
hypnotics	group	108-116	antihyperlipidemics	group	225-243	false
hypnotics	group	108-116	antigout drugs	group	251-264	false
hypnotics	group	108-116	contraceptives	group	277-290	false
hypnotics	group	108-116	bronchodilators	group	298-312	false
hypnotics	group	108-116	insulin	drug	320-326	false
hypnotics	group	108-116	beta blockers	group	338-350	false
coronary vasodilators	group	125-145	hypoglycemics	group	158-170	false
coronary vasodilators	group	125-145	NSAIDs	group	212-217	false
coronary vasodilators	group	125-145	antihyperlipidemics	group	225-243	false
coronary vasodilators	group	125-145	antigout drugs	group	251-264	false
coronary vasodilators	group	125-145	contraceptives	group	277-290	false
coronary vasodilators	group	125-145	bronchodilators	group	298-312	false
coronary vasodilators	group	125-145	insulin	drug	320-326	false
coronary vasodilators	group	125-145	beta blockers	group	338-350	false
hypoglycemics	group	158-170	NSAIDs	group	212-217	false
hypoglycemics	group	158-170	antihyperlipidemics	group	225-243	false
hypoglycemics	group	158-170	antigout drugs	group	251-264	false
hypoglycemics	group	158-170	contraceptives	group	277-290	false
hypoglycemics	group	158-170	bronchodilators	group	298-312	false
hypoglycemics	group	158-170	insulin	drug	320-326	false
hypoglycemics	group	158-170	beta blockers	group	338-350	false
NSAIDs	group	212-217	antihyperlipidemics	group	225-243	false
NSAIDs	group	212-217	antigout drugs	group	251-264	false
NSAIDs	group	212-217	contraceptives	group	277-290	false
NSAIDs	group	212-217	bronchodilators	group	298-312	false
NSAIDs	group	212-217	insulin	drug	320-326	false
NSAIDs	group	212-217	beta blockers	group	338-350	false
antihyperlipidemics	group	225-243	antigout drugs	group	251-264	false
antihyperlipidemics	group	225-243	contraceptives	group	277-290	false
antihyperlipidemics	group	225-243	bronchodilators	group	298-312	false
antihyperlipidemics	group	225-243	insulin	drug	320-326	false
antihyperlipidemics	group	225-243	beta blockers	group	338-350	false
antigout drugs	group	251-264	contraceptives	group	277-290	false
antigout drugs	group	251-264	bronchodilators	group	298-312	false
antigout drugs	group	251-264	insulin	drug	320-326	false
antigout drugs	group	251-264	beta blockers	group	338-350	false
contraceptives	group	277-290	bronchodilators	group	298-312	false
contraceptives	group	277-290	insulin	drug	320-326	false
contraceptives	group	277-290	beta blockers	group	338-350	false
bronchodilators	group	298-312	insulin	drug	320-326	false
bronchodilators	group	298-312	beta blockers	group	338-350	false
insulin	drug	320-326	beta blockers	group	338-350	false

DDI-DrugBank.d301.s14	Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.
corticosteroids	group	170-184	sex steroids	group	190-201	false

DDI-DrugBank.d304.s0	May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;
cholestyramine	drug	33-46	colestipol	drug	49-58	false
cholestyramine	drug	33-46	thiazide diuretics	group	70-87	effect
cholestyramine	drug	33-46	diuretic	group	105-112	false
colestipol	drug	49-58	thiazide diuretics	group	70-87	effect
colestipol	drug	49-58	diuretic	group	105-112	false
thiazide diuretics	group	70-87	diuretic	group	105-112	false

DDI-DrugBank.d470.s1	Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
TRISENOX	brand	24-31	antiarrhythmics	group	121-135	advise
TRISENOX	brand	24-31	thioridazine	drug	140-151	advise
TRISENOX	brand	24-31	diuretics	group	200-208	advise
TRISENOX	brand	24-31	amphotericin B	drug	213-226	advise
antiarrhythmics	group	121-135	thioridazine	drug	140-151	false
antiarrhythmics	group	121-135	diuretics	group	200-208	false
antiarrhythmics	group	121-135	amphotericin B	drug	213-226	false
thioridazine	drug	140-151	diuretics	group	200-208	false
thioridazine	drug	140-151	amphotericin B	drug	213-226	false
diuretics	group	200-208	amphotericin B	drug	213-226	false

DDI-DrugBank.d524.s0	Albuterol, Antihistamines, antidiabetic drugs, diuretics, digitalis.
Albuterol	drug	0-8	Antihistamines	group	11-24	false
Albuterol	drug	0-8	antidiabetic drugs	group	27-44	false
Albuterol	drug	0-8	diuretics	group	47-55	false
Albuterol	drug	0-8	digitalis	group	58-66	false
Antihistamines	group	11-24	antidiabetic drugs	group	27-44	false
Antihistamines	group	11-24	diuretics	group	47-55	false
Antihistamines	group	11-24	digitalis	group	58-66	false
antidiabetic drugs	group	27-44	diuretics	group	47-55	false
antidiabetic drugs	group	27-44	digitalis	group	58-66	false
diuretics	group	47-55	digitalis	group	58-66	false

DDI-DrugBank.d39.s0	Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.
antibiotics	group	20-30	methotrexate	drug	33-44	false
antibiotics	group	20-30	pyrimethamine	drug	50-62	false
antibiotics	group	20-30	folic acid	drug	75-84	false
antibiotics	group	20-30	vitamin B12	drug	90-100	false
methotrexate	drug	33-44	pyrimethamine	drug	50-62	false
methotrexate	drug	33-44	folic acid	drug	75-84	false
methotrexate	drug	33-44	vitamin B12	drug	90-100	false
pyrimethamine	drug	50-62	folic acid	drug	75-84	false
pyrimethamine	drug	50-62	vitamin B12	drug	90-100	false
folic acid	drug	75-84	vitamin B12	drug	90-100	false

DDI-DrugBank.d39.s1	Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
Colchicine	drug	0-9	para-aminosalicylic acid	drug	11-34	false
Colchicine	drug	0-9	alcohol	drug	46-52	false
Colchicine	drug	0-9	vitamin B12	drug	114-124	mechanism
para-aminosalicylic acid	drug	11-34	alcohol	drug	46-52	false
para-aminosalicylic acid	drug	11-34	vitamin B12	drug	114-124	mechanism
alcohol	drug	46-52	vitamin B12	drug	114-124	mechanism

DDI-DrugBank.d448.s0	MAO inhibitors prolong and intensify the effects of antihistamines.
MAO inhibitors	group	0-13	antihistamines	group	52-65	effect

DDI-DrugBank.d448.s1	Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
antihistamines	group	19-32	alcohol	drug	39-45	effect
antihistamines	group	19-32	tricyclic antidepressants	group	48-72	effect
antihistamines	group	19-32	barbiturates	group	75-86	effect
antihistamines	group	19-32	central nervous system depressants	group	98-131	effect
alcohol	drug	39-45	tricyclic antidepressants	group	48-72	false
alcohol	drug	39-45	barbiturates	group	75-86	false
alcohol	drug	39-45	central nervous system depressants	group	98-131	false
tricyclic antidepressants	group	48-72	barbiturates	group	75-86	false
tricyclic antidepressants	group	48-72	central nervous system depressants	group	98-131	false
barbiturates	group	75-86	central nervous system depressants	group	98-131	false

DDI-DrugBank.d448.s2	When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.
sympathomimetic drugs	group	5-25	monoamine oxidase inhibitors	group	59-86	effect

DDI-DrugBank.d448.s3	The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
methyldopa	drug	32-41	mecamylamine	drug	44-55	false
methyldopa	drug	32-41	reserpine	drug	58-66	false
methyldopa	drug	32-41	veratrum alkaloids	drug	73-90	false
methyldopa	drug	32-41	sympathomimetics	group	110-125	effect
mecamylamine	drug	44-55	reserpine	drug	58-66	false
mecamylamine	drug	44-55	veratrum alkaloids	drug	73-90	false
mecamylamine	drug	44-55	sympathomimetics	group	110-125	effect
reserpine	drug	58-66	veratrum alkaloids	drug	73-90	false
reserpine	drug	58-66	sympathomimetics	group	110-125	effect
veratrum alkaloids	drug	73-90	sympathomimetics	group	110-125	effect

DDI-DrugBank.d448.s4	Beta-adrenergic blocking agents may also interact with sympathomimetics.
Beta-adrenergic blocking agents	group	0-30	sympathomimetics	group	55-70	int

DDI-DrugBank.d448.s5	Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.
pseudoephedrine	drug	52-66	digitalis	group	95-103	effect

DDI-DrugBank.d448.s6	Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
Antacids	group	0-7	pseudoephedrine	drug	44-58	mechanism
Antacids	group	0-7	kaolin	drug	67-72	false
pseudoephedrine	drug	44-58	kaolin	drug	67-72	mechanism

DDI-DrugBank.d340.s1	Coadministration of VIRACEPT and drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.
VIRACEPT	brand	20-27	dihydropyridine calcium channel blockers	group	77-116	false

DDI-DrugBank.d340.s3	Coadministration of VIRACEPT and drugs that induce CYP3A may decrease nelfinavir plasma concentrations and reduce its therapeutic effect.
VIRACEPT	brand	20-27	nelfinavir	drug	70-79	false

DDI-DrugBank.d340.s4	Coadministration of VIRACEPT and drugs that inhibit CYP3A may increase nelfinavir plasma concentrations.
VIRACEPT	brand	20-27	nelfinavir	drug	71-80	false

DDI-DrugBank.d340.s5	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.
VIRACEPT	brand	101-108	dapsone	drug	114-120	false
VIRACEPT	brand	101-108	trimethoprim	drug	123-134	false
VIRACEPT	brand	101-108	sulfamethoxazole	drug	136-151	false
VIRACEPT	brand	101-108	clarithromycin	drug	154-167	false
VIRACEPT	brand	101-108	erythromycin	drug	170-181	false
VIRACEPT	brand	101-108	itraconazole	drug	184-195	false
VIRACEPT	brand	101-108	fluconazole	drug	200-210	false
dapsone	drug	114-120	trimethoprim	drug	123-134	false
dapsone	drug	114-120	sulfamethoxazole	drug	136-151	false
dapsone	drug	114-120	clarithromycin	drug	154-167	false
dapsone	drug	114-120	erythromycin	drug	170-181	false
dapsone	drug	114-120	itraconazole	drug	184-195	false
dapsone	drug	114-120	fluconazole	drug	200-210	false
trimethoprim	drug	123-134	sulfamethoxazole	drug	136-151	false
trimethoprim	drug	123-134	clarithromycin	drug	154-167	false
trimethoprim	drug	123-134	erythromycin	drug	170-181	false
trimethoprim	drug	123-134	itraconazole	drug	184-195	false
trimethoprim	drug	123-134	fluconazole	drug	200-210	false
sulfamethoxazole	drug	136-151	clarithromycin	drug	154-167	false
sulfamethoxazole	drug	136-151	erythromycin	drug	170-181	false
sulfamethoxazole	drug	136-151	itraconazole	drug	184-195	false
sulfamethoxazole	drug	136-151	fluconazole	drug	200-210	false
clarithromycin	drug	154-167	erythromycin	drug	170-181	false
clarithromycin	drug	154-167	itraconazole	drug	184-195	false
clarithromycin	drug	154-167	fluconazole	drug	200-210	false
erythromycin	drug	170-181	itraconazole	drug	184-195	false
erythromycin	drug	170-181	fluconazole	drug	200-210	false
itraconazole	drug	184-195	fluconazole	drug	200-210	false

DDI-DrugBank.d340.s6	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
VIRACEPT	brand	45-52	Antiarrhythmics	group	54-68	advise
VIRACEPT	brand	45-52	amiodarone	drug	71-80	advise
VIRACEPT	brand	45-52	quinidine	drug	83-91	advise
VIRACEPT	brand	45-52	Antihistamines	group	93-106	advise
VIRACEPT	brand	45-52	astemizole	drug	109-118	advise
VIRACEPT	brand	45-52	terfenadine	drug	121-131	advise
VIRACEPT	brand	45-52	ergot derivatives	group	147-163	advise
VIRACEPT	brand	45-52	Antimycobacterial agents	group	165-188	advise
VIRACEPT	brand	45-52	rifampin	drug	191-198	advise
VIRACEPT	brand	45-52	Benzodiazepines	group	200-214	advise
VIRACEPT	brand	45-52	midazolam	drug	216-224	advise
VIRACEPT	brand	45-52	triazolam	drug	227-235	advise
VIRACEPT	brand	45-52	cisapride	drug	257-265	advise
Antiarrhythmics	group	54-68	amiodarone	drug	71-80	false
Antiarrhythmics	group	54-68	quinidine	drug	83-91	false
Antiarrhythmics	group	54-68	Antihistamines	group	93-106	false
Antiarrhythmics	group	54-68	astemizole	drug	109-118	false
Antiarrhythmics	group	54-68	terfenadine	drug	121-131	false
Antiarrhythmics	group	54-68	ergot derivatives	group	147-163	false
Antiarrhythmics	group	54-68	Antimycobacterial agents	group	165-188	false
Antiarrhythmics	group	54-68	rifampin	drug	191-198	false
Antiarrhythmics	group	54-68	Benzodiazepines	group	200-214	false
Antiarrhythmics	group	54-68	midazolam	drug	216-224	false
Antiarrhythmics	group	54-68	triazolam	drug	227-235	false
Antiarrhythmics	group	54-68	cisapride	drug	257-265	false
amiodarone	drug	71-80	quinidine	drug	83-91	false
amiodarone	drug	71-80	Antihistamines	group	93-106	false
amiodarone	drug	71-80	astemizole	drug	109-118	false
amiodarone	drug	71-80	terfenadine	drug	121-131	false
amiodarone	drug	71-80	ergot derivatives	group	147-163	false
amiodarone	drug	71-80	Antimycobacterial agents	group	165-188	false
amiodarone	drug	71-80	rifampin	drug	191-198	false
amiodarone	drug	71-80	Benzodiazepines	group	200-214	false
amiodarone	drug	71-80	midazolam	drug	216-224	false
amiodarone	drug	71-80	triazolam	drug	227-235	false
amiodarone	drug	71-80	cisapride	drug	257-265	false
quinidine	drug	83-91	Antihistamines	group	93-106	false
quinidine	drug	83-91	astemizole	drug	109-118	false
quinidine	drug	83-91	terfenadine	drug	121-131	false
quinidine	drug	83-91	ergot derivatives	group	147-163	false
quinidine	drug	83-91	Antimycobacterial agents	group	165-188	false
quinidine	drug	83-91	rifampin	drug	191-198	false
quinidine	drug	83-91	Benzodiazepines	group	200-214	false
quinidine	drug	83-91	midazolam	drug	216-224	false
quinidine	drug	83-91	triazolam	drug	227-235	false
quinidine	drug	83-91	cisapride	drug	257-265	false
Antihistamines	group	93-106	astemizole	drug	109-118	false
Antihistamines	group	93-106	terfenadine	drug	121-131	false
Antihistamines	group	93-106	ergot derivatives	group	147-163	false
Antihistamines	group	93-106	Antimycobacterial agents	group	165-188	false
Antihistamines	group	93-106	rifampin	drug	191-198	false
Antihistamines	group	93-106	Benzodiazepines	group	200-214	false
Antihistamines	group	93-106	midazolam	drug	216-224	false
Antihistamines	group	93-106	triazolam	drug	227-235	false
Antihistamines	group	93-106	cisapride	drug	257-265	false
astemizole	drug	109-118	terfenadine	drug	121-131	false
astemizole	drug	109-118	ergot derivatives	group	147-163	false
astemizole	drug	109-118	Antimycobacterial agents	group	165-188	false
astemizole	drug	109-118	rifampin	drug	191-198	false
astemizole	drug	109-118	Benzodiazepines	group	200-214	false
astemizole	drug	109-118	midazolam	drug	216-224	false
astemizole	drug	109-118	triazolam	drug	227-235	false
astemizole	drug	109-118	cisapride	drug	257-265	false
terfenadine	drug	121-131	ergot derivatives	group	147-163	false
terfenadine	drug	121-131	Antimycobacterial agents	group	165-188	false
terfenadine	drug	121-131	rifampin	drug	191-198	false
terfenadine	drug	121-131	Benzodiazepines	group	200-214	false
terfenadine	drug	121-131	midazolam	drug	216-224	false
terfenadine	drug	121-131	triazolam	drug	227-235	false
terfenadine	drug	121-131	cisapride	drug	257-265	false
ergot derivatives	group	147-163	Antimycobacterial agents	group	165-188	false
ergot derivatives	group	147-163	rifampin	drug	191-198	false
ergot derivatives	group	147-163	Benzodiazepines	group	200-214	false
ergot derivatives	group	147-163	midazolam	drug	216-224	false
ergot derivatives	group	147-163	triazolam	drug	227-235	false
ergot derivatives	group	147-163	cisapride	drug	257-265	false
Antimycobacterial agents	group	165-188	rifampin	drug	191-198	false
Antimycobacterial agents	group	165-188	Benzodiazepines	group	200-214	false
Antimycobacterial agents	group	165-188	midazolam	drug	216-224	false
Antimycobacterial agents	group	165-188	triazolam	drug	227-235	false
Antimycobacterial agents	group	165-188	cisapride	drug	257-265	false
rifampin	drug	191-198	Benzodiazepines	group	200-214	false
rifampin	drug	191-198	midazolam	drug	216-224	false
rifampin	drug	191-198	triazolam	drug	227-235	false
rifampin	drug	191-198	cisapride	drug	257-265	false
Benzodiazepines	group	200-214	midazolam	drug	216-224	false
Benzodiazepines	group	200-214	triazolam	drug	227-235	false
Benzodiazepines	group	200-214	cisapride	drug	257-265	false
midazolam	drug	216-224	triazolam	drug	227-235	false
midazolam	drug	216-224	cisapride	drug	257-265	false
triazolam	drug	227-235	cisapride	drug	257-265	false

DDI-DrugBank.d340.s7	Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
VIRACEPT	brand	61-68	Antimycobacterial agents	group	70-93	advise
VIRACEPT	brand	61-68	rifabutin	drug	96-104	advise
Antimycobacterial agents	group	70-93	rifabutin	drug	96-104	false

DDI-DrugBank.d340.s8	* This table is not all inclusive ** VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly
VIRACEPT	brand	37-44	nelfinavir	drug	84-93	false

DDI-DrugBank.d340.s10	Terfenadine: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;
Terfenadine	drug	0-10	terfenadine	drug	31-41	false
Terfenadine	drug	0-10	VIRACEPT	brand	48-55	false
Terfenadine	drug	0-10	terfenadine	drug	97-107	false
terfenadine	drug	31-41	VIRACEPT	brand	48-55	false
terfenadine	drug	31-41	terfenadine	drug	97-107	false
VIRACEPT	brand	48-55	terfenadine	drug	97-107	false

DDI-DrugBank.d340.s11	therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.
VIRACEPT	brand	11-18	terfenadine	drug	65-75	advise

DDI-DrugBank.d340.s12	Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.
VIRACEPT	brand	41-48	astemizole	drug	100-109	advise

DDI-DrugBank.d340.s14	Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
Indinavir	drug	0-8	indinavir	drug	31-39	false
Indinavir	drug	0-8	VIRACEPT	brand	46-53	false
Indinavir	drug	0-8	nelfinavir	drug	86-95	false
Indinavir	drug	0-8	indinavir	drug	130-138	false
indinavir	drug	31-39	VIRACEPT	brand	46-53	mechanism
indinavir	drug	31-39	nelfinavir	drug	86-95	false
indinavir	drug	31-39	indinavir	drug	130-138	false
VIRACEPT	brand	46-53	nelfinavir	drug	86-95	false
VIRACEPT	brand	46-53	indinavir	drug	130-138	false
nelfinavir	drug	86-95	indinavir	drug	130-138	false

DDI-DrugBank.d340.s16	Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.
Ritonavir	drug	0-8	ritonavir	drug	31-39	false
Ritonavir	drug	0-8	VIRACEPT	brand	46-53	false
Ritonavir	drug	0-8	nelfinavir	drug	86-95	false
Ritonavir	drug	0-8	ritonavir	drug	134-142	false
ritonavir	drug	31-39	VIRACEPT	brand	46-53	mechanism
ritonavir	drug	31-39	nelfinavir	drug	86-95	false
ritonavir	drug	31-39	ritonavir	drug	134-142	false
VIRACEPT	brand	46-53	nelfinavir	drug	86-95	false
VIRACEPT	brand	46-53	ritonavir	drug	134-142	false
nelfinavir	drug	86-95	ritonavir	drug	134-142	false

DDI-DrugBank.d340.s18	Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
Saquinavir	drug	0-9	saquinavir	drug	32-41	false
Saquinavir	drug	0-9	saquinavir	drug	102-111	false
Saquinavir	drug	0-9	VIRACEPT	brand	126-133	false
Saquinavir	drug	0-9	nelfinavir	drug	166-175	false
Saquinavir	drug	0-9	saquinavir	drug	213-222	false
saquinavir	drug	32-41	saquinavir	drug	102-111	false
saquinavir	drug	32-41	VIRACEPT	brand	126-133	mechanism
saquinavir	drug	32-41	nelfinavir	drug	166-175	false
saquinavir	drug	32-41	saquinavir	drug	213-222	false
saquinavir	drug	102-111	VIRACEPT	brand	126-133	false
saquinavir	drug	102-111	nelfinavir	drug	166-175	false
saquinavir	drug	102-111	saquinavir	drug	213-222	false
VIRACEPT	brand	126-133	nelfinavir	drug	166-175	false
VIRACEPT	brand	126-133	saquinavir	drug	213-222	false
nelfinavir	drug	166-175	saquinavir	drug	213-222	false

DDI-DrugBank.d340.s22	Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.
Ketoconazole	drug	0-11	ketoconazole	drug	34-45	false
Ketoconazole	drug	0-11	VIRACEPT	brand	52-59	false
Ketoconazole	drug	0-11	nelfinavir	drug	91-100	false
ketoconazole	drug	34-45	VIRACEPT	brand	52-59	mechanism
ketoconazole	drug	34-45	nelfinavir	drug	91-100	false
VIRACEPT	brand	52-59	nelfinavir	drug	91-100	false

DDI-DrugBank.d340.s23	This change was not considered clinically significant and no dose adjustment is needed when ketoconazole and VIRACEPT are coadministered.
ketoconazole	drug	92-103	VIRACEPT	brand	109-116	false

DDI-DrugBank.d340.s25	Didanosine: It is recommended that didanosine be administered on an empty stomach;
Didanosine	drug	0-9	didanosine	drug	35-44	false

DDI-DrugBank.d340.s26	therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.
nelfinavir	drug	11-20	didanosine	drug	102-111	advise

DDI-DrugBank.d340.s27	A dose adjustment is not needed when zidovudine is administered with VIRACEPT.
zidovudine	drug	37-46	VIRACEPT	brand	69-76	advise

DDI-DrugBank.d340.s28	Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine.
VIRACEPT	brand	77-84	lamivudine	drug	110-119	false
VIRACEPT	brand	77-84	stavudine	drug	124-132	false
lamivudine	drug	110-119	stavudine	drug	124-132	false

DDI-DrugBank.d340.s30	Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.
Rifabutin	drug	0-8	rifabutin	drug	31-39	false
Rifabutin	drug	0-8	VIRACEPT	brand	45-52	false
Rifabutin	drug	0-8	nelfinavir	drug	84-93	false
Rifabutin	drug	0-8	rifabutin	drug	129-137	false
rifabutin	drug	31-39	VIRACEPT	brand	45-52	mechanism
rifabutin	drug	31-39	nelfinavir	drug	84-93	false
rifabutin	drug	31-39	rifabutin	drug	129-137	false
VIRACEPT	brand	45-52	nelfinavir	drug	84-93	false
VIRACEPT	brand	45-52	rifabutin	drug	129-137	false
nelfinavir	drug	84-93	rifabutin	drug	129-137	false

DDI-DrugBank.d340.s31	It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.
rifabutin	drug	35-43	VIRACEPT	brand	106-113	advise

DDI-DrugBank.d340.s32	Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
Rifampin	drug	0-7	rifampin	drug	30-37	false
Rifampin	drug	0-7	VIRACEPT	brand	43-50	false
Rifampin	drug	0-7	nelfinavir	drug	83-92	false
rifampin	drug	30-37	VIRACEPT	brand	43-50	mechanism
rifampin	drug	30-37	nelfinavir	drug	83-92	false
VIRACEPT	brand	43-50	nelfinavir	drug	83-92	false

DDI-DrugBank.d340.s33	VIRACEPT and rifampin should not be coadministered.
VIRACEPT	brand	0-7	rifampin	drug	13-20	advise

DDI-DrugBank.d340.s35	Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
Ethinyl Estradiol	drug	0-16	Norethindrone	drug	22-34	false
Ethinyl Estradiol	drug	0-16	VIRACEPT	brand	57-64	false
Ethinyl Estradiol	drug	0-16	OVCON-35	brand	71-78	false
Ethinyl Estradiol	drug	0-16	ethinyl estradiol	drug	110-126	false
Ethinyl Estradiol	drug	0-16	norethindrone	drug	151-163	false
Norethindrone	drug	22-34	VIRACEPT	brand	57-64	false
Norethindrone	drug	22-34	OVCON-35	brand	71-78	false
Norethindrone	drug	22-34	ethinyl estradiol	drug	110-126	false
Norethindrone	drug	22-34	norethindrone	drug	151-163	false
VIRACEPT	brand	57-64	OVCON-35	brand	71-78	mechanism
VIRACEPT	brand	57-64	ethinyl estradiol	drug	110-126	false
VIRACEPT	brand	57-64	norethindrone	drug	151-163	false
OVCON-35	brand	71-78	ethinyl estradiol	drug	110-126	false
OVCON-35	brand	71-78	norethindrone	drug	151-163	false
ethinyl estradiol	drug	110-126	norethindrone	drug	151-163	false

DDI-DrugBank.d244.s0	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
aminoglycosides	group	138-152	gentamicin	drug	161-170	false
aminoglycosides	group	138-152	amikacin	drug	173-180	false
aminoglycosides	group	138-152	amphotericin B	drug	184-197	false
aminoglycosides	group	138-152	cyclosporine	drug	200-211	false
aminoglycosides	group	138-152	non-steroidal anti-inflammatory	group	214-244	false
aminoglycosides	group	138-152	ibuprofen	drug	259-267	false
aminoglycosides	group	138-152	tacrolimus	drug	271-280	false
aminoglycosides	group	138-152	vancomycin	drug	283-292	false
gentamicin	drug	161-170	amikacin	drug	173-180	false
gentamicin	drug	161-170	amphotericin B	drug	184-197	false
gentamicin	drug	161-170	cyclosporine	drug	200-211	false
gentamicin	drug	161-170	non-steroidal anti-inflammatory	group	214-244	false
gentamicin	drug	161-170	ibuprofen	drug	259-267	false
gentamicin	drug	161-170	tacrolimus	drug	271-280	false
gentamicin	drug	161-170	vancomycin	drug	283-292	false
amikacin	drug	173-180	amphotericin B	drug	184-197	false
amikacin	drug	173-180	cyclosporine	drug	200-211	false
amikacin	drug	173-180	non-steroidal anti-inflammatory	group	214-244	false
amikacin	drug	173-180	ibuprofen	drug	259-267	false
amikacin	drug	173-180	tacrolimus	drug	271-280	false
amikacin	drug	173-180	vancomycin	drug	283-292	false
amphotericin B	drug	184-197	cyclosporine	drug	200-211	false
amphotericin B	drug	184-197	non-steroidal anti-inflammatory	group	214-244	false
amphotericin B	drug	184-197	ibuprofen	drug	259-267	false
amphotericin B	drug	184-197	tacrolimus	drug	271-280	false
amphotericin B	drug	184-197	vancomycin	drug	283-292	false
cyclosporine	drug	200-211	non-steroidal anti-inflammatory	group	214-244	false
cyclosporine	drug	200-211	ibuprofen	drug	259-267	false
cyclosporine	drug	200-211	tacrolimus	drug	271-280	false
cyclosporine	drug	200-211	vancomycin	drug	283-292	false
non-steroidal anti-inflammatory	group	214-244	ibuprofen	drug	259-267	false
non-steroidal anti-inflammatory	group	214-244	tacrolimus	drug	271-280	false
non-steroidal anti-inflammatory	group	214-244	vancomycin	drug	283-292	false
ibuprofen	drug	259-267	tacrolimus	drug	271-280	false
ibuprofen	drug	259-267	vancomycin	drug	283-292	false
tacrolimus	drug	271-280	vancomycin	drug	283-292	false

DDI-DrugBank.d221.s0	The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.
NovoSeven	brand	44-52	coagulation factor	group	58-75	false

DDI-DrugBank.d221.s1	Simultaneous use of activated prothrombin complex concentrates or prothrombin complex concentrates should be avoided.
activated prothrombin complex concentrates	group	20-61	prothrombin complex concentrates	group	66-97	false

DDI-DrugBank.d221.s2	Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.
tranexamic acid	drug	170-184	aminocaproic acid	drug	187-203	false
tranexamic acid	drug	170-184	NovoSeven	brand	210-218	false
aminocaproic acid	drug	187-203	NovoSeven	brand	210-218	false

DDI-DrugBank.d73.s0	Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.
reserpine	drug	35-43	beta-blocking agent	group	90-108	effect

DDI-DrugBank.d73.s2	Calcium channel blockers may also have an additive effect when given with TENORMIN .
Calcium channel blockers	group	0-23	TENORMIN	brand	74-81	effect

DDI-DrugBank.d73.s3	Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.
Beta blockers	group	0-12	clonidine	drug	89-97	effect

DDI-DrugBank.d73.s4	If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.
beta blocker	group	41-52	clonidine	drug	120-128	advise

DDI-DrugBank.d73.s5	If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
clonidine	drug	13-21	beta-blocker	group	26-37	false
clonidine	drug	13-21	beta blockers	group	68-80	false
clonidine	drug	13-21	clonidine	drug	123-131	false
beta-blocker	group	26-37	beta blockers	group	68-80	false
beta-blocker	group	26-37	clonidine	drug	123-131	false
beta blockers	group	68-80	clonidine	drug	123-131	advise

DDI-DrugBank.d73.s6	Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.
indomethacin	drug	64-75	beta blockers	group	118-130	effect

DDI-DrugBank.d73.s7	Information on concurrent usage of atenolol and aspirin is limited.
atenolol	drug	35-42	aspirin	brand	48-54	false

DDI-DrugBank.d73.s8	Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.
aspirin	brand	106-112	beta blockers	group	118-130	false

DDI-DrugBank.d492.s0	MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
MAO inhibitors	group	0-13	antihistamines	group	68-81	effect

DDI-DrugBank.d492.s1	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
Antihistamines	group	0-13	alcohol	drug	46-52	effect
Antihistamines	group	0-13	CNS depressants	group	64-78	effect
Antihistamines	group	0-13	hypnotics	group	87-95	effect
Antihistamines	group	0-13	sedatives	group	98-106	effect
Antihistamines	group	0-13	tranquilizers	group	109-121	effect
Antihistamines	group	0-13	antianxiety agents	group	124-141	effect
alcohol	drug	46-52	CNS depressants	group	64-78	false
alcohol	drug	46-52	hypnotics	group	87-95	false
alcohol	drug	46-52	sedatives	group	98-106	false
alcohol	drug	46-52	tranquilizers	group	109-121	false
alcohol	drug	46-52	antianxiety agents	group	124-141	false
CNS depressants	group	64-78	hypnotics	group	87-95	false
CNS depressants	group	64-78	sedatives	group	98-106	false
CNS depressants	group	64-78	tranquilizers	group	109-121	false
CNS depressants	group	64-78	antianxiety agents	group	124-141	false
hypnotics	group	87-95	sedatives	group	98-106	false
hypnotics	group	87-95	tranquilizers	group	109-121	false
hypnotics	group	87-95	antianxiety agents	group	124-141	false
sedatives	group	98-106	tranquilizers	group	109-121	false
sedatives	group	98-106	antianxiety agents	group	124-141	false
tranquilizers	group	109-121	antianxiety agents	group	124-141	false

DDI-DrugBank.d34.s0	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).
dorzolamide	drug	94-104	carbonic anhydrase inhibitors	group	155-183	effect
dorzolamide	drug	94-104	salicylate	group	286-295	false
carbonic anhydrase inhibitors	group	155-183	salicylate	group	286-295	false

DDI-DrugBank.d441.s1	Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
linezolid	drug	11-19	adrenergic	group	60-69	int
linezolid	drug	11-19	serotonergic agents	group	75-93	int
adrenergic	group	60-69	serotonergic agents	group	75-93	false

DDI-DrugBank.d441.s2	Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
Adrenergic Agents	group	0-16	ZYVOX	brand	45-49	false
Adrenergic Agents	group	0-16	sympathomimetic agents	group	134-155	false
Adrenergic Agents	group	0-16	vasopressor	group	158-168	false
Adrenergic Agents	group	0-16	dopaminergic agents	group	173-191	false
ZYVOX	brand	45-49	sympathomimetic agents	group	134-155	effect
ZYVOX	brand	45-49	vasopressor	group	158-168	effect
ZYVOX	brand	45-49	dopaminergic agents	group	173-191	effect
sympathomimetic agents	group	134-155	vasopressor	group	158-168	false
sympathomimetic agents	group	134-155	dopaminergic agents	group	173-191	false
vasopressor	group	158-168	dopaminergic agents	group	173-191	false

DDI-DrugBank.d441.s3	Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied.
phenylpropanolamine	drug	28-46	pseudoephedrine	drug	52-66	false

DDI-DrugBank.d441.s4	Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.
adrenergic agents	group	17-33	dopamine	drug	44-51	false
adrenergic agents	group	17-33	epinephrine	drug	56-66	false
dopamine	drug	44-51	epinephrine	drug	56-66	false

DDI-DrugBank.d441.s5	Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.
Serotonergic Agents	group	0-18	linezolid	drug	42-50	false
Serotonergic Agents	group	0-18	serotonergic agents	group	56-74	false
linezolid	drug	42-50	serotonergic agents	group	56-74	false

DDI-DrugBank.d441.s6	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
ZYVOX	brand	79-83	serotonergic agents	group	89-107	effect
ZYVOX	brand	79-83	antidepressants	group	120-134	effect
ZYVOX	brand	79-83	selective serotonin reuptake inhibitors	group	144-182	effect
ZYVOX	brand	79-83	SSRIs	group	185-189	effect
serotonergic agents	group	89-107	antidepressants	group	120-134	false
serotonergic agents	group	89-107	selective serotonin reuptake inhibitors	group	144-182	false
serotonergic agents	group	89-107	SSRIs	group	185-189	false
antidepressants	group	120-134	selective serotonin reuptake inhibitors	group	144-182	false
antidepressants	group	120-134	SSRIs	group	185-189	false
selective serotonin reuptake inhibitors	group	144-182	SSRIs	group	185-189	false

DDI-DrugBank.d441.s7	Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).
ZYVOX	brand	30-34	serotonergic agents	group	52-70	effect

DDI-DrugBank.d441.s8	If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).
ZYVOX	brand	104-108	serotonergic agents	group	125-143	advise

DDI-DrugBank.d530.s0	Non-selective monoamine oxidase (MAO) inhibitors - including phenelzine sulfate, tranylcypromine sulfate and pargyline HC1.
Non-selective monoamine oxidase (MAO) inhibitors	group	0-47	phenelzine sulfate	drug	61-78	false
Non-selective monoamine oxidase (MAO) inhibitors	group	0-47	tranylcypromine sulfate	drug	81-103	false
Non-selective monoamine oxidase (MAO) inhibitors	group	0-47	pargyline	drug	109-117	false
phenelzine sulfate	drug	61-78	tranylcypromine sulfate	drug	81-103	false
phenelzine sulfate	drug	61-78	pargyline	drug	109-117	false
tranylcypromine sulfate	drug	81-103	pargyline	drug	109-117	false

DDI-DrugBank.d530.s1	Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.
L-phenylalanine	drug	19-33	non-selective MAO inhibitors	group	39-66	effect

DDI-DrugBank.d530.s2	Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.
Selegiline	drug	0-9	L-phenylalanine	drug	13-27	false
Selegiline	drug	0-9	selective MAO inhibitor	group	37-59	false
Selegiline	drug	0-9	selegiline	drug	61-70	false
L-phenylalanine	drug	13-27	selective MAO inhibitor	group	37-59	false
L-phenylalanine	drug	13-27	selegiline	drug	61-70	effect
selective MAO inhibitor	group	37-59	selegiline	drug	61-70	false

DDI-DrugBank.d530.s3	Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.
Neuroleptic Drugs	group	0-16	L-phenylalanine	drug	20-34	effect
Neuroleptic Drugs	group	0-16	neuroleptic drugs	group	92-108	false
L-phenylalanine	drug	20-34	neuroleptic drugs	group	92-108	false

DDI-DrugBank.d224.s0	Apraclonidine should not be used in patients receiving MAO inhibitors..
Apraclonidine	drug	0-12	MAO inhibitors	group	55-68	advise

DDI-DrugBank.d224.s1	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
IOPIDINE	brand	130-137	CNS depressants	group	224-238	advise
IOPIDINE	brand	130-137	alcohol	drug	241-247	advise
IOPIDINE	brand	130-137	barbiturates	group	250-261	advise
IOPIDINE	brand	130-137	opiates	group	264-270	advise
IOPIDINE	brand	130-137	sedatives	group	273-281	advise
IOPIDINE	brand	130-137	anesthetics	group	284-294	advise
CNS depressants	group	224-238	alcohol	drug	241-247	false
CNS depressants	group	224-238	barbiturates	group	250-261	false
CNS depressants	group	224-238	opiates	group	264-270	false
CNS depressants	group	224-238	sedatives	group	273-281	false
CNS depressants	group	224-238	anesthetics	group	284-294	false
alcohol	drug	241-247	barbiturates	group	250-261	false
alcohol	drug	241-247	opiates	group	264-270	false
alcohol	drug	241-247	sedatives	group	273-281	false
alcohol	drug	241-247	anesthetics	group	284-294	false
barbiturates	group	250-261	opiates	group	264-270	false
barbiturates	group	250-261	sedatives	group	273-281	false
barbiturates	group	250-261	anesthetics	group	284-294	false
opiates	group	264-270	sedatives	group	273-281	false
opiates	group	264-270	anesthetics	group	284-294	false
sedatives	group	273-281	anesthetics	group	284-294	false

DDI-DrugBank.d224.s2	Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
Tricyclic antidepressants	group	0-24	clonidine	drug	89-97	effect

DDI-DrugBank.d224.s6	An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.
clonidine	drug	82-90	neuroleptic	group	96-106	effect

DDI-DrugBank.d224.s8	Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
apraclonidine	drug	6-18	beta-blockers	group	88-100	advise
apraclonidine	drug	6-18	antihypertensives	group	129-145	advise
apraclonidine	drug	6-18	cardiac glycosides	group	152-169	advise
beta-blockers	group	88-100	antihypertensives	group	129-145	false
beta-blockers	group	88-100	cardiac glycosides	group	152-169	false
antihypertensives	group	129-145	cardiac glycosides	group	152-169	false

DDI-DrugBank.d482.s1	Talk to your doctor if you are taking certain antibiotics such as erythromycin, clarithromycin or azithromycin.
antibiotics	group	46-56	erythromycin	drug	66-77	false
antibiotics	group	46-56	clarithromycin	drug	80-93	false
antibiotics	group	46-56	azithromycin	drug	98-109	false
erythromycin	drug	66-77	clarithromycin	drug	80-93	false
erythromycin	drug	66-77	azithromycin	drug	98-109	false
clarithromycin	drug	80-93	azithromycin	drug	98-109	false

DDI-DrugBank.d482.s3	Caution should be exercised when taking this medicine certain antibiotics, such as erythromycin, clarithromycin, or azithromycin.
antibiotics	group	62-72	erythromycin	drug	83-94	false
antibiotics	group	62-72	clarithromycin	drug	97-110	false
antibiotics	group	62-72	azithromycin	drug	116-127	false
erythromycin	drug	83-94	clarithromycin	drug	97-110	false
erythromycin	drug	83-94	azithromycin	drug	116-127	false
clarithromycin	drug	97-110	azithromycin	drug	116-127	false

DDI-DrugBank.d482.s9	Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.
escitalopram	drug	28-39	non-selective MAO inhibitor	group	59-85	advise

DDI-DrugBank.d482.s10	Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.
MAO inhibitor	group	31-43	escitalopram	drug	61-72	advise

DDI-DrugBank.d482.s14	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
blood thinner	group	63-75	Coumadin	brand	79-86	false
blood thinner	group	63-75	antidepressants	group	95-109	false
blood thinner	group	63-75	metoprolol	drug	111-120	false
blood thinner	group	63-75	antihistamines	group	122-135	false
blood thinner	group	63-75	carbamazepine	drug	137-149	false
blood thinner	group	63-75	Tegretol	brand	152-159	false
blood thinner	group	63-75	cimetidine	drug	162-171	false
blood thinner	group	63-75	Tagamet	brand	174-180	false
blood thinner	group	63-75	estrogens	group	183-191	false
blood thinner	group	63-75	fluoxetine	drug	193-202	false
blood thinner	group	63-75	Prozac	brand	205-210	false
blood thinner	group	63-75	Sporanox	brand	228-235	false
blood thinner	group	63-75	ketoconazole	drug	238-249	false
blood thinner	group	63-75	Nizoral	brand	252-258	false
blood thinner	group	63-75	levodopa	drug	261-268	false
blood thinner	group	63-75	lithium	drug	270-276	false
blood thinner	group	63-75	muscle relaxants	group	278-293	false
Coumadin	brand	79-86	antidepressants	group	95-109	false
Coumadin	brand	79-86	metoprolol	drug	111-120	false
Coumadin	brand	79-86	antihistamines	group	122-135	false
Coumadin	brand	79-86	carbamazepine	drug	137-149	false
Coumadin	brand	79-86	Tegretol	brand	152-159	false
Coumadin	brand	79-86	cimetidine	drug	162-171	false
Coumadin	brand	79-86	Tagamet	brand	174-180	false
Coumadin	brand	79-86	estrogens	group	183-191	false
Coumadin	brand	79-86	fluoxetine	drug	193-202	false
Coumadin	brand	79-86	Prozac	brand	205-210	false
Coumadin	brand	79-86	Sporanox	brand	228-235	false
Coumadin	brand	79-86	ketoconazole	drug	238-249	false
Coumadin	brand	79-86	Nizoral	brand	252-258	false
Coumadin	brand	79-86	levodopa	drug	261-268	false
Coumadin	brand	79-86	lithium	drug	270-276	false
Coumadin	brand	79-86	muscle relaxants	group	278-293	false
antidepressants	group	95-109	metoprolol	drug	111-120	false
antidepressants	group	95-109	antihistamines	group	122-135	false
antidepressants	group	95-109	carbamazepine	drug	137-149	false
antidepressants	group	95-109	Tegretol	brand	152-159	false
antidepressants	group	95-109	cimetidine	drug	162-171	false
antidepressants	group	95-109	Tagamet	brand	174-180	false
antidepressants	group	95-109	estrogens	group	183-191	false
antidepressants	group	95-109	fluoxetine	drug	193-202	false
antidepressants	group	95-109	Prozac	brand	205-210	false
antidepressants	group	95-109	Sporanox	brand	228-235	false
antidepressants	group	95-109	ketoconazole	drug	238-249	false
antidepressants	group	95-109	Nizoral	brand	252-258	false
antidepressants	group	95-109	levodopa	drug	261-268	false
antidepressants	group	95-109	lithium	drug	270-276	false
antidepressants	group	95-109	muscle relaxants	group	278-293	false
metoprolol	drug	111-120	antihistamines	group	122-135	false
metoprolol	drug	111-120	carbamazepine	drug	137-149	false
metoprolol	drug	111-120	Tegretol	brand	152-159	false
metoprolol	drug	111-120	cimetidine	drug	162-171	false
metoprolol	drug	111-120	Tagamet	brand	174-180	false
metoprolol	drug	111-120	estrogens	group	183-191	false
metoprolol	drug	111-120	fluoxetine	drug	193-202	false
metoprolol	drug	111-120	Prozac	brand	205-210	false
metoprolol	drug	111-120	Sporanox	brand	228-235	false
metoprolol	drug	111-120	ketoconazole	drug	238-249	false
metoprolol	drug	111-120	Nizoral	brand	252-258	false
metoprolol	drug	111-120	levodopa	drug	261-268	false
metoprolol	drug	111-120	lithium	drug	270-276	false
metoprolol	drug	111-120	muscle relaxants	group	278-293	false
antihistamines	group	122-135	carbamazepine	drug	137-149	false
antihistamines	group	122-135	Tegretol	brand	152-159	false
antihistamines	group	122-135	cimetidine	drug	162-171	false
antihistamines	group	122-135	Tagamet	brand	174-180	false
antihistamines	group	122-135	estrogens	group	183-191	false
antihistamines	group	122-135	fluoxetine	drug	193-202	false
antihistamines	group	122-135	Prozac	brand	205-210	false
antihistamines	group	122-135	Sporanox	brand	228-235	false
antihistamines	group	122-135	ketoconazole	drug	238-249	false
antihistamines	group	122-135	Nizoral	brand	252-258	false
antihistamines	group	122-135	levodopa	drug	261-268	false
antihistamines	group	122-135	lithium	drug	270-276	false
antihistamines	group	122-135	muscle relaxants	group	278-293	false
carbamazepine	drug	137-149	Tegretol	brand	152-159	false
carbamazepine	drug	137-149	cimetidine	drug	162-171	false
carbamazepine	drug	137-149	Tagamet	brand	174-180	false
carbamazepine	drug	137-149	estrogens	group	183-191	false
carbamazepine	drug	137-149	fluoxetine	drug	193-202	false
carbamazepine	drug	137-149	Prozac	brand	205-210	false
carbamazepine	drug	137-149	Sporanox	brand	228-235	false
carbamazepine	drug	137-149	ketoconazole	drug	238-249	false
carbamazepine	drug	137-149	Nizoral	brand	252-258	false
carbamazepine	drug	137-149	levodopa	drug	261-268	false
carbamazepine	drug	137-149	lithium	drug	270-276	false
carbamazepine	drug	137-149	muscle relaxants	group	278-293	false
Tegretol	brand	152-159	cimetidine	drug	162-171	false
Tegretol	brand	152-159	Tagamet	brand	174-180	false
Tegretol	brand	152-159	estrogens	group	183-191	false
Tegretol	brand	152-159	fluoxetine	drug	193-202	false
Tegretol	brand	152-159	Prozac	brand	205-210	false
Tegretol	brand	152-159	Sporanox	brand	228-235	false
Tegretol	brand	152-159	ketoconazole	drug	238-249	false
Tegretol	brand	152-159	Nizoral	brand	252-258	false
Tegretol	brand	152-159	levodopa	drug	261-268	false
Tegretol	brand	152-159	lithium	drug	270-276	false
Tegretol	brand	152-159	muscle relaxants	group	278-293	false
cimetidine	drug	162-171	Tagamet	brand	174-180	false
cimetidine	drug	162-171	estrogens	group	183-191	false
cimetidine	drug	162-171	fluoxetine	drug	193-202	false
cimetidine	drug	162-171	Prozac	brand	205-210	false
cimetidine	drug	162-171	Sporanox	brand	228-235	false
cimetidine	drug	162-171	ketoconazole	drug	238-249	false
cimetidine	drug	162-171	Nizoral	brand	252-258	false
cimetidine	drug	162-171	levodopa	drug	261-268	false
cimetidine	drug	162-171	lithium	drug	270-276	false
cimetidine	drug	162-171	muscle relaxants	group	278-293	false
Tagamet	brand	174-180	estrogens	group	183-191	false
Tagamet	brand	174-180	fluoxetine	drug	193-202	false
Tagamet	brand	174-180	Prozac	brand	205-210	false
Tagamet	brand	174-180	Sporanox	brand	228-235	false
Tagamet	brand	174-180	ketoconazole	drug	238-249	false
Tagamet	brand	174-180	Nizoral	brand	252-258	false
Tagamet	brand	174-180	levodopa	drug	261-268	false
Tagamet	brand	174-180	lithium	drug	270-276	false
Tagamet	brand	174-180	muscle relaxants	group	278-293	false
estrogens	group	183-191	fluoxetine	drug	193-202	false
estrogens	group	183-191	Prozac	brand	205-210	false
estrogens	group	183-191	Sporanox	brand	228-235	false
estrogens	group	183-191	ketoconazole	drug	238-249	false
estrogens	group	183-191	Nizoral	brand	252-258	false
estrogens	group	183-191	levodopa	drug	261-268	false
estrogens	group	183-191	lithium	drug	270-276	false
estrogens	group	183-191	muscle relaxants	group	278-293	false
fluoxetine	drug	193-202	Prozac	brand	205-210	false
fluoxetine	drug	193-202	Sporanox	brand	228-235	false
fluoxetine	drug	193-202	ketoconazole	drug	238-249	false
fluoxetine	drug	193-202	Nizoral	brand	252-258	false
fluoxetine	drug	193-202	levodopa	drug	261-268	false
fluoxetine	drug	193-202	lithium	drug	270-276	false
fluoxetine	drug	193-202	muscle relaxants	group	278-293	false
Prozac	brand	205-210	Sporanox	brand	228-235	false
Prozac	brand	205-210	ketoconazole	drug	238-249	false
Prozac	brand	205-210	Nizoral	brand	252-258	false
Prozac	brand	205-210	levodopa	drug	261-268	false
Prozac	brand	205-210	lithium	drug	270-276	false
Prozac	brand	205-210	muscle relaxants	group	278-293	false
Sporanox	brand	228-235	ketoconazole	drug	238-249	false
Sporanox	brand	228-235	Nizoral	brand	252-258	false
Sporanox	brand	228-235	levodopa	drug	261-268	false
Sporanox	brand	228-235	lithium	drug	270-276	false
Sporanox	brand	228-235	muscle relaxants	group	278-293	false
ketoconazole	drug	238-249	Nizoral	brand	252-258	false
ketoconazole	drug	238-249	levodopa	drug	261-268	false
ketoconazole	drug	238-249	lithium	drug	270-276	false
ketoconazole	drug	238-249	muscle relaxants	group	278-293	false
Nizoral	brand	252-258	levodopa	drug	261-268	false
Nizoral	brand	252-258	lithium	drug	270-276	false
Nizoral	brand	252-258	muscle relaxants	group	278-293	false
levodopa	drug	261-268	lithium	drug	270-276	false
levodopa	drug	261-268	muscle relaxants	group	278-293	false
lithium	drug	270-276	muscle relaxants	group	278-293	false

DDI-DrugBank.d477.s0	Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.
sympathomimetic amines	group	39-60	monoamine oxidase inhibitors	group	122-149	effect

DDI-DrugBank.d477.s1	DIDREX should not be used concomitantly with other CNS stimulants.
DIDREX	brand	0-5	CNS stimulants	group	51-64	advise

DDI-DrugBank.d477.s2	Amphetamines may decrease the hypotensive effect of antihypertensives.
Amphetamines	group	0-11	antihypertensives	group	52-68	effect

DDI-DrugBank.d477.s3	Amphetamines may enhance the effects of tricyclic antidepressants.
Amphetamines	group	0-11	tricyclic antidepressants	group	40-64	effect

DDI-DrugBank.d477.s5	Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.
Urinary acidifying	drug	0-17	amphetamines	group	74-85	mechanism

DDI-DrugBank.d239.s2	The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
Natrecor	brand	25-32	vasodilators	group	42-53	false
Natrecor	brand	25-32	nitroglycerin	drug	63-75	false
Natrecor	brand	25-32	nitroprusside	drug	78-90	false
Natrecor	brand	25-32	milrinone	drug	93-101	false
Natrecor	brand	25-32	ACE inhibitors	group	110-123	false
Natrecor	brand	25-32	Natrecor	brand	191-198	false
vasodilators	group	42-53	nitroglycerin	drug	63-75	false
vasodilators	group	42-53	nitroprusside	drug	78-90	false
vasodilators	group	42-53	milrinone	drug	93-101	false
vasodilators	group	42-53	ACE inhibitors	group	110-123	false
vasodilators	group	42-53	Natrecor	brand	191-198	false
nitroglycerin	drug	63-75	nitroprusside	drug	78-90	false
nitroglycerin	drug	63-75	milrinone	drug	93-101	false
nitroglycerin	drug	63-75	ACE inhibitors	group	110-123	false
nitroglycerin	drug	63-75	Natrecor	brand	191-198	false
nitroprusside	drug	78-90	milrinone	drug	93-101	false
nitroprusside	drug	78-90	ACE inhibitors	group	110-123	false
nitroprusside	drug	78-90	Natrecor	brand	191-198	false
milrinone	drug	93-101	ACE inhibitors	group	110-123	false
milrinone	drug	93-101	Natrecor	brand	191-198	false
ACE inhibitors	group	110-123	Natrecor	brand	191-198	false

DDI-DrugBank.d33.s0	Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
Cefizox	brand	51-57	cephalosporins	group	139-152	false
Cefizox	brand	51-57	aminoglycosides	group	158-172	false
cephalosporins	group	139-152	aminoglycosides	group	158-172	effect

DDI-DrugBank.d46.s1	- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur
Alcohol	drug	2-8	barbiturates	group	11-22	false
Alcohol	drug	2-8	narcotics	group	28-36	false
barbiturates	group	11-22	narcotics	group	28-36	false

DDI-DrugBank.d46.s3	- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required
Antidiabetic drugs	group	2-19	insulin	drug	39-45	false
Antidiabetic drugs	group	2-19	antidiabetic drug	group	73-89	false
insulin	drug	39-45	antidiabetic drug	group	73-89	false

DDI-DrugBank.d46.s7	- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
Cholestyramine	drug	2-15	colestipol	drug	21-30	false
Cholestyramine	drug	2-15	resins	group	32-37	false
Cholestyramine	drug	2-15	Cholestytamine	drug	40-53	false
Cholestyramine	drug	2-15	colestipol	drug	59-68	false
Cholestyramine	drug	2-15	resins	group	70-75	false
Cholestyramine	drug	2-15	thiazide diuretics	group	107-124	false
Cholestyramine	drug	2-15	diuretic	group	139-146	false
colestipol	drug	21-30	resins	group	32-37	false
colestipol	drug	21-30	Cholestytamine	drug	40-53	false
colestipol	drug	21-30	colestipol	drug	59-68	false
colestipol	drug	21-30	resins	group	70-75	false
colestipol	drug	21-30	thiazide diuretics	group	107-124	false
colestipol	drug	21-30	diuretic	group	139-146	false
resins	group	32-37	Cholestytamine	drug	40-53	false
resins	group	32-37	colestipol	drug	59-68	false
resins	group	32-37	resins	group	70-75	false
resins	group	32-37	thiazide diuretics	group	107-124	false
resins	group	32-37	diuretic	group	139-146	false
Cholestytamine	drug	40-53	colestipol	drug	59-68	false
Cholestytamine	drug	40-53	resins	group	70-75	false
Cholestytamine	drug	40-53	thiazide diuretics	group	107-124	mechanism
Cholestytamine	drug	40-53	diuretic	group	139-146	false
colestipol	drug	59-68	resins	group	70-75	false
colestipol	drug	59-68	thiazide diuretics	group	107-124	mechanism
colestipol	drug	59-68	diuretic	group	139-146	false
resins	group	70-75	thiazide diuretics	group	107-124	false
resins	group	70-75	diuretic	group	139-146	false
thiazide diuretics	group	107-124	diuretic	group	139-146	false

DDI-DrugBank.d46.s9	- Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia
Corticosteroids	group	2-16	ACTH	drug	19-22	false

DDI-DrugBank.d46.s13	- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant
Skeletal muscle relaxants	group	2-26	tubocurarine	drug	52-63	false
Skeletal muscle relaxants	group	2-26	muscle relaxant	group	108-122	false
tubocurarine	drug	52-63	muscle relaxant	group	108-122	false

DDI-DrugBank.d46.s15	- Lithium: Generally should not be given with diuretics.
Lithium	drug	2-8	diuretics	group	46-54	advise

DDI-DrugBank.d46.s16	Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
Diuretic agents	group	0-14	lithium	drug	46-52	mechanism
Diuretic agents	group	0-14	lithium	drug	77-83	mechanism
lithium	drug	46-52	lithium	drug	77-83	false

DDI-DrugBank.d46.s17	Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide
lithium	drug	32-38	chlorothiazide	drug	90-103	advise

DDI-DrugBank.d46.s19	- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
Non-steroidal Anti-inflammatory Drugs	group	2-38	non-steroidal anti-inflammatory agent	group	83-119	false
Non-steroidal Anti-inflammatory Drugs	group	2-38	loop diuretics	group	191-194;228-236	false
Non-steroidal Anti-inflammatory Drugs	group	2-38	potassium-sparing diuretics	group	197-213;228-236	false
Non-steroidal Anti-inflammatory Drugs	group	2-38	thiazide diuretics	drug	219-236	false
non-steroidal anti-inflammatory agent	group	83-119	loop diuretics	group	191-194;228-236	effect
non-steroidal anti-inflammatory agent	group	83-119	potassium-sparing diuretics	group	197-213;228-236	effect
non-steroidal anti-inflammatory agent	group	83-119	thiazide diuretics	drug	219-236	effect
loop diuretics	group	191-194;228-236	potassium-sparing diuretics	group	197-213;228-236	false
loop diuretics	group	191-194;228-236	thiazide diuretics	drug	219-236	false
potassium-sparing diuretics	group	197-213;228-236	thiazide diuretics	drug	219-236	false

DDI-DrugBank.d46.s20	Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained
chlorothiazide	drug	16-29	non-steroidal anti-inflammatory agents	group	35-72	advise
chlorothiazide	drug	16-29	diuretic	group	179-186	false
non-steroidal anti-inflammatory agents	group	35-72	diuretic	group	179-186	false

DDI-DrugBank.d502.s0	Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.
Ocupress	brand	0-7	beta-adrenergic blocking agent	group	69-98	advise

DDI-DrugBank.d502.s1	Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
beta-blocker	group	55-66	reserpine	drug	144-152	advise

DDI-DrugBank.d48.s0	Drugs that may increase dasatinib plasma concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate.
dasatinib	drug	24-32	Dasatinib	drug	75-83	false

DDI-DrugBank.d48.s1	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
SPRYCEL	brand	19-25	ketoconazole	drug	62-73	mechanism
SPRYCEL	brand	19-25	itraconazole	drug	76-87	mechanism
SPRYCEL	brand	19-25	erythromycin	drug	90-101	mechanism
SPRYCEL	brand	19-25	clarithromycin	drug	104-117	mechanism
SPRYCEL	brand	19-25	ritonavir	drug	120-128	mechanism
SPRYCEL	brand	19-25	atazanavir	drug	131-140	mechanism
SPRYCEL	brand	19-25	indinavir	drug	143-151	mechanism
SPRYCEL	brand	19-25	nefazodone	drug	154-163	mechanism
SPRYCEL	brand	19-25	nelfinavir	drug	166-175	mechanism
SPRYCEL	brand	19-25	saquinavir	drug	178-187	mechanism
SPRYCEL	brand	19-25	telithromycin	drug	190-202	mechanism
SPRYCEL	brand	19-25	dasatinib	drug	230-238	false
ketoconazole	drug	62-73	itraconazole	drug	76-87	false
ketoconazole	drug	62-73	erythromycin	drug	90-101	false
ketoconazole	drug	62-73	clarithromycin	drug	104-117	false
ketoconazole	drug	62-73	ritonavir	drug	120-128	false
ketoconazole	drug	62-73	atazanavir	drug	131-140	false
ketoconazole	drug	62-73	indinavir	drug	143-151	false
ketoconazole	drug	62-73	nefazodone	drug	154-163	false
ketoconazole	drug	62-73	nelfinavir	drug	166-175	false
ketoconazole	drug	62-73	saquinavir	drug	178-187	false
ketoconazole	drug	62-73	telithromycin	drug	190-202	false
ketoconazole	drug	62-73	dasatinib	drug	230-238	false
itraconazole	drug	76-87	erythromycin	drug	90-101	false
itraconazole	drug	76-87	clarithromycin	drug	104-117	false
itraconazole	drug	76-87	ritonavir	drug	120-128	false
itraconazole	drug	76-87	atazanavir	drug	131-140	false
itraconazole	drug	76-87	indinavir	drug	143-151	false
itraconazole	drug	76-87	nefazodone	drug	154-163	false
itraconazole	drug	76-87	nelfinavir	drug	166-175	false
itraconazole	drug	76-87	saquinavir	drug	178-187	false
itraconazole	drug	76-87	telithromycin	drug	190-202	false
itraconazole	drug	76-87	dasatinib	drug	230-238	false
erythromycin	drug	90-101	clarithromycin	drug	104-117	false
erythromycin	drug	90-101	ritonavir	drug	120-128	false
erythromycin	drug	90-101	atazanavir	drug	131-140	false
erythromycin	drug	90-101	indinavir	drug	143-151	false
erythromycin	drug	90-101	nefazodone	drug	154-163	false
erythromycin	drug	90-101	nelfinavir	drug	166-175	false
erythromycin	drug	90-101	saquinavir	drug	178-187	false
erythromycin	drug	90-101	telithromycin	drug	190-202	false
erythromycin	drug	90-101	dasatinib	drug	230-238	false
clarithromycin	drug	104-117	ritonavir	drug	120-128	false
clarithromycin	drug	104-117	atazanavir	drug	131-140	false
clarithromycin	drug	104-117	indinavir	drug	143-151	false
clarithromycin	drug	104-117	nefazodone	drug	154-163	false
clarithromycin	drug	104-117	nelfinavir	drug	166-175	false
clarithromycin	drug	104-117	saquinavir	drug	178-187	false
clarithromycin	drug	104-117	telithromycin	drug	190-202	false
clarithromycin	drug	104-117	dasatinib	drug	230-238	false
ritonavir	drug	120-128	atazanavir	drug	131-140	false
ritonavir	drug	120-128	indinavir	drug	143-151	false
ritonavir	drug	120-128	nefazodone	drug	154-163	false
ritonavir	drug	120-128	nelfinavir	drug	166-175	false
ritonavir	drug	120-128	saquinavir	drug	178-187	false
ritonavir	drug	120-128	telithromycin	drug	190-202	false
ritonavir	drug	120-128	dasatinib	drug	230-238	false
atazanavir	drug	131-140	indinavir	drug	143-151	false
atazanavir	drug	131-140	nefazodone	drug	154-163	false
atazanavir	drug	131-140	nelfinavir	drug	166-175	false
atazanavir	drug	131-140	saquinavir	drug	178-187	false
atazanavir	drug	131-140	telithromycin	drug	190-202	false
atazanavir	drug	131-140	dasatinib	drug	230-238	false
indinavir	drug	143-151	nefazodone	drug	154-163	false
indinavir	drug	143-151	nelfinavir	drug	166-175	false
indinavir	drug	143-151	saquinavir	drug	178-187	false
indinavir	drug	143-151	telithromycin	drug	190-202	false
indinavir	drug	143-151	dasatinib	drug	230-238	false
nefazodone	drug	154-163	nelfinavir	drug	166-175	false
nefazodone	drug	154-163	saquinavir	drug	178-187	false
nefazodone	drug	154-163	telithromycin	drug	190-202	false
nefazodone	drug	154-163	dasatinib	drug	230-238	false
nelfinavir	drug	166-175	saquinavir	drug	178-187	false
nelfinavir	drug	166-175	telithromycin	drug	190-202	false
nelfinavir	drug	166-175	dasatinib	drug	230-238	false
saquinavir	drug	178-187	telithromycin	drug	190-202	false
saquinavir	drug	178-187	dasatinib	drug	230-238	false
telithromycin	drug	190-202	dasatinib	drug	230-238	false

DDI-DrugBank.d48.s2	In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.
SPRYCEL	brand	37-43	SPRYCEL	brand	82-88	false

DDI-DrugBank.d48.s3	Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.
dasatinib	drug	24-32	dasatinib	drug	120-128	false

DDI-DrugBank.d48.s4	In patients in whom CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital) are indicated, alternative agents with less enzyme induction potential should be used.
dexamethasone	drug	41-53	phenytoin	drug	56-64	false
dexamethasone	drug	41-53	carbamazepine	drug	67-79	false
dexamethasone	drug	41-53	rifampicin	drug	82-91	false
dexamethasone	drug	41-53	phenobarbital	drug	94-106	false
phenytoin	drug	56-64	carbamazepine	drug	67-79	false
phenytoin	drug	56-64	rifampicin	drug	82-91	false
phenytoin	drug	56-64	phenobarbital	drug	94-106	false
carbamazepine	drug	67-79	rifampicin	drug	82-91	false
carbamazepine	drug	67-79	phenobarbital	drug	94-106	false
rifampicin	drug	82-91	phenobarbital	drug	94-106	false

DDI-DrugBank.d48.s5	If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered.
SPRYCEL	brand	3-9	SPRYCEL	brand	74-80	false

DDI-DrugBank.d48.s8	Antacids: Nonclinical data demonstrate that the solubility of dasatinib is pH dependent.
Antacids	group	0-7	dasatinib	drug	62-70	false

DDI-DrugBank.d48.s9	Simultaneous administration of SPRYCEL with antacids should be avoided.
SPRYCEL	brand	31-37	antacids	group	44-51	advise

DDI-DrugBank.d48.s10	If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.
antacid	group	3-9	SPRYCEL	brand	125-131	advise

DDI-DrugBank.d48.s11	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
H2 Blockers	group	0-10	Proton Pump Inhibitors	group	12-33	false
H2 Blockers	group	0-10	H2 blockers	group	87-97	false
H2 Blockers	group	0-10	proton pump inhibitors	group	102-123	false
H2 Blockers	group	0-10	famotidine	drug	130-139	false
H2 Blockers	group	0-10	omeprazole	drug	145-154	false
H2 Blockers	group	0-10	dasatinib	drug	177-185	false
Proton Pump Inhibitors	group	12-33	H2 blockers	group	87-97	false
Proton Pump Inhibitors	group	12-33	proton pump inhibitors	group	102-123	false
Proton Pump Inhibitors	group	12-33	famotidine	drug	130-139	false
Proton Pump Inhibitors	group	12-33	omeprazole	drug	145-154	false
Proton Pump Inhibitors	group	12-33	dasatinib	drug	177-185	false
H2 blockers	group	87-97	proton pump inhibitors	group	102-123	false
H2 blockers	group	87-97	famotidine	drug	130-139	false
H2 blockers	group	87-97	omeprazole	drug	145-154	false
H2 blockers	group	87-97	dasatinib	drug	177-185	effect
proton pump inhibitors	group	102-123	famotidine	drug	130-139	false
proton pump inhibitors	group	102-123	omeprazole	drug	145-154	false
proton pump inhibitors	group	102-123	dasatinib	drug	177-185	effect
famotidine	drug	130-139	omeprazole	drug	145-154	false
famotidine	drug	130-139	dasatinib	drug	177-185	effect
omeprazole	drug	145-154	dasatinib	drug	177-185	effect

DDI-DrugBank.d48.s12	The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
H2 blockers	group	23-33	proton pump inhibitors	group	38-59	false
H2 blockers	group	23-33	SPRYCEL	brand	66-72	advise
proton pump inhibitors	group	38-59	SPRYCEL	brand	66-72	advise

DDI-DrugBank.d48.s13	The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
antacids	group	11-18	H2 blockers	group	53-63	false
antacids	group	11-18	proton pump inhibitors	group	68-89	false
antacids	group	11-18	SPRYCEL	brand	113-119	false
H2 blockers	group	53-63	proton pump inhibitors	group	68-89	false
H2 blockers	group	53-63	SPRYCEL	brand	113-119	advise
proton pump inhibitors	group	68-89	SPRYCEL	brand	113-119	advise

DDI-DrugBank.d48.s14	Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4.
dasatinib	drug	58-66	Dasatinib	drug	87-95	false

DDI-DrugBank.d48.s15	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
alfentanil	drug	78-87	astemizole	drug	90-99	false
alfentanil	drug	78-87	terfenadine	drug	102-112	false
alfentanil	drug	78-87	cisapride	drug	115-123	false
alfentanil	drug	78-87	cyclosporine	drug	126-137	false
alfentanil	drug	78-87	fentanyl	drug	140-147	false
alfentanil	drug	78-87	pimozide	drug	150-157	false
alfentanil	drug	78-87	quinidine	drug	160-168	false
alfentanil	drug	78-87	sirolimus	drug	171-179	false
alfentanil	drug	78-87	tacrolimus	drug	182-191	false
alfentanil	drug	78-87	ergot alkaloids	group	197-211	false
alfentanil	drug	78-87	ergotamine	drug	214-223	false
alfentanil	drug	78-87	dihydroergotamine	drug	226-242	false
alfentanil	drug	78-87	SPRYCEL	brand	303-309	advise
astemizole	drug	90-99	terfenadine	drug	102-112	false
astemizole	drug	90-99	cisapride	drug	115-123	false
astemizole	drug	90-99	cyclosporine	drug	126-137	false
astemizole	drug	90-99	fentanyl	drug	140-147	false
astemizole	drug	90-99	pimozide	drug	150-157	false
astemizole	drug	90-99	quinidine	drug	160-168	false
astemizole	drug	90-99	sirolimus	drug	171-179	false
astemizole	drug	90-99	tacrolimus	drug	182-191	false
astemizole	drug	90-99	ergot alkaloids	group	197-211	false
astemizole	drug	90-99	ergotamine	drug	214-223	false
astemizole	drug	90-99	dihydroergotamine	drug	226-242	false
astemizole	drug	90-99	SPRYCEL	brand	303-309	advise
terfenadine	drug	102-112	cisapride	drug	115-123	false
terfenadine	drug	102-112	cyclosporine	drug	126-137	false
terfenadine	drug	102-112	fentanyl	drug	140-147	false
terfenadine	drug	102-112	pimozide	drug	150-157	false
terfenadine	drug	102-112	quinidine	drug	160-168	false
terfenadine	drug	102-112	sirolimus	drug	171-179	false
terfenadine	drug	102-112	tacrolimus	drug	182-191	false
terfenadine	drug	102-112	ergot alkaloids	group	197-211	false
terfenadine	drug	102-112	ergotamine	drug	214-223	false
terfenadine	drug	102-112	dihydroergotamine	drug	226-242	false
terfenadine	drug	102-112	SPRYCEL	brand	303-309	advise
cisapride	drug	115-123	cyclosporine	drug	126-137	false
cisapride	drug	115-123	fentanyl	drug	140-147	false
cisapride	drug	115-123	pimozide	drug	150-157	false
cisapride	drug	115-123	quinidine	drug	160-168	false
cisapride	drug	115-123	sirolimus	drug	171-179	false
cisapride	drug	115-123	tacrolimus	drug	182-191	false
cisapride	drug	115-123	ergot alkaloids	group	197-211	false
cisapride	drug	115-123	ergotamine	drug	214-223	false
cisapride	drug	115-123	dihydroergotamine	drug	226-242	false
cisapride	drug	115-123	SPRYCEL	brand	303-309	advise
cyclosporine	drug	126-137	fentanyl	drug	140-147	false
cyclosporine	drug	126-137	pimozide	drug	150-157	false
cyclosporine	drug	126-137	quinidine	drug	160-168	false
cyclosporine	drug	126-137	sirolimus	drug	171-179	false
cyclosporine	drug	126-137	tacrolimus	drug	182-191	false
cyclosporine	drug	126-137	ergot alkaloids	group	197-211	false
cyclosporine	drug	126-137	ergotamine	drug	214-223	false
cyclosporine	drug	126-137	dihydroergotamine	drug	226-242	false
cyclosporine	drug	126-137	SPRYCEL	brand	303-309	advise
fentanyl	drug	140-147	pimozide	drug	150-157	false
fentanyl	drug	140-147	quinidine	drug	160-168	false
fentanyl	drug	140-147	sirolimus	drug	171-179	false
fentanyl	drug	140-147	tacrolimus	drug	182-191	false
fentanyl	drug	140-147	ergot alkaloids	group	197-211	false
fentanyl	drug	140-147	ergotamine	drug	214-223	false
fentanyl	drug	140-147	dihydroergotamine	drug	226-242	false
fentanyl	drug	140-147	SPRYCEL	brand	303-309	advise
pimozide	drug	150-157	quinidine	drug	160-168	false
pimozide	drug	150-157	sirolimus	drug	171-179	false
pimozide	drug	150-157	tacrolimus	drug	182-191	false
pimozide	drug	150-157	ergot alkaloids	group	197-211	false
pimozide	drug	150-157	ergotamine	drug	214-223	false
pimozide	drug	150-157	dihydroergotamine	drug	226-242	false
pimozide	drug	150-157	SPRYCEL	brand	303-309	advise
quinidine	drug	160-168	sirolimus	drug	171-179	false
quinidine	drug	160-168	tacrolimus	drug	182-191	false
quinidine	drug	160-168	ergot alkaloids	group	197-211	false
quinidine	drug	160-168	ergotamine	drug	214-223	false
quinidine	drug	160-168	dihydroergotamine	drug	226-242	false
quinidine	drug	160-168	SPRYCEL	brand	303-309	advise
sirolimus	drug	171-179	tacrolimus	drug	182-191	false
sirolimus	drug	171-179	ergot alkaloids	group	197-211	false
sirolimus	drug	171-179	ergotamine	drug	214-223	false
sirolimus	drug	171-179	dihydroergotamine	drug	226-242	false
sirolimus	drug	171-179	SPRYCEL	brand	303-309	advise
tacrolimus	drug	182-191	ergot alkaloids	group	197-211	false
tacrolimus	drug	182-191	ergotamine	drug	214-223	false
tacrolimus	drug	182-191	dihydroergotamine	drug	226-242	false
tacrolimus	drug	182-191	SPRYCEL	brand	303-309	advise
ergot alkaloids	group	197-211	ergotamine	drug	214-223	false
ergot alkaloids	group	197-211	dihydroergotamine	drug	226-242	false
ergot alkaloids	group	197-211	SPRYCEL	brand	303-309	advise
ergotamine	drug	214-223	dihydroergotamine	drug	226-242	false
ergotamine	drug	214-223	SPRYCEL	brand	303-309	advise
dihydroergotamine	drug	226-242	SPRYCEL	brand	303-309	advise

DDI-DrugBank.d297.s1	Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.
MTX	drug	50-52	NSAIDs	group	55-60	false
MTX	drug	50-52	corticosteroids	group	63-77	false
MTX	drug	50-52	TNF blocking agents	group	84-102	false
MTX	drug	50-52	abatacept	drug	122-130	false
NSAIDs	group	55-60	corticosteroids	group	63-77	false
NSAIDs	group	55-60	TNF blocking agents	group	84-102	false
NSAIDs	group	55-60	abatacept	drug	122-130	false
corticosteroids	group	63-77	TNF blocking agents	group	84-102	false
corticosteroids	group	63-77	abatacept	drug	122-130	false
TNF blocking agents	group	84-102	abatacept	drug	122-130	false

DDI-DrugBank.d297.s2	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
ORENCIA	brand	115-121	MTX	drug	124-126	false
ORENCIA	brand	115-121	NSAIDs	group	129-134	false
ORENCIA	brand	115-121	corticosteroids	group	137-151	false
ORENCIA	brand	115-121	TNF blocking agents	group	154-172	false
ORENCIA	brand	115-121	azathioprine	drug	175-186	false
ORENCIA	brand	115-121	chloroquine	drug	189-199	false
ORENCIA	brand	115-121	gold	drug	202-205	false
ORENCIA	brand	115-121	hydroxychloroquine	drug	208-225	false
ORENCIA	brand	115-121	leflunomide	drug	228-238	false
ORENCIA	brand	115-121	sulfasalazine	drug	241-253	false
ORENCIA	brand	115-121	anakinra	drug	260-267	false
MTX	drug	124-126	NSAIDs	group	129-134	false
MTX	drug	124-126	corticosteroids	group	137-151	false
MTX	drug	124-126	TNF blocking agents	group	154-172	false
MTX	drug	124-126	azathioprine	drug	175-186	false
MTX	drug	124-126	chloroquine	drug	189-199	false
MTX	drug	124-126	gold	drug	202-205	false
MTX	drug	124-126	hydroxychloroquine	drug	208-225	false
MTX	drug	124-126	leflunomide	drug	228-238	false
MTX	drug	124-126	sulfasalazine	drug	241-253	false
MTX	drug	124-126	anakinra	drug	260-267	false
NSAIDs	group	129-134	corticosteroids	group	137-151	false
NSAIDs	group	129-134	TNF blocking agents	group	154-172	false
NSAIDs	group	129-134	azathioprine	drug	175-186	false
NSAIDs	group	129-134	chloroquine	drug	189-199	false
NSAIDs	group	129-134	gold	drug	202-205	false
NSAIDs	group	129-134	hydroxychloroquine	drug	208-225	false
NSAIDs	group	129-134	leflunomide	drug	228-238	false
NSAIDs	group	129-134	sulfasalazine	drug	241-253	false
NSAIDs	group	129-134	anakinra	drug	260-267	false
corticosteroids	group	137-151	TNF blocking agents	group	154-172	false
corticosteroids	group	137-151	azathioprine	drug	175-186	false
corticosteroids	group	137-151	chloroquine	drug	189-199	false
corticosteroids	group	137-151	gold	drug	202-205	false
corticosteroids	group	137-151	hydroxychloroquine	drug	208-225	false
corticosteroids	group	137-151	leflunomide	drug	228-238	false
corticosteroids	group	137-151	sulfasalazine	drug	241-253	false
corticosteroids	group	137-151	anakinra	drug	260-267	false
TNF blocking agents	group	154-172	azathioprine	drug	175-186	false
TNF blocking agents	group	154-172	chloroquine	drug	189-199	false
TNF blocking agents	group	154-172	gold	drug	202-205	false
TNF blocking agents	group	154-172	hydroxychloroquine	drug	208-225	false
TNF blocking agents	group	154-172	leflunomide	drug	228-238	false
TNF blocking agents	group	154-172	sulfasalazine	drug	241-253	false
TNF blocking agents	group	154-172	anakinra	drug	260-267	false
azathioprine	drug	175-186	chloroquine	drug	189-199	false
azathioprine	drug	175-186	gold	drug	202-205	false
azathioprine	drug	175-186	hydroxychloroquine	drug	208-225	false
azathioprine	drug	175-186	leflunomide	drug	228-238	false
azathioprine	drug	175-186	sulfasalazine	drug	241-253	false
azathioprine	drug	175-186	anakinra	drug	260-267	false
chloroquine	drug	189-199	gold	drug	202-205	false
chloroquine	drug	189-199	hydroxychloroquine	drug	208-225	false
chloroquine	drug	189-199	leflunomide	drug	228-238	false
chloroquine	drug	189-199	sulfasalazine	drug	241-253	false
chloroquine	drug	189-199	anakinra	drug	260-267	false
gold	drug	202-205	hydroxychloroquine	drug	208-225	false
gold	drug	202-205	leflunomide	drug	228-238	false
gold	drug	202-205	sulfasalazine	drug	241-253	false
gold	drug	202-205	anakinra	drug	260-267	false
hydroxychloroquine	drug	208-225	leflunomide	drug	228-238	false
hydroxychloroquine	drug	208-225	sulfasalazine	drug	241-253	false
hydroxychloroquine	drug	208-225	anakinra	drug	260-267	false
leflunomide	drug	228-238	sulfasalazine	drug	241-253	false
leflunomide	drug	228-238	anakinra	drug	260-267	false
sulfasalazine	drug	241-253	anakinra	drug	260-267	false

DDI-DrugBank.d297.s3	Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.
TNF antagonist	group	31-44	ORENCIA	brand	51-57	effect
TNF antagonist	group	31-44	TNF antagonists	group	179-193	false
ORENCIA	brand	51-57	TNF antagonists	group	179-193	false

DDI-DrugBank.d297.s4	Concurrent therapy with ORENCIA and TNF antagonists is not recommended.
ORENCIA	brand	24-30	TNF antagonists	group	36-50	advise

DDI-DrugBank.d297.s5	There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.
ORENCIA	brand	70-76	anakinra	drug	109-116	advise

DDI-DrugBank.d313.s1	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
antidiabetic products	group	134-154	ACE inhibitors	group	157-170	false
antidiabetic products	group	134-154	disopyramide	drug	173-184	false
antidiabetic products	group	134-154	fibrates	group	187-194	false
antidiabetic products	group	134-154	fluoxetine	drug	197-206	false
antidiabetic products	group	134-154	monoamine oxidase (MAO) inhibitors	group	209-242	false
antidiabetic products	group	134-154	propoxyphene	drug	245-256	false
antidiabetic products	group	134-154	salicylates	group	259-269	false
antidiabetic products	group	134-154	somatostatin analog	group	272-290	false
antidiabetic products	group	134-154	octreotide	drug	299-308	false
antidiabetic products	group	134-154	sulfonamide antibiotics	group	312-334	false
ACE inhibitors	group	157-170	disopyramide	drug	173-184	false
ACE inhibitors	group	157-170	fibrates	group	187-194	false
ACE inhibitors	group	157-170	fluoxetine	drug	197-206	false
ACE inhibitors	group	157-170	monoamine oxidase (MAO) inhibitors	group	209-242	false
ACE inhibitors	group	157-170	propoxyphene	drug	245-256	false
ACE inhibitors	group	157-170	salicylates	group	259-269	false
ACE inhibitors	group	157-170	somatostatin analog	group	272-290	false
ACE inhibitors	group	157-170	octreotide	drug	299-308	false
ACE inhibitors	group	157-170	sulfonamide antibiotics	group	312-334	false
disopyramide	drug	173-184	fibrates	group	187-194	false
disopyramide	drug	173-184	fluoxetine	drug	197-206	false
disopyramide	drug	173-184	monoamine oxidase (MAO) inhibitors	group	209-242	false
disopyramide	drug	173-184	propoxyphene	drug	245-256	false
disopyramide	drug	173-184	salicylates	group	259-269	false
disopyramide	drug	173-184	somatostatin analog	group	272-290	false
disopyramide	drug	173-184	octreotide	drug	299-308	false
disopyramide	drug	173-184	sulfonamide antibiotics	group	312-334	false
fibrates	group	187-194	fluoxetine	drug	197-206	false
fibrates	group	187-194	monoamine oxidase (MAO) inhibitors	group	209-242	false
fibrates	group	187-194	propoxyphene	drug	245-256	false
fibrates	group	187-194	salicylates	group	259-269	false
fibrates	group	187-194	somatostatin analog	group	272-290	false
fibrates	group	187-194	octreotide	drug	299-308	false
fibrates	group	187-194	sulfonamide antibiotics	group	312-334	false
fluoxetine	drug	197-206	monoamine oxidase (MAO) inhibitors	group	209-242	false
fluoxetine	drug	197-206	propoxyphene	drug	245-256	false
fluoxetine	drug	197-206	salicylates	group	259-269	false
fluoxetine	drug	197-206	somatostatin analog	group	272-290	false
fluoxetine	drug	197-206	octreotide	drug	299-308	false
fluoxetine	drug	197-206	sulfonamide antibiotics	group	312-334	false
monoamine oxidase (MAO) inhibitors	group	209-242	propoxyphene	drug	245-256	false
monoamine oxidase (MAO) inhibitors	group	209-242	salicylates	group	259-269	false
monoamine oxidase (MAO) inhibitors	group	209-242	somatostatin analog	group	272-290	false
monoamine oxidase (MAO) inhibitors	group	209-242	octreotide	drug	299-308	false
monoamine oxidase (MAO) inhibitors	group	209-242	sulfonamide antibiotics	group	312-334	false
propoxyphene	drug	245-256	salicylates	group	259-269	false
propoxyphene	drug	245-256	somatostatin analog	group	272-290	false
propoxyphene	drug	245-256	octreotide	drug	299-308	false
propoxyphene	drug	245-256	sulfonamide antibiotics	group	312-334	false
salicylates	group	259-269	somatostatin analog	group	272-290	false
salicylates	group	259-269	octreotide	drug	299-308	false
salicylates	group	259-269	sulfonamide antibiotics	group	312-334	false
somatostatin analog	group	272-290	octreotide	drug	299-308	false
somatostatin analog	group	272-290	sulfonamide antibiotics	group	312-334	false
octreotide	drug	299-308	sulfonamide antibiotics	group	312-334	false

DDI-DrugBank.d313.s2	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
corticosteroids	group	92-106	niacin	drug	109-114	false
corticosteroids	group	92-106	danazol	drug	117-123	false
corticosteroids	group	92-106	diuretics	group	126-134	false
corticosteroids	group	92-106	sympathomimetic agents	group	137-158	false
corticosteroids	group	92-106	epinephrine	drug	167-177	false
corticosteroids	group	92-106	salbutamol	drug	180-189	false
corticosteroids	group	92-106	terbutaline	drug	192-202	false
corticosteroids	group	92-106	isoniazid	drug	206-214	false
corticosteroids	group	92-106	phenothiazine derivatives	group	217-241	false
corticosteroids	group	92-106	somatropin	drug	244-253	false
corticosteroids	group	92-106	thyroid hormones	group	256-271	false
corticosteroids	group	92-106	estrogens	group	274-282	false
corticosteroids	group	92-106	progestogens	group	285-296	false
corticosteroids	group	92-106	contraceptives	group	313-326	false
niacin	drug	109-114	danazol	drug	117-123	false
niacin	drug	109-114	diuretics	group	126-134	false
niacin	drug	109-114	sympathomimetic agents	group	137-158	false
niacin	drug	109-114	epinephrine	drug	167-177	false
niacin	drug	109-114	salbutamol	drug	180-189	false
niacin	drug	109-114	terbutaline	drug	192-202	false
niacin	drug	109-114	isoniazid	drug	206-214	false
niacin	drug	109-114	phenothiazine derivatives	group	217-241	false
niacin	drug	109-114	somatropin	drug	244-253	false
niacin	drug	109-114	thyroid hormones	group	256-271	false
niacin	drug	109-114	estrogens	group	274-282	false
niacin	drug	109-114	progestogens	group	285-296	false
niacin	drug	109-114	contraceptives	group	313-326	false
danazol	drug	117-123	diuretics	group	126-134	false
danazol	drug	117-123	sympathomimetic agents	group	137-158	false
danazol	drug	117-123	epinephrine	drug	167-177	false
danazol	drug	117-123	salbutamol	drug	180-189	false
danazol	drug	117-123	terbutaline	drug	192-202	false
danazol	drug	117-123	isoniazid	drug	206-214	false
danazol	drug	117-123	phenothiazine derivatives	group	217-241	false
danazol	drug	117-123	somatropin	drug	244-253	false
danazol	drug	117-123	thyroid hormones	group	256-271	false
danazol	drug	117-123	estrogens	group	274-282	false
danazol	drug	117-123	progestogens	group	285-296	false
danazol	drug	117-123	contraceptives	group	313-326	false
diuretics	group	126-134	sympathomimetic agents	group	137-158	false
diuretics	group	126-134	epinephrine	drug	167-177	false
diuretics	group	126-134	salbutamol	drug	180-189	false
diuretics	group	126-134	terbutaline	drug	192-202	false
diuretics	group	126-134	isoniazid	drug	206-214	false
diuretics	group	126-134	phenothiazine derivatives	group	217-241	false
diuretics	group	126-134	somatropin	drug	244-253	false
diuretics	group	126-134	thyroid hormones	group	256-271	false
diuretics	group	126-134	estrogens	group	274-282	false
diuretics	group	126-134	progestogens	group	285-296	false
diuretics	group	126-134	contraceptives	group	313-326	false
sympathomimetic agents	group	137-158	epinephrine	drug	167-177	false
sympathomimetic agents	group	137-158	salbutamol	drug	180-189	false
sympathomimetic agents	group	137-158	terbutaline	drug	192-202	false
sympathomimetic agents	group	137-158	isoniazid	drug	206-214	false
sympathomimetic agents	group	137-158	phenothiazine derivatives	group	217-241	false
sympathomimetic agents	group	137-158	somatropin	drug	244-253	false
sympathomimetic agents	group	137-158	thyroid hormones	group	256-271	false
sympathomimetic agents	group	137-158	estrogens	group	274-282	false
sympathomimetic agents	group	137-158	progestogens	group	285-296	false
sympathomimetic agents	group	137-158	contraceptives	group	313-326	false
epinephrine	drug	167-177	salbutamol	drug	180-189	false
epinephrine	drug	167-177	terbutaline	drug	192-202	false
epinephrine	drug	167-177	isoniazid	drug	206-214	false
epinephrine	drug	167-177	phenothiazine derivatives	group	217-241	false
epinephrine	drug	167-177	somatropin	drug	244-253	false
epinephrine	drug	167-177	thyroid hormones	group	256-271	false
epinephrine	drug	167-177	estrogens	group	274-282	false
epinephrine	drug	167-177	progestogens	group	285-296	false
epinephrine	drug	167-177	contraceptives	group	313-326	false
salbutamol	drug	180-189	terbutaline	drug	192-202	false
salbutamol	drug	180-189	isoniazid	drug	206-214	false
salbutamol	drug	180-189	phenothiazine derivatives	group	217-241	false
salbutamol	drug	180-189	somatropin	drug	244-253	false
salbutamol	drug	180-189	thyroid hormones	group	256-271	false
salbutamol	drug	180-189	estrogens	group	274-282	false
salbutamol	drug	180-189	progestogens	group	285-296	false
salbutamol	drug	180-189	contraceptives	group	313-326	false
terbutaline	drug	192-202	isoniazid	drug	206-214	false
terbutaline	drug	192-202	phenothiazine derivatives	group	217-241	false
terbutaline	drug	192-202	somatropin	drug	244-253	false
terbutaline	drug	192-202	thyroid hormones	group	256-271	false
terbutaline	drug	192-202	estrogens	group	274-282	false
terbutaline	drug	192-202	progestogens	group	285-296	false
terbutaline	drug	192-202	contraceptives	group	313-326	false
isoniazid	drug	206-214	phenothiazine derivatives	group	217-241	false
isoniazid	drug	206-214	somatropin	drug	244-253	false
isoniazid	drug	206-214	thyroid hormones	group	256-271	false
isoniazid	drug	206-214	estrogens	group	274-282	false
isoniazid	drug	206-214	progestogens	group	285-296	false
isoniazid	drug	206-214	contraceptives	group	313-326	false
phenothiazine derivatives	group	217-241	somatropin	drug	244-253	false
phenothiazine derivatives	group	217-241	thyroid hormones	group	256-271	false
phenothiazine derivatives	group	217-241	estrogens	group	274-282	false
phenothiazine derivatives	group	217-241	progestogens	group	285-296	false
phenothiazine derivatives	group	217-241	contraceptives	group	313-326	false
somatropin	drug	244-253	thyroid hormones	group	256-271	false
somatropin	drug	244-253	estrogens	group	274-282	false
somatropin	drug	244-253	progestogens	group	285-296	false
somatropin	drug	244-253	contraceptives	group	313-326	false
thyroid hormones	group	256-271	estrogens	group	274-282	false
thyroid hormones	group	256-271	progestogens	group	285-296	false
thyroid hormones	group	256-271	contraceptives	group	313-326	false
estrogens	group	274-282	progestogens	group	285-296	false
estrogens	group	274-282	contraceptives	group	313-326	false
progestogens	group	285-296	contraceptives	group	313-326	false

DDI-DrugBank.d313.s3	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
Beta-blockers	group	0-12	clonidine	drug	15-23	false
Beta-blockers	group	0-12	lithium	drug	26-32	false
Beta-blockers	group	0-12	alcohol	drug	45-51	false
Beta-blockers	group	0-12	insulin	drug	122-128	effect
clonidine	drug	15-23	lithium	drug	26-32	false
clonidine	drug	15-23	alcohol	drug	45-51	false
clonidine	drug	15-23	insulin	drug	122-128	effect
lithium	drug	26-32	alcohol	drug	45-51	false
lithium	drug	26-32	insulin	drug	122-128	effect
alcohol	drug	45-51	insulin	drug	122-128	effect

DDI-DrugBank.d313.s5	In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.
beta-blockers	group	77-89	clonidine	drug	92-100	false
beta-blockers	group	77-89	guanethidine	drug	103-114	false
beta-blockers	group	77-89	reserpine	drug	121-129	false
clonidine	drug	92-100	guanethidine	drug	103-114	false
clonidine	drug	92-100	reserpine	drug	121-129	false
guanethidine	drug	103-114	reserpine	drug	121-129	false

DDI-DrugBank.d313.s7	A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.
NovoLog	brand	76-82	NPH human insulin	drug	89-105	false
NovoLog	brand	76-82	NovoLog	brand	191-197	false
NovoLog	brand	76-82	NovoLog	brand	259-265	false
NPH human insulin	drug	89-105	NovoLog	brand	191-197	false
NPH human insulin	drug	89-105	NovoLog	brand	259-265	false
NovoLog	brand	191-197	NovoLog	brand	259-265	false

DDI-DrugBank.d313.s8	If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first.
NovoLog	brand	3-9	NPH human insulin	drug	25-41	false
NovoLog	brand	3-9	NovoLog	brand	44-50	false
NPH human insulin	drug	25-41	NovoLog	brand	44-50	false

DDI-DrugBank.d313.s10	Because there are no data on the compatibility of NovoLog and crystalline zinc insulin preparations, NovoLog should not be mixed with these preparations.
NovoLog	brand	50-56	zinc insulin	drug	74-85	false
NovoLog	brand	50-56	NovoLog	brand	101-107	false
zinc insulin	drug	74-85	NovoLog	brand	101-107	false

DDI-DrugBank.d313.s11	The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .
NovoLog	brand	22-28	insulins	group	35-42	false
NovoLog	brand	22-28	insulin	drug	64-70	false
insulins	group	35-42	insulin	drug	64-70	false

DDI-DrugBank.d313.s13	When used in external subcutaneous infusion pumps for insulin, NovoLog should not be mixed with any other insulins or diluent.
insulin	drug	54-60	NovoLog	brand	63-69	false
insulin	drug	54-60	insulins	group	106-113	false
NovoLog	brand	63-69	insulins	group	106-113	false

DDI-DrugBank.d480.s4	Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.
Clozapine	drug	33-41	alcohol	drug	120-126	effect

DDI-DrugBank.d480.s7	similar events have been reported in patients taking other psychotropic drugs or even Clozapine by itself.
psychotropic drugs	group	59-76	Clozapine	drug	86-94	false

DDI-DrugBank.d480.s8	Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
Clozapine	drug	74-82	benzodiazepines	group	88-102	false
Clozapine	drug	74-82	psychotropics	group	113-125	false
Clozapine	drug	74-82	clozapine	drug	152-160	false
Clozapine	drug	74-82	benzodiazepine	group	196-209	false
Clozapine	drug	74-82	psychotropic drug	group	224-240	false
benzodiazepines	group	88-102	psychotropics	group	113-125	false
benzodiazepines	group	88-102	clozapine	drug	152-160	false
benzodiazepines	group	88-102	benzodiazepine	group	196-209	false
benzodiazepines	group	88-102	psychotropic drug	group	224-240	false
psychotropics	group	113-125	clozapine	drug	152-160	false
psychotropics	group	113-125	benzodiazepine	group	196-209	false
psychotropics	group	113-125	psychotropic drug	group	224-240	false
clozapine	drug	152-160	benzodiazepine	group	196-209	advise
clozapine	drug	152-160	psychotropic drug	group	224-240	advise
benzodiazepine	group	196-209	psychotropic drug	group	224-240	false

DDI-DrugBank.d480.s9	Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
Clozapine	drug	0-8	antihypertensive drugs	group	52-73	effect
Clozapine	drug	0-8	atropine	drug	110-117	effect
antihypertensive drugs	group	52-73	atropine	drug	110-117	false

DDI-DrugBank.d480.s10	The administration of epinephrine should be avoided in the treatment of drug induced hypotension because of a possible reverse epinephrine effect.
epinephrine	drug	22-32	epinephrine	drug	127-137	false

DDI-DrugBank.d480.s15	Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
Phenytoin	drug	0-8	nicotine	drug	11-18	false
Phenytoin	drug	0-8	rifampin	drug	25-32	false
Phenytoin	drug	0-8	Clozapine	drug	47-55	mechanism
Phenytoin	drug	0-8	Clozapine	drug	139-147	false
nicotine	drug	11-18	rifampin	drug	25-32	false
nicotine	drug	11-18	Clozapine	drug	47-55	mechanism
nicotine	drug	11-18	Clozapine	drug	139-147	false
rifampin	drug	25-32	Clozapine	drug	47-55	mechanism
rifampin	drug	25-32	Clozapine	drug	139-147	false
Clozapine	drug	47-55	Clozapine	drug	139-147	false

DDI-DrugBank.d480.s17	Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
Cimetidine	drug	0-9	caffeine	drug	12-19	false
Cimetidine	drug	0-9	erythromycin	drug	26-37	false
Cimetidine	drug	0-9	Clozapine	drug	69-77	mechanism
caffeine	drug	12-19	erythromycin	drug	26-37	false
caffeine	drug	12-19	Clozapine	drug	69-77	mechanism
erythromycin	drug	26-37	Clozapine	drug	69-77	mechanism

DDI-DrugBank.d480.s18	Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
Clozapine	drug	28-36	carbamazepine	drug	42-54	advise
Clozapine	drug	28-36	carbamazepine	drug	131-143	false
Clozapine	drug	28-36	Clozapine	drug	189-197	false
carbamazepine	drug	42-54	carbamazepine	drug	131-143	false
carbamazepine	drug	42-54	Clozapine	drug	189-197	false
carbamazepine	drug	131-143	Clozapine	drug	189-197	mechanism

DDI-DrugBank.d480.s19	In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.
clozapine	drug	50-58	fluvoxamine	drug	91-101	false
clozapine	drug	50-58	paroxetine	drug	106-115	false
fluvoxamine	drug	91-101	paroxetine	drug	106-115	false

DDI-DrugBank.d480.s20	After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.
clozapine	drug	66-74	N-desmethylclozapine	drug_n	97-116	false
clozapine	drug	66-74	clozapine N-oxide	drug_n	122-138	false
clozapine	drug	66-74	fluvoxamine	drug	160-170	false
N-desmethylclozapine	drug_n	97-116	clozapine N-oxide	drug_n	122-138	false
N-desmethylclozapine	drug_n	97-116	fluvoxamine	drug	160-170	false
clozapine N-oxide	drug_n	122-138	fluvoxamine	drug	160-170	false

DDI-DrugBank.d480.s21	Paroxetine produced only minor changes in the levels of clozapine and its metabolites.
Paroxetine	drug	0-9	clozapine	drug	56-64	mechanism

DDI-DrugBank.d480.s22	However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
clozapine	drug	84-92	clozapine	drug	129-137	false
clozapine	drug	84-92	paroxetine	drug	154-163	false
clozapine	drug	84-92	fluoxetine	drug	166-175	false
clozapine	drug	84-92	sertraline	drug	182-191	false
clozapine	drug	129-137	paroxetine	drug	154-163	mechanism
clozapine	drug	129-137	fluoxetine	drug	166-175	mechanism
clozapine	drug	129-137	sertraline	drug	182-191	mechanism
paroxetine	drug	154-163	fluoxetine	drug	166-175	false
paroxetine	drug	154-163	sertraline	drug	182-191	false
fluoxetine	drug	166-175	sertraline	drug	182-191	false

DDI-DrugBank.d480.s23	Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.
Clozapine	drug	115-123	fluvoxamine	drug	173-183	advise

DDI-DrugBank.d480.s26	Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine.
debrisoquin	drug	71-81	dextromethorphan	drug	84-99	false
debrisoquin	drug	71-81	tricyclic antidepressants	group	106-130	false
debrisoquin	drug	71-81	clozapine	drug	137-145	false
dextromethorphan	drug	84-99	tricyclic antidepressants	group	106-130	false
dextromethorphan	drug	84-99	clozapine	drug	137-145	false
tricyclic antidepressants	group	106-130	clozapine	drug	137-145	false

DDI-DrugBank.d480.s28	In addition, certain drugs that are metabolized by this isozyme, including many antidepressants (clozapine, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.
antidepressants	group	80-94	clozapine	drug	97-105	false
antidepressants	group	80-94	selective serotonin reuptake inhibitors	group	108-146	false
clozapine	drug	97-105	selective serotonin reuptake inhibitors	group	108-146	false

DDI-DrugBank.d480.s29	Concomitant use of clozapine with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either clozapine or the other drug.
clozapine	drug	19-27	clozapine	drug	140-148	false

DDI-DrugBank.d480.s30	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
clozapine	drug	32-40	antidepressants	group	107-121	advise
clozapine	drug	32-40	phenothiazines	group	124-137	advise
clozapine	drug	32-40	carbamazepine	drug	140-152	advise
clozapine	drug	32-40	Type 1C antiarrhythmics	group	159-181	advise
clozapine	drug	32-40	propafenone	drug	190-200	advise
clozapine	drug	32-40	flecainide	drug	203-212	advise
clozapine	drug	32-40	encainide	drug	218-226	advise
clozapine	drug	32-40	quinidine	drug	265-273	advise
antidepressants	group	107-121	phenothiazines	group	124-137	false
antidepressants	group	107-121	carbamazepine	drug	140-152	false
antidepressants	group	107-121	Type 1C antiarrhythmics	group	159-181	false
antidepressants	group	107-121	propafenone	drug	190-200	false
antidepressants	group	107-121	flecainide	drug	203-212	false
antidepressants	group	107-121	encainide	drug	218-226	false
antidepressants	group	107-121	quinidine	drug	265-273	false
phenothiazines	group	124-137	carbamazepine	drug	140-152	false
phenothiazines	group	124-137	Type 1C antiarrhythmics	group	159-181	false
phenothiazines	group	124-137	propafenone	drug	190-200	false
phenothiazines	group	124-137	flecainide	drug	203-212	false
phenothiazines	group	124-137	encainide	drug	218-226	false
phenothiazines	group	124-137	quinidine	drug	265-273	false
carbamazepine	drug	140-152	Type 1C antiarrhythmics	group	159-181	false
carbamazepine	drug	140-152	propafenone	drug	190-200	false
carbamazepine	drug	140-152	flecainide	drug	203-212	false
carbamazepine	drug	140-152	encainide	drug	218-226	false
carbamazepine	drug	140-152	quinidine	drug	265-273	false
Type 1C antiarrhythmics	group	159-181	propafenone	drug	190-200	false
Type 1C antiarrhythmics	group	159-181	flecainide	drug	203-212	false
Type 1C antiarrhythmics	group	159-181	encainide	drug	218-226	false
Type 1C antiarrhythmics	group	159-181	quinidine	drug	265-273	false
propafenone	drug	190-200	flecainide	drug	203-212	false
propafenone	drug	190-200	encainide	drug	218-226	false
propafenone	drug	190-200	quinidine	drug	265-273	false
flecainide	drug	203-212	encainide	drug	218-226	false
flecainide	drug	203-212	quinidine	drug	265-273	false
encainide	drug	218-226	quinidine	drug	265-273	false

DDI-DrugBank.d276.s0	Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
Antacids	group	0-7	magnesium trisilicate	drug	20-40	false
Antacids	group	0-7	nitrofurantoin	drug	80-93	false
magnesium trisilicate	drug	20-40	nitrofurantoin	drug	80-93	mechanism

DDI-DrugBank.d276.s1	The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.
nitrofurantoin	drug	61-74	magnesium trisilicate	drug	96-116	mechanism

DDI-DrugBank.d276.s2	Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
Uricosuric drugs	group	0-15	probenecid	drug	26-35	false
Uricosuric drugs	group	0-15	sulfinpyrazone	drug	41-54	false
Uricosuric drugs	group	0-15	nitrofurantoin	drug	96-109	mechanism
probenecid	drug	26-35	sulfinpyrazone	drug	41-54	false
probenecid	drug	26-35	nitrofurantoin	drug	96-109	mechanism
sulfinpyrazone	drug	41-54	nitrofurantoin	drug	96-109	mechanism

DDI-DrugBank.d276.s3	The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.
nitrofurantoin	drug	26-39	antibacterial	group	155-167	false

DDI-DrugBank.d213.s0	Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
Iodine	drug	0-5	iodine	drug	10-15	false
Iodine	drug	0-5	Carbimazole	drug	51-61	effect
Iodine	drug	0-5	iodine	drug	71-76	false
Iodine	drug	0-5	Carbimazole	drug	116-126	false
iodine	drug	10-15	Carbimazole	drug	51-61	false
iodine	drug	10-15	iodine	drug	71-76	false
iodine	drug	10-15	Carbimazole	drug	116-126	false
Carbimazole	drug	51-61	iodine	drug	71-76	false
Carbimazole	drug	51-61	Carbimazole	drug	116-126	false
iodine	drug	71-76	Carbimazole	drug	116-126	effect

DDI-DrugBank.d213.s1	Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
digoxin	drug	23-29	digitoxin	drug	35-43	false
digoxin	drug	23-29	antithyroid agents	group	77-94	mechanism
digitoxin	drug	35-43	antithyroid agents	group	77-94	mechanism

DDI-DrugBank.d213.s3	Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.
Antithyroid agents	group	0-17	sodium iodide I131	drug	52-69	effect
Antithyroid agents	group	0-17	Carbimazole	drug	142-152	false
sodium iodide I131	drug	52-69	Carbimazole	drug	142-152	false

DDI-DrugBank.d129.s2	Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
oxyphenbutazone	drug	29-43	androgens	group	49-57	mechanism
oxyphenbutazone	drug	29-43	oxyphenbutazone	drug	98-112	false
androgens	group	49-57	oxyphenbutazone	drug	98-112	false

DDI-DrugBank.d129.s3	In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
androgens	group	47-55	insulin	drug	99-105	effect

DDI-DrugBank.d542.s0	Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.
Vitamin B3	drug	17-26	Niacin	drug	29-34	false
Vitamin B3	drug	17-26	Antihypertensive	group	38-53	false
Vitamin B3	drug	17-26	Nicotinic acid	drug	64-77	false
Vitamin B3	drug	17-26	ganglionic blocking agents	group	109-134	false
Niacin	drug	29-34	Antihypertensive	group	38-53	false
Niacin	drug	29-34	Nicotinic acid	drug	64-77	false
Niacin	drug	29-34	ganglionic blocking agents	group	109-134	false
Antihypertensive	group	38-53	Nicotinic acid	drug	64-77	false
Antihypertensive	group	38-53	ganglionic blocking agents	group	109-134	false
Nicotinic acid	drug	64-77	ganglionic blocking agents	group	109-134	effect

DDI-DrugBank.d542.s1	Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.
Aspirin	brand	0-6	aspirin	brand	21-27	false
Aspirin	brand	0-6	nicotinic acid	drug	69-82	false
aspirin	brand	21-27	nicotinic acid	drug	69-82	mechanism

DDI-DrugBank.d377.s0	Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
Phospholine Iodide	drug	0-17	cholinesterase inhibitors	group	37-61	effect
Phospholine Iodide	drug	0-17	succinylcholine	drug	71-85	effect
Phospholine Iodide	drug	0-17	organophosphate insecticide	drug_n	90-104;120-130	effect
Phospholine Iodide	drug	0-17	carbamate insecticide	drug_n	110-130	effect
cholinesterase inhibitors	group	37-61	succinylcholine	drug	71-85	false
cholinesterase inhibitors	group	37-61	organophosphate insecticide	drug_n	90-104;120-130	false
cholinesterase inhibitors	group	37-61	carbamate insecticide	drug_n	110-130	false
succinylcholine	drug	71-85	organophosphate insecticide	drug_n	90-104;120-130	false
succinylcholine	drug	71-85	carbamate insecticide	drug_n	110-130	false
organophosphate insecticide	drug_n	90-104;120-130	carbamate insecticide	drug_n	110-130	false

DDI-DrugBank.d232.s0	After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.
interferon beta-1a	drug	23-40	AVONEX	brand	43-48	false
interferon beta-1a	drug	23-40	TYSABRI	brand	82-88	mechanism
AVONEX	brand	43-48	TYSABRI	brand	82-88	mechanism

DDI-DrugBank.d232.s1	The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).
TYSABRI	brand	22-28	AVONEX	brand	105-110	false
TYSABRI	brand	22-28	AVONEX	brand	148-153	false
TYSABRI	brand	22-28	TYSABRI	brand	239-245	false
AVONEX	brand	105-110	AVONEX	brand	148-153	false
AVONEX	brand	105-110	TYSABRI	brand	239-245	false
AVONEX	brand	148-153	TYSABRI	brand	239-245	false

DDI-DrugBank.d232.s2	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.
TYSABRI	brand	57-63	interferon beta-1a	drug	82-99	false
TYSABRI	brand	57-63	AVONEX	brand	102-107	false
TYSABRI	brand	57-63	glatiramer acetate	drug	136-153	false
TYSABRI	brand	57-63	beta-interferon	drug	224-238	false
TYSABRI	brand	57-63	glatiramer acetate	drug	243-260	false
interferon beta-1a	drug	82-99	AVONEX	brand	102-107	false
interferon beta-1a	drug	82-99	glatiramer acetate	drug	136-153	false
interferon beta-1a	drug	82-99	beta-interferon	drug	224-238	false
interferon beta-1a	drug	82-99	glatiramer acetate	drug	243-260	false
AVONEX	brand	102-107	glatiramer acetate	drug	136-153	false
AVONEX	brand	102-107	beta-interferon	drug	224-238	false
AVONEX	brand	102-107	glatiramer acetate	drug	243-260	false
glatiramer acetate	drug	136-153	beta-interferon	drug	224-238	false
glatiramer acetate	drug	136-153	glatiramer acetate	drug	243-260	false
beta-interferon	drug	224-238	glatiramer acetate	drug	243-260	false

DDI-DrugBank.d348.s0	Although the pressor activity of Desmopressin is very low compared to its antidiuretic activity, large doses of Desmopressin Tablets should be used with other pressor agents only with careful patient monitoring.
Desmopressin	drug	33-44	Desmopressin	drug	112-123	false

DDI-DrugBank.d459.s0	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
ENABLEX	brand	18-24	ketoconazole	drug	108-119	advise
ENABLEX	brand	18-24	itraconazole	drug	122-133	advise
ENABLEX	brand	18-24	ritonavir	drug	136-144	advise
ENABLEX	brand	18-24	nelfinavir	drug	147-156	advise
ENABLEX	brand	18-24	clarithromycin	drug	159-172	advise
ketoconazole	drug	108-119	itraconazole	drug	122-133	false
ketoconazole	drug	108-119	ritonavir	drug	136-144	false
ketoconazole	drug	108-119	nelfinavir	drug	147-156	false
ketoconazole	drug	108-119	clarithromycin	drug	159-172	false
itraconazole	drug	122-133	ritonavir	drug	136-144	false
itraconazole	drug	122-133	nelfinavir	drug	147-156	false
itraconazole	drug	122-133	clarithromycin	drug	159-172	false
ritonavir	drug	136-144	nelfinavir	drug	147-156	false
ritonavir	drug	136-144	clarithromycin	drug	159-172	false
nelfinavir	drug	147-156	clarithromycin	drug	159-172	false

DDI-DrugBank.d459.s1	Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
ENABLEX	brand	29-35	flecainide	drug	173-182	advise
ENABLEX	brand	29-35	thioridazine	drug	185-196	advise
ENABLEX	brand	29-35	tricyclic antidepressants	group	202-226	advise
flecainide	drug	173-182	thioridazine	drug	185-196	false
flecainide	drug	173-182	tricyclic antidepressants	group	202-226	false
thioridazine	drug	185-196	tricyclic antidepressants	group	202-226	false

DDI-DrugBank.d459.s2	The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.
ENABLEX	brand	23-29	anticholinergic agents	group	42-63	effect

DDI-DrugBank.d532.s2	These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
heparin	drug	32-38	warfarin	drug	41-48	false
heparin	drug	32-38	beta-adrenergic receptor blockers	group	51-83	false
heparin	drug	32-38	calcium channel antagonists	group	86-112	false
heparin	drug	32-38	angiotensin converting enzyme inhibitors	group	115-154	false
heparin	drug	32-38	nitrates	group	178-185	false
heparin	drug	32-38	ticlopidine	drug	188-198	false
heparin	drug	32-38	aspirin	brand	205-211	false
warfarin	drug	41-48	beta-adrenergic receptor blockers	group	51-83	false
warfarin	drug	41-48	calcium channel antagonists	group	86-112	false
warfarin	drug	41-48	angiotensin converting enzyme inhibitors	group	115-154	false
warfarin	drug	41-48	nitrates	group	178-185	false
warfarin	drug	41-48	ticlopidine	drug	188-198	false
warfarin	drug	41-48	aspirin	brand	205-211	false
beta-adrenergic receptor blockers	group	51-83	calcium channel antagonists	group	86-112	false
beta-adrenergic receptor blockers	group	51-83	angiotensin converting enzyme inhibitors	group	115-154	false
beta-adrenergic receptor blockers	group	51-83	nitrates	group	178-185	false
beta-adrenergic receptor blockers	group	51-83	ticlopidine	drug	188-198	false
beta-adrenergic receptor blockers	group	51-83	aspirin	brand	205-211	false
calcium channel antagonists	group	86-112	angiotensin converting enzyme inhibitors	group	115-154	false
calcium channel antagonists	group	86-112	nitrates	group	178-185	false
calcium channel antagonists	group	86-112	ticlopidine	drug	188-198	false
calcium channel antagonists	group	86-112	aspirin	brand	205-211	false
angiotensin converting enzyme inhibitors	group	115-154	nitrates	group	178-185	false
angiotensin converting enzyme inhibitors	group	115-154	ticlopidine	drug	188-198	false
angiotensin converting enzyme inhibitors	group	115-154	aspirin	brand	205-211	false
nitrates	group	178-185	ticlopidine	drug	188-198	false
nitrates	group	178-185	aspirin	brand	205-211	false
ticlopidine	drug	188-198	aspirin	brand	205-211	false

DDI-DrugBank.d532.s3	Heparin, other anticoagulants, thrombolytics, and anti platelet agents are associated with an increase in bleeding.
Heparin	drug	0-6	anticoagulants	group	15-28	false
Heparin	drug	0-6	thrombolytics	group	31-43	false
Heparin	drug	0-6	anti platelet agents	group	50-69	false
anticoagulants	group	15-28	thrombolytics	group	31-43	false
anticoagulants	group	15-28	anti platelet agents	group	50-69	false
thrombolytics	group	31-43	anti platelet agents	group	50-69	false

DDI-DrugBank.d532.s4	Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
diagnostic monoclonal antibodies	group	98-107;124-144	therapeutic monoclonal antibodies	group	112-144	false

DDI-DrugBank.d87.s1	TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects.
TAMBOCOR	brand	0-7	digitalis preparations	group	53-74	false
TAMBOCOR	brand	0-7	beta-adrenergic blocking agents	group	79-109	false
digitalis preparations	group	53-74	beta-adrenergic blocking agents	group	79-109	false

DDI-DrugBank.d87.s2	During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.
TAMBOCOR	brand	48-55	digoxin	drug	113-119	mechanism
TAMBOCOR	brand	48-55	digoxin	drug	151-157	false
digoxin	drug	113-119	digoxin	drug	151-157	false

DDI-DrugBank.d87.s3	In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.
TAMBOCOR	brand	48-55	propranolol	drug	61-71	mechanism
TAMBOCOR	brand	48-55	flecainide	drug	94-103	false
TAMBOCOR	brand	48-55	propranolol	drug	141-151	false
propranolol	drug	61-71	flecainide	drug	94-103	false
propranolol	drug	61-71	propranolol	drug	141-151	false
flecainide	drug	94-103	propranolol	drug	141-151	false

DDI-DrugBank.d87.s4	In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects;
TAMBOCOR	brand	34-41	propranolol	drug	47-57	false

DDI-DrugBank.d87.s6	The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.
TAMBOCOR	brand	45-52	propranolol	drug	58-68	effect

DDI-DrugBank.d87.s7	In TAMBOCOR clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects.
TAMBOCOR	brand	3-10	beta blockers	group	57-69	false

DDI-DrugBank.d87.s8	Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.
beta blockers	group	72-84	flecainide	drug	90-99	effect

DDI-DrugBank.d87.s12	TAMBOCOR has been used in a large number of patients receiving diuretics without apparent interaction.
TAMBOCOR	brand	0-7	diuretics	group	63-71	false

DDI-DrugBank.d87.s13	Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
phenytoin	drug	59-67	phenobarbital	drug	70-82	false
phenytoin	drug	59-67	carbamazepine	drug	85-97	false
phenytoin	drug	59-67	flecainide	drug	145-154	mechanism
phenobarbital	drug	70-82	carbamazepine	drug	85-97	false
phenobarbital	drug	70-82	flecainide	drug	145-154	mechanism
carbamazepine	drug	85-97	flecainide	drug	145-154	mechanism

DDI-DrugBank.d87.s14	In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.
cimetidine	drug	30-39	flecainide	drug	75-84	mechanism

DDI-DrugBank.d87.s15	When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
amiodarone	drug	5-14	flecainide	drug	28-37	mechanism
amiodarone	drug	5-14	flecainide	drug	55-64	false
amiodarone	drug	5-14	flecainide	drug	124-133	false
flecainide	drug	28-37	flecainide	drug	55-64	false
flecainide	drug	28-37	flecainide	drug	124-133	false
flecainide	drug	55-64	flecainide	drug	124-133	false

DDI-DrugBank.d87.s16	Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;
quinidine	drug	48-56	flecainide	drug	104-113	mechanism
quinidine	drug	48-56	flecainide	drug	147-156	false
flecainide	drug	104-113	flecainide	drug	147-156	false

DDI-DrugBank.d87.s18	There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil.
TAMBOCOR	brand	62-69	disopyramide	drug	82-93	false
TAMBOCOR	brand	62-69	verapamil	drug	98-106	false
disopyramide	drug	82-93	verapamil	drug	98-106	false

DDI-DrugBank.d87.s19	Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
TAMBOCOR	brand	104-111	disopyramide	drug	134-145	false
TAMBOCOR	brand	104-111	verapamil	drug	151-159	false
TAMBOCOR	brand	104-111	TAMBOCOR	brand	202-209	false
disopyramide	drug	134-145	verapamil	drug	151-159	false
disopyramide	drug	134-145	TAMBOCOR	brand	202-209	advise
verapamil	drug	151-159	TAMBOCOR	brand	202-209	advise

DDI-DrugBank.d87.s20	There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.
TAMBOCOR	brand	66-73	nifedipine	drug	80-89	false
TAMBOCOR	brand	66-73	diltiazem	drug	94-102	false
nifedipine	drug	80-89	diltiazem	drug	94-102	false

DDI-DrugBank.d55.s0	Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.
Isoproterenol hydrochloride	drug	0-26	epinephrine	drug	42-52	advise

DDI-DrugBank.d55.s2	ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
ISUPREL	brand	0-6	anesthetics	group	73-83	advise
ISUPREL	brand	0-6	halothane	drug	93-101	advise
ISUPREL	brand	0-6	sympathomimetic amines	group	179-200	false
anesthetics	group	73-83	halothane	drug	93-101	false
anesthetics	group	73-83	sympathomimetic amines	group	179-200	false
halothane	drug	93-101	sympathomimetic amines	group	179-200	false

DDI-DrugBank.d431.s1	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
lansoprazole	drug	24-35	warfarin	drug	155-162	false
lansoprazole	drug	24-35	antipyrine	drug	165-174	false
lansoprazole	drug	24-35	indomethacin	drug	177-188	false
lansoprazole	drug	24-35	ibuprofen	drug	191-199	false
lansoprazole	drug	24-35	phenytoin	drug	202-210	false
lansoprazole	drug	24-35	propranolol	drug	213-223	false
lansoprazole	drug	24-35	prednisone	drug	226-235	false
lansoprazole	drug	24-35	diazepam	drug	238-245	false
lansoprazole	drug	24-35	clarithromycin	drug	248-261	false
lansoprazole	drug	24-35	terfenadine	drug	267-277	false
warfarin	drug	155-162	antipyrine	drug	165-174	false
warfarin	drug	155-162	indomethacin	drug	177-188	false
warfarin	drug	155-162	ibuprofen	drug	191-199	false
warfarin	drug	155-162	phenytoin	drug	202-210	false
warfarin	drug	155-162	propranolol	drug	213-223	false
warfarin	drug	155-162	prednisone	drug	226-235	false
warfarin	drug	155-162	diazepam	drug	238-245	false
warfarin	drug	155-162	clarithromycin	drug	248-261	false
warfarin	drug	155-162	terfenadine	drug	267-277	false
antipyrine	drug	165-174	indomethacin	drug	177-188	false
antipyrine	drug	165-174	ibuprofen	drug	191-199	false
antipyrine	drug	165-174	phenytoin	drug	202-210	false
antipyrine	drug	165-174	propranolol	drug	213-223	false
antipyrine	drug	165-174	prednisone	drug	226-235	false
antipyrine	drug	165-174	diazepam	drug	238-245	false
antipyrine	drug	165-174	clarithromycin	drug	248-261	false
antipyrine	drug	165-174	terfenadine	drug	267-277	false
indomethacin	drug	177-188	ibuprofen	drug	191-199	false
indomethacin	drug	177-188	phenytoin	drug	202-210	false
indomethacin	drug	177-188	propranolol	drug	213-223	false
indomethacin	drug	177-188	prednisone	drug	226-235	false
indomethacin	drug	177-188	diazepam	drug	238-245	false
indomethacin	drug	177-188	clarithromycin	drug	248-261	false
indomethacin	drug	177-188	terfenadine	drug	267-277	false
ibuprofen	drug	191-199	phenytoin	drug	202-210	false
ibuprofen	drug	191-199	propranolol	drug	213-223	false
ibuprofen	drug	191-199	prednisone	drug	226-235	false
ibuprofen	drug	191-199	diazepam	drug	238-245	false
ibuprofen	drug	191-199	clarithromycin	drug	248-261	false
ibuprofen	drug	191-199	terfenadine	drug	267-277	false
phenytoin	drug	202-210	propranolol	drug	213-223	false
phenytoin	drug	202-210	prednisone	drug	226-235	false
phenytoin	drug	202-210	diazepam	drug	238-245	false
phenytoin	drug	202-210	clarithromycin	drug	248-261	false
phenytoin	drug	202-210	terfenadine	drug	267-277	false
propranolol	drug	213-223	prednisone	drug	226-235	false
propranolol	drug	213-223	diazepam	drug	238-245	false
propranolol	drug	213-223	clarithromycin	drug	248-261	false
propranolol	drug	213-223	terfenadine	drug	267-277	false
prednisone	drug	226-235	diazepam	drug	238-245	false
prednisone	drug	226-235	clarithromycin	drug	248-261	false
prednisone	drug	226-235	terfenadine	drug	267-277	false
diazepam	drug	238-245	clarithromycin	drug	248-261	false
diazepam	drug	238-245	terfenadine	drug	267-277	false
clarithromycin	drug	248-261	terfenadine	drug	267-277	false

DDI-DrugBank.d431.s3	When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.
lansoprazole	drug	5-16	theophylline	drug	54-65	mechanism
lansoprazole	drug	5-16	theophylline	drug	127-138	false
theophylline	drug	54-65	theophylline	drug	127-138	false

DDI-DrugBank.d431.s5	Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.
theophylline	drug	75-86	lansoprazole	drug	100-111	advise

DDI-DrugBank.d431.s6	Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin.
Lansoprazole	drug	0-11	amoxicillin	drug	84-94	false

DDI-DrugBank.d431.s7	In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.
lansoprazole	drug	43-54	omeprazole	drug	66-75	false
lansoprazole	drug	43-54	sucralfate	drug	130-139	false
lansoprazole	drug	43-54	proton pump inhibitors	group	167-188	false
lansoprazole	drug	43-54	sucralfate	drug	307-316	false
omeprazole	drug	66-75	sucralfate	drug	130-139	false
omeprazole	drug	66-75	proton pump inhibitors	group	167-188	false
omeprazole	drug	66-75	sucralfate	drug	307-316	false
sucralfate	drug	130-139	proton pump inhibitors	group	167-188	false
sucralfate	drug	130-139	sucralfate	drug	307-316	false
proton pump inhibitors	group	167-188	sucralfate	drug	307-316	mechanism

DDI-DrugBank.d431.s8	Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.
proton pump inhibitors	group	11-32	sucralfate	drug	79-88	advise

DDI-DrugBank.d431.s9	In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules;
antacids	group	20-27	lansoprazole	drug	66-77	false

DDI-DrugBank.d431.s12	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
lansoprazole	drug	45-56	ketoconazole	drug	171-182	mechanism
lansoprazole	drug	45-56	ampicillin	drug	185-194	mechanism
lansoprazole	drug	45-56	iron	drug	204-207	mechanism
lansoprazole	drug	45-56	digoxin	drug	216-222	mechanism
ketoconazole	drug	171-182	ampicillin	drug	185-194	false
ketoconazole	drug	171-182	iron	drug	204-207	false
ketoconazole	drug	171-182	digoxin	drug	216-222	false
ampicillin	drug	185-194	iron	drug	204-207	false
ampicillin	drug	185-194	digoxin	drug	216-222	false
iron	drug	204-207	digoxin	drug	216-222	false

DDI-DrugBank.d501.s4	In patients using cardiac glycosides (digoxin and others), plasma levels of calcium, potassium and magnesium must be carefully monitored.
cardiac glycosides	group	18-35	digoxin	drug	38-44	false

DDI-DrugBank.d501.s5	Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.
Insulin	drug	0-6	EXTRANEAL	brand	93-101	false
Insulin	drug	0-6	insulin	drug	106-112	false
Insulin	drug	0-6	insulin	drug	158-164	false
Insulin	drug	0-6	insulin	drug	205-211	false
Insulin	drug	0-6	EXTRANEAL	brand	253-261	false
EXTRANEAL	brand	93-101	insulin	drug	106-112	false
EXTRANEAL	brand	93-101	insulin	drug	158-164	false
EXTRANEAL	brand	93-101	insulin	drug	205-211	false
EXTRANEAL	brand	93-101	EXTRANEAL	brand	253-261	false
insulin	drug	106-112	insulin	drug	158-164	false
insulin	drug	106-112	insulin	drug	205-211	false
insulin	drug	106-112	EXTRANEAL	brand	253-261	false
insulin	drug	158-164	insulin	drug	205-211	false
insulin	drug	158-164	EXTRANEAL	brand	253-261	false
insulin	drug	205-211	EXTRANEAL	brand	253-261	false

DDI-DrugBank.d501.s6	However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.
EXTRANEAL	brand	85-93	insulin	drug	120-126	advise

DDI-DrugBank.d501.s7	Heparin: No human drug interaction studies with heparin were conducted.
Heparin	drug	0-6	heparin	drug	48-54	false

DDI-DrugBank.d501.s8	In vitro studies demonstrated no evidence of incompatibility of heparin with EXTRANEAL.
heparin	drug	64-70	EXTRANEAL	brand	77-85	false

DDI-DrugBank.d501.s9	Antibiotics: No human drug interaction studies with antibiotics were conducted.
Antibiotics	group	0-10	antibiotics	group	52-62	false

DDI-DrugBank.d501.s10	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
vancomycin	drug	74-83	cefazolin	drug	86-94	false
vancomycin	drug	74-83	ampicillin	drug	97-106	false
vancomycin	drug	74-83	ampicillin	drug	109-118	false
vancomycin	drug	74-83	ceftazidime	drug	135-145	false
vancomycin	drug	74-83	gentamicin	drug	148-157	false
vancomycin	drug	74-83	amphotericin	drug	164-175	false
vancomycin	drug	74-83	antibiotics	group	230-240	false
vancomycin	drug	74-83	EXTRANEAL	brand	247-255	false
cefazolin	drug	86-94	ampicillin	drug	97-106	false
cefazolin	drug	86-94	ampicillin	drug	109-118	false
cefazolin	drug	86-94	ceftazidime	drug	135-145	false
cefazolin	drug	86-94	gentamicin	drug	148-157	false
cefazolin	drug	86-94	amphotericin	drug	164-175	false
cefazolin	drug	86-94	antibiotics	group	230-240	false
cefazolin	drug	86-94	EXTRANEAL	brand	247-255	false
ampicillin	drug	97-106	ampicillin	drug	109-118	false
ampicillin	drug	97-106	ceftazidime	drug	135-145	false
ampicillin	drug	97-106	gentamicin	drug	148-157	false
ampicillin	drug	97-106	amphotericin	drug	164-175	false
ampicillin	drug	97-106	antibiotics	group	230-240	false
ampicillin	drug	97-106	EXTRANEAL	brand	247-255	false
ampicillin	drug	109-118	ceftazidime	drug	135-145	false
ampicillin	drug	109-118	gentamicin	drug	148-157	false
ampicillin	drug	109-118	amphotericin	drug	164-175	false
ampicillin	drug	109-118	antibiotics	group	230-240	false
ampicillin	drug	109-118	EXTRANEAL	brand	247-255	false
ceftazidime	drug	135-145	gentamicin	drug	148-157	false
ceftazidime	drug	135-145	amphotericin	drug	164-175	false
ceftazidime	drug	135-145	antibiotics	group	230-240	false
ceftazidime	drug	135-145	EXTRANEAL	brand	247-255	false
gentamicin	drug	148-157	amphotericin	drug	164-175	false
gentamicin	drug	148-157	antibiotics	group	230-240	false
gentamicin	drug	148-157	EXTRANEAL	brand	247-255	false
amphotericin	drug	164-175	antibiotics	group	230-240	false
amphotericin	drug	164-175	EXTRANEAL	brand	247-255	false
antibiotics	group	230-240	EXTRANEAL	brand	247-255	false

DDI-DrugBank.d407.s1	An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies
Campath	brand	22-28	antibodies	group	96-105	false

DDI-DrugBank.d379.s1	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
photosensitizing agents	group	61-83	griseofulvin	drug	93-104	false
photosensitizing agents	group	61-83	thiazide diuretics	group	107-124	false
photosensitizing agents	group	61-83	sulfonylureas	group	127-139	false
photosensitizing agents	group	61-83	phenothiazines	group	142-155	false
photosensitizing agents	group	61-83	sulfonamides	group	158-169	false
photosensitizing agents	group	61-83	tetracyclines	group	175-187	false
photosensitizing agents	group	61-83	LEVULAN KERASTICK	brand	272-288	effect
griseofulvin	drug	93-104	thiazide diuretics	group	107-124	false
griseofulvin	drug	93-104	sulfonylureas	group	127-139	false
griseofulvin	drug	93-104	phenothiazines	group	142-155	false
griseofulvin	drug	93-104	sulfonamides	group	158-169	false
griseofulvin	drug	93-104	tetracyclines	group	175-187	false
griseofulvin	drug	93-104	LEVULAN KERASTICK	brand	272-288	effect
thiazide diuretics	group	107-124	sulfonylureas	group	127-139	false
thiazide diuretics	group	107-124	phenothiazines	group	142-155	false
thiazide diuretics	group	107-124	sulfonamides	group	158-169	false
thiazide diuretics	group	107-124	tetracyclines	group	175-187	false
thiazide diuretics	group	107-124	LEVULAN KERASTICK	brand	272-288	effect
sulfonylureas	group	127-139	phenothiazines	group	142-155	false
sulfonylureas	group	127-139	sulfonamides	group	158-169	false
sulfonylureas	group	127-139	tetracyclines	group	175-187	false
sulfonylureas	group	127-139	LEVULAN KERASTICK	brand	272-288	effect
phenothiazines	group	142-155	sulfonamides	group	158-169	false
phenothiazines	group	142-155	tetracyclines	group	175-187	false
phenothiazines	group	142-155	LEVULAN KERASTICK	brand	272-288	effect
sulfonamides	group	158-169	tetracyclines	group	175-187	false
sulfonamides	group	158-169	LEVULAN KERASTICK	brand	272-288	effect
tetracyclines	group	175-187	LEVULAN KERASTICK	brand	272-288	effect

DDI-DrugBank.d258.s0	Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.
Loratadine	drug	0-9	erythromycin	drug	80-91	false
Loratadine	drug	0-9	cimetidine	drug	94-103	false
Loratadine	drug	0-9	ketoconazole	drug	110-121	false
erythromycin	drug	80-91	cimetidine	drug	94-103	false
erythromycin	drug	80-91	ketoconazole	drug	110-121	false
cimetidine	drug	94-103	ketoconazole	drug	110-121	false

DDI-DrugBank.d258.s1	Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
loratadine	drug	59-68	descarboethoxyloratadine	drug	77-100	false
loratadine	drug	59-68	loratadine	drug	146-155	false
loratadine	drug	59-68	loratadine	drug	294-303	false
descarboethoxyloratadine	drug	77-100	loratadine	drug	146-155	false
descarboethoxyloratadine	drug	77-100	loratadine	drug	294-303	false
loratadine	drug	146-155	loratadine	drug	294-303	false

DDI-DrugBank.d258.s3	No effects on plasma concentrations of cimetidine or ketoconazole were observed.
cimetidine	drug	39-48	ketoconazole	drug	53-64	false

DDI-DrugBank.d258.s4	Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.
erythromycin	drug	40-51	loratadine	drug	92-101	mechanism
erythromycin	drug	40-51	erythromycin	drug	134-145	false
loratadine	drug	92-101	erythromycin	drug	134-145	false

DDI-DrugBank.d258.s7	TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and Descarboethoxyloratadine After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers
Loratadine	drug	59-68	Descarboethoxyloratadine	drug	74-97	false
Loratadine	drug	59-68	Loratadine	drug	134-143	false
Descarboethoxyloratadine	drug	74-97	Loratadine	drug	134-143	false

DDI-DrugBank.d258.s8	Loratadine Descarboethoxyloratadine
Loratadine	drug	0-9	Descarboethoxyloratadine	drug	11-34	false

DDI-DrugBank.d258.s12	There does not appear to be an increase in adverse events in subjects who received oral contraceptives and loratadine.
contraceptives	group	88-101	loratadine	drug	107-116	false

DDI-DrugBank.d464.s0	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
Codeine	drug	0-6	narcotic analgesics	group	34-52	effect
Codeine	drug	0-6	anesthetics	group	63-73	effect
Codeine	drug	0-6	phenothiazines	group	76-89	effect
Codeine	drug	0-6	tranquilizers	group	92-104	effect
Codeine	drug	0-6	sedative-hypnotics	group	107-124	effect
Codeine	drug	0-6	CNS depressants	group	136-150	effect
Codeine	drug	0-6	alcohol	drug	163-169	effect
narcotic analgesics	group	34-52	anesthetics	group	63-73	false
narcotic analgesics	group	34-52	phenothiazines	group	76-89	false
narcotic analgesics	group	34-52	tranquilizers	group	92-104	false
narcotic analgesics	group	34-52	sedative-hypnotics	group	107-124	false
narcotic analgesics	group	34-52	CNS depressants	group	136-150	false
narcotic analgesics	group	34-52	alcohol	drug	163-169	false
anesthetics	group	63-73	phenothiazines	group	76-89	false
anesthetics	group	63-73	tranquilizers	group	92-104	false
anesthetics	group	63-73	sedative-hypnotics	group	107-124	false
anesthetics	group	63-73	CNS depressants	group	136-150	false
anesthetics	group	63-73	alcohol	drug	163-169	false
phenothiazines	group	76-89	tranquilizers	group	92-104	false
phenothiazines	group	76-89	sedative-hypnotics	group	107-124	false
phenothiazines	group	76-89	CNS depressants	group	136-150	false
phenothiazines	group	76-89	alcohol	drug	163-169	false
tranquilizers	group	92-104	sedative-hypnotics	group	107-124	false
tranquilizers	group	92-104	CNS depressants	group	136-150	false
tranquilizers	group	92-104	alcohol	drug	163-169	false
sedative-hypnotics	group	107-124	CNS depressants	group	136-150	false
sedative-hypnotics	group	107-124	alcohol	drug	163-169	false
CNS depressants	group	136-150	alcohol	drug	163-169	false

DDI-DrugBank.d162.s1	Alcohol, barbiturates, or narcotics: potentiation of orthostatic hypotension may occur.
Alcohol	drug	0-6	barbiturates	group	9-20	false
Alcohol	drug	0-6	narcotics	group	26-34	false
barbiturates	group	9-20	narcotics	group	26-34	false

DDI-DrugBank.d162.s2	Antidiabetic drugs: (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required.
Antidiabetic drugs	group	0-17	insulin	drug	37-43	false
Antidiabetic drugs	group	0-17	antidiabetic drug	group	73-89	false
insulin	drug	37-43	antidiabetic drug	group	73-89	false

DDI-DrugBank.d162.s4	Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
Cholestyramine	drug	0-13	colestipol	drug	19-28	false
Cholestyramine	drug	0-13	resins	group	30-35	false
Cholestyramine	drug	0-13	hydrochlorothiazide	drug	52-70	false
Cholestyramine	drug	0-13	anionic exchange resins	group	103-125	false
colestipol	drug	19-28	resins	group	30-35	false
colestipol	drug	19-28	hydrochlorothiazide	drug	52-70	false
colestipol	drug	19-28	anionic exchange resins	group	103-125	false
resins	group	30-35	hydrochlorothiazide	drug	52-70	false
resins	group	30-35	anionic exchange resins	group	103-125	false
hydrochlorothiazide	drug	52-70	anionic exchange resins	group	103-125	mechanism

DDI-DrugBank.d162.s5	Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
cholestyramine	drug	23-36	colestipol	drug	41-50	false
cholestyramine	drug	23-36	resins	group	52-57	false
cholestyramine	drug	23-36	hydrochlorothiazide	drug	68-86	mechanism
colestipol	drug	41-50	resins	group	52-57	false
colestipol	drug	41-50	hydrochlorothiazide	drug	68-86	mechanism
resins	group	52-57	hydrochlorothiazide	drug	68-86	false

DDI-DrugBank.d162.s6	Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.
Corticosteroids	group	0-14	ACTH	drug	17-20	false

DDI-DrugBank.d162.s8	Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the muscle relaxant.
Skeletal muscle relaxants	group	0-24	tubocurarine	drug	50-61	false
Skeletal muscle relaxants	group	0-24	muscle relaxant	group	106-120	false
tubocurarine	drug	50-61	muscle relaxant	group	106-120	false

DDI-DrugBank.d162.s9	Lithium: generally should not be given with diuretics.
Lithium	drug	0-6	diuretics	group	44-52	advise

DDI-DrugBank.d162.s10	Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
Diuretic agents	group	0-14	lithium	drug	46-52	mechanism
Diuretic agents	group	0-14	lithium	drug	77-83	effect
lithium	drug	46-52	lithium	drug	77-83	false

DDI-DrugBank.d162.s11	Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.
lithium	drug	32-38	Hydrochlorothiazide	drug	90-108	advise

DDI-DrugBank.d162.s12	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
Non-steroidal Anti-inflammatory Drugs	group	0-36	non-steroidal anti-inflammatory agent	group	81-117	false
Non-steroidal Anti-inflammatory Drugs	group	0-36	loop diuretics	group	189-192;226-234	false
Non-steroidal Anti-inflammatory Drugs	group	0-36	potassium-sparing diuretics	group	195-211;226-234	false
Non-steroidal Anti-inflammatory Drugs	group	0-36	thiazide diuretics	group	217-234	false
non-steroidal anti-inflammatory agent	group	81-117	loop diuretics	group	189-192;226-234	effect
non-steroidal anti-inflammatory agent	group	81-117	potassium-sparing diuretics	group	195-211;226-234	effect
non-steroidal anti-inflammatory agent	group	81-117	thiazide diuretics	group	217-234	effect
loop diuretics	group	189-192;226-234	potassium-sparing diuretics	group	195-211;226-234	false
loop diuretics	group	189-192;226-234	thiazide diuretics	group	217-234	false
potassium-sparing diuretics	group	195-211;226-234	thiazide diuretics	group	217-234	false

DDI-DrugBank.d162.s13	Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
Hydrochlorothiazide	drug	16-34	non-steroidal anti-inflammatory agents	group	40-77	advise
Hydrochlorothiazide	drug	16-34	diuretic	group	184-191	false
non-steroidal anti-inflammatory agents	group	40-77	diuretic	group	184-191	false

DDI-DrugBank.d509.s0	Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
aripiprazole	drug	56-67	ABILIFY	brand	98-104	false
aripiprazole	drug	56-67	centrally acting drugs	group	141-162	false
aripiprazole	drug	56-67	alcohol	drug	168-174	false
ABILIFY	brand	98-104	centrally acting drugs	group	141-162	advise
ABILIFY	brand	98-104	alcohol	drug	168-174	advise
centrally acting drugs	group	141-162	alcohol	drug	168-174	false

DDI-DrugBank.d509.s2	1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.
aripiprazole	drug	35-46	antihypertensive agents	group	99-121	effect

DDI-DrugBank.d509.s3	Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.
ABILIFY	brand	36-42	Aripiprazole	brand	44-55	false

DDI-DrugBank.d509.s7	Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.
carbamazepine	drug	31-43	aripiprazole	drug	73-84	mechanism

DDI-DrugBank.d509.s8	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
ketoconazole	drug	26-37	quinidine	drug	55-63	false
ketoconazole	drug	26-37	fluoxetine	drug	66-75	false
ketoconazole	drug	26-37	paroxetine	drug	81-90	false
ketoconazole	drug	26-37	aripiprazole	drug	105-116	mechanism
quinidine	drug	55-63	fluoxetine	drug	66-75	false
quinidine	drug	55-63	paroxetine	drug	81-90	false
quinidine	drug	55-63	aripiprazole	drug	105-116	mechanism
fluoxetine	drug	66-75	paroxetine	drug	81-90	false
fluoxetine	drug	66-75	aripiprazole	drug	105-116	mechanism
paroxetine	drug	81-90	aripiprazole	drug	105-116	mechanism

DDI-DrugBank.d509.s9	Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.
Ketoconazole	drug	0-11	ketoconazole	drug	34-45	false
Ketoconazole	drug	0-11	aripiprazole	drug	100-111	false
Ketoconazole	drug	0-11	aripiprazole	drug	134-145	false
ketoconazole	drug	34-45	aripiprazole	drug	100-111	mechanism
ketoconazole	drug	34-45	aripiprazole	drug	134-145	false
aripiprazole	drug	100-111	aripiprazole	drug	134-145	false

DDI-DrugBank.d509.s11	When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.
ketoconazole	drug	35-46	aripiprazole	drug	53-64	advise
ketoconazole	drug	35-46	aripiprazole	drug	74-85	false
aripiprazole	drug	53-64	aripiprazole	drug	74-85	false

DDI-DrugBank.d509.s15	Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
Quinidine	drug	0-8	aripiprazole	drug	54-65	false
Quinidine	drug	0-8	quinidine	drug	72-80	false
Quinidine	drug	0-8	aripiprazole	drug	159-170	false
Quinidine	drug	0-8	dehydroaripiprazole	drug_n	228-246	false
aripiprazole	drug	54-65	quinidine	drug	72-80	mechanism
aripiprazole	drug	54-65	aripiprazole	drug	159-170	false
aripiprazole	drug	54-65	dehydroaripiprazole	drug_n	228-246	false
quinidine	drug	72-80	aripiprazole	drug	159-170	false
quinidine	drug	72-80	dehydroaripiprazole	drug_n	228-246	false
aripiprazole	drug	159-170	dehydroaripiprazole	drug_n	228-246	false

DDI-DrugBank.d509.s16	Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
Aripiprazole	drug	0-11	quinidine	drug	102-110	false
Aripiprazole	drug	0-11	aripiprazole	drug	117-128	false
quinidine	drug	102-110	aripiprazole	drug	117-128	advise

DDI-DrugBank.d509.s17	Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions.
fluoxetine	drug	48-57	paroxetine	drug	62-71	false

DDI-DrugBank.d509.s19	Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.
Carbamazepine	drug	0-12	carbamazepine	drug	35-47	false
Carbamazepine	drug	0-12	aripiprazole	drug	93-104	false
Carbamazepine	drug	0-12	aripiprazole	drug	188-199	false
Carbamazepine	drug	0-12	dehydro-aripiprazole	drug_n	228-247	false
carbamazepine	drug	35-47	aripiprazole	drug	93-104	mechanism
carbamazepine	drug	35-47	aripiprazole	drug	188-199	false
carbamazepine	drug	35-47	dehydro-aripiprazole	drug_n	228-247	false
aripiprazole	drug	93-104	aripiprazole	drug	188-199	false
aripiprazole	drug	93-104	dehydro-aripiprazole	drug_n	228-247	false
aripiprazole	drug	188-199	dehydro-aripiprazole	drug_n	228-247	false

DDI-DrugBank.d509.s20	When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
carbamazepine	drug	5-17	aripiprazole	drug	31-42	advise
carbamazepine	drug	5-17	aripiprazole	drug	53-64	false
aripiprazole	drug	31-42	aripiprazole	drug	53-64	false

DDI-DrugBank.d509.s22	When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.
carbamazepine	drug	5-17	aripiprazole	drug	62-73	advise

DDI-DrugBank.d509.s23	No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).
famotidine	drug	36-45	valproate	drug	48-56	false
famotidine	drug	36-45	lithium	drug	62-68	false
famotidine	drug	36-45	aripiprazole	drug	106-117	false
valproate	drug	48-56	lithium	drug	62-68	false
valproate	drug	48-56	aripiprazole	drug	106-117	false
lithium	drug	62-68	aripiprazole	drug	106-117	false

DDI-DrugBank.d509.s24	Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.
ABILIFY	brand	14-20	Aripiprazole	drug	44-55	false

DDI-DrugBank.d509.s25	In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.
aripiprazole	drug	46-57	dextromethorphan	drug	110-125	false
aripiprazole	drug	46-57	warfarin	drug	137-144	false
aripiprazole	drug	46-57	omeprazole	drug	157-166	false
aripiprazole	drug	46-57	warfarin	drug	169-176	false
aripiprazole	drug	46-57	dextromethorphan	drug	192-207	false
dextromethorphan	drug	110-125	warfarin	drug	137-144	false
dextromethorphan	drug	110-125	omeprazole	drug	157-166	false
dextromethorphan	drug	110-125	warfarin	drug	169-176	false
dextromethorphan	drug	110-125	dextromethorphan	drug	192-207	false
warfarin	drug	137-144	omeprazole	drug	157-166	false
warfarin	drug	137-144	warfarin	drug	169-176	false
warfarin	drug	137-144	dextromethorphan	drug	192-207	false
omeprazole	drug	157-166	warfarin	drug	169-176	false
omeprazole	drug	157-166	dextromethorphan	drug	192-207	false
warfarin	drug	169-176	dextromethorphan	drug	192-207	false

DDI-DrugBank.d509.s26	Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
aripiprazole	drug	14-25	dehydroaripiprazole	drug_n	31-49	false

DDI-DrugBank.d509.s27	Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
Alcohol	drug	0-6	aripiprazole	drug	53-64	false
Alcohol	drug	0-6	ethanol	drug	86-92	false
Alcohol	drug	0-6	ethanol	drug	126-132	false
aripiprazole	drug	53-64	ethanol	drug	86-92	false
aripiprazole	drug	53-64	ethanol	drug	126-132	false
ethanol	drug	86-92	ethanol	drug	126-132	false

DDI-DrugBank.d509.s28	As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY
alcohol	drug	75-81	ABILIFY	brand	96-102	advise

DDI-DrugBank.d568.s1	Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
Alcohol	drug	0-6	LEXAPRO	brand	19-25	false
Alcohol	drug	0-6	alcohol	drug	81-87	false
Alcohol	drug	0-6	psychotropic medications	group	124-147	false
Alcohol	drug	0-6	alcohol	drug	161-167	false
Alcohol	drug	0-6	LEXAPRO	brand	188-194	false
LEXAPRO	brand	19-25	alcohol	drug	81-87	false
LEXAPRO	brand	19-25	psychotropic medications	group	124-147	false
LEXAPRO	brand	19-25	alcohol	drug	161-167	false
LEXAPRO	brand	19-25	LEXAPRO	brand	188-194	false
alcohol	drug	81-87	psychotropic medications	group	124-147	false
alcohol	drug	81-87	alcohol	drug	161-167	false
alcohol	drug	81-87	LEXAPRO	brand	188-194	false
psychotropic medications	group	124-147	alcohol	drug	161-167	false
psychotropic medications	group	124-147	LEXAPRO	brand	188-194	advise
alcohol	drug	161-167	LEXAPRO	brand	188-194	advise

DDI-DrugBank.d568.s2	Monoamine Oxidase Inhibitors (MAOIs)
Monoamine Oxidase Inhibitors	group	0-27	MAOIs	group	30-34	false

DDI-DrugBank.d568.s3	Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)
NSAIDs	group	38-43	Aspirin	brand	46-52	false
NSAIDs	group	38-43	Warfarin	drug	55-62	false
Aspirin	brand	46-52	Warfarin	drug	55-62	false

DDI-DrugBank.d568.s5	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
psychotropic drugs	group	115-132	NSAID	group	269-273	effect
psychotropic drugs	group	115-132	aspirin	brand	278-284	effect
NSAID	group	269-273	aspirin	brand	278-284	false

DDI-DrugBank.d568.s7	Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
Cimetidine	drug	0-9	citalopram	drug	71-80	false
Cimetidine	drug	0-9	cimetidine	drug	121-130	false
Cimetidine	drug	0-9	citalopram	drug	170-179	false
citalopram	drug	71-80	cimetidine	drug	121-130	mechanism
citalopram	drug	71-80	citalopram	drug	170-179	false
cimetidine	drug	121-130	citalopram	drug	170-179	false

DDI-DrugBank.d568.s9	Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
Digoxin	drug	0-6	citalopram	drug	68-77	false
Digoxin	drug	0-6	citalopram	drug	107-116	false
Digoxin	drug	0-6	digoxin	drug	122-128	false
Digoxin	drug	0-6	citalopram	drug	212-221	false
Digoxin	drug	0-6	digoxin	drug	226-232	false
citalopram	drug	68-77	citalopram	drug	107-116	false
citalopram	drug	68-77	digoxin	drug	122-128	false
citalopram	drug	68-77	citalopram	drug	212-221	false
citalopram	drug	68-77	digoxin	drug	226-232	false
citalopram	drug	107-116	digoxin	drug	122-128	false
citalopram	drug	107-116	citalopram	drug	212-221	false
citalopram	drug	107-116	digoxin	drug	226-232	false
digoxin	drug	122-128	citalopram	drug	212-221	false
digoxin	drug	122-128	digoxin	drug	226-232	false
citalopram	drug	212-221	digoxin	drug	226-232	false

DDI-DrugBank.d568.s10	Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.
Lithium	drug	0-6	citalopram	drug	38-47	false
Lithium	drug	0-6	lithium	drug	77-83	false
Lithium	drug	0-6	citalopram	drug	163-172	false
Lithium	drug	0-6	lithium	drug	177-183	false
citalopram	drug	38-47	lithium	drug	77-83	false
citalopram	drug	38-47	citalopram	drug	163-172	false
citalopram	drug	38-47	lithium	drug	177-183	false
lithium	drug	77-83	citalopram	drug	163-172	false
lithium	drug	77-83	lithium	drug	177-183	false
citalopram	drug	163-172	lithium	drug	177-183	false

DDI-DrugBank.d568.s11	Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.
lithium	drug	21-27	lithium	drug	91-97	false

DDI-DrugBank.d568.s12	Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
lithium	drug	8-14	escitalopram	drug	56-67	effect
lithium	drug	8-14	LEXAPRO	brand	103-109	false
lithium	drug	8-14	lithium	drug	115-121	false
escitalopram	drug	56-67	LEXAPRO	brand	103-109	false
escitalopram	drug	56-67	lithium	drug	115-121	false
LEXAPRO	brand	103-109	lithium	drug	115-121	advise

DDI-DrugBank.d568.s13	Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
Pimozide	drug	0-7	Celexa	brand	13-18	false
Pimozide	drug	0-7	pimozide	drug	62-69	false
Pimozide	drug	0-7	citalopram	drug	105-114	false
Pimozide	drug	0-7	pimozide	drug	238-245	false
Celexa	brand	13-18	pimozide	drug	62-69	false
Celexa	brand	13-18	citalopram	drug	105-114	false
Celexa	brand	13-18	pimozide	drug	238-245	false
pimozide	drug	62-69	citalopram	drug	105-114	effect
pimozide	drug	62-69	pimozide	drug	238-245	false
citalopram	drug	105-114	pimozide	drug	238-245	false

DDI-DrugBank.d568.s14	Racemic citalopram did not alter the mean AUC or Cmax of pimozide.
citalopram	drug	8-17	pimozide	drug	57-64	false

DDI-DrugBank.d568.s16	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
Sumatriptan	drug	0-10	selective serotonin reuptake inhibitor	group	149-186	false
Sumatriptan	drug	0-10	SSRI	group	189-192	false
Sumatriptan	drug	0-10	sumatriptan	drug	199-209	false
selective serotonin reuptake inhibitor	group	149-186	SSRI	group	189-192	false
selective serotonin reuptake inhibitor	group	149-186	sumatriptan	drug	199-209	effect
SSRI	group	189-192	sumatriptan	drug	199-209	effect

DDI-DrugBank.d568.s17	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
sumatriptan	drug	30-40	SSRI	group	49-52	advise
sumatriptan	drug	30-40	fluoxetine	drug	61-70	advise
sumatriptan	drug	30-40	fluvoxamine	drug	73-83	advise
sumatriptan	drug	30-40	paroxetine	drug	86-95	advise
sumatriptan	drug	30-40	sertraline	drug	98-107	advise
sumatriptan	drug	30-40	citalopram	drug	110-119	advise
sumatriptan	drug	30-40	escitalopram	drug	122-133	advise
SSRI	group	49-52	fluoxetine	drug	61-70	false
SSRI	group	49-52	fluvoxamine	drug	73-83	false
SSRI	group	49-52	paroxetine	drug	86-95	false
SSRI	group	49-52	sertraline	drug	98-107	false
SSRI	group	49-52	citalopram	drug	110-119	false
SSRI	group	49-52	escitalopram	drug	122-133	false
fluoxetine	drug	61-70	fluvoxamine	drug	73-83	false
fluoxetine	drug	61-70	paroxetine	drug	86-95	false
fluoxetine	drug	61-70	sertraline	drug	98-107	false
fluoxetine	drug	61-70	citalopram	drug	110-119	false
fluoxetine	drug	61-70	escitalopram	drug	122-133	false
fluvoxamine	drug	73-83	paroxetine	drug	86-95	false
fluvoxamine	drug	73-83	sertraline	drug	98-107	false
fluvoxamine	drug	73-83	citalopram	drug	110-119	false
fluvoxamine	drug	73-83	escitalopram	drug	122-133	false
paroxetine	drug	86-95	sertraline	drug	98-107	false
paroxetine	drug	86-95	citalopram	drug	110-119	false
paroxetine	drug	86-95	escitalopram	drug	122-133	false
sertraline	drug	98-107	citalopram	drug	110-119	false
sertraline	drug	98-107	escitalopram	drug	122-133	false
citalopram	drug	110-119	escitalopram	drug	122-133	false

DDI-DrugBank.d568.s18	Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
Theophylline	drug	0-11	citalopram	drug	50-59	false
Theophylline	drug	0-11	theophylline	drug	110-121	false
Theophylline	drug	0-11	theophylline	drug	186-197	false
citalopram	drug	50-59	theophylline	drug	110-121	false
citalopram	drug	50-59	theophylline	drug	186-197	false
theophylline	drug	110-121	theophylline	drug	186-197	false

DDI-DrugBank.d568.s19	The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.
theophylline	drug	14-25	citalopram	drug	54-63	false

DDI-DrugBank.d568.s20	Warfarin - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.
Warfarin	drug	0-7	citalopram	drug	47-56	false
Warfarin	drug	0-7	warfarin	drug	109-116	false
citalopram	drug	47-56	warfarin	drug	109-116	false

DDI-DrugBank.d568.s22	Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
Carbamazepine	drug	0-12	citalopram	drug	51-60	false
Carbamazepine	drug	0-12	carbamazepine	drug	90-102	false
Carbamazepine	drug	0-12	carbamazepine	drug	194-206	false
citalopram	drug	51-60	carbamazepine	drug	90-102	false
citalopram	drug	51-60	carbamazepine	drug	194-206	false
carbamazepine	drug	90-102	carbamazepine	drug	194-206	false

DDI-DrugBank.d568.s23	Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
citalopram	drug	16-25	carbamazepine	drug	98-110	false
citalopram	drug	16-25	carbamazepine	drug	134-146	false
citalopram	drug	16-25	escitalopram	drug	180-191	false
carbamazepine	drug	98-110	carbamazepine	drug	134-146	false
carbamazepine	drug	98-110	escitalopram	drug	180-191	false
carbamazepine	drug	134-146	escitalopram	drug	180-191	mechanism

DDI-DrugBank.d568.s24	Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.
Triazolam	drug	0-8	citalopram	drug	47-56	false
Triazolam	drug	0-8	triazolam	drug	119-127	false
Triazolam	drug	0-8	citalopram	drug	214-223	false
Triazolam	drug	0-8	triazolam	drug	228-236	false
citalopram	drug	47-56	triazolam	drug	119-127	false
citalopram	drug	47-56	citalopram	drug	214-223	false
citalopram	drug	47-56	triazolam	drug	228-236	false
triazolam	drug	119-127	citalopram	drug	214-223	false
triazolam	drug	119-127	triazolam	drug	228-236	false
citalopram	drug	214-223	triazolam	drug	228-236	false

DDI-DrugBank.d568.s25	Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
Ketoconazole	drug	0-11	citalopram	drug	50-59	false
Ketoconazole	drug	0-11	ketoconazole	drug	73-84	false
Ketoconazole	drug	0-11	ketoconazole	drug	125-136	false
Ketoconazole	drug	0-11	citalopram	drug	225-234	false
citalopram	drug	50-59	ketoconazole	drug	73-84	mechanism
citalopram	drug	50-59	ketoconazole	drug	125-136	false
citalopram	drug	50-59	citalopram	drug	225-234	false
ketoconazole	drug	73-84	ketoconazole	drug	125-136	false
ketoconazole	drug	73-84	citalopram	drug	225-234	false
ketoconazole	drug	125-136	citalopram	drug	225-234	false

DDI-DrugBank.d568.s26	Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.
Ritonavir	drug	0-8	ritonavir	drug	56-64	false
Ritonavir	drug	0-8	escitalopram	drug	138-149	false
Ritonavir	drug	0-8	ritonavir	drug	205-213	false
Ritonavir	drug	0-8	escitalopram	drug	218-229	false
ritonavir	drug	56-64	escitalopram	drug	138-149	false
ritonavir	drug	56-64	ritonavir	drug	205-213	false
ritonavir	drug	56-64	escitalopram	drug	218-229	false
escitalopram	drug	138-149	ritonavir	drug	205-213	false
escitalopram	drug	138-149	escitalopram	drug	218-229	false
ritonavir	drug	205-213	escitalopram	drug	218-229	false

DDI-DrugBank.d568.s28	However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.
escitalopram	drug	29-40	ritonavir	drug	54-62	false
escitalopram	drug	29-40	escitalopram	drug	157-168	false
ritonavir	drug	54-62	escitalopram	drug	157-168	false

DDI-DrugBank.d568.s29	Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.
escitalopram	drug	8-19	escitalopram	drug	123-134	false

DDI-DrugBank.d568.s31	In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.
citalopram	drug	44-53	citalopram	drug	181-190	false
citalopram	drug	44-53	escitalopram	drug	232-243	false
citalopram	drug	44-53	escitalopram	drug	332-343	false
citalopram	drug	181-190	escitalopram	drug	232-243	false
citalopram	drug	181-190	escitalopram	drug	332-343	false
escitalopram	drug	232-243	escitalopram	drug	332-343	false

DDI-DrugBank.d568.s32	However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
escitalopram	drug	89-100	escitalopram	drug	129-140	false
escitalopram	drug	89-100	tricyclic antidepressant	group	175-198	false
escitalopram	drug	89-100	desipramine	drug	200-210	false
escitalopram	drug	89-100	desipramine	drug	325-335	false
escitalopram	drug	129-140	tricyclic antidepressant	group	175-198	false
escitalopram	drug	129-140	desipramine	drug	200-210	mechanism
escitalopram	drug	129-140	desipramine	drug	325-335	false
tricyclic antidepressant	group	175-198	desipramine	drug	200-210	false
tricyclic antidepressant	group	175-198	desipramine	drug	325-335	false
desipramine	drug	200-210	desipramine	drug	325-335	false

DDI-DrugBank.d568.s35	Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).
Metoprolol	drug	0-9	LEXAPRO	brand	41-47	false
Metoprolol	drug	0-9	beta-adrenergic blocker	group	149-171	false
Metoprolol	drug	0-9	metoprolol	drug	173-182	false
LEXAPRO	brand	41-47	beta-adrenergic blocker	group	149-171	false
LEXAPRO	brand	41-47	metoprolol	drug	173-182	mechanism
beta-adrenergic blocker	group	149-171	metoprolol	drug	173-182	false

DDI-DrugBank.d568.s37	Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate.
LEXAPRO	brand	20-26	metoprolol	drug	32-41	false

DDI-DrugBank.d568.s39	Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
Citalopram	drug	40-49	Citalopram	drug	51-60	false
Citalopram	drug	40-49	escitalopram	drug	70-81	false
Citalopram	drug	40-49	citalopram	drug	115-124	false
Citalopram	drug	40-49	Celexa	brand	127-132	false
Citalopram	drug	51-60	escitalopram	drug	70-81	false
Citalopram	drug	51-60	citalopram	drug	115-124	false
Citalopram	drug	51-60	Celexa	brand	127-132	false
escitalopram	drug	70-81	citalopram	drug	115-124	advise
escitalopram	drug	70-81	Celexa	brand	127-132	advise
citalopram	drug	115-124	Celexa	brand	127-132	false

DDI-DrugBank.d249.s0	Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
Aspirin	brand	0-6	diclofenac	drug	39-48	false
Aspirin	brand	0-6	aspirin	brand	54-60	false
Aspirin	brand	0-6	diclofenac	drug	89-98	false
Aspirin	brand	0-6	aspirin	brand	177-183	false
diclofenac	drug	39-48	aspirin	brand	54-60	advise
diclofenac	drug	39-48	diclofenac	drug	89-98	false
diclofenac	drug	39-48	aspirin	brand	177-183	false
aspirin	brand	54-60	diclofenac	drug	89-98	false
aspirin	brand	54-60	aspirin	brand	177-183	false
diclofenac	drug	89-98	aspirin	brand	177-183	mechanism

DDI-DrugBank.d249.s1	Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.
Anticoagulants	group	0-13	diclofenac	drug	45-54	false
Anticoagulants	group	0-13	anticoagulants of the warfarin type	group	73-107	false
Anticoagulants	group	0-13	NSAIDs	group	197-202	false
diclofenac	drug	45-54	anticoagulants of the warfarin type	group	73-107	false
diclofenac	drug	45-54	NSAIDs	group	197-202	advise
anticoagulants of the warfarin type	group	73-107	NSAIDs	group	197-202	false

DDI-DrugBank.d249.s2	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
NSAIDs	group	65-70	NSAIDs	group	134-139	false
NSAIDs	group	65-70	diclofenac	drug	152-161	false
NSAIDs	group	65-70	warfarin	drug	168-175	false
NSAIDs	group	65-70	anticoagulant	group	253-265	false
NSAIDs	group	134-139	diclofenac	drug	152-161	false
NSAIDs	group	134-139	warfarin	drug	168-175	advise
NSAIDs	group	134-139	anticoagulant	group	253-265	false
diclofenac	drug	152-161	warfarin	drug	168-175	advise
diclofenac	drug	152-161	anticoagulant	group	253-265	false
warfarin	drug	168-175	anticoagulant	group	253-265	false

DDI-DrugBank.d249.s3	Digoxin, Methotrexate, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.
Digoxin	drug	0-6	Methotrexate	drug	9-20	false
Digoxin	drug	0-6	Cyclosporine	drug	23-34	false
Digoxin	drug	0-6	Diclofenac	drug	37-46	false
Digoxin	drug	0-6	NSAIDs	group	60-65	false
Methotrexate	drug	9-20	Cyclosporine	drug	23-34	false
Methotrexate	drug	9-20	Diclofenac	drug	37-46	false
Methotrexate	drug	9-20	NSAIDs	group	60-65	false
Cyclosporine	drug	23-34	Diclofenac	drug	37-46	false
Cyclosporine	drug	23-34	NSAIDs	group	60-65	false
Diclofenac	drug	37-46	NSAIDs	group	60-65	false

DDI-DrugBank.d249.s4	Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
diclofenac	drug	13-22	digoxin	drug	61-67	mechanism
diclofenac	drug	13-22	methotrexate	drug	73-84	mechanism
diclofenac	drug	13-22	cyclosporine	drug	99-110	effect
digoxin	drug	61-67	methotrexate	drug	73-84	false
digoxin	drug	61-67	cyclosporine	drug	99-110	false
methotrexate	drug	73-84	cyclosporine	drug	99-110	false

DDI-DrugBank.d249.s5	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
diclofenac	drug	26-35	diclofenac	drug	59-68	false
diclofenac	drug	26-35	NSAID	group	88-92	false
diclofenac	drug	26-35	digoxin	drug	107-113	effect
diclofenac	drug	26-35	methotrexate	drug	116-127	effect
diclofenac	drug	26-35	cyclosporine	drug	133-144	effect
diclofenac	drug	59-68	NSAID	group	88-92	false
diclofenac	drug	59-68	digoxin	drug	107-113	false
diclofenac	drug	59-68	methotrexate	drug	116-127	false
diclofenac	drug	59-68	cyclosporine	drug	133-144	false
NSAID	group	88-92	digoxin	drug	107-113	effect
NSAID	group	88-92	methotrexate	drug	116-127	effect
NSAID	group	88-92	cyclosporine	drug	133-144	effect
digoxin	drug	107-113	methotrexate	drug	116-127	false
digoxin	drug	107-113	cyclosporine	drug	133-144	false
methotrexate	drug	116-127	cyclosporine	drug	133-144	false

DDI-DrugBank.d249.s8	Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
Lithium	drug	0-6	Diclofenac	drug	9-18	false
Lithium	drug	0-6	lithium	drug	30-36	false
Lithium	drug	0-6	lithium	drug	68-74	false
Diclofenac	drug	9-18	lithium	drug	30-36	mechanism
Diclofenac	drug	9-18	lithium	drug	68-74	mechanism
lithium	drug	30-36	lithium	drug	68-74	false

DDI-DrugBank.d249.s9	In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
diclofenac	drug	19-28	lithium	drug	34-40	effect
diclofenac	drug	19-28	lithium	drug	57-63	false
lithium	drug	34-40	lithium	drug	57-63	false

DDI-DrugBank.d249.s10	Oral Hypoglycemics: Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents.
Hypoglycemics	group	5-17	Diclofenac	drug	20-29	false
Hypoglycemics	group	5-17	hypoglycemic agents	group	122-140	false
Diclofenac	drug	20-29	hypoglycemic agents	group	122-140	false

DDI-DrugBank.d249.s11	There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
insulin	drug	86-92	hypoglycemic agents	group	102-120	false
insulin	drug	86-92	diclofenac	drug	141-150	effect
hypoglycemic agents	group	102-120	diclofenac	drug	141-150	effect

DDI-DrugBank.d249.s13	A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
diclofenac	drug	107-116	insulin	drug	161-167	effect
diclofenac	drug	107-116	hypoglycemic agents	group	177-195	effect
insulin	drug	161-167	hypoglycemic agents	group	177-195	false

DDI-DrugBank.d249.s14	Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
Diuretics	group	0-8	Diclofenac	drug	11-20	false
Diuretics	group	0-8	NSAIDs	group	32-37	false
Diuretics	group	0-8	diuretics	group	67-75	false
Diclofenac	drug	11-20	NSAIDs	group	32-37	false
Diclofenac	drug	11-20	diuretics	group	67-75	effect
NSAIDs	group	32-37	diuretics	group	67-75	effect

DDI-DrugBank.d249.s16	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
azathioprine	drug	101-112	gold	group	115-118	false
azathioprine	drug	101-112	chloroquine	drug	121-131	false
azathioprine	drug	101-112	D-penicillamine	drug	134-148	false
azathioprine	drug	101-112	prednisolone	drug	151-162	false
azathioprine	drug	101-112	doxycycline	drug	165-175	false
azathioprine	drug	101-112	digitoxin	drug	181-189	false
azathioprine	drug	101-112	diclofenac	drug	254-263	false
gold	group	115-118	chloroquine	drug	121-131	false
gold	group	115-118	D-penicillamine	drug	134-148	false
gold	group	115-118	prednisolone	drug	151-162	false
gold	group	115-118	doxycycline	drug	165-175	false
gold	group	115-118	digitoxin	drug	181-189	false
gold	group	115-118	diclofenac	drug	254-263	false
chloroquine	drug	121-131	D-penicillamine	drug	134-148	false
chloroquine	drug	121-131	prednisolone	drug	151-162	false
chloroquine	drug	121-131	doxycycline	drug	165-175	false
chloroquine	drug	121-131	digitoxin	drug	181-189	false
chloroquine	drug	121-131	diclofenac	drug	254-263	false
D-penicillamine	drug	134-148	prednisolone	drug	151-162	false
D-penicillamine	drug	134-148	doxycycline	drug	165-175	false
D-penicillamine	drug	134-148	digitoxin	drug	181-189	false
D-penicillamine	drug	134-148	diclofenac	drug	254-263	false
prednisolone	drug	151-162	doxycycline	drug	165-175	false
prednisolone	drug	151-162	digitoxin	drug	181-189	false
prednisolone	drug	151-162	diclofenac	drug	254-263	false
doxycycline	drug	165-175	digitoxin	drug	181-189	false
doxycycline	drug	165-175	diclofenac	drug	254-263	false
digitoxin	drug	181-189	diclofenac	drug	254-263	false

DDI-DrugBank.d249.s17	Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.
Phenobarbital	drug	0-12	phenobarbital	drug	82-94	false
Phenobarbital	drug	0-12	diclofenac	drug	134-143	false
phenobarbital	drug	82-94	diclofenac	drug	134-143	effect

DDI-DrugBank.d249.s18	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
diclofenac	drug	26-35	salicylic acid	drug	100-113	mechanism
diclofenac	drug	26-35	tolbutamide	drug	142-152	mechanism
diclofenac	drug	26-35	prednisolone	drug	155-166	mechanism
diclofenac	drug	26-35	warfarin	drug	198-205	mechanism
salicylic acid	drug	100-113	tolbutamide	drug	142-152	false
salicylic acid	drug	100-113	prednisolone	drug	155-166	false
salicylic acid	drug	100-113	warfarin	drug	198-205	false
tolbutamide	drug	142-152	prednisolone	drug	155-166	false
tolbutamide	drug	142-152	warfarin	drug	198-205	false
prednisolone	drug	155-166	warfarin	drug	198-205	false

DDI-DrugBank.d249.s19	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
Benzylpenicillin	drug	0-15	ampicillin	drug	18-27	false
Benzylpenicillin	drug	0-15	oxacillin	drug	30-38	false
Benzylpenicillin	drug	0-15	chlortetracycline	drug	41-57	false
Benzylpenicillin	drug	0-15	doxycycline	drug	60-70	false
Benzylpenicillin	drug	0-15	cephalothin	drug	73-83	false
Benzylpenicillin	drug	0-15	erythromycin	drug	86-97	false
Benzylpenicillin	drug	0-15	sulfamethoxazole	drug	104-119	false
Benzylpenicillin	drug	0-15	diclofenac	drug	174-183	false
ampicillin	drug	18-27	oxacillin	drug	30-38	false
ampicillin	drug	18-27	chlortetracycline	drug	41-57	false
ampicillin	drug	18-27	doxycycline	drug	60-70	false
ampicillin	drug	18-27	cephalothin	drug	73-83	false
ampicillin	drug	18-27	erythromycin	drug	86-97	false
ampicillin	drug	18-27	sulfamethoxazole	drug	104-119	false
ampicillin	drug	18-27	diclofenac	drug	174-183	false
oxacillin	drug	30-38	chlortetracycline	drug	41-57	false
oxacillin	drug	30-38	doxycycline	drug	60-70	false
oxacillin	drug	30-38	cephalothin	drug	73-83	false
oxacillin	drug	30-38	erythromycin	drug	86-97	false
oxacillin	drug	30-38	sulfamethoxazole	drug	104-119	false
oxacillin	drug	30-38	diclofenac	drug	174-183	false
chlortetracycline	drug	41-57	doxycycline	drug	60-70	false
chlortetracycline	drug	41-57	cephalothin	drug	73-83	false
chlortetracycline	drug	41-57	erythromycin	drug	86-97	false
chlortetracycline	drug	41-57	sulfamethoxazole	drug	104-119	false
chlortetracycline	drug	41-57	diclofenac	drug	174-183	false
doxycycline	drug	60-70	cephalothin	drug	73-83	false
doxycycline	drug	60-70	erythromycin	drug	86-97	false
doxycycline	drug	60-70	sulfamethoxazole	drug	104-119	false
doxycycline	drug	60-70	diclofenac	drug	174-183	false
cephalothin	drug	73-83	erythromycin	drug	86-97	false
cephalothin	drug	73-83	sulfamethoxazole	drug	104-119	false
cephalothin	drug	73-83	diclofenac	drug	174-183	false
erythromycin	drug	86-97	sulfamethoxazole	drug	104-119	false
erythromycin	drug	86-97	diclofenac	drug	174-183	false
sulfamethoxazole	drug	104-119	diclofenac	drug	174-183	false

DDI-DrugBank.d211.s2	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
Bacteriostatic Antibiotics	group	0-25	Chloramphenicol	drug	28-42	false
Bacteriostatic Antibiotics	group	0-25	erythromycins	drug	45-57	false
Bacteriostatic Antibiotics	group	0-25	sulfonamides	group	60-71	false
Bacteriostatic Antibiotics	group	0-25	tetracyclines	group	77-89	false
Bacteriostatic Antibiotics	group	0-25	penicillins	group	137-147	false
Chloramphenicol	drug	28-42	erythromycins	drug	45-57	false
Chloramphenicol	drug	28-42	sulfonamides	group	60-71	false
Chloramphenicol	drug	28-42	tetracyclines	group	77-89	false
Chloramphenicol	drug	28-42	penicillins	group	137-147	effect
erythromycins	drug	45-57	sulfonamides	group	60-71	false
erythromycins	drug	45-57	tetracyclines	group	77-89	false
erythromycins	drug	45-57	penicillins	group	137-147	effect
sulfonamides	group	60-71	tetracyclines	group	77-89	false
sulfonamides	group	60-71	penicillins	group	137-147	effect
tetracyclines	group	77-89	penicillins	group	137-147	effect

DDI-DrugBank.d211.s5	Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
Probenecid	drug	0-9	ampicillin	drug	52-61	mechanism
Probenecid	drug	0-9	ampicillin	drug	106-115	false
ampicillin	drug	52-61	ampicillin	drug	106-115	false

DDI-DrugBank.d211.s6	Drug/Laboratory Test Interaction After treatment with ampicillin, a false-positive reaction for glucose in the urine may occur with copper sulfate tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.
ampicillin	drug	54-63	copper sulfate	drug_n	132-145	false

DDI-DrugBank.d369.s1	These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.
androgens	group	60-68	estrogens	group	71-79	false
androgens	group	60-68	progestins	group	82-91	false
androgens	group	60-68	glucocorticoids	group	97-111	false
estrogens	group	71-79	progestins	group	82-91	false
estrogens	group	71-79	glucocorticoids	group	97-111	false
progestins	group	82-91	glucocorticoids	group	97-111	false

DDI-DrugBank.d369.s2	The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.
spironolactone	drug	55-68	levodopa	drug	93-100	false
spironolactone	drug	55-68	contraceptives	group	126-139	false
spironolactone	drug	55-68	digoxin	drug	145-151	false
levodopa	drug	93-100	contraceptives	group	126-139	false
levodopa	drug	93-100	digoxin	drug	145-151	false
contraceptives	group	126-139	digoxin	drug	145-151	false

DDI-DrugBank.d369.s3	The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
Factrel	brand	16-22	phenothiazines	group	42-55	effect
Factrel	brand	16-22	dopamine antagonists	group	61-80	effect
phenothiazines	group	42-55	dopamine antagonists	group	61-80	false

DDI-DrugBank.d314.s0	Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.
Aminoglutethimide	drug	0-16	Aminoglutethimide	drug	19-35	false
Aminoglutethimide	drug	0-16	corticosteroids	group	73-87	false
Aminoglutethimide	drug	19-35	corticosteroids	group	73-87	effect

DDI-DrugBank.d314.s1	Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
Amphotericin B	drug	0-13	corticosteroids	group	62-76	false
Amphotericin B	drug	0-13	amphotericin B	drug	148-161	false
Amphotericin B	drug	0-13	diuretics	group	164-172	false
corticosteroids	group	62-76	amphotericin B	drug	148-161	advise
corticosteroids	group	62-76	diuretics	group	164-172	advise
amphotericin B	drug	148-161	diuretics	group	164-172	false

DDI-DrugBank.d314.s2	In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
amphotericin B	drug	72-85	hydrocortisone	drug	91-104	effect

DDI-DrugBank.d314.s3	Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.
Antibiotics	group	0-10	Macrolide antibiotics	group	13-33	false
Antibiotics	group	0-10	corticosteroid	group	89-102	false
Macrolide antibiotics	group	13-33	corticosteroid	group	89-102	mechanism

DDI-DrugBank.d314.s4	Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.
Anticholinesterases	group	0-18	anticholinesterase agents	group	40-64	false
Anticholinesterases	group	0-18	corticosteroids	group	70-84	false
anticholinesterase agents	group	40-64	corticosteroids	group	70-84	effect

DDI-DrugBank.d314.s5	If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.
anticholinesterase agents	group	13-37	corticosteroid	group	95-108	advise

DDI-DrugBank.d314.s6	Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.
Anticoagulants	group	0-13	corticosteroids	group	43-57	false
Anticoagulants	group	0-13	warfarin	drug	63-70	false
Anticoagulants	group	0-13	warfarin	drug	117-124	false
corticosteroids	group	43-57	warfarin	drug	63-70	effect
corticosteroids	group	43-57	warfarin	drug	117-124	false
warfarin	drug	63-70	warfarin	drug	117-124	false

DDI-DrugBank.d314.s8	Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
Antidiabetics	group	0-12	corticosteroids	group	23-37	false
Antidiabetics	group	0-12	antidiabetic agents	group	104-122	false
corticosteroids	group	23-37	antidiabetic agents	group	104-122	effect

DDI-DrugBank.d314.s10	Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.
Cholestyramine	drug	0-13	Cholestyramine	drug	16-29	false
Cholestyramine	drug	0-13	corticosteroids	group	61-75	false
Cholestyramine	drug	16-29	corticosteroids	group	61-75	mechanism

DDI-DrugBank.d314.s11	Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.
Cyclosporine	drug	0-11	cyclosporine	drug	41-52	false
Cyclosporine	drug	0-11	corticosteroids	group	58-72	false
cyclosporine	drug	41-52	corticosteroids	group	58-72	effect

DDI-DrugBank.d314.s15	Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.
Digitalis glycosides	group	0-19	digitalis glycosides	group	34-53	false

DDI-DrugBank.d314.s16	Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
Ephedrine	drug	0-8	Ephedrine	drug	11-19	false
Ephedrine	drug	0-8	corticosteroids	group	60-74	false
Ephedrine	drug	0-8	corticosteroid	group	178-191	false
Ephedrine	drug	11-19	corticosteroids	group	60-74	mechanism
Ephedrine	drug	11-19	corticosteroid	group	178-191	false
corticosteroids	group	60-74	corticosteroid	group	178-191	false

DDI-DrugBank.d314.s17	Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
Estrogens	group	0-8	contraceptives	group	26-39	false
Estrogens	group	0-8	Estrogens	group	42-50	false
Estrogens	group	0-8	corticosteroids	group	99-113	false
contraceptives	group	26-39	Estrogens	group	42-50	false
contraceptives	group	26-39	corticosteroids	group	99-113	false
Estrogens	group	42-50	corticosteroids	group	99-113	mechanism

DDI-DrugBank.d314.s18	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
barbiturates	group	124-135	phenytoin	drug	138-146	false
barbiturates	group	124-135	carbamazepine	drug	149-161	false
barbiturates	group	124-135	rifampin	drug	164-171	false
barbiturates	group	124-135	corticosteroids	group	204-218	mechanism
barbiturates	group	124-135	corticosteroid	group	255-268	false
phenytoin	drug	138-146	carbamazepine	drug	149-161	false
phenytoin	drug	138-146	rifampin	drug	164-171	false
phenytoin	drug	138-146	corticosteroids	group	204-218	mechanism
phenytoin	drug	138-146	corticosteroid	group	255-268	false
carbamazepine	drug	149-161	rifampin	drug	164-171	false
carbamazepine	drug	149-161	corticosteroids	group	204-218	mechanism
carbamazepine	drug	149-161	corticosteroid	group	255-268	false
rifampin	drug	164-171	corticosteroids	group	204-218	mechanism
rifampin	drug	164-171	corticosteroid	group	255-268	false
corticosteroids	group	204-218	corticosteroid	group	255-268	false

DDI-DrugBank.d314.s19	Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
ketoconazole	drug	35-46	macrolide antibiotics	group	49-69	false
ketoconazole	drug	35-46	erythromycin	drug	79-90	false
ketoconazole	drug	35-46	corticosteroids	group	160-174	mechanism
macrolide antibiotics	group	49-69	erythromycin	drug	79-90	false
macrolide antibiotics	group	49-69	corticosteroids	group	160-174	mechanism
erythromycin	drug	79-90	corticosteroids	group	160-174	mechanism

DDI-DrugBank.d314.s21	Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.
indinavir	drug	74-82	erythromycin	drug	85-96	false

DDI-DrugBank.d314.s22	Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.
Ketoconazole	drug	0-11	Ketoconazole	drug	14-25	false
Ketoconazole	drug	0-11	corticosteroids	group	83-97	false
Ketoconazole	drug	0-11	corticosteroid	group	142-155	false
Ketoconazole	drug	14-25	corticosteroids	group	83-97	mechanism
Ketoconazole	drug	14-25	corticosteroid	group	142-155	false
corticosteroids	group	83-97	corticosteroid	group	142-155	false

DDI-DrugBank.d314.s23	In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.
ketoconazole	drug	13-24	corticosteroid	drug	52-65	effect

DDI-DrugBank.d314.s24	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
Nonsteroidal anti-inflammatory agents	group	0-36	NSAIDS	group	39-44	false
Nonsteroidal anti-inflammatory agents	group	0-36	aspirin	brand	67-73	false
Nonsteroidal anti-inflammatory agents	group	0-36	nonsteroidal antiinflammatory agents	group	85-120	false
Nonsteroidal anti-inflammatory agents	group	0-36	corticosteroids	group	127-141	false
NSAIDS	group	39-44	aspirin	brand	67-73	false
NSAIDS	group	39-44	nonsteroidal antiinflammatory agents	group	85-120	false
NSAIDS	group	39-44	corticosteroids	group	127-141	false
aspirin	brand	67-73	nonsteroidal antiinflammatory agents	group	85-120	false
aspirin	brand	67-73	corticosteroids	group	127-141	effect
nonsteroidal antiinflammatory agents	group	85-120	corticosteroids	group	127-141	effect

DDI-DrugBank.d314.s25	Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
Aspirin	brand	0-6	corticosteroids	group	54-68	advise

DDI-DrugBank.d314.s26	The clearance of salicylates may be increased with concurrent use of corticosteroids.
salicylates	group	17-27	corticosteroids	group	69-83	mechanism

DDI-DrugBank.d314.s27	Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
Phenytoin	drug	0-8	phenytoin	drug	100-108	false
Phenytoin	drug	0-8	dexamethasone	drug	122-134	false
phenytoin	drug	100-108	dexamethasone	drug	122-134	mechanism

DDI-DrugBank.d314.s29	Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.
Thalidomide	drug	0-10	thalidomide	drug	36-46	false

DDI-DrugBank.d314.s30	Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
Vaccines	group	0-7	corticosteroid	group	22-35	false
Vaccines	group	0-7	live vaccines	group	94-97;114-121	false
Vaccines	group	0-7	inactivated vaccines	group	102-121	false
corticosteroid	group	22-35	live vaccines	group	94-97;114-121	effect
corticosteroid	group	22-35	inactivated vaccines	group	102-121	effect
live vaccines	group	94-97;114-121	inactivated vaccines	group	102-121	false

DDI-DrugBank.d314.s31	Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.
Corticosteroids	group	0-14	live attenuated vaccines	group	83-106	effect

DDI-DrugBank.d314.s32	Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.
vaccines	group	26-33	corticosteroid	group	71-84	advise

DDI-DrugBank.d124.s1	Several drug interaction studies have been completed with both INVIRASE and FORTOVASE.
INVIRASE	brand	63-70	FORTOVASE	brand	76-84	false

DDI-DrugBank.d124.s2	Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE.
FORTOVASE	brand	48-56	INVIRASE	brand	84-91	false

DDI-DrugBank.d124.s3	Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent.
ritonavir	drug	8-16	ritonavir	drug	102-110	false

DDI-DrugBank.d124.s9	Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below.
INVIRASE	brand	68-75	ritonavir	drug	81-89	false

DDI-DrugBank.d124.s12	Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir
INVIRASE	brand	45-52	Ritonavir	drug	54-62	false

DDI-DrugBank.d124.s14	Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
Antiarrhythmics	group	0-14	Amiodarone	drug	17-26	false
Antiarrhythmics	group	0-14	bepridil	drug	29-36	false
Antiarrhythmics	group	0-14	flecainide	drug	39-48	false
Antiarrhythmics	group	0-14	propafenone	drug	51-61	false
Antiarrhythmics	group	0-14	quinidine	drug	64-72	false
Amiodarone	drug	17-26	bepridil	drug	29-36	false
Amiodarone	drug	17-26	flecainide	drug	39-48	false
Amiodarone	drug	17-26	propafenone	drug	51-61	false
Amiodarone	drug	17-26	quinidine	drug	64-72	false
bepridil	drug	29-36	flecainide	drug	39-48	false
bepridil	drug	29-36	propafenone	drug	51-61	false
bepridil	drug	29-36	quinidine	drug	64-72	false
flecainide	drug	39-48	propafenone	drug	51-61	false
flecainide	drug	39-48	quinidine	drug	64-72	false
propafenone	drug	51-61	quinidine	drug	64-72	false

DDI-DrugBank.d124.s15	Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.
Antihistamines	drug	0-13	astemizole	drug	16-25	false
Antihistamines	drug	0-13	terfenadine	drug	29-39	false
astemizole	drug	16-25	terfenadine	drug	29-39	false

DDI-DrugBank.d124.s16	Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
Ergot Derivatives	group	0-16	Dihydroergotamine	drug	19-35	false
Ergot Derivatives	group	0-16	ergonovine	drug	38-47	false
Ergot Derivatives	group	0-16	ergotamine	drug	50-59	false
Ergot Derivatives	group	0-16	methylergonovine	drug	62-77	false
Ergot Derivatives	group	0-16	ergot	group	169-173	false
Dihydroergotamine	drug	19-35	ergonovine	drug	38-47	false
Dihydroergotamine	drug	19-35	ergotamine	drug	50-59	false
Dihydroergotamine	drug	19-35	methylergonovine	drug	62-77	false
Dihydroergotamine	drug	19-35	ergot	group	169-173	false
ergonovine	drug	38-47	ergotamine	drug	50-59	false
ergonovine	drug	38-47	methylergonovine	drug	62-77	false
ergonovine	drug	38-47	ergot	group	169-173	false
ergotamine	drug	50-59	methylergonovine	drug	62-77	false
ergotamine	drug	50-59	ergot	group	169-173	false
methylergonovine	drug	62-77	ergot	group	169-173	false

DDI-DrugBank.d124.s17	Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.
Antimycobacterial Agents	group	0-23	rifampin	drug	26-33	false
Antimycobacterial Agents	group	0-23	saquinavir	drug	99-108	false
Antimycobacterial Agents	group	0-23	antiretroviral	group	116-129	false
Antimycobacterial Agents	group	0-23	saquinavir	drug	176-185	false
rifampin	drug	26-33	saquinavir	drug	99-108	false
rifampin	drug	26-33	antiretroviral	group	116-129	false
rifampin	drug	26-33	saquinavir	drug	176-185	false
saquinavir	drug	99-108	antiretroviral	group	116-129	false
saquinavir	drug	99-108	saquinavir	drug	176-185	false
antiretroviral	group	116-129	saquinavir	drug	176-185	false

DDI-DrugBank.d124.s18	Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.
saquinavir	drug	64-73	FORTOVASE	brand	76-84	false
saquinavir	drug	64-73	protease inhibitor	group	99-116	false
saquinavir	drug	64-73	saquinavir	drug	147-156	false
FORTOVASE	brand	76-84	protease inhibitor	group	99-116	false
FORTOVASE	brand	76-84	saquinavir	drug	147-156	false
protease inhibitor	group	99-116	saquinavir	drug	147-156	false

DDI-DrugBank.d124.s19	No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules.
INVIRASE	brand	50-57	ritonavir	drug	59-67	false
INVIRASE	brand	50-57	FORTOVASE	brand	72-80	false
INVIRASE	brand	50-57	ritonavir	drug	82-90	false
ritonavir	drug	59-67	FORTOVASE	brand	72-80	false
ritonavir	drug	59-67	ritonavir	drug	82-90	false
FORTOVASE	brand	72-80	ritonavir	drug	82-90	false

DDI-DrugBank.d124.s22	HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.
HMG-CoA Reductase Inhibitors	group	0-27	lovastatin	drug	30-39	false
HMG-CoA Reductase Inhibitors	group	0-27	simvastatin	drug	42-52	false
lovastatin	drug	30-39	simvastatin	drug	42-52	false

DDI-DrugBank.d124.s23	Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
Sedatives	group	0-8	Hypnotics	group	10-18	false
Sedatives	group	0-8	triazolam	drug	21-29	false
Sedatives	group	0-8	midazolam	drug	32-40	false
Hypnotics	group	10-18	triazolam	drug	21-29	false
Hypnotics	group	10-18	midazolam	drug	32-40	false
triazolam	drug	21-29	midazolam	drug	32-40	false

DDI-DrugBank.d124.s26	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
calcium channel blockers	group	122-145	dapsone	drug	148-154	false
calcium channel blockers	group	122-145	disopyramide	drug	157-168	false
calcium channel blockers	group	122-145	quinine	drug	171-177	false
calcium channel blockers	group	122-145	amiodarone	drug	180-189	false
calcium channel blockers	group	122-145	quinidine	drug	192-200	false
calcium channel blockers	group	122-145	warfarin	drug	203-210	false
calcium channel blockers	group	122-145	tacrolimus	drug	213-222	false
calcium channel blockers	group	122-145	cyclosporine	drug	225-236	false
calcium channel blockers	group	122-145	ergot derivatives	group	239-255	false
calcium channel blockers	group	122-145	pimozide	drug	258-265	false
calcium channel blockers	group	122-145	carbamazepine	drug	268-280	false
calcium channel blockers	group	122-145	fentanyl	drug	283-290	false
calcium channel blockers	group	122-145	alfentanyl	drug	293-302	false
calcium channel blockers	group	122-145	alprazolam	drug	305-314	false
calcium channel blockers	group	122-145	triazolam	drug	321-329	false
calcium channel blockers	group	122-145	saquinavir	drug	397-406	mechanism
dapsone	drug	148-154	disopyramide	drug	157-168	false
dapsone	drug	148-154	quinine	drug	171-177	false
dapsone	drug	148-154	amiodarone	drug	180-189	false
dapsone	drug	148-154	quinidine	drug	192-200	false
dapsone	drug	148-154	warfarin	drug	203-210	false
dapsone	drug	148-154	tacrolimus	drug	213-222	false
dapsone	drug	148-154	cyclosporine	drug	225-236	false
dapsone	drug	148-154	ergot derivatives	group	239-255	false
dapsone	drug	148-154	pimozide	drug	258-265	false
dapsone	drug	148-154	carbamazepine	drug	268-280	false
dapsone	drug	148-154	fentanyl	drug	283-290	false
dapsone	drug	148-154	alfentanyl	drug	293-302	false
dapsone	drug	148-154	alprazolam	drug	305-314	false
dapsone	drug	148-154	triazolam	drug	321-329	false
dapsone	drug	148-154	saquinavir	drug	397-406	mechanism
disopyramide	drug	157-168	quinine	drug	171-177	false
disopyramide	drug	157-168	amiodarone	drug	180-189	false
disopyramide	drug	157-168	quinidine	drug	192-200	false
disopyramide	drug	157-168	warfarin	drug	203-210	false
disopyramide	drug	157-168	tacrolimus	drug	213-222	false
disopyramide	drug	157-168	cyclosporine	drug	225-236	false
disopyramide	drug	157-168	ergot derivatives	group	239-255	false
disopyramide	drug	157-168	pimozide	drug	258-265	false
disopyramide	drug	157-168	carbamazepine	drug	268-280	false
disopyramide	drug	157-168	fentanyl	drug	283-290	false
disopyramide	drug	157-168	alfentanyl	drug	293-302	false
disopyramide	drug	157-168	alprazolam	drug	305-314	false
disopyramide	drug	157-168	triazolam	drug	321-329	false
disopyramide	drug	157-168	saquinavir	drug	397-406	mechanism
quinine	drug	171-177	amiodarone	drug	180-189	false
quinine	drug	171-177	quinidine	drug	192-200	false
quinine	drug	171-177	warfarin	drug	203-210	false
quinine	drug	171-177	tacrolimus	drug	213-222	false
quinine	drug	171-177	cyclosporine	drug	225-236	false
quinine	drug	171-177	ergot derivatives	group	239-255	false
quinine	drug	171-177	pimozide	drug	258-265	false
quinine	drug	171-177	carbamazepine	drug	268-280	false
quinine	drug	171-177	fentanyl	drug	283-290	false
quinine	drug	171-177	alfentanyl	drug	293-302	false
quinine	drug	171-177	alprazolam	drug	305-314	false
quinine	drug	171-177	triazolam	drug	321-329	false
quinine	drug	171-177	saquinavir	drug	397-406	mechanism
amiodarone	drug	180-189	quinidine	drug	192-200	false
amiodarone	drug	180-189	warfarin	drug	203-210	false
amiodarone	drug	180-189	tacrolimus	drug	213-222	false
amiodarone	drug	180-189	cyclosporine	drug	225-236	false
amiodarone	drug	180-189	ergot derivatives	group	239-255	false
amiodarone	drug	180-189	pimozide	drug	258-265	false
amiodarone	drug	180-189	carbamazepine	drug	268-280	false
amiodarone	drug	180-189	fentanyl	drug	283-290	false
amiodarone	drug	180-189	alfentanyl	drug	293-302	false
amiodarone	drug	180-189	alprazolam	drug	305-314	false
amiodarone	drug	180-189	triazolam	drug	321-329	false
amiodarone	drug	180-189	saquinavir	drug	397-406	mechanism
quinidine	drug	192-200	warfarin	drug	203-210	false
quinidine	drug	192-200	tacrolimus	drug	213-222	false
quinidine	drug	192-200	cyclosporine	drug	225-236	false
quinidine	drug	192-200	ergot derivatives	group	239-255	false
quinidine	drug	192-200	pimozide	drug	258-265	false
quinidine	drug	192-200	carbamazepine	drug	268-280	false
quinidine	drug	192-200	fentanyl	drug	283-290	false
quinidine	drug	192-200	alfentanyl	drug	293-302	false
quinidine	drug	192-200	alprazolam	drug	305-314	false
quinidine	drug	192-200	triazolam	drug	321-329	false
quinidine	drug	192-200	saquinavir	drug	397-406	mechanism
warfarin	drug	203-210	tacrolimus	drug	213-222	false
warfarin	drug	203-210	cyclosporine	drug	225-236	false
warfarin	drug	203-210	ergot derivatives	group	239-255	false
warfarin	drug	203-210	pimozide	drug	258-265	false
warfarin	drug	203-210	carbamazepine	drug	268-280	false
warfarin	drug	203-210	fentanyl	drug	283-290	false
warfarin	drug	203-210	alfentanyl	drug	293-302	false
warfarin	drug	203-210	alprazolam	drug	305-314	false
warfarin	drug	203-210	triazolam	drug	321-329	false
warfarin	drug	203-210	saquinavir	drug	397-406	mechanism
tacrolimus	drug	213-222	cyclosporine	drug	225-236	false
tacrolimus	drug	213-222	ergot derivatives	group	239-255	false
tacrolimus	drug	213-222	pimozide	drug	258-265	false
tacrolimus	drug	213-222	carbamazepine	drug	268-280	false
tacrolimus	drug	213-222	fentanyl	drug	283-290	false
tacrolimus	drug	213-222	alfentanyl	drug	293-302	false
tacrolimus	drug	213-222	alprazolam	drug	305-314	false
tacrolimus	drug	213-222	triazolam	drug	321-329	false
tacrolimus	drug	213-222	saquinavir	drug	397-406	mechanism
cyclosporine	drug	225-236	ergot derivatives	group	239-255	false
cyclosporine	drug	225-236	pimozide	drug	258-265	false
cyclosporine	drug	225-236	carbamazepine	drug	268-280	false
cyclosporine	drug	225-236	fentanyl	drug	283-290	false
cyclosporine	drug	225-236	alfentanyl	drug	293-302	false
cyclosporine	drug	225-236	alprazolam	drug	305-314	false
cyclosporine	drug	225-236	triazolam	drug	321-329	false
cyclosporine	drug	225-236	saquinavir	drug	397-406	mechanism
ergot derivatives	group	239-255	pimozide	drug	258-265	false
ergot derivatives	group	239-255	carbamazepine	drug	268-280	false
ergot derivatives	group	239-255	fentanyl	drug	283-290	false
ergot derivatives	group	239-255	alfentanyl	drug	293-302	false
ergot derivatives	group	239-255	alprazolam	drug	305-314	false
ergot derivatives	group	239-255	triazolam	drug	321-329	false
ergot derivatives	group	239-255	saquinavir	drug	397-406	mechanism
pimozide	drug	258-265	carbamazepine	drug	268-280	false
pimozide	drug	258-265	fentanyl	drug	283-290	false
pimozide	drug	258-265	alfentanyl	drug	293-302	false
pimozide	drug	258-265	alprazolam	drug	305-314	false
pimozide	drug	258-265	triazolam	drug	321-329	false
pimozide	drug	258-265	saquinavir	drug	397-406	mechanism
carbamazepine	drug	268-280	fentanyl	drug	283-290	false
carbamazepine	drug	268-280	alfentanyl	drug	293-302	false
carbamazepine	drug	268-280	alprazolam	drug	305-314	false
carbamazepine	drug	268-280	triazolam	drug	321-329	false
carbamazepine	drug	268-280	saquinavir	drug	397-406	mechanism
fentanyl	drug	283-290	alfentanyl	drug	293-302	false
fentanyl	drug	283-290	alprazolam	drug	305-314	false
fentanyl	drug	283-290	triazolam	drug	321-329	false
fentanyl	drug	283-290	saquinavir	drug	397-406	mechanism
alfentanyl	drug	293-302	alprazolam	drug	305-314	false
alfentanyl	drug	293-302	triazolam	drug	321-329	false
alfentanyl	drug	293-302	saquinavir	drug	397-406	mechanism
alprazolam	drug	305-314	triazolam	drug	321-329	false
alprazolam	drug	305-314	saquinavir	drug	397-406	mechanism
triazolam	drug	321-329	saquinavir	drug	397-406	mechanism

DDI-DrugBank.d124.s28	Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.
INVIRASE	brand	6-13	ritonavir	drug	38-46	advise
INVIRASE	brand	6-13	ritonavir	drug	53-61	false
ritonavir	drug	38-46	ritonavir	drug	53-61	false

DDI-DrugBank.d124.s30	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
phenobarbital	drug	72-84	phenytoin	drug	87-95	false
phenobarbital	drug	72-84	dexamethasone	drug	98-110	false
phenobarbital	drug	72-84	carbamazepine	drug	113-125	false
phenobarbital	drug	72-84	saquinavir	drug	169-178	mechanism
phenytoin	drug	87-95	dexamethasone	drug	98-110	false
phenytoin	drug	87-95	carbamazepine	drug	113-125	false
phenytoin	drug	87-95	saquinavir	drug	169-178	mechanism
dexamethasone	drug	98-110	carbamazepine	drug	113-125	false
dexamethasone	drug	98-110	saquinavir	drug	169-178	mechanism
carbamazepine	drug	113-125	saquinavir	drug	169-178	mechanism

DDI-DrugBank.d181.s0	Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
Oxytocin	drug	0-7	oxytocics	group	18-26	false
Oxytocin	drug	0-7	dinoprost	drug	49-57	effect
oxytocics	group	18-26	dinoprost	drug	49-57	effect

DDI-DrugBank.d483.s1	If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
CEFOTAN	brand	3-9	aminoglycoside	group	18-31	effect

DDI-DrugBank.d483.s4	As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe  reaction and produce false increases in the levels of creatinine reported.
cephalosporins	group	14-27	cefotetan	drug	53-61	false

DDI-DrugBank.d315.s0	Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
Digoxin	drug	0-6	digoxin	drug	29-35	false
Digoxin	drug	0-6	conivaptan	drug	76-85	false
Digoxin	drug	0-6	digoxin	drug	143-149	false
digoxin	drug	29-35	conivaptan	drug	76-85	mechanism
digoxin	drug	29-35	digoxin	drug	143-149	false
conivaptan	drug	76-85	digoxin	drug	143-149	false

DDI-DrugBank.d315.s1	Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.
digoxin	drug	14-20	VAPRISOL	brand	43-50	mechanism
digoxin	drug	14-20	digoxin	drug	118-124	false
VAPRISOL	brand	43-50	digoxin	drug	118-124	false

DDI-DrugBank.d43.s1	Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine, and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS).
stavudine	drug	119-127	VIDEX	brand	195-199	false

DDI-DrugBank.d43.s2	Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
Allopurinol	drug	0-10	didanosine	drug	24-33	false
Allopurinol	drug	0-10	allopurinol	drug	67-77	false
Allopurinol	drug	0-10	VIDEX	brand	141-145	false
didanosine	drug	24-33	allopurinol	drug	67-77	false
didanosine	drug	24-33	VIDEX	brand	141-145	false
allopurinol	drug	67-77	VIDEX	brand	141-145	mechanism

DDI-DrugBank.d43.s3	The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.
allopurinol	drug	15-25	didanosine	drug	30-39	false

DDI-DrugBank.d43.s4	Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
Antacids	group	0-7	antacids	group	40-47	false
Antacids	group	0-7	magnesium	drug	60-68	false
Antacids	group	0-7	aluminum	drug	73-80	false
Antacids	group	0-7	VIDEX	brand	87-91	false
Antacids	group	0-7	antacid	group	219-225	false
antacids	group	40-47	magnesium	drug	60-68	false
antacids	group	40-47	aluminum	drug	73-80	false
antacids	group	40-47	VIDEX	brand	87-91	effect
antacids	group	40-47	antacid	group	219-225	false
magnesium	drug	60-68	aluminum	drug	73-80	false
magnesium	drug	60-68	VIDEX	brand	87-91	effect
magnesium	drug	60-68	antacid	group	219-225	false
aluminum	drug	73-80	VIDEX	brand	87-91	effect
aluminum	drug	73-80	antacid	group	219-225	false
VIDEX	brand	87-91	antacid	group	219-225	false

DDI-DrugBank.d43.s5	Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
ketoconazole	drug	93-104	itraconazole	drug	110-121	false
ketoconazole	drug	93-104	VIDEX	brand	184-188	advise
itraconazole	drug	110-121	VIDEX	brand	184-188	advise

DDI-DrugBank.d43.s6	Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
Ganciclovir	drug	0-10	VIDEX	brand	31-35	false
Ganciclovir	drug	0-10	ganciclovir	drug	78-88	false
Ganciclovir	drug	0-10	didanosine	drug	159-168	false
VIDEX	brand	31-35	ganciclovir	drug	78-88	mechanism
VIDEX	brand	31-35	didanosine	drug	159-168	false
ganciclovir	drug	78-88	didanosine	drug	159-168	false

DDI-DrugBank.d43.s7	A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
ganciclovir	drug	47-57	VIDEX	brand	77-81	false
ganciclovir	drug	47-57	ganciclovir	drug	117-127	false
VIDEX	brand	77-81	ganciclovir	drug	117-127	mechanism

DDI-DrugBank.d43.s8	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
Quinolone Antibiotic	group	0-19	VIDEX	brand	23-27	false
Quinolone Antibiotic	group	0-19	ciprofloxacin	drug	105-117	false
Quinolone Antibiotic	group	0-19	ciprofloxacin	drug	152-164	false
Quinolone Antibiotic	group	0-19	antacids	group	203-210	false
Quinolone Antibiotic	group	0-19	magnesium	drug	223-231	false
Quinolone Antibiotic	group	0-19	calcium	drug	234-240	false
Quinolone Antibiotic	group	0-19	aluminum	drug	246-253	false
VIDEX	brand	23-27	ciprofloxacin	drug	105-117	advise
VIDEX	brand	23-27	ciprofloxacin	drug	152-164	false
VIDEX	brand	23-27	antacids	group	203-210	false
VIDEX	brand	23-27	magnesium	drug	223-231	false
VIDEX	brand	23-27	calcium	drug	234-240	false
VIDEX	brand	23-27	aluminum	drug	246-253	false
ciprofloxacin	drug	105-117	ciprofloxacin	drug	152-164	false
ciprofloxacin	drug	105-117	antacids	group	203-210	false
ciprofloxacin	drug	105-117	magnesium	drug	223-231	false
ciprofloxacin	drug	105-117	calcium	drug	234-240	false
ciprofloxacin	drug	105-117	aluminum	drug	246-253	false
ciprofloxacin	drug	152-164	antacids	group	203-210	false
ciprofloxacin	drug	152-164	magnesium	drug	223-231	mechanism
ciprofloxacin	drug	152-164	calcium	drug	234-240	mechanism
ciprofloxacin	drug	152-164	aluminum	drug	246-253	mechanism
antacids	group	203-210	magnesium	drug	223-231	false
antacids	group	203-210	calcium	drug	234-240	false
antacids	group	203-210	aluminum	drug	246-253	false
magnesium	drug	223-231	calcium	drug	234-240	false
magnesium	drug	223-231	aluminum	drug	246-253	false
calcium	drug	234-240	aluminum	drug	246-253	false

DDI-DrugBank.d43.s9	In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.
ciprofloxacin	drug	56-68	ciprofloxacin	drug	127-139	false
ciprofloxacin	drug	56-68	VIDEX	brand	229-233	false
ciprofloxacin	drug	127-139	VIDEX	brand	229-233	mechanism

DDI-DrugBank.d43.s10	The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
ciprofloxacin	drug	11-23	ciprofloxacin	drug	90-102	false
ciprofloxacin	drug	11-23	didanosine	drug	108-117	false
ciprofloxacin	drug	90-102	didanosine	drug	108-117	mechanism

DDI-DrugBank.d43.s11	In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
ciprofloxacin	drug	38-50	didanosine	drug	76-85	mechanism
ciprofloxacin	drug	38-50	ciprofloxacin	drug	147-159	false
didanosine	drug	76-85	ciprofloxacin	drug	147-159	false

DDI-DrugBank.d43.s12	Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
quinolone antibiotics	group	25-45	antacids	group	84-91	false
quinolone antibiotics	group	25-45	magnesium	drug	104-112	mechanism
quinolone antibiotics	group	25-45	calcium	drug	115-121	mechanism
quinolone antibiotics	group	25-45	aluminum	drug	127-134	mechanism
antacids	group	84-91	magnesium	drug	104-112	false
antacids	group	84-91	calcium	drug	115-121	false
antacids	group	84-91	aluminum	drug	127-134	false
magnesium	drug	104-112	calcium	drug	115-121	false
magnesium	drug	104-112	aluminum	drug	127-134	false
calcium	drug	115-121	aluminum	drug	127-134	false

DDI-DrugBank.d43.s13	The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert.
VIDEX	brand	54-58	quinolone	group	111-119	false

DDI-DrugBank.d43.s14	Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
Antiretroviral Drugs	group	24-43	delavirdine	drug	82-92	false
Antiretroviral Drugs	group	24-43	indinavir	drug	104-112	false
Antiretroviral Drugs	group	24-43	VIDEX	brand	188-192	false
delavirdine	drug	82-92	indinavir	drug	104-112	false
delavirdine	drug	82-92	VIDEX	brand	188-192	mechanism
indinavir	drug	104-112	VIDEX	brand	188-192	mechanism

DDI-DrugBank.d43.s15	To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
delavirdine	drug	27-37	indinavir	drug	42-50	false
delavirdine	drug	27-37	VIDEX	brand	96-100	advise
indinavir	drug	42-50	VIDEX	brand	96-100	advise

DDI-DrugBank.d43.s16	The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal 1 hour after VIDEX.
nelfinavir	drug	24-33	VIDEX	brand	141-145	false

DDI-DrugBank.d485.s2	Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.
Acetaminophen	drug	0-12	synthetic estrogens	group	52-70	mechanism

DDI-DrugBank.d485.s3	Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.
hormonal contraceptives	group	12-34	acetaminophen	drug	82-94	mechanism

DDI-DrugBank.d485.s4	Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.
Acitretin	drug	0-8	progestin	group	66-74	effect

DDI-DrugBank.d485.s6	Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.
Aminoglutethimide	drug	0-16	progestins	group	50-59	mechanism

DDI-DrugBank.d485.s8	Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.
Antibiotics	group	0-10	ampicillin	drug	13-22	false
Antibiotics	group	0-10	tetracycline	drug	25-36	false
Antibiotics	group	0-10	antibiotics	group	173-183	false
Antibiotics	group	0-10	synthetic steroids	group	213-230	false
ampicillin	drug	13-22	tetracycline	drug	25-36	false
ampicillin	drug	13-22	antibiotics	group	173-183	false
ampicillin	drug	13-22	synthetic steroids	group	213-230	false
tetracycline	drug	25-36	antibiotics	group	173-183	false
tetracycline	drug	25-36	synthetic steroids	group	213-230	false
antibiotics	group	173-183	synthetic steroids	group	213-230	false

DDI-DrugBank.d485.s10	Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.
Anticoagulants	group	0-13	hormonal contraceptives	group	28-50	false
Anticoagulants	group	0-13	coumarin derivatives	group	92-111	false
hormonal contraceptives	group	28-50	coumarin derivatives	group	92-111	effect

DDI-DrugBank.d485.s12	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
Anticonvulsants	group	0-14	carbamazepine	drug	17-29	false
Anticonvulsants	group	0-14	felbamate	drug	32-40	false
Anticonvulsants	group	0-14	phenobarbital	drug	43-55	false
Anticonvulsants	group	0-14	phenytoin	drug	58-66	false
Anticonvulsants	group	0-14	topiramate	drug	69-78	false
Anticonvulsants	group	0-14	ethinyl estradiol	drug	109-125	mechanism
Anticonvulsants	group	0-14	progestins	group	139-148	mechanism
carbamazepine	drug	17-29	felbamate	drug	32-40	false
carbamazepine	drug	17-29	phenobarbital	drug	43-55	false
carbamazepine	drug	17-29	phenytoin	drug	58-66	false
carbamazepine	drug	17-29	topiramate	drug	69-78	false
carbamazepine	drug	17-29	ethinyl estradiol	drug	109-125	mechanism
carbamazepine	drug	17-29	progestins	group	139-148	mechanism
felbamate	drug	32-40	phenobarbital	drug	43-55	false
felbamate	drug	32-40	phenytoin	drug	58-66	false
felbamate	drug	32-40	topiramate	drug	69-78	false
felbamate	drug	32-40	ethinyl estradiol	drug	109-125	mechanism
felbamate	drug	32-40	progestins	group	139-148	mechanism
phenobarbital	drug	43-55	phenytoin	drug	58-66	false
phenobarbital	drug	43-55	topiramate	drug	69-78	false
phenobarbital	drug	43-55	ethinyl estradiol	drug	109-125	mechanism
phenobarbital	drug	43-55	progestins	group	139-148	mechanism
phenytoin	drug	58-66	topiramate	drug	69-78	false
phenytoin	drug	58-66	ethinyl estradiol	drug	109-125	mechanism
phenytoin	drug	58-66	progestins	group	139-148	mechanism
topiramate	drug	69-78	ethinyl estradiol	drug	109-125	mechanism
topiramate	drug	69-78	progestins	group	139-148	mechanism
ethinyl estradiol	drug	109-125	progestins	group	139-148	false

DDI-DrugBank.d485.s14	Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;
Ascorbic acid	drug	0-12	ascorbic acid	drug	24-36	false
Ascorbic acid	drug	0-12	vitamin C	drug	39-47	false
Ascorbic acid	drug	0-12	synthetic estrogens	group	113-131	false
ascorbic acid	drug	24-36	vitamin C	drug	39-47	false
ascorbic acid	drug	24-36	synthetic estrogens	group	113-131	mechanism
vitamin C	drug	39-47	synthetic estrogens	group	113-131	mechanism

DDI-DrugBank.d485.s16	Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.
Atorvastatin	drug	0-11	Atorvastatin	drug	14-25	false
Atorvastatin	drug	0-11	norethindrone	drug	49-61	false
Atorvastatin	drug	0-11	ethinyl estradiol	drug	67-83	false
Atorvastatin	drug	14-25	norethindrone	drug	49-61	mechanism
Atorvastatin	drug	14-25	ethinyl estradiol	drug	67-83	mechanism
norethindrone	drug	49-61	ethinyl estradiol	drug	67-83	false

DDI-DrugBank.d485.s17	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
Benzodiazepines	group	0-14	hormonal contraceptives	group	29-51	false
Benzodiazepines	group	0-14	benzodiazepines	group	88-102	false
Benzodiazepines	group	0-14	alprazolam	drug	105-114	false
Benzodiazepines	group	0-14	chlordiazepoxide	drug	117-132	false
Benzodiazepines	group	0-14	diazepam	drug	135-142	false
Benzodiazepines	group	0-14	lorazepam	drug	183-191	false
Benzodiazepines	group	0-14	oxazepam	drug	194-201	false
Benzodiazepines	group	0-14	temazepam	drug	204-212	false
hormonal contraceptives	group	29-51	benzodiazepines	group	88-102	mechanism
hormonal contraceptives	group	29-51	alprazolam	drug	105-114	mechanism
hormonal contraceptives	group	29-51	chlordiazepoxide	drug	117-132	mechanism
hormonal contraceptives	group	29-51	diazepam	drug	135-142	mechanism
hormonal contraceptives	group	29-51	lorazepam	drug	183-191	mechanism
hormonal contraceptives	group	29-51	oxazepam	drug	194-201	mechanism
hormonal contraceptives	group	29-51	temazepam	drug	204-212	mechanism
benzodiazepines	group	88-102	alprazolam	drug	105-114	false
benzodiazepines	group	88-102	chlordiazepoxide	drug	117-132	false
benzodiazepines	group	88-102	diazepam	drug	135-142	false
benzodiazepines	group	88-102	lorazepam	drug	183-191	false
benzodiazepines	group	88-102	oxazepam	drug	194-201	false
benzodiazepines	group	88-102	temazepam	drug	204-212	false
alprazolam	drug	105-114	chlordiazepoxide	drug	117-132	false
alprazolam	drug	105-114	diazepam	drug	135-142	false
alprazolam	drug	105-114	lorazepam	drug	183-191	false
alprazolam	drug	105-114	oxazepam	drug	194-201	false
alprazolam	drug	105-114	temazepam	drug	204-212	false
chlordiazepoxide	drug	117-132	diazepam	drug	135-142	false
chlordiazepoxide	drug	117-132	lorazepam	drug	183-191	false
chlordiazepoxide	drug	117-132	oxazepam	drug	194-201	false
chlordiazepoxide	drug	117-132	temazepam	drug	204-212	false
diazepam	drug	135-142	lorazepam	drug	183-191	false
diazepam	drug	135-142	oxazepam	drug	194-201	false
diazepam	drug	135-142	temazepam	drug	204-212	false
lorazepam	drug	183-191	oxazepam	drug	194-201	false
lorazepam	drug	183-191	temazepam	drug	204-212	false
oxazepam	drug	194-201	temazepam	drug	204-212	false

DDI-DrugBank.d485.s18	Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.
Clofibric acid	drug_n	0-13	hormonal contraceptives	group	28-50	false
Clofibric acid	drug_n	0-13	clofibric acid	drug_n	82-95	false
hormonal contraceptives	group	28-50	clofibric acid	drug_n	82-95	mechanism

DDI-DrugBank.d485.s19	Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;
Cyclosporine	drug	0-11	hormonal contraceptives	group	26-48	false
Cyclosporine	drug	0-11	cyclosporine	drug	80-91	false
hormonal contraceptives	group	26-48	cyclosporine	drug	80-91	mechanism

DDI-DrugBank.d485.s22	Example inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.
aminoglutethimide	drug	25-41	carbamazepine	drug	44-56	false
aminoglutethimide	drug	25-41	nafcillin	drug	59-67	false
aminoglutethimide	drug	25-41	nevirapine	drug	70-79	false
aminoglutethimide	drug	25-41	phenobarbital	drug	82-94	false
aminoglutethimide	drug	25-41	phenytoin	drug	97-105	false
aminoglutethimide	drug	25-41	rifamycins	group	112-121	false
carbamazepine	drug	44-56	nafcillin	drug	59-67	false
carbamazepine	drug	44-56	nevirapine	drug	70-79	false
carbamazepine	drug	44-56	phenobarbital	drug	82-94	false
carbamazepine	drug	44-56	phenytoin	drug	97-105	false
carbamazepine	drug	44-56	rifamycins	group	112-121	false
nafcillin	drug	59-67	nevirapine	drug	70-79	false
nafcillin	drug	59-67	phenobarbital	drug	82-94	false
nafcillin	drug	59-67	phenytoin	drug	97-105	false
nafcillin	drug	59-67	rifamycins	group	112-121	false
nevirapine	drug	70-79	phenobarbital	drug	82-94	false
nevirapine	drug	70-79	phenytoin	drug	97-105	false
nevirapine	drug	70-79	rifamycins	group	112-121	false
phenobarbital	drug	82-94	phenytoin	drug	97-105	false
phenobarbital	drug	82-94	rifamycins	group	112-121	false
phenytoin	drug	97-105	rifamycins	group	112-121	false

DDI-DrugBank.d485.s23	Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;
Griseofulvin	drug	0-11	Griseofulvin	drug	14-25	false
Griseofulvin	drug	0-11	combination hormonal contraceptives	group	56-90	false
Griseofulvin	drug	14-25	combination hormonal contraceptives	group	56-90	mechanism

DDI-DrugBank.d485.s26	Morphine: Combination hormonal contraceptives may increase the clearance of morphine.
Morphine	drug	0-7	hormonal contraceptives	group	22-44	false
Morphine	drug	0-7	morphine	drug	76-83	false
hormonal contraceptives	group	22-44	morphine	drug	76-83	mechanism

DDI-DrugBank.d485.s27	Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;
Non-nucleoside reverse transcriptase inhibitors	group	0-46	NNRTIs	group	49-54	false
Non-nucleoside reverse transcriptase inhibitors	group	0-46	Nevirapine	drug	58-67	false
Non-nucleoside reverse transcriptase inhibitors	group	0-46	combination hormonal contraceptives	group	99-133	false
NNRTIs	group	49-54	Nevirapine	drug	58-67	false
NNRTIs	group	49-54	combination hormonal contraceptives	group	99-133	false
Nevirapine	drug	58-67	combination hormonal contraceptives	group	99-133	mechanism

DDI-DrugBank.d485.s31	Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.
Prednisolone	drug	0-11	Ethinyl estradiol	drug	14-30	false
Prednisolone	drug	0-11	prednisolone	drug	62-73	false
Ethinyl estradiol	drug	14-30	prednisolone	drug	62-73	mechanism

DDI-DrugBank.d485.s32	Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
Protease inhibitors	group	0-18	Amprenavir	drug	21-30	false
Protease inhibitors	group	0-18	lopinavir	drug	33-41	false
Protease inhibitors	group	0-18	nelfinavir	drug	44-53	false
Protease inhibitors	group	0-18	ritonavir	drug	60-68	false
Protease inhibitors	group	0-18	combination hormonal contraceptives	group	115-149	false
Amprenavir	drug	21-30	lopinavir	drug	33-41	false
Amprenavir	drug	21-30	nelfinavir	drug	44-53	false
Amprenavir	drug	21-30	ritonavir	drug	60-68	false
Amprenavir	drug	21-30	combination hormonal contraceptives	group	115-149	mechanism
lopinavir	drug	33-41	nelfinavir	drug	44-53	false
lopinavir	drug	33-41	ritonavir	drug	60-68	false
lopinavir	drug	33-41	combination hormonal contraceptives	group	115-149	mechanism
nelfinavir	drug	44-53	ritonavir	drug	60-68	false
nelfinavir	drug	44-53	combination hormonal contraceptives	group	115-149	mechanism
ritonavir	drug	60-68	combination hormonal contraceptives	group	115-149	mechanism

DDI-DrugBank.d485.s34	Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.
Indinavir	drug	0-8	combination hormonal contraceptives	group	54-88	mechanism

DDI-DrugBank.d485.s36	Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
Rifampin	drug	0-7	Rifampin	drug	10-17	false
Rifampin	drug	0-7	ethinyl estradiol	drug	47-63	false
Rifampin	drug	0-7	progestins	group	74-83	false
Rifampin	drug	0-7	norethindrone	drug	86-98	false
Rifampin	drug	10-17	ethinyl estradiol	drug	47-63	mechanism
Rifampin	drug	10-17	progestins	group	74-83	mechanism
Rifampin	drug	10-17	norethindrone	drug	86-98	mechanism
ethinyl estradiol	drug	47-63	progestins	group	74-83	false
ethinyl estradiol	drug	47-63	norethindrone	drug	86-98	false
progestins	group	74-83	norethindrone	drug	86-98	false

DDI-DrugBank.d485.s38	Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.
Salicylic acid	drug	0-13	hormonal contraceptives	group	28-50	false
Salicylic acid	drug	0-13	salicylic acid	drug	82-95	false
hormonal contraceptives	group	28-50	salicylic acid	drug	82-95	mechanism

DDI-DrugBank.d485.s39	Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.
Selegiline	drug	0-9	Combination hormonal contraceptives	group	12-46	false
Selegiline	drug	0-9	selegiline	drug	88-97	false
Combination hormonal contraceptives	group	12-46	selegiline	drug	88-97	mechanism

DDI-DrugBank.d485.s40	Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.
Theophylline	drug	0-11	Ethinyl estradiol	drug	14-30	false
Theophylline	drug	0-11	theophylline	drug	62-73	false
Ethinyl estradiol	drug	14-30	theophylline	drug	62-73	mechanism

DDI-DrugBank.d485.s41	Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
Tricyclic antidepressants	group	0-24	amitriptyline	drug	27-39	false
Tricyclic antidepressants	group	0-24	imipramine	drug	42-51	false
Tricyclic antidepressants	group	0-24	nortriptyline	drug	54-66	false
Tricyclic antidepressants	group	0-24	combination hormonal contraceptives	group	101-135	mechanism
Tricyclic antidepressants	group	0-24	antidepressant	group	166-179	false
amitriptyline	drug	27-39	imipramine	drug	42-51	false
amitriptyline	drug	27-39	nortriptyline	drug	54-66	false
amitriptyline	drug	27-39	combination hormonal contraceptives	group	101-135	mechanism
amitriptyline	drug	27-39	antidepressant	group	166-179	false
imipramine	drug	42-51	nortriptyline	drug	54-66	false
imipramine	drug	42-51	combination hormonal contraceptives	group	101-135	mechanism
imipramine	drug	42-51	antidepressant	group	166-179	false
nortriptyline	drug	54-66	combination hormonal contraceptives	group	101-135	mechanism
nortriptyline	drug	54-66	antidepressant	group	166-179	false
combination hormonal contraceptives	group	101-135	antidepressant	group	166-179	false

DDI-DrugBank.d485.s43	ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.
ETHANOL	drug	0-6	caffeine	drug	62-69	false
ETHANOL	drug	0-6	combination hormonal contraceptives	group	90-124	false
ETHANOL	drug	0-6	caffeine	drug	153-160	false
caffeine	drug	62-69	combination hormonal contraceptives	group	90-124	false
caffeine	drug	62-69	caffeine	drug	153-160	false
combination hormonal contraceptives	group	90-124	caffeine	drug	153-160	effect

DDI-DrugBank.d485.s44	Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well;
ethinyl estradiol	drug	27-43	progesterone	drug	94-105	false

DDI-DrugBank.d516.s0	Theophylline: In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of lomefloxacin.
Theophylline	drug	0-11	theophylline	drug	86-97	false
Theophylline	drug	0-11	lomefloxacin	drug	177-188	false
theophylline	drug	86-97	lomefloxacin	drug	177-188	false

DDI-DrugBank.d516.s1	In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.
theophylline	drug	51-62	lomefloxacin	drug	73-84	false
theophylline	drug	51-62	theophylline	drug	139-150	false
theophylline	drug	51-62	theophylline	drug	192-203	false
lomefloxacin	drug	73-84	theophylline	drug	139-150	false
lomefloxacin	drug	73-84	theophylline	drug	192-203	false
theophylline	drug	139-150	theophylline	drug	192-203	false

DDI-DrugBank.d516.s3	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
Antacids	group	0-7	sucralfate	drug	13-22	false
Antacids	group	0-7	Sucralfate	drug	25-34	false
Antacids	group	0-7	antacids	group	40-47	false
Antacids	group	0-7	magnesium	drug	60-68	false
Antacids	group	0-7	aluminum	drug	73-80	false
Antacids	group	0-7	Videx	brand	157-161	false
Antacids	group	0-7	didanosine	drug	165-174	false
Antacids	group	0-7	lomefloxacin	drug	280-291	false
sucralfate	drug	13-22	Sucralfate	drug	25-34	false
sucralfate	drug	13-22	antacids	group	40-47	false
sucralfate	drug	13-22	magnesium	drug	60-68	false
sucralfate	drug	13-22	aluminum	drug	73-80	false
sucralfate	drug	13-22	Videx	brand	157-161	false
sucralfate	drug	13-22	didanosine	drug	165-174	false
sucralfate	drug	13-22	lomefloxacin	drug	280-291	false
Sucralfate	drug	25-34	antacids	group	40-47	false
Sucralfate	drug	25-34	magnesium	drug	60-68	false
Sucralfate	drug	25-34	aluminum	drug	73-80	false
Sucralfate	drug	25-34	Videx	brand	157-161	false
Sucralfate	drug	25-34	didanosine	drug	165-174	false
Sucralfate	drug	25-34	lomefloxacin	drug	280-291	mechanism
antacids	group	40-47	magnesium	drug	60-68	false
antacids	group	40-47	aluminum	drug	73-80	false
antacids	group	40-47	Videx	brand	157-161	false
antacids	group	40-47	didanosine	drug	165-174	false
antacids	group	40-47	lomefloxacin	drug	280-291	false
magnesium	drug	60-68	aluminum	drug	73-80	false
magnesium	drug	60-68	Videx	brand	157-161	false
magnesium	drug	60-68	didanosine	drug	165-174	false
magnesium	drug	60-68	lomefloxacin	drug	280-291	mechanism
aluminum	drug	73-80	Videx	brand	157-161	false
aluminum	drug	73-80	didanosine	drug	165-174	false
aluminum	drug	73-80	lomefloxacin	drug	280-291	mechanism
Videx	brand	157-161	didanosine	drug	165-174	false
Videx	brand	157-161	lomefloxacin	drug	280-291	mechanism
didanosine	drug	165-174	lomefloxacin	drug	280-291	mechanism

DDI-DrugBank.d516.s4	Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).
Sucralfate	drug	0-9	lomefloxacin	drug	39-50	mechanism

DDI-DrugBank.d516.s5	Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
Magnesium	drug	0-8	aluminum	drug	15-22	false
Magnesium	drug	0-8	antacids	group	35-42	false
Magnesium	drug	0-8	lomefloxacin	drug	77-88	mechanism
Magnesium	drug	0-8	lomefloxacin	drug	144-155	false
aluminum	drug	15-22	antacids	group	35-42	false
aluminum	drug	15-22	lomefloxacin	drug	77-88	mechanism
aluminum	drug	15-22	lomefloxacin	drug	144-155	false
antacids	group	35-42	lomefloxacin	drug	77-88	mechanism
antacids	group	35-42	lomefloxacin	drug	144-155	false
lomefloxacin	drug	77-88	lomefloxacin	drug	144-155	false

DDI-DrugBank.d516.s6	Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;
antacid	group	24-30	lomefloxacin	drug	36-47	mechanism

DDI-DrugBank.d516.s7	therefore, administration of these agents should precede lomefloxacin dosing by 4 hours or follow lomefloxacin dosing by at least 2 hours.
lomefloxacin	drug	57-68	lomefloxacin	drug	98-109	false

DDI-DrugBank.d516.s8	Caffeine: Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd.
Caffeine	drug	0-7	caffeine	drug	28-35	false
Caffeine	drug	0-7	lomefloxacin	drug	188-199	false
caffeine	drug	28-35	lomefloxacin	drug	188-199	false

DDI-DrugBank.d516.s9	This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either caffeine or its major metabolite, paraxanthine.
caffeine	drug	116-123	paraxanthine	drug_n	150-161	false

DDI-DrugBank.d516.s11	Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.
quinolones	group	6-15	caffeine	drug	90-97	mechanism
quinolones	group	6-15	caffeine	drug	228-235	false
caffeine	drug	90-97	caffeine	drug	228-235	false

DDI-DrugBank.d516.s12	Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.
Cimetidine	drug	0-9	Cimetidine	drug	12-21	false
Cimetidine	drug	0-9	quinolones	group	88-97	false
Cimetidine	drug	12-21	quinolones	group	88-97	mechanism

DDI-DrugBank.d516.s14	The interaction between lomefloxacin and cimetidine has not been studied.
lomefloxacin	drug	24-35	cimetidine	drug	41-50	false

DDI-DrugBank.d516.s15	Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
Cyclosporine	drug	0-11	cyclosporine	drug	39-50	false
Cyclosporine	drug	0-11	cyclosporine	drug	95-106	false
Cyclosporine	drug	0-11	quinolone class	group	134-148	false
cyclosporine	drug	39-50	cyclosporine	drug	95-106	false
cyclosporine	drug	39-50	quinolone class	group	134-148	false
cyclosporine	drug	95-106	quinolone class	group	134-148	mechanism

DDI-DrugBank.d516.s16	Interaction between lomefloxacin and cyclosporine has not been studied.
lomefloxacin	drug	20-31	cyclosporine	drug	37-48	false

DDI-DrugBank.d516.s17	Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.
Omeprazole	drug	0-9	lomefloxacin	drug	49-60	false
Omeprazole	drug	0-9	lomefloxacin	drug	140-151	false
Omeprazole	drug	0-9	omeprazole	drug	194-203	false
lomefloxacin	drug	49-60	lomefloxacin	drug	140-151	false
lomefloxacin	drug	49-60	omeprazole	drug	194-203	false
lomefloxacin	drug	140-151	omeprazole	drug	194-203	false

DDI-DrugBank.d516.s19	Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.
Phenytoin	drug	0-8	phenytoin	drug	60-68	false
Phenytoin	drug	0-8	phenytoin sodium	drug	146-161	false
Phenytoin	drug	0-8	lomefloxacin	drug	210-221	false
phenytoin	drug	60-68	phenytoin sodium	drug	146-161	false
phenytoin	drug	60-68	lomefloxacin	drug	210-221	false
phenytoin sodium	drug	146-161	lomefloxacin	drug	210-221	false

DDI-DrugBank.d516.s20	Lomefloxacin is unlikely to have a significant effect on phenytoin metabolism.
Lomefloxacin	drug	0-11	phenytoin	drug	57-65	false

DDI-DrugBank.d516.s21	Probenecid: Probenecid slows the renal elimination of lome-floxacin.
Probenecid	drug	0-9	Probenecid	drug	12-21	false

DDI-DrugBank.d516.s23	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.
Terfenadine	drug	0-10	terfenadine	drug	103-113	false
Terfenadine	drug	0-10	lomefloxacin	drug	129-140	false
Terfenadine	drug	0-10	lomefloxacin	drug	196-207	false
Terfenadine	drug	0-10	terfenadine	drug	213-223	false
terfenadine	drug	103-113	lomefloxacin	drug	129-140	false
terfenadine	drug	103-113	lomefloxacin	drug	196-207	false
terfenadine	drug	103-113	terfenadine	drug	213-223	false
lomefloxacin	drug	129-140	lomefloxacin	drug	196-207	false
lomefloxacin	drug	129-140	terfenadine	drug	213-223	false
lomefloxacin	drug	196-207	terfenadine	drug	213-223	false

DDI-DrugBank.d516.s24	Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
Warfarin	drug	0-7	Quinolones	group	10-19	false
Warfarin	drug	0-7	anticoagulant	group	57-69	false
Warfarin	drug	0-7	warfarin	drug	72-79	false
Quinolones	group	10-19	anticoagulant	group	57-69	effect
Quinolones	group	10-19	warfarin	drug	72-79	effect
anticoagulant	group	57-69	warfarin	drug	72-79	false

DDI-DrugBank.d516.s26	However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.
warfarin	drug	93-100	warfarin	drug	198-205	false
warfarin	drug	93-100	lomefloxacin	drug	211-222	false
warfarin	drug	198-205	lomefloxacin	drug	211-222	false

DDI-DrugBank.d62.s0	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
Dexbrompheniramine	drug	0-17	alcohol	drug	37-43	int
Dexbrompheniramine	drug	0-17	CNS depressants	group	54-68	int
Dexbrompheniramine	drug	0-17	antihistamines	group	144-157	false
Dexbrompheniramine	drug	0-17	anticholinergics	group	161-176	int
Dexbrompheniramine	drug	0-17	antihistamines	group	323-336	false
Dexbrompheniramine	drug	0-17	monoamine oxidase (MAO) inhibitors	group	344-377	int
Dexbrompheniramine	drug	0-17	antihistamines	group	400-413	false
Dexbrompheniramine	drug	0-17	antihistamines	group	491-504	false
alcohol	drug	37-43	CNS depressants	group	54-68	false
alcohol	drug	37-43	antihistamines	group	144-157	false
alcohol	drug	37-43	anticholinergics	group	161-176	false
alcohol	drug	37-43	antihistamines	group	323-336	false
alcohol	drug	37-43	monoamine oxidase (MAO) inhibitors	group	344-377	false
alcohol	drug	37-43	antihistamines	group	400-413	false
alcohol	drug	37-43	antihistamines	group	491-504	false
CNS depressants	group	54-68	antihistamines	group	144-157	false
CNS depressants	group	54-68	anticholinergics	group	161-176	false
CNS depressants	group	54-68	antihistamines	group	323-336	false
CNS depressants	group	54-68	monoamine oxidase (MAO) inhibitors	group	344-377	false
CNS depressants	group	54-68	antihistamines	group	400-413	false
CNS depressants	group	54-68	antihistamines	group	491-504	false
antihistamines	group	144-157	anticholinergics	group	161-176	false
antihistamines	group	144-157	antihistamines	group	323-336	false
antihistamines	group	144-157	monoamine oxidase (MAO) inhibitors	group	344-377	false
antihistamines	group	144-157	antihistamines	group	400-413	false
antihistamines	group	144-157	antihistamines	group	491-504	false
anticholinergics	group	161-176	antihistamines	group	323-336	false
anticholinergics	group	161-176	monoamine oxidase (MAO) inhibitors	group	344-377	false
anticholinergics	group	161-176	antihistamines	group	400-413	false
anticholinergics	group	161-176	antihistamines	group	491-504	false
antihistamines	group	323-336	monoamine oxidase (MAO) inhibitors	group	344-377	false
antihistamines	group	323-336	antihistamines	group	400-413	false
antihistamines	group	323-336	antihistamines	group	491-504	false
monoamine oxidase (MAO) inhibitors	group	344-377	antihistamines	group	400-413	false
monoamine oxidase (MAO) inhibitors	group	344-377	antihistamines	group	491-504	false
antihistamines	group	400-413	antihistamines	group	491-504	false

DDI-DrugBank.d29.s3	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.
esomeprazole	drug	41-52	phenytoin	drug	113-121	false
esomeprazole	drug	41-52	warfarin	drug	124-131	false
esomeprazole	drug	41-52	quinidine	drug	134-142	false
esomeprazole	drug	41-52	clarithromycin	drug	145-158	false
esomeprazole	drug	41-52	amoxicillin	drug	163-173	false
phenytoin	drug	113-121	warfarin	drug	124-131	false
phenytoin	drug	113-121	quinidine	drug	134-142	false
phenytoin	drug	113-121	clarithromycin	drug	145-158	false
phenytoin	drug	113-121	amoxicillin	drug	163-173	false
warfarin	drug	124-131	quinidine	drug	134-142	false
warfarin	drug	124-131	clarithromycin	drug	145-158	false
warfarin	drug	124-131	amoxicillin	drug	163-173	false
quinidine	drug	134-142	clarithromycin	drug	145-158	false
quinidine	drug	134-142	amoxicillin	drug	163-173	false
clarithromycin	drug	145-158	amoxicillin	drug	163-173	false

DDI-DrugBank.d29.s4	Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy.
warfarin	drug	107-114	esomeprazole	drug	120-131	false

DDI-DrugBank.d29.s6	Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
proton pump inhibitors	group	22-43	warfarin	drug	49-56	effect

DDI-DrugBank.d29.s7	Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme.
Esomeprazole	drug	0-11	esomeprazole	drug	63-74	false

DDI-DrugBank.d29.s8	Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
esomeprazole	drug	20-31	diazepam	drug	43-50	mechanism
esomeprazole	drug	20-31	diazepam	drug	117-124	false
diazepam	drug	43-50	diazepam	drug	117-124	false

DDI-DrugBank.d29.s12	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
esomeprazole	drug	11-22	ketoconazole	drug	136-147	mechanism
esomeprazole	drug	11-22	iron	drug	150-153	mechanism
esomeprazole	drug	11-22	digoxin	drug	165-171	mechanism
ketoconazole	drug	136-147	iron	drug	150-153	false
ketoconazole	drug	136-147	digoxin	drug	165-171	false
iron	drug	150-153	digoxin	drug	165-171	false

DDI-DrugBank.d29.s13	Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
contraceptives	group	25-38	diazepam	drug	41-48	false
contraceptives	group	25-38	phenytoin	drug	51-59	false
contraceptives	group	25-38	quinidine	drug	65-73	false
contraceptives	group	25-38	esomeprazole	drug	129-140	false
diazepam	drug	41-48	phenytoin	drug	51-59	false
diazepam	drug	41-48	quinidine	drug	65-73	false
diazepam	drug	41-48	esomeprazole	drug	129-140	false
phenytoin	drug	51-59	quinidine	drug	65-73	false
phenytoin	drug	51-59	esomeprazole	drug	129-140	false
quinidine	drug	65-73	esomeprazole	drug	129-140	false

DDI-DrugBank.d29.s14	Concomitant administration of clarithromycin with pimozide is contraindicated.
clarithromycin	drug	30-43	pimozide	drug	50-57	advise

DDI-DrugBank.d511.s0	A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.
FOSCAVIR	brand	31-38	pentamidine	drug	56-66	int

DDI-DrugBank.d511.s1	Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;
FOSCAVIR	brand	66-73	pentamidine	drug	91-101	effect

DDI-DrugBank.d511.s4	Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
foscarnet	drug	11-19	FOSCAVIR	brand	69-76	false
foscarnet	drug	11-19	aminoglycosides	group	154-168	false
foscarnet	drug	11-19	amphotericin B	drug	171-184	false
foscarnet	drug	11-19	pentamidine	drug	202-212	false
FOSCAVIR	brand	69-76	aminoglycosides	group	154-168	advise
FOSCAVIR	brand	69-76	amphotericin B	drug	171-184	advise
FOSCAVIR	brand	69-76	pentamidine	drug	202-212	advise
aminoglycosides	group	154-168	amphotericin B	drug	171-184	false
aminoglycosides	group	154-168	pentamidine	drug	202-212	false
amphotericin B	drug	171-184	pentamidine	drug	202-212	false

DDI-DrugBank.d511.s6	Ganciclovir: The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.
Ganciclovir	drug	0-10	foscarnet	drug	37-45	false
Ganciclovir	drug	0-10	ganciclovir	drug	51-61	false
foscarnet	drug	37-45	ganciclovir	drug	51-61	false

DDI-DrugBank.d63.s0	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
Monoamine oxidase (MAO) inhibitors	group	0-33	isocarboxazid	drug	43-55	false
Monoamine oxidase (MAO) inhibitors	group	0-33	Marplan	brand	64-70	false
Monoamine oxidase (MAO) inhibitors	group	0-33	phenelzine	drug	74-83	false
Monoamine oxidase (MAO) inhibitors	group	0-33	Nardil	brand	92-97	false
Monoamine oxidase (MAO) inhibitors	group	0-33	procarbazine	drug	101-112	false
Monoamine oxidase (MAO) inhibitors	group	0-33	Matulane	brand	121-128	false
Monoamine oxidase (MAO) inhibitors	group	0-33	selegiline	drug	132-141	false
Monoamine oxidase (MAO) inhibitors	group	0-33	Eldepryl	brand	150-157	false
Monoamine oxidase (MAO) inhibitors	group	0-33	tranylcypromine	drug	165-179	false
Monoamine oxidase (MAO) inhibitors	group	0-33	Parnate	brand	188-194	false
Monoamine oxidase (MAO) inhibitors	group	0-33	L-tryptophan	drug	225-236	false
isocarboxazid	drug	43-55	Marplan	brand	64-70	false
isocarboxazid	drug	43-55	phenelzine	drug	74-83	false
isocarboxazid	drug	43-55	Nardil	brand	92-97	false
isocarboxazid	drug	43-55	procarbazine	drug	101-112	false
isocarboxazid	drug	43-55	Matulane	brand	121-128	false
isocarboxazid	drug	43-55	selegiline	drug	132-141	false
isocarboxazid	drug	43-55	Eldepryl	brand	150-157	false
isocarboxazid	drug	43-55	tranylcypromine	drug	165-179	false
isocarboxazid	drug	43-55	Parnate	brand	188-194	false
isocarboxazid	drug	43-55	L-tryptophan	drug	225-236	false
Marplan	brand	64-70	phenelzine	drug	74-83	false
Marplan	brand	64-70	Nardil	brand	92-97	false
Marplan	brand	64-70	procarbazine	drug	101-112	false
Marplan	brand	64-70	Matulane	brand	121-128	false
Marplan	brand	64-70	selegiline	drug	132-141	false
Marplan	brand	64-70	Eldepryl	brand	150-157	false
Marplan	brand	64-70	tranylcypromine	drug	165-179	false
Marplan	brand	64-70	Parnate	brand	188-194	false
Marplan	brand	64-70	L-tryptophan	drug	225-236	false
phenelzine	drug	74-83	Nardil	brand	92-97	false
phenelzine	drug	74-83	procarbazine	drug	101-112	false
phenelzine	drug	74-83	Matulane	brand	121-128	false
phenelzine	drug	74-83	selegiline	drug	132-141	false
phenelzine	drug	74-83	Eldepryl	brand	150-157	false
phenelzine	drug	74-83	tranylcypromine	drug	165-179	false
phenelzine	drug	74-83	Parnate	brand	188-194	false
phenelzine	drug	74-83	L-tryptophan	drug	225-236	false
Nardil	brand	92-97	procarbazine	drug	101-112	false
Nardil	brand	92-97	Matulane	brand	121-128	false
Nardil	brand	92-97	selegiline	drug	132-141	false
Nardil	brand	92-97	Eldepryl	brand	150-157	false
Nardil	brand	92-97	tranylcypromine	drug	165-179	false
Nardil	brand	92-97	Parnate	brand	188-194	false
Nardil	brand	92-97	L-tryptophan	drug	225-236	false
procarbazine	drug	101-112	Matulane	brand	121-128	false
procarbazine	drug	101-112	selegiline	drug	132-141	false
procarbazine	drug	101-112	Eldepryl	brand	150-157	false
procarbazine	drug	101-112	tranylcypromine	drug	165-179	false
procarbazine	drug	101-112	Parnate	brand	188-194	false
procarbazine	drug	101-112	L-tryptophan	drug	225-236	false
Matulane	brand	121-128	selegiline	drug	132-141	false
Matulane	brand	121-128	Eldepryl	brand	150-157	false
Matulane	brand	121-128	tranylcypromine	drug	165-179	false
Matulane	brand	121-128	Parnate	brand	188-194	false
Matulane	brand	121-128	L-tryptophan	drug	225-236	false
selegiline	drug	132-141	Eldepryl	brand	150-157	false
selegiline	drug	132-141	tranylcypromine	drug	165-179	false
selegiline	drug	132-141	Parnate	brand	188-194	false
selegiline	drug	132-141	L-tryptophan	drug	225-236	false
Eldepryl	brand	150-157	tranylcypromine	drug	165-179	false
Eldepryl	brand	150-157	Parnate	brand	188-194	false
Eldepryl	brand	150-157	L-tryptophan	drug	225-236	false
tranylcypromine	drug	165-179	Parnate	brand	188-194	false
tranylcypromine	drug	165-179	L-tryptophan	drug	225-236	false
Parnate	brand	188-194	L-tryptophan	drug	225-236	false

DDI-DrugBank.d188.s0	Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
HEXALEN	brand	29-35	antidepressants of the MAO inhibitor class	group	41-82	effect
HEXALEN	brand	29-35	Cimetidine	drug	125-134	false
HEXALEN	brand	29-35	altretamine	drug	191-201	false
antidepressants of the MAO inhibitor class	group	41-82	Cimetidine	drug	125-134	false
antidepressants of the MAO inhibitor class	group	41-82	altretamine	drug	191-201	false
Cimetidine	drug	125-134	altretamine	drug	191-201	mechanism

DDI-DrugBank.d188.s1	Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
HEXALEN	brand	32-38	cisplatin	drug	44-52	effect
HEXALEN	brand	32-38	pyridoxine	drug	68-77	false
HEXALEN	brand	32-38	pyridoxine	drug	112-121	false
cisplatin	drug	44-52	pyridoxine	drug	68-77	false
cisplatin	drug	44-52	pyridoxine	drug	112-121	false
pyridoxine	drug	68-77	pyridoxine	drug	112-121	false

DDI-DrugBank.d188.s2	however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
pyridoxine	drug	65-74	HEXALEN	brand	108-114	advise
pyridoxine	drug	65-74	cisplatin	drug	123-131	advise
HEXALEN	brand	108-114	cisplatin	drug	123-131	false

DDI-DrugBank.d141.s0	Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.
Immunosuppressive Drugs	group	0-22	Fibric Acid Derivatives	group	25-47	false
Immunosuppressive Drugs	group	0-22	Niacin	drug	50-55	false
Immunosuppressive Drugs	group	0-22	Nicotinic Acid	drug	58-71	false
Immunosuppressive Drugs	group	0-22	Erythromycin	drug	74-85	false
Immunosuppressive Drugs	group	0-22	Azole Antifungals	group	88-104	false
Fibric Acid Derivatives	group	25-47	Niacin	drug	50-55	false
Fibric Acid Derivatives	group	25-47	Nicotinic Acid	drug	58-71	false
Fibric Acid Derivatives	group	25-47	Erythromycin	drug	74-85	false
Fibric Acid Derivatives	group	25-47	Azole Antifungals	group	88-104	false
Niacin	drug	50-55	Nicotinic Acid	drug	58-71	false
Niacin	drug	50-55	Erythromycin	drug	74-85	false
Niacin	drug	50-55	Azole Antifungals	group	88-104	false
Nicotinic Acid	drug	58-71	Erythromycin	drug	74-85	false
Nicotinic Acid	drug	58-71	Azole Antifungals	group	88-104	false
Erythromycin	drug	74-85	Azole Antifungals	group	88-104	false

DDI-DrugBank.d141.s1	ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid.
ANTACID	group	0-6	Magnesium-Aluminum Hydroxide	drug	9-36	false
ANTACID	group	0-6	Cerivastatin	drug	40-51	false
ANTACID	group	0-6	antacid	group	117-123	false
Magnesium-Aluminum Hydroxide	drug	9-36	Cerivastatin	drug	40-51	false
Magnesium-Aluminum Hydroxide	drug	9-36	antacid	group	117-123	false
Cerivastatin	drug	40-51	antacid	group	117-123	false

DDI-DrugBank.d141.s2	CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine.
CIMETlDINE	drug	0-9	Cerivastatin	drug	12-23	false
CIMETlDINE	drug	0-9	cimetidine	drug	89-98	false
Cerivastatin	drug	12-23	cimetidine	drug	89-98	false

DDI-DrugBank.d141.s3	CHOLESTYRAMINE: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.
CHOLESTYRAMINE	drug	0-13	cholestyramine	drug	65-78	false
CHOLESTYRAMINE	drug	0-13	cerivastatin sodium	drug	107-125	false
cholestyramine	drug	65-78	cerivastatin sodium	drug	107-125	false

DDI-DrugBank.d141.s4	In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.
cerivastatin sodium	drug	57-75	cholestyramine	drug	86-99	mechanism
cerivastatin sodium	drug	57-75	cerivastatin sodium	drug	189-207	false
cholestyramine	drug	86-99	cerivastatin sodium	drug	189-207	false

DDI-DrugBank.d141.s5	However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.
cholestyramine	drug	53-66	cerivastatin sodium	drug	110-128	mechanism
cholestyramine	drug	53-66	cerivastatin	drug	210-221	false
cholestyramine	drug	53-66	cerivastatin sodium	drug	304-322	false
cerivastatin sodium	drug	110-128	cerivastatin	drug	210-221	false
cerivastatin sodium	drug	110-128	cerivastatin sodium	drug	304-322	false
cerivastatin	drug	210-221	cerivastatin sodium	drug	304-322	false

DDI-DrugBank.d141.s6	Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.
cerivastatin sodium	drug	58-76	cholestyramine	drug	99-112	false
cerivastatin sodium	drug	58-76	cerivastatin sodium	drug	213-231	false
cholestyramine	drug	99-112	cerivastatin sodium	drug	213-231	false

DDI-DrugBank.d141.s7	DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.
DIGOXIN	drug	0-6	digoxin	drug	16-22	false
DIGOXIN	drug	0-6	digoxin	drug	35-41	false
DIGOXIN	drug	0-6	cerivastatin sodium	drug	118-136	false
digoxin	drug	16-22	digoxin	drug	35-41	false
digoxin	drug	16-22	cerivastatin sodium	drug	118-136	false
digoxin	drug	35-41	cerivastatin sodium	drug	118-136	false

DDI-DrugBank.d141.s8	Cerivastatin plasma concentrations were also not affected by co-administration of digoxin.
Cerivastatin	drug	0-11	digoxin	drug	82-88	false

DDI-DrugBank.d141.s9	WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.
WARFARIN	drug	0-7	warfarin	drug	32-39	false
WARFARIN	drug	0-7	cerivastatin	drug	45-56	false
WARFARIN	drug	0-7	warfarin	drug	191-198	false
warfarin	drug	32-39	cerivastatin	drug	45-56	false
warfarin	drug	32-39	warfarin	drug	191-198	false
cerivastatin	drug	45-56	warfarin	drug	191-198	false

DDI-DrugBank.d141.s10	The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium.
warfarin	drug	52-59	cerivastatin sodium	drug	108-126	false

DDI-DrugBank.d141.s11	Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium.
warfarin	drug	21-28	cerivastatin	drug	34-45	false
warfarin	drug	21-28	cerivastatin sodium	drug	85-103	false
cerivastatin	drug	34-45	cerivastatin sodium	drug	85-103	false

DDI-DrugBank.d141.s12	ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
ERYTHROMYCIN	drug	0-11	cerivastatin	drug	61-72	false
ERYTHROMYCIN	drug	0-11	erythromycin	drug	176-187	false
cerivastatin	drug	61-72	erythromycin	drug	176-187	mechanism

DDI-DrugBank.d141.s13	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.
cerivastatin sodium	drug	106-124	angiotensin- converting enzyme (ACE) inhibitors	group	154-200	false
cerivastatin sodium	drug	106-124	betablockers	group	203-214	false
cerivastatin sodium	drug	106-124	calcium-channel blockers	group	217-240	false
cerivastatin sodium	drug	106-124	diuretics	group	243-251	false
cerivastatin sodium	drug	106-124	nonsteroidal anti-inflammatory drugs	group	258-293	false
cerivastatin sodium	drug	106-124	NSAIDs	group	296-301	false
angiotensin- converting enzyme (ACE) inhibitors	group	154-200	betablockers	group	203-214	false
angiotensin- converting enzyme (ACE) inhibitors	group	154-200	calcium-channel blockers	group	217-240	false
angiotensin- converting enzyme (ACE) inhibitors	group	154-200	diuretics	group	243-251	false
angiotensin- converting enzyme (ACE) inhibitors	group	154-200	nonsteroidal anti-inflammatory drugs	group	258-293	false
angiotensin- converting enzyme (ACE) inhibitors	group	154-200	NSAIDs	group	296-301	false
betablockers	group	203-214	calcium-channel blockers	group	217-240	false
betablockers	group	203-214	diuretics	group	243-251	false
betablockers	group	203-214	nonsteroidal anti-inflammatory drugs	group	258-293	false
betablockers	group	203-214	NSAIDs	group	296-301	false
calcium-channel blockers	group	217-240	diuretics	group	243-251	false
calcium-channel blockers	group	217-240	nonsteroidal anti-inflammatory drugs	group	258-293	false
calcium-channel blockers	group	217-240	NSAIDs	group	296-301	false
diuretics	group	243-251	nonsteroidal anti-inflammatory drugs	group	258-293	false
diuretics	group	243-251	NSAIDs	group	296-301	false
nonsteroidal anti-inflammatory drugs	group	258-293	NSAIDs	group	296-301	false

DDI-DrugBank.d364.s0	Because alosetron is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron.
alosetron	drug	8-16	alosetron	drug	156-164	false

DDI-DrugBank.d364.s2	In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of alosetron 1 mg on the last day.
fluvoxamine	drug	64-74	alosetron	drug	160-168	false

DDI-DrugBank.d364.s3	Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
Fluvoxamine	drug	0-10	alosetron	drug	27-35	mechanism

DDI-DrugBank.d364.s4	Concomitant administration of alosetron and fluvoxamine is contraindicated.
alosetron	drug	30-38	fluvoxamine	drug	44-54	advise

DDI-DrugBank.d364.s5	Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
alosetron	drug	30-38	quinolone antibiotics	group	82-102	advise
alosetron	drug	30-38	cimetidine	drug	108-117	advise
quinolone antibiotics	group	82-102	cimetidine	drug	108-117	false

DDI-DrugBank.d364.s7	In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day.
ketoconazole	drug	64-75	alosetron	drug	133-141	false

DDI-DrugBank.d364.s8	Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.
Ketoconazole	drug	0-11	alosetron	drug	28-36	mechanism

DDI-DrugBank.d364.s9	Caution should be used when alosetron and ketoconazole are administered concomitantly.
alosetron	drug	28-36	ketoconazole	drug	42-53	advise

DDI-DrugBank.d364.s10	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
alosetron	drug	20-28	clarithromycin	drug	68-81	advise
alosetron	drug	20-28	telithromycin	drug	84-96	advise
alosetron	drug	20-28	protease inhibitors	group	99-117	advise
alosetron	drug	20-28	voriconazole	drug	120-131	advise
alosetron	drug	20-28	itraconazole	drug	138-149	advise
clarithromycin	drug	68-81	telithromycin	drug	84-96	false
clarithromycin	drug	68-81	protease inhibitors	group	99-117	false
clarithromycin	drug	68-81	voriconazole	drug	120-131	false
clarithromycin	drug	68-81	itraconazole	drug	138-149	false
telithromycin	drug	84-96	protease inhibitors	group	99-117	false
telithromycin	drug	84-96	voriconazole	drug	120-131	false
telithromycin	drug	84-96	itraconazole	drug	138-149	false
protease inhibitors	group	99-117	voriconazole	drug	120-131	false
protease inhibitors	group	99-117	itraconazole	drug	138-149	false
voriconazole	drug	120-131	itraconazole	drug	138-149	false

DDI-DrugBank.d364.s15	Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
alosetron	drug	26-34	isoniazid	drug	131-139	effect
alosetron	drug	26-34	procainamide	drug	142-153	effect
alosetron	drug	26-34	hydralazine	drug	160-170	effect
isoniazid	drug	131-139	procainamide	drug	142-153	false
isoniazid	drug	131-139	hydralazine	drug	160-170	false
procainamide	drug	142-153	hydralazine	drug	160-170	false

DDI-DrugBank.d364.s17	Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates).
alosetron	drug	26-34	contraceptive agents	group	110-129	false
alosetron	drug	26-34	ethinyl estradiol	drug	131-147	false
alosetron	drug	26-34	levonorgestrel	drug	153-166	false
contraceptive agents	group	110-129	ethinyl estradiol	drug	131-147	false
contraceptive agents	group	110-129	levonorgestrel	drug	153-166	false
ethinyl estradiol	drug	131-147	levonorgestrel	drug	153-166	false

DDI-DrugBank.d364.s18	A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride.
alosetron	drug	53-61	cisapride	drug	88-96	false

DDI-DrugBank.d336.s0	Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.
anticoagulants	group	208-221	chlordiazepoxide	drug	227-242	effect

DDI-DrugBank.d336.s1	The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
alcohol	drug	23-29	central nervous system depressants	group	40-73	false

DDI-DrugBank.d98.s0	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
vitamin D analogues	group	17-35	Vitamin D2	drug	38-47	false
vitamin D analogues	group	17-35	Vitamin D3	drug	50-59	false
vitamin D analogues	group	17-35	Calcitriol	drug	62-71	false
vitamin D analogues	group	17-35	Calcidiol	drug	78-86	false
vitamin D analogues	group	17-35	Cholestyramine	drug	90-103	false
vitamin D analogues	group	17-35	Cholestyramine	drug	106-119	false
vitamin D analogues	group	17-35	fat soluble vitamins	group	174-193	false
Vitamin D2	drug	38-47	Vitamin D3	drug	50-59	false
Vitamin D2	drug	38-47	Calcitriol	drug	62-71	false
Vitamin D2	drug	38-47	Calcidiol	drug	78-86	false
Vitamin D2	drug	38-47	Cholestyramine	drug	90-103	false
Vitamin D2	drug	38-47	Cholestyramine	drug	106-119	false
Vitamin D2	drug	38-47	fat soluble vitamins	group	174-193	false
Vitamin D3	drug	50-59	Calcitriol	drug	62-71	false
Vitamin D3	drug	50-59	Calcidiol	drug	78-86	false
Vitamin D3	drug	50-59	Cholestyramine	drug	90-103	false
Vitamin D3	drug	50-59	Cholestyramine	drug	106-119	false
Vitamin D3	drug	50-59	fat soluble vitamins	group	174-193	false
Calcitriol	drug	62-71	Calcidiol	drug	78-86	false
Calcitriol	drug	62-71	Cholestyramine	drug	90-103	false
Calcitriol	drug	62-71	Cholestyramine	drug	106-119	false
Calcitriol	drug	62-71	fat soluble vitamins	group	174-193	false
Calcidiol	drug	78-86	Cholestyramine	drug	90-103	false
Calcidiol	drug	78-86	Cholestyramine	drug	106-119	false
Calcidiol	drug	78-86	fat soluble vitamins	group	174-193	false
Cholestyramine	drug	90-103	Cholestyramine	drug	106-119	false
Cholestyramine	drug	90-103	fat soluble vitamins	group	174-193	false
Cholestyramine	drug	106-119	fat soluble vitamins	group	174-193	mechanism

DDI-DrugBank.d98.s2	Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
Phenytoin	drug	0-8	Phenobarbital	drug	10-22	false
Phenytoin	drug	0-8	phenytoin	drug	49-57	false
Phenytoin	drug	0-8	phenobarbital	drug	62-74	false
Phenytoin	drug	0-8	vitamin D	group	117-125	false
Phenytoin	drug	0-8	calcitriol	drug	171-180	false
Phenobarbital	drug	10-22	phenytoin	drug	49-57	false
Phenobarbital	drug	10-22	phenobarbital	drug	62-74	false
Phenobarbital	drug	10-22	vitamin D	group	117-125	false
Phenobarbital	drug	10-22	calcitriol	drug	171-180	false
phenytoin	drug	49-57	phenobarbital	drug	62-74	false
phenytoin	drug	49-57	vitamin D	group	117-125	false
phenytoin	drug	49-57	calcitriol	drug	171-180	mechanism
phenobarbital	drug	62-74	vitamin D	group	117-125	false
phenobarbital	drug	62-74	calcitriol	drug	171-180	mechanism
vitamin D	group	117-125	calcitriol	drug	171-180	false

DDI-DrugBank.d98.s3	Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
calcitriol	drug	21-30	Rocaltrol	brand	80-88	false

DDI-DrugBank.d98.s4	Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
Thiazides	group	0-8	Thiazides	group	11-19	false

DDI-DrugBank.d98.s5	Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
thiazides	group	63-71	vitamin D	group	78-86	effect

DDI-DrugBank.d98.s7	Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
Digitalis	group	0-8	Vitamin D	group	11-19	false
Digitalis	group	0-8	digitalis	group	95-103	false
Vitamin D	group	11-19	digitalis	group	95-103	advise

DDI-DrugBank.d98.s8	Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
Ketoconazole	drug	0-11	Ketoconazole	drug	14-25	false
Ketoconazole	drug	0-11	vitamin D	group	79-87	false
Ketoconazole	drug	14-25	vitamin D	group	79-87	mechanism

DDI-DrugBank.d98.s10	However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
ketoconazole	drug	45-56	vitamin D	group	63-71	false

DDI-DrugBank.d98.s11	Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
Corticosteroids	group	0-14	vitamin D analogues	group	72-90	false
Corticosteroids	group	0-14	corticosteroids	group	131-145	false
vitamin D analogues	group	72-90	corticosteroids	group	131-145	mechanism

DDI-DrugBank.d98.s13	Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
Vitamin D	group	0-8	vitamin D analogues	group	46-64	false

DDI-DrugBank.d98.s14	Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
Calcium	drug	0-6	calcium	drug	55-61	false

DDI-DrugBank.d98.s15	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
Magnesium	drug	0-8	Magnesium	drug	11-19	false
Magnesium	drug	0-8	antacids	group	50-57	false
Magnesium	drug	0-8	vitamin D	group	140-148	false
Magnesium	drug	11-19	antacids	group	50-57	false
Magnesium	drug	11-19	vitamin D	group	140-148	advise
antacids	group	50-57	vitamin D	group	140-148	advise

DDI-DrugBank.d4.s0	Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
xanthine bronchodilators	group	18-41	theophylline	drug	50-61	false
xanthine bronchodilators	group	18-41	ephedrine	drug	65-73	false
xanthine bronchodilators	group	18-41	sympathomimetic bronchodilators	group	86-116	effect
theophylline	drug	50-61	ephedrine	drug	65-73	false
theophylline	drug	50-61	sympathomimetic bronchodilators	group	86-116	effect
ephedrine	drug	65-73	sympathomimetic bronchodilators	group	86-116	effect

DDI-DrugBank.d4.s2	Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
dyphylline	drug	29-38	probenecid	drug	44-53	mechanism
dyphylline	drug	29-38	dyphylline	drug	145-154	false
probenecid	drug	44-53	dyphylline	drug	145-154	false

DDI-DrugBank.d305.s1	However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.
phenobarbital	drug	17-29	diazepam	drug	35-42	false
phenobarbital	drug	17-29	Dantrium	brand	62-69	false
diazepam	drug	35-42	Dantrium	brand	62-69	false

DDI-DrugBank.d305.s2	Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone.
diazepam	drug	58-65	diphenylhydantoin	drug	68-84	false
diazepam	drug	58-65	phenylbutazone	drug	90-103	false
diphenylhydantoin	drug	68-84	phenylbutazone	drug	90-103	false

DDI-DrugBank.d305.s3	Binding to plasma proteins is reduced by warfarin and clotibrate and increased by tolbutamide.
warfarin	drug	41-48	tolbutamide	drug	82-92	false

DDI-DrugBank.d305.s5	The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.
dantrolene sodium	drug	52-68	verapamil	drug	74-82	false
dantrolene sodium	drug	52-68	halothane	drug	87-95	false
verapamil	drug	74-82	halothane	drug	87-95	false

DDI-DrugBank.d305.s6	It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
dantrolene sodium	drug	54-70	calcium channel blockers	group	76-99	advise
dantrolene sodium	drug	54-70	verapamil	drug	110-118	advise
calcium channel blockers	group	76-99	verapamil	drug	110-118	false

DDI-DrugBank.d305.s7	Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
dantrolene	drug	18-27	vecuronium	drug	44-53	effect

DDI-DrugBank.d465.s0	The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.
isosorbide dinitrate	drug	28-47	vasodilators	group	85-96	effect

DDI-DrugBank.d554.s0	Certain antibiotic, cisplatin, cyclosporine, diuretic, foscarnet, and vaccines.
antibiotic	group	8-17	cisplatin	drug	20-28	false
antibiotic	group	8-17	cyclosporine	drug	31-42	false
antibiotic	group	8-17	diuretic	group	45-52	false
antibiotic	group	8-17	foscarnet	drug	55-63	false
antibiotic	group	8-17	vaccines	group	70-77	false
cisplatin	drug	20-28	cyclosporine	drug	31-42	false
cisplatin	drug	20-28	diuretic	group	45-52	false
cisplatin	drug	20-28	foscarnet	drug	55-63	false
cisplatin	drug	20-28	vaccines	group	70-77	false
cyclosporine	drug	31-42	diuretic	group	45-52	false
cyclosporine	drug	31-42	foscarnet	drug	55-63	false
cyclosporine	drug	31-42	vaccines	group	70-77	false
diuretic	group	45-52	foscarnet	drug	55-63	false
diuretic	group	45-52	vaccines	group	70-77	false
foscarnet	drug	55-63	vaccines	group	70-77	false

DDI-DrugBank.d545.s0	Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
Geocillin	brand	0-8	carbenicillin indanyl sodium	drug	11-38	false
Geocillin	brand	0-8	probenecid	drug	117-126	mechanism
carbenicillin indanyl sodium	drug	11-38	probenecid	drug	117-126	mechanism

DDI-DrugBank.d287.s0	Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.
Cevimeline	drug	0-9	beta adrenergic antagonists	group	66-92	advise

DDI-DrugBank.d321.s0	Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
Dexamethasone	drug	0-12	albendazole sulfoxide	drug	53-73	false
Dexamethasone	drug	0-12	dexamethasone	drug	107-119	false
Dexamethasone	drug	0-12	albendazole	drug	158-168	false
albendazole sulfoxide	drug	53-73	dexamethasone	drug	107-119	false
albendazole sulfoxide	drug	53-73	albendazole	drug	158-168	false
dexamethasone	drug	107-119	albendazole	drug	158-168	mechanism

DDI-DrugBank.d321.s1	Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
Praziquantel	drug	0-11	praziquantel	drug	32-43	false
Praziquantel	drug	0-11	albendazole sulfoxide	drug	128-148	false
Praziquantel	drug	0-11	albendazole	drug	245-255	false
praziquantel	drug	32-43	albendazole sulfoxide	drug	128-148	mechanism
praziquantel	drug	32-43	albendazole	drug	245-255	false
albendazole sulfoxide	drug	128-148	albendazole	drug	245-255	false

DDI-DrugBank.d321.s3	The pharmacokinetics of praziquantel were unchanged following coadministration with albendazole (400 mg).
praziquantel	drug	24-35	albendazole	drug	84-94	false

DDI-DrugBank.d321.s4	Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
Cimetidine	drug	0-9	Albendazole sulfoxide	drug	12-32	false
Cimetidine	drug	0-9	cimetidine	drug	142-151	false
Cimetidine	drug	0-9	albendazole	drug	188-198	false
Albendazole sulfoxide	drug	12-32	cimetidine	drug	142-151	mechanism
Albendazole sulfoxide	drug	12-32	albendazole	drug	188-198	false
cimetidine	drug	142-151	albendazole	drug	188-198	false

DDI-DrugBank.d321.s6	Theophylline: The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.
Theophylline	drug	0-11	theophylline	drug	38-49	false
Theophylline	drug	0-11	aminophylline	drug	52-64	false
Theophylline	drug	0-11	albendazole	drug	148-158	false
theophylline	drug	38-49	aminophylline	drug	52-64	false
theophylline	drug	38-49	albendazole	drug	148-158	false
aminophylline	drug	52-64	albendazole	drug	148-158	false

DDI-DrugBank.d510.s0	The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
Robinul	brand	22-28	anticholinergics	group	51-66	effect
Robinul	brand	22-28	phenothiazines	group	122-135	effect
Robinul	brand	22-28	antiparkinson drugs	group	138-156	effect
Robinul	brand	22-28	tricyclic antidepressants	group	162-186	effect
anticholinergics	group	51-66	phenothiazines	group	122-135	false
anticholinergics	group	51-66	antiparkinson drugs	group	138-156	false
anticholinergics	group	51-66	tricyclic antidepressants	group	162-186	false
phenothiazines	group	122-135	antiparkinson drugs	group	138-156	false
phenothiazines	group	122-135	tricyclic antidepressants	group	162-186	false
antiparkinson drugs	group	138-156	tricyclic antidepressants	group	162-186	false

DDI-DrugBank.d510.s1	Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
Robinul	brand	30-36	potassium chloride	drug	52-69	mechanism

DDI-DrugBank.d143.s0	Amiodarone is metabolized to desethylamiodarone by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.
Amiodarone	drug	0-9	desethylamiodarone	drug	29-46	false

DDI-DrugBank.d143.s7	In view of the long and variable half-life of amiodarone, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone.
amiodarone	drug	46-55	amiodarone	drug	192-201	false

DDI-DrugBank.d143.s8	Since amiodarone is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone.
amiodarone	drug	6-15	amiodarone	drug	166-175	false

DDI-DrugBank.d143.s9	Reported examples include the following: Protease Inhibitors: Protease inhibitors are known to inhibit CYP3A4 to varying degrees.
Protease Inhibitors	group	41-59	Protease inhibitors	group	62-80	false

DDI-DrugBank.d143.s10	A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
amiodarone	drug	36-45	indinavir	drug	58-66	mechanism
amiodarone	drug	36-45	amiodarone	drug	118-127	false
indinavir	drug	58-66	amiodarone	drug	118-127	false

DDI-DrugBank.d143.s13	Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.
amiodarone	drug	15-24	amiodarone	drug	61-70	false
amiodarone	drug	15-24	protease inhibitor	group	111-128	false
amiodarone	drug	61-70	protease inhibitor	group	111-128	advise

DDI-DrugBank.d143.s14	Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.
Histamine H2 antagonists	group	0-23	Cimetidine	drug	26-35	mechanism
Histamine H2 antagonists	group	0-23	amiodarone	drug	76-85	false
Cimetidine	drug	26-35	amiodarone	drug	76-85	false

DDI-DrugBank.d143.s15	Other substances: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone.
amiodarone	drug	73-82	amiodarone	drug	152-161	false

DDI-DrugBank.d143.s17	This information should be considered when changing from intravenous amiodarone to oral amiodarone .
amiodarone	drug	69-78	amiodarone	drug	88-97	false

DDI-DrugBank.d143.s18	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4.
Amiodarone	drug	0-9	CYP1A2	drug	58-63	false
Amiodarone	drug	0-9	CYP2C9	drug	66-71	false
Amiodarone	drug	0-9	CYP2D6	drug	74-79	false
Amiodarone	drug	0-9	CYP3A4	drug	86-91	false
CYP1A2	drug	58-63	CYP2C9	drug	66-71	false
CYP1A2	drug	58-63	CYP2D6	drug	74-79	false
CYP1A2	drug	58-63	CYP3A4	drug	86-91	false
CYP2C9	drug	66-71	CYP2D6	drug	74-79	false
CYP2C9	drug	66-71	CYP3A4	drug	86-91	false
CYP2D6	drug	74-79	CYP3A4	drug	86-91	false

DDI-DrugBank.d143.s20	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.
Immunosuppressive	drug	61-77	Cyclosporine	drug	81-92	false
Immunosuppressive	drug	61-77	CYP3A4	drug	95-100	false
Immunosuppressive	drug	61-77	amiodarone	drug	151-160	false
Immunosuppressive	drug	61-77	cyclosporine	drug	238-249	false
Immunosuppressive	drug	61-77	cyclosporine	drug	314-325	false
Cyclosporine	drug	81-92	CYP3A4	drug	95-100	false
Cyclosporine	drug	81-92	amiodarone	drug	151-160	false
Cyclosporine	drug	81-92	cyclosporine	drug	238-249	false
Cyclosporine	drug	81-92	cyclosporine	drug	314-325	false
CYP3A4	drug	95-100	amiodarone	drug	151-160	false
CYP3A4	drug	95-100	cyclosporine	drug	238-249	false
CYP3A4	drug	95-100	cyclosporine	drug	314-325	false
amiodarone	drug	151-160	cyclosporine	drug	238-249	false
amiodarone	drug	151-160	cyclosporine	drug	314-325	false
cyclosporine	drug	238-249	cyclosporine	drug	314-325	false

DDI-DrugBank.d143.s21	HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.
HMG-CoA Reductase Inhibitors	drug	0-27	Simvastatin	drug	30-40	false
HMG-CoA Reductase Inhibitors	drug	0-27	CYP3A4	drug	43-48	false
HMG-CoA Reductase Inhibitors	drug	0-27	amiodarone	drug	81-90	false
Simvastatin	drug	30-40	CYP3A4	drug	43-48	false
Simvastatin	drug	30-40	amiodarone	drug	81-90	false
CYP3A4	drug	43-48	amiodarone	drug	81-90	false

DDI-DrugBank.d143.s22	Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.
Cardiac glycosides	drug	17-34	digoxin	drug	59-65	false
Cardiac glycosides	drug	17-34	amiodarone	drug	99-108	false
Cardiac glycosides	drug	17-34	digoxin	drug	152-158	false
digoxin	drug	59-65	amiodarone	drug	99-108	false
digoxin	drug	59-65	digoxin	drug	152-158	false
amiodarone	drug	99-108	digoxin	drug	152-158	false

DDI-DrugBank.d143.s23	Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.
Amiodarone	drug	0-9	digoxin	drug	36-42	false
Amiodarone	drug	0-9	digoxin	drug	64-70	false
digoxin	drug	36-42	digoxin	drug	64-70	false

DDI-DrugBank.d143.s24	On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
amiodarone	drug	26-35	digitalis	group	51-59	advise

DDI-DrugBank.d143.s27	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.
Antiarrhythmics	drug	0-14	antiarrhythmic	drug	23-36	false
Antiarrhythmics	drug	0-14	quinidine	drug	53-61	false
Antiarrhythmics	drug	0-14	procainamide	drug	64-75	false
Antiarrhythmics	drug	0-14	disopyramide	drug	78-89	false
Antiarrhythmics	drug	0-14	phenytoin	drug	96-104	false
Antiarrhythmics	drug	0-14	amiodarone	drug	140-149	false
antiarrhythmic	drug	23-36	quinidine	drug	53-61	false
antiarrhythmic	drug	23-36	procainamide	drug	64-75	false
antiarrhythmic	drug	23-36	disopyramide	drug	78-89	false
antiarrhythmic	drug	23-36	phenytoin	drug	96-104	false
antiarrhythmic	drug	23-36	amiodarone	drug	140-149	false
quinidine	drug	53-61	procainamide	drug	64-75	false
quinidine	drug	53-61	disopyramide	drug	78-89	false
quinidine	drug	53-61	phenytoin	drug	96-104	false
quinidine	drug	53-61	amiodarone	drug	140-149	false
procainamide	drug	64-75	disopyramide	drug	78-89	false
procainamide	drug	64-75	phenytoin	drug	96-104	false
procainamide	drug	64-75	amiodarone	drug	140-149	false
disopyramide	drug	78-89	phenytoin	drug	96-104	false
disopyramide	drug	78-89	amiodarone	drug	140-149	false
phenytoin	drug	96-104	amiodarone	drug	140-149	false

DDI-DrugBank.d143.s28	There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone.
quinidine	drug	65-73	procainamide	drug	76-87	false
quinidine	drug	65-73	phenytoin	drug	94-102	false
quinidine	drug	65-73	amiodarone	drug	136-145	false
procainamide	drug	76-87	phenytoin	drug	94-102	false
procainamide	drug	76-87	amiodarone	drug	136-145	false
phenytoin	drug	94-102	amiodarone	drug	136-145	false

DDI-DrugBank.d143.s30	Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.
Amiodarone	drug	0-9	quinidine	drug	36-44	false
Amiodarone	drug	0-9	quinidine	drug	56-64	false
quinidine	drug	36-44	quinidine	drug	56-64	false

DDI-DrugBank.d143.s31	Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.
Amiodarone	drug	0-9	procainamide	drug	36-47	false
Amiodarone	drug	0-9	procainamide	drug	109-120	false
Amiodarone	drug	0-9	procainamide	drug	135-146	false
procainamide	drug	36-47	procainamide	drug	109-120	false
procainamide	drug	36-47	procainamide	drug	135-146	false
procainamide	drug	109-120	procainamide	drug	135-146	false

DDI-DrugBank.d143.s32	Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone.
Quinidine	drug	0-8	amiodarone	drug	97-106	false

DDI-DrugBank.d143.s33	Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone;
flecainide	drug	17-26	amiodarone	drug	83-92	false

DDI-DrugBank.d143.s34	because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.
flecainide	drug	31-40	drugs	drug	72-76	false

DDI-DrugBank.d143.s36	Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.
amiodarone	drug	15-24	antiarrhythmic	drug	37-50	false
amiodarone	drug	15-24	amiodarone	drug	218-227	false
antiarrhythmic	drug	37-50	amiodarone	drug	218-227	false

DDI-DrugBank.d143.s37	During transfer to oral amiodarone, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral amiodarone.
amiodarone	drug	24-33	amiodarone	drug	157-166	false

DDI-DrugBank.d143.s38	The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.
antiarrhythmic	drug	33-46	amiodarone	drug	94-103	false

DDI-DrugBank.d143.s40	In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.
amiodarone	drug	3-12	antiarrhythmic	drug	54-67	false

DDI-DrugBank.d143.s41	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
Antihypertensives	drug	0-16	Amiodarone	drug	19-28	false
Antihypertensives	drug	0-16	receptor	drug	82-89	false
Antihypertensives	drug	0-16	propranolol	drug	114-124	false
Antihypertensives	drug	0-16	CYP3A4	drug	129-134	false
Antihypertensives	drug	0-16	calcium channel	drug	150-164	false
Antihypertensives	drug	0-16	verapamil	drug	185-193	false
Antihypertensives	drug	0-16	CYP3A4	drug	198-203	false
Antihypertensives	drug	0-16	diltiazem	drug	220-228	false
Antihypertensives	drug	0-16	CYP3A4	drug	233-238	false
Amiodarone	drug	19-28	receptor	drug	82-89	false
Amiodarone	drug	19-28	propranolol	drug	114-124	false
Amiodarone	drug	19-28	CYP3A4	drug	129-134	false
Amiodarone	drug	19-28	calcium channel	drug	150-164	false
Amiodarone	drug	19-28	verapamil	drug	185-193	false
Amiodarone	drug	19-28	CYP3A4	drug	198-203	false
Amiodarone	drug	19-28	diltiazem	drug	220-228	false
Amiodarone	drug	19-28	CYP3A4	drug	233-238	false
receptor	drug	82-89	propranolol	drug	114-124	false
receptor	drug	82-89	CYP3A4	drug	129-134	false
receptor	drug	82-89	calcium channel	drug	150-164	false
receptor	drug	82-89	verapamil	drug	185-193	false
receptor	drug	82-89	CYP3A4	drug	198-203	false
receptor	drug	82-89	diltiazem	drug	220-228	false
receptor	drug	82-89	CYP3A4	drug	233-238	false
propranolol	drug	114-124	CYP3A4	drug	129-134	false
propranolol	drug	114-124	calcium channel	drug	150-164	false
propranolol	drug	114-124	verapamil	drug	185-193	false
propranolol	drug	114-124	CYP3A4	drug	198-203	false
propranolol	drug	114-124	diltiazem	drug	220-228	false
propranolol	drug	114-124	CYP3A4	drug	233-238	false
CYP3A4	drug	129-134	calcium channel	drug	150-164	false
CYP3A4	drug	129-134	verapamil	drug	185-193	false
CYP3A4	drug	129-134	CYP3A4	drug	198-203	false
CYP3A4	drug	129-134	diltiazem	drug	220-228	false
CYP3A4	drug	129-134	CYP3A4	drug	233-238	false
calcium channel	drug	150-164	verapamil	drug	185-193	false
calcium channel	drug	150-164	CYP3A4	drug	198-203	false
calcium channel	drug	150-164	diltiazem	drug	220-228	false
calcium channel	drug	150-164	CYP3A4	drug	233-238	false
verapamil	drug	185-193	CYP3A4	drug	198-203	false
verapamil	drug	185-193	diltiazem	drug	220-228	false
verapamil	drug	185-193	CYP3A4	drug	233-238	false
CYP3A4	drug	198-203	diltiazem	drug	220-228	false
CYP3A4	drug	198-203	CYP3A4	drug	233-238	false
diltiazem	drug	220-228	CYP3A4	drug	233-238	false

DDI-DrugBank.d143.s43	Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
Anticoagulants	drug	0-13	warfarin	drug	32-39	false
Anticoagulants	drug	0-13	CYP2C9	drug	47-52	false
Anticoagulants	drug	0-13	CYP3A4	drug	58-63	false
Anticoagulants	drug	0-13	anticoagulant	drug	76-88	false
Anticoagulants	drug	0-13	amiodarone	drug	143-152	false
warfarin	drug	32-39	CYP2C9	drug	47-52	false
warfarin	drug	32-39	CYP3A4	drug	58-63	false
warfarin	drug	32-39	anticoagulant	drug	76-88	false
warfarin	drug	32-39	amiodarone	drug	143-152	false
CYP2C9	drug	47-52	CYP3A4	drug	58-63	false
CYP2C9	drug	47-52	anticoagulant	drug	76-88	false
CYP2C9	drug	47-52	amiodarone	drug	143-152	false
CYP3A4	drug	58-63	anticoagulant	drug	76-88	false
CYP3A4	drug	58-63	amiodarone	drug	143-152	false
anticoagulant	drug	76-88	amiodarone	drug	143-152	false

DDI-DrugBank.d143.s44	Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.
warfarin	drug	40-47	amiodarone	drug	54-63	false
warfarin	drug	40-47	anticoagulant	drug	139-151	false
amiodarone	drug	54-63	anticoagulant	drug	139-151	false

DDI-DrugBank.d143.s45	Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).
drugs	drug	5-9	amiodarone	drug	64-73	false
drugs	drug	5-9	CYP3A4	drug	107-112	false
amiodarone	drug	64-73	CYP3A4	drug	107-112	false

DDI-DrugBank.d143.s47	Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.
Antibiotics	drug	61-71	Rifampin	drug	74-81	false
Antibiotics	drug	61-71	CYP3A4	drug	106-111	false
Rifampin	drug	74-81	CYP3A4	drug	106-111	false

DDI-DrugBank.d143.s48	Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.
rifampin	drug	18-25	amiodarone	drug	51-60	false
rifampin	drug	18-25	amiodarone	drug	127-136	false
rifampin	drug	18-25	desethylamiodarone	drug	142-159	false
amiodarone	drug	51-60	amiodarone	drug	127-136	false
amiodarone	drug	51-60	desethylamiodarone	drug	142-159	false
amiodarone	drug	127-136	desethylamiodarone	drug	142-159	false

DDI-DrugBank.d143.s50	Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.
amiodarone	drug	6-15	CYP3A4	drug	36-41	false
amiodarone	drug	6-15	amiodarone	drug	121-130	false
amiodarone	drug	6-15	amiodarone	drug	156-165	false
CYP3A4	drug	36-41	amiodarone	drug	121-130	false
CYP3A4	drug	36-41	amiodarone	drug	156-165	false
amiodarone	drug	121-130	amiodarone	drug	156-165	false

DDI-DrugBank.d143.s51	Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.
amiodarone	drug	33-42	Fentanyl	drug	45-52	false
amiodarone	drug	33-42	CYP3A4	drug	55-60	false
amiodarone	drug	33-42	amiodarone	drug	93-102	false
Fentanyl	drug	45-52	CYP3A4	drug	55-60	false
Fentanyl	drug	45-52	amiodarone	drug	93-102	false
CYP3A4	drug	55-60	amiodarone	drug	93-102	false

DDI-DrugBank.d143.s52	Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A4 substrate) given for local anesthesia.
amiodarone	drug	46-55	lidocaine	drug	77-85	false
amiodarone	drug	46-55	CYP3A4	drug	88-93	false
amiodarone	drug	46-55	anesthesia	drug	122-131	false
lidocaine	drug	77-85	CYP3A4	drug	88-93	false
lidocaine	drug	77-85	anesthesia	drug	122-131	false
CYP3A4	drug	88-93	anesthesia	drug	122-131	false

DDI-DrugBank.d143.s53	Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone.
lidocaine	drug	35-43	amiodarone	drug	126-135	false

DDI-DrugBank.d143.s54	Dextromethorphan is a substrate for both CYP2D6 and CYP3A4.
Dextromethorphan	drug	0-15	CYP2D6	drug	41-46	false
Dextromethorphan	drug	0-15	CYP3A4	drug	52-57	false
CYP2D6	drug	41-46	CYP3A4	drug	52-57	false

DDI-DrugBank.d143.s55	Amiodarone inhibits CYP2D6.
Amiodarone	drug	0-9	CYP2D6	drug	20-25	false

DDI-DrugBank.d143.s56	Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1/2.
Cholestyramine	drug	0-13	amiodarone	drug	54-63	false
Cholestyramine	drug	0-13	t1	drug	101-102	false
amiodarone	drug	54-63	t1	drug	101-102	false

DDI-DrugBank.d143.s58	Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation.
Fluoroquinolones	drug	0-15	macrolide antibiotics	drug	18-38	false

DDI-DrugBank.d143.s59	There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.
amiodarone	drug	85-94	fluoroquinolones	drug	101-116	false
amiodarone	drug	85-94	macrolide antibiotics	drug	119-139	false
fluoroquinolones	drug	101-116	macrolide antibiotics	drug	119-139	false

DDI-DrugBank.d143.s60	Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, diltiazem, and verapamil.
propranolol	drug	110-120	diltiazem	drug	123-131	false
propranolol	drug	110-120	verapamil	drug	138-146	false
diltiazem	drug	123-131	verapamil	drug	138-146	false

DDI-DrugBank.d143.s62	In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.
Cordarone	drug	70-78	phenytoin	drug	117-125	false
Cordarone	drug	70-78	dextromethorphan	drug	128-143	false
Cordarone	drug	70-78	methotrexate	drug	150-161	false
phenytoin	drug	117-125	dextromethorphan	drug	128-143	false
phenytoin	drug	117-125	methotrexate	drug	150-161	false
dextromethorphan	drug	128-143	methotrexate	drug	150-161	false

DDI-DrugBank.d165.s0	Both itraconazole and its major metabolite, hydroxyitraconazole, are inhibitors of the cytochrome P450 3A4 enzyme system.
itraconazole	drug	5-16	hydroxyitraconazole	drug_n	44-62	false

DDI-DrugBank.d165.s3	Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
terfenadine	drug	20-30	Itraconazole	drug	37-48	mechanism
terfenadine	drug	20-30	terfenadine	drug	95-105	false
Itraconazole	drug	37-48	terfenadine	drug	95-105	false

DDI-DrugBank.d165.s4	Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
azole antifungal	group	13-28	ketoconazole	drug	31-42	false
azole antifungal	group	13-28	astemizole	drug	72-81	false
azole antifungal	group	13-28	astemizole	drug	131-140	false
azole antifungal	group	13-28	desmethylastermizole	drug_n	168-187	false
ketoconazole	drug	31-42	astemizole	drug	72-81	mechanism
ketoconazole	drug	31-42	astemizole	drug	131-140	false
ketoconazole	drug	31-42	desmethylastermizole	drug_n	168-187	false
astemizole	drug	72-81	astemizole	drug	131-140	false
astemizole	drug	72-81	desmethylastermizole	drug_n	168-187	false
astemizole	drug	131-140	desmethylastermizole	drug_n	168-187	false

DDI-DrugBank.d165.s5	In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.
itraconazole	drug	27-38	ketoconazole	drug	58-69	false
itraconazole	drug	27-38	astemizole	drug	167-176	mechanism
ketoconazole	drug	58-69	astemizole	drug	167-176	false

DDI-DrugBank.d165.s6	Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.
itraconazole	drug	37-48	ketoconazole	drug	54-65	false
itraconazole	drug	37-48	astemizole	drug	88-97	false
itraconazole	drug	37-48	itraconazole	drug	104-115	false
ketoconazole	drug	54-65	astemizole	drug	88-97	false
ketoconazole	drug	54-65	itraconazole	drug	104-115	false
astemizole	drug	88-97	itraconazole	drug	104-115	advise

DDI-DrugBank.d165.s7	Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.
ketoconazole	drug	47-58	cisapride	drug	96-104	mechanism
ketoconazole	drug	47-58	cisapride	drug	161-169	false
cisapride	drug	96-104	cisapride	drug	161-169	false

DDI-DrugBank.d165.s8	Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
ketoconazole	drug	43-54	cisapride	drug	60-68	effect

DDI-DrugBank.d165.s9	In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;
itraconazole	drug	27-38	cisapride	drug	133-141	mechanism

DDI-DrugBank.d165.s10	therefore concomitant administration of Itraconazole with cisapride is contraindicated.
Itraconazole	drug	40-51	cisapride	drug	58-66	advise

DDI-DrugBank.d165.s11	Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
Itraconazole	drug	20-31	midazolam	drug	43-51	mechanism
Itraconazole	drug	20-31	triazolam	drug	56-64	mechanism
midazolam	drug	43-51	triazolam	drug	56-64	false

DDI-DrugBank.d165.s15	Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
Itraconazole	drug	20-31	cyclosporine	drug	37-48	mechanism
Itraconazole	drug	20-31	tacrolimus	drug	51-60	mechanism
Itraconazole	drug	20-31	digoxin	drug	65-71	mechanism
cyclosporine	drug	37-48	tacrolimus	drug	51-60	false
cyclosporine	drug	37-48	digoxin	drug	65-71	false
tacrolimus	drug	51-60	digoxin	drug	65-71	false

DDI-DrugBank.d165.s16	Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
Cyclosporine	drug	0-11	tacrolimus	drug	14-23	false
Cyclosporine	drug	0-11	digoxin	drug	29-35	false
Cyclosporine	drug	0-11	Itraconazole	drug	93-104	advise
tacrolimus	drug	14-23	digoxin	drug	29-35	false
tacrolimus	drug	14-23	Itraconazole	drug	93-104	advise
digoxin	drug	29-35	Itraconazole	drug	93-104	advise

DDI-DrugBank.d165.s17	Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.
HMG-CoA reductase inhibitors	group	55-82	immunosuppressive drugs	group	150-172	effect
HMG-CoA reductase inhibitors	group	55-82	cyclosporine	drug	184-195	effect
immunosuppressive drugs	group	150-172	cyclosporine	drug	184-195	false

DDI-DrugBank.d165.s18	When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
Itraconazole	drug	5-16	phenytoin	drug	42-50	mechanism
Itraconazole	drug	5-16	rifampin	drug	53-60	mechanism
Itraconazole	drug	5-16	itraconazole	drug	114-125	false
phenytoin	drug	42-50	rifampin	drug	53-60	false
phenytoin	drug	42-50	itraconazole	drug	114-125	false
rifampin	drug	53-60	itraconazole	drug	114-125	false

DDI-DrugBank.d165.s19	The physician is advised to monitor the plasma concentrations of itraconazole when any of these drugs is taken concurrently, and to increase the dose of Itraconazole if necessary.
itraconazole	drug	65-76	Itraconazole	drug	153-164	false

DDI-DrugBank.d165.s20	Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;
Itraconazole	drug	71-82	phenytoin	drug	88-96	mechanism
Itraconazole	drug	71-82	phenytoin	drug	126-134	false
phenytoin	drug	88-96	phenytoin	drug	126-134	false

DDI-DrugBank.d165.s21	therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.
phenytoin	drug	36-44	Itraconazole	drug	106-117	advise

DDI-DrugBank.d165.s22	It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.
Itraconazole	drug	26-37	coumarin	group	76-83	effect

DDI-DrugBank.d165.s23	Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.
Itraconazole	drug	80-91	coumarin	group	97-104	advise

DDI-DrugBank.d165.s24	Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.
azole antifungal agents	group	25-47	isoniazid	drug	90-98	mechanism

DDI-DrugBank.d165.s25	Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.
Itraconazole	drug	0-11	Itraconazole	drug	60-71	false
Itraconazole	drug	0-11	isoniazid	drug	77-85	false
Itraconazole	drug	60-71	isoniazid	drug	77-85	advise

DDI-DrugBank.d165.s26	Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.
azole antifungal agents	group	74-96	hypoglycemic agents	group	107-125	effect

DDI-DrugBank.d165.s27	Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.
Itraconazole	drug	64-75	hypoglycemic agents	group	86-104	advise

DDI-DrugBank.d165.s28	Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.
Itraconazole	drug	86-97	quinidine	drug	103-111	effect

DDI-DrugBank.d165.s29	Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.
Itraconazole	drug	60-71	dihydropyridine calcium channel blockers	group	77-116	effect

DDI-DrugBank.d165.s31	The results from a study in which eight HIV-infected individuals were treated with zidovudine, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of Itraconazole, 100 mg b.i.d.
zidovudine	drug	83-92	zidovudine	drug	152-161	false
zidovudine	drug	83-92	Itraconazole	drug	218-229	false
zidovudine	drug	152-161	Itraconazole	drug	218-229	false

DDI-DrugBank.d83.s0	Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.
warfarin-type anticoagulant	group	12-38	griseofulvin	drug	116-127	advise

DDI-DrugBank.d83.s1	Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.
barbiturates	group	19-30	griseofulvin	drug	50-61	effect

DDI-DrugBank.d83.s2	The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.
griseofulvin	drug	34-45	contraceptives	group	96-109	effect

DDI-DrugBank.d486.s0	No drug interaction studies have been conducted for COLAZAL, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.
COLAZAL	brand	52-58	antibiotics	group	100-110	false
COLAZAL	brand	52-58	mesalamine	drug	164-173	false
antibiotics	group	100-110	mesalamine	drug	164-173	false

DDI-DrugBank.d60.s0	Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.
NIMBEX	brand	39-44	succinylcholine	drug	101-115	effect

DDI-DrugBank.d60.s1	The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.
NIMBEX	brand	45-50	succinylcholine	drug	115-129	effect

DDI-DrugBank.d60.s2	Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of NIMBEX.
succinylcholine	drug	24-38	NIMBEX	brand	141-146	false

DDI-DrugBank.d60.s3	Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.
NIMBEX	brand	25-30	succinylcholine	drug	57-71	false
NIMBEX	brand	25-30	NIMBEX	brand	95-100	false
NIMBEX	brand	25-30	succinylcholine	drug	151-165	false
succinylcholine	drug	57-71	NIMBEX	brand	95-100	effect
succinylcholine	drug	57-71	succinylcholine	drug	151-165	false
NIMBEX	brand	95-100	succinylcholine	drug	151-165	false

DDI-DrugBank.d60.s4	The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
NIMBEX	brand	11-16	succinylcholine	drug	25-39	false
NIMBEX	brand	11-16	succinylcholine	drug	82-96	false
succinylcholine	drug	25-39	succinylcholine	drug	82-96	false

DDI-DrugBank.d60.s5	Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium, pancuronium, or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX.
vecuronium	drug	96-105	pancuronium	drug	108-118	false
vecuronium	drug	96-105	atracurium	drug	124-133	false
vecuronium	drug	96-105	NIMBEX	brand	225-230	false
pancuronium	drug	108-118	atracurium	drug	124-133	false
pancuronium	drug	108-118	NIMBEX	brand	225-230	false
atracurium	drug	124-133	NIMBEX	brand	225-230	false

DDI-DrugBank.d60.s6	Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
Isoflurane	drug	0-9	enflurane	drug	14-22	false
Isoflurane	drug	0-9	nitrous oxide	drug	42-54	false
Isoflurane	drug	0-9	oxygen	drug	56-61	false
Isoflurane	drug	0-9	NIMBEX	brand	208-213	effect
Isoflurane	drug	0-9	NIMBEX	brand	258-263	effect
enflurane	drug	14-22	nitrous oxide	drug	42-54	false
enflurane	drug	14-22	oxygen	drug	56-61	false
enflurane	drug	14-22	NIMBEX	brand	208-213	effect
enflurane	drug	14-22	NIMBEX	brand	258-263	effect
nitrous oxide	drug	42-54	oxygen	drug	56-61	false
nitrous oxide	drug	42-54	NIMBEX	brand	208-213	effect
nitrous oxide	drug	42-54	NIMBEX	brand	258-263	effect
oxygen	drug	56-61	NIMBEX	brand	208-213	false
oxygen	drug	56-61	NIMBEX	brand	258-263	false
NIMBEX	brand	208-213	NIMBEX	brand	258-263	false

DDI-DrugBank.d60.s8	Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.
isoflurane	drug	46-55	enflurane	drug	60-68	false
isoflurane	drug	46-55	NIMBEX	brand	136-141	false
isoflurane	drug	46-55	NIMBEX	brand	217-222	false
enflurane	drug	60-68	NIMBEX	brand	136-141	false
enflurane	drug	60-68	NIMBEX	brand	217-222	false
NIMBEX	brand	136-141	NIMBEX	brand	217-222	false

DDI-DrugBank.d60.s9	In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
enflurane	drug	35-43	isoflurane	drug	48-57	false
enflurane	drug	35-43	NIMBEX	brand	159-164	advise
isoflurane	drug	48-57	NIMBEX	brand	159-164	advise

DDI-DrugBank.d60.s11	In clinical studies propofol had no effect on the duration of action or dosing requirements for NIMBEX.
propofol	drug	20-27	NIMBEX	brand	96-101	false

DDI-DrugBank.d60.s12	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
nondepolarizing agents	group	67-88	NIMBEX	brand	98-103	effect
nondepolarizing agents	group	67-88	antibiotics	group	121-131	effect
nondepolarizing agents	group	67-88	aminoglycosides	group	141-155	effect
nondepolarizing agents	group	67-88	tetracyclines	group	158-170	effect
nondepolarizing agents	group	67-88	bacitracin	drug	173-182	effect
nondepolarizing agents	group	67-88	polymyxins	group	185-194	effect
nondepolarizing agents	group	67-88	lincomycin	drug	197-206	effect
nondepolarizing agents	group	67-88	clindamycin	drug	209-219	effect
nondepolarizing agents	group	67-88	colistin	drug	222-229	effect
nondepolarizing agents	group	67-88	sodium colistemethate	drug	236-256	effect
nondepolarizing agents	group	67-88	magnesium	group	260-268	effect
nondepolarizing agents	group	67-88	lithium	drug	277-283	effect
nondepolarizing agents	group	67-88	anesthetics	group	292-302	effect
nondepolarizing agents	group	67-88	procainamide	drug	305-316	effect
nondepolarizing agents	group	67-88	quinidine	drug	323-331	effect
NIMBEX	brand	98-103	antibiotics	group	121-131	effect
NIMBEX	brand	98-103	aminoglycosides	group	141-155	effect
NIMBEX	brand	98-103	tetracyclines	group	158-170	effect
NIMBEX	brand	98-103	bacitracin	drug	173-182	effect
NIMBEX	brand	98-103	polymyxins	group	185-194	effect
NIMBEX	brand	98-103	lincomycin	drug	197-206	effect
NIMBEX	brand	98-103	clindamycin	drug	209-219	effect
NIMBEX	brand	98-103	colistin	drug	222-229	effect
NIMBEX	brand	98-103	sodium colistemethate	drug	236-256	effect
NIMBEX	brand	98-103	magnesium	group	260-268	effect
NIMBEX	brand	98-103	lithium	drug	277-283	effect
NIMBEX	brand	98-103	anesthetics	group	292-302	effect
NIMBEX	brand	98-103	procainamide	drug	305-316	effect
NIMBEX	brand	98-103	quinidine	drug	323-331	effect
antibiotics	group	121-131	aminoglycosides	group	141-155	false
antibiotics	group	121-131	tetracyclines	group	158-170	false
antibiotics	group	121-131	bacitracin	drug	173-182	false
antibiotics	group	121-131	polymyxins	group	185-194	false
antibiotics	group	121-131	lincomycin	drug	197-206	false
antibiotics	group	121-131	clindamycin	drug	209-219	false
antibiotics	group	121-131	colistin	drug	222-229	false
antibiotics	group	121-131	sodium colistemethate	drug	236-256	false
antibiotics	group	121-131	magnesium	group	260-268	false
antibiotics	group	121-131	lithium	drug	277-283	false
antibiotics	group	121-131	anesthetics	group	292-302	false
antibiotics	group	121-131	procainamide	drug	305-316	false
antibiotics	group	121-131	quinidine	drug	323-331	false
aminoglycosides	group	141-155	tetracyclines	group	158-170	false
aminoglycosides	group	141-155	bacitracin	drug	173-182	false
aminoglycosides	group	141-155	polymyxins	group	185-194	false
aminoglycosides	group	141-155	lincomycin	drug	197-206	false
aminoglycosides	group	141-155	clindamycin	drug	209-219	false
aminoglycosides	group	141-155	colistin	drug	222-229	false
aminoglycosides	group	141-155	sodium colistemethate	drug	236-256	false
aminoglycosides	group	141-155	magnesium	group	260-268	false
aminoglycosides	group	141-155	lithium	drug	277-283	false
aminoglycosides	group	141-155	anesthetics	group	292-302	false
aminoglycosides	group	141-155	procainamide	drug	305-316	false
aminoglycosides	group	141-155	quinidine	drug	323-331	false
tetracyclines	group	158-170	bacitracin	drug	173-182	false
tetracyclines	group	158-170	polymyxins	group	185-194	false
tetracyclines	group	158-170	lincomycin	drug	197-206	false
tetracyclines	group	158-170	clindamycin	drug	209-219	false
tetracyclines	group	158-170	colistin	drug	222-229	false
tetracyclines	group	158-170	sodium colistemethate	drug	236-256	false
tetracyclines	group	158-170	magnesium	group	260-268	false
tetracyclines	group	158-170	lithium	drug	277-283	false
tetracyclines	group	158-170	anesthetics	group	292-302	false
tetracyclines	group	158-170	procainamide	drug	305-316	false
tetracyclines	group	158-170	quinidine	drug	323-331	false
bacitracin	drug	173-182	polymyxins	group	185-194	false
bacitracin	drug	173-182	lincomycin	drug	197-206	false
bacitracin	drug	173-182	clindamycin	drug	209-219	false
bacitracin	drug	173-182	colistin	drug	222-229	false
bacitracin	drug	173-182	sodium colistemethate	drug	236-256	false
bacitracin	drug	173-182	magnesium	group	260-268	false
bacitracin	drug	173-182	lithium	drug	277-283	false
bacitracin	drug	173-182	anesthetics	group	292-302	false
bacitracin	drug	173-182	procainamide	drug	305-316	false
bacitracin	drug	173-182	quinidine	drug	323-331	false
polymyxins	group	185-194	lincomycin	drug	197-206	false
polymyxins	group	185-194	clindamycin	drug	209-219	false
polymyxins	group	185-194	colistin	drug	222-229	false
polymyxins	group	185-194	sodium colistemethate	drug	236-256	false
polymyxins	group	185-194	magnesium	group	260-268	false
polymyxins	group	185-194	lithium	drug	277-283	false
polymyxins	group	185-194	anesthetics	group	292-302	false
polymyxins	group	185-194	procainamide	drug	305-316	false
polymyxins	group	185-194	quinidine	drug	323-331	false
lincomycin	drug	197-206	clindamycin	drug	209-219	false
lincomycin	drug	197-206	colistin	drug	222-229	false
lincomycin	drug	197-206	sodium colistemethate	drug	236-256	false
lincomycin	drug	197-206	magnesium	group	260-268	false
lincomycin	drug	197-206	lithium	drug	277-283	false
lincomycin	drug	197-206	anesthetics	group	292-302	false
lincomycin	drug	197-206	procainamide	drug	305-316	false
lincomycin	drug	197-206	quinidine	drug	323-331	false
clindamycin	drug	209-219	colistin	drug	222-229	false
clindamycin	drug	209-219	sodium colistemethate	drug	236-256	false
clindamycin	drug	209-219	magnesium	group	260-268	false
clindamycin	drug	209-219	lithium	drug	277-283	false
clindamycin	drug	209-219	anesthetics	group	292-302	false
clindamycin	drug	209-219	procainamide	drug	305-316	false
clindamycin	drug	209-219	quinidine	drug	323-331	false
colistin	drug	222-229	sodium colistemethate	drug	236-256	false
colistin	drug	222-229	magnesium	group	260-268	false
colistin	drug	222-229	lithium	drug	277-283	false
colistin	drug	222-229	anesthetics	group	292-302	false
colistin	drug	222-229	procainamide	drug	305-316	false
colistin	drug	222-229	quinidine	drug	323-331	false
sodium colistemethate	drug	236-256	magnesium	group	260-268	false
sodium colistemethate	drug	236-256	lithium	drug	277-283	false
sodium colistemethate	drug	236-256	anesthetics	group	292-302	false
sodium colistemethate	drug	236-256	procainamide	drug	305-316	false
sodium colistemethate	drug	236-256	quinidine	drug	323-331	false
magnesium	group	260-268	lithium	drug	277-283	false
magnesium	group	260-268	anesthetics	group	292-302	false
magnesium	group	260-268	procainamide	drug	305-316	false
magnesium	group	260-268	quinidine	drug	323-331	false
lithium	drug	277-283	anesthetics	group	292-302	false
lithium	drug	277-283	procainamide	drug	305-316	false
lithium	drug	277-283	quinidine	drug	323-331	false
anesthetics	group	292-302	procainamide	drug	305-316	false
anesthetics	group	292-302	quinidine	drug	323-331	false
procainamide	drug	305-316	quinidine	drug	323-331	false

DDI-DrugBank.d60.s13	Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
nondepolarizing neuromuscular blocking agents	group	51-95	phenytoin	drug	156-164	effect
nondepolarizing neuromuscular blocking agents	group	51-95	carbamazepine	drug	169-181	effect
phenytoin	drug	156-164	carbamazepine	drug	169-181	false

DDI-DrugBank.d60.s14	While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
phenytoin	drug	29-37	carbamazepine	drug	42-54	false
phenytoin	drug	29-37	NIMBEX	brand	81-86	effect
carbamazepine	drug	42-54	NIMBEX	brand	81-86	effect

DDI-DrugBank.d309.s0	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
antihistamines	group	39-52	CNS depressants	group	96-110	effect
antihistamines	group	39-52	barbiturates	group	122-133	effect
antihistamines	group	39-52	tranquilizers	group	136-148	effect
antihistamines	group	39-52	alcohol	drug	155-161	effect
CNS depressants	group	96-110	barbiturates	group	122-133	false
CNS depressants	group	96-110	tranquilizers	group	136-148	false
CNS depressants	group	96-110	alcohol	drug	155-161	false
barbiturates	group	122-133	tranquilizers	group	136-148	false
barbiturates	group	122-133	alcohol	drug	155-161	false
tranquilizers	group	136-148	alcohol	drug	155-161	false

DDI-DrugBank.d309.s1	Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.
antihistamines	group	19-32	CNS depressant drugs	group	88-107	advise

DDI-DrugBank.d309.s2	Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.
Monoamine oxidase (MAO) inhibitors	group	0-33	antihistamines	group	88-101	effect

DDI-DrugBank.d333.s0	Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.
Clonazepam	drug	10-19	Clonazepam	drug	61-70	false
Clonazepam	drug	10-19	phenytoin	drug	121-129	false
Clonazepam	drug	10-19	carbamazepine	drug	132-144	false
Clonazepam	drug	10-19	phenobarbital	drug	150-162	false
Clonazepam	drug	61-70	phenytoin	drug	121-129	false
Clonazepam	drug	61-70	carbamazepine	drug	132-144	false
Clonazepam	drug	61-70	phenobarbital	drug	150-162	false
phenytoin	drug	121-129	carbamazepine	drug	132-144	false
phenytoin	drug	121-129	phenobarbital	drug	150-162	false
carbamazepine	drug	132-144	phenobarbital	drug	150-162	false

DDI-DrugBank.d333.s2	Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.
Clonazepam	drug	49-58	ranitidine	drug	93-102	false
Clonazepam	drug	49-58	clonazepam	drug	169-178	false
ranitidine	drug	93-102	clonazepam	drug	169-178	false

DDI-DrugBank.d333.s3	In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
clonazepam	drug	29-38	propantheline	drug	103-115	mechanism
clonazepam	drug	29-38	anticholinergic agent	group	121-141	false
clonazepam	drug	29-38	clonazepam	drug	216-225	false
clonazepam	drug	29-38	clonazepam	drug	257-266	false
clonazepam	drug	29-38	propantheline	drug	335-347	false
propantheline	drug	103-115	anticholinergic agent	group	121-141	false
propantheline	drug	103-115	clonazepam	drug	216-225	false
propantheline	drug	103-115	clonazepam	drug	257-266	false
propantheline	drug	103-115	propantheline	drug	335-347	false
anticholinergic agent	group	121-141	clonazepam	drug	216-225	false
anticholinergic agent	group	121-141	clonazepam	drug	257-266	false
anticholinergic agent	group	121-141	propantheline	drug	335-347	false
clonazepam	drug	216-225	clonazepam	drug	257-266	false
clonazepam	drug	216-225	propantheline	drug	335-347	false
clonazepam	drug	257-266	propantheline	drug	335-347	mechanism

DDI-DrugBank.d333.s4	Fluoxetine does not affect the pharmacokinetics of clonazepam.
Fluoxetine	drug	0-9	clonazepam	drug	51-60	false

DDI-DrugBank.d333.s5	Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
phenytoin	drug	35-43	carbamazepine	drug	46-58	false
phenytoin	drug	35-43	phenobarbital	drug	64-76	false
phenytoin	drug	35-43	clonazepam	drug	86-95	mechanism
phenytoin	drug	35-43	clonazepam	drug	157-166	false
carbamazepine	drug	46-58	phenobarbital	drug	64-76	false
carbamazepine	drug	46-58	clonazepam	drug	86-95	mechanism
carbamazepine	drug	46-58	clonazepam	drug	157-166	false
phenobarbital	drug	64-76	clonazepam	drug	86-95	mechanism
phenobarbital	drug	64-76	clonazepam	drug	157-166	false
clonazepam	drug	86-95	clonazepam	drug	157-166	false

DDI-DrugBank.d333.s6	Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.
clonazepam	drug	113-122	antifungal agents	group	183-199	false
clonazepam	drug	113-122	clonazepam	drug	250-259	false
antifungal agents	group	183-199	clonazepam	drug	250-259	advise

DDI-DrugBank.d333.s7	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
benzodiazepine class	group	63-82	alcohol	drug	115-121	effect
benzodiazepine class	group	63-82	narcotics	group	124-132	effect
benzodiazepine class	group	63-82	barbiturates	group	135-146	effect
benzodiazepine class	group	63-82	nonbarbiturate hypnotics	group	149-172	effect
benzodiazepine class	group	63-82	antianxiety agents	group	175-192	effect
benzodiazepine class	group	63-82	phenothiazines classes of antipsychotic agents	group	199-212;246-276	effect
benzodiazepine class	group	63-82	thioxanthene classes of antipsychotic agents	group	215-226;246-276	effect
benzodiazepine class	group	63-82	butyrophenone classes of antipsychotic agents	group	232-276	effect
benzodiazepine class	group	63-82	monoamine oxidase inhibitors	group	279-306	effect
benzodiazepine class	group	63-82	tricyclic antidepressants	group	316-340	effect
benzodiazepine class	group	63-82	anticonvulsant drugs	group	356-375	effect
alcohol	drug	115-121	narcotics	group	124-132	false
alcohol	drug	115-121	barbiturates	group	135-146	false
alcohol	drug	115-121	nonbarbiturate hypnotics	group	149-172	false
alcohol	drug	115-121	antianxiety agents	group	175-192	false
alcohol	drug	115-121	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
alcohol	drug	115-121	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
alcohol	drug	115-121	butyrophenone classes of antipsychotic agents	group	232-276	false
alcohol	drug	115-121	monoamine oxidase inhibitors	group	279-306	false
alcohol	drug	115-121	tricyclic antidepressants	group	316-340	false
alcohol	drug	115-121	anticonvulsant drugs	group	356-375	false
narcotics	group	124-132	barbiturates	group	135-146	false
narcotics	group	124-132	nonbarbiturate hypnotics	group	149-172	false
narcotics	group	124-132	antianxiety agents	group	175-192	false
narcotics	group	124-132	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
narcotics	group	124-132	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
narcotics	group	124-132	butyrophenone classes of antipsychotic agents	group	232-276	false
narcotics	group	124-132	monoamine oxidase inhibitors	group	279-306	false
narcotics	group	124-132	tricyclic antidepressants	group	316-340	false
narcotics	group	124-132	anticonvulsant drugs	group	356-375	false
barbiturates	group	135-146	nonbarbiturate hypnotics	group	149-172	false
barbiturates	group	135-146	antianxiety agents	group	175-192	false
barbiturates	group	135-146	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
barbiturates	group	135-146	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
barbiturates	group	135-146	butyrophenone classes of antipsychotic agents	group	232-276	false
barbiturates	group	135-146	monoamine oxidase inhibitors	group	279-306	false
barbiturates	group	135-146	tricyclic antidepressants	group	316-340	false
barbiturates	group	135-146	anticonvulsant drugs	group	356-375	false
nonbarbiturate hypnotics	group	149-172	antianxiety agents	group	175-192	false
nonbarbiturate hypnotics	group	149-172	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
nonbarbiturate hypnotics	group	149-172	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
nonbarbiturate hypnotics	group	149-172	butyrophenone classes of antipsychotic agents	group	232-276	false
nonbarbiturate hypnotics	group	149-172	monoamine oxidase inhibitors	group	279-306	false
nonbarbiturate hypnotics	group	149-172	tricyclic antidepressants	group	316-340	false
nonbarbiturate hypnotics	group	149-172	anticonvulsant drugs	group	356-375	false
antianxiety agents	group	175-192	phenothiazines classes of antipsychotic agents	group	199-212;246-276	false
antianxiety agents	group	175-192	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
antianxiety agents	group	175-192	butyrophenone classes of antipsychotic agents	group	232-276	false
antianxiety agents	group	175-192	monoamine oxidase inhibitors	group	279-306	false
antianxiety agents	group	175-192	tricyclic antidepressants	group	316-340	false
antianxiety agents	group	175-192	anticonvulsant drugs	group	356-375	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	thioxanthene classes of antipsychotic agents	group	215-226;246-276	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	butyrophenone classes of antipsychotic agents	group	232-276	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	monoamine oxidase inhibitors	group	279-306	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	tricyclic antidepressants	group	316-340	false
phenothiazines classes of antipsychotic agents	group	199-212;246-276	anticonvulsant drugs	group	356-375	false
thioxanthene classes of antipsychotic agents	group	215-226;246-276	butyrophenone classes of antipsychotic agents	group	232-276	false
thioxanthene classes of antipsychotic agents	group	215-226;246-276	monoamine oxidase inhibitors	group	279-306	false
thioxanthene classes of antipsychotic agents	group	215-226;246-276	tricyclic antidepressants	group	316-340	false
thioxanthene classes of antipsychotic agents	group	215-226;246-276	anticonvulsant drugs	group	356-375	false
butyrophenone classes of antipsychotic agents	group	232-276	monoamine oxidase inhibitors	group	279-306	false
butyrophenone classes of antipsychotic agents	group	232-276	tricyclic antidepressants	group	316-340	false
butyrophenone classes of antipsychotic agents	group	232-276	anticonvulsant drugs	group	356-375	false
monoamine oxidase inhibitors	group	279-306	tricyclic antidepressants	group	316-340	false
monoamine oxidase inhibitors	group	279-306	anticonvulsant drugs	group	356-375	false
tricyclic antidepressants	group	316-340	anticonvulsant drugs	group	356-375	false

DDI-DrugBank.d105.s0	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
Anticoagulants	group	0-13	platelet aggregation inhibitors	group	75-105	false
Anticoagulants	group	0-13	nonsteroidal anti-inflammatory drugs	group	115-150	false
Anticoagulants	group	0-13	NSAIDs	group	153-158	false
Anticoagulants	group	0-13	aspirin	brand	166-172	false
Anticoagulants	group	0-13	ardeparin	drug	245-253	effect
platelet aggregation inhibitors	group	75-105	nonsteroidal anti-inflammatory drugs	group	115-150	false
platelet aggregation inhibitors	group	75-105	NSAIDs	group	153-158	false
platelet aggregation inhibitors	group	75-105	aspirin	brand	166-172	false
platelet aggregation inhibitors	group	75-105	ardeparin	drug	245-253	effect
nonsteroidal anti-inflammatory drugs	group	115-150	NSAIDs	group	153-158	false
nonsteroidal anti-inflammatory drugs	group	115-150	aspirin	brand	166-172	false
nonsteroidal anti-inflammatory drugs	group	115-150	ardeparin	drug	245-253	effect
NSAIDs	group	153-158	aspirin	brand	166-172	false
NSAIDs	group	153-158	ardeparin	drug	245-253	effect
aspirin	brand	166-172	ardeparin	drug	245-253	effect

DDI-DrugBank.d528.s0	Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
Acetaminophen	drug	0-12	methotrexate	drug	18-29	false
Acetaminophen	drug	0-12	L-methionine	drug	33-44	false
Acetaminophen	drug	0-12	acetaminophen	drug	90-102	false
Acetaminophen	drug	0-12	methotrexate	drug	134-145	false
methotrexate	drug	18-29	L-methionine	drug	33-44	false
methotrexate	drug	18-29	acetaminophen	drug	90-102	false
methotrexate	drug	18-29	methotrexate	drug	134-145	false
L-methionine	drug	33-44	acetaminophen	drug	90-102	effect
L-methionine	drug	33-44	methotrexate	drug	134-145	effect
acetaminophen	drug	90-102	methotrexate	drug	134-145	false

DDI-DrugBank.d528.s2	Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.
Gentamicin	drug	0-9	Methionine	drug	13-22	false
Gentamicin	drug	0-9	gentamicin	drug	68-77	false
Methionine	drug	13-22	gentamicin	drug	68-77	effect

DDI-DrugBank.d115.s0	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
imatinib	drug	21-28	imatinib	drug	76-83	false
imatinib	drug	21-28	Gleevec	brand	150-156	false
imatinib	drug	21-28	ketoconazole	drug	202-213	false
imatinib	drug	21-28	itraconazole	drug	216-227	false
imatinib	drug	21-28	erythromycin	drug	230-241	false
imatinib	drug	21-28	clarithromycin	drug	244-257	false
imatinib	drug	76-83	Gleevec	brand	150-156	false
imatinib	drug	76-83	ketoconazole	drug	202-213	false
imatinib	drug	76-83	itraconazole	drug	216-227	false
imatinib	drug	76-83	erythromycin	drug	230-241	false
imatinib	drug	76-83	clarithromycin	drug	244-257	false
Gleevec	brand	150-156	ketoconazole	drug	202-213	advise
Gleevec	brand	150-156	itraconazole	drug	216-227	advise
Gleevec	brand	150-156	erythromycin	drug	230-241	advise
Gleevec	brand	150-156	clarithromycin	drug	244-257	advise
ketoconazole	drug	202-213	itraconazole	drug	216-227	false
ketoconazole	drug	202-213	erythromycin	drug	230-241	false
ketoconazole	drug	202-213	clarithromycin	drug	244-257	false
itraconazole	drug	216-227	erythromycin	drug	230-241	false
itraconazole	drug	216-227	clarithromycin	drug	244-257	false
erythromycin	drug	230-241	clarithromycin	drug	244-257	false

DDI-DrugBank.d115.s2	There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).
imatinib	drug	47-54	Gleevec	brand	61-67	false
imatinib	drug	47-54	ketoconazole	drug	92-103	false
Gleevec	brand	61-67	ketoconazole	drug	92-103	mechanism

DDI-DrugBank.d115.s3	Drugs that may decrease imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations.
imatinib	drug	24-31	imatinib	drug	141-148	false

DDI-DrugBank.d115.s4	Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital or St.
dexamethasone	drug	41-53	phenytoin	drug	56-64	false
dexamethasone	drug	41-53	carbamazepine	drug	67-79	false
dexamethasone	drug	41-53	rifampin	drug	82-89	false
dexamethasone	drug	41-53	phenobarbital	drug	92-104	false
phenytoin	drug	56-64	carbamazepine	drug	67-79	false
phenytoin	drug	56-64	rifampin	drug	82-89	false
phenytoin	drug	56-64	phenobarbital	drug	92-104	false
carbamazepine	drug	67-79	rifampin	drug	82-89	false
carbamazepine	drug	67-79	phenobarbital	drug	92-104	false
rifampin	drug	82-89	phenobarbital	drug	92-104	false

DDI-DrugBank.d115.s6	Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
rifampin	drug	58-65	Gleevec	brand	96-102	mechanism
rifampin	drug	58-65	Gleevec	brand	115-121	false
Gleevec	brand	96-102	Gleevec	brand	115-121	false

DDI-DrugBank.d115.s8	Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.
Gleevec	brand	58-64	Gleevec	brand	66-72	false
Gleevec	brand	58-64	simvastatin	drug	109-119	false
Gleevec	brand	58-64	Gleevec	brand	213-219	false
Gleevec	brand	66-72	simvastatin	drug	109-119	mechanism
Gleevec	brand	66-72	Gleevec	brand	213-219	false
simvastatin	drug	109-119	Gleevec	brand	213-219	false

DDI-DrugBank.d115.s9	Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
Gleevec	brand	53-59	cyclosporine	drug	129-140	advise
Gleevec	brand	53-59	pimozide	drug	145-152	advise
cyclosporine	drug	129-140	pimozide	drug	145-152	false

DDI-DrugBank.d115.s10	Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
Gleevec	brand	0-6	benzodiazepines	group	92-106	mechanism
Gleevec	brand	0-6	dihydropyridine calcium channel blockers	group	109-148	mechanism
Gleevec	brand	0-6	HMG-CoA reductase inhibitors	group	159-186	mechanism
benzodiazepines	group	92-106	dihydropyridine calcium channel blockers	group	109-148	false
benzodiazepines	group	92-106	HMG-CoA reductase inhibitors	group	159-186	false
dihydropyridine calcium channel blockers	group	109-148	HMG-CoA reductase inhibitors	group	159-186	false

DDI-DrugBank.d115.s11	Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin.
warfarin	drug	8-15	heparin	drug	139-145	false

DDI-DrugBank.d115.s16	Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.
acetaminophen	drug	21-33	Gleevec	brand	88-94	mechanism

DDI-DrugBank.d428.s1	Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.
ELLENCE	brand	19-25	calcium channel blockers	group	99-122	advise

DDI-DrugBank.d428.s10	Cimetidine increased the AUC of epirubicin by 50%.
Cimetidine	drug	0-9	epirubicin	drug	32-41	mechanism

DDI-DrugBank.d428.s11	Cimetidine treatment should be stopped during treatment with ELLENCE.
Cimetidine	drug	0-9	ELLENCE	brand	61-67	advise

DDI-DrugBank.d525.s0	Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide.
Eprosartan	drug	0-9	digoxin	drug	71-77	false
Eprosartan	drug	0-9	warfarin	drug	107-114	false
Eprosartan	drug	0-9	glyburide	drug	120-128	false
digoxin	drug	71-77	warfarin	drug	107-114	false
digoxin	drug	71-77	glyburide	drug	120-128	false
warfarin	drug	107-114	glyburide	drug	120-128	false

DDI-DrugBank.d525.s2	Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.
eprosartan	drug	8-17	ketoconazole	drug	149-160	false
eprosartan	drug	8-17	fluconazole	drug	166-176	false
eprosartan	drug	8-17	eprosartan	drug	266-275	false
ketoconazole	drug	149-160	fluconazole	drug	166-176	false
ketoconazole	drug	149-160	eprosartan	drug	266-275	false
fluconazole	drug	166-176	eprosartan	drug	266-275	false

DDI-DrugBank.d525.s3	Ranitidine also has no effect on eprosartan pharmacokinetics.
Ranitidine	drug	0-9	eprosartan	drug	33-42	false

DDI-DrugBank.d525.s4	Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide).
Eprosartan	drug	0-9	thiazide diuretic	group	97-113	false
Eprosartan	drug	0-9	hydrochlorothiazide	drug	116-134	false
thiazide diuretic	group	97-113	hydrochlorothiazide	drug	116-134	false

DDI-DrugBank.d525.s5	Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.
Eprosartan	drug	0-9	calcium channel blockers	group	99-122	false
Eprosartan	drug	0-9	nifedipine	drug	143-152	false
calcium channel blockers	group	99-122	nifedipine	drug	143-152	false

DDI-DrugBank.d412.s0	In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.
labetalol HCl	drug	39-51	tricyclic antidepressants	group	73-97	effect
labetalol HCl	drug	39-51	labetalol HCl	drug	162-174	false
tricyclic antidepressants	group	73-97	labetalol HCl	drug	162-174	false

DDI-DrugBank.d412.s4	Cimetidine has been shown to increase the bioavailability of labetalol HCl.
Cimetidine	drug	0-9	labetalol HCl	drug	61-73	mechanism

DDI-DrugBank.d412.s6	Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.
halothane	drug	33-41	labetalol HCl	drug	85-97	effect

DDI-DrugBank.d412.s7	During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.
labetalol HCl	drug	47-59	halothane	drug	81-89	effect
labetalol HCl	drug	47-59	halothane	drug	129-137	false
halothane	drug	81-89	halothane	drug	129-137	false

DDI-DrugBank.d412.s9	Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.
Labetalol HCl	drug	0-12	nitroglycerin	drug	56-68	effect

DDI-DrugBank.d412.s10	If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.
labetalol HCl	drug	3-15	nitroglycerin	drug	30-42	effect

DDI-DrugBank.d412.s11	Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.
labetalol	drug	24-32	calcium antagonist	group	61-78	advise
labetalol	drug	24-32	verapamil	drug	88-96	false
calcium antagonist	group	61-78	verapamil	drug	88-96	false

DDI-DrugBank.d412.s16	Labetalol HCl has also been reported to produce a false positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A  (thin-layer chromatographic assay) and Emit-d.a.u.  (radioenzymatic assay).
Labetalol HCl	drug	0-12	amphetamine	drug	74-84	false

DDI-DrugBank.d412.s17	When patients being treated with labetalol have a positive urine test for amphetamine using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.
labetalol	drug	33-41	amphetamine	drug	74-84	false

DDI-DrugBank.d53.s0	Co-administration of nelfinavir at steady-state with a single dose of azithromycin.
nelfinavir	drug	21-30	azithromycin	drug	70-81	false

DDI-DrugBank.d53.s1	Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.
nelfinavir	drug	21-30	azithromycin	drug	70-81	effect
nelfinavir	drug	21-30	azithromycin	drug	125-136	false
azithromycin	drug	70-81	azithromycin	drug	125-136	false

DDI-DrugBank.d53.s2	Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
azithromycin	drug	30-41	nelfinavir	drug	100-109	advise
azithromycin	drug	30-41	azithromycin	drug	155-166	false
nelfinavir	drug	100-109	azithromycin	drug	155-166	false

DDI-DrugBank.d53.s3	Azithromycin did not affect the prothrombin time response to a single dose of warfarin.
Azithromycin	drug	0-11	warfarin	drug	78-85	false

DDI-DrugBank.d53.s4	However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.
azithromycin	drug	111-122	warfarin	drug	128-135	advise

DDI-DrugBank.d53.s5	Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.
macrolides	group	18-27	warfarin	drug	33-40	effect

DDI-DrugBank.d53.s7	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
azithromycin	drug	32-43	atorvastatin	drug	92-103	mechanism
azithromycin	drug	32-43	carbamazepine	drug	106-118	mechanism
azithromycin	drug	32-43	cetirizine	drug	121-130	mechanism
azithromycin	drug	32-43	didanosine	drug	133-142	mechanism
azithromycin	drug	32-43	efavirenz	drug	145-153	mechanism
azithromycin	drug	32-43	fluconazole	drug	156-166	mechanism
azithromycin	drug	32-43	indinavir	drug	169-177	mechanism
azithromycin	drug	32-43	midazolam	drug	180-188	mechanism
azithromycin	drug	32-43	rifabutin	drug	191-199	mechanism
azithromycin	drug	32-43	sildenafil	drug	202-211	mechanism
azithromycin	drug	32-43	theophylline	drug	214-225	mechanism
azithromycin	drug	32-43	triazolam	drug	251-259	mechanism
azithromycin	drug	32-43	trimethoprim	drug	262-273	mechanism
azithromycin	drug	32-43	sulfamethoxazole	drug	275-290	mechanism
azithromycin	drug	32-43	zidovudine	drug	295-304	mechanism
atorvastatin	drug	92-103	carbamazepine	drug	106-118	false
atorvastatin	drug	92-103	cetirizine	drug	121-130	false
atorvastatin	drug	92-103	didanosine	drug	133-142	false
atorvastatin	drug	92-103	efavirenz	drug	145-153	false
atorvastatin	drug	92-103	fluconazole	drug	156-166	false
atorvastatin	drug	92-103	indinavir	drug	169-177	false
atorvastatin	drug	92-103	midazolam	drug	180-188	false
atorvastatin	drug	92-103	rifabutin	drug	191-199	false
atorvastatin	drug	92-103	sildenafil	drug	202-211	false
atorvastatin	drug	92-103	theophylline	drug	214-225	false
atorvastatin	drug	92-103	triazolam	drug	251-259	false
atorvastatin	drug	92-103	trimethoprim	drug	262-273	false
atorvastatin	drug	92-103	sulfamethoxazole	drug	275-290	false
atorvastatin	drug	92-103	zidovudine	drug	295-304	false
carbamazepine	drug	106-118	cetirizine	drug	121-130	false
carbamazepine	drug	106-118	didanosine	drug	133-142	false
carbamazepine	drug	106-118	efavirenz	drug	145-153	false
carbamazepine	drug	106-118	fluconazole	drug	156-166	false
carbamazepine	drug	106-118	indinavir	drug	169-177	false
carbamazepine	drug	106-118	midazolam	drug	180-188	false
carbamazepine	drug	106-118	rifabutin	drug	191-199	false
carbamazepine	drug	106-118	sildenafil	drug	202-211	false
carbamazepine	drug	106-118	theophylline	drug	214-225	false
carbamazepine	drug	106-118	triazolam	drug	251-259	false
carbamazepine	drug	106-118	trimethoprim	drug	262-273	false
carbamazepine	drug	106-118	sulfamethoxazole	drug	275-290	false
carbamazepine	drug	106-118	zidovudine	drug	295-304	false
cetirizine	drug	121-130	didanosine	drug	133-142	false
cetirizine	drug	121-130	efavirenz	drug	145-153	false
cetirizine	drug	121-130	fluconazole	drug	156-166	false
cetirizine	drug	121-130	indinavir	drug	169-177	false
cetirizine	drug	121-130	midazolam	drug	180-188	false
cetirizine	drug	121-130	rifabutin	drug	191-199	false
cetirizine	drug	121-130	sildenafil	drug	202-211	false
cetirizine	drug	121-130	theophylline	drug	214-225	false
cetirizine	drug	121-130	triazolam	drug	251-259	false
cetirizine	drug	121-130	trimethoprim	drug	262-273	false
cetirizine	drug	121-130	sulfamethoxazole	drug	275-290	false
cetirizine	drug	121-130	zidovudine	drug	295-304	false
didanosine	drug	133-142	efavirenz	drug	145-153	false
didanosine	drug	133-142	fluconazole	drug	156-166	false
didanosine	drug	133-142	indinavir	drug	169-177	false
didanosine	drug	133-142	midazolam	drug	180-188	false
didanosine	drug	133-142	rifabutin	drug	191-199	false
didanosine	drug	133-142	sildenafil	drug	202-211	false
didanosine	drug	133-142	theophylline	drug	214-225	false
didanosine	drug	133-142	triazolam	drug	251-259	false
didanosine	drug	133-142	trimethoprim	drug	262-273	false
didanosine	drug	133-142	sulfamethoxazole	drug	275-290	false
didanosine	drug	133-142	zidovudine	drug	295-304	false
efavirenz	drug	145-153	fluconazole	drug	156-166	false
efavirenz	drug	145-153	indinavir	drug	169-177	false
efavirenz	drug	145-153	midazolam	drug	180-188	false
efavirenz	drug	145-153	rifabutin	drug	191-199	false
efavirenz	drug	145-153	sildenafil	drug	202-211	false
efavirenz	drug	145-153	theophylline	drug	214-225	false
efavirenz	drug	145-153	triazolam	drug	251-259	false
efavirenz	drug	145-153	trimethoprim	drug	262-273	false
efavirenz	drug	145-153	sulfamethoxazole	drug	275-290	false
efavirenz	drug	145-153	zidovudine	drug	295-304	false
fluconazole	drug	156-166	indinavir	drug	169-177	false
fluconazole	drug	156-166	midazolam	drug	180-188	false
fluconazole	drug	156-166	rifabutin	drug	191-199	false
fluconazole	drug	156-166	sildenafil	drug	202-211	false
fluconazole	drug	156-166	theophylline	drug	214-225	false
fluconazole	drug	156-166	triazolam	drug	251-259	false
fluconazole	drug	156-166	trimethoprim	drug	262-273	false
fluconazole	drug	156-166	sulfamethoxazole	drug	275-290	false
fluconazole	drug	156-166	zidovudine	drug	295-304	false
indinavir	drug	169-177	midazolam	drug	180-188	false
indinavir	drug	169-177	rifabutin	drug	191-199	false
indinavir	drug	169-177	sildenafil	drug	202-211	false
indinavir	drug	169-177	theophylline	drug	214-225	false
indinavir	drug	169-177	triazolam	drug	251-259	false
indinavir	drug	169-177	trimethoprim	drug	262-273	false
indinavir	drug	169-177	sulfamethoxazole	drug	275-290	false
indinavir	drug	169-177	zidovudine	drug	295-304	false
midazolam	drug	180-188	rifabutin	drug	191-199	false
midazolam	drug	180-188	sildenafil	drug	202-211	false
midazolam	drug	180-188	theophylline	drug	214-225	false
midazolam	drug	180-188	triazolam	drug	251-259	false
midazolam	drug	180-188	trimethoprim	drug	262-273	false
midazolam	drug	180-188	sulfamethoxazole	drug	275-290	false
midazolam	drug	180-188	zidovudine	drug	295-304	false
rifabutin	drug	191-199	sildenafil	drug	202-211	false
rifabutin	drug	191-199	theophylline	drug	214-225	false
rifabutin	drug	191-199	triazolam	drug	251-259	false
rifabutin	drug	191-199	trimethoprim	drug	262-273	false
rifabutin	drug	191-199	sulfamethoxazole	drug	275-290	false
rifabutin	drug	191-199	zidovudine	drug	295-304	false
sildenafil	drug	202-211	theophylline	drug	214-225	false
sildenafil	drug	202-211	triazolam	drug	251-259	false
sildenafil	drug	202-211	trimethoprim	drug	262-273	false
sildenafil	drug	202-211	sulfamethoxazole	drug	275-290	false
sildenafil	drug	202-211	zidovudine	drug	295-304	false
theophylline	drug	214-225	triazolam	drug	251-259	false
theophylline	drug	214-225	trimethoprim	drug	262-273	false
theophylline	drug	214-225	sulfamethoxazole	drug	275-290	false
theophylline	drug	214-225	zidovudine	drug	295-304	false
triazolam	drug	251-259	trimethoprim	drug	262-273	false
triazolam	drug	251-259	sulfamethoxazole	drug	275-290	false
triazolam	drug	251-259	zidovudine	drug	295-304	false
trimethoprim	drug	262-273	sulfamethoxazole	drug	275-290	false
trimethoprim	drug	262-273	zidovudine	drug	295-304	false
sulfamethoxazole	drug	275-290	zidovudine	drug	295-304	false

DDI-DrugBank.d53.s8	Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
efavirenz	drug	23-31	fluconazole	drug	36-46	false
efavirenz	drug	23-31	azithromycin	drug	95-106	mechanism
fluconazole	drug	36-46	azithromycin	drug	95-106	mechanism

DDI-DrugBank.d53.s13	Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.
azithromycin	drug	66-77	Digoxin	drug	162-168	false
azithromycin	drug	66-77	digoxin	drug	179-185	false
Digoxin	drug	162-168	digoxin	drug	179-185	false

DDI-DrugBank.d53.s14	Ergotamine or dihydroergotamine acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
Ergotamine	drug	0-9	dihydroergotamine	drug	14-30	false

DDI-DrugBank.d53.s15	Cyclosporine, hexobarbital and phenytoin concentrations.
Cyclosporine	drug	0-11	hexobarbital	drug	14-25	false
Cyclosporine	drug	0-11	phenytoin	drug	31-39	false
hexobarbital	drug	14-25	phenytoin	drug	31-39	false

DDI-DrugBank.d370.s1	Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.
sulfur	drug	72-77	resorcinol	drug	80-89	false
sulfur	drug	72-77	salicylic acid	drug	95-108	false
sulfur	drug	72-77	DIFFERIN	brand	130-137	false
resorcinol	drug	80-89	salicylic acid	drug	95-108	false
resorcinol	drug	80-89	DIFFERIN	brand	130-137	false
salicylic acid	drug	95-108	DIFFERIN	brand	130-137	false

DDI-DrugBank.d25.s0	Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
Corticotropin	drug	0-12	diuretic	drug	66-73	effect

DDI-DrugBank.d145.s0	Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.
anticonvulsant agents	group	17-37	cisplatin	drug	72-80	mechanism

DDI-DrugBank.d311.s0	Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.
rauwolfia alkaloid	group	9-26	MAO inhibitors	group	77-90	effect

DDI-DrugBank.d452.s0	Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.
thiazide diuretics	group	18-35	dihydrotachysterol	drug	105-122	effect

DDI-DrugBank.d338.s1	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
benzodiazepines	group	18-32	anticonvulsants	group	56-70	effect
benzodiazepines	group	18-32	antihistamines	group	73-86	effect
benzodiazepines	group	18-32	alcohol	drug	89-95	effect
benzodiazepines	group	18-32	barbiturates	group	98-109	effect
benzodiazepines	group	18-32	monoamine oxidase inhibitors	group	112-139	effect
benzodiazepines	group	18-32	narcotics	group	142-150	effect
benzodiazepines	group	18-32	phenothiazines	group	153-166	effect
benzodiazepines	group	18-32	psychotropic medications	group	169-192	effect
anticonvulsants	group	56-70	antihistamines	group	73-86	false
anticonvulsants	group	56-70	alcohol	drug	89-95	false
anticonvulsants	group	56-70	barbiturates	group	98-109	false
anticonvulsants	group	56-70	monoamine oxidase inhibitors	group	112-139	false
anticonvulsants	group	56-70	narcotics	group	142-150	false
anticonvulsants	group	56-70	phenothiazines	group	153-166	false
anticonvulsants	group	56-70	psychotropic medications	group	169-192	false
antihistamines	group	73-86	alcohol	drug	89-95	false
antihistamines	group	73-86	barbiturates	group	98-109	false
antihistamines	group	73-86	monoamine oxidase inhibitors	group	112-139	false
antihistamines	group	73-86	narcotics	group	142-150	false
antihistamines	group	73-86	phenothiazines	group	153-166	false
antihistamines	group	73-86	psychotropic medications	group	169-192	false
alcohol	drug	89-95	barbiturates	group	98-109	false
alcohol	drug	89-95	monoamine oxidase inhibitors	group	112-139	false
alcohol	drug	89-95	narcotics	group	142-150	false
alcohol	drug	89-95	phenothiazines	group	153-166	false
alcohol	drug	89-95	psychotropic medications	group	169-192	false
barbiturates	group	98-109	monoamine oxidase inhibitors	group	112-139	false
barbiturates	group	98-109	narcotics	group	142-150	false
barbiturates	group	98-109	phenothiazines	group	153-166	false
barbiturates	group	98-109	psychotropic medications	group	169-192	false
monoamine oxidase inhibitors	group	112-139	narcotics	group	142-150	false
monoamine oxidase inhibitors	group	112-139	phenothiazines	group	153-166	false
monoamine oxidase inhibitors	group	112-139	psychotropic medications	group	169-192	false
narcotics	group	142-150	phenothiazines	group	153-166	false
narcotics	group	142-150	psychotropic medications	group	169-192	false
phenothiazines	group	153-166	psychotropic medications	group	169-192	false

DDI-DrugBank.d338.s4	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
estazolam	drug	70-78	carbamazepine	drug	153-165	mechanism
estazolam	drug	70-78	phenytoin	drug	168-176	mechanism
estazolam	drug	70-78	rifampin	drug	179-186	mechanism
estazolam	drug	70-78	barbiturates	group	193-204	mechanism
estazolam	drug	70-78	estazolam	drug	237-245	mechanism
carbamazepine	drug	153-165	phenytoin	drug	168-176	false
carbamazepine	drug	153-165	rifampin	drug	179-186	false
carbamazepine	drug	153-165	barbiturates	group	193-204	false
carbamazepine	drug	153-165	estazolam	drug	237-245	false
phenytoin	drug	168-176	rifampin	drug	179-186	false
phenytoin	drug	168-176	barbiturates	group	193-204	false
phenytoin	drug	168-176	estazolam	drug	237-245	false
rifampin	drug	179-186	barbiturates	group	193-204	false
rifampin	drug	179-186	estazolam	drug	237-245	false
barbiturates	group	193-204	estazolam	drug	237-245	false

DDI-DrugBank.d338.s5	Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.
Estazolam	drug	0-8	estazolam	drug	108-116	false
Estazolam	drug	0-8	4-hydroxy-estazolam	drug_n	154-172	false
Estazolam	drug	0-8	triazolobenzodiazepines	group	202-224	false
estazolam	drug	108-116	4-hydroxy-estazolam	drug_n	154-172	false
estazolam	drug	108-116	triazolobenzodiazepines	group	202-224	false
4-hydroxy-estazolam	drug_n	154-172	triazolobenzodiazepines	group	202-224	false

DDI-DrugBank.d338.s6	Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
estazolam	drug	14-22	ketoconazole	drug	64-75	advise
estazolam	drug	14-22	itraconazole	drug	81-92	advise
ketoconazole	drug	64-75	itraconazole	drug	81-92	false

DDI-DrugBank.d338.s8	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
benzodiazepines	group	85-99	nefazodone	drug	142-151	mechanism
benzodiazepines	group	85-99	fluvoxamine	drug	154-164	mechanism
benzodiazepines	group	85-99	cimetidine	drug	167-176	mechanism
benzodiazepines	group	85-99	diltiazem	drug	179-187	mechanism
benzodiazepines	group	85-99	isoniazide	drug	190-199	mechanism
benzodiazepines	group	85-99	macrolide antibiotics	group	211-231	mechanism
nefazodone	drug	142-151	fluvoxamine	drug	154-164	false
nefazodone	drug	142-151	cimetidine	drug	167-176	false
nefazodone	drug	142-151	diltiazem	drug	179-187	false
nefazodone	drug	142-151	isoniazide	drug	190-199	false
nefazodone	drug	142-151	macrolide antibiotics	group	211-231	false
fluvoxamine	drug	154-164	cimetidine	drug	167-176	false
fluvoxamine	drug	154-164	diltiazem	drug	179-187	false
fluvoxamine	drug	154-164	isoniazide	drug	190-199	false
fluvoxamine	drug	154-164	macrolide antibiotics	group	211-231	false
cimetidine	drug	167-176	diltiazem	drug	179-187	false
cimetidine	drug	167-176	isoniazide	drug	190-199	false
cimetidine	drug	167-176	macrolide antibiotics	group	211-231	false
diltiazem	drug	179-187	isoniazide	drug	190-199	false
diltiazem	drug	179-187	macrolide antibiotics	group	211-231	false
isoniazide	drug	190-199	macrolide antibiotics	group	211-231	false

DDI-DrugBank.d338.s9	Drug Interaction with Fluoxetine: A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.
Fluoxetine	drug	22-31	fluoxetine	drug	94-103	false
Fluoxetine	drug	22-31	estazolam	drug	142-150	false
fluoxetine	drug	94-103	estazolam	drug	142-150	false

DDI-DrugBank.d338.s10	The pharmacokinetics of estazolam (Cmax and AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically significant pharmacokinetic interaction.
estazolam	drug	24-32	fluoxetine	drug	88-97	false

DDI-DrugBank.d338.s11	Estazolam: Interaction with Other Drugs that are Metabolized by Cytochrome P450 (CYP): At clinically relevant concentrations, in vitro studies indicate that estazolam (0.6 M) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.
Estazolam	drug	0-8	estazolam	drug	157-165	false

DDI-DrugBank.d32.s0	Theophylline: Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days.
Theophylline	drug	0-11	ceftibuten	drug	74-83	false

DDI-DrugBank.d32.s1	With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg).
ceftibuten	drug	25-34	theophylline	drug	103-114	false

DDI-DrugBank.d32.s3	The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.
ceftibuten	drug	14-23	theophylline	drug	52-63	false

DDI-DrugBank.d32.s4	Antacids or H 2 -receptor antagonists: The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers.
Antacids	group	0-7	H 2 -receptor antagonists	group	12-36	false
Antacids	group	0-7	ceftibuten	drug	100-109	false
H 2 -receptor antagonists	group	12-36	ceftibuten	drug	100-109	false

DDI-DrugBank.d32.s6	A single dose of liquid antacid did not affect the C max or AUC of ceftibuten;
antacid	group	24-30	ceftibuten	drug	67-76	false

DDI-DrugBank.d32.s7	however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
ranitidine	drug	19-28	ceftibuten	drug	60-69	mechanism
ranitidine	drug	19-28	ceftibuten	drug	88-97	mechanism
ceftibuten	drug	60-69	ceftibuten	drug	88-97	false

DDI-DrugBank.d32.s12	The results of assays using red cells from healthy subjects to determine whether ceftibuten would cause direct Coombs reactions in vitro showed no positive reaction at ceftibuten concentrations as high as 40  g/mL.
ceftibuten	drug	81-90	ceftibuten	drug	168-177	false

DDI-DrugBank.d295.s0	Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.
entecavir	drug	6-14	BARACLUDE	brand	76-84	false
entecavir	drug	6-14	entecavir	drug	208-216	false
BARACLUDE	brand	76-84	entecavir	drug	208-216	false

DDI-DrugBank.d295.s1	Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.
entecavir	drug	20-28	lamivudine	drug	35-44	false
entecavir	drug	20-28	adefovir dipivoxil	drug	47-64	false
entecavir	drug	20-28	tenofovir disoproxil fumarate	drug	69-97	false
lamivudine	drug	35-44	adefovir dipivoxil	drug	47-64	false
lamivudine	drug	35-44	tenofovir disoproxil fumarate	drug	69-97	false
adefovir dipivoxil	drug	47-64	tenofovir disoproxil fumarate	drug	69-97	false

DDI-DrugBank.d295.s2	The effects of coadministration of BARACLUDE with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when BARACLUDE is coadministered with such drugs.
BARACLUDE	brand	35-43	BARACLUDE	brand	218-226	false

DDI-DrugBank.d484.s0	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
Etonogestrel	drug	0-11	acetaminophen	drug	58-70	int
Etonogestrel	drug	0-11	Tylenol	brand	73-79	int
Etonogestrel	drug	0-11	antibiotics	group	83-93	int
Etonogestrel	drug	0-11	ampicillin	drug	103-112	int
Etonogestrel	drug	0-11	tetracycline	drug	118-129	int
Etonogestrel	drug	0-11	anticonvulsants	group	132-146	int
Etonogestrel	drug	0-11	Dilantin	brand	149-156	int
Etonogestrel	drug	0-11	Phenobarbital	drug	159-171	int
Etonogestrel	drug	0-11	Tegretol	brand	174-181	int
Etonogestrel	drug	0-11	Trileptal	brand	184-192	int
Etonogestrel	drug	0-11	Topamax	brand	195-201	int
Etonogestrel	drug	0-11	Felbatol	brand	204-211	int
Etonogestrel	drug	0-11	antifungals	group	215-225	int
Etonogestrel	drug	0-11	Gris-PEG	brand	228-235	int
Etonogestrel	drug	0-11	Nizoral	brand	238-244	int
Etonogestrel	drug	0-11	Sporanox	brand	247-254	int
Etonogestrel	drug	0-11	atorvastatin	drug	258-269	int
Etonogestrel	drug	0-11	Lipitor	brand	272-278	int
Etonogestrel	drug	0-11	clofibrate	drug	282-291	int
Etonogestrel	drug	0-11	Atromid-S	brand	294-302	int
Etonogestrel	drug	0-11	cyclosporine	drug	306-317	int
Etonogestrel	drug	0-11	Neoral	brand	320-325	int
Etonogestrel	drug	0-11	Sandimmune	brand	328-337	int
Etonogestrel	drug	0-11	protease inhibitors	group	365-383	int
Etonogestrel	drug	0-11	Agenerase	brand	386-394	int
Etonogestrel	drug	0-11	Crixivan	brand	397-404	int
Etonogestrel	drug	0-11	Fortovase	brand	407-415	int
Etonogestrel	drug	0-11	Invirase	brand	418-425	int
Etonogestrel	drug	0-11	Kaletra	brand	428-434	int
Etonogestrel	drug	0-11	Norvir	brand	437-442	int
Etonogestrel	drug	0-11	Viracept	brand	445-452	int
Etonogestrel	drug	0-11	morphine	drug	456-463	int
Etonogestrel	drug	0-11	Astramorph	brand	466-475	int
Etonogestrel	drug	0-11	Kadian	brand	478-483	int
Etonogestrel	drug	0-11	MS Contin	brand	486-494	int
Etonogestrel	drug	0-11	phenylbutazone	drug	498-511	int
Etonogestrel	drug	0-11	prednisolone	drug	514-525	int
Etonogestrel	drug	0-11	Prelone	brand	528-534	int
Etonogestrel	drug	0-11	rifadin	brand	538-544	int
Etonogestrel	drug	0-11	rifampin	drug	547-554	int
Etonogestrel	drug	0-11	temazepam	drug	574-582	int
Etonogestrel	drug	0-11	theophylline	drug	585-596	int
Etonogestrel	drug	0-11	Theo-Dur	brand	599-606	int
Etonogestrel	drug	0-11	vitamin C	drug	614-622	int
acetaminophen	drug	58-70	Tylenol	brand	73-79	false
acetaminophen	drug	58-70	antibiotics	group	83-93	false
acetaminophen	drug	58-70	ampicillin	drug	103-112	false
acetaminophen	drug	58-70	tetracycline	drug	118-129	false
acetaminophen	drug	58-70	anticonvulsants	group	132-146	false
acetaminophen	drug	58-70	Dilantin	brand	149-156	false
acetaminophen	drug	58-70	Phenobarbital	drug	159-171	false
acetaminophen	drug	58-70	Tegretol	brand	174-181	false
acetaminophen	drug	58-70	Trileptal	brand	184-192	false
acetaminophen	drug	58-70	Topamax	brand	195-201	false
acetaminophen	drug	58-70	Felbatol	brand	204-211	false
acetaminophen	drug	58-70	antifungals	group	215-225	false
acetaminophen	drug	58-70	Gris-PEG	brand	228-235	false
acetaminophen	drug	58-70	Nizoral	brand	238-244	false
acetaminophen	drug	58-70	Sporanox	brand	247-254	false
acetaminophen	drug	58-70	atorvastatin	drug	258-269	false
acetaminophen	drug	58-70	Lipitor	brand	272-278	false
acetaminophen	drug	58-70	clofibrate	drug	282-291	false
acetaminophen	drug	58-70	Atromid-S	brand	294-302	false
acetaminophen	drug	58-70	cyclosporine	drug	306-317	false
acetaminophen	drug	58-70	Neoral	brand	320-325	false
acetaminophen	drug	58-70	Sandimmune	brand	328-337	false
acetaminophen	drug	58-70	protease inhibitors	group	365-383	false
acetaminophen	drug	58-70	Agenerase	brand	386-394	false
acetaminophen	drug	58-70	Crixivan	brand	397-404	false
acetaminophen	drug	58-70	Fortovase	brand	407-415	false
acetaminophen	drug	58-70	Invirase	brand	418-425	false
acetaminophen	drug	58-70	Kaletra	brand	428-434	false
acetaminophen	drug	58-70	Norvir	brand	437-442	false
acetaminophen	drug	58-70	Viracept	brand	445-452	false
acetaminophen	drug	58-70	morphine	drug	456-463	false
acetaminophen	drug	58-70	Astramorph	brand	466-475	false
acetaminophen	drug	58-70	Kadian	brand	478-483	false
acetaminophen	drug	58-70	MS Contin	brand	486-494	false
acetaminophen	drug	58-70	phenylbutazone	drug	498-511	false
acetaminophen	drug	58-70	prednisolone	drug	514-525	false
acetaminophen	drug	58-70	Prelone	brand	528-534	false
acetaminophen	drug	58-70	rifadin	brand	538-544	false
acetaminophen	drug	58-70	rifampin	drug	547-554	false
acetaminophen	drug	58-70	temazepam	drug	574-582	false
acetaminophen	drug	58-70	theophylline	drug	585-596	false
acetaminophen	drug	58-70	Theo-Dur	brand	599-606	false
acetaminophen	drug	58-70	vitamin C	drug	614-622	false
Tylenol	brand	73-79	antibiotics	group	83-93	false
Tylenol	brand	73-79	ampicillin	drug	103-112	false
Tylenol	brand	73-79	tetracycline	drug	118-129	false
Tylenol	brand	73-79	anticonvulsants	group	132-146	false
Tylenol	brand	73-79	Dilantin	brand	149-156	false
Tylenol	brand	73-79	Phenobarbital	drug	159-171	false
Tylenol	brand	73-79	Tegretol	brand	174-181	false
Tylenol	brand	73-79	Trileptal	brand	184-192	false
Tylenol	brand	73-79	Topamax	brand	195-201	false
Tylenol	brand	73-79	Felbatol	brand	204-211	false
Tylenol	brand	73-79	antifungals	group	215-225	false
Tylenol	brand	73-79	Gris-PEG	brand	228-235	false
Tylenol	brand	73-79	Nizoral	brand	238-244	false
Tylenol	brand	73-79	Sporanox	brand	247-254	false
Tylenol	brand	73-79	atorvastatin	drug	258-269	false
Tylenol	brand	73-79	Lipitor	brand	272-278	false
Tylenol	brand	73-79	clofibrate	drug	282-291	false
Tylenol	brand	73-79	Atromid-S	brand	294-302	false
Tylenol	brand	73-79	cyclosporine	drug	306-317	false
Tylenol	brand	73-79	Neoral	brand	320-325	false
Tylenol	brand	73-79	Sandimmune	brand	328-337	false
Tylenol	brand	73-79	protease inhibitors	group	365-383	false
Tylenol	brand	73-79	Agenerase	brand	386-394	false
Tylenol	brand	73-79	Crixivan	brand	397-404	false
Tylenol	brand	73-79	Fortovase	brand	407-415	false
Tylenol	brand	73-79	Invirase	brand	418-425	false
Tylenol	brand	73-79	Kaletra	brand	428-434	false
Tylenol	brand	73-79	Norvir	brand	437-442	false
Tylenol	brand	73-79	Viracept	brand	445-452	false
Tylenol	brand	73-79	morphine	drug	456-463	false
Tylenol	brand	73-79	Astramorph	brand	466-475	false
Tylenol	brand	73-79	Kadian	brand	478-483	false
Tylenol	brand	73-79	MS Contin	brand	486-494	false
Tylenol	brand	73-79	phenylbutazone	drug	498-511	false
Tylenol	brand	73-79	prednisolone	drug	514-525	false
Tylenol	brand	73-79	Prelone	brand	528-534	false
Tylenol	brand	73-79	rifadin	brand	538-544	false
Tylenol	brand	73-79	rifampin	drug	547-554	false
Tylenol	brand	73-79	temazepam	drug	574-582	false
Tylenol	brand	73-79	theophylline	drug	585-596	false
Tylenol	brand	73-79	Theo-Dur	brand	599-606	false
Tylenol	brand	73-79	vitamin C	drug	614-622	false
antibiotics	group	83-93	ampicillin	drug	103-112	false
antibiotics	group	83-93	tetracycline	drug	118-129	false
antibiotics	group	83-93	anticonvulsants	group	132-146	false
antibiotics	group	83-93	Dilantin	brand	149-156	false
antibiotics	group	83-93	Phenobarbital	drug	159-171	false
antibiotics	group	83-93	Tegretol	brand	174-181	false
antibiotics	group	83-93	Trileptal	brand	184-192	false
antibiotics	group	83-93	Topamax	brand	195-201	false
antibiotics	group	83-93	Felbatol	brand	204-211	false
antibiotics	group	83-93	antifungals	group	215-225	false
antibiotics	group	83-93	Gris-PEG	brand	228-235	false
antibiotics	group	83-93	Nizoral	brand	238-244	false
antibiotics	group	83-93	Sporanox	brand	247-254	false
antibiotics	group	83-93	atorvastatin	drug	258-269	false
antibiotics	group	83-93	Lipitor	brand	272-278	false
antibiotics	group	83-93	clofibrate	drug	282-291	false
antibiotics	group	83-93	Atromid-S	brand	294-302	false
antibiotics	group	83-93	cyclosporine	drug	306-317	false
antibiotics	group	83-93	Neoral	brand	320-325	false
antibiotics	group	83-93	Sandimmune	brand	328-337	false
antibiotics	group	83-93	protease inhibitors	group	365-383	false
antibiotics	group	83-93	Agenerase	brand	386-394	false
antibiotics	group	83-93	Crixivan	brand	397-404	false
antibiotics	group	83-93	Fortovase	brand	407-415	false
antibiotics	group	83-93	Invirase	brand	418-425	false
antibiotics	group	83-93	Kaletra	brand	428-434	false
antibiotics	group	83-93	Norvir	brand	437-442	false
antibiotics	group	83-93	Viracept	brand	445-452	false
antibiotics	group	83-93	morphine	drug	456-463	false
antibiotics	group	83-93	Astramorph	brand	466-475	false
antibiotics	group	83-93	Kadian	brand	478-483	false
antibiotics	group	83-93	MS Contin	brand	486-494	false
antibiotics	group	83-93	phenylbutazone	drug	498-511	false
antibiotics	group	83-93	prednisolone	drug	514-525	false
antibiotics	group	83-93	Prelone	brand	528-534	false
antibiotics	group	83-93	rifadin	brand	538-544	false
antibiotics	group	83-93	rifampin	drug	547-554	false
antibiotics	group	83-93	temazepam	drug	574-582	false
antibiotics	group	83-93	theophylline	drug	585-596	false
antibiotics	group	83-93	Theo-Dur	brand	599-606	false
antibiotics	group	83-93	vitamin C	drug	614-622	false
ampicillin	drug	103-112	tetracycline	drug	118-129	false
ampicillin	drug	103-112	anticonvulsants	group	132-146	false
ampicillin	drug	103-112	Dilantin	brand	149-156	false
ampicillin	drug	103-112	Phenobarbital	drug	159-171	false
ampicillin	drug	103-112	Tegretol	brand	174-181	false
ampicillin	drug	103-112	Trileptal	brand	184-192	false
ampicillin	drug	103-112	Topamax	brand	195-201	false
ampicillin	drug	103-112	Felbatol	brand	204-211	false
ampicillin	drug	103-112	antifungals	group	215-225	false
ampicillin	drug	103-112	Gris-PEG	brand	228-235	false
ampicillin	drug	103-112	Nizoral	brand	238-244	false
ampicillin	drug	103-112	Sporanox	brand	247-254	false
ampicillin	drug	103-112	atorvastatin	drug	258-269	false
ampicillin	drug	103-112	Lipitor	brand	272-278	false
ampicillin	drug	103-112	clofibrate	drug	282-291	false
ampicillin	drug	103-112	Atromid-S	brand	294-302	false
ampicillin	drug	103-112	cyclosporine	drug	306-317	false
ampicillin	drug	103-112	Neoral	brand	320-325	false
ampicillin	drug	103-112	Sandimmune	brand	328-337	false
ampicillin	drug	103-112	protease inhibitors	group	365-383	false
ampicillin	drug	103-112	Agenerase	brand	386-394	false
ampicillin	drug	103-112	Crixivan	brand	397-404	false
ampicillin	drug	103-112	Fortovase	brand	407-415	false
ampicillin	drug	103-112	Invirase	brand	418-425	false
ampicillin	drug	103-112	Kaletra	brand	428-434	false
ampicillin	drug	103-112	Norvir	brand	437-442	false
ampicillin	drug	103-112	Viracept	brand	445-452	false
ampicillin	drug	103-112	morphine	drug	456-463	false
ampicillin	drug	103-112	Astramorph	brand	466-475	false
ampicillin	drug	103-112	Kadian	brand	478-483	false
ampicillin	drug	103-112	MS Contin	brand	486-494	false
ampicillin	drug	103-112	phenylbutazone	drug	498-511	false
ampicillin	drug	103-112	prednisolone	drug	514-525	false
ampicillin	drug	103-112	Prelone	brand	528-534	false
ampicillin	drug	103-112	rifadin	brand	538-544	false
ampicillin	drug	103-112	rifampin	drug	547-554	false
ampicillin	drug	103-112	temazepam	drug	574-582	false
ampicillin	drug	103-112	theophylline	drug	585-596	false
ampicillin	drug	103-112	Theo-Dur	brand	599-606	false
ampicillin	drug	103-112	vitamin C	drug	614-622	false
tetracycline	drug	118-129	anticonvulsants	group	132-146	false
tetracycline	drug	118-129	Dilantin	brand	149-156	false
tetracycline	drug	118-129	Phenobarbital	drug	159-171	false
tetracycline	drug	118-129	Tegretol	brand	174-181	false
tetracycline	drug	118-129	Trileptal	brand	184-192	false
tetracycline	drug	118-129	Topamax	brand	195-201	false
tetracycline	drug	118-129	Felbatol	brand	204-211	false
tetracycline	drug	118-129	antifungals	group	215-225	false
tetracycline	drug	118-129	Gris-PEG	brand	228-235	false
tetracycline	drug	118-129	Nizoral	brand	238-244	false
tetracycline	drug	118-129	Sporanox	brand	247-254	false
tetracycline	drug	118-129	atorvastatin	drug	258-269	false
tetracycline	drug	118-129	Lipitor	brand	272-278	false
tetracycline	drug	118-129	clofibrate	drug	282-291	false
tetracycline	drug	118-129	Atromid-S	brand	294-302	false
tetracycline	drug	118-129	cyclosporine	drug	306-317	false
tetracycline	drug	118-129	Neoral	brand	320-325	false
tetracycline	drug	118-129	Sandimmune	brand	328-337	false
tetracycline	drug	118-129	protease inhibitors	group	365-383	false
tetracycline	drug	118-129	Agenerase	brand	386-394	false
tetracycline	drug	118-129	Crixivan	brand	397-404	false
tetracycline	drug	118-129	Fortovase	brand	407-415	false
tetracycline	drug	118-129	Invirase	brand	418-425	false
tetracycline	drug	118-129	Kaletra	brand	428-434	false
tetracycline	drug	118-129	Norvir	brand	437-442	false
tetracycline	drug	118-129	Viracept	brand	445-452	false
tetracycline	drug	118-129	morphine	drug	456-463	false
tetracycline	drug	118-129	Astramorph	brand	466-475	false
tetracycline	drug	118-129	Kadian	brand	478-483	false
tetracycline	drug	118-129	MS Contin	brand	486-494	false
tetracycline	drug	118-129	phenylbutazone	drug	498-511	false
tetracycline	drug	118-129	prednisolone	drug	514-525	false
tetracycline	drug	118-129	Prelone	brand	528-534	false
tetracycline	drug	118-129	rifadin	brand	538-544	false
tetracycline	drug	118-129	rifampin	drug	547-554	false
tetracycline	drug	118-129	temazepam	drug	574-582	false
tetracycline	drug	118-129	theophylline	drug	585-596	false
tetracycline	drug	118-129	Theo-Dur	brand	599-606	false
tetracycline	drug	118-129	vitamin C	drug	614-622	false
anticonvulsants	group	132-146	Dilantin	brand	149-156	false
anticonvulsants	group	132-146	Phenobarbital	drug	159-171	false
anticonvulsants	group	132-146	Tegretol	brand	174-181	false
anticonvulsants	group	132-146	Trileptal	brand	184-192	false
anticonvulsants	group	132-146	Topamax	brand	195-201	false
anticonvulsants	group	132-146	Felbatol	brand	204-211	false
anticonvulsants	group	132-146	antifungals	group	215-225	false
anticonvulsants	group	132-146	Gris-PEG	brand	228-235	false
anticonvulsants	group	132-146	Nizoral	brand	238-244	false
anticonvulsants	group	132-146	Sporanox	brand	247-254	false
anticonvulsants	group	132-146	atorvastatin	drug	258-269	false
anticonvulsants	group	132-146	Lipitor	brand	272-278	false
anticonvulsants	group	132-146	clofibrate	drug	282-291	false
anticonvulsants	group	132-146	Atromid-S	brand	294-302	false
anticonvulsants	group	132-146	cyclosporine	drug	306-317	false
anticonvulsants	group	132-146	Neoral	brand	320-325	false
anticonvulsants	group	132-146	Sandimmune	brand	328-337	false
anticonvulsants	group	132-146	protease inhibitors	group	365-383	false
anticonvulsants	group	132-146	Agenerase	brand	386-394	false
anticonvulsants	group	132-146	Crixivan	brand	397-404	false
anticonvulsants	group	132-146	Fortovase	brand	407-415	false
anticonvulsants	group	132-146	Invirase	brand	418-425	false
anticonvulsants	group	132-146	Kaletra	brand	428-434	false
anticonvulsants	group	132-146	Norvir	brand	437-442	false
anticonvulsants	group	132-146	Viracept	brand	445-452	false
anticonvulsants	group	132-146	morphine	drug	456-463	false
anticonvulsants	group	132-146	Astramorph	brand	466-475	false
anticonvulsants	group	132-146	Kadian	brand	478-483	false
anticonvulsants	group	132-146	MS Contin	brand	486-494	false
anticonvulsants	group	132-146	phenylbutazone	drug	498-511	false
anticonvulsants	group	132-146	prednisolone	drug	514-525	false
anticonvulsants	group	132-146	Prelone	brand	528-534	false
anticonvulsants	group	132-146	rifadin	brand	538-544	false
anticonvulsants	group	132-146	rifampin	drug	547-554	false
anticonvulsants	group	132-146	temazepam	drug	574-582	false
anticonvulsants	group	132-146	theophylline	drug	585-596	false
anticonvulsants	group	132-146	Theo-Dur	brand	599-606	false
anticonvulsants	group	132-146	vitamin C	drug	614-622	false
Dilantin	brand	149-156	Phenobarbital	drug	159-171	false
Dilantin	brand	149-156	Tegretol	brand	174-181	false
Dilantin	brand	149-156	Trileptal	brand	184-192	false
Dilantin	brand	149-156	Topamax	brand	195-201	false
Dilantin	brand	149-156	Felbatol	brand	204-211	false
Dilantin	brand	149-156	antifungals	group	215-225	false
Dilantin	brand	149-156	Gris-PEG	brand	228-235	false
Dilantin	brand	149-156	Nizoral	brand	238-244	false
Dilantin	brand	149-156	Sporanox	brand	247-254	false
Dilantin	brand	149-156	atorvastatin	drug	258-269	false
Dilantin	brand	149-156	Lipitor	brand	272-278	false
Dilantin	brand	149-156	clofibrate	drug	282-291	false
Dilantin	brand	149-156	Atromid-S	brand	294-302	false
Dilantin	brand	149-156	cyclosporine	drug	306-317	false
Dilantin	brand	149-156	Neoral	brand	320-325	false
Dilantin	brand	149-156	Sandimmune	brand	328-337	false
Dilantin	brand	149-156	protease inhibitors	group	365-383	false
Dilantin	brand	149-156	Agenerase	brand	386-394	false
Dilantin	brand	149-156	Crixivan	brand	397-404	false
Dilantin	brand	149-156	Fortovase	brand	407-415	false
Dilantin	brand	149-156	Invirase	brand	418-425	false
Dilantin	brand	149-156	Kaletra	brand	428-434	false
Dilantin	brand	149-156	Norvir	brand	437-442	false
Dilantin	brand	149-156	Viracept	brand	445-452	false
Dilantin	brand	149-156	morphine	drug	456-463	false
Dilantin	brand	149-156	Astramorph	brand	466-475	false
Dilantin	brand	149-156	Kadian	brand	478-483	false
Dilantin	brand	149-156	MS Contin	brand	486-494	false
Dilantin	brand	149-156	phenylbutazone	drug	498-511	false
Dilantin	brand	149-156	prednisolone	drug	514-525	false
Dilantin	brand	149-156	Prelone	brand	528-534	false
Dilantin	brand	149-156	rifadin	brand	538-544	false
Dilantin	brand	149-156	rifampin	drug	547-554	false
Dilantin	brand	149-156	temazepam	drug	574-582	false
Dilantin	brand	149-156	theophylline	drug	585-596	false
Dilantin	brand	149-156	Theo-Dur	brand	599-606	false
Dilantin	brand	149-156	vitamin C	drug	614-622	false
Phenobarbital	drug	159-171	Tegretol	brand	174-181	false
Phenobarbital	drug	159-171	Trileptal	brand	184-192	false
Phenobarbital	drug	159-171	Topamax	brand	195-201	false
Phenobarbital	drug	159-171	Felbatol	brand	204-211	false
Phenobarbital	drug	159-171	antifungals	group	215-225	false
Phenobarbital	drug	159-171	Gris-PEG	brand	228-235	false
Phenobarbital	drug	159-171	Nizoral	brand	238-244	false
Phenobarbital	drug	159-171	Sporanox	brand	247-254	false
Phenobarbital	drug	159-171	atorvastatin	drug	258-269	false
Phenobarbital	drug	159-171	Lipitor	brand	272-278	false
Phenobarbital	drug	159-171	clofibrate	drug	282-291	false
Phenobarbital	drug	159-171	Atromid-S	brand	294-302	false
Phenobarbital	drug	159-171	cyclosporine	drug	306-317	false
Phenobarbital	drug	159-171	Neoral	brand	320-325	false
Phenobarbital	drug	159-171	Sandimmune	brand	328-337	false
Phenobarbital	drug	159-171	protease inhibitors	group	365-383	false
Phenobarbital	drug	159-171	Agenerase	brand	386-394	false
Phenobarbital	drug	159-171	Crixivan	brand	397-404	false
Phenobarbital	drug	159-171	Fortovase	brand	407-415	false
Phenobarbital	drug	159-171	Invirase	brand	418-425	false
Phenobarbital	drug	159-171	Kaletra	brand	428-434	false
Phenobarbital	drug	159-171	Norvir	brand	437-442	false
Phenobarbital	drug	159-171	Viracept	brand	445-452	false
Phenobarbital	drug	159-171	morphine	drug	456-463	false
Phenobarbital	drug	159-171	Astramorph	brand	466-475	false
Phenobarbital	drug	159-171	Kadian	brand	478-483	false
Phenobarbital	drug	159-171	MS Contin	brand	486-494	false
Phenobarbital	drug	159-171	phenylbutazone	drug	498-511	false
Phenobarbital	drug	159-171	prednisolone	drug	514-525	false
Phenobarbital	drug	159-171	Prelone	brand	528-534	false
Phenobarbital	drug	159-171	rifadin	brand	538-544	false
Phenobarbital	drug	159-171	rifampin	drug	547-554	false
Phenobarbital	drug	159-171	temazepam	drug	574-582	false
Phenobarbital	drug	159-171	theophylline	drug	585-596	false
Phenobarbital	drug	159-171	Theo-Dur	brand	599-606	false
Phenobarbital	drug	159-171	vitamin C	drug	614-622	false
Tegretol	brand	174-181	Trileptal	brand	184-192	false
Tegretol	brand	174-181	Topamax	brand	195-201	false
Tegretol	brand	174-181	Felbatol	brand	204-211	false
Tegretol	brand	174-181	antifungals	group	215-225	false
Tegretol	brand	174-181	Gris-PEG	brand	228-235	false
Tegretol	brand	174-181	Nizoral	brand	238-244	false
Tegretol	brand	174-181	Sporanox	brand	247-254	false
Tegretol	brand	174-181	atorvastatin	drug	258-269	false
Tegretol	brand	174-181	Lipitor	brand	272-278	false
Tegretol	brand	174-181	clofibrate	drug	282-291	false
Tegretol	brand	174-181	Atromid-S	brand	294-302	false
Tegretol	brand	174-181	cyclosporine	drug	306-317	false
Tegretol	brand	174-181	Neoral	brand	320-325	false
Tegretol	brand	174-181	Sandimmune	brand	328-337	false
Tegretol	brand	174-181	protease inhibitors	group	365-383	false
Tegretol	brand	174-181	Agenerase	brand	386-394	false
Tegretol	brand	174-181	Crixivan	brand	397-404	false
Tegretol	brand	174-181	Fortovase	brand	407-415	false
Tegretol	brand	174-181	Invirase	brand	418-425	false
Tegretol	brand	174-181	Kaletra	brand	428-434	false
Tegretol	brand	174-181	Norvir	brand	437-442	false
Tegretol	brand	174-181	Viracept	brand	445-452	false
Tegretol	brand	174-181	morphine	drug	456-463	false
Tegretol	brand	174-181	Astramorph	brand	466-475	false
Tegretol	brand	174-181	Kadian	brand	478-483	false
Tegretol	brand	174-181	MS Contin	brand	486-494	false
Tegretol	brand	174-181	phenylbutazone	drug	498-511	false
Tegretol	brand	174-181	prednisolone	drug	514-525	false
Tegretol	brand	174-181	Prelone	brand	528-534	false
Tegretol	brand	174-181	rifadin	brand	538-544	false
Tegretol	brand	174-181	rifampin	drug	547-554	false
Tegretol	brand	174-181	temazepam	drug	574-582	false
Tegretol	brand	174-181	theophylline	drug	585-596	false
Tegretol	brand	174-181	Theo-Dur	brand	599-606	false
Tegretol	brand	174-181	vitamin C	drug	614-622	false
Trileptal	brand	184-192	Topamax	brand	195-201	false
Trileptal	brand	184-192	Felbatol	brand	204-211	false
Trileptal	brand	184-192	antifungals	group	215-225	false
Trileptal	brand	184-192	Gris-PEG	brand	228-235	false
Trileptal	brand	184-192	Nizoral	brand	238-244	false
Trileptal	brand	184-192	Sporanox	brand	247-254	false
Trileptal	brand	184-192	atorvastatin	drug	258-269	false
Trileptal	brand	184-192	Lipitor	brand	272-278	false
Trileptal	brand	184-192	clofibrate	drug	282-291	false
Trileptal	brand	184-192	Atromid-S	brand	294-302	false
Trileptal	brand	184-192	cyclosporine	drug	306-317	false
Trileptal	brand	184-192	Neoral	brand	320-325	false
Trileptal	brand	184-192	Sandimmune	brand	328-337	false
Trileptal	brand	184-192	protease inhibitors	group	365-383	false
Trileptal	brand	184-192	Agenerase	brand	386-394	false
Trileptal	brand	184-192	Crixivan	brand	397-404	false
Trileptal	brand	184-192	Fortovase	brand	407-415	false
Trileptal	brand	184-192	Invirase	brand	418-425	false
Trileptal	brand	184-192	Kaletra	brand	428-434	false
Trileptal	brand	184-192	Norvir	brand	437-442	false
Trileptal	brand	184-192	Viracept	brand	445-452	false
Trileptal	brand	184-192	morphine	drug	456-463	false
Trileptal	brand	184-192	Astramorph	brand	466-475	false
Trileptal	brand	184-192	Kadian	brand	478-483	false
Trileptal	brand	184-192	MS Contin	brand	486-494	false
Trileptal	brand	184-192	phenylbutazone	drug	498-511	false
Trileptal	brand	184-192	prednisolone	drug	514-525	false
Trileptal	brand	184-192	Prelone	brand	528-534	false
Trileptal	brand	184-192	rifadin	brand	538-544	false
Trileptal	brand	184-192	rifampin	drug	547-554	false
Trileptal	brand	184-192	temazepam	drug	574-582	false
Trileptal	brand	184-192	theophylline	drug	585-596	false
Trileptal	brand	184-192	Theo-Dur	brand	599-606	false
Trileptal	brand	184-192	vitamin C	drug	614-622	false
Topamax	brand	195-201	Felbatol	brand	204-211	false
Topamax	brand	195-201	antifungals	group	215-225	false
Topamax	brand	195-201	Gris-PEG	brand	228-235	false
Topamax	brand	195-201	Nizoral	brand	238-244	false
Topamax	brand	195-201	Sporanox	brand	247-254	false
Topamax	brand	195-201	atorvastatin	drug	258-269	false
Topamax	brand	195-201	Lipitor	brand	272-278	false
Topamax	brand	195-201	clofibrate	drug	282-291	false
Topamax	brand	195-201	Atromid-S	brand	294-302	false
Topamax	brand	195-201	cyclosporine	drug	306-317	false
Topamax	brand	195-201	Neoral	brand	320-325	false
Topamax	brand	195-201	Sandimmune	brand	328-337	false
Topamax	brand	195-201	protease inhibitors	group	365-383	false
Topamax	brand	195-201	Agenerase	brand	386-394	false
Topamax	brand	195-201	Crixivan	brand	397-404	false
Topamax	brand	195-201	Fortovase	brand	407-415	false
Topamax	brand	195-201	Invirase	brand	418-425	false
Topamax	brand	195-201	Kaletra	brand	428-434	false
Topamax	brand	195-201	Norvir	brand	437-442	false
Topamax	brand	195-201	Viracept	brand	445-452	false
Topamax	brand	195-201	morphine	drug	456-463	false
Topamax	brand	195-201	Astramorph	brand	466-475	false
Topamax	brand	195-201	Kadian	brand	478-483	false
Topamax	brand	195-201	MS Contin	brand	486-494	false
Topamax	brand	195-201	phenylbutazone	drug	498-511	false
Topamax	brand	195-201	prednisolone	drug	514-525	false
Topamax	brand	195-201	Prelone	brand	528-534	false
Topamax	brand	195-201	rifadin	brand	538-544	false
Topamax	brand	195-201	rifampin	drug	547-554	false
Topamax	brand	195-201	temazepam	drug	574-582	false
Topamax	brand	195-201	theophylline	drug	585-596	false
Topamax	brand	195-201	Theo-Dur	brand	599-606	false
Topamax	brand	195-201	vitamin C	drug	614-622	false
Felbatol	brand	204-211	antifungals	group	215-225	false
Felbatol	brand	204-211	Gris-PEG	brand	228-235	false
Felbatol	brand	204-211	Nizoral	brand	238-244	false
Felbatol	brand	204-211	Sporanox	brand	247-254	false
Felbatol	brand	204-211	atorvastatin	drug	258-269	false
Felbatol	brand	204-211	Lipitor	brand	272-278	false
Felbatol	brand	204-211	clofibrate	drug	282-291	false
Felbatol	brand	204-211	Atromid-S	brand	294-302	false
Felbatol	brand	204-211	cyclosporine	drug	306-317	false
Felbatol	brand	204-211	Neoral	brand	320-325	false
Felbatol	brand	204-211	Sandimmune	brand	328-337	false
Felbatol	brand	204-211	protease inhibitors	group	365-383	false
Felbatol	brand	204-211	Agenerase	brand	386-394	false
Felbatol	brand	204-211	Crixivan	brand	397-404	false
Felbatol	brand	204-211	Fortovase	brand	407-415	false
Felbatol	brand	204-211	Invirase	brand	418-425	false
Felbatol	brand	204-211	Kaletra	brand	428-434	false
Felbatol	brand	204-211	Norvir	brand	437-442	false
Felbatol	brand	204-211	Viracept	brand	445-452	false
Felbatol	brand	204-211	morphine	drug	456-463	false
Felbatol	brand	204-211	Astramorph	brand	466-475	false
Felbatol	brand	204-211	Kadian	brand	478-483	false
Felbatol	brand	204-211	MS Contin	brand	486-494	false
Felbatol	brand	204-211	phenylbutazone	drug	498-511	false
Felbatol	brand	204-211	prednisolone	drug	514-525	false
Felbatol	brand	204-211	Prelone	brand	528-534	false
Felbatol	brand	204-211	rifadin	brand	538-544	false
Felbatol	brand	204-211	rifampin	drug	547-554	false
Felbatol	brand	204-211	temazepam	drug	574-582	false
Felbatol	brand	204-211	theophylline	drug	585-596	false
Felbatol	brand	204-211	Theo-Dur	brand	599-606	false
Felbatol	brand	204-211	vitamin C	drug	614-622	false
antifungals	group	215-225	Gris-PEG	brand	228-235	false
antifungals	group	215-225	Nizoral	brand	238-244	false
antifungals	group	215-225	Sporanox	brand	247-254	false
antifungals	group	215-225	atorvastatin	drug	258-269	false
antifungals	group	215-225	Lipitor	brand	272-278	false
antifungals	group	215-225	clofibrate	drug	282-291	false
antifungals	group	215-225	Atromid-S	brand	294-302	false
antifungals	group	215-225	cyclosporine	drug	306-317	false
antifungals	group	215-225	Neoral	brand	320-325	false
antifungals	group	215-225	Sandimmune	brand	328-337	false
antifungals	group	215-225	protease inhibitors	group	365-383	false
antifungals	group	215-225	Agenerase	brand	386-394	false
antifungals	group	215-225	Crixivan	brand	397-404	false
antifungals	group	215-225	Fortovase	brand	407-415	false
antifungals	group	215-225	Invirase	brand	418-425	false
antifungals	group	215-225	Kaletra	brand	428-434	false
antifungals	group	215-225	Norvir	brand	437-442	false
antifungals	group	215-225	Viracept	brand	445-452	false
antifungals	group	215-225	morphine	drug	456-463	false
antifungals	group	215-225	Astramorph	brand	466-475	false
antifungals	group	215-225	Kadian	brand	478-483	false
antifungals	group	215-225	MS Contin	brand	486-494	false
antifungals	group	215-225	phenylbutazone	drug	498-511	false
antifungals	group	215-225	prednisolone	drug	514-525	false
antifungals	group	215-225	Prelone	brand	528-534	false
antifungals	group	215-225	rifadin	brand	538-544	false
antifungals	group	215-225	rifampin	drug	547-554	false
antifungals	group	215-225	temazepam	drug	574-582	false
antifungals	group	215-225	theophylline	drug	585-596	false
antifungals	group	215-225	Theo-Dur	brand	599-606	false
antifungals	group	215-225	vitamin C	drug	614-622	false
Gris-PEG	brand	228-235	Nizoral	brand	238-244	false
Gris-PEG	brand	228-235	Sporanox	brand	247-254	false
Gris-PEG	brand	228-235	atorvastatin	drug	258-269	false
Gris-PEG	brand	228-235	Lipitor	brand	272-278	false
Gris-PEG	brand	228-235	clofibrate	drug	282-291	false
Gris-PEG	brand	228-235	Atromid-S	brand	294-302	false
Gris-PEG	brand	228-235	cyclosporine	drug	306-317	false
Gris-PEG	brand	228-235	Neoral	brand	320-325	false
Gris-PEG	brand	228-235	Sandimmune	brand	328-337	false
Gris-PEG	brand	228-235	protease inhibitors	group	365-383	false
Gris-PEG	brand	228-235	Agenerase	brand	386-394	false
Gris-PEG	brand	228-235	Crixivan	brand	397-404	false
Gris-PEG	brand	228-235	Fortovase	brand	407-415	false
Gris-PEG	brand	228-235	Invirase	brand	418-425	false
Gris-PEG	brand	228-235	Kaletra	brand	428-434	false
Gris-PEG	brand	228-235	Norvir	brand	437-442	false
Gris-PEG	brand	228-235	Viracept	brand	445-452	false
Gris-PEG	brand	228-235	morphine	drug	456-463	false
Gris-PEG	brand	228-235	Astramorph	brand	466-475	false
Gris-PEG	brand	228-235	Kadian	brand	478-483	false
Gris-PEG	brand	228-235	MS Contin	brand	486-494	false
Gris-PEG	brand	228-235	phenylbutazone	drug	498-511	false
Gris-PEG	brand	228-235	prednisolone	drug	514-525	false
Gris-PEG	brand	228-235	Prelone	brand	528-534	false
Gris-PEG	brand	228-235	rifadin	brand	538-544	false
Gris-PEG	brand	228-235	rifampin	drug	547-554	false
Gris-PEG	brand	228-235	temazepam	drug	574-582	false
Gris-PEG	brand	228-235	theophylline	drug	585-596	false
Gris-PEG	brand	228-235	Theo-Dur	brand	599-606	false
Gris-PEG	brand	228-235	vitamin C	drug	614-622	false
Nizoral	brand	238-244	Sporanox	brand	247-254	false
Nizoral	brand	238-244	atorvastatin	drug	258-269	false
Nizoral	brand	238-244	Lipitor	brand	272-278	false
Nizoral	brand	238-244	clofibrate	drug	282-291	false
Nizoral	brand	238-244	Atromid-S	brand	294-302	false
Nizoral	brand	238-244	cyclosporine	drug	306-317	false
Nizoral	brand	238-244	Neoral	brand	320-325	false
Nizoral	brand	238-244	Sandimmune	brand	328-337	false
Nizoral	brand	238-244	protease inhibitors	group	365-383	false
Nizoral	brand	238-244	Agenerase	brand	386-394	false
Nizoral	brand	238-244	Crixivan	brand	397-404	false
Nizoral	brand	238-244	Fortovase	brand	407-415	false
Nizoral	brand	238-244	Invirase	brand	418-425	false
Nizoral	brand	238-244	Kaletra	brand	428-434	false
Nizoral	brand	238-244	Norvir	brand	437-442	false
Nizoral	brand	238-244	Viracept	brand	445-452	false
Nizoral	brand	238-244	morphine	drug	456-463	false
Nizoral	brand	238-244	Astramorph	brand	466-475	false
Nizoral	brand	238-244	Kadian	brand	478-483	false
Nizoral	brand	238-244	MS Contin	brand	486-494	false
Nizoral	brand	238-244	phenylbutazone	drug	498-511	false
Nizoral	brand	238-244	prednisolone	drug	514-525	false
Nizoral	brand	238-244	Prelone	brand	528-534	false
Nizoral	brand	238-244	rifadin	brand	538-544	false
Nizoral	brand	238-244	rifampin	drug	547-554	false
Nizoral	brand	238-244	temazepam	drug	574-582	false
Nizoral	brand	238-244	theophylline	drug	585-596	false
Nizoral	brand	238-244	Theo-Dur	brand	599-606	false
Nizoral	brand	238-244	vitamin C	drug	614-622	false
Sporanox	brand	247-254	atorvastatin	drug	258-269	false
Sporanox	brand	247-254	Lipitor	brand	272-278	false
Sporanox	brand	247-254	clofibrate	drug	282-291	false
Sporanox	brand	247-254	Atromid-S	brand	294-302	false
Sporanox	brand	247-254	cyclosporine	drug	306-317	false
Sporanox	brand	247-254	Neoral	brand	320-325	false
Sporanox	brand	247-254	Sandimmune	brand	328-337	false
Sporanox	brand	247-254	protease inhibitors	group	365-383	false
Sporanox	brand	247-254	Agenerase	brand	386-394	false
Sporanox	brand	247-254	Crixivan	brand	397-404	false
Sporanox	brand	247-254	Fortovase	brand	407-415	false
Sporanox	brand	247-254	Invirase	brand	418-425	false
Sporanox	brand	247-254	Kaletra	brand	428-434	false
Sporanox	brand	247-254	Norvir	brand	437-442	false
Sporanox	brand	247-254	Viracept	brand	445-452	false
Sporanox	brand	247-254	morphine	drug	456-463	false
Sporanox	brand	247-254	Astramorph	brand	466-475	false
Sporanox	brand	247-254	Kadian	brand	478-483	false
Sporanox	brand	247-254	MS Contin	brand	486-494	false
Sporanox	brand	247-254	phenylbutazone	drug	498-511	false
Sporanox	brand	247-254	prednisolone	drug	514-525	false
Sporanox	brand	247-254	Prelone	brand	528-534	false
Sporanox	brand	247-254	rifadin	brand	538-544	false
Sporanox	brand	247-254	rifampin	drug	547-554	false
Sporanox	brand	247-254	temazepam	drug	574-582	false
Sporanox	brand	247-254	theophylline	drug	585-596	false
Sporanox	brand	247-254	Theo-Dur	brand	599-606	false
Sporanox	brand	247-254	vitamin C	drug	614-622	false
atorvastatin	drug	258-269	Lipitor	brand	272-278	false
atorvastatin	drug	258-269	clofibrate	drug	282-291	false
atorvastatin	drug	258-269	Atromid-S	brand	294-302	false
atorvastatin	drug	258-269	cyclosporine	drug	306-317	false
atorvastatin	drug	258-269	Neoral	brand	320-325	false
atorvastatin	drug	258-269	Sandimmune	brand	328-337	false
atorvastatin	drug	258-269	protease inhibitors	group	365-383	false
atorvastatin	drug	258-269	Agenerase	brand	386-394	false
atorvastatin	drug	258-269	Crixivan	brand	397-404	false
atorvastatin	drug	258-269	Fortovase	brand	407-415	false
atorvastatin	drug	258-269	Invirase	brand	418-425	false
atorvastatin	drug	258-269	Kaletra	brand	428-434	false
atorvastatin	drug	258-269	Norvir	brand	437-442	false
atorvastatin	drug	258-269	Viracept	brand	445-452	false
atorvastatin	drug	258-269	morphine	drug	456-463	false
atorvastatin	drug	258-269	Astramorph	brand	466-475	false
atorvastatin	drug	258-269	Kadian	brand	478-483	false
atorvastatin	drug	258-269	MS Contin	brand	486-494	false
atorvastatin	drug	258-269	phenylbutazone	drug	498-511	false
atorvastatin	drug	258-269	prednisolone	drug	514-525	false
atorvastatin	drug	258-269	Prelone	brand	528-534	false
atorvastatin	drug	258-269	rifadin	brand	538-544	false
atorvastatin	drug	258-269	rifampin	drug	547-554	false
atorvastatin	drug	258-269	temazepam	drug	574-582	false
atorvastatin	drug	258-269	theophylline	drug	585-596	false
atorvastatin	drug	258-269	Theo-Dur	brand	599-606	false
atorvastatin	drug	258-269	vitamin C	drug	614-622	false
Lipitor	brand	272-278	clofibrate	drug	282-291	false
Lipitor	brand	272-278	Atromid-S	brand	294-302	false
Lipitor	brand	272-278	cyclosporine	drug	306-317	false
Lipitor	brand	272-278	Neoral	brand	320-325	false
Lipitor	brand	272-278	Sandimmune	brand	328-337	false
Lipitor	brand	272-278	protease inhibitors	group	365-383	false
Lipitor	brand	272-278	Agenerase	brand	386-394	false
Lipitor	brand	272-278	Crixivan	brand	397-404	false
Lipitor	brand	272-278	Fortovase	brand	407-415	false
Lipitor	brand	272-278	Invirase	brand	418-425	false
Lipitor	brand	272-278	Kaletra	brand	428-434	false
Lipitor	brand	272-278	Norvir	brand	437-442	false
Lipitor	brand	272-278	Viracept	brand	445-452	false
Lipitor	brand	272-278	morphine	drug	456-463	false
Lipitor	brand	272-278	Astramorph	brand	466-475	false
Lipitor	brand	272-278	Kadian	brand	478-483	false
Lipitor	brand	272-278	MS Contin	brand	486-494	false
Lipitor	brand	272-278	phenylbutazone	drug	498-511	false
Lipitor	brand	272-278	prednisolone	drug	514-525	false
Lipitor	brand	272-278	Prelone	brand	528-534	false
Lipitor	brand	272-278	rifadin	brand	538-544	false
Lipitor	brand	272-278	rifampin	drug	547-554	false
Lipitor	brand	272-278	temazepam	drug	574-582	false
Lipitor	brand	272-278	theophylline	drug	585-596	false
Lipitor	brand	272-278	Theo-Dur	brand	599-606	false
Lipitor	brand	272-278	vitamin C	drug	614-622	false
clofibrate	drug	282-291	Atromid-S	brand	294-302	false
clofibrate	drug	282-291	cyclosporine	drug	306-317	false
clofibrate	drug	282-291	Neoral	brand	320-325	false
clofibrate	drug	282-291	Sandimmune	brand	328-337	false
clofibrate	drug	282-291	protease inhibitors	group	365-383	false
clofibrate	drug	282-291	Agenerase	brand	386-394	false
clofibrate	drug	282-291	Crixivan	brand	397-404	false
clofibrate	drug	282-291	Fortovase	brand	407-415	false
clofibrate	drug	282-291	Invirase	brand	418-425	false
clofibrate	drug	282-291	Kaletra	brand	428-434	false
clofibrate	drug	282-291	Norvir	brand	437-442	false
clofibrate	drug	282-291	Viracept	brand	445-452	false
clofibrate	drug	282-291	morphine	drug	456-463	false
clofibrate	drug	282-291	Astramorph	brand	466-475	false
clofibrate	drug	282-291	Kadian	brand	478-483	false
clofibrate	drug	282-291	MS Contin	brand	486-494	false
clofibrate	drug	282-291	phenylbutazone	drug	498-511	false
clofibrate	drug	282-291	prednisolone	drug	514-525	false
clofibrate	drug	282-291	Prelone	brand	528-534	false
clofibrate	drug	282-291	rifadin	brand	538-544	false
clofibrate	drug	282-291	rifampin	drug	547-554	false
clofibrate	drug	282-291	temazepam	drug	574-582	false
clofibrate	drug	282-291	theophylline	drug	585-596	false
clofibrate	drug	282-291	Theo-Dur	brand	599-606	false
clofibrate	drug	282-291	vitamin C	drug	614-622	false
Atromid-S	brand	294-302	cyclosporine	drug	306-317	false
Atromid-S	brand	294-302	Neoral	brand	320-325	false
Atromid-S	brand	294-302	Sandimmune	brand	328-337	false
Atromid-S	brand	294-302	protease inhibitors	group	365-383	false
Atromid-S	brand	294-302	Agenerase	brand	386-394	false
Atromid-S	brand	294-302	Crixivan	brand	397-404	false
Atromid-S	brand	294-302	Fortovase	brand	407-415	false
Atromid-S	brand	294-302	Invirase	brand	418-425	false
Atromid-S	brand	294-302	Kaletra	brand	428-434	false
Atromid-S	brand	294-302	Norvir	brand	437-442	false
Atromid-S	brand	294-302	Viracept	brand	445-452	false
Atromid-S	brand	294-302	morphine	drug	456-463	false
Atromid-S	brand	294-302	Astramorph	brand	466-475	false
Atromid-S	brand	294-302	Kadian	brand	478-483	false
Atromid-S	brand	294-302	MS Contin	brand	486-494	false
Atromid-S	brand	294-302	phenylbutazone	drug	498-511	false
Atromid-S	brand	294-302	prednisolone	drug	514-525	false
Atromid-S	brand	294-302	Prelone	brand	528-534	false
Atromid-S	brand	294-302	rifadin	brand	538-544	false
Atromid-S	brand	294-302	rifampin	drug	547-554	false
Atromid-S	brand	294-302	temazepam	drug	574-582	false
Atromid-S	brand	294-302	theophylline	drug	585-596	false
Atromid-S	brand	294-302	Theo-Dur	brand	599-606	false
Atromid-S	brand	294-302	vitamin C	drug	614-622	false
cyclosporine	drug	306-317	Neoral	brand	320-325	false
cyclosporine	drug	306-317	Sandimmune	brand	328-337	false
cyclosporine	drug	306-317	protease inhibitors	group	365-383	false
cyclosporine	drug	306-317	Agenerase	brand	386-394	false
cyclosporine	drug	306-317	Crixivan	brand	397-404	false
cyclosporine	drug	306-317	Fortovase	brand	407-415	false
cyclosporine	drug	306-317	Invirase	brand	418-425	false
cyclosporine	drug	306-317	Kaletra	brand	428-434	false
cyclosporine	drug	306-317	Norvir	brand	437-442	false
cyclosporine	drug	306-317	Viracept	brand	445-452	false
cyclosporine	drug	306-317	morphine	drug	456-463	false
cyclosporine	drug	306-317	Astramorph	brand	466-475	false
cyclosporine	drug	306-317	Kadian	brand	478-483	false
cyclosporine	drug	306-317	MS Contin	brand	486-494	false
cyclosporine	drug	306-317	phenylbutazone	drug	498-511	false
cyclosporine	drug	306-317	prednisolone	drug	514-525	false
cyclosporine	drug	306-317	Prelone	brand	528-534	false
cyclosporine	drug	306-317	rifadin	brand	538-544	false
cyclosporine	drug	306-317	rifampin	drug	547-554	false
cyclosporine	drug	306-317	temazepam	drug	574-582	false
cyclosporine	drug	306-317	theophylline	drug	585-596	false
cyclosporine	drug	306-317	Theo-Dur	brand	599-606	false
cyclosporine	drug	306-317	vitamin C	drug	614-622	false
Neoral	brand	320-325	Sandimmune	brand	328-337	false
Neoral	brand	320-325	protease inhibitors	group	365-383	false
Neoral	brand	320-325	Agenerase	brand	386-394	false
Neoral	brand	320-325	Crixivan	brand	397-404	false
Neoral	brand	320-325	Fortovase	brand	407-415	false
Neoral	brand	320-325	Invirase	brand	418-425	false
Neoral	brand	320-325	Kaletra	brand	428-434	false
Neoral	brand	320-325	Norvir	brand	437-442	false
Neoral	brand	320-325	Viracept	brand	445-452	false
Neoral	brand	320-325	morphine	drug	456-463	false
Neoral	brand	320-325	Astramorph	brand	466-475	false
Neoral	brand	320-325	Kadian	brand	478-483	false
Neoral	brand	320-325	MS Contin	brand	486-494	false
Neoral	brand	320-325	phenylbutazone	drug	498-511	false
Neoral	brand	320-325	prednisolone	drug	514-525	false
Neoral	brand	320-325	Prelone	brand	528-534	false
Neoral	brand	320-325	rifadin	brand	538-544	false
Neoral	brand	320-325	rifampin	drug	547-554	false
Neoral	brand	320-325	temazepam	drug	574-582	false
Neoral	brand	320-325	theophylline	drug	585-596	false
Neoral	brand	320-325	Theo-Dur	brand	599-606	false
Neoral	brand	320-325	vitamin C	drug	614-622	false
Sandimmune	brand	328-337	protease inhibitors	group	365-383	false
Sandimmune	brand	328-337	Agenerase	brand	386-394	false
Sandimmune	brand	328-337	Crixivan	brand	397-404	false
Sandimmune	brand	328-337	Fortovase	brand	407-415	false
Sandimmune	brand	328-337	Invirase	brand	418-425	false
Sandimmune	brand	328-337	Kaletra	brand	428-434	false
Sandimmune	brand	328-337	Norvir	brand	437-442	false
Sandimmune	brand	328-337	Viracept	brand	445-452	false
Sandimmune	brand	328-337	morphine	drug	456-463	false
Sandimmune	brand	328-337	Astramorph	brand	466-475	false
Sandimmune	brand	328-337	Kadian	brand	478-483	false
Sandimmune	brand	328-337	MS Contin	brand	486-494	false
Sandimmune	brand	328-337	phenylbutazone	drug	498-511	false
Sandimmune	brand	328-337	prednisolone	drug	514-525	false
Sandimmune	brand	328-337	Prelone	brand	528-534	false
Sandimmune	brand	328-337	rifadin	brand	538-544	false
Sandimmune	brand	328-337	rifampin	drug	547-554	false
Sandimmune	brand	328-337	temazepam	drug	574-582	false
Sandimmune	brand	328-337	theophylline	drug	585-596	false
Sandimmune	brand	328-337	Theo-Dur	brand	599-606	false
Sandimmune	brand	328-337	vitamin C	drug	614-622	false
protease inhibitors	group	365-383	Agenerase	brand	386-394	false
protease inhibitors	group	365-383	Crixivan	brand	397-404	false
protease inhibitors	group	365-383	Fortovase	brand	407-415	false
protease inhibitors	group	365-383	Invirase	brand	418-425	false
protease inhibitors	group	365-383	Kaletra	brand	428-434	false
protease inhibitors	group	365-383	Norvir	brand	437-442	false
protease inhibitors	group	365-383	Viracept	brand	445-452	false
protease inhibitors	group	365-383	morphine	drug	456-463	false
protease inhibitors	group	365-383	Astramorph	brand	466-475	false
protease inhibitors	group	365-383	Kadian	brand	478-483	false
protease inhibitors	group	365-383	MS Contin	brand	486-494	false
protease inhibitors	group	365-383	phenylbutazone	drug	498-511	false
protease inhibitors	group	365-383	prednisolone	drug	514-525	false
protease inhibitors	group	365-383	Prelone	brand	528-534	false
protease inhibitors	group	365-383	rifadin	brand	538-544	false
protease inhibitors	group	365-383	rifampin	drug	547-554	false
protease inhibitors	group	365-383	temazepam	drug	574-582	false
protease inhibitors	group	365-383	theophylline	drug	585-596	false
protease inhibitors	group	365-383	Theo-Dur	brand	599-606	false
protease inhibitors	group	365-383	vitamin C	drug	614-622	false
Agenerase	brand	386-394	Crixivan	brand	397-404	false
Agenerase	brand	386-394	Fortovase	brand	407-415	false
Agenerase	brand	386-394	Invirase	brand	418-425	false
Agenerase	brand	386-394	Kaletra	brand	428-434	false
Agenerase	brand	386-394	Norvir	brand	437-442	false
Agenerase	brand	386-394	Viracept	brand	445-452	false
Agenerase	brand	386-394	morphine	drug	456-463	false
Agenerase	brand	386-394	Astramorph	brand	466-475	false
Agenerase	brand	386-394	Kadian	brand	478-483	false
Agenerase	brand	386-394	MS Contin	brand	486-494	false
Agenerase	brand	386-394	phenylbutazone	drug	498-511	false
Agenerase	brand	386-394	prednisolone	drug	514-525	false
Agenerase	brand	386-394	Prelone	brand	528-534	false
Agenerase	brand	386-394	rifadin	brand	538-544	false
Agenerase	brand	386-394	rifampin	drug	547-554	false
Agenerase	brand	386-394	temazepam	drug	574-582	false
Agenerase	brand	386-394	theophylline	drug	585-596	false
Agenerase	brand	386-394	Theo-Dur	brand	599-606	false
Agenerase	brand	386-394	vitamin C	drug	614-622	false
Crixivan	brand	397-404	Fortovase	brand	407-415	false
Crixivan	brand	397-404	Invirase	brand	418-425	false
Crixivan	brand	397-404	Kaletra	brand	428-434	false
Crixivan	brand	397-404	Norvir	brand	437-442	false
Crixivan	brand	397-404	Viracept	brand	445-452	false
Crixivan	brand	397-404	morphine	drug	456-463	false
Crixivan	brand	397-404	Astramorph	brand	466-475	false
Crixivan	brand	397-404	Kadian	brand	478-483	false
Crixivan	brand	397-404	MS Contin	brand	486-494	false
Crixivan	brand	397-404	phenylbutazone	drug	498-511	false
Crixivan	brand	397-404	prednisolone	drug	514-525	false
Crixivan	brand	397-404	Prelone	brand	528-534	false
Crixivan	brand	397-404	rifadin	brand	538-544	false
Crixivan	brand	397-404	rifampin	drug	547-554	false
Crixivan	brand	397-404	temazepam	drug	574-582	false
Crixivan	brand	397-404	theophylline	drug	585-596	false
Crixivan	brand	397-404	Theo-Dur	brand	599-606	false
Crixivan	brand	397-404	vitamin C	drug	614-622	false
Fortovase	brand	407-415	Invirase	brand	418-425	false
Fortovase	brand	407-415	Kaletra	brand	428-434	false
Fortovase	brand	407-415	Norvir	brand	437-442	false
Fortovase	brand	407-415	Viracept	brand	445-452	false
Fortovase	brand	407-415	morphine	drug	456-463	false
Fortovase	brand	407-415	Astramorph	brand	466-475	false
Fortovase	brand	407-415	Kadian	brand	478-483	false
Fortovase	brand	407-415	MS Contin	brand	486-494	false
Fortovase	brand	407-415	phenylbutazone	drug	498-511	false
Fortovase	brand	407-415	prednisolone	drug	514-525	false
Fortovase	brand	407-415	Prelone	brand	528-534	false
Fortovase	brand	407-415	rifadin	brand	538-544	false
Fortovase	brand	407-415	rifampin	drug	547-554	false
Fortovase	brand	407-415	temazepam	drug	574-582	false
Fortovase	brand	407-415	theophylline	drug	585-596	false
Fortovase	brand	407-415	Theo-Dur	brand	599-606	false
Fortovase	brand	407-415	vitamin C	drug	614-622	false
Invirase	brand	418-425	Kaletra	brand	428-434	false
Invirase	brand	418-425	Norvir	brand	437-442	false
Invirase	brand	418-425	Viracept	brand	445-452	false
Invirase	brand	418-425	morphine	drug	456-463	false
Invirase	brand	418-425	Astramorph	brand	466-475	false
Invirase	brand	418-425	Kadian	brand	478-483	false
Invirase	brand	418-425	MS Contin	brand	486-494	false
Invirase	brand	418-425	phenylbutazone	drug	498-511	false
Invirase	brand	418-425	prednisolone	drug	514-525	false
Invirase	brand	418-425	Prelone	brand	528-534	false
Invirase	brand	418-425	rifadin	brand	538-544	false
Invirase	brand	418-425	rifampin	drug	547-554	false
Invirase	brand	418-425	temazepam	drug	574-582	false
Invirase	brand	418-425	theophylline	drug	585-596	false
Invirase	brand	418-425	Theo-Dur	brand	599-606	false
Invirase	brand	418-425	vitamin C	drug	614-622	false
Kaletra	brand	428-434	Norvir	brand	437-442	false
Kaletra	brand	428-434	Viracept	brand	445-452	false
Kaletra	brand	428-434	morphine	drug	456-463	false
Kaletra	brand	428-434	Astramorph	brand	466-475	false
Kaletra	brand	428-434	Kadian	brand	478-483	false
Kaletra	brand	428-434	MS Contin	brand	486-494	false
Kaletra	brand	428-434	phenylbutazone	drug	498-511	false
Kaletra	brand	428-434	prednisolone	drug	514-525	false
Kaletra	brand	428-434	Prelone	brand	528-534	false
Kaletra	brand	428-434	rifadin	brand	538-544	false
Kaletra	brand	428-434	rifampin	drug	547-554	false
Kaletra	brand	428-434	temazepam	drug	574-582	false
Kaletra	brand	428-434	theophylline	drug	585-596	false
Kaletra	brand	428-434	Theo-Dur	brand	599-606	false
Kaletra	brand	428-434	vitamin C	drug	614-622	false
Norvir	brand	437-442	Viracept	brand	445-452	false
Norvir	brand	437-442	morphine	drug	456-463	false
Norvir	brand	437-442	Astramorph	brand	466-475	false
Norvir	brand	437-442	Kadian	brand	478-483	false
Norvir	brand	437-442	MS Contin	brand	486-494	false
Norvir	brand	437-442	phenylbutazone	drug	498-511	false
Norvir	brand	437-442	prednisolone	drug	514-525	false
Norvir	brand	437-442	Prelone	brand	528-534	false
Norvir	brand	437-442	rifadin	brand	538-544	false
Norvir	brand	437-442	rifampin	drug	547-554	false
Norvir	brand	437-442	temazepam	drug	574-582	false
Norvir	brand	437-442	theophylline	drug	585-596	false
Norvir	brand	437-442	Theo-Dur	brand	599-606	false
Norvir	brand	437-442	vitamin C	drug	614-622	false
Viracept	brand	445-452	morphine	drug	456-463	false
Viracept	brand	445-452	Astramorph	brand	466-475	false
Viracept	brand	445-452	Kadian	brand	478-483	false
Viracept	brand	445-452	MS Contin	brand	486-494	false
Viracept	brand	445-452	phenylbutazone	drug	498-511	false
Viracept	brand	445-452	prednisolone	drug	514-525	false
Viracept	brand	445-452	Prelone	brand	528-534	false
Viracept	brand	445-452	rifadin	brand	538-544	false
Viracept	brand	445-452	rifampin	drug	547-554	false
Viracept	brand	445-452	temazepam	drug	574-582	false
Viracept	brand	445-452	theophylline	drug	585-596	false
Viracept	brand	445-452	Theo-Dur	brand	599-606	false
Viracept	brand	445-452	vitamin C	drug	614-622	false
morphine	drug	456-463	Astramorph	brand	466-475	false
morphine	drug	456-463	Kadian	brand	478-483	false
morphine	drug	456-463	MS Contin	brand	486-494	false
morphine	drug	456-463	phenylbutazone	drug	498-511	false
morphine	drug	456-463	prednisolone	drug	514-525	false
morphine	drug	456-463	Prelone	brand	528-534	false
morphine	drug	456-463	rifadin	brand	538-544	false
morphine	drug	456-463	rifampin	drug	547-554	false
morphine	drug	456-463	temazepam	drug	574-582	false
morphine	drug	456-463	theophylline	drug	585-596	false
morphine	drug	456-463	Theo-Dur	brand	599-606	false
morphine	drug	456-463	vitamin C	drug	614-622	false
Astramorph	brand	466-475	Kadian	brand	478-483	false
Astramorph	brand	466-475	MS Contin	brand	486-494	false
Astramorph	brand	466-475	phenylbutazone	drug	498-511	false
Astramorph	brand	466-475	prednisolone	drug	514-525	false
Astramorph	brand	466-475	Prelone	brand	528-534	false
Astramorph	brand	466-475	rifadin	brand	538-544	false
Astramorph	brand	466-475	rifampin	drug	547-554	false
Astramorph	brand	466-475	temazepam	drug	574-582	false
Astramorph	brand	466-475	theophylline	drug	585-596	false
Astramorph	brand	466-475	Theo-Dur	brand	599-606	false
Astramorph	brand	466-475	vitamin C	drug	614-622	false
Kadian	brand	478-483	MS Contin	brand	486-494	false
Kadian	brand	478-483	phenylbutazone	drug	498-511	false
Kadian	brand	478-483	prednisolone	drug	514-525	false
Kadian	brand	478-483	Prelone	brand	528-534	false
Kadian	brand	478-483	rifadin	brand	538-544	false
Kadian	brand	478-483	rifampin	drug	547-554	false
Kadian	brand	478-483	temazepam	drug	574-582	false
Kadian	brand	478-483	theophylline	drug	585-596	false
Kadian	brand	478-483	Theo-Dur	brand	599-606	false
Kadian	brand	478-483	vitamin C	drug	614-622	false
MS Contin	brand	486-494	phenylbutazone	drug	498-511	false
MS Contin	brand	486-494	prednisolone	drug	514-525	false
MS Contin	brand	486-494	Prelone	brand	528-534	false
MS Contin	brand	486-494	rifadin	brand	538-544	false
MS Contin	brand	486-494	rifampin	drug	547-554	false
MS Contin	brand	486-494	temazepam	drug	574-582	false
MS Contin	brand	486-494	theophylline	drug	585-596	false
MS Contin	brand	486-494	Theo-Dur	brand	599-606	false
MS Contin	brand	486-494	vitamin C	drug	614-622	false
phenylbutazone	drug	498-511	prednisolone	drug	514-525	false
phenylbutazone	drug	498-511	Prelone	brand	528-534	false
phenylbutazone	drug	498-511	rifadin	brand	538-544	false
phenylbutazone	drug	498-511	rifampin	drug	547-554	false
phenylbutazone	drug	498-511	temazepam	drug	574-582	false
phenylbutazone	drug	498-511	theophylline	drug	585-596	false
phenylbutazone	drug	498-511	Theo-Dur	brand	599-606	false
phenylbutazone	drug	498-511	vitamin C	drug	614-622	false
prednisolone	drug	514-525	Prelone	brand	528-534	false
prednisolone	drug	514-525	rifadin	brand	538-544	false
prednisolone	drug	514-525	rifampin	drug	547-554	false
prednisolone	drug	514-525	temazepam	drug	574-582	false
prednisolone	drug	514-525	theophylline	drug	585-596	false
prednisolone	drug	514-525	Theo-Dur	brand	599-606	false
prednisolone	drug	514-525	vitamin C	drug	614-622	false
Prelone	brand	528-534	rifadin	brand	538-544	false
Prelone	brand	528-534	rifampin	drug	547-554	false
Prelone	brand	528-534	temazepam	drug	574-582	false
Prelone	brand	528-534	theophylline	drug	585-596	false
Prelone	brand	528-534	Theo-Dur	brand	599-606	false
Prelone	brand	528-534	vitamin C	drug	614-622	false
rifadin	brand	538-544	rifampin	drug	547-554	false
rifadin	brand	538-544	temazepam	drug	574-582	false
rifadin	brand	538-544	theophylline	drug	585-596	false
rifadin	brand	538-544	Theo-Dur	brand	599-606	false
rifadin	brand	538-544	vitamin C	drug	614-622	false
rifampin	drug	547-554	temazepam	drug	574-582	false
rifampin	drug	547-554	theophylline	drug	585-596	false
rifampin	drug	547-554	Theo-Dur	brand	599-606	false
rifampin	drug	547-554	vitamin C	drug	614-622	false
temazepam	drug	574-582	theophylline	drug	585-596	false
temazepam	drug	574-582	Theo-Dur	brand	599-606	false
temazepam	drug	574-582	vitamin C	drug	614-622	false
theophylline	drug	585-596	Theo-Dur	brand	599-606	false
theophylline	drug	585-596	vitamin C	drug	614-622	false
Theo-Dur	brand	599-606	vitamin C	drug	614-622	false

DDI-DrugBank.d322.s0	Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
Amantadine	drug	0-9	tricyclic antidepressants	group	12-36	false
Amantadine	drug	0-9	MAOIs	group	43-47	false
Amantadine	drug	0-9	clidinium	drug	88-96	effect
tricyclic antidepressants	group	12-36	MAOIs	group	43-47	false
tricyclic antidepressants	group	12-36	clidinium	drug	88-96	effect
MAOIs	group	43-47	clidinium	drug	88-96	effect

DDI-DrugBank.d322.s1	Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
Clidinium	drug	0-8	phenothiazines	group	37-50	effect
Clidinium	drug	0-8	levodopa	drug	53-60	effect
Clidinium	drug	0-8	ketoconazole	drug	67-78	effect
phenothiazines	group	37-50	levodopa	drug	53-60	false
phenothiazines	group	37-50	ketoconazole	drug	67-78	false
levodopa	drug	53-60	ketoconazole	drug	67-78	false

DDI-DrugBank.d415.s0	Coumarin-Type Anticoagulants: Several short-term controlled studies failed to wshow that ibuprofen significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants.
Coumarin-Type Anticoagulants	group	0-27	ibuprofen	drug	89-97	false
Coumarin-Type Anticoagulants	group	0-27	coumarin-type anticoagulants	group	215-242	false
ibuprofen	drug	89-97	coumarin-type anticoagulants	group	215-242	false

DDI-DrugBank.d415.s1	However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
ibuprofen	drug	49-57	nonsteroidal anti-inflammatory agents	group	69-105	false
ibuprofen	drug	49-57	coumarin-type anticoagulants	group	145-172	effect
ibuprofen	drug	49-57	ibuprofen	drug	227-235	false
ibuprofen	drug	49-57	anticoagulants	group	252-265	false
nonsteroidal anti-inflammatory agents	group	69-105	coumarin-type anticoagulants	group	145-172	effect
nonsteroidal anti-inflammatory agents	group	69-105	ibuprofen	drug	227-235	false
nonsteroidal anti-inflammatory agents	group	69-105	anticoagulants	group	252-265	false
coumarin-type anticoagulants	group	145-172	ibuprofen	drug	227-235	false
coumarin-type anticoagulants	group	145-172	anticoagulants	group	252-265	false
ibuprofen	drug	227-235	anticoagulants	group	252-265	advise

DDI-DrugBank.d415.s2	Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
Aspirin	brand	0-6	aspirin	brand	35-41	false
Aspirin	brand	0-6	nonsteroidal anti-inflammatory agents	group	54-90	false
Aspirin	brand	0-6	ibuprofen	drug	103-111	false
aspirin	brand	35-41	nonsteroidal anti-inflammatory agents	group	54-90	effect
aspirin	brand	35-41	ibuprofen	drug	103-111	effect
nonsteroidal anti-inflammatory agents	group	54-90	ibuprofen	drug	103-111	false

DDI-DrugBank.d415.s3	Single dose bioavailability studies in normal volunteers have failed to wshow an effect of aspirin on ibuprofen blood levels.
aspirin	brand	91-97	ibuprofen	drug	102-110	false

DDI-DrugBank.d415.s5	Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
Methotrexate	drug	0-11	Ibuprofen	drug	14-22	false
Methotrexate	drug	0-11	nonsteroidal anti-inflammatory drugs	group	42-77	false
Methotrexate	drug	0-11	methotrexate	drug	122-133	false
Ibuprofen	drug	14-22	nonsteroidal anti-inflammatory drugs	group	42-77	false
Ibuprofen	drug	14-22	methotrexate	drug	122-133	mechanism
nonsteroidal anti-inflammatory drugs	group	42-77	methotrexate	drug	122-133	mechanism

DDI-DrugBank.d415.s6	This may indicate that ibuprofen could enhance the toxicity of methotrexate.
ibuprofen	drug	23-31	methotrexate	drug	63-74	effect

DDI-DrugBank.d415.s7	Caution should be used if ibuprofen is administered concomitantly with methotrexate.
ibuprofen	drug	26-34	methotrexate	drug	71-82	advise

DDI-DrugBank.d415.s8	H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.
cimetidine	drug	72-81	ranitidine	drug	86-95	false
cimetidine	drug	72-81	ibuprofen	drug	102-110	false
cimetidine	drug	72-81	ibuprofen	drug	141-149	false
ranitidine	drug	86-95	ibuprofen	drug	102-110	false
ranitidine	drug	86-95	ibuprofen	drug	141-149	false
ibuprofen	drug	102-110	ibuprofen	drug	141-149	false

DDI-DrugBank.d415.s9	Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	drug	0-9	ibuprofen	drug	78-86	false
Furosemide	drug	0-9	furosemide	drug	125-134	false
Furosemide	drug	0-9	thiazides	group	140-148	false
ibuprofen	drug	78-86	furosemide	drug	125-134	effect
ibuprofen	drug	78-86	thiazides	group	140-148	effect
furosemide	drug	125-134	thiazides	group	140-148	false

DDI-DrugBank.d415.s11	During concomitant therapy with ibuprofen, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
ibuprofen	drug	32-40	diuretic	group	131-138	false

DDI-DrugBank.d415.s12	Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
Lithium	drug	0-6	Ibuprofen	drug	9-17	false
Lithium	drug	0-6	lithium	drug	51-57	false
Lithium	drug	0-6	lithium	drug	91-97	false
Ibuprofen	drug	9-17	lithium	drug	51-57	mechanism
Ibuprofen	drug	9-17	lithium	drug	91-97	false
lithium	drug	51-57	lithium	drug	91-97	false

DDI-DrugBank.d415.s13	The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.
lithium	drug	17-23	lithium	drug	80-86	false

DDI-DrugBank.d415.s15	Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
ibuprofen	drug	11-19	lithium	drug	25-31	advise
ibuprofen	drug	11-19	lithium	drug	115-121	false
lithium	drug	25-31	lithium	drug	115-121	false

DDI-DrugBank.d373.s0	Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.
Beta-adrenergic Blocking Agents	group	0-30	nifedipine	drug	147-156	false
Beta-adrenergic Blocking Agents	group	0-30	beta-blocking agents	group	162-181	false
nifedipine	drug	147-156	beta-blocking agents	group	162-181	effect

DDI-DrugBank.d373.s1	Long Acting Nitrates: Nifedipine may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
Nitrates	group	12-19	Nifedipine	drug	22-31	false
Nitrates	group	12-19	nitrates	group	68-75	false
Nifedipine	drug	22-31	nitrates	group	68-75	false

DDI-DrugBank.d373.s2	Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
Digitalis	group	0-8	digoxin	drug	104-110	false
Digitalis	group	0-8	digoxin	drug	164-170	false
Digitalis	group	0-8	nifedipine	drug	176-185	false
Digitalis	group	0-8	digoxin	drug	211-217	false
Digitalis	group	0-8	nifedipine	drug	285-294	false
digoxin	drug	104-110	digoxin	drug	164-170	false
digoxin	drug	104-110	nifedipine	drug	176-185	false
digoxin	drug	104-110	digoxin	drug	211-217	false
digoxin	drug	104-110	nifedipine	drug	285-294	false
digoxin	drug	164-170	nifedipine	drug	176-185	int
digoxin	drug	164-170	digoxin	drug	211-217	false
digoxin	drug	164-170	nifedipine	drug	285-294	false
nifedipine	drug	176-185	digoxin	drug	211-217	false
nifedipine	drug	176-185	nifedipine	drug	285-294	false
digoxin	drug	211-217	nifedipine	drug	285-294	advise

DDI-DrugBank.d373.s3	Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.
nifedipine	drug	44-53	digoxin	drug	60-66	false
nifedipine	drug	44-53	digoxin	drug	78-84	false
digoxin	drug	60-66	digoxin	drug	78-84	mechanism

DDI-DrugBank.d373.s7	Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
digoxin	drug	65-71	digoxin	drug	104-110	false
digoxin	drug	65-71	nifedipine	drug	178-187	false
digoxin	drug	104-110	nifedipine	drug	178-187	advise

DDI-DrugBank.d373.s8	Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).
Quinidine	drug	0-8	quinidine	drug	94-102	false
Quinidine	drug	0-8	nifedipine	drug	108-117	false
Quinidine	drug	0-8	quinidine	drug	153-161	false
quinidine	drug	94-102	nifedipine	drug	108-117	mechanism
quinidine	drug	94-102	quinidine	drug	153-161	false
nifedipine	drug	108-117	quinidine	drug	153-161	false

DDI-DrugBank.d373.s9	Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.
Coumarin Anticoagulants	group	0-22	coumarin anticoagulants	group	103-125	false
Coumarin Anticoagulants	group	0-22	nifedipine	drug	135-144	false
coumarin anticoagulants	group	103-125	nifedipine	drug	135-144	effect

DDI-DrugBank.d373.s11	Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.
Cimetidine	drug	0-9	nifedipine	drug	85-94	false
Cimetidine	drug	0-9	cimetidine	drug	172-181	false
Cimetidine	drug	0-9	nifedipine	drug	206-215	false
nifedipine	drug	85-94	cimetidine	drug	172-181	false
nifedipine	drug	85-94	nifedipine	drug	206-215	false
cimetidine	drug	172-181	nifedipine	drug	206-215	mechanism

DDI-DrugBank.d373.s13	The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of nifedipine.
cimetidine	drug	54-63	nifedipine	drug	166-175	false

DDI-DrugBank.d373.s14	If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.
nifedipine	drug	3-12	cimetidine	drug	68-77	advise

DDI-DrugBank.d461.s0	Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.
anesthetics	group	50-60	sedatives	group	63-71	false
anesthetics	group	50-60	antianxiety drugs	group	74-90	false
anesthetics	group	50-60	hypnotics	group	93-101	false
anesthetics	group	50-60	alcohol	drug	104-110	false
anesthetics	group	50-60	opiate analgesics	group	123-139	false
sedatives	group	63-71	antianxiety drugs	group	74-90	false
sedatives	group	63-71	hypnotics	group	93-101	false
sedatives	group	63-71	alcohol	drug	104-110	false
sedatives	group	63-71	opiate analgesics	group	123-139	false
antianxiety drugs	group	74-90	hypnotics	group	93-101	false
antianxiety drugs	group	74-90	alcohol	drug	104-110	false
antianxiety drugs	group	74-90	opiate analgesics	group	123-139	false
hypnotics	group	93-101	alcohol	drug	104-110	false
hypnotics	group	93-101	opiate analgesics	group	123-139	false
alcohol	drug	104-110	opiate analgesics	group	123-139	false

DDI-DrugBank.d381.s0	ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
ERGAMISOL	brand	0-8	levamisole hydrochloride	drug	12-35	false
ERGAMISOL	brand	0-8	alcohol	drug	124-130	effect
levamisole hydrochloride	drug	12-35	alcohol	drug	124-130	effect

DDI-DrugBank.d381.s2	Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.
levamisole	drug	118-127	warfarin sodium	drug	133-147	advise
levamisole	drug	118-127	warfarin sodium	drug	232-246	false
levamisole	drug	118-127	coumarin	group	257-264	false
warfarin sodium	drug	133-147	warfarin sodium	drug	232-246	false
warfarin sodium	drug	133-147	coumarin	group	257-264	false
warfarin sodium	drug	232-246	coumarin	group	257-264	false

DDI-DrugBank.d95.s0	Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.
Cyclosporine	drug	0-11	L-arginine	drug	15-24	false
Cyclosporine	drug	0-11	cyclosporin	drug	69-79	false
L-arginine	drug	15-24	cyclosporin	drug	69-79	effect

DDI-DrugBank.d95.s1	Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.
Ibuprofen	drug	0-8	L-arginine	drug	12-21	false
Ibuprofen	drug	0-8	ibuprofen	drug	54-62	false
L-arginine	drug	12-21	ibuprofen	drug	54-62	mechanism

DDI-DrugBank.d95.s2	Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.
nitrates	group	8-15	L-arginine	drug	19-28	false
nitrates	group	8-15	nitrates	drug	94-101	false
L-arginine	drug	19-28	nitrates	drug	94-101	effect

DDI-DrugBank.d95.s3	Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.
Sildenafil citrate	drug	0-17	L-arginine	drug	36-45	false
Sildenafil citrate	drug	0-17	sildenafil citrate	drug	84-101	false
L-arginine	drug	36-45	sildenafil citrate	drug	84-101	effect

DDI-DrugBank.d472.s0	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
Central nervous system depressant	group	0-32	alcohol	drug	56-62	false
Central nervous system depressant	group	0-32	antidepressants	group	65-79	false
Central nervous system depressant	group	0-32	antihistamines	group	82-95	false
Central nervous system depressant	group	0-32	antipsychotics	group	98-111	false
Central nervous system depressant	group	0-32	reserpine	drug	142-150	false
Central nervous system depressant	group	0-32	methyldopa	drug	153-162	false
Central nervous system depressant	group	0-32	beta-blockers	group	165-177	false
Central nervous system depressant	group	0-32	muscle relaxants	group	210-225	false
Central nervous system depressant	group	0-32	narcotics	group	228-236	false
Central nervous system depressant	group	0-32	sedatives	group	239-247	false
Central nervous system depressant	group	0-32	tranquilizers	group	269-281	false
alcohol	drug	56-62	antidepressants	group	65-79	false
alcohol	drug	56-62	antihistamines	group	82-95	false
alcohol	drug	56-62	antipsychotics	group	98-111	false
alcohol	drug	56-62	reserpine	drug	142-150	false
alcohol	drug	56-62	methyldopa	drug	153-162	false
alcohol	drug	56-62	beta-blockers	group	165-177	false
alcohol	drug	56-62	muscle relaxants	group	210-225	false
alcohol	drug	56-62	narcotics	group	228-236	false
alcohol	drug	56-62	sedatives	group	239-247	false
alcohol	drug	56-62	tranquilizers	group	269-281	false
antidepressants	group	65-79	antihistamines	group	82-95	false
antidepressants	group	65-79	antipsychotics	group	98-111	false
antidepressants	group	65-79	reserpine	drug	142-150	false
antidepressants	group	65-79	methyldopa	drug	153-162	false
antidepressants	group	65-79	beta-blockers	group	165-177	false
antidepressants	group	65-79	muscle relaxants	group	210-225	false
antidepressants	group	65-79	narcotics	group	228-236	false
antidepressants	group	65-79	sedatives	group	239-247	false
antidepressants	group	65-79	tranquilizers	group	269-281	false
antihistamines	group	82-95	antipsychotics	group	98-111	false
antihistamines	group	82-95	reserpine	drug	142-150	false
antihistamines	group	82-95	methyldopa	drug	153-162	false
antihistamines	group	82-95	beta-blockers	group	165-177	false
antihistamines	group	82-95	muscle relaxants	group	210-225	false
antihistamines	group	82-95	narcotics	group	228-236	false
antihistamines	group	82-95	sedatives	group	239-247	false
antihistamines	group	82-95	tranquilizers	group	269-281	false
antipsychotics	group	98-111	reserpine	drug	142-150	false
antipsychotics	group	98-111	methyldopa	drug	153-162	false
antipsychotics	group	98-111	beta-blockers	group	165-177	false
antipsychotics	group	98-111	muscle relaxants	group	210-225	false
antipsychotics	group	98-111	narcotics	group	228-236	false
antipsychotics	group	98-111	sedatives	group	239-247	false
antipsychotics	group	98-111	tranquilizers	group	269-281	false
reserpine	drug	142-150	methyldopa	drug	153-162	false
reserpine	drug	142-150	beta-blockers	group	165-177	false
reserpine	drug	142-150	muscle relaxants	group	210-225	false
reserpine	drug	142-150	narcotics	group	228-236	false
reserpine	drug	142-150	sedatives	group	239-247	false
reserpine	drug	142-150	tranquilizers	group	269-281	false
methyldopa	drug	153-162	beta-blockers	group	165-177	false
methyldopa	drug	153-162	muscle relaxants	group	210-225	false
methyldopa	drug	153-162	narcotics	group	228-236	false
methyldopa	drug	153-162	sedatives	group	239-247	false
methyldopa	drug	153-162	tranquilizers	group	269-281	false
beta-blockers	group	165-177	muscle relaxants	group	210-225	false
beta-blockers	group	165-177	narcotics	group	228-236	false
beta-blockers	group	165-177	sedatives	group	239-247	false
beta-blockers	group	165-177	tranquilizers	group	269-281	false
muscle relaxants	group	210-225	narcotics	group	228-236	false
muscle relaxants	group	210-225	sedatives	group	239-247	false
muscle relaxants	group	210-225	tranquilizers	group	269-281	false
narcotics	group	228-236	sedatives	group	239-247	false
narcotics	group	228-236	tranquilizers	group	269-281	false
sedatives	group	239-247	tranquilizers	group	269-281	false

DDI-DrugBank.d200.s0	Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
probenecid	drug	21-30	acyclovir	drug	37-45	mechanism

DDI-DrugBank.d556.s0	Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
cephalosporins	group	83-96	aminoglycoside antibiotics	group	102-127	effect

DDI-DrugBank.d556.s1	Drug/Laboratory Test Interactions As with cephalothin, high concentrations of cefoxitin ( 100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff  reaction, and produce false increases of modest degree in the levels of creatinine reported.
cephalothin	drug	42-52	cefoxitin	drug	78-86	false

DDI-DrugBank.d242.s1	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
quinolones	group	45-54	theophylline	drug	107-118	mechanism
quinolones	group	45-54	caffeine	drug	154-161	mechanism
quinolones	group	45-54	anticoagulant	group	200-212	false
quinolones	group	45-54	warfarin	drug	214-221	effect
quinolones	group	45-54	cyclosporine	drug	345-356	effect
theophylline	drug	107-118	caffeine	drug	154-161	false
theophylline	drug	107-118	anticoagulant	group	200-212	false
theophylline	drug	107-118	warfarin	drug	214-221	false
theophylline	drug	107-118	cyclosporine	drug	345-356	false
caffeine	drug	154-161	anticoagulant	group	200-212	false
caffeine	drug	154-161	warfarin	drug	214-221	false
caffeine	drug	154-161	cyclosporine	drug	345-356	false
anticoagulant	group	200-212	warfarin	drug	214-221	false
anticoagulant	group	200-212	cyclosporine	drug	345-356	false
warfarin	drug	214-221	cyclosporine	drug	345-356	false

DDI-DrugBank.d449.s0	Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended.
antifungal agents	group	23-39	ketoconazole	drug	49-60	false
antifungal agents	group	23-39	itraconazole	drug	65-76	false
ketoconazole	drug	49-60	itraconazole	drug	65-76	false

DDI-DrugBank.d449.s1	Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
Nafazodone	drug	0-9	fluvoxamine	drug	12-22	false
Nafazodone	drug	0-9	cimetidine	drug	25-34	false
Nafazodone	drug	0-9	Xanax	brand	46-50	advise
fluvoxamine	drug	12-22	cimetidine	drug	25-34	false
fluvoxamine	drug	12-22	Xanax	brand	46-50	advise
cimetidine	drug	25-34	Xanax	brand	46-50	advise

DDI-DrugBank.d449.s2	Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).
Fluoxetine	drug	0-9	OCs	group	12-14	false
Fluoxetine	drug	0-9	sertraline	drug	17-26	false
Fluoxetine	drug	0-9	diltiazem	drug	29-37	false
Fluoxetine	drug	0-9	macrolide antibiotics	group	40-60	false
OCs	group	12-14	sertraline	drug	17-26	false
OCs	group	12-14	diltiazem	drug	29-37	false
OCs	group	12-14	macrolide antibiotics	group	40-60	false
sertraline	drug	17-26	diltiazem	drug	29-37	false
sertraline	drug	17-26	macrolide antibiotics	group	40-60	false
diltiazem	drug	29-37	macrolide antibiotics	group	40-60	false

DDI-DrugBank.d274.s0	Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.
dobutamine	drug	29-38	b-blocking drug	group	98-112	effect

DDI-DrugBank.d274.s2	Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
dobutamine	drug	57-66	nitroprusside	drug	72-84	effect

DDI-DrugBank.d274.s3	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
dobutamine	drug	72-81	digitalis preparations	group	141-162	false
dobutamine	drug	72-81	furosemide	drug	165-174	false
dobutamine	drug	72-81	spironolactone	drug	177-190	false
dobutamine	drug	72-81	lidocaine	drug	193-201	false
dobutamine	drug	72-81	glyceryl trinitrate	drug	204-222	false
dobutamine	drug	72-81	isosorbide dinitrate	drug	225-244	false
dobutamine	drug	72-81	morphine	drug	247-254	false
dobutamine	drug	72-81	atropine	drug	257-264	false
dobutamine	drug	72-81	heparin	drug	267-273	false
dobutamine	drug	72-81	protamine	drug	276-284	false
dobutamine	drug	72-81	potassium chloride	drug	287-304	false
dobutamine	drug	72-81	folic acid	drug	307-316	false
dobutamine	drug	72-81	acetaminophen	drug	323-335	false
digitalis preparations	group	141-162	furosemide	drug	165-174	false
digitalis preparations	group	141-162	spironolactone	drug	177-190	false
digitalis preparations	group	141-162	lidocaine	drug	193-201	false
digitalis preparations	group	141-162	glyceryl trinitrate	drug	204-222	false
digitalis preparations	group	141-162	isosorbide dinitrate	drug	225-244	false
digitalis preparations	group	141-162	morphine	drug	247-254	false
digitalis preparations	group	141-162	atropine	drug	257-264	false
digitalis preparations	group	141-162	heparin	drug	267-273	false
digitalis preparations	group	141-162	protamine	drug	276-284	false
digitalis preparations	group	141-162	potassium chloride	drug	287-304	false
digitalis preparations	group	141-162	folic acid	drug	307-316	false
digitalis preparations	group	141-162	acetaminophen	drug	323-335	false
furosemide	drug	165-174	spironolactone	drug	177-190	false
furosemide	drug	165-174	lidocaine	drug	193-201	false
furosemide	drug	165-174	glyceryl trinitrate	drug	204-222	false
furosemide	drug	165-174	isosorbide dinitrate	drug	225-244	false
furosemide	drug	165-174	morphine	drug	247-254	false
furosemide	drug	165-174	atropine	drug	257-264	false
furosemide	drug	165-174	heparin	drug	267-273	false
furosemide	drug	165-174	protamine	drug	276-284	false
furosemide	drug	165-174	potassium chloride	drug	287-304	false
furosemide	drug	165-174	folic acid	drug	307-316	false
furosemide	drug	165-174	acetaminophen	drug	323-335	false
spironolactone	drug	177-190	lidocaine	drug	193-201	false
spironolactone	drug	177-190	glyceryl trinitrate	drug	204-222	false
spironolactone	drug	177-190	isosorbide dinitrate	drug	225-244	false
spironolactone	drug	177-190	morphine	drug	247-254	false
spironolactone	drug	177-190	atropine	drug	257-264	false
spironolactone	drug	177-190	heparin	drug	267-273	false
spironolactone	drug	177-190	protamine	drug	276-284	false
spironolactone	drug	177-190	potassium chloride	drug	287-304	false
spironolactone	drug	177-190	folic acid	drug	307-316	false
spironolactone	drug	177-190	acetaminophen	drug	323-335	false
lidocaine	drug	193-201	glyceryl trinitrate	drug	204-222	false
lidocaine	drug	193-201	isosorbide dinitrate	drug	225-244	false
lidocaine	drug	193-201	morphine	drug	247-254	false
lidocaine	drug	193-201	atropine	drug	257-264	false
lidocaine	drug	193-201	heparin	drug	267-273	false
lidocaine	drug	193-201	protamine	drug	276-284	false
lidocaine	drug	193-201	potassium chloride	drug	287-304	false
lidocaine	drug	193-201	folic acid	drug	307-316	false
lidocaine	drug	193-201	acetaminophen	drug	323-335	false
glyceryl trinitrate	drug	204-222	isosorbide dinitrate	drug	225-244	false
glyceryl trinitrate	drug	204-222	morphine	drug	247-254	false
glyceryl trinitrate	drug	204-222	atropine	drug	257-264	false
glyceryl trinitrate	drug	204-222	heparin	drug	267-273	false
glyceryl trinitrate	drug	204-222	protamine	drug	276-284	false
glyceryl trinitrate	drug	204-222	potassium chloride	drug	287-304	false
glyceryl trinitrate	drug	204-222	folic acid	drug	307-316	false
glyceryl trinitrate	drug	204-222	acetaminophen	drug	323-335	false
isosorbide dinitrate	drug	225-244	morphine	drug	247-254	false
isosorbide dinitrate	drug	225-244	atropine	drug	257-264	false
isosorbide dinitrate	drug	225-244	heparin	drug	267-273	false
isosorbide dinitrate	drug	225-244	protamine	drug	276-284	false
isosorbide dinitrate	drug	225-244	potassium chloride	drug	287-304	false
isosorbide dinitrate	drug	225-244	folic acid	drug	307-316	false
isosorbide dinitrate	drug	225-244	acetaminophen	drug	323-335	false
morphine	drug	247-254	atropine	drug	257-264	false
morphine	drug	247-254	heparin	drug	267-273	false
morphine	drug	247-254	protamine	drug	276-284	false
morphine	drug	247-254	potassium chloride	drug	287-304	false
morphine	drug	247-254	folic acid	drug	307-316	false
morphine	drug	247-254	acetaminophen	drug	323-335	false
atropine	drug	257-264	heparin	drug	267-273	false
atropine	drug	257-264	protamine	drug	276-284	false
atropine	drug	257-264	potassium chloride	drug	287-304	false
atropine	drug	257-264	folic acid	drug	307-316	false
atropine	drug	257-264	acetaminophen	drug	323-335	false
heparin	drug	267-273	protamine	drug	276-284	false
heparin	drug	267-273	potassium chloride	drug	287-304	false
heparin	drug	267-273	folic acid	drug	307-316	false
heparin	drug	267-273	acetaminophen	drug	323-335	false
protamine	drug	276-284	potassium chloride	drug	287-304	false
protamine	drug	276-284	folic acid	drug	307-316	false
protamine	drug	276-284	acetaminophen	drug	323-335	false
potassium chloride	drug	287-304	folic acid	drug	307-316	false
potassium chloride	drug	287-304	acetaminophen	drug	323-335	false
folic acid	drug	307-316	acetaminophen	drug	323-335	false

DDI-DrugBank.d434.s1	Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
Antiepileptic Drugs	group	30-48	Felbatol	brand	67-74	false
Antiepileptic Drugs	group	30-48	antiepileptic drugs	group	80-98	false
Antiepileptic Drugs	group	30-48	AEDs	group	101-104	false
Antiepileptic Drugs	group	30-48	AEDs	group	157-160	false
Felbatol	brand	67-74	antiepileptic drugs	group	80-98	mechanism
Felbatol	brand	67-74	AEDs	group	101-104	mechanism
Felbatol	brand	67-74	AEDs	group	157-160	false
antiepileptic drugs	group	80-98	AEDs	group	101-104	false
antiepileptic drugs	group	80-98	AEDs	group	157-160	false
AEDs	group	101-104	AEDs	group	157-160	false

DDI-DrugBank.d434.s2	The net effect of these interactions is summarized in the following table: AED AED Felbatol
AED	group	75-77	AED	group	79-81	false
AED	group	75-77	Felbatol	brand	83-90	false
AED	group	79-81	Felbatol	brand	83-90	false

DDI-DrugBank.d434.s6	Carbamazepine (CBZ)
Carbamazepine	drug	0-12	CBZ	drug	15-17	false

DDI-DrugBank.d434.s11	Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
Felbatol	brand	20-27	Antiepileptic Drugs	group	39-57	false
Felbatol	brand	20-27	Phenytoin	drug	59-67	false
Felbatol	brand	20-27	Felbatol	brand	70-77	false
Felbatol	brand	20-27	phenytoin	drug	115-123	false
Antiepileptic Drugs	group	39-57	Phenytoin	drug	59-67	false
Antiepileptic Drugs	group	39-57	Felbatol	brand	70-77	false
Antiepileptic Drugs	group	39-57	phenytoin	drug	115-123	false
Phenytoin	drug	59-67	Felbatol	brand	70-77	false
Phenytoin	drug	59-67	phenytoin	drug	115-123	false
Felbatol	brand	70-77	phenytoin	drug	115-123	mechanism

DDI-DrugBank.d434.s12	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steadystate trough (Cmin) phenytoin plasma concentration was 17 5 micrograms/mL.
phenytoin	drug	57-65	phenytoin	drug	98-106	false

DDI-DrugBank.d434.s14	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.
felbamate	drug	15-23	phenytoin	drug	97-105	mechanism

DDI-DrugBank.d434.s15	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.
phenytoin	drug	21-29	felbamate	drug	82-90	false
phenytoin	drug	21-29	phenytoin	drug	115-123	false
felbamate	drug	82-90	phenytoin	drug	115-123	advise

DDI-DrugBank.d434.s16	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.
phenytoin	drug	55-63	Felbatol	brand	91-98	false
phenytoin	drug	55-63	phenytoin	drug	121-129	false
phenytoin	drug	55-63	Felbatol	brand	167-174	false
Felbatol	brand	91-98	phenytoin	drug	121-129	false
Felbatol	brand	91-98	Felbatol	brand	167-174	false
phenytoin	drug	121-129	Felbatol	brand	167-174	false

DDI-DrugBank.d434.s17	Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.
Carbamazepine	drug	0-12	Felbatol	brand	15-22	false
Carbamazepine	drug	0-12	carbamazepine	drug	63-75	false
Carbamazepine	drug	0-12	carbamazepine epoxide	drug_n	135-155	false
Felbatol	brand	15-22	carbamazepine	drug	63-75	mechanism
Felbatol	brand	15-22	carbamazepine epoxide	drug_n	135-155	false
carbamazepine	drug	63-75	carbamazepine epoxide	drug_n	135-155	false

DDI-DrugBank.d434.s18	In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8 2 micrograms/mL.
carbamazepine	drug	59-71	carbamazepine	drug	105-117	false

DDI-DrugBank.d434.s19	The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.
carbamazepine	drug	4-16	felbamate	drug	76-84	mechanism

DDI-DrugBank.d434.s20	Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.0 0.3 to 1.6 0.4 micrograms/mL with the addition of felbamate.
Carbamazepine epoxide	drug_n	0-20	felbamate	drug	128-136	false

DDI-DrugBank.d434.s21	In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen.
carbamazepine	drug	39-51	carbamazepine epoxide	drug_n	57-77	false

DDI-DrugBank.d434.s22	Valproate: Felbatol  causes an increase in steady-state valproate concentrations.
Valproate	drug	0-8	Felbatol	brand	11-18	false
Valproate	drug	0-8	valproate	drug	56-64	false
Felbatol	brand	11-18	valproate	drug	56-64	mechanism

DDI-DrugBank.d434.s23	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63 16 micrograms/mL.
valproate	drug	41-49	valproate	drug	83-91	false

DDI-DrugBank.d434.s25	Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.
felbamate	drug	15-23	valproate	drug	71-79	mechanism

DDI-DrugBank.d434.s26	Corresponding values for free valproate Cmin concentrations were 7 3, 9 4, and 11 6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol , respectively.
valproate	drug	30-38	Felbatol	brand	127-134	false

DDI-DrugBank.d434.s27	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.
valproate	drug	34-42	valproate	drug	69-77	false
valproate	drug	34-42	Felbatol	brand	163-170	false
valproate	drug	69-77	Felbatol	brand	163-170	false

DDI-DrugBank.d434.s28	Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
Phenobarbital	drug	0-12	felbamate	drug	35-43	false
Phenobarbital	drug	0-12	phenobarbital	drug	50-62	false
Phenobarbital	drug	0-12	phenobarbital	drug	86-98	false
Phenobarbital	drug	0-12	phenobarbital	drug	173-185	false
Phenobarbital	drug	0-12	phenobarbital	drug	219-231	false
felbamate	drug	35-43	phenobarbital	drug	50-62	mechanism
felbamate	drug	35-43	phenobarbital	drug	86-98	false
felbamate	drug	35-43	phenobarbital	drug	173-185	false
felbamate	drug	35-43	phenobarbital	drug	219-231	false
phenobarbital	drug	50-62	phenobarbital	drug	86-98	false
phenobarbital	drug	50-62	phenobarbital	drug	173-185	false
phenobarbital	drug	50-62	phenobarbital	drug	219-231	false
phenobarbital	drug	86-98	phenobarbital	drug	173-185	false
phenobarbital	drug	86-98	phenobarbital	drug	219-231	false
phenobarbital	drug	173-185	phenobarbital	drug	219-231	false

DDI-DrugBank.d434.s30	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
Antiepileptic Drugs	group	17-35	Felbatol	brand	40-47	false
Antiepileptic Drugs	group	17-35	Phenytoin	drug	50-58	false
Antiepileptic Drugs	group	17-35	Phenytoin	drug	61-69	false
Antiepileptic Drugs	group	17-35	Felbatol	brand	122-129	false
Antiepileptic Drugs	group	17-35	felbamate	drug	133-141	false
Antiepileptic Drugs	group	17-35	phenytoin	drug	192-200	false
Antiepileptic Drugs	group	17-35	Felbatol	brand	282-289	false
Antiepileptic Drugs	group	17-35	Felbatol	brand	324-331	false
Felbatol	brand	40-47	Phenytoin	drug	50-58	false
Felbatol	brand	40-47	Phenytoin	drug	61-69	false
Felbatol	brand	40-47	Felbatol	brand	122-129	false
Felbatol	brand	40-47	felbamate	drug	133-141	false
Felbatol	brand	40-47	phenytoin	drug	192-200	false
Felbatol	brand	40-47	Felbatol	brand	282-289	false
Felbatol	brand	40-47	Felbatol	brand	324-331	false
Phenytoin	drug	50-58	Phenytoin	drug	61-69	false
Phenytoin	drug	50-58	Felbatol	brand	122-129	false
Phenytoin	drug	50-58	felbamate	drug	133-141	false
Phenytoin	drug	50-58	phenytoin	drug	192-200	false
Phenytoin	drug	50-58	Felbatol	brand	282-289	false
Phenytoin	drug	50-58	Felbatol	brand	324-331	false
Phenytoin	drug	61-69	Felbatol	brand	122-129	mechanism
Phenytoin	drug	61-69	felbamate	drug	133-141	mechanism
Phenytoin	drug	61-69	phenytoin	drug	192-200	false
Phenytoin	drug	61-69	Felbatol	brand	282-289	false
Phenytoin	drug	61-69	Felbatol	brand	324-331	false
Felbatol	brand	122-129	felbamate	drug	133-141	false
Felbatol	brand	122-129	phenytoin	drug	192-200	false
Felbatol	brand	122-129	Felbatol	brand	282-289	false
Felbatol	brand	122-129	Felbatol	brand	324-331	false
felbamate	drug	133-141	phenytoin	drug	192-200	false
felbamate	drug	133-141	Felbatol	brand	282-289	false
felbamate	drug	133-141	Felbatol	brand	324-331	false
phenytoin	drug	192-200	Felbatol	brand	282-289	mechanism
phenytoin	drug	192-200	Felbatol	brand	324-331	false
Felbatol	brand	282-289	Felbatol	brand	324-331	false

DDI-DrugBank.d434.s31	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
Carbamazepine	drug	0-12	Carbamazepine	drug	15-27	false
Carbamazepine	drug	0-12	Felbatol	brand	84-91	false
Carbamazepine	drug	0-12	carbamazepine	drug	142-154	false
Carbamazepine	drug	0-12	Felbatol	brand	240-247	false
Carbamazepine	drug	0-12	Felbatol	brand	282-289	false
Carbamazepine	drug	15-27	Felbatol	brand	84-91	mechanism
Carbamazepine	drug	15-27	carbamazepine	drug	142-154	false
Carbamazepine	drug	15-27	Felbatol	brand	240-247	false
Carbamazepine	drug	15-27	Felbatol	brand	282-289	false
Felbatol	brand	84-91	carbamazepine	drug	142-154	false
Felbatol	brand	84-91	Felbatol	brand	240-247	false
Felbatol	brand	84-91	Felbatol	brand	282-289	false
carbamazepine	drug	142-154	Felbatol	brand	240-247	mechanism
carbamazepine	drug	142-154	Felbatol	brand	282-289	false
Felbatol	brand	240-247	Felbatol	brand	282-289	false

DDI-DrugBank.d434.s32	Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.
Valproate	drug	0-8	valproate	drug	73-81	false
Valproate	drug	0-8	Felbatol	brand	103-110	false
Valproate	drug	0-8	valproate	drug	157-165	false
Valproate	drug	0-8	Felbatol	brand	225-232	false
Valproate	drug	0-8	felbamate	drug	236-244	false
valproate	drug	73-81	Felbatol	brand	103-110	false
valproate	drug	73-81	valproate	drug	157-165	false
valproate	drug	73-81	Felbatol	brand	225-232	false
valproate	drug	73-81	felbamate	drug	236-244	false
Felbatol	brand	103-110	valproate	drug	157-165	false
Felbatol	brand	103-110	Felbatol	brand	225-232	false
Felbatol	brand	103-110	felbamate	drug	236-244	false
valproate	drug	157-165	Felbatol	brand	225-232	false
valproate	drug	157-165	felbamate	drug	236-244	false
Felbatol	brand	225-232	felbamate	drug	236-244	false

DDI-DrugBank.d434.s33	Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.
Phenobarbital	drug	0-12	phenobarbital	drug	31-43	false
Phenobarbital	drug	0-12	felbamate	drug	63-71	false
phenobarbital	drug	31-43	felbamate	drug	63-71	mechanism

DDI-DrugBank.d434.s34	Steady-state plasma felbamate concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of felbamate a day.
felbamate	drug	20-28	felbamate	drug	180-188	false

DDI-DrugBank.d434.s35	Effects of Antacids on Felbatol  The rate and extent of absorption of a 2400 mg dose of Felbatol  as monotherapy given as tablets was not affected when coadministered with antacids.
Antacids	group	11-18	Felbatol	brand	23-30	false
Antacids	group	11-18	Felbatol	brand	88-95	false
Antacids	group	11-18	antacids	group	172-179	false
Felbatol	brand	23-30	Felbatol	brand	88-95	false
Felbatol	brand	23-30	antacids	group	172-179	false
Felbatol	brand	88-95	antacids	group	172-179	false

DDI-DrugBank.d434.s36	Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.
Erythromycin	drug	11-22	Felbatol	brand	27-34	false
Erythromycin	drug	11-22	erythromycin	drug	61-72	false
Erythromycin	drug	11-22	felbamate	drug	182-190	false
Felbatol	brand	27-34	erythromycin	drug	61-72	false
Felbatol	brand	27-34	felbamate	drug	182-190	false
erythromycin	drug	61-72	felbamate	drug	182-190	false

DDI-DrugBank.d434.s37	Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
Felbatol	brand	11-18	Combination Oral Contraceptives	group	33-63	false
Felbatol	brand	11-18	contraceptive	group	146-158	false
Felbatol	brand	11-18	ethinyl estradiol	drug	185-201	false
Felbatol	brand	11-18	gestodene	drug	213-221	false
Felbatol	brand	11-18	felbamate	drug	269-277	false
Felbatol	brand	11-18	contraceptive	group	347-359	false
Combination Oral Contraceptives	group	33-63	contraceptive	group	146-158	false
Combination Oral Contraceptives	group	33-63	ethinyl estradiol	drug	185-201	false
Combination Oral Contraceptives	group	33-63	gestodene	drug	213-221	false
Combination Oral Contraceptives	group	33-63	felbamate	drug	269-277	false
Combination Oral Contraceptives	group	33-63	contraceptive	group	347-359	false
contraceptive	group	146-158	ethinyl estradiol	drug	185-201	false
contraceptive	group	146-158	gestodene	drug	213-221	false
contraceptive	group	146-158	felbamate	drug	269-277	false
contraceptive	group	146-158	contraceptive	group	347-359	false
ethinyl estradiol	drug	185-201	gestodene	drug	213-221	false
ethinyl estradiol	drug	185-201	felbamate	drug	269-277	false
ethinyl estradiol	drug	185-201	contraceptive	group	347-359	false
gestodene	drug	213-221	felbamate	drug	269-277	false
gestodene	drug	213-221	contraceptive	group	347-359	false
felbamate	drug	269-277	contraceptive	group	347-359	false

DDI-DrugBank.d434.s38	Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.
Felbamate	drug	0-8	gestodene	drug	54-62	mechanism
Felbamate	drug	0-8	ethinyl estradiol	drug	158-174	false
gestodene	drug	54-62	ethinyl estradiol	drug	158-174	false

DDI-DrugBank.d375.s0	The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.
EMTRIVA	brand	41-47	indinavir	drug	86-94	false
EMTRIVA	brand	41-47	stavudine	drug	97-105	false
EMTRIVA	brand	41-47	famciclovir	drug	108-118	false
EMTRIVA	brand	41-47	tenofovir disoproxil fumarate	drug	125-153	false
indinavir	drug	86-94	stavudine	drug	97-105	false
indinavir	drug	86-94	famciclovir	drug	108-118	false
indinavir	drug	86-94	tenofovir disoproxil fumarate	drug	125-153	false
stavudine	drug	97-105	famciclovir	drug	108-118	false
stavudine	drug	97-105	tenofovir disoproxil fumarate	drug	125-153	false
famciclovir	drug	108-118	tenofovir disoproxil fumarate	drug	125-153	false

DDI-DrugBank.d282.s0	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
DOSTINEX	brand	0-7	phenothiazines	group	78-91	advise
DOSTINEX	brand	0-7	butyrophenones	group	94-107	advise
DOSTINEX	brand	0-7	thioxanthines	group	110-122	advise
DOSTINEX	brand	0-7	metoclopramide	drug	128-141	advise
phenothiazines	group	78-91	butyrophenones	group	94-107	false
phenothiazines	group	78-91	thioxanthines	group	110-122	false
phenothiazines	group	78-91	metoclopramide	drug	128-141	false
butyrophenones	group	94-107	thioxanthines	group	110-122	false
butyrophenones	group	94-107	metoclopramide	drug	128-141	false
thioxanthines	group	110-122	metoclopramide	drug	128-141	false

DDI-DrugBank.d178.s0	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
sulfonylureas	group	27-39	nonsteroidal anti-inflammatory agents	group	87-123	effect
sulfonylureas	group	27-39	salicylates	group	172-182	effect
sulfonylureas	group	27-39	sulfonamides	group	185-196	effect
sulfonylureas	group	27-39	chloramphenicol	drug	199-213	effect
sulfonylureas	group	27-39	probenecid	drug	216-225	effect
sulfonylureas	group	27-39	coumarins	group	228-236	effect
sulfonylureas	group	27-39	monoamine oxidase inhibitors	group	239-266	effect
sulfonylureas	group	27-39	beta adrenergic blocking agents	group	273-303	effect
nonsteroidal anti-inflammatory agents	group	87-123	salicylates	group	172-182	false
nonsteroidal anti-inflammatory agents	group	87-123	sulfonamides	group	185-196	false
nonsteroidal anti-inflammatory agents	group	87-123	chloramphenicol	drug	199-213	false
nonsteroidal anti-inflammatory agents	group	87-123	probenecid	drug	216-225	false
nonsteroidal anti-inflammatory agents	group	87-123	coumarins	group	228-236	false
nonsteroidal anti-inflammatory agents	group	87-123	monoamine oxidase inhibitors	group	239-266	false
nonsteroidal anti-inflammatory agents	group	87-123	beta adrenergic blocking agents	group	273-303	false
salicylates	group	172-182	sulfonamides	group	185-196	false
salicylates	group	172-182	chloramphenicol	drug	199-213	false
salicylates	group	172-182	probenecid	drug	216-225	false
salicylates	group	172-182	coumarins	group	228-236	false
salicylates	group	172-182	monoamine oxidase inhibitors	group	239-266	false
salicylates	group	172-182	beta adrenergic blocking agents	group	273-303	false
sulfonamides	group	185-196	chloramphenicol	drug	199-213	false
sulfonamides	group	185-196	probenecid	drug	216-225	false
sulfonamides	group	185-196	coumarins	group	228-236	false
sulfonamides	group	185-196	monoamine oxidase inhibitors	group	239-266	false
sulfonamides	group	185-196	beta adrenergic blocking agents	group	273-303	false
chloramphenicol	drug	199-213	probenecid	drug	216-225	false
chloramphenicol	drug	199-213	coumarins	group	228-236	false
chloramphenicol	drug	199-213	monoamine oxidase inhibitors	group	239-266	false
chloramphenicol	drug	199-213	beta adrenergic blocking agents	group	273-303	false
probenecid	drug	216-225	coumarins	group	228-236	false
probenecid	drug	216-225	monoamine oxidase inhibitors	group	239-266	false
probenecid	drug	216-225	beta adrenergic blocking agents	group	273-303	false
coumarins	group	228-236	monoamine oxidase inhibitors	group	239-266	false
coumarins	group	228-236	beta adrenergic blocking agents	group	273-303	false
monoamine oxidase inhibitors	group	239-266	beta adrenergic blocking agents	group	273-303	false

DDI-DrugBank.d178.s4	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
thiazides	group	24-32	diuretics	group	44-52	false
thiazides	group	24-32	corticosteroids	group	55-69	false
thiazides	group	24-32	thyroid products	group	89-104	false
thiazides	group	24-32	estrogens	group	107-115	false
thiazides	group	24-32	contraceptives	group	123-136	false
thiazides	group	24-32	phenytoin	drug	139-147	false
thiazides	group	24-32	nicotinic acid	drug	150-163	false
thiazides	group	24-32	calcium channel blocking drugs	group	185-214	false
thiazides	group	24-32	isoniazid	drug	221-229	false
diuretics	group	44-52	corticosteroids	group	55-69	false
diuretics	group	44-52	thyroid products	group	89-104	false
diuretics	group	44-52	estrogens	group	107-115	false
diuretics	group	44-52	contraceptives	group	123-136	false
diuretics	group	44-52	phenytoin	drug	139-147	false
diuretics	group	44-52	nicotinic acid	drug	150-163	false
diuretics	group	44-52	calcium channel blocking drugs	group	185-214	false
diuretics	group	44-52	isoniazid	drug	221-229	false
corticosteroids	group	55-69	thyroid products	group	89-104	false
corticosteroids	group	55-69	estrogens	group	107-115	false
corticosteroids	group	55-69	contraceptives	group	123-136	false
corticosteroids	group	55-69	phenytoin	drug	139-147	false
corticosteroids	group	55-69	nicotinic acid	drug	150-163	false
corticosteroids	group	55-69	calcium channel blocking drugs	group	185-214	false
corticosteroids	group	55-69	isoniazid	drug	221-229	false
thyroid products	group	89-104	estrogens	group	107-115	false
thyroid products	group	89-104	contraceptives	group	123-136	false
thyroid products	group	89-104	phenytoin	drug	139-147	false
thyroid products	group	89-104	nicotinic acid	drug	150-163	false
thyroid products	group	89-104	calcium channel blocking drugs	group	185-214	false
thyroid products	group	89-104	isoniazid	drug	221-229	false
estrogens	group	107-115	contraceptives	group	123-136	false
estrogens	group	107-115	phenytoin	drug	139-147	false
estrogens	group	107-115	nicotinic acid	drug	150-163	false
estrogens	group	107-115	calcium channel blocking drugs	group	185-214	false
estrogens	group	107-115	isoniazid	drug	221-229	false
contraceptives	group	123-136	phenytoin	drug	139-147	false
contraceptives	group	123-136	nicotinic acid	drug	150-163	false
contraceptives	group	123-136	calcium channel blocking drugs	group	185-214	false
contraceptives	group	123-136	isoniazid	drug	221-229	false
phenytoin	drug	139-147	nicotinic acid	drug	150-163	false
phenytoin	drug	139-147	calcium channel blocking drugs	group	185-214	false
phenytoin	drug	139-147	isoniazid	drug	221-229	false
nicotinic acid	drug	150-163	calcium channel blocking drugs	group	185-214	false
nicotinic acid	drug	150-163	isoniazid	drug	221-229	false
calcium channel blocking drugs	group	185-214	isoniazid	drug	221-229	false

DDI-DrugBank.d178.s7	A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
glyburide	drug	31-39	ciprofloxacin	drug	45-57	int
glyburide	drug	31-39	fluoroquinolone antibiotic	group	62-87	false
glyburide	drug	31-39	glyburide	drug	167-175	false
ciprofloxacin	drug	45-57	fluoroquinolone antibiotic	group	62-87	false
ciprofloxacin	drug	45-57	glyburide	drug	167-175	false
fluoroquinolone antibiotic	group	62-87	glyburide	drug	167-175	false

DDI-DrugBank.d178.s9	A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
miconazole	drug	37-46	hypoglycemic agents	group	57-75	effect

DDI-DrugBank.d178.s11	Metformin: In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable.
Metformin	drug	0-8	glyburide	drug	78-86	false

DDI-DrugBank.d178.s13	Coadministration of gly-buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics.
metformin	drug	35-43	metformin	drug	85-93	false

DDI-DrugBank.d77.s2	Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
decongestants	group	38-50	anesthetics	group	62-72	false
decongestants	group	38-50	sympathomimetic amine	group	92-112	false
decongestants	group	38-50	epinephrine	drug	121-131	false
decongestants	group	38-50	norepinephrine	drug	134-147	false
decongestants	group	38-50	tricyclic antidepressants	group	183-207	advise
anesthetics	group	62-72	sympathomimetic amine	group	92-112	false
anesthetics	group	62-72	epinephrine	drug	121-131	false
anesthetics	group	62-72	norepinephrine	drug	134-147	false
anesthetics	group	62-72	tricyclic antidepressants	group	183-207	advise
sympathomimetic amine	group	92-112	epinephrine	drug	121-131	false
sympathomimetic amine	group	92-112	norepinephrine	drug	134-147	false
sympathomimetic amine	group	92-112	tricyclic antidepressants	group	183-207	advise
epinephrine	drug	121-131	norepinephrine	drug	134-147	false
epinephrine	drug	121-131	tricyclic antidepressants	group	183-207	advise
norepinephrine	drug	134-147	tricyclic antidepressants	group	183-207	advise

DDI-DrugBank.d77.s4	Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.
Imipramine hydrochloride	drug	0-23	CNS depressant drugs	group	55-74	effect

DDI-DrugBank.d77.s5	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
imipramine	drug	28-37	cimetidine	drug	127-136	mechanism
imipramine	drug	28-37	fluoxetine	drug	139-148	mechanism
imipramine	drug	28-37	barbiturates	group	228-239	mechanism
imipramine	drug	28-37	phenytoin	drug	242-250	mechanism
imipramine	drug	28-37	imipramine	drug	286-295	false
cimetidine	drug	127-136	fluoxetine	drug	139-148	false
cimetidine	drug	127-136	barbiturates	group	228-239	false
cimetidine	drug	127-136	phenytoin	drug	242-250	false
cimetidine	drug	127-136	imipramine	drug	286-295	false
fluoxetine	drug	139-148	barbiturates	group	228-239	false
fluoxetine	drug	139-148	phenytoin	drug	242-250	false
fluoxetine	drug	139-148	imipramine	drug	286-295	false
barbiturates	group	228-239	phenytoin	drug	242-250	false
barbiturates	group	228-239	imipramine	drug	286-295	false
phenytoin	drug	242-250	imipramine	drug	286-295	false

DDI-DrugBank.d77.s8	Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	group	69-93	TCAs	group	96-99	false

DDI-DrugBank.d77.s14	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	drug	0-9	antidepressants	group	66-80	false
cimetidine	drug	0-9	phenothiazines	group	83-96	false
cimetidine	drug	0-9	Type 1C antiarrhythmics	group	107-129	false
cimetidine	drug	0-9	propafenone	drug	131-141	false
cimetidine	drug	0-9	flecainide	drug	147-156	false
antidepressants	group	66-80	phenothiazines	group	83-96	false
antidepressants	group	66-80	Type 1C antiarrhythmics	group	107-129	false
antidepressants	group	66-80	propafenone	drug	131-141	false
antidepressants	group	66-80	flecainide	drug	147-156	false
phenothiazines	group	83-96	Type 1C antiarrhythmics	group	107-129	false
phenothiazines	group	83-96	propafenone	drug	131-141	false
phenothiazines	group	83-96	flecainide	drug	147-156	false
Type 1C antiarrhythmics	group	107-129	propafenone	drug	131-141	false
Type 1C antiarrhythmics	group	107-129	flecainide	drug	147-156	false
propafenone	drug	131-141	flecainide	drug	147-156	false

DDI-DrugBank.d77.s15	While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	group	14-52	SSRIs	group	55-59	false
selective serotonin reuptake inhibitors	group	14-52	fluoxetine	drug	70-79	false
selective serotonin reuptake inhibitors	group	14-52	sertraline	drug	82-91	false
selective serotonin reuptake inhibitors	group	14-52	paroxetine	drug	98-107	false
SSRIs	group	55-59	fluoxetine	drug	70-79	false
SSRIs	group	55-59	sertraline	drug	82-91	false
SSRIs	group	55-59	paroxetine	drug	98-107	false
fluoxetine	drug	70-79	sertraline	drug	82-91	false
fluoxetine	drug	70-79	paroxetine	drug	98-107	false
sertraline	drug	82-91	paroxetine	drug	98-107	false

DDI-DrugBank.d77.s16	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.
SSRI	group	20-23	TCA	group	25-27	int
SSRI	group	20-23	SSRI	group	142-145	false
TCA	group	25-27	SSRI	group	142-145	false

DDI-DrugBank.d77.s19	Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	group	19-43	tricyclic antidepressant	group	156-179	false

DDI-DrugBank.d77.s21	It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
TCA	group	27-29	TCA	group	56-58	false

DDI-DrugBank.d387.s0	Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.
doxylamine	drug	32-41	doxylamine	drug	74-83	false
doxylamine	drug	32-41	CNS depressant drugs	group	108-127	false
doxylamine	drug	74-83	CNS depressant drugs	group	108-127	effect

DDI-DrugBank.d387.s1	Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.
Antihistamines	group	0-13	heparin	drug	71-77	effect
Antihistamines	group	0-13	warfarin	drug	82-89	effect
heparin	drug	71-77	warfarin	drug	82-89	false

DDI-DrugBank.d387.s2	Doxylamine may enhance the effects of epinephrine.
Doxylamine	drug	0-9	epinephrine	drug	38-48	effect

DDI-DrugBank.d335.s1	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
clorazepate dipotassium	drug	33-55	hexobarbital	drug	90-101	effect
clorazepate dipotassium	drug	33-55	ethyl alcohol	drug	112-124	effect
clorazepate dipotassium	drug	33-55	chlorpromazine	drug	163-176	effect
hexobarbital	drug	90-101	ethyl alcohol	drug	112-124	false
hexobarbital	drug	90-101	chlorpromazine	drug	163-176	false
ethyl alcohol	drug	112-124	chlorpromazine	drug	163-176	false

DDI-DrugBank.d335.s3	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
benzodiazepines	group	19-33	barbiturates	group	57-68	effect
benzodiazepines	group	19-33	narcotics	group	71-79	effect
benzodiazepines	group	19-33	phenothiazines	group	82-95	effect
benzodiazepines	group	19-33	monoamine oxidase inhibitors	group	98-125	effect
benzodiazepines	group	19-33	antidepressants	group	136-150	effect
barbiturates	group	57-68	narcotics	group	71-79	false
barbiturates	group	57-68	phenothiazines	group	82-95	false
barbiturates	group	57-68	monoamine oxidase inhibitors	group	98-125	false
barbiturates	group	57-68	antidepressants	group	136-150	false
narcotics	group	71-79	phenothiazines	group	82-95	false
narcotics	group	71-79	monoamine oxidase inhibitors	group	98-125	false
narcotics	group	71-79	antidepressants	group	136-150	false
phenothiazines	group	82-95	monoamine oxidase inhibitors	group	98-125	false
phenothiazines	group	82-95	antidepressants	group	136-150	false
monoamine oxidase inhibitors	group	98-125	antidepressants	group	136-150	false

DDI-DrugBank.d335.s5	In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets.
antacids	group	82-89	TRANXENE	brand	168-175	false

DDI-DrugBank.d275.s1	Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.
methotrexate	drug	132-143	Kineret	brand	148-154	false

DDI-DrugBank.d275.s2	In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).
Kineret	brand	92-98	etanercept	drug	104-113	effect
Kineret	brand	92-98	etanercept	drug	211-220	false
etanercept	drug	104-113	etanercept	drug	211-220	false

DDI-DrugBank.d275.s3	Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).
Kineret	brand	50-56	etanercept	drug	62-71	effect

DDI-DrugBank.d16.s2	Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary
hydroxyurea	drug	6-16	uricosuric medication	group	76-96	effect

DDI-DrugBank.d316.s0	CYP3A4 Inhibitors Felodipine is metabolized by CYP3A4.
CYP3A4	drug	0-5	CYP3A4	drug	47-52	false

DDI-DrugBank.d316.s1	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
ketoconazole	drug	44-55	itraconazole	drug	58-69	false
ketoconazole	drug	44-55	erythromycin	drug	72-83	false
ketoconazole	drug	44-55	cimetidine	drug	104-113	false
ketoconazole	drug	44-55	felodipine	drug	121-130	false
ketoconazole	drug	44-55	felodipine	drug	192-201	false
itraconazole	drug	58-69	erythromycin	drug	72-83	false
itraconazole	drug	58-69	cimetidine	drug	104-113	false
itraconazole	drug	58-69	felodipine	drug	121-130	false
itraconazole	drug	58-69	felodipine	drug	192-201	false
erythromycin	drug	72-83	cimetidine	drug	104-113	false
erythromycin	drug	72-83	felodipine	drug	121-130	false
erythromycin	drug	72-83	felodipine	drug	192-201	false
cimetidine	drug	104-113	felodipine	drug	121-130	false
cimetidine	drug	104-113	felodipine	drug	192-201	false
felodipine	drug	121-130	felodipine	drug	192-201	false

DDI-DrugBank.d316.s3	These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor).
itraconazole	drug	59-70	CYP3A4	drug	82-87	false

DDI-DrugBank.d316.s4	Caution should be used when CYP3A4 inhibitors are co-administered with felodipine.
CYP3A4	drug	28-33	felodipine	drug	71-80	false

DDI-DrugBank.d316.s6	The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.
felodipine	drug	130-139	itraconazole	drug	146-157	false
felodipine	drug	130-139	felodipine	drug	298-307	false
itraconazole	drug	146-157	felodipine	drug	298-307	false

DDI-DrugBank.d316.s7	Erythromycin Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.
felodipine	drug	34-43	PLENDIL	drug	46-52	false
felodipine	drug	34-43	erythromycin	drug	60-71	false
felodipine	drug	34-43	felodipine	drug	191-200	false
PLENDIL	drug	46-52	erythromycin	drug	60-71	false
PLENDIL	drug	46-52	felodipine	drug	191-200	false
erythromycin	drug	60-71	felodipine	drug	191-200	false

DDI-DrugBank.d316.s8	Grapefruit juice Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine.
felodipine	drug	38-47	felodipine	drug	171-180	false

DDI-DrugBank.d316.s9	Cimetidine Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.
felodipine	drug	32-41	cimetidine	drug	48-57	false
felodipine	drug	32-41	felodipine	drug	167-176	false
cimetidine	drug	48-57	felodipine	drug	167-176	false

DDI-DrugBank.d316.s10	Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine.
felodipine	drug	49-58	metoprolol	drug	80-89	false
felodipine	drug	49-58	felodipine	drug	154-163	false
metoprolol	drug	80-89	felodipine	drug	154-163	false

DDI-DrugBank.d316.s12	In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.
beta blockers	drug	40-52	metoprolol	drug	64-73	false
beta blockers	drug	40-52	felodipine	drug	111-120	false
metoprolol	drug	64-73	felodipine	drug	111-120	false

DDI-DrugBank.d316.s13	Digoxin  When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.
PLENDIL	drug	39-45	digoxin	drug	71-77	false

DDI-DrugBank.d316.s14	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
Anticonvulsants	group	0-14	felodipine	drug	78-87	false
Anticonvulsants	group	0-14	anticonvulsant	group	148-161	false
Anticonvulsants	group	0-14	phenytoin	drug	176-184	false
Anticonvulsants	group	0-14	carbamazepine	drug	187-199	false
Anticonvulsants	group	0-14	phenobarbital	drug	205-217	false
felodipine	drug	78-87	anticonvulsant	group	148-161	mechanism
felodipine	drug	78-87	phenytoin	drug	176-184	mechanism
felodipine	drug	78-87	carbamazepine	drug	187-199	mechanism
felodipine	drug	78-87	phenobarbital	drug	205-217	mechanism
anticonvulsant	group	148-161	phenytoin	drug	176-184	false
anticonvulsant	group	148-161	carbamazepine	drug	187-199	false
anticonvulsant	group	148-161	phenobarbital	drug	205-217	false
phenytoin	drug	176-184	carbamazepine	drug	187-199	false
phenytoin	drug	176-184	phenobarbital	drug	205-217	false
carbamazepine	drug	187-199	phenobarbital	drug	205-217	false

DDI-DrugBank.d316.s17	Tacrolimus  Felodipine may increase the blood concentration of tacrolimus.
Felodipine	drug	12-21	tacrolimus	drug	63-72	false

DDI-DrugBank.d316.s18	When given concomitantly with felodipine, the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted.
felodipine	drug	30-39	tacrolimus	drug	46-55	false

DDI-DrugBank.d316.s19	Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.
felodipine	drug	102-111	indomethacin	drug	142-153	false
felodipine	drug	102-111	spironolactone	drug	158-171	false
indomethacin	drug	142-153	spironolactone	drug	158-171	false

DDI-DrugBank.d354.s1	Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
nitazoxanide	drug	53-64	warfarin	drug	207-214	mechanism

DDI-DrugBank.d191.s1	Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7
Steroids	group	0-7	edetate calcium disodium	drug	39-62	effect
Steroids	group	0-7	Edetate calcium disodium	drug	78-101	false
Steroids	group	0-7	zinc insulin	drug	133-144	false
Steroids	group	0-7	zinc	drug	176-179	false
edetate calcium disodium	drug	39-62	Edetate calcium disodium	drug	78-101	false
edetate calcium disodium	drug	39-62	zinc insulin	drug	133-144	false
edetate calcium disodium	drug	39-62	zinc	drug	176-179	false
Edetate calcium disodium	drug	78-101	zinc insulin	drug	133-144	mechanism
Edetate calcium disodium	drug	78-101	zinc	drug	176-179	false
zinc insulin	drug	133-144	zinc	drug	176-179	false

DDI-DrugBank.d560.s1	If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
steroid	group	24-30	bitolterol	drug	46-55	advise
steroid	group	24-30	steroid	group	111-117	false
bitolterol	drug	46-55	steroid	group	111-117	advise

DDI-DrugBank.d560.s2	This allows bitolterol to open air passages, increasing the effectiveness of the steroid.
bitolterol	drug	12-21	steroid	group	81-87	effect

DDI-DrugBank.d546.s0	Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.
Beta-Blockers	group	23-35	fenoldopam	drug	57-66	false
Beta-Blockers	group	23-35	beta-blockers	group	73-85	false
fenoldopam	drug	57-66	beta-blockers	group	73-85	advise

DDI-DrugBank.d546.s2	Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as digitalis and sublingual nitroglycerin.
fenoldopam	drug	96-105	digitalis	group	155-163	false
fenoldopam	drug	96-105	nitroglycerin	drug	180-192	false
digitalis	group	155-163	nitroglycerin	drug	180-192	false

DDI-DrugBank.d546.s3	There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and diuretics (both thiazide-like and loop).
antihypertensive agents	group	45-67	alpha-blockers	group	77-90	false
antihypertensive agents	group	45-67	calcium channel-blockers	group	93-116	false
antihypertensive agents	group	45-67	ACE inhibitors	group	119-132	false
antihypertensive agents	group	45-67	diuretics	group	139-147	false
antihypertensive agents	group	45-67	thiazide	group	155-162	false
alpha-blockers	group	77-90	calcium channel-blockers	group	93-116	false
alpha-blockers	group	77-90	ACE inhibitors	group	119-132	false
alpha-blockers	group	77-90	diuretics	group	139-147	false
alpha-blockers	group	77-90	thiazide	group	155-162	false
calcium channel-blockers	group	93-116	ACE inhibitors	group	119-132	false
calcium channel-blockers	group	93-116	diuretics	group	139-147	false
calcium channel-blockers	group	93-116	thiazide	group	155-162	false
ACE inhibitors	group	119-132	diuretics	group	139-147	false
ACE inhibitors	group	119-132	thiazide	group	155-162	false
diuretics	group	139-147	thiazide	group	155-162	false

DDI-DrugBank.d236.s0	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
Acidifying agents	group	0-16	Gastrointestinal acidifying agents	group	19-52	false
Acidifying agents	group	0-16	guanethidine	drug	55-66	false
Acidifying agents	group	0-16	reserpine	drug	69-77	false
Acidifying agents	group	0-16	glutamic acid HCl	drug	80-96	false
Acidifying agents	group	0-16	ascorbic acid	drug	99-111	false
Acidifying agents	group	0-16	amphetamines	group	154-165	false
Gastrointestinal acidifying agents	group	19-52	guanethidine	drug	55-66	false
Gastrointestinal acidifying agents	group	19-52	reserpine	drug	69-77	false
Gastrointestinal acidifying agents	group	19-52	glutamic acid HCl	drug	80-96	false
Gastrointestinal acidifying agents	group	19-52	ascorbic acid	drug	99-111	false
Gastrointestinal acidifying agents	group	19-52	amphetamines	group	154-165	mechanism
guanethidine	drug	55-66	reserpine	drug	69-77	false
guanethidine	drug	55-66	glutamic acid HCl	drug	80-96	false
guanethidine	drug	55-66	ascorbic acid	drug	99-111	false
guanethidine	drug	55-66	amphetamines	group	154-165	mechanism
reserpine	drug	69-77	glutamic acid HCl	drug	80-96	false
reserpine	drug	69-77	ascorbic acid	drug	99-111	false
reserpine	drug	69-77	amphetamines	group	154-165	mechanism
glutamic acid HCl	drug	80-96	ascorbic acid	drug	99-111	false
glutamic acid HCl	drug	80-96	amphetamines	group	154-165	mechanism
ascorbic acid	drug	99-111	amphetamines	group	154-165	mechanism

DDI-DrugBank.d236.s1	Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
Urinary acidifying agents	group	0-24	ammonium chloride	drug	27-43	false
Urinary acidifying agents	group	0-24	sodium acid phosphate	drug	46-66	false
Urinary acidifying agents	group	0-24	amphetamine	drug	132-142	mechanism
ammonium chloride	drug	27-43	sodium acid phosphate	drug	46-66	false
ammonium chloride	drug	27-43	amphetamine	drug	132-142	mechanism
sodium acid phosphate	drug	46-66	amphetamine	drug	132-142	mechanism

DDI-DrugBank.d236.s3	Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
Adrenergic blockers	group	0-18	Adrenergic blockers	group	21-39	false
Adrenergic blockers	group	0-18	amphetamines	group	58-69	false
Adrenergic blockers	group	21-39	amphetamines	group	58-69	effect

DDI-DrugBank.d236.s4	Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.
sodium bicarbonate	drug	59-76	amphetamines	drug	108-119	mechanism

DDI-DrugBank.d236.s5	Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
acetazolamide	drug	29-41	thiazides	group	49-57	false
acetazolamide	drug	29-41	amphetamine	drug	121-131	mechanism
thiazides	group	49-57	amphetamine	drug	121-131	mechanism

DDI-DrugBank.d236.s7	Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
Antidepressants	group	0-14	tricyclic	group	17-25	false
Antidepressants	group	0-14	Amphetamines	group	28-39	false
Antidepressants	group	0-14	tricyclic	group	69-77	false
Antidepressants	group	0-14	sympathomimetic agents	group	82-103	false
tricyclic	group	17-25	Amphetamines	group	28-39	false
tricyclic	group	17-25	tricyclic	group	69-77	false
tricyclic	group	17-25	sympathomimetic agents	group	82-103	false
Amphetamines	group	28-39	tricyclic	group	69-77	effect
Amphetamines	group	28-39	sympathomimetic agents	group	82-103	effect
tricyclic	group	69-77	sympathomimetic agents	group	82-103	false

DDI-DrugBank.d236.s8	d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
d-amphetamine	drug	0-12	desipramine	drug	19-29	mechanism
d-amphetamine	drug	0-12	protriptyline	drug	34-46	mechanism
d-amphetamine	drug	0-12	tricyclics	group	67-76	mechanism
d-amphetamine	drug	0-12	d-amphetamine	drug	141-153	false
desipramine	drug	19-29	protriptyline	drug	34-46	false
desipramine	drug	19-29	tricyclics	group	67-76	false
desipramine	drug	19-29	d-amphetamine	drug	141-153	false
protriptyline	drug	34-46	tricyclics	group	67-76	false
protriptyline	drug	34-46	d-amphetamine	drug	141-153	false
tricyclics	group	67-76	d-amphetamine	drug	141-153	false

DDI-DrugBank.d236.s10	MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
MAO inhibitors	group	0-13	MAOI antidepressants	group	16-35	false
MAO inhibitors	group	0-13	furazolidone	drug	65-76	false
MAO inhibitors	group	0-13	amphetamine	group	84-94	false
MAOI antidepressants	group	16-35	furazolidone	drug	65-76	false
MAOI antidepressants	group	16-35	amphetamine	group	84-94	mechanism
furazolidone	drug	65-76	amphetamine	group	84-94	mechanism

DDI-DrugBank.d236.s14	Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
Antihistamines	group	0-13	Amphetamines	group	16-27	false
Antihistamines	group	0-13	antihistamines	group	67-80	false
Amphetamines	group	16-27	antihistamines	group	67-80	effect

DDI-DrugBank.d236.s15	Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
Antihypertensives	group	0-16	Amphetamines	group	19-30	false
Antihypertensives	group	0-16	antihypertensives	group	74-90	false
Amphetamines	group	19-30	antihypertensives	group	74-90	effect

DDI-DrugBank.d236.s16	Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
Chlorpromazine	drug	0-13	Chlorpromazine	drug	16-29	false
Chlorpromazine	drug	0-13	amphetamines	group	125-136	false
Chlorpromazine	drug	0-13	amphetamine	group	164-174	false
Chlorpromazine	drug	16-29	amphetamines	group	125-136	effect
Chlorpromazine	drug	16-29	amphetamine	group	164-174	false
amphetamines	group	125-136	amphetamine	group	164-174	false

DDI-DrugBank.d236.s17	Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
Ethosuximide	drug	0-11	Amphetamines	group	14-25	false
Ethosuximide	drug	0-11	ethosuximide	drug	62-73	false
Amphetamines	group	14-25	ethosuximide	drug	62-73	mechanism

DDI-DrugBank.d236.s18	Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
Haloperidol	drug	0-10	Haloperidol	drug	13-23	false
Haloperidol	drug	0-10	amphetamines	group	119-130	false
Haloperidol	drug	13-23	amphetamines	group	119-130	effect

DDI-DrugBank.d236.s19	Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
Lithium carbonate	drug	0-16	amphetamines	group	46-57	false
Lithium carbonate	drug	0-16	lithium carbonate	drug	79-95	false
amphetamines	group	46-57	lithium carbonate	drug	79-95	effect

DDI-DrugBank.d236.s20	Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
Meperidine	drug	0-9	Amphetamines	group	12-23	false
Meperidine	drug	0-9	meperidine	drug	60-69	false
Amphetamines	group	12-23	meperidine	drug	60-69	effect

DDI-DrugBank.d236.s21	Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.
Methenamine	drug	0-10	amphetamines	group	42-53	false
Methenamine	drug	0-10	acidifying agents	group	97-113	false
Methenamine	drug	0-10	methenamine	drug	123-133	false
amphetamines	group	42-53	acidifying agents	group	97-113	mechanism
amphetamines	group	42-53	methenamine	drug	123-133	false
acidifying agents	group	97-113	methenamine	drug	123-133	false

DDI-DrugBank.d236.s22	Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
Norepinephrine	drug	0-13	Amphetamines	group	16-27	false
Norepinephrine	drug	0-13	norepinephrine	drug	62-75	false
Amphetamines	group	16-27	norepinephrine	drug	62-75	effect

DDI-DrugBank.d236.s23	Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
Phenobarbital	drug	0-12	Amphetamines	group	15-26	false
Phenobarbital	drug	0-12	phenobarbital	drug	63-75	false
Amphetamines	group	15-26	phenobarbital	drug	63-75	mechanism

DDI-DrugBank.d236.s25	Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
Phenytoin	drug	0-8	Amphetamines	group	11-22	false
Phenytoin	drug	0-8	phenytoin	drug	59-67	false
Amphetamines	group	11-22	phenytoin	drug	59-67	mechanism

DDI-DrugBank.d236.s27	Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
Propoxyphene	drug	0-11	propoxyphene	drug	26-37	false
Propoxyphene	drug	0-11	amphetamine	group	51-61	false
propoxyphene	drug	26-37	amphetamine	group	51-61	effect

DDI-DrugBank.d236.s28	Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
Veratrum alkaloids	group	0-17	Amphetamines	group	20-31	false
Veratrum alkaloids	group	0-17	veratrum alkaloids	group	67-84	false
Amphetamines	group	20-31	veratrum alkaloids	group	67-84	effect

DDI-DrugBank.d236.s29	Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.
Amphetamines	group	35-46	corticosteroid	group	92-105	int

DDI-DrugBank.d346.s0	Studies to evaluate possible interactions between REVIA and drugs other than opiates have not been performed.
REVIA	brand	50-54	opiates	group	77-83	false

DDI-DrugBank.d346.s2	The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
REVIA	brand	46-50	disulfiram	drug	56-65	effect

DDI-DrugBank.d346.s3	Lethargy and somnolence have been reported following doses of REVIA and thioridazine.
REVIA	brand	62-66	thioridazine	drug	72-83	effect

DDI-DrugBank.d346.s4	Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
REVIA	brand	16-20	opioid	group	43-48	effect
REVIA	brand	16-20	opioid analgesics	group	141-157	effect
opioid	group	43-48	opioid analgesics	group	141-157	false

DDI-DrugBank.d346.s5	In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.
REVIA	brand	92-96	opioid	group	113-118	effect

DDI-DrugBank.d186.s0	An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.
lithium	drug	261-267	HALDOL	brand	274-279	effect

DDI-DrugBank.d186.s1	A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established;
lithium	drug	81-87	HALDOL	brand	93-98	false

DDI-DrugBank.d186.s3	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
antipsychotic agents	group	14-33	HALDOL	brand	60-65	false
antipsychotic agents	group	14-33	CNS depressants	group	98-112	effect
antipsychotic agents	group	14-33	anesthetics	group	122-132	effect
antipsychotic agents	group	14-33	opiates	group	135-141	effect
antipsychotic agents	group	14-33	alcohol	drug	148-154	effect
HALDOL	brand	60-65	CNS depressants	group	98-112	effect
HALDOL	brand	60-65	anesthetics	group	122-132	effect
HALDOL	brand	60-65	opiates	group	135-141	effect
HALDOL	brand	60-65	alcohol	drug	148-154	effect
CNS depressants	group	98-112	anesthetics	group	122-132	false
CNS depressants	group	98-112	opiates	group	135-141	false
CNS depressants	group	98-112	alcohol	drug	148-154	false
anesthetics	group	122-132	opiates	group	135-141	false
anesthetics	group	122-132	alcohol	drug	148-154	false
opiates	group	135-141	alcohol	drug	148-154	false

DDI-DrugBank.d186.s4	In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.
haloperidol	drug	60-70	rifampin	drug	76-83	mechanism
haloperidol	drug	60-70	haloperidol	drug	93-103	false
rifampin	drug	76-83	haloperidol	drug	93-103	false

DDI-DrugBank.d186.s5	In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.
haloperidol	drug	52-62	rifampin	drug	68-75	false
haloperidol	drug	52-62	rifampin	drug	97-104	false
haloperidol	drug	52-62	haloperidol	drug	143-153	false
rifampin	drug	68-75	rifampin	drug	97-104	false
rifampin	drug	68-75	haloperidol	drug	143-153	false
rifampin	drug	97-104	haloperidol	drug	143-153	mechanism

DDI-DrugBank.d186.s6	Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.
rifampin	drug	62-69	haloperidol	drug	106-116	advise

DDI-DrugBank.d293.s0	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
levothyroxine	drug	44-56	iodine	drug	60-65	false
levothyroxine	drug	44-56	antacids	group	88-95	false
levothyroxine	drug	44-56	H2-antagonists	group	98-111	false
levothyroxine	drug	44-56	famotidine	drug	120-129	false
levothyroxine	drug	44-56	ranitidine	drug	132-141	false
levothyroxine	drug	44-56	proton pump inhibitors	group	149-170	false
levothyroxine	drug	44-56	lansoprazole	drug	179-190	false
levothyroxine	drug	44-56	omeprazole	drug	193-202	false
iodine	drug	60-65	antacids	group	88-95	false
iodine	drug	60-65	H2-antagonists	group	98-111	false
iodine	drug	60-65	famotidine	drug	120-129	false
iodine	drug	60-65	ranitidine	drug	132-141	false
iodine	drug	60-65	proton pump inhibitors	group	149-170	false
iodine	drug	60-65	lansoprazole	drug	179-190	false
iodine	drug	60-65	omeprazole	drug	193-202	false
antacids	group	88-95	H2-antagonists	group	98-111	false
antacids	group	88-95	famotidine	drug	120-129	false
antacids	group	88-95	ranitidine	drug	132-141	false
antacids	group	88-95	proton pump inhibitors	group	149-170	false
antacids	group	88-95	lansoprazole	drug	179-190	false
antacids	group	88-95	omeprazole	drug	193-202	false
H2-antagonists	group	98-111	famotidine	drug	120-129	false
H2-antagonists	group	98-111	ranitidine	drug	132-141	false
H2-antagonists	group	98-111	proton pump inhibitors	group	149-170	false
H2-antagonists	group	98-111	lansoprazole	drug	179-190	false
H2-antagonists	group	98-111	omeprazole	drug	193-202	false
famotidine	drug	120-129	ranitidine	drug	132-141	false
famotidine	drug	120-129	proton pump inhibitors	group	149-170	false
famotidine	drug	120-129	lansoprazole	drug	179-190	false
famotidine	drug	120-129	omeprazole	drug	193-202	false
ranitidine	drug	132-141	proton pump inhibitors	group	149-170	false
ranitidine	drug	132-141	lansoprazole	drug	179-190	false
ranitidine	drug	132-141	omeprazole	drug	193-202	false
proton pump inhibitors	group	149-170	lansoprazole	drug	179-190	false
proton pump inhibitors	group	149-170	omeprazole	drug	193-202	false
lansoprazole	drug	179-190	omeprazole	drug	193-202	false

DDI-DrugBank.d435.s0	Exemestane is extensively metabolized by CYP 3A4, but coadministration of ketoconazole, a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics.
Exemestane	drug	0-9	ketoconazole	drug	74-85	false
Exemestane	drug	0-9	exemestane	drug	148-157	false
ketoconazole	drug	74-85	exemestane	drug	148-157	false

DDI-DrugBank.d435.s2	Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
rifampicin	drug	42-51	phenytoin	drug	54-62	false
rifampicin	drug	42-51	carbamazepine	drug	65-77	false
rifampicin	drug	42-51	phenobarbital	drug	80-92	false
rifampicin	drug	42-51	exemestane	drug	154-163	mechanism
phenytoin	drug	54-62	carbamazepine	drug	65-77	false
phenytoin	drug	54-62	phenobarbital	drug	80-92	false
phenytoin	drug	54-62	exemestane	drug	154-163	mechanism
carbamazepine	drug	65-77	phenobarbital	drug	80-92	false
carbamazepine	drug	65-77	exemestane	drug	154-163	mechanism
phenobarbital	drug	80-92	exemestane	drug	154-163	mechanism

DDI-DrugBank.d517.s0	Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.
Tetracycline	drug	0-11	bacteriostatic antibiotic	group	16-40	false
Tetracycline	drug	0-11	penicillin	drug	84-93	effect
bacteriostatic antibiotic	group	16-40	penicillin	drug	84-93	false

DDI-DrugBank.d327.s0	There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.
etidronate	drug	100-109	warfarin	drug	124-131	effect

DDI-DrugBank.d386.s3	Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	group	69-93	TCAs	group	96-99	false

DDI-DrugBank.d386.s9	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).
cimetidine	drug	0-9	antidepressants	group	66-80	false
cimetidine	drug	0-9	phenothiazines	group	83-96	false
cimetidine	drug	0-9	flecainide	drug	148-157	false
antidepressants	group	66-80	phenothiazines	group	83-96	false
antidepressants	group	66-80	flecainide	drug	148-157	false
phenothiazines	group	83-96	flecainide	drug	148-157	false

DDI-DrugBank.d386.s10	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	group	14-52	SSRIs	group	55-59	false
selective serotonin reuptake inhibitors	group	14-52	fluoxetine	drug	69-78	false
selective serotonin reuptake inhibitors	group	14-52	paroxetine	drug	97-106	false
SSRIs	group	55-59	fluoxetine	drug	69-78	false
SSRIs	group	55-59	paroxetine	drug	97-106	false
fluoxetine	drug	69-78	paroxetine	drug	97-106	false

DDI-DrugBank.d386.s11	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	group	20-23	TCA	group	25-27	int
SSRI	group	20-23	SSRI	group	141-144	false
TCA	group	25-27	SSRI	group	141-144	false

DDI-DrugBank.d386.s12	Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.
T.A.	group	63-66	SSRIs	group	84-88	advise

DDI-DrugBank.d386.s14	Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	group	19-43	tricyclic antidepressant	group	156-179	false

DDI-DrugBank.d386.s16	It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
TCA	group	27-29	TCA	group	56-58	false

DDI-DrugBank.d386.s18	Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs.
anticholinergic	group	107-121	sympathomimetic drugs	group	126-146	false

DDI-DrugBank.d386.s23	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
desipramine hydrochloride	drug	3-27	psychotropic agents	group	58-76	effect
desipramine hydrochloride	drug	3-27	tranquilizers	group	86-98	effect
desipramine hydrochloride	drug	3-27	sedative	group	103-110	effect
desipramine hydrochloride	drug	3-27	hypnotics	group	112-120	effect
desipramine hydrochloride	drug	3-27	desipramine	drug	234-244	false
desipramine hydrochloride	drug	3-27	benzodiazepines	group	250-264	false
desipramine hydrochloride	drug	3-27	chlordiazepoxide	drug	273-288	false
desipramine hydrochloride	drug	3-27	diazepam	drug	293-300	false
psychotropic agents	group	58-76	tranquilizers	group	86-98	false
psychotropic agents	group	58-76	sedative	group	103-110	false
psychotropic agents	group	58-76	hypnotics	group	112-120	false
psychotropic agents	group	58-76	desipramine	drug	234-244	false
psychotropic agents	group	58-76	benzodiazepines	group	250-264	false
psychotropic agents	group	58-76	chlordiazepoxide	drug	273-288	false
psychotropic agents	group	58-76	diazepam	drug	293-300	false
tranquilizers	group	86-98	sedative	group	103-110	false
tranquilizers	group	86-98	hypnotics	group	112-120	false
tranquilizers	group	86-98	desipramine	drug	234-244	false
tranquilizers	group	86-98	benzodiazepines	group	250-264	false
tranquilizers	group	86-98	chlordiazepoxide	drug	273-288	false
tranquilizers	group	86-98	diazepam	drug	293-300	false
sedative	group	103-110	hypnotics	group	112-120	false
sedative	group	103-110	desipramine	drug	234-244	false
sedative	group	103-110	benzodiazepines	group	250-264	false
sedative	group	103-110	chlordiazepoxide	drug	273-288	false
sedative	group	103-110	diazepam	drug	293-300	false
hypnotics	group	112-120	desipramine	drug	234-244	false
hypnotics	group	112-120	benzodiazepines	group	250-264	false
hypnotics	group	112-120	chlordiazepoxide	drug	273-288	false
hypnotics	group	112-120	diazepam	drug	293-300	false
desipramine	drug	234-244	benzodiazepines	group	250-264	effect
desipramine	drug	234-244	chlordiazepoxide	drug	273-288	effect
desipramine	drug	234-244	diazepam	drug	293-300	effect
benzodiazepines	group	250-264	chlordiazepoxide	drug	273-288	false
benzodiazepines	group	250-264	diazepam	drug	293-300	false
chlordiazepoxide	drug	273-288	diazepam	drug	293-300	false

DDI-DrugBank.d386.s24	Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.
major tranquilizers	group	53-71	desipramine	drug	103-113	effect

DDI-DrugBank.d386.s26	Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.
cimetidine	drug	29-38	tricyclic antidepressants	group	44-68	mechanism
cimetidine	drug	29-38	tricyclic antidepressants	group	143-167	false
tricyclic antidepressants	group	44-68	tricyclic antidepressants	group	143-167	false

DDI-DrugBank.d386.s27	Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.
tricyclic antidepressants	group	46-70	cimetidine	drug	115-124	mechanism
tricyclic antidepressants	group	46-70	tricyclic antidepressant	group	190-213	false
cimetidine	drug	115-124	tricyclic antidepressant	group	190-213	false

DDI-DrugBank.d386.s28	There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.
tricyclic antidepressants	group	86-110	fluoxetine	drug	117-126	mechanism

DDI-DrugBank.d107.s0	Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
diuretics	drug	55-63	enalapril	drug	238-246	effect
diuretics	drug	55-63	enalaprilat	drug	251-261	effect
enalapril	drug	238-246	enalaprilat	drug	251-261	false

DDI-DrugBank.d107.s1	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
enalapril	drug	44-52	enalaprilat	drug	57-67	false
enalapril	drug	44-52	diuretic	drug	114-121	effect
enalapril	drug	44-52	enalapril	drug	191-199	false
enalapril	drug	44-52	enalaprilat	drug	204-214	false
enalaprilat	drug	57-67	diuretic	drug	114-121	effect
enalaprilat	drug	57-67	enalapril	drug	191-199	false
enalaprilat	drug	57-67	enalaprilat	drug	204-214	false
diuretic	drug	114-121	enalapril	drug	191-199	false
diuretic	drug	114-121	enalaprilat	drug	204-214	false
enalapril	drug	191-199	enalaprilat	drug	204-214	false

DDI-DrugBank.d107.s3	Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
enalapril	drug	61-69	enalapril	drug	75-83	false
enalapril	drug	61-69	antihypertensive agents	group	104-126	effect
enalapril	drug	61-69	diuretics	group	160-168	effect
enalapril	drug	75-83	antihypertensive agents	group	104-126	effect
enalapril	drug	75-83	diuretics	group	160-168	effect
antihypertensive agents	group	104-126	diuretics	group	160-168	false

DDI-DrugBank.d107.s4	Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.
Non-steroidal Anti-inflammatory Agents	group	0-37	nonsteroidal anti-inflammatory drugs	group	116-151	false
Non-steroidal Anti-inflammatory Agents	group	0-37	enalapril	drug	179-187	false
nonsteroidal anti-inflammatory drugs	group	116-151	enalapril	drug	179-187	effect

DDI-DrugBank.d107.s6	In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC.
indomethacin	drug	34-45	sulindac	drug	50-57	false
indomethacin	drug	34-45	VASOTEC	brand	111-117	false
sulindac	drug	50-57	VASOTEC	brand	111-117	false

DDI-DrugBank.d107.s8	However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
NSAIDs	group	30-35	ACE inhibitors	group	81-94	effect

DDI-DrugBank.d107.s9	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
NSAIDs	group	66-71	ACE inhibitors	group	92-105	advise

DDI-DrugBank.d107.s10	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
Enalapril	drug	29-37	enalapril	drug	43-51	false
Enalapril	drug	29-37	beta adrenergic-blocking agents	group	90-120	false
Enalapril	drug	29-37	methyldopa	drug	123-132	false
Enalapril	drug	29-37	nitrates	group	135-142	false
Enalapril	drug	29-37	calcium-blocking agents	group	145-167	false
Enalapril	drug	29-37	hydralazine	drug	170-180	false
Enalapril	drug	29-37	prazosin	drug	183-190	false
Enalapril	drug	29-37	digoxin	drug	196-202	false
enalapril	drug	43-51	beta adrenergic-blocking agents	group	90-120	false
enalapril	drug	43-51	methyldopa	drug	123-132	false
enalapril	drug	43-51	nitrates	group	135-142	false
enalapril	drug	43-51	calcium-blocking agents	group	145-167	false
enalapril	drug	43-51	hydralazine	drug	170-180	false
enalapril	drug	43-51	prazosin	drug	183-190	false
enalapril	drug	43-51	digoxin	drug	196-202	false
beta adrenergic-blocking agents	group	90-120	methyldopa	drug	123-132	false
beta adrenergic-blocking agents	group	90-120	nitrates	group	135-142	false
beta adrenergic-blocking agents	group	90-120	calcium-blocking agents	group	145-167	false
beta adrenergic-blocking agents	group	90-120	hydralazine	drug	170-180	false
beta adrenergic-blocking agents	group	90-120	prazosin	drug	183-190	false
beta adrenergic-blocking agents	group	90-120	digoxin	drug	196-202	false
methyldopa	drug	123-132	nitrates	group	135-142	false
methyldopa	drug	123-132	calcium-blocking agents	group	145-167	false
methyldopa	drug	123-132	hydralazine	drug	170-180	false
methyldopa	drug	123-132	prazosin	drug	183-190	false
methyldopa	drug	123-132	digoxin	drug	196-202	false
nitrates	group	135-142	calcium-blocking agents	group	145-167	false
nitrates	group	135-142	hydralazine	drug	170-180	false
nitrates	group	135-142	prazosin	drug	183-190	false
nitrates	group	135-142	digoxin	drug	196-202	false
calcium-blocking agents	group	145-167	hydralazine	drug	170-180	false
calcium-blocking agents	group	145-167	prazosin	drug	183-190	false
calcium-blocking agents	group	145-167	digoxin	drug	196-202	false
hydralazine	drug	170-180	prazosin	drug	183-190	false
hydralazine	drug	170-180	digoxin	drug	196-202	false
prazosin	drug	183-190	digoxin	drug	196-202	false

DDI-DrugBank.d107.s11	Enalapril IV has been used concomitantly with digitalis without evidence of clinically significant adverse reactions.
Enalapril	drug	0-8	digitalis	group	46-54	false

DDI-DrugBank.d107.s12	Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
Enalapril	drug	35-43	enalapril	drug	49-57	false
Enalapril	drug	35-43	thiazide-type diuretics	group	97-119	effect
enalapril	drug	49-57	thiazide-type diuretics	group	97-119	effect

DDI-DrugBank.d107.s13	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Potassium-sparing diuretics	group	0-26	spironolactone	drug	35-48	false
Potassium-sparing diuretics	group	0-26	triamterene	drug	51-61	false
Potassium-sparing diuretics	group	0-26	amiloride	drug	67-75	false
Potassium-sparing diuretics	group	0-26	potassium	drug	79-87	false
Potassium-sparing diuretics	group	0-26	potassium	drug	105-113	false
spironolactone	drug	35-48	triamterene	drug	51-61	false
spironolactone	drug	35-48	amiloride	drug	67-75	false
spironolactone	drug	35-48	potassium	drug	79-87	false
spironolactone	drug	35-48	potassium	drug	105-113	false
triamterene	drug	51-61	amiloride	drug	67-75	false
triamterene	drug	51-61	potassium	drug	79-87	false
triamterene	drug	51-61	potassium	drug	105-113	false
amiloride	drug	67-75	potassium	drug	79-87	false
amiloride	drug	67-75	potassium	drug	105-113	false
potassium	drug	79-87	potassium	drug	105-113	false

DDI-DrugBank.d107.s16	Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
Lithium	drug	0-6	Lithium	drug	9-15	false
Lithium	drug	0-6	lithium	drug	66-72	false
Lithium	drug	0-6	ACE inhibitors	group	144-157	false
Lithium	drug	9-15	lithium	drug	66-72	false
Lithium	drug	9-15	ACE inhibitors	group	144-157	false
lithium	drug	66-72	ACE inhibitors	group	144-157	effect

DDI-DrugBank.d107.s17	It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
lithium	drug	29-35	enalapril	drug	71-79	false
lithium	drug	29-35	lithium	drug	116-122	false
enalapril	drug	71-79	lithium	drug	116-122	advise

DDI-DrugBank.d521.s1	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
glimepiride	drug	14-24	aspirin	brand	96-102	advise
glimepiride	drug	14-24	salicylate	group	115-124	advise
glimepiride	drug	14-24	magnesium/choline salicylate	drug	134-161	advise
glimepiride	drug	14-24	Trilisate	brand	164-172	advise
glimepiride	drug	14-24	salsalate	drug	176-184	advise
glimepiride	drug	14-24	Disalcid	brand	187-194	advise
glimepiride	drug	14-24	choline salicylate	drug	206-223	advise
glimepiride	drug	14-24	Arthropan	drug	226-234	advise
glimepiride	drug	14-24	magnesium salicylate	drug	238-257	advise
glimepiride	drug	14-24	Magan	brand	260-264	advise
glimepiride	drug	14-24	bismuth subsalicylate	drug	271-291	advise
glimepiride	drug	14-24	Pepto-Bismol	brand	294-305	advise
aspirin	brand	96-102	salicylate	group	115-124	false
aspirin	brand	96-102	magnesium/choline salicylate	drug	134-161	false
aspirin	brand	96-102	Trilisate	brand	164-172	false
aspirin	brand	96-102	salsalate	drug	176-184	false
aspirin	brand	96-102	Disalcid	brand	187-194	false
aspirin	brand	96-102	choline salicylate	drug	206-223	false
aspirin	brand	96-102	Arthropan	drug	226-234	false
aspirin	brand	96-102	magnesium salicylate	drug	238-257	false
aspirin	brand	96-102	Magan	brand	260-264	false
aspirin	brand	96-102	bismuth subsalicylate	drug	271-291	false
aspirin	brand	96-102	Pepto-Bismol	brand	294-305	false
salicylate	group	115-124	magnesium/choline salicylate	drug	134-161	false
salicylate	group	115-124	Trilisate	brand	164-172	false
salicylate	group	115-124	salsalate	drug	176-184	false
salicylate	group	115-124	Disalcid	brand	187-194	false
salicylate	group	115-124	choline salicylate	drug	206-223	false
salicylate	group	115-124	Arthropan	drug	226-234	false
salicylate	group	115-124	magnesium salicylate	drug	238-257	false
salicylate	group	115-124	Magan	brand	260-264	false
salicylate	group	115-124	bismuth subsalicylate	drug	271-291	false
salicylate	group	115-124	Pepto-Bismol	brand	294-305	false
magnesium/choline salicylate	drug	134-161	Trilisate	brand	164-172	false
magnesium/choline salicylate	drug	134-161	salsalate	drug	176-184	false
magnesium/choline salicylate	drug	134-161	Disalcid	brand	187-194	false
magnesium/choline salicylate	drug	134-161	choline salicylate	drug	206-223	false
magnesium/choline salicylate	drug	134-161	Arthropan	drug	226-234	false
magnesium/choline salicylate	drug	134-161	magnesium salicylate	drug	238-257	false
magnesium/choline salicylate	drug	134-161	Magan	brand	260-264	false
magnesium/choline salicylate	drug	134-161	bismuth subsalicylate	drug	271-291	false
magnesium/choline salicylate	drug	134-161	Pepto-Bismol	brand	294-305	false
Trilisate	brand	164-172	salsalate	drug	176-184	false
Trilisate	brand	164-172	Disalcid	brand	187-194	false
Trilisate	brand	164-172	choline salicylate	drug	206-223	false
Trilisate	brand	164-172	Arthropan	drug	226-234	false
Trilisate	brand	164-172	magnesium salicylate	drug	238-257	false
Trilisate	brand	164-172	Magan	brand	260-264	false
Trilisate	brand	164-172	bismuth subsalicylate	drug	271-291	false
Trilisate	brand	164-172	Pepto-Bismol	brand	294-305	false
salsalate	drug	176-184	Disalcid	brand	187-194	false
salsalate	drug	176-184	choline salicylate	drug	206-223	false
salsalate	drug	176-184	Arthropan	drug	226-234	false
salsalate	drug	176-184	magnesium salicylate	drug	238-257	false
salsalate	drug	176-184	Magan	brand	260-264	false
salsalate	drug	176-184	bismuth subsalicylate	drug	271-291	false
salsalate	drug	176-184	Pepto-Bismol	brand	294-305	false
Disalcid	brand	187-194	choline salicylate	drug	206-223	false
Disalcid	brand	187-194	Arthropan	drug	226-234	false
Disalcid	brand	187-194	magnesium salicylate	drug	238-257	false
Disalcid	brand	187-194	Magan	brand	260-264	false
Disalcid	brand	187-194	bismuth subsalicylate	drug	271-291	false
Disalcid	brand	187-194	Pepto-Bismol	brand	294-305	false
choline salicylate	drug	206-223	Arthropan	drug	226-234	false
choline salicylate	drug	206-223	magnesium salicylate	drug	238-257	false
choline salicylate	drug	206-223	Magan	brand	260-264	false
choline salicylate	drug	206-223	bismuth subsalicylate	drug	271-291	false
choline salicylate	drug	206-223	Pepto-Bismol	brand	294-305	false
Arthropan	drug	226-234	magnesium salicylate	drug	238-257	false
Arthropan	drug	226-234	Magan	brand	260-264	false
Arthropan	drug	226-234	bismuth subsalicylate	drug	271-291	false
Arthropan	drug	226-234	Pepto-Bismol	brand	294-305	false
magnesium salicylate	drug	238-257	Magan	brand	260-264	false
magnesium salicylate	drug	238-257	bismuth subsalicylate	drug	271-291	false
magnesium salicylate	drug	238-257	Pepto-Bismol	brand	294-305	false
Magan	brand	260-264	bismuth subsalicylate	drug	271-291	false
Magan	brand	260-264	Pepto-Bismol	brand	294-305	false
bismuth subsalicylate	drug	271-291	Pepto-Bismol	brand	294-305	false

DDI-DrugBank.d521.s2	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
nonsteroidal anti-inflammatory drug	group	4-38	NSAID	group	41-45	false
nonsteroidal anti-inflammatory drug	group	4-38	ibuprofen	drug	56-64	false
nonsteroidal anti-inflammatory drug	group	4-38	Motrin	brand	67-72	false
nonsteroidal anti-inflammatory drug	group	4-38	Advil	brand	75-79	false
nonsteroidal anti-inflammatory drug	group	4-38	Nuprin	brand	82-87	false
nonsteroidal anti-inflammatory drug	group	4-38	ketoprofen	drug	99-108	false
nonsteroidal anti-inflammatory drug	group	4-38	Orudis	brand	111-116	false
nonsteroidal anti-inflammatory drug	group	4-38	Orudis KT	brand	119-127	false
nonsteroidal anti-inflammatory drug	group	4-38	Oruvail	brand	130-136	false
nonsteroidal anti-inflammatory drug	group	4-38	diclofenac	drug	140-149	false
nonsteroidal anti-inflammatory drug	group	4-38	Voltaren	brand	152-159	false
nonsteroidal anti-inflammatory drug	group	4-38	Cataflam	brand	162-169	false
nonsteroidal anti-inflammatory drug	group	4-38	etodolac	drug	173-180	false
nonsteroidal anti-inflammatory drug	group	4-38	Lodine	brand	183-188	false
nonsteroidal anti-inflammatory drug	group	4-38	indomethacin	drug	192-203	false
nonsteroidal anti-inflammatory drug	group	4-38	Indocin	brand	206-212	false
nonsteroidal anti-inflammatory drug	group	4-38	nabumetone	drug	216-225	false
nonsteroidal anti-inflammatory drug	group	4-38	Relafen	brand	228-234	false
nonsteroidal anti-inflammatory drug	group	4-38	oxaprozin	drug	238-246	false
nonsteroidal anti-inflammatory drug	group	4-38	Daypro	brand	249-254	false
nonsteroidal anti-inflammatory drug	group	4-38	naproxen	drug	262-269	false
nonsteroidal anti-inflammatory drug	group	4-38	Anaprox	brand	272-278	false
nonsteroidal anti-inflammatory drug	group	4-38	Naprosyn	brand	281-288	false
nonsteroidal anti-inflammatory drug	group	4-38	Aleve	brand	291-295	false
NSAID	group	41-45	ibuprofen	drug	56-64	false
NSAID	group	41-45	Motrin	brand	67-72	false
NSAID	group	41-45	Advil	brand	75-79	false
NSAID	group	41-45	Nuprin	brand	82-87	false
NSAID	group	41-45	ketoprofen	drug	99-108	false
NSAID	group	41-45	Orudis	brand	111-116	false
NSAID	group	41-45	Orudis KT	brand	119-127	false
NSAID	group	41-45	Oruvail	brand	130-136	false
NSAID	group	41-45	diclofenac	drug	140-149	false
NSAID	group	41-45	Voltaren	brand	152-159	false
NSAID	group	41-45	Cataflam	brand	162-169	false
NSAID	group	41-45	etodolac	drug	173-180	false
NSAID	group	41-45	Lodine	brand	183-188	false
NSAID	group	41-45	indomethacin	drug	192-203	false
NSAID	group	41-45	Indocin	brand	206-212	false
NSAID	group	41-45	nabumetone	drug	216-225	false
NSAID	group	41-45	Relafen	brand	228-234	false
NSAID	group	41-45	oxaprozin	drug	238-246	false
NSAID	group	41-45	Daypro	brand	249-254	false
NSAID	group	41-45	naproxen	drug	262-269	false
NSAID	group	41-45	Anaprox	brand	272-278	false
NSAID	group	41-45	Naprosyn	brand	281-288	false
NSAID	group	41-45	Aleve	brand	291-295	false
ibuprofen	drug	56-64	Motrin	brand	67-72	false
ibuprofen	drug	56-64	Advil	brand	75-79	false
ibuprofen	drug	56-64	Nuprin	brand	82-87	false
ibuprofen	drug	56-64	ketoprofen	drug	99-108	false
ibuprofen	drug	56-64	Orudis	brand	111-116	false
ibuprofen	drug	56-64	Orudis KT	brand	119-127	false
ibuprofen	drug	56-64	Oruvail	brand	130-136	false
ibuprofen	drug	56-64	diclofenac	drug	140-149	false
ibuprofen	drug	56-64	Voltaren	brand	152-159	false
ibuprofen	drug	56-64	Cataflam	brand	162-169	false
ibuprofen	drug	56-64	etodolac	drug	173-180	false
ibuprofen	drug	56-64	Lodine	brand	183-188	false
ibuprofen	drug	56-64	indomethacin	drug	192-203	false
ibuprofen	drug	56-64	Indocin	brand	206-212	false
ibuprofen	drug	56-64	nabumetone	drug	216-225	false
ibuprofen	drug	56-64	Relafen	brand	228-234	false
ibuprofen	drug	56-64	oxaprozin	drug	238-246	false
ibuprofen	drug	56-64	Daypro	brand	249-254	false
ibuprofen	drug	56-64	naproxen	drug	262-269	false
ibuprofen	drug	56-64	Anaprox	brand	272-278	false
ibuprofen	drug	56-64	Naprosyn	brand	281-288	false
ibuprofen	drug	56-64	Aleve	brand	291-295	false
Motrin	brand	67-72	Advil	brand	75-79	false
Motrin	brand	67-72	Nuprin	brand	82-87	false
Motrin	brand	67-72	ketoprofen	drug	99-108	false
Motrin	brand	67-72	Orudis	brand	111-116	false
Motrin	brand	67-72	Orudis KT	brand	119-127	false
Motrin	brand	67-72	Oruvail	brand	130-136	false
Motrin	brand	67-72	diclofenac	drug	140-149	false
Motrin	brand	67-72	Voltaren	brand	152-159	false
Motrin	brand	67-72	Cataflam	brand	162-169	false
Motrin	brand	67-72	etodolac	drug	173-180	false
Motrin	brand	67-72	Lodine	brand	183-188	false
Motrin	brand	67-72	indomethacin	drug	192-203	false
Motrin	brand	67-72	Indocin	brand	206-212	false
Motrin	brand	67-72	nabumetone	drug	216-225	false
Motrin	brand	67-72	Relafen	brand	228-234	false
Motrin	brand	67-72	oxaprozin	drug	238-246	false
Motrin	brand	67-72	Daypro	brand	249-254	false
Motrin	brand	67-72	naproxen	drug	262-269	false
Motrin	brand	67-72	Anaprox	brand	272-278	false
Motrin	brand	67-72	Naprosyn	brand	281-288	false
Motrin	brand	67-72	Aleve	brand	291-295	false
Advil	brand	75-79	Nuprin	brand	82-87	false
Advil	brand	75-79	ketoprofen	drug	99-108	false
Advil	brand	75-79	Orudis	brand	111-116	false
Advil	brand	75-79	Orudis KT	brand	119-127	false
Advil	brand	75-79	Oruvail	brand	130-136	false
Advil	brand	75-79	diclofenac	drug	140-149	false
Advil	brand	75-79	Voltaren	brand	152-159	false
Advil	brand	75-79	Cataflam	brand	162-169	false
Advil	brand	75-79	etodolac	drug	173-180	false
Advil	brand	75-79	Lodine	brand	183-188	false
Advil	brand	75-79	indomethacin	drug	192-203	false
Advil	brand	75-79	Indocin	brand	206-212	false
Advil	brand	75-79	nabumetone	drug	216-225	false
Advil	brand	75-79	Relafen	brand	228-234	false
Advil	brand	75-79	oxaprozin	drug	238-246	false
Advil	brand	75-79	Daypro	brand	249-254	false
Advil	brand	75-79	naproxen	drug	262-269	false
Advil	brand	75-79	Anaprox	brand	272-278	false
Advil	brand	75-79	Naprosyn	brand	281-288	false
Advil	brand	75-79	Aleve	brand	291-295	false
Nuprin	brand	82-87	ketoprofen	drug	99-108	false
Nuprin	brand	82-87	Orudis	brand	111-116	false
Nuprin	brand	82-87	Orudis KT	brand	119-127	false
Nuprin	brand	82-87	Oruvail	brand	130-136	false
Nuprin	brand	82-87	diclofenac	drug	140-149	false
Nuprin	brand	82-87	Voltaren	brand	152-159	false
Nuprin	brand	82-87	Cataflam	brand	162-169	false
Nuprin	brand	82-87	etodolac	drug	173-180	false
Nuprin	brand	82-87	Lodine	brand	183-188	false
Nuprin	brand	82-87	indomethacin	drug	192-203	false
Nuprin	brand	82-87	Indocin	brand	206-212	false
Nuprin	brand	82-87	nabumetone	drug	216-225	false
Nuprin	brand	82-87	Relafen	brand	228-234	false
Nuprin	brand	82-87	oxaprozin	drug	238-246	false
Nuprin	brand	82-87	Daypro	brand	249-254	false
Nuprin	brand	82-87	naproxen	drug	262-269	false
Nuprin	brand	82-87	Anaprox	brand	272-278	false
Nuprin	brand	82-87	Naprosyn	brand	281-288	false
Nuprin	brand	82-87	Aleve	brand	291-295	false
ketoprofen	drug	99-108	Orudis	brand	111-116	false
ketoprofen	drug	99-108	Orudis KT	brand	119-127	false
ketoprofen	drug	99-108	Oruvail	brand	130-136	false
ketoprofen	drug	99-108	diclofenac	drug	140-149	false
ketoprofen	drug	99-108	Voltaren	brand	152-159	false
ketoprofen	drug	99-108	Cataflam	brand	162-169	false
ketoprofen	drug	99-108	etodolac	drug	173-180	false
ketoprofen	drug	99-108	Lodine	brand	183-188	false
ketoprofen	drug	99-108	indomethacin	drug	192-203	false
ketoprofen	drug	99-108	Indocin	brand	206-212	false
ketoprofen	drug	99-108	nabumetone	drug	216-225	false
ketoprofen	drug	99-108	Relafen	brand	228-234	false
ketoprofen	drug	99-108	oxaprozin	drug	238-246	false
ketoprofen	drug	99-108	Daypro	brand	249-254	false
ketoprofen	drug	99-108	naproxen	drug	262-269	false
ketoprofen	drug	99-108	Anaprox	brand	272-278	false
ketoprofen	drug	99-108	Naprosyn	brand	281-288	false
ketoprofen	drug	99-108	Aleve	brand	291-295	false
Orudis	brand	111-116	Orudis KT	brand	119-127	false
Orudis	brand	111-116	Oruvail	brand	130-136	false
Orudis	brand	111-116	diclofenac	drug	140-149	false
Orudis	brand	111-116	Voltaren	brand	152-159	false
Orudis	brand	111-116	Cataflam	brand	162-169	false
Orudis	brand	111-116	etodolac	drug	173-180	false
Orudis	brand	111-116	Lodine	brand	183-188	false
Orudis	brand	111-116	indomethacin	drug	192-203	false
Orudis	brand	111-116	Indocin	brand	206-212	false
Orudis	brand	111-116	nabumetone	drug	216-225	false
Orudis	brand	111-116	Relafen	brand	228-234	false
Orudis	brand	111-116	oxaprozin	drug	238-246	false
Orudis	brand	111-116	Daypro	brand	249-254	false
Orudis	brand	111-116	naproxen	drug	262-269	false
Orudis	brand	111-116	Anaprox	brand	272-278	false
Orudis	brand	111-116	Naprosyn	brand	281-288	false
Orudis	brand	111-116	Aleve	brand	291-295	false
Orudis KT	brand	119-127	Oruvail	brand	130-136	false
Orudis KT	brand	119-127	diclofenac	drug	140-149	false
Orudis KT	brand	119-127	Voltaren	brand	152-159	false
Orudis KT	brand	119-127	Cataflam	brand	162-169	false
Orudis KT	brand	119-127	etodolac	drug	173-180	false
Orudis KT	brand	119-127	Lodine	brand	183-188	false
Orudis KT	brand	119-127	indomethacin	drug	192-203	false
Orudis KT	brand	119-127	Indocin	brand	206-212	false
Orudis KT	brand	119-127	nabumetone	drug	216-225	false
Orudis KT	brand	119-127	Relafen	brand	228-234	false
Orudis KT	brand	119-127	oxaprozin	drug	238-246	false
Orudis KT	brand	119-127	Daypro	brand	249-254	false
Orudis KT	brand	119-127	naproxen	drug	262-269	false
Orudis KT	brand	119-127	Anaprox	brand	272-278	false
Orudis KT	brand	119-127	Naprosyn	brand	281-288	false
Orudis KT	brand	119-127	Aleve	brand	291-295	false
Oruvail	brand	130-136	diclofenac	drug	140-149	false
Oruvail	brand	130-136	Voltaren	brand	152-159	false
Oruvail	brand	130-136	Cataflam	brand	162-169	false
Oruvail	brand	130-136	etodolac	drug	173-180	false
Oruvail	brand	130-136	Lodine	brand	183-188	false
Oruvail	brand	130-136	indomethacin	drug	192-203	false
Oruvail	brand	130-136	Indocin	brand	206-212	false
Oruvail	brand	130-136	nabumetone	drug	216-225	false
Oruvail	brand	130-136	Relafen	brand	228-234	false
Oruvail	brand	130-136	oxaprozin	drug	238-246	false
Oruvail	brand	130-136	Daypro	brand	249-254	false
Oruvail	brand	130-136	naproxen	drug	262-269	false
Oruvail	brand	130-136	Anaprox	brand	272-278	false
Oruvail	brand	130-136	Naprosyn	brand	281-288	false
Oruvail	brand	130-136	Aleve	brand	291-295	false
diclofenac	drug	140-149	Voltaren	brand	152-159	false
diclofenac	drug	140-149	Cataflam	brand	162-169	false
diclofenac	drug	140-149	etodolac	drug	173-180	false
diclofenac	drug	140-149	Lodine	brand	183-188	false
diclofenac	drug	140-149	indomethacin	drug	192-203	false
diclofenac	drug	140-149	Indocin	brand	206-212	false
diclofenac	drug	140-149	nabumetone	drug	216-225	false
diclofenac	drug	140-149	Relafen	brand	228-234	false
diclofenac	drug	140-149	oxaprozin	drug	238-246	false
diclofenac	drug	140-149	Daypro	brand	249-254	false
diclofenac	drug	140-149	naproxen	drug	262-269	false
diclofenac	drug	140-149	Anaprox	brand	272-278	false
diclofenac	drug	140-149	Naprosyn	brand	281-288	false
diclofenac	drug	140-149	Aleve	brand	291-295	false
Voltaren	brand	152-159	Cataflam	brand	162-169	false
Voltaren	brand	152-159	etodolac	drug	173-180	false
Voltaren	brand	152-159	Lodine	brand	183-188	false
Voltaren	brand	152-159	indomethacin	drug	192-203	false
Voltaren	brand	152-159	Indocin	brand	206-212	false
Voltaren	brand	152-159	nabumetone	drug	216-225	false
Voltaren	brand	152-159	Relafen	brand	228-234	false
Voltaren	brand	152-159	oxaprozin	drug	238-246	false
Voltaren	brand	152-159	Daypro	brand	249-254	false
Voltaren	brand	152-159	naproxen	drug	262-269	false
Voltaren	brand	152-159	Anaprox	brand	272-278	false
Voltaren	brand	152-159	Naprosyn	brand	281-288	false
Voltaren	brand	152-159	Aleve	brand	291-295	false
Cataflam	brand	162-169	etodolac	drug	173-180	false
Cataflam	brand	162-169	Lodine	brand	183-188	false
Cataflam	brand	162-169	indomethacin	drug	192-203	false
Cataflam	brand	162-169	Indocin	brand	206-212	false
Cataflam	brand	162-169	nabumetone	drug	216-225	false
Cataflam	brand	162-169	Relafen	brand	228-234	false
Cataflam	brand	162-169	oxaprozin	drug	238-246	false
Cataflam	brand	162-169	Daypro	brand	249-254	false
Cataflam	brand	162-169	naproxen	drug	262-269	false
Cataflam	brand	162-169	Anaprox	brand	272-278	false
Cataflam	brand	162-169	Naprosyn	brand	281-288	false
Cataflam	brand	162-169	Aleve	brand	291-295	false
etodolac	drug	173-180	Lodine	brand	183-188	false
etodolac	drug	173-180	indomethacin	drug	192-203	false
etodolac	drug	173-180	Indocin	brand	206-212	false
etodolac	drug	173-180	nabumetone	drug	216-225	false
etodolac	drug	173-180	Relafen	brand	228-234	false
etodolac	drug	173-180	oxaprozin	drug	238-246	false
etodolac	drug	173-180	Daypro	brand	249-254	false
etodolac	drug	173-180	naproxen	drug	262-269	false
etodolac	drug	173-180	Anaprox	brand	272-278	false
etodolac	drug	173-180	Naprosyn	brand	281-288	false
etodolac	drug	173-180	Aleve	brand	291-295	false
Lodine	brand	183-188	indomethacin	drug	192-203	false
Lodine	brand	183-188	Indocin	brand	206-212	false
Lodine	brand	183-188	nabumetone	drug	216-225	false
Lodine	brand	183-188	Relafen	brand	228-234	false
Lodine	brand	183-188	oxaprozin	drug	238-246	false
Lodine	brand	183-188	Daypro	brand	249-254	false
Lodine	brand	183-188	naproxen	drug	262-269	false
Lodine	brand	183-188	Anaprox	brand	272-278	false
Lodine	brand	183-188	Naprosyn	brand	281-288	false
Lodine	brand	183-188	Aleve	brand	291-295	false
indomethacin	drug	192-203	Indocin	brand	206-212	false
indomethacin	drug	192-203	nabumetone	drug	216-225	false
indomethacin	drug	192-203	Relafen	brand	228-234	false
indomethacin	drug	192-203	oxaprozin	drug	238-246	false
indomethacin	drug	192-203	Daypro	brand	249-254	false
indomethacin	drug	192-203	naproxen	drug	262-269	false
indomethacin	drug	192-203	Anaprox	brand	272-278	false
indomethacin	drug	192-203	Naprosyn	brand	281-288	false
indomethacin	drug	192-203	Aleve	brand	291-295	false
Indocin	brand	206-212	nabumetone	drug	216-225	false
Indocin	brand	206-212	Relafen	brand	228-234	false
Indocin	brand	206-212	oxaprozin	drug	238-246	false
Indocin	brand	206-212	Daypro	brand	249-254	false
Indocin	brand	206-212	naproxen	drug	262-269	false
Indocin	brand	206-212	Anaprox	brand	272-278	false
Indocin	brand	206-212	Naprosyn	brand	281-288	false
Indocin	brand	206-212	Aleve	brand	291-295	false
nabumetone	drug	216-225	Relafen	brand	228-234	false
nabumetone	drug	216-225	oxaprozin	drug	238-246	false
nabumetone	drug	216-225	Daypro	brand	249-254	false
nabumetone	drug	216-225	naproxen	drug	262-269	false
nabumetone	drug	216-225	Anaprox	brand	272-278	false
nabumetone	drug	216-225	Naprosyn	brand	281-288	false
nabumetone	drug	216-225	Aleve	brand	291-295	false
Relafen	brand	228-234	oxaprozin	drug	238-246	false
Relafen	brand	228-234	Daypro	brand	249-254	false
Relafen	brand	228-234	naproxen	drug	262-269	false
Relafen	brand	228-234	Anaprox	brand	272-278	false
Relafen	brand	228-234	Naprosyn	brand	281-288	false
Relafen	brand	228-234	Aleve	brand	291-295	false
oxaprozin	drug	238-246	Daypro	brand	249-254	false
oxaprozin	drug	238-246	naproxen	drug	262-269	false
oxaprozin	drug	238-246	Anaprox	brand	272-278	false
oxaprozin	drug	238-246	Naprosyn	brand	281-288	false
oxaprozin	drug	238-246	Aleve	brand	291-295	false
Daypro	brand	249-254	naproxen	drug	262-269	false
Daypro	brand	249-254	Anaprox	brand	272-278	false
Daypro	brand	249-254	Naprosyn	brand	281-288	false
Daypro	brand	249-254	Aleve	brand	291-295	false
naproxen	drug	262-269	Anaprox	brand	272-278	false
naproxen	drug	262-269	Naprosyn	brand	281-288	false
naproxen	drug	262-269	Aleve	brand	291-295	false
Anaprox	brand	272-278	Naprosyn	brand	281-288	false
Anaprox	brand	272-278	Aleve	brand	291-295	false
Naprosyn	brand	281-288	Aleve	brand	291-295	false

DDI-DrugBank.d521.s3	- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
sulfamethoxazole	drug	29-44	trimethoprim	drug	46-57	false
sulfamethoxazole	drug	29-44	Bactrim	brand	60-66	false
sulfamethoxazole	drug	29-44	Septra	brand	69-74	false
sulfamethoxazole	drug	29-44	sulfisoxazole	drug	78-90	false
sulfamethoxazole	drug	29-44	Gantrisin	brand	93-101	false
sulfamethoxazole	drug	29-44	sulfasalazine	drug	108-120	false
sulfamethoxazole	drug	29-44	Azulfidine	brand	123-132	false
trimethoprim	drug	46-57	Bactrim	brand	60-66	false
trimethoprim	drug	46-57	Septra	brand	69-74	false
trimethoprim	drug	46-57	sulfisoxazole	drug	78-90	false
trimethoprim	drug	46-57	Gantrisin	brand	93-101	false
trimethoprim	drug	46-57	sulfasalazine	drug	108-120	false
trimethoprim	drug	46-57	Azulfidine	brand	123-132	false
Bactrim	brand	60-66	Septra	brand	69-74	false
Bactrim	brand	60-66	sulfisoxazole	drug	78-90	false
Bactrim	brand	60-66	Gantrisin	brand	93-101	false
Bactrim	brand	60-66	sulfasalazine	drug	108-120	false
Bactrim	brand	60-66	Azulfidine	brand	123-132	false
Septra	brand	69-74	sulfisoxazole	drug	78-90	false
Septra	brand	69-74	Gantrisin	brand	93-101	false
Septra	brand	69-74	sulfasalazine	drug	108-120	false
Septra	brand	69-74	Azulfidine	brand	123-132	false
sulfisoxazole	drug	78-90	Gantrisin	brand	93-101	false
sulfisoxazole	drug	78-90	sulfasalazine	drug	108-120	false
sulfisoxazole	drug	78-90	Azulfidine	brand	123-132	false
Gantrisin	brand	93-101	sulfasalazine	drug	108-120	false
Gantrisin	brand	93-101	Azulfidine	brand	123-132	false
sulfasalazine	drug	108-120	Azulfidine	brand	123-132	false

DDI-DrugBank.d521.s4	- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);
monoamine oxidase inhibitor	group	4-30	MAOI	group	33-36	false
monoamine oxidase inhibitor	group	4-30	isocarboxazid	drug	47-59	false
monoamine oxidase inhibitor	group	4-30	Marplan	brand	62-68	false
monoamine oxidase inhibitor	group	4-30	tranylcypromine	drug	72-86	false
monoamine oxidase inhibitor	group	4-30	Parnate	brand	89-95	false
monoamine oxidase inhibitor	group	4-30	phenelzine	drug	102-111	false
monoamine oxidase inhibitor	group	4-30	Nardil	brand	114-119	false
MAOI	group	33-36	isocarboxazid	drug	47-59	false
MAOI	group	33-36	Marplan	brand	62-68	false
MAOI	group	33-36	tranylcypromine	drug	72-86	false
MAOI	group	33-36	Parnate	brand	89-95	false
MAOI	group	33-36	phenelzine	drug	102-111	false
MAOI	group	33-36	Nardil	brand	114-119	false
isocarboxazid	drug	47-59	Marplan	brand	62-68	false
isocarboxazid	drug	47-59	tranylcypromine	drug	72-86	false
isocarboxazid	drug	47-59	Parnate	brand	89-95	false
isocarboxazid	drug	47-59	phenelzine	drug	102-111	false
isocarboxazid	drug	47-59	Nardil	brand	114-119	false
Marplan	brand	62-68	tranylcypromine	drug	72-86	false
Marplan	brand	62-68	Parnate	brand	89-95	false
Marplan	brand	62-68	phenelzine	drug	102-111	false
Marplan	brand	62-68	Nardil	brand	114-119	false
tranylcypromine	drug	72-86	Parnate	brand	89-95	false
tranylcypromine	drug	72-86	phenelzine	drug	102-111	false
tranylcypromine	drug	72-86	Nardil	brand	114-119	false
Parnate	brand	89-95	phenelzine	drug	102-111	false
Parnate	brand	89-95	Nardil	brand	114-119	false
phenelzine	drug	102-111	Nardil	brand	114-119	false

DDI-DrugBank.d521.s5	- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;
beta-blocker	group	4-15	propranolol	drug	25-35	false
beta-blocker	group	4-15	Inderal	brand	38-44	false
beta-blocker	group	4-15	atenolol	drug	48-55	false
beta-blocker	group	4-15	Tenormin	brand	58-65	false
beta-blocker	group	4-15	acebutolol	drug	69-78	false
beta-blocker	group	4-15	Sectral	brand	81-87	false
beta-blocker	group	4-15	metoprolol	drug	91-100	false
beta-blocker	group	4-15	Lopressor	brand	103-111	false
propranolol	drug	25-35	Inderal	brand	38-44	false
propranolol	drug	25-35	atenolol	drug	48-55	false
propranolol	drug	25-35	Tenormin	brand	58-65	false
propranolol	drug	25-35	acebutolol	drug	69-78	false
propranolol	drug	25-35	Sectral	brand	81-87	false
propranolol	drug	25-35	metoprolol	drug	91-100	false
propranolol	drug	25-35	Lopressor	brand	103-111	false
Inderal	brand	38-44	atenolol	drug	48-55	false
Inderal	brand	38-44	Tenormin	brand	58-65	false
Inderal	brand	38-44	acebutolol	drug	69-78	false
Inderal	brand	38-44	Sectral	brand	81-87	false
Inderal	brand	38-44	metoprolol	drug	91-100	false
Inderal	brand	38-44	Lopressor	brand	103-111	false
atenolol	drug	48-55	Tenormin	brand	58-65	false
atenolol	drug	48-55	acebutolol	drug	69-78	false
atenolol	drug	48-55	Sectral	brand	81-87	false
atenolol	drug	48-55	metoprolol	drug	91-100	false
atenolol	drug	48-55	Lopressor	brand	103-111	false
Tenormin	brand	58-65	acebutolol	drug	69-78	false
Tenormin	brand	58-65	Sectral	brand	81-87	false
Tenormin	brand	58-65	metoprolol	drug	91-100	false
Tenormin	brand	58-65	Lopressor	brand	103-111	false
acebutolol	drug	69-78	Sectral	brand	81-87	false
acebutolol	drug	69-78	metoprolol	drug	91-100	false
acebutolol	drug	69-78	Lopressor	brand	103-111	false
Sectral	brand	81-87	metoprolol	drug	91-100	false
Sectral	brand	81-87	Lopressor	brand	103-111	false
metoprolol	drug	91-100	Lopressor	brand	103-111	false

DDI-DrugBank.d521.s6	- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;
diuretic	group	4-11	hydrochlorothiazide	drug	34-52	false
diuretic	group	4-11	HCTZ	drug	55-58	false
diuretic	group	4-11	Hydrodiuril	brand	61-71	false
diuretic	group	4-11	chlorothiazide	drug	75-88	false
diuretic	group	4-11	Diuril	brand	91-96	false
hydrochlorothiazide	drug	34-52	HCTZ	drug	55-58	false
hydrochlorothiazide	drug	34-52	Hydrodiuril	brand	61-71	false
hydrochlorothiazide	drug	34-52	chlorothiazide	drug	75-88	false
hydrochlorothiazide	drug	34-52	Diuril	brand	91-96	false
HCTZ	drug	55-58	Hydrodiuril	brand	61-71	false
HCTZ	drug	55-58	chlorothiazide	drug	75-88	false
HCTZ	drug	55-58	Diuril	brand	91-96	false
Hydrodiuril	brand	61-71	chlorothiazide	drug	75-88	false
Hydrodiuril	brand	61-71	Diuril	brand	91-96	false
chlorothiazide	drug	75-88	Diuril	brand	91-96	false

DDI-DrugBank.d521.s7	- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
steroid medicine	group	4-19	prednisone	drug	29-38	false
steroid medicine	group	4-19	Deltasone	brand	41-49	false
steroid medicine	group	4-19	Orasone	brand	52-58	false
steroid medicine	group	4-19	methylprednisolone	drug	70-87	false
steroid medicine	group	4-19	Medrol	brand	90-95	false
steroid medicine	group	4-19	prednisolone	drug	107-118	false
steroid medicine	group	4-19	Prelone	brand	121-127	false
steroid medicine	group	4-19	Pediapred	brand	130-138	false
prednisone	drug	29-38	Deltasone	brand	41-49	false
prednisone	drug	29-38	Orasone	brand	52-58	false
prednisone	drug	29-38	methylprednisolone	drug	70-87	false
prednisone	drug	29-38	Medrol	brand	90-95	false
prednisone	drug	29-38	prednisolone	drug	107-118	false
prednisone	drug	29-38	Prelone	brand	121-127	false
prednisone	drug	29-38	Pediapred	brand	130-138	false
Deltasone	brand	41-49	Orasone	brand	52-58	false
Deltasone	brand	41-49	methylprednisolone	drug	70-87	false
Deltasone	brand	41-49	Medrol	brand	90-95	false
Deltasone	brand	41-49	prednisolone	drug	107-118	false
Deltasone	brand	41-49	Prelone	brand	121-127	false
Deltasone	brand	41-49	Pediapred	brand	130-138	false
Orasone	brand	52-58	methylprednisolone	drug	70-87	false
Orasone	brand	52-58	Medrol	brand	90-95	false
Orasone	brand	52-58	prednisolone	drug	107-118	false
Orasone	brand	52-58	Prelone	brand	121-127	false
Orasone	brand	52-58	Pediapred	brand	130-138	false
methylprednisolone	drug	70-87	Medrol	brand	90-95	false
methylprednisolone	drug	70-87	prednisolone	drug	107-118	false
methylprednisolone	drug	70-87	Prelone	brand	121-127	false
methylprednisolone	drug	70-87	Pediapred	brand	130-138	false
Medrol	brand	90-95	prednisolone	drug	107-118	false
Medrol	brand	90-95	Prelone	brand	121-127	false
Medrol	brand	90-95	Pediapred	brand	130-138	false
prednisolone	drug	107-118	Prelone	brand	121-127	false
prednisolone	drug	107-118	Pediapred	brand	130-138	false
Prelone	brand	121-127	Pediapred	brand	130-138	false

DDI-DrugBank.d521.s8	- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;
phenothiazine	group	4-16	chlorpromazine	drug	26-39	false
phenothiazine	group	4-16	Thorazine	brand	42-50	false
phenothiazine	group	4-16	fluphenazine	drug	54-65	false
phenothiazine	group	4-16	Prolixin	brand	68-75	false
phenothiazine	group	4-16	Permitil	brand	78-85	false
phenothiazine	group	4-16	prochlorperazine	drug	89-104	false
phenothiazine	group	4-16	Compazine	brand	107-115	false
phenothiazine	group	4-16	promethazine	drug	119-130	false
phenothiazine	group	4-16	Phenergan	brand	133-141	false
chlorpromazine	drug	26-39	Thorazine	brand	42-50	false
chlorpromazine	drug	26-39	fluphenazine	drug	54-65	false
chlorpromazine	drug	26-39	Prolixin	brand	68-75	false
chlorpromazine	drug	26-39	Permitil	brand	78-85	false
chlorpromazine	drug	26-39	prochlorperazine	drug	89-104	false
chlorpromazine	drug	26-39	Compazine	brand	107-115	false
chlorpromazine	drug	26-39	promethazine	drug	119-130	false
chlorpromazine	drug	26-39	Phenergan	brand	133-141	false
Thorazine	brand	42-50	fluphenazine	drug	54-65	false
Thorazine	brand	42-50	Prolixin	brand	68-75	false
Thorazine	brand	42-50	Permitil	brand	78-85	false
Thorazine	brand	42-50	prochlorperazine	drug	89-104	false
Thorazine	brand	42-50	Compazine	brand	107-115	false
Thorazine	brand	42-50	promethazine	drug	119-130	false
Thorazine	brand	42-50	Phenergan	brand	133-141	false
fluphenazine	drug	54-65	Prolixin	brand	68-75	false
fluphenazine	drug	54-65	Permitil	brand	78-85	false
fluphenazine	drug	54-65	prochlorperazine	drug	89-104	false
fluphenazine	drug	54-65	Compazine	brand	107-115	false
fluphenazine	drug	54-65	promethazine	drug	119-130	false
fluphenazine	drug	54-65	Phenergan	brand	133-141	false
Prolixin	brand	68-75	Permitil	brand	78-85	false
Prolixin	brand	68-75	prochlorperazine	drug	89-104	false
Prolixin	brand	68-75	Compazine	brand	107-115	false
Prolixin	brand	68-75	promethazine	drug	119-130	false
Prolixin	brand	68-75	Phenergan	brand	133-141	false
Permitil	brand	78-85	prochlorperazine	drug	89-104	false
Permitil	brand	78-85	Compazine	brand	107-115	false
Permitil	brand	78-85	promethazine	drug	119-130	false
Permitil	brand	78-85	Phenergan	brand	133-141	false
prochlorperazine	drug	89-104	Compazine	brand	107-115	false
prochlorperazine	drug	89-104	promethazine	drug	119-130	false
prochlorperazine	drug	89-104	Phenergan	brand	133-141	false
Compazine	brand	107-115	promethazine	drug	119-130	false
Compazine	brand	107-115	Phenergan	brand	133-141	false
promethazine	drug	119-130	Phenergan	brand	133-141	false

DDI-DrugBank.d521.s9	- phenytoin (Dilantin);
phenytoin	drug	2-10	Dilantin	brand	13-20	false

DDI-DrugBank.d521.s10	- isoniazid (Nydrazid);
isoniazid	drug	2-10	Nydrazid	brand	13-20	false

DDI-DrugBank.d521.s11	- rifampin (Rifadin, Rifamate);
rifampin	drug	2-9	Rifadin	brand	12-18	false
rifampin	drug	2-9	Rifamate	brand	21-28	false
Rifadin	brand	12-18	Rifamate	brand	21-28	false

DDI-DrugBank.d184.s0	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
anticoagulants	group	87-100	blood thinner	group	103-115	false
anticoagulants	group	87-100	carbamazepine	drug	120-132	false
anticoagulants	group	87-100	corticotropin	drug	135-147	false
anticoagulants	group	87-100	barbiturates	group	150-161	false
anticoagulants	group	87-100	central nervous system (CNS) depressants	group	209-248	false
anticoagulants	group	87-100	barbiturates	group	278-289	false
anticoagulants	group	87-100	divalproex sodium	drug	340-356	false
anticoagulants	group	87-100	valproic acid	drug	359-371	false
anticoagulants	group	87-100	barbiturates	group	401-412	false
anticoagulants	group	87-100	contraceptives	group	488-501	false
anticoagulants	group	87-100	estrogens	group	514-522	false
anticoagulants	group	87-100	barbiturates	group	525-536	false
anticoagulants	group	87-100	contraceptives	group	583-596	false
blood thinner	group	103-115	carbamazepine	drug	120-132	false
blood thinner	group	103-115	corticotropin	drug	135-147	false
blood thinner	group	103-115	barbiturates	group	150-161	false
blood thinner	group	103-115	central nervous system (CNS) depressants	group	209-248	false
blood thinner	group	103-115	barbiturates	group	278-289	false
blood thinner	group	103-115	divalproex sodium	drug	340-356	false
blood thinner	group	103-115	valproic acid	drug	359-371	false
blood thinner	group	103-115	barbiturates	group	401-412	false
blood thinner	group	103-115	contraceptives	group	488-501	false
blood thinner	group	103-115	estrogens	group	514-522	false
blood thinner	group	103-115	barbiturates	group	525-536	false
blood thinner	group	103-115	contraceptives	group	583-596	false
carbamazepine	drug	120-132	corticotropin	drug	135-147	false
carbamazepine	drug	120-132	barbiturates	group	150-161	false
carbamazepine	drug	120-132	central nervous system (CNS) depressants	group	209-248	false
carbamazepine	drug	120-132	barbiturates	group	278-289	false
carbamazepine	drug	120-132	divalproex sodium	drug	340-356	false
carbamazepine	drug	120-132	valproic acid	drug	359-371	false
carbamazepine	drug	120-132	barbiturates	group	401-412	false
carbamazepine	drug	120-132	contraceptives	group	488-501	false
carbamazepine	drug	120-132	estrogens	group	514-522	false
carbamazepine	drug	120-132	barbiturates	group	525-536	false
carbamazepine	drug	120-132	contraceptives	group	583-596	false
corticotropin	drug	135-147	barbiturates	group	150-161	false
corticotropin	drug	135-147	central nervous system (CNS) depressants	group	209-248	false
corticotropin	drug	135-147	barbiturates	group	278-289	false
corticotropin	drug	135-147	divalproex sodium	drug	340-356	false
corticotropin	drug	135-147	valproic acid	drug	359-371	false
corticotropin	drug	135-147	barbiturates	group	401-412	false
corticotropin	drug	135-147	contraceptives	group	488-501	false
corticotropin	drug	135-147	estrogens	group	514-522	false
corticotropin	drug	135-147	barbiturates	group	525-536	false
corticotropin	drug	135-147	contraceptives	group	583-596	false
barbiturates	group	150-161	central nervous system (CNS) depressants	group	209-248	false
barbiturates	group	150-161	barbiturates	group	278-289	false
barbiturates	group	150-161	divalproex sodium	drug	340-356	false
barbiturates	group	150-161	valproic acid	drug	359-371	false
barbiturates	group	150-161	barbiturates	group	401-412	false
barbiturates	group	150-161	contraceptives	group	488-501	false
barbiturates	group	150-161	estrogens	group	514-522	false
barbiturates	group	150-161	barbiturates	group	525-536	false
barbiturates	group	150-161	contraceptives	group	583-596	false
central nervous system (CNS) depressants	group	209-248	barbiturates	group	278-289	false
central nervous system (CNS) depressants	group	209-248	divalproex sodium	drug	340-356	false
central nervous system (CNS) depressants	group	209-248	valproic acid	drug	359-371	false
central nervous system (CNS) depressants	group	209-248	barbiturates	group	401-412	false
central nervous system (CNS) depressants	group	209-248	contraceptives	group	488-501	false
central nervous system (CNS) depressants	group	209-248	estrogens	group	514-522	false
central nervous system (CNS) depressants	group	209-248	barbiturates	group	525-536	false
central nervous system (CNS) depressants	group	209-248	contraceptives	group	583-596	false
barbiturates	group	278-289	divalproex sodium	drug	340-356	false
barbiturates	group	278-289	valproic acid	drug	359-371	false
barbiturates	group	278-289	barbiturates	group	401-412	false
barbiturates	group	278-289	contraceptives	group	488-501	false
barbiturates	group	278-289	estrogens	group	514-522	false
barbiturates	group	278-289	barbiturates	group	525-536	false
barbiturates	group	278-289	contraceptives	group	583-596	false
divalproex sodium	drug	340-356	valproic acid	drug	359-371	false
divalproex sodium	drug	340-356	barbiturates	group	401-412	false
divalproex sodium	drug	340-356	contraceptives	group	488-501	false
divalproex sodium	drug	340-356	estrogens	group	514-522	false
divalproex sodium	drug	340-356	barbiturates	group	525-536	false
divalproex sodium	drug	340-356	contraceptives	group	583-596	false
valproic acid	drug	359-371	barbiturates	group	401-412	false
valproic acid	drug	359-371	contraceptives	group	488-501	false
valproic acid	drug	359-371	estrogens	group	514-522	false
valproic acid	drug	359-371	barbiturates	group	525-536	false
valproic acid	drug	359-371	contraceptives	group	583-596	false
barbiturates	group	401-412	contraceptives	group	488-501	false
barbiturates	group	401-412	estrogens	group	514-522	false
barbiturates	group	401-412	barbiturates	group	525-536	false
barbiturates	group	401-412	contraceptives	group	583-596	false
contraceptives	group	488-501	estrogens	group	514-522	false
contraceptives	group	488-501	barbiturates	group	525-536	false
contraceptives	group	488-501	contraceptives	group	583-596	false
estrogens	group	514-522	barbiturates	group	525-536	false
estrogens	group	514-522	contraceptives	group	583-596	false
barbiturates	group	525-536	contraceptives	group	583-596	effect

DDI-DrugBank.d7.s0	The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.
cyclophosphamide	drug	54-69	phenobarbital	drug	139-151	mechanism

DDI-DrugBank.d7.s1	The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.
cyclophosphamide	drug	102-117	cyclophosphamide	drug	131-146	false

DDI-DrugBank.d7.s2	Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
Cyclophosphamide	drug	0-15	succinylcholine chloride	drug	130-153	effect

DDI-DrugBank.d468.s0	Beta-Blockers: In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with nicardipine HCl.
Beta-Blockers	group	0-12	adrenergic beta-receptor blockers	group	47-79	false
Beta-Blockers	group	0-12	nicardipine HCl	drug	134-148	false
adrenergic beta-receptor blockers	group	47-79	nicardipine HCl	drug	134-148	false

DDI-DrugBank.d468.s2	Cimetidine: Cimetidine increases nicardipine HCl plasma levels.
Cimetidine	drug	0-9	Cimetidine	drug	12-21	false
Cimetidine	drug	0-9	nicardipine HCl	drug	33-47	false
Cimetidine	drug	12-21	nicardipine HCl	drug	33-47	mechanism

DDI-DrugBank.d468.s4	Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.
Digoxin	drug	0-6	calcium blockers	group	14-29	false
Digoxin	drug	0-6	digitalis preparations	group	65-86	false
calcium blockers	group	14-29	digitalis preparations	group	65-86	mechanism

DDI-DrugBank.d468.s5	Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.
Nicardipine HCl	drug	0-14	digoxin	drug	60-66	false
Nicardipine HCl	drug	0-14	digoxin	drug	84-90	false
Nicardipine HCl	drug	0-14	nicardipine HCl	drug	150-164	false
digoxin	drug	60-66	digoxin	drug	84-90	false
digoxin	drug	60-66	nicardipine HCl	drug	150-164	false
digoxin	drug	84-90	nicardipine HCl	drug	150-164	advise

DDI-DrugBank.d468.s6	Maalox * Coadministration of Maalox TC had no effect on nicardipine HCl absorption.
Maalox	brand	0-5	Maalox TC	brand	29-37	false
Maalox	brand	0-5	nicardipine HCl	drug	56-70	false
Maalox TC	brand	29-37	nicardipine HCl	drug	56-70	false

DDI-DrugBank.d468.s8	Cyclosporine: Concomitant administration of nicardipine and cyclosporine levels.
Cyclosporine	drug	0-11	nicardipine	drug	44-54	false
Cyclosporine	drug	0-11	cyclosporine	drug	60-71	false
nicardipine	drug	44-54	cyclosporine	drug	60-71	false

DDI-DrugBank.d468.s9	Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
cyclosporine	drug	25-36	nicardipine	drug	138-148	advise

DDI-DrugBank.d468.s10	When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
furosemide	drug	35-44	propranolol	drug	47-57	false
furosemide	drug	35-44	dipyridamole	drug	60-71	false
furosemide	drug	35-44	warfarin	drug	74-81	false
furosemide	drug	35-44	quinidine	drug	84-92	false
furosemide	drug	35-44	naproxen	drug	98-105	false
furosemide	drug	35-44	nicardipine HCl	drug	176-190	false
propranolol	drug	47-57	dipyridamole	drug	60-71	false
propranolol	drug	47-57	warfarin	drug	74-81	false
propranolol	drug	47-57	quinidine	drug	84-92	false
propranolol	drug	47-57	naproxen	drug	98-105	false
propranolol	drug	47-57	nicardipine HCl	drug	176-190	false
dipyridamole	drug	60-71	warfarin	drug	74-81	false
dipyridamole	drug	60-71	quinidine	drug	84-92	false
dipyridamole	drug	60-71	naproxen	drug	98-105	false
dipyridamole	drug	60-71	nicardipine HCl	drug	176-190	false
warfarin	drug	74-81	quinidine	drug	84-92	false
warfarin	drug	74-81	naproxen	drug	98-105	false
warfarin	drug	74-81	nicardipine HCl	drug	176-190	false
quinidine	drug	84-92	naproxen	drug	98-105	false
quinidine	drug	84-92	nicardipine HCl	drug	176-190	false
naproxen	drug	98-105	nicardipine HCl	drug	176-190	false

DDI-DrugBank.d76.s1	In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
serotonin reuptake inhibitor drug	group	30-62	monoamine oxidase inhibitors	group	84-111	effect
serotonin reuptake inhibitor drug	group	30-62	MAOI	group	114-117	effect
monoamine oxidase inhibitors	group	84-111	MAOI	group	114-117	false

DDI-DrugBank.d76.s4	Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.
Fluvoxamine	drug	34-44	MAOIs	group	86-90	advise
Fluvoxamine	drug	34-44	MAOI	group	145-148	advise
MAOIs	group	86-90	MAOI	group	145-148	false

DDI-DrugBank.d76.s5	After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.
Fluvoxamine	drug	15-25	MAOI	group	89-92	advise

DDI-DrugBank.d76.s6	Potential Terfenadine, Astemizole, and Cisapride Interactions
Terfenadine	drug	10-20	Astemizole	drug	23-32	false
Terfenadine	drug	10-20	Cisapride	drug	39-47	false
Astemizole	drug	23-32	Cisapride	drug	39-47	false

DDI-DrugBank.d76.s7	Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
Terfenadine	drug	0-10	astemizole	drug	13-22	false
Terfenadine	drug	0-10	cisapride	drug	28-36	false
Terfenadine	drug	0-10	ketoconazole	drug	129-140	mechanism
astemizole	drug	13-22	cisapride	drug	28-36	false
astemizole	drug	13-22	ketoconazole	drug	129-140	mechanism
cisapride	drug	28-36	ketoconazole	drug	129-140	mechanism

DDI-DrugBank.d76.s8	Increased plasma concentrations of terfenadine, astemizole, and cisapride cause QT prolongation and have been associated with torsades de pointes-type ventricular tachycardia, sometimes fatal.
terfenadine	drug	35-45	astemizole	drug	48-57	false
terfenadine	drug	35-45	cisapride	drug	64-72	false
astemizole	drug	48-57	cisapride	drug	64-72	false

DDI-DrugBank.d76.s9	As noted below, a sub- for fluvoxamine in combination with alprazolam, a drug that is known to be metabolized by the IIIA4 isozyme.
fluvoxamine	drug	27-37	alprazolam	drug	59-68	false

DDI-DrugBank.d76.s10	Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.
fluvoxamine	drug	56-66	fluvoxamine	drug	154-164	false
fluvoxamine	drug	56-66	alprazolam	drug	171-180	false
fluvoxamine	drug	154-164	alprazolam	drug	171-180	int

DDI-DrugBank.d76.s11	Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
fluvoxamine	drug	37-47	terbinafine	drug	88-98	advise
fluvoxamine	drug	37-47	astemizole	drug	101-110	advise
fluvoxamine	drug	37-47	cisapride	drug	116-124	advise
terbinafine	drug	88-98	astemizole	drug	101-110	false
terbinafine	drug	88-98	cisapride	drug	116-124	false
astemizole	drug	101-110	cisapride	drug	116-124	false

DDI-DrugBank.d76.s12	Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
Benzodiazepines	group	47-61	Benzodiazepines	group	64-78	false
Benzodiazepines	group	47-61	alprazolam	drug	120-129	false
Benzodiazepines	group	47-61	midazolam	drug	132-140	false
Benzodiazepines	group	47-61	triazolam	drug	143-151	false
Benzodiazepines	group	47-61	fluvoxamine	drug	251-261	false
Benzodiazepines	group	64-78	alprazolam	drug	120-129	false
Benzodiazepines	group	64-78	midazolam	drug	132-140	false
Benzodiazepines	group	64-78	triazolam	drug	143-151	false
Benzodiazepines	group	64-78	fluvoxamine	drug	251-261	mechanism
alprazolam	drug	120-129	midazolam	drug	132-140	false
alprazolam	drug	120-129	triazolam	drug	143-151	false
alprazolam	drug	120-129	fluvoxamine	drug	251-261	mechanism
midazolam	drug	132-140	triazolam	drug	143-151	false
midazolam	drug	132-140	fluvoxamine	drug	251-261	mechanism
triazolam	drug	143-151	fluvoxamine	drug	251-261	mechanism

DDI-DrugBank.d76.s13	The clearance of benzodiazepines metabolized by glucuronidation (e. g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine.
benzodiazepines	group	17-31	lorazepam	drug	72-80	false
benzodiazepines	group	17-31	oxazepam	drug	83-90	false
benzodiazepines	group	17-31	temazepam	drug	93-101	false
benzodiazepines	group	17-31	fluvoxamine	drug	134-144	false
lorazepam	drug	72-80	oxazepam	drug	83-90	false
lorazepam	drug	72-80	temazepam	drug	93-101	false
lorazepam	drug	72-80	fluvoxamine	drug	134-144	false
oxazepam	drug	83-90	temazepam	drug	93-101	false
oxazepam	drug	83-90	fluvoxamine	drug	134-144	false
temazepam	drug	93-101	fluvoxamine	drug	134-144	false

DDI-DrugBank.d76.s14	Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
Alprazolam	drug	0-9	fluvoxamine maleate	drug	17-35	false
Alprazolam	drug	0-9	alprazolam	drug	53-62	false
Alprazolam	drug	0-9	alprazolam	drug	194-203	false
Alprazolam	drug	0-9	alprazolam	drug	250-259	false
fluvoxamine maleate	drug	17-35	alprazolam	drug	53-62	mechanism
fluvoxamine maleate	drug	17-35	alprazolam	drug	194-203	false
fluvoxamine maleate	drug	17-35	alprazolam	drug	250-259	false
alprazolam	drug	53-62	alprazolam	drug	194-203	false
alprazolam	drug	53-62	alprazolam	drug	250-259	false
alprazolam	drug	194-203	alprazolam	drug	250-259	false

DDI-DrugBank.d76.s17	This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
fluvoxamine	drug	72-82	fluvoxamine	drug	170-180	false
fluvoxamine	drug	72-82	alprazolam	drug	256-265	false
fluvoxamine	drug	72-82	Fluvoxamine	drug	291-301	false
fluvoxamine	drug	72-82	alprazolam	drug	324-333	false
fluvoxamine	drug	170-180	alprazolam	drug	256-265	false
fluvoxamine	drug	170-180	Fluvoxamine	drug	291-301	false
fluvoxamine	drug	170-180	alprazolam	drug	324-333	false
alprazolam	drug	256-265	Fluvoxamine	drug	291-301	advise
alprazolam	drug	256-265	alprazolam	drug	324-333	false
Fluvoxamine	drug	291-301	alprazolam	drug	324-333	false

DDI-DrugBank.d76.s19	Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.
Diazepam	drug	0-7	Fluvoxamine	drug	35-45	false
Diazepam	drug	0-7	diazepam	drug	59-66	false
Fluvoxamine	drug	35-45	diazepam	drug	59-66	advise

DDI-DrugBank.d76.s20	Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
fluvoxamine	drug	8-18	diazepam	drug	50-57	mechanism
fluvoxamine	drug	8-18	N-desmethyldiazepam	drug_n	86-104	mechanism
diazepam	drug	50-57	N-desmethyldiazepam	drug_n	86-104	false

DDI-DrugBank.d76.s21	Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.
fluvoxamine	drug	75-85	diazepam	drug	91-98	advise
fluvoxamine	drug	75-85	fluvoxamine	drug	173-183	false
fluvoxamine	drug	75-85	diazepam	drug	234-241	false
diazepam	drug	91-98	fluvoxamine	drug	173-183	false
diazepam	drug	91-98	diazepam	drug	234-241	false
fluvoxamine	drug	173-183	diazepam	drug	234-241	false

DDI-DrugBank.d76.s22	In these subjects (R= B), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.
diazepam	drug	43-50	N-desmethyldiazepam	drug_n	83-101	false

DDI-DrugBank.d76.s24	Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.
alprazolam	drug	24-33	fluvoxamine	drug	50-60	effect

DDI-DrugBank.d76.s25	Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.
diazepam	drug	13-20	fluvoxamine	drug	26-36	advise

DDI-DrugBank.d76.s26	Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.
Theophylline	drug	0-11	fluvoxamine	drug	41-51	false
Theophylline	drug	0-11	Theophylline	drug	108-119	false
Theophylline	drug	0-11	aminophylline	drug	140-152	false
fluvoxamine	drug	41-51	Theophylline	drug	108-119	false
fluvoxamine	drug	41-51	aminophylline	drug	140-152	false
Theophylline	drug	108-119	aminophylline	drug	140-152	false

DDI-DrugBank.d76.s28	Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
theophylline	drug	14-25	fluvoxamine maleate	drug	51-69	advise
theophylline	drug	14-25	theophylline	drug	177-188	false
fluvoxamine maleate	drug	51-69	theophylline	drug	177-188	false

DDI-DrugBank.d76.s30	Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
Warfarin	drug	0-7	fluvoxamine maleate	drug	15-33	false
Warfarin	drug	0-7	warfarin	drug	83-90	false
Warfarin	drug	0-7	warfarin	drug	107-114	false
fluvoxamine maleate	drug	15-33	warfarin	drug	83-90	mechanism
fluvoxamine maleate	drug	15-33	warfarin	drug	107-114	false
warfarin	drug	83-90	warfarin	drug	107-114	false

DDI-DrugBank.d76.s31	Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.
anticoagulants	group	29-42	Fluvoxamine	drug	48-58	advise
anticoagulants	group	29-42	anticoagulant	group	123-135	false
Fluvoxamine	drug	48-58	anticoagulant	group	123-135	false

DDI-DrugBank.d140.s0	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), erythromycin, azole antifungals.
cyclosporine	drug	110-121	fibric acid derivatives	group	124-146	false
cyclosporine	drug	110-121	niacin	drug	149-154	false
cyclosporine	drug	110-121	nicotinic acid	drug	157-170	false
cyclosporine	drug	110-121	erythromycin	drug	174-185	false
cyclosporine	drug	110-121	azole antifungals	group	188-204	false
fibric acid derivatives	group	124-146	niacin	drug	149-154	false
fibric acid derivatives	group	124-146	nicotinic acid	drug	157-170	false
fibric acid derivatives	group	124-146	erythromycin	drug	174-185	false
fibric acid derivatives	group	124-146	azole antifungals	group	188-204	false
niacin	drug	149-154	nicotinic acid	drug	157-170	false
niacin	drug	149-154	erythromycin	drug	174-185	false
niacin	drug	149-154	azole antifungals	group	188-204	false
nicotinic acid	drug	157-170	erythromycin	drug	174-185	false
nicotinic acid	drug	157-170	azole antifungals	group	188-204	false
erythromycin	drug	174-185	azole antifungals	group	188-204	false

DDI-DrugBank.d140.s1	Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
Antacid	group	0-6	atorvastatin	drug	14-25	false
Antacid	group	0-6	Maalox TC	brand	31-39	false
Antacid	group	0-6	atorvastatin	drug	98-109	false
atorvastatin	drug	14-25	Maalox TC	brand	31-39	mechanism
atorvastatin	drug	14-25	atorvastatin	drug	98-109	false
Maalox TC	brand	31-39	atorvastatin	drug	98-109	false

DDI-DrugBank.d140.s3	Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.
Antipyrine	drug	0-9	atorvastatin	drug	20-31	false
Antipyrine	drug	0-9	antipyrine	drug	73-82	false
Antipyrine	drug	0-9	drugs	drug	109-113	false
atorvastatin	drug	20-31	antipyrine	drug	73-82	false
atorvastatin	drug	20-31	drugs	drug	109-113	false
antipyrine	drug	73-82	drugs	drug	109-113	false

DDI-DrugBank.d140.s4	Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
Colestipol	drug	0-9	atorvastatin	drug	37-48	false
Colestipol	drug	0-9	colestipol	drug	83-92	false
Colestipol	drug	0-9	atorvastatin	drug	98-109	false
atorvastatin	drug	37-48	colestipol	drug	83-92	false
atorvastatin	drug	37-48	atorvastatin	drug	98-109	false
colestipol	drug	83-92	atorvastatin	drug	98-109	mechanism

DDI-DrugBank.d140.s5	However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
atorvastatin	drug	42-53	colestipol	drug	59-68	effect

DDI-DrugBank.d140.s6	Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.
Cimetidine	drug	0-9	Atorvastatin	drug	12-23	false
Cimetidine	drug	0-9	cimetidine	drug	107-116	false
Atorvastatin	drug	12-23	cimetidine	drug	107-116	false

DDI-DrugBank.d140.s7	Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
Digoxin	drug	0-6	atorvastatin	drug	32-43	false
Digoxin	drug	0-6	digoxin	drug	49-55	false
Digoxin	drug	0-6	digoxin	drug	98-104	false
atorvastatin	drug	32-43	digoxin	drug	49-55	mechanism
atorvastatin	drug	32-43	digoxin	drug	98-104	false
digoxin	drug	49-55	digoxin	drug	98-104	false

DDI-DrugBank.d140.s9	Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
Erythromycin	drug	0-11	atorvastatin	drug	63-74	false
Erythromycin	drug	0-11	atorvastatin	drug	129-140	false
Erythromycin	drug	0-11	erythromycin	drug	146-157	false
atorvastatin	drug	63-74	atorvastatin	drug	129-140	false
atorvastatin	drug	63-74	erythromycin	drug	146-157	false
atorvastatin	drug	129-140	erythromycin	drug	146-157	mechanism

DDI-DrugBank.d140.s10	Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
Contraceptives	group	5-18	atorvastatin	drug	41-52	false
Contraceptives	group	5-18	contraceptive	group	66-78	false
Contraceptives	group	5-18	norethindrone	drug	105-117	false
Contraceptives	group	5-18	ethinyl estradiol	drug	123-139	false
atorvastatin	drug	41-52	contraceptive	group	66-78	mechanism
atorvastatin	drug	41-52	norethindrone	drug	105-117	mechanism
atorvastatin	drug	41-52	ethinyl estradiol	drug	123-139	mechanism
contraceptive	group	66-78	norethindrone	drug	105-117	false
contraceptive	group	66-78	ethinyl estradiol	drug	123-139	false
norethindrone	drug	105-117	ethinyl estradiol	drug	123-139	false

DDI-DrugBank.d140.s11	These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.
contraceptive	group	60-72	atorvastatin	drug	93-104	advise

DDI-DrugBank.d140.s12	Warfarin: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
Warfarin	drug	0-7	Atorvastatin	drug	10-21	false
Warfarin	drug	0-7	warfarin	drug	128-135	false
Atorvastatin	drug	10-21	warfarin	drug	128-135	false

DDI-DrugBank.d140.s17	Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
HMG-CoA reductase inhibitor	group	34-60	ketoconazole	drug	184-195	advise
HMG-CoA reductase inhibitor	group	34-60	spironolactone	drug	198-211	advise
HMG-CoA reductase inhibitor	group	34-60	cimetidine	drug	218-227	advise
ketoconazole	drug	184-195	spironolactone	drug	198-211	false
ketoconazole	drug	184-195	cimetidine	drug	218-227	false
spironolactone	drug	198-211	cimetidine	drug	218-227	false

DDI-DrugBank.d419.s0	The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
allopurinol	drug	33-43	ampicillin	drug	49-58	effect
allopurinol	drug	33-43	ampicillin	drug	175-184	false
ampicillin	drug	49-58	ampicillin	drug	175-184	false

DDI-DrugBank.d419.s1	It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
ampicillin	drug	45-54	allopurinol	drug	73-83	effect

DDI-DrugBank.d419.s2	In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.
AUGMENTIN XR	brand	33-44	allopurinol	drug	80-90	false
AUGMENTIN XR	brand	33-44	AUGMENTIN XR	brand	96-107	false
allopurinol	drug	80-90	AUGMENTIN XR	brand	96-107	false

DDI-DrugBank.d419.s4	However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.
AUGMENTIN XR	brand	126-137	allopurinol	drug	143-153	false

DDI-DrugBank.d419.s5	In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
broad-spectrum antibiotics	group	21-46	AUGMENTIN XR	brand	49-60	false
broad-spectrum antibiotics	group	21-46	contraceptives	group	94-107	effect
AUGMENTIN XR	brand	49-60	contraceptives	group	94-107	effect

DDI-DrugBank.d257.s0	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
Levo-Dromoran	brand	54-66	central nervous system depressants	group	77-110	effect
Levo-Dromoran	brand	54-66	alcohol	drug	117-123	effect
Levo-Dromoran	brand	54-66	sedatives	group	126-134	effect
Levo-Dromoran	brand	54-66	hypnotics	group	137-145	effect
Levo-Dromoran	brand	54-66	opioids	group	154-160	effect
Levo-Dromoran	brand	54-66	anesthetics	group	171-181	effect
Levo-Dromoran	brand	54-66	barbiturates	group	184-195	effect
Levo-Dromoran	brand	54-66	tricyclic antidepressants	group	198-222	effect
Levo-Dromoran	brand	54-66	phenothiazines	group	225-238	effect
Levo-Dromoran	brand	54-66	tranquilizers	group	241-253	effect
Levo-Dromoran	brand	54-66	skeletal muscle relaxants	group	256-280	effect
Levo-Dromoran	brand	54-66	antihistamines	group	286-299	effect
central nervous system depressants	group	77-110	alcohol	drug	117-123	false
central nervous system depressants	group	77-110	sedatives	group	126-134	false
central nervous system depressants	group	77-110	hypnotics	group	137-145	false
central nervous system depressants	group	77-110	opioids	group	154-160	false
central nervous system depressants	group	77-110	anesthetics	group	171-181	false
central nervous system depressants	group	77-110	barbiturates	group	184-195	false
central nervous system depressants	group	77-110	tricyclic antidepressants	group	198-222	false
central nervous system depressants	group	77-110	phenothiazines	group	225-238	false
central nervous system depressants	group	77-110	tranquilizers	group	241-253	false
central nervous system depressants	group	77-110	skeletal muscle relaxants	group	256-280	false
central nervous system depressants	group	77-110	antihistamines	group	286-299	false
alcohol	drug	117-123	sedatives	group	126-134	false
alcohol	drug	117-123	hypnotics	group	137-145	false
alcohol	drug	117-123	opioids	group	154-160	false
alcohol	drug	117-123	anesthetics	group	171-181	false
alcohol	drug	117-123	barbiturates	group	184-195	false
alcohol	drug	117-123	tricyclic antidepressants	group	198-222	false
alcohol	drug	117-123	phenothiazines	group	225-238	false
alcohol	drug	117-123	tranquilizers	group	241-253	false
alcohol	drug	117-123	skeletal muscle relaxants	group	256-280	false
alcohol	drug	117-123	antihistamines	group	286-299	false
sedatives	group	126-134	hypnotics	group	137-145	false
sedatives	group	126-134	opioids	group	154-160	false
sedatives	group	126-134	anesthetics	group	171-181	false
sedatives	group	126-134	barbiturates	group	184-195	false
sedatives	group	126-134	tricyclic antidepressants	group	198-222	false
sedatives	group	126-134	phenothiazines	group	225-238	false
sedatives	group	126-134	tranquilizers	group	241-253	false
sedatives	group	126-134	skeletal muscle relaxants	group	256-280	false
sedatives	group	126-134	antihistamines	group	286-299	false
hypnotics	group	137-145	opioids	group	154-160	false
hypnotics	group	137-145	anesthetics	group	171-181	false
hypnotics	group	137-145	barbiturates	group	184-195	false
hypnotics	group	137-145	tricyclic antidepressants	group	198-222	false
hypnotics	group	137-145	phenothiazines	group	225-238	false
hypnotics	group	137-145	tranquilizers	group	241-253	false
hypnotics	group	137-145	skeletal muscle relaxants	group	256-280	false
hypnotics	group	137-145	antihistamines	group	286-299	false
opioids	group	154-160	anesthetics	group	171-181	false
opioids	group	154-160	barbiturates	group	184-195	false
opioids	group	154-160	tricyclic antidepressants	group	198-222	false
opioids	group	154-160	phenothiazines	group	225-238	false
opioids	group	154-160	tranquilizers	group	241-253	false
opioids	group	154-160	skeletal muscle relaxants	group	256-280	false
opioids	group	154-160	antihistamines	group	286-299	false
anesthetics	group	171-181	barbiturates	group	184-195	false
anesthetics	group	171-181	tricyclic antidepressants	group	198-222	false
anesthetics	group	171-181	phenothiazines	group	225-238	false
anesthetics	group	171-181	tranquilizers	group	241-253	false
anesthetics	group	171-181	skeletal muscle relaxants	group	256-280	false
anesthetics	group	171-181	antihistamines	group	286-299	false
barbiturates	group	184-195	tricyclic antidepressants	group	198-222	false
barbiturates	group	184-195	phenothiazines	group	225-238	false
barbiturates	group	184-195	tranquilizers	group	241-253	false
barbiturates	group	184-195	skeletal muscle relaxants	group	256-280	false
barbiturates	group	184-195	antihistamines	group	286-299	false
tricyclic antidepressants	group	198-222	phenothiazines	group	225-238	false
tricyclic antidepressants	group	198-222	tranquilizers	group	241-253	false
tricyclic antidepressants	group	198-222	skeletal muscle relaxants	group	256-280	false
tricyclic antidepressants	group	198-222	antihistamines	group	286-299	false
phenothiazines	group	225-238	tranquilizers	group	241-253	false
phenothiazines	group	225-238	skeletal muscle relaxants	group	256-280	false
phenothiazines	group	225-238	antihistamines	group	286-299	false
tranquilizers	group	241-253	skeletal muscle relaxants	group	256-280	false
tranquilizers	group	241-253	antihistamines	group	286-299	false
skeletal muscle relaxants	group	256-280	antihistamines	group	286-299	false

DDI-DrugBank.d257.s3	Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.
MAO inhibitors	group	32-45	Levo-Dromoran	brand	51-63	false
MAO inhibitors	group	32-45	MAO inhibitors	group	119-132	false
Levo-Dromoran	brand	51-63	MAO inhibitors	group	119-132	advise

DDI-DrugBank.d257.s4	Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration.
Levo-Dromoran	brand	56-68	levorphanol	drug	277-287	false

DDI-DrugBank.d257.s6	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
Mixed Agonist/Antagonist Opioid Analgesics	group	18-59	Agonist/antagonist analgesics	group	62-90	false
Mixed Agonist/Antagonist Opioid Analgesics	group	18-59	pentazocine	drug	97-107	false
Mixed Agonist/Antagonist Opioid Analgesics	group	18-59	nalbuphine	drug	110-119	false
Mixed Agonist/Antagonist Opioid Analgesics	group	18-59	butorphanol	drug	122-132	false
Mixed Agonist/Antagonist Opioid Analgesics	group	18-59	dezocine	drug	135-142	false
Mixed Agonist/Antagonist Opioid Analgesics	group	18-59	buprenorphine	drug	148-160	false
Mixed Agonist/Antagonist Opioid Analgesics	group	18-59	pure agonist opioid analgesic	group	263-291	false
Mixed Agonist/Antagonist Opioid Analgesics	group	18-59	Levo-Dromoran	brand	301-313	false
Agonist/antagonist analgesics	group	62-90	pentazocine	drug	97-107	false
Agonist/antagonist analgesics	group	62-90	nalbuphine	drug	110-119	false
Agonist/antagonist analgesics	group	62-90	butorphanol	drug	122-132	false
Agonist/antagonist analgesics	group	62-90	dezocine	drug	135-142	false
Agonist/antagonist analgesics	group	62-90	buprenorphine	drug	148-160	false
Agonist/antagonist analgesics	group	62-90	pure agonist opioid analgesic	group	263-291	false
Agonist/antagonist analgesics	group	62-90	Levo-Dromoran	brand	301-313	advise
pentazocine	drug	97-107	nalbuphine	drug	110-119	false
pentazocine	drug	97-107	butorphanol	drug	122-132	false
pentazocine	drug	97-107	dezocine	drug	135-142	false
pentazocine	drug	97-107	buprenorphine	drug	148-160	false
pentazocine	drug	97-107	pure agonist opioid analgesic	group	263-291	false
pentazocine	drug	97-107	Levo-Dromoran	brand	301-313	advise
nalbuphine	drug	110-119	butorphanol	drug	122-132	false
nalbuphine	drug	110-119	dezocine	drug	135-142	false
nalbuphine	drug	110-119	buprenorphine	drug	148-160	false
nalbuphine	drug	110-119	pure agonist opioid analgesic	group	263-291	false
nalbuphine	drug	110-119	Levo-Dromoran	brand	301-313	advise
butorphanol	drug	122-132	dezocine	drug	135-142	false
butorphanol	drug	122-132	buprenorphine	drug	148-160	false
butorphanol	drug	122-132	pure agonist opioid analgesic	group	263-291	false
butorphanol	drug	122-132	Levo-Dromoran	brand	301-313	advise
dezocine	drug	135-142	buprenorphine	drug	148-160	false
dezocine	drug	135-142	pure agonist opioid analgesic	group	263-291	false
dezocine	drug	135-142	Levo-Dromoran	brand	301-313	advise
buprenorphine	drug	148-160	pure agonist opioid analgesic	group	263-291	false
buprenorphine	drug	148-160	Levo-Dromoran	brand	301-313	advise
pure agonist opioid analgesic	group	263-291	Levo-Dromoran	brand	301-313	advise

DDI-DrugBank.d257.s7	In opioid-dependent patients, mixed agonist/antagonist analgesics may precipitate withdrawal symptoms.
opioid	group	3-8	mixed agonist/antagonist analgesics	group	30-64	false

DDI-DrugBank.d160.s0	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
ethambutol	drug	46-55	aluminum hydroxide	drug	76-93	mechanism
ethambutol	drug	46-55	antacid	group	106-112	false
ethambutol	drug	46-55	ethambutol	drug	220-229	false
ethambutol	drug	46-55	ethambutol	drug	314-323	false
ethambutol	drug	46-55	antacid products	group	349-364	false
aluminum hydroxide	drug	76-93	antacid	group	106-112	false
aluminum hydroxide	drug	76-93	ethambutol	drug	220-229	false
aluminum hydroxide	drug	76-93	ethambutol	drug	314-323	false
aluminum hydroxide	drug	76-93	antacid products	group	349-364	false
antacid	group	106-112	ethambutol	drug	220-229	false
antacid	group	106-112	ethambutol	drug	314-323	false
antacid	group	106-112	antacid products	group	349-364	false
ethambutol	drug	220-229	ethambutol	drug	314-323	false
ethambutol	drug	220-229	antacid products	group	349-364	false
ethambutol	drug	314-323	antacid products	group	349-364	false

DDI-DrugBank.d160.s1	It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
ethambutol	drug	56-65	aluminum hydroxide	drug	72-89	advise
ethambutol	drug	56-65	antacids	group	102-109	false
ethambutol	drug	56-65	ethambutol	drug	142-151	false
aluminum hydroxide	drug	72-89	antacids	group	102-109	false
aluminum hydroxide	drug	72-89	ethambutol	drug	142-151	false
antacids	group	102-109	ethambutol	drug	142-151	false

DDI-DrugBank.d538.s0	Known drug interactions include barbiturates, tranquilizers, and alcohol.
barbiturates	group	32-43	tranquilizers	group	46-58	false
barbiturates	group	32-43	alcohol	drug	65-71	false
tranquilizers	group	46-58	alcohol	drug	65-71	false

DDI-DrugBank.d538.s1	Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
Diphenoxylate HCl	drug	0-16	atropine sulfate	drug	22-37	false
Diphenoxylate HCl	drug	0-16	MAO inhibitors	group	57-70	int
Diphenoxylate HCl	drug	0-16	diphenoxylate hydrochloride	drug	99-125	false
atropine sulfate	drug	22-37	MAO inhibitors	group	57-70	int
atropine sulfate	drug	22-37	diphenoxylate hydrochloride	drug	99-125	false
MAO inhibitors	group	57-70	diphenoxylate hydrochloride	drug	99-125	false

DDI-DrugBank.d21.s0	Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
ELSPAR	brand	48-53	methotrexate	drug	93-104	effect
ELSPAR	brand	48-53	methotrexate	drug	143-154	false
methotrexate	drug	93-104	methotrexate	drug	143-154	false

DDI-DrugBank.d21.s1	These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.
methotrexate	drug	64-75	ELSPAR	brand	82-87	advise
methotrexate	drug	64-75	ELSPAR	brand	121-126	false
ELSPAR	brand	82-87	ELSPAR	brand	121-126	false

DDI-DrugBank.d64.s0	Addition or deletion of any drug from the therapeutic regimen of patients receiving oral anticoagulants may affect patient response to the anticoagulant.
anticoagulants	group	89-102	anticoagulant	group	139-151	false

DDI-DrugBank.d64.s3	For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
cholestyramine	drug	19-32	anticoagulants	group	94-107	mechanism
cholestyramine	drug	19-32	vitamin K	group	113-121	mechanism
anticoagulants	group	94-107	vitamin K	group	113-121	false

DDI-DrugBank.d64.s4	Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.
Chloral hydrate	drug	0-14	anticoagulant	group	78-90	mechanism

DDI-DrugBank.d64.s6	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;
anticoagulant	group	47-59	adrenocortical steroids	group	143-165	effect

DDI-DrugBank.d64.s29	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
anticoagulant	group	47-59	adrenocortical steroids	group	143-165	effect
anticoagulant	group	47-59	alcohol	drug	167-173	effect
anticoagulant	group	47-59	antacids	group	176-183	effect
anticoagulant	group	47-59	antihistamines	group	185-198	effect
anticoagulant	group	47-59	barbiturates	group	200-211	effect
anticoagulant	group	47-59	carbamazepine	drug	213-225	effect
anticoagulant	group	47-59	chloral hydrate	drug	227-241	effect
anticoagulant	group	47-59	chlordiazepoxide	drug	244-259	effect
anticoagulant	group	47-59	cholestyramine	drug	261-274	effect
anticoagulant	group	47-59	vitamin K	group	289-297	effect
anticoagulant	group	47-59	diuretics	group	299-307	effect
anticoagulant	group	47-59	ethchlorvynol	drug	310-322	effect
anticoagulant	group	47-59	glutethimide	drug	324-335	effect
anticoagulant	group	47-59	griseofulvin	drug	337-348	effect
anticoagulant	group	47-59	haloperidol	drug	350-360	effect
anticoagulant	group	47-59	meprobamate	drug	362-372	effect
anticoagulant	group	47-59	contraceptives	group	379-392	effect
anticoagulant	group	47-59	paraldehyde	drug	394-404	effect
anticoagulant	group	47-59	primidone	drug	406-414	effect
anticoagulant	group	47-59	ranitidine	drug	416-425	effect
anticoagulant	group	47-59	rifampin	drug	428-435	effect
anticoagulant	group	47-59	vitamin C	drug	480-488	effect
anticoagulant	group	47-59	warfarin sodium	drug	490-504	effect
adrenocortical steroids	group	143-165	alcohol	drug	167-173	false
adrenocortical steroids	group	143-165	antacids	group	176-183	false
adrenocortical steroids	group	143-165	antihistamines	group	185-198	false
adrenocortical steroids	group	143-165	barbiturates	group	200-211	false
adrenocortical steroids	group	143-165	carbamazepine	drug	213-225	false
adrenocortical steroids	group	143-165	chloral hydrate	drug	227-241	false
adrenocortical steroids	group	143-165	chlordiazepoxide	drug	244-259	false
adrenocortical steroids	group	143-165	cholestyramine	drug	261-274	false
adrenocortical steroids	group	143-165	vitamin K	group	289-297	false
adrenocortical steroids	group	143-165	diuretics	group	299-307	false
adrenocortical steroids	group	143-165	ethchlorvynol	drug	310-322	false
adrenocortical steroids	group	143-165	glutethimide	drug	324-335	false
adrenocortical steroids	group	143-165	griseofulvin	drug	337-348	false
adrenocortical steroids	group	143-165	haloperidol	drug	350-360	false
adrenocortical steroids	group	143-165	meprobamate	drug	362-372	false
adrenocortical steroids	group	143-165	contraceptives	group	379-392	false
adrenocortical steroids	group	143-165	paraldehyde	drug	394-404	false
adrenocortical steroids	group	143-165	primidone	drug	406-414	false
adrenocortical steroids	group	143-165	ranitidine	drug	416-425	false
adrenocortical steroids	group	143-165	rifampin	drug	428-435	false
adrenocortical steroids	group	143-165	vitamin C	drug	480-488	false
adrenocortical steroids	group	143-165	warfarin sodium	drug	490-504	false
alcohol	drug	167-173	antacids	group	176-183	false
alcohol	drug	167-173	antihistamines	group	185-198	false
alcohol	drug	167-173	barbiturates	group	200-211	false
alcohol	drug	167-173	carbamazepine	drug	213-225	false
alcohol	drug	167-173	chloral hydrate	drug	227-241	false
alcohol	drug	167-173	chlordiazepoxide	drug	244-259	false
alcohol	drug	167-173	cholestyramine	drug	261-274	false
alcohol	drug	167-173	vitamin K	group	289-297	false
alcohol	drug	167-173	diuretics	group	299-307	false
alcohol	drug	167-173	ethchlorvynol	drug	310-322	false
alcohol	drug	167-173	glutethimide	drug	324-335	false
alcohol	drug	167-173	griseofulvin	drug	337-348	false
alcohol	drug	167-173	haloperidol	drug	350-360	false
alcohol	drug	167-173	meprobamate	drug	362-372	false
alcohol	drug	167-173	contraceptives	group	379-392	false
alcohol	drug	167-173	paraldehyde	drug	394-404	false
alcohol	drug	167-173	primidone	drug	406-414	false
alcohol	drug	167-173	ranitidine	drug	416-425	false
alcohol	drug	167-173	rifampin	drug	428-435	false
alcohol	drug	167-173	vitamin C	drug	480-488	false
alcohol	drug	167-173	warfarin sodium	drug	490-504	false
antacids	group	176-183	antihistamines	group	185-198	false
antacids	group	176-183	barbiturates	group	200-211	false
antacids	group	176-183	carbamazepine	drug	213-225	false
antacids	group	176-183	chloral hydrate	drug	227-241	false
antacids	group	176-183	chlordiazepoxide	drug	244-259	false
antacids	group	176-183	cholestyramine	drug	261-274	false
antacids	group	176-183	vitamin K	group	289-297	false
antacids	group	176-183	diuretics	group	299-307	false
antacids	group	176-183	ethchlorvynol	drug	310-322	false
antacids	group	176-183	glutethimide	drug	324-335	false
antacids	group	176-183	griseofulvin	drug	337-348	false
antacids	group	176-183	haloperidol	drug	350-360	false
antacids	group	176-183	meprobamate	drug	362-372	false
antacids	group	176-183	contraceptives	group	379-392	false
antacids	group	176-183	paraldehyde	drug	394-404	false
antacids	group	176-183	primidone	drug	406-414	false
antacids	group	176-183	ranitidine	drug	416-425	false
antacids	group	176-183	rifampin	drug	428-435	false
antacids	group	176-183	vitamin C	drug	480-488	false
antacids	group	176-183	warfarin sodium	drug	490-504	false
antihistamines	group	185-198	barbiturates	group	200-211	false
antihistamines	group	185-198	carbamazepine	drug	213-225	false
antihistamines	group	185-198	chloral hydrate	drug	227-241	false
antihistamines	group	185-198	chlordiazepoxide	drug	244-259	false
antihistamines	group	185-198	cholestyramine	drug	261-274	false
antihistamines	group	185-198	vitamin K	group	289-297	false
antihistamines	group	185-198	diuretics	group	299-307	false
antihistamines	group	185-198	ethchlorvynol	drug	310-322	false
antihistamines	group	185-198	glutethimide	drug	324-335	false
antihistamines	group	185-198	griseofulvin	drug	337-348	false
antihistamines	group	185-198	haloperidol	drug	350-360	false
antihistamines	group	185-198	meprobamate	drug	362-372	false
antihistamines	group	185-198	contraceptives	group	379-392	false
antihistamines	group	185-198	paraldehyde	drug	394-404	false
antihistamines	group	185-198	primidone	drug	406-414	false
antihistamines	group	185-198	ranitidine	drug	416-425	false
antihistamines	group	185-198	rifampin	drug	428-435	false
antihistamines	group	185-198	vitamin C	drug	480-488	false
antihistamines	group	185-198	warfarin sodium	drug	490-504	false
barbiturates	group	200-211	carbamazepine	drug	213-225	false
barbiturates	group	200-211	chloral hydrate	drug	227-241	false
barbiturates	group	200-211	chlordiazepoxide	drug	244-259	false
barbiturates	group	200-211	cholestyramine	drug	261-274	false
barbiturates	group	200-211	vitamin K	group	289-297	false
barbiturates	group	200-211	diuretics	group	299-307	false
barbiturates	group	200-211	ethchlorvynol	drug	310-322	false
barbiturates	group	200-211	glutethimide	drug	324-335	false
barbiturates	group	200-211	griseofulvin	drug	337-348	false
barbiturates	group	200-211	haloperidol	drug	350-360	false
barbiturates	group	200-211	meprobamate	drug	362-372	false
barbiturates	group	200-211	contraceptives	group	379-392	false
barbiturates	group	200-211	paraldehyde	drug	394-404	false
barbiturates	group	200-211	primidone	drug	406-414	false
barbiturates	group	200-211	ranitidine	drug	416-425	false
barbiturates	group	200-211	rifampin	drug	428-435	false
barbiturates	group	200-211	vitamin C	drug	480-488	false
barbiturates	group	200-211	warfarin sodium	drug	490-504	false
carbamazepine	drug	213-225	chloral hydrate	drug	227-241	false
carbamazepine	drug	213-225	chlordiazepoxide	drug	244-259	false
carbamazepine	drug	213-225	cholestyramine	drug	261-274	false
carbamazepine	drug	213-225	vitamin K	group	289-297	false
carbamazepine	drug	213-225	diuretics	group	299-307	false
carbamazepine	drug	213-225	ethchlorvynol	drug	310-322	false
carbamazepine	drug	213-225	glutethimide	drug	324-335	false
carbamazepine	drug	213-225	griseofulvin	drug	337-348	false
carbamazepine	drug	213-225	haloperidol	drug	350-360	false
carbamazepine	drug	213-225	meprobamate	drug	362-372	false
carbamazepine	drug	213-225	contraceptives	group	379-392	false
carbamazepine	drug	213-225	paraldehyde	drug	394-404	false
carbamazepine	drug	213-225	primidone	drug	406-414	false
carbamazepine	drug	213-225	ranitidine	drug	416-425	false
carbamazepine	drug	213-225	rifampin	drug	428-435	false
carbamazepine	drug	213-225	vitamin C	drug	480-488	false
carbamazepine	drug	213-225	warfarin sodium	drug	490-504	false
chloral hydrate	drug	227-241	chlordiazepoxide	drug	244-259	false
chloral hydrate	drug	227-241	cholestyramine	drug	261-274	false
chloral hydrate	drug	227-241	vitamin K	group	289-297	false
chloral hydrate	drug	227-241	diuretics	group	299-307	false
chloral hydrate	drug	227-241	ethchlorvynol	drug	310-322	false
chloral hydrate	drug	227-241	glutethimide	drug	324-335	false
chloral hydrate	drug	227-241	griseofulvin	drug	337-348	false
chloral hydrate	drug	227-241	haloperidol	drug	350-360	false
chloral hydrate	drug	227-241	meprobamate	drug	362-372	false
chloral hydrate	drug	227-241	contraceptives	group	379-392	false
chloral hydrate	drug	227-241	paraldehyde	drug	394-404	false
chloral hydrate	drug	227-241	primidone	drug	406-414	false
chloral hydrate	drug	227-241	ranitidine	drug	416-425	false
chloral hydrate	drug	227-241	rifampin	drug	428-435	false
chloral hydrate	drug	227-241	vitamin C	drug	480-488	false
chloral hydrate	drug	227-241	warfarin sodium	drug	490-504	false
chlordiazepoxide	drug	244-259	cholestyramine	drug	261-274	false
chlordiazepoxide	drug	244-259	vitamin K	group	289-297	false
chlordiazepoxide	drug	244-259	diuretics	group	299-307	false
chlordiazepoxide	drug	244-259	ethchlorvynol	drug	310-322	false
chlordiazepoxide	drug	244-259	glutethimide	drug	324-335	false
chlordiazepoxide	drug	244-259	griseofulvin	drug	337-348	false
chlordiazepoxide	drug	244-259	haloperidol	drug	350-360	false
chlordiazepoxide	drug	244-259	meprobamate	drug	362-372	false
chlordiazepoxide	drug	244-259	contraceptives	group	379-392	false
chlordiazepoxide	drug	244-259	paraldehyde	drug	394-404	false
chlordiazepoxide	drug	244-259	primidone	drug	406-414	false
chlordiazepoxide	drug	244-259	ranitidine	drug	416-425	false
chlordiazepoxide	drug	244-259	rifampin	drug	428-435	false
chlordiazepoxide	drug	244-259	vitamin C	drug	480-488	false
chlordiazepoxide	drug	244-259	warfarin sodium	drug	490-504	false
cholestyramine	drug	261-274	vitamin K	group	289-297	false
cholestyramine	drug	261-274	diuretics	group	299-307	false
cholestyramine	drug	261-274	ethchlorvynol	drug	310-322	false
cholestyramine	drug	261-274	glutethimide	drug	324-335	false
cholestyramine	drug	261-274	griseofulvin	drug	337-348	false
cholestyramine	drug	261-274	haloperidol	drug	350-360	false
cholestyramine	drug	261-274	meprobamate	drug	362-372	false
cholestyramine	drug	261-274	contraceptives	group	379-392	false
cholestyramine	drug	261-274	paraldehyde	drug	394-404	false
cholestyramine	drug	261-274	primidone	drug	406-414	false
cholestyramine	drug	261-274	ranitidine	drug	416-425	false
cholestyramine	drug	261-274	rifampin	drug	428-435	false
cholestyramine	drug	261-274	vitamin C	drug	480-488	false
cholestyramine	drug	261-274	warfarin sodium	drug	490-504	false
vitamin K	group	289-297	diuretics	group	299-307	false
vitamin K	group	289-297	ethchlorvynol	drug	310-322	false
vitamin K	group	289-297	glutethimide	drug	324-335	false
vitamin K	group	289-297	griseofulvin	drug	337-348	false
vitamin K	group	289-297	haloperidol	drug	350-360	false
vitamin K	group	289-297	meprobamate	drug	362-372	false
vitamin K	group	289-297	contraceptives	group	379-392	false
vitamin K	group	289-297	paraldehyde	drug	394-404	false
vitamin K	group	289-297	primidone	drug	406-414	false
vitamin K	group	289-297	ranitidine	drug	416-425	false
vitamin K	group	289-297	rifampin	drug	428-435	false
vitamin K	group	289-297	vitamin C	drug	480-488	false
vitamin K	group	289-297	warfarin sodium	drug	490-504	false
diuretics	group	299-307	ethchlorvynol	drug	310-322	false
diuretics	group	299-307	glutethimide	drug	324-335	false
diuretics	group	299-307	griseofulvin	drug	337-348	false
diuretics	group	299-307	haloperidol	drug	350-360	false
diuretics	group	299-307	meprobamate	drug	362-372	false
diuretics	group	299-307	contraceptives	group	379-392	false
diuretics	group	299-307	paraldehyde	drug	394-404	false
diuretics	group	299-307	primidone	drug	406-414	false
diuretics	group	299-307	ranitidine	drug	416-425	false
diuretics	group	299-307	rifampin	drug	428-435	false
diuretics	group	299-307	vitamin C	drug	480-488	false
diuretics	group	299-307	warfarin sodium	drug	490-504	false
ethchlorvynol	drug	310-322	glutethimide	drug	324-335	false
ethchlorvynol	drug	310-322	griseofulvin	drug	337-348	false
ethchlorvynol	drug	310-322	haloperidol	drug	350-360	false
ethchlorvynol	drug	310-322	meprobamate	drug	362-372	false
ethchlorvynol	drug	310-322	contraceptives	group	379-392	false
ethchlorvynol	drug	310-322	paraldehyde	drug	394-404	false
ethchlorvynol	drug	310-322	primidone	drug	406-414	false
ethchlorvynol	drug	310-322	ranitidine	drug	416-425	false
ethchlorvynol	drug	310-322	rifampin	drug	428-435	false
ethchlorvynol	drug	310-322	vitamin C	drug	480-488	false
ethchlorvynol	drug	310-322	warfarin sodium	drug	490-504	false
glutethimide	drug	324-335	griseofulvin	drug	337-348	false
glutethimide	drug	324-335	haloperidol	drug	350-360	false
glutethimide	drug	324-335	meprobamate	drug	362-372	false
glutethimide	drug	324-335	contraceptives	group	379-392	false
glutethimide	drug	324-335	paraldehyde	drug	394-404	false
glutethimide	drug	324-335	primidone	drug	406-414	false
glutethimide	drug	324-335	ranitidine	drug	416-425	false
glutethimide	drug	324-335	rifampin	drug	428-435	false
glutethimide	drug	324-335	vitamin C	drug	480-488	false
glutethimide	drug	324-335	warfarin sodium	drug	490-504	false
griseofulvin	drug	337-348	haloperidol	drug	350-360	false
griseofulvin	drug	337-348	meprobamate	drug	362-372	false
griseofulvin	drug	337-348	contraceptives	group	379-392	false
griseofulvin	drug	337-348	paraldehyde	drug	394-404	false
griseofulvin	drug	337-348	primidone	drug	406-414	false
griseofulvin	drug	337-348	ranitidine	drug	416-425	false
griseofulvin	drug	337-348	rifampin	drug	428-435	false
griseofulvin	drug	337-348	vitamin C	drug	480-488	false
griseofulvin	drug	337-348	warfarin sodium	drug	490-504	false
haloperidol	drug	350-360	meprobamate	drug	362-372	false
haloperidol	drug	350-360	contraceptives	group	379-392	false
haloperidol	drug	350-360	paraldehyde	drug	394-404	false
haloperidol	drug	350-360	primidone	drug	406-414	false
haloperidol	drug	350-360	ranitidine	drug	416-425	false
haloperidol	drug	350-360	rifampin	drug	428-435	false
haloperidol	drug	350-360	vitamin C	drug	480-488	false
haloperidol	drug	350-360	warfarin sodium	drug	490-504	false
meprobamate	drug	362-372	contraceptives	group	379-392	false
meprobamate	drug	362-372	paraldehyde	drug	394-404	false
meprobamate	drug	362-372	primidone	drug	406-414	false
meprobamate	drug	362-372	ranitidine	drug	416-425	false
meprobamate	drug	362-372	rifampin	drug	428-435	false
meprobamate	drug	362-372	vitamin C	drug	480-488	false
meprobamate	drug	362-372	warfarin sodium	drug	490-504	false
contraceptives	group	379-392	paraldehyde	drug	394-404	false
contraceptives	group	379-392	primidone	drug	406-414	false
contraceptives	group	379-392	ranitidine	drug	416-425	false
contraceptives	group	379-392	rifampin	drug	428-435	false
contraceptives	group	379-392	vitamin C	drug	480-488	false
contraceptives	group	379-392	warfarin sodium	drug	490-504	false
paraldehyde	drug	394-404	primidone	drug	406-414	false
paraldehyde	drug	394-404	ranitidine	drug	416-425	false
paraldehyde	drug	394-404	rifampin	drug	428-435	false
paraldehyde	drug	394-404	vitamin C	drug	480-488	false
paraldehyde	drug	394-404	warfarin sodium	drug	490-504	false
primidone	drug	406-414	ranitidine	drug	416-425	false
primidone	drug	406-414	rifampin	drug	428-435	false
primidone	drug	406-414	vitamin C	drug	480-488	false
primidone	drug	406-414	warfarin sodium	drug	490-504	false
ranitidine	drug	416-425	rifampin	drug	428-435	false
ranitidine	drug	416-425	vitamin C	drug	480-488	false
ranitidine	drug	416-425	warfarin sodium	drug	490-504	false
rifampin	drug	428-435	vitamin C	drug	480-488	false
rifampin	drug	428-435	warfarin sodium	drug	490-504	false
vitamin C	drug	480-488	warfarin sodium	drug	490-504	false

DDI-DrugBank.d64.s30	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;
anticoagulant	group	40-52	alcohol	drug	115-121	effect

DDI-DrugBank.d64.s79	salicylates;sulfinpyrazone;
salicylates	group	0-10	sulfinpyrazone	drug	12-25	false

DDI-DrugBank.d64.s85	trimethoprim/sulfamethoxazole;
trimethoprim	drug	0-11	sulfamethoxazole	drug	13-28	false

DDI-DrugBank.d64.s87	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
anticoagulant	group	40-52	alcohol	drug	115-121	effect
anticoagulant	group	40-52	allopurinol	drug	124-134	effect
anticoagulant	group	40-52	aminosalicylic acid	drug	136-154	effect
anticoagulant	group	40-52	amiodarone	drug	156-165	effect
anticoagulant	group	40-52	anabolic steroids	group	167-183	effect
anticoagulant	group	40-52	antibiotics	group	185-195	effect
anticoagulant	group	40-52	bromelains	drug	197-206	effect
anticoagulant	group	40-52	chloral hydrate	drug	208-222	effect
anticoagulant	group	40-52	chlorpropamide	drug	225-238	effect
anticoagulant	group	40-52	chymotrypsin	drug	240-251	effect
anticoagulant	group	40-52	cimetidine	drug	253-262	effect
anticoagulant	group	40-52	cinchophen	drug	264-273	effect
anticoagulant	group	40-52	clofibrate	drug	275-284	effect
anticoagulant	group	40-52	dextran	drug	286-292	effect
anticoagulant	group	40-52	dextrothyroxine	drug	294-308	effect
anticoagulant	group	40-52	diazoxide	drug	310-318	effect
anticoagulant	group	40-52	diflunisal	drug	341-350	effect
anticoagulant	group	40-52	disulfiram	drug	352-361	effect
anticoagulant	group	40-52	ethacrynic acid	drug	394-408	effect
anticoagulant	group	40-52	fenoprofen	drug	410-419	effect
anticoagulant	group	40-52	glucagon	drug	421-428	effect
anticoagulant	group	40-52	ibuprofen	drug	448-456	effect
anticoagulant	group	40-52	indomethacin	drug	458-469	effect
anticoagulant	group	40-52	influenza virus vaccine	group	471-493	effect
anticoagulant	group	40-52	anesthetics	group	506-516	effect
anticoagulant	group	40-52	mefenamic acid	drug	518-531	effect
anticoagulant	group	40-52	methyldopa	drug	533-542	effect
anticoagulant	group	40-52	methylphenidate	drug	544-558	effect
anticoagulant	group	40-52	metronidazole	drug	560-572	effect
anticoagulant	group	40-52	miconazole	drug	574-583	effect
anticoagulant	group	40-52	monoamine oxidase inhibitors	group	585-612	effect
anticoagulant	group	40-52	nalidixic acid	drug	614-627	effect
anticoagulant	group	40-52	naproxen	drug	629-636	effect
anticoagulant	group	40-52	oxolinic acid	drug	638-650	effect
anticoagulant	group	40-52	oxyphenbutazone	drug	652-666	effect
anticoagulant	group	40-52	pentoxifylline	drug	668-681	effect
anticoagulant	group	40-52	phenylbutazone	drug	683-696	effect
anticoagulant	group	40-52	phenyramidol	drug_n	698-709	effect
anticoagulant	group	40-52	phenytoin	drug	711-719	effect
anticoagulant	group	40-52	prolonged narcotics	group	743-761	effect
anticoagulant	group	40-52	pyrazolones	group	763-773	effect
anticoagulant	group	40-52	quinidine	drug	775-783	effect
anticoagulant	group	40-52	quinine	drug	785-791	effect
anticoagulant	group	40-52	ranitidine	drug	793-802	effect
anticoagulant	group	40-52	salicylates	group	805-815	effect
anticoagulant	group	40-52	sulfinpyrazone	drug	817-830	effect
anticoagulant	group	40-52	sulfonamides	group	832-843	effect
anticoagulant	group	40-52	sulindac	drug	858-865	effect
anticoagulant	group	40-52	thyroid drugs	group	867-879	effect
anticoagulant	group	40-52	tolbutamide	drug	881-891	effect
anticoagulant	group	40-52	triclofos sodium	drug	893-908	effect
anticoagulant	group	40-52	trimethoprim	drug	910-921	effect
anticoagulant	group	40-52	sulfamethoxazole	drug	923-938	effect
anticoagulant	group	40-52	warfarin sodium	drug	983-997	effect
alcohol	drug	115-121	allopurinol	drug	124-134	false
alcohol	drug	115-121	aminosalicylic acid	drug	136-154	false
alcohol	drug	115-121	amiodarone	drug	156-165	false
alcohol	drug	115-121	anabolic steroids	group	167-183	false
alcohol	drug	115-121	antibiotics	group	185-195	false
alcohol	drug	115-121	bromelains	drug	197-206	false
alcohol	drug	115-121	chloral hydrate	drug	208-222	false
alcohol	drug	115-121	chlorpropamide	drug	225-238	false
alcohol	drug	115-121	chymotrypsin	drug	240-251	false
alcohol	drug	115-121	cimetidine	drug	253-262	false
alcohol	drug	115-121	cinchophen	drug	264-273	false
alcohol	drug	115-121	clofibrate	drug	275-284	false
alcohol	drug	115-121	dextran	drug	286-292	false
alcohol	drug	115-121	dextrothyroxine	drug	294-308	false
alcohol	drug	115-121	diazoxide	drug	310-318	false
alcohol	drug	115-121	diflunisal	drug	341-350	false
alcohol	drug	115-121	disulfiram	drug	352-361	false
alcohol	drug	115-121	ethacrynic acid	drug	394-408	false
alcohol	drug	115-121	fenoprofen	drug	410-419	false
alcohol	drug	115-121	glucagon	drug	421-428	false
alcohol	drug	115-121	ibuprofen	drug	448-456	false
alcohol	drug	115-121	indomethacin	drug	458-469	false
alcohol	drug	115-121	influenza virus vaccine	group	471-493	false
alcohol	drug	115-121	anesthetics	group	506-516	false
alcohol	drug	115-121	mefenamic acid	drug	518-531	false
alcohol	drug	115-121	methyldopa	drug	533-542	false
alcohol	drug	115-121	methylphenidate	drug	544-558	false
alcohol	drug	115-121	metronidazole	drug	560-572	false
alcohol	drug	115-121	miconazole	drug	574-583	false
alcohol	drug	115-121	monoamine oxidase inhibitors	group	585-612	false
alcohol	drug	115-121	nalidixic acid	drug	614-627	false
alcohol	drug	115-121	naproxen	drug	629-636	false
alcohol	drug	115-121	oxolinic acid	drug	638-650	false
alcohol	drug	115-121	oxyphenbutazone	drug	652-666	false
alcohol	drug	115-121	pentoxifylline	drug	668-681	false
alcohol	drug	115-121	phenylbutazone	drug	683-696	false
alcohol	drug	115-121	phenyramidol	drug_n	698-709	false
alcohol	drug	115-121	phenytoin	drug	711-719	false
alcohol	drug	115-121	prolonged narcotics	group	743-761	false
alcohol	drug	115-121	pyrazolones	group	763-773	false
alcohol	drug	115-121	quinidine	drug	775-783	false
alcohol	drug	115-121	quinine	drug	785-791	false
alcohol	drug	115-121	ranitidine	drug	793-802	false
alcohol	drug	115-121	salicylates	group	805-815	false
alcohol	drug	115-121	sulfinpyrazone	drug	817-830	false
alcohol	drug	115-121	sulfonamides	group	832-843	false
alcohol	drug	115-121	sulindac	drug	858-865	false
alcohol	drug	115-121	thyroid drugs	group	867-879	false
alcohol	drug	115-121	tolbutamide	drug	881-891	false
alcohol	drug	115-121	triclofos sodium	drug	893-908	false
alcohol	drug	115-121	trimethoprim	drug	910-921	false
alcohol	drug	115-121	sulfamethoxazole	drug	923-938	false
alcohol	drug	115-121	warfarin sodium	drug	983-997	false
allopurinol	drug	124-134	aminosalicylic acid	drug	136-154	false
allopurinol	drug	124-134	amiodarone	drug	156-165	false
allopurinol	drug	124-134	anabolic steroids	group	167-183	false
allopurinol	drug	124-134	antibiotics	group	185-195	false
allopurinol	drug	124-134	bromelains	drug	197-206	false
allopurinol	drug	124-134	chloral hydrate	drug	208-222	false
allopurinol	drug	124-134	chlorpropamide	drug	225-238	false
allopurinol	drug	124-134	chymotrypsin	drug	240-251	false
allopurinol	drug	124-134	cimetidine	drug	253-262	false
allopurinol	drug	124-134	cinchophen	drug	264-273	false
allopurinol	drug	124-134	clofibrate	drug	275-284	false
allopurinol	drug	124-134	dextran	drug	286-292	false
allopurinol	drug	124-134	dextrothyroxine	drug	294-308	false
allopurinol	drug	124-134	diazoxide	drug	310-318	false
allopurinol	drug	124-134	diflunisal	drug	341-350	false
allopurinol	drug	124-134	disulfiram	drug	352-361	false
allopurinol	drug	124-134	ethacrynic acid	drug	394-408	false
allopurinol	drug	124-134	fenoprofen	drug	410-419	false
allopurinol	drug	124-134	glucagon	drug	421-428	false
allopurinol	drug	124-134	ibuprofen	drug	448-456	false
allopurinol	drug	124-134	indomethacin	drug	458-469	false
allopurinol	drug	124-134	influenza virus vaccine	group	471-493	false
allopurinol	drug	124-134	anesthetics	group	506-516	false
allopurinol	drug	124-134	mefenamic acid	drug	518-531	false
allopurinol	drug	124-134	methyldopa	drug	533-542	false
allopurinol	drug	124-134	methylphenidate	drug	544-558	false
allopurinol	drug	124-134	metronidazole	drug	560-572	false
allopurinol	drug	124-134	miconazole	drug	574-583	false
allopurinol	drug	124-134	monoamine oxidase inhibitors	group	585-612	false
allopurinol	drug	124-134	nalidixic acid	drug	614-627	false
allopurinol	drug	124-134	naproxen	drug	629-636	false
allopurinol	drug	124-134	oxolinic acid	drug	638-650	false
allopurinol	drug	124-134	oxyphenbutazone	drug	652-666	false
allopurinol	drug	124-134	pentoxifylline	drug	668-681	false
allopurinol	drug	124-134	phenylbutazone	drug	683-696	false
allopurinol	drug	124-134	phenyramidol	drug_n	698-709	false
allopurinol	drug	124-134	phenytoin	drug	711-719	false
allopurinol	drug	124-134	prolonged narcotics	group	743-761	false
allopurinol	drug	124-134	pyrazolones	group	763-773	false
allopurinol	drug	124-134	quinidine	drug	775-783	false
allopurinol	drug	124-134	quinine	drug	785-791	false
allopurinol	drug	124-134	ranitidine	drug	793-802	false
allopurinol	drug	124-134	salicylates	group	805-815	false
allopurinol	drug	124-134	sulfinpyrazone	drug	817-830	false
allopurinol	drug	124-134	sulfonamides	group	832-843	false
allopurinol	drug	124-134	sulindac	drug	858-865	false
allopurinol	drug	124-134	thyroid drugs	group	867-879	false
allopurinol	drug	124-134	tolbutamide	drug	881-891	false
allopurinol	drug	124-134	triclofos sodium	drug	893-908	false
allopurinol	drug	124-134	trimethoprim	drug	910-921	false
allopurinol	drug	124-134	sulfamethoxazole	drug	923-938	false
allopurinol	drug	124-134	warfarin sodium	drug	983-997	false
aminosalicylic acid	drug	136-154	amiodarone	drug	156-165	false
aminosalicylic acid	drug	136-154	anabolic steroids	group	167-183	false
aminosalicylic acid	drug	136-154	antibiotics	group	185-195	false
aminosalicylic acid	drug	136-154	bromelains	drug	197-206	false
aminosalicylic acid	drug	136-154	chloral hydrate	drug	208-222	false
aminosalicylic acid	drug	136-154	chlorpropamide	drug	225-238	false
aminosalicylic acid	drug	136-154	chymotrypsin	drug	240-251	false
aminosalicylic acid	drug	136-154	cimetidine	drug	253-262	false
aminosalicylic acid	drug	136-154	cinchophen	drug	264-273	false
aminosalicylic acid	drug	136-154	clofibrate	drug	275-284	false
aminosalicylic acid	drug	136-154	dextran	drug	286-292	false
aminosalicylic acid	drug	136-154	dextrothyroxine	drug	294-308	false
aminosalicylic acid	drug	136-154	diazoxide	drug	310-318	false
aminosalicylic acid	drug	136-154	diflunisal	drug	341-350	false
aminosalicylic acid	drug	136-154	disulfiram	drug	352-361	false
aminosalicylic acid	drug	136-154	ethacrynic acid	drug	394-408	false
aminosalicylic acid	drug	136-154	fenoprofen	drug	410-419	false
aminosalicylic acid	drug	136-154	glucagon	drug	421-428	false
aminosalicylic acid	drug	136-154	ibuprofen	drug	448-456	false
aminosalicylic acid	drug	136-154	indomethacin	drug	458-469	false
aminosalicylic acid	drug	136-154	influenza virus vaccine	group	471-493	false
aminosalicylic acid	drug	136-154	anesthetics	group	506-516	false
aminosalicylic acid	drug	136-154	mefenamic acid	drug	518-531	false
aminosalicylic acid	drug	136-154	methyldopa	drug	533-542	false
aminosalicylic acid	drug	136-154	methylphenidate	drug	544-558	false
aminosalicylic acid	drug	136-154	metronidazole	drug	560-572	false
aminosalicylic acid	drug	136-154	miconazole	drug	574-583	false
aminosalicylic acid	drug	136-154	monoamine oxidase inhibitors	group	585-612	false
aminosalicylic acid	drug	136-154	nalidixic acid	drug	614-627	false
aminosalicylic acid	drug	136-154	naproxen	drug	629-636	false
aminosalicylic acid	drug	136-154	oxolinic acid	drug	638-650	false
aminosalicylic acid	drug	136-154	oxyphenbutazone	drug	652-666	false
aminosalicylic acid	drug	136-154	pentoxifylline	drug	668-681	false
aminosalicylic acid	drug	136-154	phenylbutazone	drug	683-696	false
aminosalicylic acid	drug	136-154	phenyramidol	drug_n	698-709	false
aminosalicylic acid	drug	136-154	phenytoin	drug	711-719	false
aminosalicylic acid	drug	136-154	prolonged narcotics	group	743-761	false
aminosalicylic acid	drug	136-154	pyrazolones	group	763-773	false
aminosalicylic acid	drug	136-154	quinidine	drug	775-783	false
aminosalicylic acid	drug	136-154	quinine	drug	785-791	false
aminosalicylic acid	drug	136-154	ranitidine	drug	793-802	false
aminosalicylic acid	drug	136-154	salicylates	group	805-815	false
aminosalicylic acid	drug	136-154	sulfinpyrazone	drug	817-830	false
aminosalicylic acid	drug	136-154	sulfonamides	group	832-843	false
aminosalicylic acid	drug	136-154	sulindac	drug	858-865	false
aminosalicylic acid	drug	136-154	thyroid drugs	group	867-879	false
aminosalicylic acid	drug	136-154	tolbutamide	drug	881-891	false
aminosalicylic acid	drug	136-154	triclofos sodium	drug	893-908	false
aminosalicylic acid	drug	136-154	trimethoprim	drug	910-921	false
aminosalicylic acid	drug	136-154	sulfamethoxazole	drug	923-938	false
aminosalicylic acid	drug	136-154	warfarin sodium	drug	983-997	false
amiodarone	drug	156-165	anabolic steroids	group	167-183	false
amiodarone	drug	156-165	antibiotics	group	185-195	false
amiodarone	drug	156-165	bromelains	drug	197-206	false
amiodarone	drug	156-165	chloral hydrate	drug	208-222	false
amiodarone	drug	156-165	chlorpropamide	drug	225-238	false
amiodarone	drug	156-165	chymotrypsin	drug	240-251	false
amiodarone	drug	156-165	cimetidine	drug	253-262	false
amiodarone	drug	156-165	cinchophen	drug	264-273	false
amiodarone	drug	156-165	clofibrate	drug	275-284	false
amiodarone	drug	156-165	dextran	drug	286-292	false
amiodarone	drug	156-165	dextrothyroxine	drug	294-308	false
amiodarone	drug	156-165	diazoxide	drug	310-318	false
amiodarone	drug	156-165	diflunisal	drug	341-350	false
amiodarone	drug	156-165	disulfiram	drug	352-361	false
amiodarone	drug	156-165	ethacrynic acid	drug	394-408	false
amiodarone	drug	156-165	fenoprofen	drug	410-419	false
amiodarone	drug	156-165	glucagon	drug	421-428	false
amiodarone	drug	156-165	ibuprofen	drug	448-456	false
amiodarone	drug	156-165	indomethacin	drug	458-469	false
amiodarone	drug	156-165	influenza virus vaccine	group	471-493	false
amiodarone	drug	156-165	anesthetics	group	506-516	false
amiodarone	drug	156-165	mefenamic acid	drug	518-531	false
amiodarone	drug	156-165	methyldopa	drug	533-542	false
amiodarone	drug	156-165	methylphenidate	drug	544-558	false
amiodarone	drug	156-165	metronidazole	drug	560-572	false
amiodarone	drug	156-165	miconazole	drug	574-583	false
amiodarone	drug	156-165	monoamine oxidase inhibitors	group	585-612	false
amiodarone	drug	156-165	nalidixic acid	drug	614-627	false
amiodarone	drug	156-165	naproxen	drug	629-636	false
amiodarone	drug	156-165	oxolinic acid	drug	638-650	false
amiodarone	drug	156-165	oxyphenbutazone	drug	652-666	false
amiodarone	drug	156-165	pentoxifylline	drug	668-681	false
amiodarone	drug	156-165	phenylbutazone	drug	683-696	false
amiodarone	drug	156-165	phenyramidol	drug_n	698-709	false
amiodarone	drug	156-165	phenytoin	drug	711-719	false
amiodarone	drug	156-165	prolonged narcotics	group	743-761	false
amiodarone	drug	156-165	pyrazolones	group	763-773	false
amiodarone	drug	156-165	quinidine	drug	775-783	false
amiodarone	drug	156-165	quinine	drug	785-791	false
amiodarone	drug	156-165	ranitidine	drug	793-802	false
amiodarone	drug	156-165	salicylates	group	805-815	false
amiodarone	drug	156-165	sulfinpyrazone	drug	817-830	false
amiodarone	drug	156-165	sulfonamides	group	832-843	false
amiodarone	drug	156-165	sulindac	drug	858-865	false
amiodarone	drug	156-165	thyroid drugs	group	867-879	false
amiodarone	drug	156-165	tolbutamide	drug	881-891	false
amiodarone	drug	156-165	triclofos sodium	drug	893-908	false
amiodarone	drug	156-165	trimethoprim	drug	910-921	false
amiodarone	drug	156-165	sulfamethoxazole	drug	923-938	false
amiodarone	drug	156-165	warfarin sodium	drug	983-997	false
anabolic steroids	group	167-183	antibiotics	group	185-195	false
anabolic steroids	group	167-183	bromelains	drug	197-206	false
anabolic steroids	group	167-183	chloral hydrate	drug	208-222	false
anabolic steroids	group	167-183	chlorpropamide	drug	225-238	false
anabolic steroids	group	167-183	chymotrypsin	drug	240-251	false
anabolic steroids	group	167-183	cimetidine	drug	253-262	false
anabolic steroids	group	167-183	cinchophen	drug	264-273	false
anabolic steroids	group	167-183	clofibrate	drug	275-284	false
anabolic steroids	group	167-183	dextran	drug	286-292	false
anabolic steroids	group	167-183	dextrothyroxine	drug	294-308	false
anabolic steroids	group	167-183	diazoxide	drug	310-318	false
anabolic steroids	group	167-183	diflunisal	drug	341-350	false
anabolic steroids	group	167-183	disulfiram	drug	352-361	false
anabolic steroids	group	167-183	ethacrynic acid	drug	394-408	false
anabolic steroids	group	167-183	fenoprofen	drug	410-419	false
anabolic steroids	group	167-183	glucagon	drug	421-428	false
anabolic steroids	group	167-183	ibuprofen	drug	448-456	false
anabolic steroids	group	167-183	indomethacin	drug	458-469	false
anabolic steroids	group	167-183	influenza virus vaccine	group	471-493	false
anabolic steroids	group	167-183	anesthetics	group	506-516	false
anabolic steroids	group	167-183	mefenamic acid	drug	518-531	false
anabolic steroids	group	167-183	methyldopa	drug	533-542	false
anabolic steroids	group	167-183	methylphenidate	drug	544-558	false
anabolic steroids	group	167-183	metronidazole	drug	560-572	false
anabolic steroids	group	167-183	miconazole	drug	574-583	false
anabolic steroids	group	167-183	monoamine oxidase inhibitors	group	585-612	false
anabolic steroids	group	167-183	nalidixic acid	drug	614-627	false
anabolic steroids	group	167-183	naproxen	drug	629-636	false
anabolic steroids	group	167-183	oxolinic acid	drug	638-650	false
anabolic steroids	group	167-183	oxyphenbutazone	drug	652-666	false
anabolic steroids	group	167-183	pentoxifylline	drug	668-681	false
anabolic steroids	group	167-183	phenylbutazone	drug	683-696	false
anabolic steroids	group	167-183	phenyramidol	drug_n	698-709	false
anabolic steroids	group	167-183	phenytoin	drug	711-719	false
anabolic steroids	group	167-183	prolonged narcotics	group	743-761	false
anabolic steroids	group	167-183	pyrazolones	group	763-773	false
anabolic steroids	group	167-183	quinidine	drug	775-783	false
anabolic steroids	group	167-183	quinine	drug	785-791	false
anabolic steroids	group	167-183	ranitidine	drug	793-802	false
anabolic steroids	group	167-183	salicylates	group	805-815	false
anabolic steroids	group	167-183	sulfinpyrazone	drug	817-830	false
anabolic steroids	group	167-183	sulfonamides	group	832-843	false
anabolic steroids	group	167-183	sulindac	drug	858-865	false
anabolic steroids	group	167-183	thyroid drugs	group	867-879	false
anabolic steroids	group	167-183	tolbutamide	drug	881-891	false
anabolic steroids	group	167-183	triclofos sodium	drug	893-908	false
anabolic steroids	group	167-183	trimethoprim	drug	910-921	false
anabolic steroids	group	167-183	sulfamethoxazole	drug	923-938	false
anabolic steroids	group	167-183	warfarin sodium	drug	983-997	false
antibiotics	group	185-195	bromelains	drug	197-206	false
antibiotics	group	185-195	chloral hydrate	drug	208-222	false
antibiotics	group	185-195	chlorpropamide	drug	225-238	false
antibiotics	group	185-195	chymotrypsin	drug	240-251	false
antibiotics	group	185-195	cimetidine	drug	253-262	false
antibiotics	group	185-195	cinchophen	drug	264-273	false
antibiotics	group	185-195	clofibrate	drug	275-284	false
antibiotics	group	185-195	dextran	drug	286-292	false
antibiotics	group	185-195	dextrothyroxine	drug	294-308	false
antibiotics	group	185-195	diazoxide	drug	310-318	false
antibiotics	group	185-195	diflunisal	drug	341-350	false
antibiotics	group	185-195	disulfiram	drug	352-361	false
antibiotics	group	185-195	ethacrynic acid	drug	394-408	false
antibiotics	group	185-195	fenoprofen	drug	410-419	false
antibiotics	group	185-195	glucagon	drug	421-428	false
antibiotics	group	185-195	ibuprofen	drug	448-456	false
antibiotics	group	185-195	indomethacin	drug	458-469	false
antibiotics	group	185-195	influenza virus vaccine	group	471-493	false
antibiotics	group	185-195	anesthetics	group	506-516	false
antibiotics	group	185-195	mefenamic acid	drug	518-531	false
antibiotics	group	185-195	methyldopa	drug	533-542	false
antibiotics	group	185-195	methylphenidate	drug	544-558	false
antibiotics	group	185-195	metronidazole	drug	560-572	false
antibiotics	group	185-195	miconazole	drug	574-583	false
antibiotics	group	185-195	monoamine oxidase inhibitors	group	585-612	false
antibiotics	group	185-195	nalidixic acid	drug	614-627	false
antibiotics	group	185-195	naproxen	drug	629-636	false
antibiotics	group	185-195	oxolinic acid	drug	638-650	false
antibiotics	group	185-195	oxyphenbutazone	drug	652-666	false
antibiotics	group	185-195	pentoxifylline	drug	668-681	false
antibiotics	group	185-195	phenylbutazone	drug	683-696	false
antibiotics	group	185-195	phenyramidol	drug_n	698-709	false
antibiotics	group	185-195	phenytoin	drug	711-719	false
antibiotics	group	185-195	prolonged narcotics	group	743-761	false
antibiotics	group	185-195	pyrazolones	group	763-773	false
antibiotics	group	185-195	quinidine	drug	775-783	false
antibiotics	group	185-195	quinine	drug	785-791	false
antibiotics	group	185-195	ranitidine	drug	793-802	false
antibiotics	group	185-195	salicylates	group	805-815	false
antibiotics	group	185-195	sulfinpyrazone	drug	817-830	false
antibiotics	group	185-195	sulfonamides	group	832-843	false
antibiotics	group	185-195	sulindac	drug	858-865	false
antibiotics	group	185-195	thyroid drugs	group	867-879	false
antibiotics	group	185-195	tolbutamide	drug	881-891	false
antibiotics	group	185-195	triclofos sodium	drug	893-908	false
antibiotics	group	185-195	trimethoprim	drug	910-921	false
antibiotics	group	185-195	sulfamethoxazole	drug	923-938	false
antibiotics	group	185-195	warfarin sodium	drug	983-997	false
bromelains	drug	197-206	chloral hydrate	drug	208-222	false
bromelains	drug	197-206	chlorpropamide	drug	225-238	false
bromelains	drug	197-206	chymotrypsin	drug	240-251	false
bromelains	drug	197-206	cimetidine	drug	253-262	false
bromelains	drug	197-206	cinchophen	drug	264-273	false
bromelains	drug	197-206	clofibrate	drug	275-284	false
bromelains	drug	197-206	dextran	drug	286-292	false
bromelains	drug	197-206	dextrothyroxine	drug	294-308	false
bromelains	drug	197-206	diazoxide	drug	310-318	false
bromelains	drug	197-206	diflunisal	drug	341-350	false
bromelains	drug	197-206	disulfiram	drug	352-361	false
bromelains	drug	197-206	ethacrynic acid	drug	394-408	false
bromelains	drug	197-206	fenoprofen	drug	410-419	false
bromelains	drug	197-206	glucagon	drug	421-428	false
bromelains	drug	197-206	ibuprofen	drug	448-456	false
bromelains	drug	197-206	indomethacin	drug	458-469	false
bromelains	drug	197-206	influenza virus vaccine	group	471-493	false
bromelains	drug	197-206	anesthetics	group	506-516	false
bromelains	drug	197-206	mefenamic acid	drug	518-531	false
bromelains	drug	197-206	methyldopa	drug	533-542	false
bromelains	drug	197-206	methylphenidate	drug	544-558	false
bromelains	drug	197-206	metronidazole	drug	560-572	false
bromelains	drug	197-206	miconazole	drug	574-583	false
bromelains	drug	197-206	monoamine oxidase inhibitors	group	585-612	false
bromelains	drug	197-206	nalidixic acid	drug	614-627	false
bromelains	drug	197-206	naproxen	drug	629-636	false
bromelains	drug	197-206	oxolinic acid	drug	638-650	false
bromelains	drug	197-206	oxyphenbutazone	drug	652-666	false
bromelains	drug	197-206	pentoxifylline	drug	668-681	false
bromelains	drug	197-206	phenylbutazone	drug	683-696	false
bromelains	drug	197-206	phenyramidol	drug_n	698-709	false
bromelains	drug	197-206	phenytoin	drug	711-719	false
bromelains	drug	197-206	prolonged narcotics	group	743-761	false
bromelains	drug	197-206	pyrazolones	group	763-773	false
bromelains	drug	197-206	quinidine	drug	775-783	false
bromelains	drug	197-206	quinine	drug	785-791	false
bromelains	drug	197-206	ranitidine	drug	793-802	false
bromelains	drug	197-206	salicylates	group	805-815	false
bromelains	drug	197-206	sulfinpyrazone	drug	817-830	false
bromelains	drug	197-206	sulfonamides	group	832-843	false
bromelains	drug	197-206	sulindac	drug	858-865	false
bromelains	drug	197-206	thyroid drugs	group	867-879	false
bromelains	drug	197-206	tolbutamide	drug	881-891	false
bromelains	drug	197-206	triclofos sodium	drug	893-908	false
bromelains	drug	197-206	trimethoprim	drug	910-921	false
bromelains	drug	197-206	sulfamethoxazole	drug	923-938	false
bromelains	drug	197-206	warfarin sodium	drug	983-997	false
chloral hydrate	drug	208-222	chlorpropamide	drug	225-238	false
chloral hydrate	drug	208-222	chymotrypsin	drug	240-251	false
chloral hydrate	drug	208-222	cimetidine	drug	253-262	false
chloral hydrate	drug	208-222	cinchophen	drug	264-273	false
chloral hydrate	drug	208-222	clofibrate	drug	275-284	false
chloral hydrate	drug	208-222	dextran	drug	286-292	false
chloral hydrate	drug	208-222	dextrothyroxine	drug	294-308	false
chloral hydrate	drug	208-222	diazoxide	drug	310-318	false
chloral hydrate	drug	208-222	diflunisal	drug	341-350	false
chloral hydrate	drug	208-222	disulfiram	drug	352-361	false
chloral hydrate	drug	208-222	ethacrynic acid	drug	394-408	false
chloral hydrate	drug	208-222	fenoprofen	drug	410-419	false
chloral hydrate	drug	208-222	glucagon	drug	421-428	false
chloral hydrate	drug	208-222	ibuprofen	drug	448-456	false
chloral hydrate	drug	208-222	indomethacin	drug	458-469	false
chloral hydrate	drug	208-222	influenza virus vaccine	group	471-493	false
chloral hydrate	drug	208-222	anesthetics	group	506-516	false
chloral hydrate	drug	208-222	mefenamic acid	drug	518-531	false
chloral hydrate	drug	208-222	methyldopa	drug	533-542	false
chloral hydrate	drug	208-222	methylphenidate	drug	544-558	false
chloral hydrate	drug	208-222	metronidazole	drug	560-572	false
chloral hydrate	drug	208-222	miconazole	drug	574-583	false
chloral hydrate	drug	208-222	monoamine oxidase inhibitors	group	585-612	false
chloral hydrate	drug	208-222	nalidixic acid	drug	614-627	false
chloral hydrate	drug	208-222	naproxen	drug	629-636	false
chloral hydrate	drug	208-222	oxolinic acid	drug	638-650	false
chloral hydrate	drug	208-222	oxyphenbutazone	drug	652-666	false
chloral hydrate	drug	208-222	pentoxifylline	drug	668-681	false
chloral hydrate	drug	208-222	phenylbutazone	drug	683-696	false
chloral hydrate	drug	208-222	phenyramidol	drug_n	698-709	false
chloral hydrate	drug	208-222	phenytoin	drug	711-719	false
chloral hydrate	drug	208-222	prolonged narcotics	group	743-761	false
chloral hydrate	drug	208-222	pyrazolones	group	763-773	false
chloral hydrate	drug	208-222	quinidine	drug	775-783	false
chloral hydrate	drug	208-222	quinine	drug	785-791	false
chloral hydrate	drug	208-222	ranitidine	drug	793-802	false
chloral hydrate	drug	208-222	salicylates	group	805-815	false
chloral hydrate	drug	208-222	sulfinpyrazone	drug	817-830	false
chloral hydrate	drug	208-222	sulfonamides	group	832-843	false
chloral hydrate	drug	208-222	sulindac	drug	858-865	false
chloral hydrate	drug	208-222	thyroid drugs	group	867-879	false
chloral hydrate	drug	208-222	tolbutamide	drug	881-891	false
chloral hydrate	drug	208-222	triclofos sodium	drug	893-908	false
chloral hydrate	drug	208-222	trimethoprim	drug	910-921	false
chloral hydrate	drug	208-222	sulfamethoxazole	drug	923-938	false
chloral hydrate	drug	208-222	warfarin sodium	drug	983-997	false
chlorpropamide	drug	225-238	chymotrypsin	drug	240-251	false
chlorpropamide	drug	225-238	cimetidine	drug	253-262	false
chlorpropamide	drug	225-238	cinchophen	drug	264-273	false
chlorpropamide	drug	225-238	clofibrate	drug	275-284	false
chlorpropamide	drug	225-238	dextran	drug	286-292	false
chlorpropamide	drug	225-238	dextrothyroxine	drug	294-308	false
chlorpropamide	drug	225-238	diazoxide	drug	310-318	false
chlorpropamide	drug	225-238	diflunisal	drug	341-350	false
chlorpropamide	drug	225-238	disulfiram	drug	352-361	false
chlorpropamide	drug	225-238	ethacrynic acid	drug	394-408	false
chlorpropamide	drug	225-238	fenoprofen	drug	410-419	false
chlorpropamide	drug	225-238	glucagon	drug	421-428	false
chlorpropamide	drug	225-238	ibuprofen	drug	448-456	false
chlorpropamide	drug	225-238	indomethacin	drug	458-469	false
chlorpropamide	drug	225-238	influenza virus vaccine	group	471-493	false
chlorpropamide	drug	225-238	anesthetics	group	506-516	false
chlorpropamide	drug	225-238	mefenamic acid	drug	518-531	false
chlorpropamide	drug	225-238	methyldopa	drug	533-542	false
chlorpropamide	drug	225-238	methylphenidate	drug	544-558	false
chlorpropamide	drug	225-238	metronidazole	drug	560-572	false
chlorpropamide	drug	225-238	miconazole	drug	574-583	false
chlorpropamide	drug	225-238	monoamine oxidase inhibitors	group	585-612	false
chlorpropamide	drug	225-238	nalidixic acid	drug	614-627	false
chlorpropamide	drug	225-238	naproxen	drug	629-636	false
chlorpropamide	drug	225-238	oxolinic acid	drug	638-650	false
chlorpropamide	drug	225-238	oxyphenbutazone	drug	652-666	false
chlorpropamide	drug	225-238	pentoxifylline	drug	668-681	false
chlorpropamide	drug	225-238	phenylbutazone	drug	683-696	false
chlorpropamide	drug	225-238	phenyramidol	drug_n	698-709	false
chlorpropamide	drug	225-238	phenytoin	drug	711-719	false
chlorpropamide	drug	225-238	prolonged narcotics	group	743-761	false
chlorpropamide	drug	225-238	pyrazolones	group	763-773	false
chlorpropamide	drug	225-238	quinidine	drug	775-783	false
chlorpropamide	drug	225-238	quinine	drug	785-791	false
chlorpropamide	drug	225-238	ranitidine	drug	793-802	false
chlorpropamide	drug	225-238	salicylates	group	805-815	false
chlorpropamide	drug	225-238	sulfinpyrazone	drug	817-830	false
chlorpropamide	drug	225-238	sulfonamides	group	832-843	false
chlorpropamide	drug	225-238	sulindac	drug	858-865	false
chlorpropamide	drug	225-238	thyroid drugs	group	867-879	false
chlorpropamide	drug	225-238	tolbutamide	drug	881-891	false
chlorpropamide	drug	225-238	triclofos sodium	drug	893-908	false
chlorpropamide	drug	225-238	trimethoprim	drug	910-921	false
chlorpropamide	drug	225-238	sulfamethoxazole	drug	923-938	false
chlorpropamide	drug	225-238	warfarin sodium	drug	983-997	false
chymotrypsin	drug	240-251	cimetidine	drug	253-262	false
chymotrypsin	drug	240-251	cinchophen	drug	264-273	false
chymotrypsin	drug	240-251	clofibrate	drug	275-284	false
chymotrypsin	drug	240-251	dextran	drug	286-292	false
chymotrypsin	drug	240-251	dextrothyroxine	drug	294-308	false
chymotrypsin	drug	240-251	diazoxide	drug	310-318	false
chymotrypsin	drug	240-251	diflunisal	drug	341-350	false
chymotrypsin	drug	240-251	disulfiram	drug	352-361	false
chymotrypsin	drug	240-251	ethacrynic acid	drug	394-408	false
chymotrypsin	drug	240-251	fenoprofen	drug	410-419	false
chymotrypsin	drug	240-251	glucagon	drug	421-428	false
chymotrypsin	drug	240-251	ibuprofen	drug	448-456	false
chymotrypsin	drug	240-251	indomethacin	drug	458-469	false
chymotrypsin	drug	240-251	influenza virus vaccine	group	471-493	false
chymotrypsin	drug	240-251	anesthetics	group	506-516	false
chymotrypsin	drug	240-251	mefenamic acid	drug	518-531	false
chymotrypsin	drug	240-251	methyldopa	drug	533-542	false
chymotrypsin	drug	240-251	methylphenidate	drug	544-558	false
chymotrypsin	drug	240-251	metronidazole	drug	560-572	false
chymotrypsin	drug	240-251	miconazole	drug	574-583	false
chymotrypsin	drug	240-251	monoamine oxidase inhibitors	group	585-612	false
chymotrypsin	drug	240-251	nalidixic acid	drug	614-627	false
chymotrypsin	drug	240-251	naproxen	drug	629-636	false
chymotrypsin	drug	240-251	oxolinic acid	drug	638-650	false
chymotrypsin	drug	240-251	oxyphenbutazone	drug	652-666	false
chymotrypsin	drug	240-251	pentoxifylline	drug	668-681	false
chymotrypsin	drug	240-251	phenylbutazone	drug	683-696	false
chymotrypsin	drug	240-251	phenyramidol	drug_n	698-709	false
chymotrypsin	drug	240-251	phenytoin	drug	711-719	false
chymotrypsin	drug	240-251	prolonged narcotics	group	743-761	false
chymotrypsin	drug	240-251	pyrazolones	group	763-773	false
chymotrypsin	drug	240-251	quinidine	drug	775-783	false
chymotrypsin	drug	240-251	quinine	drug	785-791	false
chymotrypsin	drug	240-251	ranitidine	drug	793-802	false
chymotrypsin	drug	240-251	salicylates	group	805-815	false
chymotrypsin	drug	240-251	sulfinpyrazone	drug	817-830	false
chymotrypsin	drug	240-251	sulfonamides	group	832-843	false
chymotrypsin	drug	240-251	sulindac	drug	858-865	false
chymotrypsin	drug	240-251	thyroid drugs	group	867-879	false
chymotrypsin	drug	240-251	tolbutamide	drug	881-891	false
chymotrypsin	drug	240-251	triclofos sodium	drug	893-908	false
chymotrypsin	drug	240-251	trimethoprim	drug	910-921	false
chymotrypsin	drug	240-251	sulfamethoxazole	drug	923-938	false
chymotrypsin	drug	240-251	warfarin sodium	drug	983-997	false
cimetidine	drug	253-262	cinchophen	drug	264-273	false
cimetidine	drug	253-262	clofibrate	drug	275-284	false
cimetidine	drug	253-262	dextran	drug	286-292	false
cimetidine	drug	253-262	dextrothyroxine	drug	294-308	false
cimetidine	drug	253-262	diazoxide	drug	310-318	false
cimetidine	drug	253-262	diflunisal	drug	341-350	false
cimetidine	drug	253-262	disulfiram	drug	352-361	false
cimetidine	drug	253-262	ethacrynic acid	drug	394-408	false
cimetidine	drug	253-262	fenoprofen	drug	410-419	false
cimetidine	drug	253-262	glucagon	drug	421-428	false
cimetidine	drug	253-262	ibuprofen	drug	448-456	false
cimetidine	drug	253-262	indomethacin	drug	458-469	false
cimetidine	drug	253-262	influenza virus vaccine	group	471-493	false
cimetidine	drug	253-262	anesthetics	group	506-516	false
cimetidine	drug	253-262	mefenamic acid	drug	518-531	false
cimetidine	drug	253-262	methyldopa	drug	533-542	false
cimetidine	drug	253-262	methylphenidate	drug	544-558	false
cimetidine	drug	253-262	metronidazole	drug	560-572	false
cimetidine	drug	253-262	miconazole	drug	574-583	false
cimetidine	drug	253-262	monoamine oxidase inhibitors	group	585-612	false
cimetidine	drug	253-262	nalidixic acid	drug	614-627	false
cimetidine	drug	253-262	naproxen	drug	629-636	false
cimetidine	drug	253-262	oxolinic acid	drug	638-650	false
cimetidine	drug	253-262	oxyphenbutazone	drug	652-666	false
cimetidine	drug	253-262	pentoxifylline	drug	668-681	false
cimetidine	drug	253-262	phenylbutazone	drug	683-696	false
cimetidine	drug	253-262	phenyramidol	drug_n	698-709	false
cimetidine	drug	253-262	phenytoin	drug	711-719	false
cimetidine	drug	253-262	prolonged narcotics	group	743-761	false
cimetidine	drug	253-262	pyrazolones	group	763-773	false
cimetidine	drug	253-262	quinidine	drug	775-783	false
cimetidine	drug	253-262	quinine	drug	785-791	false
cimetidine	drug	253-262	ranitidine	drug	793-802	false
cimetidine	drug	253-262	salicylates	group	805-815	false
cimetidine	drug	253-262	sulfinpyrazone	drug	817-830	false
cimetidine	drug	253-262	sulfonamides	group	832-843	false
cimetidine	drug	253-262	sulindac	drug	858-865	false
cimetidine	drug	253-262	thyroid drugs	group	867-879	false
cimetidine	drug	253-262	tolbutamide	drug	881-891	false
cimetidine	drug	253-262	triclofos sodium	drug	893-908	false
cimetidine	drug	253-262	trimethoprim	drug	910-921	false
cimetidine	drug	253-262	sulfamethoxazole	drug	923-938	false
cimetidine	drug	253-262	warfarin sodium	drug	983-997	false
cinchophen	drug	264-273	clofibrate	drug	275-284	false
cinchophen	drug	264-273	dextran	drug	286-292	false
cinchophen	drug	264-273	dextrothyroxine	drug	294-308	false
cinchophen	drug	264-273	diazoxide	drug	310-318	false
cinchophen	drug	264-273	diflunisal	drug	341-350	false
cinchophen	drug	264-273	disulfiram	drug	352-361	false
cinchophen	drug	264-273	ethacrynic acid	drug	394-408	false
cinchophen	drug	264-273	fenoprofen	drug	410-419	false
cinchophen	drug	264-273	glucagon	drug	421-428	false
cinchophen	drug	264-273	ibuprofen	drug	448-456	false
cinchophen	drug	264-273	indomethacin	drug	458-469	false
cinchophen	drug	264-273	influenza virus vaccine	group	471-493	false
cinchophen	drug	264-273	anesthetics	group	506-516	false
cinchophen	drug	264-273	mefenamic acid	drug	518-531	false
cinchophen	drug	264-273	methyldopa	drug	533-542	false
cinchophen	drug	264-273	methylphenidate	drug	544-558	false
cinchophen	drug	264-273	metronidazole	drug	560-572	false
cinchophen	drug	264-273	miconazole	drug	574-583	false
cinchophen	drug	264-273	monoamine oxidase inhibitors	group	585-612	false
cinchophen	drug	264-273	nalidixic acid	drug	614-627	false
cinchophen	drug	264-273	naproxen	drug	629-636	false
cinchophen	drug	264-273	oxolinic acid	drug	638-650	false
cinchophen	drug	264-273	oxyphenbutazone	drug	652-666	false
cinchophen	drug	264-273	pentoxifylline	drug	668-681	false
cinchophen	drug	264-273	phenylbutazone	drug	683-696	false
cinchophen	drug	264-273	phenyramidol	drug_n	698-709	false
cinchophen	drug	264-273	phenytoin	drug	711-719	false
cinchophen	drug	264-273	prolonged narcotics	group	743-761	false
cinchophen	drug	264-273	pyrazolones	group	763-773	false
cinchophen	drug	264-273	quinidine	drug	775-783	false
cinchophen	drug	264-273	quinine	drug	785-791	false
cinchophen	drug	264-273	ranitidine	drug	793-802	false
cinchophen	drug	264-273	salicylates	group	805-815	false
cinchophen	drug	264-273	sulfinpyrazone	drug	817-830	false
cinchophen	drug	264-273	sulfonamides	group	832-843	false
cinchophen	drug	264-273	sulindac	drug	858-865	false
cinchophen	drug	264-273	thyroid drugs	group	867-879	false
cinchophen	drug	264-273	tolbutamide	drug	881-891	false
cinchophen	drug	264-273	triclofos sodium	drug	893-908	false
cinchophen	drug	264-273	trimethoprim	drug	910-921	false
cinchophen	drug	264-273	sulfamethoxazole	drug	923-938	false
cinchophen	drug	264-273	warfarin sodium	drug	983-997	false
clofibrate	drug	275-284	dextran	drug	286-292	false
clofibrate	drug	275-284	dextrothyroxine	drug	294-308	false
clofibrate	drug	275-284	diazoxide	drug	310-318	false
clofibrate	drug	275-284	diflunisal	drug	341-350	false
clofibrate	drug	275-284	disulfiram	drug	352-361	false
clofibrate	drug	275-284	ethacrynic acid	drug	394-408	false
clofibrate	drug	275-284	fenoprofen	drug	410-419	false
clofibrate	drug	275-284	glucagon	drug	421-428	false
clofibrate	drug	275-284	ibuprofen	drug	448-456	false
clofibrate	drug	275-284	indomethacin	drug	458-469	false
clofibrate	drug	275-284	influenza virus vaccine	group	471-493	false
clofibrate	drug	275-284	anesthetics	group	506-516	false
clofibrate	drug	275-284	mefenamic acid	drug	518-531	false
clofibrate	drug	275-284	methyldopa	drug	533-542	false
clofibrate	drug	275-284	methylphenidate	drug	544-558	false
clofibrate	drug	275-284	metronidazole	drug	560-572	false
clofibrate	drug	275-284	miconazole	drug	574-583	false
clofibrate	drug	275-284	monoamine oxidase inhibitors	group	585-612	false
clofibrate	drug	275-284	nalidixic acid	drug	614-627	false
clofibrate	drug	275-284	naproxen	drug	629-636	false
clofibrate	drug	275-284	oxolinic acid	drug	638-650	false
clofibrate	drug	275-284	oxyphenbutazone	drug	652-666	false
clofibrate	drug	275-284	pentoxifylline	drug	668-681	false
clofibrate	drug	275-284	phenylbutazone	drug	683-696	false
clofibrate	drug	275-284	phenyramidol	drug_n	698-709	false
clofibrate	drug	275-284	phenytoin	drug	711-719	false
clofibrate	drug	275-284	prolonged narcotics	group	743-761	false
clofibrate	drug	275-284	pyrazolones	group	763-773	false
clofibrate	drug	275-284	quinidine	drug	775-783	false
clofibrate	drug	275-284	quinine	drug	785-791	false
clofibrate	drug	275-284	ranitidine	drug	793-802	false
clofibrate	drug	275-284	salicylates	group	805-815	false
clofibrate	drug	275-284	sulfinpyrazone	drug	817-830	false
clofibrate	drug	275-284	sulfonamides	group	832-843	false
clofibrate	drug	275-284	sulindac	drug	858-865	false
clofibrate	drug	275-284	thyroid drugs	group	867-879	false
clofibrate	drug	275-284	tolbutamide	drug	881-891	false
clofibrate	drug	275-284	triclofos sodium	drug	893-908	false
clofibrate	drug	275-284	trimethoprim	drug	910-921	false
clofibrate	drug	275-284	sulfamethoxazole	drug	923-938	false
clofibrate	drug	275-284	warfarin sodium	drug	983-997	false
dextran	drug	286-292	dextrothyroxine	drug	294-308	false
dextran	drug	286-292	diazoxide	drug	310-318	false
dextran	drug	286-292	diflunisal	drug	341-350	false
dextran	drug	286-292	disulfiram	drug	352-361	false
dextran	drug	286-292	ethacrynic acid	drug	394-408	false
dextran	drug	286-292	fenoprofen	drug	410-419	false
dextran	drug	286-292	glucagon	drug	421-428	false
dextran	drug	286-292	ibuprofen	drug	448-456	false
dextran	drug	286-292	indomethacin	drug	458-469	false
dextran	drug	286-292	influenza virus vaccine	group	471-493	false
dextran	drug	286-292	anesthetics	group	506-516	false
dextran	drug	286-292	mefenamic acid	drug	518-531	false
dextran	drug	286-292	methyldopa	drug	533-542	false
dextran	drug	286-292	methylphenidate	drug	544-558	false
dextran	drug	286-292	metronidazole	drug	560-572	false
dextran	drug	286-292	miconazole	drug	574-583	false
dextran	drug	286-292	monoamine oxidase inhibitors	group	585-612	false
dextran	drug	286-292	nalidixic acid	drug	614-627	false
dextran	drug	286-292	naproxen	drug	629-636	false
dextran	drug	286-292	oxolinic acid	drug	638-650	false
dextran	drug	286-292	oxyphenbutazone	drug	652-666	false
dextran	drug	286-292	pentoxifylline	drug	668-681	false
dextran	drug	286-292	phenylbutazone	drug	683-696	false
dextran	drug	286-292	phenyramidol	drug_n	698-709	false
dextran	drug	286-292	phenytoin	drug	711-719	false
dextran	drug	286-292	prolonged narcotics	group	743-761	false
dextran	drug	286-292	pyrazolones	group	763-773	false
dextran	drug	286-292	quinidine	drug	775-783	false
dextran	drug	286-292	quinine	drug	785-791	false
dextran	drug	286-292	ranitidine	drug	793-802	false
dextran	drug	286-292	salicylates	group	805-815	false
dextran	drug	286-292	sulfinpyrazone	drug	817-830	false
dextran	drug	286-292	sulfonamides	group	832-843	false
dextran	drug	286-292	sulindac	drug	858-865	false
dextran	drug	286-292	thyroid drugs	group	867-879	false
dextran	drug	286-292	tolbutamide	drug	881-891	false
dextran	drug	286-292	triclofos sodium	drug	893-908	false
dextran	drug	286-292	trimethoprim	drug	910-921	false
dextran	drug	286-292	sulfamethoxazole	drug	923-938	false
dextran	drug	286-292	warfarin sodium	drug	983-997	false
dextrothyroxine	drug	294-308	diazoxide	drug	310-318	false
dextrothyroxine	drug	294-308	diflunisal	drug	341-350	false
dextrothyroxine	drug	294-308	disulfiram	drug	352-361	false
dextrothyroxine	drug	294-308	ethacrynic acid	drug	394-408	false
dextrothyroxine	drug	294-308	fenoprofen	drug	410-419	false
dextrothyroxine	drug	294-308	glucagon	drug	421-428	false
dextrothyroxine	drug	294-308	ibuprofen	drug	448-456	false
dextrothyroxine	drug	294-308	indomethacin	drug	458-469	false
dextrothyroxine	drug	294-308	influenza virus vaccine	group	471-493	false
dextrothyroxine	drug	294-308	anesthetics	group	506-516	false
dextrothyroxine	drug	294-308	mefenamic acid	drug	518-531	false
dextrothyroxine	drug	294-308	methyldopa	drug	533-542	false
dextrothyroxine	drug	294-308	methylphenidate	drug	544-558	false
dextrothyroxine	drug	294-308	metronidazole	drug	560-572	false
dextrothyroxine	drug	294-308	miconazole	drug	574-583	false
dextrothyroxine	drug	294-308	monoamine oxidase inhibitors	group	585-612	false
dextrothyroxine	drug	294-308	nalidixic acid	drug	614-627	false
dextrothyroxine	drug	294-308	naproxen	drug	629-636	false
dextrothyroxine	drug	294-308	oxolinic acid	drug	638-650	false
dextrothyroxine	drug	294-308	oxyphenbutazone	drug	652-666	false
dextrothyroxine	drug	294-308	pentoxifylline	drug	668-681	false
dextrothyroxine	drug	294-308	phenylbutazone	drug	683-696	false
dextrothyroxine	drug	294-308	phenyramidol	drug_n	698-709	false
dextrothyroxine	drug	294-308	phenytoin	drug	711-719	false
dextrothyroxine	drug	294-308	prolonged narcotics	group	743-761	false
dextrothyroxine	drug	294-308	pyrazolones	group	763-773	false
dextrothyroxine	drug	294-308	quinidine	drug	775-783	false
dextrothyroxine	drug	294-308	quinine	drug	785-791	false
dextrothyroxine	drug	294-308	ranitidine	drug	793-802	false
dextrothyroxine	drug	294-308	salicylates	group	805-815	false
dextrothyroxine	drug	294-308	sulfinpyrazone	drug	817-830	false
dextrothyroxine	drug	294-308	sulfonamides	group	832-843	false
dextrothyroxine	drug	294-308	sulindac	drug	858-865	false
dextrothyroxine	drug	294-308	thyroid drugs	group	867-879	false
dextrothyroxine	drug	294-308	tolbutamide	drug	881-891	false
dextrothyroxine	drug	294-308	triclofos sodium	drug	893-908	false
dextrothyroxine	drug	294-308	trimethoprim	drug	910-921	false
dextrothyroxine	drug	294-308	sulfamethoxazole	drug	923-938	false
dextrothyroxine	drug	294-308	warfarin sodium	drug	983-997	false
diazoxide	drug	310-318	diflunisal	drug	341-350	false
diazoxide	drug	310-318	disulfiram	drug	352-361	false
diazoxide	drug	310-318	ethacrynic acid	drug	394-408	false
diazoxide	drug	310-318	fenoprofen	drug	410-419	false
diazoxide	drug	310-318	glucagon	drug	421-428	false
diazoxide	drug	310-318	ibuprofen	drug	448-456	false
diazoxide	drug	310-318	indomethacin	drug	458-469	false
diazoxide	drug	310-318	influenza virus vaccine	group	471-493	false
diazoxide	drug	310-318	anesthetics	group	506-516	false
diazoxide	drug	310-318	mefenamic acid	drug	518-531	false
diazoxide	drug	310-318	methyldopa	drug	533-542	false
diazoxide	drug	310-318	methylphenidate	drug	544-558	false
diazoxide	drug	310-318	metronidazole	drug	560-572	false
diazoxide	drug	310-318	miconazole	drug	574-583	false
diazoxide	drug	310-318	monoamine oxidase inhibitors	group	585-612	false
diazoxide	drug	310-318	nalidixic acid	drug	614-627	false
diazoxide	drug	310-318	naproxen	drug	629-636	false
diazoxide	drug	310-318	oxolinic acid	drug	638-650	false
diazoxide	drug	310-318	oxyphenbutazone	drug	652-666	false
diazoxide	drug	310-318	pentoxifylline	drug	668-681	false
diazoxide	drug	310-318	phenylbutazone	drug	683-696	false
diazoxide	drug	310-318	phenyramidol	drug_n	698-709	false
diazoxide	drug	310-318	phenytoin	drug	711-719	false
diazoxide	drug	310-318	prolonged narcotics	group	743-761	false
diazoxide	drug	310-318	pyrazolones	group	763-773	false
diazoxide	drug	310-318	quinidine	drug	775-783	false
diazoxide	drug	310-318	quinine	drug	785-791	false
diazoxide	drug	310-318	ranitidine	drug	793-802	false
diazoxide	drug	310-318	salicylates	group	805-815	false
diazoxide	drug	310-318	sulfinpyrazone	drug	817-830	false
diazoxide	drug	310-318	sulfonamides	group	832-843	false
diazoxide	drug	310-318	sulindac	drug	858-865	false
diazoxide	drug	310-318	thyroid drugs	group	867-879	false
diazoxide	drug	310-318	tolbutamide	drug	881-891	false
diazoxide	drug	310-318	triclofos sodium	drug	893-908	false
diazoxide	drug	310-318	trimethoprim	drug	910-921	false
diazoxide	drug	310-318	sulfamethoxazole	drug	923-938	false
diazoxide	drug	310-318	warfarin sodium	drug	983-997	false
diflunisal	drug	341-350	disulfiram	drug	352-361	false
diflunisal	drug	341-350	ethacrynic acid	drug	394-408	false
diflunisal	drug	341-350	fenoprofen	drug	410-419	false
diflunisal	drug	341-350	glucagon	drug	421-428	false
diflunisal	drug	341-350	ibuprofen	drug	448-456	false
diflunisal	drug	341-350	indomethacin	drug	458-469	false
diflunisal	drug	341-350	influenza virus vaccine	group	471-493	false
diflunisal	drug	341-350	anesthetics	group	506-516	false
diflunisal	drug	341-350	mefenamic acid	drug	518-531	false
diflunisal	drug	341-350	methyldopa	drug	533-542	false
diflunisal	drug	341-350	methylphenidate	drug	544-558	false
diflunisal	drug	341-350	metronidazole	drug	560-572	false
diflunisal	drug	341-350	miconazole	drug	574-583	false
diflunisal	drug	341-350	monoamine oxidase inhibitors	group	585-612	false
diflunisal	drug	341-350	nalidixic acid	drug	614-627	false
diflunisal	drug	341-350	naproxen	drug	629-636	false
diflunisal	drug	341-350	oxolinic acid	drug	638-650	false
diflunisal	drug	341-350	oxyphenbutazone	drug	652-666	false
diflunisal	drug	341-350	pentoxifylline	drug	668-681	false
diflunisal	drug	341-350	phenylbutazone	drug	683-696	false
diflunisal	drug	341-350	phenyramidol	drug_n	698-709	false
diflunisal	drug	341-350	phenytoin	drug	711-719	false
diflunisal	drug	341-350	prolonged narcotics	group	743-761	false
diflunisal	drug	341-350	pyrazolones	group	763-773	false
diflunisal	drug	341-350	quinidine	drug	775-783	false
diflunisal	drug	341-350	quinine	drug	785-791	false
diflunisal	drug	341-350	ranitidine	drug	793-802	false
diflunisal	drug	341-350	salicylates	group	805-815	false
diflunisal	drug	341-350	sulfinpyrazone	drug	817-830	false
diflunisal	drug	341-350	sulfonamides	group	832-843	false
diflunisal	drug	341-350	sulindac	drug	858-865	false
diflunisal	drug	341-350	thyroid drugs	group	867-879	false
diflunisal	drug	341-350	tolbutamide	drug	881-891	false
diflunisal	drug	341-350	triclofos sodium	drug	893-908	false
diflunisal	drug	341-350	trimethoprim	drug	910-921	false
diflunisal	drug	341-350	sulfamethoxazole	drug	923-938	false
diflunisal	drug	341-350	warfarin sodium	drug	983-997	false
disulfiram	drug	352-361	ethacrynic acid	drug	394-408	false
disulfiram	drug	352-361	fenoprofen	drug	410-419	false
disulfiram	drug	352-361	glucagon	drug	421-428	false
disulfiram	drug	352-361	ibuprofen	drug	448-456	false
disulfiram	drug	352-361	indomethacin	drug	458-469	false
disulfiram	drug	352-361	influenza virus vaccine	group	471-493	false
disulfiram	drug	352-361	anesthetics	group	506-516	false
disulfiram	drug	352-361	mefenamic acid	drug	518-531	false
disulfiram	drug	352-361	methyldopa	drug	533-542	false
disulfiram	drug	352-361	methylphenidate	drug	544-558	false
disulfiram	drug	352-361	metronidazole	drug	560-572	false
disulfiram	drug	352-361	miconazole	drug	574-583	false
disulfiram	drug	352-361	monoamine oxidase inhibitors	group	585-612	false
disulfiram	drug	352-361	nalidixic acid	drug	614-627	false
disulfiram	drug	352-361	naproxen	drug	629-636	false
disulfiram	drug	352-361	oxolinic acid	drug	638-650	false
disulfiram	drug	352-361	oxyphenbutazone	drug	652-666	false
disulfiram	drug	352-361	pentoxifylline	drug	668-681	false
disulfiram	drug	352-361	phenylbutazone	drug	683-696	false
disulfiram	drug	352-361	phenyramidol	drug_n	698-709	false
disulfiram	drug	352-361	phenytoin	drug	711-719	false
disulfiram	drug	352-361	prolonged narcotics	group	743-761	false
disulfiram	drug	352-361	pyrazolones	group	763-773	false
disulfiram	drug	352-361	quinidine	drug	775-783	false
disulfiram	drug	352-361	quinine	drug	785-791	false
disulfiram	drug	352-361	ranitidine	drug	793-802	false
disulfiram	drug	352-361	salicylates	group	805-815	false
disulfiram	drug	352-361	sulfinpyrazone	drug	817-830	false
disulfiram	drug	352-361	sulfonamides	group	832-843	false
disulfiram	drug	352-361	sulindac	drug	858-865	false
disulfiram	drug	352-361	thyroid drugs	group	867-879	false
disulfiram	drug	352-361	tolbutamide	drug	881-891	false
disulfiram	drug	352-361	triclofos sodium	drug	893-908	false
disulfiram	drug	352-361	trimethoprim	drug	910-921	false
disulfiram	drug	352-361	sulfamethoxazole	drug	923-938	false
disulfiram	drug	352-361	warfarin sodium	drug	983-997	false
ethacrynic acid	drug	394-408	fenoprofen	drug	410-419	false
ethacrynic acid	drug	394-408	glucagon	drug	421-428	false
ethacrynic acid	drug	394-408	ibuprofen	drug	448-456	false
ethacrynic acid	drug	394-408	indomethacin	drug	458-469	false
ethacrynic acid	drug	394-408	influenza virus vaccine	group	471-493	false
ethacrynic acid	drug	394-408	anesthetics	group	506-516	false
ethacrynic acid	drug	394-408	mefenamic acid	drug	518-531	false
ethacrynic acid	drug	394-408	methyldopa	drug	533-542	false
ethacrynic acid	drug	394-408	methylphenidate	drug	544-558	false
ethacrynic acid	drug	394-408	metronidazole	drug	560-572	false
ethacrynic acid	drug	394-408	miconazole	drug	574-583	false
ethacrynic acid	drug	394-408	monoamine oxidase inhibitors	group	585-612	false
ethacrynic acid	drug	394-408	nalidixic acid	drug	614-627	false
ethacrynic acid	drug	394-408	naproxen	drug	629-636	false
ethacrynic acid	drug	394-408	oxolinic acid	drug	638-650	false
ethacrynic acid	drug	394-408	oxyphenbutazone	drug	652-666	false
ethacrynic acid	drug	394-408	pentoxifylline	drug	668-681	false
ethacrynic acid	drug	394-408	phenylbutazone	drug	683-696	false
ethacrynic acid	drug	394-408	phenyramidol	drug_n	698-709	false
ethacrynic acid	drug	394-408	phenytoin	drug	711-719	false
ethacrynic acid	drug	394-408	prolonged narcotics	group	743-761	false
ethacrynic acid	drug	394-408	pyrazolones	group	763-773	false
ethacrynic acid	drug	394-408	quinidine	drug	775-783	false
ethacrynic acid	drug	394-408	quinine	drug	785-791	false
ethacrynic acid	drug	394-408	ranitidine	drug	793-802	false
ethacrynic acid	drug	394-408	salicylates	group	805-815	false
ethacrynic acid	drug	394-408	sulfinpyrazone	drug	817-830	false
ethacrynic acid	drug	394-408	sulfonamides	group	832-843	false
ethacrynic acid	drug	394-408	sulindac	drug	858-865	false
ethacrynic acid	drug	394-408	thyroid drugs	group	867-879	false
ethacrynic acid	drug	394-408	tolbutamide	drug	881-891	false
ethacrynic acid	drug	394-408	triclofos sodium	drug	893-908	false
ethacrynic acid	drug	394-408	trimethoprim	drug	910-921	false
ethacrynic acid	drug	394-408	sulfamethoxazole	drug	923-938	false
ethacrynic acid	drug	394-408	warfarin sodium	drug	983-997	false
fenoprofen	drug	410-419	glucagon	drug	421-428	false
fenoprofen	drug	410-419	ibuprofen	drug	448-456	false
fenoprofen	drug	410-419	indomethacin	drug	458-469	false
fenoprofen	drug	410-419	influenza virus vaccine	group	471-493	false
fenoprofen	drug	410-419	anesthetics	group	506-516	false
fenoprofen	drug	410-419	mefenamic acid	drug	518-531	false
fenoprofen	drug	410-419	methyldopa	drug	533-542	false
fenoprofen	drug	410-419	methylphenidate	drug	544-558	false
fenoprofen	drug	410-419	metronidazole	drug	560-572	false
fenoprofen	drug	410-419	miconazole	drug	574-583	false
fenoprofen	drug	410-419	monoamine oxidase inhibitors	group	585-612	false
fenoprofen	drug	410-419	nalidixic acid	drug	614-627	false
fenoprofen	drug	410-419	naproxen	drug	629-636	false
fenoprofen	drug	410-419	oxolinic acid	drug	638-650	false
fenoprofen	drug	410-419	oxyphenbutazone	drug	652-666	false
fenoprofen	drug	410-419	pentoxifylline	drug	668-681	false
fenoprofen	drug	410-419	phenylbutazone	drug	683-696	false
fenoprofen	drug	410-419	phenyramidol	drug_n	698-709	false
fenoprofen	drug	410-419	phenytoin	drug	711-719	false
fenoprofen	drug	410-419	prolonged narcotics	group	743-761	false
fenoprofen	drug	410-419	pyrazolones	group	763-773	false
fenoprofen	drug	410-419	quinidine	drug	775-783	false
fenoprofen	drug	410-419	quinine	drug	785-791	false
fenoprofen	drug	410-419	ranitidine	drug	793-802	false
fenoprofen	drug	410-419	salicylates	group	805-815	false
fenoprofen	drug	410-419	sulfinpyrazone	drug	817-830	false
fenoprofen	drug	410-419	sulfonamides	group	832-843	false
fenoprofen	drug	410-419	sulindac	drug	858-865	false
fenoprofen	drug	410-419	thyroid drugs	group	867-879	false
fenoprofen	drug	410-419	tolbutamide	drug	881-891	false
fenoprofen	drug	410-419	triclofos sodium	drug	893-908	false
fenoprofen	drug	410-419	trimethoprim	drug	910-921	false
fenoprofen	drug	410-419	sulfamethoxazole	drug	923-938	false
fenoprofen	drug	410-419	warfarin sodium	drug	983-997	false
glucagon	drug	421-428	ibuprofen	drug	448-456	false
glucagon	drug	421-428	indomethacin	drug	458-469	false
glucagon	drug	421-428	influenza virus vaccine	group	471-493	false
glucagon	drug	421-428	anesthetics	group	506-516	false
glucagon	drug	421-428	mefenamic acid	drug	518-531	false
glucagon	drug	421-428	methyldopa	drug	533-542	false
glucagon	drug	421-428	methylphenidate	drug	544-558	false
glucagon	drug	421-428	metronidazole	drug	560-572	false
glucagon	drug	421-428	miconazole	drug	574-583	false
glucagon	drug	421-428	monoamine oxidase inhibitors	group	585-612	false
glucagon	drug	421-428	nalidixic acid	drug	614-627	false
glucagon	drug	421-428	naproxen	drug	629-636	false
glucagon	drug	421-428	oxolinic acid	drug	638-650	false
glucagon	drug	421-428	oxyphenbutazone	drug	652-666	false
glucagon	drug	421-428	pentoxifylline	drug	668-681	false
glucagon	drug	421-428	phenylbutazone	drug	683-696	false
glucagon	drug	421-428	phenyramidol	drug_n	698-709	false
glucagon	drug	421-428	phenytoin	drug	711-719	false
glucagon	drug	421-428	prolonged narcotics	group	743-761	false
glucagon	drug	421-428	pyrazolones	group	763-773	false
glucagon	drug	421-428	quinidine	drug	775-783	false
glucagon	drug	421-428	quinine	drug	785-791	false
glucagon	drug	421-428	ranitidine	drug	793-802	false
glucagon	drug	421-428	salicylates	group	805-815	false
glucagon	drug	421-428	sulfinpyrazone	drug	817-830	false
glucagon	drug	421-428	sulfonamides	group	832-843	false
glucagon	drug	421-428	sulindac	drug	858-865	false
glucagon	drug	421-428	thyroid drugs	group	867-879	false
glucagon	drug	421-428	tolbutamide	drug	881-891	false
glucagon	drug	421-428	triclofos sodium	drug	893-908	false
glucagon	drug	421-428	trimethoprim	drug	910-921	false
glucagon	drug	421-428	sulfamethoxazole	drug	923-938	false
glucagon	drug	421-428	warfarin sodium	drug	983-997	false
ibuprofen	drug	448-456	indomethacin	drug	458-469	false
ibuprofen	drug	448-456	influenza virus vaccine	group	471-493	false
ibuprofen	drug	448-456	anesthetics	group	506-516	false
ibuprofen	drug	448-456	mefenamic acid	drug	518-531	false
ibuprofen	drug	448-456	methyldopa	drug	533-542	false
ibuprofen	drug	448-456	methylphenidate	drug	544-558	false
ibuprofen	drug	448-456	metronidazole	drug	560-572	false
ibuprofen	drug	448-456	miconazole	drug	574-583	false
ibuprofen	drug	448-456	monoamine oxidase inhibitors	group	585-612	false
ibuprofen	drug	448-456	nalidixic acid	drug	614-627	false
ibuprofen	drug	448-456	naproxen	drug	629-636	false
ibuprofen	drug	448-456	oxolinic acid	drug	638-650	false
ibuprofen	drug	448-456	oxyphenbutazone	drug	652-666	false
ibuprofen	drug	448-456	pentoxifylline	drug	668-681	false
ibuprofen	drug	448-456	phenylbutazone	drug	683-696	false
ibuprofen	drug	448-456	phenyramidol	drug_n	698-709	false
ibuprofen	drug	448-456	phenytoin	drug	711-719	false
ibuprofen	drug	448-456	prolonged narcotics	group	743-761	false
ibuprofen	drug	448-456	pyrazolones	group	763-773	false
ibuprofen	drug	448-456	quinidine	drug	775-783	false
ibuprofen	drug	448-456	quinine	drug	785-791	false
ibuprofen	drug	448-456	ranitidine	drug	793-802	false
ibuprofen	drug	448-456	salicylates	group	805-815	false
ibuprofen	drug	448-456	sulfinpyrazone	drug	817-830	false
ibuprofen	drug	448-456	sulfonamides	group	832-843	false
ibuprofen	drug	448-456	sulindac	drug	858-865	false
ibuprofen	drug	448-456	thyroid drugs	group	867-879	false
ibuprofen	drug	448-456	tolbutamide	drug	881-891	false
ibuprofen	drug	448-456	triclofos sodium	drug	893-908	false
ibuprofen	drug	448-456	trimethoprim	drug	910-921	false
ibuprofen	drug	448-456	sulfamethoxazole	drug	923-938	false
ibuprofen	drug	448-456	warfarin sodium	drug	983-997	false
indomethacin	drug	458-469	influenza virus vaccine	group	471-493	false
indomethacin	drug	458-469	anesthetics	group	506-516	false
indomethacin	drug	458-469	mefenamic acid	drug	518-531	false
indomethacin	drug	458-469	methyldopa	drug	533-542	false
indomethacin	drug	458-469	methylphenidate	drug	544-558	false
indomethacin	drug	458-469	metronidazole	drug	560-572	false
indomethacin	drug	458-469	miconazole	drug	574-583	false
indomethacin	drug	458-469	monoamine oxidase inhibitors	group	585-612	false
indomethacin	drug	458-469	nalidixic acid	drug	614-627	false
indomethacin	drug	458-469	naproxen	drug	629-636	false
indomethacin	drug	458-469	oxolinic acid	drug	638-650	false
indomethacin	drug	458-469	oxyphenbutazone	drug	652-666	false
indomethacin	drug	458-469	pentoxifylline	drug	668-681	false
indomethacin	drug	458-469	phenylbutazone	drug	683-696	false
indomethacin	drug	458-469	phenyramidol	drug_n	698-709	false
indomethacin	drug	458-469	phenytoin	drug	711-719	false
indomethacin	drug	458-469	prolonged narcotics	group	743-761	false
indomethacin	drug	458-469	pyrazolones	group	763-773	false
indomethacin	drug	458-469	quinidine	drug	775-783	false
indomethacin	drug	458-469	quinine	drug	785-791	false
indomethacin	drug	458-469	ranitidine	drug	793-802	false
indomethacin	drug	458-469	salicylates	group	805-815	false
indomethacin	drug	458-469	sulfinpyrazone	drug	817-830	false
indomethacin	drug	458-469	sulfonamides	group	832-843	false
indomethacin	drug	458-469	sulindac	drug	858-865	false
indomethacin	drug	458-469	thyroid drugs	group	867-879	false
indomethacin	drug	458-469	tolbutamide	drug	881-891	false
indomethacin	drug	458-469	triclofos sodium	drug	893-908	false
indomethacin	drug	458-469	trimethoprim	drug	910-921	false
indomethacin	drug	458-469	sulfamethoxazole	drug	923-938	false
indomethacin	drug	458-469	warfarin sodium	drug	983-997	false
influenza virus vaccine	group	471-493	anesthetics	group	506-516	false
influenza virus vaccine	group	471-493	mefenamic acid	drug	518-531	false
influenza virus vaccine	group	471-493	methyldopa	drug	533-542	false
influenza virus vaccine	group	471-493	methylphenidate	drug	544-558	false
influenza virus vaccine	group	471-493	metronidazole	drug	560-572	false
influenza virus vaccine	group	471-493	miconazole	drug	574-583	false
influenza virus vaccine	group	471-493	monoamine oxidase inhibitors	group	585-612	false
influenza virus vaccine	group	471-493	nalidixic acid	drug	614-627	false
influenza virus vaccine	group	471-493	naproxen	drug	629-636	false
influenza virus vaccine	group	471-493	oxolinic acid	drug	638-650	false
influenza virus vaccine	group	471-493	oxyphenbutazone	drug	652-666	false
influenza virus vaccine	group	471-493	pentoxifylline	drug	668-681	false
influenza virus vaccine	group	471-493	phenylbutazone	drug	683-696	false
influenza virus vaccine	group	471-493	phenyramidol	drug_n	698-709	false
influenza virus vaccine	group	471-493	phenytoin	drug	711-719	false
influenza virus vaccine	group	471-493	prolonged narcotics	group	743-761	false
influenza virus vaccine	group	471-493	pyrazolones	group	763-773	false
influenza virus vaccine	group	471-493	quinidine	drug	775-783	false
influenza virus vaccine	group	471-493	quinine	drug	785-791	false
influenza virus vaccine	group	471-493	ranitidine	drug	793-802	false
influenza virus vaccine	group	471-493	salicylates	group	805-815	false
influenza virus vaccine	group	471-493	sulfinpyrazone	drug	817-830	false
influenza virus vaccine	group	471-493	sulfonamides	group	832-843	false
influenza virus vaccine	group	471-493	sulindac	drug	858-865	false
influenza virus vaccine	group	471-493	thyroid drugs	group	867-879	false
influenza virus vaccine	group	471-493	tolbutamide	drug	881-891	false
influenza virus vaccine	group	471-493	triclofos sodium	drug	893-908	false
influenza virus vaccine	group	471-493	trimethoprim	drug	910-921	false
influenza virus vaccine	group	471-493	sulfamethoxazole	drug	923-938	false
influenza virus vaccine	group	471-493	warfarin sodium	drug	983-997	false
anesthetics	group	506-516	mefenamic acid	drug	518-531	false
anesthetics	group	506-516	methyldopa	drug	533-542	false
anesthetics	group	506-516	methylphenidate	drug	544-558	false
anesthetics	group	506-516	metronidazole	drug	560-572	false
anesthetics	group	506-516	miconazole	drug	574-583	false
anesthetics	group	506-516	monoamine oxidase inhibitors	group	585-612	false
anesthetics	group	506-516	nalidixic acid	drug	614-627	false
anesthetics	group	506-516	naproxen	drug	629-636	false
anesthetics	group	506-516	oxolinic acid	drug	638-650	false
anesthetics	group	506-516	oxyphenbutazone	drug	652-666	false
anesthetics	group	506-516	pentoxifylline	drug	668-681	false
anesthetics	group	506-516	phenylbutazone	drug	683-696	false
anesthetics	group	506-516	phenyramidol	drug_n	698-709	false
anesthetics	group	506-516	phenytoin	drug	711-719	false
anesthetics	group	506-516	prolonged narcotics	group	743-761	false
anesthetics	group	506-516	pyrazolones	group	763-773	false
anesthetics	group	506-516	quinidine	drug	775-783	false
anesthetics	group	506-516	quinine	drug	785-791	false
anesthetics	group	506-516	ranitidine	drug	793-802	false
anesthetics	group	506-516	salicylates	group	805-815	false
anesthetics	group	506-516	sulfinpyrazone	drug	817-830	false
anesthetics	group	506-516	sulfonamides	group	832-843	false
anesthetics	group	506-516	sulindac	drug	858-865	false
anesthetics	group	506-516	thyroid drugs	group	867-879	false
anesthetics	group	506-516	tolbutamide	drug	881-891	false
anesthetics	group	506-516	triclofos sodium	drug	893-908	false
anesthetics	group	506-516	trimethoprim	drug	910-921	false
anesthetics	group	506-516	sulfamethoxazole	drug	923-938	false
anesthetics	group	506-516	warfarin sodium	drug	983-997	false
mefenamic acid	drug	518-531	methyldopa	drug	533-542	false
mefenamic acid	drug	518-531	methylphenidate	drug	544-558	false
mefenamic acid	drug	518-531	metronidazole	drug	560-572	false
mefenamic acid	drug	518-531	miconazole	drug	574-583	false
mefenamic acid	drug	518-531	monoamine oxidase inhibitors	group	585-612	false
mefenamic acid	drug	518-531	nalidixic acid	drug	614-627	false
mefenamic acid	drug	518-531	naproxen	drug	629-636	false
mefenamic acid	drug	518-531	oxolinic acid	drug	638-650	false
mefenamic acid	drug	518-531	oxyphenbutazone	drug	652-666	false
mefenamic acid	drug	518-531	pentoxifylline	drug	668-681	false
mefenamic acid	drug	518-531	phenylbutazone	drug	683-696	false
mefenamic acid	drug	518-531	phenyramidol	drug_n	698-709	false
mefenamic acid	drug	518-531	phenytoin	drug	711-719	false
mefenamic acid	drug	518-531	prolonged narcotics	group	743-761	false
mefenamic acid	drug	518-531	pyrazolones	group	763-773	false
mefenamic acid	drug	518-531	quinidine	drug	775-783	false
mefenamic acid	drug	518-531	quinine	drug	785-791	false
mefenamic acid	drug	518-531	ranitidine	drug	793-802	false
mefenamic acid	drug	518-531	salicylates	group	805-815	false
mefenamic acid	drug	518-531	sulfinpyrazone	drug	817-830	false
mefenamic acid	drug	518-531	sulfonamides	group	832-843	false
mefenamic acid	drug	518-531	sulindac	drug	858-865	false
mefenamic acid	drug	518-531	thyroid drugs	group	867-879	false
mefenamic acid	drug	518-531	tolbutamide	drug	881-891	false
mefenamic acid	drug	518-531	triclofos sodium	drug	893-908	false
mefenamic acid	drug	518-531	trimethoprim	drug	910-921	false
mefenamic acid	drug	518-531	sulfamethoxazole	drug	923-938	false
mefenamic acid	drug	518-531	warfarin sodium	drug	983-997	false
methyldopa	drug	533-542	methylphenidate	drug	544-558	false
methyldopa	drug	533-542	metronidazole	drug	560-572	false
methyldopa	drug	533-542	miconazole	drug	574-583	false
methyldopa	drug	533-542	monoamine oxidase inhibitors	group	585-612	false
methyldopa	drug	533-542	nalidixic acid	drug	614-627	false
methyldopa	drug	533-542	naproxen	drug	629-636	false
methyldopa	drug	533-542	oxolinic acid	drug	638-650	false
methyldopa	drug	533-542	oxyphenbutazone	drug	652-666	false
methyldopa	drug	533-542	pentoxifylline	drug	668-681	false
methyldopa	drug	533-542	phenylbutazone	drug	683-696	false
methyldopa	drug	533-542	phenyramidol	drug_n	698-709	false
methyldopa	drug	533-542	phenytoin	drug	711-719	false
methyldopa	drug	533-542	prolonged narcotics	group	743-761	false
methyldopa	drug	533-542	pyrazolones	group	763-773	false
methyldopa	drug	533-542	quinidine	drug	775-783	false
methyldopa	drug	533-542	quinine	drug	785-791	false
methyldopa	drug	533-542	ranitidine	drug	793-802	false
methyldopa	drug	533-542	salicylates	group	805-815	false
methyldopa	drug	533-542	sulfinpyrazone	drug	817-830	false
methyldopa	drug	533-542	sulfonamides	group	832-843	false
methyldopa	drug	533-542	sulindac	drug	858-865	false
methyldopa	drug	533-542	thyroid drugs	group	867-879	false
methyldopa	drug	533-542	tolbutamide	drug	881-891	false
methyldopa	drug	533-542	triclofos sodium	drug	893-908	false
methyldopa	drug	533-542	trimethoprim	drug	910-921	false
methyldopa	drug	533-542	sulfamethoxazole	drug	923-938	false
methyldopa	drug	533-542	warfarin sodium	drug	983-997	false
methylphenidate	drug	544-558	metronidazole	drug	560-572	false
methylphenidate	drug	544-558	miconazole	drug	574-583	false
methylphenidate	drug	544-558	monoamine oxidase inhibitors	group	585-612	false
methylphenidate	drug	544-558	nalidixic acid	drug	614-627	false
methylphenidate	drug	544-558	naproxen	drug	629-636	false
methylphenidate	drug	544-558	oxolinic acid	drug	638-650	false
methylphenidate	drug	544-558	oxyphenbutazone	drug	652-666	false
methylphenidate	drug	544-558	pentoxifylline	drug	668-681	false
methylphenidate	drug	544-558	phenylbutazone	drug	683-696	false
methylphenidate	drug	544-558	phenyramidol	drug_n	698-709	false
methylphenidate	drug	544-558	phenytoin	drug	711-719	false
methylphenidate	drug	544-558	prolonged narcotics	group	743-761	false
methylphenidate	drug	544-558	pyrazolones	group	763-773	false
methylphenidate	drug	544-558	quinidine	drug	775-783	false
methylphenidate	drug	544-558	quinine	drug	785-791	false
methylphenidate	drug	544-558	ranitidine	drug	793-802	false
methylphenidate	drug	544-558	salicylates	group	805-815	false
methylphenidate	drug	544-558	sulfinpyrazone	drug	817-830	false
methylphenidate	drug	544-558	sulfonamides	group	832-843	false
methylphenidate	drug	544-558	sulindac	drug	858-865	false
methylphenidate	drug	544-558	thyroid drugs	group	867-879	false
methylphenidate	drug	544-558	tolbutamide	drug	881-891	false
methylphenidate	drug	544-558	triclofos sodium	drug	893-908	false
methylphenidate	drug	544-558	trimethoprim	drug	910-921	false
methylphenidate	drug	544-558	sulfamethoxazole	drug	923-938	false
methylphenidate	drug	544-558	warfarin sodium	drug	983-997	false
metronidazole	drug	560-572	miconazole	drug	574-583	false
metronidazole	drug	560-572	monoamine oxidase inhibitors	group	585-612	false
metronidazole	drug	560-572	nalidixic acid	drug	614-627	false
metronidazole	drug	560-572	naproxen	drug	629-636	false
metronidazole	drug	560-572	oxolinic acid	drug	638-650	false
metronidazole	drug	560-572	oxyphenbutazone	drug	652-666	false
metronidazole	drug	560-572	pentoxifylline	drug	668-681	false
metronidazole	drug	560-572	phenylbutazone	drug	683-696	false
metronidazole	drug	560-572	phenyramidol	drug_n	698-709	false
metronidazole	drug	560-572	phenytoin	drug	711-719	false
metronidazole	drug	560-572	prolonged narcotics	group	743-761	false
metronidazole	drug	560-572	pyrazolones	group	763-773	false
metronidazole	drug	560-572	quinidine	drug	775-783	false
metronidazole	drug	560-572	quinine	drug	785-791	false
metronidazole	drug	560-572	ranitidine	drug	793-802	false
metronidazole	drug	560-572	salicylates	group	805-815	false
metronidazole	drug	560-572	sulfinpyrazone	drug	817-830	false
metronidazole	drug	560-572	sulfonamides	group	832-843	false
metronidazole	drug	560-572	sulindac	drug	858-865	false
metronidazole	drug	560-572	thyroid drugs	group	867-879	false
metronidazole	drug	560-572	tolbutamide	drug	881-891	false
metronidazole	drug	560-572	triclofos sodium	drug	893-908	false
metronidazole	drug	560-572	trimethoprim	drug	910-921	false
metronidazole	drug	560-572	sulfamethoxazole	drug	923-938	false
metronidazole	drug	560-572	warfarin sodium	drug	983-997	false
miconazole	drug	574-583	monoamine oxidase inhibitors	group	585-612	false
miconazole	drug	574-583	nalidixic acid	drug	614-627	false
miconazole	drug	574-583	naproxen	drug	629-636	false
miconazole	drug	574-583	oxolinic acid	drug	638-650	false
miconazole	drug	574-583	oxyphenbutazone	drug	652-666	false
miconazole	drug	574-583	pentoxifylline	drug	668-681	false
miconazole	drug	574-583	phenylbutazone	drug	683-696	false
miconazole	drug	574-583	phenyramidol	drug_n	698-709	false
miconazole	drug	574-583	phenytoin	drug	711-719	false
miconazole	drug	574-583	prolonged narcotics	group	743-761	false
miconazole	drug	574-583	pyrazolones	group	763-773	false
miconazole	drug	574-583	quinidine	drug	775-783	false
miconazole	drug	574-583	quinine	drug	785-791	false
miconazole	drug	574-583	ranitidine	drug	793-802	false
miconazole	drug	574-583	salicylates	group	805-815	false
miconazole	drug	574-583	sulfinpyrazone	drug	817-830	false
miconazole	drug	574-583	sulfonamides	group	832-843	false
miconazole	drug	574-583	sulindac	drug	858-865	false
miconazole	drug	574-583	thyroid drugs	group	867-879	false
miconazole	drug	574-583	tolbutamide	drug	881-891	false
miconazole	drug	574-583	triclofos sodium	drug	893-908	false
miconazole	drug	574-583	trimethoprim	drug	910-921	false
miconazole	drug	574-583	sulfamethoxazole	drug	923-938	false
miconazole	drug	574-583	warfarin sodium	drug	983-997	false
monoamine oxidase inhibitors	group	585-612	nalidixic acid	drug	614-627	false
monoamine oxidase inhibitors	group	585-612	naproxen	drug	629-636	false
monoamine oxidase inhibitors	group	585-612	oxolinic acid	drug	638-650	false
monoamine oxidase inhibitors	group	585-612	oxyphenbutazone	drug	652-666	false
monoamine oxidase inhibitors	group	585-612	pentoxifylline	drug	668-681	false
monoamine oxidase inhibitors	group	585-612	phenylbutazone	drug	683-696	false
monoamine oxidase inhibitors	group	585-612	phenyramidol	drug_n	698-709	false
monoamine oxidase inhibitors	group	585-612	phenytoin	drug	711-719	false
monoamine oxidase inhibitors	group	585-612	prolonged narcotics	group	743-761	false
monoamine oxidase inhibitors	group	585-612	pyrazolones	group	763-773	false
monoamine oxidase inhibitors	group	585-612	quinidine	drug	775-783	false
monoamine oxidase inhibitors	group	585-612	quinine	drug	785-791	false
monoamine oxidase inhibitors	group	585-612	ranitidine	drug	793-802	false
monoamine oxidase inhibitors	group	585-612	salicylates	group	805-815	false
monoamine oxidase inhibitors	group	585-612	sulfinpyrazone	drug	817-830	false
monoamine oxidase inhibitors	group	585-612	sulfonamides	group	832-843	false
monoamine oxidase inhibitors	group	585-612	sulindac	drug	858-865	false
monoamine oxidase inhibitors	group	585-612	thyroid drugs	group	867-879	false
monoamine oxidase inhibitors	group	585-612	tolbutamide	drug	881-891	false
monoamine oxidase inhibitors	group	585-612	triclofos sodium	drug	893-908	false
monoamine oxidase inhibitors	group	585-612	trimethoprim	drug	910-921	false
monoamine oxidase inhibitors	group	585-612	sulfamethoxazole	drug	923-938	false
monoamine oxidase inhibitors	group	585-612	warfarin sodium	drug	983-997	false
nalidixic acid	drug	614-627	naproxen	drug	629-636	false
nalidixic acid	drug	614-627	oxolinic acid	drug	638-650	false
nalidixic acid	drug	614-627	oxyphenbutazone	drug	652-666	false
nalidixic acid	drug	614-627	pentoxifylline	drug	668-681	false
nalidixic acid	drug	614-627	phenylbutazone	drug	683-696	false
nalidixic acid	drug	614-627	phenyramidol	drug_n	698-709	false
nalidixic acid	drug	614-627	phenytoin	drug	711-719	false
nalidixic acid	drug	614-627	prolonged narcotics	group	743-761	false
nalidixic acid	drug	614-627	pyrazolones	group	763-773	false
nalidixic acid	drug	614-627	quinidine	drug	775-783	false
nalidixic acid	drug	614-627	quinine	drug	785-791	false
nalidixic acid	drug	614-627	ranitidine	drug	793-802	false
nalidixic acid	drug	614-627	salicylates	group	805-815	false
nalidixic acid	drug	614-627	sulfinpyrazone	drug	817-830	false
nalidixic acid	drug	614-627	sulfonamides	group	832-843	false
nalidixic acid	drug	614-627	sulindac	drug	858-865	false
nalidixic acid	drug	614-627	thyroid drugs	group	867-879	false
nalidixic acid	drug	614-627	tolbutamide	drug	881-891	false
nalidixic acid	drug	614-627	triclofos sodium	drug	893-908	false
nalidixic acid	drug	614-627	trimethoprim	drug	910-921	false
nalidixic acid	drug	614-627	sulfamethoxazole	drug	923-938	false
nalidixic acid	drug	614-627	warfarin sodium	drug	983-997	false
naproxen	drug	629-636	oxolinic acid	drug	638-650	false
naproxen	drug	629-636	oxyphenbutazone	drug	652-666	false
naproxen	drug	629-636	pentoxifylline	drug	668-681	false
naproxen	drug	629-636	phenylbutazone	drug	683-696	false
naproxen	drug	629-636	phenyramidol	drug_n	698-709	false
naproxen	drug	629-636	phenytoin	drug	711-719	false
naproxen	drug	629-636	prolonged narcotics	group	743-761	false
naproxen	drug	629-636	pyrazolones	group	763-773	false
naproxen	drug	629-636	quinidine	drug	775-783	false
naproxen	drug	629-636	quinine	drug	785-791	false
naproxen	drug	629-636	ranitidine	drug	793-802	false
naproxen	drug	629-636	salicylates	group	805-815	false
naproxen	drug	629-636	sulfinpyrazone	drug	817-830	false
naproxen	drug	629-636	sulfonamides	group	832-843	false
naproxen	drug	629-636	sulindac	drug	858-865	false
naproxen	drug	629-636	thyroid drugs	group	867-879	false
naproxen	drug	629-636	tolbutamide	drug	881-891	false
naproxen	drug	629-636	triclofos sodium	drug	893-908	false
naproxen	drug	629-636	trimethoprim	drug	910-921	false
naproxen	drug	629-636	sulfamethoxazole	drug	923-938	false
naproxen	drug	629-636	warfarin sodium	drug	983-997	false
oxolinic acid	drug	638-650	oxyphenbutazone	drug	652-666	false
oxolinic acid	drug	638-650	pentoxifylline	drug	668-681	false
oxolinic acid	drug	638-650	phenylbutazone	drug	683-696	false
oxolinic acid	drug	638-650	phenyramidol	drug_n	698-709	false
oxolinic acid	drug	638-650	phenytoin	drug	711-719	false
oxolinic acid	drug	638-650	prolonged narcotics	group	743-761	false
oxolinic acid	drug	638-650	pyrazolones	group	763-773	false
oxolinic acid	drug	638-650	quinidine	drug	775-783	false
oxolinic acid	drug	638-650	quinine	drug	785-791	false
oxolinic acid	drug	638-650	ranitidine	drug	793-802	false
oxolinic acid	drug	638-650	salicylates	group	805-815	false
oxolinic acid	drug	638-650	sulfinpyrazone	drug	817-830	false
oxolinic acid	drug	638-650	sulfonamides	group	832-843	false
oxolinic acid	drug	638-650	sulindac	drug	858-865	false
oxolinic acid	drug	638-650	thyroid drugs	group	867-879	false
oxolinic acid	drug	638-650	tolbutamide	drug	881-891	false
oxolinic acid	drug	638-650	triclofos sodium	drug	893-908	false
oxolinic acid	drug	638-650	trimethoprim	drug	910-921	false
oxolinic acid	drug	638-650	sulfamethoxazole	drug	923-938	false
oxolinic acid	drug	638-650	warfarin sodium	drug	983-997	false
oxyphenbutazone	drug	652-666	pentoxifylline	drug	668-681	false
oxyphenbutazone	drug	652-666	phenylbutazone	drug	683-696	false
oxyphenbutazone	drug	652-666	phenyramidol	drug_n	698-709	false
oxyphenbutazone	drug	652-666	phenytoin	drug	711-719	false
oxyphenbutazone	drug	652-666	prolonged narcotics	group	743-761	false
oxyphenbutazone	drug	652-666	pyrazolones	group	763-773	false
oxyphenbutazone	drug	652-666	quinidine	drug	775-783	false
oxyphenbutazone	drug	652-666	quinine	drug	785-791	false
oxyphenbutazone	drug	652-666	ranitidine	drug	793-802	false
oxyphenbutazone	drug	652-666	salicylates	group	805-815	false
oxyphenbutazone	drug	652-666	sulfinpyrazone	drug	817-830	false
oxyphenbutazone	drug	652-666	sulfonamides	group	832-843	false
oxyphenbutazone	drug	652-666	sulindac	drug	858-865	false
oxyphenbutazone	drug	652-666	thyroid drugs	group	867-879	false
oxyphenbutazone	drug	652-666	tolbutamide	drug	881-891	false
oxyphenbutazone	drug	652-666	triclofos sodium	drug	893-908	false
oxyphenbutazone	drug	652-666	trimethoprim	drug	910-921	false
oxyphenbutazone	drug	652-666	sulfamethoxazole	drug	923-938	false
oxyphenbutazone	drug	652-666	warfarin sodium	drug	983-997	false
pentoxifylline	drug	668-681	phenylbutazone	drug	683-696	false
pentoxifylline	drug	668-681	phenyramidol	drug_n	698-709	false
pentoxifylline	drug	668-681	phenytoin	drug	711-719	false
pentoxifylline	drug	668-681	prolonged narcotics	group	743-761	false
pentoxifylline	drug	668-681	pyrazolones	group	763-773	false
pentoxifylline	drug	668-681	quinidine	drug	775-783	false
pentoxifylline	drug	668-681	quinine	drug	785-791	false
pentoxifylline	drug	668-681	ranitidine	drug	793-802	false
pentoxifylline	drug	668-681	salicylates	group	805-815	false
pentoxifylline	drug	668-681	sulfinpyrazone	drug	817-830	false
pentoxifylline	drug	668-681	sulfonamides	group	832-843	false
pentoxifylline	drug	668-681	sulindac	drug	858-865	false
pentoxifylline	drug	668-681	thyroid drugs	group	867-879	false
pentoxifylline	drug	668-681	tolbutamide	drug	881-891	false
pentoxifylline	drug	668-681	triclofos sodium	drug	893-908	false
pentoxifylline	drug	668-681	trimethoprim	drug	910-921	false
pentoxifylline	drug	668-681	sulfamethoxazole	drug	923-938	false
pentoxifylline	drug	668-681	warfarin sodium	drug	983-997	false
phenylbutazone	drug	683-696	phenyramidol	drug_n	698-709	false
phenylbutazone	drug	683-696	phenytoin	drug	711-719	false
phenylbutazone	drug	683-696	prolonged narcotics	group	743-761	false
phenylbutazone	drug	683-696	pyrazolones	group	763-773	false
phenylbutazone	drug	683-696	quinidine	drug	775-783	false
phenylbutazone	drug	683-696	quinine	drug	785-791	false
phenylbutazone	drug	683-696	ranitidine	drug	793-802	false
phenylbutazone	drug	683-696	salicylates	group	805-815	false
phenylbutazone	drug	683-696	sulfinpyrazone	drug	817-830	false
phenylbutazone	drug	683-696	sulfonamides	group	832-843	false
phenylbutazone	drug	683-696	sulindac	drug	858-865	false
phenylbutazone	drug	683-696	thyroid drugs	group	867-879	false
phenylbutazone	drug	683-696	tolbutamide	drug	881-891	false
phenylbutazone	drug	683-696	triclofos sodium	drug	893-908	false
phenylbutazone	drug	683-696	trimethoprim	drug	910-921	false
phenylbutazone	drug	683-696	sulfamethoxazole	drug	923-938	false
phenylbutazone	drug	683-696	warfarin sodium	drug	983-997	false
phenyramidol	drug_n	698-709	phenytoin	drug	711-719	false
phenyramidol	drug_n	698-709	prolonged narcotics	group	743-761	false
phenyramidol	drug_n	698-709	pyrazolones	group	763-773	false
phenyramidol	drug_n	698-709	quinidine	drug	775-783	false
phenyramidol	drug_n	698-709	quinine	drug	785-791	false
phenyramidol	drug_n	698-709	ranitidine	drug	793-802	false
phenyramidol	drug_n	698-709	salicylates	group	805-815	false
phenyramidol	drug_n	698-709	sulfinpyrazone	drug	817-830	false
phenyramidol	drug_n	698-709	sulfonamides	group	832-843	false
phenyramidol	drug_n	698-709	sulindac	drug	858-865	false
phenyramidol	drug_n	698-709	thyroid drugs	group	867-879	false
phenyramidol	drug_n	698-709	tolbutamide	drug	881-891	false
phenyramidol	drug_n	698-709	triclofos sodium	drug	893-908	false
phenyramidol	drug_n	698-709	trimethoprim	drug	910-921	false
phenyramidol	drug_n	698-709	sulfamethoxazole	drug	923-938	false
phenyramidol	drug_n	698-709	warfarin sodium	drug	983-997	false
phenytoin	drug	711-719	prolonged narcotics	group	743-761	false
phenytoin	drug	711-719	pyrazolones	group	763-773	false
phenytoin	drug	711-719	quinidine	drug	775-783	false
phenytoin	drug	711-719	quinine	drug	785-791	false
phenytoin	drug	711-719	ranitidine	drug	793-802	false
phenytoin	drug	711-719	salicylates	group	805-815	false
phenytoin	drug	711-719	sulfinpyrazone	drug	817-830	false
phenytoin	drug	711-719	sulfonamides	group	832-843	false
phenytoin	drug	711-719	sulindac	drug	858-865	false
phenytoin	drug	711-719	thyroid drugs	group	867-879	false
phenytoin	drug	711-719	tolbutamide	drug	881-891	false
phenytoin	drug	711-719	triclofos sodium	drug	893-908	false
phenytoin	drug	711-719	trimethoprim	drug	910-921	false
phenytoin	drug	711-719	sulfamethoxazole	drug	923-938	false
phenytoin	drug	711-719	warfarin sodium	drug	983-997	false
prolonged narcotics	group	743-761	pyrazolones	group	763-773	false
prolonged narcotics	group	743-761	quinidine	drug	775-783	false
prolonged narcotics	group	743-761	quinine	drug	785-791	false
prolonged narcotics	group	743-761	ranitidine	drug	793-802	false
prolonged narcotics	group	743-761	salicylates	group	805-815	false
prolonged narcotics	group	743-761	sulfinpyrazone	drug	817-830	false
prolonged narcotics	group	743-761	sulfonamides	group	832-843	false
prolonged narcotics	group	743-761	sulindac	drug	858-865	false
prolonged narcotics	group	743-761	thyroid drugs	group	867-879	false
prolonged narcotics	group	743-761	tolbutamide	drug	881-891	false
prolonged narcotics	group	743-761	triclofos sodium	drug	893-908	false
prolonged narcotics	group	743-761	trimethoprim	drug	910-921	false
prolonged narcotics	group	743-761	sulfamethoxazole	drug	923-938	false
prolonged narcotics	group	743-761	warfarin sodium	drug	983-997	false
pyrazolones	group	763-773	quinidine	drug	775-783	false
pyrazolones	group	763-773	quinine	drug	785-791	false
pyrazolones	group	763-773	ranitidine	drug	793-802	false
pyrazolones	group	763-773	salicylates	group	805-815	false
pyrazolones	group	763-773	sulfinpyrazone	drug	817-830	false
pyrazolones	group	763-773	sulfonamides	group	832-843	false
pyrazolones	group	763-773	sulindac	drug	858-865	false
pyrazolones	group	763-773	thyroid drugs	group	867-879	false
pyrazolones	group	763-773	tolbutamide	drug	881-891	false
pyrazolones	group	763-773	triclofos sodium	drug	893-908	false
pyrazolones	group	763-773	trimethoprim	drug	910-921	false
pyrazolones	group	763-773	sulfamethoxazole	drug	923-938	false
pyrazolones	group	763-773	warfarin sodium	drug	983-997	false
quinidine	drug	775-783	quinine	drug	785-791	false
quinidine	drug	775-783	ranitidine	drug	793-802	false
quinidine	drug	775-783	salicylates	group	805-815	false
quinidine	drug	775-783	sulfinpyrazone	drug	817-830	false
quinidine	drug	775-783	sulfonamides	group	832-843	false
quinidine	drug	775-783	sulindac	drug	858-865	false
quinidine	drug	775-783	thyroid drugs	group	867-879	false
quinidine	drug	775-783	tolbutamide	drug	881-891	false
quinidine	drug	775-783	triclofos sodium	drug	893-908	false
quinidine	drug	775-783	trimethoprim	drug	910-921	false
quinidine	drug	775-783	sulfamethoxazole	drug	923-938	false
quinidine	drug	775-783	warfarin sodium	drug	983-997	false
quinine	drug	785-791	ranitidine	drug	793-802	false
quinine	drug	785-791	salicylates	group	805-815	false
quinine	drug	785-791	sulfinpyrazone	drug	817-830	false
quinine	drug	785-791	sulfonamides	group	832-843	false
quinine	drug	785-791	sulindac	drug	858-865	false
quinine	drug	785-791	thyroid drugs	group	867-879	false
quinine	drug	785-791	tolbutamide	drug	881-891	false
quinine	drug	785-791	triclofos sodium	drug	893-908	false
quinine	drug	785-791	trimethoprim	drug	910-921	false
quinine	drug	785-791	sulfamethoxazole	drug	923-938	false
quinine	drug	785-791	warfarin sodium	drug	983-997	false
ranitidine	drug	793-802	salicylates	group	805-815	false
ranitidine	drug	793-802	sulfinpyrazone	drug	817-830	false
ranitidine	drug	793-802	sulfonamides	group	832-843	false
ranitidine	drug	793-802	sulindac	drug	858-865	false
ranitidine	drug	793-802	thyroid drugs	group	867-879	false
ranitidine	drug	793-802	tolbutamide	drug	881-891	false
ranitidine	drug	793-802	triclofos sodium	drug	893-908	false
ranitidine	drug	793-802	trimethoprim	drug	910-921	false
ranitidine	drug	793-802	sulfamethoxazole	drug	923-938	false
ranitidine	drug	793-802	warfarin sodium	drug	983-997	false
salicylates	group	805-815	sulfinpyrazone	drug	817-830	false
salicylates	group	805-815	sulfonamides	group	832-843	false
salicylates	group	805-815	sulindac	drug	858-865	false
salicylates	group	805-815	thyroid drugs	group	867-879	false
salicylates	group	805-815	tolbutamide	drug	881-891	false
salicylates	group	805-815	triclofos sodium	drug	893-908	false
salicylates	group	805-815	trimethoprim	drug	910-921	false
salicylates	group	805-815	sulfamethoxazole	drug	923-938	false
salicylates	group	805-815	warfarin sodium	drug	983-997	false
sulfinpyrazone	drug	817-830	sulfonamides	group	832-843	false
sulfinpyrazone	drug	817-830	sulindac	drug	858-865	false
sulfinpyrazone	drug	817-830	thyroid drugs	group	867-879	false
sulfinpyrazone	drug	817-830	tolbutamide	drug	881-891	false
sulfinpyrazone	drug	817-830	triclofos sodium	drug	893-908	false
sulfinpyrazone	drug	817-830	trimethoprim	drug	910-921	false
sulfinpyrazone	drug	817-830	sulfamethoxazole	drug	923-938	false
sulfinpyrazone	drug	817-830	warfarin sodium	drug	983-997	false
sulfonamides	group	832-843	sulindac	drug	858-865	false
sulfonamides	group	832-843	thyroid drugs	group	867-879	false
sulfonamides	group	832-843	tolbutamide	drug	881-891	false
sulfonamides	group	832-843	triclofos sodium	drug	893-908	false
sulfonamides	group	832-843	trimethoprim	drug	910-921	false
sulfonamides	group	832-843	sulfamethoxazole	drug	923-938	false
sulfonamides	group	832-843	warfarin sodium	drug	983-997	false
sulindac	drug	858-865	thyroid drugs	group	867-879	false
sulindac	drug	858-865	tolbutamide	drug	881-891	false
sulindac	drug	858-865	triclofos sodium	drug	893-908	false
sulindac	drug	858-865	trimethoprim	drug	910-921	false
sulindac	drug	858-865	sulfamethoxazole	drug	923-938	false
sulindac	drug	858-865	warfarin sodium	drug	983-997	false
thyroid drugs	group	867-879	tolbutamide	drug	881-891	false
thyroid drugs	group	867-879	triclofos sodium	drug	893-908	false
thyroid drugs	group	867-879	trimethoprim	drug	910-921	false
thyroid drugs	group	867-879	sulfamethoxazole	drug	923-938	false
thyroid drugs	group	867-879	warfarin sodium	drug	983-997	false
tolbutamide	drug	881-891	triclofos sodium	drug	893-908	false
tolbutamide	drug	881-891	trimethoprim	drug	910-921	false
tolbutamide	drug	881-891	sulfamethoxazole	drug	923-938	false
tolbutamide	drug	881-891	warfarin sodium	drug	983-997	false
triclofos sodium	drug	893-908	trimethoprim	drug	910-921	false
triclofos sodium	drug	893-908	sulfamethoxazole	drug	923-938	false
triclofos sodium	drug	893-908	warfarin sodium	drug	983-997	false
trimethoprim	drug	910-921	sulfamethoxazole	drug	923-938	false
trimethoprim	drug	910-921	warfarin sodium	drug	983-997	false
sulfamethoxazole	drug	923-938	warfarin sodium	drug	983-997	false

DDI-DrugBank.d64.s88	Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
anticoagulants	group	5-18	hypoglycemic agents	group	62-80	mechanism
anticoagulants	group	5-18	tolbutamide	drug	87-97	mechanism
anticoagulants	group	5-18	chlorpropamide	drug	103-116	mechanism
hypoglycemic agents	group	62-80	tolbutamide	drug	87-97	false
hypoglycemic agents	group	62-80	chlorpropamide	drug	103-116	false
tolbutamide	drug	87-97	chlorpropamide	drug	103-116	false

DDI-DrugBank.d64.s89	Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
anticoagulants	group	13-26	phenytoin	drug	73-81	mechanism
anticoagulants	group	13-26	anticonvulsant	group	104-117	false
anticoagulants	group	13-26	anticoagulant	group	142-154	false
anticoagulants	group	13-26	phenytoin	drug	160-168	false
phenytoin	drug	73-81	anticonvulsant	group	104-117	false
phenytoin	drug	73-81	anticoagulant	group	142-154	false
phenytoin	drug	73-81	phenytoin	drug	160-168	false
anticonvulsant	group	104-117	anticoagulant	group	142-154	false
anticonvulsant	group	104-117	phenytoin	drug	160-168	false
anticoagulant	group	142-154	phenytoin	drug	160-168	mechanism

DDI-DrugBank.d64.s90	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
antineoplastic agents	group	91-111	aspirin	brand	160-166	false
antineoplastic agents	group	91-111	non-steroidal anti-inflammatory drugs	group	178-214	false
antineoplastic agents	group	91-111	dipyridamole	drug	217-228	false
antineoplastic agents	group	91-111	hydrochloroquine	drug	231-246	false
antineoplastic agents	group	91-111	clofibrate	drug	249-258	false
antineoplastic agents	group	91-111	dextran	drug	261-267	false
antineoplastic agents	group	91-111	anticoagulants	group	317-330	effect
aspirin	brand	160-166	non-steroidal anti-inflammatory drugs	group	178-214	false
aspirin	brand	160-166	dipyridamole	drug	217-228	false
aspirin	brand	160-166	hydrochloroquine	drug	231-246	false
aspirin	brand	160-166	clofibrate	drug	249-258	false
aspirin	brand	160-166	dextran	drug	261-267	false
aspirin	brand	160-166	anticoagulants	group	317-330	effect
non-steroidal anti-inflammatory drugs	group	178-214	dipyridamole	drug	217-228	false
non-steroidal anti-inflammatory drugs	group	178-214	hydrochloroquine	drug	231-246	false
non-steroidal anti-inflammatory drugs	group	178-214	clofibrate	drug	249-258	false
non-steroidal anti-inflammatory drugs	group	178-214	dextran	drug	261-267	false
non-steroidal anti-inflammatory drugs	group	178-214	anticoagulants	group	317-330	effect
dipyridamole	drug	217-228	hydrochloroquine	drug	231-246	false
dipyridamole	drug	217-228	clofibrate	drug	249-258	false
dipyridamole	drug	217-228	dextran	drug	261-267	false
dipyridamole	drug	217-228	anticoagulants	group	317-330	effect
hydrochloroquine	drug	231-246	clofibrate	drug	249-258	false
hydrochloroquine	drug	231-246	dextran	drug	261-267	false
hydrochloroquine	drug	231-246	anticoagulants	group	317-330	effect
clofibrate	drug	249-258	dextran	drug	261-267	false
clofibrate	drug	249-258	anticoagulants	group	317-330	effect
dextran	drug	261-267	anticoagulants	group	317-330	effect

DDI-DrugBank.d64.s91	The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.
antiplatelet medication	group	81-92;112-121	anticoagulant medication	group	98-121	advise

DDI-DrugBank.d64.s93	Drug/Laboratory Test Interferences: Dicumarol and indanedione anticoagulants, including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.
Dicumarol	drug	36-44	indanedione anticoagulants	group	50-75	false
Dicumarol	drug	36-44	anisindione	drug	88-98	false
indanedione anticoagulants	group	50-75	anisindione	drug	88-98	false

DDI-DrugBank.d89.s3	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
caffeine	drug	36-43	caffeine	drug	126-133	false
caffeine	drug	36-43	cimetidine	drug	154-163	advise
caffeine	drug	36-43	ketoconazole	drug	169-180	advise
caffeine	drug	36-43	caffeine	drug	194-201	false
caffeine	drug	36-43	caffeine	drug	273-280	false
caffeine	drug	36-43	phenobarbital	drug	301-313	false
caffeine	drug	36-43	phenytoin	drug	319-327	false
caffeine	drug	126-133	cimetidine	drug	154-163	false
caffeine	drug	126-133	ketoconazole	drug	169-180	false
caffeine	drug	126-133	caffeine	drug	194-201	false
caffeine	drug	126-133	caffeine	drug	273-280	false
caffeine	drug	126-133	phenobarbital	drug	301-313	false
caffeine	drug	126-133	phenytoin	drug	319-327	false
cimetidine	drug	154-163	ketoconazole	drug	169-180	false
cimetidine	drug	154-163	caffeine	drug	194-201	false
cimetidine	drug	154-163	caffeine	drug	273-280	false
cimetidine	drug	154-163	phenobarbital	drug	301-313	false
cimetidine	drug	154-163	phenytoin	drug	319-327	false
ketoconazole	drug	169-180	caffeine	drug	194-201	false
ketoconazole	drug	169-180	caffeine	drug	273-280	false
ketoconazole	drug	169-180	phenobarbital	drug	301-313	false
ketoconazole	drug	169-180	phenytoin	drug	319-327	false
caffeine	drug	194-201	caffeine	drug	273-280	false
caffeine	drug	194-201	phenobarbital	drug	301-313	advise
caffeine	drug	194-201	phenytoin	drug	319-327	advise
caffeine	drug	273-280	phenobarbital	drug	301-313	false
caffeine	drug	273-280	phenytoin	drug	319-327	false
phenobarbital	drug	301-313	phenytoin	drug	319-327	false

DDI-DrugBank.d89.s4	Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.
Caffeine	drug	0-7	ketoprofen	drug	40-49	effect

DDI-DrugBank.d89.s6	Interconversion between caffeine and theophylline has been reported in preterm neonates.
caffeine	drug	24-31	theophylline	drug	37-48	false

DDI-DrugBank.d344.s0	Concomitant use of calcium supplements and L-lysine may increase calcium absorption
calcium	drug	19-25	L-lysine	drug	43-50	mechanism
calcium	drug	19-25	calcium	drug	65-71	false
L-lysine	drug	43-50	calcium	drug	65-71	false

DDI-DrugBank.d109.s0	Ketoconazole/Itraconazole, Macrolides, Including Erythromycin
Ketoconazole	drug	0-11	Itraconazole	drug	13-24	false
Ketoconazole	drug	0-11	Macrolides	group	27-36	false
Ketoconazole	drug	0-11	Erythromycin	drug	49-60	false
Itraconazole	drug	13-24	Macrolides	group	27-36	false
Itraconazole	drug	13-24	Erythromycin	drug	49-60	false
Macrolides	group	27-36	Erythromycin	drug	49-60	false

DDI-DrugBank.d226.s0	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
Adenocard	brand	12-20	adenosine	drug	23-31	false
Adenocard	brand	12-20	quinidine	drug	121-129	false
Adenocard	brand	12-20	beta-adrenergic blocking agents	group	132-162	false
Adenocard	brand	12-20	calcium channel blocking agents	group	165-195	false
Adenocard	brand	12-20	angiotensin converting enzyme inhibitors	group	202-241	false
adenosine	drug	23-31	quinidine	drug	121-129	false
adenosine	drug	23-31	beta-adrenergic blocking agents	group	132-162	false
adenosine	drug	23-31	calcium channel blocking agents	group	165-195	false
adenosine	drug	23-31	angiotensin converting enzyme inhibitors	group	202-241	false
quinidine	drug	121-129	beta-adrenergic blocking agents	group	132-162	false
quinidine	drug	121-129	calcium channel blocking agents	group	165-195	false
quinidine	drug	121-129	angiotensin converting enzyme inhibitors	group	202-241	false
beta-adrenergic blocking agents	group	132-162	calcium channel blocking agents	group	165-195	false
beta-adrenergic blocking agents	group	132-162	angiotensin converting enzyme inhibitors	group	202-241	false
calcium channel blocking agents	group	165-195	angiotensin converting enzyme inhibitors	group	202-241	false

DDI-DrugBank.d226.s1	Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
Digoxin	drug	0-6	verapamil	drug	12-20	false
Digoxin	drug	0-6	Adenocard	brand	100-108	effect
verapamil	drug	12-20	Adenocard	brand	100-108	effect

DDI-DrugBank.d226.s3	The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.
Adenocard	brand	11-19	digitalis	group	43-51	effect

DDI-DrugBank.d226.s4	The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
adenosine	drug	15-23	methylxanthines	group	44-58	effect
adenosine	drug	15-23	caffeine	drug	68-75	effect
adenosine	drug	15-23	theophylline	drug	81-92	effect
methylxanthines	group	44-58	caffeine	drug	68-75	false
methylxanthines	group	44-58	theophylline	drug	81-92	false
caffeine	drug	68-75	theophylline	drug	81-92	false

DDI-DrugBank.d226.s5	In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
methylxanthines	group	25-39	adenosine	drug	58-66	advise
methylxanthines	group	25-39	adenosine	drug	87-95	advise
adenosine	drug	58-66	adenosine	drug	87-95	false

DDI-DrugBank.d226.s6	Adenosine effects are potentiated by dipyridamole.
Adenosine	drug	0-8	dipyridamole	drug	37-48	effect

DDI-DrugBank.d226.s7	Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
adenosine	drug	23-31	dipyridamole	drug	69-80	effect

DDI-DrugBank.d226.s9	As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.
adenosine	drug	25-33	carbamazepine	drug	148-160	effect

DDI-DrugBank.d176.s0	Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.
Diuretics	group	0-8	diuretics	group	23-31	false
Diuretics	group	0-8	fosinopril sodium	drug	190-206	false
diuretics	group	23-31	fosinopril sodium	drug	190-206	effect

DDI-DrugBank.d176.s1	The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.
diuretic	group	84-91	fosinopril sodium	drug	157-173	effect

DDI-DrugBank.d176.s3	Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.
Potassium	drug	0-8	Potassium-Sparing Diuretics	group	26-52	false
Potassium	drug	0-8	Fosinopril sodium	drug	55-71	false
Potassium	drug	0-8	thiazide diuretics	group	112-129	false
Potassium-Sparing Diuretics	group	26-52	Fosinopril sodium	drug	55-71	false
Potassium-Sparing Diuretics	group	26-52	thiazide diuretics	group	112-129	false
Fosinopril sodium	drug	55-71	thiazide diuretics	group	112-129	effect

DDI-DrugBank.d176.s4	Potassium-sparing diuretics (spironolactone, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
Potassium-sparing diuretics	group	0-26	spironolactone	drug	29-42	false
Potassium-sparing diuretics	group	0-26	amiloride	drug	45-53	false
Potassium-sparing diuretics	group	0-26	triamterene	drug	55-65	false
Potassium-sparing diuretics	group	0-26	potassium	drug	83-91	false
spironolactone	drug	29-42	amiloride	drug	45-53	false
spironolactone	drug	29-42	triamterene	drug	55-65	false
spironolactone	drug	29-42	potassium	drug	83-91	false
amiloride	drug	45-53	triamterene	drug	55-65	false
amiloride	drug	45-53	potassium	drug	83-91	false
triamterene	drug	55-65	potassium	drug	83-91	false

DDI-DrugBank.d176.s6	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
Lithium	drug	0-6	lithium	drug	25-31	false
Lithium	drug	0-6	lithium	drug	56-62	false
Lithium	drug	0-6	ACE inhibitors	group	114-127	false
Lithium	drug	0-6	lithium	drug	149-155	false
lithium	drug	25-31	lithium	drug	56-62	false
lithium	drug	25-31	ACE inhibitors	group	114-127	false
lithium	drug	25-31	lithium	drug	149-155	false
lithium	drug	56-62	ACE inhibitors	group	114-127	false
lithium	drug	56-62	lithium	drug	149-155	false
ACE inhibitors	group	114-127	lithium	drug	149-155	effect

DDI-DrugBank.d176.s9	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
Antacids	group	0-7	antacid	group	67-73	false
Antacids	group	0-7	aluminum hydroxide	drug	76-93	false
Antacids	group	0-7	magnesium hydroxide	drug	96-114	false
Antacids	group	0-7	simethicone	drug	121-131	false
Antacids	group	0-7	fosinopril	drug	139-148	false
Antacids	group	0-7	fosinoprilat	drug_n	196-207	false
Antacids	group	0-7	fosinopril	drug	226-235	false
Antacids	group	0-7	antacids	group	273-280	false
Antacids	group	0-7	fosinopril	drug	307-316	false
antacid	group	67-73	aluminum hydroxide	drug	76-93	false
antacid	group	67-73	magnesium hydroxide	drug	96-114	false
antacid	group	67-73	simethicone	drug	121-131	false
antacid	group	67-73	fosinopril	drug	139-148	mechanism
antacid	group	67-73	fosinoprilat	drug_n	196-207	false
antacid	group	67-73	fosinopril	drug	226-235	false
antacid	group	67-73	antacids	group	273-280	false
antacid	group	67-73	fosinopril	drug	307-316	false
aluminum hydroxide	drug	76-93	magnesium hydroxide	drug	96-114	false
aluminum hydroxide	drug	76-93	simethicone	drug	121-131	false
aluminum hydroxide	drug	76-93	fosinopril	drug	139-148	mechanism
aluminum hydroxide	drug	76-93	fosinoprilat	drug_n	196-207	false
aluminum hydroxide	drug	76-93	fosinopril	drug	226-235	false
aluminum hydroxide	drug	76-93	antacids	group	273-280	false
aluminum hydroxide	drug	76-93	fosinopril	drug	307-316	false
magnesium hydroxide	drug	96-114	simethicone	drug	121-131	false
magnesium hydroxide	drug	96-114	fosinopril	drug	139-148	mechanism
magnesium hydroxide	drug	96-114	fosinoprilat	drug_n	196-207	false
magnesium hydroxide	drug	96-114	fosinopril	drug	226-235	false
magnesium hydroxide	drug	96-114	antacids	group	273-280	false
magnesium hydroxide	drug	96-114	fosinopril	drug	307-316	false
simethicone	drug	121-131	fosinopril	drug	139-148	mechanism
simethicone	drug	121-131	fosinoprilat	drug_n	196-207	false
simethicone	drug	121-131	fosinopril	drug	226-235	false
simethicone	drug	121-131	antacids	group	273-280	false
simethicone	drug	121-131	fosinopril	drug	307-316	false
fosinopril	drug	139-148	fosinoprilat	drug_n	196-207	false
fosinopril	drug	139-148	fosinopril	drug	226-235	false
fosinopril	drug	139-148	antacids	group	273-280	false
fosinopril	drug	139-148	fosinopril	drug	307-316	false
fosinoprilat	drug_n	196-207	fosinopril	drug	226-235	false
fosinoprilat	drug_n	196-207	antacids	group	273-280	false
fosinoprilat	drug_n	196-207	fosinopril	drug	307-316	false
fosinopril	drug	226-235	antacids	group	273-280	false
fosinopril	drug	226-235	fosinopril	drug	307-316	false
antacids	group	273-280	fosinopril	drug	307-316	mechanism

DDI-DrugBank.d176.s12	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
chlorthalidone	drug	77-90	nifedipine	drug	93-102	false
chlorthalidone	drug	77-90	propanolol	drug	105-114	false
chlorthalidone	drug	77-90	hydrochlorothiazide	drug	117-135	false
chlorthalidone	drug	77-90	cimetidine	drug	138-147	false
chlorthalidone	drug	77-90	metoclopramide	drug	150-163	false
chlorthalidone	drug	77-90	propantheline	drug	166-178	false
chlorthalidone	drug	77-90	digoxin	drug	181-187	false
chlorthalidone	drug	77-90	warfarin	drug	194-201	false
chlorthalidone	drug	77-90	fosinoprilat	drug_n	227-238	false
chlorthalidone	drug	77-90	fosinopril	drug	279-288	false
nifedipine	drug	93-102	propanolol	drug	105-114	false
nifedipine	drug	93-102	hydrochlorothiazide	drug	117-135	false
nifedipine	drug	93-102	cimetidine	drug	138-147	false
nifedipine	drug	93-102	metoclopramide	drug	150-163	false
nifedipine	drug	93-102	propantheline	drug	166-178	false
nifedipine	drug	93-102	digoxin	drug	181-187	false
nifedipine	drug	93-102	warfarin	drug	194-201	false
nifedipine	drug	93-102	fosinoprilat	drug_n	227-238	false
nifedipine	drug	93-102	fosinopril	drug	279-288	false
propanolol	drug	105-114	hydrochlorothiazide	drug	117-135	false
propanolol	drug	105-114	cimetidine	drug	138-147	false
propanolol	drug	105-114	metoclopramide	drug	150-163	false
propanolol	drug	105-114	propantheline	drug	166-178	false
propanolol	drug	105-114	digoxin	drug	181-187	false
propanolol	drug	105-114	warfarin	drug	194-201	false
propanolol	drug	105-114	fosinoprilat	drug_n	227-238	false
propanolol	drug	105-114	fosinopril	drug	279-288	false
hydrochlorothiazide	drug	117-135	cimetidine	drug	138-147	false
hydrochlorothiazide	drug	117-135	metoclopramide	drug	150-163	false
hydrochlorothiazide	drug	117-135	propantheline	drug	166-178	false
hydrochlorothiazide	drug	117-135	digoxin	drug	181-187	false
hydrochlorothiazide	drug	117-135	warfarin	drug	194-201	false
hydrochlorothiazide	drug	117-135	fosinoprilat	drug_n	227-238	false
hydrochlorothiazide	drug	117-135	fosinopril	drug	279-288	false
cimetidine	drug	138-147	metoclopramide	drug	150-163	false
cimetidine	drug	138-147	propantheline	drug	166-178	false
cimetidine	drug	138-147	digoxin	drug	181-187	false
cimetidine	drug	138-147	warfarin	drug	194-201	false
cimetidine	drug	138-147	fosinoprilat	drug_n	227-238	false
cimetidine	drug	138-147	fosinopril	drug	279-288	false
metoclopramide	drug	150-163	propantheline	drug	166-178	false
metoclopramide	drug	150-163	digoxin	drug	181-187	false
metoclopramide	drug	150-163	warfarin	drug	194-201	false
metoclopramide	drug	150-163	fosinoprilat	drug_n	227-238	false
metoclopramide	drug	150-163	fosinopril	drug	279-288	false
propantheline	drug	166-178	digoxin	drug	181-187	false
propantheline	drug	166-178	warfarin	drug	194-201	false
propantheline	drug	166-178	fosinoprilat	drug_n	227-238	false
propantheline	drug	166-178	fosinopril	drug	279-288	false
digoxin	drug	181-187	warfarin	drug	194-201	false
digoxin	drug	181-187	fosinoprilat	drug_n	227-238	false
digoxin	drug	181-187	fosinopril	drug	279-288	false
warfarin	drug	194-201	fosinoprilat	drug_n	227-238	false
warfarin	drug	194-201	fosinopril	drug	279-288	false
fosinoprilat	drug_n	227-238	fosinopril	drug	279-288	false

DDI-DrugBank.d176.s13	In a study with concomitant administration of aspirin and fosinopril sodium, the bioavailability of unbound fosinoprilat was not altered.
aspirin	brand	46-52	fosinopril sodium	drug	58-74	false
aspirin	brand	46-52	fosinoprilat	drug_n	108-119	false
fosinopril sodium	drug	58-74	fosinoprilat	drug_n	108-119	false

DDI-DrugBank.d176.s14	In a pharmacokinetic interaction study with warfarin, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.
warfarin	drug	44-51	warfarin	drug	176-183	false

DDI-DrugBank.d176.s15	Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab  RIA Kit for Digoxin.
Fosinopril	drug	33-42	digoxin	drug	87-93	false
Fosinopril	drug	33-42	Digoxin	drug	134-140	false
digoxin	drug	87-93	Digoxin	drug	134-140	false

DDI-DrugBank.d273.s0	Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between UROXATRAL and other alpha-blockers have not been determined.
UROXATRAL	brand	85-93	alpha-blockers	group	105-118	false

DDI-DrugBank.d273.s1	However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.
UROXATRAL	brand	43-51	alpha-blockers	group	98-111	advise

DDI-DrugBank.d99.s2	Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	group	69-93	TCAs	group	96-99	false

DDI-DrugBank.d99.s7	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	drug	0-9	antidepressants	group	66-80	false
cimetidine	drug	0-9	phenothiazines	group	83-96	false
cimetidine	drug	0-9	Type 1C antiarrhythmics	group	107-129	false
cimetidine	drug	0-9	propafenone	drug	131-141	false
cimetidine	drug	0-9	flecainide	drug	147-156	false
antidepressants	group	66-80	phenothiazines	group	83-96	false
antidepressants	group	66-80	Type 1C antiarrhythmics	group	107-129	false
antidepressants	group	66-80	propafenone	drug	131-141	false
antidepressants	group	66-80	flecainide	drug	147-156	false
phenothiazines	group	83-96	Type 1C antiarrhythmics	group	107-129	false
phenothiazines	group	83-96	propafenone	drug	131-141	false
phenothiazines	group	83-96	flecainide	drug	147-156	false
Type 1C antiarrhythmics	group	107-129	propafenone	drug	131-141	false
Type 1C antiarrhythmics	group	107-129	flecainide	drug	147-156	false
propafenone	drug	131-141	flecainide	drug	147-156	false

DDI-DrugBank.d99.s8	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
serotonin reuptake inhibitors	group	24-52	SSRIs	group	55-59	false
serotonin reuptake inhibitors	group	24-52	fluoxetine	drug	69-78	false
serotonin reuptake inhibitors	group	24-52	sertraline	drug	81-90	false
serotonin reuptake inhibitors	group	24-52	paroxetine	drug	97-106	false
SSRIs	group	55-59	fluoxetine	drug	69-78	false
SSRIs	group	55-59	sertraline	drug	81-90	false
SSRIs	group	55-59	paroxetine	drug	97-106	false
fluoxetine	drug	69-78	sertraline	drug	81-90	false
fluoxetine	drug	69-78	paroxetine	drug	97-106	false
sertraline	drug	81-90	paroxetine	drug	97-106	false

DDI-DrugBank.d99.s9	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	group	20-23	TCA	group	25-27	effect
SSRI	group	20-23	SSRI	group	141-144	false
TCA	group	25-27	SSRI	group	141-144	false

DDI-DrugBank.d99.s10	Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.
TCAs	group	62-65	SSRIs	group	83-87	advise

DDI-DrugBank.d99.s12	Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	group	19-43	tricyclic antidepressant	group	156-179	false

DDI-DrugBank.d99.s14	It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.
TCA	group	27-29	TCA	group	56-58	false

DDI-DrugBank.d99.s15	Monoamine Oxidase Inhibitors: Guanethidine or similarly acting compounds;
Monoamine Oxidase Inhibitors	drug	0-27	Guanethidine	drug	30-41	false

DDI-DrugBank.d99.s17	alcohol, barbiturates and other CNS depressants;
alcohol	drug	0-6	barbiturates	drug	9-20	false
alcohol	drug	0-6	CNS depressants	drug	32-46	false
barbiturates	drug	9-20	CNS depressants	drug	32-46	false

DDI-DrugBank.d99.s18	and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
disulfiram	drug	4-13	amitriptyline HCl	drug	20-36	false
disulfiram	drug	4-13	anticholinergic	drug	52-66	false
disulfiram	drug	4-13	sympathomimetic	drug	78-92	false
disulfiram	drug	4-13	epinephrine	drug	111-121	false
disulfiram	drug	4-13	anesthetics	drug	143-153	false
amitriptyline HCl	drug	20-36	anticholinergic	drug	52-66	false
amitriptyline HCl	drug	20-36	sympathomimetic	drug	78-92	false
amitriptyline HCl	drug	20-36	epinephrine	drug	111-121	false
amitriptyline HCl	drug	20-36	anesthetics	drug	143-153	false
anticholinergic	drug	52-66	sympathomimetic	drug	78-92	false
anticholinergic	drug	52-66	epinephrine	drug	111-121	false
anticholinergic	drug	52-66	anesthetics	drug	143-153	false
sympathomimetic	drug	78-92	epinephrine	drug	111-121	false
sympathomimetic	drug	78-92	anesthetics	drug	143-153	false
epinephrine	drug	111-121	anesthetics	drug	143-153	false

DDI-DrugBank.d99.s19	Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.
amitriptyline HCl	drug	36-52	anticholinergic	drug	75-89	effect
amitriptyline HCl	drug	36-52	neuroleptic	drug	106-116	false
anticholinergic	drug	75-89	neuroleptic	drug	106-116	false

DDI-DrugBank.d99.s20	Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.
tricyclic antidepressants	drug	45-69	anticholinergic	drug	91-105	effect

DDI-DrugBank.d99.s21	Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.
Cimetidine	drug	0-9	tricyclic antidepressants	drug	63-87	mechanism
Cimetidine	drug	0-9	drugs	drug	171-175	false
tricyclic antidepressants	drug	63-87	drugs	drug	171-175	false

DDI-DrugBank.d99.s22	Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.
tricyclic antidepressants	drug	59-83	cimetidine	drug	114-123	effect

DDI-DrugBank.d99.s23	Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.
tricyclic antidepressants	drug	30-54	anticholinergic	drug	121-135	false
tricyclic antidepressants	drug	30-54	cimetidine	drug	162-171	mechanism
tricyclic antidepressants	drug	30-54	drug	drug	190-193	false
anticholinergic	drug	121-135	cimetidine	drug	162-171	false
anticholinergic	drug	121-135	drug	drug	190-193	false
cimetidine	drug	162-171	drug	drug	190-193	false

DDI-DrugBank.d99.s24	Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
cimetidine	drug	19-28	tricyclic antidepressants	drug	68-92	false
cimetidine	drug	19-28	cimetidine	drug	98-107	false
cimetidine	drug	19-28	antidepressants	drug	160-174	false
tricyclic antidepressants	drug	68-92	cimetidine	drug	98-107	mechanism
tricyclic antidepressants	drug	68-92	antidepressants	drug	160-174	false
cimetidine	drug	98-107	antidepressants	drug	160-174	false

DDI-DrugBank.d99.s26	Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.
ethchlorvynol	drug	83-95	amitriptyline HCl	drug	116-132	effect

DDI-DrugBank.d38.s0	ZINECARD does not influence the pharmacokinetics of doxorubicin.
ZINECARD	brand	0-7	doxorubicin	drug	52-62	false

DDI-DrugBank.d66.s0	Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.
Human growth hormone	drug	0-19	L-glutamine	drug	42-52	false
Human growth hormone	drug	0-19	human growth hormone	drug	58-77	false
L-glutamine	drug	42-52	human growth hormone	drug	58-77	mechanism

DDI-DrugBank.d66.s2	Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.
Indomethacin	drug	0-11	L-glutamine	drug	34-44	false
Indomethacin	drug	0-11	indomethacin	drug	50-61	false
Indomethacin	drug	0-11	indomethacin	drug	122-133	false
L-glutamine	drug	34-44	indomethacin	drug	50-61	effect
L-glutamine	drug	34-44	indomethacin	drug	122-133	false
indomethacin	drug	50-61	indomethacin	drug	122-133	false

DDI-DrugBank.d66.s5	Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.
Methotrexate	drug	0-11	methotrexate	drug	40-51	false
Methotrexate	drug	0-11	L-glutamine	drug	109-119	false
methotrexate	drug	40-51	L-glutamine	drug	109-119	effect

DDI-DrugBank.d66.s6	In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.
methotrexate	drug	96-107	L-glutamine	drug	150-160	effect

DDI-DrugBank.d66.s7	Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
Paclitaxel	drug	0-9	L-glutamine	drug	28-38	false
Paclitaxel	drug	0-9	paclitaxel	drug	112-121	false
Paclitaxel	drug	0-9	paclitaxel	drug	208-217	false
L-glutamine	drug	28-38	paclitaxel	drug	112-121	effect
L-glutamine	drug	28-38	paclitaxel	drug	208-217	false
paclitaxel	drug	112-121	paclitaxel	drug	208-217	false

DDI-DrugBank.d209.s2	Compounds that have been tested in man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.
antipyrine	drug	47-56	digoxin	drug	59-65	false
antipyrine	drug	47-56	propranolol	drug	68-78	false
antipyrine	drug	47-56	theophylline	drug	81-92	false
antipyrine	drug	47-56	warfarin	drug	99-106	false
digoxin	drug	59-65	propranolol	drug	68-78	false
digoxin	drug	59-65	theophylline	drug	81-92	false
digoxin	drug	59-65	warfarin	drug	99-106	false
propranolol	drug	68-78	theophylline	drug	81-92	false
propranolol	drug	68-78	warfarin	drug	99-106	false
theophylline	drug	81-92	warfarin	drug	99-106	false

DDI-DrugBank.d209.s3	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
finasteride	drug	84-94	acetaminophen	drug	167-179	false
finasteride	drug	84-94	acetylsalicylic acid	drug	182-201	false
finasteride	drug	84-94	analgesics	group	216-225	false
finasteride	drug	84-94	angiotensin-converting enzyme (ACE) inhibitors	group	228-273	false
finasteride	drug	84-94	anticonvulsants	group	276-290	false
finasteride	drug	84-94	benzodiazepines	group	293-307	false
finasteride	drug	84-94	beta blockers	group	310-322	false
finasteride	drug	84-94	calcium-channel blockers	group	325-348	false
finasteride	drug	84-94	nitrates	group	359-366	false
finasteride	drug	84-94	diuretics	group	369-377	false
finasteride	drug	84-94	H2 antagonists	group	380-393	false
finasteride	drug	84-94	HMG-CoA reductase inhibitors	group	396-423	false
finasteride	drug	84-94	prostaglandin synthetase inhibitors	group	426-460	false
finasteride	drug	84-94	NSAIDs	group	483-488	false
finasteride	drug	84-94	quinolone anti-infectives	group	496-520	false
acetaminophen	drug	167-179	acetylsalicylic acid	drug	182-201	false
acetaminophen	drug	167-179	analgesics	group	216-225	false
acetaminophen	drug	167-179	angiotensin-converting enzyme (ACE) inhibitors	group	228-273	false
acetaminophen	drug	167-179	anticonvulsants	group	276-290	false
acetaminophen	drug	167-179	benzodiazepines	group	293-307	false
acetaminophen	drug	167-179	beta blockers	group	310-322	false
acetaminophen	drug	167-179	calcium-channel blockers	group	325-348	false
acetaminophen	drug	167-179	nitrates	group	359-366	false
acetaminophen	drug	167-179	diuretics	group	369-377	false
acetaminophen	drug	167-179	H2 antagonists	group	380-393	false
acetaminophen	drug	167-179	HMG-CoA reductase inhibitors	group	396-423	false
acetaminophen	drug	167-179	prostaglandin synthetase inhibitors	group	426-460	false
acetaminophen	drug	167-179	NSAIDs	group	483-488	false
acetaminophen	drug	167-179	quinolone anti-infectives	group	496-520	false
acetylsalicylic acid	drug	182-201	analgesics	group	216-225	false
acetylsalicylic acid	drug	182-201	angiotensin-converting enzyme (ACE) inhibitors	group	228-273	false
acetylsalicylic acid	drug	182-201	anticonvulsants	group	276-290	false
acetylsalicylic acid	drug	182-201	benzodiazepines	group	293-307	false
acetylsalicylic acid	drug	182-201	beta blockers	group	310-322	false
acetylsalicylic acid	drug	182-201	calcium-channel blockers	group	325-348	false
acetylsalicylic acid	drug	182-201	nitrates	group	359-366	false
acetylsalicylic acid	drug	182-201	diuretics	group	369-377	false
acetylsalicylic acid	drug	182-201	H2 antagonists	group	380-393	false
acetylsalicylic acid	drug	182-201	HMG-CoA reductase inhibitors	group	396-423	false
acetylsalicylic acid	drug	182-201	prostaglandin synthetase inhibitors	group	426-460	false
acetylsalicylic acid	drug	182-201	NSAIDs	group	483-488	false
acetylsalicylic acid	drug	182-201	quinolone anti-infectives	group	496-520	false
analgesics	group	216-225	angiotensin-converting enzyme (ACE) inhibitors	group	228-273	false
analgesics	group	216-225	anticonvulsants	group	276-290	false
analgesics	group	216-225	benzodiazepines	group	293-307	false
analgesics	group	216-225	beta blockers	group	310-322	false
analgesics	group	216-225	calcium-channel blockers	group	325-348	false
analgesics	group	216-225	nitrates	group	359-366	false
analgesics	group	216-225	diuretics	group	369-377	false
analgesics	group	216-225	H2 antagonists	group	380-393	false
analgesics	group	216-225	HMG-CoA reductase inhibitors	group	396-423	false
analgesics	group	216-225	prostaglandin synthetase inhibitors	group	426-460	false
analgesics	group	216-225	NSAIDs	group	483-488	false
analgesics	group	216-225	quinolone anti-infectives	group	496-520	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	anticonvulsants	group	276-290	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	benzodiazepines	group	293-307	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	beta blockers	group	310-322	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	calcium-channel blockers	group	325-348	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	nitrates	group	359-366	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	diuretics	group	369-377	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	H2 antagonists	group	380-393	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	HMG-CoA reductase inhibitors	group	396-423	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	prostaglandin synthetase inhibitors	group	426-460	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	NSAIDs	group	483-488	false
angiotensin-converting enzyme (ACE) inhibitors	group	228-273	quinolone anti-infectives	group	496-520	false
anticonvulsants	group	276-290	benzodiazepines	group	293-307	false
anticonvulsants	group	276-290	beta blockers	group	310-322	false
anticonvulsants	group	276-290	calcium-channel blockers	group	325-348	false
anticonvulsants	group	276-290	nitrates	group	359-366	false
anticonvulsants	group	276-290	diuretics	group	369-377	false
anticonvulsants	group	276-290	H2 antagonists	group	380-393	false
anticonvulsants	group	276-290	HMG-CoA reductase inhibitors	group	396-423	false
anticonvulsants	group	276-290	prostaglandin synthetase inhibitors	group	426-460	false
anticonvulsants	group	276-290	NSAIDs	group	483-488	false
anticonvulsants	group	276-290	quinolone anti-infectives	group	496-520	false
benzodiazepines	group	293-307	beta blockers	group	310-322	false
benzodiazepines	group	293-307	calcium-channel blockers	group	325-348	false
benzodiazepines	group	293-307	nitrates	group	359-366	false
benzodiazepines	group	293-307	diuretics	group	369-377	false
benzodiazepines	group	293-307	H2 antagonists	group	380-393	false
benzodiazepines	group	293-307	HMG-CoA reductase inhibitors	group	396-423	false
benzodiazepines	group	293-307	prostaglandin synthetase inhibitors	group	426-460	false
benzodiazepines	group	293-307	NSAIDs	group	483-488	false
benzodiazepines	group	293-307	quinolone anti-infectives	group	496-520	false
beta blockers	group	310-322	calcium-channel blockers	group	325-348	false
beta blockers	group	310-322	nitrates	group	359-366	false
beta blockers	group	310-322	diuretics	group	369-377	false
beta blockers	group	310-322	H2 antagonists	group	380-393	false
beta blockers	group	310-322	HMG-CoA reductase inhibitors	group	396-423	false
beta blockers	group	310-322	prostaglandin synthetase inhibitors	group	426-460	false
beta blockers	group	310-322	NSAIDs	group	483-488	false
beta blockers	group	310-322	quinolone anti-infectives	group	496-520	false
calcium-channel blockers	group	325-348	nitrates	group	359-366	false
calcium-channel blockers	group	325-348	diuretics	group	369-377	false
calcium-channel blockers	group	325-348	H2 antagonists	group	380-393	false
calcium-channel blockers	group	325-348	HMG-CoA reductase inhibitors	group	396-423	false
calcium-channel blockers	group	325-348	prostaglandin synthetase inhibitors	group	426-460	false
calcium-channel blockers	group	325-348	NSAIDs	group	483-488	false
calcium-channel blockers	group	325-348	quinolone anti-infectives	group	496-520	false
nitrates	group	359-366	diuretics	group	369-377	false
nitrates	group	359-366	H2 antagonists	group	380-393	false
nitrates	group	359-366	HMG-CoA reductase inhibitors	group	396-423	false
nitrates	group	359-366	prostaglandin synthetase inhibitors	group	426-460	false
nitrates	group	359-366	NSAIDs	group	483-488	false
nitrates	group	359-366	quinolone anti-infectives	group	496-520	false
diuretics	group	369-377	H2 antagonists	group	380-393	false
diuretics	group	369-377	HMG-CoA reductase inhibitors	group	396-423	false
diuretics	group	369-377	prostaglandin synthetase inhibitors	group	426-460	false
diuretics	group	369-377	NSAIDs	group	483-488	false
diuretics	group	369-377	quinolone anti-infectives	group	496-520	false
H2 antagonists	group	380-393	HMG-CoA reductase inhibitors	group	396-423	false
H2 antagonists	group	380-393	prostaglandin synthetase inhibitors	group	426-460	false
H2 antagonists	group	380-393	NSAIDs	group	483-488	false
H2 antagonists	group	380-393	quinolone anti-infectives	group	496-520	false
HMG-CoA reductase inhibitors	group	396-423	prostaglandin synthetase inhibitors	group	426-460	false
HMG-CoA reductase inhibitors	group	396-423	NSAIDs	group	483-488	false
HMG-CoA reductase inhibitors	group	396-423	quinolone anti-infectives	group	496-520	false
prostaglandin synthetase inhibitors	group	426-460	NSAIDs	group	483-488	false
prostaglandin synthetase inhibitors	group	426-460	quinolone anti-infectives	group	496-520	false
NSAIDs	group	483-488	quinolone anti-infectives	group	496-520	false

DDI-DrugBank.d209.s7	In clinical studies with PROPECIA (finasteride, 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.
PROPECIA	brand	25-32	finasteride	drug	35-45	false

DDI-DrugBank.d209.s8	Further, in clinical studies with PROSCAR (finasteride, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.
PROSCAR	brand	34-40	finasteride	drug	43-53	false

DDI-DrugBank.d151.s0	Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
Folic acid	drug	0-9	phenobarbital	drug	71-83	effect
Folic acid	drug	0-9	phenytoin	drug	86-94	effect
Folic acid	drug	0-9	primidone	drug	100-108	effect
phenobarbital	drug	71-83	phenytoin	drug	86-94	false
phenobarbital	drug	71-83	primidone	drug	100-108	false
phenytoin	drug	86-94	primidone	drug	100-108	false

DDI-DrugBank.d151.s1	Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.
leucovorin	drug	99-108	methotrexate	drug	234-245	false

DDI-DrugBank.d151.s2	However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
leucovorin	drug	23-32	methotrexate	drug	88-99	effect

DDI-DrugBank.d151.s3	Leucovorin may enhance the toxicity of 5-fluorouracil.
Leucovorin	drug	0-9	5-fluorouracil	drug	39-52	effect

DDI-DrugBank.d190.s1	However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis.
Xigris	brand	59-64	Xigris	brand	99-104	false

DDI-DrugBank.d190.s2	Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.
heparin	drug	93-99	unfractionated heparin	drug	102-123	false
heparin	drug	93-99	low molecular weight heparins	group	174-202	false
unfractionated heparin	drug	102-123	low molecular weight heparins	group	174-202	false

DDI-DrugBank.d190.s3	Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.
heparin	drug	41-47	Xigris	brand	122-127	false

DDI-DrugBank.d190.s4	Drug/Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).
Xigris	brand	41-46	Xigris	brand	75-80	false

DDI-DrugBank.d438.s5	Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs.
Gabapentin	drug	0-9	antiepileptic drugs	group	111-129	false

DDI-DrugBank.d438.s7	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.
Phenytoin	drug	0-8	Neurontin	brand	72-80	false
Phenytoin	drug	0-8	phenytoin	drug	124-132	false
Phenytoin	drug	0-8	gabapentin	drug	169-178	false
Phenytoin	drug	0-8	phenytoin	drug	246-254	false
Phenytoin	drug	0-8	phenytoin	drug	260-268	false
Phenytoin	drug	0-8	gabapentin	drug	287-296	false
Neurontin	brand	72-80	phenytoin	drug	124-132	false
Neurontin	brand	72-80	gabapentin	drug	169-178	false
Neurontin	brand	72-80	phenytoin	drug	246-254	false
Neurontin	brand	72-80	phenytoin	drug	260-268	false
Neurontin	brand	72-80	gabapentin	drug	287-296	false
phenytoin	drug	124-132	gabapentin	drug	169-178	false
phenytoin	drug	124-132	phenytoin	drug	246-254	false
phenytoin	drug	124-132	phenytoin	drug	260-268	false
phenytoin	drug	124-132	gabapentin	drug	287-296	false
gabapentin	drug	169-178	phenytoin	drug	246-254	false
gabapentin	drug	169-178	phenytoin	drug	260-268	false
gabapentin	drug	169-178	gabapentin	drug	287-296	false
phenytoin	drug	246-254	phenytoin	drug	260-268	false
phenytoin	drug	246-254	gabapentin	drug	287-296	false
phenytoin	drug	260-268	gabapentin	drug	287-296	false

DDI-DrugBank.d438.s8	Carbamazepine: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;
Carbamazepine	drug	0-12	carbamazepine	drug	42-54	false
Carbamazepine	drug	0-12	carbamazepine 10, 11 epoxide	drug_n	60-87	false
Carbamazepine	drug	0-12	gabapentin	drug	137-146	false
carbamazepine	drug	42-54	carbamazepine 10, 11 epoxide	drug_n	60-87	false
carbamazepine	drug	42-54	gabapentin	drug	137-146	false
carbamazepine 10, 11 epoxide	drug_n	60-87	gabapentin	drug	137-146	false

DDI-DrugBank.d438.s10	Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.
gabapentin	drug	10-19	carbamazepine	drug	56-68	false

DDI-DrugBank.d438.s11	Valproic Acid: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg TID;
Valproic Acid	drug	0-12	valproic acid	drug	50-62	false
Valproic Acid	drug	0-12	gabapentin	drug	111-120	false
valproic acid	drug	50-62	gabapentin	drug	111-120	false

DDI-DrugBank.d438.s12	N=17) were not different and neither were gabapentin pharmacokinetic parameters affected by valproic acid.
gabapentin	drug	42-51	valproic acid	drug	92-104	false

DDI-DrugBank.d438.s13	Phenobarbital: Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID;
Phenobarbital	drug	0-12	phenobarbital	drug	72-84	false
Phenobarbital	drug	0-12	gabapentin	drug	89-98	false
phenobarbital	drug	72-84	gabapentin	drug	89-98	false

DDI-DrugBank.d438.s15	Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.
Naproxen	drug	0-7	naproxen sodium	drug	37-51	false
Naproxen	drug	0-7	Neurontin	brand	76-84	false
Naproxen	drug	0-7	gabapentin	drug	129-138	false
naproxen sodium	drug	37-51	Neurontin	brand	76-84	mechanism
naproxen sodium	drug	37-51	gabapentin	drug	129-138	false
Neurontin	brand	76-84	gabapentin	drug	129-138	false

DDI-DrugBank.d438.s16	Gabapentin had no effect on naproxen pharmacokinetic parameters.
Gabapentin	drug	0-9	naproxen	drug	28-35	false

DDI-DrugBank.d438.s19	Hydrocodone: Coadministration of Neurontin  (125 to 500 mg;
Hydrocodone	drug	0-10	Neurontin	brand	33-41	false

DDI-DrugBank.d438.s22	Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg Neurontin  and 21% to 22% lower, respectively, after administration of 500 mg Neurontin .
Neurontin	brand	85-93	Neurontin	brand	163-171	false

DDI-DrugBank.d438.s24	Hydrocodone increases gabapentin AUC values by 14%.
Hydrocodone	drug	0-10	gabapentin	drug	22-31	mechanism

DDI-DrugBank.d438.s26	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
Morphine	drug	0-7	morphine	drug	77-84	false
Morphine	drug	0-7	Neurontin	brand	137-145	false
Morphine	drug	0-7	gabapentin	drug	169-178	false
Morphine	drug	0-7	gabapentin	drug	213-222	false
Morphine	drug	0-7	morphine	drug	245-252	false
morphine	drug	77-84	Neurontin	brand	137-145	mechanism
morphine	drug	77-84	gabapentin	drug	169-178	false
morphine	drug	77-84	gabapentin	drug	213-222	false
morphine	drug	77-84	morphine	drug	245-252	false
Neurontin	brand	137-145	gabapentin	drug	169-178	false
Neurontin	brand	137-145	gabapentin	drug	213-222	false
Neurontin	brand	137-145	morphine	drug	245-252	false
gabapentin	drug	169-178	gabapentin	drug	213-222	false
gabapentin	drug	169-178	morphine	drug	245-252	false
gabapentin	drug	213-222	morphine	drug	245-252	false

DDI-DrugBank.d438.s27	Morphine pharmacokinetic parameter values were not affected by administration of Neurontin  2 hours after morphine.
Morphine	drug	0-7	Neurontin	brand	81-89	false
Morphine	drug	0-7	morphine	drug	106-113	false
Neurontin	brand	81-89	morphine	drug	106-113	false

DDI-DrugBank.d438.s29	Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
Cimetidine	drug	0-9	cimetidine	drug	31-40	false
Cimetidine	drug	0-9	gabapentin	drug	99-108	false
cimetidine	drug	31-40	gabapentin	drug	99-108	mechanism

DDI-DrugBank.d438.s30	Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.
cimetidine	drug	5-14	gabapentin	drug	62-71	mechanism

DDI-DrugBank.d438.s31	This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.
gabapentin	drug	36-45	cimetidine	drug	50-59	mechanism

DDI-DrugBank.d438.s32	The effect of gabapentin on cimetidine was not evaluated.
gabapentin	drug	14-23	cimetidine	drug	28-37	false

DDI-DrugBank.d438.s33	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;
Contraceptive	group	5-17	norethindrone	drug	90-102	false
Contraceptive	group	5-17	ethinyl estradiol	drug	108-124	false
Contraceptive	group	5-17	norethindrone acetate	drug	183-203	false
Contraceptive	group	5-17	ethinyl estradiol	drug	219-235	false
Contraceptive	group	5-17	gabapentin	drug	287-296	false
norethindrone	drug	90-102	ethinyl estradiol	drug	108-124	false
norethindrone	drug	90-102	norethindrone acetate	drug	183-203	false
norethindrone	drug	90-102	ethinyl estradiol	drug	219-235	false
norethindrone	drug	90-102	gabapentin	drug	287-296	false
ethinyl estradiol	drug	108-124	norethindrone acetate	drug	183-203	false
ethinyl estradiol	drug	108-124	ethinyl estradiol	drug	219-235	false
ethinyl estradiol	drug	108-124	gabapentin	drug	287-296	false
norethindrone acetate	drug	183-203	ethinyl estradiol	drug	219-235	false
norethindrone acetate	drug	183-203	gabapentin	drug	287-296	false
ethinyl estradiol	drug	219-235	gabapentin	drug	287-296	false

DDI-DrugBank.d438.s35	The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;
norethindrone	drug	12-24	gabapentin	drug	73-82	mechanism

DDI-DrugBank.d438.s37	Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.
Antacid	group	0-6	Maalox	brand	9-14	false
Antacid	group	0-6	Maalox	brand	19-24	false
Antacid	group	0-6	gabapentin	drug	57-66	false
Maalox	brand	9-14	Maalox	brand	19-24	false
Maalox	brand	9-14	gabapentin	drug	57-66	false
Maalox	brand	19-24	gabapentin	drug	57-66	mechanism

DDI-DrugBank.d438.s38	This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.
gabapentin	drug	51-60	Maalox	brand	93-98	mechanism

DDI-DrugBank.d438.s39	It is recommended that gabapentin be taken at least 2 hours following Maalox administration.
gabapentin	drug	23-32	Maalox	brand	70-75	advise

DDI-DrugBank.d438.s40	Effect of Probenecid: Probenecid is a blocker of renal tubular secretion.
Probenecid	drug	10-19	Probenecid	drug	22-31	false

DDI-DrugBank.d438.s41	Gabapentin pharmacokinetic parameters without and with probenecid were comparable.
Gabapentin	drug	0-9	probenecid	drug	55-64	false

DDI-DrugBank.d438.s42	This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid.
gabapentin	drug	20-29	probenecid	drug	106-115	false

DDI-DrugBank.d438.s43	Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein
gabapentin	drug	149-158	antiepileptic drugs	group	179-197	false

DDI-DrugBank.d409.s0	Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
tetracyclines	group	12-24	anticoagulant	group	102-114	advise
tetracyclines	group	12-24	anticoagulant	group	165-177	false
anticoagulant	group	102-114	anticoagulant	group	165-177	false

DDI-DrugBank.d409.s1	Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.
tetracycline class	group	40-57	antibiotics	group	62-72	false
tetracycline class	group	40-57	penicillins	group	121-131	effect
antibiotics	group	62-72	penicillins	group	121-131	false

DDI-DrugBank.d409.s2	Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
tetracyclines	group	18-30	contraceptives	group	42-55	effect
tetracyclines	group	18-30	contraceptives	group	73-86	false
contraceptives	group	42-55	contraceptives	group	73-86	false

DDI-DrugBank.d146.s0	Colchicine is inhibited by acidifying agents.
Colchicine	drug	0-9	acidifying agents	group	27-43	mechanism

DDI-DrugBank.d146.s1	The action of colchicine is potentiated by alkalinizing agents.
colchicine	drug	14-23	alkalinizing agents	group	43-61	mechanism

DDI-DrugBank.d146.s2	Colchicine may increase sensitivity to the CNS depressants.
Colchicine	drug	0-9	CNS depressants	group	43-57	effect

DDI-DrugBank.d146.s3	Response to sympathomimetic agents may be enhanced by colchicine.
sympathomimetic agents	group	12-33	colchicine	drug	54-63	effect

DDI-DrugBank.d13.s0	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
Flupenthixol	drug	19-30	Monoamine oxidase inhibitors	group	67-94	int
Flupenthixol	drug	19-30	MAOI	group	97-100	int
Flupenthixol	drug	19-30	MAOI	group	104-107	false
Flupenthixol	drug	19-30	flupenthixol	drug	136-147	false
Flupenthixol	drug	19-30	Arecoline	drug_n	168-176	false
Flupenthixol	drug	19-30	Ethanol	drug	194-200	false
Flupenthixol	drug	19-30	Flupenthixol	drug	203-214	false
Flupenthixol	drug	19-30	Ethanol	drug	220-226	false
Flupenthixol	drug	19-30	Tricyclic antidepressants	group	260-284	false
Flupenthixol	drug	19-30	Flupenthixol	drug	287-298	false
Flupenthixol	drug	19-30	Tricyclic antidepressants	group	324-348	false
Monoamine oxidase inhibitors	group	67-94	MAOI	group	97-100	false
Monoamine oxidase inhibitors	group	67-94	MAOI	group	104-107	false
Monoamine oxidase inhibitors	group	67-94	flupenthixol	drug	136-147	false
Monoamine oxidase inhibitors	group	67-94	Arecoline	drug_n	168-176	false
Monoamine oxidase inhibitors	group	67-94	Ethanol	drug	194-200	false
Monoamine oxidase inhibitors	group	67-94	Flupenthixol	drug	203-214	false
Monoamine oxidase inhibitors	group	67-94	Ethanol	drug	220-226	false
Monoamine oxidase inhibitors	group	67-94	Tricyclic antidepressants	group	260-284	false
Monoamine oxidase inhibitors	group	67-94	Flupenthixol	drug	287-298	false
Monoamine oxidase inhibitors	group	67-94	Tricyclic antidepressants	group	324-348	false
MAOI	group	97-100	MAOI	group	104-107	false
MAOI	group	97-100	flupenthixol	drug	136-147	false
MAOI	group	97-100	Arecoline	drug_n	168-176	false
MAOI	group	97-100	Ethanol	drug	194-200	false
MAOI	group	97-100	Flupenthixol	drug	203-214	false
MAOI	group	97-100	Ethanol	drug	220-226	false
MAOI	group	97-100	Tricyclic antidepressants	group	260-284	false
MAOI	group	97-100	Flupenthixol	drug	287-298	false
MAOI	group	97-100	Tricyclic antidepressants	group	324-348	false
MAOI	group	104-107	flupenthixol	drug	136-147	effect
MAOI	group	104-107	Arecoline	drug_n	168-176	false
MAOI	group	104-107	Ethanol	drug	194-200	false
MAOI	group	104-107	Flupenthixol	drug	203-214	false
MAOI	group	104-107	Ethanol	drug	220-226	false
MAOI	group	104-107	Tricyclic antidepressants	group	260-284	false
MAOI	group	104-107	Flupenthixol	drug	287-298	false
MAOI	group	104-107	Tricyclic antidepressants	group	324-348	false
flupenthixol	drug	136-147	Arecoline	drug_n	168-176	false
flupenthixol	drug	136-147	Ethanol	drug	194-200	false
flupenthixol	drug	136-147	Flupenthixol	drug	203-214	false
flupenthixol	drug	136-147	Ethanol	drug	220-226	false
flupenthixol	drug	136-147	Tricyclic antidepressants	group	260-284	false
flupenthixol	drug	136-147	Flupenthixol	drug	287-298	false
flupenthixol	drug	136-147	Tricyclic antidepressants	group	324-348	false
Arecoline	drug_n	168-176	Ethanol	drug	194-200	false
Arecoline	drug_n	168-176	Flupenthixol	drug	203-214	false
Arecoline	drug_n	168-176	Ethanol	drug	220-226	false
Arecoline	drug_n	168-176	Tricyclic antidepressants	group	260-284	false
Arecoline	drug_n	168-176	Flupenthixol	drug	287-298	false
Arecoline	drug_n	168-176	Tricyclic antidepressants	group	324-348	false
Ethanol	drug	194-200	Flupenthixol	drug	203-214	false
Ethanol	drug	194-200	Ethanol	drug	220-226	false
Ethanol	drug	194-200	Tricyclic antidepressants	group	260-284	false
Ethanol	drug	194-200	Flupenthixol	drug	287-298	false
Ethanol	drug	194-200	Tricyclic antidepressants	group	324-348	false
Flupenthixol	drug	203-214	Ethanol	drug	220-226	effect
Flupenthixol	drug	203-214	Tricyclic antidepressants	group	260-284	false
Flupenthixol	drug	203-214	Flupenthixol	drug	287-298	false
Flupenthixol	drug	203-214	Tricyclic antidepressants	group	324-348	false
Ethanol	drug	220-226	Tricyclic antidepressants	group	260-284	false
Ethanol	drug	220-226	Flupenthixol	drug	287-298	false
Ethanol	drug	220-226	Tricyclic antidepressants	group	324-348	false
Tricyclic antidepressants	group	260-284	Flupenthixol	drug	287-298	false
Tricyclic antidepressants	group	260-284	Tricyclic antidepressants	group	324-348	false
Flupenthixol	drug	287-298	Tricyclic antidepressants	group	324-348	effect

DDI-DrugBank.d405.s0	Dicumarol and warfarin may decrease hypoprothrombinemic effect.
Dicumarol	drug	0-8	warfarin	drug	14-21	false

DDI-DrugBank.d405.s1	Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
alcohol	drug	27-33	barbiturates	group	36-47	false
alcohol	drug	27-33	MAOIs	group	54-58	false
alcohol	drug	27-33	ethchlorvynol	drug	110-122	effect
barbiturates	group	36-47	MAOIs	group	54-58	false
barbiturates	group	36-47	ethchlorvynol	drug	110-122	effect
MAOIs	group	54-58	ethchlorvynol	drug	110-122	effect

DDI-DrugBank.d91.s2	When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.
idoxuridine	drug	19-29	boric acid	drug	154-163	advise

DDI-DrugBank.d91.s3	Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.
Boric acid	drug	0-9	idoxuridine	drug	33-43	mechanism
Boric acid	drug	0-9	idoxuridine	drug	137-147	false
idoxuridine	drug	33-43	idoxuridine	drug	137-147	false

DDI-DrugBank.d270.s9	The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.
nevirapine	drug	33-42	antithrombotic agent	group	52-71	false
nevirapine	drug	33-42	warfarin	drug	73-80	int
antithrombotic agent	group	52-71	warfarin	drug	73-80	false

DDI-DrugBank.d270.s11	When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
warfarin	drug	5-12	nevirapine	drug	38-47	advise

DDI-DrugBank.d270.s18	Clarithromycin exposure was significantly decreased by nevirapine;
Clarithromycin	drug	0-13	nevirapine	drug	55-64	mechanism

DDI-DrugBank.d270.s20	Alternatives to clarithromycin,such as azithromycin, should be considered.
clarithromycin	drug	16-29	azithromycin	drug	39-50	false

DDI-DrugBank.d270.s24	Ethinyl estradiol and Norethindrone
Ethinyl estradiol	drug	0-16	Norethindrone	drug	22-34	false

DDI-DrugBank.d270.s25	Ethinyl estradiol Norethindrone
Ethinyl estradiol	drug	0-16	Norethindrone	drug	18-30	false

DDI-DrugBank.d270.s26	Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.
contraceptives	group	5-18	nevirapine	drug	132-141	advise

DDI-DrugBank.d270.s36	Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.
Nevirapine	drug	0-9	ketoconazole	drug	15-26	advise
Nevirapine	drug	0-9	ketoconazole	drug	88-99	false
ketoconazole	drug	15-26	ketoconazole	drug	88-99	false

DDI-DrugBank.d270.s37	Lopinavir/Ritonavir
Lopinavir	drug	0-8	Ritonavir	drug	10-18	false

DDI-DrugBank.d270.s39	A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
lopinavir	drug	19-27	ritonavir	drug	29-37	false
lopinavir	drug	19-27	nevirapine	drug	109-118	advise
ritonavir	drug	29-37	nevirapine	drug	109-118	advise

DDI-DrugBank.d270.s42	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
Methadone	drug	0-8	opiate	group	92-97	false
Methadone	drug	0-8	Methadone	drug	111-119	false
Methadone	drug	0-8	nevirapine	drug	151-160	false
Methadone	drug	0-8	methadone	drug	220-228	false
opiate	group	92-97	Methadone	drug	111-119	false
opiate	group	92-97	nevirapine	drug	151-160	false
opiate	group	92-97	methadone	drug	220-228	false
Methadone	drug	111-119	nevirapine	drug	151-160	advise
Methadone	drug	111-119	methadone	drug	220-228	false
nevirapine	drug	151-160	methadone	drug	220-228	false

DDI-DrugBank.d270.s45	The appropriate dose for nelfinavir incombination with nevirapine, with respectto safety and efficacy, has not been established.
nelfinavir	drug	25-34	nevirapine	drug	55-64	false

DDI-DrugBank.d270.s53	Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.
Nevirapine	drug	0-9	rifampin	drug	15-22	advise
Nevirapine	drug	0-9	nevirapine	drug	84-93	false
rifampin	drug	15-22	nevirapine	drug	84-93	false

DDI-DrugBank.d270.s54	Physicians needing to treatpatients co-infected with tuberculosis andusing a nevirapine containing regimen mayuse rifabutin instead.
nevirapine	drug	77-86	rifabutin	drug	114-122	false

DDI-DrugBank.d270.s58	aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
nevirapine	drug	75-84	methadone	drug	90-98	effect
nevirapine	drug	75-84	methadone	drug	165-173	false
methadone	drug	90-98	methadone	drug	165-173	false

DDI-DrugBank.d270.s63	Amiodarone, disopyramide, lidocaine
Amiodarone	drug	0-9	disopyramide	drug	12-23	false
Amiodarone	drug	0-9	lidocaine	drug	26-34	false
disopyramide	drug	12-23	lidocaine	drug	26-34	false

DDI-DrugBank.d270.s65	Carbamazepine, clonazepam, ethosuximide
Carbamazepine	drug	0-12	clonazepam	drug	15-24	false
Carbamazepine	drug	0-12	ethosuximide	drug	27-38	false
clonazepam	drug	15-24	ethosuximide	drug	27-38	false

DDI-DrugBank.d270.s69	Diltiazem, nifedipine, verapamil
Diltiazem	drug	0-8	nifedipine	drug	11-20	false
Diltiazem	drug	0-8	verapamil	drug	23-31	false
nifedipine	drug	11-20	verapamil	drug	23-31	false

DDI-DrugBank.d270.s75	Cyclosporin, tacrolimus, sirolimus
Cyclosporin	drug	0-10	tacrolimus	drug	13-22	false
Cyclosporin	drug	0-10	sirolimus	drug	25-33	false
tacrolimus	drug	13-22	sirolimus	drug	25-33	false

DDI-DrugBank.d121.s0	Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.
aminoglycoside antibiotics	group	73-98	cephalosporin antibiotics	group	104-128	effect

DDI-DrugBank.d121.s1	Concomitant administration of probenecid doubled the AUC for cefprozil.
probenecid	drug	30-39	cefprozil	drug	61-69	mechanism

DDI-DrugBank.d121.s2	The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.
cefprozil	drug	50-58	antacid	group	118-124	false

DDI-DrugBank.d411.s2	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
Levothyroxine Sodium	drug	0-19	levothyroxine sodium	drug	90-109	false
Levothyroxine Sodium	drug	0-19	aluminum hydoxide	drug	144-160	false
Levothyroxine Sodium	drug	0-19	cholestyramine	drug	163-176	false
Levothyroxine Sodium	drug	0-19	colestipol hydrochloride	drug	185-208	false
Levothyroxine Sodium	drug	0-19	ferrous sulfate	drug	211-225	false
Levothyroxine Sodium	drug	0-19	sodium polystyrene sulfonate	drug	228-255	false
Levothyroxine Sodium	drug	0-19	sucralfate	drug	296-305	false
levothyroxine sodium	drug	90-109	aluminum hydoxide	drug	144-160	mechanism
levothyroxine sodium	drug	90-109	cholestyramine	drug	163-176	mechanism
levothyroxine sodium	drug	90-109	colestipol hydrochloride	drug	185-208	mechanism
levothyroxine sodium	drug	90-109	ferrous sulfate	drug	211-225	mechanism
levothyroxine sodium	drug	90-109	sodium polystyrene sulfonate	drug	228-255	mechanism
levothyroxine sodium	drug	90-109	sucralfate	drug	296-305	mechanism
aluminum hydoxide	drug	144-160	cholestyramine	drug	163-176	false
aluminum hydoxide	drug	144-160	colestipol hydrochloride	drug	185-208	false
aluminum hydoxide	drug	144-160	ferrous sulfate	drug	211-225	false
aluminum hydoxide	drug	144-160	sodium polystyrene sulfonate	drug	228-255	false
aluminum hydoxide	drug	144-160	sucralfate	drug	296-305	false
cholestyramine	drug	163-176	colestipol hydrochloride	drug	185-208	false
cholestyramine	drug	163-176	ferrous sulfate	drug	211-225	false
cholestyramine	drug	163-176	sodium polystyrene sulfonate	drug	228-255	false
cholestyramine	drug	163-176	sucralfate	drug	296-305	false
colestipol hydrochloride	drug	185-208	ferrous sulfate	drug	211-225	false
colestipol hydrochloride	drug	185-208	sodium polystyrene sulfonate	drug	228-255	false
colestipol hydrochloride	drug	185-208	sucralfate	drug	296-305	false
ferrous sulfate	drug	211-225	sodium polystyrene sulfonate	drug	228-255	false
ferrous sulfate	drug	211-225	sucralfate	drug	296-305	false
sodium polystyrene sulfonate	drug	228-255	sucralfate	drug	296-305	false

DDI-DrugBank.d411.s3	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
levothyroxine sodium	drug	67-86	androgens	group	169-177	mechanism
levothyroxine sodium	drug	67-86	anabolic hormones	group	191-207	mechanism
levothyroxine sodium	drug	67-86	asparaginase	drug	210-221	mechanism
levothyroxine sodium	drug	67-86	clofibrate	drug	224-233	mechanism
levothyroxine sodium	drug	67-86	estrogens	group	236-244	mechanism
levothyroxine sodium	drug	67-86	estrogen-containing compounds	group	250-278	mechanism
levothyroxine sodium	drug	67-86	5-fluorouracil	drug	281-294	mechanism
levothyroxine sodium	drug	67-86	furosemide	drug	297-306	mechanism
levothyroxine sodium	drug	67-86	glucocorticoids	group	309-323	mechanism
levothyroxine sodium	drug	67-86	meclofenamic acid	drug	326-342	mechanism
levothyroxine sodium	drug	67-86	mefenamic acid	drug	345-358	mechanism
levothyroxine sodium	drug	67-86	methadone	drug	361-369	mechanism
levothyroxine sodium	drug	67-86	perphenazine	drug	372-383	mechanism
levothyroxine sodium	drug	67-86	phenylbutazone	drug	386-399	mechanism
levothyroxine sodium	drug	67-86	phenytoin	drug	402-410	mechanism
levothyroxine sodium	drug	67-86	salicylates	group	413-423	mechanism
levothyroxine sodium	drug	67-86	tamoxifen	drug	426-434	mechanism
androgens	group	169-177	anabolic hormones	group	191-207	false
androgens	group	169-177	asparaginase	drug	210-221	false
androgens	group	169-177	clofibrate	drug	224-233	false
androgens	group	169-177	estrogens	group	236-244	false
androgens	group	169-177	estrogen-containing compounds	group	250-278	false
androgens	group	169-177	5-fluorouracil	drug	281-294	false
androgens	group	169-177	furosemide	drug	297-306	false
androgens	group	169-177	glucocorticoids	group	309-323	false
androgens	group	169-177	meclofenamic acid	drug	326-342	false
androgens	group	169-177	mefenamic acid	drug	345-358	false
androgens	group	169-177	methadone	drug	361-369	false
androgens	group	169-177	perphenazine	drug	372-383	false
androgens	group	169-177	phenylbutazone	drug	386-399	false
androgens	group	169-177	phenytoin	drug	402-410	false
androgens	group	169-177	salicylates	group	413-423	false
androgens	group	169-177	tamoxifen	drug	426-434	false
anabolic hormones	group	191-207	asparaginase	drug	210-221	false
anabolic hormones	group	191-207	clofibrate	drug	224-233	false
anabolic hormones	group	191-207	estrogens	group	236-244	false
anabolic hormones	group	191-207	estrogen-containing compounds	group	250-278	false
anabolic hormones	group	191-207	5-fluorouracil	drug	281-294	false
anabolic hormones	group	191-207	furosemide	drug	297-306	false
anabolic hormones	group	191-207	glucocorticoids	group	309-323	false
anabolic hormones	group	191-207	meclofenamic acid	drug	326-342	false
anabolic hormones	group	191-207	mefenamic acid	drug	345-358	false
anabolic hormones	group	191-207	methadone	drug	361-369	false
anabolic hormones	group	191-207	perphenazine	drug	372-383	false
anabolic hormones	group	191-207	phenylbutazone	drug	386-399	false
anabolic hormones	group	191-207	phenytoin	drug	402-410	false
anabolic hormones	group	191-207	salicylates	group	413-423	false
anabolic hormones	group	191-207	tamoxifen	drug	426-434	false
asparaginase	drug	210-221	clofibrate	drug	224-233	false
asparaginase	drug	210-221	estrogens	group	236-244	false
asparaginase	drug	210-221	estrogen-containing compounds	group	250-278	false
asparaginase	drug	210-221	5-fluorouracil	drug	281-294	false
asparaginase	drug	210-221	furosemide	drug	297-306	false
asparaginase	drug	210-221	glucocorticoids	group	309-323	false
asparaginase	drug	210-221	meclofenamic acid	drug	326-342	false
asparaginase	drug	210-221	mefenamic acid	drug	345-358	false
asparaginase	drug	210-221	methadone	drug	361-369	false
asparaginase	drug	210-221	perphenazine	drug	372-383	false
asparaginase	drug	210-221	phenylbutazone	drug	386-399	false
asparaginase	drug	210-221	phenytoin	drug	402-410	false
asparaginase	drug	210-221	salicylates	group	413-423	false
asparaginase	drug	210-221	tamoxifen	drug	426-434	false
clofibrate	drug	224-233	estrogens	group	236-244	false
clofibrate	drug	224-233	estrogen-containing compounds	group	250-278	false
clofibrate	drug	224-233	5-fluorouracil	drug	281-294	false
clofibrate	drug	224-233	furosemide	drug	297-306	false
clofibrate	drug	224-233	glucocorticoids	group	309-323	false
clofibrate	drug	224-233	meclofenamic acid	drug	326-342	false
clofibrate	drug	224-233	mefenamic acid	drug	345-358	false
clofibrate	drug	224-233	methadone	drug	361-369	false
clofibrate	drug	224-233	perphenazine	drug	372-383	false
clofibrate	drug	224-233	phenylbutazone	drug	386-399	false
clofibrate	drug	224-233	phenytoin	drug	402-410	false
clofibrate	drug	224-233	salicylates	group	413-423	false
clofibrate	drug	224-233	tamoxifen	drug	426-434	false
estrogens	group	236-244	estrogen-containing compounds	group	250-278	false
estrogens	group	236-244	5-fluorouracil	drug	281-294	false
estrogens	group	236-244	furosemide	drug	297-306	false
estrogens	group	236-244	glucocorticoids	group	309-323	false
estrogens	group	236-244	meclofenamic acid	drug	326-342	false
estrogens	group	236-244	mefenamic acid	drug	345-358	false
estrogens	group	236-244	methadone	drug	361-369	false
estrogens	group	236-244	perphenazine	drug	372-383	false
estrogens	group	236-244	phenylbutazone	drug	386-399	false
estrogens	group	236-244	phenytoin	drug	402-410	false
estrogens	group	236-244	salicylates	group	413-423	false
estrogens	group	236-244	tamoxifen	drug	426-434	false
estrogen-containing compounds	group	250-278	5-fluorouracil	drug	281-294	false
estrogen-containing compounds	group	250-278	furosemide	drug	297-306	false
estrogen-containing compounds	group	250-278	glucocorticoids	group	309-323	false
estrogen-containing compounds	group	250-278	meclofenamic acid	drug	326-342	false
estrogen-containing compounds	group	250-278	mefenamic acid	drug	345-358	false
estrogen-containing compounds	group	250-278	methadone	drug	361-369	false
estrogen-containing compounds	group	250-278	perphenazine	drug	372-383	false
estrogen-containing compounds	group	250-278	phenylbutazone	drug	386-399	false
estrogen-containing compounds	group	250-278	phenytoin	drug	402-410	false
estrogen-containing compounds	group	250-278	salicylates	group	413-423	false
estrogen-containing compounds	group	250-278	tamoxifen	drug	426-434	false
5-fluorouracil	drug	281-294	furosemide	drug	297-306	false
5-fluorouracil	drug	281-294	glucocorticoids	group	309-323	false
5-fluorouracil	drug	281-294	meclofenamic acid	drug	326-342	false
5-fluorouracil	drug	281-294	mefenamic acid	drug	345-358	false
5-fluorouracil	drug	281-294	methadone	drug	361-369	false
5-fluorouracil	drug	281-294	perphenazine	drug	372-383	false
5-fluorouracil	drug	281-294	phenylbutazone	drug	386-399	false
5-fluorouracil	drug	281-294	phenytoin	drug	402-410	false
5-fluorouracil	drug	281-294	salicylates	group	413-423	false
5-fluorouracil	drug	281-294	tamoxifen	drug	426-434	false
furosemide	drug	297-306	glucocorticoids	group	309-323	false
furosemide	drug	297-306	meclofenamic acid	drug	326-342	false
furosemide	drug	297-306	mefenamic acid	drug	345-358	false
furosemide	drug	297-306	methadone	drug	361-369	false
furosemide	drug	297-306	perphenazine	drug	372-383	false
furosemide	drug	297-306	phenylbutazone	drug	386-399	false
furosemide	drug	297-306	phenytoin	drug	402-410	false
furosemide	drug	297-306	salicylates	group	413-423	false
furosemide	drug	297-306	tamoxifen	drug	426-434	false
glucocorticoids	group	309-323	meclofenamic acid	drug	326-342	false
glucocorticoids	group	309-323	mefenamic acid	drug	345-358	false
glucocorticoids	group	309-323	methadone	drug	361-369	false
glucocorticoids	group	309-323	perphenazine	drug	372-383	false
glucocorticoids	group	309-323	phenylbutazone	drug	386-399	false
glucocorticoids	group	309-323	phenytoin	drug	402-410	false
glucocorticoids	group	309-323	salicylates	group	413-423	false
glucocorticoids	group	309-323	tamoxifen	drug	426-434	false
meclofenamic acid	drug	326-342	mefenamic acid	drug	345-358	false
meclofenamic acid	drug	326-342	methadone	drug	361-369	false
meclofenamic acid	drug	326-342	perphenazine	drug	372-383	false
meclofenamic acid	drug	326-342	phenylbutazone	drug	386-399	false
meclofenamic acid	drug	326-342	phenytoin	drug	402-410	false
meclofenamic acid	drug	326-342	salicylates	group	413-423	false
meclofenamic acid	drug	326-342	tamoxifen	drug	426-434	false
mefenamic acid	drug	345-358	methadone	drug	361-369	false
mefenamic acid	drug	345-358	perphenazine	drug	372-383	false
mefenamic acid	drug	345-358	phenylbutazone	drug	386-399	false
mefenamic acid	drug	345-358	phenytoin	drug	402-410	false
mefenamic acid	drug	345-358	salicylates	group	413-423	false
mefenamic acid	drug	345-358	tamoxifen	drug	426-434	false
methadone	drug	361-369	perphenazine	drug	372-383	false
methadone	drug	361-369	phenylbutazone	drug	386-399	false
methadone	drug	361-369	phenytoin	drug	402-410	false
methadone	drug	361-369	salicylates	group	413-423	false
methadone	drug	361-369	tamoxifen	drug	426-434	false
perphenazine	drug	372-383	phenylbutazone	drug	386-399	false
perphenazine	drug	372-383	phenytoin	drug	402-410	false
perphenazine	drug	372-383	salicylates	group	413-423	false
perphenazine	drug	372-383	tamoxifen	drug	426-434	false
phenylbutazone	drug	386-399	phenytoin	drug	402-410	false
phenylbutazone	drug	386-399	salicylates	group	413-423	false
phenylbutazone	drug	386-399	tamoxifen	drug	426-434	false
phenytoin	drug	402-410	salicylates	group	413-423	false
phenytoin	drug	402-410	tamoxifen	drug	426-434	false
salicylates	group	413-423	tamoxifen	drug	426-434	false

DDI-DrugBank.d411.s4	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
aminoglutethimide	drug	228-244	p-aminosalicylic acid	drug	247-267	false
aminoglutethimide	drug	228-244	amiodarone	drug	270-279	false
aminoglutethimide	drug	228-244	androgens	group	282-290	false
aminoglutethimide	drug	228-244	thiocyanate	drug	339-349	false
aminoglutethimide	drug	228-244	perchlorate	drug	352-362	false
aminoglutethimide	drug	228-244	pertechnetate	drug	365-377	false
aminoglutethimide	drug	228-244	antithyroid drugs	group	381-397	false
aminoglutethimide	drug	228-244	b-adrenergic blocking agents	group	400-427	false
aminoglutethimide	drug	228-244	carbamazepine	drug	430-442	false
aminoglutethimide	drug	228-244	chloral hydrate	drug	445-459	false
aminoglutethimide	drug	228-244	diazepam	drug	462-469	false
aminoglutethimide	drug	228-244	dopamine	drug	472-479	false
aminoglutethimide	drug	228-244	dopamine agonists	group	485-501	false
aminoglutethimide	drug	228-244	ethionamide	drug	504-514	false
aminoglutethimide	drug	228-244	glucocorticoids	group	517-531	false
aminoglutethimide	drug	228-244	heparin	drug	534-540	false
aminoglutethimide	drug	228-244	insulin	drug	568-574	false
aminoglutethimide	drug	228-244	iodine-containing compounds	group	611-637	false
aminoglutethimide	drug	228-244	levodopa	drug	640-647	false
aminoglutethimide	drug	228-244	lovastatin	drug	650-659	false
aminoglutethimide	drug	228-244	lithium	drug	662-668	false
aminoglutethimide	drug	228-244	6-mercaptopurine	drug	671-686	false
aminoglutethimide	drug	228-244	metoclopramide	drug	689-702	false
aminoglutethimide	drug	228-244	mitotane	drug	705-712	false
aminoglutethimide	drug	228-244	nitroprusside	drug	715-727	false
aminoglutethimide	drug	228-244	phenobarbital	drug	730-742	false
aminoglutethimide	drug	228-244	phenytoin	drug	745-753	false
aminoglutethimide	drug	228-244	resorcinol	drug	756-765	false
aminoglutethimide	drug	228-244	rifampin	drug	768-775	false
aminoglutethimide	drug	228-244	somatostatin analogs	group	778-797	false
aminoglutethimide	drug	228-244	sulfonamides	group	800-811	false
aminoglutethimide	drug	228-244	sulfonylureas	group	814-826	false
aminoglutethimide	drug	228-244	thiazide diuretics	group	829-846	false
p-aminosalicylic acid	drug	247-267	amiodarone	drug	270-279	false
p-aminosalicylic acid	drug	247-267	androgens	group	282-290	false
p-aminosalicylic acid	drug	247-267	thiocyanate	drug	339-349	false
p-aminosalicylic acid	drug	247-267	perchlorate	drug	352-362	false
p-aminosalicylic acid	drug	247-267	pertechnetate	drug	365-377	false
p-aminosalicylic acid	drug	247-267	antithyroid drugs	group	381-397	false
p-aminosalicylic acid	drug	247-267	b-adrenergic blocking agents	group	400-427	false
p-aminosalicylic acid	drug	247-267	carbamazepine	drug	430-442	false
p-aminosalicylic acid	drug	247-267	chloral hydrate	drug	445-459	false
p-aminosalicylic acid	drug	247-267	diazepam	drug	462-469	false
p-aminosalicylic acid	drug	247-267	dopamine	drug	472-479	false
p-aminosalicylic acid	drug	247-267	dopamine agonists	group	485-501	false
p-aminosalicylic acid	drug	247-267	ethionamide	drug	504-514	false
p-aminosalicylic acid	drug	247-267	glucocorticoids	group	517-531	false
p-aminosalicylic acid	drug	247-267	heparin	drug	534-540	false
p-aminosalicylic acid	drug	247-267	insulin	drug	568-574	false
p-aminosalicylic acid	drug	247-267	iodine-containing compounds	group	611-637	false
p-aminosalicylic acid	drug	247-267	levodopa	drug	640-647	false
p-aminosalicylic acid	drug	247-267	lovastatin	drug	650-659	false
p-aminosalicylic acid	drug	247-267	lithium	drug	662-668	false
p-aminosalicylic acid	drug	247-267	6-mercaptopurine	drug	671-686	false
p-aminosalicylic acid	drug	247-267	metoclopramide	drug	689-702	false
p-aminosalicylic acid	drug	247-267	mitotane	drug	705-712	false
p-aminosalicylic acid	drug	247-267	nitroprusside	drug	715-727	false
p-aminosalicylic acid	drug	247-267	phenobarbital	drug	730-742	false
p-aminosalicylic acid	drug	247-267	phenytoin	drug	745-753	false
p-aminosalicylic acid	drug	247-267	resorcinol	drug	756-765	false
p-aminosalicylic acid	drug	247-267	rifampin	drug	768-775	false
p-aminosalicylic acid	drug	247-267	somatostatin analogs	group	778-797	false
p-aminosalicylic acid	drug	247-267	sulfonamides	group	800-811	false
p-aminosalicylic acid	drug	247-267	sulfonylureas	group	814-826	false
p-aminosalicylic acid	drug	247-267	thiazide diuretics	group	829-846	false
amiodarone	drug	270-279	androgens	group	282-290	false
amiodarone	drug	270-279	thiocyanate	drug	339-349	false
amiodarone	drug	270-279	perchlorate	drug	352-362	false
amiodarone	drug	270-279	pertechnetate	drug	365-377	false
amiodarone	drug	270-279	antithyroid drugs	group	381-397	false
amiodarone	drug	270-279	b-adrenergic blocking agents	group	400-427	false
amiodarone	drug	270-279	carbamazepine	drug	430-442	false
amiodarone	drug	270-279	chloral hydrate	drug	445-459	false
amiodarone	drug	270-279	diazepam	drug	462-469	false
amiodarone	drug	270-279	dopamine	drug	472-479	false
amiodarone	drug	270-279	dopamine agonists	group	485-501	false
amiodarone	drug	270-279	ethionamide	drug	504-514	false
amiodarone	drug	270-279	glucocorticoids	group	517-531	false
amiodarone	drug	270-279	heparin	drug	534-540	false
amiodarone	drug	270-279	insulin	drug	568-574	false
amiodarone	drug	270-279	iodine-containing compounds	group	611-637	false
amiodarone	drug	270-279	levodopa	drug	640-647	false
amiodarone	drug	270-279	lovastatin	drug	650-659	false
amiodarone	drug	270-279	lithium	drug	662-668	false
amiodarone	drug	270-279	6-mercaptopurine	drug	671-686	false
amiodarone	drug	270-279	metoclopramide	drug	689-702	false
amiodarone	drug	270-279	mitotane	drug	705-712	false
amiodarone	drug	270-279	nitroprusside	drug	715-727	false
amiodarone	drug	270-279	phenobarbital	drug	730-742	false
amiodarone	drug	270-279	phenytoin	drug	745-753	false
amiodarone	drug	270-279	resorcinol	drug	756-765	false
amiodarone	drug	270-279	rifampin	drug	768-775	false
amiodarone	drug	270-279	somatostatin analogs	group	778-797	false
amiodarone	drug	270-279	sulfonamides	group	800-811	false
amiodarone	drug	270-279	sulfonylureas	group	814-826	false
amiodarone	drug	270-279	thiazide diuretics	group	829-846	false
androgens	group	282-290	thiocyanate	drug	339-349	false
androgens	group	282-290	perchlorate	drug	352-362	false
androgens	group	282-290	pertechnetate	drug	365-377	false
androgens	group	282-290	antithyroid drugs	group	381-397	false
androgens	group	282-290	b-adrenergic blocking agents	group	400-427	false
androgens	group	282-290	carbamazepine	drug	430-442	false
androgens	group	282-290	chloral hydrate	drug	445-459	false
androgens	group	282-290	diazepam	drug	462-469	false
androgens	group	282-290	dopamine	drug	472-479	false
androgens	group	282-290	dopamine agonists	group	485-501	false
androgens	group	282-290	ethionamide	drug	504-514	false
androgens	group	282-290	glucocorticoids	group	517-531	false
androgens	group	282-290	heparin	drug	534-540	false
androgens	group	282-290	insulin	drug	568-574	false
androgens	group	282-290	iodine-containing compounds	group	611-637	false
androgens	group	282-290	levodopa	drug	640-647	false
androgens	group	282-290	lovastatin	drug	650-659	false
androgens	group	282-290	lithium	drug	662-668	false
androgens	group	282-290	6-mercaptopurine	drug	671-686	false
androgens	group	282-290	metoclopramide	drug	689-702	false
androgens	group	282-290	mitotane	drug	705-712	false
androgens	group	282-290	nitroprusside	drug	715-727	false
androgens	group	282-290	phenobarbital	drug	730-742	false
androgens	group	282-290	phenytoin	drug	745-753	false
androgens	group	282-290	resorcinol	drug	756-765	false
androgens	group	282-290	rifampin	drug	768-775	false
androgens	group	282-290	somatostatin analogs	group	778-797	false
androgens	group	282-290	sulfonamides	group	800-811	false
androgens	group	282-290	sulfonylureas	group	814-826	false
androgens	group	282-290	thiazide diuretics	group	829-846	false
thiocyanate	drug	339-349	perchlorate	drug	352-362	false
thiocyanate	drug	339-349	pertechnetate	drug	365-377	false
thiocyanate	drug	339-349	antithyroid drugs	group	381-397	false
thiocyanate	drug	339-349	b-adrenergic blocking agents	group	400-427	false
thiocyanate	drug	339-349	carbamazepine	drug	430-442	false
thiocyanate	drug	339-349	chloral hydrate	drug	445-459	false
thiocyanate	drug	339-349	diazepam	drug	462-469	false
thiocyanate	drug	339-349	dopamine	drug	472-479	false
thiocyanate	drug	339-349	dopamine agonists	group	485-501	false
thiocyanate	drug	339-349	ethionamide	drug	504-514	false
thiocyanate	drug	339-349	glucocorticoids	group	517-531	false
thiocyanate	drug	339-349	heparin	drug	534-540	false
thiocyanate	drug	339-349	insulin	drug	568-574	false
thiocyanate	drug	339-349	iodine-containing compounds	group	611-637	false
thiocyanate	drug	339-349	levodopa	drug	640-647	false
thiocyanate	drug	339-349	lovastatin	drug	650-659	false
thiocyanate	drug	339-349	lithium	drug	662-668	false
thiocyanate	drug	339-349	6-mercaptopurine	drug	671-686	false
thiocyanate	drug	339-349	metoclopramide	drug	689-702	false
thiocyanate	drug	339-349	mitotane	drug	705-712	false
thiocyanate	drug	339-349	nitroprusside	drug	715-727	false
thiocyanate	drug	339-349	phenobarbital	drug	730-742	false
thiocyanate	drug	339-349	phenytoin	drug	745-753	false
thiocyanate	drug	339-349	resorcinol	drug	756-765	false
thiocyanate	drug	339-349	rifampin	drug	768-775	false
thiocyanate	drug	339-349	somatostatin analogs	group	778-797	false
thiocyanate	drug	339-349	sulfonamides	group	800-811	false
thiocyanate	drug	339-349	sulfonylureas	group	814-826	false
thiocyanate	drug	339-349	thiazide diuretics	group	829-846	false
perchlorate	drug	352-362	pertechnetate	drug	365-377	false
perchlorate	drug	352-362	antithyroid drugs	group	381-397	false
perchlorate	drug	352-362	b-adrenergic blocking agents	group	400-427	false
perchlorate	drug	352-362	carbamazepine	drug	430-442	false
perchlorate	drug	352-362	chloral hydrate	drug	445-459	false
perchlorate	drug	352-362	diazepam	drug	462-469	false
perchlorate	drug	352-362	dopamine	drug	472-479	false
perchlorate	drug	352-362	dopamine agonists	group	485-501	false
perchlorate	drug	352-362	ethionamide	drug	504-514	false
perchlorate	drug	352-362	glucocorticoids	group	517-531	false
perchlorate	drug	352-362	heparin	drug	534-540	false
perchlorate	drug	352-362	insulin	drug	568-574	false
perchlorate	drug	352-362	iodine-containing compounds	group	611-637	false
perchlorate	drug	352-362	levodopa	drug	640-647	false
perchlorate	drug	352-362	lovastatin	drug	650-659	false
perchlorate	drug	352-362	lithium	drug	662-668	false
perchlorate	drug	352-362	6-mercaptopurine	drug	671-686	false
perchlorate	drug	352-362	metoclopramide	drug	689-702	false
perchlorate	drug	352-362	mitotane	drug	705-712	false
perchlorate	drug	352-362	nitroprusside	drug	715-727	false
perchlorate	drug	352-362	phenobarbital	drug	730-742	false
perchlorate	drug	352-362	phenytoin	drug	745-753	false
perchlorate	drug	352-362	resorcinol	drug	756-765	false
perchlorate	drug	352-362	rifampin	drug	768-775	false
perchlorate	drug	352-362	somatostatin analogs	group	778-797	false
perchlorate	drug	352-362	sulfonamides	group	800-811	false
perchlorate	drug	352-362	sulfonylureas	group	814-826	false
perchlorate	drug	352-362	thiazide diuretics	group	829-846	false
pertechnetate	drug	365-377	antithyroid drugs	group	381-397	false
pertechnetate	drug	365-377	b-adrenergic blocking agents	group	400-427	false
pertechnetate	drug	365-377	carbamazepine	drug	430-442	false
pertechnetate	drug	365-377	chloral hydrate	drug	445-459	false
pertechnetate	drug	365-377	diazepam	drug	462-469	false
pertechnetate	drug	365-377	dopamine	drug	472-479	false
pertechnetate	drug	365-377	dopamine agonists	group	485-501	false
pertechnetate	drug	365-377	ethionamide	drug	504-514	false
pertechnetate	drug	365-377	glucocorticoids	group	517-531	false
pertechnetate	drug	365-377	heparin	drug	534-540	false
pertechnetate	drug	365-377	insulin	drug	568-574	false
pertechnetate	drug	365-377	iodine-containing compounds	group	611-637	false
pertechnetate	drug	365-377	levodopa	drug	640-647	false
pertechnetate	drug	365-377	lovastatin	drug	650-659	false
pertechnetate	drug	365-377	lithium	drug	662-668	false
pertechnetate	drug	365-377	6-mercaptopurine	drug	671-686	false
pertechnetate	drug	365-377	metoclopramide	drug	689-702	false
pertechnetate	drug	365-377	mitotane	drug	705-712	false
pertechnetate	drug	365-377	nitroprusside	drug	715-727	false
pertechnetate	drug	365-377	phenobarbital	drug	730-742	false
pertechnetate	drug	365-377	phenytoin	drug	745-753	false
pertechnetate	drug	365-377	resorcinol	drug	756-765	false
pertechnetate	drug	365-377	rifampin	drug	768-775	false
pertechnetate	drug	365-377	somatostatin analogs	group	778-797	false
pertechnetate	drug	365-377	sulfonamides	group	800-811	false
pertechnetate	drug	365-377	sulfonylureas	group	814-826	false
pertechnetate	drug	365-377	thiazide diuretics	group	829-846	false
antithyroid drugs	group	381-397	b-adrenergic blocking agents	group	400-427	false
antithyroid drugs	group	381-397	carbamazepine	drug	430-442	false
antithyroid drugs	group	381-397	chloral hydrate	drug	445-459	false
antithyroid drugs	group	381-397	diazepam	drug	462-469	false
antithyroid drugs	group	381-397	dopamine	drug	472-479	false
antithyroid drugs	group	381-397	dopamine agonists	group	485-501	false
antithyroid drugs	group	381-397	ethionamide	drug	504-514	false
antithyroid drugs	group	381-397	glucocorticoids	group	517-531	false
antithyroid drugs	group	381-397	heparin	drug	534-540	false
antithyroid drugs	group	381-397	insulin	drug	568-574	false
antithyroid drugs	group	381-397	iodine-containing compounds	group	611-637	false
antithyroid drugs	group	381-397	levodopa	drug	640-647	false
antithyroid drugs	group	381-397	lovastatin	drug	650-659	false
antithyroid drugs	group	381-397	lithium	drug	662-668	false
antithyroid drugs	group	381-397	6-mercaptopurine	drug	671-686	false
antithyroid drugs	group	381-397	metoclopramide	drug	689-702	false
antithyroid drugs	group	381-397	mitotane	drug	705-712	false
antithyroid drugs	group	381-397	nitroprusside	drug	715-727	false
antithyroid drugs	group	381-397	phenobarbital	drug	730-742	false
antithyroid drugs	group	381-397	phenytoin	drug	745-753	false
antithyroid drugs	group	381-397	resorcinol	drug	756-765	false
antithyroid drugs	group	381-397	rifampin	drug	768-775	false
antithyroid drugs	group	381-397	somatostatin analogs	group	778-797	false
antithyroid drugs	group	381-397	sulfonamides	group	800-811	false
antithyroid drugs	group	381-397	sulfonylureas	group	814-826	false
antithyroid drugs	group	381-397	thiazide diuretics	group	829-846	false
b-adrenergic blocking agents	group	400-427	carbamazepine	drug	430-442	false
b-adrenergic blocking agents	group	400-427	chloral hydrate	drug	445-459	false
b-adrenergic blocking agents	group	400-427	diazepam	drug	462-469	false
b-adrenergic blocking agents	group	400-427	dopamine	drug	472-479	false
b-adrenergic blocking agents	group	400-427	dopamine agonists	group	485-501	false
b-adrenergic blocking agents	group	400-427	ethionamide	drug	504-514	false
b-adrenergic blocking agents	group	400-427	glucocorticoids	group	517-531	false
b-adrenergic blocking agents	group	400-427	heparin	drug	534-540	false
b-adrenergic blocking agents	group	400-427	insulin	drug	568-574	false
b-adrenergic blocking agents	group	400-427	iodine-containing compounds	group	611-637	false
b-adrenergic blocking agents	group	400-427	levodopa	drug	640-647	false
b-adrenergic blocking agents	group	400-427	lovastatin	drug	650-659	false
b-adrenergic blocking agents	group	400-427	lithium	drug	662-668	false
b-adrenergic blocking agents	group	400-427	6-mercaptopurine	drug	671-686	false
b-adrenergic blocking agents	group	400-427	metoclopramide	drug	689-702	false
b-adrenergic blocking agents	group	400-427	mitotane	drug	705-712	false
b-adrenergic blocking agents	group	400-427	nitroprusside	drug	715-727	false
b-adrenergic blocking agents	group	400-427	phenobarbital	drug	730-742	false
b-adrenergic blocking agents	group	400-427	phenytoin	drug	745-753	false
b-adrenergic blocking agents	group	400-427	resorcinol	drug	756-765	false
b-adrenergic blocking agents	group	400-427	rifampin	drug	768-775	false
b-adrenergic blocking agents	group	400-427	somatostatin analogs	group	778-797	false
b-adrenergic blocking agents	group	400-427	sulfonamides	group	800-811	false
b-adrenergic blocking agents	group	400-427	sulfonylureas	group	814-826	false
b-adrenergic blocking agents	group	400-427	thiazide diuretics	group	829-846	false
carbamazepine	drug	430-442	chloral hydrate	drug	445-459	false
carbamazepine	drug	430-442	diazepam	drug	462-469	false
carbamazepine	drug	430-442	dopamine	drug	472-479	false
carbamazepine	drug	430-442	dopamine agonists	group	485-501	false
carbamazepine	drug	430-442	ethionamide	drug	504-514	false
carbamazepine	drug	430-442	glucocorticoids	group	517-531	false
carbamazepine	drug	430-442	heparin	drug	534-540	false
carbamazepine	drug	430-442	insulin	drug	568-574	false
carbamazepine	drug	430-442	iodine-containing compounds	group	611-637	false
carbamazepine	drug	430-442	levodopa	drug	640-647	false
carbamazepine	drug	430-442	lovastatin	drug	650-659	false
carbamazepine	drug	430-442	lithium	drug	662-668	false
carbamazepine	drug	430-442	6-mercaptopurine	drug	671-686	false
carbamazepine	drug	430-442	metoclopramide	drug	689-702	false
carbamazepine	drug	430-442	mitotane	drug	705-712	false
carbamazepine	drug	430-442	nitroprusside	drug	715-727	false
carbamazepine	drug	430-442	phenobarbital	drug	730-742	false
carbamazepine	drug	430-442	phenytoin	drug	745-753	false
carbamazepine	drug	430-442	resorcinol	drug	756-765	false
carbamazepine	drug	430-442	rifampin	drug	768-775	false
carbamazepine	drug	430-442	somatostatin analogs	group	778-797	false
carbamazepine	drug	430-442	sulfonamides	group	800-811	false
carbamazepine	drug	430-442	sulfonylureas	group	814-826	false
carbamazepine	drug	430-442	thiazide diuretics	group	829-846	false
chloral hydrate	drug	445-459	diazepam	drug	462-469	false
chloral hydrate	drug	445-459	dopamine	drug	472-479	false
chloral hydrate	drug	445-459	dopamine agonists	group	485-501	false
chloral hydrate	drug	445-459	ethionamide	drug	504-514	false
chloral hydrate	drug	445-459	glucocorticoids	group	517-531	false
chloral hydrate	drug	445-459	heparin	drug	534-540	false
chloral hydrate	drug	445-459	insulin	drug	568-574	false
chloral hydrate	drug	445-459	iodine-containing compounds	group	611-637	false
chloral hydrate	drug	445-459	levodopa	drug	640-647	false
chloral hydrate	drug	445-459	lovastatin	drug	650-659	false
chloral hydrate	drug	445-459	lithium	drug	662-668	false
chloral hydrate	drug	445-459	6-mercaptopurine	drug	671-686	false
chloral hydrate	drug	445-459	metoclopramide	drug	689-702	false
chloral hydrate	drug	445-459	mitotane	drug	705-712	false
chloral hydrate	drug	445-459	nitroprusside	drug	715-727	false
chloral hydrate	drug	445-459	phenobarbital	drug	730-742	false
chloral hydrate	drug	445-459	phenytoin	drug	745-753	false
chloral hydrate	drug	445-459	resorcinol	drug	756-765	false
chloral hydrate	drug	445-459	rifampin	drug	768-775	false
chloral hydrate	drug	445-459	somatostatin analogs	group	778-797	false
chloral hydrate	drug	445-459	sulfonamides	group	800-811	false
chloral hydrate	drug	445-459	sulfonylureas	group	814-826	false
chloral hydrate	drug	445-459	thiazide diuretics	group	829-846	false
diazepam	drug	462-469	dopamine	drug	472-479	false
diazepam	drug	462-469	dopamine agonists	group	485-501	false
diazepam	drug	462-469	ethionamide	drug	504-514	false
diazepam	drug	462-469	glucocorticoids	group	517-531	false
diazepam	drug	462-469	heparin	drug	534-540	false
diazepam	drug	462-469	insulin	drug	568-574	false
diazepam	drug	462-469	iodine-containing compounds	group	611-637	false
diazepam	drug	462-469	levodopa	drug	640-647	false
diazepam	drug	462-469	lovastatin	drug	650-659	false
diazepam	drug	462-469	lithium	drug	662-668	false
diazepam	drug	462-469	6-mercaptopurine	drug	671-686	false
diazepam	drug	462-469	metoclopramide	drug	689-702	false
diazepam	drug	462-469	mitotane	drug	705-712	false
diazepam	drug	462-469	nitroprusside	drug	715-727	false
diazepam	drug	462-469	phenobarbital	drug	730-742	false
diazepam	drug	462-469	phenytoin	drug	745-753	false
diazepam	drug	462-469	resorcinol	drug	756-765	false
diazepam	drug	462-469	rifampin	drug	768-775	false
diazepam	drug	462-469	somatostatin analogs	group	778-797	false
diazepam	drug	462-469	sulfonamides	group	800-811	false
diazepam	drug	462-469	sulfonylureas	group	814-826	false
diazepam	drug	462-469	thiazide diuretics	group	829-846	false
dopamine	drug	472-479	dopamine agonists	group	485-501	false
dopamine	drug	472-479	ethionamide	drug	504-514	false
dopamine	drug	472-479	glucocorticoids	group	517-531	false
dopamine	drug	472-479	heparin	drug	534-540	false
dopamine	drug	472-479	insulin	drug	568-574	false
dopamine	drug	472-479	iodine-containing compounds	group	611-637	false
dopamine	drug	472-479	levodopa	drug	640-647	false
dopamine	drug	472-479	lovastatin	drug	650-659	false
dopamine	drug	472-479	lithium	drug	662-668	false
dopamine	drug	472-479	6-mercaptopurine	drug	671-686	false
dopamine	drug	472-479	metoclopramide	drug	689-702	false
dopamine	drug	472-479	mitotane	drug	705-712	false
dopamine	drug	472-479	nitroprusside	drug	715-727	false
dopamine	drug	472-479	phenobarbital	drug	730-742	false
dopamine	drug	472-479	phenytoin	drug	745-753	false
dopamine	drug	472-479	resorcinol	drug	756-765	false
dopamine	drug	472-479	rifampin	drug	768-775	false
dopamine	drug	472-479	somatostatin analogs	group	778-797	false
dopamine	drug	472-479	sulfonamides	group	800-811	false
dopamine	drug	472-479	sulfonylureas	group	814-826	false
dopamine	drug	472-479	thiazide diuretics	group	829-846	false
dopamine agonists	group	485-501	ethionamide	drug	504-514	false
dopamine agonists	group	485-501	glucocorticoids	group	517-531	false
dopamine agonists	group	485-501	heparin	drug	534-540	false
dopamine agonists	group	485-501	insulin	drug	568-574	false
dopamine agonists	group	485-501	iodine-containing compounds	group	611-637	false
dopamine agonists	group	485-501	levodopa	drug	640-647	false
dopamine agonists	group	485-501	lovastatin	drug	650-659	false
dopamine agonists	group	485-501	lithium	drug	662-668	false
dopamine agonists	group	485-501	6-mercaptopurine	drug	671-686	false
dopamine agonists	group	485-501	metoclopramide	drug	689-702	false
dopamine agonists	group	485-501	mitotane	drug	705-712	false
dopamine agonists	group	485-501	nitroprusside	drug	715-727	false
dopamine agonists	group	485-501	phenobarbital	drug	730-742	false
dopamine agonists	group	485-501	phenytoin	drug	745-753	false
dopamine agonists	group	485-501	resorcinol	drug	756-765	false
dopamine agonists	group	485-501	rifampin	drug	768-775	false
dopamine agonists	group	485-501	somatostatin analogs	group	778-797	false
dopamine agonists	group	485-501	sulfonamides	group	800-811	false
dopamine agonists	group	485-501	sulfonylureas	group	814-826	false
dopamine agonists	group	485-501	thiazide diuretics	group	829-846	false
ethionamide	drug	504-514	glucocorticoids	group	517-531	false
ethionamide	drug	504-514	heparin	drug	534-540	false
ethionamide	drug	504-514	insulin	drug	568-574	false
ethionamide	drug	504-514	iodine-containing compounds	group	611-637	false
ethionamide	drug	504-514	levodopa	drug	640-647	false
ethionamide	drug	504-514	lovastatin	drug	650-659	false
ethionamide	drug	504-514	lithium	drug	662-668	false
ethionamide	drug	504-514	6-mercaptopurine	drug	671-686	false
ethionamide	drug	504-514	metoclopramide	drug	689-702	false
ethionamide	drug	504-514	mitotane	drug	705-712	false
ethionamide	drug	504-514	nitroprusside	drug	715-727	false
ethionamide	drug	504-514	phenobarbital	drug	730-742	false
ethionamide	drug	504-514	phenytoin	drug	745-753	false
ethionamide	drug	504-514	resorcinol	drug	756-765	false
ethionamide	drug	504-514	rifampin	drug	768-775	false
ethionamide	drug	504-514	somatostatin analogs	group	778-797	false
ethionamide	drug	504-514	sulfonamides	group	800-811	false
ethionamide	drug	504-514	sulfonylureas	group	814-826	false
ethionamide	drug	504-514	thiazide diuretics	group	829-846	false
glucocorticoids	group	517-531	heparin	drug	534-540	false
glucocorticoids	group	517-531	insulin	drug	568-574	false
glucocorticoids	group	517-531	iodine-containing compounds	group	611-637	false
glucocorticoids	group	517-531	levodopa	drug	640-647	false
glucocorticoids	group	517-531	lovastatin	drug	650-659	false
glucocorticoids	group	517-531	lithium	drug	662-668	false
glucocorticoids	group	517-531	6-mercaptopurine	drug	671-686	false
glucocorticoids	group	517-531	metoclopramide	drug	689-702	false
glucocorticoids	group	517-531	mitotane	drug	705-712	false
glucocorticoids	group	517-531	nitroprusside	drug	715-727	false
glucocorticoids	group	517-531	phenobarbital	drug	730-742	false
glucocorticoids	group	517-531	phenytoin	drug	745-753	false
glucocorticoids	group	517-531	resorcinol	drug	756-765	false
glucocorticoids	group	517-531	rifampin	drug	768-775	false
glucocorticoids	group	517-531	somatostatin analogs	group	778-797	false
glucocorticoids	group	517-531	sulfonamides	group	800-811	false
glucocorticoids	group	517-531	sulfonylureas	group	814-826	false
glucocorticoids	group	517-531	thiazide diuretics	group	829-846	false
heparin	drug	534-540	insulin	drug	568-574	false
heparin	drug	534-540	iodine-containing compounds	group	611-637	false
heparin	drug	534-540	levodopa	drug	640-647	false
heparin	drug	534-540	lovastatin	drug	650-659	false
heparin	drug	534-540	lithium	drug	662-668	false
heparin	drug	534-540	6-mercaptopurine	drug	671-686	false
heparin	drug	534-540	metoclopramide	drug	689-702	false
heparin	drug	534-540	mitotane	drug	705-712	false
heparin	drug	534-540	nitroprusside	drug	715-727	false
heparin	drug	534-540	phenobarbital	drug	730-742	false
heparin	drug	534-540	phenytoin	drug	745-753	false
heparin	drug	534-540	resorcinol	drug	756-765	false
heparin	drug	534-540	rifampin	drug	768-775	false
heparin	drug	534-540	somatostatin analogs	group	778-797	false
heparin	drug	534-540	sulfonamides	group	800-811	false
heparin	drug	534-540	sulfonylureas	group	814-826	false
heparin	drug	534-540	thiazide diuretics	group	829-846	false
insulin	drug	568-574	iodine-containing compounds	group	611-637	false
insulin	drug	568-574	levodopa	drug	640-647	false
insulin	drug	568-574	lovastatin	drug	650-659	false
insulin	drug	568-574	lithium	drug	662-668	false
insulin	drug	568-574	6-mercaptopurine	drug	671-686	false
insulin	drug	568-574	metoclopramide	drug	689-702	false
insulin	drug	568-574	mitotane	drug	705-712	false
insulin	drug	568-574	nitroprusside	drug	715-727	false
insulin	drug	568-574	phenobarbital	drug	730-742	false
insulin	drug	568-574	phenytoin	drug	745-753	false
insulin	drug	568-574	resorcinol	drug	756-765	false
insulin	drug	568-574	rifampin	drug	768-775	false
insulin	drug	568-574	somatostatin analogs	group	778-797	false
insulin	drug	568-574	sulfonamides	group	800-811	false
insulin	drug	568-574	sulfonylureas	group	814-826	false
insulin	drug	568-574	thiazide diuretics	group	829-846	false
iodine-containing compounds	group	611-637	levodopa	drug	640-647	false
iodine-containing compounds	group	611-637	lovastatin	drug	650-659	false
iodine-containing compounds	group	611-637	lithium	drug	662-668	false
iodine-containing compounds	group	611-637	6-mercaptopurine	drug	671-686	false
iodine-containing compounds	group	611-637	metoclopramide	drug	689-702	false
iodine-containing compounds	group	611-637	mitotane	drug	705-712	false
iodine-containing compounds	group	611-637	nitroprusside	drug	715-727	false
iodine-containing compounds	group	611-637	phenobarbital	drug	730-742	false
iodine-containing compounds	group	611-637	phenytoin	drug	745-753	false
iodine-containing compounds	group	611-637	resorcinol	drug	756-765	false
iodine-containing compounds	group	611-637	rifampin	drug	768-775	false
iodine-containing compounds	group	611-637	somatostatin analogs	group	778-797	false
iodine-containing compounds	group	611-637	sulfonamides	group	800-811	false
iodine-containing compounds	group	611-637	sulfonylureas	group	814-826	false
iodine-containing compounds	group	611-637	thiazide diuretics	group	829-846	false
levodopa	drug	640-647	lovastatin	drug	650-659	false
levodopa	drug	640-647	lithium	drug	662-668	false
levodopa	drug	640-647	6-mercaptopurine	drug	671-686	false
levodopa	drug	640-647	metoclopramide	drug	689-702	false
levodopa	drug	640-647	mitotane	drug	705-712	false
levodopa	drug	640-647	nitroprusside	drug	715-727	false
levodopa	drug	640-647	phenobarbital	drug	730-742	false
levodopa	drug	640-647	phenytoin	drug	745-753	false
levodopa	drug	640-647	resorcinol	drug	756-765	false
levodopa	drug	640-647	rifampin	drug	768-775	false
levodopa	drug	640-647	somatostatin analogs	group	778-797	false
levodopa	drug	640-647	sulfonamides	group	800-811	false
levodopa	drug	640-647	sulfonylureas	group	814-826	false
levodopa	drug	640-647	thiazide diuretics	group	829-846	false
lovastatin	drug	650-659	lithium	drug	662-668	false
lovastatin	drug	650-659	6-mercaptopurine	drug	671-686	false
lovastatin	drug	650-659	metoclopramide	drug	689-702	false
lovastatin	drug	650-659	mitotane	drug	705-712	false
lovastatin	drug	650-659	nitroprusside	drug	715-727	false
lovastatin	drug	650-659	phenobarbital	drug	730-742	false
lovastatin	drug	650-659	phenytoin	drug	745-753	false
lovastatin	drug	650-659	resorcinol	drug	756-765	false
lovastatin	drug	650-659	rifampin	drug	768-775	false
lovastatin	drug	650-659	somatostatin analogs	group	778-797	false
lovastatin	drug	650-659	sulfonamides	group	800-811	false
lovastatin	drug	650-659	sulfonylureas	group	814-826	false
lovastatin	drug	650-659	thiazide diuretics	group	829-846	false
lithium	drug	662-668	6-mercaptopurine	drug	671-686	false
lithium	drug	662-668	metoclopramide	drug	689-702	false
lithium	drug	662-668	mitotane	drug	705-712	false
lithium	drug	662-668	nitroprusside	drug	715-727	false
lithium	drug	662-668	phenobarbital	drug	730-742	false
lithium	drug	662-668	phenytoin	drug	745-753	false
lithium	drug	662-668	resorcinol	drug	756-765	false
lithium	drug	662-668	rifampin	drug	768-775	false
lithium	drug	662-668	somatostatin analogs	group	778-797	false
lithium	drug	662-668	sulfonamides	group	800-811	false
lithium	drug	662-668	sulfonylureas	group	814-826	false
lithium	drug	662-668	thiazide diuretics	group	829-846	false
6-mercaptopurine	drug	671-686	metoclopramide	drug	689-702	false
6-mercaptopurine	drug	671-686	mitotane	drug	705-712	false
6-mercaptopurine	drug	671-686	nitroprusside	drug	715-727	false
6-mercaptopurine	drug	671-686	phenobarbital	drug	730-742	false
6-mercaptopurine	drug	671-686	phenytoin	drug	745-753	false
6-mercaptopurine	drug	671-686	resorcinol	drug	756-765	false
6-mercaptopurine	drug	671-686	rifampin	drug	768-775	false
6-mercaptopurine	drug	671-686	somatostatin analogs	group	778-797	false
6-mercaptopurine	drug	671-686	sulfonamides	group	800-811	false
6-mercaptopurine	drug	671-686	sulfonylureas	group	814-826	false
6-mercaptopurine	drug	671-686	thiazide diuretics	group	829-846	false
metoclopramide	drug	689-702	mitotane	drug	705-712	false
metoclopramide	drug	689-702	nitroprusside	drug	715-727	false
metoclopramide	drug	689-702	phenobarbital	drug	730-742	false
metoclopramide	drug	689-702	phenytoin	drug	745-753	false
metoclopramide	drug	689-702	resorcinol	drug	756-765	false
metoclopramide	drug	689-702	rifampin	drug	768-775	false
metoclopramide	drug	689-702	somatostatin analogs	group	778-797	false
metoclopramide	drug	689-702	sulfonamides	group	800-811	false
metoclopramide	drug	689-702	sulfonylureas	group	814-826	false
metoclopramide	drug	689-702	thiazide diuretics	group	829-846	false
mitotane	drug	705-712	nitroprusside	drug	715-727	false
mitotane	drug	705-712	phenobarbital	drug	730-742	false
mitotane	drug	705-712	phenytoin	drug	745-753	false
mitotane	drug	705-712	resorcinol	drug	756-765	false
mitotane	drug	705-712	rifampin	drug	768-775	false
mitotane	drug	705-712	somatostatin analogs	group	778-797	false
mitotane	drug	705-712	sulfonamides	group	800-811	false
mitotane	drug	705-712	sulfonylureas	group	814-826	false
mitotane	drug	705-712	thiazide diuretics	group	829-846	false
nitroprusside	drug	715-727	phenobarbital	drug	730-742	false
nitroprusside	drug	715-727	phenytoin	drug	745-753	false
nitroprusside	drug	715-727	resorcinol	drug	756-765	false
nitroprusside	drug	715-727	rifampin	drug	768-775	false
nitroprusside	drug	715-727	somatostatin analogs	group	778-797	false
nitroprusside	drug	715-727	sulfonamides	group	800-811	false
nitroprusside	drug	715-727	sulfonylureas	group	814-826	false
nitroprusside	drug	715-727	thiazide diuretics	group	829-846	false
phenobarbital	drug	730-742	phenytoin	drug	745-753	false
phenobarbital	drug	730-742	resorcinol	drug	756-765	false
phenobarbital	drug	730-742	rifampin	drug	768-775	false
phenobarbital	drug	730-742	somatostatin analogs	group	778-797	false
phenobarbital	drug	730-742	sulfonamides	group	800-811	false
phenobarbital	drug	730-742	sulfonylureas	group	814-826	false
phenobarbital	drug	730-742	thiazide diuretics	group	829-846	false
phenytoin	drug	745-753	resorcinol	drug	756-765	false
phenytoin	drug	745-753	rifampin	drug	768-775	false
phenytoin	drug	745-753	somatostatin analogs	group	778-797	false
phenytoin	drug	745-753	sulfonamides	group	800-811	false
phenytoin	drug	745-753	sulfonylureas	group	814-826	false
phenytoin	drug	745-753	thiazide diuretics	group	829-846	false
resorcinol	drug	756-765	rifampin	drug	768-775	false
resorcinol	drug	756-765	somatostatin analogs	group	778-797	false
resorcinol	drug	756-765	sulfonamides	group	800-811	false
resorcinol	drug	756-765	sulfonylureas	group	814-826	false
resorcinol	drug	756-765	thiazide diuretics	group	829-846	false
rifampin	drug	768-775	somatostatin analogs	group	778-797	false
rifampin	drug	768-775	sulfonamides	group	800-811	false
rifampin	drug	768-775	sulfonylureas	group	814-826	false
rifampin	drug	768-775	thiazide diuretics	group	829-846	false
somatostatin analogs	group	778-797	sulfonamides	group	800-811	false
somatostatin analogs	group	778-797	sulfonylureas	group	814-826	false
somatostatin analogs	group	778-797	thiazide diuretics	group	829-846	false
sulfonamides	group	800-811	sulfonylureas	group	814-826	false
sulfonamides	group	800-811	thiazide diuretics	group	829-846	false
sulfonylureas	group	814-826	thiazide diuretics	group	829-846	false

DDI-DrugBank.d411.s6	Amiodarone: Amiodarone therapy alone can cause hypothyroidism or hyperthyroidism.
Amiodarone	drug	0-9	Amiodarone	drug	12-21	false

DDI-DrugBank.d411.s7	Anticoagulants (Oral): The hypoprothrombinemic effect of anticoagulants may be potentiated, apparently by increased catabloism of vitamin K-dependent clotting factors.
Anticoagulants	group	0-13	anticoagulants	group	57-70	false

DDI-DrugBank.d411.s8	Antidiabetic Agents (Insulin, Sulfonylureas): Requirements for insulin or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
Antidiabetic Agents	group	0-18	Insulin	drug	21-27	false
Antidiabetic Agents	group	0-18	Sulfonylureas	group	30-42	false
Antidiabetic Agents	group	0-18	insulin	drug	63-69	false
Antidiabetic Agents	group	0-18	antidiabetic agents	group	79-97	false
Insulin	drug	21-27	Sulfonylureas	group	30-42	false
Insulin	drug	21-27	insulin	drug	63-69	false
Insulin	drug	21-27	antidiabetic agents	group	79-97	false
Sulfonylureas	group	30-42	insulin	drug	63-69	false
Sulfonylureas	group	30-42	antidiabetic agents	group	79-97	false
insulin	drug	63-69	antidiabetic agents	group	79-97	false

DDI-DrugBank.d411.s9	b-Adrenergic Blocking Agents: Actions of some of beta-blocking agents may be impaired when hypothyroid patients become euthyroid.
b-Adrenergic Blocking Agents	group	0-27	beta-blocking agents	group	49-68	false

DDI-DrugBank.d411.s10	Cytokines (interferon, interleukin): Cytokines have been reported to induce both hyperthyroidism and hypothyroidism.
Cytokines	group	0-8	interferon	group	11-20	false
Cytokines	group	0-8	interleukin	group	23-33	false
Cytokines	group	0-8	Cytokines	group	37-45	false
interferon	group	11-20	interleukin	group	23-33	false
interferon	group	11-20	Cytokines	group	37-45	false
interleukin	group	23-33	Cytokines	group	37-45	false

DDI-DrugBank.d411.s11	Digitalis Glycosides: Therapeutic effects of digitalis glycosides may be reduced.
Digitalis Glycosides	group	0-19	digitalis glycosides	group	45-64	false

DDI-DrugBank.d411.s13	Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.
Ketamine	drug	0-7	levothyroxine sodium	drug	115-134	false
Ketamine	drug	0-7	ketamine	drug	140-147	false
levothyroxine sodium	drug	115-134	ketamine	drug	140-147	effect

DDI-DrugBank.d411.s15	Sodium Iodide (123I and 131I), Sodium Pertechnetate Tc99m: Uptake of radiolabeled ions may be decreased.
Sodium Iodide	drug	0-12	Sodium Pertechnetate Tc99m	drug	31-56	false

DDI-DrugBank.d411.s16	Somatrem/Somatropin: Excessive concurrent use of thyroid hormone may accelerate epiphyseal closure.
Somatrem	drug	0-7	Somatropin	drug	9-18	false
Somatrem	drug	0-7	thyroid hormone	group	49-63	false
Somatropin	drug	9-18	thyroid hormone	group	49-63	false

DDI-DrugBank.d411.s17	Untreated hypothyroidism may interfere with the growth response to somatrem or somatropin.
somatrem	drug	67-74	somatropin	drug	79-88	false

DDI-DrugBank.d411.s18	Theophylline: Theophylline clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.
Theophylline	drug	0-11	Theophylline	drug	14-25	false

DDI-DrugBank.d562.s0	Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.
theophylline	drug	26-37	quinolones	group	87-96	mechanism

DDI-DrugBank.d562.s1	There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.
theophylline	drug	27-38	theophylline	drug	88-99	false
theophylline	drug	27-38	quinolone	group	101-109	false
theophylline	drug	88-99	quinolone	group	101-109	effect

DDI-DrugBank.d562.s2	Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
theophylline	drug	25-36	theophylline	drug	87-98	false

DDI-DrugBank.d562.s3	Quinolones have also been shown to interfere with the metabolism of caffeine.
Quinolones	group	0-9	caffeine	drug	68-75	mechanism

DDI-DrugBank.d562.s5	Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.
cinoxacin	drug	53-61	cinoxacin	drug	97-105	false
cinoxacin	drug	53-61	caffeine	drug	135-142	false
cinoxacin	drug	97-105	caffeine	drug	135-142	advise

DDI-DrugBank.d562.s6	Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
Antacids	group	0-7	sucralfate	drug	12-21	false
Antacids	group	0-7	quinolones	group	75-84	mechanism
sucralfate	drug	12-21	quinolones	group	75-84	mechanism

DDI-DrugBank.d562.s7	Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
quinolones	group	36-45	iron	drug	72-75	mechanism
quinolones	group	36-45	multivitamins	group	78-90	false
quinolones	group	36-45	zinc	drug	103-106	mechanism
quinolones	group	36-45	Videx	brand	112-116	mechanism
quinolones	group	36-45	didanosine	drug	119-128	mechanism
iron	drug	72-75	multivitamins	group	78-90	false
iron	drug	72-75	zinc	drug	103-106	false
iron	drug	72-75	Videx	brand	112-116	false
iron	drug	72-75	didanosine	drug	119-128	false
multivitamins	group	78-90	zinc	drug	103-106	false
multivitamins	group	78-90	Videx	brand	112-116	false
multivitamins	group	78-90	didanosine	drug	119-128	false
zinc	drug	103-106	Videx	brand	112-116	false
zinc	drug	103-106	didanosine	drug	119-128	false
Videx	brand	112-116	didanosine	drug	119-128	false

DDI-DrugBank.d562.s8	Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
Quinolones	group	0-9	cinoxacin	drug	22-30	false
Quinolones	group	0-9	anticoagulants	group	65-78	effect
Quinolones	group	0-9	warfarin	drug	89-96	effect
cinoxacin	drug	22-30	anticoagulants	group	65-78	effect
cinoxacin	drug	22-30	warfarin	drug	89-96	effect
anticoagulants	group	65-78	warfarin	drug	89-96	false

DDI-DrugBank.d562.s10	Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
quinolone class antimicrobial	group	55-83	nonsteroidal anti-inflammatory drug	group	93-127	effect
quinolone class antimicrobial	group	55-83	fenbufen	drug	129-136	effect
nonsteroidal anti-inflammatory drug	group	93-127	fenbufen	drug	129-136	false

DDI-DrugBank.d562.s13	Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.
cinoxacin	drug	110-118	nonsteroidal anti-inflammatory agents	group	132-168	advise

DDI-DrugBank.d562.s14	Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.
cyclosporine	drug	9-20	quinolones	group	82-91	false
cyclosporine	drug	9-20	cyclosporine	drug	97-108	false
quinolones	group	82-91	cyclosporine	drug	97-108	mechanism

DDI-DrugBank.d36.s0	Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.
aspirin	brand	63-69	carbonic anhydrase inhibitors	group	75-103	advise

DDI-DrugBank.d454.s0	- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives
Lofexidine	drug	2-11	alcohol	drug	55-61	effect
Lofexidine	drug	2-11	barbiturates	group	64-75	effect
Lofexidine	drug	2-11	sedatives	group	87-95	effect
alcohol	drug	55-61	barbiturates	group	64-75	false
alcohol	drug	55-61	sedatives	group	87-95	false
barbiturates	group	64-75	sedatives	group	87-95	false

DDI-DrugBank.d454.s2	- Lofexidine may enhance the effects of anti-hypertensive drug therapy
Lofexidine	drug	2-11	anti-hypertensive drug	group	40-61	effect

DDI-DrugBank.d454.s4	- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.
tricyclic antidepressants	group	21-45	lofexidine	drug	74-83	effect

DDI-DrugBank.d478.s1	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
ergotamine	drug	80-89	ergot-type medications	group	105-126	false
ergotamine	drug	80-89	dihydroergotamine	drug	134-150	false
ergotamine	drug	80-89	methysergide	drug	155-166	false
ergotamine	drug	80-89	naratriptan	drug	173-183	advise
ergot-type medications	group	105-126	dihydroergotamine	drug	134-150	false
ergot-type medications	group	105-126	methysergide	drug	155-166	false
ergot-type medications	group	105-126	naratriptan	drug	173-183	advise
dihydroergotamine	drug	134-150	methysergide	drug	155-166	false
dihydroergotamine	drug	134-150	naratriptan	drug	173-183	advise
methysergide	drug	155-166	naratriptan	drug	173-183	advise

DDI-DrugBank.d478.s2	The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients.
naratriptan	drug	22-32	5-HT1 agonists	group	45-58	false

DDI-DrugBank.d478.s3	Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.
naratriptan	drug	71-81	5-HT1 agonists	group	93-106	advise

DDI-DrugBank.d478.s4	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
Selective serotonin reuptake inhibitors	group	0-38	SSRIs	group	41-45	false
Selective serotonin reuptake inhibitors	group	0-38	fluoxetine	drug	55-64	false
Selective serotonin reuptake inhibitors	group	0-38	fluvoxamine	drug	67-77	false
Selective serotonin reuptake inhibitors	group	0-38	paroxetine	drug	80-89	false
Selective serotonin reuptake inhibitors	group	0-38	sertraline	drug	92-101	false
SSRIs	group	41-45	fluoxetine	drug	55-64	false
SSRIs	group	41-45	fluvoxamine	drug	67-77	false
SSRIs	group	41-45	paroxetine	drug	80-89	false
SSRIs	group	41-45	sertraline	drug	92-101	false
fluoxetine	drug	55-64	fluvoxamine	drug	67-77	false
fluoxetine	drug	55-64	paroxetine	drug	80-89	false
fluoxetine	drug	55-64	sertraline	drug	92-101	false
fluvoxamine	drug	67-77	paroxetine	drug	80-89	false
fluvoxamine	drug	67-77	sertraline	drug	92-101	false
paroxetine	drug	80-89	sertraline	drug	92-101	false

DDI-DrugBank.d478.s5	If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
naratriptan	drug	30-40	SSRI	group	49-52	advise

DDI-DrugBank.d551.s1	WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol, quinidine, valproic acid, and warfarin.
WelChol	brand	0-6	digoxin	drug	75-81	false
WelChol	brand	0-6	lovastatin	drug	84-93	false
WelChol	brand	0-6	metoprolol	drug	96-105	false
WelChol	brand	0-6	quinidine	drug	108-116	false
WelChol	brand	0-6	valproic acid	drug	119-131	false
WelChol	brand	0-6	warfarin	drug	138-145	false
digoxin	drug	75-81	lovastatin	drug	84-93	false
digoxin	drug	75-81	metoprolol	drug	96-105	false
digoxin	drug	75-81	quinidine	drug	108-116	false
digoxin	drug	75-81	valproic acid	drug	119-131	false
digoxin	drug	75-81	warfarin	drug	138-145	false
lovastatin	drug	84-93	metoprolol	drug	96-105	false
lovastatin	drug	84-93	quinidine	drug	108-116	false
lovastatin	drug	84-93	valproic acid	drug	119-131	false
lovastatin	drug	84-93	warfarin	drug	138-145	false
metoprolol	drug	96-105	quinidine	drug	108-116	false
metoprolol	drug	96-105	valproic acid	drug	119-131	false
metoprolol	drug	96-105	warfarin	drug	138-145	false
quinidine	drug	108-116	valproic acid	drug	119-131	false
quinidine	drug	108-116	warfarin	drug	138-145	false
valproic acid	drug	119-131	warfarin	drug	138-145	false

DDI-DrugBank.d551.s2	WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
WelChol	brand	0-6	verapamil	drug	57-65	mechanism
WelChol	brand	0-6	Calan SR	brand	68-75	mechanism
verapamil	drug	57-65	Calan SR	brand	68-75	false

DDI-DrugBank.d551.s4	In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.
WelChol	brand	41-47	atorvastatin	drug	55-66	false
WelChol	brand	41-47	lovastatin	drug	69-78	false
WelChol	brand	41-47	simvastatin	drug	84-94	false
WelChol	brand	41-47	HMG-CoA reductase inhibitor	group	154-180	false
atorvastatin	drug	55-66	lovastatin	drug	69-78	false
atorvastatin	drug	55-66	simvastatin	drug	84-94	false
atorvastatin	drug	55-66	HMG-CoA reductase inhibitor	group	154-180	false
lovastatin	drug	69-78	simvastatin	drug	84-94	false
lovastatin	drug	69-78	HMG-CoA reductase inhibitor	group	154-180	false
simvastatin	drug	84-94	HMG-CoA reductase inhibitor	group	154-180	false

DDI-DrugBank.d515.s0	The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.
ifosfamide	drug	102-111	ifosfamide	drug	125-134	false

DDI-DrugBank.d207.s1	In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).
rifampicin	drug	54-63	phenytoin	drug	68-76	false

DDI-DrugBank.d207.s2	International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.
warfarin	drug	114-121	IRESSA	brand	132-137	effect

DDI-DrugBank.d207.s4	Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
ketoconazole	drug	62-73	itraconazole	drug	79-90	false
ketoconazole	drug	62-73	gefitinib	drug	102-110	mechanism
ketoconazole	drug	62-73	gefitinib	drug	136-144	mechanism
itraconazole	drug	79-90	gefitinib	drug	102-110	mechanism
itraconazole	drug	79-90	gefitinib	drug	136-144	mechanism
gefitinib	drug	102-110	gefitinib	drug	136-144	false

DDI-DrugBank.d207.s7	Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
histamine H2-receptor antagonists	group	64-96	ranitidine	drug	106-115	false
histamine H2-receptor antagonists	group	64-96	cimetidine	drug	120-129	false
histamine H2-receptor antagonists	group	64-96	IRESSA	brand	168-173	mechanism
ranitidine	drug	106-115	cimetidine	drug	120-129	false
ranitidine	drug	106-115	IRESSA	brand	168-173	mechanism
cimetidine	drug	120-129	IRESSA	brand	168-173	mechanism

DDI-DrugBank.d207.s8	Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.
IRESSA	brand	36-41	vinorelbine	drug	47-57	false
IRESSA	brand	36-41	IRESSA	brand	103-108	false
IRESSA	brand	36-41	vinorelbine	drug	151-161	false
vinorelbine	drug	47-57	IRESSA	brand	103-108	false
vinorelbine	drug	47-57	vinorelbine	drug	151-161	false
IRESSA	brand	103-108	vinorelbine	drug	151-161	effect

DDI-DrugBank.d153.s0	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
anesthetic solutions	group	28-47	epinephrine	drug	60-70	false
anesthetic solutions	group	28-47	norepinephrine	drug	75-88	false
anesthetic solutions	group	28-47	monoamine oxidase inhibitors	group	112-139	false
anesthetic solutions	group	28-47	tricyclic antidepressants	group	144-168	false
epinephrine	drug	60-70	norepinephrine	drug	75-88	false
epinephrine	drug	60-70	monoamine oxidase inhibitors	group	112-139	effect
epinephrine	drug	60-70	tricyclic antidepressants	group	144-168	effect
norepinephrine	drug	75-88	monoamine oxidase inhibitors	group	112-139	effect
norepinephrine	drug	75-88	tricyclic antidepressants	group	144-168	effect
monoamine oxidase inhibitors	group	112-139	tricyclic antidepressants	group	144-168	false

DDI-DrugBank.d153.s3	Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
vasopressor drugs	group	29-45	ergot-type oxytocic drugs	group	54-78	false

DDI-DrugBank.d153.s4	Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
Phenothiazines	group	0-13	butyrophenones	group	19-32	false
Phenothiazines	group	0-13	epinephrine	drug	78-88	effect
butyrophenones	group	19-32	epinephrine	drug	78-88	effect

DDI-DrugBank.d290.s1	Standard therapy includes antibiotics, such as penicillin and gentamicin;
antibiotics	group	26-36	penicillin	drug	47-56	false
antibiotics	group	26-36	gentamicin	drug	62-71	false
penicillin	drug	47-56	gentamicin	drug	62-71	false

DDI-DrugBank.d290.s2	vasopressors, such as dopamine and isoproterenol;
vasopressors	group	0-11	dopamine	drug	22-29	false
vasopressors	group	0-11	isoproterenol	drug	35-47	false
dopamine	drug	22-29	isoproterenol	drug	35-47	false

DDI-DrugBank.d290.s4	and diuretics, such as furosemide.
diuretics	group	4-12	furosemide	drug	23-32	false

DDI-DrugBank.d290.s5	Caverject: The potential for pharmacokinetic drug-drug interactions between alprostadil and other agents has not been formally studied.
Caverject	brand	0-8	alprostadil	drug	76-86	false

DDI-DrugBank.d220.s1	There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol).
beta blocker	group	97-108	propranolol	drug	111-121	false

DDI-DrugBank.d220.s4	Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.
halofantrine	drug	79-90	Mefloquine	drug	147-156	advise

DDI-DrugBank.d220.s5	Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
Mefloquine	drug	30-39	quinine	drug	74-80	effect
Mefloquine	drug	30-39	quinidine	drug	83-91	effect
Mefloquine	drug	30-39	chloroquine	drug	97-107	effect
quinine	drug	74-80	quinidine	drug	83-91	false
quinine	drug	74-80	chloroquine	drug	97-107	false
quinidine	drug	83-91	chloroquine	drug	97-107	false

DDI-DrugBank.d220.s9	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
Mefloquine	drug	78-87	anti-arrhythmic	drug	185-199	effect
Mefloquine	drug	78-87	beta-adrenergic blocking agents	group	204-234	effect
Mefloquine	drug	78-87	calcium channel blockers	group	237-260	effect
Mefloquine	drug	78-87	antihistamines	group	263-276	effect
Mefloquine	drug	78-87	H1-blocking agents	group	281-298	effect
Mefloquine	drug	78-87	tricyclic antidepressants	group	301-325	effect
Mefloquine	drug	78-87	phenothiazines	group	331-344	effect
anti-arrhythmic	drug	185-199	beta-adrenergic blocking agents	group	204-234	false
anti-arrhythmic	drug	185-199	calcium channel blockers	group	237-260	false
anti-arrhythmic	drug	185-199	antihistamines	group	263-276	false
anti-arrhythmic	drug	185-199	H1-blocking agents	group	281-298	false
anti-arrhythmic	drug	185-199	tricyclic antidepressants	group	301-325	false
anti-arrhythmic	drug	185-199	phenothiazines	group	331-344	false
beta-adrenergic blocking agents	group	204-234	calcium channel blockers	group	237-260	false
beta-adrenergic blocking agents	group	204-234	antihistamines	group	263-276	false
beta-adrenergic blocking agents	group	204-234	H1-blocking agents	group	281-298	false
beta-adrenergic blocking agents	group	204-234	tricyclic antidepressants	group	301-325	false
beta-adrenergic blocking agents	group	204-234	phenothiazines	group	331-344	false
calcium channel blockers	group	237-260	antihistamines	group	263-276	false
calcium channel blockers	group	237-260	H1-blocking agents	group	281-298	false
calcium channel blockers	group	237-260	tricyclic antidepressants	group	301-325	false
calcium channel blockers	group	237-260	phenothiazines	group	331-344	false
antihistamines	group	263-276	H1-blocking agents	group	281-298	false
antihistamines	group	263-276	tricyclic antidepressants	group	301-325	false
antihistamines	group	263-276	phenothiazines	group	331-344	false
H1-blocking agents	group	281-298	tricyclic antidepressants	group	301-325	false
H1-blocking agents	group	281-298	phenothiazines	group	331-344	false
tricyclic antidepressants	group	301-325	phenothiazines	group	331-344	false

DDI-DrugBank.d220.s11	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
anticonvulsant	group	22-35	valproic acid	drug	42-54	false
anticonvulsant	group	22-35	carbamazepine	drug	57-69	false
anticonvulsant	group	22-35	phenobarbital	drug	72-84	false
anticonvulsant	group	22-35	phenytoin	drug	89-97	false
anticonvulsant	group	22-35	Mefloquine	drug	124-133	effect
anticonvulsant	group	22-35	anticonvulsant	group	199-212	false
valproic acid	drug	42-54	carbamazepine	drug	57-69	false
valproic acid	drug	42-54	phenobarbital	drug	72-84	false
valproic acid	drug	42-54	phenytoin	drug	89-97	false
valproic acid	drug	42-54	Mefloquine	drug	124-133	effect
valproic acid	drug	42-54	anticonvulsant	group	199-212	false
carbamazepine	drug	57-69	phenobarbital	drug	72-84	false
carbamazepine	drug	57-69	phenytoin	drug	89-97	false
carbamazepine	drug	57-69	Mefloquine	drug	124-133	effect
carbamazepine	drug	57-69	anticonvulsant	group	199-212	false
phenobarbital	drug	72-84	phenytoin	drug	89-97	false
phenobarbital	drug	72-84	Mefloquine	drug	124-133	effect
phenobarbital	drug	72-84	anticonvulsant	group	199-212	false
phenytoin	drug	89-97	Mefloquine	drug	124-133	effect
phenytoin	drug	89-97	anticonvulsant	group	199-212	false
Mefloquine	drug	124-133	anticonvulsant	group	199-212	false

DDI-DrugBank.d220.s13	When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.
Mefloquine	drug	5-14	live typhoid vaccines	group	48-68	effect

DDI-DrugBank.d220.s16	Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.
Mefloquine	drug	29-38	anticoagulants	group	118-131	advise

DDI-DrugBank.d220.s17	In clinical trials, the concomitant administration of sulfadoxine and pyrimethamine did not alter the adverse reaction profile.
sulfadoxine	drug	54-64	pyrimethamine	drug	70-82	false

DDI-DrugBank.d59.s0	The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
ERGOMAR	brand	15-21	triacetyloleandomycin	drug	45-65	mechanism
ERGOMAR	brand	15-21	ergotamine	drug	100-109	false
triacetyloleandomycin	drug	45-65	ergotamine	drug	100-109	mechanism

DDI-DrugBank.d59.s1	The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.
ERGOMAR	brand	23-29	vasoconstrictor drugs	group	41-61	effect

DDI-DrugBank.d45.s0	Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
etanercept	drug	29-38	anakinra	drug	74-81	effect
etanercept	drug	29-38	interleukin-1 antagonist	group	87-110	false
anakinra	drug	74-81	interleukin-1 antagonist	group	87-110	false

DDI-DrugBank.d45.s1	Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.
TNFa-blocking agents	group	6-25	REMICADE	brand	38-45	false
TNFa-blocking agents	group	6-25	anakinra	drug	73-80	effect
REMICADE	brand	38-45	anakinra	drug	73-80	effect

DDI-DrugBank.d45.s4	In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.
MTX	drug	57-59	nonsteroidal anti-inflammatory agents	group	66-102	false
MTX	drug	57-59	folic acid	drug	105-114	false
MTX	drug	57-59	corticosteroids	group	117-131	false
MTX	drug	57-59	narcotics	group	140-148	false
nonsteroidal anti-inflammatory agents	group	66-102	folic acid	drug	105-114	false
nonsteroidal anti-inflammatory agents	group	66-102	corticosteroids	group	117-131	false
nonsteroidal anti-inflammatory agents	group	66-102	narcotics	group	140-148	false
folic acid	drug	105-114	corticosteroids	group	117-131	false
folic acid	drug	105-114	narcotics	group	140-148	false
corticosteroids	group	117-131	narcotics	group	140-148	false

DDI-DrugBank.d45.s5	Concomitant Crohn s disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates.
antibiotics	group	45-55	antivirals	group	58-67	false
antibiotics	group	45-55	corticosteroids	group	70-84	false
antibiotics	group	45-55	6-MP	drug	87-90	false
antibiotics	group	45-55	AZA	drug	92-94	false
antivirals	group	58-67	corticosteroids	group	70-84	false
antivirals	group	58-67	6-MP	drug	87-90	false
antivirals	group	58-67	AZA	drug	92-94	false
corticosteroids	group	70-84	6-MP	drug	87-90	false
corticosteroids	group	70-84	AZA	drug	92-94	false
6-MP	drug	87-90	AZA	drug	92-94	false

DDI-DrugBank.d45.s6	In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents, folic acid and corticosteroids.
MTX	drug	73-75	nonsteroidal anti-inflammatory agents	group	126-162	false
MTX	drug	73-75	folic acid	drug	165-174	false
MTX	drug	73-75	corticosteroids	group	180-194	false
nonsteroidal anti-inflammatory agents	group	126-162	folic acid	drug	165-174	false
nonsteroidal anti-inflammatory agents	group	126-162	corticosteroids	group	180-194	false
folic acid	drug	165-174	corticosteroids	group	180-194	false

DDI-DrugBank.d45.s7	Patients with Crohn s disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants.
immunosuppressants	group	43-60	immunosuppressants	group	135-152	false

DDI-DrugBank.d45.s8	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.
infliximab	drug	6-15	corticosteroids	group	136-150	false
infliximab	drug	6-15	antibiotics	group	153-163	false
infliximab	drug	6-15	metronidazole	drug	166-178	false
infliximab	drug	6-15	ciprofloxacin	drug	183-195	false
corticosteroids	group	136-150	antibiotics	group	153-163	false
corticosteroids	group	136-150	metronidazole	drug	166-178	false
corticosteroids	group	136-150	ciprofloxacin	drug	183-195	false
antibiotics	group	153-163	metronidazole	drug	166-178	false
antibiotics	group	153-163	ciprofloxacin	drug	183-195	false
metronidazole	drug	166-178	ciprofloxacin	drug	183-195	false

DDI-DrugBank.d195.s2	Anastrozole did not alter the pharmacokinetics of antipyrine.
Anastrozole	drug	0-10	antipyrine	drug	50-59	false

DDI-DrugBank.d195.s3	Although there have been no formal interaction studies other than with antipyrine, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of ARIMIDEX with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.
antipyrine	drug	71-80	ARIMIDEX	brand	184-191	false

DDI-DrugBank.d195.s4	An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.
warfarin	drug	26-33	anastrozole	drug	78-88	false
warfarin	drug	26-33	warfarin	drug	93-100	false
anastrozole	drug	78-88	warfarin	drug	93-100	false

DDI-DrugBank.d195.s5	At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.
ARIMIDEX	brand	55-62	tamoxifen	drug	68-76	false
ARIMIDEX	brand	55-62	tamoxifen	drug	138-146	false
tamoxifen	drug	68-76	tamoxifen	drug	138-146	false

DDI-DrugBank.d195.s7	Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
tamoxifen	drug	67-75	anastrozole	drug	109-119	advise

DDI-DrugBank.d195.s8	Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
anastrozole	drug	21-31	tamoxifen	drug	37-45	mechanism
anastrozole	drug	21-31	anastrozole	drug	74-84	false
anastrozole	drug	21-31	anastrozole	drug	141-151	false
tamoxifen	drug	37-45	anastrozole	drug	74-84	false
tamoxifen	drug	37-45	anastrozole	drug	141-151	false
anastrozole	drug	74-84	anastrozole	drug	141-151	false

DDI-DrugBank.d195.s9	Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.
Estrogen	group	0-7	ARIMIDEX	brand	54-61	advise

DDI-DrugBank.d245.s0	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
sulfonylurea	group	27-38	nonsteroidal anti-inflammatory agents	group	86-122	effect
sulfonylurea	group	27-38	salicylates	group	171-181	effect
sulfonylurea	group	27-38	sulfonamides	group	184-195	effect
sulfonylurea	group	27-38	chloramphenicol	drug	198-212	effect
sulfonylurea	group	27-38	probenecid	drug	215-224	effect
sulfonylurea	group	27-38	coumarins	group	227-235	effect
sulfonylurea	group	27-38	monoamine oxidase inhibitors	group	238-265	effect
sulfonylurea	group	27-38	beta adrenergic blocking agents	group	272-302	effect
nonsteroidal anti-inflammatory agents	group	86-122	salicylates	group	171-181	false
nonsteroidal anti-inflammatory agents	group	86-122	sulfonamides	group	184-195	false
nonsteroidal anti-inflammatory agents	group	86-122	chloramphenicol	drug	198-212	false
nonsteroidal anti-inflammatory agents	group	86-122	probenecid	drug	215-224	false
nonsteroidal anti-inflammatory agents	group	86-122	coumarins	group	227-235	false
nonsteroidal anti-inflammatory agents	group	86-122	monoamine oxidase inhibitors	group	238-265	false
nonsteroidal anti-inflammatory agents	group	86-122	beta adrenergic blocking agents	group	272-302	false
salicylates	group	171-181	sulfonamides	group	184-195	false
salicylates	group	171-181	chloramphenicol	drug	198-212	false
salicylates	group	171-181	probenecid	drug	215-224	false
salicylates	group	171-181	coumarins	group	227-235	false
salicylates	group	171-181	monoamine oxidase inhibitors	group	238-265	false
salicylates	group	171-181	beta adrenergic blocking agents	group	272-302	false
sulfonamides	group	184-195	chloramphenicol	drug	198-212	false
sulfonamides	group	184-195	probenecid	drug	215-224	false
sulfonamides	group	184-195	coumarins	group	227-235	false
sulfonamides	group	184-195	monoamine oxidase inhibitors	group	238-265	false
sulfonamides	group	184-195	beta adrenergic blocking agents	group	272-302	false
chloramphenicol	drug	198-212	probenecid	drug	215-224	false
chloramphenicol	drug	198-212	coumarins	group	227-235	false
chloramphenicol	drug	198-212	monoamine oxidase inhibitors	group	238-265	false
chloramphenicol	drug	198-212	beta adrenergic blocking agents	group	272-302	false
probenecid	drug	215-224	coumarins	group	227-235	false
probenecid	drug	215-224	monoamine oxidase inhibitors	group	238-265	false
probenecid	drug	215-224	beta adrenergic blocking agents	group	272-302	false
coumarins	group	227-235	monoamine oxidase inhibitors	group	238-265	false
coumarins	group	227-235	beta adrenergic blocking agents	group	272-302	false
monoamine oxidase inhibitors	group	238-265	beta adrenergic blocking agents	group	272-302	false

DDI-DrugBank.d245.s4	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
thiazides	group	24-32	diuretics	group	44-52	false
thiazides	group	24-32	corticosteroids	group	55-69	false
thiazides	group	24-32	phenothiazines	group	72-85	false
thiazides	group	24-32	estrogens	group	106-114	false
thiazides	group	24-32	contraceptives	group	122-135	false
thiazides	group	24-32	phenytoin	drug	138-146	false
thiazides	group	24-32	nicotinic acid	drug	149-162	false
thiazides	group	24-32	sympathomimetics	group	165-180	false
thiazides	group	24-32	calcium channel blocking drugs	group	183-212	false
thiazides	group	24-32	isoniazid	drug	219-227	false
diuretics	group	44-52	corticosteroids	group	55-69	false
diuretics	group	44-52	phenothiazines	group	72-85	false
diuretics	group	44-52	estrogens	group	106-114	false
diuretics	group	44-52	contraceptives	group	122-135	false
diuretics	group	44-52	phenytoin	drug	138-146	false
diuretics	group	44-52	nicotinic acid	drug	149-162	false
diuretics	group	44-52	sympathomimetics	group	165-180	false
diuretics	group	44-52	calcium channel blocking drugs	group	183-212	false
diuretics	group	44-52	isoniazid	drug	219-227	false
corticosteroids	group	55-69	phenothiazines	group	72-85	false
corticosteroids	group	55-69	estrogens	group	106-114	false
corticosteroids	group	55-69	contraceptives	group	122-135	false
corticosteroids	group	55-69	phenytoin	drug	138-146	false
corticosteroids	group	55-69	nicotinic acid	drug	149-162	false
corticosteroids	group	55-69	sympathomimetics	group	165-180	false
corticosteroids	group	55-69	calcium channel blocking drugs	group	183-212	false
corticosteroids	group	55-69	isoniazid	drug	219-227	false
phenothiazines	group	72-85	estrogens	group	106-114	false
phenothiazines	group	72-85	contraceptives	group	122-135	false
phenothiazines	group	72-85	phenytoin	drug	138-146	false
phenothiazines	group	72-85	nicotinic acid	drug	149-162	false
phenothiazines	group	72-85	sympathomimetics	group	165-180	false
phenothiazines	group	72-85	calcium channel blocking drugs	group	183-212	false
phenothiazines	group	72-85	isoniazid	drug	219-227	false
estrogens	group	106-114	contraceptives	group	122-135	false
estrogens	group	106-114	phenytoin	drug	138-146	false
estrogens	group	106-114	nicotinic acid	drug	149-162	false
estrogens	group	106-114	sympathomimetics	group	165-180	false
estrogens	group	106-114	calcium channel blocking drugs	group	183-212	false
estrogens	group	106-114	isoniazid	drug	219-227	false
contraceptives	group	122-135	phenytoin	drug	138-146	false
contraceptives	group	122-135	nicotinic acid	drug	149-162	false
contraceptives	group	122-135	sympathomimetics	group	165-180	false
contraceptives	group	122-135	calcium channel blocking drugs	group	183-212	false
contraceptives	group	122-135	isoniazid	drug	219-227	false
phenytoin	drug	138-146	nicotinic acid	drug	149-162	false
phenytoin	drug	138-146	sympathomimetics	group	165-180	false
phenytoin	drug	138-146	calcium channel blocking drugs	group	183-212	false
phenytoin	drug	138-146	isoniazid	drug	219-227	false
nicotinic acid	drug	149-162	sympathomimetics	group	165-180	false
nicotinic acid	drug	149-162	calcium channel blocking drugs	group	183-212	false
nicotinic acid	drug	149-162	isoniazid	drug	219-227	false
sympathomimetics	group	165-180	calcium channel blocking drugs	group	183-212	false
sympathomimetics	group	165-180	isoniazid	drug	219-227	false
calcium channel blocking drugs	group	183-212	isoniazid	drug	219-227	false

DDI-DrugBank.d245.s7	Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.
barbiturates	group	48-59	chlorpropamide	drug	94-107	effect
barbiturates	group	48-59	barbiturates	group	110-121	false
chlorpropamide	drug	94-107	barbiturates	group	110-121	false

DDI-DrugBank.d245.s8	In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.
disulfiram	drug	20-29	alcohol	drug	81-87	false

DDI-DrugBank.d245.s9	A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
miconazole	drug	37-46	hypoglycemic agents	group	57-75	effect

DDI-DrugBank.d57.s0	In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
aminoglycoside	group	22-35	antibiotics	group	58-68	effect
aminoglycoside	group	22-35	penicillins	group	71-81	effect
aminoglycoside	group	22-35	cephalosporins	group	86-99	effect
antibiotics	group	58-68	penicillins	group	71-81	false
antibiotics	group	58-68	cephalosporins	group	86-99	false
penicillins	group	71-81	cephalosporins	group	86-99	false

DDI-DrugBank.d57.s1	Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.
aminoglycoside	group	13-26	penicillin	group	34-43	mechanism
aminoglycoside	group	13-26	aminoglycoside	group	119-132	false
penicillin	group	34-43	aminoglycoside	group	119-132	false

DDI-DrugBank.d267.s0	Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX.
succinylcholine	drug	24-38	NUROMAX	brand	115-121	false

DDI-DrugBank.d267.s1	The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
NUROMAX	brand	11-17	succinylcholine	drug	26-40	false
NUROMAX	brand	11-17	succinylcholine	drug	83-97	false
succinylcholine	drug	26-40	succinylcholine	drug	83-97	false

DDI-DrugBank.d267.s2	There are no clinical data on concomitant use of NUROMAX and other nondepolarizing neuromuscular blocking agents.
NUROMAX	brand	49-55	neuromuscular blocking agents	group	83-111	false

DDI-DrugBank.d267.s3	Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
Isoflurane	drug	0-9	enflurane	drug	12-20	false
Isoflurane	drug	0-9	halothane	drug	27-35	false
Isoflurane	drug	0-9	NUROMAX	brand	58-64	mechanism
enflurane	drug	12-20	halothane	drug	27-35	false
enflurane	drug	12-20	NUROMAX	brand	58-64	mechanism
halothane	drug	27-35	NUROMAX	brand	58-64	mechanism

DDI-DrugBank.d267.s5	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
NUROMAX	brand	98-104	antibiotics	group	122-132	effect
NUROMAX	brand	98-104	aminoglycosides	group	142-156	effect
NUROMAX	brand	98-104	tetracyclines	group	159-171	effect
NUROMAX	brand	98-104	bacitracin	group	174-183	effect
NUROMAX	brand	98-104	polymyxins	group	186-195	effect
NUROMAX	brand	98-104	lincomycin	drug	198-207	effect
NUROMAX	brand	98-104	clindamycin	drug	210-220	effect
NUROMAX	brand	98-104	colistin	drug	223-230	effect
NUROMAX	brand	98-104	sodium colistimethate	drug	237-257	effect
NUROMAX	brand	98-104	magnesium	drug	261-269	effect
NUROMAX	brand	98-104	lithium	drug	278-284	effect
NUROMAX	brand	98-104	anesthetics	group	293-303	effect
NUROMAX	brand	98-104	procainamide	drug	306-317	effect
NUROMAX	brand	98-104	quinidine	drug	324-332	effect
antibiotics	group	122-132	aminoglycosides	group	142-156	false
antibiotics	group	122-132	tetracyclines	group	159-171	false
antibiotics	group	122-132	bacitracin	group	174-183	false
antibiotics	group	122-132	polymyxins	group	186-195	false
antibiotics	group	122-132	lincomycin	drug	198-207	false
antibiotics	group	122-132	clindamycin	drug	210-220	false
antibiotics	group	122-132	colistin	drug	223-230	false
antibiotics	group	122-132	sodium colistimethate	drug	237-257	false
antibiotics	group	122-132	magnesium	drug	261-269	false
antibiotics	group	122-132	lithium	drug	278-284	false
antibiotics	group	122-132	anesthetics	group	293-303	false
antibiotics	group	122-132	procainamide	drug	306-317	false
antibiotics	group	122-132	quinidine	drug	324-332	false
aminoglycosides	group	142-156	tetracyclines	group	159-171	false
aminoglycosides	group	142-156	bacitracin	group	174-183	false
aminoglycosides	group	142-156	polymyxins	group	186-195	false
aminoglycosides	group	142-156	lincomycin	drug	198-207	false
aminoglycosides	group	142-156	clindamycin	drug	210-220	false
aminoglycosides	group	142-156	colistin	drug	223-230	false
aminoglycosides	group	142-156	sodium colistimethate	drug	237-257	false
aminoglycosides	group	142-156	magnesium	drug	261-269	false
aminoglycosides	group	142-156	lithium	drug	278-284	false
aminoglycosides	group	142-156	anesthetics	group	293-303	false
aminoglycosides	group	142-156	procainamide	drug	306-317	false
aminoglycosides	group	142-156	quinidine	drug	324-332	false
tetracyclines	group	159-171	bacitracin	group	174-183	false
tetracyclines	group	159-171	polymyxins	group	186-195	false
tetracyclines	group	159-171	lincomycin	drug	198-207	false
tetracyclines	group	159-171	clindamycin	drug	210-220	false
tetracyclines	group	159-171	colistin	drug	223-230	false
tetracyclines	group	159-171	sodium colistimethate	drug	237-257	false
tetracyclines	group	159-171	magnesium	drug	261-269	false
tetracyclines	group	159-171	lithium	drug	278-284	false
tetracyclines	group	159-171	anesthetics	group	293-303	false
tetracyclines	group	159-171	procainamide	drug	306-317	false
tetracyclines	group	159-171	quinidine	drug	324-332	false
bacitracin	group	174-183	polymyxins	group	186-195	false
bacitracin	group	174-183	lincomycin	drug	198-207	false
bacitracin	group	174-183	clindamycin	drug	210-220	false
bacitracin	group	174-183	colistin	drug	223-230	false
bacitracin	group	174-183	sodium colistimethate	drug	237-257	false
bacitracin	group	174-183	magnesium	drug	261-269	false
bacitracin	group	174-183	lithium	drug	278-284	false
bacitracin	group	174-183	anesthetics	group	293-303	false
bacitracin	group	174-183	procainamide	drug	306-317	false
bacitracin	group	174-183	quinidine	drug	324-332	false
polymyxins	group	186-195	lincomycin	drug	198-207	false
polymyxins	group	186-195	clindamycin	drug	210-220	false
polymyxins	group	186-195	colistin	drug	223-230	false
polymyxins	group	186-195	sodium colistimethate	drug	237-257	false
polymyxins	group	186-195	magnesium	drug	261-269	false
polymyxins	group	186-195	lithium	drug	278-284	false
polymyxins	group	186-195	anesthetics	group	293-303	false
polymyxins	group	186-195	procainamide	drug	306-317	false
polymyxins	group	186-195	quinidine	drug	324-332	false
lincomycin	drug	198-207	clindamycin	drug	210-220	false
lincomycin	drug	198-207	colistin	drug	223-230	false
lincomycin	drug	198-207	sodium colistimethate	drug	237-257	false
lincomycin	drug	198-207	magnesium	drug	261-269	false
lincomycin	drug	198-207	lithium	drug	278-284	false
lincomycin	drug	198-207	anesthetics	group	293-303	false
lincomycin	drug	198-207	procainamide	drug	306-317	false
lincomycin	drug	198-207	quinidine	drug	324-332	false
clindamycin	drug	210-220	colistin	drug	223-230	false
clindamycin	drug	210-220	sodium colistimethate	drug	237-257	false
clindamycin	drug	210-220	magnesium	drug	261-269	false
clindamycin	drug	210-220	lithium	drug	278-284	false
clindamycin	drug	210-220	anesthetics	group	293-303	false
clindamycin	drug	210-220	procainamide	drug	306-317	false
clindamycin	drug	210-220	quinidine	drug	324-332	false
colistin	drug	223-230	sodium colistimethate	drug	237-257	false
colistin	drug	223-230	magnesium	drug	261-269	false
colistin	drug	223-230	lithium	drug	278-284	false
colistin	drug	223-230	anesthetics	group	293-303	false
colistin	drug	223-230	procainamide	drug	306-317	false
colistin	drug	223-230	quinidine	drug	324-332	false
sodium colistimethate	drug	237-257	magnesium	drug	261-269	false
sodium colistimethate	drug	237-257	lithium	drug	278-284	false
sodium colistimethate	drug	237-257	anesthetics	group	293-303	false
sodium colistimethate	drug	237-257	procainamide	drug	306-317	false
sodium colistimethate	drug	237-257	quinidine	drug	324-332	false
magnesium	drug	261-269	lithium	drug	278-284	false
magnesium	drug	261-269	anesthetics	group	293-303	false
magnesium	drug	261-269	procainamide	drug	306-317	false
magnesium	drug	261-269	quinidine	drug	324-332	false
lithium	drug	278-284	anesthetics	group	293-303	false
lithium	drug	278-284	procainamide	drug	306-317	false
lithium	drug	278-284	quinidine	drug	324-332	false
anesthetics	group	293-303	procainamide	drug	306-317	false
anesthetics	group	293-303	quinidine	drug	324-332	false
procainamide	drug	306-317	quinidine	drug	324-332	false

DDI-DrugBank.d267.s6	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
nondepolarizing neuromuscular blocking agents	group	19-63	NUROMAX	brand	118-124	false
nondepolarizing neuromuscular blocking agents	group	19-63	phenytoin	drug	201-209	effect
nondepolarizing neuromuscular blocking agents	group	19-63	carbamazepine	drug	214-226	effect
NUROMAX	brand	118-124	phenytoin	drug	201-209	effect
NUROMAX	brand	118-124	carbamazepine	drug	214-226	effect
phenytoin	drug	201-209	carbamazepine	drug	214-226	false

DDI-DrugBank.d20.s1	A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.
INSPRA	brand	74-79	ketoconazole	drug	93-104	mechanism
INSPRA	brand	74-79	eplerenone	drug	198-207	false
INSPRA	brand	74-79	eplerenone	drug	243-252	false
ketoconazole	drug	93-104	eplerenone	drug	198-207	false
ketoconazole	drug	93-104	eplerenone	drug	243-252	false
eplerenone	drug	198-207	eplerenone	drug	243-252	false

DDI-DrugBank.d20.s3	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
eplerenone	drug	18-27	erythromycin	drug	65-76	mechanism
eplerenone	drug	18-27	verapamil	drug	90-98	mechanism
eplerenone	drug	18-27	saquinavir	drug	111-120	mechanism
eplerenone	drug	18-27	fluconazole	drug	135-145	mechanism
eplerenone	drug	18-27	eplerenone	drug	191-200	false
erythromycin	drug	65-76	verapamil	drug	90-98	false
erythromycin	drug	65-76	saquinavir	drug	111-120	false
erythromycin	drug	65-76	fluconazole	drug	135-145	false
erythromycin	drug	65-76	eplerenone	drug	191-200	false
verapamil	drug	90-98	saquinavir	drug	111-120	false
verapamil	drug	90-98	fluconazole	drug	135-145	false
verapamil	drug	90-98	eplerenone	drug	191-200	false
saquinavir	drug	111-120	fluconazole	drug	135-145	false
saquinavir	drug	111-120	eplerenone	drug	191-200	false
fluconazole	drug	135-145	eplerenone	drug	191-200	false

DDI-DrugBank.d20.s4	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).
ACE Inhibitors	group	0-13	Angiotensin II Receptor Antagonists	group	19-53	false
ACE Inhibitors	group	0-13	INSPRA	brand	152-157	false
ACE Inhibitors	group	0-13	ACE inhibitors	group	185-198	false
ACE Inhibitors	group	0-13	angiotensin II receptor antagonists	group	203-237	false
ACE Inhibitors	group	0-13	ACEI	group	240-243	false
ACE Inhibitors	group	0-13	ARB	group	245-247	false
Angiotensin II Receptor Antagonists	group	19-53	INSPRA	brand	152-157	false
Angiotensin II Receptor Antagonists	group	19-53	ACE inhibitors	group	185-198	false
Angiotensin II Receptor Antagonists	group	19-53	angiotensin II receptor antagonists	group	203-237	false
Angiotensin II Receptor Antagonists	group	19-53	ACEI	group	240-243	false
Angiotensin II Receptor Antagonists	group	19-53	ARB	group	245-247	false
INSPRA	brand	152-157	ACE inhibitors	group	185-198	false
INSPRA	brand	152-157	angiotensin II receptor antagonists	group	203-237	false
INSPRA	brand	152-157	ACEI	group	240-243	false
INSPRA	brand	152-157	ARB	group	245-247	false
ACE inhibitors	group	185-198	angiotensin II receptor antagonists	group	203-237	false
ACE inhibitors	group	185-198	ACEI	group	240-243	false
ACE inhibitors	group	185-198	ARB	group	245-247	false
angiotensin II receptor antagonists	group	203-237	ACEI	group	240-243	false
angiotensin II receptor antagonists	group	203-237	ARB	group	245-247	false
ACEI	group	240-243	ARB	group	245-247	false

DDI-DrugBank.d20.s5	Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of ACEI/ARB.
ACEI	group	97-100	ARB	group	102-104	false

DDI-DrugBank.d20.s6	ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
ACE Inhibitors	group	0-13	Angiotensin II Receptor Antagonists	group	19-53	false
ACE Inhibitors	group	0-13	INSPRA	brand	138-143	false
ACE Inhibitors	group	0-13	ACE inhibitors	group	161-174	false
ACE Inhibitors	group	0-13	angiotensin II receptor antagonists	group	180-214	false
Angiotensin II Receptor Antagonists	group	19-53	INSPRA	brand	138-143	false
Angiotensin II Receptor Antagonists	group	19-53	ACE inhibitors	group	161-174	false
Angiotensin II Receptor Antagonists	group	19-53	angiotensin II receptor antagonists	group	180-214	false
INSPRA	brand	138-143	ACE inhibitors	group	161-174	effect
INSPRA	brand	138-143	angiotensin II receptor antagonists	group	180-214	effect
ACE inhibitors	group	161-174	angiotensin II receptor antagonists	group	180-214	false

DDI-DrugBank.d20.s7	In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.
INSPRA	brand	46-51	ACE inhibitor	group	78-90	false
INSPRA	brand	46-51	enalapril	drug	92-100	effect
INSPRA	brand	46-51	enalapril	drug	189-197	false
ACE inhibitor	group	78-90	enalapril	drug	92-100	false
ACE inhibitor	group	78-90	enalapril	drug	189-197	false
enalapril	drug	92-100	enalapril	drug	189-197	false

DDI-DrugBank.d20.s8	Lithium-A drug interaction study of eplerenone with lithium has not been conducted.
Lithium	drug	0-6	eplerenone	drug	36-45	false
Lithium	drug	0-6	lithium	drug	52-58	false
eplerenone	drug	36-45	lithium	drug	52-58	false

DDI-DrugBank.d20.s9	Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.
lithium	drug	6-12	INSPRA	brand	55-60	false
lithium	drug	6-12	lithium	drug	97-103	false
INSPRA	brand	55-60	lithium	drug	97-103	advise

DDI-DrugBank.d20.s10	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	NSAIDs	group	38-43	false
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	eplerenone	drug	74-83	false
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	NSAID	group	93-97	false
NSAIDs	group	38-43	eplerenone	drug	74-83	false
NSAIDs	group	38-43	NSAID	group	93-97	false
eplerenone	drug	74-83	NSAID	group	93-97	false

DDI-DrugBank.d20.s11	The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
potassium-sparing antihypertensives	group	28-62	NSAIDs	group	69-74	effect

DDI-DrugBank.d20.s12	Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.
INSPRA	brand	16-21	NSAIDs	group	27-32	advise

DDI-DrugBank.d491.s1	The duration of the period following treatment with AMEVIVE  before one should consider starting other immunosuppressive therapy has not been evaluated.
AMEVIVE	brand	52-58	immunosuppressive	group	103-119	false

DDI-DrugBank.d491.s16	Since the effect of AMEVIVE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking AMEVIVE who become pregnant into the Biogen Pregnancy Registry by calling 1-866-AMEVIVE (1-866-263-8483).
AMEVIVE	brand	20-26	AMEVIVE	brand	188-194	false
AMEVIVE	brand	20-26	AMEVIVE	brand	268-274	false
AMEVIVE	brand	188-194	AMEVIVE	brand	268-274	false

DDI-DrugBank.d479.s0	The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators.
isosorbide mononitrate	drug	28-49	vasodilators	group	87-98	effect

DDI-DrugBank.d479.s2	Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
calcium channel blockers	group	66-89	organic nitrates	group	95-110	effect

DDI-DrugBank.d544.s0	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil.
Simulect	brand	37-44	cyclosporine	drug	102-113	false
Simulect	brand	37-44	corticosteroids	group	116-130	false
Simulect	brand	37-44	azathioprine	drug	144-155	false
Simulect	brand	37-44	mycophenolate mofetil	drug	160-180	false
cyclosporine	drug	102-113	corticosteroids	group	116-130	false
cyclosporine	drug	102-113	azathioprine	drug	144-155	false
cyclosporine	drug	102-113	mycophenolate mofetil	drug	160-180	false
corticosteroids	group	116-130	azathioprine	drug	144-155	false
corticosteroids	group	116-130	mycophenolate mofetil	drug	160-180	false
azathioprine	drug	144-155	mycophenolate mofetil	drug	160-180	false

DDI-DrugBank.d544.s3	Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
Simulect	brand	24-31	azathioprine	drug	76-87	mechanism
Simulect	brand	24-31	mycophenolate mofetil	drug	93-113	mechanism
Simulect	brand	24-31	cyclosporine	drug	168-179	false
Simulect	brand	24-31	corticosteroids	group	201-215	false
azathioprine	drug	76-87	mycophenolate mofetil	drug	93-113	false
azathioprine	drug	76-87	cyclosporine	drug	168-179	false
azathioprine	drug	76-87	corticosteroids	group	201-215	false
mycophenolate mofetil	drug	93-113	cyclosporine	drug	168-179	false
mycophenolate mofetil	drug	93-113	corticosteroids	group	201-215	false
cyclosporine	drug	168-179	corticosteroids	group	201-215	false

DDI-DrugBank.d544.s4	Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
Simulect	brand	37-44	azathioprine	drug	82-93	false
Simulect	brand	37-44	mycophenolate mofetil	drug	111-131	false
azathioprine	drug	82-93	mycophenolate mofetil	drug	111-131	false

DDI-DrugBank.d544.s5	The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.
Simulect	brand	73-80	azathioprine	drug	130-141	false
Simulect	brand	73-80	corticosteroids	group	144-158	false
Simulect	brand	73-80	cyclosporine	drug	161-172	false
Simulect	brand	73-80	mycophenolate mofetil	drug	175-195	false
Simulect	brand	73-80	muromonab-CD3	drug	202-214	false
azathioprine	drug	130-141	corticosteroids	group	144-158	false
azathioprine	drug	130-141	cyclosporine	drug	161-172	false
azathioprine	drug	130-141	mycophenolate mofetil	drug	175-195	false
azathioprine	drug	130-141	muromonab-CD3	drug	202-214	false
corticosteroids	group	144-158	cyclosporine	drug	161-172	false
corticosteroids	group	144-158	mycophenolate mofetil	drug	175-195	false
corticosteroids	group	144-158	muromonab-CD3	drug	202-214	false
cyclosporine	drug	161-172	mycophenolate mofetil	drug	175-195	false
cyclosporine	drug	161-172	muromonab-CD3	drug	202-214	false
mycophenolate mofetil	drug	175-195	muromonab-CD3	drug	202-214	false

DDI-DrugBank.d318.s0	When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.
amphotericin B	drug	70-83	Antineoplastic agents	group	86-106	effect

DDI-DrugBank.d318.s1	Antineoplastic agents (e. g., nitrogen mustard, etc.) should be given concomitantly only with great caution.
Antineoplastic agents	group	0-20	nitrogen mustard	drug	30-45	false

DDI-DrugBank.d318.s2	Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
Corticosteroids	group	0-14	Corticotropin	drug	20-32	false
Corticosteroids	group	0-14	ACTH	group	35-38	false
Corticosteroids	group	0-14	amphotericin B	drug	57-70	effect
Corticotropin	drug	20-32	ACTH	group	35-38	false
Corticotropin	drug	20-32	amphotericin B	drug	57-70	effect
ACTH	group	35-38	amphotericin B	drug	57-70	effect

DDI-DrugBank.d318.s5	Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.
Digitalis glycosides	group	0-19	amphotericin B	drug	22-35	false
Digitalis glycosides	group	0-19	digitalis	group	72-80	false
amphotericin B	drug	22-35	digitalis	group	72-80	effect

DDI-DrugBank.d318.s7	Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
Flucytosine	drug	0-10	amphotericin B	drug	51-64	false
Flucytosine	drug	0-10	flucytosine	drug	130-140	false
amphotericin B	drug	51-64	flucytosine	drug	130-140	effect

DDI-DrugBank.d318.s8	Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
Imidazoles	group	0-9	ketoconazole	drug	19-30	false
Imidazoles	group	0-9	miconazole	drug	33-42	false
Imidazoles	group	0-9	clotrimazole	drug	45-56	false
Imidazoles	group	0-9	fluconazole	drug	59-69	false
Imidazoles	group	0-9	amphotericin B	drug	131-144	false
Imidazoles	group	0-9	imidazoles	group	150-159	false
Imidazoles	group	0-9	imidazoles	group	174-183	false
Imidazoles	group	0-9	amphotericin B	drug	217-230	false
ketoconazole	drug	19-30	miconazole	drug	33-42	false
ketoconazole	drug	19-30	clotrimazole	drug	45-56	false
ketoconazole	drug	19-30	fluconazole	drug	59-69	false
ketoconazole	drug	19-30	amphotericin B	drug	131-144	false
ketoconazole	drug	19-30	imidazoles	group	150-159	false
ketoconazole	drug	19-30	imidazoles	group	174-183	false
ketoconazole	drug	19-30	amphotericin B	drug	217-230	false
miconazole	drug	33-42	clotrimazole	drug	45-56	false
miconazole	drug	33-42	fluconazole	drug	59-69	false
miconazole	drug	33-42	amphotericin B	drug	131-144	false
miconazole	drug	33-42	imidazoles	group	150-159	false
miconazole	drug	33-42	imidazoles	group	174-183	false
miconazole	drug	33-42	amphotericin B	drug	217-230	false
clotrimazole	drug	45-56	fluconazole	drug	59-69	false
clotrimazole	drug	45-56	amphotericin B	drug	131-144	false
clotrimazole	drug	45-56	imidazoles	group	150-159	false
clotrimazole	drug	45-56	imidazoles	group	174-183	false
clotrimazole	drug	45-56	amphotericin B	drug	217-230	false
fluconazole	drug	59-69	amphotericin B	drug	131-144	false
fluconazole	drug	59-69	imidazoles	group	150-159	false
fluconazole	drug	59-69	imidazoles	group	174-183	false
fluconazole	drug	59-69	amphotericin B	drug	217-230	false
amphotericin B	drug	131-144	imidazoles	group	150-159	false
amphotericin B	drug	131-144	imidazoles	group	174-183	false
amphotericin B	drug	131-144	amphotericin B	drug	217-230	false
imidazoles	group	150-159	imidazoles	group	174-183	false
imidazoles	group	150-159	amphotericin B	drug	217-230	false
imidazoles	group	174-183	amphotericin B	drug	217-230	effect

DDI-DrugBank.d318.s10	Other nephrotoxic medications: agents such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
aminoglycosides	group	46-60	cyclosporine	drug	63-74	false
aminoglycosides	group	46-60	pentamidine	drug	81-91	false
cyclosporine	drug	63-74	pentamidine	drug	81-91	false

DDI-DrugBank.d318.s12	Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
Skeletal muscle relaxants	group	0-24	amphotericin B	drug	27-40	false
Skeletal muscle relaxants	group	0-24	skeletal muscle relaxants	group	99-123	false
Skeletal muscle relaxants	group	0-24	tubocurarine	drug	132-143	false
amphotericin B	drug	27-40	skeletal muscle relaxants	group	99-123	effect
amphotericin B	drug	27-40	tubocurarine	drug	132-143	effect
skeletal muscle relaxants	group	99-123	tubocurarine	drug	132-143	false

DDI-DrugBank.d318.s14	Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.
Leukocyte transfusions	drug_n	0-21	amphotericin B	drug	101-114	false
Leukocyte transfusions	drug_n	0-21	leukocyte transfusions	drug_n	120-141	false
amphotericin B	drug	101-114	leukocyte transfusions	drug_n	120-141	effect

DDI-DrugBank.d413.s2	Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
Mercaptopurine	drug	0-13	Azathioprine	drug	15-26	false
Mercaptopurine	drug	0-13	Allopurinol	drug	29-39	false
Mercaptopurine	drug	0-13	mercaptopurine	drug	77-90	false
Mercaptopurine	drug	0-13	azathioprine	drug	96-107	false
Mercaptopurine	drug	0-13	6-thiouric acid	drug	112-126	false
Azathioprine	drug	15-26	Allopurinol	drug	29-39	false
Azathioprine	drug	15-26	mercaptopurine	drug	77-90	false
Azathioprine	drug	15-26	azathioprine	drug	96-107	false
Azathioprine	drug	15-26	6-thiouric acid	drug	112-126	false
Allopurinol	drug	29-39	mercaptopurine	drug	77-90	mechanism
Allopurinol	drug	29-39	azathioprine	drug	96-107	mechanism
Allopurinol	drug	29-39	6-thiouric acid	drug	112-126	false
mercaptopurine	drug	77-90	azathioprine	drug	96-107	false
mercaptopurine	drug	77-90	6-thiouric acid	drug	112-126	false
azathioprine	drug	96-107	6-thiouric acid	drug	112-126	false

DDI-DrugBank.d413.s4	In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
mercaptopurine	drug	22-35	Purinethol	brand	38-47	false
mercaptopurine	drug	22-35	azathioprine	drug	53-64	false
mercaptopurine	drug	22-35	Imuran	brand	67-72	false
mercaptopurine	drug	22-35	allopurinol	drug	124-134	false
mercaptopurine	drug	22-35	mercaptopurine	drug	239-252	false
mercaptopurine	drug	22-35	azathioprine	drug	257-268	false
Purinethol	brand	38-47	azathioprine	drug	53-64	false
Purinethol	brand	38-47	Imuran	brand	67-72	false
Purinethol	brand	38-47	allopurinol	drug	124-134	false
Purinethol	brand	38-47	mercaptopurine	drug	239-252	false
Purinethol	brand	38-47	azathioprine	drug	257-268	false
azathioprine	drug	53-64	Imuran	brand	67-72	false
azathioprine	drug	53-64	allopurinol	drug	124-134	false
azathioprine	drug	53-64	mercaptopurine	drug	239-252	false
azathioprine	drug	53-64	azathioprine	drug	257-268	false
Imuran	brand	67-72	allopurinol	drug	124-134	false
Imuran	brand	67-72	mercaptopurine	drug	239-252	false
Imuran	brand	67-72	azathioprine	drug	257-268	false
allopurinol	drug	124-134	mercaptopurine	drug	239-252	advise
allopurinol	drug	124-134	azathioprine	drug	257-268	advise
mercaptopurine	drug	239-252	azathioprine	drug	257-268	false

DDI-DrugBank.d413.s5	Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.
mercaptopurine	drug	34-47	azathioprine	drug	52-63	false

DDI-DrugBank.d413.s6	Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.
Dicumarol	drug	0-8	allopurinol	drug	37-47	false
Dicumarol	drug	0-8	anticoagulant	group	79-91	false
Dicumarol	drug	0-8	dicumarol	drug	94-102	false
allopurinol	drug	37-47	anticoagulant	group	79-91	false
allopurinol	drug	37-47	dicumarol	drug	94-102	mechanism
anticoagulant	group	79-91	dicumarol	drug	94-102	false

DDI-DrugBank.d413.s7	The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.
allopurinol	drug	94-104	dicumarol	drug	138-146	false

DDI-DrugBank.d413.s9	Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
Uricosuric Agents	group	0-16	oxipurinol	drug	42-51	false
Uricosuric Agents	group	0-16	uricosuric agents	group	82-98	false
Uricosuric Agents	group	0-16	oxipurinol	drug	185-194	false
oxipurinol	drug	42-51	uricosuric agents	group	82-98	false
oxipurinol	drug	42-51	oxipurinol	drug	185-194	false
uricosuric agents	group	82-98	oxipurinol	drug	185-194	mechanism

DDI-DrugBank.d413.s10	The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
uricosuric agents	group	34-50	allopurinol	drug	56-66	mechanism
uricosuric agents	group	34-50	allopurinol	drug	243-253	false
allopurinol	drug	56-66	allopurinol	drug	243-253	false

DDI-DrugBank.d413.s11	Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents, the possibility should be kept in mind.
allopurinol	drug	112-122	uricosuric agents	group	153-169	false

DDI-DrugBank.d413.s12	Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
Thiazide Diuretics	group	0-17	allopurinol	drug	60-70	false
Thiazide Diuretics	group	0-17	thiazide diuretics	group	76-93	false
Thiazide Diuretics	group	0-17	allopurinol	drug	132-142	false
allopurinol	drug	60-70	thiazide diuretics	group	76-93	effect
allopurinol	drug	60-70	allopurinol	drug	132-142	false
thiazide diuretics	group	76-93	allopurinol	drug	132-142	false

DDI-DrugBank.d413.s15	Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..
thiazide diuretics	group	172-189	allopurinol	drug	195-205	advise

DDI-DrugBank.d413.s16	Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
Ampicillin	drug	0-9	Amoxicillin	drug	11-21	false
Ampicillin	drug	0-9	ampicillin	drug	109-118	false
Ampicillin	drug	0-9	amoxicillin	drug	123-133	false
Ampicillin	drug	0-9	allopurinol	drug	153-163	false
Amoxicillin	drug	11-21	ampicillin	drug	109-118	false
Amoxicillin	drug	11-21	amoxicillin	drug	123-133	false
Amoxicillin	drug	11-21	allopurinol	drug	153-163	false
ampicillin	drug	109-118	amoxicillin	drug	123-133	false
ampicillin	drug	109-118	allopurinol	drug	153-163	effect
amoxicillin	drug	123-133	allopurinol	drug	153-163	effect

DDI-DrugBank.d413.s18	Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
Cytotoxic Agents	group	0-15	cyclophosphamide	drug	54-69	false
Cytotoxic Agents	group	0-15	cytotoxic agents	group	81-96	false
Cytotoxic Agents	group	0-15	allopurinol	drug	192-202	false
cyclophosphamide	drug	54-69	cytotoxic agents	group	81-96	false
cyclophosphamide	drug	54-69	allopurinol	drug	192-202	effect
cytotoxic agents	group	81-96	allopurinol	drug	192-202	effect

DDI-DrugBank.d413.s19	However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechlorethamine.
allopurinol	drug	86-96	cyclophosphamide	drug	160-175	false
allopurinol	drug	86-96	doxorubicin	drug	178-188	false
allopurinol	drug	86-96	bleomycin	drug	191-199	false
allopurinol	drug	86-96	procarbazine	drug	202-213	false
allopurinol	drug	86-96	mechlorethamine	drug	222-236	false
cyclophosphamide	drug	160-175	doxorubicin	drug	178-188	false
cyclophosphamide	drug	160-175	bleomycin	drug	191-199	false
cyclophosphamide	drug	160-175	procarbazine	drug	202-213	false
cyclophosphamide	drug	160-175	mechlorethamine	drug	222-236	false
doxorubicin	drug	178-188	bleomycin	drug	191-199	false
doxorubicin	drug	178-188	procarbazine	drug	202-213	false
doxorubicin	drug	178-188	mechlorethamine	drug	222-236	false
bleomycin	drug	191-199	procarbazine	drug	202-213	false
bleomycin	drug	191-199	mechlorethamine	drug	222-236	false
procarbazine	drug	202-213	mechlorethamine	drug	222-236	false

DDI-DrugBank.d413.s20	Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
Chlorpropamide	drug	0-13	Chlorpropamide	drug	16-29	false
Chlorpropamide	drug	0-13	allopurinol	drug	69-79	false
Chlorpropamide	drug	0-13	allopurinol	drug	88-98	false
Chlorpropamide	drug	0-13	chlorpropamide	drug	104-117	false
Chlorpropamide	drug	16-29	allopurinol	drug	69-79	mechanism
Chlorpropamide	drug	16-29	allopurinol	drug	88-98	false
Chlorpropamide	drug	16-29	chlorpropamide	drug	104-117	false
allopurinol	drug	69-79	allopurinol	drug	88-98	false
allopurinol	drug	69-79	chlorpropamide	drug	104-117	false
allopurinol	drug	88-98	chlorpropamide	drug	104-117	mechanism

DDI-DrugBank.d413.s21	The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
allopurinol	drug	73-83	chlorpropamide	drug	89-102	effect

DDI-DrugBank.d413.s22	Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.
Cyclosporin	drug	0-10	cyclosporine	drug	35-46	false
Cyclosporin	drug	0-10	allopurinol sodium	drug	106-123	false
cyclosporine	drug	35-46	allopurinol sodium	drug	106-123	mechanism

DDI-DrugBank.d413.s23	Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.
cyclosporine	drug	14-25	cyclosporine	drug	61-72	false

DDI-DrugBank.d196.s0	Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.
PEGASYS	brand	15-21	theophylline	drug	135-146	mechanism

DDI-DrugBank.d196.s1	Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.
Theophylline	drug	0-11	theophylline	drug	114-125	false
Theophylline	drug	0-11	PEGASYS	brand	131-137	false
theophylline	drug	114-125	PEGASYS	brand	131-137	advise

DDI-DrugBank.d196.s3	In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS, PEGASYS treatment did not affect ribavirin distribution or clearance.
PEGASYS	brand	50-56	COPEGUS	brand	78-84	false
PEGASYS	brand	50-56	PEGASYS	brand	87-93	false
PEGASYS	brand	50-56	ribavirin	drug	120-128	false
COPEGUS	brand	78-84	PEGASYS	brand	87-93	false
COPEGUS	brand	78-84	ribavirin	drug	120-128	false
PEGASYS	brand	87-93	ribavirin	drug	120-128	false

DDI-DrugBank.d196.s4	Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.
Didanosine	drug	21-30	COPEGUS	brand	53-59	false
Didanosine	drug	21-30	didanosine	drug	65-74	false
COPEGUS	brand	53-59	didanosine	drug	65-74	advise

DDI-DrugBank.d196.s6	Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
Stavudine	drug	0-8	Zidovudine	drug	14-23	false
Stavudine	drug	0-8	Ribavirin	drug	25-33	false
Stavudine	drug	0-8	stavudine	drug	85-93	false
Stavudine	drug	0-8	zidovudine	drug	99-108	false
Zidovudine	drug	14-23	Ribavirin	drug	25-33	false
Zidovudine	drug	14-23	stavudine	drug	85-93	false
Zidovudine	drug	14-23	zidovudine	drug	99-108	false
Ribavirin	drug	25-33	stavudine	drug	85-93	effect
Ribavirin	drug	25-33	zidovudine	drug	99-108	effect
stavudine	drug	85-93	zidovudine	drug	99-108	false

DDI-DrugBank.d196.s10	Use With Ribavirin Ribavirin is genotoxic and mutagenic.
Ribavirin	drug	9-17	Ribavirin	drug	19-27	false

DDI-DrugBank.d196.s29	Pregnancy: Category X: Use With Ribavirin (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin.
Ribavirin	drug	32-40	ribavirin	drug	173-181	false

DDI-DrugBank.d196.s32	Nursing Mothers It is not known whether peginterferon or ribavirin or its components are excreted in human milk.
peginterferon	drug	40-52	ribavirin	drug	57-65	false

DDI-DrugBank.d196.s33	The effect of orally ingested peginterferon or ribavirin from breast milk on the nursing infant has not been evaluated.
peginterferon	drug	30-42	ribavirin	drug	47-55	false

DDI-DrugBank.d196.s34	Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue PEGASYS and COPEGUS treatment.
PEGASYS	brand	152-158	COPEGUS	brand	164-170	false

DDI-DrugBank.d196.s35	Pediatric Use The safety and effectiveness of PEGASYS, alone or in combination with COPEGUS in patients below the age of 18 years have not been established.
PEGASYS	brand	46-52	COPEGUS	brand	84-90	false

DDI-DrugBank.d196.s36	PEGASYS contains benzyl alcohol.
PEGASYS	brand	0-6	benzyl alcohol	drug_n	17-30	false

DDI-DrugBank.d196.s39	Clinical studies of PEGASYS alone or in combination with COPEGUS did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.
PEGASYS	brand	20-26	COPEGUS	brand	57-63	false

DDI-DrugBank.d196.s40	Adverse reactions related to alpha interferons, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of PEGASYS in this population.
alpha interferon	drug	29-44	PEGASYS	brand	186-192	false

DDI-DrugBank.d196.s41	PEGASYS and COPEGUS are excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function.
PEGASYS	brand	0-6	COPEGUS	brand	12-18	false

DDI-DrugBank.d196.s43	PEGASYS should be used with caution in patients with creatinine clearance  50 mL/min and COPEGUS should not be administered to patients with creatinine clearance  50 mL/min
PEGASYS	brand	0-6	COPEGUS	brand	89-95	false

DDI-DrugBank.d427.s0	Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
theophylline	drug	26-37	quinolone	group	75-83	mechanism

DDI-DrugBank.d427.s1	There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.
theophylline	drug	27-38	quinolones	group	101-110	false
theophylline	drug	27-38	theophylline	drug	116-127	false
quinolones	group	101-110	theophylline	drug	116-127	effect

DDI-DrugBank.d427.s2	Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.
theophylline	drug	25-36	theophylline	drug	87-98	false

DDI-DrugBank.d427.s3	Quinolones have been shown to interfere with the metabolism of caffeine.
Quinolones	group	0-9	caffeine	drug	63-70	mechanism

DDI-DrugBank.d427.s5	Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
Quinolones	group	0-9	nalidixic acid	drug	22-35	false
Quinolones	group	0-9	anticoagulant	group	74-86	false
Quinolones	group	0-9	warfarin	drug	88-95	effect
nalidixic acid	drug	22-35	anticoagulant	group	74-86	false
nalidixic acid	drug	22-35	warfarin	drug	88-95	effect
anticoagulant	group	74-86	warfarin	drug	88-95	false

DDI-DrugBank.d427.s7	Nitrofurantoin interferes with the therapeutic action of nalidixic acid.
Nitrofurantoin	drug	0-13	nalidixic acid	drug	57-70	effect

DDI-DrugBank.d427.s8	Antacids containing magnesium, aluminum, or calcium;
Antacids	group	0-7	magnesium	drug	20-28	false
Antacids	group	0-7	aluminum	drug	31-38	false
Antacids	group	0-7	calcium	drug	44-50	false
magnesium	drug	20-28	aluminum	drug	31-38	false
magnesium	drug	20-28	calcium	drug	44-50	false
aluminum	drug	31-38	calcium	drug	44-50	false

DDI-DrugBank.d427.s9	sucralfate or divalent or trivalent cations such as iron;
sucralfate	drug	0-9	iron	drug	52-55	false

DDI-DrugBank.d427.s10	multivitamins containing zinc;
multivitamins	group	0-12	zinc	drug	25-28	false

DDI-DrugBank.d427.s11	and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.
Videx	brand	4-8	Didanosine	drug	13-22	false
Videx	brand	4-8	quinolones	group	145-154	mechanism
Didanosine	drug	13-22	quinolones	group	145-154	mechanism

DDI-DrugBank.d427.s13	Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.
cyclosporine	drug	25-36	quinolones	group	90-99	false
cyclosporine	drug	25-36	cyclosporine	drug	105-116	false
quinolones	group	90-99	cyclosporine	drug	105-116	mechanism

DDI-DrugBank.d427.s14	Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
cyclosporine	drug	11-22	cyclosporine	drug	73-84	false

DDI-DrugBank.d254.s0	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
CNS depressant drugs	group	6-25	barbiturates	group	33-44	false
CNS depressant drugs	group	6-25	tranquilizers	group	47-59	false
CNS depressant drugs	group	6-25	opioids	group	62-68	false
CNS depressant drugs	group	6-25	anesthetics	group	82-92	false
CNS depressant drugs	group	6-25	INAPSINE	brand	138-145	effect
barbiturates	group	33-44	tranquilizers	group	47-59	false
barbiturates	group	33-44	opioids	group	62-68	false
barbiturates	group	33-44	anesthetics	group	82-92	false
barbiturates	group	33-44	INAPSINE	brand	138-145	effect
tranquilizers	group	47-59	opioids	group	62-68	false
tranquilizers	group	47-59	anesthetics	group	82-92	false
tranquilizers	group	47-59	INAPSINE	brand	138-145	effect
opioids	group	62-68	anesthetics	group	82-92	false
opioids	group	62-68	INAPSINE	brand	138-145	effect
anesthetics	group	82-92	INAPSINE	brand	138-145	effect

DDI-DrugBank.d254.s2	Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.
INAPSINE	brand	32-39	CNS depressant drugs	group	60-79	advise

DDI-DrugBank.d503.s0	Chlorprothixene may increase the plasma-level of concomitantly given lithium.
Chlorprothixene	drug	0-14	lithium	drug	69-75	mechanism

DDI-DrugBank.d503.s1	In order to avoid lithium intoxication, lithium plasma levels should be monitored closely.
lithium	drug	18-24	lithium	drug	40-46	false

DDI-DrugBank.d503.s2	If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
chlorprothixene	drug	3-17	opioids	group	47-53	advise
chlorprothixene	drug	3-17	opioid	group	60-65	false
chlorprothixene	drug	3-17	chlorprothixene	drug	116-130	false
chlorprothixene	drug	3-17	opioids	group	186-192	false
opioids	group	47-53	opioid	group	60-65	false
opioids	group	47-53	chlorprothixene	drug	116-130	false
opioids	group	47-53	opioids	group	186-192	false
opioid	group	60-65	chlorprothixene	drug	116-130	false
opioid	group	60-65	opioids	group	186-192	false
chlorprothixene	drug	116-130	opioids	group	186-192	effect

DDI-DrugBank.d503.s3	Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
chlorprothixene	drug	29-43	tramadol	drug	49-56	advise
chlorprothixene	drug	29-43	Ultram	brand	59-64	advise
tramadol	drug	49-56	Ultram	brand	59-64	false

DDI-DrugBank.d503.s5	Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
chlorprothixene	drug	72-86	benzodiazepines	group	102-116	effect
chlorprothixene	drug	72-86	barbituates	group	121-131	effect
benzodiazepines	group	102-116	barbituates	group	121-131	false

DDI-DrugBank.d503.s7	Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
chlorprothixene	drug	38-52	anticholinergic drugs	group	65-85	advise
chlorprothixene	drug	38-52	tricyclic antidepressants	group	88-112	advise
chlorprothixene	drug	38-52	antiparkinsonian agents	group	118-140	advise
anticholinergic drugs	group	65-85	tricyclic antidepressants	group	88-112	false
anticholinergic drugs	group	65-85	antiparkinsonian agents	group	118-140	false
tricyclic antidepressants	group	88-112	antiparkinsonian agents	group	118-140	false

DDI-DrugBank.d463.s0	It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
buspirone hydrochloride	drug	23-45	MAO inhibitors	group	78-91	advise
buspirone hydrochloride	drug	23-45	buspirone HCl	drug	146-158	false
buspirone hydrochloride	drug	23-45	psychotropic drugs	group	176-193	false
buspirone hydrochloride	drug	23-45	buspirone HCl	drug	241-253	false
MAO inhibitors	group	78-91	buspirone HCl	drug	146-158	false
MAO inhibitors	group	78-91	psychotropic drugs	group	176-193	false
MAO inhibitors	group	78-91	buspirone HCl	drug	241-253	false
buspirone HCl	drug	146-158	psychotropic drugs	group	176-193	false
buspirone HCl	drug	146-158	buspirone HCl	drug	241-253	false
psychotropic drugs	group	176-193	buspirone HCl	drug	241-253	false

DDI-DrugBank.d463.s1	There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
trazodone hydrochloride	drug	59-81	Desyrel	brand	84-90	false
trazodone hydrochloride	drug	59-81	buspirone HCl	drug	97-109	effect
Desyrel	brand	84-90	buspirone HCl	drug	97-109	effect

DDI-DrugBank.d463.s3	In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.
buspirone HCl	drug	63-75	haloperidol	drug	81-91	mechanism
buspirone HCl	drug	63-75	haloperidol	drug	121-131	false
haloperidol	drug	81-91	haloperidol	drug	121-131	false

DDI-DrugBank.d463.s5	In vitro, buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins.
buspirone	drug	10-18	phenytoin	drug	63-71	false
buspirone	drug	10-18	propranolol	drug	74-84	false
buspirone	drug	10-18	warfarin	drug	91-98	false
phenytoin	drug	63-71	propranolol	drug	74-84	false
phenytoin	drug	63-71	warfarin	drug	91-98	false
propranolol	drug	74-84	warfarin	drug	91-98	false

DDI-DrugBank.d463.s6	However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.
buspirone	drug	70-78	warfarin	drug	131-138	effect

DDI-DrugBank.d463.s7	The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and levothyroxine sodium.
phenytoin	drug	43-51	phenobarbital	drug	54-66	false
phenytoin	drug	43-51	digoxin	drug	69-75	false
phenytoin	drug	43-51	levothyroxine sodium	drug	82-101	false
phenobarbital	drug	54-66	digoxin	drug	69-75	false
phenobarbital	drug	54-66	levothyroxine sodium	drug	82-101	false
digoxin	drug	69-75	levothyroxine sodium	drug	82-101	false

DDI-DrugBank.d463.s8	In vitro, buspirone may displace less firmly bound drugs like digoxin.
buspirone	drug	10-18	digoxin	drug	62-68	mechanism

DDI-DrugBank.d365.s0	Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.
Medroxyprogesterone Acetate	drug	0-26	L-histidine	drug	30-40	false
Medroxyprogesterone Acetate	drug	0-26	medroxyprogesterone acetate	drug	100-126	false
L-histidine	drug	30-40	medroxyprogesterone acetate	drug	100-126	effect

DDI-DrugBank.d365.s1	H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
H1 Blockers	group	0-1;10-17	H2 Blockers	group	7-17	false
H1 Blockers	group	0-1;10-17	L-histidine	drug	44-54	false
H1 Blockers	group	0-1;10-17	H1 blockers	group	121-122;131-138	false
H1 Blockers	group	0-1;10-17	H2 blockers	group	128-138	false
H2 Blockers	group	7-17	L-histidine	drug	44-54	false
H2 Blockers	group	7-17	H1 blockers	group	121-122;131-138	false
H2 Blockers	group	7-17	H2 blockers	group	128-138	false
L-histidine	drug	44-54	H1 blockers	group	121-122;131-138	effect
L-histidine	drug	44-54	H2 blockers	group	128-138	effect
H1 blockers	group	121-122;131-138	H2 blockers	group	128-138	false

DDI-DrugBank.d535.s1	Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.
Antiretroviral Agents	group	0-20	antiretroviral medications	group	55-80	false
Antiretroviral Agents	group	0-20	enfuvirtide	drug	147-157	false
Antiretroviral Agents	group	0-20	antiretroviral medication	group	189-213	false
antiretroviral medications	group	55-80	enfuvirtide	drug	147-157	false
antiretroviral medications	group	55-80	antiretroviral medication	group	189-213	false
enfuvirtide	drug	147-157	antiretroviral medication	group	189-213	false

DDI-DrugBank.d197.s1	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
Anesthetics	group	0-10	Sedatives	group	12-20	false
Anesthetics	group	0-10	Hypnotics	group	22-30	false
Anesthetics	group	0-10	Opioids	group	32-38	false
Anesthetics	group	0-10	PRECEDEX	brand	62-69	false
Anesthetics	group	0-10	anesthetics	group	76-86	false
Anesthetics	group	0-10	sedatives	group	89-97	false
Anesthetics	group	0-10	hypnotics	group	100-108	false
Anesthetics	group	0-10	opioids	group	115-121	false
Sedatives	group	12-20	Hypnotics	group	22-30	false
Sedatives	group	12-20	Opioids	group	32-38	false
Sedatives	group	12-20	PRECEDEX	brand	62-69	false
Sedatives	group	12-20	anesthetics	group	76-86	false
Sedatives	group	12-20	sedatives	group	89-97	false
Sedatives	group	12-20	hypnotics	group	100-108	false
Sedatives	group	12-20	opioids	group	115-121	false
Hypnotics	group	22-30	Opioids	group	32-38	false
Hypnotics	group	22-30	PRECEDEX	brand	62-69	false
Hypnotics	group	22-30	anesthetics	group	76-86	false
Hypnotics	group	22-30	sedatives	group	89-97	false
Hypnotics	group	22-30	hypnotics	group	100-108	false
Hypnotics	group	22-30	opioids	group	115-121	false
Opioids	group	32-38	PRECEDEX	brand	62-69	false
Opioids	group	32-38	anesthetics	group	76-86	false
Opioids	group	32-38	sedatives	group	89-97	false
Opioids	group	32-38	hypnotics	group	100-108	false
Opioids	group	32-38	opioids	group	115-121	false
PRECEDEX	brand	62-69	anesthetics	group	76-86	effect
PRECEDEX	brand	62-69	sedatives	group	89-97	effect
PRECEDEX	brand	62-69	hypnotics	group	100-108	effect
PRECEDEX	brand	62-69	opioids	group	115-121	effect
anesthetics	group	76-86	sedatives	group	89-97	false
anesthetics	group	76-86	hypnotics	group	100-108	false
anesthetics	group	76-86	opioids	group	115-121	false
sedatives	group	89-97	hypnotics	group	100-108	false
sedatives	group	89-97	opioids	group	115-121	false
hypnotics	group	100-108	opioids	group	115-121	false

DDI-DrugBank.d197.s2	Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.
sevoflurane	drug	51-61	isoflurane	drug	64-73	false
sevoflurane	drug	51-61	propofol	drug	76-83	false
sevoflurane	drug	51-61	alfentanil	drug	86-95	false
sevoflurane	drug	51-61	midazolam	drug	102-110	false
isoflurane	drug	64-73	propofol	drug	76-83	false
isoflurane	drug	64-73	alfentanil	drug	86-95	false
isoflurane	drug	64-73	midazolam	drug	102-110	false
propofol	drug	76-83	alfentanil	drug	86-95	false
propofol	drug	76-83	midazolam	drug	102-110	false
alfentanil	drug	86-95	midazolam	drug	102-110	false

DDI-DrugBank.d197.s3	No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.
dexmedetomidine	drug	40-54	isoflurane	drug	60-69	false
dexmedetomidine	drug	40-54	propofol	drug	72-79	false
dexmedetomidine	drug	40-54	alfentanil	drug	82-91	false
dexmedetomidine	drug	40-54	midazolam	drug	98-106	false
isoflurane	drug	60-69	propofol	drug	72-79	false
isoflurane	drug	60-69	alfentanil	drug	82-91	false
isoflurane	drug	60-69	midazolam	drug	98-106	false
propofol	drug	72-79	alfentanil	drug	82-91	false
propofol	drug	72-79	midazolam	drug	98-106	false
alfentanil	drug	82-91	midazolam	drug	98-106	false

DDI-DrugBank.d197.s4	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
PRECEDEX	brand	81-88	PRECEDEX	brand	116-123	false
PRECEDEX	brand	81-88	anesthetic	group	144-153	false
PRECEDEX	brand	81-88	sedative	group	156-163	false
PRECEDEX	brand	81-88	hypnotic	group	166-173	false
PRECEDEX	brand	81-88	opioid	group	178-183	false
PRECEDEX	brand	116-123	anesthetic	group	144-153	advise
PRECEDEX	brand	116-123	sedative	group	156-163	advise
PRECEDEX	brand	116-123	hypnotic	group	166-173	advise
PRECEDEX	brand	116-123	opioid	group	178-183	advise
anesthetic	group	144-153	sedative	group	156-163	false
anesthetic	group	144-153	hypnotic	group	166-173	false
anesthetic	group	144-153	opioid	group	178-183	false
sedative	group	156-163	hypnotic	group	166-173	false
sedative	group	156-163	opioid	group	178-183	false
hypnotic	group	166-173	opioid	group	178-183	false

DDI-DrugBank.d197.s5	Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.
Neuromuscular Blockers	group	0-21	PRECEDEX	brand	81-88	false
Neuromuscular Blockers	group	0-21	rocuronium	drug	254-263	false
PRECEDEX	brand	81-88	rocuronium	drug	254-263	false

DDI-DrugBank.d132.s0	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
Anticoagulants	group	5-18	diflunisal	drug	82-91	false
Anticoagulants	group	5-18	warfarin	drug	97-104	false
Anticoagulants	group	5-18	acenocoumarol	drug	107-119	false
Anticoagulants	group	5-18	phenprocoumon	drug	125-137	false
diflunisal	drug	82-91	warfarin	drug	97-104	effect
diflunisal	drug	82-91	acenocoumarol	drug	107-119	effect
diflunisal	drug	82-91	phenprocoumon	drug	125-137	effect
warfarin	drug	97-104	acenocoumarol	drug	107-119	false
warfarin	drug	97-104	phenprocoumon	drug	125-137	false
acenocoumarol	drug	107-119	phenprocoumon	drug	125-137	false

DDI-DrugBank.d132.s1	This may occur because diflunisal competitively displaces coumarins from protein binding sites.
diflunisal	drug	23-32	coumarins	group	58-66	mechanism

DDI-DrugBank.d132.s2	Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.
diflunisal	drug	18-27	anticoagulants	group	55-68	advise

DDI-DrugBank.d132.s4	Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.
Tolbutamide	drug	0-10	diflunisal	drug	44-53	false
Tolbutamide	drug	0-10	tolbutamide	drug	59-69	false
Tolbutamide	drug	0-10	tolbutamide	drug	108-118	false
diflunisal	drug	44-53	tolbutamide	drug	59-69	false
diflunisal	drug	44-53	tolbutamide	drug	108-118	false
tolbutamide	drug	59-69	tolbutamide	drug	108-118	false

DDI-DrugBank.d132.s5	Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
Hydrochlorothiazide	drug	0-18	diflunisal	drug	73-82	false
Hydrochlorothiazide	drug	0-18	hydrochlorothiazide	drug	88-106	false
Hydrochlorothiazide	drug	0-18	hydrochlorothiazide	drug	161-179	false
diflunisal	drug	73-82	hydrochlorothiazide	drug	88-106	mechanism
diflunisal	drug	73-82	hydrochlorothiazide	drug	161-179	false
hydrochlorothiazide	drug	88-106	hydrochlorothiazide	drug	161-179	false

DDI-DrugBank.d132.s6	Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
Diflunisal	drug	0-9	hydrochlorothiazide	drug	49-67	effect

DDI-DrugBank.d132.s7	Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.
Furosemide	drug	0-9	diflunisal	drug	68-77	false
Furosemide	drug	0-9	furosemide	drug	83-92	false
Furosemide	drug	0-9	furosemide	drug	136-145	false
diflunisal	drug	68-77	furosemide	drug	83-92	false
diflunisal	drug	68-77	furosemide	drug	136-145	false
furosemide	drug	83-92	furosemide	drug	136-145	false

DDI-DrugBank.d132.s8	Diflunisal decreased the hyperuricemic effect of furosemide.
Diflunisal	drug	0-9	furosemide	drug	49-58	effect

DDI-DrugBank.d132.s9	Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.
Antacids	group	0-7	antacids	group	40-47	false
Antacids	group	0-7	diflunisal	drug	77-86	false
antacids	group	40-47	diflunisal	drug	77-86	mechanism

DDI-DrugBank.d132.s10	This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule.
antacids	group	46-53	antacids	group	95-102	false

DDI-DrugBank.d132.s11	Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
Acetaminophen	drug	0-12	diflunisal	drug	67-76	false
Acetaminophen	drug	0-12	acetaminophen	drug	82-94	false
Acetaminophen	drug	0-12	acetaminophen	drug	156-168	false
diflunisal	drug	67-76	acetaminophen	drug	82-94	mechanism
diflunisal	drug	67-76	acetaminophen	drug	156-168	false
acetaminophen	drug	82-94	acetaminophen	drug	156-168	false

DDI-DrugBank.d132.s12	Acetaminophen had no effect on plasma levels of diflunisal.
Acetaminophen	drug	0-12	diflunisal	drug	48-57	false

DDI-DrugBank.d132.s13	Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
acetaminophen	drug	6-18	diflunisal	drug	105-114	false
acetaminophen	drug	6-18	acetaminophen	drug	120-132	false
diflunisal	drug	105-114	acetaminophen	drug	120-132	advise

DDI-DrugBank.d132.s14	Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
diflunisal	drug	30-39	acetaminophen	drug	45-57	effect
diflunisal	drug	30-39	diflunisal	drug	188-197	false
diflunisal	drug	30-39	acetaminophen	drug	199-211	false
acetaminophen	drug	45-57	diflunisal	drug	188-197	false
acetaminophen	drug	45-57	acetaminophen	drug	199-211	false
diflunisal	drug	188-197	acetaminophen	drug	199-211	false

DDI-DrugBank.d132.s16	Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
Methotrexate	drug	0-11	diflunisal	drug	40-49	false
Methotrexate	drug	0-11	methotrexate	drug	86-97	false
diflunisal	drug	40-49	methotrexate	drug	86-97	advise

DDI-DrugBank.d132.s17	Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
Nonsteroidal anti-inflammatory drugs	group	0-35	methotrexate	drug	93-104	mechanism

DDI-DrugBank.d132.s18	Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
Cyclosporine	drug	0-11	nonsteroial anti-inflammatory drugs	group	32-66	false
Cyclosporine	drug	0-11	cyclosporine	drug	87-98	false
Cyclosporine	drug	0-11	cyclosporine	drug	140-151	false
nonsteroial anti-inflammatory drugs	group	32-66	cyclosporine	drug	87-98	mechanism
nonsteroial anti-inflammatory drugs	group	32-66	cyclosporine	drug	140-151	false
cyclosporine	drug	87-98	cyclosporine	drug	140-151	false

DDI-DrugBank.d132.s19	NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
NSAIDs	group	0-5	cyclosporine	drug	54-65	advise

DDI-DrugBank.d132.s20	Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	diflunisal	drug	60-69	false
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	indomethacin	drug	102-113	false
Nonsteroidal Anti-Inflammatory Drugs	group	0-35	indomethacin	drug	194-205	false
diflunisal	drug	60-69	indomethacin	drug	102-113	mechanism
diflunisal	drug	60-69	indomethacin	drug	194-205	false
indomethacin	drug	102-113	indomethacin	drug	194-205	false

DDI-DrugBank.d132.s21	In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
indomethacin	drug	37-48	diflunisal	drug	54-63	effect

DDI-DrugBank.d132.s22	Therefore, indomethacin and diflunisal should not be used concomitantly.
indomethacin	drug	11-22	diflunisal	drug	28-37	advise

DDI-DrugBank.d132.s23	The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
diflunisal	drug	23-32	NSAIDs	group	52-57	effect

DDI-DrugBank.d132.s25	Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.
Aspirin	brand	0-6	diflunisal	drug	51-60	false
Aspirin	brand	0-6	diflunisal	drug	105-114	false
Aspirin	brand	0-6	aspirin	brand	120-126	false
diflunisal	drug	51-60	diflunisal	drug	105-114	false
diflunisal	drug	51-60	aspirin	brand	120-126	false
diflunisal	drug	105-114	aspirin	brand	120-126	mechanism

DDI-DrugBank.d132.s26	Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
Sulindac	drug	0-7	diflunisal	drug	44-53	false
Sulindac	drug	0-7	sulindac	drug	59-66	false
diflunisal	drug	44-53	sulindac	drug	59-66	mechanism

DDI-DrugBank.d132.s27	Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
Naproxen	drug	0-7	diflunisal	drug	44-53	false
Naproxen	drug	0-7	naproxen	drug	59-66	false
Naproxen	drug	0-7	naproxen	drug	127-134	false
Naproxen	drug	0-7	naproxen	drug	190-197	false
diflunisal	drug	44-53	naproxen	drug	59-66	mechanism
diflunisal	drug	44-53	naproxen	drug	127-134	false
diflunisal	drug	44-53	naproxen	drug	190-197	false
naproxen	drug	59-66	naproxen	drug	127-134	false
naproxen	drug	59-66	naproxen	drug	190-197	false
naproxen	drug	127-134	naproxen	drug	190-197	false

DDI-DrugBank.d132.s28	Naproxen had no effect on plasma levels of diflunisal.
Naproxen	drug	0-7	diflunisal	drug	43-52	false

DDI-DrugBank.d306.s0	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
progestin	group	21-29	anticonvulsants	group	98-112	false
progestin	group	21-29	phenytoin	drug	114-122	effect
progestin	group	21-29	carbamazepine	drug	125-137	effect
progestin	group	21-29	barbiturates	group	144-155	effect
progestin	group	21-29	antituberculosis drug	group	166-186	false
progestin	group	21-29	rifampin	drug	188-195	effect
anticonvulsants	group	98-112	phenytoin	drug	114-122	false
anticonvulsants	group	98-112	carbamazepine	drug	125-137	false
anticonvulsants	group	98-112	barbiturates	group	144-155	false
anticonvulsants	group	98-112	antituberculosis drug	group	166-186	false
anticonvulsants	group	98-112	rifampin	drug	188-195	false
phenytoin	drug	114-122	carbamazepine	drug	125-137	false
phenytoin	drug	114-122	barbiturates	group	144-155	false
phenytoin	drug	114-122	antituberculosis drug	group	166-186	false
phenytoin	drug	114-122	rifampin	drug	188-195	false
carbamazepine	drug	125-137	barbiturates	group	144-155	false
carbamazepine	drug	125-137	antituberculosis drug	group	166-186	false
carbamazepine	drug	125-137	rifampin	drug	188-195	false
barbiturates	group	144-155	antituberculosis drug	group	166-186	false
barbiturates	group	144-155	rifampin	drug	188-195	false
antituberculosis drug	group	166-186	rifampin	drug	188-195	false

DDI-DrugBank.d210.s0	ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
ACE inhibitors	group	0-13	NSAIDs	group	37-42	false
ACE inhibitors	group	0-13	Angiotensin Converting Enzyme (ACE) inhibitors	group	88-133	false
NSAIDs	group	37-42	Angiotensin Converting Enzyme (ACE) inhibitors	group	88-133	effect

DDI-DrugBank.d210.s1	In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
VIOXX	brand	81-85	ACE inhibitor	group	96-108	false
VIOXX	brand	81-85	benazepril	drug	110-119	effect
VIOXX	brand	81-85	ACE inhibitor	group	242-254	false
ACE inhibitor	group	96-108	benazepril	drug	110-119	false
ACE inhibitor	group	96-108	ACE inhibitor	group	242-254	false
benazepril	drug	110-119	ACE inhibitor	group	242-254	false

DDI-DrugBank.d210.s2	This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.
VIOXX	brand	66-70	ACE inhibitors	group	91-104	advise

DDI-DrugBank.d210.s3	Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
Aspirin	brand	0-6	aspirin	brand	48-54	false
Aspirin	brand	0-6	VIOXX	brand	61-65	false
Aspirin	brand	0-6	VIOXX	brand	159-163	false
aspirin	brand	48-54	VIOXX	brand	61-65	effect
aspirin	brand	48-54	VIOXX	brand	159-163	false
VIOXX	brand	61-65	VIOXX	brand	159-163	false

DDI-DrugBank.d210.s4	In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.
aspirin	brand	193-199	VIOXX	brand	206-210	false
aspirin	brand	193-199	ibuprofen	drug	253-261	false
VIOXX	brand	206-210	ibuprofen	drug	253-261	false

DDI-DrugBank.d210.s5	Patients taking low-dose aspirin plus ibuprofen were not studied.
aspirin	brand	25-31	ibuprofen	drug	38-46	false

DDI-DrugBank.d210.s6	At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.
VIOXX	brand	17-21	aspirin	brand	115-121	false

DDI-DrugBank.d210.s7	Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis.
VIOXX	brand	41-45	aspirin	brand	71-77	false

DDI-DrugBank.d210.s9	Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted.
VIOXX	brand	64-68	aspirin	brand	74-80	false

DDI-DrugBank.d210.s10	Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
Cimetidine	drug	0-9	cimetidine	drug	49-58	false
Cimetidine	drug	0-9	rofecoxib	drug	103-111	false
cimetidine	drug	49-58	rofecoxib	drug	103-111	mechanism

DDI-DrugBank.d210.s12	Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.
Digoxin	drug	0-6	Rofecoxib	drug	9-17	false
Digoxin	drug	0-6	digoxin	drug	120-126	false
Rofecoxib	drug	9-17	digoxin	drug	120-126	false

DDI-DrugBank.d210.s13	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	drug	0-9	NSAIDs	group	86-91	false
Furosemide	drug	0-9	furosemide	drug	130-139	false
Furosemide	drug	0-9	thiazides	group	145-153	false
NSAIDs	group	86-91	furosemide	drug	130-139	effect
NSAIDs	group	86-91	thiazides	group	145-153	effect
furosemide	drug	130-139	thiazides	group	145-153	false

DDI-DrugBank.d210.s15	Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib.
Ketoconazole	drug	0-11	Ketoconazole	drug	14-25	false
Ketoconazole	drug	0-11	rofecoxib	drug	112-120	false
Ketoconazole	drug	14-25	rofecoxib	drug	112-120	false

DDI-DrugBank.d210.s16	Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
Lithium	drug	0-6	NSAIDs	group	9-14	false
Lithium	drug	0-6	lithium	drug	53-59	false
Lithium	drug	0-6	lithium	drug	93-99	false
NSAIDs	group	9-14	lithium	drug	53-59	mechanism
NSAIDs	group	9-14	lithium	drug	93-99	false
lithium	drug	53-59	lithium	drug	93-99	false

DDI-DrugBank.d210.s18	Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
VIOXX	brand	11-15	lithium	drug	21-27	advise
VIOXX	brand	11-15	lithium	drug	111-117	false
lithium	drug	21-27	lithium	drug	111-117	false

DDI-DrugBank.d210.s19	Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.
Methotrexate	drug	0-11	VIOXX	brand	13-17	false
Methotrexate	drug	0-11	methotrexate	drug	131-142	false
Methotrexate	drug	0-11	methotrexate	drug	205-216	false
VIOXX	brand	13-17	methotrexate	drug	131-142	false
VIOXX	brand	13-17	methotrexate	drug	205-216	false
methotrexate	drug	131-142	methotrexate	drug	205-216	false

DDI-DrugBank.d210.s20	At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.
VIOXX	brand	34-38	methotrexate	drug	168-179	mechanism

DDI-DrugBank.d210.s21	At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
methotrexate	drug	68-79	methotrexate	drug	123-134	false
methotrexate	drug	68-79	rofecoxib	drug	166-174	false
methotrexate	drug	68-79	methotrexate	drug	186-197	false
methotrexate	drug	123-134	rofecoxib	drug	166-174	mechanism
methotrexate	drug	123-134	methotrexate	drug	186-197	false
rofecoxib	drug	166-174	methotrexate	drug	186-197	false

DDI-DrugBank.d210.s22	Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.
methotrexate	drug	23-34	VIOXX	brand	76-80	false
methotrexate	drug	23-34	methotrexate	drug	86-97	false
VIOXX	brand	76-80	methotrexate	drug	86-97	advise

DDI-DrugBank.d210.s23	Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.
Contraceptives	group	5-18	Rofecoxib	drug	20-28	false
Contraceptives	group	5-18	ethinyl estradiol	drug	102-118	false
Contraceptives	group	5-18	norethindrone	drug	124-136	false
Rofecoxib	drug	20-28	ethinyl estradiol	drug	102-118	false
Rofecoxib	drug	20-28	norethindrone	drug	124-136	false
ethinyl estradiol	drug	102-118	norethindrone	drug	124-136	false

DDI-DrugBank.d210.s24	Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.
Prednisone	drug	0-9	prednisolone	drug	11-22	false
Prednisone	drug	0-9	Rofecoxib	drug	25-33	false
Prednisone	drug	0-9	prednisolone	drug	107-118	false
Prednisone	drug	0-9	prednisone	drug	123-132	false
prednisolone	drug	11-22	Rofecoxib	drug	25-33	false
prednisolone	drug	11-22	prednisolone	drug	107-118	false
prednisolone	drug	11-22	prednisone	drug	123-132	false
Rofecoxib	drug	25-33	prednisolone	drug	107-118	false
Rofecoxib	drug	25-33	prednisone	drug	123-132	false
prednisolone	drug	107-118	prednisone	drug	123-132	false

DDI-DrugBank.d210.s25	Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.
Rifampin	drug	0-7	VIOXX	brand	31-35	false
Rifampin	drug	0-7	rifampin	drug	42-49	false
Rifampin	drug	0-7	rofecoxib	drug	145-153	false
VIOXX	brand	31-35	rifampin	drug	42-49	mechanism
VIOXX	brand	31-35	rofecoxib	drug	145-153	false
rifampin	drug	42-49	rofecoxib	drug	145-153	false

DDI-DrugBank.d210.s26	Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism.
VIOXX	brand	45-49	VIOXX	brand	113-117	false

DDI-DrugBank.d210.s27	Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.
Theophylline	drug	0-11	VIOXX	brand	13-17	false
Theophylline	drug	0-11	theophylline	drug	91-102	false
Theophylline	drug	0-11	theophylline	drug	200-211	false
VIOXX	brand	13-17	theophylline	drug	91-102	mechanism
VIOXX	brand	13-17	theophylline	drug	200-211	false
theophylline	drug	91-102	theophylline	drug	200-211	false

DDI-DrugBank.d210.s28	Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.
theophylline	drug	23-34	VIOXX	brand	97-101	false
theophylline	drug	23-34	theophylline	drug	149-160	false
VIOXX	brand	97-101	theophylline	drug	149-160	advise

DDI-DrugBank.d210.s30	Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton).
amitriptyline	drug	107-119	tacrine	drug	122-128	false
amitriptyline	drug	107-119	zileuton	drug	135-142	false
tacrine	drug	122-128	zileuton	drug	135-142	false

DDI-DrugBank.d210.s31	Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.
Warfarin	drug	0-7	VIOXX	brand	118-122	false
Warfarin	drug	0-7	warfarin	drug	154-161	false
VIOXX	brand	118-122	warfarin	drug	154-161	advise

DDI-DrugBank.d210.s32	In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.
warfarin	drug	71-78	rofecoxib	drug	84-92	effect

DDI-DrugBank.d210.s33	In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
VIOXX	brand	168-172	warfarin	drug	192-199	effect

DDI-DrugBank.d414.s0	Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
Lithium	drug	0-6	diuretics	group	43-51	mechanism
Lithium	drug	0-6	lithium	drug	116-122	false
diuretics	group	43-51	lithium	drug	116-122	false

DDI-DrugBank.d414.s2	EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
EDECRIN	brand	0-6	aminoglycoside	group	67-80	effect
EDECRIN	brand	0-6	cephalosporin antibiotics	group	91-115	effect
aminoglycoside	group	67-80	cephalosporin antibiotics	group	91-115	false

DDI-DrugBank.d414.s4	A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
ethacrynic acid	drug	29-43	warfarin	drug	74-81	mechanism

DDI-DrugBank.d414.s6	In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
non- steroidal antiinflammatory agent	group	42-78	loop diuretics	group	150-153;188-196	effect
non- steroidal antiinflammatory agent	group	42-78	potassium- sparing diuretics	group	156-173;188-196	effect
non- steroidal antiinflammatory agent	group	42-78	thiazide diuretics	group	179-196	effect
loop diuretics	group	150-153;188-196	potassium- sparing diuretics	group	156-173;188-196	false
loop diuretics	group	150-153;188-196	thiazide diuretics	group	179-196	false
potassium- sparing diuretics	group	156-173;188-196	thiazide diuretics	group	179-196	false

DDI-DrugBank.d414.s7	Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
EDECRIN	brand	16-22	non- steroidal anti- inflammatory agents	group	28-67	effect
EDECRIN	brand	16-22	diuretic	group	174-181	false
non- steroidal anti- inflammatory agents	group	28-67	diuretic	group	174-181	false

DDI-DrugBank.d252.s0	Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.
BETAGAN	brand	9-15	BETAGAN	brand	117-123	false
BETAGAN	brand	9-15	epinephrine	drug	129-139	false
BETAGAN	brand	117-123	epinephrine	drug	129-139	effect

DDI-DrugBank.d252.s1	Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.
beta-blocker	group	55-66	reserpine	drug	144-152	advise

DDI-DrugBank.d252.s2	Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
beta-adrenergic blocking agents	group	19-49	calcium antagonists	group	89-107	advise

DDI-DrugBank.d252.s4	The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
beta-adrenergic blocking agents	group	23-53	digitalis	group	60-68	effect
beta-adrenergic blocking agents	group	23-53	calcium antagonist	group	74-91	effect
digitalis	group	60-68	calcium antagonist	group	74-91	false

DDI-DrugBank.d252.s5	Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.
Phenothiazine-related compounds	group	0-30	beta-adrenergic blocking agents	group	36-66	mechanism

DDI-DrugBank.d40.s0	No drugs are known to interfere with the conversion of fosphenytoin to phenytoin.
fosphenytoin	drug	55-66	phenytoin	drug	71-79	false

DDI-DrugBank.d40.s1	Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin.
fosphenytoin	drug	240-251	phenytoin	drug	256-264	false

DDI-DrugBank.d40.s4	The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.
fosphenytoin	drug	44-55	phenytoin	drug	58-66	false
fosphenytoin	drug	44-55	diazepam	drug	73-80	false
fosphenytoin	drug	44-55	diazepam	drug	104-111	false
fosphenytoin	drug	44-55	Cerebyx	brand	117-123	false
phenytoin	drug	58-66	diazepam	drug	73-80	false
phenytoin	drug	58-66	diazepam	drug	104-111	false
phenytoin	drug	58-66	Cerebyx	brand	117-123	false
diazepam	drug	73-80	diazepam	drug	104-111	false
diazepam	drug	73-80	Cerebyx	brand	117-123	false
diazepam	drug	104-111	Cerebyx	brand	117-123	false

DDI-DrugBank.d40.s5	The most significant drug interactions following administration of Cerebyx are expected to occur with drugs that interact with phenytoin.
Cerebyx	brand	67-73	phenytoin	drug	127-135	false

DDI-DrugBank.d40.s10	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
phenytoin	drug	97-105	alcohol	drug	137-143	mechanism
phenytoin	drug	97-105	amiodarone	drug	153-162	mechanism
phenytoin	drug	97-105	chlordiazepoxide	drug	182-197	mechanism
phenytoin	drug	97-105	cimetidine	drug	200-209	mechanism
phenytoin	drug	97-105	diazepam	drug	212-219	mechanism
phenytoin	drug	97-105	dicumarol	drug	222-230	mechanism
phenytoin	drug	97-105	disulfiram	drug	233-242	mechanism
phenytoin	drug	97-105	estrogens	group	245-253	mechanism
phenytoin	drug	97-105	ethosuximide	drug	256-267	mechanism
phenytoin	drug	97-105	fluoxetine	drug	270-279	mechanism
phenytoin	drug	97-105	H2-antagonists	group	282-295	mechanism
phenytoin	drug	97-105	halothane	drug	298-306	mechanism
phenytoin	drug	97-105	isoniazid	drug	309-317	mechanism
phenytoin	drug	97-105	methylphenidate	drug	320-334	mechanism
phenytoin	drug	97-105	phenothiazines	group	337-350	mechanism
phenytoin	drug	97-105	phenylbutazone	drug	353-366	mechanism
phenytoin	drug	97-105	salicylates	group	369-379	mechanism
phenytoin	drug	97-105	succinimides	group	382-393	mechanism
phenytoin	drug	97-105	sulfonamides	group	396-407	mechanism
phenytoin	drug	97-105	tolbutamide	drug	410-420	mechanism
phenytoin	drug	97-105	trazodone	drug	423-431	mechanism
alcohol	drug	137-143	amiodarone	drug	153-162	false
alcohol	drug	137-143	chlordiazepoxide	drug	182-197	false
alcohol	drug	137-143	cimetidine	drug	200-209	false
alcohol	drug	137-143	diazepam	drug	212-219	false
alcohol	drug	137-143	dicumarol	drug	222-230	false
alcohol	drug	137-143	disulfiram	drug	233-242	false
alcohol	drug	137-143	estrogens	group	245-253	false
alcohol	drug	137-143	ethosuximide	drug	256-267	false
alcohol	drug	137-143	fluoxetine	drug	270-279	false
alcohol	drug	137-143	H2-antagonists	group	282-295	false
alcohol	drug	137-143	halothane	drug	298-306	false
alcohol	drug	137-143	isoniazid	drug	309-317	false
alcohol	drug	137-143	methylphenidate	drug	320-334	false
alcohol	drug	137-143	phenothiazines	group	337-350	false
alcohol	drug	137-143	phenylbutazone	drug	353-366	false
alcohol	drug	137-143	salicylates	group	369-379	false
alcohol	drug	137-143	succinimides	group	382-393	false
alcohol	drug	137-143	sulfonamides	group	396-407	false
alcohol	drug	137-143	tolbutamide	drug	410-420	false
alcohol	drug	137-143	trazodone	drug	423-431	false
amiodarone	drug	153-162	chlordiazepoxide	drug	182-197	false
amiodarone	drug	153-162	cimetidine	drug	200-209	false
amiodarone	drug	153-162	diazepam	drug	212-219	false
amiodarone	drug	153-162	dicumarol	drug	222-230	false
amiodarone	drug	153-162	disulfiram	drug	233-242	false
amiodarone	drug	153-162	estrogens	group	245-253	false
amiodarone	drug	153-162	ethosuximide	drug	256-267	false
amiodarone	drug	153-162	fluoxetine	drug	270-279	false
amiodarone	drug	153-162	H2-antagonists	group	282-295	false
amiodarone	drug	153-162	halothane	drug	298-306	false
amiodarone	drug	153-162	isoniazid	drug	309-317	false
amiodarone	drug	153-162	methylphenidate	drug	320-334	false
amiodarone	drug	153-162	phenothiazines	group	337-350	false
amiodarone	drug	153-162	phenylbutazone	drug	353-366	false
amiodarone	drug	153-162	salicylates	group	369-379	false
amiodarone	drug	153-162	succinimides	group	382-393	false
amiodarone	drug	153-162	sulfonamides	group	396-407	false
amiodarone	drug	153-162	tolbutamide	drug	410-420	false
amiodarone	drug	153-162	trazodone	drug	423-431	false
chlordiazepoxide	drug	182-197	cimetidine	drug	200-209	false
chlordiazepoxide	drug	182-197	diazepam	drug	212-219	false
chlordiazepoxide	drug	182-197	dicumarol	drug	222-230	false
chlordiazepoxide	drug	182-197	disulfiram	drug	233-242	false
chlordiazepoxide	drug	182-197	estrogens	group	245-253	false
chlordiazepoxide	drug	182-197	ethosuximide	drug	256-267	false
chlordiazepoxide	drug	182-197	fluoxetine	drug	270-279	false
chlordiazepoxide	drug	182-197	H2-antagonists	group	282-295	false
chlordiazepoxide	drug	182-197	halothane	drug	298-306	false
chlordiazepoxide	drug	182-197	isoniazid	drug	309-317	false
chlordiazepoxide	drug	182-197	methylphenidate	drug	320-334	false
chlordiazepoxide	drug	182-197	phenothiazines	group	337-350	false
chlordiazepoxide	drug	182-197	phenylbutazone	drug	353-366	false
chlordiazepoxide	drug	182-197	salicylates	group	369-379	false
chlordiazepoxide	drug	182-197	succinimides	group	382-393	false
chlordiazepoxide	drug	182-197	sulfonamides	group	396-407	false
chlordiazepoxide	drug	182-197	tolbutamide	drug	410-420	false
chlordiazepoxide	drug	182-197	trazodone	drug	423-431	false
cimetidine	drug	200-209	diazepam	drug	212-219	false
cimetidine	drug	200-209	dicumarol	drug	222-230	false
cimetidine	drug	200-209	disulfiram	drug	233-242	false
cimetidine	drug	200-209	estrogens	group	245-253	false
cimetidine	drug	200-209	ethosuximide	drug	256-267	false
cimetidine	drug	200-209	fluoxetine	drug	270-279	false
cimetidine	drug	200-209	H2-antagonists	group	282-295	false
cimetidine	drug	200-209	halothane	drug	298-306	false
cimetidine	drug	200-209	isoniazid	drug	309-317	false
cimetidine	drug	200-209	methylphenidate	drug	320-334	false
cimetidine	drug	200-209	phenothiazines	group	337-350	false
cimetidine	drug	200-209	phenylbutazone	drug	353-366	false
cimetidine	drug	200-209	salicylates	group	369-379	false
cimetidine	drug	200-209	succinimides	group	382-393	false
cimetidine	drug	200-209	sulfonamides	group	396-407	false
cimetidine	drug	200-209	tolbutamide	drug	410-420	false
cimetidine	drug	200-209	trazodone	drug	423-431	false
diazepam	drug	212-219	dicumarol	drug	222-230	false
diazepam	drug	212-219	disulfiram	drug	233-242	false
diazepam	drug	212-219	estrogens	group	245-253	false
diazepam	drug	212-219	ethosuximide	drug	256-267	false
diazepam	drug	212-219	fluoxetine	drug	270-279	false
diazepam	drug	212-219	H2-antagonists	group	282-295	false
diazepam	drug	212-219	halothane	drug	298-306	false
diazepam	drug	212-219	isoniazid	drug	309-317	false
diazepam	drug	212-219	methylphenidate	drug	320-334	false
diazepam	drug	212-219	phenothiazines	group	337-350	false
diazepam	drug	212-219	phenylbutazone	drug	353-366	false
diazepam	drug	212-219	salicylates	group	369-379	false
diazepam	drug	212-219	succinimides	group	382-393	false
diazepam	drug	212-219	sulfonamides	group	396-407	false
diazepam	drug	212-219	tolbutamide	drug	410-420	false
diazepam	drug	212-219	trazodone	drug	423-431	false
dicumarol	drug	222-230	disulfiram	drug	233-242	false
dicumarol	drug	222-230	estrogens	group	245-253	false
dicumarol	drug	222-230	ethosuximide	drug	256-267	false
dicumarol	drug	222-230	fluoxetine	drug	270-279	false
dicumarol	drug	222-230	H2-antagonists	group	282-295	false
dicumarol	drug	222-230	halothane	drug	298-306	false
dicumarol	drug	222-230	isoniazid	drug	309-317	false
dicumarol	drug	222-230	methylphenidate	drug	320-334	false
dicumarol	drug	222-230	phenothiazines	group	337-350	false
dicumarol	drug	222-230	phenylbutazone	drug	353-366	false
dicumarol	drug	222-230	salicylates	group	369-379	false
dicumarol	drug	222-230	succinimides	group	382-393	false
dicumarol	drug	222-230	sulfonamides	group	396-407	false
dicumarol	drug	222-230	tolbutamide	drug	410-420	false
dicumarol	drug	222-230	trazodone	drug	423-431	false
disulfiram	drug	233-242	estrogens	group	245-253	false
disulfiram	drug	233-242	ethosuximide	drug	256-267	false
disulfiram	drug	233-242	fluoxetine	drug	270-279	false
disulfiram	drug	233-242	H2-antagonists	group	282-295	false
disulfiram	drug	233-242	halothane	drug	298-306	false
disulfiram	drug	233-242	isoniazid	drug	309-317	false
disulfiram	drug	233-242	methylphenidate	drug	320-334	false
disulfiram	drug	233-242	phenothiazines	group	337-350	false
disulfiram	drug	233-242	phenylbutazone	drug	353-366	false
disulfiram	drug	233-242	salicylates	group	369-379	false
disulfiram	drug	233-242	succinimides	group	382-393	false
disulfiram	drug	233-242	sulfonamides	group	396-407	false
disulfiram	drug	233-242	tolbutamide	drug	410-420	false
disulfiram	drug	233-242	trazodone	drug	423-431	false
estrogens	group	245-253	ethosuximide	drug	256-267	false
estrogens	group	245-253	fluoxetine	drug	270-279	false
estrogens	group	245-253	H2-antagonists	group	282-295	false
estrogens	group	245-253	halothane	drug	298-306	false
estrogens	group	245-253	isoniazid	drug	309-317	false
estrogens	group	245-253	methylphenidate	drug	320-334	false
estrogens	group	245-253	phenothiazines	group	337-350	false
estrogens	group	245-253	phenylbutazone	drug	353-366	false
estrogens	group	245-253	salicylates	group	369-379	false
estrogens	group	245-253	succinimides	group	382-393	false
estrogens	group	245-253	sulfonamides	group	396-407	false
estrogens	group	245-253	tolbutamide	drug	410-420	false
estrogens	group	245-253	trazodone	drug	423-431	false
ethosuximide	drug	256-267	fluoxetine	drug	270-279	false
ethosuximide	drug	256-267	H2-antagonists	group	282-295	false
ethosuximide	drug	256-267	halothane	drug	298-306	false
ethosuximide	drug	256-267	isoniazid	drug	309-317	false
ethosuximide	drug	256-267	methylphenidate	drug	320-334	false
ethosuximide	drug	256-267	phenothiazines	group	337-350	false
ethosuximide	drug	256-267	phenylbutazone	drug	353-366	false
ethosuximide	drug	256-267	salicylates	group	369-379	false
ethosuximide	drug	256-267	succinimides	group	382-393	false
ethosuximide	drug	256-267	sulfonamides	group	396-407	false
ethosuximide	drug	256-267	tolbutamide	drug	410-420	false
ethosuximide	drug	256-267	trazodone	drug	423-431	false
fluoxetine	drug	270-279	H2-antagonists	group	282-295	false
fluoxetine	drug	270-279	halothane	drug	298-306	false
fluoxetine	drug	270-279	isoniazid	drug	309-317	false
fluoxetine	drug	270-279	methylphenidate	drug	320-334	false
fluoxetine	drug	270-279	phenothiazines	group	337-350	false
fluoxetine	drug	270-279	phenylbutazone	drug	353-366	false
fluoxetine	drug	270-279	salicylates	group	369-379	false
fluoxetine	drug	270-279	succinimides	group	382-393	false
fluoxetine	drug	270-279	sulfonamides	group	396-407	false
fluoxetine	drug	270-279	tolbutamide	drug	410-420	false
fluoxetine	drug	270-279	trazodone	drug	423-431	false
H2-antagonists	group	282-295	halothane	drug	298-306	false
H2-antagonists	group	282-295	isoniazid	drug	309-317	false
H2-antagonists	group	282-295	methylphenidate	drug	320-334	false
H2-antagonists	group	282-295	phenothiazines	group	337-350	false
H2-antagonists	group	282-295	phenylbutazone	drug	353-366	false
H2-antagonists	group	282-295	salicylates	group	369-379	false
H2-antagonists	group	282-295	succinimides	group	382-393	false
H2-antagonists	group	282-295	sulfonamides	group	396-407	false
H2-antagonists	group	282-295	tolbutamide	drug	410-420	false
H2-antagonists	group	282-295	trazodone	drug	423-431	false
halothane	drug	298-306	isoniazid	drug	309-317	false
halothane	drug	298-306	methylphenidate	drug	320-334	false
halothane	drug	298-306	phenothiazines	group	337-350	false
halothane	drug	298-306	phenylbutazone	drug	353-366	false
halothane	drug	298-306	salicylates	group	369-379	false
halothane	drug	298-306	succinimides	group	382-393	false
halothane	drug	298-306	sulfonamides	group	396-407	false
halothane	drug	298-306	tolbutamide	drug	410-420	false
halothane	drug	298-306	trazodone	drug	423-431	false
isoniazid	drug	309-317	methylphenidate	drug	320-334	false
isoniazid	drug	309-317	phenothiazines	group	337-350	false
isoniazid	drug	309-317	phenylbutazone	drug	353-366	false
isoniazid	drug	309-317	salicylates	group	369-379	false
isoniazid	drug	309-317	succinimides	group	382-393	false
isoniazid	drug	309-317	sulfonamides	group	396-407	false
isoniazid	drug	309-317	tolbutamide	drug	410-420	false
isoniazid	drug	309-317	trazodone	drug	423-431	false
methylphenidate	drug	320-334	phenothiazines	group	337-350	false
methylphenidate	drug	320-334	phenylbutazone	drug	353-366	false
methylphenidate	drug	320-334	salicylates	group	369-379	false
methylphenidate	drug	320-334	succinimides	group	382-393	false
methylphenidate	drug	320-334	sulfonamides	group	396-407	false
methylphenidate	drug	320-334	tolbutamide	drug	410-420	false
methylphenidate	drug	320-334	trazodone	drug	423-431	false
phenothiazines	group	337-350	phenylbutazone	drug	353-366	false
phenothiazines	group	337-350	salicylates	group	369-379	false
phenothiazines	group	337-350	succinimides	group	382-393	false
phenothiazines	group	337-350	sulfonamides	group	396-407	false
phenothiazines	group	337-350	tolbutamide	drug	410-420	false
phenothiazines	group	337-350	trazodone	drug	423-431	false
phenylbutazone	drug	353-366	salicylates	group	369-379	false
phenylbutazone	drug	353-366	succinimides	group	382-393	false
phenylbutazone	drug	353-366	sulfonamides	group	396-407	false
phenylbutazone	drug	353-366	tolbutamide	drug	410-420	false
phenylbutazone	drug	353-366	trazodone	drug	423-431	false
salicylates	group	369-379	succinimides	group	382-393	false
salicylates	group	369-379	sulfonamides	group	396-407	false
salicylates	group	369-379	tolbutamide	drug	410-420	false
salicylates	group	369-379	trazodone	drug	423-431	false
succinimides	group	382-393	sulfonamides	group	396-407	false
succinimides	group	382-393	tolbutamide	drug	410-420	false
succinimides	group	382-393	trazodone	drug	423-431	false
sulfonamides	group	396-407	tolbutamide	drug	410-420	false
sulfonamides	group	396-407	trazodone	drug	423-431	false
tolbutamide	drug	410-420	trazodone	drug	423-431	false

DDI-DrugBank.d40.s12	- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
phenytoin	drug	33-41	carbamazepine	drug	67-79	mechanism
phenytoin	drug	33-41	alcohol	drug	90-96	mechanism
phenytoin	drug	33-41	reserpine	drug	105-113	mechanism
carbamazepine	drug	67-79	alcohol	drug	90-96	false
carbamazepine	drug	67-79	reserpine	drug	105-113	false
alcohol	drug	90-96	reserpine	drug	105-113	false

DDI-DrugBank.d40.s14	- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.
phenytoin	drug	52-60	phenobarbital	drug	86-98	mechanism
phenytoin	drug	52-60	sodium valproate	drug	120-135	mechanism
phenobarbital	drug	86-98	sodium valproate	drug	120-135	false

DDI-DrugBank.d40.s15	Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
phenytoin	drug	26-34	phenobarbital	drug	39-51	effect
phenytoin	drug	26-34	valproic acid	drug	54-66	effect
phenytoin	drug	26-34	valproate	drug	86-94	effect
phenobarbital	drug	39-51	valproic acid	drug	54-66	false
phenobarbital	drug	39-51	valproate	drug	86-94	false
valproic acid	drug	54-66	valproate	drug	86-94	false

DDI-DrugBank.d40.s17	- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted
tricyclic antidepressants	group	40-64	Cerebyx	brand	119-125	effect

DDI-DrugBank.d40.s19	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
phenytoin	drug	38-46	anticoagulants	group	57-70	effect
phenytoin	drug	38-46	corticosteroids	group	73-87	effect
phenytoin	drug	38-46	coumarin	group	90-97	effect
phenytoin	drug	38-46	digitoxin	drug	100-108	effect
phenytoin	drug	38-46	doxycycline	drug	111-121	effect
phenytoin	drug	38-46	estrogens	group	124-132	effect
phenytoin	drug	38-46	furosemide	drug	135-144	effect
phenytoin	drug	38-46	contraceptives	group	152-165	effect
phenytoin	drug	38-46	rifampin	drug	168-175	effect
phenytoin	drug	38-46	quinidine	drug	178-186	effect
phenytoin	drug	38-46	theophylline	drug	189-200	effect
phenytoin	drug	38-46	vitamin D	group	203-211	effect
anticoagulants	group	57-70	corticosteroids	group	73-87	false
anticoagulants	group	57-70	coumarin	group	90-97	false
anticoagulants	group	57-70	digitoxin	drug	100-108	false
anticoagulants	group	57-70	doxycycline	drug	111-121	false
anticoagulants	group	57-70	estrogens	group	124-132	false
anticoagulants	group	57-70	furosemide	drug	135-144	false
anticoagulants	group	57-70	contraceptives	group	152-165	false
anticoagulants	group	57-70	rifampin	drug	168-175	false
anticoagulants	group	57-70	quinidine	drug	178-186	false
anticoagulants	group	57-70	theophylline	drug	189-200	false
anticoagulants	group	57-70	vitamin D	group	203-211	false
corticosteroids	group	73-87	coumarin	group	90-97	false
corticosteroids	group	73-87	digitoxin	drug	100-108	false
corticosteroids	group	73-87	doxycycline	drug	111-121	false
corticosteroids	group	73-87	estrogens	group	124-132	false
corticosteroids	group	73-87	furosemide	drug	135-144	false
corticosteroids	group	73-87	contraceptives	group	152-165	false
corticosteroids	group	73-87	rifampin	drug	168-175	false
corticosteroids	group	73-87	quinidine	drug	178-186	false
corticosteroids	group	73-87	theophylline	drug	189-200	false
corticosteroids	group	73-87	vitamin D	group	203-211	false
coumarin	group	90-97	digitoxin	drug	100-108	false
coumarin	group	90-97	doxycycline	drug	111-121	false
coumarin	group	90-97	estrogens	group	124-132	false
coumarin	group	90-97	furosemide	drug	135-144	false
coumarin	group	90-97	contraceptives	group	152-165	false
coumarin	group	90-97	rifampin	drug	168-175	false
coumarin	group	90-97	quinidine	drug	178-186	false
coumarin	group	90-97	theophylline	drug	189-200	false
coumarin	group	90-97	vitamin D	group	203-211	false
digitoxin	drug	100-108	doxycycline	drug	111-121	false
digitoxin	drug	100-108	estrogens	group	124-132	false
digitoxin	drug	100-108	furosemide	drug	135-144	false
digitoxin	drug	100-108	contraceptives	group	152-165	false
digitoxin	drug	100-108	rifampin	drug	168-175	false
digitoxin	drug	100-108	quinidine	drug	178-186	false
digitoxin	drug	100-108	theophylline	drug	189-200	false
digitoxin	drug	100-108	vitamin D	group	203-211	false
doxycycline	drug	111-121	estrogens	group	124-132	false
doxycycline	drug	111-121	furosemide	drug	135-144	false
doxycycline	drug	111-121	contraceptives	group	152-165	false
doxycycline	drug	111-121	rifampin	drug	168-175	false
doxycycline	drug	111-121	quinidine	drug	178-186	false
doxycycline	drug	111-121	theophylline	drug	189-200	false
doxycycline	drug	111-121	vitamin D	group	203-211	false
estrogens	group	124-132	furosemide	drug	135-144	false
estrogens	group	124-132	contraceptives	group	152-165	false
estrogens	group	124-132	rifampin	drug	168-175	false
estrogens	group	124-132	quinidine	drug	178-186	false
estrogens	group	124-132	theophylline	drug	189-200	false
estrogens	group	124-132	vitamin D	group	203-211	false
furosemide	drug	135-144	contraceptives	group	152-165	false
furosemide	drug	135-144	rifampin	drug	168-175	false
furosemide	drug	135-144	quinidine	drug	178-186	false
furosemide	drug	135-144	theophylline	drug	189-200	false
furosemide	drug	135-144	vitamin D	group	203-211	false
contraceptives	group	152-165	rifampin	drug	168-175	false
contraceptives	group	152-165	quinidine	drug	178-186	false
contraceptives	group	152-165	theophylline	drug	189-200	false
contraceptives	group	152-165	vitamin D	group	203-211	false
rifampin	drug	168-175	quinidine	drug	178-186	false
rifampin	drug	168-175	theophylline	drug	189-200	false
rifampin	drug	168-175	vitamin D	group	203-211	false
quinidine	drug	178-186	theophylline	drug	189-200	false
quinidine	drug	178-186	vitamin D	group	203-211	false
theophylline	drug	189-200	vitamin D	group	203-211	false

DDI-DrugBank.d40.s24	Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.
phenytoin	drug	75-83	Cerebyx	brand	110-116	false

DDI-DrugBank.d430.s0	Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
ranitidine	drug	12-21	alendronate	drug	71-81	mechanism

DDI-DrugBank.d430.s3	Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
calcium	drug	20-26	multivalent cations	drug	38-56	false
calcium	drug	20-26	alendronate	drug	99-109	mechanism
multivalent cations	drug	38-56	alendronate	drug	99-109	mechanism

DDI-DrugBank.d283.s0	Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.
Anticoagulants	group	5-18	COUMARIN ANTICOAGULANTS	group	53-75	false
Anticoagulants	group	5-18	TRICOR	brand	107-112	false
COUMARIN ANTICOAGULANTS	group	53-75	TRICOR	brand	107-112	advise

DDI-DrugBank.d283.s3	HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
HMG-CoA reductase inhibitors	group	0-27	TRICOR	brand	50-55	false
HMG-CoA reductase inhibitors	group	0-27	HMG-CoA reductase inhibitors	group	61-88	false
TRICOR	brand	50-55	HMG-CoA reductase inhibitors	group	61-88	advise

DDI-DrugBank.d283.s4	Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
Resins	group	0-5	bile acid sequestrants	group	14-35	false
Resins	group	0-5	TRICOR	brand	99-104	false
Resins	group	0-5	bile acid binding resin	group	150-172	false
bile acid sequestrants	group	14-35	TRICOR	brand	99-104	false
bile acid sequestrants	group	14-35	bile acid binding resin	group	150-172	false
TRICOR	brand	99-104	bile acid binding resin	group	150-172	mechanism

DDI-DrugBank.d283.s5	Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
Cyclosporine	drug	0-11	cyclosporine	drug	22-33	false
Cyclosporine	drug	0-11	fibrate drugs	group	196-208	false
Cyclosporine	drug	0-11	TRICOR	brand	220-225	false
cyclosporine	drug	22-33	fibrate drugs	group	196-208	effect
cyclosporine	drug	22-33	TRICOR	brand	220-225	effect
fibrate drugs	group	196-208	TRICOR	brand	220-225	false

DDI-DrugBank.d283.s6	The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed
TRICOR	brand	32-37	immunosuppressants	group	44-61	advise

DDI-DrugBank.d283.s8	Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
fenofibrate	drug	83-93	fenofibric acid	drug_n	99-113	false

DDI-DrugBank.d283.s12	Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .
fenofibrate	drug	11-21	bile acid binding resin	group	83-105	advise

DDI-DrugBank.d283.s13	Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
fenofibrate	drug	30-40	TRICOR	brand	63-68	false
fenofibrate	drug	30-40	pravastatin	drug	76-86	mechanism
fenofibrate	drug	30-40	pravastatin	drug	179-189	false
TRICOR	brand	63-68	pravastatin	drug	76-86	mechanism
TRICOR	brand	63-68	pravastatin	drug	179-189	false
pravastatin	drug	76-86	pravastatin	drug	179-189	false

DDI-DrugBank.d283.s14	A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid.
pravastatin	drug	17-27	fenofibric acid	drug_n	91-105	false

DDI-DrugBank.d283.s15	Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
fenofibrate	drug	30-40	TRICOR	brand	64-69	false
fenofibrate	drug	30-40	atorvastatin	drug	77-88	mechanism
fenofibrate	drug	30-40	atorvastatin	drug	205-216	false
TRICOR	brand	64-69	atorvastatin	drug	77-88	mechanism
TRICOR	brand	64-69	atorvastatin	drug	205-216	false
atorvastatin	drug	77-88	atorvastatin	drug	205-216	false

DDI-DrugBank.d283.s16	The atorvastatin Cmax values were not significantly affected by fenofibrate.
atorvastatin	drug	4-15	fenofibrate	drug	64-74	false

DDI-DrugBank.d283.s17	The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin
fenofibric acid	drug_n	24-38	atorvastatin	drug	75-86	false

DDI-DrugBank.d488.s0	Drug Interactions: a. Drugs Enhancing Heparin Effect: Oral anticoagulants: Heparin sodium may prolong the one-stage prothrombin time.
Heparin	drug	38-44	anticoagulants	group	59-72	false
Heparin	drug	38-44	Heparin sodium	drug	75-88	false
anticoagulants	group	59-72	Heparin sodium	drug	75-88	false

DDI-DrugBank.d488.s1	Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
heparin sodium	drug	16-29	dicumarol	drug	45-53	advise
heparin sodium	drug	16-29	warfarin sodium	drug	58-72	advise
dicumarol	drug	45-53	warfarin sodium	drug	58-72	false

DDI-DrugBank.d488.s2	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
Platelet inhibitors	group	0-18	acetylsalicylic acid	drug	35-54	false
Platelet inhibitors	group	0-18	dextran	drug	57-63	false
Platelet inhibitors	group	0-18	phenylbutazone	drug	66-79	false
Platelet inhibitors	group	0-18	ibuprofen	drug	82-90	false
Platelet inhibitors	group	0-18	indomethacin	drug	93-104	false
Platelet inhibitors	group	0-18	dipyridamole	drug	107-118	false
Platelet inhibitors	group	0-18	hydroxychloroquine	drug	121-138	false
Platelet inhibitors	group	0-18	heparin sodium	drug	330-343	false
acetylsalicylic acid	drug	35-54	dextran	drug	57-63	false
acetylsalicylic acid	drug	35-54	phenylbutazone	drug	66-79	false
acetylsalicylic acid	drug	35-54	ibuprofen	drug	82-90	false
acetylsalicylic acid	drug	35-54	indomethacin	drug	93-104	false
acetylsalicylic acid	drug	35-54	dipyridamole	drug	107-118	false
acetylsalicylic acid	drug	35-54	hydroxychloroquine	drug	121-138	false
acetylsalicylic acid	drug	35-54	heparin sodium	drug	330-343	effect
dextran	drug	57-63	phenylbutazone	drug	66-79	false
dextran	drug	57-63	ibuprofen	drug	82-90	false
dextran	drug	57-63	indomethacin	drug	93-104	false
dextran	drug	57-63	dipyridamole	drug	107-118	false
dextran	drug	57-63	hydroxychloroquine	drug	121-138	false
dextran	drug	57-63	heparin sodium	drug	330-343	effect
phenylbutazone	drug	66-79	ibuprofen	drug	82-90	false
phenylbutazone	drug	66-79	indomethacin	drug	93-104	false
phenylbutazone	drug	66-79	dipyridamole	drug	107-118	false
phenylbutazone	drug	66-79	hydroxychloroquine	drug	121-138	false
phenylbutazone	drug	66-79	heparin sodium	drug	330-343	effect
ibuprofen	drug	82-90	indomethacin	drug	93-104	false
ibuprofen	drug	82-90	dipyridamole	drug	107-118	false
ibuprofen	drug	82-90	hydroxychloroquine	drug	121-138	false
ibuprofen	drug	82-90	heparin sodium	drug	330-343	effect
indomethacin	drug	93-104	dipyridamole	drug	107-118	false
indomethacin	drug	93-104	hydroxychloroquine	drug	121-138	false
indomethacin	drug	93-104	heparin sodium	drug	330-343	effect
dipyridamole	drug	107-118	hydroxychloroquine	drug	121-138	false
dipyridamole	drug	107-118	heparin sodium	drug	330-343	effect
hydroxychloroquine	drug	121-138	heparin sodium	drug	330-343	effect

DDI-DrugBank.d488.s3	The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.
heparin	drug	28-34	antithrombin III	drug	77-92	effect

DDI-DrugBank.d488.s4	Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).
heparin	drug	51-57	antithrombin III	drug	96-111	advise

DDI-DrugBank.d488.s6	Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
Heparin	drug	17-23	Digitalis	group	33-41	false
Heparin	drug	17-23	tetracyclines	group	44-56	false
Heparin	drug	17-23	nicotine	drug	59-66	false
Heparin	drug	17-23	antihistamines	group	72-85	false
Heparin	drug	17-23	heparin sodium	drug	140-153	false
Digitalis	group	33-41	tetracyclines	group	44-56	false
Digitalis	group	33-41	nicotine	drug	59-66	false
Digitalis	group	33-41	antihistamines	group	72-85	false
Digitalis	group	33-41	heparin sodium	drug	140-153	effect
tetracyclines	group	44-56	nicotine	drug	59-66	false
tetracyclines	group	44-56	antihistamines	group	72-85	false
tetracyclines	group	44-56	heparin sodium	drug	140-153	effect
nicotine	drug	59-66	antihistamines	group	72-85	false
nicotine	drug	59-66	heparin sodium	drug	140-153	effect
antihistamines	group	72-85	heparin sodium	drug	140-153	effect

DDI-DrugBank.d488.s7	Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.
Heparin Sodium	drug	0-13	doxorubicin	drug	50-60	false
Heparin Sodium	drug	0-13	droperidol	drug	63-72	false
Heparin Sodium	drug	0-13	ciprofloxacin	drug	75-87	false
Heparin Sodium	drug	0-13	mitoxantrone	drug	93-104	false
Heparin Sodium	drug	0-13	heparin	drug	173-179	false
doxorubicin	drug	50-60	droperidol	drug	63-72	false
doxorubicin	drug	50-60	ciprofloxacin	drug	75-87	false
doxorubicin	drug	50-60	mitoxantrone	drug	93-104	false
doxorubicin	drug	50-60	heparin	drug	173-179	false
droperidol	drug	63-72	ciprofloxacin	drug	75-87	false
droperidol	drug	63-72	mitoxantrone	drug	93-104	false
droperidol	drug	63-72	heparin	drug	173-179	false
ciprofloxacin	drug	75-87	mitoxantrone	drug	93-104	false
ciprofloxacin	drug	75-87	heparin	drug	173-179	false
mitoxantrone	drug	93-104	heparin	drug	173-179	false

DDI-DrugBank.d65.s0	Sulfacetamide preparations are incompatible with silver preparations.
Sulfacetamide	drug	0-12	silver	drug	49-54	int

DDI-DrugBank.d42.s0	The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.
dolasetron	drug	73-82	hydrodolasetron	drug_n	88-102	false
dolasetron	drug	73-82	hydrodolasetron	drug_n	182-196	false
hydrodolasetron	drug_n	88-102	hydrodolasetron	drug_n	182-196	false

DDI-DrugBank.d42.s1	Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
hydrodolasetron	drug_n	16-30	dolasetron	drug	51-60	false
hydrodolasetron	drug_n	16-30	cimetidine	drug	86-95	false
hydrodolasetron	drug_n	16-30	rifampin	drug	197-204	false
dolasetron	drug	51-60	cimetidine	drug	86-95	mechanism
dolasetron	drug	51-60	rifampin	drug	197-204	mechanism
cimetidine	drug	86-95	rifampin	drug	197-204	false

DDI-DrugBank.d42.s4	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
furosemide	drug	19-28	nifedipine	drug	31-40	false
furosemide	drug	19-28	diltiazem	drug	43-51	false
furosemide	drug	19-28	ACE inhibitors	group	54-67	false
furosemide	drug	19-28	verapamil	drug	70-78	false
furosemide	drug	19-28	glyburide	drug	81-89	false
furosemide	drug	19-28	propranolol	drug	92-102	false
furosemide	drug	19-28	hydrodolasetron	drug_n	178-192	false
nifedipine	drug	31-40	diltiazem	drug	43-51	false
nifedipine	drug	31-40	ACE inhibitors	group	54-67	false
nifedipine	drug	31-40	verapamil	drug	70-78	false
nifedipine	drug	31-40	glyburide	drug	81-89	false
nifedipine	drug	31-40	propranolol	drug	92-102	false
nifedipine	drug	31-40	hydrodolasetron	drug_n	178-192	false
diltiazem	drug	43-51	ACE inhibitors	group	54-67	false
diltiazem	drug	43-51	verapamil	drug	70-78	false
diltiazem	drug	43-51	glyburide	drug	81-89	false
diltiazem	drug	43-51	propranolol	drug	92-102	false
diltiazem	drug	43-51	hydrodolasetron	drug_n	178-192	false
ACE inhibitors	group	54-67	verapamil	drug	70-78	false
ACE inhibitors	group	54-67	glyburide	drug	81-89	false
ACE inhibitors	group	54-67	propranolol	drug	92-102	false
ACE inhibitors	group	54-67	hydrodolasetron	drug_n	178-192	false
verapamil	drug	70-78	glyburide	drug	81-89	false
verapamil	drug	70-78	propranolol	drug	92-102	false
verapamil	drug	70-78	hydrodolasetron	drug_n	178-192	false
glyburide	drug	81-89	propranolol	drug	92-102	false
glyburide	drug	81-89	hydrodolasetron	drug_n	178-192	false
propranolol	drug	92-102	hydrodolasetron	drug_n	178-192	false

DDI-DrugBank.d42.s5	Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.
hydrodolasetron	drug_n	13-27	dolasetron mesylate	drug	57-75	false
hydrodolasetron	drug_n	13-27	atenolol	drug	127-134	false
dolasetron mesylate	drug	57-75	atenolol	drug	127-134	mechanism

DDI-DrugBank.d42.s7	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.
Dolasetron mesylate	drug	0-18	chemotherapeutic agents	group	67-89	false
Dolasetron mesylate	drug	0-18	cisplatin	drug	92-100	false
Dolasetron mesylate	drug	0-18	5-fluorouracil	drug	103-116	false
Dolasetron mesylate	drug	0-18	doxorubicin	drug	119-129	false
Dolasetron mesylate	drug	0-18	cyclophosphamide	drug	132-147	false
chemotherapeutic agents	group	67-89	cisplatin	drug	92-100	false
chemotherapeutic agents	group	67-89	5-fluorouracil	drug	103-116	false
chemotherapeutic agents	group	67-89	doxorubicin	drug	119-129	false
chemotherapeutic agents	group	67-89	cyclophosphamide	drug	132-147	false
cisplatin	drug	92-100	5-fluorouracil	drug	103-116	false
cisplatin	drug	92-100	doxorubicin	drug	119-129	false
cisplatin	drug	92-100	cyclophosphamide	drug	132-147	false
5-fluorouracil	drug	103-116	doxorubicin	drug	119-129	false
5-fluorouracil	drug	103-116	cyclophosphamide	drug	132-147	false
doxorubicin	drug	119-129	cyclophosphamide	drug	132-147	false

DDI-DrugBank.d169.s0	Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.
REVLIMID	brand	81-88	lenalidomide	drug	92-103	false
REVLIMID	brand	81-88	lenalidomide	drug	200-211	false
lenalidomide	drug	92-103	lenalidomide	drug	200-211	false

DDI-DrugBank.d169.s1	Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin.
lenalidomide	drug	48-59	R- warfarin	drug	114-115;124-131	false
lenalidomide	drug	48-59	S- warfarin	drug	121-131	false
R- warfarin	drug	114-115;124-131	S- warfarin	drug	121-131	false

DDI-DrugBank.d169.s2	Co-administration of single 25-mg dose warfarin had no effect on the pharmacokinetics of total lenalidomide.
warfarin	drug	39-46	lenalidomide	drug	95-106	false

DDI-DrugBank.d169.s3	Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.
warfarin	drug	77-84	lenalidomide	drug	153-164	false

DDI-DrugBank.d345.s0	Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids.
colestipol hydrochloride	drug	6-29	anion exchange resin	group	37-56	false

DDI-DrugBank.d345.s5	Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.
colestipol hydrochloride	drug	18-41	propranolol	drug	75-85	mechanism
colestipol hydrochloride	drug	18-41	propranolol	drug	134-144	false
propranolol	drug	75-85	propranolol	drug	134-144	false

DDI-DrugBank.d345.s6	However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;
colestipol hydrochloride	drug	80-103	propranolol	drug	109-119	false
colestipol hydrochloride	drug	80-103	propranolol	drug	207-217	false
propranolol	drug	109-119	propranolol	drug	207-217	false

DDI-DrugBank.d345.s9	Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.
propranolol	drug	23-33	COLESTID	brand	59-66	advise

DDI-DrugBank.d345.s10	Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.
chlorothiazide	drug	46-59	colestipol hydrochloride	drug	156-179	mechanism

DDI-DrugBank.d345.s11	The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
tetracycline	drug	18-29	furosemide	drug	32-41	false
tetracycline	drug	18-29	penicillin G	drug	44-55	false
tetracycline	drug	18-29	hydrochlorothiazide	drug	58-76	false
tetracycline	drug	18-29	gemfibrozil	drug	83-93	false
tetracycline	drug	18-29	colestipol hydrochloride	drug	154-177	mechanism
furosemide	drug	32-41	penicillin G	drug	44-55	false
furosemide	drug	32-41	hydrochlorothiazide	drug	58-76	false
furosemide	drug	32-41	gemfibrozil	drug	83-93	false
furosemide	drug	32-41	colestipol hydrochloride	drug	154-177	mechanism
penicillin G	drug	44-55	hydrochlorothiazide	drug	58-76	false
penicillin G	drug	44-55	gemfibrozil	drug	83-93	false
penicillin G	drug	44-55	colestipol hydrochloride	drug	154-177	mechanism
hydrochlorothiazide	drug	58-76	gemfibrozil	drug	83-93	false
hydrochlorothiazide	drug	58-76	colestipol hydrochloride	drug	154-177	mechanism
gemfibrozil	drug	83-93	colestipol hydrochloride	drug	154-177	mechanism

DDI-DrugBank.d345.s13	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
colestipol hydrochloride	drug	62-85	aspirin	brand	137-143	false
colestipol hydrochloride	drug	62-85	clindamycin	brand	146-156	false
colestipol hydrochloride	drug	62-85	clofibrate	drug	159-168	false
colestipol hydrochloride	drug	62-85	methyldopa	drug	171-180	false
colestipol hydrochloride	drug	62-85	nicotinic acid	drug	183-196	false
colestipol hydrochloride	drug	62-85	niacin	drug	199-204	false
colestipol hydrochloride	drug	62-85	tolbutamide	drug	208-218	false
colestipol hydrochloride	drug	62-85	phenytoin	drug	221-229	false
colestipol hydrochloride	drug	62-85	warfarin	drug	234-241	false
aspirin	brand	137-143	clindamycin	brand	146-156	false
aspirin	brand	137-143	clofibrate	drug	159-168	false
aspirin	brand	137-143	methyldopa	drug	171-180	false
aspirin	brand	137-143	nicotinic acid	drug	183-196	false
aspirin	brand	137-143	niacin	drug	199-204	false
aspirin	brand	137-143	tolbutamide	drug	208-218	false
aspirin	brand	137-143	phenytoin	drug	221-229	false
aspirin	brand	137-143	warfarin	drug	234-241	false
clindamycin	brand	146-156	clofibrate	drug	159-168	false
clindamycin	brand	146-156	methyldopa	drug	171-180	false
clindamycin	brand	146-156	nicotinic acid	drug	183-196	false
clindamycin	brand	146-156	niacin	drug	199-204	false
clindamycin	brand	146-156	tolbutamide	drug	208-218	false
clindamycin	brand	146-156	phenytoin	drug	221-229	false
clindamycin	brand	146-156	warfarin	drug	234-241	false
clofibrate	drug	159-168	methyldopa	drug	171-180	false
clofibrate	drug	159-168	nicotinic acid	drug	183-196	false
clofibrate	drug	159-168	niacin	drug	199-204	false
clofibrate	drug	159-168	tolbutamide	drug	208-218	false
clofibrate	drug	159-168	phenytoin	drug	221-229	false
clofibrate	drug	159-168	warfarin	drug	234-241	false
methyldopa	drug	171-180	nicotinic acid	drug	183-196	false
methyldopa	drug	171-180	niacin	drug	199-204	false
methyldopa	drug	171-180	tolbutamide	drug	208-218	false
methyldopa	drug	171-180	phenytoin	drug	221-229	false
methyldopa	drug	171-180	warfarin	drug	234-241	false
nicotinic acid	drug	183-196	niacin	drug	199-204	false
nicotinic acid	drug	183-196	tolbutamide	drug	208-218	false
nicotinic acid	drug	183-196	phenytoin	drug	221-229	false
nicotinic acid	drug	183-196	warfarin	drug	234-241	false
niacin	drug	199-204	tolbutamide	drug	208-218	false
niacin	drug	199-204	phenytoin	drug	221-229	false
niacin	drug	199-204	warfarin	drug	234-241	false
tolbutamide	drug	208-218	phenytoin	drug	221-229	false
tolbutamide	drug	208-218	warfarin	drug	234-241	false
phenytoin	drug	221-229	warfarin	drug	234-241	false

DDI-DrugBank.d345.s14	Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
digitalis preparations	group	43-64	colestipol hydrochloride	drug	120-143	effect
digitalis preparations	group	43-64	digoxin	drug	168-174	false
digitalis preparations	group	43-64	digitoxin	drug	180-188	false
colestipol hydrochloride	drug	120-143	digoxin	drug	168-174	mechanism
colestipol hydrochloride	drug	120-143	digitoxin	drug	180-188	mechanism
digoxin	drug	168-174	digitoxin	drug	180-188	false

DDI-DrugBank.d345.s16	Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.
colestipol hydrochloride	drug	14-37	resin	group	132-136	false
colestipol hydrochloride	drug	14-37	colestipol hydrochloride	drug	208-231	false
resin	group	132-136	colestipol hydrochloride	drug	208-231	false

DDI-DrugBank.d345.s17	Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
Bile acid binding resins	group	0-23	phosphate	drug	72-80	mechanism
Bile acid binding resins	group	0-23	hydrocortisone	drug	98-111	mechanism
phosphate	drug	72-80	hydrocortisone	drug	98-111	false

DDI-DrugBank.d204.s0	When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.
beta-adrenergic receptor blocking agents	group	70-109	Anesthetics	group	112-122	int
beta-adrenergic receptor blocking agents	group	70-109	anesthetics	group	185-195	false
Anesthetics	group	112-122	anesthetics	group	185-195	false

DDI-DrugBank.d204.s1	Antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia;
Antidiabetic drugs	group	0-17	insulin	drug	36-42	false

DDI-DrugBank.d74.s0	FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.
FLUOTHANE	brand	0-8	non-depolarising muscle relaxant	group	33-64	effect
FLUOTHANE	brand	0-8	aminoglycosides	group	102-116	effect
non-depolarising muscle relaxant	group	33-64	aminoglycosides	group	102-116	false

DDI-DrugBank.d74.s1	FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.
FLUOTHANE	brand	0-8	tubocurarine	drug	82-93	effect

DDI-DrugBank.d74.s2	Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.
adrenaline	drug	57-66	FLUOTHANE	brand	99-107	advise

DDI-DrugBank.d74.s3	For this reason the dose of adrenaline should be restricted and an antiarrhythmic agent administered as appropriate.
adrenaline	drug	28-37	antiarrhythmic agent	group	67-86	false

DDI-DrugBank.d74.s4	Caution should also be applied for other sympathomimetics, and for aminophylline and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.
sympathomimetics	group	41-56	aminophylline	drug	67-79	false
sympathomimetics	group	41-56	theophylline	drug	85-96	false
sympathomimetics	group	41-56	tricyclic antidepressants	group	102-126	false
aminophylline	drug	67-79	theophylline	drug	85-96	false
aminophylline	drug	67-79	tricyclic antidepressants	group	102-126	false
theophylline	drug	85-96	tricyclic antidepressants	group	102-126	false

DDI-DrugBank.d70.s11	The potential effects of fulvestrant on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.
fulvestrant	drug	25-35	fulvestrant	drug	226-236	false

DDI-DrugBank.d177.s1	Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level.
vitamin K antagonists	group	59-79	phenytoin	drug	82-90	false
vitamin K antagonists	group	59-79	theophylline	drug	97-108	false
phenytoin	drug	82-90	theophylline	drug	97-108	false

DDI-DrugBank.d177.s3	For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.
vitamin K antagonists	group	18-38	nilutamide	drug	76-85	advise
vitamin K antagonists	group	18-38	vitamin K antagonists	group	167-187	false
nilutamide	drug	76-85	vitamin K antagonists	group	167-187	false

DDI-DrugBank.d325.s0	Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.
dopamine	drug	8-15	dopamine	drug	125-132	false

DDI-DrugBank.d325.s1	Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.
MAO inhibitors	group	36-49	dopamine HCl	drug	108-119	advise
MAO inhibitors	group	36-49	dopamine HCl	drug	153-164	false
dopamine HCl	drug	108-119	dopamine HCl	drug	153-164	false

DDI-DrugBank.d325.s2	Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.
dopamine HCl	drug	38-49	diuretic agents	group	55-69	effect

DDI-DrugBank.d325.s4	Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
dopamine	drug	19-26	beta-adrenergic blocking agents	group	47-77	effect
dopamine	drug	19-26	propranolol	drug	88-98	effect
dopamine	drug	19-26	metoprolol	drug	104-113	effect
beta-adrenergic blocking agents	group	47-77	propranolol	drug	88-98	false
beta-adrenergic blocking agents	group	47-77	metoprolol	drug	104-113	false
propranolol	drug	88-98	metoprolol	drug	104-113	false

DDI-DrugBank.d325.s5	The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.
dopamine HCl	drug	56-67	alpha-adrenergic blocking agents	group	87-118	effect

DDI-DrugBank.d325.s6	Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.
Dopamine	drug	0-7	alpha-adrenergic blocking agents	group	80-85;95-120	false
Dopamine	drug	0-7	beta-adrenergic blocking agents	drug	90-120	false
alpha-adrenergic blocking agents	group	80-85;95-120	beta-adrenergic blocking agents	drug	90-120	false

DDI-DrugBank.d325.s7	Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
Butyrophenones	group	0-13	haloperidol	drug	24-34	false
Butyrophenones	group	0-13	phenothiazines	group	41-54	false
Butyrophenones	group	0-13	dopamine	drug	73-80	effect
haloperidol	drug	24-34	phenothiazines	group	41-54	false
haloperidol	drug	24-34	dopamine	drug	73-80	effect
phenothiazines	group	41-54	dopamine	drug	73-80	effect

DDI-DrugBank.d325.s8	Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
Cyclopropane	drug	0-11	halogenated hydrocarbon anesthetics	group	16-50	false
Cyclopropane	drug	0-11	catecholamines	group	177-190	effect
Cyclopropane	drug	0-11	dopamine	drug	201-208	effect
halogenated hydrocarbon anesthetics	group	16-50	catecholamines	group	177-190	effect
halogenated hydrocarbon anesthetics	group	16-50	dopamine	drug	201-208	effect
catecholamines	group	177-190	dopamine	drug	201-208	false

DDI-DrugBank.d325.s10	Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
dopamine HCl	drug	66-77	cyclopropane	drug	101-112	advise
dopamine HCl	drug	66-77	halogenated hydrocarbon anesthetics	group	117-151	advise
cyclopropane	drug	101-112	halogenated hydrocarbon anesthetics	group	117-151	false

DDI-DrugBank.d325.s11	It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
dopamine	drug	70-77	propranolol	drug	148-158	effect

DDI-DrugBank.d325.s12	The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.
vasopressor	group	23-33	ergonovine	drug	70-79	false
vasopressor	group	23-33	oxytocic drugs	group	91-104	effect
ergonovine	drug	70-79	oxytocic drugs	group	91-104	effect

DDI-DrugBank.d325.s13	Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.
phenytoin	drug	18-26	dopamine HCl	drug	50-61	effect

DDI-DrugBank.d325.s14	It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.
dopamine HCl	drug	43-54	phenytoin	drug	73-81	advise
dopamine HCl	drug	43-54	anticonvulsant	group	101-114	false
phenytoin	drug	73-81	anticonvulsant	group	101-114	false

DDI-DrugBank.d378.s0	Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.
aminoglycosides	group	62-76	MAXIPIME	brand	106-113	advise
aminoglycosides	group	62-76	aminoglycoside antibiotics	group	187-212	false
MAXIPIME	brand	106-113	aminoglycoside antibiotics	group	187-212	false

DDI-DrugBank.d378.s1	Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
cephalosporins	group	79-92	diuretics	group	106-114	effect
cephalosporins	group	79-92	furosemide	drug	124-133	effect
diuretics	group	106-114	furosemide	drug	124-133	false

DDI-DrugBank.d443.s0	Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
Uricosuric Agents	group	0-16	Aspirin	brand	19-25	false
Uricosuric Agents	group	0-16	probenecid	drug	55-64	false
Uricosuric Agents	group	0-16	sulfinpyrazone	drug	67-80	false
Uricosuric Agents	group	0-16	phenylbutazone	drug	87-100	false
Aspirin	brand	19-25	probenecid	drug	55-64	effect
Aspirin	brand	19-25	sulfinpyrazone	drug	67-80	effect
Aspirin	brand	19-25	phenylbutazone	drug	87-100	effect
probenecid	drug	55-64	sulfinpyrazone	drug	67-80	false
probenecid	drug	55-64	phenylbutazone	drug	87-100	false
sulfinpyrazone	drug	67-80	phenylbutazone	drug	87-100	false

DDI-DrugBank.d443.s1	Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.
Alcohol	drug	0-6	aspirin	brand	39-45	effect

DDI-DrugBank.d443.s2	Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
Corticosteroids	group	0-14	aspirin	brand	49-55	effect

DDI-DrugBank.d443.s3	Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
Pyrazolone Derivatives	group	0-21	phenylbutazone	drug	24-37	false
Pyrazolone Derivatives	group	0-21	oxyphenbutazone	drug	40-54	false
Pyrazolone Derivatives	group	0-21	dipyrone	drug	70-77	false
Pyrazolone Derivatives	group	0-21	aspirin	drug	113-119	effect
phenylbutazone	drug	24-37	oxyphenbutazone	drug	40-54	false
phenylbutazone	drug	24-37	dipyrone	drug	70-77	false
phenylbutazone	drug	24-37	aspirin	drug	113-119	effect
oxyphenbutazone	drug	40-54	dipyrone	drug	70-77	false
oxyphenbutazone	drug	40-54	aspirin	drug	113-119	effect
dipyrone	drug	70-77	aspirin	drug	113-119	effect

DDI-DrugBank.d443.s4	Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
Nonsteroidal Antiinflammatory	drug	0-28	Aspirin	drug	38-44	false
Nonsteroidal Antiinflammatory	drug	0-28	nonsteroidal anti-inflammatory	drug	103-132	false
Aspirin	drug	38-44	nonsteroidal anti-inflammatory	drug	103-132	advise

DDI-DrugBank.d443.s5	Urinary Alkalinizers: Decrease aspirin effectiveness by increasing the rate of salicylate renal excretion.
aspirin	brand	31-37	salicylate	group	79-88	false

DDI-DrugBank.d443.s6	Phenobarbital: Decreases aspirin effectiveness by enzyme induction.
Phenobarbital	drug	0-12	aspirin	brand	25-31	mechanism

DDI-DrugBank.d443.s7	Phenytoin: Serum phenytoin levels may be increased by aspirin.
Phenytoin	drug	0-8	phenytoin	drug	17-25	false
Phenytoin	drug	0-8	aspirin	brand	54-60	false
phenytoin	drug	17-25	aspirin	brand	54-60	effect

DDI-DrugBank.d443.s8	Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.
Propranolol	drug	0-10	aspirins	brand	26-33	effect

DDI-DrugBank.d443.s9	Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.
Antacids	group	0-7	Aspirin	brand	25-31	false
Antacids	group	0-7	antacids	group	71-78	false
Aspirin	brand	25-31	antacids	group	71-78	advise

DDI-DrugBank.d253.s0	Beta-adrenergic blocking agents: concurrent use may blunt the response to arbutamine.
Beta-adrenergic blocking agents	group	0-30	arbutamine	drug	74-83	false

DDI-DrugBank.d253.s1	Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.
Beta-adrenergic blocking agents	group	0-30	arbutamine	drug	91-100	advise

DDI-DrugBank.d253.s2	Antiarrhythmic agents, class I (such as flecainide, lidocaine, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.
Antiarrhythmic agents, class I	drug	0-29	flecainide	drug	40-49	false
Antiarrhythmic agents, class I	drug	0-29	lidocaine	drug	52-60	false
Antiarrhythmic agents, class I	drug	0-29	quinidine	drug	66-74	false
Antiarrhythmic agents, class I	drug	0-29	arbutamine	drug	98-107	false
flecainide	drug	40-49	lidocaine	drug	52-60	false
flecainide	drug	40-49	quinidine	drug	66-74	false
flecainide	drug	40-49	arbutamine	drug	98-107	false
lidocaine	drug	52-60	quinidine	drug	66-74	false
lidocaine	drug	52-60	arbutamine	drug	98-107	false
quinidine	drug	66-74	arbutamine	drug	98-107	false

DDI-DrugBank.d253.s3	Antidepressants (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
Antidepressants	group	0-14	tricyclic	group	17-25	false
Antidepressants	group	0-14	atropine	drug	29-36	false
Antidepressants	group	0-14	anticholinergic agents	group	47-68	false
Antidepressants	group	0-14	digitalis glycosides	group	74-93	false
Antidepressants	group	0-14	arbutamine	drug	116-125	false
tricyclic	group	17-25	atropine	drug	29-36	false
tricyclic	group	17-25	anticholinergic agents	group	47-68	false
tricyclic	group	17-25	digitalis glycosides	group	74-93	false
tricyclic	group	17-25	arbutamine	drug	116-125	false
atropine	drug	29-36	anticholinergic agents	group	47-68	false
atropine	drug	29-36	digitalis glycosides	group	74-93	false
atropine	drug	29-36	arbutamine	drug	116-125	false
anticholinergic agents	group	47-68	digitalis glycosides	group	74-93	false
anticholinergic agents	group	47-68	arbutamine	drug	116-125	false
digitalis glycosides	group	74-93	arbutamine	drug	116-125	false

DDI-DrugBank.d527.s1	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
ACE inhibitors	group	157-170	disopyramide	drug	173-184	false
ACE inhibitors	group	157-170	fibrates	group	187-194	false
ACE inhibitors	group	157-170	fluoxetine	drug	197-206	false
ACE inhibitors	group	157-170	MAO inhibitors	group	209-222	false
ACE inhibitors	group	157-170	propoxyphene	drug	225-236	false
ACE inhibitors	group	157-170	salicylates	group	239-249	false
ACE inhibitors	group	157-170	somatostatin analog	group	252-270	false
ACE inhibitors	group	157-170	octreotide	drug	279-288	false
ACE inhibitors	group	157-170	sulfonamide antibiotics	group	292-314	false
disopyramide	drug	173-184	fibrates	group	187-194	false
disopyramide	drug	173-184	fluoxetine	drug	197-206	false
disopyramide	drug	173-184	MAO inhibitors	group	209-222	false
disopyramide	drug	173-184	propoxyphene	drug	225-236	false
disopyramide	drug	173-184	salicylates	group	239-249	false
disopyramide	drug	173-184	somatostatin analog	group	252-270	false
disopyramide	drug	173-184	octreotide	drug	279-288	false
disopyramide	drug	173-184	sulfonamide antibiotics	group	292-314	false
fibrates	group	187-194	fluoxetine	drug	197-206	false
fibrates	group	187-194	MAO inhibitors	group	209-222	false
fibrates	group	187-194	propoxyphene	drug	225-236	false
fibrates	group	187-194	salicylates	group	239-249	false
fibrates	group	187-194	somatostatin analog	group	252-270	false
fibrates	group	187-194	octreotide	drug	279-288	false
fibrates	group	187-194	sulfonamide antibiotics	group	292-314	false
fluoxetine	drug	197-206	MAO inhibitors	group	209-222	false
fluoxetine	drug	197-206	propoxyphene	drug	225-236	false
fluoxetine	drug	197-206	salicylates	group	239-249	false
fluoxetine	drug	197-206	somatostatin analog	group	252-270	false
fluoxetine	drug	197-206	octreotide	drug	279-288	false
fluoxetine	drug	197-206	sulfonamide antibiotics	group	292-314	false
MAO inhibitors	group	209-222	propoxyphene	drug	225-236	false
MAO inhibitors	group	209-222	salicylates	group	239-249	false
MAO inhibitors	group	209-222	somatostatin analog	group	252-270	false
MAO inhibitors	group	209-222	octreotide	drug	279-288	false
MAO inhibitors	group	209-222	sulfonamide antibiotics	group	292-314	false
propoxyphene	drug	225-236	salicylates	group	239-249	false
propoxyphene	drug	225-236	somatostatin analog	group	252-270	false
propoxyphene	drug	225-236	octreotide	drug	279-288	false
propoxyphene	drug	225-236	sulfonamide antibiotics	group	292-314	false
salicylates	group	239-249	somatostatin analog	group	252-270	false
salicylates	group	239-249	octreotide	drug	279-288	false
salicylates	group	239-249	sulfonamide antibiotics	group	292-314	false
somatostatin analog	group	252-270	octreotide	drug	279-288	false
somatostatin analog	group	252-270	sulfonamide antibiotics	group	292-314	false
octreotide	drug	279-288	sulfonamide antibiotics	group	292-314	false

DDI-DrugBank.d527.s2	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
insulin	drug	94-100	corticosteroids	group	103-117	false
insulin	drug	94-100	danazol	drug	120-126	false
insulin	drug	94-100	diuretics	group	129-137	false
insulin	drug	94-100	sympathomimetic agents	group	140-161	false
insulin	drug	94-100	epinephrine	drug	170-180	false
insulin	drug	94-100	albuterol	drug	183-191	false
insulin	drug	94-100	terbutaline	drug	194-204	false
insulin	drug	94-100	isoniazid	drug	208-216	false
insulin	drug	94-100	phenothiazine derivatives	group	219-243	false
insulin	drug	94-100	somatropin	drug	246-255	false
insulin	drug	94-100	thyroid hormones	group	258-273	false
insulin	drug	94-100	estrogens	group	276-284	false
insulin	drug	94-100	progestogens	group	287-298	false
insulin	drug	94-100	contraceptives	group	315-328	false
corticosteroids	group	103-117	danazol	drug	120-126	false
corticosteroids	group	103-117	diuretics	group	129-137	false
corticosteroids	group	103-117	sympathomimetic agents	group	140-161	false
corticosteroids	group	103-117	epinephrine	drug	170-180	false
corticosteroids	group	103-117	albuterol	drug	183-191	false
corticosteroids	group	103-117	terbutaline	drug	194-204	false
corticosteroids	group	103-117	isoniazid	drug	208-216	false
corticosteroids	group	103-117	phenothiazine derivatives	group	219-243	false
corticosteroids	group	103-117	somatropin	drug	246-255	false
corticosteroids	group	103-117	thyroid hormones	group	258-273	false
corticosteroids	group	103-117	estrogens	group	276-284	false
corticosteroids	group	103-117	progestogens	group	287-298	false
corticosteroids	group	103-117	contraceptives	group	315-328	false
danazol	drug	120-126	diuretics	group	129-137	false
danazol	drug	120-126	sympathomimetic agents	group	140-161	false
danazol	drug	120-126	epinephrine	drug	170-180	false
danazol	drug	120-126	albuterol	drug	183-191	false
danazol	drug	120-126	terbutaline	drug	194-204	false
danazol	drug	120-126	isoniazid	drug	208-216	false
danazol	drug	120-126	phenothiazine derivatives	group	219-243	false
danazol	drug	120-126	somatropin	drug	246-255	false
danazol	drug	120-126	thyroid hormones	group	258-273	false
danazol	drug	120-126	estrogens	group	276-284	false
danazol	drug	120-126	progestogens	group	287-298	false
danazol	drug	120-126	contraceptives	group	315-328	false
diuretics	group	129-137	sympathomimetic agents	group	140-161	false
diuretics	group	129-137	epinephrine	drug	170-180	false
diuretics	group	129-137	albuterol	drug	183-191	false
diuretics	group	129-137	terbutaline	drug	194-204	false
diuretics	group	129-137	isoniazid	drug	208-216	false
diuretics	group	129-137	phenothiazine derivatives	group	219-243	false
diuretics	group	129-137	somatropin	drug	246-255	false
diuretics	group	129-137	thyroid hormones	group	258-273	false
diuretics	group	129-137	estrogens	group	276-284	false
diuretics	group	129-137	progestogens	group	287-298	false
diuretics	group	129-137	contraceptives	group	315-328	false
sympathomimetic agents	group	140-161	epinephrine	drug	170-180	false
sympathomimetic agents	group	140-161	albuterol	drug	183-191	false
sympathomimetic agents	group	140-161	terbutaline	drug	194-204	false
sympathomimetic agents	group	140-161	isoniazid	drug	208-216	false
sympathomimetic agents	group	140-161	phenothiazine derivatives	group	219-243	false
sympathomimetic agents	group	140-161	somatropin	drug	246-255	false
sympathomimetic agents	group	140-161	thyroid hormones	group	258-273	false
sympathomimetic agents	group	140-161	estrogens	group	276-284	false
sympathomimetic agents	group	140-161	progestogens	group	287-298	false
sympathomimetic agents	group	140-161	contraceptives	group	315-328	false
epinephrine	drug	170-180	albuterol	drug	183-191	false
epinephrine	drug	170-180	terbutaline	drug	194-204	false
epinephrine	drug	170-180	isoniazid	drug	208-216	false
epinephrine	drug	170-180	phenothiazine derivatives	group	219-243	false
epinephrine	drug	170-180	somatropin	drug	246-255	false
epinephrine	drug	170-180	thyroid hormones	group	258-273	false
epinephrine	drug	170-180	estrogens	group	276-284	false
epinephrine	drug	170-180	progestogens	group	287-298	false
epinephrine	drug	170-180	contraceptives	group	315-328	false
albuterol	drug	183-191	terbutaline	drug	194-204	false
albuterol	drug	183-191	isoniazid	drug	208-216	false
albuterol	drug	183-191	phenothiazine derivatives	group	219-243	false
albuterol	drug	183-191	somatropin	drug	246-255	false
albuterol	drug	183-191	thyroid hormones	group	258-273	false
albuterol	drug	183-191	estrogens	group	276-284	false
albuterol	drug	183-191	progestogens	group	287-298	false
albuterol	drug	183-191	contraceptives	group	315-328	false
terbutaline	drug	194-204	isoniazid	drug	208-216	false
terbutaline	drug	194-204	phenothiazine derivatives	group	219-243	false
terbutaline	drug	194-204	somatropin	drug	246-255	false
terbutaline	drug	194-204	thyroid hormones	group	258-273	false
terbutaline	drug	194-204	estrogens	group	276-284	false
terbutaline	drug	194-204	progestogens	group	287-298	false
terbutaline	drug	194-204	contraceptives	group	315-328	false
isoniazid	drug	208-216	phenothiazine derivatives	group	219-243	false
isoniazid	drug	208-216	somatropin	drug	246-255	false
isoniazid	drug	208-216	thyroid hormones	group	258-273	false
isoniazid	drug	208-216	estrogens	group	276-284	false
isoniazid	drug	208-216	progestogens	group	287-298	false
isoniazid	drug	208-216	contraceptives	group	315-328	false
phenothiazine derivatives	group	219-243	somatropin	drug	246-255	false
phenothiazine derivatives	group	219-243	thyroid hormones	group	258-273	false
phenothiazine derivatives	group	219-243	estrogens	group	276-284	false
phenothiazine derivatives	group	219-243	progestogens	group	287-298	false
phenothiazine derivatives	group	219-243	contraceptives	group	315-328	false
somatropin	drug	246-255	thyroid hormones	group	258-273	false
somatropin	drug	246-255	estrogens	group	276-284	false
somatropin	drug	246-255	progestogens	group	287-298	false
somatropin	drug	246-255	contraceptives	group	315-328	false
thyroid hormones	group	258-273	estrogens	group	276-284	false
thyroid hormones	group	258-273	progestogens	group	287-298	false
thyroid hormones	group	258-273	contraceptives	group	315-328	false
estrogens	group	276-284	progestogens	group	287-298	false
estrogens	group	276-284	contraceptives	group	315-328	false
progestogens	group	287-298	contraceptives	group	315-328	false

DDI-DrugBank.d527.s3	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
Beta-blockers	group	0-12	clonidine	drug	15-23	false
Beta-blockers	group	0-12	lithium	drug	26-32	false
Beta-blockers	group	0-12	alcohol	drug	45-51	false
Beta-blockers	group	0-12	insulin	drug	122-128	effect
clonidine	drug	15-23	lithium	drug	26-32	false
clonidine	drug	15-23	alcohol	drug	45-51	false
clonidine	drug	15-23	insulin	drug	122-128	effect
lithium	drug	26-32	alcohol	drug	45-51	false
lithium	drug	26-32	insulin	drug	122-128	effect
alcohol	drug	45-51	insulin	drug	122-128	effect

DDI-DrugBank.d527.s5	In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.
beta-blockers	group	77-89	clonidine	drug	92-100	false
beta-blockers	group	77-89	guanethidine	drug	103-114	false
beta-blockers	group	77-89	reserpine	drug	121-129	false
clonidine	drug	92-100	guanethidine	drug	103-114	false
clonidine	drug	92-100	reserpine	drug	121-129	false
guanethidine	drug	103-114	reserpine	drug	121-129	false

DDI-DrugBank.d185.s0	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/SMX).
ACZONE	brand	65-70	trimethoprim	drug	133-144	false
ACZONE	brand	65-70	sulfamethoxazole	drug	146-161	false
ACZONE	brand	65-70	TMP	drug	164-166	false
ACZONE	brand	65-70	SMX	drug	168-170	false
trimethoprim	drug	133-144	sulfamethoxazole	drug	146-161	false
trimethoprim	drug	133-144	TMP	drug	164-166	false
trimethoprim	drug	133-144	SMX	drug	168-170	false
sulfamethoxazole	drug	146-161	TMP	drug	164-166	false
sulfamethoxazole	drug	146-161	SMX	drug	168-170	false
TMP	drug	164-166	SMX	drug	168-170	false

DDI-DrugBank.d185.s1	During co-administration, systemic levels of TMP and SMX were essentially unchanged.
TMP	drug	45-47	SMX	drug	53-55	false

DDI-DrugBank.d185.s2	Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP/SMX.
dapsone hydroxylamine	drug_n	40-60	DHA	drug_n	63-65	false
dapsone hydroxylamine	drug_n	40-60	TMP	drug	109-111	false
dapsone hydroxylamine	drug_n	40-60	SMX	drug	113-115	false
DHA	drug_n	63-65	TMP	drug	109-111	false
DHA	drug_n	63-65	SMX	drug	113-115	false
TMP	drug	109-111	SMX	drug	113-115	false

DDI-DrugBank.d185.s3	Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX.
TMP	drug	118-120	SMX	drug	122-124	false

DDI-DrugBank.d185.s4	Certain concomitant medications (such as rifampin, anticonvulsants, St.
rifampin	drug	41-48	anticonvulsants	group	51-65	false

DDI-DrugBank.d185.s5	John s wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis.
dapsone hydroxylamine	drug_n	43-63	dapsone	drug	82-88	false

DDI-DrugBank.d185.s6	With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
dapsone	drug	10-16	folic acid antagonists	group	29-50	effect
dapsone	drug	10-16	pyrimethamine	drug	60-72	effect
folic acid antagonists	group	29-50	pyrimethamine	drug	60-72	false

DDI-DrugBank.d372.s0	Cytadren accelerates the metabolism of dexamethasone;
Cytadren	brand	0-7	dexamethasone	drug	39-51	mechanism

DDI-DrugBank.d372.s1	therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed.
glucocorticoid	group	14-27	hydrocortisone	drug	52-65	false

DDI-DrugBank.d372.s2	Aminoglutethimide diminishes the effect of coumarin and warfarin.
Aminoglutethimide	drug	0-16	coumarin	group	43-50	effect
Aminoglutethimide	drug	0-16	warfarin	drug	56-63	effect
coumarin	group	43-50	warfarin	drug	56-63	false

DDI-DrugBank.d416.s0	Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
PAH	drug	32-34	sulfonamides	group	103-114	effect
PAH	drug	32-34	procaine	drug	117-124	effect
PAH	drug	32-34	thiazolesulfone	drug	130-144	effect
sulfonamides	group	103-114	procaine	drug	117-124	false
sulfonamides	group	103-114	thiazolesulfone	drug	130-144	false
procaine	drug	117-124	thiazolesulfone	drug	130-144	false

DDI-DrugBank.d416.s2	Probenecid depresses tubular secretion of certain weak acids such as PAH.
Probenecid	drug	0-9	PAH	drug	69-71	mechanism

DDI-DrugBank.d416.s3	Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.
probenecid	drug	30-39	PAH	drug	79-81	effect

DDI-DrugBank.d450.s0	Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.
Potassium-depleting diuretics	group	0-28	digitalis	group	65-73	effect

DDI-DrugBank.d450.s2	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
Quinidine	drug	0-8	verapamil	drug	11-19	false
Quinidine	drug	0-8	amiodarone	drug	22-31	false
Quinidine	drug	0-8	propafenone	drug	34-44	false
Quinidine	drug	0-8	indomethacin	drug	47-58	false
Quinidine	drug	0-8	itraconazole	drug	61-72	false
Quinidine	drug	0-8	alprazolam	drug	75-84	false
Quinidine	drug	0-8	spironolactone	drug	91-104	false
Quinidine	drug	0-8	digoxin	drug	122-128	mechanism
Quinidine	drug	0-8	digitalis	group	248-256	false
verapamil	drug	11-19	amiodarone	drug	22-31	false
verapamil	drug	11-19	propafenone	drug	34-44	false
verapamil	drug	11-19	indomethacin	drug	47-58	false
verapamil	drug	11-19	itraconazole	drug	61-72	false
verapamil	drug	11-19	alprazolam	drug	75-84	false
verapamil	drug	11-19	spironolactone	drug	91-104	false
verapamil	drug	11-19	digoxin	drug	122-128	mechanism
verapamil	drug	11-19	digitalis	group	248-256	false
amiodarone	drug	22-31	propafenone	drug	34-44	false
amiodarone	drug	22-31	indomethacin	drug	47-58	false
amiodarone	drug	22-31	itraconazole	drug	61-72	false
amiodarone	drug	22-31	alprazolam	drug	75-84	false
amiodarone	drug	22-31	spironolactone	drug	91-104	false
amiodarone	drug	22-31	digoxin	drug	122-128	mechanism
amiodarone	drug	22-31	digitalis	group	248-256	false
propafenone	drug	34-44	indomethacin	drug	47-58	false
propafenone	drug	34-44	itraconazole	drug	61-72	false
propafenone	drug	34-44	alprazolam	drug	75-84	false
propafenone	drug	34-44	spironolactone	drug	91-104	false
propafenone	drug	34-44	digoxin	drug	122-128	mechanism
propafenone	drug	34-44	digitalis	group	248-256	false
indomethacin	drug	47-58	itraconazole	drug	61-72	false
indomethacin	drug	47-58	alprazolam	drug	75-84	false
indomethacin	drug	47-58	spironolactone	drug	91-104	false
indomethacin	drug	47-58	digoxin	drug	122-128	mechanism
indomethacin	drug	47-58	digitalis	group	248-256	false
itraconazole	drug	61-72	alprazolam	drug	75-84	false
itraconazole	drug	61-72	spironolactone	drug	91-104	false
itraconazole	drug	61-72	digoxin	drug	122-128	mechanism
itraconazole	drug	61-72	digitalis	group	248-256	false
alprazolam	drug	75-84	spironolactone	drug	91-104	false
alprazolam	drug	75-84	digoxin	drug	122-128	mechanism
alprazolam	drug	75-84	digitalis	group	248-256	false
spironolactone	drug	91-104	digoxin	drug	122-128	mechanism
spironolactone	drug	91-104	digitalis	group	248-256	false
digoxin	drug	122-128	digitalis	group	248-256	false

DDI-DrugBank.d450.s3	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
Erythromycin	drug	0-11	clarithromycin	drug	17-30	false
Erythromycin	drug	0-11	macrolide antibiotics	group	52-72	false
Erythromycin	drug	0-11	tetracycline	drug	79-90	false
Erythromycin	drug	0-11	digoxin	drug	105-111	mechanism
Erythromycin	drug	0-11	digoxin	drug	151-157	false
Erythromycin	drug	0-11	digitalis	group	215-223	false
clarithromycin	drug	17-30	macrolide antibiotics	group	52-72	false
clarithromycin	drug	17-30	tetracycline	drug	79-90	false
clarithromycin	drug	17-30	digoxin	drug	105-111	mechanism
clarithromycin	drug	17-30	digoxin	drug	151-157	false
clarithromycin	drug	17-30	digitalis	group	215-223	false
macrolide antibiotics	group	52-72	tetracycline	drug	79-90	false
macrolide antibiotics	group	52-72	digoxin	drug	105-111	mechanism
macrolide antibiotics	group	52-72	digoxin	drug	151-157	false
macrolide antibiotics	group	52-72	digitalis	group	215-223	false
tetracycline	drug	79-90	digoxin	drug	105-111	mechanism
tetracycline	drug	79-90	digoxin	drug	151-157	false
tetracycline	drug	79-90	digitalis	group	215-223	false
digoxin	drug	105-111	digoxin	drug	151-157	false
digoxin	drug	105-111	digitalis	group	215-223	false
digoxin	drug	151-157	digitalis	group	215-223	false

DDI-DrugBank.d450.s5	Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
Propantheline	drug	0-12	diphenoxylate	drug	18-30	false
Propantheline	drug	0-12	digoxin	drug	74-80	mechanism
diphenoxylate	drug	18-30	digoxin	drug	74-80	mechanism

DDI-DrugBank.d450.s6	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
Antacids	group	0-7	kaolin	drug	10-15	false
Antacids	group	0-7	sulfasalazine	drug	25-37	false
Antacids	group	0-7	neomycin	drug	40-47	false
Antacids	group	0-7	cholestyramine	drug	50-63	false
Antacids	group	0-7	metoclopramide	drug	96-109	false
Antacids	group	0-7	digoxin	drug	141-147	mechanism
kaolin	drug	10-15	sulfasalazine	drug	25-37	false
kaolin	drug	10-15	neomycin	drug	40-47	false
kaolin	drug	10-15	cholestyramine	drug	50-63	false
kaolin	drug	10-15	metoclopramide	drug	96-109	false
kaolin	drug	10-15	digoxin	drug	141-147	mechanism
sulfasalazine	drug	25-37	neomycin	drug	40-47	false
sulfasalazine	drug	25-37	cholestyramine	drug	50-63	false
sulfasalazine	drug	25-37	metoclopramide	drug	96-109	false
sulfasalazine	drug	25-37	digoxin	drug	141-147	mechanism
neomycin	drug	40-47	cholestyramine	drug	50-63	false
neomycin	drug	40-47	metoclopramide	drug	96-109	false
neomycin	drug	40-47	digoxin	drug	141-147	mechanism
cholestyramine	drug	50-63	metoclopramide	drug	96-109	false
cholestyramine	drug	50-63	digoxin	drug	141-147	mechanism
metoclopramide	drug	96-109	digoxin	drug	141-147	mechanism

DDI-DrugBank.d450.s7	Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.
Rifampin	drug	0-7	digoxin	drug	28-34	mechanism
Rifampin	drug	0-7	digoxin	drug	139-145	false
digoxin	drug	28-34	digoxin	drug	139-145	false

DDI-DrugBank.d450.s8	There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum digoxin concentration.
quinine	drug	81-87	penicillamine	drug	90-102	false
quinine	drug	81-87	digoxin	drug	114-120	false
penicillamine	drug	90-102	digoxin	drug	114-120	false

DDI-DrugBank.d450.s9	Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.
Thyroid	group	0-6	digoxin	drug	98-104	advise

DDI-DrugBank.d450.s10	Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.
digoxin	drug	19-25	sympathomimetics	group	31-46	effect

DDI-DrugBank.d450.s12	Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
beta-adrenergic blockers	group	9-32	calcium channel blockers	group	37-60	false
beta-adrenergic blockers	group	9-32	digoxin	drug	66-72	effect
calcium channel blockers	group	37-60	digoxin	drug	66-72	effect

DDI-DrugBank.d450.s14	Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.
digoxin	drug	56-62	digoxin	drug	230-236	false

DDI-DrugBank.d324.s1	CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
Ethanol	drug	17-23	Sonata	brand	26-31	false
Ethanol	drug	17-23	ethanol	drug	80-86	false
Ethanol	drug	17-23	ethanol	drug	152-158	false
Ethanol	drug	17-23	ethanol	drug	326-332	false
Sonata	brand	26-31	ethanol	drug	80-86	effect
Sonata	brand	26-31	ethanol	drug	152-158	false
Sonata	brand	26-31	ethanol	drug	326-332	false
ethanol	drug	80-86	ethanol	drug	152-158	false
ethanol	drug	80-86	ethanol	drug	326-332	false
ethanol	drug	152-158	ethanol	drug	326-332	false

DDI-DrugBank.d324.s3	zaleplon did not affect the pharmacokinetics of ethanol.
zaleplon	drug	0-7	ethanol	drug	48-54	false

DDI-DrugBank.d324.s4	Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
Imipramine	drug	0-9	Sonata	brand	48-53	false
Imipramine	drug	0-9	imipramine	drug	65-74	false
Sonata	brand	48-53	imipramine	drug	65-74	effect

DDI-DrugBank.d324.s6	Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.
Paroxetine	drug	0-9	Sonata	brand	49-54	false
Paroxetine	drug	0-9	paroxetine	drug	66-75	false
Sonata	brand	49-54	paroxetine	drug	66-75	false

DDI-DrugBank.d324.s7	Additionally, paroxetine did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in zaleplon s metabolism.
paroxetine	drug	14-23	Sonata	brand	63-68	false
paroxetine	drug	14-23	zaleplon	drug	117-124	false
Sonata	brand	63-68	zaleplon	drug	117-124	false

DDI-DrugBank.d324.s8	Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
Thioridazine	drug	0-11	Sonata	brand	50-55	false
Thioridazine	drug	0-11	thioridazine	drug	67-78	false
Sonata	brand	50-55	thioridazine	drug	67-78	effect

DDI-DrugBank.d324.s10	Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.
Venlafaxine	drug	0-10	zaleplon	drug	50-57	false
Venlafaxine	drug	0-10	venlafaxine	drug	87-97	false
Venlafaxine	drug	0-10	zaleplon	drug	204-211	false
Venlafaxine	drug	0-10	venlafaxine	drug	216-226	false
zaleplon	drug	50-57	venlafaxine	drug	87-97	false
zaleplon	drug	50-57	zaleplon	drug	204-211	false
zaleplon	drug	50-57	venlafaxine	drug	216-226	false
venlafaxine	drug	87-97	zaleplon	drug	204-211	false
venlafaxine	drug	87-97	venlafaxine	drug	216-226	false
zaleplon	drug	204-211	venlafaxine	drug	216-226	false

DDI-DrugBank.d324.s11	In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.
zaleplon	drug	89-96	venlafaxine	drug	102-112	false

DDI-DrugBank.d324.s12	Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
Promethazine	drug	0-11	zaleplon	drug	51-58	false
Promethazine	drug	0-11	promethazine	drug	64-75	false
Promethazine	drug	0-11	zaleplon	drug	169-176	false
zaleplon	drug	51-58	promethazine	drug	64-75	mechanism
zaleplon	drug	51-58	zaleplon	drug	169-176	false
promethazine	drug	64-75	zaleplon	drug	169-176	false

DDI-DrugBank.d324.s13	However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated.
zaleplon	drug	53-60	promethazine	drug	66-77	false

DDI-DrugBank.d324.s15	Drugs That Induce CYP3A4 Rifampin: CYP3A4 is ordinarily a minor metabolizing enzyme of zaleplon.
Rifampin	drug	25-32	zaleplon	drug	87-94	false

DDI-DrugBank.d324.s16	Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.
rifampin	drug	58-65	zaleplon	drug	128-135	mechanism

DDI-DrugBank.d324.s18	An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital.
hypnotic agent	group	36-49	rifampin	drug	112-119	false
hypnotic agent	group	36-49	phenytoin	drug	122-130	false
hypnotic agent	group	36-49	carbamazepine	drug	133-145	false
hypnotic agent	group	36-49	phenobarbital	drug	152-164	false
rifampin	drug	112-119	phenytoin	drug	122-130	false
rifampin	drug	112-119	carbamazepine	drug	133-145	false
rifampin	drug	112-119	phenobarbital	drug	152-164	false
phenytoin	drug	122-130	carbamazepine	drug	133-145	false
phenytoin	drug	122-130	phenobarbital	drug	152-164	false
carbamazepine	drug	133-145	phenobarbital	drug	152-164	false

DDI-DrugBank.d324.s19	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.
zaleplon	drug	85-92	5-oxo-desethylzaleplon	drug_n	180-201	false
zaleplon	drug	85-92	5-oxo-desethylzaleplon glucuronide	drug_n	207-240	false
zaleplon	drug	85-92	zaleplon	drug	292-299	false
5-oxo-desethylzaleplon	drug_n	180-201	5-oxo-desethylzaleplon glucuronide	drug_n	207-240	false
5-oxo-desethylzaleplon	drug_n	180-201	zaleplon	drug	292-299	false
5-oxo-desethylzaleplon glucuronide	drug_n	207-240	zaleplon	drug	292-299	false

DDI-DrugBank.d324.s20	Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
zaleplon	drug	42-49	erythromycin	drug	56-67	mechanism
zaleplon	drug	42-49	zaleplon	drug	167-174	false
erythromycin	drug	56-67	zaleplon	drug	167-174	false

DDI-DrugBank.d324.s22	Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
ketoconazole	drug	49-60	zaleplon	drug	111-118	mechanism

DDI-DrugBank.d324.s25	Diphenhydramine: Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.
Diphenhydramine	drug	0-14	Diphenhydramine	drug	17-31	false

DDI-DrugBank.d324.s26	There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.
zaleplon	drug	48-55	diphenhydramine	drug	61-75	false

DDI-DrugBank.d324.s28	Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.
Cimetidine	drug	52-61	Cimetidine	drug	64-73	false
Cimetidine	drug	52-61	zaleplon	drug	217-224	false
Cimetidine	drug	64-73	zaleplon	drug	217-224	mechanism

DDI-DrugBank.d324.s29	Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
Sonata	brand	30-35	cimetidine	drug	49-58	mechanism
Sonata	brand	30-35	zaleplon	drug	122-129	false
cimetidine	drug	49-58	zaleplon	drug	122-129	false

DDI-DrugBank.d324.s34	Drugs with a Narrow Therapeutic Index Digoxin: Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).
Digoxin	drug	38-44	Sonata	brand	47-52	false
Digoxin	drug	38-44	digoxin	drug	127-133	false
Sonata	brand	47-52	digoxin	drug	127-133	false

DDI-DrugBank.d324.s35	Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.
Warfarin	drug	0-7	Sonata	brand	33-38	false
Warfarin	drug	0-7	warfarin	drug	104-111	false
Warfarin	drug	0-7	warfarin	drug	220-227	false
Sonata	brand	33-38	warfarin	drug	104-111	false
Sonata	brand	33-38	warfarin	drug	220-227	false
warfarin	drug	104-111	warfarin	drug	220-227	false

DDI-DrugBank.d324.s36	Drugs That Alter Renal Excretion Ibuprofen: Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs.
Ibuprofen	drug	33-41	Ibuprofen	drug	44-52	false

DDI-DrugBank.d324.s37	There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug.
zaleplon	drug	58-65	ibuprofen	drug	71-79	false

DDI-DrugBank.d324.s38	This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.
zaleplon	drug	26-33	zaleplon	drug	93-100	false

DDI-DrugBank.d331.s0	- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.
bumetanide	drug	125-134	aminoglycoside antibiotics	group	156-181	advise

DDI-DrugBank.d331.s3	- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.
Lithium	drug	2-8	Lithium	drug	11-17	false
Lithium	drug	2-8	diuretics	group	54-62	false
Lithium	drug	2-8	bumetanide	drug	73-82	false
Lithium	drug	2-8	lithium	drug	148-154	false
Lithium	drug	11-17	diuretics	group	54-62	advise
Lithium	drug	11-17	bumetanide	drug	73-82	advise
Lithium	drug	11-17	lithium	drug	148-154	false
diuretics	group	54-62	bumetanide	drug	73-82	false
diuretics	group	54-62	lithium	drug	148-154	false
bumetanide	drug	73-82	lithium	drug	148-154	false

DDI-DrugBank.d331.s4	- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.
Probenecid	drug	2-11	probenecid	drug	32-41	false
Probenecid	drug	2-11	bumetanide	drug	103-112	false
probenecid	drug	32-41	bumetanide	drug	103-112	effect

DDI-DrugBank.d331.s5	This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
probenecid	drug	28-37	bumetanide	drug	42-51	mechanism
probenecid	drug	28-37	bumetanide	drug	196-205	false
bumetanide	drug	42-51	bumetanide	drug	196-205	false

DDI-DrugBank.d331.s6	Thus, probenecid should not be administered concurrently with bumetanide.
probenecid	drug	6-15	bumetanide	drug	62-71	advise

DDI-DrugBank.d331.s7	- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
Indomethacin	drug	2-13	Indomethacin	drug	16-27	false
Indomethacin	drug	2-13	bumetanide	drug	99-108	false
Indomethacin	drug	2-13	bumetanide	drug	137-146	false
Indomethacin	drug	16-27	bumetanide	drug	99-108	mechanism
Indomethacin	drug	16-27	bumetanide	drug	137-146	effect
bumetanide	drug	99-108	bumetanide	drug	137-146	false

DDI-DrugBank.d331.s9	- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
Antihypertensives	group	2-18	Bumetanide	drug	21-30	false
Antihypertensives	group	2-18	antihypertensive drugs	group	69-90	false
Bumetanide	drug	21-30	antihypertensive drugs	group	69-90	effect

DDI-DrugBank.d331.s10	- Digoxin: Interaction studies in humans have shown no effect on digoxin blood levels.
Digoxin	drug	2-8	digoxin	drug	65-71	false

DDI-DrugBank.d331.s11	- Anticoagulants: Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.
Anticoagulants	group	2-15	bumetanide	drug	59-68	false
Anticoagulants	group	2-15	warfarin	drug	91-98	false
bumetanide	drug	59-68	warfarin	drug	91-98	false

DDI-DrugBank.d337.s0	Warfarin: Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.
Warfarin	drug	0-7	daptomycin	drug	40-49	false
Warfarin	drug	0-7	warfarin	drug	96-103	false
daptomycin	drug	40-49	warfarin	drug	96-103	false

DDI-DrugBank.d337.s1	HMG-CoA Reductase Inhibitors: Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.
HMG-CoA Reductase Inhibitors	group	0-27	Inhibitors of HMG-CoA reductase	group	30-60	false

DDI-DrugBank.d337.s2	There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.
simvastatin	drug	120-130	daptomycin	drug	171-180	false

DDI-DrugBank.d337.s3	Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.
HMG-CoA reductase inhibitors	group	37-64	Fentanyl	drug	70-77	false
HMG-CoA reductase inhibitors	group	37-64	HMG-CoA reductase inhibitors	group	175-202	false
HMG-CoA reductase inhibitors	group	37-64	Fentanyl	drug	226-233	false
Fentanyl	drug	70-77	HMG-CoA reductase inhibitors	group	175-202	false
Fentanyl	drug	70-77	Fentanyl	drug	226-233	false
HMG-CoA reductase inhibitors	group	175-202	Fentanyl	drug	226-233	advise

DDI-DrugBank.d397.s0	Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
Erythromycin	drug	0-11	theophylline	drug	61-72	effect
Erythromycin	drug	0-11	theophylline	drug	118-129	false
Erythromycin	drug	0-11	theophylline	drug	152-163	false
theophylline	drug	61-72	theophylline	drug	118-129	false
theophylline	drug	61-72	theophylline	drug	152-163	false
theophylline	drug	118-129	theophylline	drug	152-163	false

DDI-DrugBank.d397.s1	In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
theophylline	drug	11-22	theophylline	drug	55-66	false
theophylline	drug	11-22	theophylline	drug	88-99	false
theophylline	drug	11-22	erythromycin	drug	162-173	false
theophylline	drug	55-66	theophylline	drug	88-99	false
theophylline	drug	55-66	erythromycin	drug	162-173	false
theophylline	drug	88-99	erythromycin	drug	162-173	advise

DDI-DrugBank.d397.s2	Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
erythromycin	drug	30-41	digoxin	drug	47-53	mechanism
erythromycin	drug	30-41	digoxin	drug	95-101	false
digoxin	drug	47-53	digoxin	drug	95-101	false

DDI-DrugBank.d397.s3	There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
erythromycin	drug	64-75	anticoagulants	group	86-99	effect

DDI-DrugBank.d397.s5	Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
erythromycin	drug	18-29	ergotamine	drug	35-44	effect
erythromycin	drug	18-29	dihydroergotamine	drug	49-65	effect
ergotamine	drug	35-44	dihydroergotamine	drug	49-65	false

DDI-DrugBank.d397.s6	Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
Erythromycin	drug	0-11	triazolam	drug	60-68	mechanism
Erythromycin	drug	0-11	midazolam	drug	74-82	mechanism
Erythromycin	drug	0-11	benzodiazepines	group	140-154	effect
triazolam	drug	60-68	midazolam	drug	74-82	false
triazolam	drug	60-68	benzodiazepines	group	140-154	false
midazolam	drug	74-82	benzodiazepines	group	140-154	false

DDI-DrugBank.d397.s8	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
erythromycin	drug	43-54	carbamazepine	drug	61-73	int
erythromycin	drug	43-54	cyclosporine	drug	76-87	int
erythromycin	drug	43-54	tacrolimus	drug	90-99	int
erythromycin	drug	43-54	hexobarbital	drug	102-113	int
erythromycin	drug	43-54	phenytoin	drug	116-124	int
erythromycin	drug	43-54	alfentanil	drug	127-136	int
erythromycin	drug	43-54	cisapride	drug	139-147	int
erythromycin	drug	43-54	disopyramide	drug	150-161	int
erythromycin	drug	43-54	lovastatin	drug	164-173	int
erythromycin	drug	43-54	bromocriptine	drug	176-188	int
erythromycin	drug	43-54	valproate	drug	191-199	int
erythromycin	drug	43-54	terfenadine	drug	202-212	int
erythromycin	drug	43-54	astemizole	drug	219-228	int
carbamazepine	drug	61-73	cyclosporine	drug	76-87	false
carbamazepine	drug	61-73	tacrolimus	drug	90-99	false
carbamazepine	drug	61-73	hexobarbital	drug	102-113	false
carbamazepine	drug	61-73	phenytoin	drug	116-124	false
carbamazepine	drug	61-73	alfentanil	drug	127-136	false
carbamazepine	drug	61-73	cisapride	drug	139-147	false
carbamazepine	drug	61-73	disopyramide	drug	150-161	false
carbamazepine	drug	61-73	lovastatin	drug	164-173	false
carbamazepine	drug	61-73	bromocriptine	drug	176-188	false
carbamazepine	drug	61-73	valproate	drug	191-199	false
carbamazepine	drug	61-73	terfenadine	drug	202-212	false
carbamazepine	drug	61-73	astemizole	drug	219-228	false
cyclosporine	drug	76-87	tacrolimus	drug	90-99	false
cyclosporine	drug	76-87	hexobarbital	drug	102-113	false
cyclosporine	drug	76-87	phenytoin	drug	116-124	false
cyclosporine	drug	76-87	alfentanil	drug	127-136	false
cyclosporine	drug	76-87	cisapride	drug	139-147	false
cyclosporine	drug	76-87	disopyramide	drug	150-161	false
cyclosporine	drug	76-87	lovastatin	drug	164-173	false
cyclosporine	drug	76-87	bromocriptine	drug	176-188	false
cyclosporine	drug	76-87	valproate	drug	191-199	false
cyclosporine	drug	76-87	terfenadine	drug	202-212	false
cyclosporine	drug	76-87	astemizole	drug	219-228	false
tacrolimus	drug	90-99	hexobarbital	drug	102-113	false
tacrolimus	drug	90-99	phenytoin	drug	116-124	false
tacrolimus	drug	90-99	alfentanil	drug	127-136	false
tacrolimus	drug	90-99	cisapride	drug	139-147	false
tacrolimus	drug	90-99	disopyramide	drug	150-161	false
tacrolimus	drug	90-99	lovastatin	drug	164-173	false
tacrolimus	drug	90-99	bromocriptine	drug	176-188	false
tacrolimus	drug	90-99	valproate	drug	191-199	false
tacrolimus	drug	90-99	terfenadine	drug	202-212	false
tacrolimus	drug	90-99	astemizole	drug	219-228	false
hexobarbital	drug	102-113	phenytoin	drug	116-124	false
hexobarbital	drug	102-113	alfentanil	drug	127-136	false
hexobarbital	drug	102-113	cisapride	drug	139-147	false
hexobarbital	drug	102-113	disopyramide	drug	150-161	false
hexobarbital	drug	102-113	lovastatin	drug	164-173	false
hexobarbital	drug	102-113	bromocriptine	drug	176-188	false
hexobarbital	drug	102-113	valproate	drug	191-199	false
hexobarbital	drug	102-113	terfenadine	drug	202-212	false
hexobarbital	drug	102-113	astemizole	drug	219-228	false
phenytoin	drug	116-124	alfentanil	drug	127-136	false
phenytoin	drug	116-124	cisapride	drug	139-147	false
phenytoin	drug	116-124	disopyramide	drug	150-161	false
phenytoin	drug	116-124	lovastatin	drug	164-173	false
phenytoin	drug	116-124	bromocriptine	drug	176-188	false
phenytoin	drug	116-124	valproate	drug	191-199	false
phenytoin	drug	116-124	terfenadine	drug	202-212	false
phenytoin	drug	116-124	astemizole	drug	219-228	false
alfentanil	drug	127-136	cisapride	drug	139-147	false
alfentanil	drug	127-136	disopyramide	drug	150-161	false
alfentanil	drug	127-136	lovastatin	drug	164-173	false
alfentanil	drug	127-136	bromocriptine	drug	176-188	false
alfentanil	drug	127-136	valproate	drug	191-199	false
alfentanil	drug	127-136	terfenadine	drug	202-212	false
alfentanil	drug	127-136	astemizole	drug	219-228	false
cisapride	drug	139-147	disopyramide	drug	150-161	false
cisapride	drug	139-147	lovastatin	drug	164-173	false
cisapride	drug	139-147	bromocriptine	drug	176-188	false
cisapride	drug	139-147	valproate	drug	191-199	false
cisapride	drug	139-147	terfenadine	drug	202-212	false
cisapride	drug	139-147	astemizole	drug	219-228	false
disopyramide	drug	150-161	lovastatin	drug	164-173	false
disopyramide	drug	150-161	bromocriptine	drug	176-188	false
disopyramide	drug	150-161	valproate	drug	191-199	false
disopyramide	drug	150-161	terfenadine	drug	202-212	false
disopyramide	drug	150-161	astemizole	drug	219-228	false
lovastatin	drug	164-173	bromocriptine	drug	176-188	false
lovastatin	drug	164-173	valproate	drug	191-199	false
lovastatin	drug	164-173	terfenadine	drug	202-212	false
lovastatin	drug	164-173	astemizole	drug	219-228	false
bromocriptine	drug	176-188	valproate	drug	191-199	false
bromocriptine	drug	176-188	terfenadine	drug	202-212	false
bromocriptine	drug	176-188	astemizole	drug	219-228	false
valproate	drug	191-199	terfenadine	drug	202-212	false
valproate	drug	191-199	astemizole	drug	219-228	false
terfenadine	drug	202-212	astemizole	drug	219-228	false

DDI-DrugBank.d397.s10	Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
Erythromycin	drug	0-11	antihistamines	group	84-97	false
Erythromycin	drug	0-11	terfenadine	drug	99-109	mechanism
Erythromycin	drug	0-11	astemizole	drug	115-124	mechanism
antihistamines	group	84-97	terfenadine	drug	99-109	false
antihistamines	group	84-97	astemizole	drug	115-124	false
terfenadine	drug	99-109	astemizole	drug	115-124	false

DDI-DrugBank.d397.s12	In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
terfenadine	drug	81-91	erythromycin	drug	97-108	effect

DDI-DrugBank.d397.s13	There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
erythromycin	drug	64-75	cisapride	drug	100-108	effect
erythromycin	drug	64-75	cisapride	drug	289-297	false
erythromycin	drug	64-75	erythromycin	drug	302-313	false
cisapride	drug	100-108	cisapride	drug	289-297	false
cisapride	drug	100-108	erythromycin	drug	302-313	false
cisapride	drug	289-297	erythromycin	drug	302-313	mechanism

DDI-DrugBank.d397.s15	Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
lovastatin	drug	31-40	erythromycin	drug	46-57	advise

DDI-DrugBank.d203.s2	Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.
warfarin	drug	32-39	theophylline	drug	42-53	false
warfarin	drug	32-39	phenytoin	drug	56-64	false
warfarin	drug	32-39	diazepam	drug	67-74	false
warfarin	drug	32-39	aminopyrine	drug	77-87	false
warfarin	drug	32-39	antipyrine	drug	93-102	false
theophylline	drug	42-53	phenytoin	drug	56-64	false
theophylline	drug	42-53	diazepam	drug	67-74	false
theophylline	drug	42-53	aminopyrine	drug	77-87	false
theophylline	drug	42-53	antipyrine	drug	93-102	false
phenytoin	drug	56-64	diazepam	drug	67-74	false
phenytoin	drug	56-64	aminopyrine	drug	77-87	false
phenytoin	drug	56-64	antipyrine	drug	93-102	false
diazepam	drug	67-74	aminopyrine	drug	77-87	false
diazepam	drug	67-74	antipyrine	drug	93-102	false
aminopyrine	drug	77-87	antipyrine	drug	93-102	false

DDI-DrugBank.d398.s0	The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
codeine	drug	11-17	alcohol	drug	90-96	effect
codeine	drug	11-17	antihistamines	group	99-112	effect
codeine	drug	11-17	psychotropics	group	115-127	effect
alcohol	drug	90-96	antihistamines	group	99-112	false
alcohol	drug	90-96	psychotropics	group	115-127	false
antihistamines	group	99-112	psychotropics	group	115-127	false

DDI-DrugBank.d398.s1	Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).
dextromethorphan	drug	31-46	monoamine oxidase inhibitors	group	71-98	effect
dextromethorphan	drug	31-46	MAOIs	group	101-105	effect
monoamine oxidase inhibitors	group	71-98	MAOIs	group	101-105	false

DDI-DrugBank.d398.s2	The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
dextromethorphan hydrobromide	drug	11-39	alcohol	drug	112-118	effect
dextromethorphan hydrobromide	drug	11-39	antihistamines	group	121-134	effect
dextromethorphan hydrobromide	drug	11-39	psychotropics	group	137-149	effect
alcohol	drug	112-118	antihistamines	group	121-134	false
alcohol	drug	112-118	psychotropics	group	137-149	false
antihistamines	group	121-134	psychotropics	group	137-149	false

DDI-DrugBank.d225.s0	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
sulfonylureas	group	66-78	nonsteroidal anti-inflammatory agents	group	126-162	effect
sulfonylureas	group	66-78	azoles	group	170-175	effect
sulfonylureas	group	66-78	salicylates	group	224-234	effect
sulfonylureas	group	66-78	sulfonamides	group	237-248	effect
sulfonylureas	group	66-78	chloramphenicol	drug	251-265	effect
sulfonylureas	group	66-78	probenecid	drug	268-277	effect
sulfonylureas	group	66-78	coumarins	group	280-288	effect
sulfonylureas	group	66-78	monoamine oxidase inhibitors	group	291-318	effect
sulfonylureas	group	66-78	beta adrenergic blocking agents	group	325-355	effect
nonsteroidal anti-inflammatory agents	group	126-162	azoles	group	170-175	false
nonsteroidal anti-inflammatory agents	group	126-162	salicylates	group	224-234	false
nonsteroidal anti-inflammatory agents	group	126-162	sulfonamides	group	237-248	false
nonsteroidal anti-inflammatory agents	group	126-162	chloramphenicol	drug	251-265	false
nonsteroidal anti-inflammatory agents	group	126-162	probenecid	drug	268-277	false
nonsteroidal anti-inflammatory agents	group	126-162	coumarins	group	280-288	false
nonsteroidal anti-inflammatory agents	group	126-162	monoamine oxidase inhibitors	group	291-318	false
nonsteroidal anti-inflammatory agents	group	126-162	beta adrenergic blocking agents	group	325-355	false
azoles	group	170-175	salicylates	group	224-234	false
azoles	group	170-175	sulfonamides	group	237-248	false
azoles	group	170-175	chloramphenicol	drug	251-265	false
azoles	group	170-175	probenecid	drug	268-277	false
azoles	group	170-175	coumarins	group	280-288	false
azoles	group	170-175	monoamine oxidase inhibitors	group	291-318	false
azoles	group	170-175	beta adrenergic blocking agents	group	325-355	false
salicylates	group	224-234	sulfonamides	group	237-248	false
salicylates	group	224-234	chloramphenicol	drug	251-265	false
salicylates	group	224-234	probenecid	drug	268-277	false
salicylates	group	224-234	coumarins	group	280-288	false
salicylates	group	224-234	monoamine oxidase inhibitors	group	291-318	false
salicylates	group	224-234	beta adrenergic blocking agents	group	325-355	false
sulfonamides	group	237-248	chloramphenicol	drug	251-265	false
sulfonamides	group	237-248	probenecid	drug	268-277	false
sulfonamides	group	237-248	coumarins	group	280-288	false
sulfonamides	group	237-248	monoamine oxidase inhibitors	group	291-318	false
sulfonamides	group	237-248	beta adrenergic blocking agents	group	325-355	false
chloramphenicol	drug	251-265	probenecid	drug	268-277	false
chloramphenicol	drug	251-265	coumarins	group	280-288	false
chloramphenicol	drug	251-265	monoamine oxidase inhibitors	group	291-318	false
chloramphenicol	drug	251-265	beta adrenergic blocking agents	group	325-355	false
probenecid	drug	268-277	coumarins	group	280-288	false
probenecid	drug	268-277	monoamine oxidase inhibitors	group	291-318	false
probenecid	drug	268-277	beta adrenergic blocking agents	group	325-355	false
coumarins	group	280-288	monoamine oxidase inhibitors	group	291-318	false
coumarins	group	280-288	beta adrenergic blocking agents	group	325-355	false
monoamine oxidase inhibitors	group	291-318	beta adrenergic blocking agents	group	325-355	false

DDI-DrugBank.d225.s3	In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol.
glipizide	drug	65-73	tolbutamide	drug	98-108	false
glipizide	drug	65-73	salicylate	group	137-146	false
glipizide	drug	65-73	dicumarol	drug	151-159	false
tolbutamide	drug	98-108	salicylate	group	137-146	false
tolbutamide	drug	98-108	dicumarol	drug	151-159	false
salicylate	group	137-146	dicumarol	drug	151-159	false

DDI-DrugBank.d225.s6	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
thiazides	group	24-32	diuretics	group	44-52	false
thiazides	group	24-32	corticosteroids	group	55-69	false
thiazides	group	24-32	phenothiazines	group	72-85	false
thiazides	group	24-32	thyroid products	group	88-103	false
thiazides	group	24-32	estrogens	group	106-114	false
thiazides	group	24-32	contraceptives	group	122-135	false
thiazides	group	24-32	phenytoin	drug	138-146	false
thiazides	group	24-32	nicotinic acid	drug	149-162	false
thiazides	group	24-32	sympathomimetics	group	165-180	false
thiazides	group	24-32	calcium channel blocking drugs	group	183-212	false
thiazides	group	24-32	isoniazid	drug	219-227	false
diuretics	group	44-52	corticosteroids	group	55-69	false
diuretics	group	44-52	phenothiazines	group	72-85	false
diuretics	group	44-52	thyroid products	group	88-103	false
diuretics	group	44-52	estrogens	group	106-114	false
diuretics	group	44-52	contraceptives	group	122-135	false
diuretics	group	44-52	phenytoin	drug	138-146	false
diuretics	group	44-52	nicotinic acid	drug	149-162	false
diuretics	group	44-52	sympathomimetics	group	165-180	false
diuretics	group	44-52	calcium channel blocking drugs	group	183-212	false
diuretics	group	44-52	isoniazid	drug	219-227	false
corticosteroids	group	55-69	phenothiazines	group	72-85	false
corticosteroids	group	55-69	thyroid products	group	88-103	false
corticosteroids	group	55-69	estrogens	group	106-114	false
corticosteroids	group	55-69	contraceptives	group	122-135	false
corticosteroids	group	55-69	phenytoin	drug	138-146	false
corticosteroids	group	55-69	nicotinic acid	drug	149-162	false
corticosteroids	group	55-69	sympathomimetics	group	165-180	false
corticosteroids	group	55-69	calcium channel blocking drugs	group	183-212	false
corticosteroids	group	55-69	isoniazid	drug	219-227	false
phenothiazines	group	72-85	thyroid products	group	88-103	false
phenothiazines	group	72-85	estrogens	group	106-114	false
phenothiazines	group	72-85	contraceptives	group	122-135	false
phenothiazines	group	72-85	phenytoin	drug	138-146	false
phenothiazines	group	72-85	nicotinic acid	drug	149-162	false
phenothiazines	group	72-85	sympathomimetics	group	165-180	false
phenothiazines	group	72-85	calcium channel blocking drugs	group	183-212	false
phenothiazines	group	72-85	isoniazid	drug	219-227	false
thyroid products	group	88-103	estrogens	group	106-114	false
thyroid products	group	88-103	contraceptives	group	122-135	false
thyroid products	group	88-103	phenytoin	drug	138-146	false
thyroid products	group	88-103	nicotinic acid	drug	149-162	false
thyroid products	group	88-103	sympathomimetics	group	165-180	false
thyroid products	group	88-103	calcium channel blocking drugs	group	183-212	false
thyroid products	group	88-103	isoniazid	drug	219-227	false
estrogens	group	106-114	contraceptives	group	122-135	false
estrogens	group	106-114	phenytoin	drug	138-146	false
estrogens	group	106-114	nicotinic acid	drug	149-162	false
estrogens	group	106-114	sympathomimetics	group	165-180	false
estrogens	group	106-114	calcium channel blocking drugs	group	183-212	false
estrogens	group	106-114	isoniazid	drug	219-227	false
contraceptives	group	122-135	phenytoin	drug	138-146	false
contraceptives	group	122-135	nicotinic acid	drug	149-162	false
contraceptives	group	122-135	sympathomimetics	group	165-180	false
contraceptives	group	122-135	calcium channel blocking drugs	group	183-212	false
contraceptives	group	122-135	isoniazid	drug	219-227	false
phenytoin	drug	138-146	nicotinic acid	drug	149-162	false
phenytoin	drug	138-146	sympathomimetics	group	165-180	false
phenytoin	drug	138-146	calcium channel blocking drugs	group	183-212	false
phenytoin	drug	138-146	isoniazid	drug	219-227	false
nicotinic acid	drug	149-162	sympathomimetics	group	165-180	false
nicotinic acid	drug	149-162	calcium channel blocking drugs	group	183-212	false
nicotinic acid	drug	149-162	isoniazid	drug	219-227	false
sympathomimetics	group	165-180	calcium channel blocking drugs	group	183-212	false
sympathomimetics	group	165-180	isoniazid	drug	219-227	false
calcium channel blocking drugs	group	183-212	isoniazid	drug	219-227	false

DDI-DrugBank.d225.s9	A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
miconazole	drug	37-46	hypoglycemic agents	group	57-75	int

DDI-DrugBank.d225.s11	The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.
fluconazole	drug	44-54	glipizide	drug	60-68	int

DDI-DrugBank.d225.s12	All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days.
glipizide	drug	22-30	fluconazole	drug	77-87	false

DDI-DrugBank.d225.s13	The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
glipizide	drug	36-44	fluconazole	drug	56-66	mechanism

DDI-DrugBank.d531.s1	Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA (efavirenz).
SUSTIVA	brand	112-118	efavirenz	drug	121-129	false

DDI-DrugBank.d531.s2	In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.
efavirenz	drug	40-48	efavirenz	drug	112-120	false

DDI-DrugBank.d531.s5	Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
phenobarbital	drug	40-52	rifampin	drug	55-62	false
phenobarbital	drug	40-52	rifabutin	drug	65-73	false
phenobarbital	drug	40-52	efavirenz	drug	123-131	mechanism
rifampin	drug	55-62	rifabutin	drug	65-73	false
rifampin	drug	55-62	efavirenz	drug	123-131	mechanism
rifabutin	drug	65-73	efavirenz	drug	123-131	mechanism

DDI-DrugBank.d531.s10	Antihistamines: Benzodiazepines GI Motility Agents Anti-Migraine Antifungal
Antihistamines	group	0-13	Benzodiazepines	group	16-30	false
Antihistamines	group	0-13	Anti-Migraine	group	51-63	false
Antihistamines	group	0-13	Antifungal	group	65-74	false
Benzodiazepines	group	16-30	Anti-Migraine	group	51-63	false
Benzodiazepines	group	16-30	Antifungal	group	65-74	false
Anti-Migraine	group	51-63	Antifungal	group	65-74	false

DDI-DrugBank.d531.s11	astemizole midazolam, triazolam cisapride ergot derivatives voriconazole
astemizole	drug	0-9	midazolam	drug	11-19	false
astemizole	drug	0-9	triazolam	drug	22-30	false
astemizole	drug	0-9	cisapride	drug	32-40	false
astemizole	drug	0-9	voriconazole	drug	60-71	false
midazolam	drug	11-19	triazolam	drug	22-30	false
midazolam	drug	11-19	cisapride	drug	32-40	false
midazolam	drug	11-19	voriconazole	drug	60-71	false
triazolam	drug	22-30	cisapride	drug	32-40	false
triazolam	drug	22-30	voriconazole	drug	60-71	false
cisapride	drug	32-40	voriconazole	drug	60-71	false

DDI-DrugBank.d531.s19	When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).
SUSTIVA	brand	25-31	atazanavir	drug	86-95	false
SUSTIVA	brand	25-31	ritonavir	drug	112-120	false
SUSTIVA	brand	25-31	SUSTIVA	brand	133-139	false
atazanavir	drug	86-95	ritonavir	drug	112-120	false
atazanavir	drug	86-95	SUSTIVA	brand	133-139	false
ritonavir	drug	112-120	SUSTIVA	brand	133-139	false

DDI-DrugBank.d531.s20	Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.
SUSTIVA	brand	27-33	atazanavir	drug	39-48	false

DDI-DrugBank.d531.s29	In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.
SUSTIVA	brand	61-67	clarithromycin	drug	73-86	effect

DDI-DrugBank.d531.s30	No dose adjustment of SUSTIVA is recommended when given with clarithromycin.
SUSTIVA	brand	22-28	clarithromycin	drug	61-74	false

DDI-DrugBank.d531.s31	Alternatives to clarithromycin, such as azithromycin, should be considered.
clarithromycin	drug	16-29	azithromycin	drug	40-51	false

DDI-DrugBank.d531.s32	Other macrolide antibiotics, such as erythromycin, have not been studied in combination with SUSTIVA.
macrolide antibiotics	group	6-26	erythromycin	drug	37-48	false
macrolide antibiotics	group	6-26	SUSTIVA	brand	93-99	false
erythromycin	drug	37-48	SUSTIVA	brand	93-99	false

DDI-DrugBank.d531.s37	The optimal dose of indinavir, when given in combination with SUSTIVA, is not known.
indinavir	drug	20-28	SUSTIVA	brand	62-68	false

DDI-DrugBank.d531.s38	Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.
indinavir	drug	15-23	indinavir	drug	93-101	false
indinavir	drug	15-23	SUSTIVA	brand	121-127	false
indinavir	drug	93-101	SUSTIVA	brand	121-127	mechanism

DDI-DrugBank.d531.s39	When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.
indinavir	drug	5-13	SUSTIVA	brand	75-81	mechanism
indinavir	drug	5-13	indinavir	drug	108-116	false
indinavir	drug	5-13	indinavir	drug	210-218	false
SUSTIVA	brand	75-81	indinavir	drug	108-116	false
SUSTIVA	brand	75-81	indinavir	drug	210-218	false
indinavir	drug	108-116	indinavir	drug	210-218	false

DDI-DrugBank.d531.s40	Lopinavir/ritonavir
Lopinavir	drug	0-8	ritonavir	drug	10-18	false

DDI-DrugBank.d531.s42	A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
lopinavir	drug	19-27	ritonavir	drug	29-37	false
lopinavir	drug	19-27	SUSTIVA	brand	149-155	advise
ritonavir	drug	29-37	SUSTIVA	brand	149-155	advise

DDI-DrugBank.d531.s45	Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.
methadone	drug	121-129	opiate	group	144-149	false

DDI-DrugBank.d531.s50	Plasma concentrations increased by SUSTIVA (efavirenz);
SUSTIVA	brand	35-41	efavirenz	drug	44-52	false

DDI-DrugBank.d531.s52	Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.
efavirenz	drug	37-45	contraceptives	group	57-70	advise
efavirenz	drug	37-45	contraceptives	group	184-197	false
contraceptives	group	57-70	contraceptives	group	184-197	false

DDI-DrugBank.d531.s56	Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.
rifabutin	drug	22-30	rifabutin	drug	55-63	false

DDI-DrugBank.d531.s63	Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.
SUSTIVA	brand	48-54	ritonavir	drug	84-92	advise

DDI-DrugBank.d531.s67	Should not be used as sole protease inhibitor in combination with SUSTIVA.
protease inhibitor	group	27-44	SUSTIVA	brand	66-72	false

DDI-DrugBank.d531.s72	Anticoagulants: Warfarin
Anticoagulants	group	0-13	Warfarin	drug	16-23	false

DDI-DrugBank.d531.s74	Anticonvulsants: Phenytoin Phenobarbital Carbamazepine
Anticonvulsants	group	0-14	Phenytoin	drug	17-25	false
Anticonvulsants	group	0-14	Phenobarbital	drug	27-39	false
Anticonvulsants	group	0-14	Carbamazepine	drug	41-53	false
Phenytoin	drug	17-25	Phenobarbital	drug	27-39	false
Phenytoin	drug	17-25	Carbamazepine	drug	41-53	false
Phenobarbital	drug	27-39	Carbamazepine	drug	41-53	false

DDI-DrugBank.d531.s75	Potential for reduction in anticonvulsant and/or efavirenz plasma levels;
anticonvulsant	group	27-40	efavirenz	drug	49-57	mechanism

DDI-DrugBank.d531.s77	Antifungals: Itraconazole Ketoconazole
Antifungals	group	0-10	Itraconazole	drug	13-24	false
Antifungals	group	0-10	Ketoconazole	drug	26-37	false
Itraconazole	drug	13-24	Ketoconazole	drug	26-37	false

DDI-DrugBank.d531.s78	Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.
SUSTIVA	brand	30-36	imidazole antifungals	group	48-56;71-81	false
SUSTIVA	brand	30-36	triazole antifungals	group	62-81	false
imidazole antifungals	group	48-56;71-81	triazole antifungals	group	62-81	false

DDI-DrugBank.d531.s79	SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
SUSTIVA	brand	0-6	itraconazole	drug	63-74	mechanism
SUSTIVA	brand	0-6	ketoconazole	drug	80-91	mechanism
itraconazole	drug	63-74	ketoconazole	drug	80-91	false

DDI-DrugBank.d531.s80	Anti-HIV protease inhibitors: Saquinavir/ritonavir combination
Anti-HIV protease inhibitors	group	0-27	Saquinavir	drug	30-39	false
Anti-HIV protease inhibitors	group	0-27	ritonavir	drug	41-49	false
Saquinavir	drug	30-39	ritonavir	drug	41-49	false

DDI-DrugBank.d531.s87	Expected to substantially decrease plasma levels of efavirenz;has not been studied in combination with SUSTIVA.
efavirenz	drug	52-60	SUSTIVA	brand	103-109	false

DDI-DrugBank.d531.s90	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
SUSTIVA	brand	104-110	efavirenz	drug	113-121	false
SUSTIVA	brand	104-110	aluminum/magnesium hydroxide antacids	group	153-189	false
SUSTIVA	brand	104-110	azithromycin	drug	192-203	false
SUSTIVA	brand	104-110	cetirizine	drug	206-215	false
SUSTIVA	brand	104-110	famotidine	drug	218-227	false
SUSTIVA	brand	104-110	fluconazole	drug	230-240	false
SUSTIVA	brand	104-110	lamivudine	drug	243-252	false
SUSTIVA	brand	104-110	lorazepam	drug	255-263	false
SUSTIVA	brand	104-110	nelfinavir	drug	266-275	false
SUSTIVA	brand	104-110	paroxetine	drug	278-287	false
SUSTIVA	brand	104-110	zidovudine	drug	294-303	false
efavirenz	drug	113-121	aluminum/magnesium hydroxide antacids	group	153-189	false
efavirenz	drug	113-121	azithromycin	drug	192-203	false
efavirenz	drug	113-121	cetirizine	drug	206-215	false
efavirenz	drug	113-121	famotidine	drug	218-227	false
efavirenz	drug	113-121	fluconazole	drug	230-240	false
efavirenz	drug	113-121	lamivudine	drug	243-252	false
efavirenz	drug	113-121	lorazepam	drug	255-263	false
efavirenz	drug	113-121	nelfinavir	drug	266-275	false
efavirenz	drug	113-121	paroxetine	drug	278-287	false
efavirenz	drug	113-121	zidovudine	drug	294-303	false
aluminum/magnesium hydroxide antacids	group	153-189	azithromycin	drug	192-203	false
aluminum/magnesium hydroxide antacids	group	153-189	cetirizine	drug	206-215	false
aluminum/magnesium hydroxide antacids	group	153-189	famotidine	drug	218-227	false
aluminum/magnesium hydroxide antacids	group	153-189	fluconazole	drug	230-240	false
aluminum/magnesium hydroxide antacids	group	153-189	lamivudine	drug	243-252	false
aluminum/magnesium hydroxide antacids	group	153-189	lorazepam	drug	255-263	false
aluminum/magnesium hydroxide antacids	group	153-189	nelfinavir	drug	266-275	false
aluminum/magnesium hydroxide antacids	group	153-189	paroxetine	drug	278-287	false
aluminum/magnesium hydroxide antacids	group	153-189	zidovudine	drug	294-303	false
azithromycin	drug	192-203	cetirizine	drug	206-215	false
azithromycin	drug	192-203	famotidine	drug	218-227	false
azithromycin	drug	192-203	fluconazole	drug	230-240	false
azithromycin	drug	192-203	lamivudine	drug	243-252	false
azithromycin	drug	192-203	lorazepam	drug	255-263	false
azithromycin	drug	192-203	nelfinavir	drug	266-275	false
azithromycin	drug	192-203	paroxetine	drug	278-287	false
azithromycin	drug	192-203	zidovudine	drug	294-303	false
cetirizine	drug	206-215	famotidine	drug	218-227	false
cetirizine	drug	206-215	fluconazole	drug	230-240	false
cetirizine	drug	206-215	lamivudine	drug	243-252	false
cetirizine	drug	206-215	lorazepam	drug	255-263	false
cetirizine	drug	206-215	nelfinavir	drug	266-275	false
cetirizine	drug	206-215	paroxetine	drug	278-287	false
cetirizine	drug	206-215	zidovudine	drug	294-303	false
famotidine	drug	218-227	fluconazole	drug	230-240	false
famotidine	drug	218-227	lamivudine	drug	243-252	false
famotidine	drug	218-227	lorazepam	drug	255-263	false
famotidine	drug	218-227	nelfinavir	drug	266-275	false
famotidine	drug	218-227	paroxetine	drug	278-287	false
famotidine	drug	218-227	zidovudine	drug	294-303	false
fluconazole	drug	230-240	lamivudine	drug	243-252	false
fluconazole	drug	230-240	lorazepam	drug	255-263	false
fluconazole	drug	230-240	nelfinavir	drug	266-275	false
fluconazole	drug	230-240	paroxetine	drug	278-287	false
fluconazole	drug	230-240	zidovudine	drug	294-303	false
lamivudine	drug	243-252	lorazepam	drug	255-263	false
lamivudine	drug	243-252	nelfinavir	drug	266-275	false
lamivudine	drug	243-252	paroxetine	drug	278-287	false
lamivudine	drug	243-252	zidovudine	drug	294-303	false
lorazepam	drug	255-263	nelfinavir	drug	266-275	false
lorazepam	drug	255-263	paroxetine	drug	278-287	false
lorazepam	drug	255-263	zidovudine	drug	294-303	false
nelfinavir	drug	266-275	paroxetine	drug	278-287	false
nelfinavir	drug	266-275	zidovudine	drug	294-303	false
paroxetine	drug	278-287	zidovudine	drug	294-303	false

DDI-DrugBank.d531.s91	Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.
SUSTIVA	brand	63-69	NRTIs	group	75-79	false
SUSTIVA	brand	63-69	lamivudine	drug	92-101	false
SUSTIVA	brand	63-69	zidovudine	drug	107-116	false
NRTIs	group	75-79	lamivudine	drug	92-101	false
NRTIs	group	75-79	zidovudine	drug	107-116	false
lamivudine	drug	92-101	zidovudine	drug	107-116	false

DDI-DrugBank.d531.s92	Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.
NRTIs	group	68-72	efavirenz	drug	117-125	false

DDI-DrugBank.d455.s4	In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam.
entacapone	drug	60-69	warfarin	drug	109-116	false
entacapone	drug	60-69	salicylic acid	drug	119-132	false
entacapone	drug	60-69	phenylbutazone	drug	135-148	false
entacapone	drug	60-69	diazepam	drug	155-162	false
warfarin	drug	109-116	salicylic acid	drug	119-132	false
warfarin	drug	109-116	phenylbutazone	drug	135-148	false
warfarin	drug	109-116	diazepam	drug	155-162	false
salicylic acid	drug	119-132	phenylbutazone	drug	135-148	false
salicylic acid	drug	119-132	diazepam	drug	155-162	false
phenylbutazone	drug	135-148	diazepam	drug	155-162	false

DDI-DrugBank.d455.s6	Treatment with entacapone coadministered with levodopa/dopa decarboxylase inhibitor does not change these effects.
entacapone	drug	15-24	levodopa	drug	46-53	false
entacapone	drug	15-24	dopa decarboxylase inhibitor	group	55-82	false
levodopa	drug	46-53	dopa decarboxylase inhibitor	group	55-82	false

DDI-DrugBank.d455.s7	No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).
MAO-B inhibitor	group	34-48	selegiline	drug	50-59	false
MAO-B inhibitor	group	34-48	entacapone	drug	107-116	false
MAO-B inhibitor	group	34-48	levodopa	drug	144-151	false
MAO-B inhibitor	group	34-48	dopa decarboxylase inhibitor	group	153-180	false
selegiline	drug	50-59	entacapone	drug	107-116	false
selegiline	drug	50-59	levodopa	drug	144-151	false
selegiline	drug	50-59	dopa decarboxylase inhibitor	group	153-180	false
entacapone	drug	107-116	levodopa	drug	144-151	false
entacapone	drug	107-116	dopa decarboxylase inhibitor	group	153-180	false
levodopa	drug	144-151	dopa decarboxylase inhibitor	group	153-180	false

DDI-DrugBank.d455.s8	More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor.
selegiline	drug	71-80	entacapone	drug	102-111	false
selegiline	drug	71-80	levodopa	drug	117-124	false
selegiline	drug	71-80	dopa decarboxylase inhibitor	group	126-153	false
entacapone	drug	102-111	levodopa	drug	117-124	false
entacapone	drug	102-111	dopa decarboxylase inhibitor	group	126-153	false
levodopa	drug	117-124	dopa decarboxylase inhibitor	group	126-153	false

DDI-DrugBank.d455.s9	As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone.
entacapone	drug	8-17	entacapone	drug	207-216	false

DDI-DrugBank.d455.s10	These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).
probenecid	drug	14-23	cholestyramine	drug	26-39	false
probenecid	drug	14-23	antibiotics	group	51-61	false
probenecid	drug	14-23	erythromycin	drug	69-80	false
probenecid	drug	14-23	ampicillin	drug	96-105	false
probenecid	drug	14-23	chloramphenicol	drug	111-125	false
cholestyramine	drug	26-39	antibiotics	group	51-61	false
cholestyramine	drug	26-39	erythromycin	drug	69-80	false
cholestyramine	drug	26-39	ampicillin	drug	96-105	false
cholestyramine	drug	26-39	chloramphenicol	drug	111-125	false
antibiotics	group	51-61	erythromycin	drug	69-80	false
antibiotics	group	51-61	ampicillin	drug	96-105	false
antibiotics	group	51-61	chloramphenicol	drug	111-125	false
erythromycin	drug	69-80	ampicillin	drug	96-105	false
erythromycin	drug	69-80	chloramphenicol	drug	111-125	false
ampicillin	drug	96-105	chloramphenicol	drug	111-125	false

DDI-DrugBank.d455.s11	No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.
tricyclic antidepressant	group	24-47	imipramine	drug	49-58	false
tricyclic antidepressant	group	24-47	entacapone	drug	98-107	false
tricyclic antidepressant	group	24-47	levodopa	drug	132-139	false
tricyclic antidepressant	group	24-47	dopa-decarboxylase inhibitor	group	141-168	false
imipramine	drug	49-58	entacapone	drug	98-107	false
imipramine	drug	49-58	levodopa	drug	132-139	false
imipramine	drug	49-58	dopa-decarboxylase inhibitor	group	141-168	false
entacapone	drug	98-107	levodopa	drug	132-139	false
entacapone	drug	98-107	dopa-decarboxylase inhibitor	group	141-168	false
levodopa	drug	132-139	dopa-decarboxylase inhibitor	group	141-168	false

DDI-DrugBank.d444.s0	The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.
FLUDARA	brand	11-17	pentostatin	drug	53-63	advise

DDI-DrugBank.d44.s1	RAPTIVA should not be used with other immunosuppressive drugs.
RAPTIVA	brand	0-6	immunosuppressive drugs	group	38-60	advise

DDI-DrugBank.d44.s2	Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
Acellular vaccines	group	0-8;36-43	live vaccines	group	11-14;36-43	false
Acellular vaccines	group	0-8;36-43	live-attenuated vaccines	group	20-43	false
Acellular vaccines	group	0-8;36-43	RAPTIVA	brand	79-85	advise
live vaccines	group	11-14;36-43	live-attenuated vaccines	group	20-43	false
live vaccines	group	11-14;36-43	RAPTIVA	brand	79-85	advise
live-attenuated vaccines	group	20-43	RAPTIVA	brand	79-85	advise

DDI-DrugBank.d12.s0	Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.
anticoagulants	group	33-46	Atromid-S	brand	78-86	advise

DDI-DrugBank.d12.s3	Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
Atromid-S	brand	0-8	phenytoin	drug	44-52	mechanism
Atromid-S	brand	0-8	tolbutamide	drug	57-67	mechanism
phenytoin	drug	44-52	tolbutamide	drug	57-67	false

DDI-DrugBank.d12.s5	The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.
tolbutamide	drug	27-37	Atromid-S	brand	74-82	effect

DDI-DrugBank.d12.s6	Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.
fibrate	group	113-119	lovastatin	drug	125-134	effect

DDI-DrugBank.d12.s7	For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.
lovastatin	drug	168-177	fibrate	group	185-191	effect

DDI-DrugBank.d12.s8	While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.
fibrates	group	59-66	gemfibrozil	drug	79-89	false
fibrates	group	59-66	fibrates	group	170-177	false
fibrates	group	59-66	clofibrate	drug	196-205	false
gemfibrozil	drug	79-89	fibrates	group	170-177	false
gemfibrozil	drug	79-89	clofibrate	drug	196-205	false
fibrates	group	170-177	clofibrate	drug	196-205	false

DDI-DrugBank.d12.s9	Therefore, the combined use of lovastatin with fibrates should generally be avoided.
lovastatin	drug	31-40	fibrates	group	47-54	advise

DDI-DrugBank.d406.s0	May interact with cefamandole naftate, cephalothin sodium, magnesium sulfate, prednisolone sodium succinate, and prochlorperazine edisylate.
cefamandole naftate	drug	18-36	cephalothin sodium	drug	39-56	false
cefamandole naftate	drug	18-36	magnesium sulfate	drug	59-75	false
cefamandole naftate	drug	18-36	prednisolone sodium succinate	drug	78-106	false
cefamandole naftate	drug	18-36	prochlorperazine edisylate	drug	113-138	false
cephalothin sodium	drug	39-56	magnesium sulfate	drug	59-75	false
cephalothin sodium	drug	39-56	prednisolone sodium succinate	drug	78-106	false
cephalothin sodium	drug	39-56	prochlorperazine edisylate	drug	113-138	false
magnesium sulfate	drug	59-75	prednisolone sodium succinate	drug	78-106	false
magnesium sulfate	drug	59-75	prochlorperazine edisylate	drug	113-138	false
prednisolone sodium succinate	drug	78-106	prochlorperazine edisylate	drug	113-138	false

DDI-DrugBank.d395.s0	Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
Bismuth	drug	0-6	Bismuth subsalicylate	drug	9-29	false
Bismuth	drug	0-6	enoxacin	drug	57-64	false
Bismuth	drug	0-6	enoxacin	drug	90-97	false
Bismuth	drug	0-6	enoxacin	drug	125-132	false
Bismuth subsalicylate	drug	9-29	enoxacin	drug	57-64	mechanism
Bismuth subsalicylate	drug	9-29	enoxacin	drug	90-97	false
Bismuth subsalicylate	drug	9-29	enoxacin	drug	125-132	false
enoxacin	drug	57-64	enoxacin	drug	90-97	false
enoxacin	drug	57-64	enoxacin	drug	125-132	false
enoxacin	drug	90-97	enoxacin	drug	125-132	false

DDI-DrugBank.d395.s1	Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
enoxacin	drug	36-43	bismuth subsalicylate	drug	49-69	advise

DDI-DrugBank.d395.s2	Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
Caffeine	drug	0-7	Enoxacin	drug	10-17	false
Caffeine	drug	0-7	methylxanthines	group	108-122	false
Enoxacin	drug	10-17	methylxanthines	group	108-122	mechanism

DDI-DrugBank.d395.s3	In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
enoxacin	drug	26-33	caffeine	drug	103-110	mechanism
enoxacin	drug	26-33	caffeine	drug	149-156	false
enoxacin	drug	26-33	caffeine	drug	239-246	false
caffeine	drug	103-110	caffeine	drug	149-156	false
caffeine	drug	103-110	caffeine	drug	239-246	false
caffeine	drug	149-156	caffeine	drug	239-246	false

DDI-DrugBank.d395.s4	Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
enoxacin	drug	14-21	caffeine	drug	56-63	false
enoxacin	drug	14-21	enoxacin	drug	69-76	false
caffeine	drug	56-63	enoxacin	drug	69-76	mechanism

DDI-DrugBank.d395.s5	Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
Caffeine	drug	0-7	caffeine	drug	69-76	false
Caffeine	drug	0-7	enoxacin	drug	100-107	false
caffeine	drug	69-76	enoxacin	drug	100-107	effect

DDI-DrugBank.d395.s6	Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
Cyclosporine	drug	0-11	cyclosporine	drug	39-50	false
Cyclosporine	drug	0-11	cyclosporine	drug	95-106	false
Cyclosporine	drug	0-11	quinolone class	group	134-148	false
cyclosporine	drug	39-50	cyclosporine	drug	95-106	false
cyclosporine	drug	39-50	quinolone class	group	134-148	false
cyclosporine	drug	95-106	quinolone class	group	134-148	mechanism

DDI-DrugBank.d395.s7	Digoxin: Enoxacin may raise serum digoxin levels in some individuals.
Digoxin	drug	0-6	Enoxacin	drug	9-16	false
Digoxin	drug	0-6	digoxin	drug	34-40	false
Enoxacin	drug	9-16	digoxin	drug	34-40	mechanism

DDI-DrugBank.d395.s8	If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
digoxin	drug	36-42	enoxacin	drug	64-71	false
digoxin	drug	36-42	digoxin	drug	77-83	false
digoxin	drug	36-42	digoxin	drug	149-155	false
digoxin	drug	36-42	digoxin	drug	175-181	false
enoxacin	drug	64-71	digoxin	drug	77-83	effect
enoxacin	drug	64-71	digoxin	drug	149-155	false
enoxacin	drug	64-71	digoxin	drug	175-181	false
digoxin	drug	77-83	digoxin	drug	149-155	false
digoxin	drug	77-83	digoxin	drug	175-181	false
digoxin	drug	149-155	digoxin	drug	175-181	false

DDI-DrugBank.d395.s9	Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.
Non-steroidal anti-inflammatory agents	group	0-37	enoxacin	drug	87-94	false
Non-steroidal anti-inflammatory agents	group	0-37	nonsteroidal anti-inflammatory drug	group	119-153	false
Non-steroidal anti-inflammatory agents	group	0-37	fenbufen	drug	155-162	false
enoxacin	drug	87-94	nonsteroidal anti-inflammatory drug	group	119-153	false
enoxacin	drug	87-94	fenbufen	drug	155-162	effect
nonsteroidal anti-inflammatory drug	group	119-153	fenbufen	drug	155-162	false

DDI-DrugBank.d395.s12	Sucralfate and antacids: Quinolones form chelates with metal cations.
Sucralfate	drug	0-9	antacids	group	15-22	false
Sucralfate	drug	0-9	Quinolones	group	25-34	false
antacids	group	15-22	Quinolones	group	25-34	false

DDI-DrugBank.d395.s13	Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;
quinolones	group	29-38	antacids	group	45-52	false
quinolones	group	29-38	calcium	drug	65-71	false
quinolones	group	29-38	magnesium	drug	74-82	false
quinolones	group	29-38	aluminum	drug	88-95	false
antacids	group	45-52	calcium	drug	65-71	false
antacids	group	45-52	magnesium	drug	74-82	false
antacids	group	45-52	aluminum	drug	88-95	false
calcium	drug	65-71	magnesium	drug	74-82	false
calcium	drug	65-71	aluminum	drug	88-95	false
magnesium	drug	74-82	aluminum	drug	88-95	false

DDI-DrugBank.d395.s16	or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
multivitamins	group	8-20	zinc	drug	33-36	false
multivitamins	group	8-20	quinolone	group	132-140	false
zinc	drug	33-36	quinolone	group	132-140	mechanism

DDI-DrugBank.d395.s17	Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
Antacids	group	0-7	aluminum hydroxide	drug	20-37	false
Antacids	group	0-7	magnesium hydroxide	drug	43-61	false
Antacids	group	0-7	enoxacin	drug	93-100	false
aluminum hydroxide	drug	20-37	magnesium hydroxide	drug	43-61	false
aluminum hydroxide	drug	20-37	enoxacin	drug	93-100	mechanism
magnesium hydroxide	drug	43-61	enoxacin	drug	93-100	mechanism

DDI-DrugBank.d395.s18	The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
enoxacin	drug	28-35	ranitidine	drug	80-89	mechanism

DDI-DrugBank.d395.s20	Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
Theophylline	drug	0-11	Enoxacin	drug	14-21	false
Theophylline	drug	0-11	methylxanthines	group	112-126	false
Enoxacin	drug	14-21	methylxanthines	group	112-126	mechanism

DDI-DrugBank.d395.s21	Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
Enoxacin	drug	0-7	theophylline	drug	43-54	mechanism
Enoxacin	drug	0-7	theophylline	drug	107-118	false
theophylline	drug	43-54	theophylline	drug	107-118	false

DDI-DrugBank.d395.s22	Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
Theophylline	drug	0-11	theophylline	drug	68-79	false
Theophylline	drug	0-11	enoxacin	drug	85-92	false
theophylline	drug	68-79	enoxacin	drug	85-92	effect

DDI-DrugBank.d395.s23	Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
Warfarin	drug	0-7	Quinolones	group	10-19	false
Warfarin	drug	0-7	enoxacin	drug	32-39	false
Warfarin	drug	0-7	R-warfarin	drug	68-77	false
Warfarin	drug	0-7	warfarin	drug	114-121	false
Quinolones	group	10-19	enoxacin	drug	32-39	false
Quinolones	group	10-19	R-warfarin	drug	68-77	mechanism
Quinolones	group	10-19	warfarin	drug	114-121	false
enoxacin	drug	32-39	R-warfarin	drug	68-77	mechanism
enoxacin	drug	32-39	warfarin	drug	114-121	false
R-warfarin	drug	68-77	warfarin	drug	114-121	false

DDI-DrugBank.d395.s24	Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.
Enoxacin	drug	0-7	enoxacin	drug	120-127	false
Enoxacin	drug	0-7	warfarin	drug	133-140	false
enoxacin	drug	120-127	warfarin	drug	133-140	false

DDI-DrugBank.d395.s25	Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
warfarin	drug	95-102	enoxacin	drug	127-134	advise

DDI-DrugBank.d471.s0	Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
Mineral oil	drug	0-10	fat-soluble vitamins	group	46-65	mechanism
Mineral oil	drug	0-10	vitamin D preparations	group	78-99	mechanism
fat-soluble vitamins	group	46-65	vitamin D preparations	group	78-99	false

DDI-DrugBank.d471.s1	Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.
thiazide diuretics	group	18-35	ergocalciferol	drug	105-118	effect

DDI-DrugBank.d111.s0	Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.
Non-selective MAO inhibitors	group	0-27	tranylcypromine sulfate	drug	39-61	false
Non-selective MAO inhibitors	group	0-27	phenelzine sulfate	drug	64-81	false
Non-selective MAO inhibitors	group	0-27	pargyline	drug	88-96	false
Non-selective MAO inhibitors	group	0-27	L-tyrosine	drug	122-131	false
Non-selective MAO inhibitors	group	0-27	MAO inhibitors	group	151-164	false
tranylcypromine sulfate	drug	39-61	phenelzine sulfate	drug	64-81	false
tranylcypromine sulfate	drug	39-61	pargyline	drug	88-96	false
tranylcypromine sulfate	drug	39-61	L-tyrosine	drug	122-131	false
tranylcypromine sulfate	drug	39-61	MAO inhibitors	group	151-164	false
phenelzine sulfate	drug	64-81	pargyline	drug	88-96	false
phenelzine sulfate	drug	64-81	L-tyrosine	drug	122-131	false
phenelzine sulfate	drug	64-81	MAO inhibitors	group	151-164	false
pargyline	drug	88-96	L-tyrosine	drug	122-131	false
pargyline	drug	88-96	MAO inhibitors	group	151-164	false
L-tyrosine	drug	122-131	MAO inhibitors	group	151-164	effect

DDI-DrugBank.d460.s1	Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.
Starlix	brand	0-6	tolbutamide	drug	131-141	mechanism

DDI-DrugBank.d460.s3	Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.
Glyburide	drug	0-8	Starlix	brand	114-120	false
Glyburide	drug	0-8	glyburide	drug	183-191	false
Starlix	brand	114-120	glyburide	drug	183-191	false

DDI-DrugBank.d460.s5	Metformin: When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.
Metformin	drug	0-8	Starlix	brand	16-22	false
Metformin	drug	0-8	metformin	drug	99-107	false
Starlix	brand	16-22	metformin	drug	99-107	false

DDI-DrugBank.d460.s6	Digoxin: When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.
Digoxin	drug	0-6	Starlix	brand	14-20	false
Digoxin	drug	0-6	digoxin	drug	101-107	false
Starlix	brand	14-20	digoxin	drug	101-107	false

DDI-DrugBank.d460.s7	Warfarin: When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.
Warfarin	drug	0-7	Starlix	brand	50-56	false
Warfarin	drug	0-7	warfarin	drug	147-154	false
Starlix	brand	50-56	warfarin	drug	147-154	false

DDI-DrugBank.d460.s9	Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.
Diclofenac	drug	0-9	Starlix	brand	57-63	false
Diclofenac	drug	0-9	diclofenac	drug	115-124	false
Starlix	brand	57-63	diclofenac	drug	115-124	false

DDI-DrugBank.d460.s11	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
furosemide	drug	70-79	propranolol	drug	82-92	false
furosemide	drug	70-79	captopril	drug	95-103	false
furosemide	drug	70-79	nicardipine	drug	106-116	false
furosemide	drug	70-79	pravastatin	drug	119-129	false
furosemide	drug	70-79	glyburide	drug	132-140	false
furosemide	drug	70-79	warfarin	drug	143-150	false
furosemide	drug	70-79	phenytoin	drug	153-161	false
furosemide	drug	70-79	acetylsalicylic acid	drug	164-183	false
furosemide	drug	70-79	tolbutamide	drug	186-196	false
furosemide	drug	70-79	metformin	drug	203-211	false
furosemide	drug	70-79	nateglinide	drug	250-260	false
propranolol	drug	82-92	captopril	drug	95-103	false
propranolol	drug	82-92	nicardipine	drug	106-116	false
propranolol	drug	82-92	pravastatin	drug	119-129	false
propranolol	drug	82-92	glyburide	drug	132-140	false
propranolol	drug	82-92	warfarin	drug	143-150	false
propranolol	drug	82-92	phenytoin	drug	153-161	false
propranolol	drug	82-92	acetylsalicylic acid	drug	164-183	false
propranolol	drug	82-92	tolbutamide	drug	186-196	false
propranolol	drug	82-92	metformin	drug	203-211	false
propranolol	drug	82-92	nateglinide	drug	250-260	false
captopril	drug	95-103	nicardipine	drug	106-116	false
captopril	drug	95-103	pravastatin	drug	119-129	false
captopril	drug	95-103	glyburide	drug	132-140	false
captopril	drug	95-103	warfarin	drug	143-150	false
captopril	drug	95-103	phenytoin	drug	153-161	false
captopril	drug	95-103	acetylsalicylic acid	drug	164-183	false
captopril	drug	95-103	tolbutamide	drug	186-196	false
captopril	drug	95-103	metformin	drug	203-211	false
captopril	drug	95-103	nateglinide	drug	250-260	false
nicardipine	drug	106-116	pravastatin	drug	119-129	false
nicardipine	drug	106-116	glyburide	drug	132-140	false
nicardipine	drug	106-116	warfarin	drug	143-150	false
nicardipine	drug	106-116	phenytoin	drug	153-161	false
nicardipine	drug	106-116	acetylsalicylic acid	drug	164-183	false
nicardipine	drug	106-116	tolbutamide	drug	186-196	false
nicardipine	drug	106-116	metformin	drug	203-211	false
nicardipine	drug	106-116	nateglinide	drug	250-260	false
pravastatin	drug	119-129	glyburide	drug	132-140	false
pravastatin	drug	119-129	warfarin	drug	143-150	false
pravastatin	drug	119-129	phenytoin	drug	153-161	false
pravastatin	drug	119-129	acetylsalicylic acid	drug	164-183	false
pravastatin	drug	119-129	tolbutamide	drug	186-196	false
pravastatin	drug	119-129	metformin	drug	203-211	false
pravastatin	drug	119-129	nateglinide	drug	250-260	false
glyburide	drug	132-140	warfarin	drug	143-150	false
glyburide	drug	132-140	phenytoin	drug	153-161	false
glyburide	drug	132-140	acetylsalicylic acid	drug	164-183	false
glyburide	drug	132-140	tolbutamide	drug	186-196	false
glyburide	drug	132-140	metformin	drug	203-211	false
glyburide	drug	132-140	nateglinide	drug	250-260	false
warfarin	drug	143-150	phenytoin	drug	153-161	false
warfarin	drug	143-150	acetylsalicylic acid	drug	164-183	false
warfarin	drug	143-150	tolbutamide	drug	186-196	false
warfarin	drug	143-150	metformin	drug	203-211	false
warfarin	drug	143-150	nateglinide	drug	250-260	false
phenytoin	drug	153-161	acetylsalicylic acid	drug	164-183	false
phenytoin	drug	153-161	tolbutamide	drug	186-196	false
phenytoin	drug	153-161	metformin	drug	203-211	false
phenytoin	drug	153-161	nateglinide	drug	250-260	false
acetylsalicylic acid	drug	164-183	tolbutamide	drug	186-196	false
acetylsalicylic acid	drug	164-183	metformin	drug	203-211	false
acetylsalicylic acid	drug	164-183	nateglinide	drug	250-260	false
tolbutamide	drug	186-196	metformin	drug	203-211	false
tolbutamide	drug	186-196	nateglinide	drug	250-260	false
metformin	drug	203-211	nateglinide	drug	250-260	false

DDI-DrugBank.d460.s12	Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
nateglinide	drug	11-21	propranolol	drug	72-82	false
nateglinide	drug	11-21	glyburide	drug	85-93	false
nateglinide	drug	11-21	nicardipine	drug	96-106	false
nateglinide	drug	11-21	warfarin	drug	109-116	false
nateglinide	drug	11-21	phenytoin	drug	119-127	false
nateglinide	drug	11-21	acetylsalicylic acid	drug	130-149	false
nateglinide	drug	11-21	tolbutamide	drug	156-166	false
propranolol	drug	72-82	glyburide	drug	85-93	false
propranolol	drug	72-82	nicardipine	drug	96-106	false
propranolol	drug	72-82	warfarin	drug	109-116	false
propranolol	drug	72-82	phenytoin	drug	119-127	false
propranolol	drug	72-82	acetylsalicylic acid	drug	130-149	false
propranolol	drug	72-82	tolbutamide	drug	156-166	false
glyburide	drug	85-93	nicardipine	drug	96-106	false
glyburide	drug	85-93	warfarin	drug	109-116	false
glyburide	drug	85-93	phenytoin	drug	119-127	false
glyburide	drug	85-93	acetylsalicylic acid	drug	130-149	false
glyburide	drug	85-93	tolbutamide	drug	156-166	false
nicardipine	drug	96-106	warfarin	drug	109-116	false
nicardipine	drug	96-106	phenytoin	drug	119-127	false
nicardipine	drug	96-106	acetylsalicylic acid	drug	130-149	false
nicardipine	drug	96-106	tolbutamide	drug	156-166	false
warfarin	drug	109-116	phenytoin	drug	119-127	false
warfarin	drug	109-116	acetylsalicylic acid	drug	130-149	false
warfarin	drug	109-116	tolbutamide	drug	156-166	false
phenytoin	drug	119-127	acetylsalicylic acid	drug	130-149	false
phenytoin	drug	119-127	tolbutamide	drug	156-166	false
acetylsalicylic acid	drug	130-149	tolbutamide	drug	156-166	false

DDI-DrugBank.d460.s14	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
nonsteroidal anti-inflammatory agents	group	25-61	NSAIDs	group	64-69	false
nonsteroidal anti-inflammatory agents	group	25-61	salicylates	group	73-83	false
nonsteroidal anti-inflammatory agents	group	25-61	monoamine oxidase inhibitors	group	86-113	false
nonsteroidal anti-inflammatory agents	group	25-61	non-selective beta-adrenergic-blocking agents	group	120-164	false
nonsteroidal anti-inflammatory agents	group	25-61	Starlix	brand	208-214	effect
nonsteroidal anti-inflammatory agents	group	25-61	antidiabetic drugs	group	231-248	effect
NSAIDs	group	64-69	salicylates	group	73-83	false
NSAIDs	group	64-69	monoamine oxidase inhibitors	group	86-113	false
NSAIDs	group	64-69	non-selective beta-adrenergic-blocking agents	group	120-164	false
NSAIDs	group	64-69	Starlix	brand	208-214	effect
NSAIDs	group	64-69	antidiabetic drugs	group	231-248	effect
salicylates	group	73-83	monoamine oxidase inhibitors	group	86-113	false
salicylates	group	73-83	non-selective beta-adrenergic-blocking agents	group	120-164	false
salicylates	group	73-83	Starlix	brand	208-214	effect
salicylates	group	73-83	antidiabetic drugs	group	231-248	effect
monoamine oxidase inhibitors	group	86-113	non-selective beta-adrenergic-blocking agents	group	120-164	false
monoamine oxidase inhibitors	group	86-113	Starlix	brand	208-214	effect
monoamine oxidase inhibitors	group	86-113	antidiabetic drugs	group	231-248	effect
non-selective beta-adrenergic-blocking agents	group	120-164	Starlix	brand	208-214	effect
non-selective beta-adrenergic-blocking agents	group	120-164	antidiabetic drugs	group	231-248	effect
Starlix	brand	208-214	antidiabetic drugs	group	231-248	false

DDI-DrugBank.d460.s15	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
thiazides	group	24-32	corticosteroids	group	35-49	false
thiazides	group	24-32	thyroid products	group	52-67	false
thiazides	group	24-32	sympathomimetics	group	74-89	false
thiazides	group	24-32	Starlix	brand	129-135	effect
thiazides	group	24-32	antidiabetic drugs	group	152-169	effect
corticosteroids	group	35-49	thyroid products	group	52-67	false
corticosteroids	group	35-49	sympathomimetics	group	74-89	false
corticosteroids	group	35-49	Starlix	brand	129-135	effect
corticosteroids	group	35-49	antidiabetic drugs	group	152-169	effect
thyroid products	group	52-67	sympathomimetics	group	74-89	false
thyroid products	group	52-67	Starlix	brand	129-135	effect
thyroid products	group	52-67	antidiabetic drugs	group	152-169	effect
sympathomimetics	group	74-89	Starlix	brand	129-135	effect
sympathomimetics	group	74-89	antidiabetic drugs	group	152-169	effect
Starlix	brand	129-135	antidiabetic drugs	group	152-169	false

DDI-DrugBank.d351.s0	Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
Probenecid	drug	0-9	b-lactam antibiotics	group	26-45	false
Probenecid	drug	0-9	loracarbef	drug	67-76	false
Probenecid	drug	0-9	probenecid	drug	94-103	false
Probenecid	drug	0-9	loracarbef	drug	164-173	false
b-lactam antibiotics	group	26-45	loracarbef	drug	67-76	false
b-lactam antibiotics	group	26-45	probenecid	drug	94-103	mechanism
b-lactam antibiotics	group	26-45	loracarbef	drug	164-173	false
loracarbef	drug	67-76	probenecid	drug	94-103	mechanism
loracarbef	drug	67-76	loracarbef	drug	164-173	false
probenecid	drug	94-103	loracarbef	drug	164-173	false

DDI-DrugBank.d512.s1	Effect of Sensipar on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar  is a strong in vitro inhibitor of CYP2D6.
Sensipar	brand	10-17	Sensipar	brand	86-93	false

DDI-DrugBank.d512.s2	Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine and most tricyclic antidepressants) may be required.
flecainide	drug	143-152	vinblastine	drug	155-165	false
flecainide	drug	143-152	thioridazine	drug	168-179	false
flecainide	drug	143-152	tricyclic antidepressants	group	190-214	false
vinblastine	drug	155-165	thioridazine	drug	168-179	false
vinblastine	drug	155-165	tricyclic antidepressants	group	190-214	false
thioridazine	drug	168-179	tricyclic antidepressants	group	190-214	false

DDI-DrugBank.d512.s3	Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
Amitriptyline	drug	0-12	cinacalcet	drug	60-69	false
Amitriptyline	drug	0-12	amitriptyline	drug	82-94	false
Amitriptyline	drug	0-12	amitriptyline	drug	106-118	false
Amitriptyline	drug	0-12	nortriptyline	drug_n	133-145	false
cinacalcet	drug	60-69	amitriptyline	drug	82-94	mechanism
cinacalcet	drug	60-69	amitriptyline	drug	106-118	false
cinacalcet	drug	60-69	nortriptyline	drug_n	133-145	false
amitriptyline	drug	82-94	amitriptyline	drug	106-118	false
amitriptyline	drug	82-94	nortriptyline	drug_n	133-145	false
amitriptyline	drug	106-118	nortriptyline	drug_n	133-145	false

DDI-DrugBank.d512.s4	Effect of other drugs on Sensipar : Sensipar  is metabolized by multiple cytochrome P450 enzymes, primarily CYP3A4, CYP2D6, and CYP1A2.
Sensipar	brand	25-32	Sensipar	brand	36-43	false

DDI-DrugBank.d512.s5	Ketoconazole: Sensipar is metabolized in part by CYP3A4.
Ketoconazole	drug	0-11	Sensipar	brand	14-21	false

DDI-DrugBank.d512.s6	Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.
ketoconazole	drug	21-32	cinacalcet	drug	75-84	mechanism
ketoconazole	drug	21-32	Sensipar	brand	128-135	false
cinacalcet	drug	75-84	Sensipar	brand	128-135	false

DDI-DrugBank.d512.s7	Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
Sensipar	brand	19-26	ketoconazole	drug	198-209	advise
Sensipar	brand	19-26	erythromycin	drug	212-223	advise
Sensipar	brand	19-26	itraconazole	drug	226-237	advise
ketoconazole	drug	198-209	erythromycin	drug	212-223	false
ketoconazole	drug	198-209	itraconazole	drug	226-237	false
erythromycin	drug	212-223	itraconazole	drug	226-237	false

DDI-DrugBank.d466.s0	Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.
Erythromycin	drug	22-33	Ketoconazole	drug	39-50	false
Erythromycin	drug	22-33	Fexofenadine	drug	52-63	false
Ketoconazole	drug	39-50	Fexofenadine	drug	52-63	false

DDI-DrugBank.d466.s1	However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.
fexofenadine hydrochloride	drug	31-56	ketoconazole	drug	70-81	mechanism
fexofenadine hydrochloride	drug	31-56	erythromycin	drug	86-97	mechanism
fexofenadine hydrochloride	drug	31-56	fexofenadine	drug	141-152	false
ketoconazole	drug	70-81	erythromycin	drug	86-97	false
ketoconazole	drug	70-81	fexofenadine	drug	141-152	false
erythromycin	drug	86-97	fexofenadine	drug	141-152	false

DDI-DrugBank.d466.s2	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.
Fexofenadine	drug	0-11	erythromycin	drug	61-72	false
Fexofenadine	drug	0-11	ketoconazole	drug	77-88	false
erythromycin	drug	61-72	ketoconazole	drug	77-88	false

DDI-DrugBank.d466.s3	In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).
fexofenadine hydrochloride	drug	23-48	erythromycin	drug	127-138	false
fexofenadine hydrochloride	drug	23-48	ketoconazole	drug	164-175	false
erythromycin	drug	127-138	ketoconazole	drug	164-175	false

DDI-DrugBank.d466.s4	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.
fexofenadine hydrochloride	drug	95-120	erythromycin	drug	158-169	false
fexofenadine hydrochloride	drug	95-120	ketoconazole	drug	174-185	false
erythromycin	drug	158-169	ketoconazole	drug	174-185	false

DDI-DrugBank.d466.s5	The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)
fexofenadine	drug	93-104	fexofenadine hydrochloride	drug	162-187	false

DDI-DrugBank.d466.s17	These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.
ketoconazole	drug	28-39	erythromycin	drug	44-55	false
ketoconazole	drug	28-39	fexofenadine	drug	84-95	mechanism
erythromycin	drug	44-55	fexofenadine	drug	84-95	mechanism

DDI-DrugBank.d466.s18	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.
fexofenadine	drug	49-60	ketoconazole	drug	205-216	false
fexofenadine	drug	49-60	fexofenadine	drug	228-239	false
fexofenadine	drug	49-60	erythromycin	drug	275-286	false
ketoconazole	drug	205-216	fexofenadine	drug	228-239	mechanism
ketoconazole	drug	205-216	erythromycin	drug	275-286	false
fexofenadine	drug	228-239	erythromycin	drug	275-286	false

DDI-DrugBank.d466.s19	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
Antacids	group	23-30	fexofenadine hydrochloride	drug	60-85	false
Antacids	group	23-30	aluminum	drug	131-138	false
Antacids	group	23-30	magnesium	drug	144-152	false
Antacids	group	23-30	antacid	group	165-171	false
Antacids	group	23-30	Maalox	brand	174-179	false
Antacids	group	23-30	fexofenadine	drug	193-204	false
fexofenadine hydrochloride	drug	60-85	aluminum	drug	131-138	mechanism
fexofenadine hydrochloride	drug	60-85	magnesium	drug	144-152	mechanism
fexofenadine hydrochloride	drug	60-85	antacid	group	165-171	mechanism
fexofenadine hydrochloride	drug	60-85	Maalox	brand	174-179	mechanism
fexofenadine hydrochloride	drug	60-85	fexofenadine	drug	193-204	false
aluminum	drug	131-138	magnesium	drug	144-152	false
aluminum	drug	131-138	antacid	group	165-171	false
aluminum	drug	131-138	Maalox	brand	174-179	false
aluminum	drug	131-138	fexofenadine	drug	193-204	false
magnesium	drug	144-152	antacid	group	165-171	false
magnesium	drug	144-152	Maalox	brand	174-179	false
magnesium	drug	144-152	fexofenadine	drug	193-204	false
antacid	group	165-171	Maalox	brand	174-179	false
antacid	group	165-171	fexofenadine	drug	193-204	false
Maalox	brand	174-179	fexofenadine	drug	193-204	false

DDI-DrugBank.d466.s20	ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.
ALLEGRA	brand	0-6	aluminum	drug	49-56	advise
ALLEGRA	brand	0-6	magnesium	drug	62-70	advise
ALLEGRA	brand	0-6	antacids	group	83-90	false
aluminum	drug	49-56	magnesium	drug	62-70	false
aluminum	drug	49-56	antacids	group	83-90	false
magnesium	drug	62-70	antacids	group	83-90	false

DDI-DrugBank.d466.s27	Therefore, to maximize the effects of fexofenadine, it is recommended that ALLEGRA should be taken with water
fexofenadine	drug	38-49	ALLEGRA	brand	75-81	false

DDI-DrugBank.d82.s0	In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.
indomethacin	drug	31-42	diflunisal	drug	67-76	false
indomethacin	drug	31-42	indomethacin	drug	157-168	false
diflunisal	drug	67-76	indomethacin	drug	157-168	mechanism

DDI-DrugBank.d82.s1	In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.
INDOCIN	brand	34-40	diflunisal	drug	46-55	effect

DDI-DrugBank.d82.s2	Therefore, diflunisal and INDOCIN should not be used concomitantly.
diflunisal	drug	11-20	INDOCIN	brand	26-32	advise

DDI-DrugBank.d82.s3	In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.
aspirin	brand	97-103	indomethacin	drug	123-134	mechanism

DDI-DrugBank.d82.s4	The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
INDOCIN	brand	23-29	NSAIDs	group	42-47	advise

DDI-DrugBank.d82.s5	Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants.
INDOCIN	brand	33-39	anticoagulants	group	96-109	false

DDI-DrugBank.d82.s6	However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.
INDOCIN	brand	45-51	anticoagulant	group	95-107	advise

DDI-DrugBank.d82.s7	In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.
anticoagulants	group	99-112	INDOCIN	brand	118-124	effect

DDI-DrugBank.d82.s8	Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.
INDOCIN	brand	33-39	anticoagulants	group	45-58	advise

DDI-DrugBank.d82.s9	When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.
INDOCIN	brand	5-11	probenecid	drug	44-53	mechanism
INDOCIN	brand	5-11	indomethacin	drug	77-88	false
probenecid	drug	44-53	indomethacin	drug	77-88	false

DDI-DrugBank.d82.s12	Caution should be used if INDOCIN is administered simultaneously with methotrexate.
INDOCIN	brand	26-32	methotrexate	drug	70-81	advise

DDI-DrugBank.d82.s13	INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
INDOCIN	brand	0-6	methotrexate	drug	63-74	mechanism

DDI-DrugBank.d82.s14	Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
non-steroidal anti-inflammatory drugs	group	18-54	cyclosporine	drug	75-86	effect
non-steroidal anti-inflammatory drugs	group	18-54	cyclosporine	drug	128-139	false
cyclosporine	drug	75-86	cyclosporine	drug	128-139	false

DDI-DrugBank.d82.s15	NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
NSAIDs	group	0-5	cyclosporine	drug	54-65	advise

DDI-DrugBank.d82.s16	Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.
INDOCIN	brand	9-15	lithium	drug	81-87	mechanism
INDOCIN	brand	9-15	lithium	drug	112-118	false
INDOCIN	brand	9-15	lithium	drug	199-205	false
lithium	drug	81-87	lithium	drug	112-118	false
lithium	drug	81-87	lithium	drug	199-205	false
lithium	drug	112-118	lithium	drug	199-205	false

DDI-DrugBank.d82.s18	As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.
INDOCIN	brand	23-29	lithium	drug	35-41	advise
INDOCIN	brand	23-29	lithium	drug	122-128	false
lithium	drug	35-41	lithium	drug	122-128	false

DDI-DrugBank.d82.s21	INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
INDOCIN	brand	0-6	digoxin	drug	33-39	mechanism
INDOCIN	brand	0-6	digoxin	drug	124-130	false
digoxin	drug	33-39	digoxin	drug	124-130	false

DDI-DrugBank.d82.s22	Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.
INDOCIN	brand	16-22	digoxin	drug	28-34	advise
INDOCIN	brand	16-22	digoxin	drug	66-72	false
digoxin	drug	28-34	digoxin	drug	66-72	false

DDI-DrugBank.d82.s23	In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
INDOCIN	brand	40-46	loop diuretics	group	118-121;156-164	effect
INDOCIN	brand	40-46	potassium-sparing diuretics	group	124-140;156-164	effect
INDOCIN	brand	40-46	thiazide diuretics	group	147-164	effect
loop diuretics	group	118-121;156-164	potassium-sparing diuretics	group	124-140;156-164	false
loop diuretics	group	118-121;156-164	thiazide diuretics	group	147-164	false
potassium-sparing diuretics	group	124-140;156-164	thiazide diuretics	group	147-164	false

DDI-DrugBank.d82.s24	Therefore, when INDOCIN and INDOCIN.
INDOCIN	brand	16-22	INDOCIN	brand	28-34	false

DDI-DrugBank.d82.s25	(Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
Indomethacin	drug	1-12	diuretics	group	15-23	false
Indomethacin	drug	1-12	diuretic	group	130-137	false
diuretics	group	15-23	diuretic	group	130-137	false

DDI-DrugBank.d82.s26	INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion.
INDOCIN	brand	0-6	furosemide	drug	97-106	false

DDI-DrugBank.d82.s28	It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.
triamterene	drug	42-52	INDOCIN	brand	83-89	effect

DDI-DrugBank.d82.s29	INDOCIN and triamterene should not be administered together.
INDOCIN	brand	0-6	triamterene	drug	12-22	advise

DDI-DrugBank.d82.s30	INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels.
INDOCIN	brand	0-6	potassium-sparing diuretics	group	12-38	false

DDI-DrugBank.d82.s31	The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.
INDOCIN	brand	25-31	potassium-sparing diuretics	group	37-63	effect

DDI-DrugBank.d82.s32	Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.
diuretics	group	37-45	INDOCIN	brand	152-158	effect

DDI-DrugBank.d82.s33	Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.
beta-adrenoceptor blocking agents	group	43-75	non-steroidal antiinflammatory drugs	group	80-115	effect
beta-adrenoceptor blocking agents	group	43-75	INDOCIN	brand	127-133	effect
non-steroidal antiinflammatory drugs	group	80-115	INDOCIN	brand	127-133	false

DDI-DrugBank.d82.s35	INDOCIN can reduce the antihypertensive effects of captopril and losartan.
INDOCIN	brand	0-6	captopril	drug	51-59	effect
INDOCIN	brand	0-6	losartan	drug	65-72	effect
captopril	drug	51-59	losartan	drug	65-72	false

DDI-DrugBank.d505.s0	No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE  (dipyridamole USP) Tablets.
PERSANTINE	brand	69-78	dipyridamole	drug	82-93	false

DDI-DrugBank.d505.s2	Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
Adenosine	drug	0-8	Dipyridamole	drug	11-22	false
Adenosine	drug	0-8	adenosine	drug	102-110	false
Dipyridamole	drug	11-22	adenosine	drug	102-110	mechanism

DDI-DrugBank.d505.s4	Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
Cholinesterase Inhibitors	group	0-24	Dipyridamole	drug	27-38	false
Cholinesterase Inhibitors	group	0-24	cholinesterase inhibitors	group	88-112	false
Dipyridamole	drug	27-38	cholinesterase inhibitors	group	88-112	effect

DDI-DrugBank.d561.s0	Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.
Diuretics	group	0-8	diuretics	group	23-31	false
Diuretics	group	0-8	Lotensin	brand	203-210	false
diuretics	group	23-31	Lotensin	brand	203-210	effect

DDI-DrugBank.d561.s1	The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.
Lotensin	brand	44-51	diuretic	group	98-105	false
Lotensin	brand	44-51	Lotensin	brand	175-182	false
diuretic	group	98-105	Lotensin	brand	175-182	advise

DDI-DrugBank.d561.s3	Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.
Potassium	drug	0-8	Potassium-Sparing Diuretics	group	26-52	false
Potassium	drug	0-8	thiazide diuretics	group	102-119	false
Potassium-Sparing Diuretics	group	26-52	thiazide diuretics	group	102-119	effect

DDI-DrugBank.d561.s4	Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
Potassium-sparing diuretics	group	0-26	spironolactone	drug	29-42	false
Potassium-sparing diuretics	group	0-26	amiloride	drug	45-53	false
Potassium-sparing diuretics	group	0-26	triamterene	drug	56-66	false
Potassium-sparing diuretics	group	0-26	potassium	drug	84-92	false
spironolactone	drug	29-42	amiloride	drug	45-53	false
spironolactone	drug	29-42	triamterene	drug	56-66	false
spironolactone	drug	29-42	potassium	drug	84-92	false
amiloride	drug	45-53	triamterene	drug	56-66	false
amiloride	drug	45-53	potassium	drug	84-92	false
triamterene	drug	56-66	potassium	drug	84-92	false

DDI-DrugBank.d561.s6	Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.
Anticoagulants	group	5-18	warfarin	drug	45-52	false
Anticoagulants	group	5-18	acenocoumarol	drug	58-70	false
Anticoagulants	group	5-18	anticoagulants	group	181-194	false
warfarin	drug	45-52	acenocoumarol	drug	58-70	false
warfarin	drug	45-52	anticoagulants	group	181-194	false
acenocoumarol	drug	58-70	anticoagulants	group	181-194	false

DDI-DrugBank.d561.s7	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
Lithium	drug	0-6	lithium	drug	25-31	false
Lithium	drug	0-6	lithium	drug	56-62	false
Lithium	drug	0-6	ACE inhibitors	group	114-127	false
Lithium	drug	0-6	lithium	drug	149-155	false
lithium	drug	25-31	lithium	drug	56-62	false
lithium	drug	25-31	ACE inhibitors	group	114-127	false
lithium	drug	25-31	lithium	drug	149-155	false
lithium	drug	56-62	ACE inhibitors	group	114-127	false
lithium	drug	56-62	lithium	drug	149-155	false
ACE inhibitors	group	114-127	lithium	drug	149-155	mechanism

DDI-DrugBank.d561.s9	If a diuretic is also used, the risk of lithium toxicity may be increased.
diuretic	group	5-12	lithium	drug	40-46	effect

DDI-DrugBank.d561.s10	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or cimetidine.
Lotensin	brand	73-80	hydrochlorothiazide	drug	118-136	false
Lotensin	brand	73-80	chlorthalidone	drug	139-152	false
Lotensin	brand	73-80	furosemide	drug	155-164	false
Lotensin	brand	73-80	digoxin	drug	167-173	false
Lotensin	brand	73-80	propranolol	drug	176-186	false
Lotensin	brand	73-80	atenolol	drug	189-196	false
Lotensin	brand	73-80	naproxen	drug	199-206	false
Lotensin	brand	73-80	cimetidine	drug	212-221	false
hydrochlorothiazide	drug	118-136	chlorthalidone	drug	139-152	false
hydrochlorothiazide	drug	118-136	furosemide	drug	155-164	false
hydrochlorothiazide	drug	118-136	digoxin	drug	167-173	false
hydrochlorothiazide	drug	118-136	propranolol	drug	176-186	false
hydrochlorothiazide	drug	118-136	atenolol	drug	189-196	false
hydrochlorothiazide	drug	118-136	naproxen	drug	199-206	false
hydrochlorothiazide	drug	118-136	cimetidine	drug	212-221	false
chlorthalidone	drug	139-152	furosemide	drug	155-164	false
chlorthalidone	drug	139-152	digoxin	drug	167-173	false
chlorthalidone	drug	139-152	propranolol	drug	176-186	false
chlorthalidone	drug	139-152	atenolol	drug	189-196	false
chlorthalidone	drug	139-152	naproxen	drug	199-206	false
chlorthalidone	drug	139-152	cimetidine	drug	212-221	false
furosemide	drug	155-164	digoxin	drug	167-173	false
furosemide	drug	155-164	propranolol	drug	176-186	false
furosemide	drug	155-164	atenolol	drug	189-196	false
furosemide	drug	155-164	naproxen	drug	199-206	false
furosemide	drug	155-164	cimetidine	drug	212-221	false
digoxin	drug	167-173	propranolol	drug	176-186	false
digoxin	drug	167-173	atenolol	drug	189-196	false
digoxin	drug	167-173	naproxen	drug	199-206	false
digoxin	drug	167-173	cimetidine	drug	212-221	false
propranolol	drug	176-186	atenolol	drug	189-196	false
propranolol	drug	176-186	naproxen	drug	199-206	false
propranolol	drug	176-186	cimetidine	drug	212-221	false
atenolol	drug	189-196	naproxen	drug	199-206	false
atenolol	drug	189-196	cimetidine	drug	212-221	false
naproxen	drug	199-206	cimetidine	drug	212-221	false

DDI-DrugBank.d561.s11	Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
Lotensin	brand	0-7	beta-adrenergic-blocking agents	group	42-72	false
Lotensin	brand	0-7	calcium-channel-blocking agents	group	75-105	false
Lotensin	brand	0-7	diuretics	group	108-116	false
Lotensin	brand	0-7	digoxin	drug	119-125	false
Lotensin	brand	0-7	hydralazine	drug	132-142	false
beta-adrenergic-blocking agents	group	42-72	calcium-channel-blocking agents	group	75-105	false
beta-adrenergic-blocking agents	group	42-72	diuretics	group	108-116	false
beta-adrenergic-blocking agents	group	42-72	digoxin	drug	119-125	false
beta-adrenergic-blocking agents	group	42-72	hydralazine	drug	132-142	false
calcium-channel-blocking agents	group	75-105	diuretics	group	108-116	false
calcium-channel-blocking agents	group	75-105	digoxin	drug	119-125	false
calcium-channel-blocking agents	group	75-105	hydralazine	drug	132-142	false
diuretics	group	108-116	digoxin	drug	119-125	false
diuretics	group	108-116	hydralazine	drug	132-142	false
digoxin	drug	119-125	hydralazine	drug	132-142	false

DDI-DrugBank.d561.s12	Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
Benazepril	drug	0-9	ACE inhibitors	group	23-36	false
Benazepril	drug	0-9	beta-adrenergic blockers	group	79-102	effect
ACE inhibitors	group	23-36	beta-adrenergic blockers	group	79-102	effect

DDI-DrugBank.d47.s0	Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.
LODOSYN	brand	89-95	Carbidopa	drug	98-106	false
LODOSYN	brand	89-95	levodopa	drug	120-127	false
LODOSYN	brand	89-95	carbidopa	drug	132-140	false
LODOSYN	brand	89-95	levodopa	drug	142-149	false
Carbidopa	drug	98-106	levodopa	drug	120-127	false
Carbidopa	drug	98-106	carbidopa	drug	132-140	false
Carbidopa	drug	98-106	levodopa	drug	142-149	false
levodopa	drug	120-127	carbidopa	drug	132-140	false
levodopa	drug	120-127	levodopa	drug	142-149	false
carbidopa	drug	132-140	levodopa	drug	142-149	false

DDI-DrugBank.d47.s2	Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
Dopamine D2 receptor antagonists	group	0-31	phenothiazines	group	40-53	false
Dopamine D2 receptor antagonists	group	0-31	butyrophenones	group	56-69	false
Dopamine D2 receptor antagonists	group	0-31	risperidone	drug	72-82	false
Dopamine D2 receptor antagonists	group	0-31	isoniazid	drug	89-97	false
Dopamine D2 receptor antagonists	group	0-31	levodopa	drug	137-144	effect
phenothiazines	group	40-53	butyrophenones	group	56-69	false
phenothiazines	group	40-53	risperidone	drug	72-82	false
phenothiazines	group	40-53	isoniazid	drug	89-97	false
phenothiazines	group	40-53	levodopa	drug	137-144	effect
butyrophenones	group	56-69	risperidone	drug	72-82	false
butyrophenones	group	56-69	isoniazid	drug	89-97	false
butyrophenones	group	56-69	levodopa	drug	137-144	effect
risperidone	drug	72-82	isoniazid	drug	89-97	false
risperidone	drug	72-82	levodopa	drug	137-144	effect
isoniazid	drug	89-97	levodopa	drug	137-144	effect

DDI-DrugBank.d47.s3	In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
levodopa	drug	39-46	phenytoin	drug	107-115	effect
levodopa	drug	39-46	papaverine	drug	121-130	effect
phenytoin	drug	107-115	papaverine	drug	121-130	false

DDI-DrugBank.d47.s4	Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.
LODOSYN	brand	33-39	levodopa	drug	45-52	false
LODOSYN	brand	33-39	carbidopa	drug	57-65	false
LODOSYN	brand	33-39	levodopa	drug	67-74	false
levodopa	drug	45-52	carbidopa	drug	57-65	false
levodopa	drug	45-52	levodopa	drug	67-74	false
carbidopa	drug	57-65	levodopa	drug	67-74	false

DDI-DrugBank.d47.s5	Iron salts may reduce the bioavailability of carbidopa and levodopa.
Iron	drug	0-3	carbidopa	drug	45-53	mechanism
Iron	drug	0-3	levodopa	drug	59-66	mechanism
carbidopa	drug	45-53	levodopa	drug	59-66	false

DDI-DrugBank.d47.s7	Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
metoclopramide	drug	9-22	levodopa	drug	60-67	mechanism
metoclopramide	drug	9-22	metoclopramide	drug	101-114	false
levodopa	drug	60-67	metoclopramide	drug	101-114	false

DDI-DrugBank.d523.s1	Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.
baclofen	drug	47-54	morphine	drug	79-86	effect

DDI-DrugBank.d523.s2	SIDE EFFECTS (KEMSTRO) The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%).
KEMSTRO	brand	14-20	baclofen	drug	78-85	false

DDI-DrugBank.d523.s16	The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets.
KEMSTROTM	brand	41-49	baclofen	drug	81-88	false

DDI-DrugBank.d266.s0	In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
CASODEX	brand	28-34	coumarin anticoagulant	group	49-70	mechanism
CASODEX	brand	28-34	warfarin	drug	82-89	mechanism
coumarin anticoagulant	group	49-70	warfarin	drug	82-89	false

DDI-DrugBank.d266.s1	It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
CASODEX	brand	26-32	coumarin anticoagulants	group	75-97	advise
CASODEX	brand	26-32	anticoagulant	group	168-180	advise
coumarin anticoagulants	group	75-97	anticoagulant	group	168-180	false

DDI-DrugBank.d94.s2	Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase Carbamazepine is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active carbamazepine 10,11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase.
Carbamazepine	drug	72-84	carbamazepine 10,11-epoxide	drug	151-177	false

DDI-DrugBank.d94.s4	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
EQUETROTM	brand	102-110	Acetazolamide	drug	131-143	mechanism
EQUETROTM	brand	102-110	azole antifungals	group	146-162	mechanism
EQUETROTM	brand	102-110	cimetidine	drug	165-174	mechanism
EQUETROTM	brand	102-110	clarithromycin	drug	177-190	mechanism
EQUETROTM	brand	102-110	dalfopristin	drug	196-207	mechanism
EQUETROTM	brand	102-110	danazol	drug	210-216	mechanism
EQUETROTM	brand	102-110	delavirdine	drug	219-229	mechanism
EQUETROTM	brand	102-110	diltiazem	drug	232-240	mechanism
EQUETROTM	brand	102-110	erythromycin	drug	243-254	mechanism
EQUETROTM	brand	102-110	fluoxetine	drug	260-269	mechanism
EQUETROTM	brand	102-110	fluvoxamine	drug	272-282	mechanism
EQUETROTM	brand	102-110	isoniazid	drug	303-311	mechanism
EQUETROTM	brand	102-110	itraconazole	drug	314-325	mechanism
EQUETROTM	brand	102-110	ketoconazole	drug	328-339	mechanism
EQUETROTM	brand	102-110	loratadine	drug	342-351	mechanism
EQUETROTM	brand	102-110	nefazodone	drug	354-363	mechanism
EQUETROTM	brand	102-110	niacinamide	drug	366-376	mechanism
EQUETROTM	brand	102-110	nicotinamide	drug	379-390	mechanism
EQUETROTM	brand	102-110	protease inhibitors	group	393-411	mechanism
EQUETROTM	brand	102-110	propoxyphene	drug	414-425	mechanism
EQUETROTM	brand	102-110	quinine	drug	428-434	mechanism
EQUETROTM	brand	102-110	quinupristin	drug	437-448	mechanism
EQUETROTM	brand	102-110	troleandomycin	drug	451-464	mechanism
EQUETROTM	brand	102-110	valproate	drug	467-475	mechanism
EQUETROTM	brand	102-110	verapamil	drug	481-489	mechanism
EQUETROTM	brand	102-110	zileuton	drug	492-499	mechanism
Acetazolamide	drug	131-143	azole antifungals	group	146-162	false
Acetazolamide	drug	131-143	cimetidine	drug	165-174	false
Acetazolamide	drug	131-143	clarithromycin	drug	177-190	false
Acetazolamide	drug	131-143	dalfopristin	drug	196-207	false
Acetazolamide	drug	131-143	danazol	drug	210-216	false
Acetazolamide	drug	131-143	delavirdine	drug	219-229	false
Acetazolamide	drug	131-143	diltiazem	drug	232-240	false
Acetazolamide	drug	131-143	erythromycin	drug	243-254	false
Acetazolamide	drug	131-143	fluoxetine	drug	260-269	false
Acetazolamide	drug	131-143	fluvoxamine	drug	272-282	false
Acetazolamide	drug	131-143	isoniazid	drug	303-311	false
Acetazolamide	drug	131-143	itraconazole	drug	314-325	false
Acetazolamide	drug	131-143	ketoconazole	drug	328-339	false
Acetazolamide	drug	131-143	loratadine	drug	342-351	false
Acetazolamide	drug	131-143	nefazodone	drug	354-363	false
Acetazolamide	drug	131-143	niacinamide	drug	366-376	false
Acetazolamide	drug	131-143	nicotinamide	drug	379-390	false
Acetazolamide	drug	131-143	protease inhibitors	group	393-411	false
Acetazolamide	drug	131-143	propoxyphene	drug	414-425	false
Acetazolamide	drug	131-143	quinine	drug	428-434	false
Acetazolamide	drug	131-143	quinupristin	drug	437-448	false
Acetazolamide	drug	131-143	troleandomycin	drug	451-464	false
Acetazolamide	drug	131-143	valproate	drug	467-475	false
Acetazolamide	drug	131-143	verapamil	drug	481-489	false
Acetazolamide	drug	131-143	zileuton	drug	492-499	false
azole antifungals	group	146-162	cimetidine	drug	165-174	false
azole antifungals	group	146-162	clarithromycin	drug	177-190	false
azole antifungals	group	146-162	dalfopristin	drug	196-207	false
azole antifungals	group	146-162	danazol	drug	210-216	false
azole antifungals	group	146-162	delavirdine	drug	219-229	false
azole antifungals	group	146-162	diltiazem	drug	232-240	false
azole antifungals	group	146-162	erythromycin	drug	243-254	false
azole antifungals	group	146-162	fluoxetine	drug	260-269	false
azole antifungals	group	146-162	fluvoxamine	drug	272-282	false
azole antifungals	group	146-162	isoniazid	drug	303-311	false
azole antifungals	group	146-162	itraconazole	drug	314-325	false
azole antifungals	group	146-162	ketoconazole	drug	328-339	false
azole antifungals	group	146-162	loratadine	drug	342-351	false
azole antifungals	group	146-162	nefazodone	drug	354-363	false
azole antifungals	group	146-162	niacinamide	drug	366-376	false
azole antifungals	group	146-162	nicotinamide	drug	379-390	false
azole antifungals	group	146-162	protease inhibitors	group	393-411	false
azole antifungals	group	146-162	propoxyphene	drug	414-425	false
azole antifungals	group	146-162	quinine	drug	428-434	false
azole antifungals	group	146-162	quinupristin	drug	437-448	false
azole antifungals	group	146-162	troleandomycin	drug	451-464	false
azole antifungals	group	146-162	valproate	drug	467-475	false
azole antifungals	group	146-162	verapamil	drug	481-489	false
azole antifungals	group	146-162	zileuton	drug	492-499	false
cimetidine	drug	165-174	clarithromycin	drug	177-190	false
cimetidine	drug	165-174	dalfopristin	drug	196-207	false
cimetidine	drug	165-174	danazol	drug	210-216	false
cimetidine	drug	165-174	delavirdine	drug	219-229	false
cimetidine	drug	165-174	diltiazem	drug	232-240	false
cimetidine	drug	165-174	erythromycin	drug	243-254	false
cimetidine	drug	165-174	fluoxetine	drug	260-269	false
cimetidine	drug	165-174	fluvoxamine	drug	272-282	false
cimetidine	drug	165-174	isoniazid	drug	303-311	false
cimetidine	drug	165-174	itraconazole	drug	314-325	false
cimetidine	drug	165-174	ketoconazole	drug	328-339	false
cimetidine	drug	165-174	loratadine	drug	342-351	false
cimetidine	drug	165-174	nefazodone	drug	354-363	false
cimetidine	drug	165-174	niacinamide	drug	366-376	false
cimetidine	drug	165-174	nicotinamide	drug	379-390	false
cimetidine	drug	165-174	protease inhibitors	group	393-411	false
cimetidine	drug	165-174	propoxyphene	drug	414-425	false
cimetidine	drug	165-174	quinine	drug	428-434	false
cimetidine	drug	165-174	quinupristin	drug	437-448	false
cimetidine	drug	165-174	troleandomycin	drug	451-464	false
cimetidine	drug	165-174	valproate	drug	467-475	false
cimetidine	drug	165-174	verapamil	drug	481-489	false
cimetidine	drug	165-174	zileuton	drug	492-499	false
clarithromycin	drug	177-190	dalfopristin	drug	196-207	false
clarithromycin	drug	177-190	danazol	drug	210-216	false
clarithromycin	drug	177-190	delavirdine	drug	219-229	false
clarithromycin	drug	177-190	diltiazem	drug	232-240	false
clarithromycin	drug	177-190	erythromycin	drug	243-254	false
clarithromycin	drug	177-190	fluoxetine	drug	260-269	false
clarithromycin	drug	177-190	fluvoxamine	drug	272-282	false
clarithromycin	drug	177-190	isoniazid	drug	303-311	false
clarithromycin	drug	177-190	itraconazole	drug	314-325	false
clarithromycin	drug	177-190	ketoconazole	drug	328-339	false
clarithromycin	drug	177-190	loratadine	drug	342-351	false
clarithromycin	drug	177-190	nefazodone	drug	354-363	false
clarithromycin	drug	177-190	niacinamide	drug	366-376	false
clarithromycin	drug	177-190	nicotinamide	drug	379-390	false
clarithromycin	drug	177-190	protease inhibitors	group	393-411	false
clarithromycin	drug	177-190	propoxyphene	drug	414-425	false
clarithromycin	drug	177-190	quinine	drug	428-434	false
clarithromycin	drug	177-190	quinupristin	drug	437-448	false
clarithromycin	drug	177-190	troleandomycin	drug	451-464	false
clarithromycin	drug	177-190	valproate	drug	467-475	false
clarithromycin	drug	177-190	verapamil	drug	481-489	false
clarithromycin	drug	177-190	zileuton	drug	492-499	false
dalfopristin	drug	196-207	danazol	drug	210-216	false
dalfopristin	drug	196-207	delavirdine	drug	219-229	false
dalfopristin	drug	196-207	diltiazem	drug	232-240	false
dalfopristin	drug	196-207	erythromycin	drug	243-254	false
dalfopristin	drug	196-207	fluoxetine	drug	260-269	false
dalfopristin	drug	196-207	fluvoxamine	drug	272-282	false
dalfopristin	drug	196-207	isoniazid	drug	303-311	false
dalfopristin	drug	196-207	itraconazole	drug	314-325	false
dalfopristin	drug	196-207	ketoconazole	drug	328-339	false
dalfopristin	drug	196-207	loratadine	drug	342-351	false
dalfopristin	drug	196-207	nefazodone	drug	354-363	false
dalfopristin	drug	196-207	niacinamide	drug	366-376	false
dalfopristin	drug	196-207	nicotinamide	drug	379-390	false
dalfopristin	drug	196-207	protease inhibitors	group	393-411	false
dalfopristin	drug	196-207	propoxyphene	drug	414-425	false
dalfopristin	drug	196-207	quinine	drug	428-434	false
dalfopristin	drug	196-207	quinupristin	drug	437-448	false
dalfopristin	drug	196-207	troleandomycin	drug	451-464	false
dalfopristin	drug	196-207	valproate	drug	467-475	false
dalfopristin	drug	196-207	verapamil	drug	481-489	false
dalfopristin	drug	196-207	zileuton	drug	492-499	false
danazol	drug	210-216	delavirdine	drug	219-229	false
danazol	drug	210-216	diltiazem	drug	232-240	false
danazol	drug	210-216	erythromycin	drug	243-254	false
danazol	drug	210-216	fluoxetine	drug	260-269	false
danazol	drug	210-216	fluvoxamine	drug	272-282	false
danazol	drug	210-216	isoniazid	drug	303-311	false
danazol	drug	210-216	itraconazole	drug	314-325	false
danazol	drug	210-216	ketoconazole	drug	328-339	false
danazol	drug	210-216	loratadine	drug	342-351	false
danazol	drug	210-216	nefazodone	drug	354-363	false
danazol	drug	210-216	niacinamide	drug	366-376	false
danazol	drug	210-216	nicotinamide	drug	379-390	false
danazol	drug	210-216	protease inhibitors	group	393-411	false
danazol	drug	210-216	propoxyphene	drug	414-425	false
danazol	drug	210-216	quinine	drug	428-434	false
danazol	drug	210-216	quinupristin	drug	437-448	false
danazol	drug	210-216	troleandomycin	drug	451-464	false
danazol	drug	210-216	valproate	drug	467-475	false
danazol	drug	210-216	verapamil	drug	481-489	false
danazol	drug	210-216	zileuton	drug	492-499	false
delavirdine	drug	219-229	diltiazem	drug	232-240	false
delavirdine	drug	219-229	erythromycin	drug	243-254	false
delavirdine	drug	219-229	fluoxetine	drug	260-269	false
delavirdine	drug	219-229	fluvoxamine	drug	272-282	false
delavirdine	drug	219-229	isoniazid	drug	303-311	false
delavirdine	drug	219-229	itraconazole	drug	314-325	false
delavirdine	drug	219-229	ketoconazole	drug	328-339	false
delavirdine	drug	219-229	loratadine	drug	342-351	false
delavirdine	drug	219-229	nefazodone	drug	354-363	false
delavirdine	drug	219-229	niacinamide	drug	366-376	false
delavirdine	drug	219-229	nicotinamide	drug	379-390	false
delavirdine	drug	219-229	protease inhibitors	group	393-411	false
delavirdine	drug	219-229	propoxyphene	drug	414-425	false
delavirdine	drug	219-229	quinine	drug	428-434	false
delavirdine	drug	219-229	quinupristin	drug	437-448	false
delavirdine	drug	219-229	troleandomycin	drug	451-464	false
delavirdine	drug	219-229	valproate	drug	467-475	false
delavirdine	drug	219-229	verapamil	drug	481-489	false
delavirdine	drug	219-229	zileuton	drug	492-499	false
diltiazem	drug	232-240	erythromycin	drug	243-254	false
diltiazem	drug	232-240	fluoxetine	drug	260-269	false
diltiazem	drug	232-240	fluvoxamine	drug	272-282	false
diltiazem	drug	232-240	isoniazid	drug	303-311	false
diltiazem	drug	232-240	itraconazole	drug	314-325	false
diltiazem	drug	232-240	ketoconazole	drug	328-339	false
diltiazem	drug	232-240	loratadine	drug	342-351	false
diltiazem	drug	232-240	nefazodone	drug	354-363	false
diltiazem	drug	232-240	niacinamide	drug	366-376	false
diltiazem	drug	232-240	nicotinamide	drug	379-390	false
diltiazem	drug	232-240	protease inhibitors	group	393-411	false
diltiazem	drug	232-240	propoxyphene	drug	414-425	false
diltiazem	drug	232-240	quinine	drug	428-434	false
diltiazem	drug	232-240	quinupristin	drug	437-448	false
diltiazem	drug	232-240	troleandomycin	drug	451-464	false
diltiazem	drug	232-240	valproate	drug	467-475	false
diltiazem	drug	232-240	verapamil	drug	481-489	false
diltiazem	drug	232-240	zileuton	drug	492-499	false
erythromycin	drug	243-254	fluoxetine	drug	260-269	false
erythromycin	drug	243-254	fluvoxamine	drug	272-282	false
erythromycin	drug	243-254	isoniazid	drug	303-311	false
erythromycin	drug	243-254	itraconazole	drug	314-325	false
erythromycin	drug	243-254	ketoconazole	drug	328-339	false
erythromycin	drug	243-254	loratadine	drug	342-351	false
erythromycin	drug	243-254	nefazodone	drug	354-363	false
erythromycin	drug	243-254	niacinamide	drug	366-376	false
erythromycin	drug	243-254	nicotinamide	drug	379-390	false
erythromycin	drug	243-254	protease inhibitors	group	393-411	false
erythromycin	drug	243-254	propoxyphene	drug	414-425	false
erythromycin	drug	243-254	quinine	drug	428-434	false
erythromycin	drug	243-254	quinupristin	drug	437-448	false
erythromycin	drug	243-254	troleandomycin	drug	451-464	false
erythromycin	drug	243-254	valproate	drug	467-475	false
erythromycin	drug	243-254	verapamil	drug	481-489	false
erythromycin	drug	243-254	zileuton	drug	492-499	false
fluoxetine	drug	260-269	fluvoxamine	drug	272-282	false
fluoxetine	drug	260-269	isoniazid	drug	303-311	false
fluoxetine	drug	260-269	itraconazole	drug	314-325	false
fluoxetine	drug	260-269	ketoconazole	drug	328-339	false
fluoxetine	drug	260-269	loratadine	drug	342-351	false
fluoxetine	drug	260-269	nefazodone	drug	354-363	false
fluoxetine	drug	260-269	niacinamide	drug	366-376	false
fluoxetine	drug	260-269	nicotinamide	drug	379-390	false
fluoxetine	drug	260-269	protease inhibitors	group	393-411	false
fluoxetine	drug	260-269	propoxyphene	drug	414-425	false
fluoxetine	drug	260-269	quinine	drug	428-434	false
fluoxetine	drug	260-269	quinupristin	drug	437-448	false
fluoxetine	drug	260-269	troleandomycin	drug	451-464	false
fluoxetine	drug	260-269	valproate	drug	467-475	false
fluoxetine	drug	260-269	verapamil	drug	481-489	false
fluoxetine	drug	260-269	zileuton	drug	492-499	false
fluvoxamine	drug	272-282	isoniazid	drug	303-311	false
fluvoxamine	drug	272-282	itraconazole	drug	314-325	false
fluvoxamine	drug	272-282	ketoconazole	drug	328-339	false
fluvoxamine	drug	272-282	loratadine	drug	342-351	false
fluvoxamine	drug	272-282	nefazodone	drug	354-363	false
fluvoxamine	drug	272-282	niacinamide	drug	366-376	false
fluvoxamine	drug	272-282	nicotinamide	drug	379-390	false
fluvoxamine	drug	272-282	protease inhibitors	group	393-411	false
fluvoxamine	drug	272-282	propoxyphene	drug	414-425	false
fluvoxamine	drug	272-282	quinine	drug	428-434	false
fluvoxamine	drug	272-282	quinupristin	drug	437-448	false
fluvoxamine	drug	272-282	troleandomycin	drug	451-464	false
fluvoxamine	drug	272-282	valproate	drug	467-475	false
fluvoxamine	drug	272-282	verapamil	drug	481-489	false
fluvoxamine	drug	272-282	zileuton	drug	492-499	false
isoniazid	drug	303-311	itraconazole	drug	314-325	false
isoniazid	drug	303-311	ketoconazole	drug	328-339	false
isoniazid	drug	303-311	loratadine	drug	342-351	false
isoniazid	drug	303-311	nefazodone	drug	354-363	false
isoniazid	drug	303-311	niacinamide	drug	366-376	false
isoniazid	drug	303-311	nicotinamide	drug	379-390	false
isoniazid	drug	303-311	protease inhibitors	group	393-411	false
isoniazid	drug	303-311	propoxyphene	drug	414-425	false
isoniazid	drug	303-311	quinine	drug	428-434	false
isoniazid	drug	303-311	quinupristin	drug	437-448	false
isoniazid	drug	303-311	troleandomycin	drug	451-464	false
isoniazid	drug	303-311	valproate	drug	467-475	false
isoniazid	drug	303-311	verapamil	drug	481-489	false
isoniazid	drug	303-311	zileuton	drug	492-499	false
itraconazole	drug	314-325	ketoconazole	drug	328-339	false
itraconazole	drug	314-325	loratadine	drug	342-351	false
itraconazole	drug	314-325	nefazodone	drug	354-363	false
itraconazole	drug	314-325	niacinamide	drug	366-376	false
itraconazole	drug	314-325	nicotinamide	drug	379-390	false
itraconazole	drug	314-325	protease inhibitors	group	393-411	false
itraconazole	drug	314-325	propoxyphene	drug	414-425	false
itraconazole	drug	314-325	quinine	drug	428-434	false
itraconazole	drug	314-325	quinupristin	drug	437-448	false
itraconazole	drug	314-325	troleandomycin	drug	451-464	false
itraconazole	drug	314-325	valproate	drug	467-475	false
itraconazole	drug	314-325	verapamil	drug	481-489	false
itraconazole	drug	314-325	zileuton	drug	492-499	false
ketoconazole	drug	328-339	loratadine	drug	342-351	false
ketoconazole	drug	328-339	nefazodone	drug	354-363	false
ketoconazole	drug	328-339	niacinamide	drug	366-376	false
ketoconazole	drug	328-339	nicotinamide	drug	379-390	false
ketoconazole	drug	328-339	protease inhibitors	group	393-411	false
ketoconazole	drug	328-339	propoxyphene	drug	414-425	false
ketoconazole	drug	328-339	quinine	drug	428-434	false
ketoconazole	drug	328-339	quinupristin	drug	437-448	false
ketoconazole	drug	328-339	troleandomycin	drug	451-464	false
ketoconazole	drug	328-339	valproate	drug	467-475	false
ketoconazole	drug	328-339	verapamil	drug	481-489	false
ketoconazole	drug	328-339	zileuton	drug	492-499	false
loratadine	drug	342-351	nefazodone	drug	354-363	false
loratadine	drug	342-351	niacinamide	drug	366-376	false
loratadine	drug	342-351	nicotinamide	drug	379-390	false
loratadine	drug	342-351	protease inhibitors	group	393-411	false
loratadine	drug	342-351	propoxyphene	drug	414-425	false
loratadine	drug	342-351	quinine	drug	428-434	false
loratadine	drug	342-351	quinupristin	drug	437-448	false
loratadine	drug	342-351	troleandomycin	drug	451-464	false
loratadine	drug	342-351	valproate	drug	467-475	false
loratadine	drug	342-351	verapamil	drug	481-489	false
loratadine	drug	342-351	zileuton	drug	492-499	false
nefazodone	drug	354-363	niacinamide	drug	366-376	false
nefazodone	drug	354-363	nicotinamide	drug	379-390	false
nefazodone	drug	354-363	protease inhibitors	group	393-411	false
nefazodone	drug	354-363	propoxyphene	drug	414-425	false
nefazodone	drug	354-363	quinine	drug	428-434	false
nefazodone	drug	354-363	quinupristin	drug	437-448	false
nefazodone	drug	354-363	troleandomycin	drug	451-464	false
nefazodone	drug	354-363	valproate	drug	467-475	false
nefazodone	drug	354-363	verapamil	drug	481-489	false
nefazodone	drug	354-363	zileuton	drug	492-499	false
niacinamide	drug	366-376	nicotinamide	drug	379-390	false
niacinamide	drug	366-376	protease inhibitors	group	393-411	false
niacinamide	drug	366-376	propoxyphene	drug	414-425	false
niacinamide	drug	366-376	quinine	drug	428-434	false
niacinamide	drug	366-376	quinupristin	drug	437-448	false
niacinamide	drug	366-376	troleandomycin	drug	451-464	false
niacinamide	drug	366-376	valproate	drug	467-475	false
niacinamide	drug	366-376	verapamil	drug	481-489	false
niacinamide	drug	366-376	zileuton	drug	492-499	false
nicotinamide	drug	379-390	protease inhibitors	group	393-411	false
nicotinamide	drug	379-390	propoxyphene	drug	414-425	false
nicotinamide	drug	379-390	quinine	drug	428-434	false
nicotinamide	drug	379-390	quinupristin	drug	437-448	false
nicotinamide	drug	379-390	troleandomycin	drug	451-464	false
nicotinamide	drug	379-390	valproate	drug	467-475	false
nicotinamide	drug	379-390	verapamil	drug	481-489	false
nicotinamide	drug	379-390	zileuton	drug	492-499	false
protease inhibitors	group	393-411	propoxyphene	drug	414-425	false
protease inhibitors	group	393-411	quinine	drug	428-434	false
protease inhibitors	group	393-411	quinupristin	drug	437-448	false
protease inhibitors	group	393-411	troleandomycin	drug	451-464	false
protease inhibitors	group	393-411	valproate	drug	467-475	false
protease inhibitors	group	393-411	verapamil	drug	481-489	false
protease inhibitors	group	393-411	zileuton	drug	492-499	false
propoxyphene	drug	414-425	quinine	drug	428-434	false
propoxyphene	drug	414-425	quinupristin	drug	437-448	false
propoxyphene	drug	414-425	troleandomycin	drug	451-464	false
propoxyphene	drug	414-425	valproate	drug	467-475	false
propoxyphene	drug	414-425	verapamil	drug	481-489	false
propoxyphene	drug	414-425	zileuton	drug	492-499	false
quinine	drug	428-434	quinupristin	drug	437-448	false
quinine	drug	428-434	troleandomycin	drug	451-464	false
quinine	drug	428-434	valproate	drug	467-475	false
quinine	drug	428-434	verapamil	drug	481-489	false
quinine	drug	428-434	zileuton	drug	492-499	false
quinupristin	drug	437-448	troleandomycin	drug	451-464	false
quinupristin	drug	437-448	valproate	drug	467-475	false
quinupristin	drug	437-448	verapamil	drug	481-489	false
quinupristin	drug	437-448	zileuton	drug	492-499	false
troleandomycin	drug	451-464	valproate	drug	467-475	false
troleandomycin	drug	451-464	verapamil	drug	481-489	false
troleandomycin	drug	451-464	zileuton	drug	492-499	false
valproate	drug	467-475	verapamil	drug	481-489	false
valproate	drug	467-475	zileuton	drug	492-499	false
verapamil	drug	481-489	zileuton	drug	492-499	false

DDI-DrugBank.d94.s5	Thus, if a patient has been titrated to a stable dosage of EQUETROTM, and then begins a course of treatment with one of these CYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for EQUETROTM may be necessary.
EQUETROTM	brand	59-67	EQUETROTM	brand	219-227	false

DDI-DrugBank.d94.s8	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
EQUETROTM	brand	97-105	Cisplatin	drug	126-134	mechanism
EQUETROTM	brand	97-105	doxorubicin HCL	drug	137-151	mechanism
EQUETROTM	brand	97-105	felbamate	drug	154-162	mechanism
EQUETROTM	brand	97-105	rifampin	drug	165-172	mechanism
EQUETROTM	brand	97-105	phenobarbital	drug	175-187	mechanism
EQUETROTM	brand	97-105	Phenytoin	drug	190-198	mechanism
EQUETROTM	brand	97-105	primidone	drug	204-212	mechanism
EQUETROTM	brand	97-105	methsuximide	drug	215-226	mechanism
EQUETROTM	brand	97-105	theophylline	drug	233-244	mechanism
EQUETROTM	brand	97-105	EQUETROTM	brand	305-313	false
EQUETROTM	brand	97-105	EQUETROTM	brand	441-449	false
Cisplatin	drug	126-134	doxorubicin HCL	drug	137-151	false
Cisplatin	drug	126-134	felbamate	drug	154-162	false
Cisplatin	drug	126-134	rifampin	drug	165-172	false
Cisplatin	drug	126-134	phenobarbital	drug	175-187	false
Cisplatin	drug	126-134	Phenytoin	drug	190-198	false
Cisplatin	drug	126-134	primidone	drug	204-212	false
Cisplatin	drug	126-134	methsuximide	drug	215-226	false
Cisplatin	drug	126-134	theophylline	drug	233-244	false
Cisplatin	drug	126-134	EQUETROTM	brand	305-313	false
Cisplatin	drug	126-134	EQUETROTM	brand	441-449	false
doxorubicin HCL	drug	137-151	felbamate	drug	154-162	false
doxorubicin HCL	drug	137-151	rifampin	drug	165-172	false
doxorubicin HCL	drug	137-151	phenobarbital	drug	175-187	false
doxorubicin HCL	drug	137-151	Phenytoin	drug	190-198	false
doxorubicin HCL	drug	137-151	primidone	drug	204-212	false
doxorubicin HCL	drug	137-151	methsuximide	drug	215-226	false
doxorubicin HCL	drug	137-151	theophylline	drug	233-244	false
doxorubicin HCL	drug	137-151	EQUETROTM	brand	305-313	false
doxorubicin HCL	drug	137-151	EQUETROTM	brand	441-449	false
felbamate	drug	154-162	rifampin	drug	165-172	false
felbamate	drug	154-162	phenobarbital	drug	175-187	false
felbamate	drug	154-162	Phenytoin	drug	190-198	false
felbamate	drug	154-162	primidone	drug	204-212	false
felbamate	drug	154-162	methsuximide	drug	215-226	false
felbamate	drug	154-162	theophylline	drug	233-244	false
felbamate	drug	154-162	EQUETROTM	brand	305-313	false
felbamate	drug	154-162	EQUETROTM	brand	441-449	false
rifampin	drug	165-172	phenobarbital	drug	175-187	false
rifampin	drug	165-172	Phenytoin	drug	190-198	false
rifampin	drug	165-172	primidone	drug	204-212	false
rifampin	drug	165-172	methsuximide	drug	215-226	false
rifampin	drug	165-172	theophylline	drug	233-244	false
rifampin	drug	165-172	EQUETROTM	brand	305-313	false
rifampin	drug	165-172	EQUETROTM	brand	441-449	false
phenobarbital	drug	175-187	Phenytoin	drug	190-198	false
phenobarbital	drug	175-187	primidone	drug	204-212	false
phenobarbital	drug	175-187	methsuximide	drug	215-226	false
phenobarbital	drug	175-187	theophylline	drug	233-244	false
phenobarbital	drug	175-187	EQUETROTM	brand	305-313	false
phenobarbital	drug	175-187	EQUETROTM	brand	441-449	false
Phenytoin	drug	190-198	primidone	drug	204-212	false
Phenytoin	drug	190-198	methsuximide	drug	215-226	false
Phenytoin	drug	190-198	theophylline	drug	233-244	false
Phenytoin	drug	190-198	EQUETROTM	brand	305-313	false
Phenytoin	drug	190-198	EQUETROTM	brand	441-449	false
primidone	drug	204-212	methsuximide	drug	215-226	false
primidone	drug	204-212	theophylline	drug	233-244	false
primidone	drug	204-212	EQUETROTM	brand	305-313	false
primidone	drug	204-212	EQUETROTM	brand	441-449	false
methsuximide	drug	215-226	theophylline	drug	233-244	false
methsuximide	drug	215-226	EQUETROTM	brand	305-313	false
methsuximide	drug	215-226	EQUETROTM	brand	441-449	false
theophylline	drug	233-244	EQUETROTM	brand	305-313	false
theophylline	drug	233-244	EQUETROTM	brand	441-449	false
EQUETROTM	brand	305-313	EQUETROTM	brand	441-449	false

DDI-DrugBank.d94.s9	Agents with Decreased Levels in the Presence of Carbamazepine due to Induction of Cytochrome P450 Enzymes Carbamazepine is known to induce CYP1A2 and CYP3A4.
Carbamazepine	drug	48-60	Carbamazepine	drug	106-118	false

DDI-DrugBank.d94.s11	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
EQUETROTM	brand	96-104	Acetaminophen	drug	157-169	mechanism
EQUETROTM	brand	96-104	alprazolam	drug	172-181	mechanism
EQUETROTM	brand	96-104	amitriptyline	drug	184-196	mechanism
EQUETROTM	brand	96-104	bupropion	drug	199-207	mechanism
EQUETROTM	brand	96-104	buspirone	drug	210-218	mechanism
EQUETROTM	brand	96-104	citalopram	drug	221-230	mechanism
EQUETROTM	brand	96-104	clobazam	drug	233-240	mechanism
EQUETROTM	brand	96-104	clonazepam	drug	243-252	mechanism
EQUETROTM	brand	96-104	clozapine	drug	255-263	mechanism
EQUETROTM	brand	96-104	cyclosporin	drug	266-276	mechanism
EQUETROTM	brand	96-104	delavirdine	drug	279-289	mechanism
EQUETROTM	brand	96-104	desipramine	drug	292-302	mechanism
EQUETROTM	brand	96-104	diazepam	drug	305-312	mechanism
EQUETROTM	brand	96-104	dicumarol	drug	315-323	mechanism
EQUETROTM	brand	96-104	doxycycline	drug	326-336	mechanism
EQUETROTM	brand	96-104	ethosuximide	drug	339-350	mechanism
EQUETROTM	brand	96-104	felbamate	drug	353-361	mechanism
EQUETROTM	brand	96-104	felodipine	drug	364-373	mechanism
EQUETROTM	brand	96-104	glucocorticoids	group	376-390	mechanism
EQUETROTM	brand	96-104	haloperidol	drug	393-403	mechanism
EQUETROTM	brand	96-104	itraconazole	drug	406-417	mechanism
EQUETROTM	brand	96-104	lamotrigine	drug	420-430	mechanism
EQUETROTM	brand	96-104	levothyroxine	drug	433-445	mechanism
EQUETROTM	brand	96-104	lorazepam	drug	448-456	mechanism
EQUETROTM	brand	96-104	methadone	drug	459-467	mechanism
EQUETROTM	brand	96-104	midazolam	drug	470-478	mechanism
EQUETROTM	brand	96-104	mirtazapine	drug	481-491	mechanism
EQUETROTM	brand	96-104	nortriptyline	drug	494-506	mechanism
EQUETROTM	brand	96-104	olanzapine	drug	509-518	mechanism
EQUETROTM	brand	96-104	contraceptives	group	526-539	mechanism
EQUETROTM	brand	96-104	oxcarbazepine	drug	545-557	mechanism
EQUETROTM	brand	96-104	Phenytoin	drug	560-568	mechanism
EQUETROTM	brand	96-104	praziquantel	drug	574-585	mechanism
EQUETROTM	brand	96-104	protease inhibitors	group	588-606	mechanism
EQUETROTM	brand	96-104	quetiapine	drug	609-618	mechanism
EQUETROTM	brand	96-104	risperidone	drug	621-631	mechanism
EQUETROTM	brand	96-104	theophylline	drug	634-645	mechanism
EQUETROTM	brand	96-104	topiramate	drug	648-657	mechanism
EQUETROTM	brand	96-104	tiagabine	drug	660-668	mechanism
EQUETROTM	brand	96-104	tramadol	drug	671-678	mechanism
EQUETROTM	brand	96-104	triazolam	drug	681-689	mechanism
EQUETROTM	brand	96-104	valproate	drug	692-700	mechanism
EQUETROTM	brand	96-104	warfarin	drug	703-710	mechanism
EQUETROTM	brand	96-104	ziprasidone	drug	717-727	mechanism
EQUETROTM	brand	96-104	zonisamide	drug	734-743	mechanism
Acetaminophen	drug	157-169	alprazolam	drug	172-181	false
Acetaminophen	drug	157-169	amitriptyline	drug	184-196	false
Acetaminophen	drug	157-169	bupropion	drug	199-207	false
Acetaminophen	drug	157-169	buspirone	drug	210-218	false
Acetaminophen	drug	157-169	citalopram	drug	221-230	false
Acetaminophen	drug	157-169	clobazam	drug	233-240	false
Acetaminophen	drug	157-169	clonazepam	drug	243-252	false
Acetaminophen	drug	157-169	clozapine	drug	255-263	false
Acetaminophen	drug	157-169	cyclosporin	drug	266-276	false
Acetaminophen	drug	157-169	delavirdine	drug	279-289	false
Acetaminophen	drug	157-169	desipramine	drug	292-302	false
Acetaminophen	drug	157-169	diazepam	drug	305-312	false
Acetaminophen	drug	157-169	dicumarol	drug	315-323	false
Acetaminophen	drug	157-169	doxycycline	drug	326-336	false
Acetaminophen	drug	157-169	ethosuximide	drug	339-350	false
Acetaminophen	drug	157-169	felbamate	drug	353-361	false
Acetaminophen	drug	157-169	felodipine	drug	364-373	false
Acetaminophen	drug	157-169	glucocorticoids	group	376-390	false
Acetaminophen	drug	157-169	haloperidol	drug	393-403	false
Acetaminophen	drug	157-169	itraconazole	drug	406-417	false
Acetaminophen	drug	157-169	lamotrigine	drug	420-430	false
Acetaminophen	drug	157-169	levothyroxine	drug	433-445	false
Acetaminophen	drug	157-169	lorazepam	drug	448-456	false
Acetaminophen	drug	157-169	methadone	drug	459-467	false
Acetaminophen	drug	157-169	midazolam	drug	470-478	false
Acetaminophen	drug	157-169	mirtazapine	drug	481-491	false
Acetaminophen	drug	157-169	nortriptyline	drug	494-506	false
Acetaminophen	drug	157-169	olanzapine	drug	509-518	false
Acetaminophen	drug	157-169	contraceptives	group	526-539	false
Acetaminophen	drug	157-169	oxcarbazepine	drug	545-557	false
Acetaminophen	drug	157-169	Phenytoin	drug	560-568	false
Acetaminophen	drug	157-169	praziquantel	drug	574-585	false
Acetaminophen	drug	157-169	protease inhibitors	group	588-606	false
Acetaminophen	drug	157-169	quetiapine	drug	609-618	false
Acetaminophen	drug	157-169	risperidone	drug	621-631	false
Acetaminophen	drug	157-169	theophylline	drug	634-645	false
Acetaminophen	drug	157-169	topiramate	drug	648-657	false
Acetaminophen	drug	157-169	tiagabine	drug	660-668	false
Acetaminophen	drug	157-169	tramadol	drug	671-678	false
Acetaminophen	drug	157-169	triazolam	drug	681-689	false
Acetaminophen	drug	157-169	valproate	drug	692-700	false
Acetaminophen	drug	157-169	warfarin	drug	703-710	false
Acetaminophen	drug	157-169	ziprasidone	drug	717-727	false
Acetaminophen	drug	157-169	zonisamide	drug	734-743	false
alprazolam	drug	172-181	amitriptyline	drug	184-196	false
alprazolam	drug	172-181	bupropion	drug	199-207	false
alprazolam	drug	172-181	buspirone	drug	210-218	false
alprazolam	drug	172-181	citalopram	drug	221-230	false
alprazolam	drug	172-181	clobazam	drug	233-240	false
alprazolam	drug	172-181	clonazepam	drug	243-252	false
alprazolam	drug	172-181	clozapine	drug	255-263	false
alprazolam	drug	172-181	cyclosporin	drug	266-276	false
alprazolam	drug	172-181	delavirdine	drug	279-289	false
alprazolam	drug	172-181	desipramine	drug	292-302	false
alprazolam	drug	172-181	diazepam	drug	305-312	false
alprazolam	drug	172-181	dicumarol	drug	315-323	false
alprazolam	drug	172-181	doxycycline	drug	326-336	false
alprazolam	drug	172-181	ethosuximide	drug	339-350	false
alprazolam	drug	172-181	felbamate	drug	353-361	false
alprazolam	drug	172-181	felodipine	drug	364-373	false
alprazolam	drug	172-181	glucocorticoids	group	376-390	false
alprazolam	drug	172-181	haloperidol	drug	393-403	false
alprazolam	drug	172-181	itraconazole	drug	406-417	false
alprazolam	drug	172-181	lamotrigine	drug	420-430	false
alprazolam	drug	172-181	levothyroxine	drug	433-445	false
alprazolam	drug	172-181	lorazepam	drug	448-456	false
alprazolam	drug	172-181	methadone	drug	459-467	false
alprazolam	drug	172-181	midazolam	drug	470-478	false
alprazolam	drug	172-181	mirtazapine	drug	481-491	false
alprazolam	drug	172-181	nortriptyline	drug	494-506	false
alprazolam	drug	172-181	olanzapine	drug	509-518	false
alprazolam	drug	172-181	contraceptives	group	526-539	false
alprazolam	drug	172-181	oxcarbazepine	drug	545-557	false
alprazolam	drug	172-181	Phenytoin	drug	560-568	false
alprazolam	drug	172-181	praziquantel	drug	574-585	false
alprazolam	drug	172-181	protease inhibitors	group	588-606	false
alprazolam	drug	172-181	quetiapine	drug	609-618	false
alprazolam	drug	172-181	risperidone	drug	621-631	false
alprazolam	drug	172-181	theophylline	drug	634-645	false
alprazolam	drug	172-181	topiramate	drug	648-657	false
alprazolam	drug	172-181	tiagabine	drug	660-668	false
alprazolam	drug	172-181	tramadol	drug	671-678	false
alprazolam	drug	172-181	triazolam	drug	681-689	false
alprazolam	drug	172-181	valproate	drug	692-700	false
alprazolam	drug	172-181	warfarin	drug	703-710	false
alprazolam	drug	172-181	ziprasidone	drug	717-727	false
alprazolam	drug	172-181	zonisamide	drug	734-743	false
amitriptyline	drug	184-196	bupropion	drug	199-207	false
amitriptyline	drug	184-196	buspirone	drug	210-218	false
amitriptyline	drug	184-196	citalopram	drug	221-230	false
amitriptyline	drug	184-196	clobazam	drug	233-240	false
amitriptyline	drug	184-196	clonazepam	drug	243-252	false
amitriptyline	drug	184-196	clozapine	drug	255-263	false
amitriptyline	drug	184-196	cyclosporin	drug	266-276	false
amitriptyline	drug	184-196	delavirdine	drug	279-289	false
amitriptyline	drug	184-196	desipramine	drug	292-302	false
amitriptyline	drug	184-196	diazepam	drug	305-312	false
amitriptyline	drug	184-196	dicumarol	drug	315-323	false
amitriptyline	drug	184-196	doxycycline	drug	326-336	false
amitriptyline	drug	184-196	ethosuximide	drug	339-350	false
amitriptyline	drug	184-196	felbamate	drug	353-361	false
amitriptyline	drug	184-196	felodipine	drug	364-373	false
amitriptyline	drug	184-196	glucocorticoids	group	376-390	false
amitriptyline	drug	184-196	haloperidol	drug	393-403	false
amitriptyline	drug	184-196	itraconazole	drug	406-417	false
amitriptyline	drug	184-196	lamotrigine	drug	420-430	false
amitriptyline	drug	184-196	levothyroxine	drug	433-445	false
amitriptyline	drug	184-196	lorazepam	drug	448-456	false
amitriptyline	drug	184-196	methadone	drug	459-467	false
amitriptyline	drug	184-196	midazolam	drug	470-478	false
amitriptyline	drug	184-196	mirtazapine	drug	481-491	false
amitriptyline	drug	184-196	nortriptyline	drug	494-506	false
amitriptyline	drug	184-196	olanzapine	drug	509-518	false
amitriptyline	drug	184-196	contraceptives	group	526-539	false
amitriptyline	drug	184-196	oxcarbazepine	drug	545-557	false
amitriptyline	drug	184-196	Phenytoin	drug	560-568	false
amitriptyline	drug	184-196	praziquantel	drug	574-585	false
amitriptyline	drug	184-196	protease inhibitors	group	588-606	false
amitriptyline	drug	184-196	quetiapine	drug	609-618	false
amitriptyline	drug	184-196	risperidone	drug	621-631	false
amitriptyline	drug	184-196	theophylline	drug	634-645	false
amitriptyline	drug	184-196	topiramate	drug	648-657	false
amitriptyline	drug	184-196	tiagabine	drug	660-668	false
amitriptyline	drug	184-196	tramadol	drug	671-678	false
amitriptyline	drug	184-196	triazolam	drug	681-689	false
amitriptyline	drug	184-196	valproate	drug	692-700	false
amitriptyline	drug	184-196	warfarin	drug	703-710	false
amitriptyline	drug	184-196	ziprasidone	drug	717-727	false
amitriptyline	drug	184-196	zonisamide	drug	734-743	false
bupropion	drug	199-207	buspirone	drug	210-218	false
bupropion	drug	199-207	citalopram	drug	221-230	false
bupropion	drug	199-207	clobazam	drug	233-240	false
bupropion	drug	199-207	clonazepam	drug	243-252	false
bupropion	drug	199-207	clozapine	drug	255-263	false
bupropion	drug	199-207	cyclosporin	drug	266-276	false
bupropion	drug	199-207	delavirdine	drug	279-289	false
bupropion	drug	199-207	desipramine	drug	292-302	false
bupropion	drug	199-207	diazepam	drug	305-312	false
bupropion	drug	199-207	dicumarol	drug	315-323	false
bupropion	drug	199-207	doxycycline	drug	326-336	false
bupropion	drug	199-207	ethosuximide	drug	339-350	false
bupropion	drug	199-207	felbamate	drug	353-361	false
bupropion	drug	199-207	felodipine	drug	364-373	false
bupropion	drug	199-207	glucocorticoids	group	376-390	false
bupropion	drug	199-207	haloperidol	drug	393-403	false
bupropion	drug	199-207	itraconazole	drug	406-417	false
bupropion	drug	199-207	lamotrigine	drug	420-430	false
bupropion	drug	199-207	levothyroxine	drug	433-445	false
bupropion	drug	199-207	lorazepam	drug	448-456	false
bupropion	drug	199-207	methadone	drug	459-467	false
bupropion	drug	199-207	midazolam	drug	470-478	false
bupropion	drug	199-207	mirtazapine	drug	481-491	false
bupropion	drug	199-207	nortriptyline	drug	494-506	false
bupropion	drug	199-207	olanzapine	drug	509-518	false
bupropion	drug	199-207	contraceptives	group	526-539	false
bupropion	drug	199-207	oxcarbazepine	drug	545-557	false
bupropion	drug	199-207	Phenytoin	drug	560-568	false
bupropion	drug	199-207	praziquantel	drug	574-585	false
bupropion	drug	199-207	protease inhibitors	group	588-606	false
bupropion	drug	199-207	quetiapine	drug	609-618	false
bupropion	drug	199-207	risperidone	drug	621-631	false
bupropion	drug	199-207	theophylline	drug	634-645	false
bupropion	drug	199-207	topiramate	drug	648-657	false
bupropion	drug	199-207	tiagabine	drug	660-668	false
bupropion	drug	199-207	tramadol	drug	671-678	false
bupropion	drug	199-207	triazolam	drug	681-689	false
bupropion	drug	199-207	valproate	drug	692-700	false
bupropion	drug	199-207	warfarin	drug	703-710	false
bupropion	drug	199-207	ziprasidone	drug	717-727	false
bupropion	drug	199-207	zonisamide	drug	734-743	false
buspirone	drug	210-218	citalopram	drug	221-230	false
buspirone	drug	210-218	clobazam	drug	233-240	false
buspirone	drug	210-218	clonazepam	drug	243-252	false
buspirone	drug	210-218	clozapine	drug	255-263	false
buspirone	drug	210-218	cyclosporin	drug	266-276	false
buspirone	drug	210-218	delavirdine	drug	279-289	false
buspirone	drug	210-218	desipramine	drug	292-302	false
buspirone	drug	210-218	diazepam	drug	305-312	false
buspirone	drug	210-218	dicumarol	drug	315-323	false
buspirone	drug	210-218	doxycycline	drug	326-336	false
buspirone	drug	210-218	ethosuximide	drug	339-350	false
buspirone	drug	210-218	felbamate	drug	353-361	false
buspirone	drug	210-218	felodipine	drug	364-373	false
buspirone	drug	210-218	glucocorticoids	group	376-390	false
buspirone	drug	210-218	haloperidol	drug	393-403	false
buspirone	drug	210-218	itraconazole	drug	406-417	false
buspirone	drug	210-218	lamotrigine	drug	420-430	false
buspirone	drug	210-218	levothyroxine	drug	433-445	false
buspirone	drug	210-218	lorazepam	drug	448-456	false
buspirone	drug	210-218	methadone	drug	459-467	false
buspirone	drug	210-218	midazolam	drug	470-478	false
buspirone	drug	210-218	mirtazapine	drug	481-491	false
buspirone	drug	210-218	nortriptyline	drug	494-506	false
buspirone	drug	210-218	olanzapine	drug	509-518	false
buspirone	drug	210-218	contraceptives	group	526-539	false
buspirone	drug	210-218	oxcarbazepine	drug	545-557	false
buspirone	drug	210-218	Phenytoin	drug	560-568	false
buspirone	drug	210-218	praziquantel	drug	574-585	false
buspirone	drug	210-218	protease inhibitors	group	588-606	false
buspirone	drug	210-218	quetiapine	drug	609-618	false
buspirone	drug	210-218	risperidone	drug	621-631	false
buspirone	drug	210-218	theophylline	drug	634-645	false
buspirone	drug	210-218	topiramate	drug	648-657	false
buspirone	drug	210-218	tiagabine	drug	660-668	false
buspirone	drug	210-218	tramadol	drug	671-678	false
buspirone	drug	210-218	triazolam	drug	681-689	false
buspirone	drug	210-218	valproate	drug	692-700	false
buspirone	drug	210-218	warfarin	drug	703-710	false
buspirone	drug	210-218	ziprasidone	drug	717-727	false
buspirone	drug	210-218	zonisamide	drug	734-743	false
citalopram	drug	221-230	clobazam	drug	233-240	false
citalopram	drug	221-230	clonazepam	drug	243-252	false
citalopram	drug	221-230	clozapine	drug	255-263	false
citalopram	drug	221-230	cyclosporin	drug	266-276	false
citalopram	drug	221-230	delavirdine	drug	279-289	false
citalopram	drug	221-230	desipramine	drug	292-302	false
citalopram	drug	221-230	diazepam	drug	305-312	false
citalopram	drug	221-230	dicumarol	drug	315-323	false
citalopram	drug	221-230	doxycycline	drug	326-336	false
citalopram	drug	221-230	ethosuximide	drug	339-350	false
citalopram	drug	221-230	felbamate	drug	353-361	false
citalopram	drug	221-230	felodipine	drug	364-373	false
citalopram	drug	221-230	glucocorticoids	group	376-390	false
citalopram	drug	221-230	haloperidol	drug	393-403	false
citalopram	drug	221-230	itraconazole	drug	406-417	false
citalopram	drug	221-230	lamotrigine	drug	420-430	false
citalopram	drug	221-230	levothyroxine	drug	433-445	false
citalopram	drug	221-230	lorazepam	drug	448-456	false
citalopram	drug	221-230	methadone	drug	459-467	false
citalopram	drug	221-230	midazolam	drug	470-478	false
citalopram	drug	221-230	mirtazapine	drug	481-491	false
citalopram	drug	221-230	nortriptyline	drug	494-506	false
citalopram	drug	221-230	olanzapine	drug	509-518	false
citalopram	drug	221-230	contraceptives	group	526-539	false
citalopram	drug	221-230	oxcarbazepine	drug	545-557	false
citalopram	drug	221-230	Phenytoin	drug	560-568	false
citalopram	drug	221-230	praziquantel	drug	574-585	false
citalopram	drug	221-230	protease inhibitors	group	588-606	false
citalopram	drug	221-230	quetiapine	drug	609-618	false
citalopram	drug	221-230	risperidone	drug	621-631	false
citalopram	drug	221-230	theophylline	drug	634-645	false
citalopram	drug	221-230	topiramate	drug	648-657	false
citalopram	drug	221-230	tiagabine	drug	660-668	false
citalopram	drug	221-230	tramadol	drug	671-678	false
citalopram	drug	221-230	triazolam	drug	681-689	false
citalopram	drug	221-230	valproate	drug	692-700	false
citalopram	drug	221-230	warfarin	drug	703-710	false
citalopram	drug	221-230	ziprasidone	drug	717-727	false
citalopram	drug	221-230	zonisamide	drug	734-743	false
clobazam	drug	233-240	clonazepam	drug	243-252	false
clobazam	drug	233-240	clozapine	drug	255-263	false
clobazam	drug	233-240	cyclosporin	drug	266-276	false
clobazam	drug	233-240	delavirdine	drug	279-289	false
clobazam	drug	233-240	desipramine	drug	292-302	false
clobazam	drug	233-240	diazepam	drug	305-312	false
clobazam	drug	233-240	dicumarol	drug	315-323	false
clobazam	drug	233-240	doxycycline	drug	326-336	false
clobazam	drug	233-240	ethosuximide	drug	339-350	false
clobazam	drug	233-240	felbamate	drug	353-361	false
clobazam	drug	233-240	felodipine	drug	364-373	false
clobazam	drug	233-240	glucocorticoids	group	376-390	false
clobazam	drug	233-240	haloperidol	drug	393-403	false
clobazam	drug	233-240	itraconazole	drug	406-417	false
clobazam	drug	233-240	lamotrigine	drug	420-430	false
clobazam	drug	233-240	levothyroxine	drug	433-445	false
clobazam	drug	233-240	lorazepam	drug	448-456	false
clobazam	drug	233-240	methadone	drug	459-467	false
clobazam	drug	233-240	midazolam	drug	470-478	false
clobazam	drug	233-240	mirtazapine	drug	481-491	false
clobazam	drug	233-240	nortriptyline	drug	494-506	false
clobazam	drug	233-240	olanzapine	drug	509-518	false
clobazam	drug	233-240	contraceptives	group	526-539	false
clobazam	drug	233-240	oxcarbazepine	drug	545-557	false
clobazam	drug	233-240	Phenytoin	drug	560-568	false
clobazam	drug	233-240	praziquantel	drug	574-585	false
clobazam	drug	233-240	protease inhibitors	group	588-606	false
clobazam	drug	233-240	quetiapine	drug	609-618	false
clobazam	drug	233-240	risperidone	drug	621-631	false
clobazam	drug	233-240	theophylline	drug	634-645	false
clobazam	drug	233-240	topiramate	drug	648-657	false
clobazam	drug	233-240	tiagabine	drug	660-668	false
clobazam	drug	233-240	tramadol	drug	671-678	false
clobazam	drug	233-240	triazolam	drug	681-689	false
clobazam	drug	233-240	valproate	drug	692-700	false
clobazam	drug	233-240	warfarin	drug	703-710	false
clobazam	drug	233-240	ziprasidone	drug	717-727	false
clobazam	drug	233-240	zonisamide	drug	734-743	false
clonazepam	drug	243-252	clozapine	drug	255-263	false
clonazepam	drug	243-252	cyclosporin	drug	266-276	false
clonazepam	drug	243-252	delavirdine	drug	279-289	false
clonazepam	drug	243-252	desipramine	drug	292-302	false
clonazepam	drug	243-252	diazepam	drug	305-312	false
clonazepam	drug	243-252	dicumarol	drug	315-323	false
clonazepam	drug	243-252	doxycycline	drug	326-336	false
clonazepam	drug	243-252	ethosuximide	drug	339-350	false
clonazepam	drug	243-252	felbamate	drug	353-361	false
clonazepam	drug	243-252	felodipine	drug	364-373	false
clonazepam	drug	243-252	glucocorticoids	group	376-390	false
clonazepam	drug	243-252	haloperidol	drug	393-403	false
clonazepam	drug	243-252	itraconazole	drug	406-417	false
clonazepam	drug	243-252	lamotrigine	drug	420-430	false
clonazepam	drug	243-252	levothyroxine	drug	433-445	false
clonazepam	drug	243-252	lorazepam	drug	448-456	false
clonazepam	drug	243-252	methadone	drug	459-467	false
clonazepam	drug	243-252	midazolam	drug	470-478	false
clonazepam	drug	243-252	mirtazapine	drug	481-491	false
clonazepam	drug	243-252	nortriptyline	drug	494-506	false
clonazepam	drug	243-252	olanzapine	drug	509-518	false
clonazepam	drug	243-252	contraceptives	group	526-539	false
clonazepam	drug	243-252	oxcarbazepine	drug	545-557	false
clonazepam	drug	243-252	Phenytoin	drug	560-568	false
clonazepam	drug	243-252	praziquantel	drug	574-585	false
clonazepam	drug	243-252	protease inhibitors	group	588-606	false
clonazepam	drug	243-252	quetiapine	drug	609-618	false
clonazepam	drug	243-252	risperidone	drug	621-631	false
clonazepam	drug	243-252	theophylline	drug	634-645	false
clonazepam	drug	243-252	topiramate	drug	648-657	false
clonazepam	drug	243-252	tiagabine	drug	660-668	false
clonazepam	drug	243-252	tramadol	drug	671-678	false
clonazepam	drug	243-252	triazolam	drug	681-689	false
clonazepam	drug	243-252	valproate	drug	692-700	false
clonazepam	drug	243-252	warfarin	drug	703-710	false
clonazepam	drug	243-252	ziprasidone	drug	717-727	false
clonazepam	drug	243-252	zonisamide	drug	734-743	false
clozapine	drug	255-263	cyclosporin	drug	266-276	false
clozapine	drug	255-263	delavirdine	drug	279-289	false
clozapine	drug	255-263	desipramine	drug	292-302	false
clozapine	drug	255-263	diazepam	drug	305-312	false
clozapine	drug	255-263	dicumarol	drug	315-323	false
clozapine	drug	255-263	doxycycline	drug	326-336	false
clozapine	drug	255-263	ethosuximide	drug	339-350	false
clozapine	drug	255-263	felbamate	drug	353-361	false
clozapine	drug	255-263	felodipine	drug	364-373	false
clozapine	drug	255-263	glucocorticoids	group	376-390	false
clozapine	drug	255-263	haloperidol	drug	393-403	false
clozapine	drug	255-263	itraconazole	drug	406-417	false
clozapine	drug	255-263	lamotrigine	drug	420-430	false
clozapine	drug	255-263	levothyroxine	drug	433-445	false
clozapine	drug	255-263	lorazepam	drug	448-456	false
clozapine	drug	255-263	methadone	drug	459-467	false
clozapine	drug	255-263	midazolam	drug	470-478	false
clozapine	drug	255-263	mirtazapine	drug	481-491	false
clozapine	drug	255-263	nortriptyline	drug	494-506	false
clozapine	drug	255-263	olanzapine	drug	509-518	false
clozapine	drug	255-263	contraceptives	group	526-539	false
clozapine	drug	255-263	oxcarbazepine	drug	545-557	false
clozapine	drug	255-263	Phenytoin	drug	560-568	false
clozapine	drug	255-263	praziquantel	drug	574-585	false
clozapine	drug	255-263	protease inhibitors	group	588-606	false
clozapine	drug	255-263	quetiapine	drug	609-618	false
clozapine	drug	255-263	risperidone	drug	621-631	false
clozapine	drug	255-263	theophylline	drug	634-645	false
clozapine	drug	255-263	topiramate	drug	648-657	false
clozapine	drug	255-263	tiagabine	drug	660-668	false
clozapine	drug	255-263	tramadol	drug	671-678	false
clozapine	drug	255-263	triazolam	drug	681-689	false
clozapine	drug	255-263	valproate	drug	692-700	false
clozapine	drug	255-263	warfarin	drug	703-710	false
clozapine	drug	255-263	ziprasidone	drug	717-727	false
clozapine	drug	255-263	zonisamide	drug	734-743	false
cyclosporin	drug	266-276	delavirdine	drug	279-289	false
cyclosporin	drug	266-276	desipramine	drug	292-302	false
cyclosporin	drug	266-276	diazepam	drug	305-312	false
cyclosporin	drug	266-276	dicumarol	drug	315-323	false
cyclosporin	drug	266-276	doxycycline	drug	326-336	false
cyclosporin	drug	266-276	ethosuximide	drug	339-350	false
cyclosporin	drug	266-276	felbamate	drug	353-361	false
cyclosporin	drug	266-276	felodipine	drug	364-373	false
cyclosporin	drug	266-276	glucocorticoids	group	376-390	false
cyclosporin	drug	266-276	haloperidol	drug	393-403	false
cyclosporin	drug	266-276	itraconazole	drug	406-417	false
cyclosporin	drug	266-276	lamotrigine	drug	420-430	false
cyclosporin	drug	266-276	levothyroxine	drug	433-445	false
cyclosporin	drug	266-276	lorazepam	drug	448-456	false
cyclosporin	drug	266-276	methadone	drug	459-467	false
cyclosporin	drug	266-276	midazolam	drug	470-478	false
cyclosporin	drug	266-276	mirtazapine	drug	481-491	false
cyclosporin	drug	266-276	nortriptyline	drug	494-506	false
cyclosporin	drug	266-276	olanzapine	drug	509-518	false
cyclosporin	drug	266-276	contraceptives	group	526-539	false
cyclosporin	drug	266-276	oxcarbazepine	drug	545-557	false
cyclosporin	drug	266-276	Phenytoin	drug	560-568	false
cyclosporin	drug	266-276	praziquantel	drug	574-585	false
cyclosporin	drug	266-276	protease inhibitors	group	588-606	false
cyclosporin	drug	266-276	quetiapine	drug	609-618	false
cyclosporin	drug	266-276	risperidone	drug	621-631	false
cyclosporin	drug	266-276	theophylline	drug	634-645	false
cyclosporin	drug	266-276	topiramate	drug	648-657	false
cyclosporin	drug	266-276	tiagabine	drug	660-668	false
cyclosporin	drug	266-276	tramadol	drug	671-678	false
cyclosporin	drug	266-276	triazolam	drug	681-689	false
cyclosporin	drug	266-276	valproate	drug	692-700	false
cyclosporin	drug	266-276	warfarin	drug	703-710	false
cyclosporin	drug	266-276	ziprasidone	drug	717-727	false
cyclosporin	drug	266-276	zonisamide	drug	734-743	false
delavirdine	drug	279-289	desipramine	drug	292-302	false
delavirdine	drug	279-289	diazepam	drug	305-312	false
delavirdine	drug	279-289	dicumarol	drug	315-323	false
delavirdine	drug	279-289	doxycycline	drug	326-336	false
delavirdine	drug	279-289	ethosuximide	drug	339-350	false
delavirdine	drug	279-289	felbamate	drug	353-361	false
delavirdine	drug	279-289	felodipine	drug	364-373	false
delavirdine	drug	279-289	glucocorticoids	group	376-390	false
delavirdine	drug	279-289	haloperidol	drug	393-403	false
delavirdine	drug	279-289	itraconazole	drug	406-417	false
delavirdine	drug	279-289	lamotrigine	drug	420-430	false
delavirdine	drug	279-289	levothyroxine	drug	433-445	false
delavirdine	drug	279-289	lorazepam	drug	448-456	false
delavirdine	drug	279-289	methadone	drug	459-467	false
delavirdine	drug	279-289	midazolam	drug	470-478	false
delavirdine	drug	279-289	mirtazapine	drug	481-491	false
delavirdine	drug	279-289	nortriptyline	drug	494-506	false
delavirdine	drug	279-289	olanzapine	drug	509-518	false
delavirdine	drug	279-289	contraceptives	group	526-539	false
delavirdine	drug	279-289	oxcarbazepine	drug	545-557	false
delavirdine	drug	279-289	Phenytoin	drug	560-568	false
delavirdine	drug	279-289	praziquantel	drug	574-585	false
delavirdine	drug	279-289	protease inhibitors	group	588-606	false
delavirdine	drug	279-289	quetiapine	drug	609-618	false
delavirdine	drug	279-289	risperidone	drug	621-631	false
delavirdine	drug	279-289	theophylline	drug	634-645	false
delavirdine	drug	279-289	topiramate	drug	648-657	false
delavirdine	drug	279-289	tiagabine	drug	660-668	false
delavirdine	drug	279-289	tramadol	drug	671-678	false
delavirdine	drug	279-289	triazolam	drug	681-689	false
delavirdine	drug	279-289	valproate	drug	692-700	false
delavirdine	drug	279-289	warfarin	drug	703-710	false
delavirdine	drug	279-289	ziprasidone	drug	717-727	false
delavirdine	drug	279-289	zonisamide	drug	734-743	false
desipramine	drug	292-302	diazepam	drug	305-312	false
desipramine	drug	292-302	dicumarol	drug	315-323	false
desipramine	drug	292-302	doxycycline	drug	326-336	false
desipramine	drug	292-302	ethosuximide	drug	339-350	false
desipramine	drug	292-302	felbamate	drug	353-361	false
desipramine	drug	292-302	felodipine	drug	364-373	false
desipramine	drug	292-302	glucocorticoids	group	376-390	false
desipramine	drug	292-302	haloperidol	drug	393-403	false
desipramine	drug	292-302	itraconazole	drug	406-417	false
desipramine	drug	292-302	lamotrigine	drug	420-430	false
desipramine	drug	292-302	levothyroxine	drug	433-445	false
desipramine	drug	292-302	lorazepam	drug	448-456	false
desipramine	drug	292-302	methadone	drug	459-467	false
desipramine	drug	292-302	midazolam	drug	470-478	false
desipramine	drug	292-302	mirtazapine	drug	481-491	false
desipramine	drug	292-302	nortriptyline	drug	494-506	false
desipramine	drug	292-302	olanzapine	drug	509-518	false
desipramine	drug	292-302	contraceptives	group	526-539	false
desipramine	drug	292-302	oxcarbazepine	drug	545-557	false
desipramine	drug	292-302	Phenytoin	drug	560-568	false
desipramine	drug	292-302	praziquantel	drug	574-585	false
desipramine	drug	292-302	protease inhibitors	group	588-606	false
desipramine	drug	292-302	quetiapine	drug	609-618	false
desipramine	drug	292-302	risperidone	drug	621-631	false
desipramine	drug	292-302	theophylline	drug	634-645	false
desipramine	drug	292-302	topiramate	drug	648-657	false
desipramine	drug	292-302	tiagabine	drug	660-668	false
desipramine	drug	292-302	tramadol	drug	671-678	false
desipramine	drug	292-302	triazolam	drug	681-689	false
desipramine	drug	292-302	valproate	drug	692-700	false
desipramine	drug	292-302	warfarin	drug	703-710	false
desipramine	drug	292-302	ziprasidone	drug	717-727	false
desipramine	drug	292-302	zonisamide	drug	734-743	false
diazepam	drug	305-312	dicumarol	drug	315-323	false
diazepam	drug	305-312	doxycycline	drug	326-336	false
diazepam	drug	305-312	ethosuximide	drug	339-350	false
diazepam	drug	305-312	felbamate	drug	353-361	false
diazepam	drug	305-312	felodipine	drug	364-373	false
diazepam	drug	305-312	glucocorticoids	group	376-390	false
diazepam	drug	305-312	haloperidol	drug	393-403	false
diazepam	drug	305-312	itraconazole	drug	406-417	false
diazepam	drug	305-312	lamotrigine	drug	420-430	false
diazepam	drug	305-312	levothyroxine	drug	433-445	false
diazepam	drug	305-312	lorazepam	drug	448-456	false
diazepam	drug	305-312	methadone	drug	459-467	false
diazepam	drug	305-312	midazolam	drug	470-478	false
diazepam	drug	305-312	mirtazapine	drug	481-491	false
diazepam	drug	305-312	nortriptyline	drug	494-506	false
diazepam	drug	305-312	olanzapine	drug	509-518	false
diazepam	drug	305-312	contraceptives	group	526-539	false
diazepam	drug	305-312	oxcarbazepine	drug	545-557	false
diazepam	drug	305-312	Phenytoin	drug	560-568	false
diazepam	drug	305-312	praziquantel	drug	574-585	false
diazepam	drug	305-312	protease inhibitors	group	588-606	false
diazepam	drug	305-312	quetiapine	drug	609-618	false
diazepam	drug	305-312	risperidone	drug	621-631	false
diazepam	drug	305-312	theophylline	drug	634-645	false
diazepam	drug	305-312	topiramate	drug	648-657	false
diazepam	drug	305-312	tiagabine	drug	660-668	false
diazepam	drug	305-312	tramadol	drug	671-678	false
diazepam	drug	305-312	triazolam	drug	681-689	false
diazepam	drug	305-312	valproate	drug	692-700	false
diazepam	drug	305-312	warfarin	drug	703-710	false
diazepam	drug	305-312	ziprasidone	drug	717-727	false
diazepam	drug	305-312	zonisamide	drug	734-743	false
dicumarol	drug	315-323	doxycycline	drug	326-336	false
dicumarol	drug	315-323	ethosuximide	drug	339-350	false
dicumarol	drug	315-323	felbamate	drug	353-361	false
dicumarol	drug	315-323	felodipine	drug	364-373	false
dicumarol	drug	315-323	glucocorticoids	group	376-390	false
dicumarol	drug	315-323	haloperidol	drug	393-403	false
dicumarol	drug	315-323	itraconazole	drug	406-417	false
dicumarol	drug	315-323	lamotrigine	drug	420-430	false
dicumarol	drug	315-323	levothyroxine	drug	433-445	false
dicumarol	drug	315-323	lorazepam	drug	448-456	false
dicumarol	drug	315-323	methadone	drug	459-467	false
dicumarol	drug	315-323	midazolam	drug	470-478	false
dicumarol	drug	315-323	mirtazapine	drug	481-491	false
dicumarol	drug	315-323	nortriptyline	drug	494-506	false
dicumarol	drug	315-323	olanzapine	drug	509-518	false
dicumarol	drug	315-323	contraceptives	group	526-539	false
dicumarol	drug	315-323	oxcarbazepine	drug	545-557	false
dicumarol	drug	315-323	Phenytoin	drug	560-568	false
dicumarol	drug	315-323	praziquantel	drug	574-585	false
dicumarol	drug	315-323	protease inhibitors	group	588-606	false
dicumarol	drug	315-323	quetiapine	drug	609-618	false
dicumarol	drug	315-323	risperidone	drug	621-631	false
dicumarol	drug	315-323	theophylline	drug	634-645	false
dicumarol	drug	315-323	topiramate	drug	648-657	false
dicumarol	drug	315-323	tiagabine	drug	660-668	false
dicumarol	drug	315-323	tramadol	drug	671-678	false
dicumarol	drug	315-323	triazolam	drug	681-689	false
dicumarol	drug	315-323	valproate	drug	692-700	false
dicumarol	drug	315-323	warfarin	drug	703-710	false
dicumarol	drug	315-323	ziprasidone	drug	717-727	false
dicumarol	drug	315-323	zonisamide	drug	734-743	false
doxycycline	drug	326-336	ethosuximide	drug	339-350	false
doxycycline	drug	326-336	felbamate	drug	353-361	false
doxycycline	drug	326-336	felodipine	drug	364-373	false
doxycycline	drug	326-336	glucocorticoids	group	376-390	false
doxycycline	drug	326-336	haloperidol	drug	393-403	false
doxycycline	drug	326-336	itraconazole	drug	406-417	false
doxycycline	drug	326-336	lamotrigine	drug	420-430	false
doxycycline	drug	326-336	levothyroxine	drug	433-445	false
doxycycline	drug	326-336	lorazepam	drug	448-456	false
doxycycline	drug	326-336	methadone	drug	459-467	false
doxycycline	drug	326-336	midazolam	drug	470-478	false
doxycycline	drug	326-336	mirtazapine	drug	481-491	false
doxycycline	drug	326-336	nortriptyline	drug	494-506	false
doxycycline	drug	326-336	olanzapine	drug	509-518	false
doxycycline	drug	326-336	contraceptives	group	526-539	false
doxycycline	drug	326-336	oxcarbazepine	drug	545-557	false
doxycycline	drug	326-336	Phenytoin	drug	560-568	false
doxycycline	drug	326-336	praziquantel	drug	574-585	false
doxycycline	drug	326-336	protease inhibitors	group	588-606	false
doxycycline	drug	326-336	quetiapine	drug	609-618	false
doxycycline	drug	326-336	risperidone	drug	621-631	false
doxycycline	drug	326-336	theophylline	drug	634-645	false
doxycycline	drug	326-336	topiramate	drug	648-657	false
doxycycline	drug	326-336	tiagabine	drug	660-668	false
doxycycline	drug	326-336	tramadol	drug	671-678	false
doxycycline	drug	326-336	triazolam	drug	681-689	false
doxycycline	drug	326-336	valproate	drug	692-700	false
doxycycline	drug	326-336	warfarin	drug	703-710	false
doxycycline	drug	326-336	ziprasidone	drug	717-727	false
doxycycline	drug	326-336	zonisamide	drug	734-743	false
ethosuximide	drug	339-350	felbamate	drug	353-361	false
ethosuximide	drug	339-350	felodipine	drug	364-373	false
ethosuximide	drug	339-350	glucocorticoids	group	376-390	false
ethosuximide	drug	339-350	haloperidol	drug	393-403	false
ethosuximide	drug	339-350	itraconazole	drug	406-417	false
ethosuximide	drug	339-350	lamotrigine	drug	420-430	false
ethosuximide	drug	339-350	levothyroxine	drug	433-445	false
ethosuximide	drug	339-350	lorazepam	drug	448-456	false
ethosuximide	drug	339-350	methadone	drug	459-467	false
ethosuximide	drug	339-350	midazolam	drug	470-478	false
ethosuximide	drug	339-350	mirtazapine	drug	481-491	false
ethosuximide	drug	339-350	nortriptyline	drug	494-506	false
ethosuximide	drug	339-350	olanzapine	drug	509-518	false
ethosuximide	drug	339-350	contraceptives	group	526-539	false
ethosuximide	drug	339-350	oxcarbazepine	drug	545-557	false
ethosuximide	drug	339-350	Phenytoin	drug	560-568	false
ethosuximide	drug	339-350	praziquantel	drug	574-585	false
ethosuximide	drug	339-350	protease inhibitors	group	588-606	false
ethosuximide	drug	339-350	quetiapine	drug	609-618	false
ethosuximide	drug	339-350	risperidone	drug	621-631	false
ethosuximide	drug	339-350	theophylline	drug	634-645	false
ethosuximide	drug	339-350	topiramate	drug	648-657	false
ethosuximide	drug	339-350	tiagabine	drug	660-668	false
ethosuximide	drug	339-350	tramadol	drug	671-678	false
ethosuximide	drug	339-350	triazolam	drug	681-689	false
ethosuximide	drug	339-350	valproate	drug	692-700	false
ethosuximide	drug	339-350	warfarin	drug	703-710	false
ethosuximide	drug	339-350	ziprasidone	drug	717-727	false
ethosuximide	drug	339-350	zonisamide	drug	734-743	false
felbamate	drug	353-361	felodipine	drug	364-373	false
felbamate	drug	353-361	glucocorticoids	group	376-390	false
felbamate	drug	353-361	haloperidol	drug	393-403	false
felbamate	drug	353-361	itraconazole	drug	406-417	false
felbamate	drug	353-361	lamotrigine	drug	420-430	false
felbamate	drug	353-361	levothyroxine	drug	433-445	false
felbamate	drug	353-361	lorazepam	drug	448-456	false
felbamate	drug	353-361	methadone	drug	459-467	false
felbamate	drug	353-361	midazolam	drug	470-478	false
felbamate	drug	353-361	mirtazapine	drug	481-491	false
felbamate	drug	353-361	nortriptyline	drug	494-506	false
felbamate	drug	353-361	olanzapine	drug	509-518	false
felbamate	drug	353-361	contraceptives	group	526-539	false
felbamate	drug	353-361	oxcarbazepine	drug	545-557	false
felbamate	drug	353-361	Phenytoin	drug	560-568	false
felbamate	drug	353-361	praziquantel	drug	574-585	false
felbamate	drug	353-361	protease inhibitors	group	588-606	false
felbamate	drug	353-361	quetiapine	drug	609-618	false
felbamate	drug	353-361	risperidone	drug	621-631	false
felbamate	drug	353-361	theophylline	drug	634-645	false
felbamate	drug	353-361	topiramate	drug	648-657	false
felbamate	drug	353-361	tiagabine	drug	660-668	false
felbamate	drug	353-361	tramadol	drug	671-678	false
felbamate	drug	353-361	triazolam	drug	681-689	false
felbamate	drug	353-361	valproate	drug	692-700	false
felbamate	drug	353-361	warfarin	drug	703-710	false
felbamate	drug	353-361	ziprasidone	drug	717-727	false
felbamate	drug	353-361	zonisamide	drug	734-743	false
felodipine	drug	364-373	glucocorticoids	group	376-390	false
felodipine	drug	364-373	haloperidol	drug	393-403	false
felodipine	drug	364-373	itraconazole	drug	406-417	false
felodipine	drug	364-373	lamotrigine	drug	420-430	false
felodipine	drug	364-373	levothyroxine	drug	433-445	false
felodipine	drug	364-373	lorazepam	drug	448-456	false
felodipine	drug	364-373	methadone	drug	459-467	false
felodipine	drug	364-373	midazolam	drug	470-478	false
felodipine	drug	364-373	mirtazapine	drug	481-491	false
felodipine	drug	364-373	nortriptyline	drug	494-506	false
felodipine	drug	364-373	olanzapine	drug	509-518	false
felodipine	drug	364-373	contraceptives	group	526-539	false
felodipine	drug	364-373	oxcarbazepine	drug	545-557	false
felodipine	drug	364-373	Phenytoin	drug	560-568	false
felodipine	drug	364-373	praziquantel	drug	574-585	false
felodipine	drug	364-373	protease inhibitors	group	588-606	false
felodipine	drug	364-373	quetiapine	drug	609-618	false
felodipine	drug	364-373	risperidone	drug	621-631	false
felodipine	drug	364-373	theophylline	drug	634-645	false
felodipine	drug	364-373	topiramate	drug	648-657	false
felodipine	drug	364-373	tiagabine	drug	660-668	false
felodipine	drug	364-373	tramadol	drug	671-678	false
felodipine	drug	364-373	triazolam	drug	681-689	false
felodipine	drug	364-373	valproate	drug	692-700	false
felodipine	drug	364-373	warfarin	drug	703-710	false
felodipine	drug	364-373	ziprasidone	drug	717-727	false
felodipine	drug	364-373	zonisamide	drug	734-743	false
glucocorticoids	group	376-390	haloperidol	drug	393-403	false
glucocorticoids	group	376-390	itraconazole	drug	406-417	false
glucocorticoids	group	376-390	lamotrigine	drug	420-430	false
glucocorticoids	group	376-390	levothyroxine	drug	433-445	false
glucocorticoids	group	376-390	lorazepam	drug	448-456	false
glucocorticoids	group	376-390	methadone	drug	459-467	false
glucocorticoids	group	376-390	midazolam	drug	470-478	false
glucocorticoids	group	376-390	mirtazapine	drug	481-491	false
glucocorticoids	group	376-390	nortriptyline	drug	494-506	false
glucocorticoids	group	376-390	olanzapine	drug	509-518	false
glucocorticoids	group	376-390	contraceptives	group	526-539	false
glucocorticoids	group	376-390	oxcarbazepine	drug	545-557	false
glucocorticoids	group	376-390	Phenytoin	drug	560-568	false
glucocorticoids	group	376-390	praziquantel	drug	574-585	false
glucocorticoids	group	376-390	protease inhibitors	group	588-606	false
glucocorticoids	group	376-390	quetiapine	drug	609-618	false
glucocorticoids	group	376-390	risperidone	drug	621-631	false
glucocorticoids	group	376-390	theophylline	drug	634-645	false
glucocorticoids	group	376-390	topiramate	drug	648-657	false
glucocorticoids	group	376-390	tiagabine	drug	660-668	false
glucocorticoids	group	376-390	tramadol	drug	671-678	false
glucocorticoids	group	376-390	triazolam	drug	681-689	false
glucocorticoids	group	376-390	valproate	drug	692-700	false
glucocorticoids	group	376-390	warfarin	drug	703-710	false
glucocorticoids	group	376-390	ziprasidone	drug	717-727	false
glucocorticoids	group	376-390	zonisamide	drug	734-743	false
haloperidol	drug	393-403	itraconazole	drug	406-417	false
haloperidol	drug	393-403	lamotrigine	drug	420-430	false
haloperidol	drug	393-403	levothyroxine	drug	433-445	false
haloperidol	drug	393-403	lorazepam	drug	448-456	false
haloperidol	drug	393-403	methadone	drug	459-467	false
haloperidol	drug	393-403	midazolam	drug	470-478	false
haloperidol	drug	393-403	mirtazapine	drug	481-491	false
haloperidol	drug	393-403	nortriptyline	drug	494-506	false
haloperidol	drug	393-403	olanzapine	drug	509-518	false
haloperidol	drug	393-403	contraceptives	group	526-539	false
haloperidol	drug	393-403	oxcarbazepine	drug	545-557	false
haloperidol	drug	393-403	Phenytoin	drug	560-568	false
haloperidol	drug	393-403	praziquantel	drug	574-585	false
haloperidol	drug	393-403	protease inhibitors	group	588-606	false
haloperidol	drug	393-403	quetiapine	drug	609-618	false
haloperidol	drug	393-403	risperidone	drug	621-631	false
haloperidol	drug	393-403	theophylline	drug	634-645	false
haloperidol	drug	393-403	topiramate	drug	648-657	false
haloperidol	drug	393-403	tiagabine	drug	660-668	false
haloperidol	drug	393-403	tramadol	drug	671-678	false
haloperidol	drug	393-403	triazolam	drug	681-689	false
haloperidol	drug	393-403	valproate	drug	692-700	false
haloperidol	drug	393-403	warfarin	drug	703-710	false
haloperidol	drug	393-403	ziprasidone	drug	717-727	false
haloperidol	drug	393-403	zonisamide	drug	734-743	false
itraconazole	drug	406-417	lamotrigine	drug	420-430	false
itraconazole	drug	406-417	levothyroxine	drug	433-445	false
itraconazole	drug	406-417	lorazepam	drug	448-456	false
itraconazole	drug	406-417	methadone	drug	459-467	false
itraconazole	drug	406-417	midazolam	drug	470-478	false
itraconazole	drug	406-417	mirtazapine	drug	481-491	false
itraconazole	drug	406-417	nortriptyline	drug	494-506	false
itraconazole	drug	406-417	olanzapine	drug	509-518	false
itraconazole	drug	406-417	contraceptives	group	526-539	false
itraconazole	drug	406-417	oxcarbazepine	drug	545-557	false
itraconazole	drug	406-417	Phenytoin	drug	560-568	false
itraconazole	drug	406-417	praziquantel	drug	574-585	false
itraconazole	drug	406-417	protease inhibitors	group	588-606	false
itraconazole	drug	406-417	quetiapine	drug	609-618	false
itraconazole	drug	406-417	risperidone	drug	621-631	false
itraconazole	drug	406-417	theophylline	drug	634-645	false
itraconazole	drug	406-417	topiramate	drug	648-657	false
itraconazole	drug	406-417	tiagabine	drug	660-668	false
itraconazole	drug	406-417	tramadol	drug	671-678	false
itraconazole	drug	406-417	triazolam	drug	681-689	false
itraconazole	drug	406-417	valproate	drug	692-700	false
itraconazole	drug	406-417	warfarin	drug	703-710	false
itraconazole	drug	406-417	ziprasidone	drug	717-727	false
itraconazole	drug	406-417	zonisamide	drug	734-743	false
lamotrigine	drug	420-430	levothyroxine	drug	433-445	false
lamotrigine	drug	420-430	lorazepam	drug	448-456	false
lamotrigine	drug	420-430	methadone	drug	459-467	false
lamotrigine	drug	420-430	midazolam	drug	470-478	false
lamotrigine	drug	420-430	mirtazapine	drug	481-491	false
lamotrigine	drug	420-430	nortriptyline	drug	494-506	false
lamotrigine	drug	420-430	olanzapine	drug	509-518	false
lamotrigine	drug	420-430	contraceptives	group	526-539	false
lamotrigine	drug	420-430	oxcarbazepine	drug	545-557	false
lamotrigine	drug	420-430	Phenytoin	drug	560-568	false
lamotrigine	drug	420-430	praziquantel	drug	574-585	false
lamotrigine	drug	420-430	protease inhibitors	group	588-606	false
lamotrigine	drug	420-430	quetiapine	drug	609-618	false
lamotrigine	drug	420-430	risperidone	drug	621-631	false
lamotrigine	drug	420-430	theophylline	drug	634-645	false
lamotrigine	drug	420-430	topiramate	drug	648-657	false
lamotrigine	drug	420-430	tiagabine	drug	660-668	false
lamotrigine	drug	420-430	tramadol	drug	671-678	false
lamotrigine	drug	420-430	triazolam	drug	681-689	false
lamotrigine	drug	420-430	valproate	drug	692-700	false
lamotrigine	drug	420-430	warfarin	drug	703-710	false
lamotrigine	drug	420-430	ziprasidone	drug	717-727	false
lamotrigine	drug	420-430	zonisamide	drug	734-743	false
levothyroxine	drug	433-445	lorazepam	drug	448-456	false
levothyroxine	drug	433-445	methadone	drug	459-467	false
levothyroxine	drug	433-445	midazolam	drug	470-478	false
levothyroxine	drug	433-445	mirtazapine	drug	481-491	false
levothyroxine	drug	433-445	nortriptyline	drug	494-506	false
levothyroxine	drug	433-445	olanzapine	drug	509-518	false
levothyroxine	drug	433-445	contraceptives	group	526-539	false
levothyroxine	drug	433-445	oxcarbazepine	drug	545-557	false
levothyroxine	drug	433-445	Phenytoin	drug	560-568	false
levothyroxine	drug	433-445	praziquantel	drug	574-585	false
levothyroxine	drug	433-445	protease inhibitors	group	588-606	false
levothyroxine	drug	433-445	quetiapine	drug	609-618	false
levothyroxine	drug	433-445	risperidone	drug	621-631	false
levothyroxine	drug	433-445	theophylline	drug	634-645	false
levothyroxine	drug	433-445	topiramate	drug	648-657	false
levothyroxine	drug	433-445	tiagabine	drug	660-668	false
levothyroxine	drug	433-445	tramadol	drug	671-678	false
levothyroxine	drug	433-445	triazolam	drug	681-689	false
levothyroxine	drug	433-445	valproate	drug	692-700	false
levothyroxine	drug	433-445	warfarin	drug	703-710	false
levothyroxine	drug	433-445	ziprasidone	drug	717-727	false
levothyroxine	drug	433-445	zonisamide	drug	734-743	false
lorazepam	drug	448-456	methadone	drug	459-467	false
lorazepam	drug	448-456	midazolam	drug	470-478	false
lorazepam	drug	448-456	mirtazapine	drug	481-491	false
lorazepam	drug	448-456	nortriptyline	drug	494-506	false
lorazepam	drug	448-456	olanzapine	drug	509-518	false
lorazepam	drug	448-456	contraceptives	group	526-539	false
lorazepam	drug	448-456	oxcarbazepine	drug	545-557	false
lorazepam	drug	448-456	Phenytoin	drug	560-568	false
lorazepam	drug	448-456	praziquantel	drug	574-585	false
lorazepam	drug	448-456	protease inhibitors	group	588-606	false
lorazepam	drug	448-456	quetiapine	drug	609-618	false
lorazepam	drug	448-456	risperidone	drug	621-631	false
lorazepam	drug	448-456	theophylline	drug	634-645	false
lorazepam	drug	448-456	topiramate	drug	648-657	false
lorazepam	drug	448-456	tiagabine	drug	660-668	false
lorazepam	drug	448-456	tramadol	drug	671-678	false
lorazepam	drug	448-456	triazolam	drug	681-689	false
lorazepam	drug	448-456	valproate	drug	692-700	false
lorazepam	drug	448-456	warfarin	drug	703-710	false
lorazepam	drug	448-456	ziprasidone	drug	717-727	false
lorazepam	drug	448-456	zonisamide	drug	734-743	false
methadone	drug	459-467	midazolam	drug	470-478	false
methadone	drug	459-467	mirtazapine	drug	481-491	false
methadone	drug	459-467	nortriptyline	drug	494-506	false
methadone	drug	459-467	olanzapine	drug	509-518	false
methadone	drug	459-467	contraceptives	group	526-539	false
methadone	drug	459-467	oxcarbazepine	drug	545-557	false
methadone	drug	459-467	Phenytoin	drug	560-568	false
methadone	drug	459-467	praziquantel	drug	574-585	false
methadone	drug	459-467	protease inhibitors	group	588-606	false
methadone	drug	459-467	quetiapine	drug	609-618	false
methadone	drug	459-467	risperidone	drug	621-631	false
methadone	drug	459-467	theophylline	drug	634-645	false
methadone	drug	459-467	topiramate	drug	648-657	false
methadone	drug	459-467	tiagabine	drug	660-668	false
methadone	drug	459-467	tramadol	drug	671-678	false
methadone	drug	459-467	triazolam	drug	681-689	false
methadone	drug	459-467	valproate	drug	692-700	false
methadone	drug	459-467	warfarin	drug	703-710	false
methadone	drug	459-467	ziprasidone	drug	717-727	false
methadone	drug	459-467	zonisamide	drug	734-743	false
midazolam	drug	470-478	mirtazapine	drug	481-491	false
midazolam	drug	470-478	nortriptyline	drug	494-506	false
midazolam	drug	470-478	olanzapine	drug	509-518	false
midazolam	drug	470-478	contraceptives	group	526-539	false
midazolam	drug	470-478	oxcarbazepine	drug	545-557	false
midazolam	drug	470-478	Phenytoin	drug	560-568	false
midazolam	drug	470-478	praziquantel	drug	574-585	false
midazolam	drug	470-478	protease inhibitors	group	588-606	false
midazolam	drug	470-478	quetiapine	drug	609-618	false
midazolam	drug	470-478	risperidone	drug	621-631	false
midazolam	drug	470-478	theophylline	drug	634-645	false
midazolam	drug	470-478	topiramate	drug	648-657	false
midazolam	drug	470-478	tiagabine	drug	660-668	false
midazolam	drug	470-478	tramadol	drug	671-678	false
midazolam	drug	470-478	triazolam	drug	681-689	false
midazolam	drug	470-478	valproate	drug	692-700	false
midazolam	drug	470-478	warfarin	drug	703-710	false
midazolam	drug	470-478	ziprasidone	drug	717-727	false
midazolam	drug	470-478	zonisamide	drug	734-743	false
mirtazapine	drug	481-491	nortriptyline	drug	494-506	false
mirtazapine	drug	481-491	olanzapine	drug	509-518	false
mirtazapine	drug	481-491	contraceptives	group	526-539	false
mirtazapine	drug	481-491	oxcarbazepine	drug	545-557	false
mirtazapine	drug	481-491	Phenytoin	drug	560-568	false
mirtazapine	drug	481-491	praziquantel	drug	574-585	false
mirtazapine	drug	481-491	protease inhibitors	group	588-606	false
mirtazapine	drug	481-491	quetiapine	drug	609-618	false
mirtazapine	drug	481-491	risperidone	drug	621-631	false
mirtazapine	drug	481-491	theophylline	drug	634-645	false
mirtazapine	drug	481-491	topiramate	drug	648-657	false
mirtazapine	drug	481-491	tiagabine	drug	660-668	false
mirtazapine	drug	481-491	tramadol	drug	671-678	false
mirtazapine	drug	481-491	triazolam	drug	681-689	false
mirtazapine	drug	481-491	valproate	drug	692-700	false
mirtazapine	drug	481-491	warfarin	drug	703-710	false
mirtazapine	drug	481-491	ziprasidone	drug	717-727	false
mirtazapine	drug	481-491	zonisamide	drug	734-743	false
nortriptyline	drug	494-506	olanzapine	drug	509-518	false
nortriptyline	drug	494-506	contraceptives	group	526-539	false
nortriptyline	drug	494-506	oxcarbazepine	drug	545-557	false
nortriptyline	drug	494-506	Phenytoin	drug	560-568	false
nortriptyline	drug	494-506	praziquantel	drug	574-585	false
nortriptyline	drug	494-506	protease inhibitors	group	588-606	false
nortriptyline	drug	494-506	quetiapine	drug	609-618	false
nortriptyline	drug	494-506	risperidone	drug	621-631	false
nortriptyline	drug	494-506	theophylline	drug	634-645	false
nortriptyline	drug	494-506	topiramate	drug	648-657	false
nortriptyline	drug	494-506	tiagabine	drug	660-668	false
nortriptyline	drug	494-506	tramadol	drug	671-678	false
nortriptyline	drug	494-506	triazolam	drug	681-689	false
nortriptyline	drug	494-506	valproate	drug	692-700	false
nortriptyline	drug	494-506	warfarin	drug	703-710	false
nortriptyline	drug	494-506	ziprasidone	drug	717-727	false
nortriptyline	drug	494-506	zonisamide	drug	734-743	false
olanzapine	drug	509-518	contraceptives	group	526-539	false
olanzapine	drug	509-518	oxcarbazepine	drug	545-557	false
olanzapine	drug	509-518	Phenytoin	drug	560-568	false
olanzapine	drug	509-518	praziquantel	drug	574-585	false
olanzapine	drug	509-518	protease inhibitors	group	588-606	false
olanzapine	drug	509-518	quetiapine	drug	609-618	false
olanzapine	drug	509-518	risperidone	drug	621-631	false
olanzapine	drug	509-518	theophylline	drug	634-645	false
olanzapine	drug	509-518	topiramate	drug	648-657	false
olanzapine	drug	509-518	tiagabine	drug	660-668	false
olanzapine	drug	509-518	tramadol	drug	671-678	false
olanzapine	drug	509-518	triazolam	drug	681-689	false
olanzapine	drug	509-518	valproate	drug	692-700	false
olanzapine	drug	509-518	warfarin	drug	703-710	false
olanzapine	drug	509-518	ziprasidone	drug	717-727	false
olanzapine	drug	509-518	zonisamide	drug	734-743	false
contraceptives	group	526-539	oxcarbazepine	drug	545-557	false
contraceptives	group	526-539	Phenytoin	drug	560-568	false
contraceptives	group	526-539	praziquantel	drug	574-585	false
contraceptives	group	526-539	protease inhibitors	group	588-606	false
contraceptives	group	526-539	quetiapine	drug	609-618	false
contraceptives	group	526-539	risperidone	drug	621-631	false
contraceptives	group	526-539	theophylline	drug	634-645	false
contraceptives	group	526-539	topiramate	drug	648-657	false
contraceptives	group	526-539	tiagabine	drug	660-668	false
contraceptives	group	526-539	tramadol	drug	671-678	false
contraceptives	group	526-539	triazolam	drug	681-689	false
contraceptives	group	526-539	valproate	drug	692-700	false
contraceptives	group	526-539	warfarin	drug	703-710	false
contraceptives	group	526-539	ziprasidone	drug	717-727	false
contraceptives	group	526-539	zonisamide	drug	734-743	false
oxcarbazepine	drug	545-557	Phenytoin	drug	560-568	false
oxcarbazepine	drug	545-557	praziquantel	drug	574-585	false
oxcarbazepine	drug	545-557	protease inhibitors	group	588-606	false
oxcarbazepine	drug	545-557	quetiapine	drug	609-618	false
oxcarbazepine	drug	545-557	risperidone	drug	621-631	false
oxcarbazepine	drug	545-557	theophylline	drug	634-645	false
oxcarbazepine	drug	545-557	topiramate	drug	648-657	false
oxcarbazepine	drug	545-557	tiagabine	drug	660-668	false
oxcarbazepine	drug	545-557	tramadol	drug	671-678	false
oxcarbazepine	drug	545-557	triazolam	drug	681-689	false
oxcarbazepine	drug	545-557	valproate	drug	692-700	false
oxcarbazepine	drug	545-557	warfarin	drug	703-710	false
oxcarbazepine	drug	545-557	ziprasidone	drug	717-727	false
oxcarbazepine	drug	545-557	zonisamide	drug	734-743	false
Phenytoin	drug	560-568	praziquantel	drug	574-585	false
Phenytoin	drug	560-568	protease inhibitors	group	588-606	false
Phenytoin	drug	560-568	quetiapine	drug	609-618	false
Phenytoin	drug	560-568	risperidone	drug	621-631	false
Phenytoin	drug	560-568	theophylline	drug	634-645	false
Phenytoin	drug	560-568	topiramate	drug	648-657	false
Phenytoin	drug	560-568	tiagabine	drug	660-668	false
Phenytoin	drug	560-568	tramadol	drug	671-678	false
Phenytoin	drug	560-568	triazolam	drug	681-689	false
Phenytoin	drug	560-568	valproate	drug	692-700	false
Phenytoin	drug	560-568	warfarin	drug	703-710	false
Phenytoin	drug	560-568	ziprasidone	drug	717-727	false
Phenytoin	drug	560-568	zonisamide	drug	734-743	false
praziquantel	drug	574-585	protease inhibitors	group	588-606	false
praziquantel	drug	574-585	quetiapine	drug	609-618	false
praziquantel	drug	574-585	risperidone	drug	621-631	false
praziquantel	drug	574-585	theophylline	drug	634-645	false
praziquantel	drug	574-585	topiramate	drug	648-657	false
praziquantel	drug	574-585	tiagabine	drug	660-668	false
praziquantel	drug	574-585	tramadol	drug	671-678	false
praziquantel	drug	574-585	triazolam	drug	681-689	false
praziquantel	drug	574-585	valproate	drug	692-700	false
praziquantel	drug	574-585	warfarin	drug	703-710	false
praziquantel	drug	574-585	ziprasidone	drug	717-727	false
praziquantel	drug	574-585	zonisamide	drug	734-743	false
protease inhibitors	group	588-606	quetiapine	drug	609-618	false
protease inhibitors	group	588-606	risperidone	drug	621-631	false
protease inhibitors	group	588-606	theophylline	drug	634-645	false
protease inhibitors	group	588-606	topiramate	drug	648-657	false
protease inhibitors	group	588-606	tiagabine	drug	660-668	false
protease inhibitors	group	588-606	tramadol	drug	671-678	false
protease inhibitors	group	588-606	triazolam	drug	681-689	false
protease inhibitors	group	588-606	valproate	drug	692-700	false
protease inhibitors	group	588-606	warfarin	drug	703-710	false
protease inhibitors	group	588-606	ziprasidone	drug	717-727	false
protease inhibitors	group	588-606	zonisamide	drug	734-743	false
quetiapine	drug	609-618	risperidone	drug	621-631	false
quetiapine	drug	609-618	theophylline	drug	634-645	false
quetiapine	drug	609-618	topiramate	drug	648-657	false
quetiapine	drug	609-618	tiagabine	drug	660-668	false
quetiapine	drug	609-618	tramadol	drug	671-678	false
quetiapine	drug	609-618	triazolam	drug	681-689	false
quetiapine	drug	609-618	valproate	drug	692-700	false
quetiapine	drug	609-618	warfarin	drug	703-710	false
quetiapine	drug	609-618	ziprasidone	drug	717-727	false
quetiapine	drug	609-618	zonisamide	drug	734-743	false
risperidone	drug	621-631	theophylline	drug	634-645	false
risperidone	drug	621-631	topiramate	drug	648-657	false
risperidone	drug	621-631	tiagabine	drug	660-668	false
risperidone	drug	621-631	tramadol	drug	671-678	false
risperidone	drug	621-631	triazolam	drug	681-689	false
risperidone	drug	621-631	valproate	drug	692-700	false
risperidone	drug	621-631	warfarin	drug	703-710	false
risperidone	drug	621-631	ziprasidone	drug	717-727	false
risperidone	drug	621-631	zonisamide	drug	734-743	false
theophylline	drug	634-645	topiramate	drug	648-657	false
theophylline	drug	634-645	tiagabine	drug	660-668	false
theophylline	drug	634-645	tramadol	drug	671-678	false
theophylline	drug	634-645	triazolam	drug	681-689	false
theophylline	drug	634-645	valproate	drug	692-700	false
theophylline	drug	634-645	warfarin	drug	703-710	false
theophylline	drug	634-645	ziprasidone	drug	717-727	false
theophylline	drug	634-645	zonisamide	drug	734-743	false
topiramate	drug	648-657	tiagabine	drug	660-668	false
topiramate	drug	648-657	tramadol	drug	671-678	false
topiramate	drug	648-657	triazolam	drug	681-689	false
topiramate	drug	648-657	valproate	drug	692-700	false
topiramate	drug	648-657	warfarin	drug	703-710	false
topiramate	drug	648-657	ziprasidone	drug	717-727	false
topiramate	drug	648-657	zonisamide	drug	734-743	false
tiagabine	drug	660-668	tramadol	drug	671-678	false
tiagabine	drug	660-668	triazolam	drug	681-689	false
tiagabine	drug	660-668	valproate	drug	692-700	false
tiagabine	drug	660-668	warfarin	drug	703-710	false
tiagabine	drug	660-668	ziprasidone	drug	717-727	false
tiagabine	drug	660-668	zonisamide	drug	734-743	false
tramadol	drug	671-678	triazolam	drug	681-689	false
tramadol	drug	671-678	valproate	drug	692-700	false
tramadol	drug	671-678	warfarin	drug	703-710	false
tramadol	drug	671-678	ziprasidone	drug	717-727	false
tramadol	drug	671-678	zonisamide	drug	734-743	false
triazolam	drug	681-689	valproate	drug	692-700	false
triazolam	drug	681-689	warfarin	drug	703-710	false
triazolam	drug	681-689	ziprasidone	drug	717-727	false
triazolam	drug	681-689	zonisamide	drug	734-743	false
valproate	drug	692-700	warfarin	drug	703-710	false
valproate	drug	692-700	ziprasidone	drug	717-727	false
valproate	drug	692-700	zonisamide	drug	734-743	false
warfarin	drug	703-710	ziprasidone	drug	717-727	false
warfarin	drug	703-710	zonisamide	drug	734-743	false
ziprasidone	drug	717-727	zonisamide	drug	734-743	false

DDI-DrugBank.d94.s13	Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
Carbamazepine	drug	48-60	EQUETROTM	brand	63-71	false
Carbamazepine	drug	48-60	Clomipramine HCl	drug	126-141	false
Carbamazepine	drug	48-60	Phenytoin	drug	144-152	false
Carbamazepine	drug	48-60	primidone	drug	162-170	false
Carbamazepine	drug	48-60	EQUETROTM	brand	314-322	false
EQUETROTM	brand	63-71	Clomipramine HCl	drug	126-141	mechanism
EQUETROTM	brand	63-71	Phenytoin	drug	144-152	mechanism
EQUETROTM	brand	63-71	primidone	drug	162-170	mechanism
EQUETROTM	brand	63-71	EQUETROTM	brand	314-322	false
Clomipramine HCl	drug	126-141	Phenytoin	drug	144-152	false
Clomipramine HCl	drug	126-141	primidone	drug	162-170	false
Clomipramine HCl	drug	126-141	EQUETROTM	brand	314-322	false
Phenytoin	drug	144-152	primidone	drug	162-170	false
Phenytoin	drug	144-152	EQUETROTM	brand	314-322	false
primidone	drug	162-170	EQUETROTM	brand	314-322	false

DDI-DrugBank.d94.s14	Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.
Carbamazepine	drug	50-62	carbamazepine	drug	94-106	false
Carbamazepine	drug	50-62	lithium	drug	112-118	false
carbamazepine	drug	94-106	lithium	drug	112-118	effect

DDI-DrugBank.d94.s15	Given the anticonvulsant properties of carbamazepine, EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants.
carbamazepine	drug	39-51	EQUETROTM	brand	54-62	false
carbamazepine	drug	39-51	anticonvulsants	group	128-142	false
EQUETROTM	brand	54-62	anticonvulsants	group	128-142	false

DDI-DrugBank.d94.s16	Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
anti-malarial drugs	group	14-32	chloroquine	drug	43-53	false
anti-malarial drugs	group	14-32	mefloquine	drug	59-68	false
anti-malarial drugs	group	14-32	carbamazepine	drug	102-114	effect
chloroquine	drug	43-53	mefloquine	drug	59-68	false
chloroquine	drug	43-53	carbamazepine	drug	102-114	effect
mefloquine	drug	59-68	carbamazepine	drug	102-114	effect

DDI-DrugBank.d94.s18	Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
EQUETROTM	brand	63-71	centrally acting drugs	group	93-114	advise
EQUETROTM	brand	63-71	alcohol	drug	120-126	advise
centrally acting drugs	group	93-114	alcohol	drug	120-126	false

DDI-DrugBank.d291.s0	When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
Bezalip	brand	5-11	Bezalip retard	brand	16-29	false
Bezalip	brand	5-11	Bezalip	brand	146-152	false
Bezalip	brand	5-11	Bezalip retard	brand	158-171	false
Bezalip	brand	5-11	anticoagulants of the coumarin type	group	199-233	false
Bezalip retard	brand	16-29	Bezalip	brand	146-152	false
Bezalip retard	brand	16-29	Bezalip retard	brand	158-171	false
Bezalip retard	brand	16-29	anticoagulants of the coumarin type	group	199-233	false
Bezalip	brand	146-152	Bezalip retard	brand	158-171	false
Bezalip	brand	146-152	anticoagulants of the coumarin type	group	199-233	effect
Bezalip retard	brand	158-171	anticoagulants of the coumarin type	group	199-233	effect

DDI-DrugBank.d291.s1	For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
anticoagulant	drug	33-45	Bezalip	brand	108-114	advise
anticoagulant	drug	33-45	Bezalip	brand	119-125	advise
Bezalip	brand	108-114	Bezalip	brand	119-125	false

DDI-DrugBank.d291.s3	- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
sulphonylureas	group	16-29	insulin	drug	35-41	false
sulphonylureas	group	16-29	Bezalip	brand	62-68	effect
sulphonylureas	group	16-29	Bezalip retard	brand	73-86	effect
insulin	drug	35-41	Bezalip	brand	62-68	effect
insulin	drug	35-41	Bezalip retard	brand	73-86	effect
Bezalip	brand	62-68	Bezalip retard	brand	73-86	false

DDI-DrugBank.d291.s6	- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.
immuno-suppressant	group	211-228	bezafibrate	drug	254-264	effect

DDI-DrugBank.d291.s9	- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
Bezalip	brand	7-13	Bezalip retard	brand	18-31	false
Bezalip	brand	7-13	anion-exchange resins	group	59-79	advise
Bezalip	brand	7-13	cholestryramine	drug	87-101	advise
Bezalip	brand	7-13	Bezalip	brand	209-215	false
Bezalip	brand	7-13	Bezalip retard	brand	220-233	false
Bezalip retard	brand	18-31	anion-exchange resins	group	59-79	advise
Bezalip retard	brand	18-31	cholestryramine	drug	87-101	advise
Bezalip retard	brand	18-31	Bezalip	brand	209-215	false
Bezalip retard	brand	18-31	Bezalip retard	brand	220-233	false
anion-exchange resins	group	59-79	cholestryramine	drug	87-101	false
anion-exchange resins	group	59-79	Bezalip	brand	209-215	false
anion-exchange resins	group	59-79	Bezalip retard	brand	220-233	false
cholestryramine	drug	87-101	Bezalip	brand	209-215	false
cholestryramine	drug	87-101	Bezalip retard	brand	220-233	false
Bezalip	brand	209-215	Bezalip retard	brand	220-233	false

DDI-DrugBank.d291.s11	- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
Perhexiline hydrogen maleate	drug	2-29	MAO-inhibitors	group	34-47	false
Perhexiline hydrogen maleate	drug	2-29	Bezalip	brand	117-123	advise
Perhexiline hydrogen maleate	drug	2-29	Bezalip retard	brand	128-141	advise
MAO-inhibitors	group	34-47	Bezalip	brand	117-123	advise
MAO-inhibitors	group	34-47	Bezalip retard	brand	128-141	advise
Bezalip	brand	117-123	Bezalip retard	brand	128-141	false

DDI-DrugBank.d284.s0	If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.
adrenergic drugs	group	14-29	BROVANA	brand	166-172	advise

DDI-DrugBank.d284.s1	When paroxetine, a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered.
paroxetine	drug	5-14	BROVANA	brand	72-78	false

DDI-DrugBank.d284.s3	Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
methylxanthines	group	27-41	aminophylline	drug	44-56	false
methylxanthines	group	27-41	theophylline	drug	59-70	false
methylxanthines	group	27-41	steroids	group	74-81	false
methylxanthines	group	27-41	diuretics	group	87-95	false
methylxanthines	group	27-41	adrenergic agonists	group	138-156	effect
aminophylline	drug	44-56	theophylline	drug	59-70	false
aminophylline	drug	44-56	steroids	group	74-81	false
aminophylline	drug	44-56	diuretics	group	87-95	false
aminophylline	drug	44-56	adrenergic agonists	group	138-156	effect
theophylline	drug	59-70	steroids	group	74-81	false
theophylline	drug	59-70	diuretics	group	87-95	false
theophylline	drug	59-70	adrenergic agonists	group	138-156	effect
steroids	group	74-81	diuretics	group	87-95	false
steroids	group	74-81	adrenergic agonists	group	138-156	effect
diuretics	group	87-95	adrenergic agonists	group	138-156	effect

DDI-DrugBank.d284.s4	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
non-potassium sparing diuretics	group	78-108	loop diuretics	group	119-122;136-144	false
non-potassium sparing diuretics	group	78-108	thiazide diuretics	group	127-144	false
non-potassium sparing diuretics	group	78-108	beta-agonists	group	174-186	effect
non-potassium sparing diuretics	group	78-108	beta-agonist	group	233-244	false
loop diuretics	group	119-122;136-144	thiazide diuretics	group	127-144	false
loop diuretics	group	119-122;136-144	beta-agonists	group	174-186	effect
loop diuretics	group	119-122;136-144	beta-agonist	group	233-244	false
thiazide diuretics	group	127-144	beta-agonists	group	174-186	effect
thiazide diuretics	group	127-144	beta-agonist	group	233-244	false
beta-agonists	group	174-186	beta-agonist	group	233-244	false

DDI-DrugBank.d284.s5	Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.
beta-agonists	group	113-125	non-potassium sparing diuretics	group	132-162	advise

DDI-DrugBank.d284.s6	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
BROVANA	brand	0-6	beta2-agonists	group	23-36	false
BROVANA	brand	0-6	monoamine oxidase inhibitors	group	114-141	advise
BROVANA	brand	0-6	tricyclic antidepressants	group	144-168	advise
BROVANA	brand	0-6	adrenergic agonists	group	236-254	false
beta2-agonists	group	23-36	monoamine oxidase inhibitors	group	114-141	advise
beta2-agonists	group	23-36	tricyclic antidepressants	group	144-168	advise
beta2-agonists	group	23-36	adrenergic agonists	group	236-254	false
monoamine oxidase inhibitors	group	114-141	tricyclic antidepressants	group	144-168	false
monoamine oxidase inhibitors	group	114-141	adrenergic agonists	group	236-254	effect
tricyclic antidepressants	group	144-168	adrenergic agonists	group	236-254	effect

DDI-DrugBank.d284.s8	The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by patients receiving BROVANA has not been completely evaluated.
methylxanthines	group	59-73	aminophylline	drug	82-94	false
methylxanthines	group	59-73	theophylline	drug	97-108	false
methylxanthines	group	59-73	BROVANA	brand	133-139	false
aminophylline	drug	82-94	theophylline	drug	97-108	false
aminophylline	drug	82-94	BROVANA	brand	133-139	false
theophylline	drug	97-108	BROVANA	brand	133-139	false

DDI-DrugBank.d284.s9	In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant theophylline at study entry.
BROVANA	brand	64-70	BROVANA	brand	154-160	false
BROVANA	brand	64-70	theophylline	drug	201-212	false
BROVANA	brand	154-160	theophylline	drug	201-212	false

DDI-DrugBank.d284.s10	In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA -treated subjects received concomitant theophylline at study entry.
BROVANA	brand	65-71	BROVANA	brand	93-99	false
BROVANA	brand	65-71	theophylline	drug	140-151	false
BROVANA	brand	93-99	theophylline	drug	140-151	false

DDI-DrugBank.d284.s12	Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
Beta-adrenergic receptor antagonists	group	0-35	beta-blockers	group	38-50	false
Beta-adrenergic receptor antagonists	group	0-35	BROVANA	brand	57-63	effect
beta-blockers	group	38-50	BROVANA	brand	57-63	effect

DDI-DrugBank.d284.s13	Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.
Beta-blockers	group	0-12	beta-agonists	group	56-68	effect

DDI-DrugBank.d175.s0	Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
Diuretic	group	26-33	diuretics	group	56-64	false
Diuretic	group	26-33	diuretic	group	95-102	false
Diuretic	group	26-33	captopril	drug	338-346	false
diuretics	group	56-64	diuretic	group	95-102	false
diuretics	group	56-64	captopril	drug	338-346	effect
diuretic	group	95-102	captopril	drug	338-346	false

DDI-DrugBank.d175.s1	The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
captopril	drug	44-52	diuretic	group	99-106	effect
captopril	drug	44-52	captopril	drug	199-207	false
captopril	drug	44-52	captopril	drug	210-218	false
diuretic	group	99-106	captopril	drug	199-207	false
diuretic	group	99-106	captopril	drug	210-218	false
captopril	drug	199-207	captopril	drug	210-218	false

DDI-DrugBank.d175.s5	Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available;
vasodilators	group	83-94	captopril	drug	118-126	false

DDI-DrugBank.d175.s6	therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
nitroglycerin	drug	11-23	nitrates	group	34-41	false
nitroglycerin	drug	11-23	captopril	drug	174-182	advise
nitrates	group	34-41	captopril	drug	174-182	advise

DDI-DrugBank.d175.s8	Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.
Captopril	drug	29-37	antihypertensive agents	group	69-91	effect

DDI-DrugBank.d175.s9	For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.
diuretics	group	13-21	thiazides	group	30-38	false

DDI-DrugBank.d175.s10	Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics.
captopril	drug	148-156	diuretics	group	172-180	false

DDI-DrugBank.d175.s11	Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution.
ganglionic blocking agents	group	56-81	adrenergic neuron blocking agents	group	86-118	false

DDI-DrugBank.d175.s12	Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.
Beta-adrenergic blocking drugs	group	0-29	captopril	drug	75-83	effect

DDI-DrugBank.d175.s14	Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
Potassium-sparing diuretics	group	0-26	spironolactone	drug	36-49	false
Potassium-sparing diuretics	group	0-26	triamterene	drug	52-62	false
Potassium-sparing diuretics	group	0-26	amiloride	drug	68-76	false
Potassium-sparing diuretics	group	0-26	potassium	drug	82-90	false
spironolactone	drug	36-49	triamterene	drug	52-62	false
spironolactone	drug	36-49	amiloride	drug	68-76	false
spironolactone	drug	36-49	potassium	drug	82-90	false
triamterene	drug	52-62	amiloride	drug	68-76	false
triamterene	drug	52-62	potassium	drug	82-90	false
amiloride	drug	68-76	potassium	drug	82-90	false

DDI-DrugBank.d175.s16	Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
indomethacin	drug	75-86	captopril	drug	130-138	effect

DDI-DrugBank.d175.s17	Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.
nonsteroidal anti-inflammatory agents	group	6-42	aspirin	brand	51-57	false

DDI-DrugBank.d175.s18	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
Lithium	drug	0-6	lithium	drug	25-31	false
Lithium	drug	0-6	lithium	drug	56-62	false
Lithium	drug	0-6	lithium	drug	126-132	false
Lithium	drug	0-6	ACE inhibitor	group	138-150	false
lithium	drug	25-31	lithium	drug	56-62	false
lithium	drug	25-31	lithium	drug	126-132	false
lithium	drug	25-31	ACE inhibitor	group	138-150	false
lithium	drug	56-62	lithium	drug	126-132	false
lithium	drug	56-62	ACE inhibitor	group	138-150	false
lithium	drug	126-132	ACE inhibitor	group	138-150	effect

DDI-DrugBank.d175.s20	If a diuretic is also used, it may increase the risk of lithium toxicity.
diuretic	group	5-12	lithium	drug	56-62	effect

DDI-DrugBank.d175.s21	Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.
Cardiac Glycosides	group	0-17	captopril	drug	102-110	false
Cardiac Glycosides	group	0-17	digoxin	drug	112-118	false
captopril	drug	102-110	digoxin	drug	112-118	false

DDI-DrugBank.d175.s22	Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
Loop Diuretics	group	0-13	Furosemide	drug	16-25	false
Loop Diuretics	group	0-13	captopril	drug	58-66	false
Loop Diuretics	group	0-13	captopril	drug	107-115	false
Furosemide	drug	16-25	captopril	drug	58-66	false
Furosemide	drug	16-25	captopril	drug	107-115	false
captopril	drug	58-66	captopril	drug	107-115	false

DDI-DrugBank.d175.s23	Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for 6 days.
Allopurinol	drug	0-10	captopril	drug	108-116	false
Allopurinol	drug	0-10	allopurinol	drug	122-132	false
captopril	drug	108-116	allopurinol	drug	122-132	false

DDI-DrugBank.d310.s0	It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .
calcium channel blockers	group	55-78	Nimotop	brand	117-123	effect

DDI-DrugBank.d310.s1	In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;
Nimotop	brand	11-17	antihypertensive compounds	group	73-98	effect

DDI-DrugBank.d310.s3	A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.
nimodipine	drug	74-83	cimetidine	drug	183-192	false
nimodipine	drug	74-83	nimodipine	drug	214-223	false
cimetidine	drug	183-192	nimodipine	drug	214-223	mechanism

DDI-DrugBank.d310.s4	This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by cimetidine, which could decrease first pass metabolism of nimodipine.
cimetidine	drug	84-93	nimodipine	drug	142-151	false

DDI-DrugBank.d163.s0	Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects
Vitamin A	group	0-8	Accutane	brand	42-49	false
Vitamin A	group	0-8	vitamin A	group	54-62	false
Vitamin A	group	0-8	vitamin supplements	group	107-125	false
Vitamin A	group	0-8	vitamin A	group	138-146	false
Accutane	brand	42-49	vitamin A	group	54-62	effect
Accutane	brand	42-49	vitamin supplements	group	107-125	false
Accutane	brand	42-49	vitamin A	group	138-146	false
vitamin A	group	54-62	vitamin supplements	group	107-125	false
vitamin A	group	54-62	vitamin A	group	138-146	false
vitamin supplements	group	107-125	vitamin A	group	138-146	false

DDI-DrugBank.d163.s2	Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
Tetracyclines	group	0-12	Accutane	brand	42-49	false
Tetracyclines	group	0-12	tetracyclines	group	55-67	false
Tetracyclines	group	0-12	Accutane	brand	95-102	false
Tetracyclines	group	0-12	tetracyclines	group	252-264	false
Accutane	brand	42-49	tetracyclines	group	55-67	advise
Accutane	brand	42-49	Accutane	brand	95-102	false
Accutane	brand	42-49	tetracyclines	group	252-264	false
tetracyclines	group	55-67	Accutane	brand	95-102	false
tetracyclines	group	55-67	tetracyclines	group	252-264	false
Accutane	brand	95-102	tetracyclines	group	252-264	effect

DDI-DrugBank.d163.s4	Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.
Progesterone	drug	12-23	progesterone	drug	51-62	false
Progesterone	drug	12-23	estrogen	group	111-118	false
Progesterone	drug	12-23	Accutane	brand	173-180	false
progesterone	drug	51-62	estrogen	group	111-118	false
progesterone	drug	51-62	Accutane	brand	173-180	effect
estrogen	group	111-118	Accutane	brand	173-180	false

DDI-DrugBank.d163.s5	Although other hormonal contraceptives are highly effective, there have been reports of pregnancy from women who have used combined oral contraceptives, as well as topical/injectable/implantable/insertable hormonal birth control products.
hormonal contraceptives	group	15-37	combined oral contraceptives	group	123-150	false

DDI-DrugBank.d163.s7	It is not known if hormonal contraceptives differ in their effectiveness when used with Accutane.
hormonal contraceptives	group	19-41	Accutane	brand	88-95	false

DDI-DrugBank.d163.s10	Phenytoin: Accutane has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.
Phenytoin	drug	0-8	Accutane	brand	11-18	false
Phenytoin	drug	0-8	phenytoin	drug	72-80	false
Accutane	brand	11-18	phenytoin	drug	72-80	false

DDI-DrugBank.d163.s13	No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between phenytoin and Accutane.
phenytoin	drug	112-120	Accutane	brand	126-133	false

DDI-DrugBank.d163.s16	Systemic Corticosteroids: Systemic corticosteroids are known to cause osteoporosis.
Systemic Corticosteroids	group	0-23	Systemic corticosteroids	group	26-49	false

DDI-DrugBank.d163.s17	No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between systemic corticosteroids and Accutane.
systemic corticosteroids	group	112-135	Accutane	brand	141-148	false

DDI-DrugBank.d206.s0	Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.
antacids	group	77-84	lactulose	drug	110-118	mechanism
antacids	group	77-84	lactulose	drug	144-152	false
lactulose	drug	110-118	lactulose	drug	144-152	false

DDI-DrugBank.d193.s0	A drug interaction study was performed in which ERBITUX was administered in combination with irinotecan.
ERBITUX	brand	48-54	irinotecan	drug	93-102	false

DDI-DrugBank.d193.s1	There was no evidence of any pharmacokinetic interactions between ERBITUX and irinotecan.
ERBITUX	brand	66-72	irinotecan	drug	78-87	false

DDI-DrugBank.d17.s6	Antihypertensive medications, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery
Antihypertensive medications	group	0-27	diazoxide	drug	48-56	false
Antihypertensive medications	group	0-27	anesthetic	group	65-74	false
Antihypertensive medications	group	0-27	skeletal-muscle relaxants	group	117-141	false
diazoxide	drug	48-56	anesthetic	group	65-74	false
diazoxide	drug	48-56	skeletal-muscle relaxants	group	117-141	false
anesthetic	group	65-74	skeletal-muscle relaxants	group	117-141	false

DDI-DrugBank.d17.s9	Amphotericin B or Corticosteroids or Corticotropin (ACTH)
Amphotericin B	drug	0-13	Corticosteroids	group	18-32	false
Amphotericin B	drug	0-13	Corticotropin	drug	37-49	false
Amphotericin B	drug	0-13	ACTH	drug	52-55	false
Corticosteroids	group	18-32	Corticotropin	drug	37-49	false
Corticosteroids	group	18-32	ACTH	drug	52-55	false
Corticotropin	drug	37-49	ACTH	drug	52-55	false

DDI-DrugBank.d17.s12	(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)
thiazide diuretics	group	21-38	digitalis	group	71-79	effect

DDI-DrugBank.d17.s18	for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;
hypoglycemic medications	group	48-71	thiazide diuretic	group	107-123	advise

DDI-DrugBank.d17.s21	(Concurrent use with thiazide diuretics is not recommended, as they may provoke lithium toxicity because of reduced renal clearance.)
thiazide diuretics	group	21-38	lithium	drug	80-86	false

DDI-DrugBank.d17.s25	(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
steroidal anti-inflammatory agent	group	23-55	loop diuretics	group	127-130;165-173	effect
steroidal anti-inflammatory agent	group	23-55	potassium sparing diuretics	group	133-149;165-173	effect
steroidal anti-inflammatory agent	group	23-55	thiazide diuretics	group	156-173	effect
loop diuretics	group	127-130;165-173	potassium sparing diuretics	group	133-149;165-173	false
loop diuretics	group	127-130;165-173	thiazide diuretics	group	156-173	false
potassium sparing diuretics	group	133-149;165-173	thiazide diuretics	group	156-173	false

DDI-DrugBank.d17.s26	Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)
hydroflumethiazide	drug	16-33	nonsteroidal anti-inflammatory agents	group	39-75	advise
hydroflumethiazide	drug	16-33	diuretic	group	182-189	false
nonsteroidal anti-inflammatory agents	group	39-75	diuretic	group	182-189	false

DDI-DrugBank.d17.s28	(Thiazides may decrease arterial responsiveness to norepinephrine.
Thiazides	group	1-9	norepinephrine	drug	51-64	effect

DDI-DrugBank.d17.s31	(Thiazide drugs may increase the responsiveness to tubocurarine.)
Thiazide drugs	group	1-14	tubocurarine	drug	51-62	effect

DDI-DrugBank.d495.s0	Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.
clonidine hydrochloride	drug	30-52	tricyclic antidepressants	group	69-93	effect
clonidine hydrochloride	drug	30-52	clonidine	drug	110-118	false
tricyclic antidepressants	group	69-93	clonidine	drug	110-118	false

DDI-DrugBank.d495.s1	Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
Clonidine hydrochloride	drug	0-22	alcohol	drug	66-72	effect
Clonidine hydrochloride	drug	0-22	barbiturates	group	75-86	effect
Clonidine hydrochloride	drug	0-22	sedatives	group	97-105	effect
alcohol	drug	66-72	barbiturates	group	75-86	false
alcohol	drug	66-72	sedatives	group	97-105	false
barbiturates	group	75-86	sedatives	group	97-105	false

DDI-DrugBank.d495.s2	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
Amitriptyline	drug	0-12	clonidine	drug	34-42	effect
Amitriptyline	drug	0-12	Clonidine	drug	117-125	false
Amitriptyline	drug	0-12	alcohol	drug	171-177	false
Amitriptyline	drug	0-12	barbiturates	group	180-191	false
Amitriptyline	drug	0-12	sedating drugs	group	202-215	false
clonidine	drug	34-42	Clonidine	drug	117-125	false
clonidine	drug	34-42	alcohol	drug	171-177	false
clonidine	drug	34-42	barbiturates	group	180-191	false
clonidine	drug	34-42	sedating drugs	group	202-215	false
Clonidine	drug	117-125	alcohol	drug	171-177	effect
Clonidine	drug	117-125	barbiturates	group	180-191	effect
Clonidine	drug	117-125	sedating drugs	group	202-215	effect
alcohol	drug	171-177	barbiturates	group	180-191	false
alcohol	drug	171-177	sedating drugs	group	202-215	false
barbiturates	group	180-191	sedating drugs	group	202-215	false

DDI-DrugBank.d495.s3	Narcotic analgesics may potentiate the hypotensive effects of clonidine.
Narcotic analgesics	group	0-18	clonidine	drug	62-70	effect

DDI-DrugBank.d495.s4	Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.
Tricyclic antidepressants	group	0-24	clonidine	drug	68-76	effect

DDI-DrugBank.d495.s5	The effects of tricyclic antidepressants on clonidines analgesic actions are not known.
tricyclic antidepressants	group	15-39	clonidine	drug	44-52	false

DDI-DrugBank.d495.s6	Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.
Beta blockers	group	0-12	clonidine	drug	65-73	effect

DDI-DrugBank.d495.s7	Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
clonidine	drug	125-133	digitalis	group	213-221	advise
clonidine	drug	125-133	calcium channel blockers	group	224-247	advise
clonidine	drug	125-133	beta-blockers	group	254-266	advise
digitalis	group	213-221	calcium channel blockers	group	224-247	false
digitalis	group	213-221	beta-blockers	group	254-266	false
calcium channel blockers	group	224-247	beta-blockers	group	254-266	false

DDI-DrugBank.d495.s8	There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.
fluphenazine	drug	100-111	clonidine	drug	122-130	effect

DDI-DrugBank.d495.s9	Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine.
clonidine	drug	23-31	clonidine	drug	99-107	false

DDI-DrugBank.d495.s10	Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.
clonidine	drug	9-17	anesthetics	group	87-97	effect

DDI-DrugBank.d440.s0	Calcium Supplements/Antacids
Calcium	drug	0-6	Antacids	group	20-27	false

DDI-DrugBank.d440.s1	Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
calcium	drug	20-26	aluminum	drug	67-74	false
calcium	drug	20-26	magnesium	drug	77-85	false
calcium	drug	20-26	iron	drug	88-91	false
calcium	drug	20-26	Ibandronate	drug	137-147	mechanism
aluminum	drug	67-74	magnesium	drug	77-85	false
aluminum	drug	67-74	iron	drug	88-91	false
aluminum	drug	67-74	Ibandronate	drug	137-147	mechanism
magnesium	drug	77-85	iron	drug	88-91	false
magnesium	drug	77-85	Ibandronate	drug	137-147	mechanism
iron	drug	88-91	Ibandronate	drug	137-147	mechanism

DDI-DrugBank.d440.s2	Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).
Ibandronate	drug	0-10	antacids	group	118-125	advise
Ibandronate	drug	0-10	vitamins	group	143-150	advise
antacids	group	118-125	vitamins	group	143-150	false

DDI-DrugBank.d440.s3	H2 Blockers and Proton Pump Inhibitors (PPIs)
H2 Blockers	group	0-10	Proton Pump Inhibitors	group	16-37	false
H2 Blockers	group	0-10	PPIs	group	40-43	false
Proton Pump Inhibitors	group	16-37	PPIs	group	40-43	false

DDI-DrugBank.d440.s4	Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs).
Ibandronate	drug	38-48	H2 blockers	group	136-146	false
Ibandronate	drug	38-48	PPIs	group	152-155	false
H2 blockers	group	136-146	PPIs	group	152-155	false

DDI-DrugBank.d440.s7	Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily.
Ibandronate	drug	111-121	Ibandronate	drug	188-198	false

DDI-DrugBank.d440.s8	Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Aspirin	brand	0-6	Nonsteroidal Antiinflammatory Drug	group	8-41	false
Aspirin	brand	0-6	NSAIDs	group	45-50	false
Nonsteroidal Antiinflammatory Drug	group	8-41	NSAIDs	group	45-50	false

DDI-DrugBank.d440.s9	In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients.
aspirin	brand	63-69	nonsteroidal anti-inflammatory drugs	group	75-110	false

DDI-DrugBank.d440.s10	Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).
aspirin	brand	6-12	NSAID	group	17-21	false
aspirin	brand	6-12	ibandronate	drug	110-120	false
NSAID	group	17-21	ibandronate	drug	110-120	false

DDI-DrugBank.d440.s11	Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients.
aspirin	brand	51-57	nonsteroidal anti-inflammatory drugs	group	63-98	false

DDI-DrugBank.d440.s12	The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).
aspirin	brand	80-86	NSAIDs	group	91-96	false
aspirin	brand	80-86	ibandronate	drug	129-139	false
NSAIDs	group	91-96	ibandronate	drug	129-139	false

DDI-DrugBank.d440.s13	However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
aspirin	brand	15-21	NSAIDs	group	24-29	false
aspirin	brand	15-21	bisphosphonates	group	36-50	false
aspirin	brand	15-21	aspirin	brand	159-165	false
aspirin	brand	15-21	NSAIDs	group	170-175	false
aspirin	brand	15-21	Ibandronate	drug	182-192	false
NSAIDs	group	24-29	bisphosphonates	group	36-50	false
NSAIDs	group	24-29	aspirin	brand	159-165	false
NSAIDs	group	24-29	NSAIDs	group	170-175	false
NSAIDs	group	24-29	Ibandronate	drug	182-192	false
bisphosphonates	group	36-50	aspirin	brand	159-165	false
bisphosphonates	group	36-50	NSAIDs	group	170-175	false
bisphosphonates	group	36-50	Ibandronate	drug	182-192	false
aspirin	brand	159-165	NSAIDs	group	170-175	false
aspirin	brand	159-165	Ibandronate	drug	182-192	advise
NSAIDs	group	170-175	Ibandronate	drug	182-192	advise

DDI-DrugBank.d138.s0	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
ALPHAGAN P	brand	72-81	CNS depressants	group	143-157	advise
ALPHAGAN P	brand	72-81	alcohol	drug	160-166	advise
ALPHAGAN P	brand	72-81	barbiturates	group	169-180	advise
ALPHAGAN P	brand	72-81	opiates	group	183-189	advise
ALPHAGAN P	brand	72-81	sedatives	group	192-200	advise
ALPHAGAN P	brand	72-81	anesthetics	group	206-216	advise
CNS depressants	group	143-157	alcohol	drug	160-166	false
CNS depressants	group	143-157	barbiturates	group	169-180	false
CNS depressants	group	143-157	opiates	group	183-189	false
CNS depressants	group	143-157	sedatives	group	192-200	false
CNS depressants	group	143-157	anesthetics	group	206-216	false
alcohol	drug	160-166	barbiturates	group	169-180	false
alcohol	drug	160-166	opiates	group	183-189	false
alcohol	drug	160-166	sedatives	group	192-200	false
alcohol	drug	160-166	anesthetics	group	206-216	false
barbiturates	group	169-180	opiates	group	183-189	false
barbiturates	group	169-180	sedatives	group	192-200	false
barbiturates	group	169-180	anesthetics	group	206-216	false
opiates	group	183-189	sedatives	group	192-200	false
opiates	group	183-189	anesthetics	group	206-216	false
sedatives	group	192-200	anesthetics	group	206-216	false

DDI-DrugBank.d138.s2	Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.
beta-blockers	group	43-55	anti-hypertensives	group	84-101	false
beta-blockers	group	43-55	cardiac glycosides	group	110-127	false
anti-hypertensives	group	84-101	cardiac glycosides	group	110-127	false

DDI-DrugBank.d138.s3	Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.
Tricyclic antidepressants	group	0-24	clonidine	drug	89-97	effect
Tricyclic antidepressants	group	0-24	ALPHAGAN P	brand	163-172	false
clonidine	drug	89-97	ALPHAGAN P	brand	163-172	false

DDI-DrugBank.d170.s0	Agents Affecting Cytochrome P450 3A4 Isoenzyme System Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when DURAGESIC  is given concurrently with agents that affect CYP3A4 activity.
Fentanyl	drug	54-61	DURAGESIC	brand	194-202	false

DDI-DrugBank.d170.s2	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
fentanyl	drug	35-42	ritonavir	drug	49-57	mechanism
fentanyl	drug	35-42	ketoconazole	drug	98-109	mechanism
fentanyl	drug	35-42	itraconazole	drug	112-123	mechanism
fentanyl	drug	35-42	troleandomycin	drug	126-139	mechanism
fentanyl	drug	35-42	clarithromycin	drug	142-155	mechanism
fentanyl	drug	35-42	nelfinavir	drug	158-167	mechanism
fentanyl	drug	35-42	fentanyl	drug	214-221	false
ritonavir	drug	49-57	ketoconazole	drug	98-109	false
ritonavir	drug	49-57	itraconazole	drug	112-123	false
ritonavir	drug	49-57	troleandomycin	drug	126-139	false
ritonavir	drug	49-57	clarithromycin	drug	142-155	false
ritonavir	drug	49-57	nelfinavir	drug	158-167	false
ritonavir	drug	49-57	fentanyl	drug	214-221	false
ketoconazole	drug	98-109	itraconazole	drug	112-123	false
ketoconazole	drug	98-109	troleandomycin	drug	126-139	false
ketoconazole	drug	98-109	clarithromycin	drug	142-155	false
ketoconazole	drug	98-109	nelfinavir	drug	158-167	false
ketoconazole	drug	98-109	fentanyl	drug	214-221	false
itraconazole	drug	112-123	troleandomycin	drug	126-139	false
itraconazole	drug	112-123	clarithromycin	drug	142-155	false
itraconazole	drug	112-123	nelfinavir	drug	158-167	false
itraconazole	drug	112-123	fentanyl	drug	214-221	false
troleandomycin	drug	126-139	clarithromycin	drug	142-155	false
troleandomycin	drug	126-139	nelfinavir	drug	158-167	false
troleandomycin	drug	126-139	fentanyl	drug	214-221	false
clarithromycin	drug	142-155	nelfinavir	drug	158-167	false
clarithromycin	drug	142-155	fentanyl	drug	214-221	false
nelfinavir	drug	158-167	fentanyl	drug	214-221	false

DDI-DrugBank.d170.s3	The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
diltiazem	drug	55-63	erythromycin	drug	69-80	false
diltiazem	drug	55-63	fentanyl	drug	99-106	mechanism
diltiazem	drug	55-63	fentanyl	drug	142-149	false
erythromycin	drug	69-80	fentanyl	drug	99-106	mechanism
erythromycin	drug	69-80	fentanyl	drug	142-149	false
fentanyl	drug	99-106	fentanyl	drug	142-149	false

DDI-DrugBank.d170.s5	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
Central Nervous System Depressants	group	0-33	DURAGESIC	brand	59-67	false
Central Nervous System Depressants	group	0-33	fentanyl	drug	71-78	false
Central Nervous System Depressants	group	0-33	central nervous system depressants	group	111-144	false
Central Nervous System Depressants	group	0-33	opioids	group	182-188	false
Central Nervous System Depressants	group	0-33	sedatives	group	191-199	false
Central Nervous System Depressants	group	0-33	hypnotics	group	202-210	false
Central Nervous System Depressants	group	0-33	tranquilizers	group	213-225	false
Central Nervous System Depressants	group	0-33	benzodiazepines	group	234-248	false
Central Nervous System Depressants	group	0-33	anesthetics	group	260-270	false
Central Nervous System Depressants	group	0-33	phenothiazines	group	273-286	false
Central Nervous System Depressants	group	0-33	skeletal muscle relaxants	group	289-313	false
Central Nervous System Depressants	group	0-33	alcohol	drug	320-326	false
DURAGESIC	brand	59-67	fentanyl	drug	71-78	false
DURAGESIC	brand	59-67	central nervous system depressants	group	111-144	effect
DURAGESIC	brand	59-67	opioids	group	182-188	effect
DURAGESIC	brand	59-67	sedatives	group	191-199	effect
DURAGESIC	brand	59-67	hypnotics	group	202-210	effect
DURAGESIC	brand	59-67	tranquilizers	group	213-225	effect
DURAGESIC	brand	59-67	benzodiazepines	group	234-248	effect
DURAGESIC	brand	59-67	anesthetics	group	260-270	effect
DURAGESIC	brand	59-67	phenothiazines	group	273-286	effect
DURAGESIC	brand	59-67	skeletal muscle relaxants	group	289-313	effect
DURAGESIC	brand	59-67	alcohol	drug	320-326	effect
fentanyl	drug	71-78	central nervous system depressants	group	111-144	effect
fentanyl	drug	71-78	opioids	group	182-188	effect
fentanyl	drug	71-78	sedatives	group	191-199	effect
fentanyl	drug	71-78	hypnotics	group	202-210	effect
fentanyl	drug	71-78	tranquilizers	group	213-225	effect
fentanyl	drug	71-78	benzodiazepines	group	234-248	effect
fentanyl	drug	71-78	anesthetics	group	260-270	effect
fentanyl	drug	71-78	phenothiazines	group	273-286	effect
fentanyl	drug	71-78	skeletal muscle relaxants	group	289-313	effect
fentanyl	drug	71-78	alcohol	drug	320-326	effect
central nervous system depressants	group	111-144	opioids	group	182-188	false
central nervous system depressants	group	111-144	sedatives	group	191-199	false
central nervous system depressants	group	111-144	hypnotics	group	202-210	false
central nervous system depressants	group	111-144	tranquilizers	group	213-225	false
central nervous system depressants	group	111-144	benzodiazepines	group	234-248	false
central nervous system depressants	group	111-144	anesthetics	group	260-270	false
central nervous system depressants	group	111-144	phenothiazines	group	273-286	false
central nervous system depressants	group	111-144	skeletal muscle relaxants	group	289-313	false
central nervous system depressants	group	111-144	alcohol	drug	320-326	false
opioids	group	182-188	sedatives	group	191-199	false
opioids	group	182-188	hypnotics	group	202-210	false
opioids	group	182-188	tranquilizers	group	213-225	false
opioids	group	182-188	benzodiazepines	group	234-248	false
opioids	group	182-188	anesthetics	group	260-270	false
opioids	group	182-188	phenothiazines	group	273-286	false
opioids	group	182-188	skeletal muscle relaxants	group	289-313	false
opioids	group	182-188	alcohol	drug	320-326	false
sedatives	group	191-199	hypnotics	group	202-210	false
sedatives	group	191-199	tranquilizers	group	213-225	false
sedatives	group	191-199	benzodiazepines	group	234-248	false
sedatives	group	191-199	anesthetics	group	260-270	false
sedatives	group	191-199	phenothiazines	group	273-286	false
sedatives	group	191-199	skeletal muscle relaxants	group	289-313	false
sedatives	group	191-199	alcohol	drug	320-326	false
hypnotics	group	202-210	tranquilizers	group	213-225	false
hypnotics	group	202-210	benzodiazepines	group	234-248	false
hypnotics	group	202-210	anesthetics	group	260-270	false
hypnotics	group	202-210	phenothiazines	group	273-286	false
hypnotics	group	202-210	skeletal muscle relaxants	group	289-313	false
hypnotics	group	202-210	alcohol	drug	320-326	false
tranquilizers	group	213-225	benzodiazepines	group	234-248	false
tranquilizers	group	213-225	anesthetics	group	260-270	false
tranquilizers	group	213-225	phenothiazines	group	273-286	false
tranquilizers	group	213-225	skeletal muscle relaxants	group	289-313	false
tranquilizers	group	213-225	alcohol	drug	320-326	false
benzodiazepines	group	234-248	anesthetics	group	260-270	false
benzodiazepines	group	234-248	phenothiazines	group	273-286	false
benzodiazepines	group	234-248	skeletal muscle relaxants	group	289-313	false
benzodiazepines	group	234-248	alcohol	drug	320-326	false
anesthetics	group	260-270	phenothiazines	group	273-286	false
anesthetics	group	260-270	skeletal muscle relaxants	group	289-313	false
anesthetics	group	260-270	alcohol	drug	320-326	false
phenothiazines	group	273-286	skeletal muscle relaxants	group	289-313	false
phenothiazines	group	273-286	alcohol	drug	320-326	false
skeletal muscle relaxants	group	289-313	alcohol	drug	320-326	false

DDI-DrugBank.d170.s7	MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
MAO Inhibitors	group	0-13	DURAGESIC	brand	16-24	false
MAO Inhibitors	group	0-13	MAOI	group	84-87	false
MAO Inhibitors	group	0-13	MAO inhibitors	group	153-166	false
MAO Inhibitors	group	0-13	opioid analgesics	group	191-207	false
DURAGESIC	brand	16-24	MAOI	group	84-87	advise
DURAGESIC	brand	16-24	MAO inhibitors	group	153-166	false
DURAGESIC	brand	16-24	opioid analgesics	group	191-207	false
MAOI	group	84-87	MAO inhibitors	group	153-166	false
MAOI	group	84-87	opioid analgesics	group	191-207	false
MAO inhibitors	group	153-166	opioid analgesics	group	191-207	advise

DDI-DrugBank.d246.s0	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
butorphanol	drug	18-28	central nervous system depressants	group	35-68	effect
butorphanol	drug	18-28	alcohol	drug	77-83	effect
butorphanol	drug	18-28	barbiturates	group	86-97	effect
butorphanol	drug	18-28	tranquilizers	group	100-112	effect
butorphanol	drug	18-28	antihistamines	group	119-132	effect
butorphanol	drug	18-28	central nervous system depressant	group	159-191	false
central nervous system depressants	group	35-68	alcohol	drug	77-83	false
central nervous system depressants	group	35-68	barbiturates	group	86-97	false
central nervous system depressants	group	35-68	tranquilizers	group	100-112	false
central nervous system depressants	group	35-68	antihistamines	group	119-132	false
central nervous system depressants	group	35-68	central nervous system depressant	group	159-191	false
alcohol	drug	77-83	barbiturates	group	86-97	false
alcohol	drug	77-83	tranquilizers	group	100-112	false
alcohol	drug	77-83	antihistamines	group	119-132	false
alcohol	drug	77-83	central nervous system depressant	group	159-191	false
barbiturates	group	86-97	tranquilizers	group	100-112	false
barbiturates	group	86-97	antihistamines	group	119-132	false
barbiturates	group	86-97	central nervous system depressant	group	159-191	false
tranquilizers	group	100-112	antihistamines	group	119-132	false
tranquilizers	group	100-112	central nervous system depressant	group	159-191	false
antihistamines	group	119-132	central nervous system depressant	group	159-191	false

DDI-DrugBank.d246.s1	When used concurrently with such drugs, the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of opioids.
butorphanol	drug	52-62	opioids	group	231-237	false

DDI-DrugBank.d246.s2	In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.
butorphanol	drug	62-72	STADOL NS	brand	90-98	false
butorphanol	drug	62-72	sumatriptan	drug	180-190	false
STADOL NS	brand	90-98	sumatriptan	drug	180-190	false

DDI-DrugBank.d246.s3	However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.
butorphanol	drug	73-83	STADOL NS	brand	179-187	false
butorphanol	drug	73-83	sumatriptan	drug	237-247	false
STADOL NS	brand	179-187	sumatriptan	drug	237-247	mechanism

DDI-DrugBank.d246.s5	When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.
STADOL NS	brand	9-17	sumatriptan	drug	57-67	mechanism
STADOL NS	brand	9-17	butorphanol	drug	93-103	false
sumatriptan	drug	57-67	butorphanol	drug	93-103	false

DDI-DrugBank.d246.s6	In neither case were the pharmacokinetics of sumatriptan affected by coadministration with STADOL NS.
sumatriptan	drug	45-55	STADOL NS	brand	91-99	false

DDI-DrugBank.d246.s7	These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.
STADOL NS	brand	51-59	sumatriptan	drug	117-127	effect

DDI-DrugBank.d246.s8	The safety of using STADOL NS and IMITREX (sumatriptan) Nasal Spray during the same episode of migraine has not been established.
STADOL NS	brand	20-28	IMITREX	brand	34-40	false
STADOL NS	brand	20-28	sumatriptan	drug	43-53	false
IMITREX	brand	34-40	sumatriptan	drug	43-53	false

DDI-DrugBank.d246.s10	The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).
butorphanol	drug	39-49	STADOL NS	brand	67-75	false
butorphanol	drug	39-49	cimetidine	drug	122-131	false
STADOL NS	brand	67-75	cimetidine	drug	122-131	false

DDI-DrugBank.d246.s11	Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.
STADOL NS	brand	34-42	butorphanol	drug	50-60	false
STADOL NS	brand	34-42	cimetidine	drug	122-131	false
butorphanol	drug	50-60	cimetidine	drug	122-131	false

DDI-DrugBank.d246.s12	It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
butorphanol	drug	34-44	erythromycin	drug	126-137	advise

DDI-DrugBank.d246.s13	The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (oxymetazoline), but the rate of absorption is decreased.
STADOL NS	brand	16-24	nasal vasoconstrictor	group	88-108	false
STADOL NS	brand	16-24	oxymetazoline	drug	111-123	false
nasal vasoconstrictor	group	88-108	oxymetazoline	drug	111-123	false

DDI-DrugBank.d246.s14	Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.
STADOL NS	brand	48-56	nasal vasoconstrictor	group	122-142	effect

DDI-DrugBank.d246.s15	No information is available about the use of butorphanol concurrently with MAO inhibitors.
butorphanol	drug	45-55	MAO inhibitors	group	75-88	false

DDI-DrugBank.d487.s1	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
phenobarbital	drug	42-54	phenytoin	drug	57-65	false
phenobarbital	drug	42-54	rifampin	drug	71-78	false
phenobarbital	drug	42-54	corticosteroids	group	110-124	mechanism
phenobarbital	drug	42-54	corticosteroid	group	155-168	advise
phenytoin	drug	57-65	rifampin	drug	71-78	false
phenytoin	drug	57-65	corticosteroids	group	110-124	mechanism
phenytoin	drug	57-65	corticosteroid	group	155-168	advise
rifampin	drug	71-78	corticosteroids	group	110-124	mechanism
rifampin	drug	71-78	corticosteroid	group	155-168	advise
corticosteroids	group	110-124	corticosteroid	group	155-168	false

DDI-DrugBank.d487.s2	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
troleandomycin	drug	14-27	ketoconazole	drug	33-44	false
troleandomycin	drug	14-27	corticosteroids	group	76-90	mechanism
ketoconazole	drug	33-44	corticosteroids	group	76-90	mechanism

DDI-DrugBank.d487.s4	Corticosteroids may increase the clearance of chronic high dose aspirin.
Corticosteroids	group	0-14	aspirin	brand	64-70	effect

DDI-DrugBank.d487.s5	This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
salicylate	group	29-38	salicylate	group	77-86	false
salicylate	group	29-38	corticosteroid	drug	102-115	false
salicylate	group	77-86	corticosteroid	drug	102-115	effect

DDI-DrugBank.d487.s6	Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.
Aspirin	brand	0-6	cortico-steroids	group	54-69	advise

DDI-DrugBank.d487.s7	The effect of corticosteroids on oral anticoagulants is variable.
corticosteroids	group	14-28	anticoagulants	group	38-51	effect

DDI-DrugBank.d487.s8	There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
anticoagulants	group	63-76	corticosteroids	group	107-121	effect

DDI-DrugBank.d323.s0	Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
MYOBLOC	brand	21-27	aminoglycosides	group	33-47	advise
MYOBLOC	brand	21-27	curare-like compounds	group	116-136	advise
MYOBLOC	brand	21-27	toxin	drug	198-202	false
aminoglycosides	group	33-47	curare-like compounds	group	116-136	false
aminoglycosides	group	33-47	toxin	drug	198-202	false
curare-like compounds	group	116-136	toxin	drug	198-202	false

DDI-DrugBank.d425.s1	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
anticonvulsant medications	group	62-87	phenytoin	drug	98-106	false
anticonvulsant medications	group	62-87	primidone	drug	113-121	false
anticonvulsant medications	group	62-87	metformin	drug	124-132	false
anticonvulsant medications	group	62-87	sulfasalazine	drug	199-211	false
anticonvulsant medications	group	62-87	triamterene	drug	298-308	false
anticonvulsant medications	group	62-87	diuretic	group	313-320	false
anticonvulsant medications	group	62-87	Methotrexate	drug	323-334	false
anticonvulsant medications	group	62-87	vitamin B12	drug	389-399	false
anticonvulsant medications	group	62-87	folic acid	drug	405-414	false
phenytoin	drug	98-106	primidone	drug	113-121	false
phenytoin	drug	98-106	metformin	drug	124-132	false
phenytoin	drug	98-106	sulfasalazine	drug	199-211	false
phenytoin	drug	98-106	triamterene	drug	298-308	false
phenytoin	drug	98-106	diuretic	group	313-320	false
phenytoin	drug	98-106	Methotrexate	drug	323-334	false
phenytoin	drug	98-106	vitamin B12	drug	389-399	false
phenytoin	drug	98-106	folic acid	drug	405-414	false
primidone	drug	113-121	metformin	drug	124-132	false
primidone	drug	113-121	sulfasalazine	drug	199-211	false
primidone	drug	113-121	triamterene	drug	298-308	false
primidone	drug	113-121	diuretic	group	313-320	false
primidone	drug	113-121	Methotrexate	drug	323-334	false
primidone	drug	113-121	vitamin B12	drug	389-399	false
primidone	drug	113-121	folic acid	drug	405-414	false
metformin	drug	124-132	sulfasalazine	drug	199-211	false
metformin	drug	124-132	triamterene	drug	298-308	false
metformin	drug	124-132	diuretic	group	313-320	false
metformin	drug	124-132	Methotrexate	drug	323-334	false
metformin	drug	124-132	vitamin B12	drug	389-399	false
metformin	drug	124-132	folic acid	drug	405-414	false
sulfasalazine	drug	199-211	triamterene	drug	298-308	false
sulfasalazine	drug	199-211	diuretic	group	313-320	false
sulfasalazine	drug	199-211	Methotrexate	drug	323-334	false
sulfasalazine	drug	199-211	vitamin B12	drug	389-399	false
sulfasalazine	drug	199-211	folic acid	drug	405-414	false
triamterene	drug	298-308	diuretic	group	313-320	false
triamterene	drug	298-308	Methotrexate	drug	323-334	false
triamterene	drug	298-308	vitamin B12	drug	389-399	false
triamterene	drug	298-308	folic acid	drug	405-414	false
diuretic	group	313-320	Methotrexate	drug	323-334	false
diuretic	group	313-320	vitamin B12	drug	389-399	false
diuretic	group	313-320	folic acid	drug	405-414	false
Methotrexate	drug	323-334	vitamin B12	drug	389-399	false
Methotrexate	drug	323-334	folic acid	drug	405-414	false
vitamin B12	drug	389-399	folic acid	drug	405-414	int

DDI-DrugBank.d425.s5	Therefore, intake of supplemental folic acid should not exceed 1000 micrograms ( g, sometimes mcg) per day to prevent folic acid from masking symptoms of vitamin B12 deficiency.
folic acid	drug	34-43	folic acid	drug	118-127	false

DDI-DrugBank.d425.s6	It is important for older adults to be aware of the relationship between folic acid and vitamin B12 because they are at greater risk of having a vitamin B12 deficiency.
folic acid	drug	73-82	vitamin B12	drug	88-98	false

DDI-DrugBank.d429.s0	Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
Antacids	group	0-7	kaolin	drug	13-18	false
Antacids	group	0-7	Antacids	group	21-28	false
Antacids	group	0-7	kaolin	drug	34-39	false
Antacids	group	0-7	chloroquine	drug	66-76	false
kaolin	drug	13-18	Antacids	group	21-28	false
kaolin	drug	13-18	kaolin	drug	34-39	false
kaolin	drug	13-18	chloroquine	drug	66-76	false
Antacids	group	21-28	kaolin	drug	34-39	false
Antacids	group	21-28	chloroquine	drug	66-76	mechanism
kaolin	drug	34-39	chloroquine	drug	66-76	mechanism

DDI-DrugBank.d429.s2	Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
Cimetidine	drug	0-9	Cimetidine	drug	12-21	false
Cimetidine	drug	0-9	chloroquine	drug	53-63	false
Cimetidine	drug	12-21	chloroquine	drug	53-63	mechanism

DDI-DrugBank.d429.s4	Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
Ampicillin	drug	0-9	chloroquine	drug	46-56	false
Ampicillin	drug	0-9	ampicillin	drug	103-112	false
chloroquine	drug	46-56	ampicillin	drug	103-112	mechanism

DDI-DrugBank.d429.s6	Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.
Cyclosporin	drug	0-10	chloroquine	drug	35-45	false
Cyclosporin	drug	0-10	cyclosporin	drug	87-97	false
chloroquine	drug	35-45	cyclosporin	drug	87-97	mechanism

DDI-DrugBank.d429.s7	Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued.
cyclosporin	drug	37-47	chloroquine	drug	89-99	false

DDI-DrugBank.d154.s0	The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.
aspirin	brand	24-30	fenoprofen	drug	68-77	mechanism
aspirin	brand	24-30	hydroxylated fenoprofen	drug_n	161-183	false
fenoprofen	drug	68-77	hydroxylated fenoprofen	drug_n	161-183	false

DDI-DrugBank.d154.s1	Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.
fenoprofen	drug	46-55	aspirin	brand	61-67	mechanism
fenoprofen	drug	46-55	fenoprofen	drug	128-137	false
aspirin	brand	61-67	fenoprofen	drug	128-137	false

DDI-DrugBank.d154.s2	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
Nalfon	brand	8-13	aspirin	brand	93-99	false
Nalfon	brand	8-13	aspirin	brand	119-125	false
Nalfon	brand	8-13	Nalfon	brand	162-167	false
Nalfon	brand	8-13	Nalfon	brand	193-198	false
Nalfon	brand	8-13	salicylates	group	204-214	false
aspirin	brand	93-99	aspirin	brand	119-125	false
aspirin	brand	93-99	Nalfon	brand	162-167	false
aspirin	brand	93-99	Nalfon	brand	193-198	false
aspirin	brand	93-99	salicylates	group	204-214	false
aspirin	brand	119-125	Nalfon	brand	162-167	mechanism
aspirin	brand	119-125	Nalfon	brand	193-198	false
aspirin	brand	119-125	salicylates	group	204-214	false
Nalfon	brand	162-167	Nalfon	brand	193-198	false
Nalfon	brand	162-167	salicylates	group	204-214	false
Nalfon	brand	193-198	salicylates	group	204-214	advise

DDI-DrugBank.d154.s3	Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.
phenobarbital	drug	26-38	fenoprofen	drug	126-135	mechanism

DDI-DrugBank.d154.s4	When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.
phenobarbital	drug	5-17	Nalfon	brand	81-86	advise

DDI-DrugBank.d154.s7	Patients receiving hydantoins, sulfonamides, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.
hydantoins	group	19-28	sulfonamides	group	31-42	false
hydantoins	group	19-28	sulfonylureas	group	48-60	false
sulfonamides	group	31-42	sulfonylureas	group	48-60	false

DDI-DrugBank.d154.s8	In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.
coumarin-type anticoagulants	group	22-49	Nalfon	brand	68-73	effect

DDI-DrugBank.d154.s10	Patients treated with Nalfon may be resistant to the effects of loop diuretics.
Nalfon	brand	22-27	loop diuretics	group	64-77	effect

DDI-DrugBank.d154.s11	In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.
Nalfon	brand	22-27	steroid	group	35-41	advise
Nalfon	brand	22-27	steroid	group	75-81	false
Nalfon	brand	22-27	steroid	group	163-169	false
steroid	group	35-41	steroid	group	75-81	false
steroid	group	35-41	steroid	group	163-169	false
steroid	group	75-81	steroid	group	163-169	false

DDI-DrugBank.d208.s0	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
Benzthiazide	drug	0-11	alcohol	drug	31-37	int
Benzthiazide	drug	0-11	blood thinner	group	40-52	int
Benzthiazide	drug	0-11	decongestant drugs	group	56-73	int
Benzthiazide	drug	0-11	lithium	drug	129-135	int
Benzthiazide	drug	0-11	norepinephrine	drug	138-151	int
Benzthiazide	drug	0-11	NSAIDs	group	154-159	int
Benzthiazide	drug	0-11	Aleve	brand	166-170	int
Benzthiazide	drug	0-11	Ibuprofen	drug	175-183	int
alcohol	drug	31-37	blood thinner	group	40-52	false
alcohol	drug	31-37	decongestant drugs	group	56-73	false
alcohol	drug	31-37	lithium	drug	129-135	false
alcohol	drug	31-37	norepinephrine	drug	138-151	false
alcohol	drug	31-37	NSAIDs	group	154-159	false
alcohol	drug	31-37	Aleve	brand	166-170	false
alcohol	drug	31-37	Ibuprofen	drug	175-183	false
blood thinner	group	40-52	decongestant drugs	group	56-73	false
blood thinner	group	40-52	lithium	drug	129-135	false
blood thinner	group	40-52	norepinephrine	drug	138-151	false
blood thinner	group	40-52	NSAIDs	group	154-159	false
blood thinner	group	40-52	Aleve	brand	166-170	false
blood thinner	group	40-52	Ibuprofen	drug	175-183	false
decongestant drugs	group	56-73	lithium	drug	129-135	false
decongestant drugs	group	56-73	norepinephrine	drug	138-151	false
decongestant drugs	group	56-73	NSAIDs	group	154-159	false
decongestant drugs	group	56-73	Aleve	brand	166-170	false
decongestant drugs	group	56-73	Ibuprofen	drug	175-183	false
lithium	drug	129-135	norepinephrine	drug	138-151	false
lithium	drug	129-135	NSAIDs	group	154-159	false
lithium	drug	129-135	Aleve	brand	166-170	false
lithium	drug	129-135	Ibuprofen	drug	175-183	false
norepinephrine	drug	138-151	NSAIDs	group	154-159	false
norepinephrine	drug	138-151	Aleve	brand	166-170	false
norepinephrine	drug	138-151	Ibuprofen	drug	175-183	false
NSAIDs	group	154-159	Aleve	brand	166-170	false
NSAIDs	group	154-159	Ibuprofen	drug	175-183	false
Aleve	brand	166-170	Ibuprofen	drug	175-183	false

DDI-DrugBank.d127.s2	DOXIL  may interact with drugs known to interact with the conventional formulation of doxorubicin HCl.
DOXIL	brand	0-4	doxorubicin HCl	drug	86-100	false

DDI-DrugBank.d564.s0	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
anesthetic solutions	group	28-47	epinephrine	drug	60-70	false
anesthetic solutions	group	28-47	norepinephrine	drug	75-88	false
anesthetic solutions	group	28-47	monoamine oxidase inhibitors	group	112-139	false
anesthetic solutions	group	28-47	tricyclic antidepressants	group	144-168	false
epinephrine	drug	60-70	norepinephrine	drug	75-88	false
epinephrine	drug	60-70	monoamine oxidase inhibitors	group	112-139	effect
epinephrine	drug	60-70	tricyclic antidepressants	group	144-168	effect
norepinephrine	drug	75-88	monoamine oxidase inhibitors	group	112-139	effect
norepinephrine	drug	75-88	tricyclic antidepressants	group	144-168	effect
monoamine oxidase inhibitors	group	112-139	tricyclic antidepressants	group	144-168	false

DDI-DrugBank.d564.s1	Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
Phenothiazines	group	0-13	butyrophenones	group	19-32	false
Phenothiazines	group	0-13	epinephrine	drug	78-88	effect
butyrophenones	group	19-32	epinephrine	drug	78-88	effect

DDI-DrugBank.d564.s4	Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
vasopressor drugs	group	29-45	ergot-type oxytocic drugs	group	114-138	false

DDI-DrugBank.d569.s1	In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
Angiomax	brand	73-80	heparin	drug	87-93	effect
Angiomax	brand	73-80	warfarin	drug	96-103	effect
Angiomax	brand	73-80	thrombolytics	group	106-118	effect
heparin	drug	87-93	warfarin	drug	96-103	false
heparin	drug	87-93	thrombolytics	group	106-118	false
warfarin	drug	96-103	thrombolytics	group	106-118	false

DDI-DrugBank.d569.s2	There is no experience with co-administration of Angiomax and plasma expanders such as dextran.
Angiomax	brand	49-56	dextran	drug	87-93	false

DDI-DrugBank.d569.s5	Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests.
Angiomax	brand	32-39	bivalirudin	drug	135-145	false

DDI-DrugBank.d167.s1	Anticholinesterases (neostgmine, physostigmine), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.
Anticholinesterases	group	0-18	physostigmine	drug	33-45	false
Anticholinesterases	group	0-18	lignocaine	drug	49-58	false
Anticholinesterases	group	0-18	quinine	drug	61-67	false
Anticholinesterases	group	0-18	procainamide	drug	70-81	false
physostigmine	drug	33-45	lignocaine	drug	49-58	false
physostigmine	drug	33-45	quinine	drug	61-67	false
physostigmine	drug	33-45	procainamide	drug	70-81	false
lignocaine	drug	49-58	quinine	drug	61-67	false
lignocaine	drug	49-58	procainamide	drug	70-81	false
quinine	drug	61-67	procainamide	drug	70-81	false

DDI-DrugBank.d167.s2	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.
anesthetics	group	66-76	anesthetics	group	85-95	false
anesthetics	group	66-76	lidocaine	drug	102-110	false
anesthetics	group	66-76	procaine	drug	113-120	false
anesthetics	group	66-76	beta-blockers	group	123-135	false
anesthetics	group	66-76	metaclopramide	drug	138-151	false
anesthetics	group	66-76	lithium carbonate	drug	154-170	false
anesthetics	group	66-76	terbutaline	drug	177-187	false
anesthetics	group	85-95	lidocaine	drug	102-110	false
anesthetics	group	85-95	procaine	drug	113-120	false
anesthetics	group	85-95	beta-blockers	group	123-135	false
anesthetics	group	85-95	metaclopramide	drug	138-151	false
anesthetics	group	85-95	lithium carbonate	drug	154-170	false
anesthetics	group	85-95	terbutaline	drug	177-187	false
lidocaine	drug	102-110	procaine	drug	113-120	false
lidocaine	drug	102-110	beta-blockers	group	123-135	false
lidocaine	drug	102-110	metaclopramide	drug	138-151	false
lidocaine	drug	102-110	lithium carbonate	drug	154-170	false
lidocaine	drug	102-110	terbutaline	drug	177-187	false
procaine	drug	113-120	beta-blockers	group	123-135	false
procaine	drug	113-120	metaclopramide	drug	138-151	false
procaine	drug	113-120	lithium carbonate	drug	154-170	false
procaine	drug	113-120	terbutaline	drug	177-187	false
beta-blockers	group	123-135	metaclopramide	drug	138-151	false
beta-blockers	group	123-135	lithium carbonate	drug	154-170	false
beta-blockers	group	123-135	terbutaline	drug	177-187	false
metaclopramide	drug	138-151	lithium carbonate	drug	154-170	false
metaclopramide	drug	138-151	terbutaline	drug	177-187	false
lithium carbonate	drug	154-170	terbutaline	drug	177-187	false

DDI-DrugBank.d263.s0	Zidovudine: There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.
Zidovudine	drug	0-9	ZDV	drug	72-74	false
Zidovudine	drug	0-9	zalcitabine	drug	80-90	false
ZDV	drug	72-74	zalcitabine	drug	80-90	false

DDI-DrugBank.d263.s1	Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
Zalcitabine	drug	0-10	ZDV	drug	83-85	effect

DDI-DrugBank.d263.s2	In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.
didanosine	drug	36-45	stavudine	drug	51-59	false
didanosine	drug	36-45	zalcitabine	drug	127-137	false
stavudine	drug	51-59	zalcitabine	drug	127-137	false

DDI-DrugBank.d263.s3	Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.
Lamivudine	drug	0-9	lamivudine	drug	104-113	false
Lamivudine	drug	0-9	zalcitabine	drug	139-149	false
lamivudine	drug	104-113	zalcitabine	drug	139-149	effect

DDI-DrugBank.d263.s5	Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);
Zalcitabine	drug	0-10	lamivudine	drug	22-31	effect

DDI-DrugBank.d263.s6	however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine.
lamivudine	drug	78-87	lamivudine	drug	135-144	false
lamivudine	drug	78-87	zalcitabine	drug	206-216	false
lamivudine	drug	135-144	zalcitabine	drug	206-216	false

DDI-DrugBank.d263.s7	These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.
zalcitabine	drug	66-76	lamivudine	drug	82-91	effect
zalcitabine	drug	66-76	zalcitabine	drug	173-183	false
zalcitabine	drug	66-76	antiretroviral	group	216-229	false
zalcitabine	drug	66-76	zalcitabine	drug	241-251	false
lamivudine	drug	82-91	zalcitabine	drug	173-183	false
lamivudine	drug	82-91	antiretroviral	group	216-229	false
lamivudine	drug	82-91	zalcitabine	drug	241-251	false
zalcitabine	drug	173-183	antiretroviral	group	216-229	false
zalcitabine	drug	173-183	zalcitabine	drug	241-251	false
antiretroviral	group	216-229	zalcitabine	drug	241-251	false

DDI-DrugBank.d263.s9	Concomitant use of zalcitabine and lamivudine is not recommended.
zalcitabine	drug	19-29	lamivudine	drug	35-44	advise

DDI-DrugBank.d263.s10	Saquinavir: The combination of HIVID, saquinavir, and ZDV has been studied (as triple combination) in adults.
Saquinavir	drug	0-9	HIVID	drug	31-35	false
Saquinavir	drug	0-9	saquinavir	drug	38-47	false
Saquinavir	drug	0-9	ZDV	drug	54-56	false
HIVID	drug	31-35	saquinavir	drug	38-47	false
HIVID	drug	31-35	ZDV	drug	54-56	false
saquinavir	drug	38-47	ZDV	drug	54-56	false

DDI-DrugBank.d263.s13	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
antiretroviral nucleoside analogues	drug	67-101	chloramphenicol	drug	104-118	false
antiretroviral nucleoside analogues	drug	67-101	cisplatin	drug	121-129	false
antiretroviral nucleoside analogues	drug	67-101	dapsone	drug	132-138	false
antiretroviral nucleoside analogues	drug	67-101	disulfiram	drug	141-150	false
antiretroviral nucleoside analogues	drug	67-101	ethionamide	drug	153-163	false
antiretroviral nucleoside analogues	drug	67-101	glutethimide	drug	166-177	false
antiretroviral nucleoside analogues	drug	67-101	gold	drug	180-183	false
antiretroviral nucleoside analogues	drug	67-101	hydralazine	drug	186-196	false
antiretroviral nucleoside analogues	drug	67-101	iodoquinol	drug	199-208	false
antiretroviral nucleoside analogues	drug	67-101	isoniazid	drug	211-219	false
antiretroviral nucleoside analogues	drug	67-101	metronidazole	drug	222-234	false
antiretroviral nucleoside analogues	drug	67-101	nitrofurantoin	drug	237-250	false
antiretroviral nucleoside analogues	drug	67-101	phenytoin	drug	253-261	false
antiretroviral nucleoside analogues	drug	67-101	ribavirin	drug	264-272	false
antiretroviral nucleoside analogues	drug	67-101	vincristine	drug	279-289	false
chloramphenicol	drug	104-118	cisplatin	drug	121-129	false
chloramphenicol	drug	104-118	dapsone	drug	132-138	false
chloramphenicol	drug	104-118	disulfiram	drug	141-150	false
chloramphenicol	drug	104-118	ethionamide	drug	153-163	false
chloramphenicol	drug	104-118	glutethimide	drug	166-177	false
chloramphenicol	drug	104-118	gold	drug	180-183	false
chloramphenicol	drug	104-118	hydralazine	drug	186-196	false
chloramphenicol	drug	104-118	iodoquinol	drug	199-208	false
chloramphenicol	drug	104-118	isoniazid	drug	211-219	false
chloramphenicol	drug	104-118	metronidazole	drug	222-234	false
chloramphenicol	drug	104-118	nitrofurantoin	drug	237-250	false
chloramphenicol	drug	104-118	phenytoin	drug	253-261	false
chloramphenicol	drug	104-118	ribavirin	drug	264-272	false
chloramphenicol	drug	104-118	vincristine	drug	279-289	false
cisplatin	drug	121-129	dapsone	drug	132-138	false
cisplatin	drug	121-129	disulfiram	drug	141-150	false
cisplatin	drug	121-129	ethionamide	drug	153-163	false
cisplatin	drug	121-129	glutethimide	drug	166-177	false
cisplatin	drug	121-129	gold	drug	180-183	false
cisplatin	drug	121-129	hydralazine	drug	186-196	false
cisplatin	drug	121-129	iodoquinol	drug	199-208	false
cisplatin	drug	121-129	isoniazid	drug	211-219	false
cisplatin	drug	121-129	metronidazole	drug	222-234	false
cisplatin	drug	121-129	nitrofurantoin	drug	237-250	false
cisplatin	drug	121-129	phenytoin	drug	253-261	false
cisplatin	drug	121-129	ribavirin	drug	264-272	false
cisplatin	drug	121-129	vincristine	drug	279-289	false
dapsone	drug	132-138	disulfiram	drug	141-150	false
dapsone	drug	132-138	ethionamide	drug	153-163	false
dapsone	drug	132-138	glutethimide	drug	166-177	false
dapsone	drug	132-138	gold	drug	180-183	false
dapsone	drug	132-138	hydralazine	drug	186-196	false
dapsone	drug	132-138	iodoquinol	drug	199-208	false
dapsone	drug	132-138	isoniazid	drug	211-219	false
dapsone	drug	132-138	metronidazole	drug	222-234	false
dapsone	drug	132-138	nitrofurantoin	drug	237-250	false
dapsone	drug	132-138	phenytoin	drug	253-261	false
dapsone	drug	132-138	ribavirin	drug	264-272	false
dapsone	drug	132-138	vincristine	drug	279-289	false
disulfiram	drug	141-150	ethionamide	drug	153-163	false
disulfiram	drug	141-150	glutethimide	drug	166-177	false
disulfiram	drug	141-150	gold	drug	180-183	false
disulfiram	drug	141-150	hydralazine	drug	186-196	false
disulfiram	drug	141-150	iodoquinol	drug	199-208	false
disulfiram	drug	141-150	isoniazid	drug	211-219	false
disulfiram	drug	141-150	metronidazole	drug	222-234	false
disulfiram	drug	141-150	nitrofurantoin	drug	237-250	false
disulfiram	drug	141-150	phenytoin	drug	253-261	false
disulfiram	drug	141-150	ribavirin	drug	264-272	false
disulfiram	drug	141-150	vincristine	drug	279-289	false
ethionamide	drug	153-163	glutethimide	drug	166-177	false
ethionamide	drug	153-163	gold	drug	180-183	false
ethionamide	drug	153-163	hydralazine	drug	186-196	false
ethionamide	drug	153-163	iodoquinol	drug	199-208	false
ethionamide	drug	153-163	isoniazid	drug	211-219	false
ethionamide	drug	153-163	metronidazole	drug	222-234	false
ethionamide	drug	153-163	nitrofurantoin	drug	237-250	false
ethionamide	drug	153-163	phenytoin	drug	253-261	false
ethionamide	drug	153-163	ribavirin	drug	264-272	false
ethionamide	drug	153-163	vincristine	drug	279-289	false
glutethimide	drug	166-177	gold	drug	180-183	false
glutethimide	drug	166-177	hydralazine	drug	186-196	false
glutethimide	drug	166-177	iodoquinol	drug	199-208	false
glutethimide	drug	166-177	isoniazid	drug	211-219	false
glutethimide	drug	166-177	metronidazole	drug	222-234	false
glutethimide	drug	166-177	nitrofurantoin	drug	237-250	false
glutethimide	drug	166-177	phenytoin	drug	253-261	false
glutethimide	drug	166-177	ribavirin	drug	264-272	false
glutethimide	drug	166-177	vincristine	drug	279-289	false
gold	drug	180-183	hydralazine	drug	186-196	false
gold	drug	180-183	iodoquinol	drug	199-208	false
gold	drug	180-183	isoniazid	drug	211-219	false
gold	drug	180-183	metronidazole	drug	222-234	false
gold	drug	180-183	nitrofurantoin	drug	237-250	false
gold	drug	180-183	phenytoin	drug	253-261	false
gold	drug	180-183	ribavirin	drug	264-272	false
gold	drug	180-183	vincristine	drug	279-289	false
hydralazine	drug	186-196	iodoquinol	drug	199-208	false
hydralazine	drug	186-196	isoniazid	drug	211-219	false
hydralazine	drug	186-196	metronidazole	drug	222-234	false
hydralazine	drug	186-196	nitrofurantoin	drug	237-250	false
hydralazine	drug	186-196	phenytoin	drug	253-261	false
hydralazine	drug	186-196	ribavirin	drug	264-272	false
hydralazine	drug	186-196	vincristine	drug	279-289	false
iodoquinol	drug	199-208	isoniazid	drug	211-219	false
iodoquinol	drug	199-208	metronidazole	drug	222-234	false
iodoquinol	drug	199-208	nitrofurantoin	drug	237-250	false
iodoquinol	drug	199-208	phenytoin	drug	253-261	false
iodoquinol	drug	199-208	ribavirin	drug	264-272	false
iodoquinol	drug	199-208	vincristine	drug	279-289	false
isoniazid	drug	211-219	metronidazole	drug	222-234	false
isoniazid	drug	211-219	nitrofurantoin	drug	237-250	false
isoniazid	drug	211-219	phenytoin	drug	253-261	false
isoniazid	drug	211-219	ribavirin	drug	264-272	false
isoniazid	drug	211-219	vincristine	drug	279-289	false
metronidazole	drug	222-234	nitrofurantoin	drug	237-250	false
metronidazole	drug	222-234	phenytoin	drug	253-261	false
metronidazole	drug	222-234	ribavirin	drug	264-272	false
metronidazole	drug	222-234	vincristine	drug	279-289	false
nitrofurantoin	drug	237-250	phenytoin	drug	253-261	false
nitrofurantoin	drug	237-250	ribavirin	drug	264-272	false
nitrofurantoin	drug	237-250	vincristine	drug	279-289	false
phenytoin	drug	253-261	ribavirin	drug	264-272	false
phenytoin	drug	253-261	vincristine	drug	279-289	false
ribavirin	drug	264-272	vincristine	drug	279-289	false

DDI-DrugBank.d263.s14	Concomitant use of HIVID with didanosine is not recommended.
HIVID	drug	19-23	didanosine	drug	30-39	advise

DDI-DrugBank.d263.s15	Intravenous Pentamidine: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.
Pentamidine	drug	12-22	HIVID	drug	40-44	false

DDI-DrugBank.d263.s16	Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.
pentamidine	drug	68-78	HIVID	drug	84-88	effect

DDI-DrugBank.d263.s17	If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.
pentamidine	drug	15-25	HIVID	drug	95-99	advise

DDI-DrugBank.d263.s18	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
Amphotericin	drug	0-11	Foscarnet	drug	14-22	false
Amphotericin	drug	0-11	Aminoglycosides	group	29-43	false
Amphotericin	drug	0-11	amphotericin	drug	60-71	false
Amphotericin	drug	0-11	foscarnet	drug	74-82	false
Amphotericin	drug	0-11	aminoglycosides	group	89-103	false
Amphotericin	drug	0-11	HIVID	drug	172-176	false
Amphotericin	drug	0-11	zalcitabine	drug	247-257	false
Foscarnet	drug	14-22	Aminoglycosides	group	29-43	false
Foscarnet	drug	14-22	amphotericin	drug	60-71	false
Foscarnet	drug	14-22	foscarnet	drug	74-82	false
Foscarnet	drug	14-22	aminoglycosides	group	89-103	false
Foscarnet	drug	14-22	HIVID	drug	172-176	false
Foscarnet	drug	14-22	zalcitabine	drug	247-257	false
Aminoglycosides	group	29-43	amphotericin	drug	60-71	false
Aminoglycosides	group	29-43	foscarnet	drug	74-82	false
Aminoglycosides	group	29-43	aminoglycosides	group	89-103	false
Aminoglycosides	group	29-43	HIVID	drug	172-176	false
Aminoglycosides	group	29-43	zalcitabine	drug	247-257	false
amphotericin	drug	60-71	foscarnet	drug	74-82	false
amphotericin	drug	60-71	aminoglycosides	group	89-103	false
amphotericin	drug	60-71	HIVID	drug	172-176	effect
amphotericin	drug	60-71	zalcitabine	drug	247-257	mechanism
foscarnet	drug	74-82	aminoglycosides	group	89-103	false
foscarnet	drug	74-82	HIVID	drug	172-176	effect
foscarnet	drug	74-82	zalcitabine	drug	247-257	mechanism
aminoglycosides	group	89-103	HIVID	drug	172-176	effect
aminoglycosides	group	89-103	zalcitabine	drug	247-257	mechanism
HIVID	drug	172-176	zalcitabine	drug	247-257	false

DDI-DrugBank.d263.s20	Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
Probenecid	drug	0-9	Cimetidine	drug	14-23	false
Probenecid	drug	0-9	probenecid	drug	56-65	false
Probenecid	drug	0-9	cimetidine	drug	70-79	false
Probenecid	drug	0-9	zalcitabine	drug	110-120	false
Probenecid	drug	0-9	zalcitabine	drug	179-189	false
Cimetidine	drug	14-23	probenecid	drug	56-65	false
Cimetidine	drug	14-23	cimetidine	drug	70-79	false
Cimetidine	drug	14-23	zalcitabine	drug	110-120	false
Cimetidine	drug	14-23	zalcitabine	drug	179-189	false
probenecid	drug	56-65	cimetidine	drug	70-79	false
probenecid	drug	56-65	zalcitabine	drug	110-120	mechanism
probenecid	drug	56-65	zalcitabine	drug	179-189	false
cimetidine	drug	70-79	zalcitabine	drug	110-120	mechanism
cimetidine	drug	70-79	zalcitabine	drug	179-189	false
zalcitabine	drug	110-120	zalcitabine	drug	179-189	false

DDI-DrugBank.d263.s21	Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.
zalcitabine	drug	51-61	zalcitabine	drug	121-131	false

DDI-DrugBank.d263.s22	Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.
Magnesium	drug	0-8	Aluminum	drug	10-17	false
Magnesium	drug	0-8	Antacid Products	group	30-45	false
Magnesium	drug	0-8	zalcitabine	drug	62-72	false
Magnesium	drug	0-8	magnesium	drug	141-149	false
Magnesium	drug	0-8	aluminum	drug	151-158	false
Magnesium	drug	0-8	antacid products	group	171-186	false
Aluminum	drug	10-17	Antacid Products	group	30-45	false
Aluminum	drug	10-17	zalcitabine	drug	62-72	false
Aluminum	drug	10-17	magnesium	drug	141-149	false
Aluminum	drug	10-17	aluminum	drug	151-158	false
Aluminum	drug	10-17	antacid products	group	171-186	false
Antacid Products	group	30-45	zalcitabine	drug	62-72	false
Antacid Products	group	30-45	magnesium	drug	141-149	false
Antacid Products	group	30-45	aluminum	drug	151-158	false
Antacid Products	group	30-45	antacid products	group	171-186	false
zalcitabine	drug	62-72	magnesium	drug	141-149	false
zalcitabine	drug	62-72	aluminum	drug	151-158	false
zalcitabine	drug	62-72	antacid products	group	171-186	false
magnesium	drug	141-149	aluminum	drug	151-158	false
magnesium	drug	141-149	antacid products	group	171-186	false
aluminum	drug	151-158	antacid products	group	171-186	false

DDI-DrugBank.d263.s23	The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
zalcitabine	drug	64-74	magnesium	drug	130-138	advise
zalcitabine	drug	64-74	aluminum	drug	140-147	advise
zalcitabine	drug	64-74	antacids	group	160-167	advise
magnesium	drug	130-138	aluminum	drug	140-147	false
magnesium	drug	130-138	antacids	group	160-167	false
aluminum	drug	140-147	antacids	group	160-167	false

DDI-DrugBank.d263.s24	Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.
Metoclopramide	drug	0-13	zalcitabine	drug	75-85	false
Metoclopramide	drug	0-13	metoclopramide	drug	91-104	false
zalcitabine	drug	75-85	metoclopramide	drug	91-104	mechanism

DDI-DrugBank.d263.s25	Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.
Doxorubicin	drug	0-10	Doxorubicin	drug	13-23	false
Doxorubicin	drug	0-10	zalcitabine	drug	46-56	false
Doxorubicin	drug	13-23	zalcitabine	drug	46-56	effect

DDI-DrugBank.d260.s0	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
Probenecid	drug	0-9	Probenecid	drug	13-22	false
Probenecid	drug	0-9	acetaminophen	drug	113-125	false
Probenecid	drug	0-9	acyclovir	drug	128-136	false
Probenecid	drug	0-9	angiotensin-converting enzyme inhibitors	group	139-178	false
Probenecid	drug	0-9	aminosalicylic acid	drug	181-199	false
Probenecid	drug	0-9	barbiturates	group	202-213	false
Probenecid	drug	0-9	benzodiazepines	group	216-230	false
Probenecid	drug	0-9	bumetanide	drug	233-242	false
Probenecid	drug	0-9	clofibrate	drug	245-254	false
Probenecid	drug	0-9	methotrexate	drug	257-268	false
Probenecid	drug	0-9	famotidine	drug	271-280	false
Probenecid	drug	0-9	furosemide	drug	283-292	false
Probenecid	drug	0-9	nonsteroidal anti-inflammatory	group	295-324	false
Probenecid	drug	0-9	theophylline	drug	334-345	false
Probenecid	drug	0-9	zidovudine	drug	352-361	false
Probenecid	drug	13-22	acetaminophen	drug	113-125	mechanism
Probenecid	drug	13-22	acyclovir	drug	128-136	mechanism
Probenecid	drug	13-22	angiotensin-converting enzyme inhibitors	group	139-178	mechanism
Probenecid	drug	13-22	aminosalicylic acid	drug	181-199	mechanism
Probenecid	drug	13-22	barbiturates	group	202-213	mechanism
Probenecid	drug	13-22	benzodiazepines	group	216-230	mechanism
Probenecid	drug	13-22	bumetanide	drug	233-242	mechanism
Probenecid	drug	13-22	clofibrate	drug	245-254	mechanism
Probenecid	drug	13-22	methotrexate	drug	257-268	mechanism
Probenecid	drug	13-22	famotidine	drug	271-280	mechanism
Probenecid	drug	13-22	furosemide	drug	283-292	mechanism
Probenecid	drug	13-22	nonsteroidal anti-inflammatory	group	295-324	mechanism
Probenecid	drug	13-22	theophylline	drug	334-345	mechanism
Probenecid	drug	13-22	zidovudine	drug	352-361	mechanism
acetaminophen	drug	113-125	acyclovir	drug	128-136	false
acetaminophen	drug	113-125	angiotensin-converting enzyme inhibitors	group	139-178	false
acetaminophen	drug	113-125	aminosalicylic acid	drug	181-199	false
acetaminophen	drug	113-125	barbiturates	group	202-213	false
acetaminophen	drug	113-125	benzodiazepines	group	216-230	false
acetaminophen	drug	113-125	bumetanide	drug	233-242	false
acetaminophen	drug	113-125	clofibrate	drug	245-254	false
acetaminophen	drug	113-125	methotrexate	drug	257-268	false
acetaminophen	drug	113-125	famotidine	drug	271-280	false
acetaminophen	drug	113-125	furosemide	drug	283-292	false
acetaminophen	drug	113-125	nonsteroidal anti-inflammatory	group	295-324	false
acetaminophen	drug	113-125	theophylline	drug	334-345	false
acetaminophen	drug	113-125	zidovudine	drug	352-361	false
acyclovir	drug	128-136	angiotensin-converting enzyme inhibitors	group	139-178	false
acyclovir	drug	128-136	aminosalicylic acid	drug	181-199	false
acyclovir	drug	128-136	barbiturates	group	202-213	false
acyclovir	drug	128-136	benzodiazepines	group	216-230	false
acyclovir	drug	128-136	bumetanide	drug	233-242	false
acyclovir	drug	128-136	clofibrate	drug	245-254	false
acyclovir	drug	128-136	methotrexate	drug	257-268	false
acyclovir	drug	128-136	famotidine	drug	271-280	false
acyclovir	drug	128-136	furosemide	drug	283-292	false
acyclovir	drug	128-136	nonsteroidal anti-inflammatory	group	295-324	false
acyclovir	drug	128-136	theophylline	drug	334-345	false
acyclovir	drug	128-136	zidovudine	drug	352-361	false
angiotensin-converting enzyme inhibitors	group	139-178	aminosalicylic acid	drug	181-199	false
angiotensin-converting enzyme inhibitors	group	139-178	barbiturates	group	202-213	false
angiotensin-converting enzyme inhibitors	group	139-178	benzodiazepines	group	216-230	false
angiotensin-converting enzyme inhibitors	group	139-178	bumetanide	drug	233-242	false
angiotensin-converting enzyme inhibitors	group	139-178	clofibrate	drug	245-254	false
angiotensin-converting enzyme inhibitors	group	139-178	methotrexate	drug	257-268	false
angiotensin-converting enzyme inhibitors	group	139-178	famotidine	drug	271-280	false
angiotensin-converting enzyme inhibitors	group	139-178	furosemide	drug	283-292	false
angiotensin-converting enzyme inhibitors	group	139-178	nonsteroidal anti-inflammatory	group	295-324	false
angiotensin-converting enzyme inhibitors	group	139-178	theophylline	drug	334-345	false
angiotensin-converting enzyme inhibitors	group	139-178	zidovudine	drug	352-361	false
aminosalicylic acid	drug	181-199	barbiturates	group	202-213	false
aminosalicylic acid	drug	181-199	benzodiazepines	group	216-230	false
aminosalicylic acid	drug	181-199	bumetanide	drug	233-242	false
aminosalicylic acid	drug	181-199	clofibrate	drug	245-254	false
aminosalicylic acid	drug	181-199	methotrexate	drug	257-268	false
aminosalicylic acid	drug	181-199	famotidine	drug	271-280	false
aminosalicylic acid	drug	181-199	furosemide	drug	283-292	false
aminosalicylic acid	drug	181-199	nonsteroidal anti-inflammatory	group	295-324	false
aminosalicylic acid	drug	181-199	theophylline	drug	334-345	false
aminosalicylic acid	drug	181-199	zidovudine	drug	352-361	false
barbiturates	group	202-213	benzodiazepines	group	216-230	false
barbiturates	group	202-213	bumetanide	drug	233-242	false
barbiturates	group	202-213	clofibrate	drug	245-254	false
barbiturates	group	202-213	methotrexate	drug	257-268	false
barbiturates	group	202-213	famotidine	drug	271-280	false
barbiturates	group	202-213	furosemide	drug	283-292	false
barbiturates	group	202-213	nonsteroidal anti-inflammatory	group	295-324	false
barbiturates	group	202-213	theophylline	drug	334-345	false
barbiturates	group	202-213	zidovudine	drug	352-361	false
benzodiazepines	group	216-230	bumetanide	drug	233-242	false
benzodiazepines	group	216-230	clofibrate	drug	245-254	false
benzodiazepines	group	216-230	methotrexate	drug	257-268	false
benzodiazepines	group	216-230	famotidine	drug	271-280	false
benzodiazepines	group	216-230	furosemide	drug	283-292	false
benzodiazepines	group	216-230	nonsteroidal anti-inflammatory	group	295-324	false
benzodiazepines	group	216-230	theophylline	drug	334-345	false
benzodiazepines	group	216-230	zidovudine	drug	352-361	false
bumetanide	drug	233-242	clofibrate	drug	245-254	false
bumetanide	drug	233-242	methotrexate	drug	257-268	false
bumetanide	drug	233-242	famotidine	drug	271-280	false
bumetanide	drug	233-242	furosemide	drug	283-292	false
bumetanide	drug	233-242	nonsteroidal anti-inflammatory	group	295-324	false
bumetanide	drug	233-242	theophylline	drug	334-345	false
bumetanide	drug	233-242	zidovudine	drug	352-361	false
clofibrate	drug	245-254	methotrexate	drug	257-268	false
clofibrate	drug	245-254	famotidine	drug	271-280	false
clofibrate	drug	245-254	furosemide	drug	283-292	false
clofibrate	drug	245-254	nonsteroidal anti-inflammatory	group	295-324	false
clofibrate	drug	245-254	theophylline	drug	334-345	false
clofibrate	drug	245-254	zidovudine	drug	352-361	false
methotrexate	drug	257-268	famotidine	drug	271-280	false
methotrexate	drug	257-268	furosemide	drug	283-292	false
methotrexate	drug	257-268	nonsteroidal anti-inflammatory	group	295-324	false
methotrexate	drug	257-268	theophylline	drug	334-345	false
methotrexate	drug	257-268	zidovudine	drug	352-361	false
famotidine	drug	271-280	furosemide	drug	283-292	false
famotidine	drug	271-280	nonsteroidal anti-inflammatory	group	295-324	false
famotidine	drug	271-280	theophylline	drug	334-345	false
famotidine	drug	271-280	zidovudine	drug	352-361	false
furosemide	drug	283-292	nonsteroidal anti-inflammatory	group	295-324	false
furosemide	drug	283-292	theophylline	drug	334-345	false
furosemide	drug	283-292	zidovudine	drug	352-361	false
nonsteroidal anti-inflammatory	group	295-324	theophylline	drug	334-345	false
nonsteroidal anti-inflammatory	group	295-324	zidovudine	drug	352-361	false
theophylline	drug	334-345	zidovudine	drug	352-361	false

DDI-DrugBank.d260.s2	Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
Zidovudine	drug	0-9	probenecid	drug	98-107	advise
Zidovudine	drug	0-9	VISTIDE	brand	123-129	false
probenecid	drug	98-107	VISTIDE	brand	123-129	false

DDI-DrugBank.d260.s3	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
VISTIDE	brand	51-57	aminoglycosides	group	116-130	advise
VISTIDE	brand	51-57	tobramycin	drug	139-148	advise
VISTIDE	brand	51-57	gentamicin	drug	151-160	advise
VISTIDE	brand	51-57	amikacin	drug	167-174	advise
VISTIDE	brand	51-57	amphotericin B	drug	178-191	advise
VISTIDE	brand	51-57	foscarnet	drug	194-202	advise
VISTIDE	brand	51-57	pentamidine	drug	217-227	advise
VISTIDE	brand	51-57	vancomycin	drug	230-239	advise
VISTIDE	brand	51-57	non-steroidal anti-inflammatory agents	group	246-283	advise
aminoglycosides	group	116-130	tobramycin	drug	139-148	false
aminoglycosides	group	116-130	gentamicin	drug	151-160	false
aminoglycosides	group	116-130	amikacin	drug	167-174	false
aminoglycosides	group	116-130	amphotericin B	drug	178-191	false
aminoglycosides	group	116-130	foscarnet	drug	194-202	false
aminoglycosides	group	116-130	pentamidine	drug	217-227	false
aminoglycosides	group	116-130	vancomycin	drug	230-239	false
aminoglycosides	group	116-130	non-steroidal anti-inflammatory agents	group	246-283	false
tobramycin	drug	139-148	gentamicin	drug	151-160	false
tobramycin	drug	139-148	amikacin	drug	167-174	false
tobramycin	drug	139-148	amphotericin B	drug	178-191	false
tobramycin	drug	139-148	foscarnet	drug	194-202	false
tobramycin	drug	139-148	pentamidine	drug	217-227	false
tobramycin	drug	139-148	vancomycin	drug	230-239	false
tobramycin	drug	139-148	non-steroidal anti-inflammatory agents	group	246-283	false
gentamicin	drug	151-160	amikacin	drug	167-174	false
gentamicin	drug	151-160	amphotericin B	drug	178-191	false
gentamicin	drug	151-160	foscarnet	drug	194-202	false
gentamicin	drug	151-160	pentamidine	drug	217-227	false
gentamicin	drug	151-160	vancomycin	drug	230-239	false
gentamicin	drug	151-160	non-steroidal anti-inflammatory agents	group	246-283	false
amikacin	drug	167-174	amphotericin B	drug	178-191	false
amikacin	drug	167-174	foscarnet	drug	194-202	false
amikacin	drug	167-174	pentamidine	drug	217-227	false
amikacin	drug	167-174	vancomycin	drug	230-239	false
amikacin	drug	167-174	non-steroidal anti-inflammatory agents	group	246-283	false
amphotericin B	drug	178-191	foscarnet	drug	194-202	false
amphotericin B	drug	178-191	pentamidine	drug	217-227	false
amphotericin B	drug	178-191	vancomycin	drug	230-239	false
amphotericin B	drug	178-191	non-steroidal anti-inflammatory agents	group	246-283	false
foscarnet	drug	194-202	pentamidine	drug	217-227	false
foscarnet	drug	194-202	vancomycin	drug	230-239	false
foscarnet	drug	194-202	non-steroidal anti-inflammatory agents	group	246-283	false
pentamidine	drug	217-227	vancomycin	drug	230-239	false
pentamidine	drug	217-227	non-steroidal anti-inflammatory agents	group	246-283	false
vancomycin	drug	230-239	non-steroidal anti-inflammatory agents	group	246-283	false

DDI-DrugBank.d150.s0	FLEXERIL may have life-threatening interactions with MAO inhibitors.
FLEXERIL	brand	0-7	MAO inhibitors	group	53-66	int

DDI-DrugBank.d150.s1	FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
FLEXERIL	brand	0-7	alcohol	drug	36-42	effect
FLEXERIL	brand	0-7	barbiturates	group	45-56	effect
FLEXERIL	brand	0-7	CNS depressants	group	69-83	effect
alcohol	drug	36-42	barbiturates	group	45-56	false
alcohol	drug	36-42	CNS depressants	group	69-83	false
barbiturates	group	45-56	CNS depressants	group	69-83	false

DDI-DrugBank.d150.s2	Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.
Tricyclic antidepressants	group	0-24	guanethidine	drug	67-78	effect

DDI-DrugBank.d150.s3	Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol
Tricyclic antidepressants	group	0-24	tramadol	drug	74-81	effect

DDI-DrugBank.d15.s0	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
Fondaparinux	drug	35-46	anticoagulants	group	77-90	false
Fondaparinux	drug	35-46	warfarin	drug	93-100	false
Fondaparinux	drug	35-46	platelet inhibitors	group	104-122	false
Fondaparinux	drug	35-46	acetylsalicylic acid	drug	125-144	false
Fondaparinux	drug	35-46	NSAIDs	group	148-153	false
Fondaparinux	drug	35-46	piroxicam	drug	156-164	false
Fondaparinux	drug	35-46	digoxin	drug	172-178	false
Fondaparinux	drug	35-46	fondaparinux sodium	drug	250-268	false
anticoagulants	group	77-90	warfarin	drug	93-100	false
anticoagulants	group	77-90	platelet inhibitors	group	104-122	false
anticoagulants	group	77-90	acetylsalicylic acid	drug	125-144	false
anticoagulants	group	77-90	NSAIDs	group	148-153	false
anticoagulants	group	77-90	piroxicam	drug	156-164	false
anticoagulants	group	77-90	digoxin	drug	172-178	false
anticoagulants	group	77-90	fondaparinux sodium	drug	250-268	false
warfarin	drug	93-100	platelet inhibitors	group	104-122	false
warfarin	drug	93-100	acetylsalicylic acid	drug	125-144	false
warfarin	drug	93-100	NSAIDs	group	148-153	false
warfarin	drug	93-100	piroxicam	drug	156-164	false
warfarin	drug	93-100	digoxin	drug	172-178	false
warfarin	drug	93-100	fondaparinux sodium	drug	250-268	false
platelet inhibitors	group	104-122	acetylsalicylic acid	drug	125-144	false
platelet inhibitors	group	104-122	NSAIDs	group	148-153	false
platelet inhibitors	group	104-122	piroxicam	drug	156-164	false
platelet inhibitors	group	104-122	digoxin	drug	172-178	false
platelet inhibitors	group	104-122	fondaparinux sodium	drug	250-268	false
acetylsalicylic acid	drug	125-144	NSAIDs	group	148-153	false
acetylsalicylic acid	drug	125-144	piroxicam	drug	156-164	false
acetylsalicylic acid	drug	125-144	digoxin	drug	172-178	false
acetylsalicylic acid	drug	125-144	fondaparinux sodium	drug	250-268	false
NSAIDs	group	148-153	piroxicam	drug	156-164	false
NSAIDs	group	148-153	digoxin	drug	172-178	false
NSAIDs	group	148-153	fondaparinux sodium	drug	250-268	false
piroxicam	drug	156-164	digoxin	drug	172-178	false
piroxicam	drug	156-164	fondaparinux sodium	drug	250-268	false
digoxin	drug	172-178	fondaparinux sodium	drug	250-268	false

DDI-DrugBank.d15.s1	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.
Fondaparinux	drug	13-24	warfarin	drug	69-76	false
Fondaparinux	drug	13-24	acetylsalicylic acid	drug	79-98	false
Fondaparinux	drug	13-24	piroxicam	drug	101-109	false
Fondaparinux	drug	13-24	digoxin	drug	116-122	false
Fondaparinux	drug	13-24	digoxin	drug	153-159	false
warfarin	drug	69-76	acetylsalicylic acid	drug	79-98	false
warfarin	drug	69-76	piroxicam	drug	101-109	false
warfarin	drug	69-76	digoxin	drug	116-122	false
warfarin	drug	69-76	digoxin	drug	153-159	false
acetylsalicylic acid	drug	79-98	piroxicam	drug	101-109	false
acetylsalicylic acid	drug	79-98	digoxin	drug	116-122	false
acetylsalicylic acid	drug	79-98	digoxin	drug	153-159	false
piroxicam	drug	101-109	digoxin	drug	116-122	false
piroxicam	drug	101-109	digoxin	drug	153-159	false
digoxin	drug	116-122	digoxin	drug	153-159	false

DDI-DrugBank.d15.s4	In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%.
coumarin	group	86-93	fondaparinux	drug	98-109	mechanism

DDI-DrugBank.d15.s6	Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.
fondaparinux	drug	6-17	fondaparinux sodium	drug	124-142	false

DDI-DrugBank.d559.s0	The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
butalbital	drug	19-28	monoamine oxidase (MAO) inhibitors	group	49-82	effect

DDI-DrugBank.d559.s1	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
Butalbital	drug	0-9	acetaminophen	drug	12-24	false
Butalbital	drug	0-9	caffeine	drug	30-37	false
Butalbital	drug	0-9	narcotic analgesic	group	73-90	effect
Butalbital	drug	0-9	alcohol	drug	94-100	effect
Butalbital	drug	0-9	anesthetics	group	111-121	effect
Butalbital	drug	0-9	tranquilizers	group	124-136	effect
Butalbital	drug	0-9	chlordiazepoxide	drug	146-161	effect
Butalbital	drug	0-9	sedative-hypnotics	group	164-181	effect
Butalbital	drug	0-9	CNS depressants	group	193-207	effect
acetaminophen	drug	12-24	caffeine	drug	30-37	false
acetaminophen	drug	12-24	narcotic analgesic	group	73-90	effect
acetaminophen	drug	12-24	alcohol	drug	94-100	effect
acetaminophen	drug	12-24	anesthetics	group	111-121	effect
acetaminophen	drug	12-24	tranquilizers	group	124-136	effect
acetaminophen	drug	12-24	chlordiazepoxide	drug	146-161	effect
acetaminophen	drug	12-24	sedative-hypnotics	group	164-181	effect
acetaminophen	drug	12-24	CNS depressants	group	193-207	effect
caffeine	drug	30-37	narcotic analgesic	group	73-90	effect
caffeine	drug	30-37	alcohol	drug	94-100	effect
caffeine	drug	30-37	anesthetics	group	111-121	effect
caffeine	drug	30-37	tranquilizers	group	124-136	effect
caffeine	drug	30-37	chlordiazepoxide	drug	146-161	effect
caffeine	drug	30-37	sedative-hypnotics	group	164-181	effect
caffeine	drug	30-37	CNS depressants	group	193-207	effect
narcotic analgesic	group	73-90	alcohol	drug	94-100	false
narcotic analgesic	group	73-90	anesthetics	group	111-121	false
narcotic analgesic	group	73-90	tranquilizers	group	124-136	false
narcotic analgesic	group	73-90	chlordiazepoxide	drug	146-161	false
narcotic analgesic	group	73-90	sedative-hypnotics	group	164-181	false
narcotic analgesic	group	73-90	CNS depressants	group	193-207	false
alcohol	drug	94-100	anesthetics	group	111-121	false
alcohol	drug	94-100	tranquilizers	group	124-136	false
alcohol	drug	94-100	chlordiazepoxide	drug	146-161	false
alcohol	drug	94-100	sedative-hypnotics	group	164-181	false
alcohol	drug	94-100	CNS depressants	group	193-207	false
anesthetics	group	111-121	tranquilizers	group	124-136	false
anesthetics	group	111-121	chlordiazepoxide	drug	146-161	false
anesthetics	group	111-121	sedative-hypnotics	group	164-181	false
anesthetics	group	111-121	CNS depressants	group	193-207	false
tranquilizers	group	124-136	chlordiazepoxide	drug	146-161	false
tranquilizers	group	124-136	sedative-hypnotics	group	164-181	false
tranquilizers	group	124-136	CNS depressants	group	193-207	false
chlordiazepoxide	drug	146-161	sedative-hypnotics	group	164-181	false
chlordiazepoxide	drug	146-161	CNS depressants	group	193-207	false
sedative-hypnotics	group	164-181	CNS depressants	group	193-207	false

DDI-DrugBank.d157.s0	Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.
cimetidine	drug	34-43	warfarin	drug	49-56	false
cimetidine	drug	34-43	Femara	brand	97-102	false
warfarin	drug	49-56	Femara	brand	97-102	false

DDI-DrugBank.d157.s1	(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.
Femara	brand	48-53	tamoxifen	drug	59-67	mechanism
Femara	brand	48-53	letrozole	drug	108-116	false
tamoxifen	drug	59-67	letrozole	drug	108-116	false

